[Title 21 CFR ]
[Code of Federal Regulations (annual edition) - April 1, 2013 Edition]
[From the U.S. Government Printing Office]



[[Page i]]

          

Title 21

Food and Drugs


________________________

Part 500 to 599

                         Revised as of April 1, 2013

          Containing a codification of documents of general 
          applicability and future effect

          As of April 1, 2013
                    Published by the Office of the Federal Register 
                    National Archives and Records Administration as a 
                    Special Edition of the Federal Register

[[Page ii]]

          U.S. GOVERNMENT OFFICIAL EDITION NOTICE

          Legal Status and Use of Seals and Logos
          
          
          The seal of the National Archives and Records Administration 
              (NARA) authenticates the Code of Federal Regulations (CFR) as 
              the official codification of Federal regulations established 
              under the Federal Register Act. Under the provisions of 44 
              U.S.C. 1507, the contents of the CFR, a special edition of the 
              Federal Register, shall be judicially noticed. The CFR is 
              prima facie evidence of the original documents published in 
              the Federal Register (44 U.S.C. 1510).

          It is prohibited to use NARA's official seal and the stylized Code 
              of Federal Regulations logo on any republication of this 
              material without the express, written permission of the 
              Archivist of the United States or the Archivist's designee. 
              Any person using NARA's official seals and logos in a manner 
              inconsistent with the provisions of 36 CFR part 1200 is 
              subject to the penalties specified in 18 U.S.C. 506, 701, and 
              1017.

          Use of ISBN Prefix

          This is the Official U.S. Government edition of this publication 
              and is herein identified to certify its authenticity. Use of 
              the 0-16 ISBN prefix is for U.S. Government Printing Office 
              Official Editions only. The Superintendent of Documents of the 
              U.S. Government Printing Office requests that any reprinted 
              edition clearly be labeled as a copy of the authentic work 
              with a new ISBN.

              
              
          U . S . G O V E R N M E N T P R I N T I N G O F F I C E

          ------------------------------------------------------------------

          U.S. Superintendent of Documents  Washington, DC 
              20402-0001

          http://bookstore.gpo.gov

          Phone: toll-free (866) 512-1800; DC area (202) 512-1800

[[Page iii]]




                            Table of Contents



                                                                    Page
  Explanation.................................................       v

  Title 21:
          Chapter I--Food and Drug Administration, Department 
          of Health and Human Services (Continued)                   3
  Finding Aids:
      Table of CFR Titles and Chapters........................     589
      Alphabetical List of Agencies Appearing in the CFR......     609
      List of CFR Sections Affected...........................     619

[[Page iv]]





                     ----------------------------

                     Cite this Code: CFR
                     To cite the regulations in 
                       this volume use title, 
                       part and section number. 
                       Thus, 21 CFR 500.23 refers 
                       to title 21, part 500, 
                       section 23.

                     ----------------------------

[[Page v]]



                               EXPLANATION

    The Code of Federal Regulations is a codification of the general and 
permanent rules published in the Federal Register by the Executive 
departments and agencies of the Federal Government. The Code is divided 
into 50 titles which represent broad areas subject to Federal 
regulation. Each title is divided into chapters which usually bear the 
name of the issuing agency. Each chapter is further subdivided into 
parts covering specific regulatory areas.
    Each volume of the Code is revised at least once each calendar year 
and issued on a quarterly basis approximately as follows:

Title 1 through Title 16.................................as of January 1
Title 17 through Title 27..................................as of April 1
Title 28 through Title 41...................................as of July 1
Title 42 through Title 50................................as of October 1

    The appropriate revision date is printed on the cover of each 
volume.

LEGAL STATUS

    The contents of the Federal Register are required to be judicially 
noticed (44 U.S.C. 1507). The Code of Federal Regulations is prima facie 
evidence of the text of the original documents (44 U.S.C. 1510).

HOW TO USE THE CODE OF FEDERAL REGULATIONS

    The Code of Federal Regulations is kept up to date by the individual 
issues of the Federal Register. These two publications must be used 
together to determine the latest version of any given rule.
    To determine whether a Code volume has been amended since its 
revision date (in this case, April 1, 2013), consult the ``List of CFR 
Sections Affected (LSA),'' which is issued monthly, and the ``Cumulative 
List of Parts Affected,'' which appears in the Reader Aids section of 
the daily Federal Register. These two lists will identify the Federal 
Register page number of the latest amendment of any given rule.

EFFECTIVE AND EXPIRATION DATES

    Each volume of the Code contains amendments published in the Federal 
Register since the last revision of that volume of the Code. Source 
citations for the regulations are referred to by volume number and page 
number of the Federal Register and date of publication. Publication 
dates and effective dates are usually not the same and care must be 
exercised by the user in determining the actual effective date. In 
instances where the effective date is beyond the cut-off date for the 
Code a note has been inserted to reflect the future effective date. In 
those instances where a regulation published in the Federal Register 
states a date certain for expiration, an appropriate note will be 
inserted following the text.

OMB CONTROL NUMBERS

    The Paperwork Reduction Act of 1980 (Pub. L. 96-511) requires 
Federal agencies to display an OMB control number with their information 
collection request.

[[Page vi]]

Many agencies have begun publishing numerous OMB control numbers as 
amendments to existing regulations in the CFR. These OMB numbers are 
placed as close as possible to the applicable recordkeeping or reporting 
requirements.

PAST PROVISIONS OF THE CODE

    Provisions of the Code that are no longer in force and effect as of 
the revision date stated on the cover of each volume are not carried. 
Code users may find the text of provisions in effect on any given date 
in the past by using the appropriate List of CFR Sections Affected 
(LSA). For the convenience of the reader, a ``List of CFR Sections 
Affected'' is published at the end of each CFR volume. For changes to 
the Code prior to the LSA listings at the end of the volume, consult 
previous annual editions of the LSA. For changes to the Code prior to 
2001, consult the List of CFR Sections Affected compilations, published 
for 1949-1963, 1964-1972, 1973-1985, and 1986-2000.

``[RESERVED]'' TERMINOLOGY

    The term ``[Reserved]'' is used as a place holder within the Code of 
Federal Regulations. An agency may add regulatory information at a 
``[Reserved]'' location at any time. Occasionally ``[Reserved]'' is used 
editorially to indicate that a portion of the CFR was left vacant and 
not accidentally dropped due to a printing or computer error.

INCORPORATION BY REFERENCE

    What is incorporation by reference? Incorporation by reference was 
established by statute and allows Federal agencies to meet the 
requirement to publish regulations in the Federal Register by referring 
to materials already published elsewhere. For an incorporation to be 
valid, the Director of the Federal Register must approve it. The legal 
effect of incorporation by reference is that the material is treated as 
if it were published in full in the Federal Register (5 U.S.C. 552(a)). 
This material, like any other properly issued regulation, has the force 
of law.
    What is a proper incorporation by reference? The Director of the 
Federal Register will approve an incorporation by reference only when 
the requirements of 1 CFR part 51 are met. Some of the elements on which 
approval is based are:
    (a) The incorporation will substantially reduce the volume of 
material published in the Federal Register.
    (b) The matter incorporated is in fact available to the extent 
necessary to afford fairness and uniformity in the administrative 
process.
    (c) The incorporating document is drafted and submitted for 
publication in accordance with 1 CFR part 51.
    What if the material incorporated by reference cannot be found? If 
you have any problem locating or obtaining a copy of material listed as 
an approved incorporation by reference, please contact the agency that 
issued the regulation containing that incorporation. If, after 
contacting the agency, you find the material is not available, please 
notify the Director of the Federal Register, National Archives and 
Records Administration, 8601 Adelphi Road, College Park, MD 20740-6001, 
or call 202-741-6010.

CFR INDEXES AND TABULAR GUIDES

    A subject index to the Code of Federal Regulations is contained in a 
separate volume, revised annually as of January 1, entitled CFR Index 
and Finding Aids. This volume contains the Parallel Table of Authorities 
and Rules. A list of CFR titles, chapters, subchapters, and parts and an 
alphabetical list of agencies publishing in the CFR are also included in 
this volume.

[[Page vii]]

    An index to the text of ``Title 3--The President'' is carried within 
that volume.
    The Federal Register Index is issued monthly in cumulative form. 
This index is based on a consolidation of the ``Contents'' entries in 
the daily Federal Register.
    A List of CFR Sections Affected (LSA) is published monthly, keyed to 
the revision dates of the 50 CFR titles.

REPUBLICATION OF MATERIAL

    There are no restrictions on the republication of material appearing 
in the Code of Federal Regulations.

INQUIRIES

    For a legal interpretation or explanation of any regulation in this 
volume, contact the issuing agency. The issuing agency's name appears at 
the top of odd-numbered pages.
    For inquiries concerning CFR reference assistance, call 202-741-6000 
or write to the Director, Office of the Federal Register, National 
Archives and Records Administration, 8601 Adelphi Road, College Park, MD 
20740-6001 or e-mail [email protected].

SALES

    The Government Printing Office (GPO) processes all sales and 
distribution of the CFR. For payment by credit card, call toll-free, 
866-512-1800, or DC area, 202-512-1800, M-F 8 a.m. to 4 p.m. e.s.t. or 
fax your order to 202-512-2104, 24 hours a day. For payment by check, 
write to: US Government Printing Office - New Orders, P.O. Box 979050, 
St. Louis, MO 63197-9000.

ELECTRONIC SERVICES

    The full text of the Code of Federal Regulations, the LSA (List of 
CFR Sections Affected), The United States Government Manual, the Federal 
Register, Public Laws, Public Papers of the Presidents of the United 
States, Compilation of Presidential Documents and the Privacy Act 
Compilation are available in electronic format via www.ofr.gov. For more 
information, contact the GPO Customer Contact Center, U.S. Government 
Printing Office. Phone 202-512-1800, or 866-512-1800 (toll-free). E-
mail, [email protected].
    The Office of the Federal Register also offers a free service on the 
National Archives and Records Administration's (NARA) World Wide Web 
site for public law numbers, Federal Register finding aids, and related 
information. Connect to NARA's web site at www.archives.gov/federal-
register.
    The e-CFR is a regularly updated, unofficial editorial compilation 
of CFR material and Federal Register amendments, produced by the Office 
of the Federal Register and the Government Printing Office. It is 
available at www.ecfr.gov.

    Charles A. Barth,
    Director,
    Office of the Federal Register.
    April 1, 2013.







[[Page ix]]



                               THIS TITLE

    Title 21--Food and Drugs is composed of nine volumes. The parts in 
these volumes are arranged in the following order: Parts 1-99, 100-169, 
170-199, 200-299, 300-499, 500-599, 600-799, 800-1299 and 1300 to end. 
The first eight volumes, containing parts 1-1299, comprise Chapter I--
Food and Drug Administration, Department of Health and Human Services. 
The ninth volume, containing part 1300 to end, includes Chapter II--Drug 
Enforcement Administration, Department of Justice, and Chapter III--
Office of National Drug Control Policy. The contents of these volumes 
represent all current regulations codified under this title of the CFR 
as of April 1, 2013.

    For this volume, Jonn V. Lilyea was Chief Editor. The Code of 
Federal Regulations publication program is under the direction of 
Michael L. White, assisted by Ann Worley.

[[Page 1]]



                        TITLE 21--FOOD AND DRUGS




                  (This book contains parts 500 to 599)

  --------------------------------------------------------------------
                                                                    Part

chapter i--Food and Drug Administration, Department of 
  Health and Human Services (Continued).....................         500

[[Page 3]]



CHAPTER I--FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN 
                          SERVICES (CONTINUED)




  --------------------------------------------------------------------


  Editorial Note: Nomenclature changes to chapter I appear at 69 FR 
13717, Mar. 24, 2004, and 69 FR 18803, Apr. 9, 2004.

         SUBCHAPTER E--ANIMAL DRUGS, FEEDS, AND RELATED PRODUCTS
Part                                                                Page
500             General.....................................           5
501             Animal food labeling........................          15
502             Common or usual names for nonstandardized 
                    animal foods............................          32
509             Unavoidable contaminants in animal food and 
                    food-packaging material.................          34
510             New animal drugs............................          38
511             New animal drugs for investigational use....          49
514             New animal drug applications................          54
515             Medicated feed mill license.................          89
516             New animal drugs for minor use and minor 
                    species.................................          93
520             Oral dosage form new animal drugs...........         118
522             Implantation or injectable dosage form new 
                    animal drugs............................         241
524             Ophthalmic and topical dosage form new 
                    animal drugs............................         325
526             Intramammary dosage form new animal drugs...         352
528             New animal drugs in genetically engineered 
                    animals.................................         358
529             Certain other dosage form new animal drugs..         358
530             Extralabel drug use in animals..............         364
556             Tolerances for residues of new animal drugs 
                    in food.................................         371
558             New animal drugs for use in animal feeds....         384
564

[Reserved]

570             Food additives..............................         521
571             Food additive petitions.....................         529
573             Food additives permitted in feed and 
                    drinking water of animals...............         534

[[Page 4]]

579             Irradiation in the production, processing, 
                    and handling of animal feed and pet food         554
582             Substances generally recognized as safe.....         555
584             Food substances affirmed as generally 
                    recognized as safe in feed and drinking 
                    water of animals........................         579
589             Substances prohibited from use in animal 
                    food or feed............................         580
590-599

[Reserved]

[[Page 5]]



         SUBCHAPTER E_ANIMAL DRUGS, FEEDS, AND RELATED PRODUCTS





PART 500_GENERAL--Table of Contents



Subpart A [Reserved]

         Subpart B_Specific Administrative Rulings and Decisions

Sec.
500.23 Thermally processed low-acid foods packaged in hermetically 
          sealed containers.
500.24 Emergency permit control.
500.25 Anthelmintic drugs for use in animals.
500.26 Timed-release dosage form drugs.
500.27 Methylene blue-containing drugs for use in animals.
500.29 Gentian violet for use in animal feed.
500.30 Gentian violet for animal drug use.
500.35 Animal feeds contaminated with Salmonella microorganisms.
500.45 Use of polychlorinated biphenyls (PCB's) in the production, 
          handling, and storage of animal feed.
500.46 Hexachlorophene in animal drugs.
500.50 Propylene glycol in or on cat food.

               Subpart C_Animal Drug Labeling Requirements

500.51 Labeling of animal drugs; misbranding.
500.52 Use of terms such as ``tonic'', ``tone'', ``toner'', or 
          ``conditioner'' in the labeling of preparations intended for 
          use in or on animals.
500.55 Exemption from certain drug-labeling requirements.

            Subpart D_Requirements for Specific Animal Drugs

500.65 Epinephrine injection 1:1,000 in 10-milliliter containers for 
          emergency treatment of anaphylactoid shock in cattle, horses, 
          sheep, and swine.

 Subpart E_Regulation of Carcinogenic Compounds Used in Food-Producing 
                                 Animals

500.80 Scope of this subpart.
500.82 Definitions.
500.84 Conditions for approval of the sponsored compound.
500.86 Marker residue and target tissue.
500.88 Regulatory method.
500.90 Waiver of requirements.
500.92 Implementation.



 Subpart F_Methods for Detection of Residues of Carcinogenic Compounds 
                     Used in Food-Producing Animals

500.1410 N-methyl-2-pyrrolidone.

    Authority: 21 U.S.C. 321, 331, 342, 343, 348, 351, 352, 353, 360b, 
371, 379e.

    Source: 40 FR 13802, Mar. 27, 1975, unless otherwise noted.

Subpart A [Reserved]



         Subpart B_Specific Administrative Rulings and Decisions



Sec. 500.23  Thermally processed low-acid foods packaged in 
hermetically sealed containers.

    The provisions of part 113 of this chapter shall apply to the 
manufacture, processing or packing of low-acid foods in hermetically 
sealed containers, and intended for use as food for animals.

[61 FR 37681, July 19, 1996]



Sec. 500.24  Emergency permit control.

    The provisions of part 108 of this chapter shall apply to the 
issuance of emergency control permits for the manufacturer or packer of 
thermally processed low-acid foods packaged in hermetically sealed 
containers, and intended for use as food for animals.

[61 FR 37681, July 19, 1996]



Sec. 500.25  Anthelmintic drugs for use in animals.

    (a) The Commissioner of Food and Drugs has determined that, in order 
to assure that anthelmintic drugs, including animal feeds bearing or 
containing such drugs, which do not carry the prescription statement are 
labeled to provide adequate directions for their effective use, labeling 
of these anthelmintic drugs shall bear, in addition to other required 
information, a statement that a veterinarian should be consulted for 
assistance in the diagnosis, treatment, and control of parasitism.

[[Page 6]]

    (b) The label and any labeling furnishing or purporting to furnish 
directions for use, shall bear conspicuously the following statement: 
``Consult your veterinarian for assistance in the diagnosis, treatment, 
and control of parasitism.''
    (c) For drugs covered by approved new animal drug applications, the 
labeling revisions required for compliance with this section may be 
placed into effect without prior approval, as provided for in Sec. 
514.8(c)(3) of this chapter. For drugs listed in the index, the labeling 
revisions required for compliance with this section may be placed into 
effect without prior granting of a request for a modification, as 
provided for in Sec. 516.161(b)(1) of this chapter.
    (d) Labeling revisions required for compliance with this section 
shall be placed into effect by February 25, 1975, following which, any 
such drugs that are introduced into interstate commerce and not in 
compliance with this section will be subject to regulatory proceedings.

[40 FR 13802, Mar. 27, 1975, as amended at 71 FR 74782, Dec. 13, 2006; 
72 FR 69120, Dec. 6, 2007]



Sec. 500.26  Timed-release dosage form drugs.

    (a) Drugs are being offered in dosage forms that are designed to 
release the active ingredients over a prolonged period of time. There is 
a possibility of unsafe overdosage or ineffective dosage if such 
products are improperly made and the active ingredients are released at 
one time, over too short or too long a period of time, or not released 
at all. Drugs marketed in this form, which are referred to by such terms 
as timed-release, controlled-release, prolonged-release, sustained-
release, or delayed-release drugs, are regarded as new animal drugs 
within the meaning of section 201(v) of the Federal Food, Drug, and 
Cosmetic Act.
    (b) Timed-release dosage form animal drugs that are introduced into 
interstate commerce are deemed to be adulterated within the meaning of 
section 501(a)(5) of the act and subject to regulatory action, unless 
such animal drug is the subject of an approved new animal drug 
application, or listed in the index, as required by paragraph (a) of 
this section.
    (c) The fact that the labeling of this kind of drug may claim 
delayed, prolonged, controlled, or sustained-release of all or only some 
of the active ingredients does not affect the new animal drug status of 
such articles. A new animal drug application or index listing is 
required in any such case.
    (d) New animal drug applications for timed-release dosage form 
animal drugs must contain, among other things, data to demonstrate 
safety and effectiveness by establishing that the article is 
manufactured using procedures and controls to ensure release of the 
total dosage at a safe and effective rate. Data submitted in the new 
animal drug application must demonstrate that the formulation of the 
drug and the procedures used in its manufacture will ensure release of 
the active ingredient(s) of the drug at a safe and effective rate and 
that these release characteristics will be maintained until the 
expiration date of the drug. When the drug is intended for use in food-
producing animals, data submitted must also demonstrate that, with 
respect to possible residues of the drug, food derived from treated 
animals is safe for consumption.

[42 FR 8635, Feb. 11, 1977, as amended at 60 FR 38480, July 27, 1995; 72 
FR 69120, Dec. 6, 2007]



Sec. 500.27  Methylene blue-containing drugs for use in animals.

    (a) New information requires a re- evaluation of the status of drugs 
containing methylene blue (tetramethylthionine chloride) for oral use in 
cats or dogs.
    (1)(i) It has been demonstrated that two orally administered urinary 
antiseptic-antispasmodic preparations that contained methylene blue 
cause Heinz body hemolytic anemia in cats when used according to label 
directions. The specific cause of the reaction was determined to be the 
methylene blue contained in the preparations. The reaction can be severe 
enough to cause death of treated animals.
    (ii) The Heinz body hemolytic anemia reaction to methylene blue has 
also

[[Page 7]]

been demonstrated in dogs under laboratory conditions. The precise 
mechanism by which methylene blue produces the characteristic 
erythrocytic inclusion bodies (Heinz bodies) and associated hemolytic 
anemia is unclear.
    (2) The effectiveness of orally administered methylene blue as a 
urinary antiseptic is open to question. It appears that following oral 
administration, methylene blue is poorly and erratically absorbed and 
also slowly and erratically excreted in the urine. Studies in the dog 
indicate it is excreted in the urine essentially as leukomethylene blue 
stabilized in some manner. Methylene blue itself is stepwise 
demethylated in alkaline solutions (alkaline urine being a frequent 
consequence of urinary infection) to Azure B, Azure A, and Azure C. The 
antiseptic efficacy of all of these excretion products is 
unsubstantiated.
    (3) In view of the foregoing, the Commissioner has concluded that 
animal drugs containing methylene blue for oral use in cats or dogs are 
neither safe nor generally recognized as effective within the meaning of 
section 201(v) of the act and are therefore considered new animal drugs. 
Accordingly, all prior formal and informal opinions expressed by the 
Food and Drug Administration that such drugs are ``not new drugs'' or 
``no longer new drugs'' are hereby revoked.
    (b) Animal drugs that contain methylene blue for oral use in cats or 
dogs and not the subject of an approved new animal drug application 
(NADA) are deemed to be adulterated under the provisions of section 
501(a) (5) and/or (6) and/or misbranded under section 502(a) of the act 
and subject to regulatory action as of April 10, 1978.
    (c) Sponsors of animal drugs that contain methylene blue for oral 
use in cats or dogs and not the subject of an approved new animal drug 
application (NADA) may submit an application in conformity with Sec. 
514.1 of this chapter. Such applications will be processed in accordance 
with section 512 of the act. Submission of an NADA will not constitute 
grounds for continued marketing of this drug substance until such 
application is approved.
    (d) New animal drug applications required by this regulation 
pursuant to section 512 of the act shall be submitted to the Food and 
Drug Administration. Center for Veterinary Medicine, Office of New 
Animal Drug Evaluation (HFV-100), 7500 Standish Pl., Rockville, MD 
20855.

[43 FR 9803, Mar. 10, 1978; 43 FR 12310, Mar. 24, 1978, as amended at 54 
FR 18279, Apr. 28, 1989; 57 FR 6475, Feb. 25, 1992; 60 FR 38480, July 
27, 1995]



Sec. 500.29  Gentian violet for use in animal feed.

    The Food and Drug Administration has determined that gentian violet 
is not generally recognized as safe for use in animal feed and is a food 
additive subject to section 409 of the Federal Food, Drug, and Cosmetic 
Act (the act), unless it is intended for use as a new animal drug, in 
which case it is subject to section 512 of the act. The Food and Drug 
Administration has determined that gentian violet is not prior 
sanctioned for any use in animal feed.

[56 FR 40506, Aug. 15, 1991]



Sec. 500.30  Gentian violet for animal drug use.

    The Food and Drug Administration (FDA) has determined that gentian 
violet is not generally recognized as safe and effective for any 
veterinary drug use in food animals and is a new animal drug subject to 
section 512 of the Federal Food, Drug, and Cosmetic Act. FDA has 
determined that gentian violet is not exempted from new animal drug 
status under the ``grandfather'' provisions of the Drug Amendments of 
1962 (21 U.S.C. 342).

[56 FR 40507, Aug. 15, 1991]



Sec. 500.35  Animal feeds contaminated with Salmonella microorganisms.

    (a) Investigations by the Food and Drug Administration, the Centers 
for Disease Control of the U.S. Public Health Service, the Animal Health 
Division of the Agricultural Research Service, U.S. Department of 
Agriculture, and by various State public health agencies have revealed 
that processed fish meal, poultry meal, meat meal, tankage, and other 
animal byproducts intended for use in animal

[[Page 8]]

feed may be contaminated with Salmonella bacteria, an organism 
pathogenic to man and animals. Contamination of these products may occur 
through inadequate heat treatment of the product during its processing 
or through recontamination of the heat-treated product during a time of 
improper storage or handling subsequent to processing.
    (b) Articles used in food for animals are included within the 
definition of food in section 201(f) of the Federal Food, Drug, and 
Cosmetic Act. Further, Salmonella contamination of such animal feeds 
having the potentiality for producing infection and disease in animals 
must be regarded as an adulterant within the meaning of section 402(a) 
of the act. Therefore, the Food and Drug Administration will regard as 
adulterated within the meaning of section 402(a) of the act shipments of 
the following when intended for animal feed and encountered in 
interstate commerce and found upon examination to be contaminated with 
Salmonella microorganisms: Bone meal, blood meal, crab meal, feather 
meal, fish meal, fish solubles, meat scraps, poultry meat meal, tankage, 
or other similar animal byproducts, or blended mixtures of these.

[40 FR 13802, Mar. 27, 1975, as amended at 54 FR 18279, Apr. 28, 1989]



Sec. 500.45  Use of polychlorinated biphenyls (PCB's) in the 
production, handling, and storage of animal feed.

    (a) Polychlorinated biphenyls (PCB's) represent a class of toxic 
industrial chemicals manufactured and sold under a variety of trade 
names, including: Aroclor (United States); Phenoclor (France); Colphen 
(Germany); and Kanaclor (Japan). PCB's are highly stable, heat 
resistant, and nonflammable chemicals. Industrial uses of PCB's include, 
or did include in the past, their use as electrical transformer and 
capacitor fluids, heat transfer fluids, hydraulic fluids, plasticizers, 
and in formulations of lubricants, coatings, and inks. Their unique 
physical and chemical properties and widespread, uncontrolled industrial 
applications have caused PCB's to be a persistent and ubiquitous 
contaminant in the environment, causing the contamination of certain 
foods. In addition, incidents have occurred in which PCB's have directly 
contaminated animal feeds as a result of industrial accidents (leakage 
or spillage of PCB fluids from plant equipment). These accidents in turn 
cause the contamination of food intended for human consumption (meat, 
milk, and eggs). Investigations by the Food and Drug Administration have 
revealed that heat exchange fluids for certain pasteurization equipment 
used in processing animal feed contain PCB's. Although heat exchange 
fluids in such equipment are considered to be in closed systems, leakage 
has occurred that resulted in direct contamination of animal feed with 
PCB's and subsequently resulted in the transfer of PCB's to human food 
produced by animals consuming the contaminated feed. The use of PCB-
containing coatings on the inner walls of silos has resulted in the 
contamination of silage which has in turn caused PCB residues in the 
milk of dairy cows consuming the contaminated silage. Since PCB's are 
toxic chemicals, the PCB contamination of food as a result of these and 
other incidents represent a hazard to public health. It is therefore 
necessary to place certain restrictions on the industrial uses of PCB's 
in the production, handling, and storage of animal feed.
    (b) The following special provisions are necessary to preclude 
accidental PCB contamination of animal feed:
    (1) Coatings or paints for use on the contact surfaces of feed 
storage areas may not contain PCB's or any other harmful or deleterious 
substances likely to contaminate feed.
    (2) New equipment or machinery for handling or processing feed in or 
around an establishment producing animal feed shall not contain PCB's.
    (3) On or before Sept. 4, 1973, the management of establishments 
producing animal feed shall:
    (i) Have the heat exchange fluid used in existing equipment or 
machinery for handling and processing feed sampled and tested to 
determine whether it contains PCB's, or verify the absence of PCB's in 
such formulations by other appropriate means. On or before Sept. 4, 
1973, any such fluid formulated with

[[Page 9]]

PCB's must to the fullest extent possible commensurate with current good 
manufacturing practices, be replaced with a heat exchange fluid that 
does not contain PCB's.
    (ii) Eliminate to the fullest extent possible commensurate with 
current good manufacturing practices from the animal feed producing 
establishment any PCB-containing lubricants for equipment or machinery 
used for handling or processing animal feed.
    (iii) Eliminate to the fullest extent possible commensurate with 
current good manufacturing practices from the animal feed producing 
establishment any other PCB-containing materials, whenever there is a 
reasonable expectation that such materials could cause animal feed to 
become contaminated with PCB's either as a result of normal use or as a 
result of accident, breakage, or other mishap.
    (iv) The toxicity and other characteristics of fluids selected as 
PCB replacements must be adequately determined so that the least 
potentially hazardous replacement should be used. In making this 
determination with respect to a given fluid, consideration should be 
given to (a) its toxicity; (b) the maximum quantity that could be 
spilled onto a given quantity of food before it would be noticed, taking 
into account its color and odor; (c) possible signaling devices in the 
equipment to indicate a loss of fluid, etc.; (d) and its environmental 
stability and tendency to survive and be concentrated through the food 
chain. The judgment as to whether a replacement fluid is sufficiently 
non-hazardous is to be made on an individual installation and operation 
basis.
    (c) For the purpose of this section, the provisions do not apply to 
electrical transformers and condensers containing PCB's in sealed 
containers.
    (d) For the purpose of this section, the term animal feed includes 
all articles used for food or drink for animals other than man.



Sec. 500.46  Hexachlorophene in animal drugs.

    (a) The Commissioner of Food and Drugs has determined that there are 
no adequate data to establish that animal drugs containing 
hexachlorophene are safe and effective for any animal use other than in 
topical products for use on non-food-producing animals as part of a 
product preservative system at a level not to exceed 0.1 percent; that 
there is no information on the potential risk to humans from exposure to 
hexachlorophene by persons who apply animal products containing the drug 
at levels higher than 0.1 percent; and that there is likewise no 
information on human exposure to animals on which these animal drugs 
have been used and no information on possible residues of 
hexachlorophene in edible products of food-producing animals treated 
with new animal drugs that contain any quantity of hexachlorophene.
    (b) Animal drugs containing hexachlorophene for other than 
preservative use on non-food-producing animals at levels not exceeding 
0.1 percent are considered new animal drugs and shall be the subject of 
new animal drug applications (NADA's).
    (c) Any person currently marketing animal drugs that contain 
hexachlorophene other than as part of a product preservative system for 
products used on non-food-producing animals at a level not exceeding 0.1 
percent shall submit a new animal drug application, supplement an 
existing application, or reformulate the product by September 29, 1977. 
Each application or supplemental application shall include adequate data 
to establish that the animal drug is safe and effective. If the animal 
drug is currently subject to an approved new animal drug application, 
each reformulation shall require an approved supplemental application. 
The interim marketing of these animal drugs may continue until the 
application has been approved, until it has been determined that the 
application is not approvable under the provisions of Sec. 514.111 of 
this chapter, or until an existing approved application has been 
withdrawn.
    (d) After September 29, 1977, animal drugs that contain 
hexachlorophene other than for preservative use on non-food-producing 
animals at a level not exceeding 0.1 percent that are introduced into 
interstate commerce shall be deemed to be adulterated within the meaning 
of section 501(a)(5) of the act (21 U.S.C. 351(a)(5)) unless such animal 
drug is the subject of a new animal

[[Page 10]]

drug application submitted pursuant to paragraph (c) of this section. 
Action to withdraw approval of new animal drug applications will be 
initiated if supplemental new animal drug applications have not been 
submitted in accordance with this section.
    (e) New animal drug applications submitted for animal drugs 
containing hexachlorophene for use in or on food-producing animals shall 
include adequate data to assure that edible products from treated 
animals are safe for human consumption under the labeled conditions of 
use.

[42 FR 33725, July 1, 1977; 42 FR 37975, July 26, 1977]



Sec. 500.50  Propylene glycol in or on cat food.

    The Food and Drug Administration has determined that propylene 
glycol in or on cat food is not generally recognized as safe and is a 
food additive subject to section 409 of the Federal Food, Drug, and 
Cosmetic Act (the act). The Food and Drug Administration also has 
determined that this use of propylene glycol is not prior sanctioned.

[61 FR 19544, May 2, 1996]



               Subpart C_Animal Drug Labeling Requirements



Sec. 500.51  Labeling of animal drugs; misbranding.

    (a) Among the representations on the label or labeling of an animal 
drug which will render the drug misbranded are any broad statements 
suggesting or implying that the drug is not safe and effective for use 
when used in accordance with labeling direction, or suggesting or 
implying that the labeling does not contain adequate warnings or 
adequate directions for use. Such statements include, but are not 
limited to:
    (1) Any statement that disclaims liability when the drug is used in 
accordance with directions for use contained on the label or labeling.
    (2) Any statement that disclaims liability when the drug is used 
under ``abnormal'' or ``unforeseeable'' conditions.
    (3) Any statement limiting the warranty for the products to a 
warranty that the drug in the package contains the ingredients listed on 
the label.
    (b) This regulation is not intended to prohibit any liability 
disclaimer that purports to limit the amount of damages or that sets 
forth the legal theory under which damages are to be recovered.
    (c) Any person wishing to obtain an evaluation of an animal drug 
liability disclaimer under this regulation may submit it to Division of 
Compliance, (HFV-230), Center for Veterinary Medicine, Food and Drug 
Administration, 7500 Standish Pl., Rockville, MD 20855. A supplemental 
NADA providing appropriately revised labeling shall be submitted for any 
approved new animal drug the labeling of which is not in compliance with 
this regulation.

[41 FR 8473, Feb. 27, 1976, as amended at 54 FR 18279, Apr. 28, 1989; 57 
FR 6475, Feb. 25, 1992]



Sec. 500.52  Use of terms such as ``tonic'', ``tone'', ``toner'', or 
``conditioner'' in the labeling of preparations intended for use in 

or on animals.

    (a) The use of terms such as tonic, tone, toner, and similar terms 
in the labeling of a product intended for use in or on animals implies 
that such product is capable of a therapeutic effect(s) and causes such 
a product to be a drug within the meaning of section 201(g) of the 
Federal Food, Drug, and Cosmetic Act. The unqualified use of such terms 
in a product's labeling fails to provide adequate directions and 
indications for use of such product and causes it to be misbranded 
within the meaning of section 502(a) and (f)(1) of the act. The terms 
tonic, tone, toner, and similar terms may be used in labeling only when 
appropriately qualified so as to fully inform the user regarding the 
intended use(s) of the product.
    (b) The unqualified use of the term conditioner and similar terms in 
the labeling of a product intended for use in or on animals implies that 
such product is capable of a therapeutic effect(s) and causes such a 
product to be a drug within the meaning of section 201(g) of the act. 
The unqualified use of such terms in a product's labeling fails to 
provide adequate directions and indications for use of such product and 
causes it to be misbranded within the

[[Page 11]]

meaning of section 502(a) and (f)(1) of the act. The term conditioner 
and similar terms may be used in labeling only when appropriately 
qualified so as to fully inform the user regarding the intended use(s) 
of the product. A product labeled as a ``conditioner'' or with a similar 
term can be either a food or drug depending upon the manner in which the 
term is qualified in the labeling to reflect the product's intended use.
    (c) An article so qualified as to be represented as a drug must be 
the subject of an approved new animal drug application unless the use of 
the article under the conditions set forth in its labeling is generally 
recognized as safe and effective among experts qualified by scientific 
training and experience to evaluate the safety and effectiveness of 
animal drugs.



Sec. 500.55  Exemption from certain drug-labeling requirements.

    (a) Section 201.105(c) of this chapter provides that in the case of 
certain drugs for which directions, hazards, warnings, and use 
information are commonly known to practitioners licensed by law, such 
information may be omitted from the dispensing package. Under this 
proviso, the Commissioner of Food and Drugs will offer an opinion, upon 
written request, stating reasonable grounds therefore on a proposal to 
omit such information from the dispensing package.
    (b) The Commissioner of Food and Drugs has considered submitted 
material covering a number of drug products and has offered the opinion 
that the following drugs when intended for those veterinary uses for 
which they are now generally employed by the veterinary medical 
profession, should be exempt from the requirements of Sec. 201.105(c) 
of this chapter, provided that they meet the conditions prescribed in 
this paragraph. Preparations that are not in dosage unit form (for 
example, solutions) will be regarded as meeting the conditions with 
respect to the maximum quantity of drug per dosage unit if they are 
prepared in a manner that enables accurate and ready administration of a 
quantity of drug not in excess of the stated maximum per dosage unit:

Atropine sulfate. As an injectable for cattle, goats, horses, pigs, and 
sheep, not in excess of 15 milligrams per dosage unit; as an injectable 
for cats and dogs, not in excess of 0.6 milligram per dosage unit.
Barbital sodium. For oral use in cats and dogs, not in excess of 300 
milligrams per dosage unit.
Epinephrine injection. 1:1,000. For cats, dogs, cattle, goats, horses, 
pigs, and sheep (except as provided in Sec. 500.65).
Morphine sulfate. As an injectable for dogs, not in excess of 15 
milligrams per dosage unit.
Pentobarbital sodium. For oral use in cats and dogs, not in excess of 
100 milligrams per dosage unit.
Phenobarbital sodium. For oral use in cats and dogs, not in excess of 
100 milligrams per dosage unit.
Procaine hydrochloride injection. Containing not in excess of 2 percent 
procaine hydrochloride, with or without epinephrine up to a 
concentration of 1:50,000. For use in cats, dogs, cattle, goats, horses, 
pigs, and sheep.
Thyroid. For oral use in dogs, not in excess of 60 milligrams per dosage 
unit.



            Subpart D_Requirements for Specific Animal Drugs



Sec. 500.65  Epinephrine injection 1:1,000 in 10-milliliter containers 
for emergency treatment of anaphylactoid shock in cattle, horses, 

sheep, and swine.

    (a) Anaphylactoid reactions in cattle, horses, sheep, and swine 
occur occasionally from the injection of antibiotics, bacterins, and 
vaccines. Adequate directions for use of these antibiotics, bacterins, 
and vaccines can generally be written for use by the laity and thus are 
available to livestock producers. Epinephrine injection is effective for 
the treatment of anaphylactoid reactions in animals and would be of 
value in saving lives of animals if it were readily available at the 
time of administration of the causative agents. In connection with this 
problem the Food and Drug Administration has obtained the views of the 
Advisory Committee on Veterinary Medicine, and other experts, and has 
concluded that adequate directions for over-the-counter sale of 
epinephrine injection 1:1,000 can be prepared.
    (b) In view of the above, the Commissioner of Food and Drugs has 
concluded that it is in the public interest to make epinephrine 
injection 1:1,000 available

[[Page 12]]

for sale without a prescription provided that it is packaged in vials 
not exceeding 10 milliliters and its label bears, in addition to other 
required information, the following statements in a prominent and 
conspicuous manner: ``For emergency use only in treating anaphylactoid 
shock. Usual Dosage: Cattle, horses, sheep, and swine--1 cubic 
centimeter per 100 pounds of body weight. Inject subcutaneously''.
    (c) The labeling must also bear a description of the symptoms of 
anaphylactoid shock including glassy eyes, increased salivation, 
grinding of the teeth, rapid breathing, muscular tremors, staggering 
gait, and collapse with death following. These symptoms may appear 
shortly after injection of a bacterin, vaccine, or antibiotic.



 Subpart E_Regulation of Carcinogenic Compounds Used in Food-Producing 
                                 Animals

    Source: 52 FR 49586, Dec. 31, 1987, unless otherwise noted.



Sec. 500.80  Scope of this subpart.

    (a) The Federal Food, Drug, and Cosmetic Act requires that sponsored 
compounds intended for use in food-producing animals be shown to be safe 
and that food produced from animals exposed to these compounds be shown 
to be safe for consumption by people. The statute prohibits the use in 
food-producing animals of any compound found to induce cancer when 
ingested by people or animals unless it can be determined by methods of 
examination prescribed or approved by the Secretary (a function 
delegated to the Commissioner of Food and Drugs) that no residue of that 
compound will be found in the food produced from those animals under 
conditions of use reasonably certain to be followed in practice. This 
subpart identifies the steps a sponsor of a compound shall follow to 
secure the approval of the compound. FDA guidance documents contain the 
procedures and protocols FDA recommends for the implementation of this 
subpart. These guidance documents are available from the Division of 
Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers 
Lane, rm. 1061, Rockville, MD 20852. Requests for these guidance 
documents should be identified with Docket No. 1983D-0288.
    (b) If FDA concludes on the basis of the threshold assessment that a 
sponsor shall conduct carcinogenicity testing on the sponsored compound, 
FDA will also determine whether and to what extent the sponsor shall 
conduct carcinogenicity testing on metabolites of the sponsored 
compound. The bioassays that a sponsor conducts must be designed to 
assess carcinogenicity and to determine the quantitative aspects of any 
carcinogenic response.
    (c) If FDA concludes on the basis of the threshold assessment or at 
a later time during the approval process that the data show that the 
sponsored compound and its metabolites should not be subject to this 
subpart, FDA will continue to consider the compound for approval under 
the general safety provisions of the act for risks other than cancer.
    (d) This subpart does not apply to essential nutrients.

[52 FR 49586, Dec. 31, 1987, as amended at 59 FR 14365, Mar. 28, 1994; 
62 FR 66983, Dec. 23, 1997; 65 FR 56480, Sept. 19, 2000; 67 FR 78174, 
Dec. 23, 2002; 68 FR 24879, May 9, 2003; 69 FR 17292, Apr. 2, 2004]



Sec. 500.82  Definitions.

    (a) The definitions and interpretations contained in section 201 of 
the act apply to those terms when used in this subpart.
    (b) The following definitions apply to this subpart:
    Act means the Federal Food, Drug, and Cosmetic Act (sections 201-
901, 52 Stat. 1040 et seq. as amended (21 U.S.C. 301-392)).
    Essential nutrients means compounds that are found in the tissues of 
untreated, healthy target animals and not produced in sufficient 
quantity to support the animal's growth, development, function, or 
reproduction, e.g., vitamins, essential minerals, essential amino acids, 
and essential fatty acids. These compounds must be supplied from 
external sources.
    FDA means the Food and Drug Administration.
    Limit of detection (LOD) means the lowest concentration of analyte 
that can be confirmed by the approved regulatory method.

[[Page 13]]

    Marker residue means the residue selected for assay whose 
concentration is in a known relationship to the concentration of the 
residue of carcinogenic concern in the last tissue to deplete to its 
Sm.
    Preslaughter withdrawal period or milk discard time means the time 
after cessation of administration of the sponsored compound at which no 
residue is detectable in the edible product using the approved 
regulatory method (i.e., the marker residue is below the LOD).
    Regulatory method means the aggregate of all experimental procedures 
for measuring and confirming the presence of the marker residue of the 
sponsored compound in the target tissue of the target animal.
    Rm means the concentration of the marker residue in the 
target tissue when the residue of carcinogenic concern is equal to 
Sm.
    Residue means any compound present in edible tissues of the target 
animal which results from the use of the sponsored compound, including 
the sponsored compound, its metabolites, and any other substances formed 
in or on food because of the sponsored compound's use.
    Residue of carcinogenic concern means all compounds in the total 
residue of a demonstrated carcinogen excluding any compounds judged by 
FDA not to present a carcinogenic risk.
    Sm means the concentration of a residue of carcinogenic concern in a 
specific edible tissue corresponding to no significant increase in the 
risk of cancer to the human consumer. For the purpose of Sec. 
500.84(c)(1), FDA will assume that this Sm will correspond to 
the concentration of residue in a specific edible tissue that 
corresponds to a maximum lifetime risk of cancer in the test animals of 
1 in 1 million.
    So means the concentration of a residue of carcinogenic concern in 
the total human diet that represents no significant increase in the risk 
of cancer to the human consumer. For the purpose of Sec. 500.84(c)(1), 
FDA will assume that this So will correspond to the 
concentration of test compound in the total diet of test animals that 
corresponds to a maximum lifetime risk of cancer in the test animals of 
1 in 1 million.
    Sponsor means the person or organization proposing or holding an 
approval by FDA for the use of a sponsored compound.
    Sponsored compound means any drug or food additive or color additive 
proposed for use, or used, in food-producing animals or in their feed.
    Target animals means the production class of animals in which a 
sponsored compound is proposed or intended for use.
    Target tissue means the edible tissue selected to monitor for 
residues in the target animals, including, where appropriate, milk or 
eggs.
    Test animals means the species selected for use in the toxicity 
tests.
    Threshold assessment means FDA's review of data and information 
about a sponsored compound to determine whether chronic bioassays in 
test animals are necessary to resolve questions concerning the 
carcinogenicity of the compound.

[52 FR 49586, Dec. 31, 1987, as amended at 67 FR 78174, Dec. 23, 2002; 
77 FR 50593, Aug. 22, 2012]



Sec. 500.84  Conditions for approval of the sponsored compound.

    (a) On the basis of the results of the chronic bioassays and other 
information, FDA will determine whether any of the substances tested are 
carcinogenic.
    (b) If FDA concludes that the results of the bioassays do not 
establish carcinogenicity, then FDA will not subject the sponsored 
compound to the remainder of the requirements of this subpart.
    (c) For each sponsored compound that FDA decides should be regulated 
as a carcinogen, FDA will either analyze the data from the bioassays 
using a statistical extrapolation procedure as outlined in paragraph 
(c)(1) of this section or evaluate an alternate procedure proposed by 
the sponsor as provided in Sec. 500.90. In either case, paragraphs 
(c)(2) and (3) of this section apply.
    (1) For each substance tested in separate bioassays, FDA will 
calculate the concentration of the residue of carcinogenic concern that 
corresponds to a maximum lifetime risk to the test animal of 1 in 1 
million. FDA will designate the lowest value obtained as So.

[[Page 14]]

Because the total diet is not derived from food-producing animals, FDA 
will make corrections for food intake. FDA will designate as 
Sm the concentration of residue in a specific edible tissue 
corresponding to a maximum lifetime risk of cancer in test animals of 1 
in 1 million.
    (2) From the appropriate residue chemistry data FDA will calculate 
the Rm as described in Sec. 500.86(c). The sponsor must 
provide a regulatory method in accordance with Sec. 500.88(b). FDA will 
calculate the LOD of the method from data submitted by the sponsor under 
Sec. 500.88. The LOD must be less than or equal to Rm.
    (3) FDA will conclude that the provisions of this subpart are 
satisfied when no residue of the compound is detectable (that is, the 
marker residue is below the LOD) using the approved regulatory method 
under the conditions of use of the sponsored compound, including any 
required preslaughter withdrawal period or milk discard time.

[52 FR 49586, Dec. 31, 1987, as amended at 67 FR 78174, Dec. 23, 2002; 
77 FR 50593, Aug. 22, 2012]



Sec. 500.86  Marker residue and target tissue.

    (a) For each edible tissue, the sponsor shall measure the depletion 
of the residue of carcinogenic concern until its concentration is at or 
below Sm.
    (b) In one or more edible tissues, the sponsor shall also measure 
the depletion of one or more potential marker residues until the 
concentration of the residue of carcinogenic concern is at or below 
Sm.
    (c) From these data, FDA will select a target tissue and a marker 
residue and designate the concentration of marker residue 
(Rm) that the regulatory method must be capable of measuring 
in the target tissue. FDA will select Rm such that the 
absence of the marker residue in the target tissue above Rm 
can be taken as confirmation that the residue of carcinogenic concern 
does not exceed Sm in each of the edible tissues and, 
therefore, that the residue of carcinogenic concern in the diet of 
people does not exceed So.
    (d) When a compound is to be used in milk- or egg-producing animals, 
milk or eggs must be the target tissue in addition to the tissue 
selected to monitor for residues in the edible carcass.

(Approved by the Office of Management and Budget under control number 
0910-0228)



Sec. 500.88  Regulatory method.

    (a) The sponsor shall submit for evaluation and validation a 
regulatory method developed to monitor compliance with FDA's operational 
definition of no residue.
    (b) The regulatory method must be able to confirm the identity of 
the marker residue in the target tissue at a minimum concentration 
corresponding to the Rm. FDA will determine the LOD from the 
submitted analytical method validation data.
    (c) FDA will publish in the Federal Register the complete regulatory 
method for ascertaining the marker residue in the target tissue in 
accordance with the provisions of sections 409(c)(3)(A), 512(d)(1)(I), 
and 721(b)(5)(B) of the act.

(Approved by the Office of Management and Budget under control number 
0910-0228)

[52 FR 49586, Dec. 31, 1987, as amended at 67 FR 78174, Dec. 23, 2002]



Sec. 500.90  Waiver of requirements.

    In response to a petition or on the Commissioner's own initiative, 
the Commissioner may waive, in whole or in part, the requirements of 
this subpart except those provided under Sec. 500.88. A petition for 
this waiver may be filed by any person who would be adversely affected 
by the application of the requirements to a particular compound. The 
petition shall explain and document why the requirements from which a 
waiver is requested are not reasonably applicable to the compound, and 
set forth clearly the reasons why the alternative procedures will 
provide the basis for concluding that approval of the compound satisfies 
the requirements of the anticancer provisions of the act. If the 
Commissioner determines that waiver of any of the requirements of this 
subpart is appropriate, the Commissioner will state the basis for that 
determination in the regulation approving marketing of the sponsored 
compound.

(Approved by the Office of Management and Budget under control number 
0910-0228)

[[Page 15]]



Sec. 500.92  Implementation.

    (a) This subpart E applies to all new animal drug applications, food 
additive petitions, and color additive petitions concerning any compound 
intended for use in food-producing animals (including supplemental 
applications and amendments to petitions).
    (b) This subpart E also applies in the following manner to compounds 
already approved:
    (1) For those compounds that FDA determines may induce cancer when 
ingested by man or animals, i.e., suspect carcinogens, Sec. Sec. 
500.80(b), 500.82, and 500.90 apply.
    (2) For those compounds that FDA determines have been shown to 
induce cancer when ingested by man or animals, Sec. Sec. 500.82 through 
500.90 apply.



 Subpart F_Methods for Detection of Residues of Carcinogenic Compounds 
                     Used in Food-Producing Animals

    Source: 76 FR 72618, Nov. 25, 2011, unless otherwise noted.



Sec. 500.1410  N-methyl-2-pyrrolidone.

    (a) Standard for residues. No residues of n-methyl-2-pyrrolidone may 
be found in the uncooked edible tissues of cattle as determined by a 
method entitled ``Method of Analysis: N-methyl-2-pyrrolidone,'' 
September 26, 2011, Center for Veterinary Medicine, Food and Drug 
Administration, which is incorporated by reference with the approval of 
the Director of the Federal Register under 5 U.S.C. 522(a) and 1 CFR 
part 51. You may obtain a copy of the method from the Communications 
Staff (HFV-12), Center for Veterinary Medicine, Food and Drug 
Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9120; or 
go to http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/
CVMFOIAElectronicReadingRoom/default.htm. You may inspect a copy at the 
Division of Dockets Management (HFA-305), Food and Drug Administration, 
5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, (301) 827-6860, 
between 9 a.m. and 4 p.m., Monday through Friday or at the National 
Archives and Records Administration (NARA). For information on the 
availability of this material at NARA, call (202) 741-6030, or go to: 
http://www.archives.gov/federal-register/cfr/ibr-locations.html.
    (b) Related conditions of use. See Sec. Sec. 522.814 and 522.955 of 
this chapter.

[76 FR 72618, Nov. 25, 2011, as amended at 77 FR 9528, Feb. 17, 2012]



PART 501_ANIMAL FOOD LABELING--Table of Contents



                      Subpart A_General Provisions

Sec.
501.1 Principal display panel of package form animal food.
501.2 Information panel of package for animal food.
501.3 Identity labeling of animal food in package form.
501.4 Animal food; designation of ingredients.
501.5 Animal food; name and place of business of manufacturer, packer, 
          or distributor.
501.8 Labeling of animal food with number of servings.
501.15 Animal food; prominence of required statements.
501.17 Animal food labeling warning statements.
501.18 Misbranding of animal food.

          Subpart B_Specific Animal Food Labeling Requirements

501.22 Animal foods; labeling of spices, flavorings, colorings, and 
          chemical preservatives.

Subparts C-E [Reserved]

       Subpart F_Exemptions From Animal Food Labeling Requirements

501.100 Animal food; exemptions from labeling.
501.103 Petitions requesting exemptions from or special requirements for 
          label declaration of ingredients.
501.105 Declaration of net quantity of contents when exempt.
501.110 Animal feed labeling; collective names for feed ingredients.

    Authority: 15 U.S.C. 1453, 1454, 1455; 21 U.S.C. 321, 331, 342, 343, 
348, 371.

    Source: 41 FR 38619, Sept. 10, 1976, unless otherwise noted.

[[Page 16]]



                      Subpart A_General Provisions



Sec. 501.1  Principal display panel of package form animal food.

    The term principal display panel as it applies to food in package 
form and as used in this part, means the part of a label that is most 
likely to be displayed, presented, shown, or examined under customary 
conditions of display for retail sale. The principal display panel shall 
be large enough to accommodate all the mandatory label information 
required to be placed thereon by this part with clarity and 
conspicuousness and without obscuring design, vignettes, or crowding. 
Where packages bear alternate principal display panels, information 
required to be placed on the principal display panel shall be duplicated 
on each principal display panel. For the purpose of obtaining uniform 
type size in declaring the quantity of contents for all packages of 
substantially the same size, the term area of the principal display 
panel means the area of the side or surface that bears the principal 
display panel, which area shall be:
    (a) In the case of a rectangular package where one entire side 
properly can be considered to be the principal display panel side, the 
product of the height times the width of that side;
    (b) In the case of a cylindrical or nearly cylindrical container, 40 
percent of the product of the height of the container times the 
circumference;
    (c) In the case of any otherwise shaped container, 40 percent of the 
total surface of the container: Provided, however, That where such 
container presents an obvious principal display panel such as the top of 
a triangular or circular package, the area shall consist of the entire 
top surface. In determining the area of the principal display panel, 
exclude tops, bottoms, flanges at tops and bottoms of cans, and 
shoulders and necks of bottles or jars. In the case of cylindrical or 
nearly cylindrical containers, information required by this part to 
appear on the principal display panel shall appear within that 40 
percent of the circumference which is most likely to be displayed, 
presented, shown, or examined under customary conditions of display for 
retail sale.



Sec. 501.2  Information panel of package for animal food.

    (a) The term information panel as it applies to packaged food means 
that part of the label immediately contiguous and to the right of the 
principal display panel as observed by an individual facing the 
principal display panel with the following exceptions:
    (1) If the part of the label immediately contiguous and to the right 
of the principal display panel is too small to accommodate the necessary 
information or is otherwise unusable label space, e.g., folded flaps or 
can ends, the panel immediately contiguous and to the right of this part 
of the label may be used.
    (2) If the package has one or more alternate principal display 
panels, the information panel is immediately contiguous and to the right 
of any principal display panel.
    (3) If the top of the container is the principal display panel and 
the package has no alternate principal display panel, the information 
panel is any panel adjacent to the principal display panel.
    (b) All information required to appear on the label of any package 
of food pursuant to Sec. Sec. 501.4, 501.5, 501.8 and 501.17 shall 
appear either on the principal display panel or on the information 
panel, unless otherwise specified by regulations in this chapter.
    (c) All information appearing on the principal display panel or the 
information panel pursuant to this section shall appear prominently and 
conspicuously, but in no case may the letters and/or numbers be less 
than \1/16\ inch in height unless an exemption pursuant to paragraph (f) 
of this section is established. The requirements for conspicuousness and 
legibility shall include the specifications of Sec. Sec. 501.15 and 
501.105(h) (1) and (2).
    (1) Packaged foods are exempt from the type size requirements of 
this paragraph: Provided, That:
    (i) The package is designed such that it has a surface area that can 
bear an information panel and/or an alternate principal display panel.
    (ii) The area of surface available for labeling on the principal 
display panel of the package as this term is defined in Sec. 501.1 is 
less than 10 square inches.

[[Page 17]]

    (iii) The label information includes a full list of ingredients in 
accordance with regulations in this part.
    (iv) The information required by paragraph (b) of this section 
appears on the principal display panel or information panel label in 
accordance with the provisions of this paragraph (c) except that the 
type size is not less than \3/64\ inch in height.
    (2) Packaged foods are exempt from the type size requirements of 
this paragraph: Provided, That:
    (i) The package is designed such that it has a single obvious 
principal display panel as this term is defined in Sec. 501.1 and has 
no other available surface area for an information panel or alternate 
principal display panel.
    (ii) The area of surface available for labeling on the principal 
display panel of the package as this term is defined in Sec. 501.1 is 
less than 12 square inches and bears all labeling appearing on the 
package.
    (iii) The label information includes a full list of ingredients in 
accordance with regulations in this part.
    (iv) The information required by paragraph (b) of this section 
appears on the single, obvious principal display panel in accordance 
with the provisions of this paragraph (c) except that the type size is 
not less than \1/32\ inch in height.
    (3) Packaged foods are exempt from the type size requirements of 
this paragraph: Provided, That:
    (i) The package is designed such that it has a total surface area 
available to bear labeling of less than 12 square inches.
    (ii) The label information includes a full list of ingredients in 
accordance with regulations in this part.
    (iii) The information required by paragraph (b) of this section 
appears on the principal display panel or information panel label in 
accordance with the provisions of this paragraph (c) except that the 
type size is not less than \1/32\ inch in height.
    (d) All information required to appear on the principal display 
panel or on the information panel pursuant to this section shall appear 
on the same panel unless there is insufficient space. In determining the 
sufficiency of the available space, any vignettes, design, and other 
nonmandatory label information shall not be considered. If there is 
insufficient space for all of this information to appear on a single 
panel, it may be divided between these two panels except that the 
information required pursuant to any given section or part shall all 
appear on the same panel. A food whose label is required to bear the 
ingredient statement on the principal display panel may bear all other 
information specified in paragraph (b) of this section on the 
information panel.
    (e) All information appearing on the information panel pursuant to 
this section shall appear in one place without other intervening 
material.
    (f) If the label of any package of food is too small to accommodate 
all of the information required by Sec. Sec. 501.4, 501.5, 501.8, and 
501.17, the Commissioner may establish by regulation an acceptable 
alternative method of disseminating such information to the public, 
e.g., a type size smaller than one-sixteenth inch in height, or labeling 
attached to or inserted in the package or available at the point of 
purchase. A petition requesting such a regulation, as an amendment to 
this paragraph shall be submitted pursuant to part 10 of this chapter.

[41 FR 38619, Sept. 10, 1976, as amended at 42 FR 4716, Jan. 25, 1977; 
42 FR 15675, Mar. 22, 1977]



Sec. 501.3  Identity labeling of animal food in package form.

    (a) The principal display panel of a food in package form shall bear 
as one of its principal features a statement of the identity of the 
commodity.
    (b) Such statement of identity shall be in terms of:
    (1) The name now or hereafter specified in or required by any 
applicable Federal law or regulation; or, in the absence thereof,
    (2) The common or usual name of the food; or, in the absence 
thereof,
    (3) An appropriately descriptive term, or when the nature of the 
food is obvious, a fanciful name commonly used by the public for such 
food.
    (c) Where a food is marketed in various optional forms (whole, 
slices, diced, etc.), the particular form shall be considered to be a 
necessary part of

[[Page 18]]

the statement of identity and shall be declared in letters of a type 
size bearing a reasonable relation to the size of the letters forming 
the other components of the statement of identity; except that if the 
optional form is visible through the container or is depicted by an 
appropriate vignette, the particular form need not be included in the 
statement. This specification does not affect the required declarations 
of identity under definitions and standards for foods promulgated 
pursuant to section 401 of the act.
    (d) This statement of identity shall be presented in bold type on 
the principal display panel, shall be in a size reasonably related to 
the most prominent printed matter on such panel, and shall be in lines 
generally parallel to the base on which the package rests as it is 
designed to be displayed.
    (e) Under the provisions of section 403(c) of the Federal Food, 
Drug, and Cosmetic Act, a food shall be deemed to be misbranded if it is 
an imitation of another food unless its label bears, in type of uniform 
size and prominence, the word imitation and, immediately thereafter, the 
name of the food imitated.
    (1) A food shall be deemed to be an imitation and thus subject to 
the requirements of section 403(c) of the act if it is a substitute for 
and resembles another food but is nutritionally inferior to that food.
    (2) A food that is a substitute for and resembles another food shall 
not be deemed to be an imitation provided it meets each of the following 
requirements:
    (i) It is not nutritionally inferior to the food for which it 
substitutes and which it resembles.
    (ii) Its label bears a common or usual name that complies with the 
provisions of Sec. 502.5 of this chapter and that is not false or 
misleading, or in the absence of an existing common or usual name, an 
appropriately descriptive term that is not false or misleading. The 
label may, in addition, bear a fanciful name which is not false or 
misleading.
    (3) A food for which a common or usual name is established by 
regulation (e.g., in a standard of identity pursuant to section 401 of 
the act, in a common or usual name regulation and may, in addition, bear 
a fanciful name which is not false or misleading, and established 
pursuant to part 502 of this chapter), and which complies with all of 
the applicable requirements of such regulation(s), shall not be deemed 
to be an imitation.
    (4) Nutritional inferiority includes:
    (i) Any reduction in the content of an essential nutrient that is 
present in a measurable amount.
    (ii) If the Commissioner concludes that a food is a substitute for 
and resembles another food but is inferior to the food imitated for 
reasons other than those set forth in this paragraph, he may propose 
appropriate revisions to this regulation or he may propose a separate 
regulation governing the particular food.
    (f) A label may be required to bear the percentage(s) of a 
characterizing ingredient(s) or information concerning the presence or 
absence of an ingredient(s) or the need to add an ingredient(s) as part 
of the common or usual name of the food pursuant to part 502 of this 
chapter.

[41 FR 38619, Sept. 10, 1976, as amended at 42 FR 14091, Mar. 15, 1977; 
54 FR 18279, Apr. 28, 1989]



Sec. 501.4  Animal food; designation of ingredients.

    (a) Ingredients required to be declared on the label of a food, 
including foods that comply with standards of identity that require 
labeling in compliance with this part 501, except those exempted by 
Sec. 501.100, shall be listed by common or usual name in descending 
order of predominance by weight on either the principal display panel or 
the information panel in accordance with the provisions of Sec. 501.2.
    (b) The name of an ingredient shall be a specific name and not a 
collective (generic) name, except that:
    (1) Spices, flavorings, colorings and chemical preservatives shall 
be declared according to the provisions of Sec. 501.22.
    (2) An ingredient which itself contains two or more ingredients and 
which has an established common or usual name, conforms to a standard 
established pursuant to the Meat Inspection or Poultry Products 
Inspection

[[Page 19]]

Acts by the U.S. Department of Agriculture, or conforms to a definition 
and standard of identity established pursuant to section 401 of the 
Federal Food, Drug, and Cosmetic Act, shall be designated in the 
statement of ingredients on the label of such food by either of the 
following alternatives:
    (i) By declaring the established common or usual name of the 
ingredient followed by a parenthetical listing of all ingredients 
contained therein in descending order of predominance except that, if 
the ingredient is a food subject to a definition and standard of 
identity established in this subchapter E, only the ingredients required 
to be declared by the definition and standard of identity need be 
listed; or
    (ii) By incorporating into the statement of ingredients in 
descending order of predominance in the finished food, the common or 
usual name of every component of the ingredient without listing the 
ingredient itself.
    (3) Skim milk, concentrated skim milk, reconstituted skim milk, and 
nonfat dry milk may be declared as skim milk or nonfat milk.
    (4) Milk, concentrated milk, reconstituted milk, and dry whole milk 
may be declared as milk.
    (5) Bacterial cultures may be declared by the word cultured followed 
by the name of the substrate, e.g., made from cultured skim milk or 
cultured buttermilk.
    (6) Sweetcream buttermilk, concentrated sweetcream buttermilk, 
reconstituted sweetcream buttermilk, and dried sweetcream buttermilk may 
be declared as buttermilk.
    (7) Whey, concentrated whey, reconstituted whey, and dried whey may 
be declared as whey.
    (8) Cream, reconstituted cream, dried cream, and plastic cream 
(sometimes known as concentrated milkfat) may be declared as cream.
    (9) Butteroil and anhydrous butterfat may be declared as butterfat.
    (10) Dried whole eggs, frozen whole eggs, and liquid whole eggs may 
be declared as eggs.
    (11) Dried egg whites, frozen egg whites, and liquid egg whites may 
be declared as egg whites.
    (12) Dried egg yolks, frozen egg yolks, and liquid egg yolks may be 
declared as egg yolks.
    (13) A livestock or poultry feed may be declared by a collective 
name listed in Sec. 501.110 if it is an animal feed within the meaning 
of section 201(w) of the act and meets the requirements for the use of a 
collective name as prescribed in Sec. 501.110 for certain feed 
ingredients.
    (14) [Reserved]
    (15) When all the ingredients of a wheat flour are declared in an 
ingredient statement, the principal ingredient of the flour shall be 
declared by the name(s) specified in Sec. Sec. 137.105, 137.200, 
137.220, 137.225 of this chapter, i.e., the first ingredient designated 
in the ingredient list of flour, or bromated flour, or enriched flour, 
or self-rising flour is flour, white flour, wheat flour, or plain flour; 
the first ingredient designated in the ingredient list of durum flour is 
durum flour; the first ingredient designated in the ingredient list of 
whole wheat flour, or bromated whole wheat flour is whole wheat flour, 
graham flour, or entire wheat flour; and the first ingredient designated 
in the ingredient list of whole durum wheat flour is whole durum wheat 
flour.
    (c) When water is added to reconstitute, completely or partially, an 
ingredient permitted by paragraph (b) of this section to be declared by 
a class name, the position of the ingredient class name in the 
ingredient statement shall be determined by the weight of the 
unreconstituted ingredient plus the weight of the quantity of water 
added to reconstitute that ingredient, up to the amount of water needed 
to reconstitute the ingredient to single strength. Any water added in 
excess of the amount of water needed to reconstitute the ingredient to 
single strength shall be declared as water in the ingredient statement.

[41 FR 38619, Sept. 10, 1976, as amended at 42 FR 14091, Mar. 15, 1977; 
60 FR 38480, July 27, 1995]



Sec. 501.5  Animal food; name and place of business of manufacturer, 
packer, or distributor.

    (a) The label of a food in packaged form shall specify conspicuously 
the

[[Page 20]]

name and place of business of the manufacturer, packer, or distributor.
    (b) The requirement for declaration of the name of the manufacturer, 
packer, or distributor shall be deemed to be satisfied, in the case of a 
corporation, only by the actual corporate name, which may be preceded or 
followed by the name of the particular division of the corporation. In 
the case of an individual, partnership, or association, the name under 
which the business is conducted shall be used.
    (c) Where the food is not manufactured by the person whose name 
appears on the label, the name shall be qualified by a phrase that 
reveals the connection such person has with such food; such as 
``Manufactured for ------------,'' ``Distributed by ------------,'' or 
any other wording that expresses the facts.
    (d) The statement of the place of business shall include the street 
address, city, state, and ZIP Code; however, the street address may be 
omitted if it is shown in a current city directory or telephone 
directory. The requirement for inclusion of the ZIP Code shall apply 
only to consumer commodity labels developed or revised after the 
effective date of this section. In the case of nonconsumer packages, the 
ZIP Code shall appear either on the label or the labeling (including 
invoice).
    (e) If a person manufactures, packs, or distributes a food at a 
place other than his principal place of business, the label may state 
the principal place of business in lieu of the actual place where such 
food was manufactured or packed or is to be distributed, unless such 
statement would be misleading.



Sec. 501.8  Labeling of animal food with number of servings.

    (a) The label of any package of a food which bears a representation 
as to the number of servings contained in such package shall bear in 
immediate conjunction with such statement, and in the same size type as 
is used for such statement, a statement of the net quantity (in terms of 
weight, measure, or numerical count) of each such serving; however, such 
statement may be expressed in terms that differ from the terms used in 
the required statement of net quantity of contents (for example, 
cupfuls, tablespoonfuls, etc.) when such differing term is common to 
cookery and describes a constant quantity. Such statement may not be 
misleading in any particular. A statement of the number of units in a 
package is not in itself a statement of the number of servings.
    (b) If there exists a voluntary product standard promulgated 
pursuant to the procedures found in 15 CFR part 10 by the Department of 
Commerce, quantitatively defining the meaning of the term serving with 
respect to a particular food, then any label representation as to the 
number of servings in such packaged food shall correspond with such 
quantitative definition. (Copies of published standards are available 
upon request from the National Bureau of Standards, Department of 
Commerce, Washington, DC 20234.)



Sec. 501.15  Animal food; prominence of required statements.

    (a) A word, statement, or other information required by or under 
authority of the act to appear on the label may lack that prominence and 
conspicuousness required by section 403(f) of the act by reason (among 
other reasons) of:
    (1) The failure of such word, statement, or information to appear on 
the part or panel of the label which is presented or displayed under 
customary conditions of purchase;
    (2) The failure of such word, statement, or information to appear on 
two or more parts or panels of the label, each of which has sufficient 
space therefor, and each of which is so designed as to render it likely 
to be, under customary conditions of purchase, the part or panel 
displayed;
    (3) The failure of the label to extend over the area of the 
container or package available for such extension, so as to provide 
sufficient label space for the prominent placing of such word, 
statement, or information;
    (4) Insufficiency of label space (for the prominent placing of such 
word, statement, or information) resulting from the use of label space 
for any word, statement, design, or device

[[Page 21]]

which is not required by or under authority of the act to appear on the 
label;
    (5) Insufficiency of label space (for the prominent placing of such 
word, statement, or information) resulting from the use of label space 
to give materially greater conspicuousness to any other word, statement, 
or information, or to any design or device; or
    (6) Smallness or style of type in which such word, statement, or 
information appears, insufficient background contrast, obscuring designs 
or vignettes, or crowding with other written, printed, or graphic 
matter.
    (b) No exemption depending on insufficiency of label space, as 
prescribed in regulations promulgated under section 403(e) or (i) of the 
act, shall apply if such insufficiency is caused by:
    (1) The use of label space for any word, statement, design, or 
device which is not required by or under authority of the act to appear 
on the label;
    (2) The use of label space to give greater conspicuousness to any 
word, statement, or other information that is required by section 403(f) 
of the act; or
    (3) The use of label space for any representation in a foreign 
language.
    (c)(1) All words, statements, and other information required by or 
under authority of the act to appear on the label or labeling shall 
appear thereon in the English language: Provided, however, That in the 
case of articles distributed solely in the Commonwealth of Puerto Rico 
or in a territory where the predominant language is one other than 
English, the predominant language may be substituted for English.
    (2) If the label contains any representation in a foreign language, 
all words, statements, and other information required by or under 
authority of the act to appear on the label shall appear thereon in the 
foreign language.
    (3) If any article of labeling (other than a label) contains any 
representation in a foreign language, all words, statements, and other 
information required by or under authority of the act to appear on the 
label or labeling shall appear on such article of labeling.



Sec. 501.17  Animal food labeling warning statements.

    (a) Self-pressurized containers. (1) The label of a food packaged in 
a self-pressurized container and intended to be expelled from the 
package under pressure shall bear the following warning:
    Warning Avoid spraying in eyes. Contents under pressure. Do not 
puncture or incinerate. Do not store at temperature above 120 [deg]F. 
Keep out of reach of children.
    (2) In the case of products intended for use by children, the phrase 
``except under adult supervision'' may be added at the end of the last 
sentence in the warning required by paragraph (a)(1) of this section.
    (3) In the case of products packaged in glass containers, the word 
``break'' may be substituted for the word ``puncture'' in the warning 
required by paragraph (a)(1) of this section.
    (4) The words ``Avoid spraying in eyes'' may be deleted from the 
warning required by paragraph (a)(1) of this section in the case of a 
product not expelled as a spray.
    (b) Self-pressurized containers with halocarbon or hydrocarbon 
propellants. (1) In addition to the warning required by paragraph (a) of 
this section, the label of a food packaged in a self-pressurized 
container in which the propellant consists in whole or in part of a 
halocarbon or a hydrocarbon shall bear the following warning:
    Warning Use only as directed. Intentional misuse by deliberately 
concentrating and inhaling the contents can be harmful or fatal.
    (2) The warning required by paragraph (b)(1) of this section is not 
required for the following products:
    (i) Products expelled in the form of a foam or cream, which contain 
less than 10 percent propellant in the container.
    (ii) Products in a container with a physical barrier that prevents 
escape of the propellant at the time of use.
    (iii) Products of a net quantity of contents of less than 2 ozs that 
are designed to release a measured amount of product with each valve 
actuation.
    (iv) Products of a net quantity of contents of less than \1/2\ oz.
    (c) Animal food containing or manufactured with a chlorofluorocarbon 
or other

[[Page 22]]

ozone-depleting substance. Labeling requirements for animal foods that 
contain or are manufactured with a chlorofluorocarbon or other ozone-
depleting substance designated by the Environmental Protection Agency 
(EPA) are set forth in 40 CFR part 82.

[41 FR 38619, Sept. 10, 1976, as amended at 42 FR 22033, Apr. 29, 1977; 
61 FR 20101, May 3, 1996]



Sec. 501.18  Misbranding of animal food.

    (a) Among representations in the labeling of a food which render 
such food misbranded is a false or misleading representation with 
respect to another food or a drug, device, or cosmetic.
    (b) The labeling of a food which contains two or more ingredients 
may be misleading by reason (among other reasons) of the designation of 
such food in such labeling by a name which includes or suggests the name 
of one or more but not all such ingredients, even though the names of 
all such ingredients are stated elsewhere in the labeling.
    (c) Among representations in the labeling of a food which render 
such food misbranded is any representation that expresses or implies a 
geographical origin of the food or any ingredient of the food except 
when such representation is either:
    (1) A truthful representation of geographical origin.
    (2) A trademark or trade name provided that as applied to the 
article in question its use is not deceptively misdescriptive. A 
trademark or trade name comprised in whole or in part of geographical 
words shall not be considered deceptively misdescriptive if it:
    (i) Has been so long and exclusively used by a manufacturer or 
distributor that it is generally understood by the consumer to mean the 
product of a particular manufacturer or distributor; or
    (ii) Is so arbitrary or fanciful that it is not generally understood 
by the consumer to suggest geographic origin.
    (3) A part of the name required by applicable Federal law or 
regulation.
    (4) A name whose market significance is generally understood by the 
consumer to connote a particular class, kind, type, or style of food 
rather than to indicate geographical origin.



          Subpart B_Specific Animal Food Labeling Requirements



Sec. 501.22  Animal foods; labeling of spices, flavorings, colorings, 
and chemical preservatives.

    (a)(1) The term artificial flavor or artificial flavoring means any 
substance, the function of which is to impart flavor, which is not 
derived from a spice, fruit or fruit juice, vegetable or vegetable 
juice, edible yeast, herb, bark, bud, root, leaf or similar plant 
material, meat, fish, poultry, eggs, dairy products, or fermentation 
products thereof. Artificial flavor includes the substances listed in 
Sec. Sec. 172.515(b) and 582.60 of this chapter except where these are 
derived from natural sources.
    (2) The term spice means any aromatic vegetable substance in the 
whole, broken, or ground form, except for those substances which have 
been traditionally regarded as foods, such as onions, garlic and celery; 
whose significant function in food is seasoning rather than nutritional; 
that is true to name; and from which no portion of any volatile oil or 
other flavoring principle has been removed. Spices include the spices 
listed in subpart A of part 582 of this chapter, such as the following:

Allspice, Anise, Basil, Bay leaves, Caraway seed, Cardamon, Celery seed, 
Chervil, Cinnamon, Cloves, Coriander, Cumin seed, Dill seed, Fennel 
seed, Fenugreek, Ginger, Horseradish, Mace, Marjoram, Mustard flour, 
Nutmeg, Oregano, Paprika, Parsley, Pepper, black; Pepper, white; Pepper, 
red; Rosemary, Saffron, Sage, Savory, Star aniseed, Tarragon, Thyme, 
Turmeric.


Paprika, turmeric, and saffron or other spices which are also colors, 
shall be declared as spice and coloring unless declared by their common 
or usual name.
    (3) The term natural flavor or natural flavoring means the essential 
oil, oleoresin, essence or extractive, protein hydrolysate, distillate, 
or any product of roasting, heating or enzymolysis, which contains the 
flavoring constituents derived from a spice, fruit or fruit juice, 
vegetable or vegetable juice, edible yeast, herb, bark, bud, root, leaf 
or similar plant material, meat, seafood, poultry, eggs, dairy products, 
or fermentation products thereof, whose significant function in food is 
flavoring

[[Page 23]]

rather than nutritional. Natural flavors, include the natural essence or 
extractives obtained from plants listed in subpart A of part 582 of this 
chapter, and the substances listed in Sec. 172.510 of this chapter.
    (4) The term artificial color or artificial coloring means any color 
additive as defined in Sec. 70.3(f) of this chapter.
    (5) The term chemical preservative means any chemical that, when 
added to food, tends to prevent or retard deterioration thereof, but 
does not include common salt, sugars, vinegars, spices, or oils 
extracted from spices, substances added to food by direct exposure 
thereof to wood smoke, or chemicals applied for their insecticidal or 
herbicidal properties.
    (b) A food which is subject to the requirements of section 403(k) of 
the act shall bear labeling, even though such food is not in package 
form.
    (c) A statement of artificial flavoring, artificial coloring, or 
chemical preservative shall be placed on the food, or on its container 
or wrapper, or on any two or all of these, as may be necessary to render 
such statement likely to be read by the ordinary individual under 
customary conditions of purchase and use of such food.
    (d) A food shall be exempt from compliance with the requirements of 
section 403(k) of the act if it is not in package form and the units 
thereof are so small that a statement of artificial flavoring, 
artificial coloring, or chemical preservative, as the case may be, 
cannot be placed on such units with such conspicuousness as to render it 
likely to be read by the ordinary individual under customary conditions 
of purchase and use.
    (e) A food shall be exempt while held for sale from the requirements 
of section 403(k) of the act (requiring label statement of any 
artificial flavoring, artificial coloring, or chemical preservatives) if 
said food, having been received in bulk containers at a retail 
establishment, is displayed to the purchaser with either (1) the 
labeling of the bulk container plainly in view or (2) a counter card, 
sign, or other appropriate device bearing prominently and conspicuously 
the information required to be stated on the label pursuant to section 
403(k) of the act.
    (f) A fruit or vegetable shall be exempt from compliance with the 
requirements of section 403(k) of the act with respect to a chemical 
preservative applied to the fruit or vegetable as a pesticide chemical 
prior to harvest.
    (g) A flavor shall be labeled in the following way when shipped to a 
food manufacturer or processor (but not a consumer) for use in the 
manufacture of a fabricated food, unless it is a flavor for which a 
standard of identity has been promulgated, in which case it shall be 
labeled as provided in the standard:
    (1) If the flavor consists of one ingredient, it shall be declared 
by its common or usual name.
    (2) If the flavor consists of two or more ingredients, the label 
either may declare each ingredient by its common or usual name or may 
state ``All flavor ingredients contained in this product are approved 
for use in a regulation of the Food and Drug Administration.'' Any 
flavor ingredient not contained in one of these regulations, and any 
nonflavor ingredient, shall be separately listed on the label.
    (3) In cases where the flavor contains a solely natural flavor(s), 
the flavor shall be so labeled, e.g., strawberry flavor, banana flavor, 
or natural strawberry flavor. In cases where the flavor contains both a 
natural flavor and an artificial flavor, the flavor shall be so labeled, 
e.g., natural and artificial strawberry flavor. In cases where the 
flavor contains a solely artificial flavor(s), the flavor shall be so 
labeled, e.g., artificial strawberry flavor.
    (h) The label of a food to which flavor is added shall declare the 
flavor in the statement of ingredients in the following way:
    (1) Spice, natural flavor, and artificial flavor may be declared as 
spice, natural flavor, or artificial flavor, or any combination thereof, 
as the case may be.
    (2) An incidental additive in a food, originating in a spice or 
flavor used in the manufacture of the food, need not be declared in the 
statement of ingredients if it meets the requirements of Sec. 
501.100(a)(3).
    (3) Substances obtained by cutting, grinding, drying, pulping, or 
similar processing of tissues derived from fruit,

[[Page 24]]

vegetable, meat, fish, or poultry, e.g., powdered or granulated onions, 
garlic powder, and celery powder, are commonly understood by consumers 
to be food rather than flavor and shall be declared by their common or 
usual name.
    (4) Any salt (sodium chloride) used as an ingredient in food shall 
be declared by its common or usual name salt.
    (5) Any monosodium glutamate used as an ingredient in food shall be 
declared by its common or usual name monosodium glutamate.
    (6) Any pyroligneous acid or other artificial smoke flavors used as 
an ingredient in a food may be declared as artificial flavor or 
artificial smoke flavor. No representation may be made, either directly 
or implied, that a food flavored with pyroligneous acid or other 
artificial smoke flavor has been smoked or has a true smoked flavor, or 
that a seasoning sauce or similar product containing pyroligneous acid 
or other artificial smoke flavor and used to season or flavor other 
foods will result in a smoked product or one having a true smoked 
flavor.
    (i) If the label, labeling, or advertising of a food makes any 
direct or indirect representations with respect to the primary 
recognizable flavor(s), by word, vignette, e.g., depiction of a fruit, 
or other means, or if for any other reason the manufacturer or 
distributor of a food wishes to designate the type of flavor in the food 
other than through the statement of ingredients, such flavor shall be 
considered the characterizing flavor and shall be declared in the 
following way:
    (1) If the food contains no artificial flavor which simulates, 
resembles or reinforces the characterizing flavor, the name of the food 
on the principal display panel or panels of the label shall be 
accompanied by the common or usual name of the characterizing flavor in 
letters not less than one-half the height of the letters used in the 
name of the food, except that:
    (i) If the food is one that is commonly expected to contain a 
characterizing food ingredient, and the food contains natural flavor 
derived from such ingredient and an amount of characterizing ingredient 
insufficient to independently characterize the food, or the food 
contains no such ingredient, the name of the characterizing flavor may 
be immediately preceded by the word natural and shall be immediately 
followed by the word flavored in letters not less than one-half the 
height of the letters in the name of the characterizing flavor.
    (ii) If none of the natural flavor used in the food is derived from 
the product whose flavor is simulated, the food in which the flavor is 
used shall be labeled either with the flavor of the product from which 
the flavor is derived or as artificially flavored.
    (iii) If the food contains both a characterizing flavor from the 
product whose flavor is simulated and other natural flavor which 
simulates, resembles or reinforces the characterizing flavor, the food 
shall be labeled in accordance with the introductory text and paragraph 
(i)(1)(i) of this section and the name of the food shall be immediately 
followed by the words with other natural flavor in letters not less than 
one-half the height of the letters used in the name of the 
characterizing flavor.
    (2) If the food contains any artificial flavor which simulates, 
resembles or reinforces the characterizing flavor, the name of the food 
on the principal display panel or panels of the label shall be 
accompanied by the common or usual name(s) of the characterizing flavor, 
in letters not less than one-half the height of the letters used in the 
name of the food and the name of the characterizing flavor shall be 
accompanied by the word(s) artificial or artificially flavored, in 
letters not less than one-half the height of the letters in the name of 
the characterizing flavor.
    (3) Wherever the name of the characterizing flavor appears on the 
label (other than in the statement of ingredients) so conspicuously as 
to be easily seen under customary conditions of purchase, the words 
prescribed by this paragraph shall immediately and conspicuously precede 
or follow such name, without any intervening written, printed, or 
graphic matter, except:
    (i) Where the characterizing flavor and a trademark or brand are 
presented together, other written, printed, or graphic matter that is a 
part of or is associated with the trademark or brand may intervene if 
the required

[[Page 25]]

words are in such relationship with the trademark or brand as to be 
clearly related to the characterizing flavor; and
    (ii) If the finished product contains more than one flavor subject 
to the requirements of this paragraph, the statements required by this 
paragraph need appear only once in each statement of characterizing 
flavors present in such food.
    (iii) If the finished product contains three or more distinguishable 
characterizing flavors, or a blend of flavors with no primary 
recognizable flavor, the flavor may be declared by an appropriately 
descriptive generic term in lieu of naming each flavor.
    (4) A flavor supplier shall certify, in writing, that any flavor he 
supplies which is designated as containing no artificial flavor does 
not, to the best of his knowledge and belief, contain any artificial 
flavor, and that he has added no artificial flavor to it. The 
requirement for such certification may be satisfied by a guarantee under 
section 303(c)(2) of the act which contains such a specific statement. A 
flavor used shall be required to make such a written certification only 
where he adds to or combines another flavor with a flavor which has been 
certified by a flavor supplier as containing no artificial flavor, but 
otherwise such user may rely upon the supplier's certification and need 
make no separate certification. All such certifications shall be 
retained by the certifying party throughout the period in which the 
flavor is supplied and for a minimum of 3 years thereafter, and shall be 
subject to the following conditions:
    (i) The certifying party shall make such certifications available 
upon request at all reasonable hours to any duly authorized officer, or 
employee of the Food and Drug Administration or any other employee 
acting on behalf of the Secretary of Health and Human Services. Such 
certifications are regarded by the Food and Drug Administration as 
reports to the government and as guarantees or other undertakings within 
the meaning of section 301(h) of the act and subject the certifying 
party to the penalties for making any false report to the government 
under 18 U.S.C. 1001 and any false guarantee or undertaking under 
section 303(a) of the act. The defenses provided under section 303(c)(2) 
of the act shall be applicable to the certifications provided for in 
this section.
    (ii) Wherever possible, the Food and Drug Administration shall 
verify the accuracy of a reasonable number of certifications made 
pursuant to this section, constituting a representative sample of such 
certifications, and shall not request all such certifications.
    (iii) Where no person authorized to provide such information is 
reasonably available at the time of inspection, the certifying party 
shall arrange to have such person and the relevant materials and records 
ready for verification as soon as practicable; provided that, whenever 
the Food and Drug Administration has reason to believe that the supplier 
or user may utilize this period to alter inventories or records, such 
additional time shall not be permitted. Where such additional time is 
provided, the Food and Drug Administration may require the certifying 
party to certify that relevant inventories have not been materially 
disturbed and relevant records have not been altered or concealed during 
such period.
    (iv) The certifying party shall provide, to an officer or 
representative duly designated by the Secretary, such qualitative 
statement of the composition of the flavor or product covered by the 
certification as may be reasonably expected to enable the Secretary's 
representatives to determine which relevant raw and finished materials 
and flavor ingredient records are reasonably necessary to verify the 
certifications. The examination conducted by the Secretary's 
representative shall be limited to inspection and review of inventories 
and ingredient records for those certifications which are to be 
verified.
    (v) Review of flavor ingredient records shall be limited to the 
qualitative formula and shall not include the quantitative formula. The 
person verifying the certifications may make only such notes as are 
necessary to enable him to verify such certification. Only such notes or 
such flavor ingredient records as are necessary to verify

[[Page 26]]

such certification or to show a potential or actual violation may be 
removed or transmitted from the certifying party's place of business: 
Provided, That, where such removal or transmittal is necessary for such 
purposes the relevant records and notes shall be retained as separate 
documents in Food and Drug Administration files, shall not be copied in 
other reports, and shall not be disclosed publicly other than in a 
judicial proceeding brought pursuant to the act or 18 U.S.C. 1001.
    (j) A food to which a chemical preservative(s) is added shall, 
except when exempt pursuant to Sec. 501.100, bear a label declaration 
stating both the common or usual name of the ingredient(s) and a 
separate description of its function, e.g., preservative, to retard 
spoilage, a mold inhibitor, to help protect flavor or to promote color 
retention.

[41 FR 38619, Sept. 10, 1976, as amended at 42 FR 14091, Mar. 15, 1977; 
42 FR 15675, Mar. 22, 1977]

    Effective Date Note: At 76 FR 71254, Nov. 17, 2011, Sec. 501.22 was 
amended by adding paragraph (k), effective Nov. 18, 2013. For the 
convenience of the user, the added text is set forth as follows:



Sec. 501.22  Animal foods; labeling of spices, flavorings, colorings, 
          and chemical preservatives.

                                * * * * *

    (k) The label of an animal food to which any coloring has been added 
shall declare the coloring in the statement of ingredients in the manner 
specified in paragraphs (k)(1) and (k)(2) of this section.
    (1) A color additive or the lake of a color additive subject to 
certification under section 721(c) of the act shall be declared by the 
name of the color additive listed in the applicable regulation in part 
74 or part 82 of this chapter, except that it is not necessary to 
include the ``FD&C'' prefix or the term ``No.'' in the declaration, but 
the term ``Lake'' shall be included in the declaration of the lake of 
the certified color additive (e.g., Blue 1 Lake). Manufacturers may 
parenthetically declare an appropriate alternative name of the certified 
color additive following its common or usual name as specified in part 
74 or part 82 of this chapter.
    (2) Color additives not subject to certification may be declared as 
``Artificial Color,'' ``Artificial Color Added,'' or ``Color Added'' (or 
by an equally informative term that makes clear that a color additive 
has been used in the food). Alternatively, such color additives may be 
declared as ``Colored with --------'' or ``-------- color,'' the blank 
to be filled with the name of the color additive listed in the 
applicable regulation in part 73 of this chapter.

Subparts C-E [Reserved]



       Subpart F_Exemptions From Animal Food Labeling Requirements



Sec. 501.100  Animal food; exemptions from labeling.

    (a) The following foods are exempt from compliance with the 
requirements of section 403(i)(2) of the act (requiring a declaration on 
the label of the common or usual name of each ingredient when the food 
is fabricated from two or more ingredients).
    (1) An assortment of different items of food, when variations in the 
items that make up different packages packed from such assortment 
normally occur in good packing practice and when such variations result 
in variations in the ingredients in different packages, with respect to 
any ingredient that is not common to all packages. Such exemption, 
however, shall be on the condition that the label shall bear, in 
conjunction with the names of such ingredients as are common to all 
packages, a statement (in terms that are as informative as practicable 
and that are not misleading) indicating by name other ingredients which 
may be present.
    (2) A food having been received in bulk containers at a retail 
establishment, if displayed to the purchaser with either (i) the 
labeling of the bulk container plainly in view or (ii) a counter card, 
sign, or other appropriate device bearing prominently and conspicuously 
the information required to be stated on the label pursuant to section 
403(i)(2) of the act.
    (3) Incidental additives that are present in a food at insignificant 
levels and do not have any technical or functional effect in that food. 
For the purposes of this paragraph (a)(3), incidental additives are:
    (i) Substances that have no technical or functional effect but are 
present in a

[[Page 27]]

food by reason of having been incorporated into the food as an 
ingredient of another food, in which the substance did have a functional 
or technical effect.
    (ii) Processing aids, which are as follows:
    (a) Substances that are added to a food during the processing of 
such food but are removed in some manner from the food before it is 
packaged in its finished form.
    (b) Substances that are added to a food during processing, are 
converted into constituents normally present in the food, and do not 
significantly increase the amount of the constituents naturally found in 
the food.
    (c) Substances that are added to a food for their technical or 
functional effect in the processing but are present in the finished food 
at insignificant levels and do not have any technical or functional 
effect in that food.
    (iii) Substances migrating to food from equipment or packaging or 
otherwise affecting food that are not food additives as defined in 
section 201(s) of the act; or if they are food additives as so defined, 
they are used in conformity with regulations established pursuant to 
section 409 of the act.
    (b) A food repackaged in a retail establishment is exempt from the 
following provisions of the act if the conditions specified are met.
    (1) Section 403(e)(1) of the act (requiring a statement on the label 
of the name and place of business of the manufacturer, packer, or 
distributor).
    (2) Section 403(g)(2) of the act (requiring the label of a food 
which purports to be or is represented as one for which a definition and 
standard of identity has been prescribed to bear the name of the food 
specified in the definition and standard and, insofar as may be required 
by the regulation establishing the standard the common names of the 
optional ingredients present in the food), if the food is displayed to 
the purchaser with its interstate labeling clearly in view, or with a 
counter card, sign, or other appropriate device bearing prominently and 
conspicuously the information required by these provisions.
    (3) Section 403(i)(1) of the act (requiring the label to bear the 
common or usual name of the food), if the food is displayed to the 
purchaser with its interstate labeling clearly in view, or with a 
counter card, sign, or other appropriate device bearing prominently and 
conspicuously the common or usual name of the food, or if the common or 
usual name of the food is clearly revealed by its appearance.
    (c) [Reserved]
    (d) Except as provided by paragraphs (e) and (f) of this section, a 
shipment or other delivery of a food which is, in accordance with the 
practice of the trade, to be processed, labeled, or repacked in 
substantial quantity at an establishment other than that where 
originally processed or packed, shall be exempt, during the time of 
introduction into and movement in interstate commerce and the time of 
holding in such establishment, from compliance with the labeling 
requirements of section 403 (c), (e), (g), (h), (i), (j) and (k) of the 
act if:
    (1) The person who introduced such shipment or delivery into 
interstate commerce is the operator of the establishment where such food 
is to be processed, labeled, or repacked; or
    (2) In case such person is not such operator, such shipment or 
delivery is made to such establishment under a written agreement, signed 
by and containing the post office addresses of such person and such 
operator, and containing such specifications for the processing, 
labeling, or repacking, as the case may be, of such food in such 
establishment as will ensure, if such specifications are followed, that 
such food will not be adulterated or misbranded within the meaning of 
the act upon completion of such processing, labeling, or repacking. Such 
person and such operator shall each keep a copy of such agreement until 
2 years after the final shipment or delivery of such food from such 
establishment, and shall make such copies available for inspection at 
any reasonable hour to any officer or employee of the Department who 
requests them.
    (e) Conditions affecting expiration of exemptions.
    (1) An exemption of a shipment or other delivery of a food under 
paragraph (d)(1) of this section shall, at the beginning of the act of 
removing such shipment or delivery, or any part

[[Page 28]]

thereof, from such establishment become void ab initio if the food 
comprising such shipment, delivery, or part is adulterated or misbranded 
within the meaning of the act when so removed.
    (2) An exemption of a shipment or other delivery of a food under 
paragraph (d)(2) of this section shall become void ab initio with 
respect to the person who introduced such shipment or delivery into 
interstate commerce upon refusal by such person to make available for 
inspection a copy of the agreement, as required by paragraph (d)(2) of 
this section.
    (3) An exemption of a shipment or other delivery of a food under 
paragraph (d)(2) of this section shall expire:
    (i) At the beginning of the act of removing such shipment or 
delivery, or any part thereof, from such establishment if the food 
comprising such shipment, delivery, or part is adulterated or misbranded 
within the meaning of the act when so removed; or
    (ii) Upon refusal by the operator of the establishment where such 
food is to be processed, labeled, or repacked, to make available for 
inspection a copy of the agreement as required by such paragraph.
    (f) [Reserved]
    (g) The label declaration of a harmless marker used to identify a 
particular manufacturer's product may result in unfair competition 
through revealing a trade secret. Exemption from the label declaration 
of such a marker is granted, therefore, provided that the following 
conditions are met:
    (1) The person desiring to use the marker without label declaration 
of its presence has submitted to the Commissioner of Food and Drugs full 
information concerning the proposed usage and the reasons why he 
believes label declaration of the marker should be subject to this 
exemption; and
    (2) The person requesting the exemption has received from the 
Commissioner of Food and Drugs a finding that the marker is harmless and 
that the exemption has been granted.



Sec. 501.103  Petitions requesting exemptions from or special 
requirements for label declaration of ingredients.

    The Commissioner of Food and Drugs, either on his own initiative or 
on behalf of any interested person who has submitted a petition pursuant 
to part 10 of this chapter may issue a proposal to amend Sec. 501.4 to 
specify the manner in which an ingredient(s) shall be declared, i.e., by 
specific or class name, or Sec. 501.100 to exempt an ingredient(s) from 
the requirements for label declaration.

[41 FR 38619, Sept. 10, 1976, as amended at 42 FR 15675, Mar. 22, 1977]



Sec. 501.105  Declaration of net quantity of contents when exempt.

    (a) The principal display panel of a food in package form shall bear 
a declaration of the net quantity of contents. This shall be expressed 
in the terms of weight, measure, numerical count, or a combination of 
numerical count and weight or measure. The statement shall be in terms 
of fluid measure if the food is liquid, or in terms of weight if the 
food is solid, semisolid, or viscous, or a mixture of solid and liquid; 
except that such statement may be in terms of dry measure if the food is 
a fresh fruit, fresh vegetable, or other dry commodity that is 
customarily sold by dry measure. If there is a firmly established 
general consumer usage and trade custom of declaring the contents of a 
liquid by weight, or a solid, semisolid, or viscous product by fluid 
measure, it may be used. Whenever the Commissioner determines that an 
existing practice of declaring net quantity of contents by weight, 
measure, numerical count, or a combination in the case of a specific 
packaged food does not facilitate value comparisons by consumers and 
offers opportunity for consumer confusion, he will by regulation 
designate the appropriate term or terms to be used for such commodity.
    (b)(1) Statements of weight shall be in terms of avoirdupois pound 
and ounce.
    (2) Statements of fluid measure shall be in terms of the U.S. gallon 
of 231 cubic inches and quart, pint, and fluid ounce subdivisions 
thereof, and shall:

[[Page 29]]

    (i) In the case of frozen food that is sold and consumed in a frozen 
state, express the volume at the frozen temperature.
    (ii) In the case of refrigerated food that is sold in the 
refrigerated state, express the volume at 40 [deg]F (4 [deg]C).
    (iii) In the case of other foods, express the volume at 68 [deg]F 
(20 [deg]C).
    (3) Statements of dry measure shall be in terms of the U.S. bushel 
of 2,150.42 cubic inches and peck, dry quart, and dry pint subdivisions 
thereof.
    (c) When the declaration of quantity of contents by numerical count 
does not give adequate information as to the quantity of food in the 
package, it shall be combined with such statement of weight, measure, or 
size of the individual units of the foods as will provide such 
information.
    (d) The declaration may contain common or decimal fractions. A 
common fraction shall be in terms of halves, quarters, eighths, 
sixteenths, or thirty-seconds; except that if there exists a firmly 
established general consumer usage and trade custom of employing 
different common fractions in the net quantity declaration of a 
particular commodity, they may be employed. A common fraction shall be 
reduced to its lowest terms; a decimal fraction shall not be carried out 
to more than two places. A statement that includes small fractions of an 
ounce shall be deemed to permit smaller variations than one which does 
not include such fractions.
    (e) The declaration shall be located on the principal display panel 
of the label, and with respect to packages bearing alternate principal 
panels it shall be duplicated on each principal display panel.
    (f) The declaration shall appear as a distinct item on the principal 
display panel, shall be separated (by at least a space equal to the 
height of the lettering used in the declaration) from other printed 
label information appearing above or below the declaration and (by at 
least a space equal to twice the width of the letter ``N'' of the style 
of type used in the quantity of contents statement) from other printed 
label information appearing to the left or right of the declaration. It 
shall not include any term qualifying a unit of weight, measure, or 
count (such as jumbo quart and full gallon) that tends to exaggerate the 
amount of the food in the container. It shall be placed on the principal 
display panel within the bottom 30 percent of the area of the label 
panel in lines generally parallel to the base on which the package rests 
as it is designed to be displayed: Provided, That on packages having a 
principal display panel of 5 square inches or less, the requirement for 
placement within the bottom 30 percent of the area of the label panel 
shall not apply when the declaration of net quantity of contents meets 
the other requirements of this part.
    (g) The declaration shall accurately reveal the quantity of food in 
the package exclusive of wrappers and other material packed therewith; 
provided that in the case of foods packed in containers designed to 
deliver the food under pressure, the declaration shall state the net 
quantity of the contents that will be expelled when the instructions for 
use as shown on the container are followed. The propellant is included 
in the net quantity declaration.
    (h) The declaration shall appear in conspicuous and easily legible 
boldface print or type in distinct contrast (by typography, layout, 
color, embossing, or molding) to other matter on the package; except 
that a declaration of net quantity blown, embossed, or molded on a glass 
or plastic surface is permissible when all label information is so 
formed on the surface. Requirements of conspicuousness and legibility 
shall include the specifications that:
    (1) The ratio of height to width (of the letter) shall not exceed a 
differential of 3 units to 1 unit (no more than 3 times as high as it is 
wide).
    (2) Letter heights pertain to upper case or capital letters. When 
upper and lower case or all lower case letters are used, it is the lower 
case letter ``o'' or its equivalent that shall meet the minimum 
standards.
    (3) When fractions are used, each component numeral shall meet one-
half the minimum height standards.
    (i) The declaration shall be in letters and numerals in a type size 
established in relationship to the area of the principal display panel 
of the package and

[[Page 30]]

shall be uniform for all packages of substantially the same size by 
complying with the following type specifications:
    (1) Not less than \1/16\ inch in height on packages the principal 
display panel of which has an area of 5 square inches or less.
    (2) Not less than \1/8\ inch in height on packages the principal 
display panel of which has an area of more than 5 but not more than 25 
square inches.
    (3) Not less than \3/16\ inch in height on packages the principal 
display panel of which has an area of more than 25 but not more than 100 
square inches.
    (4) Not less than \1/4\ inch in height on packages the principal 
display panel of which has an area of more than 100 square inches, 
except not less than \1/2\ inch in height if the area is more than 400 
square inches.


Where the declaration is blown, embossed, or molded on a glass or 
plastic surface rather than by printing, typing, or coloring, the 
lettering sizes specified in paragraphs (i) (1) through (4) of this 
section shall be increased by \1/16\ of an inch.
    (j) On packages containing less than 4 pounds or 1 gallon and 
labeled in terms of weight or fluid measure:
    (1) The declaration shall be expressed both in ounces, with 
identification by weight or by liquid measure and, if applicable (1 
pound or 1 pint or more) followed in parentheses by a declaration in 
pounds for weight units, with any remainder in terms of ounces or common 
or decimal fractions of the pound (see examples set forth in paragraphs 
(m) (1) and (2) of this section), or in the case of liquid measure, in 
the largest whole units (quarts, quarts and pints, or pints, as 
appropriate) with any remainder in terms of fluid ounces or common or 
decimal fractions of the pint or quart (see examples in paragraphs (m) 
(3) and (4) of this section).
    (2) If the net quantity of contents declaration appears on a random 
package, that is a package which is one of a lot, shipment, or delivery 
of packages of the same consumer commodity with varying weights and with 
no fixed weight pattern, it may, when the net weight exceeds 1 pound, be 
expressed in terms of pounds and decimal fractions of the pound carried 
out to not more than two decimal places. When the net weight does not 
exceed 1 pound, the declaration on the random package may be in decimal 
fractions of the pound in lieu of ounces (see example in paragraph 
(m)(5) of this section).
    (3) The declaration may appear in more than one line. The term net 
weight shall be used when stating the net quantity of contents in terms 
of weight. Use of the terms net or net contents in terms of fluid 
measure or numerical count is optional. It is sufficient to distinguish 
avoirdupois ounce from fluid ounce through association of terms; for 
example, Net wt. 6 oz. or 6 oz. net wt. and 6 fl. oz. or net contents 6 
fl. oz.
    (k) On packages containing 4 pounds or 1 gallon or more and labeled 
in terms of weight or fluid measure, the declaration shall be expressed 
in pounds for weight units with any remainder in terms of ounces or 
common or decimal fraction of the pound, or in the case of fluid 
measure, it shall be expressed in the largest whole unit (gallons 
followed by common or decimal fraction of a gallon or by the next 
smaller whole unit or units (quarts, or quarts and pints)) with any 
remainder in terms of fluid ounces or common or decimal fractions of the 
pint or quart (see paragraph (m)(6) of this section).
    (l) [Reserved]
    (m) Examples: (1) A declaration of 1\1/2\ pounds weight shall be 
expressed as Net Wt. 24 oz. (1 lb. 8 oz.), Net Wt. 24 oz. (1\1/2\ lb.), 
or Net Wt. 24 oz. (1.5 lb.).
    (2) A declaration of \3/4\ pound avoirdupois weight shall be 
expressed as Net Wt. 12 oz.
    (3) A declaration of 1 quart liquid measure shall be expressed as 
Net 32 fl. oz. (1 qt.).
    (4) A declaration of 1\3/4\ quarts liquid measure shall be expressed 
as Net contents 56 fluid ounces (1 quart 1\1/2\ pints) or as Net 56 
fluid oz. (1 qt. 1 pt. 8 oz.), but not in terms of quart and ounce such 
as Net 56 fluid oz. (1 quart 24 ounces).
    (5) On a random package, declaration of \3/4\ pound avoirdupois may 
be expressed as Net Wt. .75 lb.
    (6) A declaration of 2\1/2\ gallons liquid measure shall be 
expressed as Net contents 2\1/2\ gallons, Net contents 2.5 gallons, or 
Net contents 2 gallons 2 quarts and not as 2 gallons 4 pints.

[[Page 31]]

    (n) For quantities, the following abbreviations and none other may 
be employed (periods and plural forms are optional):

weight wt.
ounce oz.
pound lb.
gallon gal.
pint pt.
quart qt.
fluid fl.

    (o) Nothing in this section shall prohibit supplemental statements 
at locations other than the principal display panel(s) describing in 
nondeceptive terms the net quantity of contents; provided, that such 
supplemental statements of net quantity of contents shall not include 
any term qualifying a unit of weight, measure, or count that tends to 
exaggerate the amount of the food contained in the package; for example, 
jumbo quart and full gallon. Dual or combination declarations of net 
quantity of contents as provided for in paragraphs (a), (c), and (j) of 
this section (for example, a combination of net weight plus numerical 
count, net contents plus dilution directions of a concentrate, etc.) are 
not regarded as supplemental net quantity statements and may be located 
on the principal display panel.
    (p) A separate statement of the net quantity of contents in terms of 
the metric system is not regarded as a supplemental statement and an 
accurate statement of the net quantity of contents in terms of the 
metric system of weight or measure may also appear on the principal 
display panel or on other panels.
    (q) The declaration of net quantity of contents shall express an 
accurate statement of the quantity of contents of the package. 
Reasonable variations caused by loss or gain of moisture during the 
course of good distribution practice or by unavoidable deviations in 
good manufacturing practice will be recognized. Variations from stated 
quantity of contents shall not be unreasonably large.
    (r) [Reserved]
    (s) On a multiunit retail package, a statement of the quantity of 
contents shall appear on the outside of the package and shall include 
the number of individual units, the quantity of each individual unit, 
and, in parentheses, the total quantity of contents of the multiunit 
package in terms of avoirdupois or fluid ounces, except that such 
declaration of total quantity need not be followed by an additional 
parenthetical declaration in terms of the largest whole units and 
subdivisions thereof, as required by paragraph (j)(1) of this section. A 
multiunit retail package may thus be properly labeled: 6-16 oz. 
bottles--(96 fl. oz.) or 3-16 oz. cans--(net wt. 48 oz). For the 
purposes of this section, multiunit retail package means a package 
containing two or more individually packaged units of the identical 
commodity and in the same quantity, intended to be sold as part of the 
multiunit retail package but capable of being individually sold in full 
compliance with all requirements of the regulations in this part. Open 
multiunit retail packages that do not obscure the number of units nor 
prevent examination of the labeling on each of the individual units are 
not subject to this paragraph if the labeling of each individual unit 
complies with the requirements of paragraphs (f) and (i) of this 
section.
    (t) Where the declaration of net quantity of contents is in terms of 
net weight and/or drained weight or volume and does not accurately 
reflect the actual quantity of the contents or the product falls below 
the applicable standard of fill of container because of equipment 
malfunction or otherwise unintentional product variation, and the label 
conforms in all other respects to the requirements of this chapter 
(except the requirement that food falling below the applicable standard 
of fill of container shall bear the general statement of substandard 
fill specified in Sec. 564.14(b) of this chapter), the mislabeled food 
product, including any food product that fails to bear the general 
statement of substandard fill specified in Sec. 564.14(b) of this 
chapter, may be sold by the manufacturer or processor directly to 
institutions operated by Federal, State or local governments: Provided, 
That:
    (1) The purchaser shall sign a statement at the time of sale stating 
that he is aware that the product is mislabeled to include 
acknowledgement of the nature and extent of the mislabeling, e.g., 
``Actual net weight may be as low as ----% below labeled

[[Page 32]]

quantity'' and that any subsequent distribution by him of said product 
except for his own institutional use is unlawful. This statement shall 
be kept on file at the principal place of business of the manufacturer 
or processor for 2 years subsequent to the date of shipment of the 
product and shall be available to the Food and Drug Administration upon 
request.
    (2) The product shall be labeled on the outside of its shipping 
container with the statement(s):
    (i) When the variation concerns net weight and/or drained weight of 
volume--``Product Mislabeled. Actual net weight (drained weight or 
volume where appropriate) may be as low as ----% below labeled quantity. 
This Product Not for Retail Distribution,'' the blank to be filled in 
with the maximum percentage variance between the labeled and actual 
weight or volume of contents of the individual packages in the shipping 
container, and
    (ii) When the variation is in regard to a fill of container 
standard--``Product Mislabeled. Actual fill may be as low as ----% below 
standard of fill. This Product Not for Retail Distribution.''
    (3) The statements required by paragraphs (t)(2) (i) and (ii) of 
this section, which may be consolidated where appropriate, shall appear 
prominently and conspicuously as compared to other printed matter on the 
shipping container and in boldface print or type on a clear, contrasting 
background in order to render them likely to be read and understood by 
the purchaser under ordinary conditions of purchase.

[41 FR 38619, Sept. 10, 1976, as amended at 54 FR 18279, Apr. 28, 1989]



Sec. 501.110  Animal feed labeling; collective names for feed 
ingredients.

    (a) An animal feed shall be exempt from the requirements of section 
403(i)(2) of the act with respect to its label bearing the common or 
usual names of the animal feed ingredients listed in paragraph (b) of 
this section under the following prescribed conditions:
    (1) The animal feed is intended solely for livestock and poultry.
    (2) The label of the animal feed bears the collective name(s) 
prescribed in paragraph (b) of this section in lieu of the corresponding 
common or usual names of the individual feed ingredients contained 
therein.
    (3) The label of the animal feed otherwise conforms to the 
requirements of section 403(i)(2) of the act.
    (4) The ingredients of any feed listed in paragraph (b) of this 
section neither contain nor are food additives as defined in section 
201(s) of the act unless provided for by and in conformity with 
applicable regulations established pursuant to section 409 of the act.
    (b) Each collective name referred to in this paragraph may be used 
for the purpose of labeling where one or more of the ingredients listed 
for that collective name are present. The animal feed ingredients listed 
under each of the collective names are the products defined by the 
Association of American Feed Control Officials. The collective names are 
as follows:
    (1) Animal protein products include one or more of the following: 
Animal products, marine products, and milk products.
    (2) Forage products include one or more of the following: Alfalfa 
meals, entire plant meals, hays, and stem meals.
    (3) Grain products include one or more of the following: Barley, 
grain sorghums, maize (corn), oats, rice, rye, and wheat.
    (4) Plant protein products include one or more of the following: 
Algae meals, coconut meals (copra), cottonseed meals, guar meal, linseed 
meals, peanut meals, safflower meals, soybean meals, sunflower meals, 
and yeasts.
    (5) Processed grain byproducts include one or more of the following: 
Brans, brewers dried grains, distillers grains, distillers solubles, 
flours, germ meals, gluten feeds, gluten meals, grits, groats, hominy 
feeds, malt sprouts, middlings, pearled, polishings, shorts, and wheat 
mill run.
    (6) Roughage products include one or more of the following: Cobs, 
hulls, husks, pulps, and straws.



PART 502_COMMON OR USUAL NAMES FOR NONSTANDARDIZED ANIMAL FOODS--
Table of Contents



Sec.
502.5 General principles.

[[Page 33]]

502.19 Petitions.

    Authority: 21 U.S.C. 321, 343, 371.



Sec. 502.5  General principles.

    (a) The common or usual name of a food, which may be a coined term, 
shall accurately identify or describe, in as simple and direct terms as 
possible, the basic nature of the food or its characterizing properties 
or ingredients. The name shall be uniform among all identical or similar 
products and may not be confusingly similar to the name of any other 
food that is not reasonably encompassed within the same name. Each class 
or subclass of food shall be given its own common or usual name that 
states, in clear terms, what it is in a way that distinguishes it from 
different foods.
    (b) The common or usual name of a food shall include the 
percentage(s) of any characterizing ingredient(s) or component(s) when 
the proportion of such ingredient(s) or component(s) in the food has a 
material bearing on price or consumer acceptance or when the labeling or 
the appearance of the food may otherwise create an erroneous impression 
that such ingredient(s) or component(s) is present in an amount greater 
than is actually the case. The following requirements shall apply unless 
modified by a specific regulation in this part.
    (1) The percentage of a characterizing ingredient or component shall 
be declared on the basis of its quantity in the finished product (i.e., 
weight/weight in the case of solids, or volume/volume in the case of 
liquids).
    (2) The percentage of a characterizing ingredient or component shall 
be declared by the words ``containing (or contains) ---- percent (or %) 
----'' or ``---- percent (or %) ----'' with the first blank filled in 
with the percentage expressed as a whole number not greater than the 
actual percentage of the ingredient or component named and the second 
blank filled in with the common or usual name of the ingredient or 
component. The word ``containing'' (or ``contains''), when used, shall 
appear on a line immediately below the part of the common or usual name 
of the food required by paragraph (a) of this section. For each 
characterizing ingredient or component, the words ``---- percent (or %) 
----''shall appear following or directly below the word ``containing'' 
(or ``contains''), or directly below the part of the common or usual 
name of the food required by paragraph (a) of this section when the word 
``containing'' (or ``contains'') is not used, in easily legible boldface 
print or type in distinct contrast to other printed or graphic matter, 
and in a height not less than the larger of the following alternatives:
    (i) Not less than one-sixteenth inch in height on packages having a 
principal display panel with an area of 5 square inches or less and not 
less than one-eighth inch in height if the area of the principal display 
panel is greater than 5 square inches; or
    (ii) Not less than one-half the height of the largest type appearing 
in the part of the common or usual name of the food required by 
paragraph (a) of this section.
    (c) The common or usual name of a food shall include a statement of 
the presence or absence of any characterizing ingredient(s) or 
component(s) and/or the need for the user to add any characterizing 
ingredient(s) or component(s) when the presence or absence of such 
ingredient(s) or component(s) in the food has a material bearing on 
price or consumer acceptance or when the labeling or the appearance of 
the food may otherwise create an erroneous impression that such 
ingredient(s) or component(s) is present when it is not, and consumers 
may otherwise be misled about the presence or absence of the 
ingredient(s) or component(s) in the food. The following requirements 
shall apply unless modified by a specific regulation in this part.
    (1) The presence or absence of a characterizing ingredient or 
component shall be declared by the words ``containing (or contains) ----
----'' or ``containing (or contains) ----------'' or ``no ----------'' 
or ``does not contain ----------'', with the blank being filled in with 
the common or usual name of the ingredient or component.
    (2) The need for the user of a food to add any characterizing 
ingredient(s) or component(s) shall be declared by an appropriate 
informative statement.

[[Page 34]]

    (3) The statement(s) required under paragraph (c) (1) and/or (2) of 
this section shall appear following or directly below the part of the 
common or usual name of the food required by paragraphs (a) and (b) of 
this section, in easily legible boldface print or type in distinct 
contrast to other printed or graphic matter, and in a height not less 
than the larger of the alternatives established under paragraph (b)(2) 
(i) and (ii) of this section.
    (d) A common or usual name of a food may be established by common 
usage or by establishment of a regulation in this part, in a standard of 
identity, or in other regulations in this chapter.

[41 FR 38627, Sept. 10, 1976. Redesignated at 42 FR 14091, Mar. 15, 
1977]



Sec. 502.19  Petitions.

    (a) The Commissioner of Food and Drugs, either on his own initiative 
or on behalf of any interested person who has submitted a petition, may 
publish a proposal to issue, amend, or revoke, under this part, a 
regulation prescribing a common or usual name for a food, pursuant to 
part 10 of this chapter.
    (b) If the principal display panel of a food for which a common or 
usual name regulation is established is too small to accommodate all 
mandatory requirements, the Commissioner may establish by regulation an 
acceptable alternative, e.g., a smaller type size. A petition requesting 
such a regulation, which would amend the applicable regulation, shall be 
submitted pursuant to part 10 of this chapter.

[42 FR 4716, Jan. 25, 1977; 42 FR 10980, Feb. 25, 1977. Redesignated at 
42 FR 14091, Mar. 15, 1977, and amended at 42 FR 15675, Mar. 22, 1977; 
42 FR 24254, May 13, 1977]



PART 509_UNAVOIDABLE CONTAMINANTS IN ANIMAL FOOD AND FOOD-PACKAGING 
MATERIAL--Table of Contents



                      Subpart A_General Provisions

Sec.
509.3 Definitions and interpretations.
509.4 Establishment of tolerances, regulatory limits, and action levels.
509.5 Petitions.
509.6 Added poisonous or deleterious substances.
509.7 Unavoidability.
509.15 Use of polychlorinated biphenyls (PCB's) in establishments 
          manufacturing food-packaging materials.

Subpart B_Tolerances for Unavoidable Poisonous or Deleterious Substances

509.30 Temporary tolerances for polychlorinated biphenyls (PCB's).

Subpart C--Regulatory Limits for Added Poisonous or Deleterious Substances 
[Reserved]

Subpart D--Naturally Occurring Poisonous or Deleterious Substances 
[Reserved]

    Authority: 21 U.S.C. 336, 342, 346, 346a, 348, 371.

    Source: 42 FR 52821, Sept. 30, 1977, unless otherwise noted.



                      Subpart A_General Provisions



Sec. 509.3  Definitions and interpretations.

    (a) Act means the Federal Food, Drug, and Cosmetic Act.
    (b) The definitions of terms contained in section 201 of the act are 
applicable to such terms when used in this part unless modified in this 
section.
    (c) A naturally occurring poisonous or deleterious substance is a 
poisonous or deleterious substance that is an inherent natural 
constituent of a food and is not the result of environmental, 
agricultural, industrial, or other contamination.
    (d) An added poisonous or deleterious substance is a poisonous or 
deleterious substance that is not a naturally occurring poisonous or 
deleterious substance. When a naturally occurring poisonous or 
deleterious substance is increased to abnormal levels through 
mishandling or other intervening acts, it is an added poisonous or 
deleterious substance to the extent of such increase.
    (e) Food includes pet food, animal feed, and substances migrating to 
food from food-contact articles.



Sec. 509.4  Establishment of tolerances, regulatory limits, and action 
levels.

    (a) When appropriate under the criteria of Sec. 509.6, a tolerance 
for an added

[[Page 35]]

poisonous or deleterious substance, which may be a food additive, may be 
established by regulation in subpart B of this part under the provisions 
of section 406 of the act. A tolerance may prohibit any detectable 
amount of the substance in food.
    (b) When appropriate under the criteria of Sec. 509.6, and under 
section 402(a)(1) of the act, a regulatory limit for an added poisonous 
or deleterious substance, which may be a food additive, may be 
established by regulation in subpart C of this part under the provisions 
of sections 402(a)(1) and 701(a) of the act. A regulatory limit may 
prohibit any detectable amount of the substance in food. The regulatory 
limit established represents the level at which food is adulterated 
within the meaning of section 402(a)(1) of the act.
    (c)(1) When appropriate under the criteria of Sec. 509.6, an action 
level for an added poisonous or deleterious substance, which may be a 
food additive, may be established to define a level of contamination at 
which a food may be regarded as adulterated.
    (2) Whenever an action level is established or changed, a notice 
shall be published in the Federal Register as soon as practicable 
thereafter. The notice shall call attention to the material supporting 
the action level which shall be on file with the Division of Dockets 
Management before the notice is published. The notice shall invite 
public comment on the action level.
    (d) A regulation may be established in subpart D of this part to 
identify a food containing a naturally occurring poisonous or 
deleterious substance which will be deemed to be adulterated under 
section 402(a)(1) of the act. These regulations do not constitute a 
complete list of such foods.

[42 FR 52821, Sept. 30, 1977, as amended at 55 FR 20786, May 21, 1990]



Sec. 509.5  Petitions.

    The Commissioner of Food and Drugs, either on his own initiative or 
on behalf of any interested person who has submitted a petition, may 
issue a proposal to establish, revoke, or amend a regulation under this 
part. Any such petition shall include an adequate factual basis to 
support the petition, shall be in the form set forth in Sec. 10.30 of 
this chapter, and will be published in the Federal Register for comment 
if it contains reasonable grounds for the proposed regulation.

[42 FR 52821, Sept. 30, 1977, as amended at 54 FR 18280, Apr. 28, 1989]



Sec. 509.6  Added poisonous or deleterious substances.

    (a) Use of an added poisonous or deleterious substance, other than a 
pesticide chemical, that is also a food additive will be controlled by a 
regulation issued under section 409 of the act when possible. When such 
a use cannot be approved under the criteria of section 409 of the act, 
or when the added poisonous or deleterious substance is not a food 
additive, a tolerance, regulatory limit, or action level may be 
established pursuant to the criteria in paragraphs (b), (c), or (d) of 
this section. Residues resulting from the use of an added poisonous or 
deleterious substance that is also a pesticide chemical will ordinarily 
be controlled by a tolerance established in a regulation issued under 
sections 406, 408, or 409 of the act by the U.S. Environmental 
Protection Agency (EPA). When such a regulation has not been issued, an 
action level for an added poisonous or deleterious substance that is 
also a pesticide chemical may be established by the Food and Drug 
Administration. The Food and Drug Administration will request EPA to 
recommend such an action level pursuant to the criteria established in 
paragraph (d) of this section.
    (b) A tolerance for an added poisonous or deleterious substance in 
any food may be established when the following criteria are met:
    (1) The substance cannot be avoided by good manufacturing practice.
    (2) The tolerance established is sufficient for the protection of 
the public health, taking into account the extent of which the presence 
of the substance cannot be avoided and the other ways in which the 
consumer may be affected by the same or related poisonous or deleterious 
substances.
    (3) No technological or other changes are foreseeable in the near 
future that might affect the appropriateness of the tolerance 
established. Examples of

[[Page 36]]

changes that might affect the appropriateness of the tolerance include 
anticipated improvements in good manufacturing practice that would 
change the extent to which use of the substance is unavoidable and 
anticipated studies expected to provide significant new toxicological or 
use data.
    (c) A regulatory limit for an added poisonous or deleterious 
substance in any food may be established when each of the following 
criteria is met:
    (1) The substance cannot be avoided by current good manufacturing 
practices.
    (2) There is no tolerance established for the substance in the 
particular food under sections 406, 408, or 409 of the act.
    (3) There is insufficient information by which a tolerance may be 
established for the substance under section 406 of the act or 
technological changes appear reasonably possible that may affect the 
appropriateness of a tolerance. The regulatory limit established 
represents the level at which food is adulterated within the meaning of 
section 402(a)(1) of the act.
    (d) An action level for an added poisonous or deleterious substance 
in any food may be established when the criteria in paragraph (b) of 
this section are met, except that technological or other changes that 
might affect the appropriateness of the tolerance are foreseeable in the 
near future. An action level for an added poisonous or deleterious 
substance in any food may be established at a level at which the Food 
and Drug Administration may regard the food as adulterated within the 
meaning of section 402(a)(1) of the act, without regard to the criteria 
in paragraph (b) of this section or in section 406 of the act. An action 
level will be withdrawn when a tolerance or regulatory limit for the 
same substance and use has been established.
    (e) Tolerances will be established under authority appropriate for 
action levels (sections 306, 402(a), and 701(a) of the act, together 
with section 408 or 409 of the act, if appropriate) as well as under 
authority appropriate for tolerances (sections 406 and 701 of the act). 
In the event the effectiveness of a tolerance is stayed pursuant to 
section 701(e)(2) of the act by the filing of an objection, the order 
establishing the tolerance shall be deemed to be an order establishing 
an action level until final action is taken upon such objection.

[42 FR 52821, Sept. 30, 1977, as amended at 55 FR 20786, May 21, 1990]



Sec. 509.7  Unavoidability.

    (a) Tolerances and action levels in this part are established at 
levels based on the unavoidability of the poisonous or deleterious 
substance concerned and do not establish a permissible level of 
contamination where it is avoidable.
    (b) Compliance with tolerances, regulatory limits, and action levels 
does not excuse failure to observe either the requirement in section 
402(a)(4) of the act that food may not be prepared, packed, or held 
under insanitary conditions or the other requirements in this chapter 
that food manufacturers must observe current good manufacturing 
practices. Evidence obtained through factory inspection or otherwise 
indicating such a violation renders the food unlawful, even though the 
amounts of poisonous or deleterious substances are lower than the 
currently established tolerances, regulatory limits, or action levels. 
The manufacturer of food must at all times utilize quality control 
procedures which will reduce contamination to the lowest level currently 
feasible.

[42 FR 52821, Sept. 30, 1977, as amended at 55 FR 20786, May 21, 1990]



Sec. 509.15  Use of polychlorinated biphenyls (PCB's) in establishments 
manufacturing food-packaging materials.

    (a) Polychlorinated biphenyls (PCB's) represent a class of toxic 
industrial chemicals manufactured and sold under a variety of trade 
names, including: Aroclor (United States); Phenoclor (France); Colphen 
(Germany); and Kanaclor (Japan). PCB's are highly stable, heat 
resistant, and nonflammable chemicals. Industrial uses of PCB's include, 
or did include in the past, their use as electrical transformer and 
capacitor fluids, heat transfer fluids, hydraulic fluids, and 
plasticizers, and in formulations of lubricants, coatings, and inks. 
Their unique physical and chemical properties and widespread, 
uncontrolled industrial applications

[[Page 37]]

have caused PCB's to be a persistent and ubiquitous contaminant in the 
environment, causing the contamination of certain foods. In addition, 
incidents have occurred in which PCB's have directly contaminated animal 
feeds as a result of industrial accidents (leakage or spillage of PCB 
fluids from plant equipment). These accidents in turn caused the 
contamination of food products intended for human consumption (meat, 
milk and eggs). Investigations by the Food and Drug Administration have 
revealed that a significant percentage of paper food-packaging material 
contains PCB's which can migrate to the packaged food. The origin of 
PCB's in such material is not fully understood. Reclaimed fibers 
containing carbonless copy paper (contains 3 to 5 percent PCB's) have 
been identified as a primary source of PCB's in paper products. Some 
virgin paper products have also been found to contain PCB's, the source 
of which is generally attributed to direct contamination from industrial 
accidents from the use of PCB-containing equipment and machinery in 
food-packaging manufacturing establishments. Since PCB's are toxic 
chemicals, the PCB contamination of food-packaging materials as a result 
of industrial accidents, which can cause the PCB contamination of food, 
represents a hazard to public health. It is therefore necessary to place 
certain restrictions on the industrial uses of PCB's in establishments 
manufacturing food-packaging materials.
    (b) The following special provisions are necessary to preclude the 
accidental PCB contamination of food-packaging materials:
    (1) New equipment or machinery for manufacturing food-packaging 
materials shall not contain or use PCB's.
    (2) On or before September 4, 1973, the management of establishments 
manufacturing food-packaging materials shall:
    (i) Have the heat exchange fluid used in existing equipment for 
manufacturing food-packaging materials sampled and tested to determine 
whether it contains PCB's or verify the absence of PCB's in such 
formulations by other appropriate means. On or before Sept. 4, 1973, any 
such fluid formulated with PCB's must to the fullest extent possible 
commensurate with current good manufacturing practices be replaced with 
a heat exchange fluid that does not contain PCB's.
    (ii) Eliminate to the fullest extent possible commensurate with 
current good manufacturing practices from the establishment any other 
PCB-containing equipment, machinery and materials wherever there is a 
reasonable expectation that such articles could cause food-packaging 
materials to become contaminated with PCB's either as a result of normal 
use or as a result of accident, breakage, or other mishap.
    (iii) The toxicity and other characteristics of fluids selected as 
PCB replacements must be adequately determined so that the least 
potentially hazardous replacement is used. In making this determination 
with respect to a given fluid, consideration should be given to (a) its 
toxicity; (b) the maximum quantity that could be spilled onto a given 
quantity of food before it would be noticed, taking into account its 
color and odor; (c) possible signaling devices in the equipment to 
indicate a loss of fluid, etc.; and (d) its environmental stability and 
tendency to survive and be concentrated through the food chain. The 
judgment as to whether a replacement fluid is sufficiently non-hazardous 
is to be made on an individual installation and operation basis.
    (c) The provisions of this section do not apply to electrical 
transformers and condensers containing PCB's in sealed containers.



Subpart B_Tolerances for Unavoidable Poisonous or Deleterious Substances



Sec. 509.30  Temporary tolerances for polychlorinated biphenyls (PCB's).

    (a) Polychlorinated biphenyls (PCB's) are toxic, industrial 
chemicals. Because of their widespread, uncontrolled industrial 
applications, PCB's have become a persistent and ubiquitous contaminant 
in the environment. As a result, certain foods and animal feeds, 
principally those of animal and marine origin, contain PCB's as 
unavoidable, environmental contaminants. PCB's are transmitted to the 
food portion

[[Page 38]]

(meat, milk, and eggs) of food producing animals ingesting PCB 
contaminated animal feed. In addition, a significant percentage of paper 
food-packaging materials contain PCB's which may migrate to the packaged 
food. The source of PCB's in paper food-packaging materials is primarily 
of certain types of carbonless copy paper (containing 3 to 5 percent 
PCB's) in waste paper stocks used for manufacturing recycled paper. 
Therefore, temporary tolerances for residues of PCB's as unavoidable 
environmental or industrial contaminants are established for a 
sufficient period of time following the effective date of this paragraph 
to permit the elimination of such contaminants at the earliest 
practicable time. For the purposes of this paragraph, the term 
polychlorinated biphenyls (PCB's) is applicable to mixtures of 
chlorinated biphenyl compounds, irrespective of which mixture of PCB's 
is present as the residue. The temporary tolerances for residues of 
PCB's are as follows:
    (1) 0.2 part per million in finished animal feed for food-producing 
animals (except the following finished animal feeds: feed concentrates, 
feed supplements, and feed premixes).
    (2) 2 parts per million in animal feed components of animal origin, 
including fishmeal and other by-products of marine origin and in 
finished animal feed concentrates, supplements, and premixes intended 
for food-producing animals.
    (3) 10 parts per million in paper food-packaging material intended 
for or used with finished animal feed and any components intended for 
animal feeds. The tolerance shall not apply to paper food-packaging 
material separated from the food therein by a functional barrier which 
is impermeable to migration of PCB's.
    (b) A compilation entitled ``Analytical Methodology for 
Polychlorinated Biphenyls, February 1973'' for determining compliance 
with the tolerances established in this section is available from the 
Division of Dockets Management, Food and Drug Administration, 5630 
Fishers Lane, rm. 1061, Rockville, MD 20852.

[42 FR 52821, Sept. 30, 1977, as amended at 46 FR 8460, Jan. 27, 1981; 
59 FR 14365, Mar. 28, 1994; 68 FR 24879, May 9, 2003]

Subpart C--Regulatory Limits for Added Poisonous or Deleterious Substances 
[Reserved]

Subpart D--Naturally Occurring Poisonous or Deleterious Substances 
[Reserved]



PART 510_NEW ANIMAL DRUGS--Table of Contents



                      Subpart A_General Provisions

Sec.
510.3 Definitions and interpretations.
510.4 Biologics; products subject to license control.
510.7 Consignees of new animal drugs for use in the manufacture of 
          animal feed.
510.95 [Reserved]

         Subpart B_Specific Administrative Rulings and Decisions

510.105 Labeling of drugs for use in milk-producing animals.
510.106 Labeling of antibiotic and antibiotic-containing drugs intended 
          for use in milk-producing animals.
510.110 Antibiotics used in food-producing animals.
510.112 Antibiotics used in veterinary medicine and for nonmedical 
          purposes; required data.

Subpart C [Reserved]

                      Subpart D_Records and Reports

510.301 Records and reports concerning experience with animal feeds 
          bearing or containing new animal drugs for which an approved 
          medicated feed mill license application is in effect.
510.305 Maintenance of copies of approved medicated feed mill licenses 
          to manufacture animal feed bearing or containing new animal 
          drugs.

          Subpart E_Requirements for Specific New Animal Drugs

510.410 Corticosteroids for oral, injectable, and ophthalmic use in 
          animals; warnings and labeling requirements.
510.440 Injectable iron preparations.
510.455 Requirements for free-choice medicated feeds.

[[Page 39]]

Subpart F [Reserved]

               Subpart G_Sponsors of Approved Applications

510.600 Names, addresses, and drug labeler codes of sponsors of approved 
          applications.

    Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

    Source: 40 FR 13807, Mar. 27, 1975, unless otherwise noted.



                      Subpart A_General Provisions



Sec. 510.3  Definitions and interpretations.

    As used in this part:
    (a) The term act means the Federal Food, Drug, and Cosmetic Act, as 
amended (secs. 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 
321-392).
    (b) Department means the Department of Health and Human Services.
    (c) Secretary means the Secretary of Health and Human Services.
    (d) Commissioner means the Commissioner of Food and Drugs.
    (e) Person means individuals, partnerships, corporations, and 
associations.
    (f) The definitions and interpretations of terms contained in 
section 201 of the act shall be applicable to such terms when used in 
the regulations in this part.
    (g) The term new animal drug means any drug intended for use for 
animals other than man, including any drug intended for use in animal 
feed but not including such animal feed:
    (1) The composition of which is such that such drug is not generally 
recognized, among experts qualified by scientific training and 
experience to evaluate the safety and effectiveness of animal drugs, as 
safe and effective for use under the conditions prescribed, recommended, 
or suggested in the labeling thereof; except that such a drug not so 
recognized shall not be deemed to be a new animal drug if at any time 
prior to June 25, 1938, it was subject to the Food and Drug Act of June 
30, 1906, as amended, and if at such time its labeling contained the 
same representations concerning the conditions of its use; or
    (2) The composition of which is such that such drug, as a result of 
investigations to determine its safety and effectiveness for use under 
such conditions, has become so recognized but which has not, otherwise 
than in such investigations, been used to a material extent or for a 
material time under such conditions.
    (h) The term animal feed means an article which is intended for use 
for food for animals other than man and which is intended for use as a 
substantial source of nutrients in the diet of the animal, and is not 
limited to a mixture intended to be the sole ration of the animal.
    (i) The newness of an animal drug, including a new animal drug 
intended for use in or on animal feed, may arise by reason of: (1) The 
newness for its intended drug use of any substance of which the drug is 
comprised, in whole or in part, whether it be an active substance or a 
menstruum, excipient, carrier, coating, or other component; (2) the 
newness for its intended drug use of a combination of two or more 
substances, none of which is itself a new animal drug; (3) the newness 
for its intended drug use of the proportion of a substance in a 
combination, even though such combination containing such substance in 
other proportion is not a new animal drug; (4) the newness for its 
intended drug use in a different species of animal; (5) the newness of 
its intended drug use in diagnosing, curing, mitigating, treating, or 
preventing a disease, or to affect a structure or function of the animal 
body, even though such drug is not a new animal drug when used in 
another disease or to affect another structure or function of the body; 
or (6) the newness of a dosage, or method or duration of administration 
or application, or any other condition of use prescribed, recommended, 
or suggested in the labeling of such drug, even though such drug or 
animal feed containing such drug when used in another dosage, or another 
method or duration of administration or application, or different 
condition, is not a new animal drug.
    (j) Animals used only for laboratory research and laboratory 
research animals mean individual animals or groups of animals intended 
for use and used solely for laboratory research purposes, regardless of 
species, and does not include animals intended to be used for

[[Page 40]]

any food purposes or animals intended to be kept as livestock.
    (k) Sponsor means the person requesting designation for a minor-use 
or minor-species drug as defined in part 516 of this chapter, who must 
be the real party in interest of the development and the intended or 
actual production and sales of such drug (in this context, the sponsor 
may be an individual, partnership, organization, or association). 
Sponsor also means the person responsible for an investigation of a new 
animal drug. In this context, the sponsor may be an individual, 
partnership, corporation, or Government agency or may be a manufacturer, 
scientific institution, or an investigator regularly and lawfully 
engaged in the investigation of new animal drugs. Sponsor also means the 
person submitting or receiving approval for a new animal drug 
application (in this context, the sponsor may be an individual, 
partnership, organization, or association). In all contexts, the sponsor 
is responsible for compliance with applicable provisions of the act and 
regulations.

[40 FR 13807, Mar. 27, 1975, as amended at 50 FR 7517, Feb. 22, 1985; 54 
FR 22741, May 26, 1989; 64 FR 69190, Dec. 10, 1999; 72 FR 41017, July 
26, 2007]



Sec. 510.4  Biologics; products subject to license control.

    An animal drug produced and distributed in full conformance with the 
animal virus, serum, and toxin law of March 4, 1913 (37 Stat. 832; 21 
U.S.C. 151 et seq. ) and any regulations issued thereunder shall not be 
deemed to be subject to section 512 of the Federal Food, Drug, and 
Cosmetic Act.



Sec. 510.7  Consignees of new animal drugs for use in the manufacture 
of animal feed.

    (a) A new animal drug intended for use in the manufacture of animal 
feed shall be deemed to be unsafe unless at the time of its removal from 
the establishment of a manufacturer, packer, or distributor of such 
drug, such manufacturer, packer, or distributor has an unrevoked written 
statement from the consignee of such drug, or a notice from the 
Secretary, to the effect that with respect to the use of such drug in 
animal feed the consignee:
    (1) Holds a license issued under Sec. 515.20 of this chapter; or
    (2) Will, if the consignee is not the user of the drug, ship such 
drug only to a holder of an approved application under Sec. 515.10 of 
this chapter.
    (b) The requirements of paragraph (a) of this section do not apply:
    (1) Where such drugs are intended for export and/or
    (2) When the use of such drug in the manufacture of a finished feed 
has been exempted from the requirements of section 512(m) of the act 
under the conditions specified by regulations published in part 558 of 
this chapter.

[40 FR 13807, Mar. 27, 1975, as amended at 64 FR 63203, Nov. 19, 1999]



Sec. 510.95  [Reserved]



         Subpart B_Specific Administrative Rulings and Decisions



Sec. 510.105  Labeling of drugs for use in milk-producing animals.

    (a) Part 526 of this chapter provides for new animal drugs intended 
for intramammary use in animals and includes conditions of use intended 
to prevent the contamination of milk from the use of such drugs.
    (b) Preparations containing antibiotics and other potent drugs 
labeled with directions for use in milk-producing animals will be 
misbranded under section 502(f)(2) of the act unless their labeling 
bears appropriate warnings and directions for use to avoid adulteration 
of milk under section 402(a)(2)(c)(ii) of the act.
    (c) It is the position of the Food and Drug Administration that the 
labeling for such preparations should bear a clear warning that either:
    (1) The article should not be administered to animals producing 
milk, since to do so would result in contamination of the milk; or
    (2) The label should bear the following statement: ``Warning: Milk 
that has been taken from animals during treatment and for ---- hours 
after the latest treatment must not be used for food'', the blank being 
filled in with the figure that the manufacturer has

[[Page 41]]

determined by appropriate investigation is needed to insure that the 
milk will not carry violative residues resulting from use of the 
preparation. If the use of the preparation as recommended does not 
result in contamination of the milk, neither of the above warning 
statements is required.

[40 FR 13807, Mar. 27, 1975, as amended at 63 FR 32980, June 17, 1998; 
64 FR 51241, Sept. 22, 1999]



Sec. 510.106  Labeling of antibiotic and antibiotic-containing drugs 
intended for use in milk-producing animals.

    Whenever the labeling of an antibiotic drug included in the 
regulations in this chapter suggests or recommends its use in milk-
producing animals, the label of such drugs shall bear either the 
statement ``Warning: Not for use in animals producing milk, since this 
use will result in contamination of the milk'' or the statement 
``Warning: Milk that has been taken from animals during treatment and 
for ----hours after the latest treatment must not be used for food'', 
the blank being filled in with the figure that the Commissioner has 
authorized the manufacturer of the drug to use. The Commissioner shall 
determine what such figures shall be from information submitted by the 
manufacturer and which the Commissioner considers is adequate to prove 
that period of time after the latest treatment that the milk from 
treated animals will contain no violative residues from use of the 
preparation. If the Commissioner determines from the information 
submitted that the use of the antibiotic drug as recommended does not 
result in its appearance in the milk, the Commissioner may exempt the 
drug from bearing either of the above warning statements.

[63 FR 32980, June 17, 1998]



Sec. 510.110  Antibiotics used in food-producing animals.

    (a) The Food and Drug Administration in the interest of fulfilling 
its responsibilities with regard to protection of the public health has 
requested an evaluation of the public health aspects of the use of 
antibiotics in veterinary medical and nonmedical uses. There is 
particular concern with regard to the potential hazards associated with 
the extensive use of antibiotics administered to food-producing animals. 
Accordingly, an ad hoc committee on the Veterinary Medical and 
Nonmedical Uses of Antibiotics was established by the Food and Drug 
Administration to study and advise the Commissioner of Food and Drugs on 
the uses of antibiotics in veterinary medicine and for various 
nonmedical purposes as such uses may affect the enforcement of the 
Federal Food, Drug, and Cosmetic Act with respect to their safety and 
effectiveness.
    (b) Based upon an evaluation of the conclusions of said Committee 
and other relevant material, Sec. 510.112 was published in the Federal 
Register of August 23, 1966 (31 FR 11141), asking sponsors of drugs 
containing any antibiotic intended for use in food-producing animals to 
submit data to establish whether such antibiotic and its metabolites are 
present as residues in edible tissues, milk, and eggs from treated 
animals. The data on the residues of antibiotics in milk from 
intramammary infusion preparations were requested within 60 days and the 
data on all other products were requested within 180 days following the 
date of publication of Sec. 510.112 in the Federal Register.
    (c) An evaluation of the data now available shows that use of many 
antibiotic preparations cause residues in edible products of treated 
animals for varying and, in some cases, for long periods of time 
following the last administration. Because of the accumulation of new 
information with regard to the development of resistance of bacteria to 
antibiotics, the ability of bacteria to transfer this resistance, and 
the development of sensitivity to antibiotics in humans, unauthorized 
and unsafe residues of antibiotics cannot be permitted in food obtained 
from treated animals.
    (d) Based on evaluation of information available, including the 
conclusions of the aforementioned ad hoc Committee, the Commissioner 
concludes that antibiotic preparations intended for use in food-
producing animals, other than topical and ophthalmic preparations, are 
not generally recognized among qualified experts as having been shown to 
be safe for their intended use(s) within the meaning of

[[Page 42]]

section 201(s) of the Federal Food, Drug, and Cosmetic Act.
    (e) Therefore, all exemptions from the provisions of section 409 of 
the act for use of antibiotics in food-producing animals based on 
sanctions or approvals granted prior to enactment of the Food Additives 
Amendment of 1958 (Pub. L. 85-929; 72 Stat. 1784) will be revoked and 
the uses which are concluded to be safe will be covered by food additive 
regulations. On those products for which there are inadequate residue 
data, actions will be initiated to withdraw approval of new-drug 
applications under the provisions of section 505 of the act. Antibiotic 
preparations, other than those for topical and ophthalmic application in 
food-producing animals, which are not covered by food additive 
regulations will be subject to regulatory action within 180 days after 
publication of the forthcoming revocation order.
    (f) Because of the variation in the period of time that antibiotic 
residues may remain in edible products from treated animals, all 
injectable, intramammary infusion, intrauterine, and oral preparations, 
including medicated premixes intended for use in food-producing animals, 
are deemed to be new drugs as well as food additives.

[40 FR 13807, Mar. 27, 1975, as amended at 54 FR 18280, Apr. 28, 1989; 
64 FR 403, Jan. 5, 1999]



Sec. 510.112  Antibiotics used in veterinary medicine and for 
nonmedical purposes; required data.

    (a) An ad hoc committee, Committee on the Veterinary Medical and 
Nonmedical Uses of Antibiotics, was formed by the Food and Drug 
Administration to study, and advise the Commissioner on, the use of 
antibiotics in veterinary medicine and for various nonmedical purposes 
as such uses may affect the enforcement of the Federal Food, Drug, and 
Cosmetic Act with respect to the safety and effectiveness of such 
substances. A copy of the report may be obtained from the Food and Drug 
Administration, Office of Public Affairs, Room 15-05, Parklawn Building, 
5600 Fishers Lane, Rockville, MD 20857.
    (b) On the basis of the report of the Committee and other 
information, sponsors of drugs containing any antibiotic intended for 
use in food-producing animals shall submit data for determining whether 
or not such antibiotics and their metabolites are present as residues in 
edible tissues, milk, and eggs from treated animals; however, in the 
case of a drug for which such data have already been submitted and for 
which a regulation has been promulgated under section 409 of the act, 
only such data as has been accumulated since the issuance of the 
regulation need be submitted.
    (c) The required data shall be submitted within 180 days of the date 
of publication of this section in the Federal Register; except that in 
the case of data on intramammary infusion preparations the data shall be 
submitted within 60 days of such publication. Data demonstrating the 
absence in milk of residues of intramammary infusion preparations when 
used as directed in their labeling are needed within the 60-day period 
because of the importance of milk in the human diet.
    (d) Regulatory proceedings including revocation of prior sanctions, 
or actions to suspend or amend new drug or antibiotic approvals granted 
prior to passage of the Food Additives Amendment of 1958 (72 Stat. 
1784), may be initiated with regard to the continued marketing of any 
antibiotic preparation on which the required information is not 
submitted within the period of time prescribed by paragraph (c) of this 
section.
    (e) Questions relating to the acceptability of proposed research 
protocols and assay methods for determining the amount of antibiotic 
residues in food should be directed to the Director, Center for 
Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., 
Rockville, MD 20855.

[40 FR 13807, Mar. 27, 1975, as amended at 46 FR 8460, Jan. 27, 1981; 54 
FR 18280, Apr. 28, 1989; 57 FR 6475, Feb. 25, 1992]

Subpart C [Reserved]

[[Page 43]]



                      Subpart D_Records and Reports



Sec. 510.301  Records and reports concerning experience with animal 
feeds bearing or containing new animal drugs for which an approved 

medicated feed mill license application is in effect.

    Records and reports of clinical and other experience with the new 
animal drug will be maintained and reported, appropriately identified 
with the new animal drug application(s) or index listing(s) to which 
they relate, to the Center for Veterinary Medicine in duplicate in 
accordance with the following:
    (a) Immediately upon receipt by the applicant, complete records or 
reports covering information of the following kinds:
    (1) Information concerning any mixup in the new animal drug or its 
labeling with another article.
    (2) Information concerning any bacteriological or any significant 
chemical, physical, or other change or deterioration in the drug, or any 
failure of one or more distributed batches of the drug to meet the 
specifications established for it in the new animal drug application or 
request for determination of eligibility for indexing.
    (b) As soon as possible, and in any event within 15 working days of 
its receipt by the applicant, complete records or reports concerning any 
information of the following kinds:
    (1) Information concerning any unexpected side effect, injury, 
toxicity, or sensitivity reaction or any unexpected incidence or 
severity thereof associated with clinical uses, studies, investigations, 
or tests, whether or not determined to be attributable to the new animal 
drug, except that this requirement shall not apply to the submission of 
information described in a written communication to the applicant from 
the Food and Drug Administration as types of information that may be 
submitted at other designated intervals. Unexpected as used in this 
paragraph refers to conditions or developments not previously submitted 
as part of the new animal drug application or in support of the index 
listing or not encountered during clinical trials of the drug, or 
conditions or developments occurring at a rate higher than shown by 
information previously submitted as part of the new animal drug 
application or in support of the index listing or at a rate higher than 
encountered during such clinical trials.
    (2) Information concerning any unusual failure of the new animal 
drug to exhibit its expected pharmacological activity.

[40 FR 13807, Mar. 27, 1975, as amended at 54 FR 18280, Apr. 28, 1989; 
72 FR 69121, Dec. 6, 2007]



Sec. 510.305  Maintenance of copies of approved medicated feed mill 
licenses to manufacture animal feed bearing or containing new animal 

drugs.

    Each applicant shall maintain in a single accessible location:
    (a) A copy of the approved medicated feed mill license (Form FDA 
3448) on the premises of the manufacturing establishment; and
    (b) Approved or index listed labeling for each Type B and/or Type C 
feed being manufactured on the premises of the manufacturing 
establishment or the facility where the feed labels are generated.

[64 FR 63203, Nov. 19, 1999, as amended at 72 FR 69121, Dec. 6, 2007]



          Subpart E_Requirements for Specific New Animal Drugs



Sec. 510.410  Corticosteroids for oral, injectable, and ophthalmic 
use in animals; warnings and labeling requirements.

    (a) The Food and Drug Administration has received reports of side 
effects associated with the oral, injectable, and ophthalmic use of 
corticosteroid animal drugs. The use of these drugs administered orally 
or by injection has resulted in premature parturition when administered 
during the last trimester of pregnancy. Premature parturition may be 
followed by dystocia, fetal death, retained placenta, and metritis. 
Additionally, corticosteroids used in dogs, rabbits, and rodents during 
pregnancy have produced cleft palate in offspring. Use in dogs has 
resulted in other congenital anomalies, including deformed forelegs, 
phocomelia, and anasarca. Drugs subject to this section are required to 
carry the veterinary

[[Page 44]]

prescription legend and are subject to the labeling requirements of 
Sec. 201.105 of this chapter.
    (b) In view of these potentially serious side effects, the Food and 
Drug Administration has concluded that the labeling on or within 
packaged corticosteroid-containing preparations intended for animal use 
shall bear conspicuously the following warning statement:

    Warning: Clinical and experimental data have demonstrated that 
corticosteroids administered orally or by injection to animals may 
induce the first stage of parturition if used during the last trimester 
of pregnancy and may precipitate premature parturition followed by 
dystocia, fetal death, retained placenta, and metritis.
    Additionally, corticosteroids administered to dogs, rabbits, and 
rodents during pregnancy have resulted in cleft palate in offspring. 
Corticosteroids administered to dogs during pregnancy have also resulted 
in other congenital anomalies, including deformed forelegs, phocomelia, 
and anasarca.

[49 FR 48535, Dec. 13, 1984]



Sec. 510.440  Injectable iron preparations.

    There has been an increasing interest in the use of injectable iron 
compounds for the prevention or treatment of iron-deficiency anemia in 
animals. Although some such preparations have been shown to be safe, 
such articles are regarded as new animal drugs within the meaning of the 
Federal Food, Drug, and Cosmetic Act. Accordingly, an approved new 
animal drug application is required prior to the marketing of such 
preparations within the jurisdiction of the act. In addition to the need 
for demonstrating the safety of such articles, the labeling of such 
preparations should not only recommend appropriate dosages of iron but 
also declare the amount (in milligrams) of available iron (Fe) per 
milliliter of the subject product.



Sec. 510.455  Requirements for free-choice medicated feeds.

    (a) What is free-choice medicated feed? For the purpose of this 
part, free-choice medicated feed is medicated feed that is placed in 
feeding or grazing areas and is not intended to be consumed fully at a 
single feeding or to constitute the entire diet of the animal. Free-
choice feeds include, but are not limited to, medicated blocks 
(agglomerated feed compressed or rendered into a solid mass and cohesive 
enough to hold its form), mineral mixes, and liquid feed tank 
supplements (``lick tank'' supplements) containing one or more new 
animal drugs. The manufacture of medicated free-choice feeds is subject 
to the current good manufacturing practice regulations in part 225 of 
this chapter for medicated feeds.
    (b) What is required for new animal drugs intended for use in free-
choice feed? Any new animal drug intended for use in free-choice feed 
must be approved for such use under section 512 of the Federal Food, 
Drug, and Cosmetic Act (the act) (21 U.S.C. 360(b)) or listed in the 
index under section 572 of the act (21 U.S.C. 360ccc-1). Such approvals 
under section 512 of the act must be:
    (1) An original new animal drug application (NADA),
    (2) A supplemental NADA, or
    (3) An abbreviated NADA.
    (c) What are the approval requirements under section 512 of the act 
for new animal drugs intended for use in free-choice feed? An approval 
under section 512 of the act for a Type A medicated article intended for 
use in free-choice feed must contain the following information:
    (1) Data, or reference to data in a master file (MF), showing that 
the target animal consumes the new animal drug in the Type C free-choice 
feed in an amount that is safe and effective (consumption/effectiveness 
data); and
    (2) Data, or reference to data in an MF, showing the relevant ranges 
of conditions under which the drug will be chemically and physically 
stable in the Type C free-choice feed under field conditions.
    (d) How are consumption/effectiveness and/or stability data to be 
submitted? The data must be submitted as follows:
    (1) Directly in the NADA, by a sponsor; and/or
    (2) To an MF that a sponsor may then reference in its NADA with 
written consent of the MF holder.
    (e) What will be stated in the published approval for a new animal 
drug intended for use in free-choice feed? The approval of a new animal 
drug intended for use

[[Page 45]]

in free-choice feed, as published in this subchapter, will include:
    (1) The formula and/or specifications of the free-choice medicated 
feed, where the owner of this information requests such publication, or
    (2) A statement that the approval has been granted for a proprietary 
formula and/or specifications.
    (f) When is a medicated feed mill license required for the 
manufacture of a free-choice medicated feed? An approved medicated feed 
mill license is required for the manufacture of the following types of 
feeds:
    (1) All free-choice medicated feeds that contain a Category II drug, 
and
    (2) Free-choice medicated feeds that contain a Category I drug and 
use a proprietary formula and/or specifications.

[69 FR 30197, May 27, 2004, as amended at 72 FR 69121, Dec. 6, 2007]

Subpart F [Reserved]



               Subpart G_Sponsors of Approved Applications



Sec. 510.600  Names, addresses, and drug labeler codes of sponsors 
of approved applications.

    (a) Section 512(i) of the act requires publication of names and 
addresses of sponsors of approved applications for new animal drugs.
    (b) In this section each name and address is identified by a 
numerical drug labeler code. The labeler codes identify the sponsors of 
the new animal drug applications associated with the regulations 
published pursuant to section 512(i) of the act. The codes appear in the 
appropriate regulations and serve as a reference to the names and 
addresses listed in this section. The drug labeler code is established 
pursuant to section 510 of the act.
    (c) The names, addresses, and drug labeler codes of sponsors of 
approved new animal drug applications are as follows:

                  (1) Alphabetical Listing of Sponsors
------------------------------------------------------------------------
                                                           Drug labeler
                  Firm name and address                        code
------------------------------------------------------------------------
A & G Pharmaceuticals, Inc., 1030 West Commodore Blvd.,           057699
 Jackson, NJ 08527......................................
AB Science, 3 Avenue George V, 75008 Paris, France......          052913
Abbott Laboratories, North Chicago, IL 60064............          000044
Accord Healthcare, Inc., 1009 Slater Rd., suite 210-B,            016729
 Durham, NC 27703.......................................
ADM Alliance Nutrition, Inc., 1000 North 30th St.,                012286
 Quincy, IL 62305-3115..................................
Agri Laboratories, Ltd., P.O. Box 3103, St. Joseph, MO            057561
 64503..................................................
Agri-Tech, Inc., 4722 Broadway, Kansas City, MO 64112...          017762
Alaco, Inc., 1500 North Wilmot Rd., suite 290-C, Tucson,          064146
 AZ 85712...............................................
Alpharma, LLC, a wholly owned subsidiary of Pfizer,               046573
 Inc., 235 East 42d St., New York, NY 10017.............
Alstoe, Ltd., Animal Health, Pera Innovation Park,                062408
 Nottingham Rd., Melton Mowbray, Leicestershire, England
 LE13 0PB...............................................
American Pharmaceuticals and Cosmetics, Inc., 1401 Joel           065531
 East Rd., Fort Worth, TX 76140.........................
Anika Therapeutics Inc., 236 West Cummings Park, Woburn,          060865
 MA 01801...............................................
Argent Laboratories, 8702 152d Ave. NE., Redmond, WA              051212
 98052..................................................
Ark Sciences, Inc., 1101 East 33rd St., suite B304,               076175
 Baltimore, MD 21218....................................
B.L. Mitchell, Inc., 103 Hwy. 82 E., Leland, MS 38756...          067188
Baxter Healthcare Corp., One Baxter Pkwy., Deerfield, IL          010019
 60015..................................................
Bayer HealthCare LLC, Animal Health Division, P.O. Box            000859
 390, Shawnee Mission, KS 66201.........................
Belcher Pharmaceuticals, LLC, 6911 Bryan Dairy Rd.,               062250
 Largo, FL 33777........................................
Bioniche Animal Health USA, Inc., 119 Rowe Rd., Athens,           064847
 GA 30601...............................................
Boehringer Ingelheim Vetmedica, Inc., 2621 North Belt             000010
 Highway, St. Joseph, MO 64506-2002.....................
Cephazone Pharma, LLC, 250 East Bonita Ave., Pomona, CA           068330
 91767..................................................
Ceva Sante Animale, 10 Avenue de la Ballasti[egrave]re,           013744
 33500 Libourne, France.................................
Chanelle Pharmaceuticals Manufacturing Ltd., Loughrea,            061651
 County Galway, Ireland.................................
ConAgra Pet Products Co., 3902 Leavenworth St., Omaha,            021091
 NE 68105...............................................
Contemporary Products, Inc., 3788 Elm Springs Rd.,                055462
 Springdale, AR 72764-6067..............................
Cooperative Research Farms, Box 69, Charlotteville, NY            051267
 12036..................................................
Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght,               061623
 Dublin 24, Ireland.....................................
Dechra, Ltd., Dechra House, Jamage Industrial Estate,             043264
 Talke Pits, Stoke-on-Trent, Staffordshire, ST7 1XW,
 United Kingdom.........................................
ECO LLC, 344 Nassau St., Princeton, NJ 08540............          066916
Eka Chemicals, Inc., 1850 Parkway Pl. SE., suite 1200,            061088
 Marietta, GA 30067.....................................
Elanco Animal Health, A Division of Eli Lilly & Co.,              000986
 Lilly Corporate Center, Indianapolis, IN 46285.........
Farnam Companies, Inc., 301 West Osborn, Phoenix, AZ              017135
 85013-3928.............................................
First Priority, Inc., 1590 Todd Farm Dr., Elgin, IL               058829
 60123..................................................
Fleming Laboratories, Inc., P.O. Box 34384, Charlotte,            015565
 NC 28234...............................................

[[Page 46]]

 
Fort Dodge Animal Health, Division of Wyeth, a wholly             000856
 owned subsidiary of Pfizer, Inc., 235 East 42d St., New
 York, NY 10017.........................................
Fort Dodge Animal Health, Division of Wyeth Holdings              053501
 Corp., a wholly owned subsidiary of Pfizer, Inc., 235
 East 42d St., New York, NY 10017.......................
Fougera Pharmaceuticals, Inc., P.O. Box 2006, 60 Baylis           025463
 Rd., Melville, NY 11747................................
G. C. Hanford Manufacturing Co., P.O. Box 1017,                   010515
 Syracuse, NY 13201.....................................
Gossett Nutrition, Inc., 1676 Cascade Dr., Marion, OH             050972
 43302..................................................
GTC Biotherapeutics, Inc., 175 Crossing Blvd.,                    042976
 Framingham, MA 01702...................................
Halocarbon Products Corp., 887 Kinderkamack Rd., River            012164
 Edge, NJ 07661.........................................
Happy Jack, Inc., Snow Hill, NC 28580...................          023851
Heska Corp., 1825 Sharp Point Dr., Fort Collins, CO               063604
 80525..................................................
Hess & Clark, Inc., 944 Nandino Blvd., Lexington, KY              050749
 40511..................................................
Hospira, Inc., 275 North Field Dr., Lake Forest, IL               000409
 60045..................................................
Huvepharma AD, 5th Floor, 3A Nikolay Haitov Str., 1113            016592
 Sofia, Bulgaria........................................
IDEXX Pharmaceuticals, Inc., 7009 Albert Pick Rd.,                065274
 Greensboro, NC 27409...................................
IMPAX Laboratories, Inc., 30831 Huntwood Ave., Hayward,           000115
 CA 94544...............................................
International Nutrition, Inc., 7706 `I' Plaza, Omaha, NE          043733
 68127..................................................
Intervet, Inc., 556 Morris Ave., Summit, NJ 07901.......          000061
JBS United Animal Health II LLC, 322 S. Main St.,                 051233
 Sheridan, IN 46069.....................................
Jurox Pty. Ltd., 85 Gardiner St., Rutherford, NSW 2320,           049480
 Australia..............................................
Land O' Lakes Purina Feed LLC, 100 Danforth Dr., Gray             066071
 Summit, MO 63039.......................................
Lloyd, Inc., 604 W. Thomas Ave., Shenandoah, IA 51601...          061690
Luitpold Pharmaceuticals, Inc., Animal Health Division,           010797
 Shirley, NY 11967......................................
Macleod Pharmaceuticals, Inc., 2600 Canton Ct., Fort              058711
 Collins, CO 80525......................................
Med-Pharmex, Inc., 2727 Thompson Creek Rd., Pomona, CA            054925
 91767-1861.............................................
Medicis Dermatologics, Inc., 8125 North Hayden Rd.,               099207
 Scottsdale, AZ 85258...................................
Merial Ltd., 3239 Satellite Blvd., Bldg. 500, Duluth, GA          050604
 30096-4640.............................................
Micro Beef Technologies LTD, P.O. Box 9262, Amarillo, TX          047126
 79105..................................................
Mylan Institutional, Inc., 12720 Dairy Ashford Rd.,               051079
 Sugar Land, TX 77478...................................
Mylan Institutional LLC, 4901 Hiawatha Dr., Rockford, IL          063286
 61103..................................................
Natchez Animal Supply Co., 201 John R. Junkin Dr.,                049968
 Natchez, MS 39120......................................
Nexcyon Pharmaceuticals, Inc., 644 W. Washington Ave.,            050929
 Madison, WI 53703......................................
Norbrook Laboratories, Ltd., Station Works, Newry BT35            055529
 6JP, Northern Ireland..................................
Novartis Animal Health US, Inc., 3200 Northline Ave.,             058198
 suite 300, Greensboro, NC 27408........................
NutriBasics Co., North Highway 71, P.O. Box 1014,                 053740
 WIllmar, MN 56201......................................
Orion Corp., Orionintie 1, 02200 Espoo, Finland.........          052483
OPK Biotech, LLC, 11 and 39 Hurley St., Cambridge, MA             063075
 02141..................................................
OXIS International, Inc., 6040 N. Cutter Circle, Suite            024991
 317, Portland, OR 97217-3935...........................
Paladin Labs (USA), Inc., 160 Greentree Dr., suite 101,           046129
 Dover, DE 19904........................................
Parnell Technologies Pty. Ltd., unit 4, 476 Gardeners             068504
 Rd., Alexandria, New South Wales 2015, Australia.......
Pegasus Laboratories, Inc., 8809 Ely Rd., Pensacola, FL           055246
 32514..................................................
Pennfield Oil Co., 14040 Industrial Rd., Omaha, NE 68144          048164
Pfizer, Inc., 235 East 42d St., New York, NY 10017......          000069
Pharmaceutical Ventures, Ltd., P.O. Box D1400, Pomona,            050057
 NY 10970...............................................
Pharmacia & Upjohn Co., a Division of Pfizer, Inc., 235           000009
 East 42d St., New York, NY 10017.......................
Pharmacosmos, Inc., 776 Mountain Blvd., Watchung, NJ              042552
 07069..................................................
Pharmaq AS, Skogmo Industriomrade, N-7863 Overhalla,              015331
 Norway.................................................
Phibro Animal Health Corp., GlenPointe Centre East, 3d            066104
 floor, 300 Frank W. Burr Blvd., suite 21, Teaneck, NJ
 07666..................................................
Piramal Critical Care, Inc., 3850 Schelden Circle,                066794
 Bethlehem, PA 18017....................................
Piramal Healthcare Ltd., Piramal Tower, Ganpatrao Kadam           065085
 Marg, Lower Parel, Mumbai - 400 013, India.............
Planalquimica Industrial Ltda., Rua das Magnolias nr.             060728
 2405, Jardim das Bandeiras, CEP 13053-120, Campinas,
 Sao Paulo, Brazil......................................
Provimi North America, Inc., 6531 State Rte. 503,                 017790
 Lewisburg, OH 45338....................................
Purina Mills, Inc., P.O. Box 66812, St. Louis, MO 63166-          017800
 6812...................................................
Putney, Inc., 400 Congress St., suite 200, Portland, ME           026637
 04101..................................................
Quali-Tech Products, Inc., 318 Lake Hazeltine Drive,              016968
 Chaska, MN 55318.......................................
Quo Vademus, LLC, 277 Faison McGowan Rd., Kenansville,            076475
 NC 28349...............................................
R. P. Scherer North America, P.O. Box 5600, Clearwater,           011014
 FL 33518...............................................
Ridley Block Operations Inc., 424 North Riverfront Dr.,           068287
 P.O. Box 8500, Mankato, MN 56002-8500..................
Ridley U.S. Holdings, Inc., 424 North Riverfront Dr.,             067949
 P.O. Box 8500, Mankato, MN 56002-8500..................
RSR Laboratories, Inc., 501 Fifth St., Bristol, TN 37620          058670
Seeco Inc., Box 1014, North Highway 71, Willmar, MN               011749
 56201..................................................
Sioux Biochemical, Inc., 204 Third St. NW., Sioux                 063112
 Center, IA 51250.......................................
Southern Micro-Blenders, Inc., 3801 North Hawthorne St.,          049685
 Chattanooga, TN 37406..................................
Sparhawk Laboratories, Inc., 12340 Santa Fe Trail Dr.,            058005
 Lenexa, KS 66215.......................................
Squire Laboratories, Inc., 100 Mill St., Revere, MA               017153
 02151..................................................
Summit Hill Laboratories, P.O. Box 535, Navesink, NJ              037990
 07752..................................................
Superior Equine Pharmaceuticals, Inc., Pleasant Grove,            027053
 UT 84062...............................................
Taro Pharmaceuticals U.S.A., Inc., 3 Skyline Dr.,                 051672
 Hawthorne, NY 10532....................................
Teva Canada Ltd., 30 Novopharm Ct., Toronto, Ontario,             043806
 Canada M1B 2K9.........................................

[[Page 47]]

 
Therio, Inc., 8801 Anderson Ave., Manhattan, KS 66503...          052923
Thorn Bioscience LLC, 1044 East Chestnut St.,                     051330
 Louisville, KY 40204...................................
Veterinary Service, Inc., 4100 Bangs Ave., Modesto, CA            033008
 95356..................................................
V[eacute]toquinol N.-A., Inc., 2000 chemin Georges,               059320
 Lavaltrie (PQ), Canada, J5T 3S5........................
Virbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX 76137          051311
Walco International, Inc., 15 West Putnam, Porterville,           049185
 CA 93257
Watson Laboratories, Inc., 311 Bonnie Circle, Corona, CA          000402
 92880..................................................
Wayne Feed Division, Continental Grain Co., P.O. Box              034936
 459, Libertyville, IL 60048............................
Wellmark International, 1501 East Woodfield Rd., suite            011536
 200 West, Schaumburg, IL 60173.........................
West Agro, Inc., 11100 N. Congress Ave., Kansas City, MO          033392
 64153..................................................
West-Ward Pharmaceutical Corp., 465 Industrial Way West,          000143
 Eatontown, NJ 07724....................................
Western Chemical, Inc., 1269 Lattimore Rd., Ferndale, WA          050378
 98248..................................................
Wildlife Laboratories, Inc., 1401 Duff Dr., Suite 600,            053923
 Fort Collins, CO 80524.................................
------------------------------------------------------------------------


                    (2) Numerical Listing of Sponsors
------------------------------------------------------------------------
 Drug labeler
     code                         Firm name and address
------------------------------------------------------------------------
        000008  Wyeth Laboratories, Division American Home Products
                 Corp., P.O. Box 8299, Philadelphia, PA 19101.
        000009  Pharmacia & Upjohn Co., a Division of Pfizer, Inc., 235
                 East 42d St., New York, NY 10017.
        000010  Boehringer Ingelheim Vetmedica, Inc., 2621 North Belt
                 Highway, St. Joseph, MO 64506-2002.
        000044  Abbott Laboratories, North Chicago, IL 60064
        000061  Intervet, Inc., 556 Morris Ave., Summit, NJ 07901.
        000069  Pfizer, Inc., 235 East 42d St., New York, NY 10017.
        000115  IMPAX Laboratories, Inc., 30831 Huntwood Ave., Hayward,
                 CA 94544
        000143  West-Ward Pharmaceutical Corp., 465 Industrial Way West,
                 Eatontown, NJ 07724.
        000402  Watson Laboratories, Inc., 311 Bonnie Circle, Corona, CA
                 92880.
        000409  Hospira Inc., 275 North Field Dr., Lake Forest, IL
                 60045.
        000856  Fort Dodge Animal Health, Division of Wyeth, a wholly
                 owned subsidiary of Pfizer, Inc., 235 East 42d St., New
                 York, NY 10017
        000859  Bayer HealthCare LLC, Animal Health Division, P.O. Box
                 390, Shawnee Mission, KS 66201.
        000986  Elanco Animal Health, A Division of Eli Lilly & Co.,
                 Lilly Corporate Center, Indianapolis, IN 46285.
        010019  Baxter Healthcare Corp., One Baxter Pkwy., Deerfield, IL
                 60015.
        010515  G. C. Hanford Manufacturing Co., P.O. Box 1017,
                 Syracuse, NY 13201.
        010797  Luitpold Pharmaceuticals, Inc., Animal Health Division,
                 Shirley, NY 11967.
        011014  R. P. Scherer North America, P.O. Box 5600, Clearwater,
                 FL 33518.
        011536  Wellmark International, 1501 East Woodfield Rd., suite
                 200 West, Schaumburg, IL 60173.
        012164  Halocarbon Products Corp., 887 Kinderkamack Rd., River
                 Edge, NJ 07661.
        012286  ADM Alliance Nutrition, Inc., 1000 North 30th St.,
                 Quincy, IL 62305-3115.
        012578  Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340
                 Beerse, Belgium
        013744  Ceva Sante Animale, 10 Avenue de la Ballasti[egrave]re,
                 33500 Libourne, France.
        015331  Pharmaq AS, Skogmo Industriomrade, N-7863 Overhalla,
                 Norway.
        015565  Fleming Laboratories, Inc., P.O. Box 34384, Charlotte,
                 NC 28234.
        016592  Huvepharma AD, 5th Floor, 3A Nikolay Haitov Str., 1113
                 Sofia, Bulgaria.
        016729  Accord Healthcare, Inc., 1009 Slater Rd., suite 210-B,
                 Durham, NC 27703
        016968  Quali-Tech Products, Inc., 318 Lake Hazeltine Dr.,
                 Chaska, MN 55318.
        017135  Farnam Companies, Inc., 301 West Osborn, Phoenix, AZ
                 85013-3928.
        017153  Squire Laboratories, Inc., 100 Mill St., Revere, MA
                 02151.
        017762  Agri-Tech, Inc., 4722 Broadway, Kansas City, MO 64112.
        017790  Provimi North America, Inc., 6531 State Rte. 503,
                 Lewisburg, OH 45338.
        017800  Purina Mills, Inc., P.O. Box 66812, St. Louis, MO 63166-
                 6812.
        021091  ConAgra Pet Products Co., 3902 Leavenworth St., Omaha,
                 NE 68105.
        023851  Happy Jack, Inc., Snow Hill, NC 28580.
        024991  OXIS International, Inc., 6040 N. Cutter Circle, Suite
                 317 Portland, OR 97217-3935.
        025463  Fougera Pharmaceuticals, Inc., P.O. Box 2006, 60 Baylis
                 Rd., Melville, NY 11747.
        026637  Putney, Inc., 400 Congress St., suite 200, Portland, ME
                 04101.
        027053  Superior Equine Pharmaceuticals, Inc., Pleasant Grove,
                 UT 84062.
        033008  Veterinary Service, Inc., 4100 Bangs Ave., Modesto, CA
                 95356.
        033392  West Agro, Inc., 11100 N. Congress Ave., Kansas City, MO
                 64153.
        034936  Wayne Feed Division, Continental Grain Co., P.O. Box
                 459, Libertyville, IL 60048.
        037990  Summit Hill Laboratories, P.O. Box 535, Navesink, NJ
                 07752.
        042552  Pharmacosmos, Inc., 776 Mountain Blvd., Watchung, NJ
                 07069.
        042976  GTC Biotherapeutics, Inc., 175 Crossing Blvd.,
                 Framingham, MA 01702.
        043264  Dechra, Ltd., Dechra House, Jamage Industrial Estate,
                 Talke Pits, Stoke-on-Trent, Staffordshire, ST7 1XW,
                 United Kingdom.
        043733  International Nutrition, Inc., 7706 `I' Plaza, Omaha, NE
                 68127.
        043806  Teva Canada Ltd., 30 Novopharm Ct., Toronto, Ontario,
                 Canada M1B 2K9.
        046129  Paladin Labs (USA), Inc., 160 Greentree Dr., suite 101,
                 Dover, DE 19904.
        046573  Alpharma, LLC, a wholly owned subsidiary of Pfizer,
                 Inc., 235 East 42d St., New York, NY 10017
        047126  Micro Beef Technologies LTD, P.O. Box 9262, Amarillo, TX
                 79105.

[[Page 48]]

 
        048164  Pennfield Oil Co., 14040 Industrial Rd., Omaha, NE
                 68144.
        049185  Walco International, Inc., 15 West Putnam, Porterville,
                 CA 93257.
        049480  Jurox Pty. Ltd., 85 Gardiner St., Rutherford, NSW 2320,
                 Australia
        049968  Natchez Animal Supply Co., 201 John R. Junkin Dr.,
                 Natchez, MS 39120.
        050057  Pharmaceutical Ventures, Ltd., P.O. Box D1400, Pomona,
                 NY 10970.
        050378  Western Chemical, Inc., 1269 Lattimore Rd., Ferndale, WA
                 98248.
        050604  Merial Ltd., 3239 Satellite Blvd., Bldg. 500, Duluth, GA
                 30096-4640.
        050749  Hess & Clark, Inc., 944 Nandino Blvd., Lexington, KY
                 40511.
        050972  Gossett Nutrition, Inc., 1676 Cascade Dr., Marion, OH
                 43302.
        050929  Nexcyon Pharmaceuticals, Inc., 644 W. Washington Ave.,
                 Madison, WI 53703
        051079  Mylan Institutional, Inc., 12720 Dairy Ashford Rd.,
                 Sugar Land, TX 77478.
        051212  Argent Laboratories, 8702 152d Ave. NE., Redmond, WA
                 98052.
        051233  JBS United Animal Health II LLC, 322 S. Main St.,
                 Sheridan, IN 46069.
        051267  Cooperative Research Farms, Box 69, Charlotteville, NY
                 12036.
        051311  Virbac AH, Inc., 3200 Meacham Blvd., Ft. Worth, TX
                 76137.
        051330  Thorn Bioscience LLC, 1044 East Chestnut St.,
                 Louisville, KY 40204
        051672  Taro Pharmaceuticals U.S.A., Inc., 3 Skyline Dr.,
                 Hawthorne, NY 10532.
        052483  Orion Corp., Orionintie 1, 02200 Espoo, Finland.
        052913  AB Science, 3 Avenue George V, 75008 Paris, France.
        052923  Therio, Inc., 8801 Anderson Ave., Manhattan, KS 66503
        053501  Fort Dodge Animal Health, Division of Wyeth Holdings
                 Corp., a wholly owned subsidiary of Pfizer, Inc., 235
                 East 42d St., New York, NY 10017
        053923  Wildlife Laboratories, Inc., 1401 Duff Dr., Suite 600,
                 Fort Collins, CO 80524.
        054925  Med-Pharmex, Inc., 2727 Thompson Creek Rd., Pomona, CA
                 91767-1861.
        055246  Pegasus Laboratories, Inc., 8809 Ely Rd., Pensacola, FL
                 32514.
        055462  Contemporary Products, Inc., 3788 Elm Springs Rd.,
                 Springdale, AR 72764-6067.
        055529  Norbrook Laboratories, Ltd., Station Works, Newry BT35
                 6JP, Northern Ireland.
        057561  Agri Laboratories, Ltd., P.O. Box 3103, St. Joseph, MO
                 64503.
        057699  A & G Pharmaceuticals, Inc., 1030 West Commodore Blvd.,
                 Jackson, NJ 08527.
        058005  Sparhawk Laboratories, Inc., 12340 Santa Fe Trail Dr.,
                 Lenexa, KS 66215.
        058198  Novartis Animal Health US, Inc., 3200 Northline Ave.,
                 suite 300, Greensboro, NC 27408.
        058670  RSR Laboratories, Inc., 501 Fifth St., Bristol, TN
                 37620.
        058711  Macleod Pharmaceuticals, Inc., 2600 Canton Ct., Fort
                 Collins, CO 80525.
        058829  First Priority, Inc., 1590 Todd Farm Dr., Elgin, IL
                 60123.
        059320  V[eacute]toquinol N.-A., Inc., 2000 chemin Georges,
                 Lavaltrie (PQ), Canada, J5T 3S5.
        060728  Planalquimica Industrial Ltda., Rua das Magnolias nr.
                 Jardim das Bandeiras, CEP 13053-120, Campinas, Sao
                 Alto, Brazil.
        060865  Anika Therapeutics Inc., 236 West Cummings Park, Woburn,
                 MA 01801.
        061088  Eka Chemicals, Inc., 1850 Parkway Pl. SE., suite 1200,
                 Marietta, GA 30067
        061623  Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght,
                 Dublin 24, Ireland.
        061651  Chanelle Pharmaceuticals Manufacturing Ltd., Loughrea,
                 County Galway, Ireland.
        061690  Lloyd, Inc., 604 W. Thomas Ave., Shenandoah, IA 51601.
        062250  Belcher Pharmaceuticals, LLC, 6911 Bryan Dairy Rd.,
                 Largo, FL 33777.
        062408  Alstoe, Ltd., Animal Health, Pera Innovation Park,
                 Nottingham Rd., Melton Mowbray, Leicestershire, England
                 LE13 0PB.
        062794  Mylan Bertek Pharmaceuticals, Inc., 12720 Dairy Ashford,
                 Sugar Land, TX 77478
        063075  OPK Biotech, LLC, 11 and 39 Hurley St., Cambridge, MA
                 02141
        063112  Sioux Biochemical, Inc., 204 Third St. NW., Sioux
                 Center, IA 51250.
        063286  Mylan Institutional, LLC, 4901 Hiawatha Dr., Rockford,
                 IL 61103.
        063604  Heska Corp., 1825 Sharp Point Dr., Fort Collins, CO
                 80525.
        064146  Alaco, Inc., 1500 North Wilmot Rd., suite 290-C, Tucson,
                 AZ 85712.
        064847  Bioniche Animal Health USA, Inc., 119 Rowe Rd., Athens,
                 GA 30601.
        065085  Piramal Healthcare Ltd., Piramal Tower, Ganpatrao Kadam
                 Marg, Lower Parel, Mumbai - 400 013, India.
        065274  IDEXX Pharmaceuticals, Inc., 7009 Albert Pick Rd.,
                 Greensboro, NC 27409.
        065531  American Pharmaceuticals and Cosmetics, Inc., 1401 Joel
                 East Rd., Fort Worth, TX 76140.
        066071  Land O' Lakes Purina Feed LLC, 100 Danforth Dr., Gray
                 Summit, MO 63039.
        066104  Phibro Animal Health Corp., GlenPointe Centre East, 3d
                 floor, 300 Frank W. Burr Blvd., suite 21, Teaneck, NJ
                 07666
        066794  Piramal Critical Care, Inc., 3850 Schelden Circle,
                 Bethlehem, PA 18017.
        066916  ECO LLC, 344 Nassau St., Princeton, NJ 08540.
        067188  B.L. Mitchell, Inc., 103 Hwy. 82 E., Leland, MS 38756.
        067949  Ridley U.S. Holdings, Inc., 424 N. Riverfront Dr., P.O.
                 Box 8500, Mankato, MN 56002-8500.
        068287  Ridley Block Operations Inc., 424 North Riverfront Dr.,
                 P.O. Box 8500, Mankato, MN 56002-8500.
        068330  Cephazone Pharma, LLC, 250 East Bonita Ave., Pomona, CA
                 91767
        068504  Parnell Technologies Pty. Ltd., unit 4, 476 Gardeners
                 Rd., Alexandria, New South Wales 2015, Australia
        076175  Ark Sciences, Inc., 1101 East 33rd St., suite B304,
                 Baltimore, MD 21218.
        076475  Quo Vademus, LLC, 277 Faison McGowan Rd., Kenansville,
                 NC 28349
        099207  Medicis Dermatologics, Inc., 8125 North Hayden Rd.,
                 Scottsdale, AZ 85258.
------------------------------------------------------------------------


[40 FR 13807, Mar. 27, 1975]

[[Page 49]]


    Editorial Note: For Federal Register citations affecting Sec. 
510.600, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.

    Editorial Note: At 72 FR 36595, July 5, 2007, Sec. 510.600, in the 
table in paragraph (c)(2), was amended by removing the entry for 
``062749''; however, the amendment could not be incorporated because the 
entry does not exist.

    Editorial Note: At 77 FR 46613, Aug. 6, 2012, Sec. 510.600 was 
amended by removing the entry for ``012758'' in the table in paragraph 
(c)(2); however, the amendment could not be incorporated because 
``012758'' doesn't exist.



PART 511_NEW ANIMAL DRUGS FOR INVESTIGATIONAL USE--Table of Contents



Sec.
511.1 New animal drugs for investigational use exempt from section 
          512(a) of the act.
511.3 Definitions.

    Authority: 21 U.S.C. 321, 351, 352, 353, 360b, 371.



Sec. 511.1  New animal drugs for investigational use exempt from 
section 512(a) of the act.

    (a) New animal drugs for tests in vitro and in laboratory research 
animals. (1) A shipment or other delivery of a new animal drug or animal 
feed bearing or containing a new animal drug intended solely for tests 
in vitro or in animals used only for laboratory research purposes shall 
be exempt from section 512 (a) and (m) of the act if it is labeled as 
follows:

    Caution. Contains a new animal drug for investigational use only in 
laboratory research animals or for tests in vitro. Not for use in 
humans.

    (2) The person distributing or causing the distribution of new 
animal drugs for tests in vitro or in animals used only for laboratory 
research purposes under this exemption shall use due diligence to assure 
that the consignee is regularly engaged in conducting such tests and 
that the shipment of the new animal drug will actually be used for tests 
in vitro or in animals used only for laboratory research.
    (3) The person who introduced such shipment or who delivered the new 
animal drug for introduction into interstate commerce shall maintain 
adequate records showing the name and post office address of the expert 
or expert organization to whom the new animal drug is shipped and the 
date, quantity, and batch or code mark of each shipment and delivery for 
a period of 2 years after such shipment and delivery. Upon the request 
of a properly authorized employee of the Department at reasonable times, 
he shall make such records available for inspection and copying.
    (4) The exemption allowed in this paragraph shall not apply to any 
new animal drug intended for in vitro use in the regular course of 
diagnosing or treating disease, including antibacterial sensitivity 
discs impregnated with any new animal drug or drugs, which discs are 
intended for use in determining susceptibility of microorganisms to the 
new animal drug or drugs.
    (b) New animal drugs for clinical investigation in animals. A 
shipment or other delivery of a new animal drug or an animal feed 
containing a new animal drug intended for clinical investigational use 
in animals shall be exempt from section 512(a) and (m) of the act if all 
the following conditions are met:
    (1) The label shall bear the statements:

    Caution. Contains a new animal drug for use only in investigational 
animals in clinical trials. Not for use in humans. Edible products of 
investigational animals are not to be used for food unless authorization 
has been granted by the U.S. Food and Drug Administration or by the U.S. 
Department of Agriculture.

    In the case of containers too small or otherwise unable to 
accommodate a label with sufficient space to bear the caution statements 
required by paragraph (a) or (b) of this section, the statements may be 
included on the carton label and other labeling on or within the package 
from which the new animal drug is to be dispensed.
    (2) The person or firm distributing or causing the distribution of 
the new animal drug or animal feed containing a new animal drug shall 
use due diligence to assure that the new animal

[[Page 50]]

drug or animal feed containing a new animal drug will actually be used 
for tests in animals and is not used in humans.
    (3) The person who introduced such shipment or who delivered the new 
animal drug or animal feed containing a new animal drug for introduction 
into interstate commerce shall maintain adequate records showing the 
name and post office address of the investigator to whom the new animal 
drug or animal feed containing a new animal drug is shipped and the 
date, quantity, and batch or code mark of each shipment and delivery for 
a period of 2 years after such shipment and delivery. Upon the request 
of a properly authorized employee of the Department at reasonable times, 
such records shall be made available for inspection and copying.
    (4) Prior to shipment of the new animal drug for clinical tests in 
animals, the sponsor of the investigation shall submit in triplicate to 
FDA a ``Notice of Claimed Investigational Exemption for a New Animal 
Drug'' including a signed statement containing the following 
information:
    (i) The identity of the new animal drug.
    (ii) All labeling and other pertinent information to be supplied to 
the investigators. When such pertinent information includes nonclinical 
laboratory studies, the information shall include, with respect to each 
nonclinical study, either a statement that the study was conducted in 
compliance with the requirements set forth in part 58 of this chapter, 
or, if the study was not conducted in compliance with such regulations, 
a brief statement of the reason for the noncompliance.
    (iii) The name and address of each clinical investigator.
    (iv) The approximate number of animals to be treated (or if not 
available, the amount of new animal drug to be shipped).
    (v) If the new animal drug is given to food-producing animals, the 
statement shall contain the following additional information:
    (a) A commitment that the edible products from such animals shall 
not be used for food without prior authorization in accordance with the 
provisions prescribed in this section.
    (b) Approximate dates of the beginning and end of the experiment or 
series of experiments.
    (c) The maximum daily dose(s) to be administered to a given species, 
the size of animal, maximum duration of administration, method(s) of 
administration, and proposed withdrawal time, if any.
    (vi) If a sponsor has transferred any obligations for the conduct of 
any clinical study to a contract research organization, a statement 
containing the name and address of the contract research organization, 
identification of the clinical study, and a listing of the obligations 
transferred. If all obligations governing the conduct of the study have 
been transferred, a general statement of this transfer--in lieu of a 
listing of the specific obligations transferred--may be submitted.
    (5) Authorization for use of edible products derived from a treated 
food-producing animal may be granted under the provisions of this 
section and when the following specified conditions are met, except that 
in the case of an animal administered any unlicensed experimental 
veterinary biological product regulated under the viruses, serums, 
toxins statute (21 U.S.C., chapter V, sec. 151 et seq. ) the product 
shall be exempt from the requirements of this section when U.S. 
Department of Agriculture approval has been obtained as provided in 9 
CFR 103.2. Conditional authorization may be granted in advance of 
identification of the name(s) and address(es) of the clinical 
investigator(s) as required by paragraph (b)(4)(iii) of this section. 
Information required for authorization shall include, in addition to all 
other requirements of this section, the following:
    (i) Data to show that consumption of food derived from animals 
treated at the maximum levels with the minimum withdrawal periods, if 
any, specified in accordance with paragraph (b)(4)(v)(c) of this 
section, will not be inconsistent with the public health; or
    (ii) Data to show that food derived from animals treated at the 
maximum levels and with the minimum withdrawal periods, if any, 
specified in accordance with paragraph (b)(4)(v)(c) of

[[Page 51]]

this section, does not contain drug residues or metabolites.
    (iii) The name and location of the packing plant where the animals 
will be processed, except that this requirement may be waived, on 
request, by the terms of the authorization.

Authorizations granted under this paragraph do not exempt 
investigational animals and their products from compliance with other 
applicable inspection requirements. Any person who contests a refusal to 
grant such authorization shall have an opportunity for a regulatory 
hearing before FDA pursuant to part 16 of this chapter.
    (6) On written request of FDA, the sponsor shall submit any 
additional information reported to or otherwise received by him with 
respect to the investigation deemed necessary to facilitate a 
determination whether there are grounds in the interest of public health 
for terminating the exemption.
    (7) The sponsor shall assure himself that the new animal drug is 
shipped only to investigators who:
    (i) Are qualified by scientific training and/experience to evaluate 
the safety and/or effectiveness of the new animal drug.
    (ii) Shall maintain complete records of the investigations, 
including complete records of the receipt and disposition of each 
shipment or delivery of the new animal drug under investigation. Copies 
of all records of the investigation shall be retained by the 
investigator for 2 years after the termination of the investigation or 
approval of a new animal drug application.
    (iii) Shall furnish adequate and timely reports of the investigation 
to the sponsor.
    (8) The sponsor:
    (i) Shall retain all reports received from investigators for 2 years 
after the termination of the investigation or approval of a new animal 
drug application and make such reports available to a duly authorized 
employee of the Department for inspection at all reasonable times.
    (ii) Shall provide for current monitoring of the investigation by a 
person qualified by scientific training and experience to evaluate 
information obtained from the investigation, and shall promptly 
investigate and report to FDA and to all investigators any findings 
associated with use of the new animal drug that may suggest significant 
hazards pertinent to the safety of the new animal drug.
    (iii) Shall not unduly prolong distribution of the new animal drug 
for investigational use.
    (iv) Shall not, nor shall any person acting for or on behalf of the 
sponsor, represent that the new animal drug is safe or effective for the 
purposes for which it is under investigation. This requirement is not 
intended to restrict the full exchange of scientific information.
    (v) Shall not commercially distribute nor test-market the new animal 
drug until a new animal drug application is approved pursuant to section 
512(c) of the act.
    (9) If the shipment or other delivery of the new animal drug is 
imported or offered for importation into the United States for clinical 
investigational use in animals, it shall also meet the following 
conditions:
    (i) The importer of all such shipments or deliveries is an agent of 
the foreign exporter residing in the United States or the ultimate 
consignee, which person has, prior to such shipments and deliveries, 
informed FDA of his intention to import the new animal drug as sponsor 
in compliance with the conditions prescribed in this subdivision; or
    (ii) The new animal drug is shipped directly to a scientific 
institution with adequate facilities and qualified personnel to conduct 
laboratory or clinical investigations and is intended solely for use in 
such institutions and which institution has submitted a statement as 
sponsor of the investigation.
    (10) The sponsor shall submit either a claim for categorical 
exclusion under Sec. 25.30 or Sec. 25.33 of this chapter or an 
environmental assessment under Sec. 25.40 of this chapter.
    (c) Disqualification of a clinical investigator. (1) If FDA has 
information indicating that an investigator (including a sponsor-
investigator) has repeatedly or deliberately failed to comply with the 
conditions of these exempting regulations or has repeatedly or 
deliberately submitted to FDA or to the

[[Page 52]]

sponsor false information in any required report, the Center for 
Veterinary Medicine will furnish the investigator written notice of the 
matter complained of and offer the investigator an opportunity to 
explain the matter in writing, or, at the option of the investigator, in 
an informal conference. If an explanation is offered and accepted by the 
Center for Veterinary Medicine, the Center will discontinue the 
disqualification proceeding. If an explanation is offered but not 
accepted by the Center for Veterinary Medicine, the investigator will be 
given an opportunity for a regulatory hearing under part 16 of this 
chapter on the question of whether the investigator is eligible to 
receive test articles under this part and eligible to conduct any 
clinical investigation that supports an application for a research or 
marketing permit for products regulated by FDA.
    (2) After evaluating all available information, including any 
explanation presented by the investigator, if the Commissioner 
determines that the investigator has repeatedly or deliberately failed 
to comply with the conditions of the exempting regulations in this 
subchapter, or has repeatedly or deliberately submitted to FDA or to the 
sponsor false information in any required report, the Commissioner will 
notify the investigator and the sponsor of any investigation in which 
the investigator has been named as a participant that the investigator 
is not eligible to receive test articles under this part. The 
notification to the investigator and sponsor will provide a statement of 
the basis for such determination. The notification also will explain 
that an investigator determined to be ineligible to receive test 
articles under this part will be ineligible to conduct any clinical 
investigation that supports an application for a research or marketing 
permit for products regulated by FDA, including drugs, biologics, 
devices, new animal drugs, foods, including dietary supplements, that 
bear a nutrient content claim or a health claim, infant formulas, food 
and color additives, and tobacco products.
    (3) Each application or submission to FDA under the provisions of 
this chapter containing data reported by an investigator who has been 
determined to be ineligible to receive FDA-regulated test articles is 
subject to examination to determine whether the investigator has 
submitted unreliable data that are essential to the continuation of an 
investigation or essential to the approval of a marketing application, 
or essential to the continued marketing of an FDA-regulated product.
    (4) If the Commissioner determines, after the unreliable data 
submitted by the investigator are eliminated from consideration, that 
the data remaining are inadequate to support a conclusion that it is 
reasonably safe to continue the investigation, the Commissioner will 
notify the sponsor, who shall have an opportunity for a regulatory 
hearing under part 16 of this chapter. If a danger to the public health 
exists, however, the Commissioner shall terminate the exemption 
immediately and notify the sponsor of the termination. In such case, the 
sponsor shall have an opportunity for a regulatory hearing before FDA 
under part 16 on the question of whether the exemption should be 
reinstated. The determination that an investigation may not be 
considered in support of a research or marketing application or a 
notification or petition submission does not, however, relieve the 
sponsor of any obligation under any other applicable regulation to 
submit to FDA the results of the investigation.
    (5) If the Commissioner determines, after the unreliable data 
submitted by the investigator are eliminated from consideration, that 
the continued approval of the product for which the data were submitted 
cannot be justified, the Commissioner will proceed to withdraw approval 
of the product in accordance with the applicable provisions of the 
relevant statutes.
    (6) An investigator who has been determined to be ineligible under 
paragraph (c)(2) of this section may be reinstated as eligible when the 
Commissioner determines that the investigator has presented adequate 
assurances that the investigator will employ all test articles, and will 
conduct any clinical investigation that supports an application for a 
research or marketing permit for products regulated by FDA, solely in 
compliance with the applicable provisions of this chapter.

[[Page 53]]

    (d) Termination of exemption. If the Commissioner finds that:
    (1) The sponsor of the investigation has failed to comply with any 
of the conditions for the exemption established under this section, or
    (2) The continuance of the investigation is unsafe or otherwise 
contrary to the public interest or the drug is being or has been used 
for purposes other than bona fide scientific investigation, he shall 
first notify the sponsor and invite his immediate correction. If the 
conditions of the exemption are not immediately met, the sponsor shall 
have an opportunity for a regulatory hearing before FDA pursuant of part 
16 of this chapter on whether the exemption should be terminated. If the 
exemption is terminated the sponsor shall recall or have destroyed the 
unused supplies of the new animal drug.
    (e) Statements and requests. ``Notice(s) of Claimed Investigational 
Exemption for a New Animal Drug'' and requests for authorization to use 
investigational animals and their products for food should be addressed 
to the Department of Health and Human Services, Food and Drug 
Administration, Center for Veterinary Medicine, 7500 Standish Pl., 
Rockville, MD 20855.
    (f) Contract research organizations. (1) For purposes of this part 
and part 514, contract research organization means a person that 
assumes, as an independent contractor with the sponsor, one or more of 
the obligations of a sponsor, e.g., design of a protocol, selection or 
monitoring of investigations, evaluation of reports, and preparation of 
materials to be submitted to FDA.
    (2) A sponsor may transfer responsibility for any or all of the 
obligations set forth in this part to a contract research organization. 
Any such transfer shall be in writing and, if not all obligations are 
transferred, shall describe each of the obligations being assumed by the 
contract research organization. If all obligations are transferred, a 
general statement that all obligations have been transferred is 
acceptable. Any obligation not covered by the written description shall 
be deemed not to have been transferred.
    (3) A contract research organization that assumes any obligation of 
a sponsor shall comply with the specific regulations in this chapter 
applicable to this obligation and shall be subject to the same 
regulatory action as a sponsor for failure to comply with any obligation 
assumed under these regulations. Thus, all references to sponsor in this 
part apply to a contract research organization to the extent that it 
assumes one or more obligations of the sponsor.
    (g) Index of legally marketed unapproved new animal drugs for minor 
species. All provisions of part 511 apply to new animal drugs for 
investigational use in support of indexing, as described in section 572 
of the act, subject to the provisions of Sec. 516.125 of this chapter.

[40 FR 13823, Mar. 27, 1975, as amended at 41 FR 48268, Nov. 2, 1976; 42 
FR 15675, Mar. 22, 1977; 50 FR 7517, Feb. 22, 1985; 50 FR 16668, Apr. 
26, 1985; 52 FR 8847, Mar. 19, 1987; 54 FR 18280, Apr. 28, 1989; 57 FR 
6475, Feb. 25, 1992; 62 FR 40599, July 29, 1997; 72 FR 69121, Dec. 6, 
2007; 77 FR 25359, Apr. 30, 2012]



Sec. 511.3  Definitions.

    As used in this part:
    Contract research organization means a person that assumes, as an 
independent contractor with the sponsor, one or more of the obligations 
of a sponsor, e.g., design of a protocol, selection or monitoring of 
investigations, evaluation of reports, and preparation of materials to 
be submitted to the Food and Drug Administration.
    Investigator means an individual who actually conducts a clinical 
investigation (i.e., under whose immediate direction the drug is 
administered or dispensed to a subject). In the event an investigation 
is conducted by a team of individuals, the investigator is the 
responsible leader of the team. ``Subinvestigator'' includes any other 
individual member of that team.
    Sponsor means a person who takes responsibility for and initiates a 
clinical investigation. The sponsor may be an individual or 
pharmaceutical company, governmental agency, academic institution, 
private organization, or other organization. The sponsor does not 
actually conduct the investigation unless the sponsor is a sponsor-
investigator. A person other than an individual that uses one or more of 
its own employees to conduct an investigation that it has

[[Page 54]]

initiated is a sponsor, not a sponsor-investigator, and the employees 
are investigators.
    Sponsor-Investigator means an individual who both initiates and 
conducts an investigation, and under whose immediate direction the 
investigational drug is administered or dispensed. The term does not 
include any person other than an individual. The requirements applicable 
to a sponsor-investigator under this part include both those applicable 
to an investigator and a sponsor.

[77 FR 25359, Apr. 30, 2012]



PART 514_NEW ANIMAL DRUG APPLICATIONS--Table of Contents



                      Subpart A_General Provisions

Sec.
514.1 Applications.
514.3 Definitions.
514.4 Substantial evidence.
514.5 Presubmission conferences.
514.6 Amended applications.
514.7 Withdrawal of applications without prejudice.
514.8 Supplements and other changes to an approved application.
514.11 Confidentiality of data and information in a new animal drug 
          application file.
514.12 Confidentiality of data and information in an investigational new 
          animal drug notice.
514.15 Untrue statements in applications.

            Subpart B_Administrative Actions on Applications

514.80 Records and reports concerning experience with approved new 
          animal drugs.
514.100 Evaluation and comment on applications.
514.105 Approval of applications.
514.106 Approval of supplemental applications.
514.110 Reasons for refusing to file applications.
514.111 Refusal to approve an application.
514.115 Withdrawal of approval of applications.
514.116 Notice of withdrawal of approval of application.
514.117 Adequate and well-controlled studies.
514.120 Revocation of order refusing to approve an application or 
          suspending or withdrawing approval of an application.
514.121 Service of notices and orders.

                      Subpart C_Hearing Procedures

514.200 Contents of notice of opportunity for a hearing.
514.201 Procedures for hearings.

Subparts D-E [Reserved]

                        Subpart F_Judicial Review

514.235 Judicial review.

    Authority: 21 U.S.C. 321, 331, 351, 352, 356a, 360b, 371, 379e, 381.

    Source: 40 FR 13825, Mar. 27, 1975, unless otherwise noted.



                      Subpart A_General Provisions



Sec. 514.1  Applications.

    (a) Applications to be filed under section 512(b) of the act shall 
be submitted in the form and contain the information described in 
paragraph (b) of this section, as appropriate to support the particular 
submission. If any part of the application is in a foreign language, an 
accurate and complete English translation shall be appended to such 
part. Translations of literature printed in a foreign language shall be 
accompanied by copies of the original publication. The application must 
be signed by the applicant or by an authorized attorney, agent, or 
official. If the applicant or such authorized representative does not 
reside or have a place of business within the United States, the 
application must also furnish the name and post office address of, and 
must be countersigned by, an authorized attorney, agent, or official 
residing or maintaining a place of business within the United States. 
Pertinent information may be incorporated in, and will be considered as 
part of, an application on the basis of specific reference to such 
information, including information submitted under the provisions of 
Sec. 511.1 of this chapter, in the files of the Food and Drug 
Administration; however, the reference must be specific in identifying 
the information. Any reference to information furnished by a person 
other than the applicant may not be considered unless its use is 
authorized in a written statement signed by the person who submitted it.
    (b) Applications for new animal drugs shall be submitted in 
triplicate and assembled in the manner prescribed by

[[Page 55]]

paragraph (b)(15) of this section, and shall include the following 
information, as appropriate to support the particular submission:
    (1) Identification. Whether the submission is an original or 
supplemental application; the name and the address of the applicant; the 
date of the application; the trade name(s) (if one has been proposed) 
and chemical name(s) of the new animal drug. Upon receipt, the 
application will be assigned a number NADA ----, which shall be used for 
all correspondence with respect to the application.
    (2) Table of contents and summary. The application shall be 
organized in a cohesive fashion, shall contain a table of contents which 
identifies the data and other material submitted, and shall contain a 
well-organized summary and evaluation of the data in the following form:
    (i) Chemistry:
    (a) Chemical structural formula or description for any new animal 
drug substance.
    (b) Relationship to other chemically or pharmacologically related 
drugs.
    (c) Description of dosage form and quantitative composition.
    (ii) Scientific rationale and purpose the new animal drug is to 
serve:
    (a) Clinical purpose.
    (b) Highlights of laboratory studies: The reasons why certain types 
of studies were done or omitted as related to the proposed conditions of 
use and to information already known about this class of compounds. 
Emphasize any unusual or particularly significant pharmacological 
effects or toxicological findings.
    (c) Highlights of clinical studies: The rationale of the clinical 
study plan showing why types of studies were done, amended, or omitted 
as related to laboratory studies and prior clinical experience.
    (d) Conclusions: A short statement of conclusions combining the 
major points of effectiveness and safety as they relate to the use of 
the new animal drug.
    (3) Labeling. Three copies of each piece of all labeling to be used 
for the article (total of 9).
    (i) All labeling should be identified to show its position on, or 
the manner in which it is to accompany the market package.
    (ii) Labeling for nonprescription new animal drugs should include 
adequate directions for use by the layman under all conditions of use 
for which the new animal drug is intended, recommended, or suggested in 
any of the labeling or advertising sponsored by the applicant.
    (iii) Labeling for prescription veterinary drugs should bear 
adequate information for use under which veterinarians can use the new 
animal drug safely and for the purposes for which it is intended, 
including those purposes for which it is to be advertised or 
represented, in accord with Sec. 201.105 of this chapter.
    (iv) All labeling for prescription or nonprescription new animal 
drugs shall be submitted with any necessary use restrictions prominently 
and conspicuously displayed.
    (v) Labeling for new animal drugs intended for use in the 
manufacture of medicated feeds shall include:
    (a) Specimens of labeling to be used for such new animal drug with 
adequate directions for the manufacture and use of finished feeds for 
all conditions for which the new animal drug is intended, recommended, 
or suggested in any of the labeling, including advertising, sponsored by 
the applicant. Ingredient labeling may utilize collective names as 
provided in Sec. 501.110 of this chapter.
    (b) Representative labeling proposed to be used for Type B and Type 
C medicated feeds containing the new animal drug.
    (vi) Draft labeling may be submitted for preliminary consideration 
of an application. Final printed labeling will ordinarily be required 
prior to approval of an application. Proposed advertising for veterinary 
prescription drugs may be submitted for comment or approval.
    (4) Components and composition. A complete list of all articles used 
for production of the new animal drug including a full list of the 
composition of each article:
    (i) A full list of the articles used as components of the new animal 
drug. This list should include all substances used in the synthesis, 
extraction, or other method of preparation of any

[[Page 56]]

new animal drug and in the preparation of the finished dosage form, 
regardless of whether they undergo chemical change or are removed in the 
process. Each component should be identified by its established name, if 
any, or complete chemical name, using structural formulas when necessary 
for specific identification. If any proprietary name is used, it should 
be followed by a complete quantitative statement of composition. 
Reasonable alternatives for any listed component may be specified.
    (ii) A full statement of the composition of the new animal drug. The 
statement shall set forth the name and amount of each ingredient, 
whether active or not, contained in a stated quantity of the new animal 
drug in the form in which it is to be distributed (for example, amount 
per tablet or milliliter) and a batch formula representative of that to 
be employed for the manufacture of the finished dosage form. All 
components should be included in the batch formula regardless of whether 
they appear in the finished product. Any calculated excess of an 
ingredient over the label declaration should be designated as such and 
percent excess shown. Reasonable variation may be specified.
    (iii) If it is a new animal drug produced by fermentation:
    (a) Source and type of microorganism used to produce the new animal 
drug.
    (b) Composition of media used to produce the new animal drug.
    (c) Type of precursor used, if any, to guide or enhance production 
of the antibiotic during fermentation.
    (d) Name and composition of preservative, if any, used in the broth.
    (e) A complete description of the extraction and purification 
processes including the names and compositions of the solvents, 
precipitants, ion exchange resins, emulsifiers, and all other agents 
used.
    (f) If the new animal drug is produced by a catalytic hydrogenation 
process (such as tetracycline from chlortetracycline), a complete 
description of each chemical reaction with graphic formulas used to 
produce the new animal drug, including the names of the catalyst used, 
how it is removed, and how the new animal drug is extracted and 
purified.
    (5) Manufacturing methods, facilities, and controls. A full 
description of the methods used in, and the facilities and controls used 
for, the manufacture, processing, and packing of the new animal drug. 
This description should include full information with respect to any new 
animal drug in sufficient detail to permit evaluation of the adequacy of 
the described methods of manufacture, processing, and packing, and the 
described facilities and controls to determine and preserve the 
identity, strength, quality, and purity of the new animal drug, and the 
following:
    (i) If the applicant does not himself perform all the manufacturing, 
processing, packaging, labeling, and control operations for any new 
animal drug, he shall: Identify each person who will perform any part of 
such operations and designate the part; and provide a signed statement 
from each such person fully describing, directly or by reference, the 
methods, facilities, and controls he will use in his part of the 
operation. The statement shall include a commitment that no changes will 
be made without prior approval by the Food and Drug Administration, 
unless permitted under Sec. 514.8.
    (ii) A description of the qualifications, including educational 
background and experience, of the technical and professional personnel 
who are responsible for assuring that the new animal drug has the 
identity, strength, quality, and purity it purports or is represented to 
possess, and a statement of their responsibilities.
    (iii) A description of the physical facilities including building 
and equipment used in manufacturing, processing, packaging, labeling, 
storage, and control operations.
    (iv) The methods used in the synthesis, extraction, isolation, or 
purification of any new animal drug. When the specifications and 
controls applied to such new animal drugs are inadequate in themselves 
to determine its identity, strength, quality, and purity, the methods 
should be described in sufficient detail, including quantities used, 
times, temperature, pH, solvents, etc., to determine these 
characteristics. Alternative methods or variations

[[Page 57]]

in methods within reasonable limits that do not affect such 
characteristics of the new animal drug may be specified. A flow sheet 
and indicated equations should be submitted when needed to explain the 
process.
    (v) Precautions to insure proper identity, strength, quality, and 
purity of the raw materials, whether active or not, including:
    (a) The specifications for acceptance and methods of testing for 
each lot of raw material.
    (b) A statement as to whether or not each lot of raw materials is 
given a serial number to identify it, and the use made of such numbers 
in subsequent plant operations.
    (vi) The instructions used in the manufacturing, processing, 
packaging, and labeling of each dosage form of the new animal drug, 
including:
    (a) The method of preparation of the master formula records and 
individual batch records and the manner in which these records are used.
    (b) The number of individuals checking weight or volume of each 
individual ingredient entering into each batch of the new animal drug.
    (c) A statement as to whether or not the total weight or volume of 
each batch is determined at any stage of the manufacturing process 
subsequent to making up a batch according to the formula card and, if 
so, at what stage and by whom it is done.
    (d) The precautions used in checking the actual package yield 
produced from a batch of the new animal drug with the theoretical yield. 
This should include a description of the accounting for such items as 
discards, breakage, etc., and the criteria used in accepting or 
rejecting batches of drugs in the event of an unexplained discrepancy.
    (e) The precautions used to assure that each lot of the new animal 
drug is packaged with the proper label and labeling, including 
provisions for labeling storage and inventory control.
    (f) Any special precautions used in the operations.
    (vii) The analytical controls used during the various stages of the 
manufacturing, processing, packaging, and labeling of the new animal 
drug, including a detailed description of the collection of samples and 
the analytical procedures to which they are subjected. The analytical 
procedures should be capable of determining the active components within 
a reasonable degree of accuracy and of assuring the identity of such 
components.
    (a) A description of practicable methods of analysis of adequate 
sensitivity to determine the amount of the new animal drug in the final 
dosage form should be included. The dosage form may be a finished 
pharmaceutical product, a Type A medicated article, a Type B or a Type C 
medicated feed, or a product for use in animal drinking water. Where two 
or more active ingredients are included, methods should be quantitative 
and specific for each active ingredient.
    (b) If the article is one that is represented to be sterile, the 
same information with regard to the manufacturing, processing, 
packaging, and the collection of samples of the drug should be given for 
sterility controls. Include the standards used for acceptance of each 
lot of the finished drug.
    (viii) An explanation of the exact significance of any batch control 
numbers used in the manufacturing, processing, packaging, and labeling 
of the new animal drug, including such control numbers that may appear 
on the label of the finished article. State whether these numbers enable 
determination of the complete manufacturing history of the product. 
Describe any methods used to permit determination of the distribution of 
any batch if its recall is required.
    (ix) Adequate information with respect to the characteristics of and 
the test methods employed for the container, closure, or other component 
parts of the drug package to assure their suitability for the intended 
use.
    (x) A complete description of, and data derived from, studies of the 
stability of the new animal drug in the final dosage form, including 
information showing the suitability of the analytical methods used. A 
description of any additional stability studies underway or planned. 
Stability data for the finished dosage form of the new animal drug in 
the container in which it is to be marketed, including any proposed 
multiple dose container, and, if it is to

[[Page 58]]

be put into solution at the time of dispensing, for the solution 
prepared as directed. If the new animal drug is intended for use in the 
manufacture of Type C medicated feed as defined in Sec. 558.3 of this 
chapter, stability data derived from studies in which representative 
formulations of the medicated feed articles are used. Similar data may 
be required for Type B medicated feeds as determined by the Food and 
Drug Administration on a case-by-case basis. Expiration dates shall be 
proposed for finished pharmaceutical dosage forms and Type A medicated 
articles. If the data indicate that an expiration date is needed for 
Type B or Type C medicated feeds, the applicant shall propose such 
expiration date. If no expiration date is proposed for Type B or Type C 
medicated feeds, the applicant shall justify its absence with data.
    (xi) Additional procedures employed which are designed to prevent 
contamination and otherwise assure proper control of the product. An 
application may be refused unless it includes adequate information 
showing that the methods used in, and the facilities and controls used 
for, the manufacturing, processing, and packaging of the new animal drug 
are adequate to preserve its identity, strength, quality, and purity in 
conformity with good manufacturing practice and identifies each 
establishment, showing the location of the plant conducting these 
operations.
    (6) Samples. Samples of the new animal drug and articles used as 
components and information concerning them may be requested by the 
Center for Veterinary Medicine as follows:
    (i) Each sample shall consist of four identical, separately packaged 
subdivisions, each containing at least three times the amount required 
to perform the laboratory test procedures described in the application 
to determine compliance with its control specifications for identity and 
assays. Each of the samples submitted shall be appropriately packaged 
and labeled to preserve its characteristics, to identify the material 
and the quantity in each subdivision of the sample, and to identify each 
subdivision with the name of the applicant and the new animal drug 
application to which it relates. Included are:
    (a) A sample or samples of any reference standard and blank used in 
the procedures described in the application for assaying each new animal 
drug and other assayed components of the finished new animal drug.
    (b) A representative sample or samples of each strength of the 
finished dosage form proposed in the application and employed in the 
clinical investigations and a representative sample or samples of each 
new animal drug from the batch(es) employed in the production of such 
dosage form.
    (c) A representative sample or samples of finished market packages 
of each strength of the dosage form of the new animal drug prepared for 
initial marketing and, if any such sample is not from a representative 
commercial-scale production batch, such a sample from a representative 
commercial-scale production batch, and a representative sample or 
samples of each new animal drug from the batch(es) employed in the 
production of such dosage form, provided that in the case of new animal 
drugs marketed in large packages the sample should contain only three 
times a sufficient quantity of the new animal drug to allow for 
performing the control tests for drug identity and assays.
    (ii) The following information shall be included for the samples 
when requested:
    (a) For each sample submitted, full information regarding its 
identity and the origin of any new animal drug contained therein 
(including a statement whether it was produced on a laboratory, pilot-
plant, or full-production scale) and detailed results of all laboratory 
tests made to determine the identity, strength, quality, and purity of 
the batch represented by the sample, including assays.
    (b) For any reference standard submitted, a complete description of 
its preparation and the results of all laboratory tests on it. If the 
test methods used differed from those described in the application, full 
details of the methods employed in obtaining the reporting results.
    (7) Analytical methods for residues. Applications shall include a 
description of practicable methods for determining the quantity, if any, 
of the new animal

[[Page 59]]

drug in or on food, and any substance formed in or on food because of 
its use, and the proposed tolerance or withdrawal period or other use 
restrictions to ensure that the proposed use of this drug will be safe. 
When data or other adequate information establish that it is not 
reasonable to expect the new animal drug to become a component of food 
at concentrations considered unsafe, a regulatory method is not 
required.
    (i) The kind of information required by this subdivision may 
include: Complete experimental protocols for determining drug residue 
levels in the edible products, and the length of time required for 
residues to be eliminated from such products following the drug's use; 
residue studies conducted under appropriate (consistent with the 
proposed usage) conditions of dosage, time, and route of administration 
to show levels, if any, of the drug and/or its metabolites in test 
animals during and upon cessation of treatment and at intervals 
thereafter in order to establish a disappearance curve; if the drug is 
to be used in combination with other drugs, possible effects of 
interaction demonstrated by the appropriate disappearance curve or 
depletion patterns after drug withdrawal under appropriate (consistent 
with the proposed usage) conditions of dosage, time, and route of 
administration; if the drug is given in the feed or water, appropriate 
consumption records of the medicated feed or water and appropriate 
performance data in the treated animal; if the drug is to be used in 
more than one species, drug residue studies or appropriate metabolic 
studies conducted for each species that is food-producing. To provide 
these data, a sufficient number of birds or animals should be used at 
each sample interval. Appropriate use of labeled compounds (e.g. 
radioactive tracers), may be utilized to establish metabolism and 
depletion curves. Drug residue levels ordinarily should be determined in 
muscle, liver, kidney, and fat and where applicable, in skin, milk, and 
eggs (yolk and egg white). As a part of the metabolic studies, levels of 
the drug or metabolite should be determined in blood where feasible. 
Samples may be combined where necessary. Where residues are suspected or 
known to be present in litter from treated animals, it may be necessary 
to include data with respect to such residues becoming components of 
other agricultural commodities because of use of litter from treated 
animals.
    (ii) A new animal drug that has the potential to contaminate human 
food with residues whose consumption could present a risk of cancer to 
people must satisfy the requirements of subpart E of part 500 of this 
chapter.
    (8) Evidence to establish safety and effectiveness. (i) An 
application may be refused unless it contains full reports of adequate 
tests by all methods reasonably applicable to show whether or not the 
new animal drug is safe and effective for use as suggested in the 
proposed labeling.
    (ii) An application may be refused unless it includes substantial 
evidence of the effectiveness of the new animal drug as defined in Sec. 
514.4.
    (iii) An application may be refused unless it contains detailed 
reports of the investigations, including studies made on laboratory 
animals, in which the purpose, methods, and results obtained are clearly 
set forth of acute, subacute, and chronic toxicity, and unless it 
contains appropriate clinical laboratory results related to safety and 
efficacy. Such information should include identification of the person 
who conducted each investigation, a statement of where the 
investigations were conducted, and where the raw data are available in 
the application.
    (iv) All information pertinent to an evaluation of the safety and 
effectiveness of the new animal drug received or otherwise obtained by 
the applicant from any source, including information derived from other 
investigations or commercial marketing (for example, outside the United 
States), or reports in the scientific literature, both favorable and 
unfavorable, involving the new animal drug that is the subject of the 
application and related new animal drugs shall be submitted. An adequate 
summary may be acceptable in lieu of a reprint of a published report 
that only supports other data submitted. Include any evaluation of the 
safety or effectiveness of the new animal drug that has been made by the 
applicant's

[[Page 60]]

veterinary or medical department, expert committee, or consultants.
    (v) If the new animal drug is a combination of active ingredients or 
animal drugs, an application may be refused unless it includes 
substantial evidence of the effectiveness of the combination new animal 
drug as required in Sec. 514.4.
    (vi) An application shall include a complete list of the names and 
post office addresses of all investigators who received the new animal 
drug. This may be incorporated in whole or in part by reference to 
information submitted under the provisions of Sec. 511.1 of this 
chapter.
    (vii) Explain any omission of reports from any investigator to whom 
the investigational new animal drug has been made available. The 
unexplained omission of any reports of investigations made with the new 
animal drug by the applicant or submitted to him by an investigator or 
the unexplained omission of any pertinent reports of investigations or 
clinical experience received or otherwise obtained by the applicant from 
published literature or other sources that would bias an evaluation of 
the safety of the new animal drug or its effectiveness in use, 
constitutes grounds for the refusal or withdrawal of the approval of an 
application.
    (viii) If a sponsor has transferred any obligations for the conduct 
of any clinical study to a contract research organization, the 
application is required to include a statement containing the name and 
address of the contract research organization, identifying the clinical 
study, and listing the obligations transferred. If all obligations 
governing the conduct of the study have been transferred, a general 
statement of this transfer--in lieu of a listing of the specific 
obligations transferred--may be submitted.
    (ix) If original subject records were audited or reviewed by the 
sponsor in the course of monitoring any clinical study to verify the 
accuracy of the case reports submitted to the sponsor, a list 
identifying each clinical study so audited or reviewed.
    (9) Veterinary feed directive. Three copies of a veterinary feed 
directive (VFD) must be submitted in the format described under Sec. 
558.6(a)(4) of this chapter.
    (10) Supplemental applications. If it is a supplemental application, 
full information shall be submitted on each proposed change concerning 
any statement made in the approved application.
    (11) Applicant's commitment. It is understood that the labeling and 
advertising for the new animal drug will prescribe, recommend, or 
suggest its use only under the conditions stated in the labeling which 
is part of this application and if the article is a prescription new 
animal drug, it is understood that any labeling which furnishes or 
purports to furnish information for use or which prescribes, recommends, 
or suggests a dosage for use of the new animal drug will also contain, 
in the same language and emphasis, information for its use including 
indications, effects, dosages, routes, methods, and frequency and 
duration of administration, any relevant hazards, contraindications, 
side effects, and precautions contained in the labeling which is part of 
this application. It is understood that all representations in this 
application apply to the drug produced until changes are made in 
conformity with Sec. 514.8.
    (12) Additional commitments. (i) New animal drugs as defined in 
Sec. 510.3 of this chapter, intended for use in the manufacture of 
animal feeds in any State will be shipped only to persons who may 
receive such drugs in accordance with Sec. 510.7 of this chapter.
    (ii) The methods, facilities, and controls described under item 5 of 
this application conform to the current good manufacturing practice 
regulations in subchapter C of this chapter.
    (iii) With respect to each nonclinical laboratory study contained in 
the application, either a statement that the study was conducted in 
compliance with the good laboratory practice regulations set forth in 
part 58 of this chapter, or, if the study was not conducted in 
compliance with such regulations, a brief statement of the reason for 
the noncompliance.
    (13) [Reserved]
    (14) Environmental assessment. The applicant is required to submit 
either a claim for categorical exclusion under

[[Page 61]]

Sec. 25.30 or Sec. 25.33 of this chapter or an environmental 
assessment under Sec. 25.40 of this chapter.
    (15) Assembling and binding the application. Assemble and bind an 
original and two copies of the application as follows:
    (i) Bind the original or ribbon copy of the application as copy No. 
1.
    (ii) Bind two identical copies as copy No. 2 and copy No. 3.
    (iii) Identify each front cover with the name of the applicant, new 
animal drug, and the copy number.
    (iv) Number each page of the application sequentially in the upper 
right hand corner or in another location so that the page numbers remain 
legible after the application has been bound, and organize the 
application consistent with paragraphs (b) (1) through (14) of this 
section. Each copy should bear the same page numbering, whether 
sequential in each volume or continuous and sequential throughout the 
application.
    (v) Include complete labeling in each of the copies. It is suggested 
that labeling be identified by date of printing or date of preparation.
    (vi) Submit separate applications for each different dosage form of 
the drug proposed. Repeating basic information pertinent to all dosage 
forms in each application is unnecessary if reference is made to the 
application containing such information. Include in each application 
information applicable to the specific dosage form, such as labeling, 
composition, stability data, and method of manufacture.
    (vii) Submit in folders amendments, supplements, and other 
correspondence sent after submission of an original application. The 
front cover of these submissions should be identified with the name of 
the applicant, new animal drug, copy number, and the new animal drug 
application number, if known.
    (c) When a new animal drug application is submitted for a new animal 
drug which has a stimulant, depressant, or hallucinogenic effect on the 
central nervous system, if it appears that the drug has a potential for 
abuse, the Commissioner shall forward that information to the Attorney 
General of the United States.

[40 FR 13825, Mar. 27, 1975]

    Editorial Note: For Federal Register citations affecting Sec. 
514.1, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 514.3  Definitions.

    The definition and interpretation of terms contained in this section 
apply to those terms as used throughout subchapter E.
    Adverse drug experience is any adverse event associated with the use 
of a new animal drug, whether or not considered to be drug related, and 
whether or not the new animal drug was used in accordance with the 
approved labeling (i.e., used according to label directions or used in 
an extralabel manner, including but not limited to different route of 
administration, different species, different indications, or other than 
labeled dosage). Adverse drug experience includes, but is not limited 
to:
    (1) An adverse event occurring in animals in the course of the use 
of an animal drug product by a veterinarian or by a livestock producer 
or other animal owner or caretaker.
    (2) Failure of a new animal drug to produce its expected 
pharmacological or clinical effect (lack of expected effectiveness).
    (3) An adverse event occurring in humans from exposure during 
manufacture, testing, handling, or use of a new animal drug.
    ANADA is an abbreviated new animal drug application including all 
amendments and supplements.
    Applicant is a person or entity who owns or holds on behalf of the 
owner the approval for an NADA or an ANADA, and is responsible for 
compliance with applicable provisions of the act and regulations.
    Increased frequency of adverse drug experience is an increased rate 
of occurrence of a particular serious adverse drug event, expected or 
unexpected, after appropriate adjustment for drug exposure.
    NADA is a new animal drug application including all amendments and 
supplements.
    Nonapplicant is any person other than the applicant whose name 
appears on the label and who is engaged in manufacturing, packing, 
distribution, or labeling of the product.

[[Page 62]]

    Potential applicant means any person:
    (1) Intending to investigate a new animal drug under section 512(j) 
of the Federal Food, Drug, and Cosmetic Act (the act),
    (2) Investigating a new animal drug under section 512(j) of the act,
    (3) Intending to file a new animal drug application (NADA) or 
supplemental NADA under section 512(b)(1) of the act, or
    (4) Intending to file an abbreviated new animal drug application 
(ANADA) under section 512(b)(2) of the act.
    Presubmission conference means one or more conferences between a 
potential applicant and FDA to reach a binding agreement establishing a 
submission or investigational requirement.
    Presubmission conference agreement means that section of the 
memorandum of conference headed ``Presubmission Conference Agreement'' 
that records any agreement on the submission or investigational 
requirement reached by a potential applicant and FDA during the 
presubmission conference.
    Product defect/manufacturing defect is the deviation of a 
distributed product from the standards specified in the approved 
application, or any significant chemical, physical, or other change, or 
deterioration in the distributed drug product, including any microbial 
or chemical contamination. A manufacturing defect is a product defect 
caused or aggravated by a manufacturing or related process. A 
manufacturing defect may occur from a single event or from deficiencies 
inherent to the manufacturing process. These defects are generally 
associated with product contamination, product deterioration, 
manufacturing error, defective packaging, damage from disaster, or 
labeling error. For example, a labeling error may include any incident 
that causes a distributed product to be mistaken for, or its labeling 
applied to, another product.
    Serious adverse drug experience is an adverse event that is fatal, 
or life-threatening, or requires professional intervention, or causes an 
abortion, or stillbirth, or infertility, or congenital anomaly, or 
prolonged or permanent disability, or disfigurement.
    Unexpected adverse drug experience is an adverse event that is not 
listed in the current labeling for the new animal drug and includes any 
event that may be symptomatically and pathophysiologically related to an 
event listed on the labeling, but differs from the event because of 
greater severity or specificity. For example, under this definition 
hepatic necrosis would be unexpected if the labeling referred only to 
elevated hepatic enzymes or hepatitis.

[68 FR 15365, Mar. 31, 2003, as amended at 69 FR 51170, Aug. 18, 2004]



Sec. 514.4  Substantial evidence.

    (a) Definition of substantial evidence. Substantial evidence means 
evidence consisting of one or more adequate and well-controlled studies, 
such as a study in a target species, study in laboratory animals, field 
study, bioequivalence study, or an in vitro study, on the basis of which 
it could fairly and reasonably be concluded by experts qualified by 
scientific training and experience to evaluate the effectiveness of the 
new animal drug involved that the new animal drug will have the effect 
it purports or is represented to have under the conditions of use 
prescribed, recommended, or suggested in the labeling or proposed 
labeling thereof. Substantial evidence shall include such adequate and 
well-controlled studies that are, as a matter of sound scientific 
judgment, necessary to establish that a new animal drug will have its 
intended effect.
    (b) Characteristics of substantial evidence--(1) Qualifications of 
experts. Any study that is intended to be part of substantial evidence 
of the effectiveness of a new animal drug shall be conducted by experts 
qualified by scientific training and experience.
    (2) Intended uses and conditions of use. Substantial evidence of 
effectiveness of a new animal drug shall demonstrate that the new animal 
drug is effective for each intended use and associated conditions of use 
for and under which approval is sought.
    (i) Dose range labeling. Sponsors should, to the extent possible, 
provide for a dose range because it increases the utility of the new 
animal drug by

[[Page 63]]

providing the user flexibility in the selection of a safe and effective 
dose. In general, substantial evidence to support dose range labeling 
for a new animal drug intended for use in the diagnosis, cure, 
mitigation, treatment, or prevention of disease must consist of at least 
one adequate and well-controlled study on the basis of which qualified 
experts could fairly and reasonably conclude that the new animal drug 
will be effective for the intended use at the lowest dose of the dose 
range suggested in the proposed labeling for that intended use. 
Substantial evidence to support dose range labeling for a new animal 
drug intended to affect the structure or function of the body of an 
animal generally must consist of at least one adequate and well-
controlled study on the basis of which qualified experts could fairly 
and reasonably conclude that the new animal drug will be effective for 
the intended use at all doses within the range suggested in the proposed 
labeling for the intended use.
    (ii) [Reserved]
    (3) Studies--(i) Number. Substantial evidence of the effectiveness 
of a new animal drug for each intended use and associated conditions of 
use shall consist of a sufficient number of current adequate and well-
controlled studies of sufficient quality and persuasiveness to permit 
qualified experts:
    (A) To determine that the parameters selected for measurement and 
the measured responses reliably reflect the effectiveness of the new 
animal drug;
    (B) To determine that the results obtained are likely to be 
repeatable, and that valid inferences can be drawn to the target animal 
population; and
    (C) To conclude that the new animal drug is effective for the 
intended use at the dose or dose range and associated conditions of use 
prescribed, recommended, or suggested in the proposed labeling.
    (ii) Types. Adequate and well-controlled studies that are intended 
to provide substantial evidence of the effectiveness of a new animal 
drug may include, but are not limited to, published studies, foreign 
studies, studies using models, and studies conducted by or on behalf of 
the sponsor. Studies using models shall be validated to establish an 
adequate relationship of parameters measured and effects observed in the 
model with one or more significant effects of treatment.
    (c) Substantial evidence for combination new animal drugs--(1) 
Definitions. The following definitions of terms apply to this section:
    (i) Combination new animal drug means a new animal drug that 
contains more than one active ingredient or animal drug that is applied 
or administered simultaneously in a single dosage form or simultaneously 
in or on animal feed or drinking water.
    (ii) Dosage form combination new animal drug means a combination new 
animal drug intended for use other than in animal feed or drinking 
water.
    (iii) Antibacterial with respect to a particular target animal 
species means an active ingredient or animal drug: That is approved in 
that species for the diagnosis, cure, mitigation, treatment, or 
prevention of bacterial disease; or that is approved for use in that 
species for any other use that is attributable to its antibacterial 
properties. But, antibacterial does not include ionophores or arsenicals 
intended for use in combination in animal feed or drinking water.
    (iv) Appropriate concurrent use exists when there is credible 
evidence that the conditions for which the combination new animal drug 
is intended can occur simultaneously.
    (2) Combination new animal drugs that contain only active 
ingredients or animal drugs that have previously been separately 
approved. (i) For dosage form combination new animal drugs, except for 
those that contain a nontopical antibacterial, that contain only active 
ingredients or animal drugs that have previously been separately 
approved for the particular uses and conditions of use for which they 
are intended in combination, a sponsor shall demonstrate:
    (A) By substantial evidence, as defined in this section, that any 
active ingredient or animal drug intended only for the same use as 
another active ingredient or animal drug in the combination makes a 
contribution to the effectiveness of the combination new animal drug;
    (B) That each active ingredient or animal drug intended for at least 
one

[[Page 64]]

use that is different from all the other active ingredients or animal 
drugs used in the combination provides appropriate concurrent use for 
the intended target animal population; and
    (C) That the active ingredients or animal drugs are physically 
compatible and do not have disparate dosing regimens if FDA, based on 
scientific information, has reason to believe the active ingredients or 
animal drugs are physically incompatible or have disparate dosing 
regimens.
    (ii) For combination new animal drugs intended for use in animal 
feed or drinking water that contain only active ingredients or animal 
drugs that have previously been separately approved for the particular 
uses and conditions of use for which they are intended in combination, 
the sponsor shall demonstrate:
    (A) By substantial evidence, as defined in this section, that any 
active ingredient or animal drug intended only for the same use as 
another active ingredient or animal drug in the combination makes a 
contribution to the effectiveness of the combination new animal drug;
    (B) For such combination new animal drugs that contain more than one 
antibacterial ingredient or animal drug, by substantial evidence, as 
defined in this section, that each antibacterial makes a contribution to 
labeled effectiveness;
    (C) That each active ingredient or animal drug intended for at least 
one use that is different from all other active ingredients or animal 
drugs used in the combination provides appropriate concurrent use for 
the intended target animal population; and
    (D) That the active ingredients or animal drugs intended for use in 
drinking water are physically compatible if FDA, based on scientific 
information, has reason to believe the active ingredients or animal 
drugs are physically incompatible.
    (3) Other combination new animal drugs. For all other combination 
new animal drugs, the sponsor shall demonstrate by substantial evidence, 
as defined in this section, that the combination new animal drug will 
have the effect it purports or is represented to have under the 
conditions of use prescribed, recommended, or suggested in the proposed 
labeling and that each active ingredient or animal drug contributes to 
the effectiveness of the combination new animal drug.

[64 FR 40756, July 28, 1999]



Sec. 514.5  Presubmission conferences.

    (a) General principle underlying the conduct of a presubmission 
conference. The general principle underlying the conduct of any 
presubmission conference is that there should be candid, full, and open 
communication.
    (b) Requesting a presubmission conference. A potential applicant is 
entitled to one or more conferences prior to the submission of an NADA, 
supplemental NADA, or an ANADA to reach an agreement establishing part 
or all of a submission or investigational requirement. A potential 
applicant's request for a presubmission conference must be submitted to 
FDA in a signed letter. The letter must include a proposed agenda that 
clearly outlines the scope, purpose, and objectives of the presubmission 
conference and must list the names and positions of the representatives 
who are expected to attend the presubmission conference on behalf of the 
applicant.
    (c) Timing. A potential applicant may request one or more 
presubmission conferences at any time prior to the filing of a NADA, 
supplemental NADA, or an ANADA. A request for a presubmission conference 
must be received by FDA at least 30 calendar days in advance of the 
requested conference date. FDA will schedule the presubmission 
conference at a time agreeable to both FDA and the potential applicant.
    (d) Advance information. The potential applicant must provide to 
FDA, at least 30 calendar days before a scheduled presubmission 
conference, a detailed agenda, a copy of any materials to be presented 
at the conference, a list of proposed indications and, if available, a 
copy of the proposed labeling for the product under consideration, and 
copies of materials evaluated or referenced relative to issues listed in 
the agenda for the conference. If the materials are not provided or are 
not sufficient to provide the basis for meaningful discussion, FDA may 
elect to postpone part or all of the meeting

[[Page 65]]

until sufficient materials are provided to FDA.
    (e) Conduct of a presubmission conference. The potential applicant 
and FDA may each bring consultants to the presubmission conference. The 
presubmission conference(s) will be directed primarily at establishing 
agreement between FDA and the potential applicant regarding a submission 
or investigational requirement. The submission or investigational 
requirement may include, among other things, the number, types, and 
general design of studies that are necessary to demonstrate the safety 
and effectiveness of a new animal drug for the intended uses and 
conditions of use prescribed, recommended, or suggested in the proposed 
labeling for the new animal drug.
    (f) Documentation of a presubmission conference--(1) Memorandum of 
conference--(i) Preparation. FDA will prepare a memorandum for each 
presubmission conference that will include, among other things, any 
background pertinent to the request for meeting; a summary of the key 
points of discussion; agreements; and action items and assignments of 
responsibility. That portion of the memorandum of conference that 
documents any agreements reached regarding all or part of a submission 
or investigational requirement will be included under the heading 
``Presubmission Conference Agreement.'' If the presubmission conference 
agreement section of the memorandum is silent on an issue, including one 
that was discussed in the conference or addressed by materials provided 
for the conference, such silence does not constitute agreement between 
FDA and the potential applicant on the issue.
    (ii) Sending a copy to the potential applicant. FDA will send a copy 
of the memorandum to the potential applicant for review no later than 45 
calendar days after the date of the conference
    (iii) Requests for changes or clarification. If a potential 
applicant requests changes to, or clarification of, the substance of the 
memorandum, the request must be sent to FDA within 30 calendar days from 
the date a copy of the memorandum is sent to the applicant. If the 
potential applicant requests changes or clarification, FDA will send the 
potential applicant a response to their request no later than 45 
calendar days after the date of receipt of the request.
    (iv) Administrative record. A copy of FDA's original memorandum of 
conference and, as appropriate, a copy of an amended memorandum to 
correct or clarify the content of the original memorandum will be made 
part of the administrative file.
    (2) Field studies. If FDA requires more than one field study to 
establish by substantial evidence that the new animal drug is effective 
for its intended uses under the conditions of use prescribed, 
recommended, or suggested in the proposed labeling, FDA will provide 
written scientific justification for requiring more than one field 
study. Such justification must be provided no later than 25 calendar 
days after the date of the conference at which the requirement for more 
than one field study is established. If FDA does not believe more than 
one field study is required but the potential applicant voluntarily 
proposes to conduct more than one field study, FDA will not provide such 
written justification. If FDA requires one field study to be conducted 
at multiple locations, FDA will provide justification for requiring 
multiple locations verbally during the presubmission conference and in 
writing as part of the memorandum of conference.
    (g) Modification of presubmission conference agreements. An 
agreement made under a presubmission conference requested under section 
512(b)(3) of the act and documented in a memorandum of conference is 
binding on the potential applicant and FDA and may only be modified if:
    (1) FDA and the potential applicant mutually agree to modify, in 
part or in whole, the agreement and such modification is documented and 
provided to the potential applicant as described in paragraph (f)(1) of 
this section; or
    (2) FDA by written order determines that a substantiated scientific 
requirement essential to the determination of safety or effectiveness of 
the new animal drug appeared after the conference.

[[Page 66]]

    (h) When the terms of a presubmission conference agreement are not 
valid--(1) A presubmission conference agreement will no longer be valid 
if:
    (i) The potential applicant makes to FDA, before, during, or after 
the presubmission conference, any untrue statement of material fact; or
    (ii) The potential applicant fails to follow any material term of 
the agreement; and
    (2) A presubmission conference may no longer be valid if the 
potential applicant submits false or misleading data relating to a new 
animal drug to FDA.
    (i) Dispute resolution. FDA is committed to resolving differences 
between a potential applicant and FDA reviewing divisions with respect 
to requirements for the investigation of new animal drugs and for NADAs, 
supplemental NADAs, and ANADAs as quickly and amicably as possible 
through a cooperative exchange of information and views. When 
administrative or procedural disputes arise, a potential applicant 
should first attempt to resolve the matter within the appropriate review 
division beginning with the individual(s) most directly assigned to the 
review of the application or investigational exemption. If the dispute 
cannot be resolved after such attempts, the dispute shall be evaluated 
and administered in accordance with applicable regulations (21 CFR 
10.75). Dispute resolution procedures may be further explained by 
guidance available from the Center for Veterinary Medicine.

[69 FR 51170, Aug. 18, 2004]



Sec. 514.6  Amended applications.

    The applicant may submit an amendment to an application that is 
pending, including changes that may alter the conditions of use, the 
labeling, safety, effectiveness, identity, strength, quality, or purity 
of the drug or the adequacy of the manufacturing methods, facilities, 
and controls to preserve them, in which case the unamended application 
may be considered as withdrawn and the amended application may be 
considered resubmitted on the date on which the amendment is received by 
the Food and Drug Administration. The applicant will be notified of such 
date.



Sec. 514.7  Withdrawal of applications without prejudice.

    The sponsor may withdraw his pending application from consideration 
as a new animal drug application upon written notification to the Food 
and Drug Administration. Such withdrawal may be made without prejudice 
to a future filing. Upon resubmission, the time limitation will begin to 
run from the date the resubmission is received by the Food and Drug 
Administration. The original application will be retained by the Food 
and Drug Administration although it is considered withdrawn. The 
applicant shall be furnished a copy at cost on request.



Sec. 514.8  Supplements and other changes to an approved application.

    (a) Definitions. (1) The definitions and interpretations contained 
in section 201 of the Federal Food, Drug, and Cosmetic Act (the act) 
apply to those terms when used in this part.
    (2) The following definitions of terms apply to this part:
    (i) Assess the effects of the change means to evaluate the effects 
of a manufacturing change on the identity, strength, quality, purity, 
and potency of a drug as these factors may relate to the safety or 
effectiveness of the drug.
    (ii) Drug substance means an active ingredient as defined under 
Sec. 210.3(b)(7) of this chapter.
    (iii) Minor changes and stability report (MCSR) means an annual 
report that is submitted to the application once each year within 60 
days before or after the anniversary date of the application's original 
approval or on a mutually agreed upon date. The report must include 
minor manufacturing and control changes made according to Sec. 
514.8(b)(4) or state that no changes were made; and stability data 
generated on commercial or production batches according to an approved 
stability protocol or commitment.
    (iv) Specification means the quality standard (i.e., tests, 
analytical procedures, and acceptance criteria) provided in an approved 
application to confirm the quality of drugs including, for example, drug 
substances, Type A medicated articles, drug products, intermediates, raw 
materials, reagents,

[[Page 67]]

components, in-process materials, container closure systems, and other 
materials used in the production of a drug. For the purpose of this 
definition, the term ``acceptance criteria'' means numerical limits, 
ranges, or other criteria for the tests described.
    (b) Manufacturing changes to an approved application--(1) General 
provisions. (i) The applicant must notify FDA about each change in each 
condition established in an approved application beyond the variations 
already provided for in the application. The notice is required to 
describe the change fully. Depending on the type of change, the 
applicant must notify FDA about it in a supplement under paragraph 
(b)(2) or (b)(3) of this section or by inclusion of the information in 
the annual report to the application under paragraph (b)(4) of this 
section.
    (ii) The holder of an approved application under section 512 of the 
act must assess the effects of the change before distributing a drug 
made with a manufacturing change.
    (iii) Notwithstanding the requirements of paragraphs (b)(2) and 
(b)(3) of this section, an applicant must make a change provided for in 
those paragraphs in accordance with a regulation or guidance that 
provides for a less burdensome notification of the change (for example, 
by submission of a supplement that does not require approval prior to 
distribution of the drug, or by notification in the next annual report 
described in paragraph (b)(4) of this section).
    (iv) In each supplement and amendment to a supplement providing for 
a change under paragraph (b)(2) or (b)(3) of this section, the applicant 
must include a statement certifying that a field copy has been provided 
to the appropriate FDA district office. No field copy is required for a 
supplement providing for a change made to a drug manufactured outside of 
the United States.
    (v) A supplement or annual report described in paragraph (b)(4) of 
this section must include a list of all changes contained in the 
supplement or annual report. For supplements, this list must be provided 
in the cover letter.
    (2) Changes requiring submission and approval of a supplement prior 
to distribution of the drug made using the change (major changes). (i) A 
supplement must be submitted for any change in the drug, production 
process, quality controls, equipment, or facilities that has a 
substantial potential to have an adverse effect on the identity, 
strength, quality, purity, or potency of the drug as these factors may 
relate to the safety or effectiveness of the drug.
    (ii) These changes include, but are not limited to:
    (A) Except those described in paragraphs (b)(3) and (b)(4) of this 
section, changes in the qualitative or quantitative formulation of the 
drug, including inactive ingredients, or in the specifications provided 
in the approved application;
    (B) Changes requiring completion of appropriate clinical studies to 
demonstrate the equivalence of the drug to the drug as manufactured 
without the change;
    (C) Changes that may affect drug substance or drug product sterility 
assurance, such as changes in drug substance, drug product or component 
sterilization method(s) or an addition, deletion, or substitution of 
steps in an aseptic processing operation;
    (D) Changes in the synthesis or manufacture of the drug substance 
that may affect the impurity profile and/or the physical, chemical, or 
biological properties of the drug substance;
    (E) Changes in a drug product container closure system that controls 
the drug delivered to the animal or changes in the type or composition 
of a packaging component that may affect the impurity profile of the 
drug product;
    (F) Changes solely affecting a natural product, a recombinant DNA-
derived protein/polypeptide, or a complex or conjugate of a drug 
substance with a monoclonal antibody for the following:
    (1) Changes in the virus or adventitious agent removal or 
inactivation method(s),
    (2) Changes in the source material or cell line, and
    (3) Establishment of a new master cell bank or seed;

[[Page 68]]

    (G) Changes to a drug under an application that is subject to a 
validity assessment because of significant questions regarding the 
integrity of the data supporting that application.
    (iii) The applicant must obtain approval of a supplement from FDA 
prior to distribution of a drug made using a change under paragraph 
(b)(2) of this section. The supplement must be labeled ``Prior Approval 
Supplement.'' Except for submissions under paragraph (b)(2)(v) of this 
section, the following information must be contained in the supplement:
    (A) A completed Form FDA 356V;
    (B) A detailed description of the proposed change;
    (C) The drug(s) involved;
    (D) The manufacturing site(s) or area(s) affected;
    (E) A description of the methods used and studies performed to 
assess the effects of the change;
    (F) The data derived from such studies;
    (G) Appropriate documentation (for example, updated master batch 
records, specification sheets) including previously approved 
documentation (with the changes highlighted) or references to previously 
approved documentation;
    (H) For a natural product, a recombinant DNA-derived protein/
polypeptide, or a complex or conjugate of a drug substance with a 
monoclonal antibody, relevant validation protocols and standard 
operating procedures must be provided in addition to the requirements in 
paragraphs (b)(2)(iii)(E) and (b)(2)(iii)(F) of this section;
    (I) For sterilization process and test methodologies related to 
sterilization process validation, relevant validation protocols and a 
list of relevant standard operating procedures must be provided in 
addition to the requirements in paragraphs (b)(2)(iii)(E) and 
(b)(2)(iii)(F) of this section; and
    (J) Any other information as directed by FDA.
    (iv) An applicant may ask FDA to expedite its review of a supplement 
for public health reasons or if a delay in making the change described 
in it would impose an extraordinary hardship on the applicant. Such a 
supplement and its mailing cover must be plainly marked: ``Prior 
Approval Supplement-Expedited Review Requested.''
    (v) Comparability Protocols. An applicant may submit one or more 
protocols describing the specific tests and studies and acceptance 
criteria to be achieved to demonstrate the lack of adverse effect for 
specified types of manufacturing changes on the identity, strength, 
quality, purity, and potency of the drug as these factors may relate to 
the safety or effectiveness of the drug. Any such protocols, if not 
included in the approved application, or changes to an approved 
protocol, must be submitted as a supplement requiring approval from FDA 
prior to distribution of the drug produced with the manufacturing 
change. The supplement, if approved, may subsequently justify a reduced 
reporting category for the particular change because the use of the 
protocol for that type of change reduces the potential risk of an 
adverse effect. A comparability protocol supplement must be labeled 
``Prior Approval Supplement--Comparability Protocol.''
    (3) Changes requiring submission of a supplement at least 30 days 
prior to distribution of the drug made using the change (moderate 
changes). (i) A supplement must be submitted for any change in the drug, 
production process, quality controls, equipment, or facilities that has 
a moderate potential to have an adverse effect on the identity, 
strength, quality, purity, or potency of the drug as these factors may 
relate to the safety or effectiveness of the drug.
    (ii) These changes include, but are not limited to:
    (A) A change in the container closure system that does not affect 
the quality of the drug except as otherwise described in paragraphs 
(b)(2) and (b)(4) of this section;
    (B) Changes solely affecting a natural protein, a recombinant DNA-
derived protein/polypeptide or a complex or conjugate of a drug 
substance with a monoclonal antibody, including:
    (1) An increase or decrease in production scale during finishing 
steps that involves different equipment, and
    (2) Replacement of equipment with that of a different design that 
does not affect the process methodology or process operating parameters.

[[Page 69]]

    (C) Relaxation of an acceptance criterion or deletion of a test to 
comply with an official compendium that is consistent with FDA statutory 
and regulatory requirements.
    (iii) A supplement submitted under paragraph (b)(3)(i) or (b)(3)(vi) 
of this section is required to give a full explanation of the basis for 
the change and identify the date on which the change is made. The 
supplement submitted under paragraph (b)(3)(i) must be labeled 
``Supplement-Changes Being Effected in 30 Days.''
    (iv) Pending approval of the supplement by FDA and except as 
provided in paragraph (b)(3)(vi) of this section, distribution of the 
drug made using the change may begin not less than 30 days after receipt 
of the supplement by FDA. The information listed in paragraphs 
(b)(2)(iii)(A) through (b)(2)(iii)(J) of this section must be contained 
in the supplement.
    (v) The applicant must not distribute the drug made using the change 
if within 30 days following FDA's receipt of the supplement, FDA informs 
the applicant that either:
    (A) The change requires approval prior to distribution of the drug 
in accordance with paragraph (b)(2) of this section; or
    (B) Any of the information required under paragraph (b)(3)(iv) of 
this section is missing. In this case, the applicant must not distribute 
the drug made using the change until the supplement has been amended to 
provide the missing information.
    (vi) The agency may designate a category of changes for the purpose 
of providing that, in the case of a change in such category, the holder 
of an approved application may commence distribution of the drug 
involved upon receipt by the agency of a supplement for the change. The 
information listed in paragraphs (b)(2)(iii)(A) through (b)(2)(iii)(J) 
of this section must be contained in the supplement. The supplement must 
be labeled ``Supplement-Changes Being Effected.'' These changes include, 
but are not limited to:
    (A) Addition to a specification or changes in the methods or 
controls to provide increased assurance that the drug will have the 
characteristics of identity, strength, quality, purity, or potency that 
it purports or is represented to possess; and
    (B) A change in the size and/or shape of a container for a 
nonsterile drug product, except for solid dosage forms, without a change 
in the labeled amount of drug product or from one container closure 
system to another.
    (vii) If the agency disapproves the supplemental application, it may 
order the manufacturer to cease distribution of the drug(s) made with 
the manufacturing change.
    (4) Changes and updated stability data to be described and submitted 
in an annual report (minor changes). (i) Changes in the drug, production 
process, quality controls, equipment, or facilities that have a minimal 
potential to have an adverse effect on the identity, strength, quality, 
purity, or potency of the drug as these factors may relate to the safety 
or effectiveness of the drug must be documented by the applicant in an 
annual report to the application as described under paragraph 
(a)(2)(iii) of this section. The report must be labeled ``Minor Changes 
and Stability Report.''
    (ii) These changes include but are not limited to:
    (A) Any change made to comply with a change to an official 
compendium, except a change in paragraph (b)(3)(ii)(C) of this section, 
that is consistent with FDA statutory and regulatory requirements;
    (B) The deletion or reduction of an ingredient intended to affect 
only the color of the drug product;
    (C) Replacement of equipment with that of the same design and 
operating principles except for those equipment changes described in 
paragraph (b)(3)(ii)(B)(2) of this section;
    (D) A change in the size and/or shape of a container containing the 
same number of dosage units for a nonsterile solid dosage form drug 
product, without a change from one container closure system to another;
    (E) A change within the container closure system for a nonsterile 
drug product, based upon a showing of equivalency to the approved system 
under a protocol approved in the application or published in an official 
compendium;

[[Page 70]]

    (F) An extension of an expiration dating period based upon full 
shelf-life data on production batches obtained from a protocol approved 
in the application;
    (G) The addition or revision of an alternative analytical procedure 
that provides the same or increased assurance of the identity, strength, 
quality, purity, or potency of the drug being tested as the analytical 
procedure described in the approved application, or deletion of an 
alternative analytical procedure; and
    (H) The addition by embossing, debossing, or engraving of a code 
imprint to a solid oral dosage form drug product other than a modified 
release dosage form, or a minor change in an existing code imprint.
    (iii) For changes under this category, the applicant is required to 
submit in the annual report:
    (A) A completed Form FDA 356V;
    (B) A statement by the holder of the approved application that the 
effects of the change have been assessed;
    (C) A detailed description of the change(s);
    (D) The manufacturing site(s) or area(s) involved;
    (E) The date each change was implemented;
    (F) Data from studies and tests performed to assess the effects of 
the change;
    (G) For a natural product, recombinant DNA-derived protein/
polypeptide, complex or conjugate of a drug substance with a monoclonal 
antibody, sterilization process or test methodology related to 
sterilization process validation, relevant validation protocols and/or 
standard operating procedures;
    (H) Appropriate documentation (for example, updated master batch 
records, specification sheets, etc.) including previously approved 
documentation (with the changes highlighted) or references to previously 
approved documentation;
    (I) Updated stability data generated on commercial or production 
batches according to an approved stability protocol or commitment; and
    (J) Any other information as directed by FDA.
    (c) Labeling and other changes to an approved application--(1) 
General provisions. The applicant must notify FDA about each change in 
each condition established in an approved application beyond the 
variations already provided for in the application. The notice is 
required to describe the change fully.
    (2) Labeling changes requiring the submission and approval of a 
supplement prior to distribution of the drug made using the change 
(major changes). (i) Addition of intended uses and changes to package 
labeling require a supplement. These changes include, but are not 
limited to:
    (A) Revision in labeling, such as updating information pertaining to 
effects, dosages, adverse reactions, contraindications, which includes 
information headed ``adverse reactions,'' ``warnings,'' ``precautions,'' 
and ``contraindications,'' except ones described in (c)(3) of this 
section;
    (B) Addition of an intended use;
    (C) If it is a prescription drug, any mailing or promotional piece 
used after the drug is placed on the market is labeling requiring a 
supplemental application, unless:
    (1) The parts of the labeling furnishing directions, warnings, and 
information for use of the drug are the same in language and emphasis as 
labeling approved or permitted; and
    (2) Any other parts of the labeling are consistent with and not 
contrary to such approved or permitted labeling.
    (3) Prescription drug labeling not requiring an approved 
supplemental application is submitted in accordance with Sec. 
514.80(b)(5)(ii).
    (D) Any other changes in labeling, except ones described in 
paragraph (c)(3) of this section.
    (ii) The applicant must obtain approval of the supplement from FDA 
prior to distribution of the drug. The supplement must contain the 
following:
    (A) A completed Form FDA 356V;
    (B) A detailed description of the proposed change;
    (C) The drug(s) involved;
    (D) The data derived from studies in support of the change; and
    (E) Any other information as directed by FDA.

[[Page 71]]

    (3) Labeling changes to be placed into effect prior to receipt of a 
written notice of approval of a supplemental application. (i) Labeling 
changes of the following kinds that increase the assurance of drug 
safety proposed in supplemental applications must be placed into effect 
immediately:
    (A) The addition to package labeling, promotional labeling, or 
prescription drug advertising of additional warning, contraindication, 
adverse reaction, and precaution information;
    (B) The deletion from package labeling, promotional labeling, or 
drug advertising of false, misleading, or unsupported intended uses or 
claims for effectiveness; and
    (C) Any other changes as directed by FDA.
    (ii) Labeling changes (for example, design and style) that do not 
decrease safety of drug use proposed in supplemental applications may be 
placed into effect prior to written notice of approval from FDA of a 
supplemental application.
    (iii) A supplement submitted under paragraph (c)(3) of this section 
must include the following information:
    (A) A full explanation of the basis for the changes, the date on 
which such changes are being effected, and plainly marked on the mailing 
cover and on the supplement, ``Supplement--Labeling Changes Being 
Effected'';
    (B) Two sets of printed copies of any revised labeling to be placed 
in use, identified with the new animal drug application number; and
    (C) A statement by the applicant that all promotional labeling and 
all drug advertising will promptly be revised consistent with the 
changes made in the labeling on or within the new animal drug package no 
later than upon approval of the supplemental application.
    (iv) If the supplemental application is not approved and the drug is 
being distributed with the proposed labeling, FDA may initiate an 
enforcement action because the drug is misbranded under section 502 of 
the act and/or adulterated under section 501 of the act. In addition, 
under section 512(e) of the act, FDA may, after due notice and 
opportunity for a hearing, issue an order withdrawing approval of the 
application.
    (4) Changes providing for additional distributors to be reported 
under Records and reports concerning experience with approved new animal 
drugs (Sec. 514.80). Supplemental applications as described under 
paragraph (c)(2) of this section will not be required for an additional 
distributor to distribute a drug that is the subject of an approved new 
animal drug application or abbreviated new animal drug application if 
the conditions described under Sec. 514.80(b)(5)(iii) are met.
    (d) Patent information. The applicant must comply with the patent 
information requirements under section 512(c)(3) of the act.
    (e) Claimed exclusivity. If an applicant claims exclusivity under 
section 512(c)(2)(F) of the act upon approval of a supplemental 
application for a change in its previously approved drug, the applicant 
must include such a statement.
    (f) Good laboratory practice for nonclinical laboratory studies. A 
supplemental application that contains nonclinical laboratory studies 
must include, with respect to each nonclinical study, either a statement 
that the study was conducted in compliance with the requirements set 
forth in part 58 of this chapter, or, if the study was not conducted in 
compliance with such regulations, a brief statement of the reason for 
the noncompliance.

[71 FR 74782, Dec. 13, 2006]



Sec. 514.11  Confidentiality of data and information in a new animal 
drug application file.

    (a) For purposes of this section the NADA file includes all data and 
information submitted with or incorporated by reference in the NADA, 
INAD's incorporated into the NADA, supplemental NADA's, reports under 
Sec. Sec. 514.80 and 510.301 of this chapter, master files, and other 
related submissions. The availability for public disclosure of any 
record in the NADA file shall be handled in accordance with the 
provisions of this section.
    (b) The existence of an NADA file will not be disclosed by the Food 
and

[[Page 72]]

Drug Administration before an approval has been published in the Federal 
Register, unless it has previously been publicly disclosed or 
acknowledged.
    (c) If the existence of an NADA file has not been publicly disclosed 
or acknowledged, no data or information in the NADA file is available 
for public disclosure.
    (d) If the existence of an NADA file has been publicly disclosed or 
acknowledged before an approval has been published in the Federal 
Register, no data or information contained in the file is available for 
public disclosure before such approval is published, but the 
Commissioner may, in his discretion, disclose a summary of such selected 
portions of the safety and effectiveness data as are appropriate for 
public consideration of a specific pending issue, e.g., at an open 
session of a Food and Drug Administration advisory committee or pursuant 
to an exchange of important regulatory information with a foreign 
government.
    (e) After an approval has been published in the Federal Register, 
the following data and information in the NADA file are immediately 
available for public disclosure unless extraordinary circumstances are 
shown:
    (1) All safety and effectiveness data and information previously 
disclosed to the public, as defined in Sec. 20.81 of this chapter.
    (2) A summary or summaries of the safety and effectiveness data and 
information submitted with or incorporated by reference in the NADA 
file. Such summaries do not constitute the full reports of 
investigations under section 512(b)(1) of the act (21 U.S.C. 360b(b)(1)) 
on which the safety or effectiveness of the drug may be approved. Such 
summaries shall consist of the following:
    (i) For an NADA approved prior to July 1, 1975, internal agency 
records that describe such data and information, e.g., a summary of 
basis for approval or internal reviews of the data and information, 
after deletion of:
    (a) Names and any information that would identify the investigators.
    (b) Any inappropriate gratuitous comments unnecessary to an 
objective analysis of the data and information.
    (ii) For an NADA approved on or after July 1, 1975, a summary of 
such data and information prepared in one of the following two 
alternative ways shall be publicly released when the approval is 
published in the Federal Register.
    (a) The Center for Veterinary Medicine may at an appropriate time 
prior to approval of the NADA require the applicant to prepare a summary 
of such data and information, which will be reviewed and, where 
appropriate, revised by the Center.
    (b) The Center for Veterinary Medicine may prepare its own summary 
of such data and information.
    (3) A protocol for a test or study, unless it is shown to fall 
within the exemption established for trade secrets and confidential 
commercial information in Sec. 20.61 of this chapter.
    (4) Adverse reaction reports, product experience reports, consumer 
complaints, and other similar data and information, after deletion of:
    (i) Names and any information that would identify the person using 
the product.
    (ii) Names and any information that would identify any third party 
involved with the report, such as a physician, hospital, or other 
institution.
    (5) A list of all active ingredients and any inactive ingredients 
previously disclosed to the public as defined in Sec. 20.81 of this 
chapter.
    (6) An assay method or other analytical method, unless it serves no 
regulatory or compliance purpose and is shown to fall within the 
exemption established in Sec. 20.61 of this chapter.
    (7) All correspondence and written summaries of oral discussions 
relating to the NADA, in accordance with the provisions of part 20 of 
this chapter.
    (f) All safety and effectiveness data and information not previously 
disclosed to the public are available for public disclosure at the time 
any one of the following events occurs unless extraordinary 
circumstances are known:
    (1) The NADA has been abandoned and no further work is being 
undertaken with respect to it.
    (2) A final determination is made that the NADA is not approvable, 
and all legal appeals have been exhausted.

[[Page 73]]

    (3) Approval of the NADA is withdrawn, and all legal appeals have 
been exhausted.
    (4) A final determination has been made that the animal drug is not 
a new animal drug.
    (5) A final determination has been made that the animal drug may be 
marketed without submission of such safety and/or effectiveness data and 
information.
    (g) The following data and information in an NADA file are not 
available for public disclosure unless they have been previously 
disclosed to the public as defined in Sec. 20.81 of this chapter or 
they relate to a product or ingredient that has been abandoned and they 
no longer represent a trade secret or confidential commercial or 
financial information as defined in Sec. 20.61 of this chapter:
    (1) Manufacturing methods or processes, including quality control 
procedures.
    (2) Production, sales, distribution, and similar data and 
information, except that any compilation of such data and information 
aggregated and prepared in a way that does not reveal data or 
information which is not available for public disclosure under this 
provision is available for public disclosure.
    (3) Quantitative or semiquantitative formulas.
    (h) For purposes of this regulation, safety and effectiveness data 
include all studies and tests of an animal drug on animals and all 
studies and tests on the animal drug for identity, stability, purity, 
potency, and bioavailability.

[40 FR 13825, Mar. 27, 1975, as amended at 42 FR 3109, Jan. 14, 1977; 42 
FR 15675, Mar. 22, 1977; 54 FR 18280, Apr. 28, 1989; 68 FR 15365, Mar. 
31, 2003]



Sec. 514.12  Confidentiality of data and information in an 
investigational new animal drug notice.

    (a) The existence of an INAD notice will not be disclosed by the 
Food and Drug Administration unless it has previously been publicly 
disclosed or acknowledged.
    (b) The availability for public disclosure of all data and 
information in an INAD file shall be handled in accordance with 
provisions established in Sec. 514.11.



Sec. 514.15  Untrue statements in applications.

    Among the reasons why an application for a new animal drug or animal 
feed bearing or containing a new animal drug may contain an untrue 
statement of a material fact are:
    (a) Differences in:
    (1) Conditions of use prescribed, recommended, or suggested by the 
applicant for the product from the conditions of such use stated in the 
application;
    (2) Articles used as components of the product from those listed in 
the application;
    (3) Composition of the product from that stated in the application;
    (4) Methods used in or the facilities and controls used for the 
manufacture, processing, or packing of the product from such methods, 
facilities, and controls described in the application;
    (5) Labeling from the specimens contained in the application; or
    (b) The unexplained omission in whole or in part from an application 
or from an amendment or supplement to an application or from any record 
or report required under the provisions of section 512 of the act and 
Sec. 514.80 or Sec. 510.301 of this chapter of any information 
obtained from:
    (1) Investigations as to the safety, effectiveness, identity, 
strength, quality, or purity of the drug, made by the applicant on the 
drug, or
    (2) Investigations or experience with the product that is the 
subject of the application, or any related product, available to the 
applicant from any source if such information is pertinent to an 
evaluation of the safety, effectiveness, identity, strength, quality, or 
purity of the drug, when such omission would bias an evaluation of the 
safety or effectiveness of the product.
    (c) Any nonclinical laboratory study contained in the application 
was not conducted in compliance with the good laboratory practice 
regulations as set forth in part 58 of this chapter, and the application 
fails to include a brief

[[Page 74]]

statement of the reason for the noncompliance.

[40 FR 13825, Mar. 27, 1975, as amended at 49 FR 7226, Feb. 28, 1984; 50 
FR 7517, Feb. 22, 1985; 68 FR 15365, Mar. 31, 2003]



            Subpart B_Administrative Actions on Applications



Sec. 514.80  Records and reports concerning experience with approved 
new animal drugs.

    The following table outlines the purpose for each paragraph of this 
section:

------------------------------------------------------------------------
                 Purpose                    21 CFR Paragraph and Title
------------------------------------------------------------------------
What information must be reported         514.80(a) Applicability.
 concerning approved NADAs or ANADAs?
------------------------------------------------------------------------
What authority does FDA have for          514.80(a)(1).
 requesting records and reports?
Who is required to establish, maintain,
 and report required information
 relating to experiences with a new
 animal drug?
Is information from foreign sources
 required?
------------------------------------------------------------------------
What records must be established and      514.80(a)(2).
 maintained and what reports filed with
 FDA?
------------------------------------------------------------------------
What is FDA's purpose for requiring       514.80(a)(3).
 reports?
------------------------------------------------------------------------
Do applicants of Type A medicated         514.80(a)(4).
 articles have to establish, maintain,
 and report information required under
 Sec. 514.80?
------------------------------------------------------------------------
How do the requirements under Sec. 514.80(a)(5).
 514.80 relate to current good
 manufacturing practices?
------------------------------------------------------------------------
                                          514.80(b) Reporting
                                           requirements.
------------------------------------------------------------------------
What are the requirements for reporting   514.80(b)(1) Three-day NADA/
 product/manufacturing defects?            ANADA field alert report.
------------------------------------------------------------------------
                                          514.80(b)(2) Fifteen-day NADA/
                                           ANADA alert report.
------------------------------------------------------------------------
What are the requirements for reporting   514.80(b)(2)(i) Initial
 serious and unexpected adverse drug       report.
 experiences?
------------------------------------------------------------------------
What are the requirements for followup    514.80(b)(2)(ii) Followup
 reporting of serious and unexpected       report.
 adverse drug experiences?
------------------------------------------------------------------------
What are the requirements for             514.80(b)(3) Nonapplicant
 nonapplicants for reporting adverse       report.
 drug experiences?
------------------------------------------------------------------------
What are the general requirements for     514.80(b)(4) Periodic drug
 submission of periodic drug experience    experience report.
 reports, e.g., forms to be submitted,
 submission date and frequency, when is
 it to be submitted, how many copies?
How do I petition to change the date of
 submission or frequency of submissions?
------------------------------------------------------------------------
What must be submitted in the periodic    514.80(b)(4)(i) through
 drug experience reports?                  (b)(4)(iv).
------------------------------------------------------------------------
What distribution data must be            514.80(b)(4)(i) Distribution
 submitted?                                data.
How should the distribution data be
 submitted?
------------------------------------------------------------------------
What labeling materials should be         514.80(b)(4)(ii) Labeling.
 submitted?
How do I report changes to the labeling
 materials since the last report?
------------------------------------------------------------------------
                                          514.80(b)(4)(iii) Nonclinical
                                           laboratory studies and
                                           clinical data not previously
                                           reported.
------------------------------------------------------------------------
What are the requirements for submission  514.80(b)(4)(iii)(A).
 of nonclinical laboratory studies?
------------------------------------------------------------------------
What are the requirements for submission  514.80(b)(4)(iii)(B).
 of clinical laboratory data?
------------------------------------------------------------------------
When must results of clinical trials      514.80(b)(4)(iii)(C).
 conducted by or for the applicant be
 reported?
------------------------------------------------------------------------

[[Page 75]]

 
                                          514.80(b)(4)(iv) Adverse drug
                                           experiences.
------------------------------------------------------------------------
How do I report product/manufacturing     514.80(b)(4)(iv)(A).
 defects and adverse drug experiences
 not previously reported to FDA?
------------------------------------------------------------------------
What are the requirements for submitting  514.80(b)(4)(iv)(B).
 adverse drug experiences cited in
 literature?
------------------------------------------------------------------------
What are the requirements for submitting  514.80(b)(4)(iv)(C).
 adverse drug experiences in
 postapproval studies and clinical
 trials?
------------------------------------------------------------------------
What are the requirements for reporting   514.80(b)(4)(v) Summary report
 increases in the frequency of serious,    of increased frequency of
 expected, and unexpected adverse drug     adverse drug experience.
 experiences?
------------------------------------------------------------------------
                                          514.80(b)(5) Other reporting.
------------------------------------------------------------------------
Can FDA request that an applicant submit  514.80(b)(5)(i) Special drug
 information at different times than       experience report.
 stated specifically in this regulation?
------------------------------------------------------------------------
What are the requirements for submission  514.80(b)(5)(ii)
 of advertisement and promotional          Advertisements and
 labeling to FDA?                          promotional labeling.
------------------------------------------------------------------------
What are the requirements for adding a    514.80(b)(5)(iii)
 new distributor to the approved           Distributor's statement.
 application?
------------------------------------------------------------------------
What labels and how many labels need to   514.80(b)(5)(iii)(A).
 be submitted for review?
------------------------------------------------------------------------
What changes are required and allowed to  514.80(b)(5)(iii)(A)(1).
 distributor labeling?
------------------------------------------------------------------------
What are the requirements for making      514.80(b)(5)(iii)(A)(2).
 other changes to the distributor
 labeling?
------------------------------------------------------------------------
What information should be included in    514.80(b)(5)(iii)(B)(1)
 each new distributor's signed             through (b)(5)(iii)(B)(5).
 statement?
------------------------------------------------------------------------
What are the conditions for submitting    514.80(c) Multiple
 information that is common to more than   applications.
 one application? (i.e., can I submit
 common information to one application?)
------------------------------------------------------------------------
What information has to be submitted to   514.80(c)(1) through (c)(4).
 the common application and related
 application?
------------------------------------------------------------------------
What forms do I need?                     514.80(d) Reporting forms.
What are Forms FDA 1932 and 2301?
How can I get them?
Can I use computer-generated
 equivalents?
------------------------------------------------------------------------
How long must I maintain Form FDA 1932    514.80(e) Records to be
 and records and reports of other          maintained.
 required information, i.e., how long do
 I need to maintain this information?
------------------------------------------------------------------------
What are the requirements for allowing    514.80(f) Access to records
 access to these records and reports,      and reports.
 and copying by authorized FDA officer
 or employee?
------------------------------------------------------------------------
How do I obtain Forms FDA 1932 and 2301?  514.80(g) Mailing addresses.
Where do I mail FDA's required forms,
 records, and reports?
------------------------------------------------------------------------
What happens if the applicant fails to    514.80(h) Withdrawal of
 establish, maintain, or make the          approval.
 required reports?
What happens if the applicant refuses to
 allow FDA access to, and/or copying and/
 or verify records and reports?
------------------------------------------------------------------------
Does an adverse drug experience reflect   514.80(i) Disclaimer.
 a conclusion that the report or
 information constitutes an admission
 that the drug caused an adverse effect?
------------------------------------------------------------------------

    (a) Applicability. (1) Each applicant must establish and maintain 
indexed and complete files containing full records of all information 
pertinent to safety or effectiveness of a new animal drug that has not 
been previously submitted as part of the NADA or ANADA. Such records 
must include information from domestic as well as foreign

[[Page 76]]

sources. Each nonapplicant must establish and maintain indexed and 
complete files containing full records of all information pertinent to 
safety or effectiveness of a new animal drug that is received or 
otherwise obtained by the nonapplicant. Such records must include 
information from domestic as well as foreign sources.
    (2) Each applicant must submit reports of data, studies, and other 
information concerning experience with new animal drugs to the Food and 
Drug Administration (FDA) for each approved NADA and ANADA, as required 
in this section. A nonapplicant must submit data, studies, and other 
information concerning experience with new animal drugs to the 
appropriate applicant, as required in this section. The applicant, in 
turn, must report the nonapplicant's data, studies, and other 
information to FDA. Applicants and nonapplicants must submit data, 
studies, and other information described in this section from domestic, 
as well as foreign sources.
    (3) FDA reviews the records and reports required in this section to 
facilitate a determination under section 512(e) of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 360b(e)) as to whether there may be 
grounds for suspending or withdrawing approval of the NADA or ANADA.
    (4) The requirements of this section also apply to any approved Type 
A medicated article. In addition, the requirements contained in Sec. 
514.80(b)(1), (b)(2), (b)(4)(iv), and (b)(4)(v) apply to any approved 
Type A medicated article incorporated in animal feeds.
    (5) The records and reports referred to in this section are in 
addition to those required by the current good manufacturing practice 
regulations in parts 211, 225, and 226 of this chapter.
    (b) Reporting requirements--(1) Three-day NADA/ANADA field alert 
report. This report provides information pertaining to product and 
manufacturing defects that may result in serious adverse drug events. 
The applicant (or nonapplicant through the applicant) must submit the 
report to the appropriate FDA District Office or local FDA resident post 
within 3 working days of first becoming aware that a defect may exist. 
The information initially may be provided by telephone or other 
telecommunication means, with prompt written followup using Form FDA 
1932 ``Veterinary Adverse Drug Reaction, Lack of Effectiveness, Product 
Defect Report.'' The mailing cover for these reports must be plainly 
marked ``3-Day NADA/ANADA Field Alert Report.''
    (2) Fifteen-day NADA/ANADA alert report--(i) Initial report. This 
report provides information on each serious, unexpected adverse drug 
event, regardless of the source of the information. The applicant (or 
nonapplicant through the applicant) must submit the report to FDA within 
15 working days of first receiving the information. The report must be 
submitted on Form FDA 1932, and its mailing cover must be plainly marked 
``15-Day NADA/ANADA Alert Report.''
    (ii) Followup report. The applicant must promptly investigate all 
adverse drug events that are the subject of 15-day NADA/ANADA alert 
reports. If this investigation reveals significant new information, a 
followup report must be submitted within 15 working days of receiving 
such information. A followup report must be submitted on Form FDA 1932, 
and its mailing cover must be plainly marked ``15-Day NADA/ANADA Alert 
Report Followup.'' The followup report must state the date of the 
initial report and provide the additional information. If additional 
information is sought but not obtained within 3 months of the initial 
report, a followup report is required describing the steps taken and why 
additional information was not obtained.
    (3) Nonapplicant report. Nonapplicants must forward reports of 
adverse drug experiences to the applicant within 3 working days of first 
receiving the information. The applicant must then submit the report(s) 
to FDA as required in this section. The nonapplicant must maintain 
records of all nonapplicant reports, including the date the nonapplicant 
received the information concerning adverse drug experiences, the name 
and address of the applicant, and a copy of the adverse drug experience 
report including the date such report was submitted to the applicant. If 
the nonapplicant elects to

[[Page 77]]

also report directly to FDA, the nonapplicant should submit the report 
on Form FDA 1932 within 15 working days of first receiving the 
information.
    (4) Periodic drug experience report. This report must be accompanied 
by a completed Form FDA 2301 ``Transmittal of Periodic Reports and 
Promotional Materials for New Animal Drugs.'' It must be submitted every 
6 months for the first 2 years following approval of an NADA or ANADA 
and yearly thereafter. Reports required by this section must contain 
data and information for the full reporting period. The 6-month periodic 
drug experience reports must be submitted within 30 days following the 
end of the 6-month reporting period. The yearly periodic drug experience 
reports must be submitted within 60 days of the anniversary date of the 
approval of the NADA or ANADA. Any previously submitted information 
contained in the report must be identified as such. For yearly (annual) 
periodic drug experience reports, the applicant may petition FDA to 
change the date of submission or frequency of reporting, and after 
approval of such petition, file such reports on the new filing date or 
at the new reporting frequency. Also, FDA may require a report at 
different times or more frequently. The periodic drug experience report 
must contain the following:
    (i) Distribution data. Information about the distribution of each 
new animal drug product, including information on any distributor-
labeled product. This information must include the total number of 
distributed units of each size, strength, or potency (e.g., 100,000 
bottles of 100 5-milligram tablets; 50,000 10-milliliter vials of 5-
percent solution). This information must be presented in two categories: 
Quantities distributed domestically and quantities exported.
    (ii) Labeling. Applicant and distributor current package labeling, 
including package inserts (if any). For large-size package labeling or 
large shipping cartons, a representative copy must be submitted (e.g., a 
photocopy of pertinent areas of large feed bags). A summary of any 
changes in labeling made since the last report (listed by date of 
implementation) must be included with the labeling or if there have been 
no changes, a statement of such fact must be included with the labeling.
    (iii) Nonclinical laboratory studies and clinical data not 
previously reported.
    (A) Copies of in vitro studies (e.g., mutagenicity) and other 
nonclinical laboratory studies conducted by or otherwise obtained by the 
applicant.
    (B) Copies of published clinical trials of the new animal drug (or 
abstracts of them) including clinical trials on safety and 
effectiveness, clinical trials on new uses, and reports of clinical 
experience pertinent to safety conducted by or otherwise obtained by the 
applicant. Review articles, papers, and abstracts in which the drug is 
used as a research tool, promotional articles, press clippings, and 
papers that do not contain tabulations or summaries of original data are 
not required to be reported.
    (C) Descriptions of completed clinical trials conducted by or for 
the applicant must be submitted no later than 1 year after completion of 
research. Supporting information is not to be reported.
    (iv) Adverse drug experiences. (A) Product/manufacturing defects and 
adverse drug experiences not previously reported under Sec. 
514.80(b)(1) and (b)(2) must be reported individually on Form FDA 1932.
    (B) Reports of adverse drug experiences in the literature must be 
noted in the periodic drug experience report. A bibliography of 
pertinent references must be included with the report. Upon FDA's 
request, the applicant must provide a full text copy of these 
publications.
    (C) Reports of previously not reported adverse drug experiences that 
occur in postapproval studies must be reported separately from other 
experiences in the periodic drug experience report and clearly marked or 
highlighted.
    (v) Summary report of increased frequency of adverse drug 
experience. The applicant must periodically review the incidence of 
reports of adverse drug experiences to determine if there has been an 
increased frequency of serious (expected and unexpected) adverse drug 
events. The applicant must evaluate

[[Page 78]]

the increased frequency of serious (expected or unexpected) adverse drug 
events at least as often as reporting of periodic drug experience 
reports. The applicant must report the increased frequency of serious 
(expected and unexpected) adverse drug events in the periodic drug 
experience report. Summaries of reports of increased frequency of 
adverse drug events must be submitted in narrative form. The summaries 
must state the time period on which the increased frequency is based, 
time period comparisons in determining increased frequency, references 
to any previously submitted Form FDA 1932, the method of analysis, and 
the interpretation of the results. The summaries must be submitted in a 
separate section within the periodic drug experience report.
    (5) Other reporting--(i) Special drug experience report. Upon 
written request, FDA may require that the applicant submit a report 
required under Sec. 514.80 at different times or more frequently than 
the timeframes stated in Sec. 514.80.
    (ii) Advertisements and promotional labeling. The applicant must 
submit at the time of initial dissemination one set of specimens of 
mailing pieces and other labeling for prescription and over-the-counter 
new animal drugs. For prescription new animal drugs, the applicant must 
also submit one set of specimens of any advertisement at the time of 
initial publication or broadcast. Mailing pieces and labeling designed 
to contain product samples must be complete except that product samples 
may be omitted. Each submission of promotional labeling or 
advertisements must be accompanied by a completed Form FDA 2301.
    (iii) Distributor's statement. At the time of initial distribution 
of a new animal drug product by a distributor, the applicant must submit 
a special drug experience report accompanied by a completed Form FDA 
2301 containing the following:
    (A) The distributor's current product labeling.
    (1) The distributor's labeling must be identical to that in the 
approved NADA/ANADA except for a different and suitable proprietary name 
(if used) and the name and address of the distributor. The name and 
address of the distributor must be preceded by an appropriate qualifying 
phrase as permitted by the regulations such as ``manufactured for'' or 
``distributed by.''
    (2) Other labeling changes must be the subject of a supplemental 
NADA or ANADA as described under Sec. 514.8.
    (B) A signed statement by the distributor stating:
    (1) The category of the distributor's operations (e.g., wholesale or 
retail),
    (2) That the distributor will distribute the new animal drug only 
under the approved labeling,
    (3) That the distributor will promote the product only for use under 
the conditions stated in the approved labeling,
    (4) That the distributor will adhere to the records and reports 
requirements of this section, and
    (5) That the distributor is regularly and lawfully engaged in the 
distribution or dispensing of prescription products if the product is a 
prescription new animal drug.
    (c) Multiple applications. Whenever an applicant is required to 
submit a periodic drug experience report under the provisions of Sec. 
514.80(b)(4) with respect to more than one approved NADA or ANADA for 
preparations containing the same new animal drug so that the same 
information is required to be reported for more than one application, 
the applicant may elect to submit as a part of the report for one such 
application (the primary application) all the information common to such 
applications in lieu of reporting separately and repetitively on each. 
If the applicant elects to do this, the applicant must do the following:
    (1) State when a report applies to multiple applications and 
identify all related applications for which the report is submitted by 
NADA or ANADA number.
    (2) Ensure that the primary application contains a list of the NADA 
or ANADA numbers of all related applications.
    (3) Submit a completed Form FDA 2301 to the primary application and 
each related application with reference to the primary application by 
NADA/ANADA number and submission date for the complete report of the 
common information.

[[Page 79]]

    (4) All other information specific to a particular NADA/ANADA must 
be included in the report for that particular NADA/ANADA.
    (d) Reporting forms. Applicant must report adverse drug experiences 
and product/manufacturing defects on Form FDA 1932, ``Veterinary Adverse 
Drug Reaction, Lack of Effectiveness, Product Defect Report.'' Periodic 
drug experience reports and special drug experience reports must be 
accompanied by a completed Form FDA 2301 ``Transmittal of Periodic 
Reports and Promotional Material for New Animal Drugs,'' in accordance 
with directions provided on the forms. Computer-generated equivalents of 
Form FDA 1932 or Form FDA 2301, approved by FDA before use, may be used. 
Form FDA 1932 and Form FDA 2301 may be obtained on the Internet at 
http://www.fda.gov/cvm/forms/forms.html, by telephoning the Division of 
Surveillance (HFV-210), or by submitting a written request to the 
following address: Food and Drug Administration, Center for Veterinary 
Medicine, Division of Surveillance (HFV-210), 7500 Standish Pl., 
Rockville, MD 20855-2764.
    (e) Records to be maintained. The applicants and nonapplicants must 
maintain records and reports of all information required by this section 
for a period of 5 years after the date of submission.
    (f) Access to records and reports. The applicant and nonapplicant 
must, upon request from any authorized FDA officer or employee, at all 
reasonable times, permit such officer or employee to have access to copy 
and to verify all such required records and reports.
    (g) Mailing addresses. Completed 15-day alert reports, periodic drug 
experience reports, and special drug experience reports must be 
submitted to the following address: Food and Drug Administration, Center 
for Veterinary Medicine, Document Control Unit (HFV-199), 7500 Standish 
Pl., Rockville, MD 20855-2764. Three-day alert reports must be submitted 
to the appropriate FDA district office or local FDA resident post. 
Addresses for district offices and resident posts may be obtained from 
the Internet at http://www.fda.gov (click on ``Contact FDA,'' then ``FDA 
Field Offices'').
    (h) Withdrawal of approval. If FDA finds that the applicant has 
failed to establish the required records, or has failed to maintain 
those records, or failed to make the required reports, or has refused 
access to an authorized FDA officer or employee to copy or to verify 
such records or reports, FDA may withdraw approval of the application to 
which such records or reports relate. If FDA determines that withdrawal 
of the approval is necessary, the agency shall give the applicant notice 
and opportunity for hearing, as provided in Sec. 514.200, on the 
question of whether to withdraw approval of the application.
    (i) Disclaimer. Any report or information submitted under this 
section and any release of that report or information by FDA will be 
without prejudice and does not necessarily reflect a conclusion that the 
report or information constitutes an admission that the drug caused or 
contributed to an adverse event. A person need not admit, and may deny, 
that the report or information constitutes an admission that a drug 
caused or contributed to an adverse event.

[68 FR 15365, Mar. 31, 2003]



Sec. 514.100  Evaluation and comment on applications.

    (a) After the filed application has been evaluated, the applicant 
will be furnished written comment on any apparent deficiencies in the 
application.
    (b) When the description of the methods used in, and the facilities 
and controls used for, the manufacture, processing, and packing of such 
new animal drug appears adequate on its face, but it is not feasible to 
reach a conclusion as to the safety and effectiveness of the new animal 
drug solely from consideration of this description, the applicant may be 
notified that an establishment inspection is required to verify their 
adequacy.
    (c) A request for samples of a new animal drug or any edible tissues 
and byproducts of animals treated with such a drug, shall specify the 
quantity deemed adequate to permit tests of analytical methods to 
determine their adequacy for regulatory purposes. The request should be 
made as early in the 180-day period as possible to assure

[[Page 80]]

timely completion. The date used for computing the 180-day limit for the 
purposes of section 512(c) of the act shall be moved forward 1 day for 
each day after the mailing date of the request until all of the 
requested samples are received. If the samples are not received within 
90 days after the request, the application will be considered withdrawn 
without prejudice.
    (d) The information contained in an application may be insufficient 
to determine whether a new animal drug is safe or effective in use if it 
fails to include (among other things) a statement showing whether such 
drug is to be limited to prescription sale and exempt under section 
502(f) of the act from the requirement that its labeling bear adequate 
directions for lay use. If such drug is to be exempt, the information 
may also be insufficient if:
    (1) The specimen labeling proposed fails to bear adequate 
information for professional use including indications, effects, 
dosages, routes, methods, and frequency and duration of administration 
and any relevant hazards, contraindications, side effects, and 
precautions under which practitioners licensed by law to administer such 
drug can use the drug for the purposes for which it is intended, 
including all purposes for which it is to be advertised, or represented, 
in accordance with Sec. 201.105 of this chapter, and information 
concerning hazards, contraindications, side effects, and precautions 
relevant with respect to any uses for which such drug is to be 
prescribed.
    (2) The application fails to show that the labeling and advertising 
of such drug will offer the drug for use only under those conditions for 
which it is offered in the labeling that is part of the application.
    (3) The application fails to show that all labeling that furnishes 
or purports to furnish information for professional use of such drug 
will contain, in the same language and emphasis, the information for use 
including indications, effects, dosages, routes, methods, and frequency 
and duration of administration and any relevant warnings, hazards, 
contraindications, side effects, and precautions, which is contained in 
the labeling that is part of the application in accordance with Sec. 
201.105 of this chapter.
    (e) The information contained in an application will be considered 
insufficient to determine whether a new animal drug is safe and 
effective for use when there is a refusal or failure upon written notice 
to furnish inspectors authorized by the Food and Drug Administration an 
adequate opportunity to inspect the facilities, controls, and records 
pertinent to the application.
    (f) On the basis of preliminary consideration of an application or 
supplemental application containing typewritten or other draft labeling 
in lieu of final printed labeling, an applicant may be informed that 
such application is approvable when satisfactory final printed labeling 
identical in content to such draft copy is submitted.
    (g) When an application has been found incomplete on the basis of a 
need for the kind of information described in Sec. 514.6, such 
application shall be considered withdrawn without prejudice to future 
filing on the date of issuance of the letter citing the inadequacies 
contained in the application, unless within 30 days the sponsor chooses 
to avail himself of the opportunity for hearing as prescribed by Sec. 
514.111.



Sec. 514.105  Approval of applications.

    (a) The Commissioner shall forward for publication in the Federal 
Register a regulation prescribing the conditions under which the new 
animal drug may be used, including the name and address of the 
applicant; the conditions and indications for use covered by the 
application; any tolerance, withdrawal period, or other use 
restrictions; any tolerance required for the new animal drug substance 
or its metabolites in edible products of food-producing animals; and, if 
such new animal drug is intended for use in animal feed, appropriate 
purposes and conditions of use (including special labeling requirements) 
applicable to any animal feed; and such other information the 
Commissioner deems necessary to assure safe and effective use.
    (b) He shall notify the applicant by sending him a copy of the 
proposed

[[Page 81]]

publication as described in paragraph (a)(1) of this section.

[40 FR 13825, Mar. 27, 1975, as amended at 51 FR 7392, Mar. 3, 1986; 64 
FR 63203, Nov. 19, 1999]



Sec. 514.106  Approval of supplemental applications.

    (a) Within 180 days after a supplement to an approved application is 
filed pursuant to Sec. 514.8, the Commissioner shall approve the 
supplemental application in accordance with procedures set forth in 
Sec. 514.105(a)(1) and (2) if he/she determines that the application 
satisfies the requirements of applicable statutory provisions and 
regulations.
    (b) The Commissioner will assign a supplemental application to its 
proper category to ensure processing of the application.
    (1) Category I. Supplements that ordinarily do not require a 
reevaluation of any of the safety or effectiveness data in the parent 
application. Category I supplements include the following:
    (i) A corporate change that alters the identity or address of the 
sponsor of the new animal drug application (NADA).
    (ii) The sale, purchase, or construction of manufacturing 
facilities.
    (iii) The sale or purchase of an NADA.
    (iv) A change in container, container style, shape, size, or 
components.
    (v) A change in approved labeling (color, style, format, addition, 
deletion, or revision of certain statements, e.g., trade name, storage, 
expiration dates, etc).
    (vi) A change in promotional material for a prescription new animal 
drug not exempted by Sec. 514.8(c)(2)(i)(C)(1) through (c)(2)(i)(C)(3).
    (vii) Changes in manufacturing processes that do not alter the 
method of manufacture or change the final dosage form.
    (viii) A change in bulk drug shipments.
    (ix) A change in an analytical method or control procedures that do 
not alter the approved standards.
    (x) A change in an expiration date.
    (xi) Addition of an alternate manufacturer, repackager, or relabeler 
of the drug product.
    (xii) Addition of an alternate supplier of the new drug substance.
    (xiii) A change permitted in advance of approval as described under 
Sec. 514.8(b)(3).
    (2) Category II. Supplements that may require a reevaluation of 
certain safety or effectiveness data in the parent application. Category 
II supplements include the following:
    (i) A change in the active ingredient concentration or composition 
of the final product.
    (ii) A change in quality, purity, strength, and identity 
specifications of the active or inactive ingredients.
    (iii) A change in dose (amount of drug administered per dose).
    (iv) A change in the treatment regimen (schedule of dosing).
    (v) Addition of a new therapeutic claim to the approved uses of the 
product.
    (vi) Addition of a new or revised animal production claim.
    (vii) Addition of a new species.
    (viii) A change in the prescription or over-the-counter status of a 
drug product.
    (ix) A change in statements regarding side effects, warnings, 
precautions, and contraindications, except the addition of approved 
statements to container, package, and promotional labeling, and 
prescription drug advertising.
    (x) A change in the drug withdrawal period prior to slaughter or in 
the milk discard time.
    (xi) A change in the tolerance for drug residues.
    (xii) A change in analytical methods for drug residues.
    (xiii) A revised method of synthesis or fermentation of the new drug 
substance.
    (xiv) Updating or changes in the manufacturing process of the new 
drug substance and/or final dosage form (other than a change in 
equipment that does not alter the method of manufacture of a new animal 
drug, or a change from one commercial batch size to another without any 
change in manufacturing procedure), or changes in the methods, 
facilities, or controls used for the manufacture, processing, packaging, 
or holding of the new animal drug (other than use of an establishment 
not covered by the approval that

[[Page 82]]

is in effect) that give increased assurance that the drug will have the 
characteristics of identity, strength, quality, and purity which it 
purports or is represented to possess.

[55 FR 46052, Nov. 1, 1990; 55 FR 49973, Dec. 3, 1990; 56 FR 12422, Mar. 
25, 1991; 71 FR 74785, Dec. 13, 2006]



Sec. 514.110  Reasons for refusing to file applications.

    (a) The date of receipt of an application for a new animal drug 
shall be the date on which the application shall be deemed to be filed.
    (b) An application for a new animal drug shall not be considered 
acceptable for filing for any of the following reasons:
    (1) It does not contain complete and accurate English translations 
of any pertinent part in a foreign language.
    (2) Fewer than three copies are submitted.
    (3) It is incomplete on its face in that it is not properly 
organized and indexed.
    (4) On its face the information concerning required matter is so 
inadequate that the application is clearly not approvable.
    (5) The new animal drug is to be manufactured, prepared, propagated, 
compounded, or processed in whole or in part in any State in an 
establishment that has not been registered or exempted from registration 
under the provisions of section 510 of the act.
    (6) The sponsor does not reside or maintain a place of business 
within the United States and the application has not been countersigned 
by an attorney, agent, or other representative of the applicant, which 
representative resides in the United States and has been duly authorized 
to act on behalf of the applicant and to receive communications on all 
matters pertaining to the application.
    (7) The new animal drug is a drug subject to licensing under the 
animal virus, serum, and toxin law of March 4, 1913 (37 Stat. 832; 21 
U.S.C. 151 et seq. ). Such applications will be referred to the U.S. 
Department of Agriculture for action.
    (8) It fails to include, with respect to each nonclinical laboratory 
study contained in the application, either a statement that the study 
was conducted in compliance with the good laboratory practice 
regulations set forth in part 58 of this chapter, or, if the study was 
not conducted in compliance with such regulations, a brief statement of 
the reasons for the noncompliance.
    (9) [Reserved]
    (10) The applicant fails to submit a complete environmental 
assessment under Sec. 25.40 of this chapter or fails to provide 
sufficient information to establish that the requested action is subject 
to categorical exclusion under Sec. 25.30 or Sec. 25.33 of this 
chapter.
    (c) If an application is determined not to be acceptable for filing, 
the applicant shall be notified within 30 days of receipt of the 
application and shall be given the reasons therefore.
    (d) If the applicant disputes the findings that his application is 
not acceptable for filing, he may make written request that the 
application be filed over protest, in which case it will be filed as of 
the day originally received.

[40 FR 13825, Mar. 27, 1975, as amended at 50 FR 7517, Feb. 22, 1985; 50 
FR 16668, Apr. 26, 1985; 62 FR 40600, July 29, 1997]



Sec. 514.111  Refusal to approve an application.

    (a) The Commissioner shall, within 180 days after the filing of the 
application, inform the applicant in writing of his intention to issue a 
notice of opportunity for a hearing on a proposal to refuse to approve 
the application, if the Commissioner determines upon the basis of the 
application, or upon the basis of other information before him with 
respect to a new animal drug, that:
    (1) The reports of investigations required to be submitted pursuant 
to section 512(b) of the act do not include adequate tests by all 
methods reasonably applicable to show whether or not such drug is safe 
for use under the conditions prescribed, recommended, or suggested in 
the proposed labeling thereof; or
    (2) The results of such tests show that such drug is unsafe for use 
under such conditions or do not show that such drug is safe for use 
under such conditions; or

[[Page 83]]

    (3) The methods used in and the facilities and controls used for the 
manufacture, processing, and packing of such drug are inadequate to 
preserve its identity, strength, quality, and purity; or
    (4) Upon the basis of the information submitted to the Food and Drug 
Administration as part of the application, or upon the basis of any 
other information before it with respect to such drug, it has 
insufficient information to determine whether such drug is safe for use 
under such conditions. In making this determination the Commissioner 
shall consider, among other relevant factors:
    (i) The probable consumption of such drug and of any substance 
formed in or on food because of the use of such drug;
    (ii) The cumulative effect on man or animal of such drug, taking 
into account any chemically or pharmacologically related substances;
    (iii) Safety factors which, in the opinion of experts qualified by 
scientific training and experience to evaluate the safety of such drugs, 
are appropriate for the use of animal experimentation data; and
    (iv) Whether the conditions of use prescribed, recommended, or 
suggested in the proposed labeling are reasonably certain to be followed 
in practice; or
    (5) Evaluated on the basis of information submitted as part of the 
application and any other information before the Food and Drug 
Administration with respect to such drug, there is lack of substantial 
evidence as defined in Sec. 514.4.
    (6) Failure to include an appropriate proposed tolerance for 
residues in edible products derived from animals or a withdrawal period 
or other restrictions for use of such drug if any tolerance or 
withdrawal period or other restrictions for use are required in order to 
assure that the edible products derived from animals treated with such 
drug will be safe.
    (7) Based on a fair evaluation of all material facts, the labeling 
is false or misleading in any particular; or
    (8) Such drug induces cancer when ingested by man or animal or, 
after appropriate tests for evaluation of the safety of such drug, 
induces cancer in man or animal, except that this subparagraph shall not 
apply with respect to such drug if the Commissioner finds that, under 
the conditions of use specified in proposed labeling and reasonably 
certain to be followed in practice:
    (i) Such drug will not adversely affect the animal for which it is 
intended; and
    (ii) No residue of such drug will be found (by methods of 
examination prescribed or approved by the Commissioner by regulations) 
in any edible portion of such animal after slaughter or in any food 
yielded by, or derived from the living animals.
    (9) The applicant fails to submit an adequate environmental 
assessment under Sec. 25.40 of this chapter or fails to provide 
sufficient information to establish that the requested action is subject 
to categorical exclusion under Sec. 25.30 or Sec. 25.33 of this 
chapter.
    (10) The drug fails to satisfy the requirements of subpart E of part 
500 of this chapter.
    (11) Any nonclinical laboratory study that is described in the 
application and that is essential to show that the drug is safe for use 
under the conditions prescribed, recommended, or suggested in its 
proposed labeling, was not conducted in compliance with the good 
laboratory practice regulations as set forth in part 58 of this chapter 
and no reason for the noncompliance is provided or, if it is, the 
differences between the practices used in conducting the study and the 
good laboratory practice regulations do not support the validity of the 
study.
    (b) The Commissioner, as provided in Sec. 514.200 of this chapter, 
shall expeditiously notify the applicant of an opportunity for a hearing 
on the question of whether such application is approvable, unless by the 
30th day following the date of issuance of the letter informing the 
applicant of the intention to issue a notice of opportunity for a 
hearing the applicant:
    (1) Withdraws the application; or
    (2) Waives the opportunity for a hearing; or

[[Page 84]]

    (3) Agrees with the Commissioner on an additional period to precede 
issuance of such notice of hearing.

[40 FR 13825, Mar. 27, 1975, as amended at 43 FR 22675, May 26, 1978; 44 
FR 16007, Mar. 16, 1979; 50 FR 7517, Feb. 22, 1985; 50 FR 16668, Apr. 
26, 1985; 52 FR 49588, Dec. 31, 1987; 54 FR 18280, Apr. 28, 1989; 62 FR 
40600, July 29, 1997; 63 FR 10770, Mar. 5, 1998; 64 FR 40757, July 28, 
1999; 64 FR 63204, Nov. 19, 1999]



Sec. 514.115  Withdrawal of approval of applications.

    (a) The Secretary may suspend approval of an application approved 
pursuant to section 512(c) of the act and give the applicant prompt 
notice of his action and afford the applicant the opportunity for an 
expedited hearing on a finding that there is an imminent hazard to the 
health of man or of the animals for which such new animal drug or animal 
feed is intended.
    (b) The Commissioner shall notify in writing the person holding an 
application approved pursuant to section 512(c) of the act and afford an 
opportunity for a hearing on a proposal to withdraw approval of such 
application if he finds:
    (1) That the application contains any untrue statement of a material 
fact; or
    (2) That the applicant has made any changes from the standpoint of 
safety or effectiveness beyond the variations provided for in the 
application unless he has supplemented the application by filing with 
the Secretary adequate information respecting all such changes and 
unless there is in effect an approval of the supplemental application, 
or such changes are those for which written authorization or approval is 
not required as provided for in Sec. 514.8. The supplemental 
application shall be treated in the same manner as the original 
application.
    (3) That in the case of an application for use of a new animal drug 
approved or deemed approved pursuant to section 512(c) of the act:
    (i) Experience or scientific data show that such drug is unsafe for 
use under the conditions of use upon the basis of which the application 
was approved; or
    (ii) New evidence not contained in such application or not available 
to the Secretary until after such application was approved, or tests by 
new methods, or tests by methods not deemed reasonably applicable when 
such application was approved, evaluated together with the evidence 
available to the Secretary when the application was approved, shows that 
such drug is not shown to be safe for use under the conditions of use 
upon the basis of which the application was approved or that section 512 
(d)(1)(H) of the act applies to such drug; or
    (iii) On the basis of new information before him with respect to 
such drug, evaluated together with the evidence available to him when 
the application was approved, there is a lack of substantial evidence 
that such drug will have the effect it purports or is represented to 
have under the conditions of use prescribed, recommended, or suggested 
in the labeling thereof.
    (4) That any nonclinical laboratory study that is described in the 
application and that is essential to show that the drug is safe for use 
under the conditions prescribed, recommended, or suggested in its 
proposed labeling, was not conducted in compliance with the good 
laboratory practice regulations as set forth in part 58 of this chapter 
and no reason for the noncompliance is provided or, if it is, the 
differences between the practices used in conducting the study and the 
good laboratory practice regulations do not support the validity of the 
study.
    (c) The Commissioner may notify in writing the person holding an 
application approved pursuant to section 512(c) of the act and afford an 
opportunity for a hearing on a proposal to withdraw approval of such 
application if he finds:
    (1) That the applicant has failed to establish a system for 
maintaining required records, or has repeatedly or deliberately failed 
to maintain such records or to make required reports in accordance with 
a regulation or order under section 512(l)(1) of the act, or the 
applicant has refused to permit access to, or copying, or verification 
of, such records as required by section 512(l)(2) of the act; or
    (2) That on the basis of new information before him evaluated 
together with the evidence before him when the application was approved, 
the methods used in, or the facilities and controls

[[Page 85]]

used for, the manufacture, processing, and packing of such drug or 
animal feed are inadequate to assure and preserve its identity, 
strength, quality, and purity and were not made adequate within a 
reasonable time after receipt of written notice from the Secretary 
specifying the matter complained of; or
    (3) That on the basis of new information before him, evaluated 
together with the evidence before him when the application was approved, 
the labeling of such drug, based on a fair evaluation of all material 
facts, is false or misleading in any particular and was not corrected 
within a reasonable time after receipt of written notice from the 
Secretary specifying the matter complained of.
    (d) Approval of an application pursuant to section 512(c) of the act 
will be withdrawn on the basis of a request for its withdrawal submitted 
in writing by a person holding an approved new animal drug application 
on the grounds that the drug subject to such application is no longer 
being marketed and information is included in support of this finding, 
provided none of the conditions cited in paragraphs (a), (b), and (c) of 
this section pertain to the subject drug. A written request for such 
withdrawal shall be construed as a waiver of the opportunity for a 
hearing as otherwise provided for in this section. Withdrawal of 
approval of an application under the provisions of this paragraph shall 
be without prejudice.
    (e) On the basis of the withdrawal of approval of an application for 
a new animal drug approved pursuant to section 512(c) of the act, the 
regulation published pursuant to section 512(i) of the act covering the 
conditions of use of such drug as provided for in the application shall 
be revoked.

[40 FR 13825, Mar. 27, 1975, as amended at 50 FR 7517, Feb. 22, 1985; 64 
FR 63204, Nov. 19, 1999]



Sec. 514.116  Notice of withdrawal of approval of application.

    When an approval of an application submitted pursuant to section 512 
of the act is withdrawn by the Commissioner, he will give appropriate 
public notice of such action by publication in the Federal Register.



Sec. 514.117  Adequate and well-controlled studies.

    (a) Purpose. The primary purpose of conducting adequate and well-
controlled studies of a new animal drug is to distinguish the effect of 
the new animal drug from other influences, such as spontaneous change in 
the course of the disease, normal animal production performance, or 
biased observation. One or more adequate and well-controlled studies are 
required to establish, by substantial evidence, that a new animal drug 
is effective. The characteristics described in paragraph (b) of this 
section have been developed over a period of years and are generally 
recognized as the essentials of an adequate and well-controlled study. 
Well controlled, as used in the phrase adequate and well controlled, 
emphasizes an important aspect of adequacy. The Food and Drug 
Administration (FDA) considers these characteristics in determining 
whether a study is adequate and well controlled for purposes of section 
512 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 
360b). Adequate and well-controlled studies, in addition to providing a 
basis for determining whether a new animal drug is effective, may also 
be relied upon to support target animal safety. The report of an 
adequate and well-controlled study should provide sufficient details of 
study design, conduct, and analysis to allow critical evaluation and a 
determination of whether the characteristics of an adequate and well-
controlled study are present.
    (b) Characteristics. An adequate and well-controlled study has the 
following characteristics:
    (1) The protocol for the study (protocol) and the report of the 
study results (study report) must include a clear statement of the study 
objective(s).
    (2) The study is conducted in accordance with an appropriate 
standard of conduct that addresses, among other issues, study conduct, 
study personnel, study facilities, and study documentation. The protocol 
contains a statement acknowledging the applicability of, and intention 
to follow, a standard of conduct acceptable to FDA. The study report 
contains a statement describing adherence to the standard.

[[Page 86]]

    (3) The study is conducted with a new animal drug that is produced 
in accordance with appropriate manufacturing practices, which include, 
but are not necessarily limited to, the manufacture, processing, 
packaging, holding, and labeling of the new animal drug such that the 
critical characteristics of identity, strength, quality, purity, and 
physical form of the new animal drug are known, recorded, and 
reproducible, to permit meaningful evaluations of and comparisons with 
other studies conducted with the new animal drug. The physical form of a 
new animal drug includes the formulation and physical characterization 
(including delivery systems thereof, if any) of the new animal drug as 
presented to the animal. The protocol and study report must include an 
identification number which can be correlated with the specific 
formulation and production process used to manufacture the new animal 
drug used in the study.
    (4) The study uses a design that permits a valid comparison with one 
or more controls to provide a quantitative evaluation of drug effects. 
The protocol and the study report must describe the precise nature of 
the study design, e.g., duration of treatment periods, whether 
treatments are parallel, sequential, or crossover, and the determination 
of sample size. Within the broad range of studies conducted to support a 
determination of the effectiveness of a new animal drug, certain of the 
controls listed below would be appropriate and preferred depending on 
the study conducted:
    (i) Placebo concurrent control. The new animal drug is compared with 
an inactive preparation designed to resemble the new animal drug as far 
as possible.
    (ii) Untreated concurrent control. The new animal drug is compared 
with the absence of any treatment. The use of this control may be 
appropriate when objective measurements of effectiveness, not subject to 
observer bias, are available.
    (iii) Active treatment concurrent control. The new animal drug is 
compared with known effective therapy. The use of this control is 
appropriate when the use of a placebo control or of an untreated 
concurrent control would unreasonably compromise the welfare of the 
animals. Similarity of the new animal drug and the active control drug 
can mean either that both drugs were effective or that neither was 
effective. The study report should assess the ability of the study to 
have detected a difference between treatments. The evaluation of the 
study should explain why the new animal drugs should be considered 
effective in the study, for example, by reference to results in previous 
placebo-controlled studies of the active control.
    (iv) Historical control. The results of treatment with the new 
animal drug are quantitatively compared with experience historically 
derived from the adequately documented natural history of the disease or 
condition, or with a regimen (therapeutic, diagnostic, prophylactic) 
whose effectiveness is established, in comparable animals. Because 
historical control populations usually cannot be as well assessed with 
respect to pertinent variables as can concurrent control populations, 
historical control designs are usually reserved for special 
circumstances. Examples include studies in which the effect of the new 
animal drug is self-evident or studies of diseases with high and 
predictable mortality, or signs and symptoms of predictable duration or 
severity, or, in the case of prophylaxis, predictable morbidity.
    (5) The study uses a method of selecting animals that provides 
adequate assurances that the animals are suitable for the purposes of 
the study. For example, the animals can reasonably be expected to have 
animal production characteristics typical of the class(es) of animals 
for which the new animal drug is intended, there is adequate assurance 
that the animals have the disease or condition being studied, or, in the 
case of prophylactic agents, evidence of susceptibility and exposure to 
the condition against which prophylaxis is desired has been provided. 
The protocol and the study report describe the method of selecting 
animals for the study.
    (6) The study uses a method to assign a treatment or a control to 
each experimental unit of animals that is random and minimizes bias. 
Experimental units of animals are groups of animals that are comparable 
with respect to

[[Page 87]]

pertinent variables such as age, sex, class of animal, severity of 
disease, duration of disease, dietary regimen, level of animal 
production, and use of drugs or therapy other than the new animal drug. 
The protocol and the study report describe the method of assignment of 
animals to an experimental unit to account for pertinent variables and 
method of assignment of a treatment or a control to the experimental 
units. When the effect of such variables is accounted for by an 
appropriate design, and when, within the same animal, effects due to the 
test drug can be obtained free of the effects of such variables, the 
same animal may be used for both the test drug and the control using the 
controls set forth in paragraph (b)(4) of this section.
    (7) The study uses methods to minimize bias on the part of observers 
and analysts of the data that are adequate to prevent undue influences 
on the results and interpretation of the study data. The protocol and 
study report explain the methods of observation and recording of the 
animal response variables and document the methods, such as ``blinding'' 
or ``masking,'' used in the study for excluding or minimizing bias in 
the observations.
    (8) The study uses methods to assess animal response that are well 
defined and reliable. The protocol and study report describe the methods 
for conducting the study, including any appropriate analytical and 
statistical methods, used to collect and analyze the data resulting from 
the conduct of the study, describe the criteria used to assess response, 
and, when appropriate, justify the selection of the methods to assess 
animal response.
    (9) There is an analysis and evaluation of the results of the study 
in accord with the protocol adequate to assess the effects of the new 
animal drug. The study report evaluates the methods used to conduct, and 
presents and evaluates the results of, the study as to their adequacy to 
assess the effects of the new animal drug. This evaluation of the 
results of the study assesses, among other items, the comparability of 
treatment and control groups with respect to pertinent variables and the 
effects of any interim analyses performed.
    (c) Field studies. (1) Field conditions as used in this section 
refers to conditions which closely approximate the conditions under 
which the new animal drug, if approved, is intended to be applied or 
administered.
    (2) Studies of a new animal drug conducted under field conditions 
shall, consistent with generally recognized scientific principles and 
procedures, use an appropriate control that permits comparison, employ 
procedures to minimize bias, and have the characteristics generally 
described in paragraph (b) of this section. However, because field 
studies are conducted under field conditions, it is recognized that the 
level of control over some study conditions need not or should not be 
the same as the level of control in laboratory studies. While not all 
conditions relating to a field study need to be or should be controlled, 
observations of the conditions under which the new animal drug is tested 
shall be recorded in sufficient detail to permit evaluation of the 
study. Adequate and well-controlled field studies shall balance the need 
to control study conditions with the need to observe the true effect of 
the new animal drug under closely approximated actual use conditions.
    (d) Waiver. The Director of the Center for Veterinary Medicine (the 
Director) may, on the Director's own initiative or on the petition of an 
interested person, waive in whole or in part any of the criteria in 
paragraph (b) of this section with respect to a specific study. A 
petition for a waiver is required to set forth clearly and concisely the 
specific criteria from which waiver is sought, why the criteria are not 
reasonably applicable to the particular study, what alternative 
procedures, if any, are to be, or have been employed, and what results 
have been obtained. The petition is also required to state why the 
studies so conducted will yield, or have yielded, substantial evidence 
of effectiveness, notwithstanding nonconformance with the criteria for 
which waiver is requested.
    (e) Uncontrolled studies. Uncontrolled studies or partially 
controlled studies are not acceptable as the sole basis for the approval 
of claims of effectiveness or target animal safety. Such studies, 
carefully conducted and documented,

[[Page 88]]

may provide corroborative support of adequate and well-controlled 
studies regarding effectiveness and may yield valuable data regarding 
safety of the new animal drug. Such studies will be considered on their 
merits in light of the characteristics listed here. Isolated case 
reports, random experience, and reports lacking the details which permit 
scientific evaluation will not be considered.

[63 FR 10770, Mar. 5, 1998]



Sec. 514.120  Revocation of order refusing to approve an application 
or suspending or withdrawing approval of an application.

    The Commissioner, upon his own initiative or upon request of an 
applicant stating reasonable grounds therefor and if he finds that the 
facts so require, may issue an order approving an application that 
previously has had its approval refused, suspended, or withdrawn.



Sec. 514.121  Service of notices and orders.

    All notices and orders under this subchapter E and section 512 of 
the act pertaining to new animal drug applications shall be served:
    (a) In person by any officer or employee of the Department 
designated by the Commissioner; or
    (b) By mailing the order by certified mail addressed to the 
applicant or respondent at his last known address in the records of the 
Food and Drug Administration.



                      Subpart C_Hearing Procedures



Sec. 514.200  Contents of notice of opportunity for a hearing.

    (a) The notice to the applicant of opportunity for a hearing on a 
proposal by the Commissioner to refuse to approve an application or to 
withdraw the approval of an application will specify the grounds upon 
which he proposes to issue his order. On request of the applicant, the 
Commissioner will explain the reasons for his action. The notice of 
opportunity for a hearing will be published in the Federal Register and 
will specify that the applicant has 30 days after issuance of the notice 
within which he is required to file a written appearance electing 
whether:
    (1) To avail himself of the opportunity for a hearing; or
    (2) Not to avail himself of the opportunity for a hearing.
    (b) If the applicant fails to file a written appearance in answer to 
the notice of opportunity for hearing, his failure will be construed as 
an election not to avail himself of the opportunity for the hearing, and 
the Commissioner without further notice may enter a final order.
    (c) If the applicant elects to avail himself of the opportunity for 
a hearing, he is required to file a written appearance requesting the 
hearing within 30 days after the publication of the notice, giving the 
reason why the application should not be refused or should not be 
withdrawn, together with a well-organized and full-factual analysis of 
the clinical and other investigational data he is prepared to prove in 
support of his opposition to the Commissioner's proposal. A request for 
a hearing may not rest upon mere allegations or denials, but must set 
forth specific facts showing there is a genuine and substantial issue of 
fact that requires a hearing. When it clearly appears from the data in 
the application and from the reasons and a factual analysis in the 
request for the hearing that no genuine and substantial issue of fact 
precludes the refusal to approve the application or the withdrawal of 
approval of the application (for example, no adequate and well-
controlled clinical investigations to support the claims of 
effectiveness have been identified), the Commissioner will enter an 
order on this data, stating his findings and conclusions. If a hearing 
is requested and is justified by the applicant's response to the notice 
of opportunity for a hearing, the issues will be defined, an 
Administrative Law Judge will be named, and he shall issue a written 
notice of the time and place at which the hearing will commence. In the 
case of denial of approval, such time shall be not more than 90 days 
after the expiration of such 30 days unless the Administrative Law Judge 
and the applicant otherwise agree; and, in the case of withdrawal of 
approval, such time shall be as soon as practicable.

[[Page 89]]

    (d) The hearing will be open to the public; however, if the 
Commissioner finds that portions of the application which serve as a 
basis for the hearing contain information concerning a method or process 
entitled to protection as a trade secret, the part of the hearing 
involving such portions will not be public, unless the respondent so 
specifies in his appearance.

[40 FR 13825, Mar. 27, 1975, as amended at 43 FR 1941, Jan. 13, 1978]



Sec. 514.201  Procedures for hearings.

    Hearings relating to new animal drugs under section 512(d) and (e) 
of the act shall be governed by part 12 of this chapter.

[64 FR 63204, Nov. 19, 1999]

Subparts D-E [Reserved]



                        Subpart F_Judicial Review



Sec. 514.235  Judicial review.

    (a) The transcript and record shall be certified by the 
Commissioner. In any case in which the Commissioner enters an order 
without a hearing pursuant to Sec. 314.200(g) of this chapter, the 
request(s) for hearing together with the data and information submitted 
and the Commissioner's findings and conclusions shall be included in the 
record certified by the Commissioner.
    (b) Judicial review of an order withdrawing approval of a new drug 
application, whether or not a hearing has been held, may be sought by a 
manufacturer or distributor of an identical, related, or similar drug 
product, as defined in Sec. 310.6 of this chapter, in a United States 
court of appeals pursuant to section 505(h) of the act.

[42 FR 4717, Jan. 25, 1977]



PART 515_MEDICATED FEED MILL LICENSE--Table of Contents



                         Subpart A_Applications

Sec.
515.10 Medicated feed mill license applications.
515.11 Supplemental medicated feed mill license applications.

              Subpart B_Administrative Actions on Licenses

515.20 Approval of medicated feed mill license applications.
515.21 Refusal to approve a medicated feed mill license application.
515.22 Suspension and/or revocation of approval of a medicated feed mill 
          license.
515.23 Voluntary revocation of medicated feed mill license.
515.24 Notice of revocation of a medicated feed mill license.
515.25 Revocation of order refusing to approve a medicated feed mill 
          license application or suspending or revoking a license.
515.26 Services of notices and orders.

                      Subpart C_Hearing Procedures

515.30 Contents of notice of opportunity for a hearing.
515.31 Procedures for hearings.

                        Subpart D_Judicial Review

515.40 Judicial review.

    Authority: 21 U.S.C. 360b, 371.

    Source: 64 FR 63204, Nov. 19, 1999 unless otherwise noted.



                         Subpart A_Applications



Sec. 515.10  Medicated feed mill license applications.

    (a) Medicated feed mill license applications (Forms FDA 3448) may be 
obtained from the Public Health Service, Consolidated Forms and 
Publications Distribution Center, Washington Commerce Center, 3222 
Hubbard Rd., Landover, MD 20785, or electronically from the Center for 
Veterinary Medicine home page at http://www.fda.gov/cvm.
    (b) A completed medicated feed mill license must contain the 
following information:
    (1) The full business name and address of the facility at which the 
manufacturing is to take place.
    (2) The facility's FDA registration number as required by section 
510 of the Federal Food, Drug, and Cosmetic Act (the act).
    (3) The name, title, and signature of the responsible individual or 
individuals for that facility.
    (4) A certification that the animal feeds bearing or containing new 
animal drugs are manufactured and labeled in

[[Page 90]]

accordance with the applicable regulations published under section 
512(i) of the act or in accordance with the index listing published 
under section 572(e)(2) of the act.
    (5) A certification that the methods used in, and the facilities and 
controls used for, manufacturing, processing, packaging, and holding 
such animal feeds conform to current good manufacturing practice as 
described in section 501(a)(2)(B) of the act and in part 225 of this 
chapter.
    (6) A certification that the facility will establish and maintain 
all records required by regulation or order issued under sections 
512(m)(5)(A) or 504(a)(3)(A) of the act, and will permit access to, or 
copying or verification of such records.
    (7) A commitment that current approved or index listed Type B and/or 
Type C medicated feed labeling for each Type B and/or Type C medicated 
feed to be manufactured will be in the possession of the feed 
manufacturing facility prior to receiving the Type A medicated article 
containing such drug.
    (8) A commitment to renew registration every year with FDA as 
required in Sec. Sec. 207.20 and 207.21 of this chapter.
    (c) Applications must be completed, signed, and submitted to the 
Division of Animal Feeds (HFV-220), Center for Veterinary Medicine, Food 
and Drug Administration, 7500 Standish Pl., Rockville, MD 20855.
    (d) Applications that are facially deficient will be returned to the 
applicant. All reasons for the return of the application will be made 
known to the applicant.
    (e) Upon approval, the original copy of the application will be 
signed by an authorized employee of FDA designated by the Commissioner 
of Food and Drugs, and a copy will be returned to the applicant.

[64 FR 63204, Nov. 19, 1999, as amended at 72 FR 69121, Dec. 6, 2007]



Sec. 515.11  Supplemental medicated feed mill license applications.

    (a) After approval of a medicated feed mill license application to 
manufacture animal feed, a supplemental application shall be submitted 
for a change in ownership and/or a change in mailing address of the 
facility site.
    (b) Each supplemental application should be accompanied by a fully 
completed Form FDA 3448 and include an explanation of the change.
    (c) Within 30 working days after a supplemental application has been 
filed, if the Commissioner of Food and Drugs determines that the 
application provides adequate information respecting the change in 
ownership and/or postal address of the facility site, then an authorized 
employee of the Food and Drug Administration designated by the 
Commissioner shall notify the applicant that it is approved by signing 
and mailing to the applicant a copy of the Form FDA 3448. Supplemental 
applications that do not provide adequate information shall be returned 
to the applicant and all reasons for the return of the application shall 
be made known to the applicant.



              Subpart B_Administrative Actions on Licenses



Sec. 515.20  Approval of medicated feed mill license applications.

    Within 90 days after an application has been filed under Sec. 
515.10, if the Commissioner of Food and Drugs (the Commissioner) 
determines that none of the grounds for denying approval specified in 
section 512(m)(3) of the Federal Food, Drug, and Cosmetic Act (the act) 
applies, an authorized employee of the Food and Drug Administration 
designated by the Commissioner shall notify the applicant that it is 
approved by signing and mailing to the applicant a copy of the Form FDA 
3448.



Sec. 515.21  Refusal to approve a medicated feed mill license application.

    (a) The Commissioner of Food and Drugs (the Commissioner) shall 
within 90 days, or such additional period as may be agreed upon by the 
Commissioner and the applicant, after the filing of an application under 
Sec. 515.10, inform the applicant in writing of his/her intention to 
issue a notice of opportunity for a hearing on a proposal to refuse to 
approve the application, if the Commissioner determines upon the basis 
of the application, on the basis of a preapproval inspection, or upon 
the

[[Page 91]]

basis of any other information before him that:
    (1) The application is incomplete, false, or misleading in any 
particular; or
    (2) The methods used in and the facilities and controls used for the 
manufacturing, processing, and packaging of such animal feed are not 
adequate to preserve the identity, strength, quality, and purity of the 
new animal drug therein; or
    (3) The facility manufactures animal feeds bearing or containing new 
animal drugs in a manner that does not accord with the specifications 
for manufacture or labels animal feeds bearing or containing new animal 
drugs in a manner that does not accord with the conditions or 
indications of use that are published under section 512(i) or 572(e)(2) 
of the act.
    (b) The Commissioner, as provided in Sec. 515.30, shall 
expeditiously notify the applicant of an opportunity for a hearing on 
the question of whether such application is approvable, unless by the 
30th day following the date of issuance of the letter informing the 
applicant of the intention to issue a notice of opportunity for a 
hearing the applicant:
    (1) Withdraws the application; or
    (2) Waives the opportunity for a hearing; or
    (3) Agrees with the Commissioner on an additional period to precede 
issuance of such notice of hearing.

[64 FR 63204, Nov. 19, 1999, as amended at 72 FR 69121, Dec. 6, 2007]



Sec. 515.22  Suspension and/or revocation of approval of a medicated 
feed mill license.

    (a) The Secretary of Health and Human Services may suspend a 
medicated feed mill license approved under section 512(m)(2) of the 
Federal Food, Drug, and Cosmetic Act (the act) and give the person 
holding the medicated feed mill license application prompt notice of 
this action and afford the applicant the opportunity for an expedited 
hearing on a finding that there is an imminent hazard to the health of 
man or of the animals for which such animal feed is intended.
    (b) The Commissioner of Food and Drugs (the Commissioner) shall 
notify in writing the person holding an application approved under 
section 512(m)(2) of the act and afford an opportunity for a hearing on 
a proposal to revoke approval of such application if the Commissioner 
finds:
    (1) That the application contains any untrue statement of a material 
fact; or
    (2) That the applicant has made any changes that would cause the 
application to contain any untrue statements of material fact or that 
would affect the safety or effectiveness of the animal feeds 
manufactured at the facility unless the applicant has supplemented the 
application by filing a supplemental application under Sec. 515.11.
    (c) The Commissioner may notify in writing the person holding an 
application approved under section 512(m)(2) of the act and afford an 
opportunity for a hearing on a proposal to revoke approval of such 
application if the Commissioner finds:
    (1) That the applicant has failed to establish a system for 
maintaining required records, or has repeatedly or deliberately failed 
to maintain such records or to make required reports in accordance with 
a regulation or order under sections 512(m)(5)(A) or 504(a)(3)(A) of the 
act, or the applicant has refused to permit access to, or copying, or 
verification of, such records as required by sections 512(m)(5)(B) or 
504(a)(3)(B) of the act; or
    (2) That on the basis of new information before him, evaluated 
together with the evidence before him when such license was issued, the 
methods used in, or the facilities and controls used for, the 
manufacture, processing, packing, and holding of such animal feed are 
inadequate to assure and preserve the identity, strength, quality, and 
purity of the new animal drug therein, and were not made adequate within 
a reasonable time after receipt of written notice from the Commissioner 
specifying the matter complained of; or
    (3) That on the basis of new information before him, evaluated 
together with the evidence before him when such license was issued, the 
labeling of any animal feeds, based on a fair evaluation of all material 
facts, is false or misleading in any particular and was not corrected 
within a reasonable time after receipt of written notice from the

[[Page 92]]

Commissioner specifying the matter complained of; or
    (4) That on the basis of new information before him, evaluated 
together with the evidence before him when such license was issued, the 
facility has manufactured, processed, packed, or held animal feed 
bearing or containing a new animal drug adulterated under section 
501(a)(6) of the act, and the facility did not discontinue the 
manufacture, processing, packing, or holding of such animal feed within 
a reasonable time after receipt of written notice from the Commissioner 
specifying the matter complained of.



Sec. 515.23  Voluntary revocation of medicated feed mill license.

    A license issued under section 512(m)(2) of the Federal Food, Drug, 
and Cosmetic Act (the act) will be revoked on the basis of a request for 
its revocation submitted in writing by a responsible individual holding 
such license on the grounds that the facility no longer manufactures any 
animal feed covered under Sec. 558.4(b) of this chapter. A written 
request for such revocation shall be construed as a waiver of the 
opportunity for a hearing as otherwise provided for in this section. 
Revocation of approval of a medicated feed mill license under the 
provisions of this paragraph shall be without prejudice.



Sec. 515.24  Notice of revocation of a medicated feed mill license.

    When a license approved under section 512 of the Federal Food, Drug, 
and Cosmetic Act (the act) is revoked by the Commissioner of Food and 
Drugs (the Commissioner), the Commissioner will give appropriate public 
notice of such action by publication in the Federal Register.



Sec. 515.25  Revocation of order refusing to approve a medicated feed 
mill license application or suspending or revoking a license.

    The Commissioner of Food and Drugs (the Commissioner), upon his/her 
own initiative or upon request of an applicant stating reasonable 
grounds therefor and if the Commissioner finds that the facts so 
require, may issue an order approving a medicated feed mill license 
application that previously has had its approval refused, suspended, or 
revoked.



Sec. 515.26  Services of notices and orders.

    All notices and orders under this part 515 and section 512 of the 
Federal Food, Drug, and Cosmetic Act (the act) pertaining to medicated 
feed mill licenses shall be served:
    (a) In person by any officer or employee of the Department of Health 
and Human Services designated by the Commissioner of Food and Drugs; or
    (b) By mailing the order by certified mail addressed to the 
applicant or respondent at the applicant or respondent's last known 
address in the records of the Food and Drug Administration.



                      Subpart C_Hearing Procedures



Sec. 515.30  Contents of notice of opportunity for a hearing.

    (a) The notice to the applicant of opportunity for a hearing on a 
proposal by the Commissioner of Food and Drugs (the Commissioner) to 
refuse to approve a medicated feed mill license application or to revoke 
the approval of a medicated feed mill license will specify the grounds 
upon which the Commissioner proposes to issue this order. On request of 
the applicant, the Commissioner will explain the reasons for the action. 
The notice of opportunity for a hearing will be published in the Federal 
Register and will specify that the applicant has 30 days after issuance 
of the notice within which the Commissioner is required to file a 
written appearance electing whether:
    (1) To avail himself of the opportunity for a hearing; or
    (2) Not to avail himself of the opportunity for a hearing.
    (b) If the applicant fails to file a written appearance in answer to 
the notice of opportunity for hearing, this failure will be construed as 
an election not to avail himself of the opportunity for the hearing, and 
the Commissioner without further notice may enter a final order.
    (c) If the applicant elects to avail himself of the opportunity for 
a hearing, the applicant is required to file a written appearance 
requesting the

[[Page 93]]

hearing within 30 days after the publication of the notice, giving the 
reason why the application should not be refused or the medicated feed 
mill license should not be revoked, together with a well-organized and 
full-factual analysis of the information the applicant is prepared to 
prove in support of his opposition to the Commissioner's proposal. A 
request for a hearing may not rest upon mere allegations or denials, but 
must set forth specific facts showing there is a genuine and substantial 
issue of fact that requires a hearing. When it clearly appears from the 
information in the application and from the reasons and factual analysis 
in the request for the hearing that no genuine and substantial issue of 
fact precludes the refusal to approve the application or the revocation 
of approval of the application, the Commissioner will enter an order on 
this information, stating his/her findings and conclusions. If a hearing 
is requested and is justified by the applicant's response to the notice 
of opportunity for a hearing, the issues will be defined, an 
Administrative Law Judge will be named, and the Judge shall issue a 
written notice of the time and place at which the hearing will commence. 
In the case of denial of approval, such time shall be not more than 90 
days after the expiration of such 30 days unless the Administrative Law 
Judge and the applicant otherwise agree; and, in the case of withdrawal 
of approval, such time shall be as soon as practicable.
    (d) The hearing will be open to the public; however, if the 
Commissioner finds that portions of the application which serve as a 
basis for the hearing contain information concerning a method or process 
entitled to protection as a trade secret, the part of the hearing 
involving such portions will not be public, unless the respondent so 
specifies in the appearance.



Sec. 515.31  Procedures for hearings.

    Hearings relating to new animal drugs under section 512(m)(3) and 
(m)(4) of the Federal Food, Drug, and Cosmetic Act (the act) shall be 
governed by part 12 of this chapter.



                        Subpart D_Judicial Review



Sec. 515.40  Judicial review.

    The transcript and record shall be certified by the Commissioner of 
Food and Drugs (the Commissioner). In any case in which the Commissioner 
enters an order without a hearing under Sec. 314.200(g) of this 
chapter, the request(s) for hearing together with the data and 
information submitted and the Commissioner's findings and conclusions 
shall be included in the record certified by the Commissioner.



PART 516_NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES--Table of Contents



                      Subpart A_General Provisions

Sec.
516.1 Scope.
516.2 Purpose.
516.3 Definitions.

  Subpart B_Designation of a Minor Use or Minor Species New Animal Drug

516.11 Scope of this subpart.
516.12 Purpose.
516.13 Definitions.
516.14 Submission of requests for designation.
516.16 Eligibility to request designation.
516.20 Content and format of a request for MUMS-drug designation.
516.21 Documentation of minor use status.
516.22 Permanent-resident U.S. agent for foreign sponsor.
516.23 Timing of requests for MUMS-drug designation.
516.24 Granting MUMS-drug designation.
516.25 Refusal to grant MUMS-drug designation.
516.26 Amendment to MUMS-drug designation.
516.27 Change in sponsorship.
516.28 Publication of MUMS-drug designations.
516.29 Termination of MUMS-drug designation.
516.30 Annual reports for a MUMS-designated drug.
516.31 Scope of MUMS-drug exclusive marketing rights.
516.34 FDA recognition of exclusive marketing rights.
516.36 Insufficient quantities of MUMS-designated drugs.

[[Page 94]]

516.52 Availability for public disclosure of data and information in 
          requests.

  Subpart C_Index of Legally Marketed Unapproved New Animal Drugs for 
                              Minor Species

516.111 Scope of this subpart.
516.115 Definitions.
516.117 Submission of correspondence under this subpart.
516.119 Permanent-resident U.S. agent for foreign requestors and 
          holders.
516.121 Meetings.
516.123 Informal conferences regarding agency administrative actions.
516.125 Investigational use of minor species new animal drugs to support 
          indexing.
516.129 Content and format of a request for determination of eligibility 
          for indexing.
516.131 Refuse to file a request for determination of eligibility for 
          indexing.
516.133 Denying a request for determination of eligibility for indexing.
516.135 Granting a request for determination of eligibility for 
          indexing.
516.137 Notification of decision regarding eligibility for indexing.
516.141 Qualified expert panels.
516.143 Written report.
516.145 Content and format of a request for addition to the index.
516.147 Refuse to file a request for addition to the index.
516.149 Denying a request for addition to the index.
516.151 Granting a request for addition to the index.
516.153 Notification of decision regarding index listing.
516.155 Labeling of indexed drugs.
516.157 Publication of the index and content of an index listing.
516.161 Modifications to indexed drugs.
516.163 Change in ownership of an index file.
516.165 Records and reports.
516.167 Removal from the index.
516.171 Confidentiality of data and information in an index file.

Subpart D [Reserved]

  Subpart E_Conditionally Approved New Animal Drugs For Minor Use and 
                              Minor Species

516.1318 xMasitinib.

    Authority: 21 U.S.C. 360ccc-1, 360ccc-2, 371.

    Source: 72 FR 41017, July 26, 2007, unless otherwise noted.



                      Subpart A_General Provisions



Sec. 516.1  Scope.

    (a) This part implements section 573 of the Federal Food, Drug, and 
Cosmetic Act (the act) (21 U.S.C. 360ccc-2) and contains the following 
subparts:
    (1) Subpart A--General Provisions.
    (2) Subpart B--Designation of a Minor Use or Minor Species New 
Animal Drug.
    (3) Subpart C [Reserved]
    (4) Subpart D [Reserved]
    (b) References in this part to regulatory sections of the Code of 
Federal Regulations are to Chapter I of Title 21, unless otherwise 
noted.



Sec. 516.2  Purpose.

    This part establishes standards and procedures for implementing 
section 573 of the act, including designation of minor use or minor 
species new animal drugs and associated exclusive marketing rights.



Sec. 516.3  Definitions.

    (a) The definitions and interpretations contained in section 201 of 
the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 321) apply 
to those terms when used in this part.
    (b) The following definitions of terms apply to all subparts of part 
516:
    Active moiety means the molecule or ion, excluding those appended 
portions of the molecule that cause the drug to be an ester, salt 
(including a salt with hydrogen or coordination bonds), or other 
noncovalent derivative (such as a complex, chelate, or clathrate) of the 
molecule, responsible for the pharmacological action of the drug 
substance.
    Functionally superior means that a drug has been shown to provide a 
significant therapeutic or physiologic advantage over that provided by a 
conditionally-approved or approved MUMS drug, that is otherwise the same 
drug, in one or more of the following ways:
    (i) The drug has been shown to be more effective, as assessed by 
effect on a clinically meaningful endpoint in adequate and well-
controlled clinical trials, than a conditionally approved or approved 
MUMS drug, that is otherwise the same drug. Generally, this would 
represent the same kind of evidence needed to support a comparative

[[Page 95]]

effectiveness claim for two different drugs; in most cases, direct 
comparative clinical trials will be necessary; or
    (ii) The drug has been shown to be safer than a conditionally-
approved or approved MUMS drug, that is otherwise the same drug, in a 
substantial portion of the target population, for example, by the 
elimination of an ingredient or contaminant that is associated with 
relatively frequent adverse effects. In some cases, direct comparative 
clinical trials will be necessary.
    Infrequently, as used in the minor use definition, means a disease 
or condition that is uncommon or that occurs only sporadically on an 
annualized basis.
    Limited geographical areas, as used in the minor use definition, 
means regions of the United States distinguished by physical, chemical, 
or biological factors that limit the distribution of a disease or 
condition.
    Major species means cattle, horses, swine, chickens, turkeys, dogs, 
and cats.
    Minor species means animals, other than humans, that are not major 
species.
    Minor use means the intended use of a drug in a major species for an 
indication that occurs infrequently and in only a small number of 
animals or in limited geographical areas and in only a small number of 
animals annually.
    MUMS drug means a new animal drug, as defined in section 201 of the 
act, intended for a minor use or for use in a minor species.
    Same dosage form means the same as one of the dosage form categories 
specified in the following parts of this chapter:
    (i) Part 520: Oral dosage form new animal drugs (excluding use in 
animal feeds as specified in part 558 of this chapter).
    (ii) Part 522: Implantation or injectable dosage form new animal 
drugs.
    (iii) Part 524: Ophthalmic and topical dosage form new animal drugs.
    (iv) Part 526: Intramammary dosage forms.
    (v) Part 529: Certain other dosage form new animal drugs.
    (vi) Part 558: New animal drugs for use in animal feeds.
    Same drug means a MUMS drug for which designation, indexing, or 
conditional approval is sought that meets the following criteria:
    (i) If it is a MUMS drug composed of small molecules and contains 
the same active moiety as a prior designated, conditionally-approved, or 
approved MUMS drug, even if the particular ester or salt (including a 
salt with hydrogen or coordination bonds) or other noncovalent 
derivative such as a complex, chelate or clathrate is not the same, it 
is considered the same drug; except that, if the prior MUMS drug is 
conditionally approved or approved and the second MUMS drug is shown to 
be functionally superior to the conditionally approved or approved MUMS 
drug for the same intended use, it is not considered the same drug.
    (ii) If it is a MUMS drug composed of large molecules 
(macromolecules) and contains the same principal molecular structural 
features (but not necessarily all of the same structural features) as a 
prior designated, conditionally approved, or approved MUMS drug, it is 
considered the same drug; except that, if the prior MUMS drug is 
conditionally approved or approved and the second MUMS drug is shown to 
be functionally superior to the conditionally approved or approved MUMS 
drug for the same intended use, it is not considered the same drug. This 
criterion will be applied as follows to different kinds of 
macromolecules:
    (A) Two protein drugs would be considered the same if the only 
differences in structure between them were due to post-translational 
events or infidelity of translation or transcription or were minor 
differences in amino acid sequence; other potentially important 
differences, such as different glycosylation patterns or different 
tertiary structures, would not cause the drugs to be considered 
different unless the subsequent drug is shown to be functionally 
superior.
    (B) Two polysaccharide drugs would be considered the same if they 
had identical saccharide repeating units, even if the number of units 
were to vary and even if there were postpolymerization modifications, 
unless the subsequent drug is shown to be functionally superior.

[[Page 96]]

    (C) Two polynucleotide drugs consisting of two or more distinct 
nucleotides would be considered the same if they had an identical 
sequence of purine and pyrimidine bases (or their derivatives) bound to 
an identical sugar backbone (ribose, deoxyribose, or modifications of 
these sugars), unless the subsequent drug is shown to be functionally 
superior.
    (D) Closely related, complex partly definable drugs with similar 
pharmacologic intent would be considered the same unless the subsequent 
drug is shown to be functionally superior.
    Same intended use means an intended use of a MUMS drug, for which 
designation, indexing, or conditional approval is sought, that is 
determined to be the same as (or not different from) a previously 
designated, conditionally approved, or approved intended use of a MUMS 
drug. Same intended use is established by comparing two intended uses 
and not by simply comparing the specific language by means of which the 
intent is established in labeling in accordance with the following 
criteria:
    (i) Two intended uses are considered the same if one of the intended 
uses falls completely within the scope of the other.
    (ii) For intended uses associated with diseases or conditions with 
multiple causative organisms, two intended uses are not considered the 
same when they involve different causative organisms or different 
subsets of causative organisms of that disease or condition when the 
causative organisms involved can reliably be shown to be clinically 
significant causes of the disease or condition.
    (iii) Two intended uses of a drug are not considered the same if 
they involve different intended species or different definable 
subpopulations (including ``production classes'') of a species.
    Small number of animals means equal to or less than 50,000 horses; 
70,000 dogs; 120,000 cats; 310,000 cattle; 1,450,000 pigs; 14,000,000 
turkeys; and 72,000,000 chickens.
    Sponsor means the person requesting designation for a MUMS drug who 
must be the real party in interest of the development and the intended 
or actual production and sales of such drug (in this context, the 
sponsor may be an individual, partnership, organization, or 
association). Sponsor also means the person responsible for an 
investigation of a new animal drug (in this context, the sponsor may be 
an individual, partnership, corporation, or Government agency or may be 
a manufacturer, scientific institution, or an investigator regularly and 
lawfully engaged in the investigation of new animal drugs). Sponsor also 
means the person submitting or receiving approval for a new animal drug 
application (in this context, the sponsor may be an individual, 
partnership, organization, or association). In all contexts, the sponsor 
is responsible for compliance with applicable provisions of the act and 
regulations.

[72 FR 41017, July 26, 2007, as amended at 74 FR 43050, Aug. 25, 2009; 
75 FR 69588, Nov. 15, 2010]



  Subpart B_Designation of a Minor Use or Minor Species New Animal Drug



Sec. 516.11  Scope of this subpart.

    This subpart implements section 573 of the act. Specifically, this 
subpart sets forth the procedures and requirements for submissions to 
FDA of requests for designation of a new animal drug for a minor use or 
a minor species.



Sec. 516.12  Purpose.

    This subpart establishes standards and procedures for determining 
eligibility for designation and the associated incentives and benefits 
described in section 573 of the act, including a 7-year period of 
exclusive marketing rights.



Sec. 516.13  Definitions.

    The following definitions of terms apply only in the context of 
subpart B of this part:
    Director means the Director of the Office of Minor Use and Minor 
Species Animal Drug Development of the FDA Center for Veterinary 
Medicine.
    Intended use means the intended treatment, control or prevention of 
a disease or condition, or the intention to affect the structure or 
function of

[[Page 97]]

the body of animals within an identified species, subpopulation of a 
species, or collection of species.
    MUMS-designated drug means a new animal drug, as defined in section 
201 of the act, intended for a minor use or for use in a minor species 
that has been designated under section 573 of the act.
    MUMS-drug exclusive marketing rights or exclusive marketing rights 
means that, effective on the date of FDA conditional approval or 
approval as stated in the approval letter of an application for a MUMS-
designated drug, no conditional approval or approval will be given to a 
subsequent application for the same drug, in the same dosage form, for 
the same intended use for 7 years, except as otherwise provided by law 
or in this subpart.



Sec. 516.14  Submission of requests for designation.

    All correspondence relating to a request for designation of a MUMS 
drug must be addressed to the Director of the Office of Minor Use and 
Minor Species Animal Drug Development. Submissions not including all 
elements specified in Sec. 516.20 will be returned to the sponsor 
without review.



Sec. 516.16  Eligibility to request designation.

    The person requesting designation must be the sponsor and the real 
party in interest of the development and the intended or actual 
production and sales of the drug or the permanent-resident U.S. agent 
for such a sponsor.



Sec. 516.20  Content and format of a request for MUMS-drug designation.

    (a) A sponsor that submits a request for designation of a new animal 
drug intended for a minor use or minor species must submit each request 
in the form and containing the information required in paragraph (b) of 
this section. While a request for designation may involve multiple 
intended uses, each request for designation must constitute a separate 
submission. A sponsor may request MUMS-drug designation of a previously 
unapproved drug, or a new intended use or dosage form for an already 
conditionally approved or approved drug. Only one sponsor may receive 
MUMS-drug designation of the same drug, in the same dosage form, for the 
same intended use.
    (b) A sponsor must submit two copies of a completed, dated, and 
signed request for designation that contains the following information:
    (1) A request for designation of a new animal drug for a minor use 
or use in a minor species, which must be specific.
    (2) The name and address of the sponsor; the name of the sponsor's 
primary contact person and/or permanent-resident U.S. agent including 
title, address, and telephone number; the established name (and 
proprietary name, if any) of the active pharmaceutical ingredient of the 
drug; and the name and address of the source of the active 
pharmaceutical ingredient of the drug.
    (3) A description of the proposed intended use for which the drug is 
being or will be investigated.
    (4) A description of the drug and dosage form.
    (5) A discussion of the scientific rationale for the intended use of 
the drug; specific reference, including date(s) of submission, to all 
data from nonclinical laboratory studies, clinical investigations, 
copies of pertinent unpublished and published papers, and other relevant 
data that are available to the sponsor, whether positive, negative, or 
inconclusive.
    (6) A specific description of the product development plan for the 
drug, its dosage form, and its intended use.
    (7) If the drug is intended for a minor use in a major species, 
documentation in accordance with Sec. 516.21, with appended 
authoritative references, to demonstrate that such use is a minor use.
    (8) A statement that the sponsor submitting the request is the real 
party in interest of the development and the intended or actual 
production and sales of the product.
    (9) A statement that the sponsor acknowledges that, upon granting a 
request for MUMS designation, FDA will make information regarding the 
designation publicly available as specified in Sec. 516.28.

[72 FR 41017, July 26, 2007, as amended at 75 FR 69588, Nov. 15, 2010; 
77 FR 18685, Mar. 28, 2012]

[[Page 98]]



Sec. 516.21  Documentation of minor use status.

    So that FDA can determine whether a drug qualifies for MUMS-drug 
designation as a minor use in a major species under section 573 of the 
act, the sponsor shall include in its request to FDA for MUMS-drug 
designation under Sec. 516.20 documentation demonstrating that the use 
is limited to a small number of animals (annualized). This documentation 
must include the following information:
    (a) The estimated total number of animals to which the drug could 
potentially be administered on an annual basis for the treatment, 
control, or prevention of the disease or condition for which the drug is 
being developed, including animals administered the drug as part of herd 
or flock treatment, together with a list of the sources (including dates 
of information provided and literature citations) for the estimate.
    (b) The estimated total number of animals referred to in paragraph 
(a) of this section may be further reduced to only a subset of the 
estimated total number of animals if administration of the drug is only 
medically justified for this subset. To establish this, requestors must 
demonstrate that administration of the drug to animals subject to the 
disease or condition for which the drug is being developed other than 
the subset is not medically justified. The sponsor must also include a 
list of the sources (including dates of information provided and 
literature citations) for the justification that administration of the 
drug to animals other than the targeted subset is medically 
inappropriate.

[72 FR 41017, July 26, 2007, as amended at 74 FR 43050, Aug. 25, 2009]



Sec. 516.22  Permanent-resident U.S. agent for foreign sponsor.

    Every foreign sponsor that seeks MUMS-drug designation shall name a 
permanent resident of the United States as the sponsor's agent upon whom 
service of all processes, notices, orders, decisions, requirements, and 
other communications may be made on behalf of the sponsor. Notifications 
of changes in such agents or changes of address of agents should 
preferably be provided in advance, but not later than 60 days after the 
effective date of such changes. The permanent-resident U.S. agent may be 
an individual, firm, or domestic corporation and may represent any 
number of sponsors. The name and address of the permanent-resident U.S. 
agent shall be provided to the Director of the Office of Minor Use and 
Minor Species Animal Drug Development.



Sec. 516.23  Timing of requests for MUMS-drug designation.

    A sponsor may request MUMS-drug designation at any time in the drug 
development process prior to the submission of an application for either 
conditional approval or approval of the MUMS drug for which designation 
is being requested.



Sec. 516.24  Granting MUMS-drug designation.

    (a) FDA may grant the request for MUMS-drug designation if none of 
the reasons described in Sec. 516.25 for refusal to grant such a 
request apply.
    (b) When a request for MUMS-drug designation is granted, FDA will 
notify the sponsor in writing and will give public notice of the MUMS-
drug designation in accordance with Sec. 516.28.



Sec. 516.25  Refusal to grant MUMS-drug designation.

    (a) FDA will refuse to grant a request for MUMS-drug designation if 
any of the following reasons apply:
    (1) The drug is not intended for use in a minor species or FDA 
determines that there is insufficient evidence to demonstrate that the 
drug is intended for a minor use in a major species.
    (2) The drug is the same drug in the same dosage form for the same 
intended use as one that already has a MUMS-drug designation but has not 
yet been conditionally approved or approved.
    (3) The drug is the same drug in the same dosage form for the same 
intended use as one that is already conditionally approved or approved. 
A drug that FDA has found to be functionally superior is not considered 
the same drug as an already conditionally approved or approved drug even 
if it is

[[Page 99]]

otherwise the same drug in the same dosage form for the same intended 
use.
    (4) The sponsor has failed to provide:
    (i) A credible scientific rationale in support of the intended use,
    (ii) Sufficient information about the product development plan for 
the drug, its dosage form, and its intended use to establish that 
adherence to the plan can lead to successful drug development in a 
timely manner, and
    (iii) Any other information required under Sec. 516.20.
    (b) FDA may refuse to grant a request for MUMS-drug designation if 
the request for designation contains an untrue statement of material 
fact or omits material information.



Sec. 516.26  Amendment to MUMS-drug designation.

    (a) At any time prior to conditional approval or approval of an 
application for a MUMS-designated drug, the sponsor may apply for an 
amendment to the designated intended use if the proposed change is due 
to new and unexpected findings in research on the drug, information 
arising from FDA recommendations, or other unforeseen developments.
    (b) FDA will grant the amendment if it finds:
    (1) That the initial designation request was made in good faith;
    (2) That the amendment is intended to make the MUMS-drug designated 
intended use conform to the results of new and unexpected findings in 
research on the drug, information arising from FDA recommendations, or 
other unforeseen developments; and
    (3) In the case of a minor use, that as of the date of the 
submission of the amendment request, the amendment would not result in 
the intended use of the drug no longer being considered a minor use.



Sec. 516.27  Change in sponsorship.

    (a) A sponsor may transfer sponsorship of a MUMS-designated drug to 
another person. A change of sponsorship will also transfer the 
designation status of the drug which will remain in effect for the new 
sponsor subject to the same conditions applicable to the former sponsor 
provided that at the time of a potential transfer, the new and former 
sponsors submit the following information in writing and obtain 
permission from FDA:
    (1) The former sponsor shall submit a letter to FDA that documents 
the transfer of sponsorship of the MUMS-designated drug. This letter 
shall specify the date of the transfer. The former sponsor shall also 
certify in writing to FDA that a complete copy of the request for MUMS-
drug designation, including any amendments to the request, and 
correspondence relevant to the MUMS-drug designation, has been provided 
to the new sponsor.
    (2) The new sponsor shall submit a letter or other document 
containing the following information:
    (i) A statement accepting the MUMS-drug designated file or 
application;
    (ii) The date that the change in sponsorship is intended to be 
effective;
    (iii) A statement that the new sponsor has a complete copy of the 
request for MUMS-drug designation, including any amendments to the 
request and any correspondence relevant to the MUMS-drug designation;
    (iv) A statement that the new sponsor understands and accepts the 
responsibilities of a sponsor of a MUMS-designated drug established 
elsewhere in this subpart;
    (v) The name and address of a new primary contact person or 
permanent resident U.S. agent; and
    (vi) Evidence that the new sponsor is capable of actively pursuing 
approval with due diligence.
    (b) No sponsor may relieve itself of responsibilities under the act 
or under this subpart by assigning rights to another person without:
    (1) Assuring that the new sponsor will carry out such 
responsibilities; and
    (2) Obtaining prior permission from FDA.



Sec. 516.28  Publication of MUMS-drug designations.

    FDA will periodically update a publicly available list of MUMS-
designated drugs. This list will be placed on file at the FDA Division 
of Dockets Management, and will contain the following information for 
each MUMS-designated drug:

[[Page 100]]

    (a) The name and address of the sponsor;
    (b) The established name and trade name, if any, of the drug;
    (c) The dosage form of the drug;
    (d) The species and the proposed intended use for which MUMS-drug 
designation was granted; and
    (e) The date designation was granted.



Sec. 516.29  Termination of MUMS-drug designation.

    (a) The sponsor of a MUMS-designated drug must notify FDA of any 
decision to discontinue active pursuit of conditional approval or 
approval of such MUMS drug. FDA must terminate the designation upon such 
notification.
    (b) A conditionally-approved or approved MUMS-designated drug 
sponsor must notify FDA at least 1 year before it intends to discontinue 
the manufacture of such MUMS drug. FDA must terminate designation upon 
such notification.
    (c) MUMS designation shall terminate upon the expiration of any 
applicable period of exclusive marketing rights under this subpart.
    (d) FDA may terminate designation if it independently determines 
that the sponsor is not actively pursuing conditional approval or 
approval with due diligence. At a minimum, due diligence must be 
demonstrated by:
    (1) Submission of annual progress reports in a timely manner in 
accordance with Sec. 516.30 that demonstrate that the sponsor is 
progressing in accordance with the drug development plan submitted to 
the agency under Sec. 516.20 and
    (2) Compliance with all applicable requirements of part 511 of this 
chapter.
    (e) Designation of a conditionally approved or approved MUMS-
designated drug and the associated exclusive marketing rights may be 
terminated if the sponsor is unable to provide sufficient quantities of 
the drug to meet the needs for which it is designated.
    (f) FDA may also terminate MUMS-drug designation for any drug if the 
agency finds that:
    (1) The request for designation contained an untrue statement of 
material fact; or
    (2) The request for designation omitted material information 
required by this subpart; or
    (3) FDA subsequently finds that the drug in fact had not been 
eligible for MUMS-drug designation at the time of submission of the 
request;
    (4) The same drug, in the same dosage form, for the same intended 
use becomes conditionally approved or approved for another sponsor; or
    (5) FDA withdraws the conditional approval or approval of the 
application for the new animal drug.
    (g) For a conditionally approved or approved drug, termination of 
MUMS-drug designation also terminates the sponsor's exclusive marketing 
rights for the drug but does not withdraw the conditional approval or 
approval of the drug's application.
    (h) Where a drug has been MUMS-designated for a minor use in a major 
species, its designation will not be terminated on the grounds that the 
number of animals to which the drug could potentially be administered on 
an annual basis for the treatment, control, or prevention of the disease 
or condition for which the drug is being developed, including animals 
administered the drug as part of herd or flock treatment, subsequently 
increases.
    (i) When a MUMS-drug designation is terminated, FDA will notify the 
sponsor in writing and will give public notice of the termination of the 
MUMS-drug designation.



Sec. 516.30  Annual reports for a MUMS-designated drug.

    Within 14 months after the date on which a MUMS drug is granted 
designation and annually thereafter until approval, the sponsor of a 
MUMS-designated drug shall submit a brief progress report on the drug to 
the investigational new animal drug file addressed to the Director of 
the Office of Minor Use and Minor Species Animal Drug Development that 
includes the following information:
    (a) A short account of the progress of drug development including a 
description of studies initiated, ongoing, and completed, and a short 
summary of the status or results of such studies;
    (b) A description of the investigational plan for the coming year, 
as well as any anticipated difficulties in development, testing, and 
marketing; and

[[Page 101]]

    (c) A brief discussion of any changes that may affect the MUMS-
designated drug status of the product. For example, situations in which 
testing data demonstrate that the proposed intended use is inappropriate 
due to unexpected issues of safety or effectiveness.



Sec. 516.31  Scope of MUMS-drug exclusive marketing rights.

    (a) After conditional approval or approval of an application for a 
MUMS-designated drug in the dosage form and for the intended use for 
which MUMS-drug designation has been granted, FDA will not conditionally 
approve or approve another application or abbreviated application for 
the same drug in the same dosage form for the same intended use before 
the expiration of 7 years after the date of conditional approval or 
approval as stated in the approval letter from FDA, except that such an 
application can be conditionally approved or approved sooner if, and at 
such time as, any of the following occurs:
    (1) FDA terminates the MUMS-drug designation and associated 
exclusive marketing rights under Sec. 516.29; or
    (2) FDA withdraws the conditional approval or approval of the 
application for the drug for any reason; or
    (3) The sponsor with exclusive marketing rights provides written 
consent to FDA to conditionally approve or approve another application 
before the expiration of 7 years; or
    (4) The sponsor fails to assure a sufficient quantity of the drug in 
accordance with section 573 of the act and Sec. 516.36.
    (b) If an application for a MUMS drug cannot be approved until the 
expiration of the period of exclusive marketing of a MUMS-designated 
drug, FDA will so notify the sponsor in writing.



Sec. 516.34  FDA recognition of exclusive marketing rights.

    (a) FDA will send the sponsor (or the permanent-resident U.S. agent, 
if applicable) timely written notice recognizing exclusive marketing 
rights when an application for a MUMS-designated drug has been 
conditionally approved or approved. The written notice will inform the 
sponsor of the requirements for maintaining MUMS-designated drug 
exclusive marketing rights for the full 7-year term. This notice will 
generally be contained in the letter conditionally approving or 
approving the application.
    (b) When an application is conditionally approved or approved for a 
MUMS-designated drug that qualifies for exclusive marketing rights, FDA 
will publish this information in the Federal Register at the time of the 
conditional approval or approval. This notice will generally be 
contained in the notice of conditional approval or approval of the 
application.



Sec. 516.36  Insufficient quantities of MUMS-designated drugs.

    (a) Under section 573 of the act, whenever FDA has reason to believe 
that sufficient quantities of a conditionally-approved or approved, 
MUMS-designated drug to meet the needs for which the drug was designated 
cannot be assured by the sponsor, FDA will so notify the sponsor of this 
possible insufficiency and will offer the sponsor the following options, 
one of which must be exercised by a time that FDA specifies:
    (1) Provide FDA information and data regarding how the sponsor can 
assure the availability of sufficient quantities of the MUMS-designated 
drug within a reasonable time to meet the needs for which the drug was 
designated; or
    (2) Provide FDA in writing the sponsor's consent for the conditional 
approval or approval of other applications for the same drug before the 
expiration of the 7-year period of exclusive marketing rights.
    (b) If, within the time that FDA specifies, the sponsor fails to 
consent to the conditional approval or approval of other applications 
and if FDA finds that the sponsor has not shown that it can assure the 
availability of sufficient quantities of the MUMS-designated drug to 
meet the needs for which the drug was designated, FDA will issue a 
written order terminating designation of the MUMS drug and the 
associated exclusive marketing rights. This order will state FDA's 
findings and conclusions and will constitute final agency

[[Page 102]]

action. An order terminating designation and associated exclusive 
marketing rights may issue whether or not there are other sponsors that 
can assure the availability of alternative sources of supply. Such an 
order will not withdraw the conditional approval or approval of an 
application. Once terminated under this section, neither designation, 
nor exclusive marketing rights may be reinstated.



Sec. 516.52  Availability for public disclosure of data and 
information in requests.

    (a) FDA will not publicly disclose the existence of a request for 
MUMS-drug designation under section 573 of the act prior to final FDA 
action on the request unless the existence of the request has been 
previously publicly disclosed or acknowledged.
    (b) Whether or not the existence of a pending request for 
designation has been publicly disclosed or acknowledged, no data or 
information in the request are available for public disclosure prior to 
final FDA action on the request.
    (c) Except as provided in paragraph (d) of this section, upon final 
FDA action on a request for designation, the public availability of data 
and information in the request will be determined in accordance with 
part 20 of this chapter and other applicable statutes and regulations.
    (d) In accordance with Sec. 516.28, FDA will make a cumulative list 
of all MUMS-drug designations available to the public and update such 
list periodically. In accordance with Sec. 516.29, FDA will give public 
notice of the termination of all MUMS-drug designations.



  Subpart C_Index of Legally Marketed Unapproved New Animal Drugs for 
                              Minor Species

    Source: 72 FR 69121, Dec. 6, 2007, unless otherwise noted.



Sec. 516.111  Scope of this subpart.

    This subpart implements section 572 of the act and provides 
standards and procedures to establish an index of legally marketed 
unapproved new animal drugs. This subpart applies only to minor species 
and not to minor use in major species. This index is only available for 
new animal drugs intended for use in a minor species for which there is 
a reasonable certainty that the animal or edible products from the 
animal will not be consumed by humans or food-producing animals and for 
new animal drugs intended for use only in a hatchery, tank, pond, or 
other similar contained man-made structure in an early, nonfood life 
stage of a food-producing minor species, where safety for humans is 
demonstrated in accordance with the standard of section 512(d) of the 
act (including, for an antimicrobial new animal drug, with respect to 
antimicrobial resistance). The index shall not include a new animal drug 
that is contained in, or a product of, a transgenic animal. Among its 
topics, this subpart sets forth the standards and procedures for:
    (a) Investigational exemptions for indexing purposes;
    (b) Submissions to FDA of requests for determination of eligibility 
of a new animal drug for indexing;
    (c) Establishment and operation of expert panels;
    (d) Submissions to FDA of requests for addition of a new animal drug 
to the index;
    (e) Modifications to index listings;
    (f) Publication of the index; and
    (g) Records and reports.



Sec. 516.115  Definitions.

    (a) The following definitions of terms apply only in the context of 
subpart C of this part:
    Director OMUMS means the Director of the Office of Minor Use and 
Minor Species Animal Drug Development of the FDA Center for Veterinary 
Medicine.
    Holder means the requestor of an index listing after the request is 
granted and the new animal drug is added to the index.
    Index means FDA's list of legally marketed unapproved new animal 
drugs for minor species.
    Intended use has the same meaning as that given in Sec. 516.13 of 
this chapter.
    Qualified expert panel means a panel that is composed of experts 
qualified by scientific training and experience to evaluate the target 
animal safety and

[[Page 103]]

effectiveness of a new animal drug under consideration for indexing.
    Requestor means the person making a request for determination of 
eligibility for indexing or a request for addition to the index.
    Transgenic animal means an animal whose genome contains a nucleotide 
sequence that has been intentionally modified in vitro, and the progeny 
of such an animal, provided that the term `transgenic animal' does not 
include an animal of which the nucleotide sequence of the genome has 
been modified solely by selective breeding.
    (b) The definitions of the following terms are given in Sec. 514.3 
of this chapter:
    Adverse drug experience.
    Product defect/manufacturing defect.
    Serious adverse drug experience.
    Unexpected adverse drug experience.
    (c) The definitions of the following terms are given in Sec. 516.3 
of this chapter:
    Same dosage form.
    Same drug.
    Same intended use.



Sec. 516.117  Submission of correspondence under this subpart.

    Unless directed otherwise by FDA, all correspondence relating to any 
aspect of the new animal drug indexing process described in this subpart 
must be addressed to the Director, OMUMS. The initial correspondence for 
a particular index listing should include the name and address of the 
authorized contact person. Notifications of changes in such person or 
changes of address of such person should be provided in a timely manner.



Sec. 516.119  Permanent-resident U.S. agent for foreign requestors 
and holders.

    Every foreign requestor and holder shall name a permanent resident 
of the United States as their agent upon whom service of all processes, 
notices, orders, decisions, requirements, and other communications may 
be made on behalf of the requestor or holder. Notifications of changes 
in such agents or changes of address of agents should preferably be 
provided in advance, but not later than 60 days after the effective date 
of such changes. The permanent resident U.S. agent may be an individual, 
firm, or domestic corporation and may represent any number of requestors 
or holders. The name and address of the permanent-resident U.S. agent 
shall be submitted to the Director, OMUMS, and included in the index 
file.



Sec. 516.121  Meetings.

    (a) A requestor or potential requestor is entitled to one or more 
meetings to discuss the requirements for indexing a new animal drug.
    (b) Requests for such meetings should be in writing, be addressed to 
the Director, OMUMS, specify the participants attending on behalf of the 
requestor or potential requestor, and contain a proposed agenda for the 
meeting.
    (c) Within 30 days of receiving a request for a meeting, FDA will 
attempt to schedule the meeting at a time agreeable to both FDA and the 
person making the request.



Sec. 516.123  Informal conferences regarding agency administrative 
actions.

    (a) Should FDA make an initial decision denying a request for 
determination of eligibility for indexing, terminating an 
investigational exemption, determining that a qualified expert panel 
does not meet the selection criteria, denying a request for addition to 
the index, or removing a new animal drug from the index, FDA will give 
written notice that specifies the grounds for the initial decision and 
provides an opportunity for an informal conference for review of the 
decision.
    (b) The written notice will include information for scheduling the 
informal conference and state that a written request for a conference 
must be made within 60 days of the date FDA sends its notice.
    (c) Within 45 days of receiving a request for an informal 
conference, FDA will schedule and hold the informal conference at a time 
agreeable to both FDA and the person making the request.
    (d) Such an informal conference will be conducted by a presiding 
officer who will be the Director of the Center for

[[Page 104]]

Veterinary Medicine or his or her designee, excluding the Director of 
the Office of Minor Use and Minor Species Animal Drug Development and 
other persons significantly involved in the initial decision.
    (e) The person requesting an informal conference must provide a 
written response to FDA's initial decision at least 2 weeks prior to the 
date of the scheduled meeting. Generally, this written response would be 
attached to the request for an informal conference. At the option of the 
person requesting an informal conference, such written response to FDA's 
initial decision may act in lieu of a face-to-face meeting. In this 
case, the informal conference will consist of a review by the presiding 
officer of the submitted written response.
    (f) The purpose of an informal conference is to discuss scientific 
and factual issues. It will involve a discussion of FDA's initial 
decision and any written response to that decision.
    (g) Internal agency review of a decision must be based on the 
information in the administrative file. If the person requesting an 
informal conference presents new information not in the file, the matter 
will be returned to the appropriate lower level in the agency for 
reevaluation based on the new information.
    (h) Informal conferences under this part are not subject to the 
separation of functions rules in Sec. 10.55 of this chapter.
    (i) The rules of evidence do not apply to informal conferences. No 
motions or objections relating to the admissibility of information and 
views will be made or considered, but any party to the conference may 
comment upon or rebut all such data, information and views.
    (j) [Reserved]
    (k) The presiding officer will prepare a written report regarding 
the subject of the informal conference that states and describes the 
basis for his or her findings. Whenever time permits, the parties to the 
informal conference will have 30 days to review and comment on the 
report.
    (l) The administrative record of the informal conference will 
consist of:
    (1) The notice providing an opportunity for an informal conference 
and the written response to the notice.
    (2) All written information and views submitted to the presiding 
officer at the conference or, at the discretion of the presiding 
officer, thereafter.
    (3) The presiding officer's written report.
    (4) All correspondence and memoranda of any and all meetings between 
the participants and the presiding officer.
    (m) The administrative record of the informal conference is closed 
to the submission of information at the close of the conference, unless 
the presiding officer specifically permits additional time for further 
submission.
    (n) The administrative record of the informal conference specified 
herein constitutes the exclusive record for decision.



Sec. 516.125  Investigational use of minor species new animal drugs 
to support indexing.

    (a) The investigational use of a new animal drug or animal feed 
bearing or containing a new animal drug intended solely for 
investigational use in minor species shall meet the requirements of part 
511 of this chapter if the investigational use is for the purpose of:
    (1) Demonstrating human food safety under section 572(a)(1)(B) of 
the act;
    (2) Demonstrating safety with respect to individuals exposed to the 
new animal drug through its manufacture and use under section 
572(c)(1)(F) of the act;
    (3) Conducting an environmental assessment under section 
572(c)(1)(E) of the act; or
    (4) Obtaining approval of a new animal drug application or 
abbreviated new animal drug application under section 512(b) of the act.
    (b) Correspondence and information associated with investigations 
described in paragraph (a) of this section shall not be sent to the 
Director, OMUMS, but shall be submitted to FDA in accordance with the 
provisions of part 511 of this chapter.
    (c) The investigational use of a new animal drug or animal feed 
bearing or containing a new animal drug intended solely for 
investigational use in minor

[[Page 105]]

species, other than for an investigational use described in paragraph 
(a) of this section, shall meet the requirements of this section. For 
such investigations, all provisions of part 511 of this chapter apply 
with the following modifications:
    (1) Under Sec. 511.1(a)(1) of this chapter, the label statement is 
as follows:
    ``Caution. Contains a new animal drug for investigational use only 
in laboratory animals or for tests in vitro in support of index listing. 
Not for use in humans.''
    (2) Under Sec. 511.1(b)(1) of this chapter, the label statement is 
as follows:
    ``Caution. Contains a new animal drug for use only in 
investigational animals in clinical trials in support of index listing. 
Not for use in humans. Edible products of investigational animals are 
not to be used for food for humans or other animals unless authorization 
has been granted by the U.S. Food and Drug Administration or by the U.S. 
Department of Agriculture.''
    (3) Under Sec. 511.1(b)(4) of this chapter, the notice is titled 
``Notice of Claimed Investigational Exemption for a New Animal Drug for 
Index Listing'' and is submitted in duplicate to the Director, OMUMS.
    (4) Under Sec. 511.1(c)(3) of this chapter, if an investigator is 
determined to be ineligible to receive new animal drugs, each ``Notice 
of Claimed Investigational Exemption for a New Animal Drug for Index 
Listing'' and each request for indexing shall be examined with respect 
to the reliability of information submitted by the investigator.
    (5) Under Sec. 511.1(c)(4) and (d)(2) of this chapter, with respect 
to termination of exemptions, the sponsor of an investigation shall not 
be granted an opportunity for a regulatory hearing before FDA pursuant 
to part 16 of this chapter. Instead, the sponsor shall have an 
opportunity for an informal conference as described in Sec. 516.123.
    (6) Under Sec. 511.1(c)(5) of this chapter, if the Commissioner of 
Food and Drugs determines, after the unreliable data submitted by the 
investigator are eliminated from consideration, that the data remaining 
are such that a request for addition to the index would have been 
denied, FDA will remove the new animal drug from the index in accordance 
with Sec. 516.167.
    (d) The investigational use of a new animal drug or animal feed 
bearing or containing a new animal drug subject to paragraph (c) of this 
section shall not be subject to the good laboratory practice 
requirements in part 58 of this chapter.
    (e) Correspondence and information associated with investigations 
described in paragraph (c) of this section shall be sent to the 
Director, OMUMS, in accordance with the provisions of this section.



Sec. 516.129  Content and format of a request for determination of 
eligibility for indexing.

    (a) Each request for determination of eligibility:
    (1) May involve only one drug (or one combination of drugs) in one 
dosage form;
    (2) May not involve a new animal drug that is contained in or a 
product of a transgenic animal;
    (3) May not involve the same drug in the same dosage form for the 
same intended use as a drug that is already approved or conditionally 
approved; and
    (4) Must be submitted separately.
    (b) A request for determination of eligibility for indexing may 
involve multiple intended uses and/or multiple minor species. However, 
if a request for determination of eligibility for indexing that contains 
multiple intended uses and/or multiple minor species cannot be granted 
in any part, the entire request will be denied.
    (c) A requestor must submit two copies of a dated request signed by 
the authorized contact person for determination of eligibility for 
indexing that contains the following:
    (1) Identification of the minor species or groups of minor species 
for which the new animal drug is intended;
    (2) Information regarding drug components and composition;
    (3) A statement of the intended use(s) of the new animal drug in the 
identified minor species or groups of minor species;
    (4) A statement of the proposed conditions of use associated with 
the stated intended use(s) of the new animal drug, including the 
proposed dosage,

[[Page 106]]

route of administration, contraindications, warnings, and any other 
significant limitations associated with the intended use(s) of the new 
animal drug;
    (5) A brief discussion of the need for the new animal drug for the 
intended use(s);
    (6) An estimate of the anticipated annual distribution of the new 
animal drug, in terms of the total quantity of active ingredient, after 
indexing;
    (7) Information to establish that the new animal drug is intended 
for use:
    (i) In a minor species for which there is a reasonable certainty 
that the animal or edible products from the animal will not be consumed 
by humans or food-producing animals; or
    (ii) In a hatchery, tank, pond, or other similar contained man-made 
structure in (which includes on) an early, non-food life stage of a 
food-producing minor species, and information to demonstrate food safety 
in accordance with the standards of section 512(d) of the act and Sec. 
514.111 of this chapter (including, for an antimicrobial new animal 
drug, with respect to antimicrobial resistance);
    (8) A description of the methods used in, and the facilities and 
controls used for, the manufacture, processing and packing of the new 
animal drug sufficient to demonstrate that the requestor has established 
appropriate specifications for the manufacture and control of the new 
animal drug and that the requestor has an understanding of current good 
manufacturing practices;
    (9) Either a claim for categorical exclusion under Sec. 25.30 or 
Sec. 25.33 of this chapter or an environmental assessment under Sec. 
25.40 of this chapter;
    (10) Information sufficient to support the conclusion that the new 
animal drug is safe under section 512(d) of the act with respect to 
individuals exposed to the new animal drug through its manufacture and 
use; and
    (11) The name and address of the contact person or permanent-
resident U.S. agent.



Sec. 516.131  Refuse to file a request for determination of 
eligibility for indexing.

    (a) If a request for determination of eligibility for indexing 
contains all of the information required by Sec. 516.129, FDA shall 
file it, and the filing date shall be the date FDA receives the request.
    (b) If a request for a determination of eligibility lacks any of the 
information required by Sec. 516.129, FDA will not file it, but will 
inform the requestor in writing within 30 days of receiving the request 
as to what information is lacking.



Sec. 516.133  Denying a request for determination of eligibility 
for indexing.

    (a) FDA will deny a request for determination of eligibility for 
indexing if it determines upon the basis of the request evaluated 
together with any other information before it with respect to the new 
animal drug that:
    (1) The same drug in the same dosage form for the same intended use 
is already approved or conditionally approved;
    (2) There is insufficient information to demonstrate that the new 
animal drug is intended for use:
    (i) In a minor species for which there is a reasonable certainty 
that the animal or edible products from the animal will not be consumed 
by humans or food-producing animals, or
    (ii) In a hatchery, tank, pond, or other similar contained man-made 
structure in (which includes on) an early, non-food life stage of a 
food-producing minor species, and there is insufficient evidence to 
demonstrate safety for humans in accordance with the standard of section 
512(d) of the act and Sec. 514.111 of this chapter (including, for an 
antimicrobial new animal drug, with respect to antimicrobial 
resistance);
    (3) The new animal drug is contained in or is a product of a 
transgenic animal;
    (4) There is insufficient information to demonstrate that the 
requestor has established appropriate specifications for the manufacture 
and control of the new animal drug and that the requestor has an 
understanding of current good manufacturing practices;
    (5) The requester fails to submit an adequate environmental 
assessment under Sec. 25.40 of this chapter or fails to

[[Page 107]]

provide sufficient information to establish that the requested action is 
subject to categorical exclusion under Sec. 25.30 or Sec. 25.33 of 
this chapter;
    (6) There is insufficient information to determine that the new 
animal drug is safe with respect to individuals exposed to the new 
animal drug through its manufacture or use; or
    (7) The request for determination of eligibility for indexing fails 
to contain any other information required under the provisions of Sec. 
516.129.
    (b) FDA may deny a request for determination of eligibility for 
indexing if it contains any untrue statement of a material fact or omits 
material information.
    (c) When a request for determination of eligibility for indexing is 
denied, FDA will notify the requestor in accordance with Sec. 516.137.



Sec. 516.135  Granting a request for determination of eligibility for 
indexing.

    (a) FDA will grant the request for determination of eligibility for 
indexing if none of the reasons described in Sec. 516.133 for denying 
such a request applies.
    (b) When a request for determination of eligibility for indexing is 
granted, FDA will notify the requestor in accordance with Sec. 516.137.



Sec. 516.137  Notification of decision regarding eligibility for 
indexing.

    (a) Within 90 days after the filing of a request for a determination 
of eligibility for indexing based on Sec. 516.129(c)(7)(i), or 180 days 
for a request based on Sec. 516.129(c)(7)(ii), FDA shall grant or deny 
the request, and notify the requestor of FDA's decision in writing.
    (b) If FDA denies the request, FDA shall provide due notice and an 
opportunity for an informal conference as described in Sec. 516.123 
regarding its decision. A decision of FDA to deny a request for 
determination of eligibility for indexing following an informal 
conference shall constitute final agency action subject to judicial 
review.



Sec. 516.141  Qualified expert panels.

    (a) Establishment of a qualified expert panel. Establishing a 
qualified expert panel is the first step in the process of requesting 
the addition of a new animal drug to the index. A qualified expert panel 
may not be established until FDA has determined that the new animal drug 
is eligible for indexing. The requestor must choose members for the 
qualified expert panel in accordance with selection criteria listed in 
paragraph (b) of this section and submit information about these 
proposed members to FDA. FDA must determine whether the proposed 
qualified expert panel meets the selection criteria prior to the panel 
beginning its work. Qualified expert panels operate external to FDA and 
are not subject to the Federal Advisory Committee Act, as amended, 5 
U.S.C. App.
    (b) Criteria for the selection of a qualified expert panel. (1) A 
qualified expert panel member must be an expert qualified by training 
and experience to evaluate a significant aspect of target animal safety 
or effectiveness of the new animal drug under consideration.
    (2) A qualified expert panel member must certify that he or she has 
a working knowledge of section 572 of the act (the indexing provisions 
of the statute) and this subpart, and that he or she has also read and 
understood a clear written statement provided by the requestor stating 
his or her duties and responsibilities with respect to reviewing the new 
animal drug proposed for addition to the index.
    (3) A qualified expert panel member may not be an FDA employee.
    (4) A qualified expert panel must have at least three members.
    (5) A qualified expert panel must have members with a range of 
expertise such that the panel, as a whole, is qualified by training and 
experience to evaluate the target animal safety and effectiveness of the 
new animal drug under consideration.
    (6) Unless FDA makes a determination to allow participation 
notwithstanding an otherwise disqualifying financial interest, a 
qualified expert panel member must not have a conflict of interest or 
the appearance of a conflict of interest, as described in paragraph (g) 
of this section.
    (c) Requestor responsibilities. (1) The requestor must:

[[Page 108]]

    (i) Choose members for the qualified expert panel in accordance with 
selection criteria listed in paragraph (b) of this section.
    (ii) Provide each potential expert panel member a copy of section 
572 of the act (the indexing provisions of the statute) and this subpart 
and obtain certification that he or she has a working knowledge of the 
information.
    (iii) Provide each potential expert panel member a written statement 
describing the purpose and scope of his or her participation on the 
qualified expert panel and obtain certification that he or she has read 
and understood the information. The written statement should describe 
the duties and responsibilities of qualified expert panels and their 
members established by paragraphs (e) and (f) of this section, including 
the need to prepare a written report under Sec. 516.143.
    (iv) Obtain information from each potential expert panel member 
demonstrating that he or she is qualified by training and experience to 
evaluate the target animal safety and effectiveness of the new animal 
drug under consideration. This information can be obtained from a 
comprehensive curriculum vitae or similar document.
    (v) Notify each potential expert panel member that he or she must 
submit information relating to potential conflict of interest directly 
to FDA in a timely manner, as required in paragraph (e)(6) of this 
section.
    (2) The requestor must submit, in writing, the names and addresses 
of the proposed qualified expert panel members and sufficient 
information about each proposed member for FDA to determine whether the 
panel meets the selection criteria listed in paragraphs (b)(1) through 
(b)(5) of this section.
    (3) After FDA has determined that the qualified expert panel meets 
the selection criteria, the requestor must provide to the panel all 
information known by the requestor that is relevant to a determination 
of the target animal safety and the effectiveness of the new animal drug 
at issue. In addition, the requestor must notify FDA of the name of the 
qualified expert panel leader.
    (4) The requestor must immediately notify FDA if it believes a 
qualified expert panel member no longer meets the selection criteria 
listed in paragraph (b) of this section or is otherwise not in 
compliance with the requirements of this section.
    (5) If a qualified expert panel member cannot complete the review 
for which he or she was selected, the requestor must either choose a 
replacement or justify the continued work of the panel in the absence of 
the lost panelist. In either case, the requestor must submit sufficient 
information for FDA to determine whether the proposed revised qualified 
expert panel meets the selection criteria listed in paragraphs (b)(1) 
through (b)(5) of this section.
    (6) The requestor must keep copies of all information provided to, 
or received from, qualified expert panel members, including the written 
report, for 2 years after the completion of the report, or the product 
is added to the index, whichever occurs later, and make them available 
to a duly authorized employee of the agency at all reasonable times.
    (d) FDA responsibilities. (1) FDA will determine whether the 
requestor's proposed qualified expert panel meets the selection criteria 
listed in paragraph (b) of this section. FDA will expeditiously inform 
the requestor, in writing, of its determination. If FDA determines that 
the qualified expert panel does not meet the selection criteria, FDA 
will provide due notice and an opportunity for an informal conference as 
described in Sec. 516.123. A determination by FDA that a proposed 
qualified expert panel does not meet the selection criteria following an 
informal conference shall constitute final agency action subject to 
judicial review.
    (2) If FDA determines that a qualified expert panel no longer meets 
the selection criteria listed in paragraph (b) of this section or that 
the panel or its members are not in compliance with the requirements of 
this section, the agency will expeditiously inform the requestor, in 
writing, of this determination and provide due notice and an opportunity 
for an informal conference as described in Sec. 516.123. A 
determination by FDA, following an informal conference, that a qualified 
expert

[[Page 109]]

panel no longer meets the selection criteria listed in paragraph (b) of 
this section or that the panel or its members are not in compliance with 
the requirements of this section shall constitute final agency action 
subject to judicial review.
    (e) Responsibilities of a qualified expert panel member. A qualified 
expert panel member must do the following:
    (1) Continue to meet all selection criteria described in paragraph 
(b) of this section.
    (2) Act in accordance with generally accepted professional and 
ethical business practices.
    (3) Review all information relevant to a determination of the target 
animal safety and effectiveness of the new animal drug provided by the 
requestor. The panel should also consider all relevant information 
otherwise known by the panel members, including anecdotal information.
    (4) Participate in the preparation of the written report of the 
findings of the qualified expert panel, described in Sec. 516.143.
    (5) Sign, or otherwise approve in writing, the written report. Such 
signature or other written approval will serve as certification that the 
written report meets the requirements of the written report in Sec. 
516.143.
    (6) Provide the information relating to potential conflict of 
interest described in paragraph (g) of this section to FDA for its 
consideration. Such information should be submitted directly to the 
Director, OMUMS, when notified by the requestor.
    (7) Immediately notify the requestor and FDA of any change in 
conflict of interest status.
    (8) Certify at the time of submission of the written report that 
there has been no change in conflict of interest status, or identify and 
document to FDA any such change.
    (f) Additional responsibilities of a qualified expert panel leader. 
(1) The qualified expert panel leader must ensure that the activities of 
the panel are performed efficiently and in accordance with generally 
accepted professional and ethical business practices.
    (2) The qualified expert panel leader serves as the principal point 
of contact between representatives of the agency and the panel.
    (3) The qualified expert panel leader is responsible for submitting 
the written report and all notes or minutes relating to panel 
deliberations to the requestor.
    (4) The qualified expert panel leader must maintain a copy of the 
written report and all notes or minutes relating to panel deliberations 
that are submitted to the requestor for 2 years after the report is 
submitted. Such records must be made available to a duly authorized 
employee of the agency for inspection at all reasonable times.
    (g) Prevention of conflicts of interest. (1) For the purposes of 
this subpart, FDA will consider a conflict of interest to be any 
financial or other interest that could impair a person's objectivity in 
serving on the qualified expert panel or could create an unfair 
competitive advantage for a person or organization.
    (2) Factors relevant to whether there is a conflict of interest or 
the appearance of a conflict of interest include whether the qualified 
expert panel member, their spouse, their minor children, their general 
partners, or any organizations in which they serve as an officer, 
director, trustee, general partner or employee:
    (i) Is currently receiving or seeking funding from the requestor 
through a contract or research grant (either directly or indirectly 
through another entity, such as a university).
    (ii) Has any employment, contractual, or other financial arrangement 
with the requestor other than receiving a reasonable fee for serving as 
a member of the qualified expert panel.
    (iii) Has any ownership or financial interest in any drug, drug 
manufacturer, or drug distributor which will benefit from either a 
favorable or unfavorable evaluation or opinion.
    (iv) Has any ownership or financial interest in the new animal drug 
being reviewed by the qualified expert panel.
    (v) Has participated in the design, manufacture, or distribution of 
any drug that will benefit from either a favorable or unfavorable 
opinion of the qualified expert panel.

[[Page 110]]

    (vi) Has provided within 1 year any consultative services regarding 
the new animal drug being reviewed by the qualified expert panel.
    (vii) Has entered into an agreement in which fees charged or 
accepted are contingent upon the panel member making a favorable 
evaluation or opinion.
    (viii) Receives payment for services related to preparing 
information the requestor presents to the qualified expert panel, other 
than for services related to the written report described in Sec. 
516.143.
    (3) To permit FDA to make a decision regarding potential conflict of 
interest, a potential qualified expert panel member must submit to the 
Director, OMUMS, the following information relating to themselves, their 
spouse, their minor children, their general partners, or any 
organizations in which they serve as an officer, director, trustee, 
general partner or employee, regarding the following issues to the 
extent that they are, in any way, relevant to the subject of the review 
of the qualified expert panel:
    (i) Investments (for example, stocks, bonds, retirement plans, 
trusts, partnerships, sector funds, etc.), including for each the 
following: Name of the firm, type of investment, owner (self, spouse, 
etc.), number of shares / current value.
    (ii) Employment (full or part time, current or under negotiation), 
including for each the following: Name of the firm, relationship (self, 
spouse, etc.), position in firm, date employment or negotiation began.
    (iii) Consultant/advisor (current or under negotiation), including 
for each the following: Name of the firm, topic/issue, amount received, 
date initiated.
    (iv) Contracts, grants, Cooperation Research and Development 
Agreement (CRADAs) (current or under negotiation), including for each 
the following: Type of agreement, product under study and indications, 
amount of remuneration (institution/self), time period, sponsor 
(government, firm, institution, individual), role of the person (site 
investigator, principal investigator, co-investigator, partner, no 
involvement, other), awardee.
    (v) Patents/royalties/trademarks, including for each the following: 
Description, name of firm involved, income received.
    (vi) Expert witness (last 12 months or under negotiation), including 
for each the following: For or against, name of firm, issue, amount 
received.
    (vii) Speaking/writing (last 12 months or under negotiation), 
including for each the following: Firm, topic/issue, amount received 
(honorarium/travel), date.
    (viii) Whether the potential qualified expert panel member, their 
spouse, their minor children, their general partners or any 
organizations in which they serve as an officer, director, trustee, 
general partner or employee, have had, at any time in the past, 
involvement of the kind noted in paragraph (g)(3)(i) through (g)(3)(vii) 
of this section with respect to the animal drug that is the subject of 
the qualified expert panel review.
    (ix) Whether there are any other involvements (other kinds of 
relationships) that would give the appearance of a conflict of interest 
which have not been described in paragraph (g)(3)(i) through 
(g)(3)(viii) of this section.
    (x) In all cases, a response of ``no,'' ``none,'' or ``not 
applicable'' is satisfactory when there is no relevant information to 
submit.
    (xi) A certification statement signed by the potential qualified 
expert panel member to the effect that all information submitted is true 
and complete to the best of their knowledge, that they have read and 
understood their obligations as an expert panel member, and that they 
will notify FDA and the requestor of any change in their conflict of 
interest status.
    (4) The fact that a qualified expert panel member receives a 
reasonable fee for services as a member of the qualified expert panel, 
provided that the fee is no more than commensurate with the value of the 
time that the member devotes to the review process, does not constitute 
a conflict of interest or the appearance of a conflict of interest.



Sec. 516.143  Written report.

    The written report required in Sec. 516.145(b)(3) shall:

[[Page 111]]

    (a) Be written in English by a qualified expert panel meeting the 
requirements of Sec. 516.141;
    (b) Describe the panel's evaluation of all available target animal 
safety and effectiveness information relevant to the proposed use of the 
new animal drug, including anecdotal information;
    (c) For all information considered, including anecdotal information, 
include either a citation to published literature or a summary of the 
information;
    (d) State the panel's opinion regarding whether the benefits of 
using the new animal drug for the proposed use in a minor species 
outweigh its risks to the target animal, taking into account the harm 
being caused by the absence of an approved or conditionally-approved new 
animal drug for the minor species in question;
    (e) Be signed, or otherwise approved in writing, by all panel 
members, in accordance with Sec. 516.141; and
    (f) If the panel unanimously concludes that the benefits of using 
the new animal drug for the proposed use in a minor species outweigh its 
risks to the target animal, taking into account the harm being caused by 
the absence of an approved or conditionally-approved new animal drug for 
the minor species in question, the written report shall:
    (1) Provide draft labeling that includes all conditions of use and 
limitations of use of the new animal drug deemed necessary by the panel 
to assure that the benefits of use of the new animal drug outweigh the 
risks, or provide narrative information from which such labeling can be 
written by the requestor; and
    (2) Include a recommendation regarding whether the new animal drug 
should be limited to use under the professional supervision of a 
licensed veterinarian.



Sec. 516.145  Content and format of a request for addition to the 
index.

    (a) A requestor may request addition of a new animal drug to the 
index only after the new animal drug has been granted eligibility for 
indexing.
    (b) A requestor shall submit two copies of a dated request signed by 
the authorized contact for addition of a new animal drug to the index 
that contains the following:
    (1) A copy of FDA's determination of eligibility issued under Sec. 
516.137;
    (2) A copy of FDA's written determination that the proposed 
qualified expert panel meets the selection criteria provided for in 
Sec. 516.141(b);
    (3) A written report that meets the requirements of Sec. 516.143;
    (4) A proposed index entry that contains the information described 
in Sec. 516.157;
    (5) Proposed labeling, including representative labeling proposed to 
be used for Type B and Type C medicated feeds if the drug is intended 
for use in the manufacture of medicated feeds;
    (6) Anticipated annual distribution of the new animal drug, in terms 
of the total quantity of active ingredient, after indexing;
    (7) A written commitment to manufacture the new animal drug and 
animal feeds bearing or containing such new animal drug according to 
current good manufacturing practices;
    (8) A written commitment to label, distribute, and promote the new 
animal drug only in accordance with the index entry;
    (9) The name and address of the contact person or permanent-resident 
U.S. agent; and
    (10) A draft Freedom of Information summary which includes the 
following information:
    (i) A general information section that contains the name and address 
of the requestor and a description of the drug, route of administration, 
indications, and recommended dosage.
    (ii) A list of the names and affiliations of the members of the 
qualified expert panel, not including their addresses or other contact 
information.
    (iii) A summary of the findings of the qualified expert panel 
concerning the target animal safety and effectiveness of the drug.
    (iv) Citations of all publicly-available literature considered by 
the qualified expert panel.
    (v) For an early life stage of a food-producing minor species 
animal, a human food safety summary.
    (c) Upon specific request by FDA, the requestor shall submit the 
information described in Sec. 516.141 that it submitted

[[Page 112]]

to the qualified expert panel. Any such information not in English 
should be accompanied by an English translation.



Sec. 516.147  Refuse to file a request for addition to the index.

    (a) If a request for addition to the index contains all of the 
information required by Sec. 516.145(b), FDA shall file it, and the 
filing date shall be the date FDA receives the request.
    (b) If a request for addition to the index lacks any of the 
information required by Sec. 516.145, FDA will not file it, but will 
inform the requestor in writing within 30 days of receiving the request 
as to what information is lacking.



Sec. 516.149  Denying a request for addition to the index.

    (a) FDA will deny a request for addition to the index if it finds 
the following:
    (1) The same drug in the same dosage form for the same intended use 
is already approved or conditionally approved;
    (2) On the basis of new information, the new animal drug no longer 
meets the conditions for eligibility for indexing;
    (3) The request for indexing fails to contain information required 
under the provisions of Sec. 516.145;
    (4) The qualified expert panel fails to meet any of the selection 
criteria listed in Sec. 516.141(b);
    (5) The written report of the qualified expert panel and other 
information available to FDA is insufficient to permit FDA to determine 
that the benefits of using the new animal drug for the proposed use in a 
minor species outweigh its risks to the target animal, taking into 
account the harm caused by the absence of an approved or conditionally-
approved new animal drug for the minor species in question;
    (6) On the basis of the report of the qualified expert panel and 
other information available to FDA, the benefits of using the new animal 
drug for the proposed use in a minor species do not outweigh its risks 
to the target animal, taking into account the harm caused by the absence 
of an approved or conditionally-approved new animal drug for the minor 
species in question; or
    (7) The request contains any untrue statement of a material fact or 
omits material information.
    (b) When a request for addition to the index is denied, FDA will 
notify the requestor in accordance with Sec. 516.153.



Sec. 516.151  Granting a request for addition to the index.

    (a) FDA will grant the request for addition of a new animal drug to 
the index if none of the reasons described in Sec. 516.149 for denying 
such a request applies.
    (b) When a request for addition of a new animal drug to the index is 
granted, FDA will notify the requestor in accordance with Sec. 516.153.



Sec. 516.153  Notification of decision regarding index listing.

    (a) Within 180 days after the filing of a request for addition of a 
new animal drug to the index, FDA shall grant or deny the request and 
notify the requestor of FDA's decision in writing.
    (b) If FDA denies the request for addition of a new animal drug to 
the index, FDA shall provide due notice and an opportunity for an 
informal conference as described in Sec. 516.123. A decision of FDA to 
deny a request to index a new animal drug following an informal 
conference shall constitute final agency action subject to judicial 
review.



Sec. 516.155  Labeling of indexed drugs.

    (a) The labeling of an indexed drug that is found to be eligible for 
indexing under Sec. 516.129(c)(7)(i) shall state, prominently and 
conspicuously: ``NOT APPROVED BY FDA.--Legally marketed as an FDA 
indexed product. Extra-label use is prohibited.'' ``This product is not 
to be used in animals intended for use as food for humans or other 
animals.''
    (b) The labeling of an indexed drug that was found to be eligible 
for indexing for use in an early, non-food life stage of a food-
producing minor species animal, under Sec. 516.129(c)(7)(ii), shall 
state, prominently and conspicuously: ``NOT APPROVED BY FDA.--Legally 
marketed as an FDA indexed product. Extra-label use is prohibited.''

[[Page 113]]

    (c) The labeling of an indexed drug shall contain such other 
information as may be prescribed in the index listing.



Sec. 516.157  Publication of the index and content of an index listing.

    (a) FDA will make the list of indexed drugs available through the 
FDA Web site. A printed copy can be obtained by writing to the FDA 
Division of Freedom of Information or by visiting FDA's Division of 
Freedom of Information Public Reading Room.
    (b) The list will contain the following information for each indexed 
drug:
    (1) The name and address of the person who holds the index listing;
    (2) The name of the drug and the intended use and conditions of use 
for which it is indexed;
    (3) Product labeling; and
    (4) Conditions and any limitations that FDA deems necessary 
regarding use of the drug.

[72 FR 69121, Dec. 6, 2007, 76 FR 31470, June 1, 2011]



Sec. 516.161  Modifications to indexed drugs.

    (a) After a drug is listed in the index, certain modifications to 
the index listing may be requested. Any modification of an index listing 
may not cause an indexed drug to be a different drug (or different 
combination of drugs) or a different dosage form. If such modification 
is requested, FDA will notify the holder that a new index listing is 
required for the new drug or dosage form.
    (b) Modifications to the indexed drug will fall under one of three 
categories and must be submitted as follows:
    (1) Urgent changes. (i) The following modifications to an indexed 
drug or its labeling should be made as soon as possible, and a request 
to modify the indexed drug should be concurrently submitted:
    (A) The addition to package labeling, promotional labeling, or 
prescription drug advertising of additional warning, contraindication, 
side effect, or cautionary information.
    (B) The deletion from package labeling, promotional labeling, and 
drug advertising of false, misleading, or unsupported indications for 
use or claims for effectiveness.
    (C) Changes in manufacturing methods or controls required to correct 
product or manufacturing defects that may result in serious adverse drug 
events.
    (ii) The modifications described in paragraph (b)(1)(i) of this 
section must be submitted to the Director, OMUMS, in the form of a 
request for modification of an indexed drug, and must contain sufficient 
information to permit FDA to determine the need for the modification and 
whether the modification appropriately addresses the need.
    (iii) FDA will take no action against an indexed drug or index 
holder solely because modifications of the kinds described in paragraph 
(b)(1)(i) of this section are placed into effect by the holder prior to 
receipt of a written notice granting the request if all the following 
conditions are met:
    (A) A request to modify the indexed drug providing a full 
explanation of the basis for the modifications has been submitted, 
plainly marked on the mailing cover and on the request as follows: 
``Special indexing request-- modifications being effected;''
    (B) The holder specifically informs FDA of the date on which such 
modifications are to be effected and submits two printed copies of any 
revised labeling to be placed in use, and
    (C) All promotional labeling and all drug advertising are promptly 
revised consistent with modifications made in the labeling on or within 
the indexed drug package.
    (2) Significant changes. (i) The following modifications to an 
indexed drug or its labeling may be made only after a request has been 
submitted to and subsequently granted by FDA:
    (A) Addition of an intended use.
    (B) Addition of a species.
    (C) Addition or alteration of an active ingredient.
    (D) Alteration of the concentration of an active ingredient.
    (E) Alteration of dose or dosage regimen.
    (F) Alteration of prescription or over-the-counter status.
    (ii) Each modification described in paragraph (b)(2)(i) of this 
section must go through the same review process as

[[Page 114]]

an original index listing and is subject to the same standards for 
review.
    (iii) Each submission of a request for a modification described in 
paragraph (b)(2)(i) of this section should contain only one type of 
modification unless one modification is actually necessitated by 
another, such as a modification of dose necessitated by a modification 
of the concentration of an active ingredient. Submissions relating to 
addition of an intended use for an existing species or addition of a 
species should be submitted separately, but each such submission may 
include multiple additional intended uses and/or multiple additional 
species.
    (3) Minor changes. All modifications other than those described in 
paragraphs (b)(1) and (b)(2) of this section including, but not limited 
to, formulation, labeling, and manufacturing methods and controls (at 
the same level of detail that these were described in the request for 
determination of eligibility for indexing) must be submitted as part of 
the annual indexed drug experience report or as otherwise required by 
Sec. 516.165.
    (c) When changes affect the index listing, it will be updated 
accordingly.



Sec. 516.163  Change in ownership of an index file.

    (a) A holder may transfer ownership of a drug's index file to 
another person.
    (1) The former owner shall submit in writing to FDA a statement that 
all rights in the index file have been transferred, giving the name and 
address of the new owner and the date of the transfer. The former owner 
shall also certify that a complete copy of the following, to the extent 
that they exist at the time of the transfer of ownership, has been 
provided to the new owner:
    (i) The request for determination of eligibility;
    (ii) The request for addition to the index;
    (iii) Any modifications to the index listing;
    (iv) Any records and reports under Sec. 516.165; and
    (v) All correspondence with FDA relevant to the indexed drug and its 
index listing.
    (2) The new owner shall submit the following information in writing 
to FDA:
    (i) The date that the change in ownership is effective;
    (ii) A statement that the new owner has a complete copy of all 
documents listed in paragraph (a)(1) of this section to the extent that 
they exist at the time of the transfer of ownership;
    (iii) A statement that the new owner understands and accepts the 
responsibilities of a holder of an indexed drug;
    (iv) The name and address of a new primary contact person or 
permanent-resident U.S. agent; and
    (v) A list of labeling changes associated with the change of 
ownership (e.g., a new trade name) as draft labeling, with complete 
final printed labeling to be submitted in the indexed drug annual report 
in accordance with Sec. Sec. 516.161 and 516.165.
    (b) Upon receiving the necessary information to support a change of 
ownership of a drug's index file, FDA will update its publicly-available 
listing in accordance with Sec. 516.157.



Sec. 516.165  Records and reports.

    (a) Scope and purpose. (1) The recordkeeping and reporting 
requirements of this section apply to all holders of indexed drugs, 
including indexed drugs intended for use in medicated feeds.
    (2) A holder is not required to report information under this 
section if the holder has reported the same information under Sec. 
514.80 of this chapter.
    (3) The records and reports referred to in this section are in 
addition to those required by the current good manufacturing practice 
regulations in parts 211, 225, and 226 of this chapter.
    (4) FDA will review the records and reports required in this section 
to determine, or facilitate a determination, whether there may be 
grounds for removing a drug from the index under section 572(f) of the 
act.
    (b) Recordkeeping requirements. (1) Each holder of an indexed drug 
must establish and maintain complete files containing full records of 
all information pertinent to the safety or effectiveness of the indexed 
drug. Such records must include information from foreign and domestic 
sources.

[[Page 115]]

    (2) The holder must, upon request from any authorized FDA officer or 
employee, at all reasonable times, permit such officer or employee to 
have access to copy and to verify all such records.
    (c) Reporting requirements. (1) Three-day indexed drug field alert 
report. The holder must inform the appropriate FDA District Office or 
local FDA resident post of any product or manufacturing defects that may 
result in serious adverse drug events within 3 working days of first 
becoming aware that such a defect may exist. The holder may initially 
provide this information by telephone or other electronic communication 
means, with prompt written followup. The mailing cover must be plainly 
marked ``3-Day Indexed Drug Field Alert Report.''
    (2) Fifteen-day indexed drug alert report. The holder must submit a 
report on each serious, unexpected adverse drug event, regardless of the 
source of the information. The holder must submit the report within 15 
working days of first receiving the information. The mailing cover must 
be plainly marked ``15-Day Indexed Drug Alert Report.''
    (3) Annual indexed drug experience report. The holder must submit 
this report every year on the anniversary date of the letter granting 
the request for addition of the new animal drug to the index, or within 
60 days thereafter. The report must contain data and information for the 
full reporting period. Any previously submitted information contained in 
the report must be identified as such. The holder may ask FDA to change 
the date of submission and, after approval of such request, file such 
reports by the new filing date. The report must contain the following:
    (i) The number of distributed units of each size, strength, or 
potency (e.g., 100,000 bottles of 100 5-milligram tablets; 50,000 10-
milliliter vials of 5- percent solution) distributed during the 
reporting period. This information must be presented in two categories: 
Quantities distributed domestically and quantities exported. This 
information must include any distributor-labeled product.
    (ii) If the labeling has changed since the last report, include a 
summary of those changes and the holder's and distributor's current 
package labeling, including any package inserts. For large-size package 
labeling or large shipping cartons, submit a representative copy (e.g., 
a photocopy of pertinent areas of large feed bags). If the labeling has 
not changed since the last report, include a statement of such fact.
    (iii) A summary of any changes made during the reporting period in 
the methods used in, and facilities and controls used for, manufacture, 
processing, and packing. This information must be presented in the same 
level of detail that it was presented in the request for determination 
of eligibility for indexing. Do not include changes that have already 
been submitted under Sec. 516.161.
    (iv) Nonclinical laboratory studies and clinical data not previously 
reported under this section.
    (v) Adverse drug experiences not previously reported under this 
section.
    (vi) Any other information pertinent to safety or effectiveness of 
the indexed drug not previously reported under this section.
    (4) Distributor's statement. At the time of initial distribution of 
an indexed drug by a distributor, the holder must submit a report 
containing the following:
    (i) The distributor's current product labeling. This must be 
identical to that in the index listing except for a different and 
suitable proprietary name (if used) and the name and address of the 
distributor. The name and address of the distributor must be preceded by 
an appropriate qualifying phrase such as ``manufactured for'' or 
``distributed by.''
    (ii) A signed statement by the distributor stating:
    (A) The category of the distributor's operations (e.g., wholesale or 
retail);
    (B) That the distributor will distribute the drug only under the 
indexed drug labeling;
    (C) That the distributor will promote the indexed drug only for use 
under the conditions stated in the index listing; and
    (D) If the indexed drug is a prescription new animal drug, that the 
distributor is regularly and lawfully engaged in the distribution or 
dispensing of prescription products.

[[Page 116]]

    (5) Other reporting. FDA may by order require that a holder submit 
information in addition to that required by this section or that the 
holder submit the same information but at different times or reporting 
periods.



Sec. 516.167  Removal from the index.

    (a) After due notice to the holder of the index listing and an 
opportunity for an informal conference as described in Sec. 516.123, 
FDA shall remove a new animal drug from the index if FDA finds that:
    (1) The same drug in the same dosage form for the same intended use 
has been approved or conditionally approved;
    (2) The expert panel failed to meet the requirements in Sec. 
516.141;
    (3) On the basis of new information before FDA, evaluated together 
with the evidence available to FDA when the new animal drug was listed 
in the index, the benefits of using the new animal drug for the indexed 
use do not outweigh its risks to the target animal, taking into account 
the harm caused by the absence of an approved or conditionally-approved 
new animal drug for the minor species in question;
    (4) Any of the conditions in Sec. 516.133(a)(2), (5), or (6) are 
present;
    (5) The manufacture of the new animal drug is not in accordance with 
current good manufacturing practices;
    (6) The labeling, distribution, or promotion of the new animal drug 
is not in accordance with the index listing;
    (7) The conditions and limitations of use associated with the index 
listing have not been followed; or
    (8) Any information used to support the request for addition to the 
index contains any untrue statement of material fact.
    (b) The agency may partially remove an indexing listing if, in the 
opinion of the agency, such partial removal would satisfactorily resolve 
a safety or effectiveness issue otherwise warranting removal of the 
listing under section 572(f)(1)(B) of the act.
    (c) FDA may immediately suspend a new animal drug from the index if 
FDA determines that there is a reasonable probability that the use of 
the drug would present a risk to the health of humans or other animals. 
The agency will subsequently provide due notice and an opportunity for 
an informal conference as described in Sec. 516.123.
    (d) A decision of FDA to remove a new animal drug from the index 
following an informal conference, if any, shall constitute final agency 
action subject to judicial review.



Sec. 516.171  Confidentiality of data and information in an index file.

    (a) For purposes of this section, the index file includes all data 
and information submitted to or incorporated by reference into the index 
file, such as data and information related to investigational use 
exemptions under Sec. 516.125, requests for determination of 
eligibility for indexing, requests for addition to the index, 
modifications to indexed drugs, changes in ownership, reports submitted 
under Sec. 516.165, and master files. The availability for public 
disclosure of any record in the index file shall be handled in 
accordance with the provisions of this section.
    (b) The existence of an index file will not be disclosed by FDA 
before an index listing has been made public by FDA, unless it has 
previously been publicly disclosed or acknowledged by the requestor.
    (c) If the existence of an index file has not been publicly 
disclosed or acknowledged, no data or information in the index file are 
available for public disclosure.
    (d) If the existence of an index file has been publicly disclosed or 
acknowledged before an index listing has been made public by FDA, no 
data or information contained in the file will be available for public 
disclosure before such index listing is made public, but the agency may, 
at its discretion, disclose a brief summary of such selected portions of 
the safety and effectiveness data as are appropriate for public 
consideration of a specific pending issue, e.g., at an open session of a 
Food and Drug Administration advisory committee or pursuant to an 
exchange of important regulatory information with a foreign government.
    (e) After FDA sends a written notice to the requestor granting a 
request for addition to the index, the following data and information in 
the index file

[[Page 117]]

are available for public disclosure unless extraordinary circumstances 
are shown:
    (1) All safety and effectiveness data and information previously 
disclosed to the public, as defined in Sec. 20.81 of this chapter.
    (2) A summary or summaries of the safety and effectiveness data and 
information submitted with or incorporated by reference in the index 
file. Such summaries do not constitute the full information described 
under section 572(c) and (d) of the act on which the safety or 
effectiveness of the drug may be determined. Such summaries will be 
based on the draft Freedom of Information summary submitted under Sec. 
516.145, which will be reviewed and, where appropriate, revised by FDA.
    (3) A protocol for a test or study, unless it is shown to fall 
within the exemption established for trade secrets and confidential 
commercial information in Sec. 20.61 of this chapter.
    (4) Adverse reaction reports, product experience reports, consumer 
complaints, and other similar data and information, after deletion of 
the following:
    (i) Names and any information that would identify the person using 
the product.
    (ii) Names and any information that would identify any third party 
involved with the report, such as a veterinarian.
    (5) A list of all active ingredients and any inactive ingredients 
previously disclosed to the public as defined in Sec. 20.81 of this 
chapter.
    (6) An assay method or other analytical method, unless it serves no 
regulatory or compliance purpose and is shown to fall within the 
exemption established in Sec. 20.61 of this chapter.
    (7) All correspondence and written summaries of oral discussions 
relating to the index file, in accordance with the provisions of part 20 
of this chapter.
    (f) The following data and information in an index file are not 
available for public disclosure unless they have been previously 
disclosed to the public as defined in Sec. 20.81 of this chapter, or 
they relate to a product or ingredient that has been abandoned and they 
no longer represent a trade secret or confidential commercial or 
financial information as defined in Sec. 20.61 of this chapter:
    (1) Manufacturing methods or processes, including quality control 
procedures.
    (2) Production, sales, distribution, and similar data and 
information, except that any compilation of such data and information 
aggregated and prepared in a way that does not reveal data or 
information which is not available for public disclosure under this 
provision is available for public disclosure.
    (3) Quantitative or semiquantitative formulas.
    (g) Subject to the disclosure provisions of this section, the agency 
shall regard the contents of an index file as confidential information 
unless specifically notified in writing by the holder of the right to 
disclose, to reference, or otherwise utilize such information on behalf 
of another named person.
    (h) For purposes of this regulation, safety and effectiveness data 
include all studies and tests of an animal drug on animals and all 
studies and tests on the animal drug for identity, stability, purity, 
potency, and bioavailability.
    (i) Safety and effectiveness data and information that have not been 
previously disclosed to the public are available for public disclosure 
at the time any of the following events occurs unless extraordinary 
circumstances are shown:
    (1) No work is being or will be undertaken to have the drug indexed 
in accordance with the request.
    (2) A final determination is made that the drug cannot be indexed 
and all legal appeals have been exhausted.
    (3) The drug has been removed from the index and all legal appeals 
have been exhausted.
    (4) A final determination has been made that the animal drug is not 
a new animal drug.

Subpart D [Reserved]



  Subpart E_Conditionally Approved New Animal Drugs For Minor Use and 
                              Minor Species

    Source: 72 FR 57200, Oct. 9, 2007, unless otherwise noted.

[[Page 118]]



Sec. 516.1318  Masitinib.

    (a) Specifications. Each tablet contains 50 or 150 milligrams (mg) 
masitinib mesylate.
    (b) Sponsor. See No. 052913 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. 12.5 mg/kilograms (5.7 
mg/lb) of body weight daily.
    (2) Indications for use. For the treatment of nonresectable Grade II 
or III cutaneous mast cell tumors in dogs that have not previously 
received radiotherapy and/or chemotherapy except corticosteroids.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian. It is a violation of Federal law to 
use this product other than as directed in the labeling.

[76 FR 6327, Feb. 4, 2011, as amended at 77 FR 35837, June 15, 2012]



PART 520_ORAL DOSAGE FORM NEW ANIMAL DRUGS--Table of Contents



Sec.
520.23 Acepromazine.
520.44 Acetazolamide sodium soluble powder.
520.45 Albendazole oral dosage forms.
520.45a Albendazole suspension.
520.45b Albendazole paste.
520.48 Altrenogest.
520.62 Aminopentamide hydrogen sulphate tablets.
520.82 Aminopropazine fumarate oral dosage forms.
520.82a Aminopropazine fumarate tablets.
520.82b Aminopropazine fumarate, neomycin sulfate tablets.
520.88 Amoxicillin oral dosage forms.
520.88a Amoxicillin trihydrate film-coated tablets.
520.88b Amoxicillin trihydrate for oral suspension.
520.88c Amoxicillin trihydrate oral suspension.
520.88d Amoxicillin trihydrate soluble powder.
520.88e Amoxicillin trihydrate boluses.
520.88f Amoxicillin trihydrate tablets.
520.88g Amoxicillin trihydrate and clavulanate potassium film-coated 
          tablets.
520.88h Amoxicillin trihydrate and clavulanate potassium for oral 
          suspension.
520.90 Ampicillin oral dosage forms.
520.90a Ampicillin capsules.
520.90b Ampicillin trihydrate tablets.
520.90c Ampicillin trihydrate capsules.
520.90d Ampicillin trihydrate for oral suspension.
520.90e Ampicillin trihydrate soluble powder.
520.90f Ampicillin trihydrate boluses.
520.100 Amprolium.
520.110 Apramycin sulfate soluble powder.
520.154 Bacitracin oral dosage forms.
520.154a Bacitracin methylene disalicylate.
520.154b Bacitracin methylene disalicylate and streptomycin sulfate 
          powder.
520.154c Bacitracin zinc soluble powder.
520.222 Bunamidine hydrochloride.
520.246 Butorphanol tartrate tablets.
520.260 n-Butyl chloride.
520.300 Cambendazole oral dosage forms.
520.300a Cambendazole suspension.
520.300b Cambendazole pellets.
520.300c Cambendazole paste.
520.309 Carprofen.
520.310 Caramiphen ethanedisulfonate and ammonium chloride tablets.
520.312 Carnidazole tablets.
520.314 Cefadroxil.
520.370 Cefpodoxime tablets.
520.376 Cephalexin.
520.390 Chloramphenicol oral dosage forms.
520.390a Chloramphenicol tablets.
520.390b Chloramphenicol capsules.
520.390c Chloramphenicol palmitate oral suspension.
520.420 Chlorothiazide tablets and boluses.
520.434 Chlorphenesin carbamate tablets.
520.441 Chlortetracycline powder.
520.443 Chlortetracycline tablets and boluses.
520.445 Chlortetracycline and sulfamethazine powder.
520.446 Clindamycin capsules and tablets.
520.447 Clindamycin solution.
520.452 Clenbuterol syrup.
520.455 Clomipramine tablets.
520.462 Clorsulon drench.
520.522 Cyclosporine.
520.530 Cythioate oral liquid.
520.531 Cythioate tablets.
520.534 Decoquinate.
520.538 Deracoxib.
520.540 Dexamethasone oral dosage forms.
520.540a Dexamethasone powder.
520.540b Dexamethasone tablets and boluses.
520.540c Dexamethasone chewable tablets.
520.550 Glucose/glycine/electrolyte.
520.563 Diatrizoate meglumine and diatrizoate sodium oral solution.
520.580 Dichlorophene and toluene.
520.581 Dichlorophene tablets.
520.600 Dichlorvos.
520.606 Diclazuril.
520.608 Dicloxacillin sodium monohydrate capsules.
520.620 Diethylcarbamazine oral dosage forms.
520.622 Diethylcarbamazine citrate oral dosage forms.
520.622a Diethylcarbamazine citrate tablets.

[[Page 119]]

520.622b Diethylcarbamazine citrate syrup.
520.622c Diethylcarbamazine citrate chew- able tablets.
520.622d Diethylcarbamazine citrate capsules.
520.623 Diethylcarbamazine citrate, oxibendazole chewable tablets.
520.645 Difloxacin.
520.666 Dirlotapide.
520.763 Dithiazanine iodide oral dosage forms.
520.763a Dithiazanine iodide tablets.
520.763b Dithiazanine iodide powder.
520.763c Dithiazanine iodide and piperazine citrate suspension.
520.766 Domperidone.
520.784 Doxylamine succinate tablets.
520.804 Enalapril tablets.
520.812 Enrofloxacin.
520.816 Epsiprantel tablets.
520.823 Erythromycin phosphate.
520.852 Estriol.
520.863 Ethylisobutrazine hydrochloride tablets.
520.870 Etodolac.
520.903 Febantel oral dosage forms.
520.903a Febantel paste.
520.903b Febantel suspension.
520.903c [Reserved]
520.903d Febantel-praziquantel paste.
520.903e Febantel tablets.
520.905 Fenbendazole oral dosage forms.
520.905a Fenbendazole suspension.
520.905b Fenbendazole granules.
520.905c Fenbendazole paste.
520.905d Fenbendazole powder.
520.905e Fenbendazole blocks.
520.928 Firocoxib tablets.
520.930 Firocoxib paste.
520.955 Florfenicol.
520.960 Flumethasone tablets.
520.970 Flunixin.
520.980 Fluoxetine.
520.1010 Furosemide.
520.1044 Gentamicin sulfate oral dosage forms.
520.1044a Gentamicin sulfate oral solution.
520.1044b Gentamicin sulfate pig pump oral solution.
520.1044c Gentamicin sulfate powder.
520.1100 Griseofulvin.
520.1120 Haloxon oral dosage forms.
520.1120a Haloxon drench.
520.1120b Haloxon boluses.
520.1130 Hetacillin.
520.1157 Iodinated casein tablets.
520.1158 Iodochlorhydroxyquin boluses.
520.1182 Iron dextran suspension.
520.1192 Ivermectin paste.
520.1193 Ivermectin tablets and chewables.
520.1194 Ivermectin meal.
520.1195 Ivermectin liquid.
520.1196 Ivermectin and pyrantel pamoate chewable tablets.
520.1197 Ivermectin sustained-release bolus.
520.1198 Ivermectin and praziquantel paste.
520.1199 Ivermectin, pyrantel, and praziquantel tablets.
520.1200 Ivermectin, fenbendazole, and praziquantel tablets.
520.1204 Kanamycin, bismuth subcarbonate, activated attapulgite.
520.1242 Levamisole.
520.1242a Levamisole powder.
520.1242b Levamisole hydrochloride tablet or oblet (bolus).
520.1242c Levamisole hydrochloride and piperazine dihydrochloride.
520.1242d Levamisole resinate.
520.1242e Levamisole hydrochloride effervescent tablets.
520.1242f Levamisole hydrochloride gel.
520.1242g Levamisole resinate and famphur paste.
520.1263 Lincomycin.
520.1263a Lincomycin hydrochloride monohydrate tablets and sirup.
520.1263b [Reserved]
520.1263c Lincomycin powder.
520.1265 Lincomycin and spectinomycin powder.
520.1284 Sodium liothyronine tablets.
520.1288 Lufenuron tablets.
520.1289 Lufenuron suspension.
520.1310 Marbofloxacin tablets.
520.1315 Maropitant.
520.1320 Mebendazole oral.
520.1326 Mebendazole and trichlorfon oral dosage forms.
520.1326a Mebendazole and trichlorfon powder.
520.1326b Mebendazole and trichlorfon paste.
520.1330 Meclofenamic acid granules.
520.1331 Meclofenamic acid tablets.
520.1341 Megestrol acetate tablets.
520.1350 Meloxicam.
520.1372 Methimazole.
520.1380 Methocarbamol tablets.
520.1408 Methylprednisolone tablets.
520.1409 Methylprednisolone, aspirin tablets.
520.1422 Metoserpate hydrochloride.
520.1430 Mibolerone.
520.1441 Milbemycin oxime.
520.1443 Milbemycin oxime and lufenuron.
520.1445 Milbemycin oxime and praziquantel.
520.1447 Milbemycin oxime, lufenuron, and praziquantel tablets.
520.1450 Morantel tartrate oral dosage forms.
520.1450a Morantel tartrate bolus.
520.1450b Morantel tartrate cartridge.
520.1450c Morantel tartrate sustained-release trilaminate cylinder/
          sheet.
520.1451 Moxidectin tablets.
520.1452 Moxidectin gel.
520.1453 Moxidectin and praziquantel gel.
520.1454 Moxidectin solution.
520.1468 Naproxen granules.
520.1484 Neomycin.
520.1510 Nitenpyram tablets.
520.1615 Omeprazole.

[[Page 120]]

520.1616 Orbifloxacin tablets..
520.1618 Orbifloxacin suspension.
520.1628 Oxfendazole powder and pellets.
520.1629 Oxfendazole paste.
520.1630 Oxfendazole suspension.
520.1631 Oxfendazole and trichlorfon paste.
520.1638 Oxibendazole paste.
520.1640 Oxibendazole suspension.
520.1660 Oxytetracycline.
520.1660a Oxytetracycline and carbomycin in combination.
520.1660b Oxytetracycline hydrochloride capsules.
520.1660c Oxytetracycline hydrochloride tablets/boluses.
520.1660d Oxytetracycline powder.
520.1696 Penicillin.
520.1696a [Reserved]
520.1696b Penicillin G powder.
520.1696c Penicillin V powder.
520.1696d Penicillin V tablets.
520.1705 Pergolide.
520.1720 Phenylbutazone oral dosage forms.
520.1720a Phenylbutazone tablets and boluses.
520.1720b Phenylbutazone granules.
520.1720c Phenylbutazone paste.
520.1720d Phenylbutazone gel.
520.1720e Phenylbutazone powder.
520.1760 Phenylpropanolamine.
520.1780 Pimobendan.
520.1802 Piperazine-carbon disulfide complex oral dosage forms.
520.1802a Piperazine-carbon disulfide complex suspension.
520.1802b Piperazine-carbon disulfide complex boluses.
520.1802c Piperazine-carbon disulfide complex with phenothiazine 
          suspension.
520.1803 Piperazine citrate capsules.
520.1804 Piperazine phosphate capsules.
520.1805 Piperazine phosphate with thenium closylate tablets.
520.1806 Piperazine suspension.
520.1807 Piperazine.
520.1840 Poloxalene.
520.1846 Polyoxyethylene (23) lauryl ether blocks.
520.1855 Ponazuril.
520.1860 Pradofloxacin.
520.1870 Praziquantel tablets.
520.1871 Praziquantel and pyrantel.
520.1872 Praziquantel, pyrantel pamoate, and febantel tablets.
520.1880 Prednisolone tablets.
520.1900 Primidone tablets.
520.1920 Prochlorperazine, isopropamide sustained release capsules.
520.1921 Prochlorperazine, isopropamide, with neomycin sustained-release 
          capsules.
520.1962 Promazine hydrochloride.
520.2002 Propiopromazine hydrochloride.
520.2041 Pyrantel pamoate chewable tablets.
520.2042 Pyrantel pamoate tablets.
520.2043 Pyrantel pamoate suspension.
520.2044 Pyrantel pamoate paste.
520.2045 Pyrantel tartrate powder; pyrantel tartrate pellets.
520.2075 Robenacoxib.
520.2087 Roxarsone soluble powder.
520.2088 Roxarsone tablets.
520.2089 Roxarsone liquid.
520.2098 Selegiline hydrochloride tablets.
520.2100 Selenium, vitamin E capsules.
520.2123 Spectinomycin oral dosage forms.
520.2123a Spectinomycin tablets.
520.2123b Spectinomycin powder.
520.2123c Spectinomycin solution.
520.2130 Spinosad.
520.2134 Spinosad and milbemycin.
520.2150 Stanozolol oral dosage forms.
520.2150a Stanozolol tablets.
520.2150b Stanozolol chewable tablets.
520.2158 Streptomycin/dihydrostreptomycin oral dosage forms.
520.2158a Streptomycin sulfate oral solution.
520.2158b Dihydrostreptomycin tablets.
520.2158c Dihydrostreptomycin oral suspension.
520.2160 Styrylpyridinium, diethylcarbamazine oral dosage forms.
520.2170 Sulfabromomethazine sodium boluses.
520.2184 Sodium sulfachloropyrazine monohydrate.
520.2200 Sulfachlorpyridazine.
520.2215 Sulfadiazine/pyrimethamine suspension.
520.2218 Sulfamerazine, sulfamethazine, and sulfaquinoxaline powder.
520.2220 Sulfadimethoxine oral dosage forms.
520.2220a Sulfadimethoxine oral solution and soluble powder.
520.2220b Sulfadimethoxine tablets and boluses.
520.2220c Sulfadimethoxine oral suspension.
520.2220d Sulfadimethoxine-ormetoprim tablets.
520.2240 Sulfaethoxypyridazine.
520.2240a Sulfaethoxypyridazine drinking water.
520.2240b Sulfaethoxypyridazine tablets.
520.2260 Sulfamethazine oral dosage forms.
520.2260a Sulfamethazine oblet, tablet, and bolus.
520.2260b Sulfamethazine sustained-release boluses.
520.2260c Sulfamethazine sustained-release tablets.
520.2261 Sulfamethazine sodium oral dosage forms.
520.2261a Sulfamethazine solution.
520.2261b Sulfamethazine powder.
520.2280 Sulfamethizole and methenamine mandelate tablets.
520.2325 Sulfaquinoxaline oral dosage forms.
520.2325a Sulfaquinoxaline drinking water.
520.2325b Sulfaquinoxaline drench.
520.2330 Sulfisoxazole tablets.
520.2340 Tepoxalin.
520.2345 Tetracycline.

[[Page 121]]

520.2345a Tetracycline hydrochloride capsules.
520.2345b Tetracycline tablets.
520.2345c Tetracycline boluses.
520.2345d Tetracycline powder.
520.2345e Tetracycline oral liquid.
520.2345f Tetracycline phosphate complex and sodium novobiocin capsules.
520.2345g Tetracycline hydrochloride and sodium novobiocin tablets.
520.2345h Tetracycline hydrochloride, sodium novobiocin, and 
          prednisolone tablets.
520.2362 Thenium closylate tablets.
520.2380 Thiabendazole oral dosage forms.
520.2380a Thiabendazole top dressing and mineral protein block.
520.2380b Thiabendazole drench or oral paste.
520.2380c Thiabendazole bolus.
520.2380d Thiabendazole, piperazine citrate suspension.
520.2380e Thiabendazole with trichlorfon.
520.2380f Thiabendazole, piperazine phosphate powder.
520.2455 Tiamulin.
520.2473 Tioxidazole oral dosage forms.
520.2473a Tioxidazole granules.
520.2473b Tioxidazole paste.
520.2475 Toceranib.
520.2481 Triamcinolone acetonide tablets.
520.2482 Triamcinolone acetonide oral powder.
520.2483 Triamcinolone.
520.2520 Trichlorfon oral dosage forms.
520.2520b Trichlorfon and atropine.
520.2520e Trichlorofon boluses.
520.2520f Trichlorofon granules.
520.2520g Trichlorfon, phenothiazine, and piperazine dihydrochloride 
          powder.
520.2582 Triflupromazine hydrochloride tablets.
520.2598 Trilostane.
520.2604 Trimeprazine tartrate and prednisolone tablets.
520.2605 Trimeprazine tartrate and prednisolone capsules.
520.2610 Trimethoprim and sulfadiazine tablets.
520.2611 Trimethoprim and sulfadiazine paste.
520.2612 Trimethoprim and sulfadiazine oral suspension.
520.2613 Trimethoprim and sulfadiazine powder.
520.2640 Tylosin.
520.2645 Tylvalosin.

    Authority: 21 U.S.C. 360b.

    Source: 40 FR 13838, Mar. 27, 1975, unless otherwise noted.



Sec. 520.23  Acepromazine.

    (a) Specifications. Each tablet contains 5, 10, or 25 milligrams 
(mg) acepromazine maleate.
    (b) Sponsors. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. 0.25 to 1.0 mg per 
pound (/lb) body weight orally.
    (ii) Indications for use. As an aid in tranquilization and as a 
preanesthetic agent.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Cats--(i) Amount. 0.5 to 1.0 mg/lb body weight orally.
    (ii) Indications for use. As a tranquilizer.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

[75 FR 10165, Mar. 5, 2010]



Sec. 520.44  Acetazolamide sodium soluble powder.

    (a) Specifications. The drug is in a powder form containing 
acetazolamide sodium, USP equivalent to 25 percent acetazolamide 
activity.
    (b) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is used in dogs as an aid in the 
treatment of mild congestive heart failure and for rapid reduction of 
intraocular pressure.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (2) It is administered orally at a dosage level of 5 to 15 
milligrams per pound of body weight daily.\1\
    (3) For use only by or on the order of a licensed veterinarian.\1\

[40 FR 13838, Mar. 27, 1975, as amended at 67 FR 78355, Dec. 24, 2002]



Sec. 520.45  Albendazole oral dosage forms.



Sec. 520.45a  Albendazole suspension.

    (a) Specifications. Each milliliter of suspension contains 45.5 
milligrams (mg) (4.55 percent) or 113.6 mg (11.36 percent) albendazole.
    (b) Sponsor. See No. 000069 in Sec. 510.600 of this chapter.
    (c) Related tolerances. See Sec. 556.34 of this chapter.

[[Page 122]]

    (d) Special considerations. See Sec. 500.25 of this chapter.
    (e) Conditions of use--(1) Cattle. Administer 11.36 percent 
suspension:
    (i) Amount. 4.54 mg/pound (lb) body weight (10 mg/kilogram (kg)) as 
a single oral dose using dosing gun or dosing syringe.
    (ii) Indications for use. For removal and control of adult liver 
flukes (Fasciola hepatica); heads and segments of tapeworms (Moniezia 
benedeni and M. expansa); adult and 4th stage larvae of stomach worms 
(brown stomach worms including 4th stage inhibited larvae (Ostertagia 
ostertagi), barberpole worm (Haemonchus contortus and H. placei), small 
stomach worm (Trichostrongylus axei)); adult and 4th stage larvae of 
intestinal worms (thread-necked intestinal worm (Nematodirus spathiger 
and N. helvetianus), small intestinal worm (Cooperia punctata and C. 
oncophora)); adult stages of intestinal worms (hookworm (Bunostomum 
phlebotomum), bankrupt worm (Trichostrongylus colubriformis), nodular 
worm (Oesophagostomum radiatum)); adult and 4th stage larvae of 
lungworms (Dictyocaulus viviparus).
    (iii) Limitations. Do not slaughter within 27 days of last 
treatment. Do not use in female dairy cattle of breeding age: Do not 
administer to female cattle during first 45 days of pregnancy or for 45 
days after removal of bulls.
    (2) Sheep. Administer 4.45 or 11.36 percent suspension:
    (i) Amount. 3.4 mg/lb body weight (7.5 mg/kg) as a single oral dose 
using dosing gun or dosing syringe.
    (ii) Indications for use. For removal and control of adult liver 
flukes (Fasciola hepatica and Fascioloides magna); heads and segments of 
common tapeworms (Moniezia expansa) and fringed tapeworm (Thysanosoma 
actinioides); adult and fourth stage larvae of stomach worms (brown 
stomach worm (Ostertagia circumcinta and Marshallagia marshalli), 
barberpole worm (Haemonchus contortus), small stomach worm 
(Trichostrongylus axei)); adult and fourth stage larvae of intestinal 
worms (thread-necked intestinal worm (Nematodirus spathiger and N. 
filicollis), Cooper's worm (Cooperia oncophora), bankrupt worm 
(Trichostrongylus colubriformis), nodular worm (Oesophagostomum 
columbianum), and large-mouth bowel worm (Chabertia ovina)); adult and 
larval stages of lungworms (Dictyocaulus filaria).
    (iii) Limitations. Do not slaughter within 7 days of last treatment. 
Do not administer to ewes during first 30 days of pregnancy or for 30 
days after removal of rams.
    (3) Goats. Administer 11.36 percent suspension:
    (i) Amount. 4.54 mg/lb body weight (10 mg/kg) as a single oral dose 
using dosing gun or dosing syringe.
    (ii) Indications for use. For the treatment of adult liver flukes 
(Fasciola hepatica) in nonlactating goats.
    (iii) Limitations. Do not slaughter within 7 days of last treatment. 
Do not administer to does during the first 30 days of pregnancy or for 
30 days after removal of bucks.

[73 FR 11027, Feb. 29, 2008]



Sec. 520.45b  Albendazole paste.

    (a) Specifications. The product contains 30 percent albendazole.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.34 of this chapter.
    (d) Conditions of use in cattle--(1) Amount. Equivalent to 4.54 
milligrams per 1 pound of body weight (10 milligrams per kilogram).
    (2) Indications for use. For removal and control of the following 
internal parasites of cattle: adult liver flukes (Fasciola hepatica); 
heads and segments of tapeworms (Moniezia benedeni, M. expansa); adult 
and 4th stage larvae of stomach worms (brown stomach worms including 4th 
stage inhibited larvae (Ostertagia ostertagi); barberpole worm 
(Haemonchus contortus, H. placei); small stomach worm (Trichostrongylus 
axei)); adult and 4th stages larvae of intestinal worms (thread-necked 
intestinal worm (Nematodirus spathiger, N. helvetianus); small 
intestinal worm (Cooperia punctata and C. oncophora)); adult stages of 
intestinal worms (hookworm (Bunostomum phlebotmum); bankrupt worm 
(Trichostrongylus colubriformis), nodular worm (Oesophagostomum 
radiatum)); adult and 4th stage larvae of lungworms (Dictyocaulus 
viviparus).

[[Page 123]]

    (3) Limitations. Administer as a single oral dose. Do not slaughter 
within 27 days of last treatment. Do not use in female dairy cattle of 
breeding age. Do not administer to female cattle during first 45 days of 
pregnancy or for 45 days after removal of bulls. Consult your 
veterinarian for assistance in the diagnosis, treatment, and control of 
parasitism.

[54 FR 51385, Dec. 15, 1989, as amended at 56 FR 50653, Oct. 8, 1991; 60 
FR 55658, Nov. 2, 1995]



Sec. 520.48  Altrenogest.

    (a) Specifications. Each milliliter (mL) of solution contains 2.2 
milligrams (mg) altrenogest.
    (b) Sponsors. See sponsor listings in Sec. 510.600(c) of this 
chapter:
    (1) No. 000061 for use as in paragraph (d) of this section.
    (2) No. 013744 for use as in paragraph (d)(1) of this section.
    (c) Tolerances. See Sec. 556.36 of this chapter.
    (d) Conditions of use--(1) Horses--(i) Amount. 1.0 mL per 110 pounds 
body weight (0.044 mg/kg) daily for 15 consecutive days.
    (ii) Indications for use. For suppression of estrus in mares.
    (iii) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.
    (2) Swine--(i) Amount. Administer 6.8 mL (15 mg altrenogest) per 
gilt once daily for 14 consecutive days by top-dressing on a portion of 
each gilt's daily feed.
    (ii) Indications for use. For synchronization of estrus in sexually 
mature gilts that have had at least one estrous cycle.
    (iii) Limitations. Do not use in gilts having a previous or current 
history of uterine inflammation (i.e., acute, subacute or chronic 
endometritis). Gilts must not be slaughtered for human consumption for 
21 days after the last treatment.

[66 FR 47960, Sept. 17, 2001, as amended at 68 FR 62006, Oct. 31, 2003; 
72 FR 9455, Feb. 21, 2008; 74 FR 61516, Nov. 25, 2009; 77 FR 32012, May 
31, 2012]



Sec. 520.62  Aminopentamide hydrogen sulphate tablets.

    (a) Chemical name. 4-(Dimethylamino)-2,2-diphenylvaleramide hydrogen 
sulfate.
    (b) Specifications. Each tablet contains 0.2 milligram of the drug.
    (c) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) It is intended for use in dogs and cats 
only for the treatment of vomiting and/or diarrhea, nausea, acute 
abdominal visceral spasm, pylorospasm, or hypertrophic gastritis.

    Note: Not for use in animals with glaucoma because of the occurrence 
of mydriasis.

    (2) Dosage is administered by oral tablet every 8 to 12 hours, as 
follows:

------------------------------------------------------------------------
                                                               Dosage in
                 Weight of animal in pounds                   milligrams
------------------------------------------------------------------------
Up to 10....................................................         0.1
11 to 20....................................................         0.2
21 to 50....................................................         0.3
51 to 100...................................................         0.4
Over 100....................................................         0.5
------------------------------------------------------------------------


Dosage may be gradually increased up to a maximum of five times the 
suggested dosage. Oral administration of tablets may be preceded by 
subcutaneous or intramuscular use of the injectable form of the drug.
    (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 53 FR 27851, July 25, 1988]



Sec. 520.82  Aminopropazine fumarate oral dosage forms.



Sec. 520.82a  Aminopropazine fumarate tablets.

    (a) Specifications. The drug is in tablet form. Each tablet contains 
aminopropazine fumarate equivalent to 25 milligrams of aminopropazine 
base.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used in dogs and cats for 
reducing excessive smooth muscle contractions, such as occur in urethral 
spasms associated with urolithiasis.\1\
    (2) It is administered at a dosage level of 1 to 2 milligrams per 
pound of body weight. The dosage can be repeated every 12 hours, as 
indicated.\1\

[[Page 124]]

    (3) Not for use in animals intended for food purposes.
    (4) For use only by or on the order of a licensed veterinarian.\1\

[40 FR 13838, Mar. 27, 1975, as amended at 46 FR 48642, Oct. 2, 1981; 61 
FR 8873, Mar. 6, 1996; 62 FR 61624, Nov. 19, 1997]



Sec. 520.82b  Aminopropazine fumarate, neomycin sulfate tablets.

    (a) Specifications. The drug is in tablet form. Each tablet contains 
both aminopropazine fumarate equivalent to 25 milligrams of 
aminopropazine base and neomycin sulfate equivalent to 50 milligrams of 
neomycin base.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used in dogs to control 
bacterial diarrhea caused by organisms susceptible to neomycin and to 
reduce smooth muscle contractions.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (2) It is administered at a dosage level of one to two tablets per 
10 pounds of body weight twice daily for 3 days.\1\
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.\1\

[40 FR 13838, Mar. 27, 1975, as amended at 46 FR 48642, Oct. 2, 1981; 61 
FR 8873, Mar. 6, 1996; 62 FR 61624, Nov. 19, 1997]



Sec. 520.88  Amoxicillin oral dosage forms.



Sec. 520.88a  Amoxicillin trihydrate film-coated tablets.

    (a) Specifications. Each tablet contains amoxicillin trihydrate 
equivalent to 50, 100, 150, 200, or 400 milligrams of amoxicillin.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. 5 milligrams per pound 
of body weight, twice a day.
    (ii) Indications for use. Treatment of infections of the respiratory 
tract (tonsillitis, tracheobronchitis), genitourinary tract (cystitis), 
gastrointestinal tract (bacterial gastroenteritis), and soft tissues 
(abscesses, lacerations, wounds), caused by susceptible strains of 
Staphylococcus aureus, Streptococcus spp., Escherichia coli, Proteus 
mirabilis, and bacterial dermatitis caused by S. aureus, Streptococcus 
spp., and P. mirabilis.
    (iii) Limitations. Administer for 5 to 7 days or 48 hours after all 
symptoms have subsided. If no improvement is seen in 5 days, review 
diagnosis and change therapy. Federal law restricts this drug to use by 
or on the order of a licensed veterinarian.
    (2) Cats--(i) Amount. 50 milligrams (5 to 10 milligrams per pound of 
body weight) once a day.
    (ii) Indications for use. Treatment of infections caused by 
susceptible organisms as follows: upper respiratory tract due to S. 
aureus, Streptococcus spp., and E. coli; genitourinary tract (cystitis) 
due to S. aureus, Streptococcus spp., E. coli, and P. mirabilis; 
gastrointestinal tract due to E. coli; and skin and soft tissue 
(abscesses, lacerations, and wounds) due to S. aureus, Streptococcus 
spp., E. coli, and Pasteurella multocida.
    (iii) Limitations. Administer for 5 to 7 days or 48 hours after all 
symptoms have subsided. If no improvement is seen in 5 days, review 
diagnosis and change therapy. Federal law restricts this drug to use by 
or on the order of a licensed veterinarian.

[57 FR 37319, Aug. 18, 1992, as amended at 60 FR 55658, Nov. 2, 1995]



Sec. 520.88b  Amoxicillin trihydrate for oral suspension.

    (a) Specifications. When reconstituted, each milliliter contains 
amoxicillin trihydrate equivalent to 50 milligrams of amoxicillin.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (1) Conditions of use--(i) Dogs--(A) Amount. 5 milligrams per pound 
of body weight twice daily.
    (B) Indications for use. Treatment of infections caused by 
susceptible strains of organisms as follows: respiratory tract 
(tonsillitis, tracheobronchitis) caused by Staphylococcus aureus, 
Streptococcus spp., Escherichia coli, and Proteus mirabilis; 
genitourinary tract (cystitis) caused by S. aureus, Streptococcus spp., 
E. coli, and P. mirabilis; gastrointestinal tract (bacterial

[[Page 125]]

gastroenteritis) caused by S. aureus, Streptococcus spp., E. coli, and 
P. mirabilis; bacterial dermatitis caused by S. aureus, Streptococcus 
spp., and P. mirabilis; and soft tissues (abscesses, lacerations, and 
wounds) caused by S. aureus, Streptococcus spp., E. coli, and P. 
mirabilis.
    (C) Limitations. Use for 5 to 7 days or 48 hours after all symptoms 
have subsided. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.
    (ii) Cats--(A) Amount. 50 milligrams (5 to 10 milligrams per pound) 
once daily.
    (B) Indications for use. Treatment of infections caused by 
susceptible strains of organisms as follows: upper respiratory tract due 
to Staphylococcus spp., Streptococcus spp., Hemophilus spp., E. coli, 
Pasteurella spp., and P. mirabilis; genitourinary tract (cystitis) due 
to S. aureus, Streptococcus spp., E. coli, P. mirabilis, and 
Corynebacterium spp.; gastrointestinal tract due to E. coli, Proteus 
spp., Staphylococcus spp., and Streptococcus spp.; skin and soft tissue 
(abscesses, lacerations, and wounds) due to Staphylococcus spp., 
Streptococcus spp., E. coli, and Pasteurella multocida.
    (C) Limitations. Use for 5 to 7 days or 48 hours after all symptoms 
have subsided. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.
    (2) [Reserved]
    (c) Sponsors. See Nos. 000856 and 051311 in Sec. 510.600(c) of this 
chapter.
    (1) Conditions of use. Dogs--(i) Amount. 5 milligrams per pound of 
body weight twice daily.
    (ii) Indications for use. Treatment of bacterial dermatitis due to 
S. aureus, Streptococcus spp., Staphylococcus spp., and E. coli, and 
soft tissue infections (abscesses, wounds, lacerations) due to S. 
aureus, Streptococcus spp., E. coli, P. mirabilis and Staphylococcus 
spp.
    (iii) Limitations. Use for 5 to 7 days. Continue for 48 hours after 
all symptoms have subsided. If no improvement is seen in 5 days, review 
diagnosis and change therapy. Federal law restricts this drug to use by 
or on the order of a licensed veterinarian.
    (2) [Reserved]

[57 FR 37319, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992, as amended at 
60 FR 55658, Nov. 2, 1995; 62 FR 13302, Mar. 20, 1997; 67 FR 67521, Nov. 
6, 2002; 68 FR 54658, Sept. 18, 2003; 68 FR 55824, Sept. 29, 2003]



Sec. 520.88c  Amoxicillin trihydrate oral suspension.

    (a) Specifications. Each 0.8-milliliter dose contains amoxicillin 
trihydrate equivalent to 40 milligrams of amoxicillin.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.510 of this chapter.
    (d) Conditions of use. Swine--(1) Amount. 40 milligrams orally, 
twice a day using a dosing pump.
    (2) Indications for use. Treatment of baby pigs under 10 pounds for 
porcine colibacillosis caused by Escherichia coli susceptible to 
amoxicillin.
    (3) Limitations. Treat animals for 48 hours after all symptoms have 
subsided but not beyond 5 days. Do not slaughter during treatment or for 
15 days after latest treatment. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.

[57 FR 37319, Aug. 18, 1992, as amended at 60 FR 55658, Nov. 2, 1995]



Sec. 520.88d  Amoxicillin trihydrate soluble powder.

    (a) Specifications. Each gram contains amoxicillin trihydrate 
equivalent to 115.4 milligrams of amoxicillin.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.38 of this chapter.
    (d) Conditions of use. Preruminating calves including veal calves--
(1) Amount. 400 milligrams per 100 pounds of body weight twice daily.
    (2) Indications for use. Treatment of bacterial enteritis when due 
to susceptible Escherichia coli in preruminating calves including veal 
calves.
    (3) Limitations. Administer by drench or by mixing in milk. 
Treatment should be continued for 48 hours after all symptoms have 
subsided but not to exceed 5 days. For use in preruminating calves 
including veal

[[Page 126]]

calves only, not for use in other animals which are raised for food 
production. Do not slaughter animals during treatment or for 20 days 
after the latest treatment. Federal law restricts this drug to use by or 
on the order of a licensed veterinarian.

[57 FR 37319, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992; 58 FR 18304, 
Apr. 8, 1993, as amended at 60 FR 55658, Nov. 2, 1995; 62 FR 5525, Feb. 
6, 1997]



Sec. 520.88e  Amoxicillin trihydrate boluses.

    (a) Specifications. Each bolus contains the equivalent of 400 
milligrams of amoxicillin.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.38 of this chapter.
    (d) Conditions of use. Preruminating calves including veal calves--
(1) Amount. 400 milligrams per 100 pounds of body weight twice daily.
    (2) Indications for use. Treatment of bacterial enteritis when due 
to susceptible Escherichia coli in preruminating calves including veal 
calves.
    (3) Limitations. For oral use in preruminating calves including veal 
calves only, not for use in other animals which are raised for food 
production. Treatment should be continued for 48 hours after all 
symptoms have subsided but not to exceed 5 days. Do not slaughter 
animals during treatment or for 20 days after the latest treatment. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.

[57 FR 37320, Aug. 18, 1992, as amended at 60 FR 55659, Nov. 2, 1995; 62 
FR 5526, Feb. 6, 1997]



Sec. 520.88f  Amoxicillin trihydrate tablets.

    (a) Specifications. Each tablet contains amoxicillin trihydrate 
equivalent to 50, 100, 200, or 400 milligrams of amoxicillin.
    (b) Sponsors. See Nos. 000856 and 051311 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. 5 milligrams per pound 
of body weight twice a day.
    (ii) Indications for use. Treatment of bacterial dermatitis due to 
Staphylococcus aureus, Streptococcus spp., Staphylococcus spp., and 
Escherichia coli; and soft tissue infections (abscesses, wounds, 
lacerations) due to S. aureus, Streptococcus spp., E. coli, Proteus 
mirabilis, and Staphylococcus spp.
    (iii) Limitations. Use for 5 to 7 days or 48 hours after all 
symptoms have subsided. If no improvement is seen in 5 days, review 
diagnosis and change therapy. Federal law restricts this drug to use by 
or on the order of a licensed veterinarian.
    (2) [Reserved]

[57 FR 37320, Aug. 18, 1992, as amended at 62 FR 13302, Mar. 20, 1997; 
67 FR 67521, Nov. 6, 2002; 68 FR 54658, Sept. 18, 2003; 68 FR 55824, 
Sept. 29, 2003]



Sec. 520.88g  Amoxicillin trihydrate and clavulanate potassium 
film-coated tablets.

    (a) Specifications. Each tablet contains amoxicillin trihydrate and 
clavulanate potassium, equivalent to either 50 milligrams of amoxicillin 
and 12.5 milligrams clavulanic acid, or 100 milligrams of amoxicillin 
and 25 milligrams clavulanic acid, or 200 milligrams amoxicillin and 50 
milligrams clavulanic acid or 300 milligrams amoxicillin and 75 
milligrams clavulanic acid.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. 6.25 milligrams 
(equivalent to 5 milligrams amoxicillin and 1.25 milligrams clavulanic 
acid) per pound of body weight twice daily.
    (ii) Indications for use. Treatment of skin and soft tissue 
infections such as wounds, abscesses, cellulitis, superficial/juvenile 
and deep pyoderma due to susceptible strains of beta-lactamase 
(penicillinase) Staphylococcus aureus, nonbeta-lactamase S. aureus, 
Staphylococcus spp., Streptococcus spp., and Escherichia coli. Treatment 
of periodontal infections due to susceptible strains of aerobic and 
anaerobic bacteria.
    (iii) Limitations. Wounds, abscesses, cellulitis, and superficial/
juvenile pyoderma: Treat for 5 to 7 days or for 48 hours after all signs 
have subsided. If no improvement is seen after 5 days of treatment, 
discontinue therapy and reevaluate diagnosis. Deep pyoderma may require 
treatment for 21 days; do not treat for more than 30 days. Not for

[[Page 127]]

use in dogs maintained for breeding. Federal law restricts this drug to 
use by or on the order of a licensed veterinarian.
    (2) Cats--(i) Amount. 62.5 milligrams (1 milliliter) (50 milligrams 
amoxicillin and 12.5 milligrams clavulanic acid) twice daily.
    (ii) Indications for use. Treatment of skin and soft tissue 
infections, such as wounds, abscesses and cellulitis/dermatitis due to 
susceptible strains of beta-lactamase (penicillinase) producing S. 
aureus, nonbeta-lactamase producing S. aureus, Staphylococcus spp., 
Streptococcus spp., E. coli, and Pasteurella spp. Also, treatment of 
urinary tract infections (cystitis) due to susceptible strains of E. 
coli.
    (iii) Limitations. Skin and soft tissue infections: abscesses, 
cellulitis/dermatitis should be treated for 5 to 7 days or for 48 hours 
after all signs have subsided. If no response is seen after 3 days of 
treatment, therapy should be discontinued and diagnosis reevaluated. 
Urinary tract infections may require treatment for 10 to 14 days or 
longer. The maximum duration of treatment should not exceed 30 days. 
Safety of use in pregnant or breeding animals has not been established. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.

[57 FR 37320, Aug. 18, 1992, as amended at 60 FR 55659, Nov. 2, 1995; 63 
FR 13121, Mar. 18, 1998]



Sec. 520.88h  Amoxicillin trihydrate and clavulanate potassium for 
oral suspension.

    (a) Specifications. When reconstituted, each milliliter contains 
amoxicillin trihydrate equivalent to 50 milligrams of amoxicillin with 
clavulanate potassium equivalent to 12.5 milligrams of clavulanic acid.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. 6.25 milligrams 
(equivalent to 5 milligrams amoxicillin and 1.25 milligrams clavulanic 
acid) per pound of body weight twice daily.
    (ii) Indications for use. Treatment of skin and soft tissue 
infections such as wounds, abscesses, cellulitis, superficial/juvenile 
and deep pyoderma due to susceptible strains of beta-lactamase 
(penicillinase) producing Staphylococcus aureus, nonbeta-lactamase 
Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and 
Escherichia coli. Treatment of periodontal infections due to susceptible 
strains of aerobic and anaerobic bacteria.
    (iii) Limitations. Administer for 5 to 7 days or 48 hours after all 
symptoms subsided. Deep pyoderma may require 21 days, not to exceed 30 
days. If no improvement is seen in 5 days, discontinue therapy and 
reevaluate the case. Not for use in dogs maintained for breeding. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.
    (2) Cats--(i) Amount. 62.5 milligrams (1 milliliter) (50 milligrams 
of amoxicillin and 12.5 milligrams clavulanic acid) twice daily.
    (ii) Indications for use. Treatment of feline skin and soft tissue 
infections, such as wounds, abscesses and cellulitis/dermatitis due to 
susceptible strains of beta-lactamase (penicillinase) producing S. 
aureus, nonbeta-lactamase S. aureus, Staphylococcus spp., Streptococcus 
spp., E. coli, Pasteurella multocida, and Pasteurella spp.
    (iii) Limitations. Administer 48 hours after all symptoms have 
subsided. If no improvement is seen after 3 days of treatment, 
discontinue therapy and reevaluate diagnosis. Maximum duration of 
treatment should not exceed 30 days. Not for use in cats maintained for 
breeding. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[57 FR 37320, Aug. 18, 1992, as amended at 60 FR 55659, Nov. 2, 1995; 63 
FR 13121, Mar. 18, 1998]



Sec. 520.90  Ampicillin oral dosage forms.



Sec. 520.90a  Ampicillin capsules.

    (a) Specifications. Each capsule contains 125 milligrams or 250 
milligrams of ampicillin.
    (b) Sponsor. See No. 000008 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. 5 to 10 milligrams per 
pound of body weight, e.g., one 125 mg capsule per 14 to 25 pounds, 
given 2 to 4 times

[[Page 128]]

daily; for animals weighing 6 to 14 pounds, one capsule twice daily.
    (ii) Indications for use. Treatment of urinary tract infections 
(cystitis) due to Proteus spp., hemolytic and nonhemolytic streptococci, 
beta hemolytic streptococci, and Escherichia coli. In upper respiratory 
tract infections tracheobronchitis (kennel cough), tonsillitis due to 
alpha and beta hemolytic streptococci, hemolytic positive staphylococci, 
E. coli, and Proteus spp. In infections associated with abscesses, 
lacerations, and wounds due to Staphylococcus spp. and Streptococcus 
spp.
    (iii) Limitations. Bacteriologic studies to determine the causative 
organisms and their susceptibility to ampicillin should be performed. 
Use of the drug is contraindicated in animals with a history of an 
allergic reaction to any of the penicillins. Ampicillin is 
contraindicated in infections caused by penicillinase-producing 
organisms. Not for use in animals which are raised for food production. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.
    (2) Cats--(i) Amount. 125 milligrams twice daily; in more acute 
conditions three times daily.
    (ii) Indications for use. Treatment of respiratory tract infections 
(bacterial pneumonia) due to alpha and beta hemolytic streptococci, 
hemolytic positive staphylococci, E. coli, and Proteus spp. In 
infections associated with abscesses, lacerations, and wounds due to 
Staphylococcus spp. and Streptococcus spp.
    (iii) Limitations. Bacteriologic studies to determine the causative 
organisms and their susceptibility to ampicillin should be performed. 
Use of the drug is contraindicated in animals with a history of an 
allergic reaction to any of the penicillins. Ampicillin is 
contraindicated in infections caused by penicillinase-producing 
organisms. Not for use in animals which are raised for food production. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.

[57 FR 37321, Aug. 18, 1992]



Sec. 520.90b  Ampicillin trihydrate tablets.

    (a) Specifications. Each tablet contains ampicillin trihydrate 
equivalent to 50 or 100 milligrams of ampicillin.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. Dogs--(1) Amount. 5 milligrams per pound of 
body weight, at 8-hour intervals, 1 to 2 hours prior to feeding, to be 
continued 36 to 48 hours after all symptoms have subsided. If no 
improvement is seen within 5 days, stop treatment, reevaluate diagnosis, 
and change therapy.
    (2) Indications for use. Oral treatment of infections caused by 
susceptible organisms as follows: Upper respiratory infections, 
tonsillitis, and bronchitis due to Streptococcus spp., Staphylococcus 
spp., Escherichia coli, Proteus mirabilis, and Pasteurella spp., urinary 
tract infections (cystitis) due to Streptococcus spp., Staphylococcus 
spp., E., coli, P. mirabilis, and Enterococcus spp.; gastrointestinal 
infections due to Staphylococcus spp., Streptococcus spp., Enterococcus 
spp., and E. coli. ; infections associated with abscesses, lacerations, 
and wounds caused by Staphylococcus spp., and Streptococcus spp.
    (3) Limitations. Not for use in animals which have shown 
hypersensitivity to penicillin or for infections caused by 
penicillinase-producing organisms. Not for use in animals which are 
raised for food production. Federal law restricts this drug to use by or 
on the order of a licensed veterinarian.

[57 FR 37321, Aug. 18, 1992, as amended at 60 FR 55659, Nov. 2, 1995]



Sec. 520.90c  Ampicillin trihydrate capsules.

    (a) Specifications. Each capsule contains ampicillin trihydrate 
equivalent to 125, 250, or 500 milligrams of ampicillin.
    (b) Sponsor. See No. 055529 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. 5 to 10 milligrams per 
pound of body weight two or three times daily. In severe or acute 
conditions, 10 milligrams per pound of body weight, three times daily. 
Administer 1 to 2 hours prior to feeding.
    (ii) Indications for use. Treatment against strains of gram-negative 
and gram-positive organisms sensitive to ampicillin and associated with 
respiratory tract infections

[[Page 129]]

(tracheobronchitis and tonsillitis); urinary tract infections 
(cystitis); bacterial gastroenteritis; generalized infections 
(septicemia) associated with abscesses, lacerations, and wounds; and 
bacterial dermatitis.
    (iii) Limitations. The drug may be given as an emergency measure; 
however, in vitro sensitivity tests on samples collected prior to 
treatment should be made. Ampicillin is contraindicated for use in 
infections caused by penicillinase-producing organisms and for use in 
animals known to be allergic to any of the penicillins. Not for use in 
animals raised for food production. Federal law restricts this drug to 
use by or on the order of a licensed veterinarian.
    (2) Cats--(i) Amount. 10 to 30 milligrams per pound of body weight 
or three times daily. Administer 1 to 2 hours prior to feeding.
    (ii) Indications for use. Treatment against strains of gram-negative 
and gram-positive organisms sensitive to ampicillin and associated with 
respiratory tract infections (bacterial pneumonia); urinary tract 
infections (cystitis); and generalized infections (septicemia) 
associated with abscesses, lacerations, and wounds.
    (iii) Limitations. The drug may be given as an emergency measure; 
however, in vitro sensitivity tests on samples collected prior to 
treatment should be made. Ampicillin is contraindicated for use in 
infections caused by penicillinase-producing organisms and for use in 
animals known to be allergic to any of the penicillins. Not for use in 
animals raised for food production. Federal law restricts this drug to 
use by or on the order of a licensed veterinarian.

[57 FR 37321, Aug. 18, 1992, as amended at 58 FR 61016, Nov. 19, 1993]



Sec. 520.90d  Ampicillin trihydrate for oral suspension.

    (a) Specifications. When reconstituted as directed, each milliliter 
contains ampicillin trihydrate equivalent to 25 milligrams of 
ampicillin.
    (b) Sponsor. See No. 055529 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. 5 to 10 milligrams per 
pound of body weight orally, 2 or 3 times daily, 1 to 2 hours prior to 
feeding. In severe or acute conditions, 10 milligrams per pound of body 
weight 3 times daily.
    (ii) Indications for use. Treatment of respiratory tract infections 
(tracheobronchitis and tonsillitis) due to Escherichia coli, Pseudomonas 
spp., Proteus spp., Staphylococcus spp., and Streptococcus spp., urinary 
tract infections (cystitis) due to E. coli, Staphylococcus spp., 
Streptococcus spp., and Proteus spp.; bacterial gastroenteritis due to 
E. coli; generalized infections (septicemia) associated with abscesses, 
lacerations, and wounds, due to Staphylococcus spp. and Streptococcus 
spp.; bacterial dermatitis due to Staphylococcus spp., Streptococcus 
spp., Proteus spp., and Pseudomonas spp.
    (iii) Limitations. Duration of treatment is usually 3 to 5 days. 
Continue treatment 48 hours after the animal's temperature has returned 
to normal and all other signs of infection have subsided. If no response 
is obtained within 3 to 5 days, reevaluate diagnosis and treatment. 
Appropriate laboratory tests should be conducted, including in vitro 
culturing and susceptibility tests on samples collected prior to 
treatment. Federal law restricts this drug to use by or on the order of 
a licensed veterinarian.
    (2) Cats--(i) Amount. 10 to 30 milligrams per pound of body weight 
orally, 2 or 3 times daily, 1 to 2 hours prior to feeding.
    (ii) Indications for use. Treatment of respiratory tract infections 
(bacterial pneumonia) due to Staphylococcus spp., Streptococcus spp., E. 
coli, and Proteus spp.; urinary tract infections (cystitis) due to E. 
coli, Staphylococcus spp., Streptococcus spp., Proteus spp., and 
Corynebacterium spp.; generalized infections (septicemia) associated 
with abscesses, lacerations, and wounds, due to Staphylococcus spp., 
Streptococcus spp., Bacillus spp., and Pasteurella spp.
    (iii) Limitations. Duration of treatment is usually 3 to 5 days. 
Continue treatment 48 hours after the animal's temperature has returned 
to normal and all other signs of infection have subsided. If no response 
is obtained within 3 to 5 days, reevaluate diagnosis and treatment. 
Appropriate laboratory tests should be conducted, including in vitro 
culturing and susceptibility tests

[[Page 130]]

on samples collected prior to treatment. Federal law restricts this drug 
to use by or on the order of a licensed veterinarian.

[57 FR 37321, Aug. 18, 1992, as amended at 58 FR 61016, Nov. 19, 1993]



Sec. 520.90e  Ampicillin trihydrate soluble powder.

    (a) Specifications. Each gram contains ampicillin trihydrate 
equivalent to 88.2 milligrams of ampicillin.
    (b) Sponsor. See No. 055529 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.40 of this chapter.
    (d) Conditions of use. Swine--(1) Amount. 5 milligrams of ampicillin 
per pound of body weight twice daily, orally by gavage or in drinking 
water for up to 5 days.
    (2) Indications for use. Oral treatment of porcine colibacillosis 
(Escherichia coli) and salmonellosis (Salmonella spp.) infections in 
swine up to 75 pounds of body weight, and bacterial pneumonia caused by 
Pasteurella multocida, Staphylococcus spp., Streptococcus spp., and 
Salmonella spp.
    (3) Limitations. For use in swine only. Not for use in other animals 
which are raised for food production. Treated swine must not be 
slaughtered for food during treatment and for 24 hours following the 
last treatment. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[57 FR 37322, Aug. 18, 1992, as amended at 58 FR 61016, Nov. 19, 1993]



Sec. 520.90f  Ampicillin trihydrate boluses.

    (a) Specifications. Each bolus contains ampicillin trihydrate 
equivalent to 400 milligrams of ampicillin.
    (b) Sponsor. See No. 055529 in Sec. 510.600(c) of this chapter for 
use as in paragraph (d)(1), 000069 for use as in paragraph (d)(2).
    (c) Related tolerances. See Sec. 556.40 of this chapter.
    (d) Conditions of use. Nonruminating calves--(1) Amount. 5 
milligrams per pound of body weight twice daily for up to 5 days.
    (i) Indications for use. Oral treatment of colibacillosis caused by 
Escherichia coli, bacterial enteritis caused by Salmonella spp., and 
bacterial pneumonia caused by Pasteurella spp.
    (ii) Limitations. Treated calves must not be slaughtered for food 
during treatment and for 15 days after the last treatment. Not for use 
in other animals raised for food production. Federal law restricts this 
drug to use by or on the order of a licensed veterinarian.
    (2) Amount. 5 milligrams per pound of body weight twice daily not to 
exceed 4 days.
    (i) Indications for use. Oral treatment of bacterial enteritis 
(colibacillosis) caused by E. coli.
    (ii) Limitations. Treated calves must not be slaughtered for food 
during treatment and for 7 days after the last treatment. Not for use in 
other animals raised for food production. Federal law restricts this 
drug to use by or on the order of a licensed veterinarian.

[57 FR 37322, Aug. 18, 1992, as amended at 58 FR 61016, Nov. 19, 1993; 
60 FR 55659, Nov. 2, 1995]



Sec. 520.100  Amprolium.

    (a) Specifications--(1) Each milliliter of solution contains 96 
milligrams (mg) amprolium (9.6 percent solution).
    (2) Each gram of powder contains 200 mg amprolium (20 percent).
    (3) Each ounce (28.4 grams) of crumbles contains 355 mg amprolium 
(1.25 percent).
    (b) Sponsors. See sponsors in 510.600(c) of this chapter.
    (1) No. 016592 for use of products described in paragraph (a) of 
this section as in paragraph (d) of this section.
    (2) No. 66104 for use of product described in paragraph (a)(1) of 
this section as in paragraph (d)(1) of this section.
    (3) No. 000859 for use of product described in paragraph (a)(1) of 
this section as in paragraph (d) of this section.
    (4) No. 061623 for use of products described in paragraphs (a)(1) 
and (a)(2) of this section as in paragraph (d) of this section.
    (c) Related tolerances. See Sec. 556.50 of this chapter.
    (d) Conditions of use--(1) Growing chickens, turkeys, and laying 
hens. It is used in drinking water as follows:
    (i) Amount. Administer at the 0.012 percent level in drinking water 
as soon as coccidiosis is diagnosed and continue for 3 to 5 days (in 
severe outbreaks, give amprolium at the 0.024

[[Page 131]]

percent level); continue with 0.006 percent amprolium-medicated water 
for an additional 1 to 2 weeks.
    (ii)Indications for use. For the treatment of coccidiosis.
    (iii) Limitations. Use as the sole source of amprolium.
    (2) Calves. Administer crumbles top-dressed on or thoroughly mixed 
in the daily feed ration; administer concentrate solution or soluble 
powder as a drench or in drinking water as follows:
    (i) Indications for use and amounts--(A) As an aid in the prevention 
of coccidiosis caused by Eimeria bovis and E. zurnii, administer 5 mg 
per kilogram (mg/kg) body weight for 21 days during periods of exposure 
or when experience indicates that coccidiosis is likely to be a hazard.
    (B) As an aid in the treatment of coccidiosis caused by E. bovis and 
E. zurnii, administer 10 mg/kg body weight for 5 days.
    (ii) Limitations. Withdraw 24 hours before slaughter. A withdrawal 
period has not been established for this product in preruminating 
calves. Do not use in calves to be processed for veal. Use as the sole 
source of amprolium.

[71 FR 56346, Sept. 27, 2006, as amended at 72 FR 60551, Oct. 25, 2007; 
73 FR 45611, Aug. 6, 2008; 73 FR 70276, Nov. 20, 2008; 74 FR 10484, Mar. 
11, 2009; 76 FR 38554, July 1, 2011; 76 FR 40808, July 12, 2011; 78 FR 
23, Jan. 2, 2013; 78 FR 17596, Mar. 22, 2013]



Sec. 520.110  Apramycin sulfate soluble powder.

    (a) Specifications. A water soluble powder used to make a medicated 
drinking water containing apramycin sulfate equivalent to 0.375 gram of 
apramycin activity per gallon of drinking water.
    (b) Sponsor. See No. 000986 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.52 of this chapter.
    (d) Conditions of use. (1) In swine for control of porcine 
colibacillosis (weanling pig scours) caused by strains of E. coli 
sensitive to apramycin.
    (2) It is administered for 7 days in drinking water at the rate of 
12.5 milligrams of apramycin per kilogram (5.7 milligrams per pound) of 
body weight per day. Swine will normally consume 1 gallon per day of 
medicated water containing 375 milligrams of apramycin for each 66 
pounds of body weight. Water consumption should be monitored to 
determine that the required amount of apramycin is being consumed. The 
drug concentration should be adjusted according to water consumption 
which varies depending on ambient temperature, humidity, and other 
factors.
    (3) Prepare fresh medicated water daily.
    (4) Do not slaughter treated swine for 28 days following treatment

[47 FR 15771, Apr. 13, 1982, as amended at 49 FR 19642, May 9, 1984; 53 
FR 37753, Sept. 28, 1988]



Sec. 520.154  Bacitracin oral dosage forms.



Sec. 520.154a  Bacitracin methylene disalicylate.

    (a) Specifications. Each pound of soluble powder contains the 
equivalent of 50 grams of bacitracin activity for use as in paragraph 
(d)(1) or (d)(2) of this section, or the equivalent of 200 grams of 
bacitracin activity for use as in paragraph (d) of this section.
    (b) Sponsor. See No. 046573 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.70 of this chapter.
    (d) Conditions of use--(1) Growing turkeys--(i) Amount. 400 
milligrams (mg) per gallon (gal) in drinking water.
    (ii) Indications for use. Aid in the control of transmissible 
enteritis complicated by organisms susceptible to bacitracin methylene 
disalicylate.
    (iii) Limitations. Prepare a fresh solution daily.
    (2) Broiler and replacement chickens--(i) Amount. 100 mg per gal in 
drinking water.
    (A) Indications for use. Aid in the prevention of necrotic enteritis 
caused by Clostridium perfringens susceptible to bacitracin methylene 
disalicylate.
    (B) Limitations. Prepare a fresh solution daily.
    (ii) Amount. 200 to 400 mg per gal in drinking water. Administer 
continuously 5 to 7 days or as long as clinical signs persist, then 
reduce to prevention levels (100 mg/gal).
    (A) Indications for use. Treatment of necrotic enteritis caused by 
C.

[[Page 132]]

perfringens susceptible to bacitracin methylene disalicylate.
    (B) Limitations. Prepare a fresh solution daily.
    (3) Swine--(i) Amount. 1 gram per gallon in drinking water.
    (ii) Indications for use. Treatment of swine dysentery associated 
with Treponema hyodysenteriae. Administer continuously for 7 days or 
until signs of dysentery disappear.
    (iii) Limitations. Prepare a fresh solution daily. Treatment not to 
exceed 14 days. If symptoms persist after 4 to 5 days consult a 
veterinarian. Not to be given to swine that weigh more than 250 pounds.
    (4) Growing quail--(i) Amount. 400 mg per gal in drinking water.
    (ii) Indications for use. For prevention of ulcerative enteritis due 
to Clostridium colinum susceptible to bacitracin methylene disalicylate.
    (iii) Limitations. Prepare fresh solution daily. Use as sole source 
of drinking water.

[57 FR 37322, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992, as amended at 
63 FR 38474, July 17, 1998; 64 FR 13068, Mar. 17, 1999; 76 FR 53050, 
Aug. 25, 2011]



Sec. 520.154b  Bacitracin methylene disalicylate and streptomycin 
sulfate powder.

    (a) Specifications. Each gram of powder contains 200 units 
bacitracin methylene disalicylate and streptomycin sulfate equivalent to 
20 milligrams of streptomycin.
    (b) Sponsor. See No. 046573 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Administer 1 level 
teaspoonful per 10 pounds of body weight three times daily, mixed in a 
small quantity of liquid or feed.
    (2) Indications for use. For the treatment of bacterial enteritis 
caused by pathogens susceptible to bacitracin and streptomycin such as 
Escherichia coli, Proteus spp., Staphylococcus spp., and Streptococcus 
spp., and for the symptomatic treatment of associated diarrhea.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[71 FR 17702, Apr. 7, 2006]



Sec. 520.154c  Bacitracin zinc soluble powder.

    (a) Specifications. Each pound contains the equivalent of not less 
than 5 grams of bacitracin.
    (b) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.70 of this chapter.
    (d) Conditions of use--(1) Broiler chickens--(i) Amount. 100 
milligrams per gallon in drinking water.
    (A) Indications for use. Prevention of necrotic enteritis caused by 
Clostridium perfringens susceptible to bacitracin zinc.
    (B) Limitations. Prepare a fresh solution daily.
    (ii) Amount. 200 to 400 milligrams per gallon in drinking water.
    (A) Indications for use. Control of necrotic enteritis caused by 
Clostridium perfringens susceptible to bacitracin zinc.
    (B) Limitations. Prepare a fresh solution daily.
    (2) Growing quail--(i) Amount. 500 milligrams per gallon in drinking 
water for 5 days followed by 165 milligrams per gallon in drinking water 
for 10 days.
    (ii) Indications for use. Control of ulcerative enteritis caused by 
Clostridium spp. susceptible to bacitracin zinc.
    (iii) Limitations. Prepare a fresh solution daily.

[57 FR 37322, Aug. 18, 1992, as amended at 67 FR 78355, Dec. 24, 2002]



Sec. 520.222  Bunamidine hydrochloride.

    (a) Chemical name. N,N-Dibutyl-4-(hexyloxy)-1-naphthamidine 
hydrochloride.
    (b) Specifications. The drug is an oral tablet containing 100, 200, 
or 400 milligrams of bunamidine hydrochloride.
    (c) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) The drug is intended for oral 
administration to dogs for the treatment of the tapeworms Dipylidium 
caninum, Taenia pisiformis, and Echinococcus granulosus, and to cats for 
the treatment of the tapeworms Dipylidium caninum and Taenia 
taeniaeformis.
    (2) It is administered to cats and dogs at the rate of 25 to 50 
milligrams per kilogram of body weight. The drug

[[Page 133]]

should be given on an empty stomach and food should not be given for 3 
hours following treatment.
    (3) Tablets should not be crushed, mixed with food, or dissolved in 
liquid. Repeat treatments should not be given within 14 days. The drug 
should not be given to male dogs within 28 days prior to their use for 
breeding. Do not administer to dogs or cats having known heart 
conditions.
    (4) For use only by or on the order of a licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 42 FR 13018, Mar. 8, 1977; 46 
FR 48642, Oct. 2, 1981; 61 FR 8873, Mar. 6, 1996; 62 FR 61624, Nov. 19, 
1997]



Sec. 520.246  Butorphanol tartrate tablets.

    (a) Specifications. Each tablet contains 1, 5, or 10 milligrams of 
butorphanol base activity as butorphanol tartrate.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. The drug is used for the treatment of dogs as 
follows:
    (1) Amount. 0.25 milligram of butorphanol base activity per pound of 
body weight.
    (2) Indications for use. For the relief of chronic nonproductive 
cough associated with tracheo-bronchitis, tracheitis, tonsillitis, 
laryngitis, and pharyngitis associated with inflammatory conditions of 
the upper respiratory tract.
    (3) Limitations. For oral use in dogs only. Repeat at intervals of 6 
to 12 hours as required. If necessary, increase dose to a maximum of 0.5 
milligram per pound of body weight. Treatment should not normally be 
required for longer than 7 days. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.

[47 FR 14702, Apr. 6, 1982, as amended at 53 FR 27851, July 25, 1988]



Sec. 520.260  n-Butyl chloride.

    (a)(1) Specifications. n-Butyl chloride capsules, veterinary contain 
272 milligrams or 816 milligrams of n-butyl chloride in each capsule.
    (2) Sponsor. See No. 021091 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) It is used for the removal of ascarids 
(Toxocara canis and Toxascaris leonina) and hookworms (Ancylostoma 
caninum, Ancylostoma braziliense, and Uncinaria stenocephala) from dogs 
and of the ascarid (Toxocara cati) and hookworm (Ancylostoma tubaeforme) 
from cats.
    (ii)(a) Animals should not be fed for 18 to 24 hours before being 
given the drug. Puppies and kittens should be wormed at 6 weeks of age. 
However, if heavily infested, they may be wormed at 4 or 5 weeks of age. 
Administration of the drug should be followed in \1/2\ to 1 hour with a 
teaspoonful to a tablespoonful of milk of magnesia or 1 or 2 milk of 
magnesia tablets. Normal rations may be resumed 4 to 8 hours after 
treatment. Puppies and kittens should be given a repeat treatment in a 
week or 10 days. After that they should be treated every 2 months (or as 
symptoms reappear) until a year old. When the puppy or kitten is a year 
old, one treatment every 3 to 6 months is sufficient.
    (b) For dogs or cats that have been wormed regularly, treatment 
every 3 to 6 months will be sufficient. If a dog or cat has not been 
wormed previously and has the symptoms of large roundworms a dose should 
be given and repeated in 10 days. Removal of hookworms may require 3 or 
4 doses at 10-day intervals.
    (c) Puppies, dogs, cats, or kittens weighing 1 to 3 pounds should be 
given 2 capsules per dose which contain 272 milligrams of n-butyl 
chloride each. Such animals weighing 4 to 5 pounds should be given 3 
such capsules. Animals weighing 6 to 7 pounds should be given 4 such 
capsules and animals weighing 8 to 9 pounds should be given 5 such 
capsules. Animals weighing 10 to 20 pounds should be given 3 capsules 
which contain 816 milligrams of n-butyl chloride each, animals weighing 
20 to 40 pounds should be given 4 such capsules and animals weighing 
over 40 pounds should be given 5 such capsules with the maximum dosage 
being 5 capsules, each of which contains 816 milligrams of n-butyl 
chloride.
    (iii) A veterinarian should be consulted before using in severely 
debilitated dogs or cats and also prior to repeated use in cases which 
present signs of persistent parasitism.
    (b)(1) Specifications. n-Butyl chloride capsules contain 221, 442, 
884, or 1,768

[[Page 134]]

milligrams or 4.42 grams of n-butyl chloride in each capsule. \1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter.
---------------------------------------------------------------------------

    (2) Sponsors. See No. 023851 in Sec. 510.600(c) of this chapter for 
221, 442, 884, or 1,768 milligram or 4.42 gram capsules; No. 038782 for 
884 or 1,768 milligram or 4.42 gram capsules; and No. 000069 for 221 
milligram capsules.
    (3) Conditions of use. (i) It is used for the removal of ascarids 
(Toxocara canis and Toxascaris leonina) and hookworms (Ancylostoma 
caninum, Ancylostoma braziliense, and Uncinaria stenocephala) from dogs. 
\1\
    (ii)(a) Dogs should not be fed for 18 to 24 hours before being given 
the drug. Administration of the drug should be followed in \1/2\ to 1 
hour with a mild cathartic. Normal feeding may be resumed 4 to 8 hours 
after treatment. Animals subject to reinfection may be retreated in 2 
weeks. \1\
    (b) The drug is administered orally to dogs. Capsules containing 221 
milligrams of n-butyl chloride are administered to dogs weighing under 5 
pounds at a dosage level of 1 capsule per 1\1/4\ pound of body weight. 
Capsules containing 442 milligrams of n-butyl chloride are administered 
to dogs weighing under 5 pounds at a dosage level of 1 capsule per 2\1/
2\ pounds body weight. Capsules containing 884 milligrams of n-butyl 
chloride are administered to dogs as follows: Weighing under 5 pounds, 1 
capsule; weighing 5 to 10 pounds, 2 capsules; weighing 10 to 20 pounds, 
3 capsules; weighing 20 to 40 pounds, 4 capsules; over 40 pounds, 5 
capsules. Capsules containing 1,768 milligrams of n-butyl chloride are 
administered at a dosage level of 1 capsule per dog weighing 5 to 10 
pounds. Capsules containing 4.42 grams of n-butyl chloride are 
administered at a dosage level of 1 capsule per dog weighing 40 pounds 
or over. \1\
    (iii) A veterinarian should be consulted before using in severely 
debilitated dogs. \1\

[40 FR 13838, Mar. 27, 1975, as amended at 40 FR 39858, Aug. 29, 1975; 
44 FR 10059, Feb. 16, 1979; 54 FR 38515, Sept. 19, 1989; 55 FR 24556, 
June 18, 1990; 64 FR 15684, Apr. 1, 1999; 70 FR 50182, Aug. 26, 2005; 78 
FR 14669, Mar. 7, 2013]

    Editorial Note: At 78 FR 14669, Mar. 7, 2013, Sec. 520.260 was 
amended by adding paragraphs (b)(1) through (3); however, the amendment 
could not be incorporated because (b)(1) through (3) already exist.



Sec. 520.300  Cambendazole oral dosage forms.



Sec. 520.300a  Cambendazole suspension.

    (a) Specifications. Each fluid ounce contains 0.9 gram of 
cambendazole.
    (b) Sponsor. No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is used in horses for the control of 
large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small 
strongyles (Trichonema, Poteriostomum, Cylicobrachytus, Craterostomum, 
Oesophagodontus); roundworms (Parascaris); pinworms. (Oxyuris); and 
threadworms (Strongyloides).
    (2) It is administered by stomach tube or as a drench at a dose of 
0.9 gram of cambendazole per 100 pounds of body weight (20 milligrams 
per kilogram).
    (3) For animals maintained on premises where reinfection is likely 
to occur, re-treatments may be necessary. For most effective results, 
re-treat in 6 to 8 weeks.
    (4) Not for use in horses intended for food.
    (5) Caution: Do not administer to pregnant mares during first 3 
months of pregnancy.
    (6) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13838, Mar. 27, 1975. Redesignated at 41 FR 1276, Jan. 7, 1976, 
and amended at 42 FR 3838, Jan. 21, 1977; 62 FR 63270, Nov. 28, 1997]



Sec. 520.300b  Cambendazole pellets.

    (a) Specifications. The drug is in feed pellets containing 5.3 
percent cambendazole.
    (b) Sponsor. No. 050604 in Sec. 510.600(c) of this chapter.

[[Page 135]]

    (c) Conditions of use. (1) It is used in horses for the control of 
large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small 
strongyles (Trichonema, Poteriostomum, Cylicobrachytus, Craterostomum, 
Oesophagodontus); roundworms (Parascaris); pinworms (Oxyuris); and 
threadworms (Strongyloides).
    (2) Administer 20 milligrams cambendazole per kilogram body weight 
(6 ounces per 1,000 pounds) by mixing with normal grain ration given at 
one feeding. Doses for individual horses should be mixed and fed 
separately to assure that each horse will consume the correct amount.
    (3) For animals maintained on premises where reinfection is likely 
to occur, re-treatments may be necessary. For most effective results, 
re-treat in 6 to 8 weeks.
    (4) Not for use in horses intended for food.
    (5) Caution: Do not administer to pregnant mares during first 3 
months of pregnancy.
    (6) Consult your veterinarian for assistance in the diagnosis, 
treatment, and control of parasitism.

[41 FR 1276, Jan. 7, 1976, as amended at 42 FR 3838, Jan. 21, 1977; 62 
FR 63270, Nov. 28, 1997]



Sec. 520.300c  Cambendazole paste.

    (a) Specifications. The drug is a paste containing 45 percent 
cambendazole.
    (b) Sponsor. No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is used in horses for the control of 
large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small 
strongyles (Trichonema, Poteriostomum, Cylicobrachytus, Craterostomum, 
Oesophagodontus); roundworms (Parascaris); pinworms (Oxyuris); and 
threadworms (Strongyloides).
    (2) Administer 20 milligrams cambendazole per kilogram body weight 
(5 grams per 550 pounds (250 kilograms)) by depositing the paste on the 
back of the tongue using a dosing gun.
    (3) For animals maintained on premises where reinfection is likely 
to occur, re-treatments may be necessary. For most effective results, 
re-treat in 6 to 8 weeks.
    (4) Not for use in horses intended for food.
    (5) Caution: Do not administer to pregnant mares during first 3 
months of pregnancy.
    (6) Consult your veterinarian for assistance in the diagnosis, 
treatment, and control of parasitism.

[41 FR 1276, Jan. 7, 1976, as amended at 42 FR 3838, Jan. 21, 1977; 62 
FR 63270, Nov. 28, 1997]



Sec. 520.309  Carprofen.

    (a) Specifications. (1) Each caplet contains 25, 75, or 100 
milligrams (mg) carprofen.
    (2) Each chewable tablet contains 25, 75, or 100 mg carprofen.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
uses as in paragraph (d) of this section.
    (1) No. 000069 for use of products described in paragraph (a) of 
this section as in paragraph (d) of this section.
    (2) Nos. 000115, 055529, and 062250 for use of product described in 
paragraph (a)(1) as in paragraph (d) of this section.
    (c) [Reserved]
    (d) Conditions of use in dogs--(1) Amount. 2 mg per pound (/lb) of 
body weight once daily or 1 mg/lb twice daily. For the control of 
postoperative pain, administer approximately 2 hours before the 
procedure.
    (2) Indications for use. For the relief of pain and inflammation 
associated with osteoarthritis and for the control of postoperative pain 
associated with soft tissue and orthopedic surgeries.
    (3) Limitations. Federal Law restricts this drug to use by or on the 
order of a licensed veterinarian.

[61 FR 66581, Dec. 18, 1996, as amended at 64 FR 32181, June 16, 1999; 
66 FR 63165, Dec. 5, 2001; 67 FR 6866, Feb. 14, 2002; 67 FR 65038, Oct. 
23, 2002; 67 FR 65697, Oct. 28, 2002; 70 FR 30626, May 27, 2005; 71 FR 
51995, Sept. 1, 2006; 72 FR 68478, Dec. 5, 2007; 74 FR 21768, May 11, 
2009]



Sec. 520.310  Caramiphen ethanedisulfonate and ammonium chloride 
tablets.

    (a) Specifications. Each tablet contains 10 milligrams of 5st 
caramiphen

[[Page 136]]

ethanedisulfonate and 80 milligrams of ammonium chloride.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. One tablet per 15 to 30 
pounds of body weight every 4 to 6 hours.\1\
    (2) Indications for use. For relief of cough.\1\

[43 FR 55385, Nov. 28, 1978]



Sec. 520.312  Carnidazole tablets.

    (a) Specifications. Each tablet contains 10 milligrams of 
carnidazole.
    (b) Sponsor. See 053923 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. Adult pigeons: 1 tablet (10 
milligrams); newly weaned pigeons: \1/2\ tablet (5 milligrams).
    (2) Indications for use. For treating trichomoniasis (canker) in 
ornamental and homing pigeons.
    (3) Limitations. Not for use in pigeons intended for human food. 
Consult your veterinarian for assistance in the diagnosis, treatment, 
and control of parasitism or when severely ill birds do not respond to 
treatment.

[54 FR 32336, Aug. 7, 1989]



Sec. 520.314  Cefadroxil.

    (a) Specifications.--(1) Each tablet contains 50, 100, or 200 
milligrams (mg) or 1 gram of cefadroxil.
    (2) Each milliliter of suspension constituted from powder contains 
50 mg of cefadroxil.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs and cats--(1) Amount--(i) Dogs. 
Administer 10 mg per pound (/lb) body weight twice daily orally.
    (ii) Cats. Administer 10 mg/lb body weight once daily orally.
    (2) Indications for use--(i) Dogs. For the treatment of skin and 
soft tissue infections including cellulitis, pyoderma, dermatitis, wound 
infections, and abscesses due to susceptible strains of Staphylococcus 
aureus. For the treatment of genitourinary tract infections (cystitis) 
due to susceptible strains of Escherichia coli, Proteus mirabilis, and 
S. aureus.
    (ii) Cats. For the treatment of skin and soft tissue infections 
including abscesses, wound infections, cellulitis, and dermatitis caused 
by susceptible strains of Pasteurella multocida, S. aureus, 
Staphylococcus epidermidis, and Streptococcus spp.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[75 FR 10165, Mar. 5, 2010]



Sec. 520.370  Cefpodoxime tablets.

    (a) Specifications. Each tablet contains cefpodoxime proxetil 
equivalent to 100 or 200 milligrams (mg) cefpodoxime.
    (b) Sponsors. See Nos. 000009 and 026637 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use in dogs--(1) Amount. 5 to 10 mg per kilogram 
(2.3 to 4.5 mg per pound) body weight daily for 5 to 7 days, or for 2 to 
3 days beyond the cessation of clinical signs, up to a maximum of 28 
days.
    (2) Indications for use. For the treatment of skin infections 
(wounds and abscesses) caused by susceptible strains of Staphylococcus 
intermedius, S. aureus, Streptococcus canis (group G, -hemolytic), 
Escherichia coli, Pasteurella multocida, and Proteus mirabilis.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[69 FR 52815, Aug. 30, 2004, as amended at 78 FR 5714, Jan. 28, 2013]



Sec. 520.376  Cephalexin.

    (a) Specifications. Each chewable tablet contains 75, 150, 300, or 
600 milligrams (mg) cephalexin.
    (b) Sponsor. See No. 051311 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. Administer 22 mg per 
kilogram of body weight twice daily for 28 days.
    (ii) Indications for use. For the treatment of secondary superficial 
bacterial pyoderma in dogs caused by susceptible strains of 
Staphylococcus pseudintermedius.

[[Page 137]]

    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) [Reserved]

[77 FR 47512, Aug. 9, 2012]



Sec. 520.390  Chloramphenicol oral dosage forms.



Sec. 520.390a  Chloramphenicol tablets.

    (a) Specifications. Each tablet contains 50, 100, 250, or 500 
milligrams (mg); 1 or 2.5 grams (g) of chloramphenicol.
    (b) Sponsors. See Sec. 510.600(c) of this chapter:
    (1) For use as in paragraphs (c)(1), (c)(2)(i), and (c)(3) of this 
section:
    (i) No. 000010 for 100-, 250-, and 500-mg; and 1- and 2.5-g tablets;
    (ii) No. 000856 for 100-, 250-, and 500-mg tablets;
    (iii) No. 000069 for 250-mg tablets.
    (2) For use as in paragraphs (c)(1), (c)(2)(ii), and (c)(3) of this 
section:
    (i) No. 061623 for 50-, 100-, 250-, and 500-mg; and 1-g tablets;
    (ii) [Reserved]
    (c) Conditions of use in dogs--(1) Amount. Administer 25 mg per 
pound of body weight by mouth every 6 hours.
    (2) Indications for use--(i) For the treatment of bacterial 
pulmonary infections, bacterial infections of the urinary tract, 
bacterial enteritis, and bacterial infections associated with canine 
distemper caused by susceptible organisms.
    (ii) For the treatment of bacterial gastroenteritis associated with 
bacterial diarrhea, bacterial pulmonary infections, and bacterial 
infections of the urinary tract caused by susceptible organisms.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian. Federal law prohibits the extralabel 
use of this drug in food-producing animals.

[77 FR 4896, Feb. 1, 2012]



Sec. 520.390b  Chloramphenicol capsules.

    (a) Specifications. Each capsule contains 50, 100, 250, or 500 
milligrams (mg) chloramphenicol.
    (b) Sponsors. See Nos. 000069 and 050057 in Sec. 510.600(c) of this 
chapter for use as in paragraph (d) of this section.
    (c) Special considerations. Federal law prohibits the extralabel use 
of this product in food-producing animals.
    (d) Conditions of use in dogs--(1) Amount. 25 mg per pound of body 
weight every 6 hours.
    (2) Indications for use. For treatment of bacterial pulmonary 
infections, bacterial infections of the urinary tract, bacterial 
enteritis, and bacterial infections associated with canine distemper 
caused by susceptible organisms.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[70 FR 75398, Dec. 20, 2005, as amended at 73 FR 18442, Apr. 4, 2008; 75 
FR 55676, Sept. 14, 2010]



Sec. 520.390c  Chloramphenicol palmitate oral suspension.

    (a) Specifications. Each milliliter contains chloramphenicol 
palmitate equivalent to 30 milligrams of chloramphenicol.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. Dogs--(1) Amount. 25 milligrams per pound of 
body weight every 6 hours. If no response is obtained in 3 to 5 days, 
discontinue use and reevaluate diagnosis.
    (2) Indications for use. Treatment of bacterial pulmonary 
infections, infections of the urinary tract, enteritis, and infections 
associated with canine distemper that are caused by organisms 
susceptible to chloramphenicol.
    (3) Limitations. Not for use in animals that are raised for food 
production. Must not be used in meat-, egg-, or milk-producing animals. 
The length of time that residues persist in milk or tissues has not been 
determined. Federal law restricts this drug to use by or on the order of 
a licensed veterinarian.

[57 FR 37323, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992]



Sec. 520.420  Chlorothiazide tablets and boluses.

    (a)(1) Specifications. Each tablet contains 0.25 gram of 
chlorothiazide.
    (2) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use--(i) Amount. Usual dosage is 5 to 10 
milligrams per

[[Page 138]]

pound of body weight two or three times daily. \1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (ii) Indications for use. For use in dogs for treatment of 
congestive heart failure and renal edema. \1\
    (iii) Limitations. (a) Dosage must be adjusted to meet the changing 
needs of the individual animal. In mild and responsive cases, it is 
suggested that a dose of 5 milligrams per pound of body weight be 
administered two or three times daily. In moderately edematous and 
moderately responsive animals, a dose of 7.5 to 10 milligrams per pound 
of body weight may be administered three times daily. Severe conditions 
may require higher doses. Certain animals may respond adequately to 
intermittent therapy; in these cases, the drug may be administered 
either every other day or for 3 to 5 days each week.
    (b) Animals should be regularly and carefully observed for early 
signs of fluid and electrolyte imbalance. Take appropriate 
countermeasures if this should occur. In some dogs, hypochloremic 
alkalosis may occur (that is, excretion of chloride in relation to 
sodium is excessive; the plasma bicarbonate level increases and 
alkalosis results). Federal law restricts this drug to use by or on the 
order of a licensed veterinarian. \1\
    (b)(1) Specifications. Each bolus contains 2 grams of 
chlorothiazide.
    (2) Sponsor. See No. 000006 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use--(i) Amount. 2 grams once or twice daily for 3 
or 4 days. \1\
    (ii) Indications for use. For use in cattle as an aid in reduction 
of postparturient udder edema. \1\
    (iii) Limitations. Animals should be regularly and carefully 
observed for early signs of fluid and electrolyte imbalance. Take 
appropriate countermeasures if this should occur. Milk taken from dairy 
animals during treatment and for 72 hours (six milkings) after latest 
treatment must not be used for food. Federal law restricts this drug to 
use by or on the order of a licensed veterinarian. \1\

[43 FR 39085, Sept. 1, 1978, as amended at 62 FR 63270, Nov. 28, 1997]



Sec. 520.434  Chlorphenesin carbamate tablets.

    (a) Specifications. Each tablet contains 400 milligrams of 
chlorphenesin carbamate.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. 50 milligrams per pound 
of body weight on first day; 25 milligrams per pound of body weight each 
following day. Divide total daily dose into 2 or 3 equal doses--
administer at 12- or 8-hour intervals.
    (2) Indications for use. For use as an adjunct to therapy of acute 
inflammatory and traumatic conditions of skeletal muscles. The drug 
provides relief of the signs of discomfort associated with myositis, 
muscle sprains, traumatic injuries, stifle injuries--especially when 
administered before or after surgery--and invertebral disc syndrome (can 
be used concurrently with adrenal corticosteroids).
    (3) Limitations. Not recommended for pregnant animals or those with 
a known hepatic dysfunction. Periodic liver function studies are 
recommended for animals on prolonged treatment. If no response is 
evident within 5 days of the beginning of treatment, the diagnosis 
should be redetermined and appropriate therapy instituted. Not 
recommended for use with general anesthetics other than the 
barbiturates. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[44 FR 16009, Mar. 16, 1979]



Sec. 520.441  Chlortetracycline powder.

    (a) Specifications. Chlortetracycline powder contains not less than 
15 milligrams per gram chlortetracycline hydrochloride, or 
chlortetracycline bisulfate equivalent to 25.6, 64 or 102.4 grams per 
pound (56.4, 141 or 225.6 milligrams per gram) chlortetracycline 
hydrochloride.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (d) of this section.

[[Page 139]]

    (1) No. 048164 for use as in paragraph (d) of this section.
    (2) Nos. 046573 and 000010 for use as in paragraph (d) of this 
section.
    (3) No. 000010 for use as in paragraphs (d)(4)(i)(A), (d)(4)(i)(B), 
and (d)(4)(ii) through (d)(4)(iv) of this section. (d)(4)(ii) through 
(iv) of this section.
    (4) Nos. 012286 and 076475 for use as in paragraphs (d)(4)(i)(A), 
(d)(4)(i)(B), (d)(4)(ii), and (d)(4)(iii) of this section.
    (c) Related tolerances. See Sec. 556.150 of this chapter.
    (d) Conditions of use. (1) Use as chlortetracycline hydrochloride in 
drinking water as follows:
    (i) Swine--(A) Amount. Ten milligrams per pound of body weight daily 
in divided doses.
    (1) Indications for use. Control and treatment of bacterial 
enteritis (scours) caused by Escherichia coli and bacterial pneumonia 
associated with Pasteurella spp., Actinobacillus pleuropneumoniae 
(Hemophilus spp.), and Klebsiella spp.
    (2) Limitations. Prepare a fresh solution twice daily; as sole 
source of chlortetracycline; administer for not more than 5 days.
    (B) [Reserved]
    (ii) [Reserved]
    (2) Use as chlortetracycline hydrochloride in a drench or drinking 
water as follows:
    (i) Calves--(A) Amount. Ten milligrams per pound of body weight 
daily in divided doses.
    (1) Control and treatment of bacterial enteritis (scours) caused by 
E. coli and bacterial pneumonia (shipping fever) associated with 
Pasteurella spp., A. pleuropneumoniae (Hemophilus spp.), and Klebsiella 
spp.
    (2) Limitations. Prepare fresh solution daily; as sole source of 
chlortetracycline; administer for not more than 5 days; do not slaughter 
animals for food within 24 hours of treatment; do not administer this 
product with milk or milk replacers; administer 1 hour before or 2 hours 
after feeding milk or milk replacers; a withdrawal period has not been 
established in preruminating calves; do not use in calves to be 
processed for veal.
    (B) [Reserved]
    (ii) [Reserved]
    (3) [Reserved]
    (4) The following uses of chlortetracycline hydrochloride or 
chlortetracycline bisulfate in drinking water or drench were reviewed by 
the National Academy of Sciences/National Research Council (NAS/NRC) and 
found effective:
    (i) Chickens--(A) Amount. 200 to 400 milligrams per gallon.
    (1) Indications for use. Control of infectious synovitis caused by 
Mycoplasma synoviae.
    (2) Limitations. Prepare fresh solution daily; as sole source of 
chlortetracycline; do not use for more than 14 days; do not slaughter 
animals for food within 24 hours of treatment; do not use in laying 
chickens.
    (B) Amount. 400 to 800 milligrams per gallon.
    (1) Indications for use. Control of chronic respiratory disease and 
air-sac infections caused by M. gallisepticum and E. coli.
    (2) Limitations. Prepare fresh solution daily; as sole source of 
chlortetracycline; do not use for more than 14 days; do not slaughter 
animals for food within 24 hours of treatment; do not use in laying 
chickens.
    (C) Amount. One thousand milligrams per gallon.
    (1) Indications for use. Control of mortality due to fowl cholera 
caused by Pasteurella multocida susceptible to chlortetracycline.
    $(2) Limitations. See paragraph (d)(4)(i)(A)(2) of this section.
    (ii) Growing turkeys--(A) Amount. 400 milligrams per gallon.
    (1) Indications for use. Control of infectious synovitis caused by 
M. synoviae.
    (2) Limitations. Prepare fresh solution daily; as sole source of 
chlortetracycline; do not use for more than 14 days; do not slaughter 
animals for food within 24 hours of treatment.
    (B) Amount. 25 milligrams per pound of body weight daily.
    (1) Indications for use. Control of complicating bacterial organisms 
associated with bluecomb (transmissible enteritis, coronaviral 
enteritis).
    (2) Limitations. Prepare fresh solution daily; as sole source of 
chlortetracycline; do not use for more than 14 days; do not slaughter 
animals for food within 24 hours of treatment.

[[Page 140]]

    (iii) Swine--(A) Amount. 10 milligrams per pound body weight daily 
in divided doses.
    (B) Indications for use. Control and treatment of bacterial 
enteritis (scours) caused by E. coli and Salmonella spp. and bacterial 
pneumonia associated with Pasteurella spp., Actinobacillus 
pleuropneumoniae (Hemophilus spp.), and Klebsiella spp.
    (C) Limitations. Prepare fresh solution daily; as sole source of 
chlortetracycline; do not use for more than 5 days. For Nos. 000010 and 
021930, do not slaughter animals for food within 5 days of treatment. 
For No. 000010, do not slaughter animals for food within 24 hours of 
treatment.
    (iv) Calves, beef cattle, and nonlactating dairy cattle--(A) Amount. 
10 milligrams per pound daily in divided doses.
    (B) Indications for use. Control and treatment of bacterial 
enteritis (scours) caused by E. coli and Salmonella spp. and bacterial 
pneumonia (shipping fever complex) associated with Pasteurella spp., A. 
pleuropneumoniae (Hemophilus spp.), and Klebsiella spp.
    (C) Limitations. Prepare fresh solution daily; use as a drench; as 
sole source of chlortetracycline; do not use for more than 5 days; do 
not slaughter animals for food within 24 hours of treatment; do not use 
in lactating cattle; do not administer this product with milk or milk 
replacers; administer 1 hour before or 2 hours after feeding milk or 
milk replacers; a withdrawal period has not been established in 
preruminating calves; do not use in calves to be processed for veal.
    (5) Use in a drench or drinking water as follows:
    (i) Chickens--(A) Amount. 200 to 400 mg/gal, for 7 to 14 days.
    (1) Indications for use. Control of infectious synovitis caused by 
M. synoviae susceptible to chlortetracycline.
    (2) Limitations. Prepare fresh solution daily; use as the sole 
source of chlortetracycline; do not use for more than 14 consecutive 
days; do not use in laying chickens; do not administer to chickens 
within 24 hours of slaughter.
    (B) Amount. 400 to 800 mg/gal, for 7 to 14 days.
    (1) Indications for use. Control of chronic respiratory disease 
(CRD) and air-sac infections caused by M. gallisepticum and E. coli 
susceptible to chlortetracycline.
    (2) Limitations. As in paragraph (d)(5)(i)(A)(2) of this section.
    (C) Amount. One thousand mg/gal, for 7 to 14 days.
    (1) Indications for use. Control of mortality due to fowl cholera 
caused by Pasteurella multocida susceptible to chlortetracycline.
    (2) Limitations. As in paragraph (d)(5)(i)(A)(2) of this section.
    (ii) Growing Turkeys--(A) Amount. 400 mg/gal, for 7 to 14 days.
    (1) Indications for use. Control of infectious synovitis caused by 
Mycoplasma synoviae susceptible to chlortetracycline.
    (2) Limitations. Prepare fresh solution daily; use as the sole 
source of chlortetracycline; do not use for more than 14 consecutive 
days; do not administer to growing turkeys within 24 hours of slaughter.
    (B) Amount. 25 mg/lb body weight daily, for 7 to 14 days.
    (1) Indications for use. Control of complicating bacterial organisms 
associated with bluecomb (transmissible enteritis, coronaviral 
enteritis) susceptible to chlortetracycline.
    (2) Limitations. As in paragraph (d)(5)(ii)(A)(2) of this section.
    (iii) Swine--(A) Amount. 10 mg/lb body weight daily, for 3 to 5 
days.
    (B) Indications for use. Control and treatment of bacterial 
enteritis (scours) caused by E. coli and Salmonella spp., and bacterial 
pneumonia associated with Pasteurella spp., A. pleuropneumoniae, and 
Klebsiella spp. susceptible to chlortetracycline.
    (C) Limitations. Prepare fresh solution daily; use as the sole 
source of chlortetracycline; do not use for more than 5 days; do not 
administer to swine within 24 hours of slaughter.
    (iv) Calves, beef cattle, and nonlactating dairy cattle--(A) Amount. 
10 mg/lb body weight daily in divided doses, for 3 to 5 days.
    (B) Indications for use. Control and treatment of bacterial 
enteritis (scours) caused by Escherichia coli and Salmonella spp., and 
bacterial pneumonia associated with Pasteurella spp.,

[[Page 141]]

Histophilus spp., and Klebsiella spp. susceptible to chlortetracycline.
    (C) Limitations. Prepare fresh solution daily; use as a drench; use 
as the sole source of chlortetracycline; do not use for more than 5 
days; do not administer to cattle within 24 hours of slaughter; do not 
use in lactating dairy cattle; do not administer this product with milk 
or milk replacers; administer 1 hour before or 2 hours after feeding 
milk or milk replacers; a withdrawal period has not been established in 
preruminating calves; do not use in calves to be processed for veal.

[57 FR 37324, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992; 58 FR 61015, 
Nov. 19, 1993; 59 FR 39439, Aug. 3, 1994; 60 FR 26827, May 19, 1995; 60 
FR 47052, Sept. 11, 1995; 62 FR 27691, May 21, 1997; 62 FR 35076, June 
30, 1997; 62 FR 60656, Nov. 12, 1997; 64 FR 37673, July 13, 1999; 65 FR 
10706, Feb. 29, 2000; 66 FR 35898, July 10, 2001; 67 FR 78355, Dec. 24, 
2002; 69 FR 62406, Oct. 26, 2004; 72 FR 1174, Jan. 10, 2007; 72 FR 
63987, Nov. 14, 2007; 73 FR 35340, June 23, 2008; 74 FR 62491, Nov. 30, 
2009. Redesignated and amended at 76 FR 49649, Aug. 11, 2011; 77 FR 
5700, Feb. 6, 2012]



Sec. 520.443  Chlortetracycline tablets and boluses.

    (a) Specifications. Each tablet/bolus contains 25, 250, or 500 
milligrams (mg) chlortetracycline hydrochloride.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.150 of this chapter.
    (d) Conditions of use in calves--(1) Amount. One 250 milligram bolus 
per 50 pounds of body weight twice a day for 3 to 5 days.
    (i) Indications for use. Treatment of bacterial enteritis (scours) 
caused by Escherichia coli and bacterial pneumonia associated with 
Pasteurella spp., Klesbsiella spp., and Hemophilus spp.
    (ii) Limitations. Administer bolus directly by mouth or crush and 
dissolve in milk or water for drenching or bucket feeding; if no 
improvement is noted after 3 days of treatment, consult a veterinarian; 
do not use for more than 5 days; do not administer within 24 hours of 
slaughter.
    (2) Amount. One 25 milligram tablet for each 5 pounds of body weight 
every 12 hours daily for 3 to 5 days.
    (i) Indications for use. Control and treatment of bacterial 
enteritis (scours) caused by E. coli and Salmonella spp. and bacterial 
pneumonia associated with Pasteurella spp., Hemophilus spp., and 
Klebsiella spp., susceptible to chlortetracycline.
    (ii) Limitations. Administer tablet directly by mouth or crush and 
dissolve in water for drenching; if no improvement is noted after 3 days 
of treatment, consult a veterinarian; do not use for more than 5 days; 
when feeding milk or milk replacer, administration 1 hour before or 2 
hours after feeding; do not administer within 24 hours of slaughter.
    (3) Amount. One 500 milligram bolus per 100 pounds of body weight 
twice a day for 3 to 5 days.
    (i) Indications for use. Treatment of bacterial enteritis (scours) 
caused by E. coli and Salmonella spp., and bacterial pneumonia 
associated with Pasteurella spp., Hemophilus spp., and Klebsiella spp., 
susceptible to chlortetracycline.
    (ii) Limitations. Administer directly by mouth or crush and dissolve 
in water for drenching; if no improvement is noted after 3 days of 
treatment, consult a veterinarian; do not use for more than 5 days; do 
not administer within 24 hours of slaughter.

[57 FR 37325, Aug. 18, 1992, as amended at 67 FR 78355, Dec. 24, 2002. 
Redesignated and amended at 76 FR 49649, Aug. 11, 2011]



Sec. 520.445  Chlortetracycline and sulfamethazine powder.

    (a) Specifications. Each pound of soluble powder contains 
chlortetracycline bisulfate equivalent to 102.4 grams (g) of 
chlortetracycline hydrochloride and sulfamethazine bisulfate equivalent 
to 102.4 g of sulfamethazine.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. Sec. 556.150 and 556.670 of this 
chapter.
    (d) Conditions of use in swine. Administer in drinking water as 
follows:
    (1) Amount. 250 milligrams (mg) of chlortetracycline and 250 mg of 
sulfamethazine per gallon.
    (2) Indications for use. For the prevention and treatment of 
bacterial enteritis; as an aid in the reduction of the incidence of 
cervical abscesses; and as an aid in the maintenance of weight gains in 
the presence of bacterial enteritis and atrophic rhinitis.

[[Page 142]]

    (3) Limitations. Use as the sole source of chlortetracycline and 
sulfonamide. Not to be used for more than 28 consecutive days. Withdraw 
15 days before slaughter.

[76 FR 49649, Aug. 11, 2011]



Sec. 520.446  Clindamycin capsules and tablets.

    (a) Specifications--(1) Each capsule contains the equivalent of 25, 
75, 150, or 300 milligrams (mg) clindamycin as the hydrochloride salt.
    (2) Each tablet contains the equivalent of 25, 75, or 150 mg 
clindamycin as the hydrochloride salt.
    (3) Each capsule contains the equivalent of 25, 75, or 150 mg 
clindamycin as the hydrochloride salt.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter as 
follows:
    (1) Nos. 000009 and 000859 for use of capsules described in 
paragraph (a)(1) of this section.
    (2) No. 051311 for use of tablets described in paragraph (a)(2) of 
this section.
    (3) No. 043806 for use of tablets described in paragraph (a)(3) of 
this section.
    (c) Conditions of use in dogs--(1) Amount. Wounds, abscesses, and 
dental infections: 2.5 to 15 mg per pound (/lb) body weight every 12 
hours for a maximum of 28 days. Osteomyelitis: 5.0 to 15 mg/lb body 
weight every 12 hours for a minimum of 28 days.
    (2) Indications for use. For the treatment of skin infections 
(wounds and abscesses) due to susceptible strains of coagulase-positive 
staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and 
abscesses due to susceptible strains of Bacteroides fragilis, Prevotella 
melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens, 
dental infections due to susceptible strains of S. aureus, B. fragilis, 
P. melaninogenicus, F. necrophorum, and C. perfringens, and 
osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. 
melaninogenicus, F. necrophorum, and C. perfringens.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[67 FR 54954, Aug. 27, 2002, as amended at 68 FR 55824, Sept. 29, 2003; 
69 FR 32273, June 9, 2004; 71 FR 39204, July 12, 2006; 73 FR 4077, Jan. 
24, 2008; 78 FR 17596, Mar. 22, 2013]



Sec. 520.447  Clindamycin solution.

    (a) Specifications. Each milliliter of solution contains the 
equivalent of 25 milligrams (mg) clindamycin as the hydrochloride salt.
    (b) Sponsors. See Nos. 000009, 000859, 051311, and 058829 in Sec. 
510.600(c) of this chapter.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Conditions of use--(1) Dogs--(i) Amount. Wounds, abscesses, and 
dental infections: 2.5 to 15 mg per pound (/lb) body weight every 12 
hours for a maximum of 28 days. Osteomyelitis: 5.0 to 15 mg/lb body 
weight every 12 hours for a minimum of 28 days.
    (ii) Indications for use. For the treatment of skin infections 
(wounds and abscesses) due to susceptible strains of coagulase-positive 
staphylococci (Staphylococcus aureus or S. intermedius), deep wounds and 
abscesses due to susceptible strains of Bacteroides fragilis, Prevotella 
melaninogenicus, Fusobacterium necrophorum, and Clostridium perfringens; 
dental infections due to susceptible strains of S. aureus, B. fragilis, 
P. melaninogenicus, F. necrophorum, and C. perfringens; and 
osteomyelitis due to susceptible strains of S. aureus, B. fragilis, P. 
melaninogenicus, F. necrophorum, and C. perfringens.
    (2) Cats--(i) Amount. 5.0 to 15.0 mg/lb body weight every 24 hours 
for a maximum of 14 days.
    (ii) Indications for use. For the treatment of skin infections 
(wounds and abscesses) due to susceptible strains of Staphylococcus 
aureus, S. intermedius, Streptococcus spp.; deep wounds and abscesses 
due to susceptible strains of Clostridium perfringens and Bacteroides 
fragilis; and dental infections due to susceptible strains of S. aureus, 
S.

[[Page 143]]

intermedius, Streptococcus spp., C. perfringens, and B. fragilis.

[67 FR 54954, Aug. 27, 2002, as amended at 67 FR 78684, Dec. 26, 2002; 
68 FR 55824, Sept. 29, 2003; 69 FR 31734, June 7, 2004; 71 FR 39543, 
July 13, 2006; 72 FR 19796, Apr. 20, 2007; 78 FR 17596, Mar. 22, 2013]



Sec. 520.452  Clenbuterol syrup.

    (a) Specifications. Each milliliter contains 72.5 micrograms of 
clenbuterol hydrochloride.
    (b) Sponsor. See 000010 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Horses--(i) Amount. Administer orally 
twice a day (b.i.d.). Initial dose is 0.5 milliliter per 100 pounds body 
weight (0.8 micrograms per kilogram) for 3 days (6 treatments). If no 
improvement, administer 1 milliliter per 100 pounds (1.6 micrograms per 
kilogram) for 3 days (6 treatments). If no improvement, administer 1.5 
milliliters per 100 pounds (2.4 micrograms per kilogram) for 3 days (6 
treatments). If no improvement, administer 2.0 milliliters per 100 
pounds (3.2 micrograms per kilogram) for 3 days (6 treatments). If no 
improvement, horse is nonresponder to clenbuterol and treatment should 
be discontinued.
    (ii) Indications for use. Indicated for the management of horses 
affected with airway obstruction, such as occurs in chronic obstructive 
pulmonary disease (COPD).
    (iii) Limitations. Treat at effective dose for 30 days. At the end 
of the 30-day treatment period, drug should be withdrawn. If signs 
return, the 30-day treatment period may be repeated. If repeating 
treatment, the step-wise dosage schedule should be repeated. The effect 
of this drug on breeding stallions and brood mares has not been 
determined. Treatment starting with dosages higher than the initial dose 
is not recommended. Federal law prohibits the extralabel use of this 
drug in food animals. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) [Reserved]

[63 FR 41419, Aug. 4, 1998]



Sec. 520.455  Clomipramine tablets.

    (a) Specifications. Each tablet contains 5, 20, 40, or 80 milligrams 
(mg) clomipramine hydrochloride.
    (b) Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 2 to 4 milligrams of clomipramine 
hydrochloride per kilogram (0.9 to 1.8 milligrams per pound) of body 
weight per day, administered as a single daily dose or divided twice 
daily.
    (2) Indications for use. For use as part of a comprehensive 
behavioral management program to treat separation anxiety in dogs 
greater than 6 months of age.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[64 FR 1762, Jan. 12, 1999, as amended at 72 FR 262, Jan. 4, 2007]



Sec. 520.462  Clorsulon drench.

    (a) Specifications. The drug is a suspension containing 8.5 percent 
clorsulon (85 milligrams per milliliter).
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. Cattle--(1) Amount. One-quarter fluid ounce 
per 200 pounds of body weight (7 milligrams per kilogram or 3.2 
milligrams per pound of body weight).
    (2) Indications for use. For the treatment of immature and adult 
liver fluke (Fasciola hepatica) infestations in cattle.
    (3) Limitations. Using dose syringe, deposit drench over back of 
tongue. Do not treat cattle within 8 days of slaughter. Because a 
withdrawal time in milk has not been established, do not use in female 
dairy cattle of breeding age. Consult your veterinarian for assistance 
in the diagnosis, treatment, and control of parasitism.

[50 FR 10221, Mar. 14, 1985, as amended at 62 FR 63270, Nov. 28, 1997]



Sec. 520.522  Cyclosporine.

    (a) Specifications--(1) Each cyclosporine capsule, USP (MODIFIED) 
contains 10, 25, 50, or 100 milligrams (mg) cyclosporine.
    (2) Each milliliter of cyclosporine oral solution, USP (MODIFIED) 
contains 100 mg cyclosporine.

[[Page 144]]

    (b) Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Dogs. Use capsules described in paragraph 
(a)(1) of this section as follow:
    (i) Amount. Administer 5 mg per kilogram (mg/kg) of body weight 
given orally as a single daily dose for 30 days. Following this initial 
daily treatment period, the dosage may be tapered by decreasing the 
frequency of administration to every other day or two times a week, 
until a minimum frequency is reached which will maintain the desired 
therapeutic effect.
    (ii) Indications for use. For the control of atopic dermatitis in 
dogs weighing at least 4 pounds.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Cats. Use the solution described in paragraph (a)(2) of this 
section as follow:
    (i) Amount. Administer 7 mg/kg of body weight orally as a single 
daily dose for a minimum of 4 to 6 weeks or until resolution of clinical 
signs. Following this initial daily treatment period, the dosage may be 
tapered by decreasing the frequency of administration to every other day 
or twice weekly to maintain the desired therapeutic effect.
    (ii) Indications for use. For the control of feline allergic 
dermatitis in cats at least 6 months of age and weighing at least 3 
pounds.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

[68 FR 54804, Sept. 19, 2003, as amended at 76 FR 78815, Dec. 20, 2011]



Sec. 520.530  Cythioate oral liquid.

    (a) Specifications. Each milliliter contains 15 milligrams of 
cythioate.
    (b) Sponsor. See Nos. 000859 and 053501 in Sec. 510.600 of this 
chapter.
    (c) Special considerations. Cythioate is a cholinesterase inhibitor. 
Do not use this product in animals simultaneously with or within a few 
days before or after treatment with or exposure to cholinesterase-
inhibiting drugs, insecticides, pesticides, or chemicals.
    (d) Conditions of use--(1) Amount. 15 milligrams cythioate per 10 
pounds of body weight every third day or twice a week.
    (2) Indications for use. Dogs, for control of fleas.
    (3) Limitations. For oral use in dogs only. Do not use in greyhounds 
or in animals that are pregnant, sick, under stress, or recovering from 
surgery. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[49 FR 5614, Feb. 14, 1984, as amended at 67 FR 78355, Dec. 24, 2002]



Sec. 520.531  Cythioate tablets.

    (a) [Reserved]
    (b) Sponsors. See No. 000859 in Sec. 510.600(c) of this chapter for 
use of 30- and 90-milligram (mg) tablets and see No. 053501 in Sec. 
510.600(c) of this chapter for use of 30-mg tablet.
    (c) Special considerations. Cythioate is a cholinesterase inhibitor. 
Do not use this product in animals simultaneously with or within a few 
days before or after treatment with or exposure to cholinesterase-
inhibiting drugs, insecticides, pesticides, or chemicals.
    (d) Conditions of use--(1) Amount. 30 milligrams cythioate per 20 
pounds of body weight every third day or twice a week.
    (2) Indications for use. Dogs, for control of fleas.
    (3) Limitations. For oral use in dogs only. Do not use in greyhounds 
or in animals that are pregnant, sick, under stress, or recovering from 
surgery. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[49 FR 5615, Feb. 14, 1984, as amended at 59 FR 26942, May 25, 1994; 67 
FR 78355, Dec. 24, 2002]



Sec. 520.534  Decoquinate.

    (a) Specifications. The drug is a powder containing 0.8 percent 
decoquinate.
    (b) Sponsor. See No. 046573 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.170 of this chapter.
    (d) Conditions of use. Calves--(1) Amount. Feed 22.7 milligrams per 
100 pounds of body weight (0.5 milligram per kilogram) per day.
    (2) Indications for use. For the prevention of coccidiosis in 
ruminating and nonruminating calves, including veal calves, caused by 
Eimeria bovis and E. zuernii.

[[Page 145]]

    (3) Limitations. Feed in whole milk at the rate of 22.7 milligrams 
per 100 pounds body weight daily (0.5 milligram per kilogram) for at 
least 28 days.

[64 FR 10103, Mar. 2, 1999, as amended at 64 FR 30386, June 8, 1999]



Sec. 520.538  Deracoxib.

    (a) Specifications. Each tablet contains 12, 25, 50, 75, or 100 
milligrams (mg) deracoxib.
    (b) Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use in dogs--(1) Amount. Administer orally as 
needed, as a single daily dose based on body weight:
    (i) 1 to 2 mg/kilogram (kg) (0.45 to 0.91 mg/pound (lb)), for use as 
in paragraph (d)(2)(i) of this section.
    (ii) 1 to 2 mg/kg (0.45 to 0.91 mg/lb) for 3 days, for use as in 
paragraph (d)(2)(ii) of this section.
    (iii) 3 to 4 mg/kg (1.4 to 1.8 mg/lb) for up to 7 days, for use as 
in paragraph (d)(2)(iii) of this section.
    (2) Indications for use. (i) For the control of pain and 
inflammation associated with osteoarthritis.
    (ii) For the control of postoperative pain and inflammation 
associated with dental surgery.
    (iii) For the control of postoperative pain and inflammation 
associated with orthopedic surgery.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[67 FR 68760, Nov. 13, 2002, as amended at 68 FR 18882, Apr. 17, 2003; 
72 FR 37437, July 10, 2007; 73 FR 33692, June 13, 2008; 77 FR 3928, Jan. 
26, 2012]



Sec. 520.540  Dexamethasone oral dosage forms.



Sec. 520.540a  Dexamethasone powder.

    (a) Specifications. Dexamethasone powder is packaged in packets 
containing 10 milligrams of dexamethasone.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) Dexamethasone powder is indicated in 
cases where cattle and horses require additional steroid therapy 
following its parenteral administration. The drug is used as supportive 
therapy for management or inflammatory conditions such as acute 
arthritic lameness, and for various stress conditions where 
corticosteroids are required while the animal is being treated for a 
specific condition.
    (2) The drug is administered at a dosage level of 5 to 10 milligrams 
per animal the first day then 5 milligrams per day as required by drench 
or by sprinkling on a small amount of feed.
    (3) Clinical and experimental data have demonstrated that 
corticosteroids administered orally or parenterally to animals may 
induce the first stage of parturition when administered during the last 
trimester of pregnancy and may precipitate premature parturition 
followed by dystocia, fetal death, retained placenta, and metritis.
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian. A withdrawal period has not been established for 
this product in preruminating calves. Do not use in calves to be 
processed for veal.

[40 FR 13838, Mar. 27, 1975; 41 FR 9149, Mar. 3, 1976; 52 FR 7832, Mar. 
13, 1987; 70 FR 16934, Apr. 4, 2005]



Sec. 520.540b  Dexamethasone tablets and boluses.

    (a)(1) Specifications. Each bolus is half-scored and contains 10 
milligrams of dexamethasone.
    (2) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) Dexamethasone bolus is indicated in cases 
where cattle and horses require additional steroid therapy following its 
parenteral administration. The drug may be used as supportive therapy 
for management of inflammatory conditions such as acute arthritic 
lamenesses, and for various stress conditions where corticosteroids are 
required while the animal is being treated for a specific condition.
    (ii) Administered orally, 5 to 10 milligrams for the first day, then 
5 milligrams per day as required.
    (iii) Do not use in viral infections during the viremic stage. With 
bacterial infections, appropriate antibacterial therapy should be used.
    (iv) Do not use in animals with chronic nephritis and 
hypercorticalism

[[Page 146]]

(cushingoid syndrome), except for emergency therapy.
    (v) Clinical and experimental data have demonstrated that 
corticosteroids administered orally or by injection to animals may 
induce the first stage of parturition when administered during the last 
trimester of pregnancy and may precipitate premature parturition 
followed by dystocia, fetal death, retained placenta, and metritis.
    (vi) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian. A withdrawal period has not been established for 
this product in preruminating calves. Do not use in calves to be 
processed for veal.
    (b)(1) Specifications. Each tablet contains 0.25 milligram of 
dexamethasone.\1\
    (2) Sponsors. See Nos. 000061 and 061623 in Sec. 510.600(c) of this 
chapter.
    (3) Conditions of use--(i) Amount. Dogs: Administer orally at 0.25 
to 1.25 milligrams per day for up to 7 days. Cats: 0.125 to 0.5 
milligram per day for up to 7 days.\1\
    (ii) Indications for use. In treatment of dogs and cats as an anti-
inflammatory agent.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter.
---------------------------------------------------------------------------

    (iii) Limitations. (a) Clinical and experimental data have 
demonstrated that corticosteriods administered orally or by injection to 
animals may induce the first stage of parturition when administered 
during the last trimester of pregnancy; and they may precipitate 
premature parturition followed by dystocia, fetal death, retained 
placenta, and metritis.
    (b) Do not use in viral infections. Anti-inflammatory action of 
corticosteroids may mask signs of infections. Do not use in animals with 
tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers, 
except for emergency therapy.\1\
    (c) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.\1\

[40 FR 26273, June 23, 1975, as amended at 44 FR 7130, Feb. 6, 1979; 50 
FR 49372, Dec. 2, 1985; 52 FR 7832, Mar. 13, 1987; 55 FR 8461, Mar. 8, 
1990; 66 FR 14073, Mar. 9, 2001; 68 FR 4914, Jan. 31, 2003; 70 FR 16934, 
Apr. 4, 2005]



Sec. 520.540c  Dexamethasone chewable tablets.

    (a) Specifications. Each half-scored tablet contains 0.25 milligram 
of dexamethasone.\1\
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 0.25 to 1.25 milligrams per 
day.\1\
    (2) Indications for use. Supportive therapy in nonspecific 
dermatosis and inflammatory conditions in dogs.\1\
    (3) Limitations. (i) Administer by free-choice feeding or crumble 
over food. Administer 0.25 to 1.25 milligrams daily in single or two 
divided doses until response is noted or 7 days have elapsed. When 
response is attained, dosage should be gradually reduced by 0.125 
milligram per day until maintenance level is achieved.
    (ii) Clinical and experimental data have demonstrated that 
corticosteriods administered orally or parenterally to animals may 
induce the first stage of parturition when administered during the last 
trimester of pregnancy; and they may precipitate premature parturition 
followed by dystocia, fetal death, retained placenta, and metritis.
    (iii) Do not use in viral infections. Anti-inflammatory action of 
corticosteriods may mask signs of infection. Do not use in animals with 
tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers, 
except for emergency therapy.\1\
    (iv) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[44 FR 7130, Feb. 6, 1979, as amended at 56 FR 50653, Oct. 8, 1991; 60 
FR 55659, Nov. 2, 1995]



Sec. 520.550  Glucose/glycine/electrolyte.

    (a) Specifications. The product is distributed in packets each of 
which contains the following ingredients: Sodium chloride 8.82 grams, 
potassium phosphate 4.20 grams, citric acid anhydrous 0.5 gram, 
potassium citrate 0.12 gram, aminoacetic acid (glycine) 6.36 grams, and 
glucose 44.0 grams.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) Glucose/glycine/electrolyte is indicated 
for use in the control of dehydration associated with diarrhea (scours) 
in calves. It is used as an early treatment at the first

[[Page 147]]

signs of scouring. It may also be used as followup treatment following 
intravenous fluid therapy.
    (2) Dissolve each packet in two quarts of warm water and administer 
to each calf as follows:
    (i) Scouring and/or dehydrated calves. Feed 2 quarts of solution, 
twice daily for 2 days (four feedings). No milk or milk replacer should 
be fed during this period. For the next four feedings (days 3 and 4), 
use 1 quart of solution together with 1 quart of milk replacer. 
Thereafter, feed as normal.
    (ii) Newly purchased calves. Feed 2 quarts of solution instead of 
milk as the first feed upon arrival. For the next scheduled feeding, use 
1 quart of solution mixed together with 1 quart of milk or milk 
replacer. Thereafter, feed as normal.
    (3) The product should not be used in animals with severe 
dehydration (down, comatose, or in a state of shock). Such animals need 
intravenous therapy. A veterinarian should be consulted in severely 
scouring calves. The product is not nutritionally complete if 
administered by itself for long periods of time. It should not be 
administered beyond the recommended treatment period without the 
addition of milk or milk replacer.

[48 FR 38606, Aug. 25, 1983, as amended at 56 FR 50653, Oct. 8, 1991; 60 
FR 55659, Nov. 2, 1995; 76 FR 17336, Mar. 29, 2011]



Sec. 520.563  Diatrizoate meglumine and diatrizoate sodium oral 
solution.

    (a) Specifications. Diatrizoate meglumine oral solution is a water 
soluble radiopaque medium containing 66 percent diatrizoate meglumine 
and 10 percent diatrizoate sodium.
    (b) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is indicated for radiography of the 
gastrointestinal tract in dogs and cats.
    (2) It is administered orally at a dosage level of 0.5 to 1.0 
milliliter per pound of body weight by gavage or stomach tube. It is 
administered rectally at a dosage level of 0.5 to 1.0 milliliter per 
pound of body weight diluted with 1 part of the drug to 5 parts of 
water.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[44 FR 12993, Mar. 9, 1979, as amended at 50 FR 41489, Oct. 11, 1985]



Sec. 520.580  Dichlorophene and toluene.

    (a) Specifications. Each capsule contains 50 milligrams (mg) of 
dichlorophene and 60 mg of toluene, or multiples thereof.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (c) of this section:
    (1) Nos. 017135, 023851, 051311, and 058670 for use only as a single 
dose.
    (2) Nos. 000010 and 000061 for use in a single dose or divided-
dosage regimen.
    (c) Required statement. Consult your veterinarian for assistance in 
the diagnosis, treatment, and control of parasitism, and before 
administering to weak or debilitated animals.
    (1) Amount. Administer as follows:
    (i) Single dose: Administer 100 mg of dicholorophene and 120 mg of 
toluene per pound of body weight.
    (ii) Divided dose: Administer 100 mg of dichlorophene and 120 mg of 
toluene per 5 pounds of body weight (20 and 24 mg per pound) daily for 6 
days.
    (2) Indications for use. For the removal of ascarids (Toxocara canis 
and Toxascaris leonina) and hookworms (Ancylostoma caninum and Uncinaria 
stenocephala); and as an aid in removing tapeworms (Taenia pisiformis, 
Dipylidium caninum, and Echinococcus granulosus) from dogs and cats.
    (3) Limitations. Withhold solid foods and milk for at least 12 hours 
prior to medication and for 4 hours afterward. Repeat treatment in 2 to 
4 weeks in animals subject to reinfection.

[45 FR 10332, Feb. 15, 1980]

    Editorial Note: For Federal Register citations affecting Sec. 
520.580, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 520.581  Dichlorophene tablets.

    (a) Specifications. Each tablet contains 1 gram of dichlorophene.
    (b) Sponsor. See 023851 in Sec. 510.600(c) of this chapter.

[[Page 148]]

    (c) Required statement. Consult your veterinarian for assistance in 
the diagnosis, treatment, and control of parasitism, and before 
administering to weak or debilitated animals.
    (d) Conditions of use. Dogs--(1) Amount. Single dose of 1 tablet (1 
gram of dichlorophene) for each 10 pounds of body weight.
    (2) Indications for use. It is used as an aid in the removal of 
tapeworms (Taenia pisiformis and Dipylidium caninum).
    (3) Limitations. Withhold solid foods and milk for at least 12 hours 
prior to medication and for 4 hours afterward.

[45 FR 10333, Feb. 15, 1980]



Sec. 520.600  Dichlorvos.

    (a) Chemical name. 2,2-Dichlorvinyl dimethyl phosphate.
    (b) [Reserved]
    (c) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (d) Related tolerances. See Sec. 556.180 of this chapter.
    (e) Conditions of use in swine. (1) It is recommended for the 
removal and control of sexually mature (adult), sexually immature and/or 
4th stage larvae of the whipworm (Trichuris suis), nodular worms 
(Oesophagostomum spp.), large round-worm (Ascaris suum), and the mature 
thick stomach worm (Ascarops strongylina) occurring in the lumen of the 
gastrointestinal tract of pigs, boars, and open or bred gilts and sows.
    (2) The preparation should be added to the indicated amount of feed 
as set forth in paragraph (e)(2) of this section and administered 
shortly after mixing, as follows:

------------------------------------------------------------------------
                                                  Pounds of
                                     Pounds of   mixed feed    Number of
                                    feed to be      to be     pigs to be
    Weight of animal in pounds      mixed with  administered    treated
                                     each 0.08   to each pig   per 0.08
                                     ounce of    as a single   ounce of
                                    dichlorvos    treatment   dichlorvos
------------------------------------------------------------------------
20-30.............................           4         0.33           12
31-40.............................           5         0.56            9
41-60.............................           6         1.00            6
61-80.............................           5         1.00            5
81-100............................           4         1.00            4
Adult Gilts, Sows, and Boars......          16         4.00            4
------------------------------------------------------------------------

    (3) Do not use this product on animals either simultaneously or 
within a few days before or after treatment with or exposure to 
cholinesterase inhibiting drugs, pesticides, or chemicals. The 
preparation should be mixed thoroughly with the feed on a clean, 
impervious surface. Do not allow swine access to feed other than that 
containing the preparation until treatment is complete. Do not treat 
pigs with signs of scours until these signs subside or are alleviated by 
proper medication. Resume normal feeding schedule afterwards. Swine may 
be retreated in 4 to 5 weeks.
    (f) Conditions of use in dogs. (1) For removal of Toxocara canis and 
Toxascaris leonina (roundworms), Ancylostoma caninum and Uncinaria 
stenocephala (hookworms), and Trichuris vulpis (whipworm) residing in 
the lumen of the gastrointestinal tract.
    (2) The drug is in capsule form for direct administration and in 
pellet form for administration in about one-third of the regular canned 
dog food ration or in ground meat. Dogs may be treated with any 
combination of capsules and/or pellets so that the animal receives a 
single dose equaling 12 to 15 milligrams of the active ingredient per 
pound of body weight. One-half of the single recommended dosage may be 
given, and the other half may be administered 8 to 24 hours later. This 
split dosage schedule should be used in animals which are very old, 
heavily parasitized, anemic, or otherwise debilitated. The drug should 
not be used in dogs weighing less than 2 pounds.
    (3) In some dogs, efficacy against Trichurias vulpis (whipworm) may 
be erratic. Dogs that do not develop a negative stool for Trichuris 
vulpis ova 10 to 14 days following initial treatment should be re-
treated. If a negative stool is not obtained in 10 to 14 days following 
re-treatment, alternate means of therapy should be considered.
    (4) Do not use in dogs infected with Dirofilaria immitis.
    (5) Do not use with other anthelmintics, taeniacides, antifilarial 
agents, muscle relaxants, or tranquilizers.
    (6) The drug is a cholinesterase inhibitor. Not for use 
simultaneously or

[[Page 149]]

within a few days before or after treatment with or exposure to 
cholinesterase-inhibiting drugs, pesticides, or chemicals.
    (7) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (g) Conditions of use in horses when administered in grain. (1) It 
is recommended for the removal and control of bots (Gastrophilus 
intestinalis, G. nasalis), large strongyles (Strongylus vulgaris, S. 
equinus, S. edentatus), small strongyles (of the genera Cyathostomum, 
Cylicocercus, Cylicocyclus, Cylicodontophorus, Triodontophorus, 
Poteriostomum, Gyalocephalus), pinworms (Oxyuris equi), and large 
roundworm (Parascaris equorum) in horses including ponies and mules. Not 
for use in foals (sucklings and young weanlings).
    (2) For a satisfactory diagnosis, a microscopic fecal examination 
should be performed by a veterinarian or a diagnostic laboratory prior 
to worming.
    (3) It is administered in the grain portion of the ration at a 
dosage of 14.2 milligrams to 18.5 milligrams per pound of body weight as 
a single dose. It may be administered at one-half of the single 
recommended dosage and repeated 8 to 12 hours later in the treatment of 
very aged, emaciated or debilitated subjects or those reluctant to 
consume medicated feed. In suspected cases of severe ascarid infection 
sufficient to cause concern over mechanical blockage of the intestinal 
tract, the split dosage should be utilized.
    (4) Do not use in horses which are severely debilitated, suffering 
from diarrhea or severe constipation, infectious disease, toxemia or 
colic. Do not administer in conjunction with or within 1 week of 
administration of muscle relaxant drugs, phenothiazine derived 
tranquilizers or central nervous system depressant drugs. Horses should 
not be subjected to insecticide treatment for 5 days prior to or after 
treating with the drug. Do not administer to horses afflicted with 
chronic alveolar emphysema (heaves) or related respiratory conditions. 
The product is a cholinesterase inhibitor and should not be used 
simultaneously or within a few days before or after treatment with or 
exposure to cholinesterase inhibiting drugs, pesticides or chemicals.
    (5) Do not use in animals other than horses, ponies, and mules. Do 
not use in horses, ponies, and mules intended for food purposes. Do not 
allow fowl access to feed containing this preparation or to fecal 
excrement from treated animals.
    (h) Conditions of use in horses when administered orally by syringe. 
(1) It is recommended for the removal and control of first, second, and 
third instar bots (Gastrophilus intestinalis and G. nasalis), sexually 
mature and sexually immature (4th stage) ascarids (Parascaris equorum) 
in horses and foals.
    (2) The product is in the form of a gel which is administered 
directly from a syringe onto the horse's tongue. The product is 
administered at a dosage level of 20 milligrams of dichlorvos per 
kilogram of body weight for the removal of bots and ascarids. The same 
dosage level is repeated every 21 to 28 days for the control of bots and 
ascarids. For the control of bots only, the repeat dosage is 10 
milligrams per kilogram of body weight every 21 to 28 days during bot 
fly season.
    (3) Do not use this product in animals simultaneously or within a 
few days before or after treatment with or exposure to cholinesterase-
inhibiting drugs, pesticides or chemicals. Do not administer in 
conjunction with or within 1 week of administration of muscle-relaxant 
drugs, phenothiazine derived tranquilizers, or central nervous system 
depressants.
    (4) Do not use in horses which are severly debilitated or suffering 
from diarrhea or severe constipation, infectious disease, toxemia, or 
colic. Do not administer to horses affected with chronic alveolar 
emphysema (heaves) or other respiratory conditions.
    (5) Do not use in horses intended for food purposes.
    (6) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (i) Conditions of use in dogs, cats, puppies, and kittens. (1) Each 
tablet contains 2, 5, 10, or 20 milligrams of dichlorvos.
    (2) It is administered orally at 5 milligrams of dichlorvos per 
pound of body weight.

[[Page 150]]

    (3) Dogs and puppies: Removal and control of intestinal roundworms 
(Toxocara canis and Toxascaris leonina) and hookworms (Ancylostoma 
caninum and Uncinaria stenocephala).
    (4) Cats and kittens: Removal and control of intestinal roundworms 
(Toxocara cati and Toxascaris leonina) and hookworms (Ancylostoma 
tubaeforme and Uncinaria stenocephala).
    (5) Dichlorvos is a cholinesterase inhibitor. Do not use 
simultaneously with or within a few days before or after treatment with 
or exposure to cholinesterase-inhibiting drugs, pesticides, or 
chemicals.
    (6) Do not use in animals under 10 days of age or 1 pound of body 
weight.
    (7) Do not administer to animals showing signs of constipation, 
mechanical blockage of the intestinal tract, impaired liver function, or 
recently exposed to or showing signs of infectious disease.
    (8) Do not use in dogs or puppies infected with Dirofilaria immitis.
    (9) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 48 FR 40704, Sept. 9, 1983; 
51 FR 28546, Aug. 8, 1986; 62 FR 35076, June 30, 1997; 64 FR 18571, Apr. 
15, 1999]



Sec. 520.606  Diclazuril.

    (a) Specifications. Each 100 grams (g) of pellets contain 1.56 g 
diclazuril.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. Administer 1 milligram 
(mg) per kilogram (0.45 mg per pound) of body weight in the daily grain 
ration for 28 days.
    (2) Indications for use. For the treatment of equine protozoal 
myeloencephalitis (EPM) caused by Sarcocystis neurona.
    (3) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[72 FR 20943, Apr. 27, 2007]



Sec. 520.608  Dicloxacillin sodium monohydrate capsules.

    (a) Specifications. Each capsule contains dicloxacillin sodium 
monohydrate equivalent to 50, 100, 200, or 500 milligrams of 
dicloxacillin.
    (b) Sponsor. See No. 000856 in Sec. 510.600 (c) of this chapter.
    (c) Conditions of use. Dogs--(1) Amount. 5 to 10 milligrams per 
pound of body weight, three times daily. In severe cases, up to 25 
milligrams per pound of body weight three times daily.
    (2) Indications for use. Treatment of pyoderma (pyogenic dermatitis) 
due to penicillinase-producing staphylococci sensitive to the drug.
    (3) Limitations. For the treatment of dogs only. Continue treatment 
for 24 to 48 hours after the animal has become afebrile or asymptomatic, 
Administer 1 to 2 hours before feeding to ensure maximum absorption. Not 
for use in animals which are raised for food production. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.

[57 FR 37325, Aug. 18, 1992]



Sec. 520.620  Diethylcarbamazine oral dosage forms.



Sec. 520.622  Diethylcarbamazine citrate oral dosage forms.



Sec. 520.622a  Diethylcarbamazine citrate tablets.

    (a) Sponsors. (1) [Reserved]
    (2) See 053501 in Sec. 510.600(c) of this chapter for use of 100, 
200, and 300 milligram tablets for prevention of heartworm disease in 
dogs and as an aid in the treatment of ascarid infections in dogs.
    (3) See 061623 in Sec. 510.600(c) of this chapter for use of 50, 
100, 200, 300, or 400 milligram tablets for prevention of heartworm 
disease in dogs, as an aid in the control of ascarid infections in dogs, 
and as an aid in the treatment of ascarid infections in dogs and cats.
    (4) [Reserved]
    (5) See No. 000061 in Sec. 510.600(c) of this chapter for use of 
60, 120, or 180 milligram tablets for prevention of heartworm disease in 
dogs, as an aid in the control of ascarid infections in dogs, and as an 
aid in the treatment of ascarid infections in dogs and cats.
    (6) See No. 000010 in Sec. 510.600(c) of this chapter for use of 
50, 100, 200, 300, or 400 milligram tablets for prevention of heartworm 
disease in dogs, as an aid in

[[Page 151]]

the control of ascarid infections in dogs, and as an aid in the 
treatment of ascarid infections in dogs and cats.
    (b) Conditions of use--(1) Dosage/indications for use. (i) Three 
milligrams per pound of body weight daily for prevention of heartworm 
disease (Dirofilaria immitis) in dogs.
    (ii) Three milligrams per pound of body weight daily as an aid in 
the control of ascarid infections (Toxocara canis) in dogs.
    (iii) Twenty-five to 50 milligrams per pound of body weight as an 
aid in the treatment of ascarid infections in dogs (Toxocara canis) and 
cats (Toxocara canis and Toxascaris leonina).
    (2) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[46 FR 23230, Apr. 24, 1981, as amended at 46 FR 41038, Aug. 14, 1981; 
46 FR 46315, Sept. 18, 1981; 46 FR 61653, Dec. 18, 1981; 47 FR 10805, 
Mar. 12, 1982; 47 FR 14150, Apr. 2, 1982; 50 FR 41489, Oct. 11, 1985; 50 
FR 49372, Dec. 2, 1985; 53 FR 40056, Oct. 13, 1988; 53 FR 40727, Oct. 
18, 1988; 55 FR 8461, Mar. 8, 1990; 61 FR 34728, July 3, 1996; 62 FR 
35076, June 30, 1997; 66 FR 14073, Mar. 9, 2001; 68 FR 4914, Jan. 31, 
2003; 76 FR 17777, Mar. 31, 2011; 77 FR 4896, Feb. 1, 2012]



Sec. 520.622b  Diethylcarbamazine citrate syrup.

    (a)(1) Specifications. Each milliliter of syrup contains 60 
milligrams of diethylcarbamazine citrate.
    (2) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) The drug is indicated for use in dogs for 
the prevention of infection with Dirofilaria immitis and T. canis and T. 
leonina. It is also indicated for treatment of ascarid infections of T. 
canis and T. leonina in dogs and T. cati in cats.
    (ii) For prevention of heartworm and ascarid infections in dogs, the 
drug may be added to the daily diet at a dosage rate of 3.0 milligrams 
per pound of body weight per day or given directly by mouth at the same 
dosage rate. For treatment of ascarid infections in dogs and cats, the 
drug is administered at a dosage level of 25 to 50 milligrams per pound 
of body weight preferably administered immediately after feeding.
    (iii) Older dogs should be proven negative for the presence of 
Dirofilaria immitis infection before administration of the drug. Those 
with proven infection of Dirofilaria immitis should be rendered negative 
using adulticidal and microfilaricidal drugs before administration of 
this drug.
    (iv) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (b) [Reserved]
    (c)(1) Specifications. Each milliliter of syrup contains 60 
milligrams of diethylcarbamazine citrate.
    (2) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) The drug is used in dogs between 4 weeks 
and 8 months of age for the removal of ascarids (Toxacara canis) and in 
animals over 4 weeks of age for the prevention of heartworm disease 
(Dirofilaria immitis).
    (ii) The drug is administered (a) for removal of ascarids at a 
dosage of 50 milligrams per pound of body weight divided into two equal 
doses and administered 8 to 12 hours apart (morning and night), orally 
or mixed with either dry or wet food, and (b) for prevention of 
heartworm disease at a dosage of 3 milligrams per pound of body weight 
daily, orally or in food, in heartworm endemic areas, from the beginning 
of mosquito activity, during the mosquito season, and for 2 months 
following the end thereof.
    (iii) Dogs older than 8 months of age may be infected with 
Dirofilaria immitis. Use of the drug is contraindicated in dogs with 
active D. immitis infections.
    (iv) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 41 FR 28265, July 9, 1976; 44 
FR 3967, Jan. 19, 1979; 47 FR 14150, Apr. 2, 1982; 47 FR 35186, Aug. 13, 
1982; 49 FR 33997, Aug. 28, 1984; 50 FR 41489, Oct. 11, 1985; 53 FR 
47027, Oct. 18, 1988; 61 FR 34728, July 3, 1996; 62 FR 35076, June 30, 
1997; 62 FR 38906, July 21, 1997; 77 FR 4897, Feb. 1, 2012]



Sec. 520.622c  Diethylcarbamazine citrate chewable tablets.

    (a) Specifications. Each chewable tablet contains 30, 45, 60, 120, 
150, or 180 milligrams of diethylcarbamazine citrate.
    (b) Sponsors. See drug listing nos. in Sec. 510.600(c) of this 
chapter for identification of sponsors as follows:

[[Page 152]]

    (1) [Reserved]
    (2) For 000069, use of 60, 120, or 180 milligram tablets as in 
paragraph (c)(2)(ii) of this section.
    (3) For 061690, use of 45 or 150 milligram tablets as in paragraph 
(c)(2)(iii) of this section.
    (4) For 061133, use of 60-, 120-, or 180-milligram tablets as in 
paragraph (c)(2)(i) of this section.
    (5) For 000061, use of 60-milligram tablets as in paragraph 
(c)(2)(i) of this section.
    (6) For 000010, use of 30, 60, 120, or 180 milligram tablets as in 
paragraph (c)(2)(i) of this section.
    (c) Conditions of use--(1) Amount. 3 milligrams per pound of body 
weight per day for prevention of heartworm disease and control of 
ascarids; 25 to 50 milligrams per pound of body weight as an aid in 
treatment of ascarid infections.
    (2) Indications for use. (i) For prevention of heartworm disease 
(Dirofilaria immitis) in dogs; as an aid in control of ascarids 
(Toxocara canis) in dogs; as an aid in treatment of ascarid (Toxocara 
canis and Toxascaris leonina) infections in dogs and cats.
    (ii) For prevention of infection with Dirofilaria immitis (heartworm 
disease) in dogs; as an aid in treatment of ascarid (Toxocara canis and 
Toxascaris leonina) infections in dogs.
    (iii) For prevention of heartworm disease (Dirofilaria immitis) in 
dogs.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[43 FR 6941, Feb. 17, 1978]

    Editorial Note: For Federal Register citations affecting Sec. 
520.622c, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 520.622d  Diethylcarbamazine citrate capsules.

    (a) Specifications. Each capsule contains 12.5, 50, 200, or 400 
milligrams (mg) diethylcarbamazine citrate.
    (b) Sponsor. See No. 011014 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount/indications for use. 3 mg 
per pound (/lb) body weight daily for prevention of heartworm disease 
(Dirofilaria immitis); 25 to 50 mg/lb body weight in a single dose as an 
aid in the treatment of ascarid infections (Toxocara canis and 
Toxascaris leonina).
    (2) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[70 FR 50182, Aug. 26, 2005]



Sec. 520.623  Diethylcarbamazine citrate, oxibendazole chewable tablets.

    (a) Specifications. Each tablet contains either 60, 120, or 180 
milligrams of diethylcarbamazine citrate with 45, 91, or 136 milligrams 
of oxibendazole, respectively.
    (b) Sponsor. See 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Administer orally to dogs 
at a dosage level of 6.6 milligrams of diethylcarbamazine citrate per 
kilogram of body weight (3 milligrams per pound of body weight) and 5.0 
milligrams of oxibendazole per kilogram of body weight (2.27 milligrams 
per pound of body weight).
    (2) Indications for use. For prevention of infection with 
Dirofilaria immitis (heartworm disease) and Ancylostoma caninum 
(hookworm infection) and for removal and control of Trichuris vulpis 
(whipworm infection) and mature and immature stages of intestinal 
Toxocara canis (ascarid infection).
    (3) Limitations. Orally administer daily during heartworm season. 
For free-choice feeding or broken and placed on or mixed with feed. Do 
not use in dogs that may harbor adult heartworms. Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.

[50 FR 28768, July 16, 1985, as amended at 53 FR 45759, Nov. 14, 1988; 
54 FR 3776, Jan. 26, 1989; 54 FR 6804, Feb. 14, 1989; 56 FR 50653, Oct. 
8, 1991; 60 FR 55659, Nov. 2, 1995]



Sec. 520.645  Difloxacin.

    (a) Specifications. Each tablet contains 11.4, 45.4, or 136 
milligrams (mg) of difloxacin hydrochloride.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(i) Amount. Administer 5 to 10 mg per 
kilogram (2.3 to 4.6 mg per pound) of body weight orally

[[Page 153]]

once a day for 2 to 3 days beyond cessation of clinical signs of disease 
up to a maximum of 30 days.
    (ii) Indications for use. For management of diseases in dogs 
associated with bacteria susceptible to difloxacin.
    (iii) Limitations. Federal law prohibits the extra-label use of this 
drug in food-producing animals. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (2) [Reserved]

[63 FR 8123, Feb. 18, 1998, as amended at 75 FR 10165, Mar. 5, 2010]



Sec. 520.666  Dirlotapide.

    (a) Specifications. Each milliliter (mL) of solution contains 5 
milligrams (mg) dirlotapide.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. The initial dosage is 
0.01 mL/kg (0.0045 mL/lb) body weight for the first 14 days. After the 
first 14 days of treatment, the dose volume is doubled to 0.02 mL/kg 
(0.009 mL/lb) body weight for the next 14 days (days 15 to 28 of 
treatment). Dogs should be weighed monthly and the dose volume adjusted 
every month, as necessary, to maintain a target percent weight loss 
until the desired weight is achieved.
    (2) Indications for use. For the management of obesity.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[72 FR 263, Jan. 4, 2007]



Sec. 520.763  Dithiazanine iodide oral dosage forms.



Sec. 520.763a  Dithiazanine iodide tablets.

    (a) Chemical name. 3-Ethyl-2-[5-(3-ethyl - 2 - 
benzothiazolinylidene) - 1,3 - pentadienyl]-benzothiazolium iodide.
    (b) Specifications. Dithiazanine iodide tablets contain 10 
milligrams, 50 milligrams, 100 milligrams, or 200 milligrams of 
dithiazanine iodide in each tablet.
    (c) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) The tablets are administered orally to 
dogs immediately after feeding using the following dosage schedule for 
various parasite infestations:

------------------------------------------------------------------------
                                             Milligrams
                                              per pound     Length of
                                               of body   treatment--days
                                               weight
------------------------------------------------------------------------
Large roundworms (Toxocara canis,                    10            3-5
 Toxascaris leonina).......................
Hookworms (Ancylostoma caninum, Uncinaria            10              7
 stenocephala).............................
Whipworms (Trichuris vulpis)...............          10
Strongyloides (Strongyloides canis,                  10          10-12
 Strongyloides stercoralis)................
Heartworm microfilariae (Dirofilaria                3-5           7-10
 immitus)..................................
------------------------------------------------------------------------
Note: Treatment with dithiazanine iodide for heartworm microfilariae
  should follow 6 weeks after therapy for adult worms.

    (2) The drug is contraindicated in animals sensitive to dithiazanine 
iodide and should be used cautiously, if at all, in dogs with reduced 
renal function.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (e) Use for treating dogs for large roundworms, hookworms, 
whipworms, and strongyloides as provided for in this section has been 
NAS/NRC reviewed and deemed effective. Applications for these uses need 
not include effectiveness data as specified by Sec. 514.111 of this 
chapter, but may require bioequivalency and safety information.

[40 FR 13838, Mar. 27, 1975, as amended at 47 FR 51564, Nov. 16, 1982; 
48 FR 32342, July 15, 1983; 53 FR 40727, Oct. 18, 1988; 62 FR 35076, 
June 30, 1997]



Sec. 520.763b  Dithiazanine iodide powder.

    (a) Chemical name. 3-Ethyl-2-[5-(3-ethyl-2-benzothiazolinylidene)-
1,3-pentadienyl]-benzothiazoliumiodide.
    (b) Specifications. Dithiazanine iodide powder contains 200 
milligrams of dithiazanine iodide per level standard tablespoon.
    (c) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) Dithiazanine iodide powder is 
administered to dogs by mixing the proper dosage in the dog's food, 
using the following dosage schedule for various parasite infestations:

------------------------------------------------------------------------
                                             Milligrams
                                              per pound     Length of
                                               of body   treatment--days
                                               weight
------------------------------------------------------------------------
Large roundworms (Toxocara canis,                    10            3-5
 Toxascaris leonina).......................

[[Page 154]]

 
Hookworms (Ancylostoma caninum, Uncinaria            10              7
 stenocephala).............................
Whipworms (Trichuris vulpis)...............          10              7
Strongyloides (Strongyloides canis,                  10          10-12
 Strongyloides stercoralis)................
Heartworm microfilariae (Dirofilaria                3-5           7-10
 immitus)..................................
------------------------------------------------------------------------
Note: Treatment with dithiazanine iodide for heartworm microfilariae
  should follow 6 weeks after therapy for adult worms.

    (2) The drug is contraindicated in animals sensitive to dithiazanine 
iodide and should be used cautiously, if at all, in dogs with reduced 
renal function.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (e) Use for treating dogs for large roundworms, hookworms, 
whipworms, and strongyloides as provided for in this section has been 
NAS/NRC reviewed and deemed effective. Applications for these uses need 
not include effectiveness data as specified by Sec. 514.111 of this 
chapter, but may require bioequivalency and safety information.

[40 FR 13838, Mar. 27, 1975, as amended at 47 FR 51564, Nov. 16, 1982; 
48 FR 32342, July 15, 1983; 53 FR 40727, Oct. 18, 1988; 62 FR 35076, 
June 30, 1997]



Sec. 520.763c  Dithiazanine iodide and piperazine citrate suspension.

    (a) Specifications. Each milliliter of the drug contains 69 
milligrams of dithiazanine iodide and 83 milligrams of piperazine base 
(as piperazine citrate).
    (b) Sponsor. See 000010 in Sec. 510.600(c) of this chapter.
    (c) NAS/NRC status. The conditions of use are NAS/NRC reviewed and 
found effective. Applications for these uses need not include 
effectiveness data as specified by Sec. 514.111 of this chapter, but 
may require bioequivalency and safety information.
    (d) Conditions of use--(1) Amount. 1 ounce (30 milliliters) per 100 
pounds of body weight for the first 500 pounds; \3/4\ ounce for each 100 
pounds thereafter, up to 1,200 pounds; 10\1/4\ ounces to animals over 
1,200 pounds.
    (2) Indications for use. For control of large roundworms, Parascaris 
equorum; small strongyles; large strongyles, Strongylus vulgaris; and 
pinworms, Oxyuris equi.
    (3) Limitations. Administer by drench or mixed with the daily ration 
as a single dose. Treatment is recommended in spring and fall. In a 
heavily infested environment, treatment may be repeated every 30 days. 
Not for use in horses intended for food purposes. Severely debilitated 
animals should not be wormed except on the advice of a veterinarian. If 
the drug is for administration by stomach tube, it shall be labeled: 
``Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.''

[47 FR 52696, Nov. 23, 1982, as amended at 48 FR 32342, July 15, 1983; 
53 FR 40727, Oct. 18, 1988; 62 FR 35076, June 30, 1997]



Sec. 520.766  Domperidone.

    (a) Specifications. Each milliliter of gel contains 110 milligrams 
(mg) domperidone.
    (b) Sponsor. See No. 043264 in Sec. 510.600 of this chapter.
    (c) Conditions of use in horses--(1) Amount. Administer 0.5 mg per 
pound (mg/lb) (1.1 mg/kilogram (kg)) by mouth once daily starting 10 to 
15 days prior to the expected foaling date. Treatment may be continued 
for up to 5 days after foaling if mares are not producing adequate milk.
    (2) Indications for use. For prevention of fescue toxicosis in 
periparturient mares.
    (3) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[75 FR 67031, Nov. 1, 2010]



Sec. 520.784  Doxylamine succinate tablets.

    (a) Specifications. The drug is in tablet form and contains 
doxylamine succinate as the active drug ingredient.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.

[[Page 155]]

    (c) Conditions of use. (1) The drug is used in conditions in which 
antihistaminic therapy may be expected to alleviate some signs of 
disease in horses, dogs, and cats. \1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter.
---------------------------------------------------------------------------

    (2) It is administered orally to horses at a dosage level of 1 to 2 
milligrams per pound of body weight per day divided into 3 or 4 equal 
doses. It is administered orally to dogs and cats at a dosage level of 2 
to 3 milligrams per pound of body weight per day divided into 3 or 4 
equal doses. \1\
    (3) Not for use in horses intended for food. \1\
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian. \1\

[40 FR 13838, Mar. 27, 1975, as amended at 42 FR 60140, Nov. 25, 1977; 
46 FR 48642, Oct. 2, 1981; 61 FR 8873, Mar. 6, 1996; 62 FR 61624, Nov. 
19, 1997]



Sec. 520.804  Enalapril tablets.

    (a) Specifications. Each tablet contains either 1.0, 2.5, 5.0, 10.0, 
or 20.0 milligrams of enalapril maleate.
    (b) Sponsor. See 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. 0.5 to 1.0 milligram of 
enalapril maleate per kilogram of body weight per day.
    (ii) Indications for use. Treatment of mild, moderate, and severe 
(modified New York Heart Association Class II, III, IV) heart failure in 
dogs.
    (iii) Limitations. Use 0.5 milligram per kilogram once daily. In the 
absence of adequate clinical response within a 2-week period, use may be 
increased to twice daily (a total of 1.0 milligram per kilogram). 
Enalapril maleate is administered as conjunctive therapy with furosemide 
and digoxin in the treatment of dilated cardiomyopathy and furosemide 
with or without digoxin in the treatment of chronic valvular disease. 
The safety of enalapril for use in breeding dogs has not been 
established. Use in pregnant bitches is not recommended. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.
    (2) [Reserved]

[59 FR 17694, Apr. 14, 1994, as amended at 62 FR 63270, Nov. 28, 1997]



Sec. 520.812  Enrofloxacin tablets.

    (a) Specifications. Each tablet contains either 22.7, 68.0, or 136.0 
milligrams of enrofloxacin.
    (b) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Amount. 5 to 20 milligrams per kilogram 
(2.27 to 9.07 milligrams per pound) of body weight.
    (2) Indications for use. Dogs and cats for management of diseases 
associated with bacteria susceptible to enrofloxacin.
    (3) Limitations. Administer orally as a single dose or divided into 
2 equal doses at 12 hour intervals, daily. Administer for at least 2 to 
3 days beyond cessation of clinical symptoms, for a maximum of 30 days. 
Safety in breeding or pregnant cats has not been established. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.

[54 FR 3444, Jan. 24, 1989, as amended at 55 FR 43327, Oct. 29, 1990; 62 
FR 38906, July 21, 1997; 64 FR 48295, Sept. 3, 1999]



Sec. 520.816  Epsiprantel tablets.

    (a) Specifications. Each tablet contains either 12.5, 25, 50, or 100 
milligrams of epsiprantel.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. 2.5 milligrams per 
pound of body weight.
    (ii) Indications for use. Removal of canine cestodes Dipylidium 
caninum and Taenia pisiformis.
    (2) Cats--(i) Amount. 1.25 milligrams per pound of body weight.
    (ii) Indications for use. Removal of feline cestodes D. caninum and 
T. taeniaeformis.
    (3) Limitations. For oral use only as a single dose. Do not use in 
animals less than 7 weeks of age. Safety of use in pregnant or breeding 
animals has not been established. Federal law restricts

[[Page 156]]

this drug to use by or on the order of a licensed veterinarian.

[54 FR 50615, Dec. 8, 1989, as amended at 56 FR 50653, Oct. 8, 1991; 60 
FR 55659, Nov. 2, 1995]



Sec. 520.823  Erythromycin phosphate.

    (a) Specifications. Erythromycin phosphate is the phosphate salt of 
the antibiotic substance produced by the growth of Streptomyces 
erythreus or the same antibiotic substance produced by any other means. 
One gram of erythromycin phosphate is equivalent to 0.89 gram of 
erythromycin master standard.
    (b) Sponsor. See No. 061623 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.230 of this chapter.
    (d) Conditions of use. It is used in drinking water as follows:
    (1) Broiler and replacement chickens--(i) Amount. 0.500 gram per 
gallon.
    (ii) Indications for use. As an aid in the control of chronic 
respiratory disease due to Mycoplasma gallisepticum susceptible to 
erythromycin.
    (iii) Limitations. Administer for 5 days; do not use in replacement 
pullets over 16 weeks of age; do not use in chickens producing eggs for 
human consumption; to assure effectiveness, treated birds must consume 
enough medicated water to provide a therapeutic dosage; solutions older 
than 3 days should not be used; withdraw 1 day before slaughter.
    (2) Replacement chickens and chicken breeders--(i) Amount. 0.500 
gram per gallon.
    (ii) Indications for use. As an aid in the control of infectious 
coryza due to Hemophilus gallinarum susceptible to erythromycin.
    (iii) Limitations. Administer for 7 days; do not use in replacement 
pullets over 16 weeks of age; do not use in chickens producing eggs for 
human consumption; to assure effectiveness, treated birds must consume 
enough medicated water to provide a therapeutic dosage; solutions older 
than 3 days should not be used; withdraw 1 day before slaughter.
    (3) Growing turkeys--(i) Amount. 0.500 gram per gallon.
    (ii) Indications for use. As an aid in the control of blue comb 
(nonspecific infectious enteritis) caused by organisms susceptible to 
erythromycin.
    (iii) Limitations. Administer for 7 days; do not use in turkeys 
producing eggs for human consumption; to assure effectiveness, treated 
birds must consume enough medicated water to provide a therapeutic 
dosage; solutions older than 3 days should not be used; withdraw 1 day 
before slaughter.

[40 FR 13838, Mar. 27, 1975, as amended at 45 FR 56798, Aug. 26, 1980; 
66 FR 14073, Mar. 9, 2001; 68 FR 4914, Jan. 31, 2003]



Sec. 520.852  Estriol.

    (a) Specifications. Each tablet contains 1 milligram (mg) estriol.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Administer at an initial 
dose of 2 mg per dog per day. The dosage may be titrated to as low as 
0.5 mg per dog every second day, depending on response.
    (2) Indications for use. For the control of estrogen-responsive 
urinary incontinence in ovariohysterectomized female dogs.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[76 FR 78150, Dec. 16, 2011]



Sec. 520.863  Ethylisobutrazine hydrochloride tablets.

    (a) Specifications. Each tablet contains either 10 milligrams or 50 
milligrams of ethylisobutrazine hydrochloride.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is administered orally to dogs as a 
tranquilizer.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (2) It is administered once daily at a dosage level of 2 to 5 
milligrams of ethylisobutrazine hydrochloride per pound of body 
weight.\1\
    (3) It is not to be used in conjunction with organophosphates and/or 
procaine hydrochloride because phenothiazine may potentiate the toxicity 
of

[[Page 157]]

organophosphates and the activity of procaine hydrochloride.\1\
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.\1\

[40 FR 13838, Mar. 27, 1975, as amended at 46 FR 48642, Oct. 2, 1981; 61 
FR 8873, Mar. 6, 1996; 62 FR 61624, Nov. 19, 1997]



Sec. 520.870  Etodolac.

    (a) Specifications. Each tablet contains 150, 300, or 500 milligrams 
(mg) of etodolac.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(i) Amount. Administer 10 to 15 mg per 
kilogram (4.5 to 6.8 mg per pound) of body weight per day orally.
    (ii) Indications for use. For the management of pain and 
inflammation associated with osteoarthritis in dogs.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) [Reserved]

[63 FR 51300, Sept. 25, 1998, as amended at 68 FR 51705, Aug. 28, 2003; 
75 FR 10166, Mar. 5, 2010]



Sec. 520.903  Febantel oral dosage forms.



Sec. 520.903a  Febantel paste.

    (a) Chemical name. Dimethyl [[2-[(methoxyacetyl)amino]-4-(phenyl-
thio)phenyl] carbonimidoyl]bis [carbamate].
    (b) Specifications. The drug is a paste containing 45.5 percent 
febantel.
    (c) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use--(1) Amount. Six milligrams per kilogram (2.73 
milligrams per pound) of body weight in horses.
    (2) Indications for use. For removal of large strongyles (Strongylus 
vulgaris, S. edentatus, S. equinus); ascarids (Parascaris equorum-- 
sexually mature and immature); pinworms (Oxyuris equi-- adult and 4th 
stage larva); and the various small strongyles in horses, foals, and 
ponies.
    (3) Limitations. (i) The paste may be administered on the base of 
the tongue or well mixed into a portion of the normal grain ration.
    (ii) [Reserved]
    (iii) For animals maintained on premises where reinfection is likely 
to occur, retreatment may be necessary. For most effective results, 
retreat in 6 to 8 weeks.
    (iv) Not for use in horses intended for food.
    (v) Consult your veterinarian for assistance in the diagnosis, 
treatment, and control of parasitism.

[43 FR 8797, Mar. 3, 1978; 43 FR 12311, Mar. 24, 1978, as amended at 43 
FR 60882, Dec. 29, 1978. Redesignated at 45 FR 8587, Feb. 8, 1980]



Sec. 520.903b  Febantel suspension.

    (a) Specifications. The suspension contains 9.3 percent (2.75 grams 
per ounce) febantel.
    (b) Sponsor. See 000859 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 3 milliliters per 100 pounds body 
weight or 1 fluid ounce per 1000 pounds (6 milligrams per kilogram body 
weight).
    (2) Indications for use. For removal of ascarids (Parascaris 
equorum--adult and sexually immature), pinworms (Oxyuris equi--adult and 
4th stage larvae), large strongyles (Strongylus vulgaris, S. edentatus, 
S. equinus), and the various small strongyles in horses, breeding 
stallions and mares, pregnant mares, foals, and ponies.
    (3) Limitations. Administer by stomach tube or drench, or by mixing 
well into a portion of the normal grain ration. For animals maintained 
on premises where reinfection is likely to occur, retreatment may be 
necessary. For most effective results, retreat in 6 to 8 weeks. Not for 
use in horses intended for food. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Special considerations. Febantel suspension may be used in 
combination with trichlorfon oral liquid in accordance with the 
provisions of Sec. 520.2520c, this section, and the following 
conditions:
    (1) Combine 1 part febantel suspension with 5 parts trichlorfon 
liquid.
    (2) Allow animal to consume a portion of daily grain ration; 
administer mixture by stomach tube at rate of 18 milliliters per 100 
pounds of body weight.

[45 FR 8587, Feb. 8, 1980]

[[Page 158]]



Sec. 520.903c  [Reserved]



Sec. 520.903d  Febantel-praziquantel paste.

    (a) Specifications. Each gram of paste contains 34 milligrams of 
febantel and 3.4 milligrams of praziquantel.
    (b) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount--(i) Dogs and cats (over 6 months 
of age): 10 milligrams of febantel and 1 milligram of praziquantel per 
kilogram of body weight (1 gram of paste per 7.5 pounds body weight) 
administered by mouth or in the food once daily for 3 days.
    (ii) Puppies and kittens (less than 6 months of age): 15 milligrams 
of febantel and 1.5 milligrams of praziquantel per kilogram of body 
weight (1 gram of paste per 5 pounds body weight) administered by mouth 
on a full stomach once daily for 3 days.
    (2) Indications for use. (i) Dogs and puppies: For removal of 
hookworms (Ancylostoma caninum and Uncinaria stenocephala), whipworms 
(Trichuris vulpis), ascarids (Toxocara canis and Toxascaris leonina), 
and tapeworms (Dipylidium caninum and Taenia pisiformis).
    (ii) Cats and kittens: For removal of hookworms (Ancylostoma 
tubaeforme), ascarids (Toxocara cati) and tapeworms (Dipylidium caninum 
and Taenia taeniaeformis).
    (3) Limitations. Do not use in pregnant animals. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.
    (4) Special considerations. Consider alternative therapy or use with 
caution in animals with pre-existing liver or kidney dysfunction.

[50 FR 19167, May 7, 1985, as amended at 53 FR 48533, Dec. 1, 1988; 56 
FR 50813, Oct. 9, 1991]



Sec. 520.903e  Febantel tablets.

    (a) Specifications. Each scored tablet contains 27.2 milligrams of 
febantel for use in dogs, puppies, cats, and kittens or 163.3 milligrams 
of febantel for use in dogs, puppies, and cats.
    (b) Sponsor. See 000859 in Sec. 510.600(c)(2) of this chapter.
    (c) Conditions of use--(1) Amount--(i) Dogs and cats. Ten milligrams 
per kilogram body weight. Administer once daily for 3 consecutive days.
    (ii) Puppies and kittens fewer than 6 months of age. Fifteen 
milligrams per kilogram body weight. Administer once daily for 3 
consecutive days.
    (2) Indications for use. (i) For removal of hookworms (Ancylostoma 
caninum and Uncinaria stenocephala), ascarids (Toxocara canis and 
Toxascaris leonina) and whipworms (Trichuris vulpis) in dogs and 
puppies.
    (ii) For removal of hookworms (Ancylostoma tubaeforme) and ascarids 
(Toxocara cati) in cats and kittens.
    (3) Limitations. Do not use in pregnant animals. Consider 
alternative therapy or use with caution in animals with preexisting 
liver or kidney dysfunction. Administer to puppies and kittens on a full 
stomach. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[56 FR 50655, Oct. 8, 1991]



Sec. 520.905  Fenbendazole oral dosage forms.



Sec. 520.905a  Fenbendazole suspension.

    (a) Specifications. Each milliliter of suspension contains 100 
milligrams (mg) fenbendazole.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.275 of this chapter.
    (d) Special considerations. (1) See Sec. 500.25 of this chapter.
    (2) Fenbendazole suspension 10 percent and approved forms of 
trichlorfon, when used concomitantly for treating the indications 
provided in paragraph (e) of this section and for treating infections of 
stomach bot as provided in Sec. 520.2520, have been shown to be 
compatible and not to interfere with one another.
    (e) Conditions of use--(1) Horses--(i) Amount. Administer orally 5 
mg per kilogram (/kg) (2.3 mg per pound (/lb)) for the control of large 
strongyles, small strongyles, and pinworms; 10 mg/kg for the control of 
ascarids.
    (ii) Indications for use. For the control of large strongyles 
(Strongylus edentatus, S. equinus, S. vulgaris), small strongyles 
(Cyanthostomum spp., Cylicocyclus spp., Cylicostephanus spp., 
Triodontophorus spp.), pinworms

[[Page 159]]

(Oxyuris equi), and ascarids (Parascaris equorum) in horses.
    (iii) Limitations. Administer by dose syringe or suitable plastic 
syringe. Do not use in horses intended for human consumption.
    (2) Cattle including dairy cows of breeding age--(i) Amount. 
Administer orally 5 mg/kg of body weight (2.3 mg/lb). Retreatment may be 
needed after 4 to 6 weeks.
    (ii) Indications for use. For the removal and control of lungworm 
(Dictyocaulus viviparus); stomach worm (adults)--brown stomach worm 
(Ostertagia ostertagi); stomach worms (adults and 4th-stage larvae)--
barberpole worm (Haemonchus contortus and H. placei) and small stomach 
worm (Trichostongylus axei); intestinal worms (adults and 4th-stage 
larvae)--hookworm (Bunostonmum phlebotomum), threadnecked intestinal 
worm (Nematodirus helvetianus), small intestinal worm (Cooperia punctata 
and C. oncophora), bankrupt worm (Trichostrongylus colubriformis), and 
nodular worm (Oesophagostomum radiatum).
    (iii) Limitations. Cattle must not be slaughtered within 8 days 
following last treatment. A withdrawal period has not been established 
for this product in preruminating calves. Do not use in calves to be 
processed for veal.
    (3) Beef cattle--(i) Amount. Administer orally 10 mg/kg of body 
weight (2.3 mg/lb). Retreatment may be needed after 4 to 6 weeks.
    (ii) Indications for use. For the removal and control of stomach 
worm (4th stage inhibited larvae/type II ostertagiasis), Ostertagia 
ostertagi, and tapeworm, Moniezia benedeni.
    (iii) Limitations. Cattle must not be slaughtered within 8 days 
following last treatment. A withdrawal period has not been established 
for this product in preruminating calves. Do not use in calves to be 
processed for veal. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.
    (4) Goats--(i) Amount. Administer orally 5 mg/kg of body weight (2.3 
mg/lb).
    (ii) Indications for use. For the removal and control of stomach 
worms (adults) Haemonchus contortus and Teladorsagia circumcincta.
    (iii) Limitations. Retreatment may be needed after 4 to 6 weeks. 
Goats must not be slaughtered for food within 6 days following last 
treatment. Do not use in lactating goats.

[42 FR 59069, Nov. 15, 1977; 43 FR 12311, Mar. 24, 1978. Redesignated at 
44 FR 1375, Jan. 5, 1979, and amended at 46 FR 29464, June 2, 1981; 47 
FR 15327, Apr. 9, 1982; 48 FR 42809, Sept. 20, 1983; 49 FR 1983, Jan. 
17, 1984; 53 FR 40058, Oct. 13, 1988; 59 FR 26943, May 25, 1994; 61 FR 
29478, June 11, 1996; 63 FR 63983, Nov. 18, 1998; 66 FR 47960, Sept. 17, 
2001; 68 FR 26205, May 15, 2003; 74 FR 17770, Apr. 17, 2009; 74 FR 
61516, Nov. 25, 2009; 76 FR 17336, Mar. 29, 2011]



Sec. 520.905b  Fenbendazole granules.

    (a) Specifications. Each gram of granules contains 222 milligrams 
(mg) fenbendazole.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. See Sec. 500.25 of this chapter.
    (d) Conditions of use--(1) Horses--(i) Amount. 5 mg/kilogram (kg) 
for large strongyles, small strongyles, and pinworms; 10 mg/kg for 
ascarids.
    (ii) Indications for use. For the control of infections of large 
strongyles (Strongylus edentatus, S. equinus, S. vulgaris), small 
strongyles, pinworms (Oxyuris equi), and ascarids (Parascaris equorum).
    (iii) Limitations. Sprinkle the appropriate amount of drug on a 
small amount of the usual grain ration. Prepare for each horse 
individually. Withholding feed or water is not necessary. Retreat in 6 
to 8 weeks if required. Do not use in horses intended for food.
    (2) Dogs--(i) Amount. 50 mg/kg daily for 3 consecutive days.
    (ii) Indications for use. For the treatment and control of ascarids 
(Toxocara canis, Toxascaris leonina), hookworms (Ancylostoma caninum, 
Uncinaria stenocephala), whipworms (Trichuris vulpis), and tapeworms 
(Taenia pisiformis).
    (iii) Limitations. Mix the appropriate amount of drug with a small 
amount of the usual food; dry dog food may require slight moistening to 
facilitate mixing. Medicated food must be fully consumed.

[[Page 160]]

    (3) Zoo and wildlife animals--(i) Amount. 10 mg/kg per day for 3 
days.
    (ii) Indications for use. For control of internal parasites of 
Felidae and Ursidae as follows:
    (A) Lion (Panthera leo) and Tiger (Panthera tigris): Ascarid 
(Toxocara cati, Toxascaris leonina), Hookworm (Ancylostoma spp.).
    (B) Cheetah (Acinonyx jubatus): Ascarid (Toxocara cati, Toxascaris 
leonina).
    (C) Puma (Felis concolor), Panther (Panthera spp.), Leopard 
(Panthera pardus), Jaguar (Panthera onca): Ascarid (Toxocara cati, 
Toxascaris leonina), Hookworm (Ancylostoma spp.), Tapeworm (Taenia 
hydatigena, T. krabbei, T. taeniaeformis).
    (D) Black Bear (Ursus americanus): Ascarid (Baylisascaris transfuga, 
Toxascaris leonina), Hookworm (Ancylostoma caninum), Tapeworm (Taenia 
hydatigena, T. krabbei).
    (E) Polar Bear (Ursus maritimus) and Grizzly Bear (Ursus 
horribilis): Ascarid (Baylisascaris transfuga, Toxascaris leonina).
    (iii) Limitations. Top dress or mix with a small portion of food. 
Must be fully consumed prior to feeding. Federal law restricts this drug 
to use by or on the order of a licensed veterinarian. Do not use 14 days 
before or during the hunting season.

[44 FR 1375, Jan. 5, 1979, as amended at 47 FR 15327, Apr. 9, 1982; 48 
FR 50528, Nov. 2, 1983; 59 FR 35252, July 11, 1994; 66 FR 47960, Sept. 
17, 2001; 67 FR 47450, July 19, 2002; 71 FR 19429, Apr. 14, 2006; 74 FR 
61516, Nov. 25, 2009]



Sec. 520.905c  Fenbendazole paste.

    (a) Specifications. Each gram of paste contains 100 milligrams (mg) 
fenbendazole (10 percent).
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.275 of this chapter.
    (d) Special considerations. See Sec. 500.25 of this chapter.
    (e) Conditions of use--(1) Horses--(i) Indications for use and 
amounts--(A) For control of large strongyles (Strongylus edentatus, S. 
equinus, S. vulgaris), small strongyles, pinworms (Oxyuris equi), and 
ascarids (Parascaris equorum): 2.3 mg per pound (/lb) of body weight, or 
for foals and weanlings (less than 18 months of age), 4.6 mg/lb of body 
weight. Retreatment at intervals of 6 to 8 weeks may be required.
    (B) For control of arteritis caused by the fourth-stage larvae of S. 
vulgaris: 4.6 mg/lb of body weight daily for 5 days. Treatment should be 
initiated in the spring and repeated in 6 months.
    (C) For treatment of encysted mucosal cyathostome (small strongyle) 
larvae including early third-stage (hypobiotic), late third-stage, and 
fourth-stage larvae: 4.6 mg/lb of body weight daily for 5 consecutive 
days.
    (D) Fenbendazole paste 10 percent may be used concomitantly with 
approved forms of trichlorfon for the indications provided in paragraph 
(e)(1)(i)(A) of this section and for treating infections of stomach bots 
as provided in Sec. 520.2520.
    (ii) Limitations. Do not use in horses intended for human 
consumption.
    (2) Cattle--(i) Amount. 2.3 mg/lb of body weight. Retreatment may be 
needed after 4 to 6 weeks.
    (ii) Indications for use. For the removal and control of lungworms 
(Dictyocaulus viviparus), stomach worms (Haemonchus contortus, 
Ostertagia ostertagi, Trichostrongylus axei), and intestinal worms 
(Bunostomum phlebotomum, Nematodirus helvetianus, Cooperia punctata, C. 
oncophora, Trichostrongylus colubriformis, and Oesophagostomum 
radiatum).
    (iii) Limitations. Cattle must not be slaughtered within 8 days 
following last treatment. A withdrawal period has not been established 
for this product in preruminating calves. Do not use in calves to be 
processed for veal.

[72 FR 24185, May 2, 2007, as amended at 74 FR 61516, Nov. 25, 2009; 76 
FR 17337, Mar. 29, 2011]



Sec. 520.905d  Fenbendazole powder.

    (a) Specifications. (1) Each 2-ounce packet contains 2.27 grams (4 
percent) of fenbendazole plus other inert ingredients.
    (2) Each 4-ounce packet contains 1.7 grams (1.5 percent) of 
fenbendazole plus other inert ingredients.
    (b) Sponsors. (1) See No. 000061 in Sec. 510.600(c) of this chapter 
for use of the 4-percent product.

[[Page 161]]

    (2) See No. 051311 in Sec. 510.600(c) of this chapter for use of 
the 1.5-percent product.
    (c) Related tolerances. See Sec. 556.275 of this chapter.
    (d) Conditions of use. It is administered to swine as follows:
    (1) Amount. 3 milligrams fenbendazole per kilogram body weight per 
day (1.36 milligrams per pound per day).
    (2) Indications for use. For removal and control of large roundworms 
(Ascaris suum); lungworms (Metastrongylus apri); nodular worms 
(Oesophagostomum dentatum, O. quadrispinulatum); small stomach worms 
(Hyostrongylus rubidus); whipworms (Trichuris suis); and kidneyworms 
(Stephanurus dentatus-- mature and immature).
    (3) Limitations. Thoroughly mix the contents of the packet(s) with 
swine ration and administer according to label directions. Feed as sole 
ration for 3 consecutive days. Can be fed to pregnant sows. No prior 
withdrawal of feed or water is necessary. Consult your veterinarian for 
assistance in the diagnosis, treatment, and control of parasitism.

[49 FR 18090, Apr. 27, 1984, as amended at 49 FR 20485, May 15, 1984; 66 
FR 47960, Sept. 17, 2001; 70 FR 32489, June 3, 2005; 74 FR 61516, Nov. 
25, 2009]



Sec. 520.905e  Fenbendazole blocks.

    (a) Specifications. (1) Each pound of molasses block contains 750 
milligrams of fenbendazole.
    (2) Each pound of protein block contains 750 milligrams of 
fenbendazole.
    (b) Sponsor. See 000061 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.275 of this chapter.
    (d) Conditions of use--(1) Amount. 0.1 pound of block per 100 pounds 
of body weight per day for 3 days. Total dose for the 3-day period is 
2.27 milligrams of fenbendazole per pound of body weight for mature 
cattle.
    (2) Indications for use. For removal and control of infections of 
lungworms (Dictyocaulus viviparus) and gastrointestinal roundworms 
(Haemonchus contortus, Ostertagia ostertagi, Trichostrongylus axei, 
Bunostomum phlebotomum, Nematodirus helvetianus, Cooperia oncophora and 
C. punctata, Trichostrongylus colubriformis, and Oesophagostomum 
radiatum) in beef cattle.
    (3) Limitations. Administer free choice of beef cattle on pasture 
that have become accustomed to nonmedicated block feeding during an 
adaptation period of 12 to 19 days. Molasses block: Cattle must not be 
slaughtered within 11 days following last treatment. Protein block: 
Cattle must not be slaughtered within 16 days following last treatment; 
do not use in dairy cattle of breeding age. Animals maintained under 
conditions of constant worm exposure may require retreatment within 6 to 
8 weeks. Consult your veterinarian for assistance in the diagnosis, 
treatment, and control of parasitism.

[51 FR 41783, Nov. 19, 1986, as amended at 54 FR 20787, May 15, 1989; 66 
FR 47960, Sept. 17, 2001; 74 FR 61516, Nov. 25, 2009]



Sec. 520.928  Firocoxib tablets.

    (a) Specifications. Each chewable tablet contains 57 or 227 
milligrams (mg) firocoxib.
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. 5 mg/kg (2.27 mg/lb) body 
weight. Administer once daily for osteoarthritis. Administer 
approximately 2 hours before soft-tissue or orthopedic surgery.
    (2) Indications for use. For the control of pain and inflammation 
associated with osteoarthritis; and for the control of postoperative 
pain and inflammation associated with soft-tissue and orthopedic 
surgery.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[69 FR 51171, Aug. 18, 2004, as amended at 73 FR 2808, Jan. 16, 2008; 73 
FR 64885, Oct. 31, 2008]



Sec. 520.930  Firocoxib paste.

    (a) Specifications. Each milligram (mg) of paste contains 0.82 mg 
firocoxib.
    (b) Sponsors. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. 0.1 mg per kilogram 
(0.045 mg per pound) body weight daily for up to 14 days.

[[Page 162]]

    (2) Indications for use. For the control of pain and inflammation 
associated with osteoarthritis.
    (3) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[71 FR 5788, Feb. 3, 2006]



Sec. 520.955  Florfenicol.

    (a) Specifications. Each milliliter (mL) contains 23 milligrams (mg) 
florfenicol.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.283 of this chapter.
    (d) Conditions of use in swine--(1) Amount. Administer in drinking 
water ad libitum at 400 mg per gallon (100 parts per million (ppm)) for 
5 consecutive days.
    (2) Indications for use. For the treatment of swine respiratory 
disease (SRD) associated with Actinobacillus pleuropneumoniae, 
Pasteurella multocida, Salmonella choleraesuis and Streptococcus suis.
    (3) Limitations. Do not slaughter within 16 days of last treatment. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.

[67 FR 78357, Dec. 24, 2002, as amended at 72 FR 262, Jan. 4, 2007]



Sec. 520.960  Flumethasone tablets.

    (a) Specifications. Each tablet contains 0.0625 milligram of 
flumethasone.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. (i) Dogs: Administer orally from 
0.0625 to 0.25 milligram daily in divided doses.
    (ii) Cats: Administer orally from 0.03125 to 0.125 milligram daily 
in divided doses.
    (2) Indications for use. (i) Dogs: It is used for musculoskeletal 
conditions due to inflammation of muscles or joints and accessory 
structures, where permanent structural changes do not exist, such as 
arthritis, the disc syndrome, and myositis.
    (ii) Dogs and cats: It is used in certain acute and chronic 
dermatoses of varying etiology to help control the pruritus, irritation, 
and inflammation associated with these conditions.
    (3) Limitations. Do not use in viral infections. Anti-inflammatory 
action of corticosteroids may mask signs of infection. Do not use in 
animals with tuberculosis, chronic nephritis, cushingoid syndrome, or 
where peptic ulcers occur, except for emergency therapy. Clinical and 
experimental data have demonstrated that corticosteroids administered 
orally or parenterally to animals may induce the first stage of 
parturition when administered during last trimester of pregnancy and may 
precipitate premature parturition followed by dystocia, fetal death, 
retained placenta, and metritis. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.

[44 FR 7131, Feb. 6, 1979, as amended at 61 FR 5506, Feb. 13, 1996]



Sec. 520.970  Flunixin.

    (a) Specifications. (1) Each 10-gram (g) packet of granules contains 
flunixin meglumine equivalent to 250 milligrams (mg) of flunixin.
    (2) Each 30-g syringe of paste contains flunixin meglumine 
equivalent to 1,500 mg of flunixin.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. 0.5 mg of flunixin per 
pound of body weight per day.
    (2) Indications for use. For alleviation of inflammation and pain 
associated with musculoskeletal disorders.
    (3) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[76 FR 53051, Aug. 25, 2011]



Sec. 520.980  Fluoxetine.

    (a) Specifications. Each chewable tablet contains 8, 16, 32, or 64 
milligrams (mg) fluoxetine hydrochloride.
    (b) Sponsor. See No. 000986 in Sec. 510.600 of this chapter.
    (c) Conditions of use in dogs--(1) Amount. 1 to 2 mg per kilogram 
body weight once daily.
    (2) Indications for use. For the treatment of canine separation 
anxiety in conjunction with a behavior modification plan.

[[Page 163]]

    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[72 FR 6463, Feb. 12, 2007]



Sec. 520.1010  Furosemide.

    (a) Specifications. (1) Each tablet contains 12.5 or 50 milligrams 
(mg) furosemide.
    (2) Each bolus contains 2 grams (g) furosemide.
    (3) Each packet of powder contains 2 g furosemide.
    (4) Each milliliter of syrup contains 10 mg furosemide.
    (b) Sponsors. See sponsor numbers in Sec. 510.600(c) of this 
chapter for use of dosage forms and strengths listed in paragraph (a) of 
this section for uses as in paragraph (d) of this section.
    (1) No. 000010 for tablets in paragraph (a)(1) of this section for 
conditions of use in paragraphs (d)(2)(i), (d)(2)(ii)(A), and (d)(3) of 
this section.
    (2) No. 000061 for tablets in paragraph (a)(1) of this section for 
conditions of use in paragraphs (d)(2)(i), (d)(2)(ii)(A), and (d)(3) of 
this section; for boluses in paragraph (a)(2) of this section and powder 
in paragraph (a)(3) of this section for conditions of use in paragraph 
(d)(1) of this section; and for syrup in paragraph (a)(4) of this 
section for conditions of use in paragraphs (d)(2)(i) and (d)(2)(ii)(A).
    (3) Nos. 000859 and 058829 for use of syrup in paragraph (a)(4) of 
this section for conditions of use in paragraph (d)(2)(i) and 
(d)(2)(ii)(A) of this section.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Conditions of use. It is used as follows:
    (1) Cattle--(i) Amount. 1 to 2 mg per pound (/lb) body weight using 
powder, or one 2-g bolus per animal, per day.
    (ii) Indications for use. For treatment of physiological parturient 
edema of the mammary gland and associated structures.
    (iii) Limitations. Treatment not to exceed 48 hours post-
parturition. Milk taken during treatment and for 48 hours after the last 
treatment must not be used for food. Cattle must not be slaughtered for 
food within 48 hours following last treatment.
    (2) Dogs--(i) Amount. 1 to 2 mg/lb body weight, once or twice daily.
    (ii) Indications for use--(A) For treatment of edema (pulmonary 
congestion, ascites) associated with cardiac insufficiency and acute 
noninflammatory tissue edema.
    (B) For treatment of edema (pulmonary congestion, ascites) 
associated with cardiac insufficiency.
    (3) Cats--(i) Amount. 1 to 2 mg/lb body weight, once or twice daily.
    (ii) Indications for use. For treatment of edema (pulmonary 
congestion, ascites) associated with cardiac insufficiency and acute 
noninflammatory tissue edema.

[66 FR 47960, Sept. 17, 2001, as amended at 69 FR 74419, Dec. 14, 2004; 
70 FR 50182, Aug. 26, 2005; 70 FR 76396, Dec. 27, 2005; 74 FR 61516, 
Nov. 25, 2009; 78 FR 17596, Mar. 22, 2013]



Sec. 520.1044  Gentamicin sulfate oral dosage forms.



Sec. 520.1044a  Gentamicin sulfate oral solution.

    (a) Specifications. Each milliliter of aqueous solution contains 
gentamicin sulfate equivalent to 50 milligrams of gentamicin.
    (b) Sponsor. See Nos. 000061 and 054925 in Sec. 510.600(c) of this 
chapter.
    (c) Related tolerances. See Sec. 556.300 of this chapter.
    (d) Conditions of use--(1) Amount. Colibacillosis: 1 milliliter per 
2 gallons of drinking water for 3 consecutive days, to provide 0.5 
milligram/pound/day; swine dysentery: 1 milliliter per 1 gallon of 
drinking water for 3 consecutive days, to provide 1.0 milligram/pound/
day.
    (2) Indications for use. In weanling swine for control and treatment 
of colibacillosis caused by strains of E. coli sensitive to gentamicin, 
and in swine for control and treatment of swine dysentery associated 
with Treponema hyodysenteriae.
    (3) Limitations. For use in swine drinking water only. Do not store 
or offer medicated drinking water in rusty containers since the drug is 
quickly destroyed in such containers. Medicated drinking water should be 
prepared daily and be the sole source of drinking water for 3 
consecutive days. Treatment may be repeated if dysentery recurs. Do not 
slaughter treated

[[Page 164]]

swine for food for at least 3 days following treatment.

[48 FR 10302, Mar. 11, 1983. Redesignated at 49 FR 572, Jan. 5, 1984, 
and amended at 49 FR 14332, Apr. 11, 1984; 52 FR 7832, Mar. 13, 1987; 62 
FR 34169, June 25, 1997; 71 FR 13542, Mar. 16, 2006]



Sec. 520.1044b  Gentamicin sulfate pig pump oral solution.

    (a) Specifications. Each milliliter of pig pump oral solution 
contains gentamicin sulfate equivalent to 4.35 milligrams of gentamicin.
    (b) Sponsor. See Nos. 000061 and 000859 in Sec. 510.600(c) of this 
chapter.
    (c) Related tolerances. See Sec. 556.300 of this chapter.
    (d) Conditions of use--(1) Amount. Administer 1.15 milliliters of 
pig pump oral solution (5 milligrams of gentamicin) orally per pig one 
time.
    (2) Indications for use. In neonatal swine 1 to 3 days of age for 
control and treatment of colibacillosis caused by strains of E. coli 
sensitive to gentamicin.
    (3) Limitations. For use in neonatal swine only. Do not slaughter 
treated swine for food for at least 14 days following treatment.

[49 FR 572, Jan. 5, 1984, as amended at 52 FR 7832, Mar. 13, 1987; 62 FR 
29011, May 29, 1997; 78 FR 17596, Mar. 22, 2013]



Sec. 520.1044c  Gentamicin sulfate powder.

    (a) Specifications. Each gram of powder contains gentamicin sulfate 
equivalent to:
    (1) 16.7, 66.7, or 333.3 milligrams (mg) gentamicin.
    (2) 333.3 mg gentamicin.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (d) of this section as follows:
    (1) No. 000061 for products described in paragraph (a)(1) of this 
section.
    (2) Nos. 057561 and 061623 for product described in paragraph (a)(2) 
of this section.
    (c) Related tolerances. See Sec. 556.300 of this chapter.
    (d) Conditions of use in swine--(1) Amount. Administer in drinking 
water for 3 consecutive days as follows:
    (i) For colibacillosis: Gentamicin sulfate equivalent to 25 mg of 
gentamicin per gallon of drinking water to provide 0.5 mg per pound of 
body weight per day;
    (ii) For swine dysentery: Gentamicin sulfate equivalent to 50 mg of 
gentamicin per gallon of drinking water to provide 1 mg per pound of 
body weight per day. Treatment may be repeated if dysentery recurs.
    (2) Indications for use. For control and treatment of colibacillosis 
in weanling swine caused by strains of Escherichia coli sensitive to 
gentamicin, and for control and treatment of swine dysentery associated 
with Treponema hyodysenteriae.
    (3) Limitations. For use in swine drinking water only. Do not store 
or offer medicated drinking water in rusty containers since the drug is 
quickly destroyed in such containers. Medicated drinking water should be 
prepared daily and be the sole source of drinking water.
    (4) Withdrawal period. 10 days.

[77 FR 4226, Jan. 27, 2012]



Sec. 520.1100  Griseofulvin.

    (a) Specifications--(1) The powder complies with U.S.P. for 
griseofulvin, microsize.
    (2) Each bolus contains 2.5 grams griseofulvin.
    (3) Each tablet contains 125 or 500 milligrams griseofulvin.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter.
    (1) No. 000061 for use of products described in paragraph (a) for 
use as in paragraph (d) of this section.
    (2) No. 061623 for use of the powder described in paragraph (a)(1) 
for use as in paragraphs (d)(1)(i)(A) and (d)(1)(ii) of this section.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Conditions of use--(1) Horses--(i) Amount and indications for 
use--(A) For equine ringworm infection caused by Trichophyton equinum or 
Microsporum gypseum, administer soluble powder described in paragraph 
(a)(1) of this section daily as a drench or as a top dressing on feed 
for not less than 10 days as follows: adults, 2.5 grams; yearlings, 1.25 
to 2.5 grams; and foals, 1.25 grams.
    (B) For treating ringworm infection caused by T. equinum, administer 
boluses described in paragraph (a)(2) of

[[Page 165]]

this section daily for not less than 10 days as follows: adults, 1 
bolus; yearlings, one-half to 1 bolus; and foals, one-half bolus.
    (ii) Limitations. Not for use in horses intended for food.
    (2) Dogs and cats: (i) Amount. 125- and 500-milligram tablets 
administered orally as follows:
    (A) Daily (single or divided) dose:

------------------------------------------------------------------------
                                                               Dosage
                   Body weight (pounds)                     (milligrams)
------------------------------------------------------------------------
Up to 6...................................................         62.5
6 to 18...................................................          125
18 to 36..................................................          250
36 to 48..................................................          375
48 to 75..................................................          500
------------------------------------------------------------------------

    (B) Weekly (single) dose: If experience indicates that treatment is 
more effective for the drug given in large doses, administer at 
intervals of 7 to 10 days, a dose equal to 10 milligrams/pound of body 
weight x body weight x number of days between treatments. Dosage should 
be adjusted according to response. Administer additional dose after the 
animal is free of infection.
    (ii) Indications for use. For treatment of fungal infections of the 
skin, hair, and claws caused by Trichophyton mentagrophytes, T. rubrum, 
T. schoenleini, T. sulphurem, T. verrucosum, T. interdigitale, 
Epidermophyton floccosum, Microsporum gypseum, M. canis, M. audouini.

[40 FR 13838, Mar. 27, 1975, as amended at 41 FR 42948, Sept. 29, 1976; 
43 FR 28458, June 30, 1978; 52 FR 7832, Mar. 13, 1987; 54 FR 30205, July 
19, 1989; 71 FR 38073, July 5, 2006; 77 FR 28253, May 14, 2012]



Sec. 520.1120  Haloxon oral dosage forms.



Sec. 520.1120a  Haloxon drench.

    (a) Chemical name. 3-Choloro-7-hydoxy-4-methylcoumarin bis (2-
chloroethyl) phosphate.
    (b) Specifications. Haloxon assay of not less than 96 percent by 
infrared spectrum at 8.62 microns.
    (c) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (d) Special considerations. Do not use any drug, insecticide, 
pesticide, or other chemical having cholinesterase-inhibiting activity 
either simultaneously or within a few days before or after treatment 
with haloxon.
    (e) Related tolerances. See Sec. 556.310 of this chapter.
    (f) Conditions of use. It is used as a drench as follows:
    (1) Cattle--(i) Amount. 141.5 grams per packet.
    (ii) Indications for use. Control of gastrointestinal roundworms of 
the genera Haemonchus, Ostertagia, Trichostrongylus, and Cooperia.
    (iii) Limitations. (a) Dissolve each packet in 32 fluid ounces of 
water and administer as follows:

------------------------------------------------------------------------
                                                                 Dose
                  Weight of animal (pounds)                     (fluid
                                                                ounces)
------------------------------------------------------------------------
Up to 100...................................................       \1/2\
100 to 150..................................................       \3/4\
150 to 200..................................................           1
200 to 300..................................................      1\1/2\
300 to 450..................................................           2
450 to 700..................................................           3
700 to 1,000................................................           4
1,000 to 1,200..............................................           5
Over 1,200..................................................           6
------------------------------------------------------------------------

    (b) Do not treat within 1 week of slaughter; do not treat dairy 
animals of breeding age; animals should be retreated in 3 to 4 weeks.

[40 FR 13838, Mar. 27, 1975, as amended at 45 FR 10333, Feb. 15, 1980; 
46 FR 48642, Oct. 2, 1981; 61 FR 8873, Mar. 6, 1996; 62 FR 61624, Nov. 
19, 1997]



Sec. 520.1120b  Haloxon boluses.

    (a) Chemical name. 3-Chloro-7-hydroxy-4-methylcoumarin bis (2-
chloroethyl) phosphate.
    (b) Specifications. Each bolus contains 10.1 grams of haloxon.
    (c) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (d) Related tolerances. See Sec. 556.310 of this chapter.
    (e) Conditions of use. (1) Haloxon bolus is an anthelmintic used in 
cattle for the control of gastrointestinal roundworms of the genera 
Haemonchus, Ostertagia, Trichostrongylus and Cooperia.
    (2) It is administered by giving one bolus per approximately 500 
pounds body weight (35 to 50 milligrams per kilogram of body weight).
    (3) For most effective results, re-treat animals in 3 to 4 weeks. If 
reinfection is likely to occur, additional re-treatments may be 
necessary.
    (4) Do not use any drug, pesticide or other chemical having 
cholinesterase

[[Page 166]]

inhibiting activity either simultaneously or within a few days before or 
after treatment with haloxon.
    (5) Do not treat animals within one week of slaughter.
    (6) Do not treat dairy animals of breeding age or older.

[40 FR 13838, Mar. 27, 1975, as amended at 44 FR 61591, Oct. 29, 1979; 
46 FR 48642, Oct. 2, 1981; 61 FR 8873, Mar. 6, 1996; 62 FR 61625, Nov. 
19, 1997]



Sec. 520.1130  Hetacillin.

    (a) Specifications.--(1) Each capsule or tablet contains hetacillin 
potassium equivalent to 50, 100, or 200 milligrams (mg) of ampicillin.
    (2) Each milliliter of suspension contains hetacillin potassium 
equivalent to 50 mg of ampicillin.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs and cats--(1) Amount--(i) Dogs. 
Administer 5 mg per pound (/lb) of body weight orally, twice daily. In 
severe infections, administer 5 mg/lb three times daily, or up to 10 mg/
lb twice daily. For stubborn urinary tract infections, administer up to 
20 mg/lb twice daily.
    (ii) Cats. Administer 50 mg twice daily.
    (2) Indications for use. For the treatment of respiratory tract 
infections, urinary tract infections, gastrointestinal infections, skin 
infections, soft tissue infections, and postsurgical infections 
associated with strains of organisms susceptible to hetacillin 
potassium.
    (3) Limitations. Federal law restricts this drug to use only by or 
on the order of a licensed veterinarian.

[75 FR 10166, Mar. 5, 2010]



Sec. 520.1157  Iodinated casein tablets.

    (a) Specifications. Each 1-gram tablet contains 25 milligrams of 
iodinated casein.
    (b) Sponsor. See No. 017762 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. \1/5\ to 1 tablet per 10 pounds 
of body weight (equivalent to 0.5 to 2.5 milligrams of iodinated casein 
per pound of body weight).
    (2) Indications for use. For dogs for apparent decreased thyroid 
activity where the signs are alopecia, scaliness of the skin surface, 
loss of hair, seborrhea, thickening of the skin, hyperpigmentation, and 
lethargy.
    (3) Limitations. If no response is observed in 30 to 45 days, the 
drug should be withdrawn and the diagnosis reconsidered. Do not use in 
the presence of cardiac disease, ischemia, adrenal insufficiency, or 
nephrosis. Federal law restricts this drug to use by or on the order of 
a licensed veterinarian.

[49 FR 22469, May 30, 1984]



Sec. 520.1158  Iodochlorhydroxyquin boluses.

    (a) Specifications. Each bolus contains 10 grams of 
iodochlorhydroxyquin.
    (b) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 1 bolus (10 grams) daily for a 
1,000-pound horse.
    (2) Indications for use. For treatment of equine diarrhea.
    (3) Limitations. For horses only; not to be administered to food-
producing animals. Do not administer to horses intended for use as food. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.

[48 FR 8054, Feb. 25, 1983, as amended at 50 FR 41489, Oct. 11, 1985]



Sec. 520.1182  Iron dextran suspension.

    (a) Specifications. Each milliliter (mL) of suspension contains 
55.56 milligrams (mg) iron as ferric hydroxide in complex with a low 
molecular weight dextran.
    (b) Sponsor. See No. 051311 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in swine--(1) Amount. Administer 100 mg (1.8 
mL) orally by automatic dose dispenser.
    (2) Indications for use. For the prevention of iron deficiency 
anemia in baby pigs.
    (3) Limitations. Treat each pig within 24 hours of farrowing.

[70 FR 32489, June 3, 2005]



Sec. 520.1192  Ivermectin paste.

    (a) Specifications. Each milligram (mg) of paste contains 0.0187 mg 
(1.87 percent) or 0.00153 mg (0.153 percent) of ivermectin.

[[Page 167]]

    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (e) of this section:
    (1) No. 050604 for use of a 1.87 percent paste as in (e)(1) of this 
section and a 0.153 percent paste for use as in paragraph (e)(2) of this 
section.
    (2) Nos. 000859, 051311, 054925, and 061623 for use of a 1.87 
percent paste for use as in paragraph (e)(1) of this section.
    (c) Related tolerances. See Sec. 556.344 of this chapter.
    (d) Special considerations. See Sec. 500.25 of this chapter.
    (e) Conditions of use--(1) Horses--(i) Amount. 200 micrograms per 
kilogram (91 micrograms per pound) of body weight.
    (ii) Indications for use. For treatment and control of Large 
Strongyles (adults): Strongylus vulgaris (also early forms in blood 
vessels), S. edentatus (also tissue stages), S. equinus, Triodontophorus 
spp. including T. brevicauda and T. serratus, and Craterostomum 
acuticaudatum; Small Strongyles (adults, including those resistant to 
some benzimidazole class compounds): Coronocyclus spp. including C. 
coronatus, C. labiatus, and C. labratus, Cyathostomum spp. including C. 
catinatum and C. pateratum, Cylicocyclus spp. including C. insigne, C. 
leptostomum, C. nassatus, and C. brevicapsulatus, Cylicodontophorus 
spp., Cylicostephanus spp. including C. calicatus, C. goldi, C. 
longibursatus, and C. minutus, and Petrovinema poculatum; Small 
Strongyles (fourth-stage larvae); Pinworms (adults and fourth-stage 
larvae): Oxyuris equi; Ascarids (adults and third- and fourth-stage 
larvae): Parascaris equorum; Hairworms (adults): Trichostrongylus axei; 
Large mouth Stomach Worms (adults): Habronema muscae; Bots (oral and 
gastric stages): Gasterophilus spp. including G. intestinalis and G. 
nasalis; Lungworms (adults and fourth-stage larvae): Dictyocaulus 
arnfieldi; Intestinal Threadworms (adults): Strongyloides westeri; 
Summer Sores caused by Habronema and Draschia spp. cutaneous third-stage 
larvae; Dermatitis caused by neck threadworm microfilariae, Onchocerca 
sp.
    (iii) Limitations. For oral use only. Do not use in horses intended 
for human consumption.
    (2) Cattle--(i) Amount. 23 milligrams per 250 pounds of body weight.
    (ii) Indications for use. It is used in cattle for the treatment and 
control of gastrointestinal roundworms (adults and fourth-stage larvae) 
(Ostertagia ostertagi (including inhibited forms), O. lyrata, Haemonchus 
placei, Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C. 
punctata, Nematodirus helvetianus, Bunostomum phlebotomum, Strongyloides 
papillosus (adults only), Oesophagostomum radiatum, Trichuris ovis 
(adults only)); lungworms (adults and fourth-stage larvae) (Dictyocaulus 
viviparus); grubs (first, second, and third instars) (Hypoderma bovis, 
H. lineatum); and sucking lice (Linognathus vituli, Haematopinus 
eurysternus).
    (iii) Limitations. For oral use only. Do not treat cattle within 24 
days of slaughter. Because withdrawal time in milk has not been 
established, do not use in female dairy cattle of breeding age.

[49 FR 22275, May 29, 1984, as amended at 50 FR 27819, July 8, 1985; 51 
FR 44449, Dec. 10, 1986; 53 FR 51273, Dec. 21, 1988; 62 FR 63270, Nov. 
28, 1997; 65 FR 70661, Nov. 27, 2000; 67 FR 71820, Dec. 3, 2002; 68 FR 
43294, July 22, 2003; 69 FR 59131, Oct. 4, 2004; 70 FR 8514, Feb. 22, 
2005; 71 FR 40010, July 14, 2006; 71 FR 67298, Nov. 21, 2006; 73 FR 
34184, June 17, 2008; 74 FR 6542, Feb. 10, 2009; 78 FR 17596, Mar. 22, 
2013]



Sec. 520.1193  Ivermectin tablets and chewables.

    (a) Specifications. (1) Each tablet or chewable contains 68, 136, or 
272 micrograms (mcg) ivermectin.
    (2) Each chewable contains 55 or 165 mcg ivermectin.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (d) of this section.
    (1) No. 050604 for use of tablets or chewables described in 
paragraph (a)(1) as in paragraph (d)(1) and chewables described in 
paragraph (a)(2) as in paragraph (d)(2) of this section.
    (2) Nos. 051311 and 059130 for use of tablets described in paragraph 
(a)(1) as in paragraph (d)(1) of this section.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.

[[Page 168]]

    (d) Conditions of use--(1) Dogs. For use in dogs 6 weeks of age and 
older as follows:
    (i) Amount. 6.0 mcg per kilogram (kg) of body weight (2.72 mcg per 
pound (lb)), minimum. Up to 25 lb, 68 mcg; 26 to 50 lb, 136 mcg; 51 to 
100 lb, 272 mcg; over 100 lb, a combination of the appropriate tablets. 
Administer at monthly dosing intervals.
    (ii) Indications for use. To prevent canine heartworm disease by 
eliminating the tissue stage of heartworm larvae (Dirofilaria immitis) 
for 1 month (30 days) after infection.
    (2) Cats. For use in cats 6 weeks of age and older as follows:
    (i) Amount. Up to 2.3 kilograms (up to 5 lb), 55 mcg; 2.3 to 6.8 
kilograms (5 to 15 lb), 165 mcg; over 6.8 kilograms (15 lb), a 
combination of the appropriate chewables (recommended minimum dose of 24 
mcg/kg of body weight (10.9 mcg/lb)). Administer once a month.
    (ii) Indications for use. To prevent feline heartworm disease by 
eliminating the tissue stage of heartworm larvae Dirofilaria immitis for 
a month (30 days) after infection, and for removal and control of adult 
and immature (L4) hookworms Ancylostoma tubaeforme and A. braziliense.

[67 FR 11230, Mar. 13, 2002, as amended at 67 FR 21996, May 2, 2002; 69 
FR 43735, July 22, 2004]



Sec. 520.1194  Ivermectin meal.

    (a) Specifications. Each gram of meal contains 6 milligrams 
ivermectin (0.6 percent).
    (b) Sponsor. See No. 017135 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. See Sec. 500.25 of this chapter.
    (d) Conditions of use in horses--(1) Amount. Administer 136 
micrograms (mcg) ivermectin per pound (/lb) body weight (300 mcg/
kilogram) as a single dose on approximately 2 lb grain or sweet feed.
    (2) Indications for use. For treatment and control of Large 
Strongyles (adults): Strongylus vulgaris (also early forms in blood 
vessels), S. edentatus (also tissue stages), S. equinus, Triodontophorus 
spp. including T. brevicauda and T. serratus, and Craterostomum 
acuticaudatum; Small Strongyles (adults, including those resistant to 
some benzimidazole class compounds): Coronocyclus spp. including C. 
coronatus, C. labiatus, and C. labratus, Cyathostomum spp. including C. 
catinatum and C. pateratum, Cylicocyclus spp. including C. insigne, C. 
leptostomum, C. nassatus, and C. brevicapsulatus, Cylicodontophorus 
spp., Cylicostephanus spp. including C. calicatus, C. goldi, C. 
longibursatus, and C. minutus, and Petrovinema poculatum; Small 
Strongyles (fourth-stage larvae); Pinworms (adults and fourth stage 
larvae): Oxyuris equi; Ascarids (adults and third- and fourth-stage 
larvae): Parascaris equorum; Hairworms (adults): Trichostrongylus axei; 
Large Mouth Stomach Worms (adults): Habronema muscae; Bots (oral and 
gastric stages): Gasterophilus spp. including G. intestinalis and G. 
nasalis; Lungworms (adults and fourth-stage larvae): Dictyocaulus 
arnfieldi; Intestinal Threadworms (adults): Strongyloides westeri; 
Summer Sores caused by Habronema and Draschia spp. cutaneous third-stage 
larvae; Dermatitis caused by neck threadworm microfilariae, Onchocerca 
sp.
    Limitations. Do not use in horses intended for human consumption.

[70 FR 1817, Jan. 11, 2005, as amended at 70 FR 19262, Apr. 13, 2005]



Sec. 520.1195  Ivermectin liquid.

    (a) Specifications--(1) Each milliliter (mL) contains 10 milligrams 
(mg) ivermectin.
    (2) Each mL of micellar solution contains 0.8 mg ivermectin.
    (b) Sponsors. See sponsor numbers in Sec. 510.600(c) of this 
chapter.
    (1) Nos. 000859, 050604, and 054925 for use of product described in 
paragraph (a)(1) of this section as in paragraphs (e)(1)(i), 
(e)(1)(ii)(A), and (e)(1)(iii) of this section.
    (2) Nos. 058005 and 058829 for use of product described in paragraph 
(a)(1) of this section as in paragraphs (e)(1)(i), (e)(1)(ii)(B), and 
(e)(1)(iii) of this section.
    (3) Nos. 050604 and 058829 for use of product described in paragraph 
(a)(2) of this section as in paragraph (e)(2) of this section.
    (c) Related tolerances. See Sec. 556.344 of this chapter.

[[Page 169]]

    (d) Special considerations. See Sec. 500.25 of this chapter.
    (e) Conditions of use--(1) Horses--(i) Amount. 200 micrograms (mcg) 
per kilogram (/kg) of body weight as a single dose by stomach tube or as 
an oral drench.
    (ii) Indications for use. For treatment and control of:
    (A) Large Strongyles (adults): Strongylus vulgaris (also early forms 
in blood vessels), S. edentatus (also tissue stages), S. equinus, 
Triodontophorus spp. including T. brevicauda and T. serratus, and 
Craterostomum acuticaudatum; Small Strongyles (adults, including those 
resistant to some benzimidazole class compounds): Coronocyclus spp. 
including C. coronatus, C. labiatus, and C. labratus, Cyathostomum spp. 
including C. catinatum and C. pateratum, Cylicocyclus spp. including C. 
insigne, C. leptostomum, C. nassatus, and C. brevicapsulatus, 
Cylicodontophorus spp., Cylicostephanus spp. including C. calicatus, C. 
goldi, C. longibursatus, and C. minutus, and Petrovinema poculatum; 
Small Strongyles (fourth-stage larvae); Pinworms (adults and fourth 
stage larvae): Oxyuris equi; Ascarids (adults and third- and fourth-
stage larvae): Parascaris equorum; Hairworms (adults): Trichostrongylus 
axei; Large mouth Stomach Worms (adults): Habronema muscae; Bots (oral 
and gastric stages): Gasterophilus spp. including G. intestinalis and G. 
nasalis; Lungworms (adults and fourth-stage larvae): Dictyocaulus 
arnfieldi; Intestinal Threadworms (adults), Strongyloides westeri; 
Summer Sores caused by Habronema and Draschia spp. cutaneous third-stage 
larvae; Dermatitis caused by neck threadworm microfilariae, Onchocerca 
sp.
    (B) Large Strongyles (Strongylus equinus (adult), S. vulgaris (adult 
and arterial larval stages), S. endentatus (adult and migrating tissue 
stages), Triodontophorus spp. (adult)); Small Strongyles including those 
resistant to some benzimidazole class compounds (Cyathostomum spp. 
(adult and fourth-stage larvae), Cylicocyclus spp., Cylicodontophorus 
spp., Cylicostephanus spp.); Pinworms (Oxyuris equi (adult and fourth-
stage larvae)); Ascarids (Parascaris equorum (adult and third- and 
fourth-stage larvae)); Hairworms (Trichostongylus axei(adult)); Large 
mouth Stomach Worms (Habronema muscae (adult)); Stomach Bots 
(Gastrophilus spp. (oral and gastric stages)); Lungworms (Dictyocaulus 
arnfieldi (adult and fourth-stage larvae)); intestinal threadworms 
(Strongyloides westeri (adult)); Summer Sores caused by Habronema and 
Draschia spp. cutaneous third-stage larvae; and Dermatitis caused by 
neck threadworm microfilariae (Onchocerca spp.).
    (iii) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.
    (2) Sheep--(i) Amount. 200 mcg/kg (3 mL/26 pounds) of body weight as 
a single dose oral drench.
    (ii) Indications for use. For treatment and control of the adult and 
fourth-stage larvae of gastrointestinal roundworms (Haemonchus 
contortus, H. placei (adults only), Ostertagia circumcincta, 
Trichostrongylus axei, T. colubriformis, Cooperia oncophora (adults 
only), C. curticei, Oesophagostomum columbianum, O. venulosum(adults 
only), Nematodirus battus, N. spathiger, S. papillosus (adults only), 
Chabertia ovina (adult only), Trichuris ovis (adults only)); lungworms 
(D. filaria); and all larval stages of the nasal bot Oestrus ovis.
    (iii) Limitations. For use in sheep only. Do not use in other animal 
species as severe adverse reactions, including fatalities in dogs, may 
result. Do not treat sheep within 11 days of slaughter.

[67 FR 50597, Aug. 5, 2002, as amended at 69 FR 57173, Sept. 24, 2004; 
71 FR 13542, Mar. 16, 2006; 71 FR 38072, July 5, 2006; 72 FR 9456, Feb. 
21, 2008; 78 FR 17596, Mar. 22, 2013]



Sec. 520.1196  Ivermectin and pyrantel pamoate chewable tablets.

    (a) Specifications. Each chewable tablet contains either 68 
micrograms ([micro]g) of ivermectin and 57 milligrams (mg) of pyrantel 
(as pamoate salt), or 136 [micro]g and 114 mg, or 272 [micro]g and 227 
mg, respectively.
    (b) Sponsors. See Nos. 050604, 051311, and 063604 in Sec. 
510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. A minimum of 6 [micro]g 
of ivermectin and 5 mg of pyrantel (as

[[Page 170]]

pamoate salt) per kilogram (2.72 [micro]g and 2.27 mg per pound) of body 
weight.
    (ii) Indications for use. To prevent canine heartworm disease by 
eliminating the tissue larval stages of Dirofilaria immitis for up to a 
month (30 days) after infection and treatment and control of adult 
ascarids Toxocara canis and Toxascaris leonina, and adult hookworms 
Ancylostoma caninum, A. braziliense, and Uncinaria stenocephala.
    (iii) Limitations. Use monthly. Recommended for dogs 6 weeks of age 
and older. Federal law restricts this drug to use by or on the order of 
a licensed veterinarian.
    (2) [Reserved]

[58 FR 8542, Feb. 16, 1993, as amended at 61 FR 15186, Apr. 5, 1996; 61 
FR 59004, Nov. 20, 1996; 62 FR 63270, Nov. 28, 1997; 66 FR 35756, July 
9, 2001; 67 FR 21996, May 2, 2002; 68 FR 55823, Sept. 29, 2003]



Sec. 520.1197  Ivermectin sustained-release bolus.

    (a) Specifications. Each sustained-release bolus contains 1.72 grams 
of ivermectin.
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.344 of this chapter.
    (d) Conditions of use in ruminating calves--(1) Amount. Administer 
one bolus per calf weighing at least 275 pounds (lb) (125 kilograms 
(kg)) and not more than 660 lb (300 kg) on the day of administration.
    (2) Indications. For treatment and control, throughout the grazing 
season (approximately 130 days), of gastrointestinal roundworms 
Haemonchus placei, Ostertagia ostertagi (including inhibited fourth-
stage larvae), Trichostrongylus axei, T. colubriformis, Cooperia spp., 
Nematodirus helvetianus, Bunostomum phlebotomum, Oesophagostomum 
radiatum; lungworms Dictyocaulus viviparus; grubs Hypoderma spp.; 
sucking lice Linognathus vituli, Solenopotes capillatus; mange mites 
Psoroptes ovis, Sarcoptes scabiei, and ticks Amblyomma americanum.
    (3) Limitations. The bolus was specifically designed for use in 
cattle; do not use in other animal species. Calves must be ruminating 
and older than 12 weeks of age. Do not administer to calves weighing 
less than 275 lb (125 kg). Do not administer a damaged bolus. Because a 
milk withdrawal time has not been established, do not use in female 
dairy cattle of breeding age. Do not slaughter cattle within 180 days of 
treatment. Consult your veterinarian for assistance in the diagnosis, 
treatment, and control of parasitism.

[61 FR 67452, Dec. 23, 1996, as amended at 62 FR 63270, Nov. 28, 1997; 
65 FR 45876, July 26, 2000]



Sec. 520.1198  Ivermectin and praziquantel paste.

    (a) Specifications. Each milligram (mg) of paste contains:
    (1) 0.0155 mg (1.55 percent) ivermectin and 0.0775 mg (7.75 percent) 
praziquantel.
    (2) 0.0187 mg (1.87 percent) ivermectin and 0.1403 mg (14.03 
percent) praziquantel.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
uses as in paragraph (d) of this section.--
    (1) No. 050604 for use of product described in paragraph (a)(1) of 
this section as in paragraphs (d)(1)(i), (d)(2)(i) and (d)(3) of this 
section.
    (2) No. 051311 for use of product described in paragraph (a)(2) of 
this section as in paragraphs (d)(1)(ii), (d)(2)(ii), and (d)(3) of this 
section.
    (c) Special considerations. See Sec. 500.25 of this chapter.
    (d) Conditions of use in horses--(1) Amount--(i) 200 micrograms 
(mcg) per kilogram (/kg) ivermectin (91 mcg per pound (/lb)) and 1 mg/kg 
praziquantel (454 mcg/lb) body weight.
    (ii) 200 mcg/kg ivermectin (91 mcg/lb) and 1.5 mg/kg praziquantel 
(681 mcg/lb) body weight.
    (2) Indications for use. For treatment and control of:
    (i) Tapeworms--Anoplocephala perfoliata; Large strongyles (adults)--
Strongylus vulgaris (also early forms in blood vessels), S. edentatus 
(also tissue stages), S. equinus, Triodontophorus spp. including T. 
brevicauda and T. serratus, and Craterostomum acuticaudatum; Small 
Strongyles (adults, including those resistant to some benzimidazole 
class compounds)--Coronocyclus spp. including C. coronatus, C. labiatus, 
and C. labratus, Cyathostomum spp. including C. catinatum and C. 
pateratum, Cylicocyclus spp. including C. insigne, C.

[[Page 171]]

leptostomum, C. nassatus, and C. brevicapsulatus, Cylicodontophorus 
spp., Cylicostephanus spp. including C. calicatus, C. goldi, C. 
longibursatus, and C. minutus, and Petrovinema poculatum; Small 
Strongyles--fourth-stage larvae; Pinworms (adults and fourth-stage 
larvae)--Oxyuris equi; Ascarids (adults and third- and fourth-stage 
larvae)--Parascaris equorum; Hairworms (adults)--Trichostrongylus axei; 
Large-mouth Stomach Worms (adults)--Habronema muscae; Bots (oral and 
gastric stages)--Gasterophilus spp. including G. intestinalis and G. 
nasalis; Lungworms (adults and fourth-stage larvae)--Dictyocaulus 
arnfieldi; Intestinal Threadworms (adults)--Strongyloides westeri; 
Summer Sores caused by Habronema and Draschia spp. cutaneous third-stage 
larvae; Dermatitis caused by neck threadworm microfilariae, Onchocerca 
sp.
    (ii) Tapeworms--Anoplocephala perfoliata; Large Strongyles 
(adults)--Strongylus vulgaris (also early forms in blood vessels), 
S.edentatus (also tissue stages), S. equinus, Triodontophorus spp.; 
Small Strongyles (adults, including those resistant to some 
benzimidazole class compounds)--Cyathostomum spp., Cylicocyclus spp., 
Cylicostephanus spp., Cylicodontophorus spp.; Small Strongyles--fourth-
stage larvae; Pinworms (adults and fourth-stage larvae)--Oxyuris equi; 
Ascarids (adults and third- and fourth-stage larvae)--Parascaris 
equorum; Hairworms (adults)--Trichostrongylus axei; Large-mouth Stomach 
Worms (adults)--Habronema muscae; Bots (oral and gastric stages)--
Gasterophilus spp.; Lungworms (adults and fourth-stage larvae)--
Dictyocaulus arnfieldi; Intestinal Threadworms (adults)--Strongyloides 
westeri; Summer Sores caused by Habronema and Draschia spp. cutaneous 
third-stage larvae; Dermatitis caused by neck threadworm microfilariae, 
Onchocerca sp.
    (3) Limitations. For oral use only. Do not use in horses intended 
for human consumption.

[68 FR 55309, Sept. 25, 2003, as amended at 69 FR 49808, Aug. 12, 2004; 
70 FR 65835, Nov. 1, 2005]



Sec. 520.1199  Ivermectin, pyrantel, and praziquantel tablets.

    (a) Specifications. Each chewable tablet contains:
    (1) 34 micrograms (mcg) ivermectin, 28.5 milligrams (mg) pyrantel 
pamoate, and 28.5 mg praziquantel;
    (2) 68 mcg ivermectin, 57 mg pyrantel pamoate, and 57 mg 
praziquantel;
    (3) 136 mcg ivermectin, 114 mg pyrantel pamoate, and 114 mg 
praziquantel; or
    (4) 272 mcg ivermectin, 228 mg pyrantel pamoate, and 228 mg 
praziquantel.
    (b) Sponsors. See No. 051311 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Administer monthly 
according to body weight as follows:
    (i) 6 to 12 lb: one tablet as described in paragraph (a)(1) of this 
section.
    (ii) 12.1 to 25 lb: one tablet as described in paragraph (a)(2) of 
this section.
    (iii) 25.1 to 50 lb: one tablet as described in paragraph (a)(3) of 
this section.
    (iv) 50.1 to 100 lb: one tablet as described in paragraph (a)(4) of 
this section.
    (v) Greater than 100 lb: use the appropriate combination of tablets.
    (2) Indications for use. Prevents canine heartworm disease by 
eliminating the tissue stage of heartworm larvae (Dirofilaria immitis) 
for 1 month (30 days) after infection and for the treatment and control 
of roundworm (Toxocara canis, Toxascaris leonina), hookworm (Ancylostoma 
caninum, Uncinaria stenocephala, Ancylostoma braziliense) and tapeworm 
(Dipylidium caninum, Taenia pisiformis) infections.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[71 FR 65052, Nov. 7, 2006]



Sec. 520.1200  Ivermectin, fenbendazole, and praziquantel tablets.

    (a) Specifications. Each chewable tablet contains either:
    (1) 68 micrograms ([micro]g) ivermectin, 1.134 grams fenbendazole, 
and 57 milligrams (mg) praziquantel; or
    (2) 27 [micro]g ivermectin, 454 mg fenbendazole, and 23 mg 
praziquantel.

[[Page 172]]

    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Administer tablets to 
provide 6 [micro]g per kilogram (/kg) ivermectin, 100 mg/kg 
fenbendazole, and 5 mg/kg praziquantel.
    (2) Indications for use. For the treatment and control of adult 
Toxocara canis (roundworm), Ancylostoma caninum (hookworm), Trichuris 
vulpis (whipworm), and Dipylidium caninum (tapeworm), and for the 
prevention of heartworm disease caused by Dirofilaria immitis in adult 
dogs.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[73 FR 33692, June 13, 2008, as amended at 74 FR 61516, Nov. 25, 2009]



Sec. 520.1204  Kanamycin, bismuth subcarbonate, activated attapulgite.

    (a) Specifications--(1) Each 5 milliliters (mL) of suspension 
contains 100 milligrams (mg) kanamycin (as the sulfate), 250 mg bismuth 
subcarbonate, and 500 mg activated attapulgite (aluminum magnesium 
silicate).
    (2) Each tablet contains 100 mg kanamycin (as the sulfate), 250 mg 
bismuth subcarbonate, and 500 mg activated attapulgite.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. 5 mL of suspension or 1 
tablet per 20 pounds body weight every 8 hours. Maximum dose: 5 mL of 
suspension or 3 tablets every 8 hours. Dogs under 10 pounds: 2.5 mL of 
suspension or \1/2\ tablet every 8 hours. A recommended initial loading 
dose should be twice the amount of a single dose.
    (2) Indications for use. For the treatment of bacterial enteritis 
caused by organisms susceptible to kanamycin and the symptomatic relief 
of the associated diarrhea.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 53 FR 27851, July 25, 1988; 
56 FR 8710, Mar. 1, 1991; 64 FR 403, Jan. 5, 1999; 71 FR 43968, Aug. 3, 
2006]



Sec. 520.1242  Levamisole.



Sec. 520.1242a  Levamisole powder.

    (a) Specifications. Each package of powder contains 9.075, 11.7, 
18.15, 46.8, 362.7, or 544.5 grams (g) levamisole hydrochloride.
    (b) Sponsors. See sponsors in Sec. 510.600(c) for use as follows:
    (1) No. 000061 for use of 46.8- and 544.5-g packages as in paragraph 
(e)(1)(i), (e)(1)(ii)(B), and (e)(1)(iii) of this section; for 11.7-, 
46.8-, and 544.5-g packages as in paragraph (e)(2)(i), (e)(2)(ii)(B), 
and (e)(2)(iii) of this section; and for an 18.15-g package as in 
paragraph (e)(3) of this section.
    (2) No. 053501 for use of a 46.8-g package as in paragraph 
(e)(1)(i), (e)(1)(ii)(A), and (e)(1)(iii) of this section; for 11.7- and 
46.8-g packages as in paragraph (e)(2)(i), (e)(2)(ii)(A), and 
(e)(2)(iii) of this section; and for 9.075- and 18.15-g packages as in 
paragraph (e)(3) of this section.
    (3) No. 057561 for use of 46.8- and 544.5-g packages as in 
paragraphs (e)(1)(i), (e)(1)(ii)(A), and (e)(1)(iii) and (e)(2)(i), 
(e)(2)(ii)(A), and (e)(2)(iii) of this section.
    (4) No. 059130 for use of 46.8-, 362.7-, and 544.5-g packages as in 
paragraphs (e)(1)(i), (e)(1)(ii)(B), (e)(1)(iii), (e)(2)(i), 
(e)(2)(ii)(B), and (e)(2)(iii) of this section; and for use of an 18.15-
g package as in paragraph (e)(3) of this section.
    (c) Related tolerances. See Sec. 556.350 of this chapter.
    (d) Special considerations. See Sec. 500.25 of this chapter.
    (e) Conditions of use. It is used as an anthelmintic as follows:
    (1) Cattle--(i) Amount. 8 milligrams per kilogram (mg/kg) body 
weight as a drench.
    (ii) Indications for use--(A) Effective against the following 
nematode infections: Stomach worms (Haemonchus, Trichostrongylus, 
Ostertagia); intestinal worms (Trichostrongylus, Cooperia, Nematodirus, 
Bunostomum, Oesophagostomum); and lungworms (Dictyocaulus).
    (B) Effective against the following adult nematode infections: 
Stomach worms (Haemonchus placei, Ostertagia ostertagi, Trichostrongylus 
axei); intestinal worms (T. longispicularis, Cooperia oncophora, C. 
punctata, Nematodirus

[[Page 173]]

spathiger, Bunostomum phlebotomum, Oesophagostomum radiatum); and 
lungworms (Dictyocaulus viviparus).
    (iii) Limitations. Do not slaughter for food within 48 hours of 
treatment. Not for use in dairy animals of breeding age. Conditions of 
constant helminth exposure may require retreatment 2 to 4 weeks after 
the first treatment. Consult your veterinarian before using in severely 
debilitated animals.
    (2) Sheep--(i) Amount. 8 mg/kg body weight as a drench.
    (ii) Indications for use--(A) Effective against the following 
nematode infections: Stomach worms (Haemonchus, Trichostrongylus, 
Ostertagia); intestinal worms (Trichostrongylus, Cooperia, Nematodirus, 
Bunostomum, Oesophagostomum, Chabertia); and lungworms (Dictyocaulus).
    (B) Effective against the following adult nematode infections: 
Stomach worms (Haemonchus contortus, Trichostrongylus axei, Teladorsagia 
circumcincta); intestinal worms (Trichostrongylus colubriformis, 
Cooperia curticei, Nematodirus spathiger, Bunostomum trigonocephalum, 
Oesophagostomum columbianum, Chabertia ovina), and lungworms 
(Dictyocaulus filaria).
    (iii) Limitations. Do not slaughter for food within 72 hours of 
treatment. Conditions of constant helminth exposure may require 
retreatment 2 to 4 weeks after the first treatment. Consult veterinarian 
before using in severely debilitated animals.
    (3) Swine--(i) Amount. 8 mg/kg body weight in drinking water.
    (ii) Indications for use. Effective against the following nematode 
infections: Large roundworms (Ascaris suum), nodular worms 
(Oesophagostomum spp.), intestinal thread worms (Strongyloides ransomi) 
and lungworms (Metastrongylus spp. ).
    (iii) Limitations. Do not administer within 72 hours of slaughter 
for food. Pigs maintained under conditions of constant exposure to worms 
may require retreatment within 4 to 5 weeks after the first treatment. 
Consult your veterinarian before administering to sick swine.

[69 FR 9753, Mar. 2, 2004, as amended at 69 FR 33839, June 17, 2004; 70 
FR 2353, Jan. 13, 2005; 77 FR 28253, May 14, 2012]



Sec. 520.1242b  Levamisole hydrochloride tablet or oblet (bolus).

    (a) Chemical name. (-)-2,3,5,6-Tetrahydro-6-phenylimidazo [2,1-b] 
thiazole monohydrochloride.
    (b) Specifications. Assay of not less than 98 percent by nonaqueous 
titration with 0.1 N potassium isopropoxide; 1 isomer minimum 95 percent 
pure by optical rotation.
    (c) Sponsor. See Nos. 000061 and 053501 in Sec. 510.600(c) of this 
chapter.
    (d) Required labeling. Consult your veterinarian for assistance in 
the diagnosis, treatment, and control of parasitism.
    (e) Related tolerances. See Sec. 556.350 of this chapter.
    (f) Conditions of use. (1) It is used in an oblet for cattle as 
follows:
    (i) Amount. 2.19 grams per oblet.
    (ii) Indications for use. Anthelmintic effective against the 
following nematode infections: Stomach worms (Haemonchus, 
Trichostrongylus, Ostertagia), intestinal worms (Trichostrongylus, 
Cooperia, Nematodirus, Bunostomum, Oesophagostomum), and lungworms 
(Dictyocaulus).
    (iii) Limitations. Administer as a single dose as follows: 250 to 
450 pounds, \1/2\ oblet; 450 to 750 pounds, 1 oblet; and 750 to 1,050 
pounds, 1\1/2\ oblets; conditions of constant helminth exposure may 
require re-treatment within 2 to 4 weeks after the first treatment; do 
not slaughter for food within 48 hours of treatment; not for use in 
dairy animals of breeding age; consult veterinarian before using in 
severely debilitated animals.
    (2) It is used in a tablet for sheep as follows:
    (i) Amount. 0.184 gram per tablet.
    (ii) Indications for use. Anthelmintic effective against the 
following nematode infections: Stomach worms (Haemonchus, 
Trichostrongylus, Ostertagia), intestinal worms (Trichostrongylus, 
Cooperia, Nematodirus, Bunostomum, Oesophagostomum, Chabertia), and 
lungworms (Dictyocaulus).
    (iii) Limitations. Administer one tablet for each 50 pounds of body 
weight; conditions of constant helminth exposure may require re-
treatment within 2 to 4 weeks after the first treatment; do

[[Page 174]]

not slaughter for food within 72 hours of treatment; consult a 
veterinarian before using in severely debilitated animals.

[40 FR 13838, Mar. 27, 1975, as amended at 44 FR 59507, Oct. 16, 1979; 
62 FR 61625, Nov. 19, 1997; 67 FR 63055, Oct. 10, 2002]



Sec. 520.1242c  Levamisole hydrochloride and piperazine dihydrochloride.

    (a) Specifications. (1) The drug is an aqueous solution which 
contains in each fluid ounce 0.36 gram of levamisole hydrochloride and 
piperazine dihydrochloride equivalent to 3.98 grams of piperazine base.
    (2) The drug is a soluble powder which when reconstituted with water 
contains in each fluid ounce 0.45 gram of levamisole hydrochloride and 
piperazine dihydrochloride equivalent to 5.0 grams of piperazine base.
    (b) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use. It is used as a drench for horses as follows:
    (1) Indications for use. An anthelmintic effective against 
infections of large strongyles (Strongylus vulgaris, S. edentatus), 
small strongyles (Cylicocercus spp., Cylicocylclus spp., 
Cylicodontophorus spp., Cylicostephanus spp., Cylicotetrapedon spp. ), 
ascarids (Parascaris equorum), and pinworms (Oxyuris equii).
    (2) Limitations. Aqueous solution: administer by stomach tube or 
drench 1 fluid ounce per 100 pounds of body weight. Reconstituted 
soluble powder: administer by stomach tube 1 fluid ounce per 125 pounds 
of body weight. If reinfection occurs, re-treat animals at 6- to 8-week 
intervals. Do not treat animals intended for food. Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.

[40 FR 32831, Aug. 5, 1975, as amended at 41 FR 48731, Nov. 5, 1976; 43 
FR 11176 Mar. 17, 1978; 67 FR 63055, Oct. 10, 2002]



Sec. 520.1242d  Levamisole resinate.

    (a) Specifications. The drug is levamisole adsorbed on a resin, in a 
concentration equivalent to 10 percent levamisole hydrochloride. Each 
2.05-ounce (58.1 gram) packet contains levamisole equivalent to 5.806 
grams of levamisole hydrochloride.
    (b) Sponsor. See No. 043781 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.350 of this chapter.
    (d) Conditions of use. In swine it is used as follows:
    (1) Amount. The equivalent of 8 milligrams per kilogram of body 
weight, as a single dose, mixed in the animal's ration.
    (2) Indications for use. For the removal of and control of the 
following nematode infections: large roundworms (Ascaris suum), nodular 
worms (Oesophagostomum spp.), lungworms (Metastrongylus spp.), 
intestinal threadworms (Strongyloides ransomi), and swine kidney worms 
(Stephanurus dentatum).
    (3) Limitations. For pigs from weaning to market weight, mix one 
58.1-gram packet of levamisole resinate containing the equivalent of 10-
percent levamisole hydrochloride in 40 pounds of feed and administer 1 
pound of medicated feed per 40 pounds of body weight as sole ration. For 
breeding swine, mix 1 packet of the 10-percent resinate in 16 pounds of 
feed and administer 1 pound of medicated feed per 100 pounds of body 
weight as sole ration. Administer as single doses. Withhold regular feed 
overnight and administer medicated feed the following morning. Do not 
withhold water during fasting. Do not treat within 72 hours of 
slaughter. Salivation or muzzle foam may be observed. The reaction will 
disappear a short time after feeding. If pigs are infected with mature 
lungworms, coughing and vomiting may be observed. Consult your 
veterinarian for assistance in the diagnosis, treatment, and control of 
parasitism.

[43 FR 18171, Apr. 28, 1978, as amended at 45 FR 3574, Jan. 18, 1980]



Sec. 520.1242e  Levamisole hydrochloride effervescent tablets.

    (a) Specifications. Each tablet contains 907 milligrams of 
levamisole hydrochloride.
    (b) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.350 of this chapter.
    (d) Conditions of use. It is used for swine as follows:

[[Page 175]]

    (1) Amount. The equivalent of 8 milligrams of levamisole 
hydrochloride per kilogram of body weight, as a single dose.
    (2) Indications for use. See Sec. 520.1242a(f)(3)(ii).
    (3) Limitations. Withholding water from pigs before treatment is not 
necessary. Add one tablet for each 2\1/2\ gallons of water; mix 
thoroughly. Allow 1 gallon of medicated water for each 100 pounds body 
weight of pigs to be treated. No other source of water should be 
offered. After pigs have consumed medicated water, resume use of regular 
water. Pigs maintained under conditions of constant worm exposure may 
require re-treatment within 4 to 5 weeks. Consult your veterinarian 
before administering to sick swine. Consult your veterinarian for 
assistance in the diagnosis, treatment, and control of parasitism. Do 
not administer within 72 hours of slaughter for food.

[45 FR 6087, Jan. 25, 1980, as amended at 67 FR 63055, Oct. 10, 2002]



Sec. 520.1242f  Levamisole hydrochloride gel.

    (a) Specifications. The drug is a gel containing 11.5 percent 
levamisole hydrochloride.
    (b) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.350 of this chapter.
    (d) Conditions of use--(1) Cattle--(i) Amount. Eight milligrams of 
levamisole hydrochloride per kilogram of body weight, as a single oral 
dose.
    (ii) Indications for use. Anthelmintic effective against the 
following nematode infections: Stomach worms (Haemonchus, 
Trichostrongylus, Ostertagia), intestinal worms (Trichostrongylus, 
Cooperia, Nematodirus, Bunostomum, Oesophagostomum), and lungworms 
(Dictyocaulus).
    (iii) Limitations. Conditions of constant helminth exposure may 
require re-treatment within 2 to 4 weeks after the first treatment; do 
not administer to cattle within 6 days of slaughter for food; do not 
administer to dairy animals of breeding age; consult veterinarian before 
using in severely debilitated animals.
    (2) Breeding swine--(i) Amount. Eight milligrams per kilogram of 
body weight (3.6 milligrams per pound) as a single oral dose.
    (ii) Conditions of use. For treating breeding swine infected with 
the following nematodes: Large roundworms (Ascaris suum), nodular worms 
(Oesophagostomum spp.), lungworms (Metastrongylus spp.), intestinal 
threadworms (Strongyloides ransomi), and kidney worms (Stephanurus 
dentatus).
    (iii) Limitations. May require retreatment in 4 to 5 weeks. Do not 
use within 11 days of slaughter for food. Consult your veterinarian for 
assistance before using in severely debilitated animals and in the 
diagnosis, treatment, and control of parasitism.

[47 FR 22517, May 25, 1982; 47 FR 30242, July 13, 1982, as amended at 48 
FR 11429, Mar. 18, 1983; 51 FR 29215, Aug. 15, 1986; 67 FR 63055, Oct. 
10, 2002]



Sec. 520.1242g  Levamisole resinate and famphur paste.

    (a) Chemical name of famphur. O, O-Dimethyl O-[p-(dimethylsulfamoyl) 
phenyl] phosphorothioate.
    (b) Specifications. The drug is a paste containing 11.6 percent 
levamisole resinate (50 percent potency) and 23.6 percent famphur.
    (c) Sponsor. See 000061 in Sec. 510.600(c) of this chapter.
    (d) Special considerations. Do not use any cholinesterase-inhibiting 
drugs, pesticides, insecticides, or chemicals on cattle simultaneously 
or within a few days before or after treatment with this product.
    (e) Related tolerances. See Sec. 556.350 of this chapter for 
levamisole and Sec. 556.273 of this chapter for famphur.
    (f) Conditions of use in cattle--(1) Amount. 8 milligrams of 
levamisole hydrochloride (equivalent) and 30 milligrams of famphur 
activity per kilogram of body weight.
    (2) Indications for use. For treatment of cattle infected with the 
following parasites: Stomach worms (Haemonchus, Trichostrongylus, 
Ostertagia), intestinal worms (Trichostrongylus, Cooperia, Nematodirus, 
Bunostomum, Oesophagostomum), lungworms (Dictyocaulus), cattle grubs

[[Page 176]]

(Hypoderma), biting lice (Bovicola), and sucking lice (Linognathus, 
Solenoptes).
    (3) Limitations. Drug is not effective against lice eggs. Conditions 
of constant helminth and ectoparasitic exposure may require retreatment 
within 2 to 4 weeks after first treatment. Do not administer to cattle 
within 19 days of slaughter. Do not administer to dairy animals of 
breeding age. Do not use in calves less than 3 months old, or in 
debilitated animals. Do not treat Brahman bulls. Consult your 
veterinarian for assistance in the diagnosis, treatment, and control of 
parasitism.

[53 FR 23757, June 24, 1988, as amended at 54 FR 1353, Jan. 13, 1989; 57 
FR 7652, Mar. 4, 1992; 62 FR 55160, Oct. 23, 1997; 62 FR 61625, Nov. 19, 
1997]



Sec. 520.1263  Lincomycin.



Sec. 520.1263a  Lincomycin hydrochloride monohydrate tablets and sirup.

    (a) Specifications. The sirup contains lincomycin hydrochloride 
equivalent to either 25 milligrams or 50 milligrams of lincomycin.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is indicated in infections 
caused by gram-positive organisms which are sensitive to its action, 
particularly streptococci and staphylococci.
    (2) It is administered orally to dogs and cats at a dosage level of 
10 mgs per pound of body weight every 12 hours, or 7 mgs per pound of 
body weight every 8 hours. Treatment may be continued for periods as 
long as 12 days if clinical judgment indicates.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 44 FR 7130, Feb. 6, 1979; 64 
FR 403, Jan. 5, 1999]



Sec. 520.1263b  [Reserved]



Sec. 520.1263c  Lincomycin powder.

    (a) Specifications. Each gram of soluble powder contains lincomycin 
hydrochloride equivalent to 0.4 grams of lincomycin.
    (b) Sponsors. See sponsor numbers in Sec. 510.600(c) of this 
chapter for use as in paragraph (d) of this section.
    (1) No. 000009 for use as in paragraph (d) of this section.
    (2) Nos. 046573, 054925, 061623, and 076475 for use as in paragraphs 
(d)(1) and (d)(2) of this section.
    (c) Tolerances. See Sec. 556.360 of this chapter.
    (d) Conditions of use--(1) Swine--(i) Amount. 250 milligrams per 
gallon of drinking water to provide 3.8 milligrams per pound of body 
weight per day.
    (ii) Indications for use. For the treatment of swine dysentery 
(bloody scours).
    (iii) Limitations. Discard medicated drinking water if not used 
within 2 days. Prepare fresh stock solution daily. Do not use for more 
than 10 days. If clinical signs of disease have not improved within 6 
days, discontinue treatment and reevaluate diagnosis. The safety of 
lincomycin has not been demonstrated in pregnant swine or swine intended 
for breeding. For No. 051259: Do not slaughter swine for 6 days 
following last treatment.
    (2) Chickens--(i) Amount. 64 milligrams per gallon of drinking 
water.
    (ii) Indications for use. For the control of necrotic enteritis 
caused by Clostridium perfringens susceptible to lincomycin in broiler 
chickens.
    (iii) Limitations. Discard medicated drinking water if not used 
within 2 days. Prepare fresh stock solution daily. Administer for 7 
consecutive days. Do not allow rabbits, hamsters, guinea pigs, horses, 
or ruminants access to water containing lincomycin. Not for use in layer 
and breeder chickens.
    (3) Honey bees--(i) Amount. Mix 100 milligrams lincomycin with 20 
grams confectioners'/powdered sugar and dust over the top bars of the 
brood chamber once weekly for 3 weeks.
    (ii) Indications for use. For the control of American foulbrood 
(Paenibacillus larvae).
    (iii) Limitations. The drug should be fed early in the spring or 
late in the fall and consumed by the bees before the main honey flow 
begins to avoid contamination of production honey.

[[Page 177]]

Complete treatments at least 4 weeks before main honey flow.

[48 FR 3966, Jan. 28, 1983, as amended at 55 FR 3209, Jan. 31, 1990; 60 
FR 14217, Mar. 16, 1995; 62 FR 65020, Dec. 10, 1997; 64 FR 13341, Mar. 
18, 1999; 64 FR 13508, Mar. 19, 1999; 64 FR 66382, Nov. 26, 1999; 65 FR 
10705, Feb. 29, 2000; 67 FR 17284, Apr. 10, 2002; 67 FR 71819, Dec. 3, 
2002; 67 FR 78356, Dec. 24, 2002; 68 FR 3817, Jan. 27, 2003; 70 FR 1818, 
Jan. 11, 2005; 77 FR 20988, Apr. 9, 2012; 77 FR 29217, May 17, 2012]



Sec. 520.1265  Lincomycin and spectinomycin powder.

    (a) Specifications. The following salts of lincomycin and 
spectinomycin are present in a soluble powder in the ratio of 1 to 2 on 
the basis of equivalency of lincomycin base to equivalency of 
spectinomycin base:
    (1) Lincomycin hydrochloride monohydrate and spectinomycin sulfate 
tetrahydrate.
    (2) Lincomycin hydrochloride monohydrate and spectinomycin 
dihydrochloride pentahydrate.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (d) of this section.
    (1) No. 000009 for use of product described in paragraph (a)(1) of 
this section.
    (2) Nos. 057561, 061623, and 066104 for use of product described in 
paragraph (a)(2) of this section.
    (c) Tolerances. See Sec. Sec. 556.360 and 556.600 of this chapter.
    (d) Conditions of use in chickens--(1) Amount. 2 grams of antibiotic 
activity per gallon of drinking water; administer as the sole source of 
water for the first 5 to 7 days of life.
    (2) Indications for use. As an aid in the control of airsacculitis 
caused by either Mycoplasma synoviae or M. gallisepticum susceptible to 
lincomycin-spectinomycin and complicated chronic respiratory disease 
(air sac infection) caused by Escherichia coli and M. gallisepticum 
susceptible to lincomycin-spectinomycin.

[69 FR 13220, Mar. 22, 2004, as amended at 70 FR 40881, July 15, 2005; 
71 FR 71038, Dec. 8, 2006; 77 FR 56770, Sept. 14, 2012]



Sec. 520.1284  Sodium liothyronine tablets.

    (a) Specifications. Sodium liothyronine tablets consist of tablets 
intended for oral administration which contain liothyronine at 60 or 120 
micrograms per tablet, as the sodium salt.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is indicated in cases of 
hypothyroidism in dogs.
    (2) It is administered orally to dogs at levels up to 12.8 
micrograms per kilogram of body weight per day. Dosage should be 
adjusted according to the severity of the condition and the response of 
the patient. Dosage at the total replacement level (12.8[micro]g per 
kilogram of body weight) should be considered for initiating therapy and 
then titrated downward for optimum maintenance effect. Twice daily 
administration is recommended.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 56 FR 50653, Oct. 8, 1991; 60 
FR 55659, Nov. 2, 1995]



Sec. 520.1288  Lufenuron tablets.

    (a) Specifications--(1) Tablets containing 45, 90, 204.9, or 409.8 
milligrams (mg) lufenuron for use as in paragraphs (c)(1)(i), 
(c)(1)(ii)(A), (c)(1)(iii), (c)(2)(i), (c)(2)(ii)(A), and (c)(2)(iii) of 
this section.
    (2) Flavored tablets containing 45, 90, 204.9, or 409.8 milligrams 
(mg) lufenuron for use as in paragraphs (c)(1)(i), (c)(1)(ii)(A) or 
(c)(1)(ii)(B), and (c)(1)(iii) of this section.
    (3) Flavored tablets containing 90 or 204.9 mg lufenuron for use as 
in paragraphs (c)(2)(i), (c)(2)(ii)(A) or (c)(2)(ii)(B), and (c)(2)(iii) 
of this section.
    (4) Flavored tablets containing 135 or 270 mg lufenuron for use as 
in paragraphs (c)(2)(i), (c)(2)(ii)(A), and (c)(2)(iii) of this section.
    (b) Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. Minimum of 10 mg 
lufenuron per kilogram (4.5 mg per pound (lb)) of body weight, once a 
month.
    (ii) Indications for use--(A) For the prevention and control of flea 
populations.

[[Page 178]]

    (B) The concurrent use of flavored lufenuron tablets described in 
paragraph (a)(2) of this section as in paragraph (c)(1)(ii)(A) of this 
section with nitenpyram tablets as in Sec. 520.1510(d)(1) of this 
chapter is indicated to kill adult fleas and prevent flea eggs from 
hatching.
    (iii) Limitations. For use in dogs and puppies 4 weeks of age and 
older.
    (2) Cats--(i) Amount. Minimum of 30 mg lufenuron per kilogram (13.6 
mg/lb) of body weight, once a month.
    (ii) Indications for use--(A) For the control of flea populations.
    (B) The concurrent use of flavored lufenuron tablets described in 
paragraph (a)(3) of this section as in paragraph (c)(2)(ii)(A) of this 
section with nitenpyram tablets as in Sec. 520.1510(d)(2) of this 
chapter is indicated to kill adult fleas and prevent flea eggs from 
hatching.
    (iii) Limitations. For use in cats and kittens 4 weeks of age and 
older.

[68 FR 51905, Aug. 29, 2003]



Sec. 520.1289  Lufenuron suspension.

    (a) Specifications. Each individual dose pack contains either 135 or 
270 milligrams of lufenuron.
    (b) Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in cats--(1) Amount. Minimum of 13.6 
milligrams per pound of body weight (30 milligrams per kilogram). 
Recommended dose of 135 milligrams for up to 10 pounds of body weight or 
270 milligrams for 11 to 20 pounds. Cats over 20 pounds are provided the 
appropriate combination of packs.
    (2) Indications for use. For control of flea populations.
    (3) Limitations. For oral use in cats 6 weeks of age or older, once 
a month, mixed with food. Administer in conjunction with a full meal to 
ensure adequate absorption. Treat all cats in the household to ensure 
maximum benefits. Because the drug has no affect on adult fleas, the 
concurrent use of insecticides that kill adults may be necessary 
depending on the severity of the infestation.

[60 FR 20402, Apr. 26, 1995, as amended at 62 FR 8371, Feb. 25, 1997]



Sec. 520.1310  Marbofloxacin tablets.

    (a) Specifications. Each tablet contains 25, 50, 100, or 200 
milligrams (mg) marbofloxacin.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Amount. 1.25 mg per pound (/lb) of body 
weight once daily, but may be increased to 2.5 mg/lb of body weight once 
daily.
    (2) Indications for use. For the treatment of infections in dogs and 
cats associated with bacteria susceptible to marbofloxacin.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian. Federal law prohibits the extralabel 
use of this drug in food-producing animals.

[64 FR 39919, July 23, 1999, as amended at 66 FR 46369, Sept. 5, 2001]



Sec. 520.1315  Maropitant.

    (a) Specifications. Each tablet contains 16, 24, 60, or 160 
milligrams (mg) maropitant as maropitant citrate.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Indications for use and amount. 
For the prevention of acute vomiting, administer a minimum of 2.0 mg per 
kilogram (/kg) body weight once daily for up to 5 consecutive days. For 
the prevention of vomiting due to motion sickness, administer a minimum 
of 8.0 mg/kg body weight once daily for up to 2 consecutive days.
    (2) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[72 FR 9243, Mar. 1, 2007]



Sec. 520.1320  Mebendazole oral.

    (a) Chemical name. Methyl 5-benzoyl-benzimindazole-2-carbamate.
    (b) Specifications. As oral powder: Each gram contains either 40 or 
166.7 milligrams of mebendazole. As oral paste: Each gram contains 200 
milligrams of mebendazole. As oral suspension: Each milliliter contains 
33.3 milligrams of mebendazole.
    (c) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use--(1) Horses--(i) Amount. 1 gram of mebendazole 
per 250

[[Page 179]]

pounds of body weight per dose, as an oral powder, paste or suspension.
    (ii) Indications for use. It is used in horses for treatment of 
infections caused by large roundworms (Parascaris equorum); large 
strongyles (Strongylus edentatus, S. equinus, S. vulgaris); small 
strongyles; and mature and immature (4th larval stage pinworms (Oxyuris 
equi)).
    (iii) Limitations--(a) Oral powder. The drug is given by sprinkling 
directly on the grain portion of the ration or dissolving in 2 to 4 
pints of water and administering by stomach tube. The drug is compatible 
with carbon disulfide, which can be used concurrently for both control 
(Gastrophilus spp. ). Routine cautions regarding the use of carbon 
disulfide must be observed. Do not administer to horses intended for use 
as food. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (b) Oral paste. The drug is given by dosing gun (syringe), inserting 
the tip of the gun at the interdental space in the horse's mouth and 
depositing the paste on the animal's tongue. The hand is placed under 
the animal's jaw, and the head is raised to assure that the paste is 
deposited on the roof of the mouth. Not for use in horses intended for 
food. Consult your veterinarian for assistance in the diagnosis, 
treatment, and control of parasitism.
    (c) Oral suspension. The drug is administered by stomach tube. Not 
for horses intended for food use. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (2) Dogs--(i) Amount. One hundred milligrams of mebendazole per 10 
pounds of body weight, once daily for 3 days, as an oral powder.
    (ii) Indications for use. The drug is used for treatment of 
infections of roundworms (Toxocara canis), hookworms (Ancylostoma 
caninum, Uncinaria stenocephala), whipworms (Trichuris vulpis), and 
tapeworms (Taenia pisiformis).
    (iii) Limitations. Administer as an oral powder by mixing with a 
small quantity of food, preferably before the regular meal. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.

[42 FR 61255, Dec. 2, 1977, as amended at 43 FR 35686, Aug. 11, 1978; 45 
FR 3574, Jan. 18, 1980; 46 FR 47218, Sept. 25, 1981; 46 FR 53658, Oct. 
30, 1981; 62 FR 61625, Nov. 19, 1997]



Sec. 520.1326  Mebendazole and trichlorfon oral dosage forms.



Sec. 520.1326a  Mebendazole and trichlorfon powder.

    (a) Specifications. Each gram of powder contains 83.3 milligrams of 
mebendazole and 375.0 milligrams of trichlorofon.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. Horses--(1) Amount. 8.8 milligrams of 
mebendazole and 40 milligrams of trichlorofon per kilogram of body 
weight.
    (2) Indications for use. It is used in horses for the treatment of 
infections of bots (Gastrophilus intestinalis and G. nasalis), large 
roundworms (Parascaris equorum), large strongyles (Strongylus edentatus, 
S. equinus, S. vulgaris), small strongyles, and pinworms (Oxyuris equi.)
    (3) Limitations. Administer orally as an individual dose by stomach 
tube or throughly mixed in the ground grain portion of the ration to be 
consumed in one feeding. Discard treated feed not consumed. Do not 
administer more than once every 30 days. Do not treat sick or 
debilitated animals, foals under 4 months of age, or mares in the last 
month of pregnancy. Trichlorofon is a cholinesterase inhibitor. Do not 
administer simultaneously or within a few days before or after treatment 
with, or exposure to, cholinesterase-inhibiting drugs, pesticides or 
chemicals. Do not administer intravenous anesthetics, especially muscle 
relaxants, concurrently. Not for horses intended for food use. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.

[45 FR 10759, Feb. 19, 1980, as amended at 46 FR 52330, Oct. 27, 1981. 
Redesignated at 51 FR 13212, Apr. 18, 1986, as amended at 62 FR 61625, 
Nov. 19, 1997]

[[Page 180]]



Sec. 520.1326b  Mebendazole and trichlorfon paste.

    (a) Specifications. Each gram of paste contains 100 milligrams of 
mebendazole and 454 milligrams of trichlorfon.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 8.8 milligrams of mebendazole and 
40 milligrams of trichlorfon per kilogram of body weight.
    (2) Indications for use. It is used in horses for treatment of 
infections of bots (Gastrophilus intestinalis and G. nasalis), large 
roundworms (Parascaris equorum), large strongyles (Strongylus edentatus, 
S. equinus, S. vulgaris), small strongyles, and pinworms (Oxyuris equi).
    (3) Limitations. Do not administer more than once every 30 days. Do 
not treat sick or debilitated animals, foals under 4 months of age, or 
mares in the last month of pregnancy. Trichlorfon is a cholinesterase 
inhibitor. Do not administer simultaneously or within a few days before 
or after treatment with, or exposure to, cholinesterase-inhibiting 
drugs, pesticides, or chemicals. Do not administer intravenous 
anesthetics, especially muscle relaxants, concurrently. Not for use in 
horses intended for food. Consult your veterinarian for assistance in 
the diagnosis, treatment, and control of parasitism.

[51 FR 13212, Apr. 18, 1986, as amended at 62 FR 61625, Nov. 19, 1997]



Sec. 520.1330  Meclofenamic acid granules.

    (a) Chemical name. N-(2,6-Dichlorom-tolyl) anthranilic acid.
    (b) Specifications. The drug is in granular form containing 5 
percent meclofenamic acid.
    (c) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) The drug is used in horses for the 
treatment of acute or chronic inflammatory diseases involving the 
musculoskeletal system.
    (2) It is administered orally at a dosage of 1 milligram per pound 
of body weight (1 gram per 1,000 pounds) once daily for 5 to 7 days by 
addition to the daily grain ration.
    (3) Treatment beyond the initial 5- to 7-day period may be 
indicated. A maintenance dosage level should be individualized for each 
animal.
    (4) This drug should not be administered to horses with active 
gastrointestinal, hepatic, or renal disease.
    (5) Not for use in horses intended for food.
    (6) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[41 FR 5632, Feb. 9, 1976, as amended at 53 FR 23390, June 22, 1988]



Sec. 520.1331  Meclofenamic acid tablets.

    (a) Specifications. Each tablet contains either 10 or 20 milligrams 
of meclofenamic acid.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. 1.1 milligrams per 
kilogram (0.5 milligram per pound) daily for 5 to 7 days.
    (2) Indications for use. For the relief of signs and symptoms of 
chronic inflammatory disease involving the musculoskeletal system.
    (3) Limitations. For oral use only. Should not be administered to 
animals with congestive heart failure or active gastrointestinal, 
hepatic, or renal disease. Federal law restricts this drug to use by or 
on the order of a licensed veterinarian.

[50 FR 43385, Oct. 25, 1985, as amended at 53 FR 23390, June 22, 1988]



Sec. 520.1341  Megestrol acetate tablets.

    (a) Specifications. Each tablet contains 5 or 20 milligrams of 
megestrol acetate.
    (b) Sponsor. No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used in female dogs for the 
postponement of estrus and the alleviation of false pregnancy.
    (2) It is administered orally, intact, or crushed and mixed with 
food as follows:
    (i) For the postponement of estrus by proestrus treatment, 1 
milligram per pound of body weight per day for 8 days.
    (ii) For the postponement of estrus by anestrus treatment, 0.25 
milligram per pound of body weight per day for 32 days.

[[Page 181]]

    (iii) For alleviation of false pregnancy, 1 milligram per pound of 
body weight per day for 8 days.
    (3) Full dosage regimen must be completed to produce the desired 
effect.
    (4) Examination of vaginal smears is recommended to confirm 
detection of proestrus.
    (5) Do not administer for more than two consecutive treatments.
    (6) Once therapy is started, the animal should be confined for 3 to 
8 days or until cessation of bleeding, since dogs in proestrus accept a 
male.
    (7) Do not use prior to or during first estrus cycle.
    (8) Do not use in pregnant animals.
    (9) Do not use in the presence of a disease of the reproductive 
system or with mammary tumors.
    (10) Should estrus occur within 30 days after cessation of 
treatment, mating should be prevented.
    (11) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 52 FR 7832, Mar. 13, 1987]



Sec. 520.1350  Meloxicam.

    (a) Specifications. Each milliliter of suspension contains 0.5 or 
1.5 milligrams (mg) meloxicam.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter for 
uses as in paragraph (c) of this section.
    (c) Conditions of use in dogs--(1) Amount. Administer orally as a 
single dose at 0.09 mg per pound (mg/lb) body weight (0.2 mg per 
kilogram (mg/kg)) on the first day of treatment. For all treatment after 
day 1, administer 0.045 mg/lb (0.1 mg/kg) body weight once daily.
    (2) Indications for use. For the control of pain and inflammation 
associated with osteoarthritis.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[68 FR 42968, July 21, 2003, as amended at 69 FR 69523, Nov. 30, 2004]



Sec. 520.1372  Methimazole.

    (a) Specifications. Each tablet contains 2.5 or 5 milligrams (mg) 
methimazole.
    (b) Sponsor. See No. 043264 in Sec. 510.600 of this chapter.
    (c) Conditions of use in cats--(1) Amount. The starting dose is 2.5 
mg every 12 hours. Following 3 weeks of treatment, the dose should be 
titrated to effect based on individual serum total T4 levels and 
clinical response.
    (2) Indications for use. For the treatment of hyperthyroidism.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[74 FR 27707, June 11, 2009]



Sec. 520.1380  Methocarbamol tablets.

    (a) Chemical name. 3-(O-Methoxyphenoxy)-1,2-propanediol 1-carbamate.
    (b) Specifications. Each tablet contains 500 milligrams of 
methocarbamol.
    (c) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) The drug is administered to dogs and cats 
as an adjunct to therapy for acute inflammatory and traumatic conditions 
of the skeletal muscles in order to reduce muscular spasms.
    (2) Dosage is based upon severity of symptoms and response noted. 
The usual initial dose in 60 milligrams per pound of body weight in two 
or three equally divided doses followed by 30 to 60 milligrams per pound 
of body weight each following day, usually not to exceed 14 to 21 days.
    (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 67 FR 67521, Nov. 6, 2002]



Sec. 520.1408  Methylprednisolone tablets.

    (a) Specifications. Each table contains 1, 2, or 4 milligrams of 
methylprednisolone.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter for 
use of 1- and 4-milligram tablets; see No. 000010 for use of 1- and 2-
milligram tablets.
    (c) NAS/NRC status. The conditions of use have been NAS/NRC reviewed 
and found effective. NADA's for approval of drugs for these conditions 
of use need not include effectiveness data specified by Sec. 514.111 of 
this chapter, but may require bioequivalency and safety information.

[[Page 182]]

    (d) Special consideration. (1) Clinical and experimental data have 
demonstrated that corticosteroids administered orally or parenterally to 
animals may induce the first stage of parturition when administered 
during the last trimester of pregnancy and may precipitate premature 
parturition followed by dystocia, fetal death, retained placenta, and 
metritis.
    (2) Systemic therapy with methylprednisolone is contraindicated in 
animals with arrested tuberculosis, peptic ulcer, acute psychoses, or 
cushingoid syndrome. The presence of active tuberculosis, diabetes, 
osteoporosis, chronic psychotic reactions, predisposition to 
thrombophlebitis, hypertension, congestive heart failure, or renal 
insufficiency necessitates carefully controlled use of corticosteroids. 
Some of these conditions occur only rarely in dogs and cats but should 
be kept in mind.
    (3) Anti-inflammatory action of corticosteroids may mask signs of 
infection.
    (e) Conditions of use--(1) Amount. Dogs and cats: 5 to 15 pounds, 2 
milligrams; 15 to 40 pounds, 2 to 4 milligrams; 40 to 80 pounds, 4 to 8 
milligrams.
    (2) Indications for use. For use in dogs and cats as an anti-
inflammatory agent.
    (3) Limitations. Administer total daily dose orally in equally 
divided doses 6 to 10 hours apart until response is noted or 7 days have 
elapsed. When response is attained, dosage should be gradually reduced 
until maintenance level is achieved. Hazardous for human use. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.

[47 FR 52697, Nov. 23, 1982, as amended at 49 FR 20810, May 17, 1984; 50 
FR 32844, Aug. 15, 1985; 53 FR 40727, Oct. 18, 1988; 62 FR 35076, June 
30, 1997]



Sec. 520.1409  Methylprednisolone, aspirin tablets.

    (a) Specifications. Each tablet contains 0.5 milligram of 
methylprednisolone and 300 milligrams of aspirin.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) NAS/NRC status. The conditions of use have been NAS/NRC reviewed 
and found effective. New animal drug applications for approval of drugs 
for these conditions of use need not include effectiveness data 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
    (d) Special considerations. (1) Clinical and experimental data have 
demonstrated that corticosteroids administered orally or parenterally to 
animals may induce the first stage of parturition when administered 
during the last trimester of pregnancy and may precipitate premature 
parturition followed by dystocia, fetal death, retained placenta, and 
metritis.
    (2) Systemic therapy with methylprednisolone is contraindicated in 
animals with tuberculosis, chronic nephritis, peptic ulcer, or 
Cushingoid syndrome. The presence of diabetes mellitus, osteoporosis, 
predisposition to thrombophlebitis, hypertension, congestive heart 
failure, or renal insufficiency necessitates carefully controlled use of 
corticosteroids.
    (3) Anti-inflammatory action of corticosteroids may mask signs of 
infection.
    (e) Conditions of use--(1) Amount. Dogs under 15 pounds, \1/4\ to 1 
tablet daily; 15 to 60 pounds, 1 to 2 tablets daily; 60 pounds and over, 
2 tablets daily.
    (2) Indications for use. As an anti-inflammatory and analgesic agent 
in dogs.
    (3) Limitations. Administer total daily dose in divided doses 6 to 
10 hours apart, with a light feeding. When response is attained, dosage 
should be gradually reduced until maintenance level is achieved. Do not 
administer to cats. Do not overdose. Federal law restricts this drug to 
use by or on the order of a licensed veterinarian.

[48 FR 21566, May 13, 1983]



Sec. 520.1422  Metoserpate hydrochloride.

    (a) Chemical name. Methyl-o-methyl-18-epireserpate hydrochloride.
    (b) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.410 of this chapter.
    (d) Conditions of use. It is used in drinking water for replacement 
chickens as follows:

[[Page 183]]

    (1) Amount. 568.5 milligrams per gallon (0.015 percent).
    (i) Indications for use. As a tranquilizer for flock treatment of 
chickens prior to handling.
    (ii) Limitations. To be used one time as a treatment for replacement 
chickens up to 16 weeks of age; usual drinking water should be withheld 
prior to treatment to provide adequate consumption of medicated drinking 
water; not for use in laying chickens; chickens slaughtered within 72 
hours following treatment must not be used for food.
    (2) Amount. 2 to 4 milligrams per 2.2 pounds of body weight.
    (i) Indications for use. As an aid in control of hysteria.
    (ii) Limitations. To be used as a treatment for replacement chickens 
up to 16 weeks of age; usual drinking water should be withheld prior to 
treatment to provide adequate consumption of medicated drinking water; 
the drug should be administered at a dosage level of 4 milligrams per 
2.2 pounds of body weight followed by 2 treatments at 4-day intervals of 
2 milligrams per 2.2 pounds of body weight; not for use in laying 
chickens; chickens slaughtered within 72 hours following treatment must 
not be used for food.

[40 FR 13838, Mar. 27, 1975, as amended at 76 FR 17337, Mar. 29, 2011]



Sec. 520.1430  Mibolerone.

    (a) Specifications. Each milliliter contains 100 micrograms of 
mibolerone.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 30 micrograms for animals 
weighing 1 to 25 pounds; 60 micrograms for animals weighing 26 to 50 
pounds; 120 micrograms for animals weighing 51 to 100 pounds; 180 
micrograms for animals weighing over 100 pounds, German Shepherds, or 
German Shepherd mix.
    (2) Indications for use. For the prevention of estrus (heat) in 
adult female dogs not intended primarily for breeding purposes.
    (3) Limitations. Administer daily, orally or in a small amount of 
food, at least 30 days before expected initiation of heat, and continue 
daily as long as desired, but not for more than 24 months. Mibolerone 
should not be used in bitches before the first estrous period. It is not 
intended for animals being used primarily for breeding purposes. Use 
orally in adult female dogs only. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.

[43 FR 15625, Apr. 14, 1978]



Sec. 520.1441  Milbemycin oxime.

    (a) Specifications--(1) Dogs. Each tablet contains 2.3, 5.75, 11.5, 
or 23.0 milligrams of milbemycin oxime.
    (2) Cats. Each tablet contains 5.75, 11.5, or 23.0 milligrams of 
milbemycin oxime.
    (b) Sponsor. See 058198 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Dogs and puppies--(i) Amount. For 
hookworm, roundworm, and whipworm, use 0.23 milligram per pound of body 
weight (0.5 milligram per kilogram). For heartworm, use 0.05 milligram 
per pound of body weight (0.1 milligram per kilogram).
    (ii) Indications for use. For prevention of heartworm disease caused 
by Dirofilaria immitis, control of hookworm infections caused by 
Ancylostoma caninum, and removal and control of adult roundworm 
infections caused by Toxocara canis and Toxascaris leonina and whipworm 
infections caused by Trichuris vulpis in dogs and in puppies 4 weeks of 
age or greater and 2 pounds of body weight or greater.
    (iii) Limitations. Do not use in puppies less than 4 weeks of age 
and less than 2 pounds of body weight. Administer once a month. First 
dose given within 1 month after first exposure to mosquitoes and 
continue regular use until at least 1 month after end of mosquito 
season. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (2) Cats and kittens--(i) Amount. 0.91 milligram per pound of body 
weight (2.0 milligrams per kilogram).
    (ii) Indications for use. For prevention of heartworm disease caused 
by Dirofilaria immitis and the removal of adult Toxocara cati 
(roundworm) and Ancylostoma tubaeforme (hookworm) infections in cats 6 
weeks of age or greater and 1.5 pounds body weight or greater.

[[Page 184]]

    (iii) Limitations. Do not use in kittens less than 6 weeks of age or 
1.5 pounds body weight. Administer once a month. Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.

[55 FR 25301, June 21, 1990, as amended at 55 FR 49888, Dec. 3, 1990; 58 
FR 5608, Jan. 22, 1993; 60 FR 50097, Sept. 28, 1995; 61 FR 43654, Aug. 
26, 1996; 63 FR 29352, May 29, 1998; 63 FR 41189, Aug. 3, 1998. 
Redesignated at 77 FR 47512, Aug. 9, 2012]



Sec. 520.1443  Milbemycin oxime and lufenuron.

    (a) Specifications--(1) Tablets containing: 2.3 milligrams (mg) 
milbemycin oxime and 46 mg lufenuron, 5.75 mg milbemycin oxime and 115 
mg lufenuron, 11.5 mg milbemycin oxime and 230 mg lufenuron, or 23 mg 
milbemycin oxime and 460 mg lufenuron.
    (2) Flavored tablets containing: 2.3 mg milbemycin oxime and 46 mg 
lufenuron, 5.75 mg milbemycin oxime and 115 mg lufenuron, 11.5 mg 
milbemycin oxime and 230 mg lufenuron, or 23 mg milbemycin oxime and 460 
mg lufenuron.
    (b) Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Dogs--(i) Amount. 0.5 mg milbemycin oxime 
and 10 mg lufenuron per kilogram of body weight, once a month.
    (ii) Indications for use--(A) For use in dogs and puppies for the 
prevention of heartworm disease caused by Dirofilaria immitis, for 
prevention and control of flea populations, for control of adult 
Ancylostoma caninum (hookworm), and for removal and control of adult 
Toxocara canis, Toxascaris leonina (roundworm), and Trichuris vulpis 
(whipworm) infections.
    (B) The concurrent use of flavored milbemycin oxime and lufenuron 
tablets described in paragraph (a)(2) of this section as in paragraph 
(d)(1)(ii)(A) of this section with nitenpyram tablets as in Sec. 
520.1510(d)(1) of this chapter is indicated to kill adult fleas and 
prevent flea eggs from hatching.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) [Reserved]

[62 FR 28629, May 27, 1997, as amended at 63 FR 41190, Aug. 3, 1998; 68 
FR 51905, Aug. 29, 2003. Redesignated at 77 FR 47512, Aug. 9, 2012]



Sec. 520.1445  Milbemycin oxime and praziquantel.

    (a) Specifications. Each chewable tablet contains:
    (1) 2.3 milligrams (mg) milbemycin oxime and 22.8 mg praziquantel;
    (2) 5.75 mg milbemycin oxime and 57 mg praziquantel;
    (3) 11.5 mg milbemycin oxime and 114 mg praziquantel; or
    (4) 23 mg milbemycin oxime and 228 mg praziquantel.
    (b) Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. Administer orally, once 
a month, a minimum dosage of 0.23 mg per pound (mg/lb) of body weight 
(0.5 mg per kilogram (mg/kg)) milbemycin oxime and 2.28 mg/lb of body 
weight (5 mg/kg) praziquantel.
    (ii) Indications for use. For the prevention of heartworm disease 
caused by Dirofilaria immitis and for the treatment and control of adult 
roundworm (Toxocara canis, Toxascaris leonina), adult hookworm 
(Ancylostoma caninum), adult whipworm (Trichuris vulpis), and adult 
tapeworm (Taenia pisiformis, Echinococcus multilocularis, and E. 
granulosus) infections in dogs and puppies 2 pounds of body weight or 
greater and 6 weeks of age and older.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) [Reserved]

[77 FR 47512, Aug. 9, 2012]



Sec. 520.1447  Milbemycin oxime, lufenuron, and praziquantel tablets.

    (a) Specifications. Each tablet contains:
    (1) 2.3 milligrams (mg) milbemycin oxime, 46 mg lufenuron, and 22.8 
mg praziquantel;
    (2) 5.75 mg milbemycin oxime, 115 mg lufenuron, and 57 mg 
praziquantel;
    (3) 11.5 mg milbemycin oxime, 230 mg lufenuron, and 114 mg 
praziquantel; or
    (4) 23 mg milbemycin oxime, 460 mg lufenuron, and 228 mg 
praziquantel.

[[Page 185]]

    (b) Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Dogs--(i) Amount. 0.5 mg milbemycin 
oxime, 10 mg lufenuron, and 5 mg of praziquantel per kilogram of body 
weight, once a month.
    (ii) Indications for use. For the prevention of heartworm disease 
caused by Dirofilaria immitis; for the prevention and control of flea 
populations (Ctenocephalides felis); and for the treatment and control 
of adult roundworm (Toxocara canis, Toxascaris leonina), adult hookworm 
(Ancylostoma caninum), adult whipworm (Trichuris vulpis), and adult 
tapeworm (Taenia pisiformis, Echinococcus multilocularis, and E. 
granulosus) infections in dogs and puppies 2 pounds of body weight or 
greater and 6 weeks of age and older.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) [Reserved]

[77 FR 4225, Jan. 27, 2012]



Sec. 520.1450  Morantel tartrate oral dosage forms.



Sec. 520.1450a  Morantel tartrate bolus.

    (a) Specifications. Each bolus contains 2.2 grams morantel tartrate 
equivalent to 1.3 grams of morantel base.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.425 of this chapter.
    (d) Conditions of use--(1) Amount. One bolus per 500 pounds of body 
weight (4.4 milligrams per pound of body weight) as a single oral dose. 
Boluses may be divided in half for more accurate dosing as follows: up 
to 325 pounds, \1/2\ bolus; 326 to 600 pounds, 1 bolus; 601 to 900 
pounds, 1\1/2\ boluses; and 901 to 1,200 pounds, 2 boluses.
    (2) Indications for use. For removal and control of mature 
gastrointestinal nematode infections of cattle including stomach worms 
(Haemonchus spp., Ostertagia spp., Trichostrongylus spp.), worms of the 
small intestine (Cooperia spp., Trichostrongylus spp., Nematodirus 
spp.), and worms of the large intestine (Oesophagostomum radiatum).
    (3) Limitations. Conditions of constant worm exposure may require 
retreatment in 2 to 4 weeks. Consult your veterinarian before 
administering to severely debilitated animals and for assistance in the 
diagnosis, treatment, and control of parasitism. Do not treat within 14 
days of slaughter.

[46 FR 50949, Oct. 16, 1981. Redesignated at 49 FR 47831, Dec. 7, 1984, 
and amended at 51 FR 9005, Mar. 17, 1986]



Sec. 520.1450b  Morantel tartrate cartridge.

    (a) Specifications. The drug product consists of a stainless-steel 
cylinder having both ends closed with polyethylene diffusing discs and 
containing a morantel tartrate paste. The paste contains 22.7 grams of 
morantel tartrate equivalent to 13.5 grams of morantel base.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.425 of this chapter.
    (d) Conditions of use--(1) Amount. Grazing cattle: Administer 1 
cartridge to each animal at the start of the grazing season.
    (2) Indications for use. For control of the adult stage of the 
following gastrointestinal nematode infections in weaned calves and 
yearling cattle weighing a minimum of 200 pounds: Ostertagia spp., 
Trichostrongylus axei, Cooperia spp., and Oesophagostomum radiatum.
    (3) Limitations. Administer orally with the dosing gun to all cattle 
that will be grazing the same pasture. Effectiveness of the drug product 
is dependent upon continuous control of the gastrointestinal parasites 
for approximately 90 days following administration. Therefore, treated 
cattle should not be moved to pastures grazed in the same grazing 
season/calendar year by untreated cattle. Do not administer to cattle 
within 106 days of slaughter. Consult your veterinarian before 
administering to severely debilitated animals and for assistance in the 
diagnosis, treatment, and control of parasitism.

[49 FR 47831, Dec. 7, 1984, as amended at 51 FR 23415, June 27, 1986; 51 
FR 41081, Nov. 13, 1986]

[[Page 186]]



Sec. 520.1450c  Morantel tartrate sustained-release trilaminate 
cylinder/sheet.

    (a) Specifications. The drug product consists of a trilaminated, 
perforated, plastic sheet formed into a cylinder having plastic plugs in 
its ends. The core lamina contains 19.8 grams of morantel tartrate 
equivalent to 11.8 grams of morantel base.
    (b) Sponsor. See 000069 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.425 of this chapter.
    (d) Conditions of use--(1) Amount. Grazing cattle: Administer 1 
cartridge to each animal at the start of the grazing season.
    (2) Indications for use. For control of the adult stage of the 
following gastrointestinal nematode infections in weaned calves and 
yearling cattle weighing a minimum of 200 pounds: Ostertagia spp., 
Trichostrongylus axei, Cooperia spp., and Oesophagostomum radiatum.
    (3) Limitations. Administer orally with the dosing gun to all cattle 
that will be grazing the same pasture. Effectiveness of the drug product 
is dependent upon continuous control of the gastrointestinal parasites 
for approximately 90 days following administration. Therefore, treated 
cattle should not be moved to pastures grazed in the same grazing 
season/calendar year by untreated cattle. Do not administer to cattle 
within 102 days of slaughter. Consult your veterinarian before 
administering to severely debilitated animals and for assistance in the 
diagnosis, treatment, and control of parasitism.

[56 FR 13396, Apr. 2, 1991]



Sec. 520.1451  Moxidectin tablets.

    (a) Specifications. Each tablet contains 30, 68, or 136 micrograms 
of moxidectin.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Amount. 3 micrograms per kilogram (1.36 
micrograms per pound) of body weight.
    (2) Indications for use. To prevent infection by the canine 
heartworm Dirofilaria immitis and the subsequent development of canine 
heartworm disease.
    (3) Limitations. Use once-a-month in dogs at 8 weeks of age or 
older. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[62 FR 37713, July 15, 1997]



Sec. 520.1452  Moxidectin gel.

    (a) Specifications. Each milliliter of gel contains 20 milligrams (2 
percent) moxidectin.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. See Sec. 500.25 of this chapter.
    (d) Conditions of use in horses and ponies--(1) Amount. 0.4 
milligram moxidectin per kilogram (2.2 pounds) of body weight.
    (2) Indications for use. For the treatment and control of large 
strongyles: Strongylus vulgaris (adults and L4/L5 arterial stages), S. 
edentatus (adult and tissue stages), Triodontophorus brevicauda 
(adults), and T. serratus (adults); small strongyles (adults): 
Cyathostomum spp., including C. catinatum and C. pateratum; 
Cylicocyclus. spp., including C. insigne, C. leptostomum, C. nassatus, 
and C. radiatus; Cyliocostephanus spp., including C. calicatus, C. 
goldi, C. longibursatus, and C. minutus; Coronocyclus spp., including C. 
coronatus, C. labiatus, and C. labratus; Gyalocephalus capitatus; and 
Petrovinema poculatus; small strongyles: undifferentiated lumenal 
larvae; encysted cyathostomes (late L3 and L4 mucosal cyathostome 
larvae); ascarids: Parascaris equorum (adults and L4 larval stages); 
pinworms: Oxyuris equi (adults and L4 larval stages); hairworms: 
Trichostrongylus axei (adults); large-mouth stomach worms: Habronema 
muscae (adults); and horse stomach bots: Gasterophilus intestinalis (2nd 
and 3rd instars) and G. nasalis (3rd instars). One dose also suppresses 
strongyle egg production for 84 days.
    (3) Limitations. For oral use in horses and ponies 6 months of age 
and older. Not for use in horses and ponies intended for food.

[62 FR 42902, Aug. 11, 1997, as amended at 64 FR 66105, Nov. 24, 1999; 
68 FR 51445, Aug. 27, 2003; 69 FR 24959, May 5, 2004; 70 FR 75017, Dec. 
19, 2005]

[[Page 187]]



Sec. 520.1453  Moxidectin and praziquantel gel.

    (a) Specifications. Each milliliter of gel contains 20 milligrams 
(mg) (2.0 percent) moxidectin and 125 mg (12.5 percent) praziquantel.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. See Sec. 500.25 of this chapter.
    (d) Conditions of use in horses and ponies--(1) Amount. Administer 
by mouth as a single dose: 0.4 mg moxidectin per kilogram and 2.5 mg 
praziquantel per kilogram (2.2 pounds) body weight.
    (2) Indications for use. For the treatment and control of large 
strongyles: Strongylus vulgaris (adults and L4/L5 arterial stages), S. 
edentatus (adult and tissue stages), Triodontophorus brevicauda 
(adults), and T. serratus (adults); small strongyles (adults): 
(Cyathostomum spp., including C. catinatum and C. pateratum; 
Cylicocyclus spp., including C. insigne, C. leptostomum, C. nassatus, 
and C. radiatus; Cylicostephanus spp., including C. calicatus, C. goldi, 
C. longibursatus, and C. minutus; Coronocyclus spp., including C. 
coronatus, C. labiatus, and C. labratus; Gyalocephalus capitatus; and 
Petrovinema poculatus; small strongyles: undifferentiated lumenal 
larvae; encysted cyathostomes (late L3 and L4 mucosal cyathostome 
larvae); ascarids: Parascaris equorum (adults and L4 larval stages); 
pinworms: Oxyuris equi (adults and L4 larval stages); hairworms: 
Trichostrongylus axei (adults); large-mouth stomach worms: Habronema 
muscae (adults); horse stomach bots: Gasterophilus intestinalis (2nd and 
3rd instars) and G. nasalis (3rd instars); and tapeworms: Anoplocephala 
perfoliata (adults). One dose also suppresses strongyle egg production 
for 84 days.
    (3) Limitations. For oral use in horses and ponies 6 months of age 
and older. Not for use in horses and ponies intended for food.

[68 FR 51446, Aug. 27, 2003, as amended at 69 FR 21956, Apr. 23, 2004; 
70 FR 75017, Dec. 19, 2005]



Sec. 520.1454  Moxidectin solution.

    (a) Specifications. Each milliliter (mL) of solution contains 1 
milligram (mg) moxidectin.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.426 of this chapter.
    (d) Special considerations. See Sec. 500.25 of this chapter.
    (e) Conditions of use in sheep--(1) Amount. Administer 1 mL per 11 
pounds body weight (1 mL per 5 kilograms) by mouth.
    (2) Indications for use. For the treatment and control of the adult 
and L4 larval stages of Haemonchus contortus, Teladorsagia circumcincta, 
T. trifurcata, Trichostrongylus axei, T. colubriformis, T. vitrinus, 
Cooperia curticei, C. oncophora, Oesophagostomum columbianum, O. 
venulosum, Nematodirus battus, N. filicollis, and N. spathiger.
    (3) Limitations. Sheep must not be slaughtered for human consumption 
within 7 days of treatment. Because a withholding time in milk has not 
been established for this product, do not use in female sheep providing 
milk for human consumption.

[70 FR 76163, Dec. 23, 2005, as amended at 76 FR 48714, Aug. 9, 2011]



Sec. 520.1468  Naproxen granules.

    (a) Specifications. Naproxen granules contain 50 percent naproxen.
    (b) Sponsor. No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Horses. The drug is used for the relief 
of inflammation and associated pain and lameness exhibited with 
arthritis, as well as myositis and other soft tissue diseases of the 
musculoskeletal system of the horse.
    (2)(i) For oral maintenance therapy following initial intravenous 
dosage, administer 10 milligrams naproxen per kilogram of animal body 
weight twice daily as top dressing in the animal's feed for up to 14 
consecutive days. The initial intravenous dosage is 5 milligrams per 
kilogram of body weight.
    (ii) For oral dosage only, administer 10 milligrams naproxen per 
kilogram of animal body weight twice daily as a top dressing in the 
animal's feed for up to 14 consecutive days.

[[Page 188]]

    (3) Not for use in horses intended for food.
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[41 FR 14188, Apr. 2, 1976, as amended at 51 FR 24525, July 7, 1986; 61 
FR 5506, Feb. 13, 1996]



Sec. 520.1484  Neomycin.

    (a) Specifications--(1) Each ounce of powder contains 20.3 grams (g) 
neomycin sulfate (equivalent to 14.2 g neomycin base).
    (2) Each milliliter of solution contains 200 milligrams (mg) 
neomycin sulfate (equivalent to 140 mg neomycin base).
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (e) of this section.
    (1) Nos. 000069 and 054925 for use of product described in paragraph 
(a)(1) as in paragraph (e)(1) of this section.
    (2) Nos. 000009, 046573, 058005, and 061623 for use of product 
described in paragraph (a)(1) as in paragraphs (e)(1) and (e)(2) of this 
section.
    (3) Nos. 000009, 000859, 054925, and 058005 for use of product 
described in paragraph (a)(2) as in paragraph (e)(1) of this section.
    (c) Related tolerances. See Sec. 556.430 of this chapter.
    (d) Special labeling considerations. Labeling shall bear the 
following warning statements: ``A withdrawal period has not been 
established for use in preruminating calves. Do not use in calves to be 
processed for veal. Use of more than one product containing neomycin or 
failure to follow withdrawal times may result in illegal drug 
residues.''
    (e) Conditions of use--(1) Cattle, swine, sheep, and goats--(i) 
Amount. 10 mg per pound (/lb) of body weight per day (22 mg per kilogram 
(/kg)) in divided doses for a maximum of 14 days.
    (ii) Indications for use. For the treatment and control of 
colibacillosis (bacterial enteritis) caused by Escherichia coli 
susceptible to neomycin sulfate.
    (iii) Limitations. Add powder to drinking water or milk; not for use 
in liquid supplements. Administer solution undiluted or in drinking 
water. Prepare a fresh solution in drinking water daily. If symptoms 
persist after using this preparation for 2 or 3 days, consult a 
veterinarian. Treatment should continue 24 to 48 hours beyond remission 
of disease symptoms, but not to exceed a total of 14 consecutive days. 
Discontinue treatment prior to slaughter as follows: Cattle, 1 day; 
sheep, 2 days; swine and goats, 3 days.
    (2) Turkeys--(i) Amount. 10 mg/lb of body weight per day (22 mg/kg) 
for 5 days.
    (ii) Indications for use. For the control of mortality associated 
with E. coli susceptible to neomycin sulfate in growing turkeys.
    (iii) Limitations. Add to drinking water; not for use in liquid 
supplements. Prepare a fresh solution daily. If symptoms persist after 
using this preparation for 2 or 3 days, consult a veterinarian. 
Treatment should continue 24 to 48 hours beyond remission of disease 
symptoms, but not to exceed a total of 5 consecutive days.

[71 FR 56866, Sept. 28, 2006, as amended at 71 FR 68738, Nov. 28, 2006; 
78 FR 17596, Mar. 22, 2013]



Sec. 520.1510  Nitenpyram tablets.

    (a) Specifications. Each tablet contains 11.4 or 57 milligrams (mg) 
nitenpyram.
    (b) Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. The concurrent use of nitenpyram tablets 
and flavored milbemycin/lufenuron tablets as in paragraph (d)(1)(ii)(B) 
of this section shall be by or on the order of a licensed veterinarian.
    (d) Conditions of use--(1) Dogs--(i) Amount--(A) One 11.4-mg tablet 
for dogs weighing less than 25 pounds (lb) or one 57-mg tablet for dogs 
weighing more than 25 lb, as needed, for use as in paragraph 
(d)(1)(ii)(A) of this section.
    (B) One 11.4-mg tablet for dogs weighing less than 25 lb or one 57 
mg tablet for dogs weighing more than 25 lbs, once or twice weekly, for 
use as in paragraph (d)(1)(ii)(B) of this section.
    (ii) Indications for use--(A) For the treatment of flea infestations 
on dogs and puppies 4 weeks of age and older and 2 lbs of body weight or 
greater.
    (B) The concurrent use of nitenpyram tablets as in paragraph 
(d)(1)(i)(B) of this section with either flavored lufenuron tablets as 
in Sec. 520.1288(c)(1) of

[[Page 189]]

this chapter or flavored milbemycin and lufenuron tablets as in Sec. 
520.1446(d)(1) of this chapter is indicated to kill adult fleas and 
prevent flea eggs from hatching.
    (2) Cats--(i) Amount--(A) One 11.4-mg tablet, as needed, for use as 
in paragraph (d)(2)(ii)(A) of this section.
    (B) One 11.4-mg tablet, once or twice weekly, for use as in 
paragraph (d)(2)(ii)(B) of this section.
    (ii) Indications for use--(A) For the treatment of flea infestations 
on cats and kittens 4 weeks of age and older and 2 lbs of body weight or 
greater.
    (B) The concurrent use of nitenpyram tablets as in paragraph 
(d)(2)(i)(B) of this section with flavored lufenuron tablets as in Sec. 
520.1288(c)(2) of this chapter is indicated to kill adult fleas and 
prevent flea eggs from hatching.

[68 FR 51906, Aug. 29, 2003]



Sec. 520.1615  Omeprazole.

    (a) Specifications. Each gram of paste contains 0.37 gram 
omeprazole.
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. When labeled for use as in paragraph 
(d)(2)(i) of this section, product labeling shall bear: ``Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.''
    (d) Conditions of use in horses--(1) Amount--(i) For treatment of 
gastric ulcers, 1.8 milligrams per pound (mg/lb) of body weight (4 
milligrams per kilogram (mg/kg)) once daily for 4 weeks. For prevention 
of recurrence of gastric ulcers, 0.9 mg/lb of body weight (2 mg/kg) once 
daily for at least an additional 4 weeks.
    (ii) For prevention of gastric ulcers using the premarked syringe, 
one dose per day for 8 or 28 days. Each dose delivers at least 1 mg/kg 
of body weight. Horses over 1,200 lb body weight should receive two 
doses per day.
    (2) Indications for use. (i) For treatment and prevention of 
recurrence of gastric ulcers in horses and foals 4 weeks of age and 
older.
    (ii) For prevention of gastric ulcers in horses.
    (3) Limitations. Do not use in horses intended for human 
consumption.

[69 FR 13220, Mar. 22, 2004, as amended at 71 FR 59374, Oct. 10, 2006]



Sec. 520.1616  Orbifloxacin tablets.

    (a) Specifications. Each tablet contains 5.7, 22.7, or 68 milligrams 
(mg) orbifloxacin.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs and cats--(1) Amount. 2.5 to 7.5 mg 
per kilogram body weight once daily.
    (2) Indications for use. For management of diseases associated with 
bacteria susceptible to orbifloxacin.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian. Federal law prohibits the extralabel 
use of this drug in food producing animals.

[71 FR 14643, Mar. 23, 2006, as amended at 75 FR 26646, May 12, 2010]



Sec. 520.1618  Orbifloxacin suspension.

    (a) Specifications. Each milliliter of suspension contains 30 
milligrams (mg) orbifloxacin.
    (b) Sponsor. See No. 000061 in 510.600(c) of this chapter.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian. Federal law prohibits the 
extralabel use of this drug in food-producing animals.
    (d) Conditions of use--(1) Dogs--(i) Amount. 1.1 to 3.4 mg/lb (2.5 
to 7.5 mg/kg) of body weight once daily.
    (ii) Indications for use. For the treatment of urinary tract 
infections (cystitis) in dogs caused by susceptible strains of 
Staphylococcus pseudintermedius, Proteus mirabilis, Escherichia coli, 
and Enterococcus faecalis and skin and soft tissue infections (wounds 
and abscesses) in dogs caused by susceptible strains of Staphylococcus 
pseudintermedius, Staphylococcus aureus, coagulase-positive 
staphylococci, Pasteurella multocida, Proteus mirabilis, Pseudomonas 
spp., Klebsiella pneumoniae, E. coli, Enterobacter spp., Citrobacter 
spp., E. faecalis, [beta]-hemolytic streptococci (Group G), and 
Streptococcus equisimilis.
    (2) Cats--(i) Amount. 3.4 mg/lb (7.5 mg/kg) of body weight once 
daily.

[[Page 190]]

    (ii) Indications for use. For the treatment of skin infections 
(wounds and abscesses) in cats caused by susceptible strains of S. 
aureus, E. coli, and P. multocida.

[75 FR 26646, May 12, 2010]



Sec. 520.1628  Oxfendazole powder and pellets.

    (a) Specifications--(1) Powder for suspension. Each gram of powder 
contains 7.57 percent oxfendazole.
    (2) Pellets. Each gram of pellets contains 6.49 percent oxfendazole.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 10 milligrams per kilogram of 
body weight.
    (2) Indications for use. The drug is used in horses for removal of 
the following gastrointestinal worms: Large roundworms (Parascaris 
equorum), mature and immature pinworms (Oxyuris equi), large strongyles 
(Strongylus edentatus, Strongylus vulgaris, and Strongylus equinus), and 
small strongyles.
    (3) Limitations--(i) Powder for suspension. For gravity 
administration via stomach tube or for positive administration via 
stomach tube and dose syringe. Discard unused portions of suspension 
after 24 hours. Mix drug according to directions prior to use. 
Administer drug with caution to sick or debilitated horses. Not for use 
in horses intended for food. Federal law restricts this drug to use by 
or on the order of a licensed veterinarian.
    (ii) Pellets. The drug is given by sprinkling on the grain portion 
of the ration. Withholding feed or water prior to administration is not 
necessary. Administer drug with caution to sick or debilitated horses. 
Not for use in horses intended for food. Consult your veterinarian for 
assistance in the diagnosis, treatment, and control of parasitism.

[44 FR 35211, June 19, 1979, as amended at 46 FR 26301, May 12, 1981; 46 
FR 60570, Dec. 11, 1981; 49 FR 28549, July 13, 1984; 61 FR 5506, Feb. 
13, 1996]



Sec. 520.1629  Oxfendazole paste.

    (a)(1) Specifications. Each gram of paste contains 0.375 gram 
oxfendazole (37.5 percent).
    (2) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use--(i) Amount. 10 milligrams per kilogram (2.2 
pounds) of body weight.
    (ii) Indications for use. The drug is used in horses for removal of 
the following gastrointestinal worms: Large roundworms (Parascaris 
equorum), mature and 4th stage larvae pinworms (Oxyuris equi), large 
strongyles (Strongylus edentatus, S. vulgaris, and S. equinus), and 
small strongyles.
    (iii) Limitations. Horses maintained on premises where reinfection 
is likely to occur should be retreated in 6 to 8 weeks. Withholding feed 
or water prior to use is unnecessary. Administer drug with caution to 
sick or debilitated horses. Not for use in horses intended for food. 
Consult your veterinarian for assistance in the diagnosis, treatment, 
and control of parasitism.
    (b)(1) Specifications. Each gram of paste contains 185 milligrams of 
oxfendazole (18.5 percent).
    (2) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (3) Related tolerances. See Sec. 556.495 of this chapter.
    (4) Conditions of use--(i) Amount. 4.5 milligrams per kilogram of 
body weight (2.05 milligrams per pound).
    (ii) Indications for use. The drug is used in cattle for the removal 
and control of the following worms: lungworms (Dictyocaulus viviparus--
adult, L4); stomach worms: barberpole worms (Haemonchus contortus and H. 
placei--adult), small stomach worms (Trichostrongylus axei--adult), 
brown stomach worms (Ostertagia ostertagi--adult, L4, inhibited L4); 
intestinal worms; nodular worms (Oesophagostomum radiatum--adult), 
hookworms (Bunostomum phlebotomum--adult), small intestinal worms 
(Cooperia punctata, C. oncophora, and C. mcmasteri--adult, L4); and 
tapeworms (Moniezia benedeni--adult).
    (iii) Limitations. For use in cattle only. Treatment may be repeated 
in 4 to 6 weeks. Cattle must not be slaughtered until 11 days after 
treatment. Do

[[Page 191]]

not use in female dairy cattle of breeding age. Consult a veterinarian 
for assistance in the diagnosis, treatment, and control of parasitism.

[49 FR 38250, Sept. 28, 1984, as amended at 58 FR 39443, July 23, 1993; 
61 FR 5506, Feb. 13, 1996]



Sec. 520.1630  Oxfendazole suspension.

    (a) Specifications. Each milliliter of suspension contains:
    (1) 90.6 milligrams (mg) oxfendazole (9.06 percent).
    (2) 225.0 mg oxfendazole (22.5 percent).
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.495 of this chapter.
    (d) Special considerations. See Sec. 500.25 of this chapter. If 
labeled for administration by stomach tube: Federal law restricts this 
drug to use by or on the order of a licensed veterinarian.
    (e) Conditions of use--(1) Horses. Use the product described in 
paragraph (a)(1) of this section as follows:
    (i) Amount. 10 mg per kilogram (/kg) of body weight by stomach tube 
or dose syringe. Horses maintained on premises where reinfection is 
likely to occur should be retreated in 6 to 8 weeks.
    (ii) Indications for use. For removal of large roundworms 
(Parascaris equorum), mature and 4th stage larvae pinworms (Oxyuris 
equi), large strongyles (Strongylus edentatus, S. vulgaris, and S. 
equinus), and small strongyles.
    (iii) Limitations. Withholding feed or water prior to use is 
unnecessary. Administer drug with caution to sick or debilitated horses. 
Do not use in horses intended for human consumption.
    (2) Cattle. Use the products described in paragraphs (a)(1) and 
(a)(2) of this section as follows:
    (i) Amount. 4.5 mg/kg of body weight by dose syringe. Treatment may 
be repeated in 4 to 6 weeks.
    (ii) Indications for use. For the removal and control of: lungworms 
(Dictyocaulus viviparus--adult, L4); stomach worms: barberpole worms 
(Haemonchus contortus and H. placei--adult), small stomach worms 
(Trichostrongylus axei--adult), brown stomach worms (Ostertagia 
ostertagi--adult, L4, inhibited L4); intestinal worms; nodular worms 
(Oesophagostomum radiatum--adult), hookworms (Bunostomum phlebotomum--
adult), small intestinal worms (Cooperia punctata, C. oncophora, and C. 
surnabada--adult, L4), and tapeworms (Moniezia benedeni--adult).
    (iii) Limitations. Cattle must not be slaughtered until 7 days after 
treatment. Because a withdrawal time in milk has not been established, 
do not use in female dairy cattle of breeding age.

[55 FR 46943, Nov. 8, 1990, as amended at 56 FR 8710, Mar. 1, 1991; 61 
FR 5506, Feb. 13, 1996; 72 FR 10596, Mar. 9, 2007; 73 FR 45610, Aug. 6, 
2008; 75 FR 10166, Mar. 5, 2010]



Sec. 520.1631  Oxfendazole and trichlorfon paste.

    (a) Specifications. Each gram of paste contains 28.5 milligrams 
oxfendazole and 454.5 milligrams trichlorfon.
    (b) Sponsor. See 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 2.5 milligrams of oxfendazole and 
40 milligrams of trichlorfon per kilogram of body weight.
    (2) Indications for use. The drug is used in horses for removal of 
bots (Gasterophilus intestinalis, 2nd and 3rd instars; G. nasalis, 3rd 
instar) and the following gastrointestinal worms: Large roundworms 
(Parascaris equorum), pinworms (Oxyuris equi), adult and 4th stage 
larvae; large strongyles (Strongylus edentatus, S. vulgaris, and S. 
equinus); and small strongyles.
    (3) Limitations. Horses maintained on premises where reinfection is 
likely to occur should be retreated in 6 to 8 weeks. Withholding feed or 
water before use is unnecessary. Administer with caution to sick or 
debilitated horses. Not for use in horses intended for food. Do not 
administer to mares during the last month of pregnancy. Trichlorfon is a 
cholinesterase inhibitor. Do not use this product in animals 
simultaneously with, or within a few days before or after treatment with 
or exposure to, cholinesterase-inhibiting drugs, pesticides, or 
chemicals. Consult your veterinarian for assistance in the diagnosis, 
treatment, and control of parasitism.

[50 FR 50291, Dec. 10, 1985, as amended at 61 FR 5506, Feb. 13, 1996]

[[Page 192]]



Sec. 520.1638  Oxibendazole paste.

    (a) Specifications. The paste contains 22.7 percent oxibendazole.
    (b) Sponsor. See 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. For uses other than for 
threadworms (Strongyloides westeri), 10 milligrams of oxibendazole per 
kilogram of body weight; for threadworms (Strongyloides westeri), 15 
milligrams per kilogram.
    (2) Indications for use. For removal and control of large strongyles 
(Strongylus edentatus, S. equinus, S. vulgaris); small strongyles 
(genera Cylicostephanus, Cylicocyclus, Cyathostomum, Triodontophorus, 
Cylicodontophorus, and Gyalocephalus); large roundworms (Parascaris 
equorum); pinworms (Oxyuris equi) including various larval stages; and 
threadworms (Strongyloides westeri).
    (3) Limitations. Administer orally by syringe. Horses maintained on 
premises where reinfection is likely to occur should be re-treated in 6 
to 8 weeks. Not for use in horses intended for human consumption. 
Consult a veterinarian for assistance in the diagnosis, treatment, and 
control of parasitism.

[46 FR 50948, Oct. 16, 1981, as amended at 47 FR 36418, Aug. 20, 1982; 
56 FR 50653, Oct. 8, 1991; 60 FR 55659, Nov. 2, 1995; 71 FR 33237, June 
8, 2006]



Sec. 520.1640  Oxibendazole suspension.

    (a) Specifications. The suspension contains 10 percent oxibendazole.
    (b) Sponsor. See 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. For use other than 
threadworms (Strongyloides westeri), 10 milligrams of oxibendazole per 
kilogram of body weight; for threadworms, 15 milligrams per kilogram of 
body weight.
    (2) Indications for use. For removal and control of large strongyles 
(Strongylus edentatus, S. equinus, S. vulgaris); small strongyles 
(species of the genera Cylicostephanus Cylicocyclus, Cyathostomum, 
Triodontophorus, Cylicodontophorus, and Gyalocephalus); large roundworms 
(Parascaris equorum); pinworms (Oxyuris equi) including various larval 
stages; and threadworms (Strongyloides westeri).
    (3) Limitations. Administer by stomach tube in 3 to 4 pints of warm 
water, or by top dressing or mixing into a portion of the normal grain 
ration. Prepare individual doses to ensure that each animal receives the 
correct amount. Horses maintained on premises where reinfection is 
likely to occur should be re-treated in 6 to 8 weeks. Not for use in 
horses intended for human consumption. Federal law restricts this drug 
to use by or on the order of a licensed veterinarian.

[45 FR 78119, Nov. 28, 1980, as amended at 47 FR 39812, Sept. 10, 1982; 
56 FR 50653, Oct. 8, 1991; 60 FR 55659, Nov. 2, 1995; 71 FR 33237, June 
8, 2006]



Sec. 520.1660  Oxytetracycline.



Sec. 520.1660a  Oxytetracycline and carbomycin in combination.

    (a) Specifications. (1) Oxytetracycline: The antibiotic substance 
produced by growth of Streptomyces rimosus or the same antibiotic 
substance produced by any other means.
    (2) Carbomycin: The antibiotic substance produced by growth of 
Streptomyces halstedii or the same antibiotic substance produced by any 
other means.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. The quantities of oxytetracycline in 
paragraph (e) of this section refer to the activity of oxytetracycline 
hydrochloride and the quantities of carbomycin listed refer to the 
activity of an appropriate standard.
    (d) Related tolerances. See Sec. Sec. 556.110 and 556.500 of this 
chapter.
    (e) Conditions of use. It is used as oxytetracycline hydrochloride 
plus carbomycin base in drinking water of chickens as follows:
    (1) Amount. 1.0 gram of oxytetracycline and 1.0 gram carbomycin per 
gallon.
    (2) Indications for use. As an aid in the prevention and treatment 
of complicated chronic respiratory disease (air-sac infection) caused by 
Mycoplasma gallisepticum and secondary bacterial organisms associated 
with chronic respiratory disease such as E. coli.

[[Page 193]]

    (3) Limitations. Administer for not more than 5 days; not for use in 
chickens producing eggs for human consumption; withdraw 24 hours before 
slaughter.



Sec. 520.1660b  Oxytetracycline hydrochloride capsules.

    (a) Specifications. The drug is in capsule form with each capsule 
containing 125 or 250 milligrams of oxytetracycline hydrochloride. 
Oxytetracycline is the antibiotic substance produced by growth of 
Streptomyces rimosus or the same antibiotic substance produced by any 
other means.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is used in dogs and cats for the 
treatment of bacterial pneumonia caused by Brucella bronchiseptica, 
tonsilitis caused by Streptococcus hemolyticus, bacterial enteritis 
caused by Escherichia coli, urinary tract infections caused by 
Escherichia coli, and wound infections caused by Staphylococcus aureus. 
\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (2) The drug is administered orally to dogs and cats at a dosage 
level of 25-50 milligrams per pound of body weight per day in divided 
doses at 12-hour intervals. The drug can be used for continuation of 
compatible antibiotic therapy following parenteral oxytetracycline 
administration where rapidly attained, sustained antibiotic blood levels 
are required. The duration of treatment required to obtain favorable 
response will depend to some extent on the severity and degree of 
involvement and the susceptibility of the infectious agent. Clinical 
response to antibiotic therapy usually occurs within 48 to 72 hours. If 
improvement is not observed within that period, the diagnosis and course 
of treatment should be reconsidered. To assure adequate treatment, 
administration of the drug should continue for at least 48 hours 
following favorable clinical response.\1\
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.\1\



Sec. 520.1660c  Oxytetracycline hydrochloride tablets/boluses.

    (a) Specifications. Each tablet or bolus contains 250, 500, or 1,000 
milligrams of oxytetracycline hydrochloride.
    (b) Sponsors. For sponsors in Sec. 510.600(c) of this chapter: See 
000010 for use of 500 and 1,000 milligram boluses. See 000069 for use of 
250 and 500 milligram tablets.
    (c) Tolerances. See Sec. 556.500 of this chapter.
    (d) Conditions of use in beef and dairy cattle--(1)(i) Amount. 250 
milligrams per 100 pounds of body weight every 12 hours (5 milligrams 
per pound of body weight daily in two doses).
    (ii) Indications for use. For control of bacterial enteritis caused 
by Salmonella typhimurium and Escherichia coli (colibacillosis) and 
bacterial pneumonia (shipping fever complex, pasteurellosis) caused by 
Pasteurella multocida.
    (2)(i) Amount. 500 milligrams per 100 pound of body weight every 12 
hours (10 milligrams per pound of body weight daily in two doses).
    (ii) Indications for use. For treatment of bacterial enteritis 
caused by Salmonella typhimurium and Escherichia coli (colibacillosis) 
and bacterial pneumonia (shipping fever complex, pasteurellosis) caused 
by Pasteurella multocida.
    (3) Limitations. Dosage should continue until the animal returns to 
normal and for 24 hours to 48 hours after symptoms have subsided. 
Treatment should not exceed 4 consecutive days. Do not exceed 500 
milligrams per 100 pounds of body weight every 12 hours (10 milligrams 
per pound daily). For sponsor 000069: Discontinue treatment 7 days prior 
to slaughter. Not for use in lactating dairy cattle. A withdrawal period 
has not been established for this product in preruminating calves. Do 
not use in calves to be processed for veal.

[46 FR 32440, June 23, 1981, as amended at 50 FR 1045, Jan. 9, 1985; 63 
FR 70334, Dec. 21, 1998; 70 FR 16394, Apr. 4, 2005]



Sec. 520.1660d  Oxytetracycline powder.

    (a) Specifications. The drug is a soluble powder distributed in 
packets or pails having several concentrations of

[[Page 194]]

oxytetracycline hydrochloride (independent of the various net weights) 
as follows:
    (1) Each 18.14 grams of powder contains 1 gram of oxytetracycline 
hydrochloride (OTC HCl) (packets: 4, 6.4, and 16 oz.).
    (2) Each 4.43 grams of powder contains 1 gram of OTC HCl (packets: 4 
and 16 oz.).
    (3) Each 1.32 grams of powder contains 1 gram of OTC HCl (packets: 
2.39, 4.78, and 9.55 oz.; jars: 2.25 lbs.; and pails: 4.5 lbs.).
    (4) Each 2.73 grams of powder contains 1 gram of OTC HCl (packets: 
2.46 and 9.87 oz; pail: 3.09 lb).
    (5) Each 4.2 grams of powder contains 1 gram of OTC HCl (packets: 
3.8 and 15.2 oz; pails: 4.74 and 23.7 lb).
    (6) Each 1.32 grams of powder contains 1 gram of OTC HCl (packet: 
4.78 oz.; pail: 5 lb). Each 2.73 grams of powder contains 1 gram of OTC 
HCl (packet: 9.87 oz).
    (7) Each 1.32 grams of powder contains 1 gram of OTC HCl (packet: 
4.78 and 9.6 oz.; pails: 2 and 5 lb); each 18.1 grams of powder contains 
1 gram of OTC HCl (packet: 6.4 oz.; pails: 2 and 5 lb).
    (8) Each 135.5-gram packet (4.78 ounce) contains 102.4 grams of OTC 
HCl. Each 677.5-gram packet (23.9 ounce) contains 512 grams of OTC HCl.
    (9) Each 2.73 grams of powder contains 1 gram of OTC HCl (packets: 
9.87 and, 19.75 oz, and 3.91 lb; pails: 3.09 and 5 lb).
    (10) Each 2.73 grams of powder contains 1 gram of OTC HCl (packets: 
9.87 and 19.74 oz; pails: 5 lb).
    (b) Sponsor. See sponsor numbers in Sec. 510.600(c) of this chapter 
as follows:
    (1) No. 000069 for use of OTC HCl concentrations in paragraphs 
(a)(1), (a)(2), and (a)(3) of this section in chickens, turkeys, swine, 
cattle, sheep, and honey bees.
    (2) No. 046573 for use of OTC HCl concentration in paragraph (a)(4) 
of this section in chickens, turkeys, and swine.
    (3) No. 000010 for use of OTC HCl concentration in paragraph (a)(5) 
of this section in turkeys and chickens.
    (4) No. 057561 for use of OTC HCl concentration in paragraph (a)(6) 
of this section in chickens, turkeys, and swine.
    (5) No. 061623 for use of OTC HCl concentration in paragraph (a)(7) 
of this section in chickens, turkeys, swine, cattle, sheep, and 
honeybees.
    (6) No. 048164 for use of OTC HCl concentrations in paragraph (a)(8) 
of this section in chickens, turkeys, swine, cattle, sheep, and honey 
bees.
    (7) No. 061623 for use of OTC HCl concentration in paragraph (a)(9) 
of this section in chickens, turkeys, and swine.
    (8) No. 059320 for use of OTC concentration in paragraph (a)(10) of 
this section in chickens, turkeys, and swine as in paragraph (d) of this 
section.
    (c) Related tolerances. See Sec. 556.500 of this chapter.
    (d) Conditions of use. (1) It is used in drinking water as follows:
    (i) Chickens--(A)(1) Amount per gallon. 200 to 400 milligrams.
    (2) Indications for use. Control of infectious synovitis caused by 
Mycoplasma synoviae susceptible to oxytetracycline.
    (3) Limitations. Prepare a fresh solution daily. Administer 7 to 14 
days. Not to be used for more than 14 consecutive days. Use as sole 
source of drinking water. Do not use in birds producing eggs for human 
consumption.
    (B)(1) Amount per gallon. 400 to 800 milligrams.
    (2) Indications for use. Control of chronic respiratory disease 
(CRD) and air sac infections caused by Mycoplasma gallisepticum and E. 
coli susceptible to oxytetracycline; control of fowl cholera caused by 
Pasteurella multocida susceptible to oxytetracycline.
    (3) Limitations. Prepare a fresh solution daily. Administer 7 to 14 
days. Not to be used for more than 14 consecutive days. Use as sole 
source of drinking water. Do not use in birds producing eggs for human 
consumption.
    (ii) Turkeys--(A)(1) Amount per gallon. 200 to 400 milligrams.
    (2) Indications for use. Control of hexamitiasis caused by Hexamita 
meleagridis susceptible to oxytetracycline.
    (3) Limitations. Prepare a fresh solution daily. Administer 7 to 14 
days. Not to be used for more than 14 consecutive

[[Page 195]]

days. Use as sole source of drinking water. Do not use in birds 
producing eggs for human consumption. Withdraw 5 days prior to slaughter 
those products sponsored by Nos. 000069, and 061623 in Sec. 510.600(c) 
of this chapter. Withdraw 4 days prior to slaughter those products 
sponsored by No. 000010. Zero-day withdrawal for those products 
sponsored by Nos. 046573, 053389, 057561, 059320, and 061133.
    (B)(1) Amount per gallon. 400 milligrams.
    (2) Indications for use. Control of infectious synovitis caused by 
Mycoplasma synoviae susceptible to oxytetracycline.
    (3) Limitations. Prepare a fresh solution daily. Administer 7 to 14 
days. Not to be used for more than 14 consecutive days. Use as sole 
source of drinking water. Do not use in birds producing eggs for human 
consumption. Withdraw 5 days prior to slaughter those products sponsored 
by Nos. 000069, and 061623 in Sec. 510.600(c) of this chapter. Withdraw 
4 days prior to slaughter those products sponsored by No. 000010. Zero-
day withdrawal for those products sponsored by Nos. 046573, 053389, 
057561, 059320, and 061133.
    (C)(1) Amount. 25 milligrams per pound of body weight.
    (2) Indications for use. Growing turkeys. Control of complicating 
bacterial organisms associated with bluecomb (transmissible enteritis, 
coronaviral enteritis) susceptible to oxytetracycline.
    (3) Limitations. Prepare a fresh solution daily. Administer 7 to 14 
days. Not to be used for more than 14 consecutive days. Use as sole 
source of drinking water. Do not use in birds producing eggs for human 
consumption. Withdraw 5 days prior to slaughter those products sponsored 
by Nos. 000069, and 061623 in Sec. 510.600(c) of this chapter. Withdraw 
4 days prior to salughter those products sponsored by No. 000010. Zero-
day withdrawal for those products sponsored by Nos. 046573, 053389, 
057561, 059320, and 061133.
    (iii) Swine--(A) Amount. 10 milligrams per pound of body weight 
daily.
    (B) Indications for use. Control and treatment of bacterial 
enteritis caused by Escherichia coli and Salmonella choleraesuis and 
bacterial pneumonia caused by Pasteurella multocida susceptible to 
oxytetracycline. For breeding swine: Control and treatment of 
leptospirosis (reducing the incidence of abortions and shedding of 
leptospira) caused by Leptospira pomona susceptible to oxytetracycline.
    (C) Limitations. Prepare a fresh solution daily. Use as sole source 
of OTC. Administer up to 14 days; do not use for more than 14 
consecutive days; withdraw zero days prior to slaughter those products 
sponsored by Nos. 000069 and 061623. Administer up to 5 days; do not use 
for more than 5 consecutive days; withdraw zero days prior to slaughter 
those products sponsored by Nos. 046573, 053389, 057561, 059320, and 
061133.
    (iv) Calves, beef cattle, and nonlactating dairy cattle--(A) Amount. 
10 milligrams per pound of body weight daily.
    (B) Indications for use. Control and treatment of bacterial 
enteritis caused by E. coli and bacterial pneumonia (shipping fever 
complex) caused by P. multocida susceptible to oxytetracycline.
    (C) Limitations. Prepare a fresh solution daily. Administer up to 14 
days. Do not use for more than 14 consecutive days. Use as sole source 
of oxytetracycline. Do not administer this product with milk or milk 
replacers. Administer 1 hour before or 2 hours after feeding milk or 
milk replacers. Withdraw 5 days prior to slaughter. A milk discard 
period has not been established for this product in lactating dairy 
cattle. Do not use in female dairy cattle 20 months of age or older.
    (v) Sheep--(A) Amount. 10 milligrams per pound of body weight daily.
    (B) Indications for use. Control and treatment of bacterial 
enteritis caused by E. coli and bacterial pneumonia (shipping fever 
complex) caused by P. multocida susceptible to oxytetracycline.
    (C) Limitations. Prepare a fresh solution daily. Administer up to 14 
days. Do not use for more than 14 consecutive days. Use as sole source 
of oxytetracycline. Withdraw 5 days prior to slaughter.
    (2) It is used in the food of honey bees as follows:
    (i) Amount. 200 milligrams per colony, administered via either a 1:1 
sugar syrup (equal parts of sugar and water

[[Page 196]]

weight to weight) or dusting with a powdered sugar mixture.
    (ii) Indications for use. For control of American foulbrood caused 
by Paenibacillus larvae and European foulbrood caused by Streptococcus 
pluton susceptible to oxytetracycline.
    (iii) Limitations. The drug is administered in 3 applications of 
sugar syrup or 3 dustings at 4- to 5-day intervals. The drug should be 
fed early in the spring or fall and consumed by the bees before main 
honey flow begins to avoid contamination of production honey. Remove at 
least 6 weeks prior to main honey flow.

[50 FR 32694, Aug. 14, 1985]

    Editorial Note: For Federal Register citations affecting Sec. 
520.1660d, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 520.1696  Penicillin.



Sec. 520.1696a  [Reserved]



Sec. 520.1696b  Penicillin G powder.

    (a) Specifications. Each gram of powder contains penicillin G 
potassium equivalent to 1.54 million units of penicillin G.
    (b) Sponsors. See Nos. 010515, 046573, 053501, 059320, 061623 and 
076475 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in turkeys-- (1) Amount. 1,500,000 units per 
gallon drinking water for 5 days.
    (2) Indications for use. Treatment of erysipelas caused by 
Erysipelothrix rhusiopathiae.
    (3) Limitations. Prepare concentrated stock solution for use with 
medication proportioners fresh every 24 hours. Prepare recommended use 
levels for gravity flow watering system fresh every 12 hours. For best 
results, treatment should be started at the first sign of infection. 
Discontinue treatment at least 1 day prior to slaughter. Not for use in 
turkeys producing eggs for human consumption.

[57 FR 37326, Aug. 18, 1992, as amended at 59 FR 42493, Aug. 18, 1994; 
60 FR 26359, May 17, 1995; 62 FR 55160, Oct. 23, 1997; 65 FR 10705, Feb. 
29, 2000; 66 FR 14073, Mar. 9, 2001; 68 FR 4914, Jan. 31, 2003; 68 FR 
26204, May 15, 2003; 69 FR 9946, Mar. 3, 2004; 69 FR 41428, July 9, 
2004; 77 FR 20988, Apr. 9, 2012]



Sec. 520.1696c  Penicillin V powder.

    (a) Specifications. When reconstituted, each milliliter contains 25 
milligrams (40,000 units) of penicillin V.
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use. Dogs and cats--(1) Amount. 10 to 15 
milligrams per pound of body weight every 6 to 8 hours.
    (2) Indications for use. Treatment of respiratory, urogenital, skin, 
and soft tissue infections and septicemia caused by pathogens 
susceptible to penicillin V potassium.
    (3) Limitations. Administer orally 1 to 2 hours prior to feeding for 
maximum absorption. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[57 FR 37326, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992; 77 FR 20988, 
Apr. 9, 2012]



Sec. 520.1696d  Penicillin V tablets.

    (a) Specifications. Each tablet contains penicillin V potassium 
equivalent to 125 milligrams (200,000 units) or 250 milligrams (400,000 
units) of penicillin V.
    (b) Sponsors. See Nos. 050604 and 053501 in Sec. 510.600(c) of this 
chapter.
    (c) [Reserved]
    (d) Conditions of use. Dogs and Cats--(1) Amount. 10 to 15 
milligrams per pound of body weight every 6 to 8 hours.
    (2) Indications for use. Treatment of respiratory, urogenital, skin 
and soft tissue infections and septicemia caused by pathogens 
susceptible to penicillin V potassium.
    (3) Limitations. Administer orally 1 to 2 hours prior to feeding for 
maximum absorption. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[57 FR 37327, Aug. 18, 1992, as amended at 59 FR 58775, Nov. 15, 1994]



Sec. 520.1705  Pergolide.

    (a) Specifications. Each tablet contains 1 milligram (mg) pergolide 
mesylate.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.

[[Page 197]]

    (c) Conditions of use in horses--(1) Amount. Administer orally at a 
starting dose of 2 micrograms/kilograms ([micro]/kg) once daily. Dosage 
may be adjusted to effect, not to exceed 4 [micro]g/kg daily.
    (2) Indications for use. For the control of clinical signs 
associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing's 
Disease).
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[77 FR 15960, Mar. 19, 2012]



Sec. 520.1720  Phenylbutazone oral dosage forms.



Sec. 520.1720a  Phenylbutazone tablets and boluses.

    (a) Specifications. Each tablet contains 100, 200, or 400 milligrams 
(mg), or 1 gram (g) of phenylbutazone. Each bolus contains 1, 2, or 4 
gram g of phenylbutazone.
    (b) Sponsors. See sponsor numbers in Sec. 510.600(c) of this 
chapter, as follows:
    (1) No. 000061 for use of 100- or 400-mg or 1-g tablets, or 2- or 4-
g boluses, in dogs and horses.
    (2) Nos. 000010 and 000859 for use of 100- or 200-mg or 1-g tablets 
in dogs and horses.
    (3) Nos. 000856 and 061623 for use of 100-mg or 1-g tablets in dogs 
and horses.
    (4) [Reserved]
    (5) No. 000143 for use of 1-g tablets in horses.
    (6) No. 058829 for use of 100-mg or 1-g tablets in dogs and horses.
    (c) Conditions of use--(1) Dogs--(i) Amount. 20 mg per pound of body 
weight daily.
    (ii) Indications for use. For the relief of inflammatory conditions 
associated with the musculoskeletal system.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Horses--(i) Amount. 1 to 2 g per 500 pounds of body weight 
daily.
    (ii) Indications for use. For the relief of inflammatory conditions 
associated with the musculoskeletal system.
    (iii) Limitations. Do not use in horses intended for human 
consumption. Federal law prohibits the use of this drug in female dairy 
cattle 20 months of age or older. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.

[73 FR 8192, Feb. 13, 2008, as amended at 74 FR 1146, Jan. 12, 2009; 76 
FR 11331, Mar. 2, 2011; 76 FR 17777, Mar. 31, 2011; 78 FR 17596, Mar. 
22, 2013]



Sec. 520.1720b  Phenylbutazone granules.

    (a) Specifications. The drug is in granular form. It is packaged to 
contain either 8 grams of phenylbutazone per package or 1 gram of 
phenylbutazone per package.
    (b) Sponsor. See 000061 in Sec. 510.600(c) for 8-gram package, see 
059320 for 1-gram package.
    (c) NAS/NRC status. The conditions of use have been NAS/NRC reviewed 
and found effective. NADA's for approval of drugs for these conditions 
of use need not include effectiveness data specified by Sec. 514.111 of 
this chapter, but may require bioequivalency and safety information.
    (d) Conditions of use--(1) Horses--(i) Amount. 1 to 2 grams per 500 
pounds of body weight, not to exceed 4 grams, daily, as required.
    (ii) Indications. For the treatment of inflammatory conditions 
associated with the musculoskeletal system.
    (iii) Limitations. Administer orally by adding to a portion of the 
usual grain ration. Use a relatively high dose for the first 48 hours, 
then gradually reduce to a maintenance level at the lowest level capable 
of producing the desired clinical response. Treated animals should not 
be slaughtered for food use. Federal law restricts this drug to use by 
or on the order of a licensed veterinarian.

[46 FR 18960, Mar. 27, 1981, as amended at 46 FR 48642, Oct. 2, 1981; 57 
FR 2836, Jan. 24, 1992; 61 FR 8873, Mar. 6, 1996; 62 FR 61625, Nov. 19, 
1997; 65 FR 20731, Apr. 18, 2000]



Sec. 520.1720c  Phenylbutazone paste.

    (a) Specifications--(1) Each gram of paste contains 0.2 grams 
phenylbutazone.
    (2) Each gram of paste contains 0.35 grams phenylbutazone.
    (b) Sponsors. See sponsor numbers in Sec. 510.600(c) of this 
chapter.
    (1) No. 000061 for use of product described in paragraph (a)(1) of 
this section.

[[Page 198]]

    (2) No. 064847 for use of product described in paragraph (a)(2) of 
this section.
    (c) Conditions of use in horses--(1) Amount. 1 to 2 grams of 
phenylbutazone per 500 pounds of body weight, not to exceed 4 grams 
daily.
    (2) Indications for use. For relief of inflammatory conditions 
associated with the musculoskeletal system.
    (3) Limitations. Use a relatively high dose for the first 48 hours, 
then gradually reduce to a maintenance level of the lowest level capable 
of producing the desired clinical response. Do not use in horses 
intended for human consumption. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.

[45 FR 84762, Dec. 23, 1980, as amended at 58 FR 29777, May 24, 1993; 61 
FR 8873, Mar. 6, 1996; 62 FR 61625, Nov. 19, 1997; 68 FR 43926, July 25, 
2003; 72 FR 60550, Oct. 25, 2007; 77 FR 4897, Feb. 1, 2012]



Sec. 520.1720d  Phenylbutazone gel.

    (a) Specifications. Each 30 grams of gel contains 4 grams of 
phenylbutazone.
    (b) Sponsor. See No. 061623 in Sec. 510.600(c) of this chapter.
    (c) NAS/NRC status. The conditions of use are NAS/NRC reviewed and 
found effective. Applications for these uses need not include 
effectiveness data as specified in Sec. 514.111 of this chapter, but 
may require bioequivalency and safety information.
    (d) Conditions of use in horses--(1) Amount. 1 to 2 grams of 
phenylbutazone per 500 pounds of body weight, not to exceed 4 grams 
daily.
    (2) Indications for use. For relief of inflammatory conditions 
associated with the musculoskeletal system of horses.
    (3) Limitations. Use a relatively high dose for the first 48 hours, 
then gradually reduce to a maintenance level at the lowest level capable 
of producing the desired clinical response. Not for use in horses 
intended for food. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[50 FR 13561, Apr. 5, 1985, as amended at 50 FR 49372, Dec. 2, 1985; 55 
FR 8462, Mar. 8, 1990; 66 FR 14073, Mar. 9, 2001; 68 FR 4915, Jan. 31, 
2003]



Sec. 520.1720e  Phenylbutazone powder.

    (a) Specifications--(1) Each 1.15 grams (g) of powder contains 1 g 
phenylbutazone.
    (2) Each 10 g of powder contains 1 g phenylbutazone.
    (b) Sponsors. See sponsor numbers in Sec. 510.600(c) of this 
chapter.
    (1) No. 027053 for use of product described in paragraph (a)(1) of 
this section.
    (2) No. 057699 for use of product described in paragraph (a)(2) of 
this section.
    (c) Conditions of use in horses--(1) Amount. Administer 1 to 2 g (1 
to 2 level scoops, using the scoop provided) per 500 pounds of body 
weight on a small amount of palatable feed, not exceed 4 g per animal 
daily.
    (2) Indications for use. For the relief of inflammatory conditions 
associated with the musculosketetal system.
    (3) Limitations. Do not use in horses intended for human 
consumption. Federal law prohibits the extralabel use of this product in 
female cattle 20 months of age or older. Federal law restricts this drug 
to use by or on the order of a licensed veterinarian.

[72 FR 27956, May 18, 2007]



Sec. 520.1760  Phenylpropanolamine.

    (a) Specifications. Each chewable tablet contains 25, 50, or 75 
milligram (mg) phenylpropanolamine hydrochloride.
    (b) Sponsors. See No. 055246 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Administer 2 mg/kg of 
body weight twice daily.
    (2) Indications for use. For the control of urinary incontinence due 
to urethral sphincter hypotonus in dogs.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[77 FR 15961, Mar. 19, 2012]



Sec. 520.1780  Pimobendan.

    (a) Specifications. Each chewable tablet contains 1.25, 2.5, or 5 
milligrams (mg) pimobendan.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Administer orally at a 
total daily dose of 0.23 mg per pound (0.5 mg

[[Page 199]]

per kilogram) body weight, using a suitable combination of whole or half 
tablets. The total daily dose should be divided into two portions 
administered approximately 12 hours apart.
    (2) Indications for use. For the management of the signs of mild, 
moderate, or severe (modified New York Heart Association Class II, III, 
or IV) congestive heart failure due to atrioventricular valvular 
insufficiency or dilated cardiomyopathy; for use with concurrent therapy 
for congestive heart failure as appropriate on a case-by-case basis.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[72 FR 27733, May 17, 2007]



Sec. 520.1802  Piperazine-carbon disulfide complex oral dosage forms.



Sec. 520.1802a  Piperazine-carbon disulfide complex suspension.

    (a) Specifications. Each fluid ounce of suspension contains 7.5 
grams of piperazine-carbon disulfide complex. The piperazine-carbon 
disulfide complex contains equimolar parts of piperazine and carbon 
disulfide (1 gram contains 530 mgs of piperazine and 470 mgs of carbon 
disulfide).
    (b) Sponsor. See 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. Horses and ponies--(1) Amount. One fluid 
ounce per 100 pounds of body weight.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and found effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (2) Indications for use. For removing ascarids (large roundworms, 
Parascaris equorum), bots (Gastrophilus spp.), small strongyles, large 
strongyles (Strongyles spp.), and pinworms (Oxyuris equi).\1\
    (3) Limitations. Administer by stomach tube or dose syringe after 
withholding feed overnight or for 8 to 10 hours. Provide water as usual. 
Resume regular feeding 4 to 6 hours after treatment. Treatment of 
debilitated or anemic animals is contraindicated. Do not administer to 
animals that are or were recently affected with colic, diarrhea, or 
infected with a serious infectious disease. As with most anthelmintics, 
drastic cathartics and other gastrointestinal irritants should not be 
administered in conjunction with this drug. Animals in poor condition or 
heavily parasitized should be given one half the recommended dose and 
treated again in 2 or 3 weeks. Federal law restricts this drug to use by 
or on the order of a licensed veterinarian.\1\

[45 FR 52781, Aug. 8, 1980]



Sec. 520.1802b  Piperazine-carbon disulfide complex boluses.

    (a) Specifications. Each bolus contains 20 grams of piperazine-
carbon disulfide complex.
    (b) Sponsor. See 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use: Horses and ponies--(1) Amount. For removal of 
ascarids and small strongyles, 1 bolus (20 grams) per 500 pounds body 
weight; removal of large strongyles, pinworms, and bots, 1 bolus per 250 
pounds body weight.\1\
    (2) Indications for use. For removing ascarids (large roundworms, 
Parascaris equorum), large strongyles (Strongylus spp.) bots 
(Gastrophilus spp.), small strongyles, and pinworms (Oxyuris equi).\1\
    (3) Limitations. Withhold feed overnight or for 8 to 10 hours. Give 
water just before and/or after treatment. Resume regular feeding 4 to 6 
hours after treatment. Treatment of debilitated or anemic animals is 
contraindicated. Do not administer to animals that are or were recently 
affected with colic, diarrhea, or infected with a serious infectious 
disease. As with most anthelmintics, drastic cathartics or other 
gastrointestinal irritants should not be administered in conjunction 
with this drug. Animals in poor condition or heavily parasitized should 
be given one half the recommended dose and treated again in 2 or 3 
weeks. Consult your veterinarian for assistance in the diagnosis, 
treatment, and control of parasitism.\1\

[45 FR 52782, Aug. 8, 1980]

[[Page 200]]



Sec. 520.1802c  Piperazine-carbon disulfide complex with phenothiazine 
suspension.

    (a) Specifications. Each fluid ounce contains 5 grams of piperazine-
carbon disulfide complex and 0.83 gram of phenothiazine.
    (b) Sponsor. See 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use: Horses and ponies--(1) Amount. One fluid 
ounce per 100 pounds of body weight.
    (2) Indications for use. For removing ascarids (large roundworms, 
Parascaris equorum), bots (Gastrophilus spp.), small strongyles, and 
large strongyles (Strongylus spp.).
    (3) Limitations. See Sec. 520.1802a(c)(3).

[45 FR 52782, Aug. 8, 1980]



Sec. 520.1803  Piperazine citrate capsules.

    (a) Specifications. Piperazine citrate capsules contain piperazine 
citrate equivalent to 140 milligrams of piperazine base in each capsule.
    (b) Sponsor. See No. 021091 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is used in dogs and cats for the 
removal of large roundworms (Toxocara canis and Toxascaris leonina).
    (2) The contents of 1 capsule should be mixed with the food of the 
animal for each 5 pounds, or fraction thereof of body weight, except 
dogs weighing over 25 pounds should be given the contents of 6 capsules. 
The drug should be mixed in \1/2\ of the regular feeding and when the 
animal has finished eating the dosed food, the remainder of the food may 
be given. Dogs and cats may be wormed at 6 to 8 weeks of age. The first 
treatment should be repeated 10 days later. Reinfection may occur. 
Repeat treatment if indicated.
    (3) Severely debilitated animals should not be wormed except on the 
advice of a veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 54 FR 38515, Sept. 19, 1989]



Sec. 520.1804  Piperazine phosphate capsules.

    (a) Specifications. Each capsule contains 120, 300, or 600 
milligrams of piperazine phosphate monohydrate.
    (b) Sponsor. See No. 051311 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 60 milligrams of piperazine 
phosphate monohydrate per pound of body weight.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (2) Indications for use--(i) Dogs. It is used for the removal of 
large roundworms (ascarids) Toxocara canis and Toxascaris leonina. \1\
    (ii) Cats. It is used for the removal of large roundworms (ascarids) 
Toxocara mystax and Toxacaris leonina. \1\
    (3) Limitations. Administer in animal's food or milk. For animals up 
to 1 year of age administer every 2 or 3 months; for animals over 1 year 
old, administer periodically as necessary. Consult your veterinarian for 
assistance in the diagnosis, treatment, and control of parasitism.\1\

[43 FR 6941, Feb. 17, 1978; 43 FR 9804, Mar. 10, 1978, as amended at 46 
FR 20158, Apr. 3, 1981; 69 FR 31878, June 8, 2004]



Sec. 520.1805  Piperazine phosphate with thenium closylate tablets.

    (a) Specifications. Each scored tablet contains the equivalent of 
250 milligrams piperazine hexahydrate (as piperazine phosphate) and 125 
milligrams thenium (as thenium closylate) or 500 milligrams piperazine 
hexahydrate (as piperazine phosphate) and 250 milligrams thenium (as 
thenium closylate).
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. Administer orally to dogs as 
follows:

               Number of Tablets at Each of the Two Doses
------------------------------------------------------------------------
                Animal weight (lb)                    375 mg     750 mg
------------------------------------------------------------------------
2 but less than 5.................................      \1/2\  .........
5 but less than 10................................          1      \1/2\
10 or heavier.....................................          2          1
------------------------------------------------------------------------

    (2) Indications for use. For removal of immature (fourth stage 
larvae) and adult hookworms (Ancylostoma caninum, A. braziliense, and 
Uncinaria stenocephala) and ascarids (Toxocara canis) from weaned pups 
and adult dogs.

[[Page 201]]

    (3) Limitations. Do not use this product to treat dogs weighing less 
than 2 pounds, unweaned pups, or pups under 5 weeks of age. Maximum 
efficacy against hookworms necessitates two doses in 1 day of treatment. 
The interval between the doses should be not less than 4 hours or more 
than 24 hours. Administer the first dose in the morning before feeding. 
Do not permit dog to chew tablet. Feed the dog between doses. Do not 
feed milk or other fatty foods during treatment. Retreatment may be 
needed in 7 to 28 days as determined by laboratory fecal examinations or 
in animals kept in known contaminated quarters. Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.

[43 FR 32747, July 28, 1978, as amended at 47 FR 55476, Dec. 10, 1982; 
61 FR 8873, Mar. 6, 1996; 62 FR 61625, Nov. 19, 1997]



Sec. 520.1806  Piperazine suspension.

    (a) Specifications. Each milliliter of suspension contains 
piperazine monohydrochloride equivalent to 33.5 milligrams (mg) 
piperazine base.
    (b) Sponsor. See No. 017135 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. See Sec. 500.25(c) of this chapter.
    (d) Conditions of use in dogs--(1) Indications for use. For the 
removal of roundworms (Toxocara canisand Toxascaris leonina).
    (2) Dosage. Administer 20 to 30 mg piperazine base per pound body 
weight as a single dose.
    (3) Limitations. Administer by mixing into the animal's ration to be 
consumed at one feeding. For animals in heavily contaminated areas, 
reworm at monthly intervals. Not for use in unweaned pups or animals 
less than 3 weeks of age.

[70 FR 17319, Apr. 6, 2005]



Sec. 520.1807  Piperazine.

    (a) Specifications. A soluble powder or liquid containing piperazine 
dihydrochloride or dipiperazine sulfate, equivalent to 17, 34, or 230 
grams of piperazine per pound or 100 milliliters.
    (b) Sponsor. See 015565 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.513 of this chapter.
    (d) Conditions of use--(1) Chickens--(i) Amount. 50 milligrams per 
bird under 6 weeks, 100 milligrams per bird over 6 weeks.
    (ii) Indications for use. For removal of large roundworm (Ascaridia 
spp.).
    (iii) Limitations. For use in drinking water or feed. Use as sole 
source of drinking water. Prepare fresh solution daily. Use as 1-day 
single treatment. Withdraw 14 days prior to slaughter. Do not use for 
chickens producing eggs for human consumption. Consult your veterinarian 
for assistance in the diagnosis, treatment, and control of parasitism.
    (2) Turkeys--(i) Amount. 100 milligrams per bird up to 12 weeks and 
200 milligrams per bird over 12 weeks.
    (ii) Indications for use. For removal of large roundworm (Ascaridia 
spp.).
    (iii) Limitations. For use in drinking water or feed. Use as sole 
source of drinking water. Prepare fresh solution daily. Use as 1-day 
single treatment. Withdraw 14 days prior to slaughter. Consult your 
veterinarian for assistance in the diagnosis, treatment, and control of 
parasitism.
    (3) Swine--(i) Amount. 50 milligrams per pound of body weight.
    (ii) Indications for use. For removal of large roundworm (Ascaris 
suum) and nodular worms (Oesophagostomum spp.).
    (iii) Limitations. For use in drinking water or feed. Use as sole 
source of drinking water. Prepare fresh solution daily. Use as 1-day 
single treatment. Withdraw 21 days prior to slaughter. Consult your 
veterinarian for assistance in the diagnosis, treatment, and control of 
parasitism.

[64 FR 23018, Apr. 29, 1999]



Sec. 520.1840  Poloxalene.

    (a) Specifications. Polyoxypropylene-polyoxyethylene glycol nonionic 
block polymer.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (d) of this section.
    (1) No. 000069 for use as in paragraphs (d)(1) and (d)(3) of this 
section.
    (2) No. 051311 for use as in paragraph (d)(4) of this section.
    (3) No. 067949 for use as in paragraph (d)(2) of this section.
    (4) No. 066104 for use as in paragraph (d)(3) of this section.

[[Page 202]]

    (c) [Reserved]
    (d) Conditions of use. (1) For treatment of legume (alfalfa, clover) 
bloat in cattle. Administer as a drench at the rate of 25 grams for 
animals up to 500 pounds and 50 grams for animals over 500 pounds of 
body weight.
    (2) For control of legume (alfalfa, clover) bloat in cattle. 
Administer, in molasses block containing 6.6 percent poloxalene, at the 
rate of 0.8 oz. of block (1.5 grams poloxalene) per 100 lbs. of body 
weight per day.
    (3) For prevention of legume (alfalfa, clover) and wheat pasture 
bloat in cattle. A 53-percent poloxalene top dressing on individual 
rations of ground feed. Dosage is 1 gram of poloxalene per 100 pounds of 
body weight daily. If bloating conditions are severe, the dose is 
doubled. Treatment should be started 2 to 3 days before exposure to 
bloat-producing conditions. Repeat use of the drug if animals are 
exposed to bloat-producing conditions for more than 12 hours after the 
last treatment. Do not exceed the double dose in any 24-hour period.
    (4) For control of legume (alfalfa, clover) and wheat pasture bloat 
in cattle. Administer in molasses block containing 6.6 percent 
poloxalene, at the rate of 0.8 ounce of block (1.5 grams of poloxalene) 
per 100 pounds of body weight per day. Provide access to blocks at least 
7 days before exposure to bloat-producing conditions.

[40 FR 13838, Mar. 27, 1975, as amended at 40 FR 39857, Aug. 29, 1975; 
42 FR 41854, Aug. 19, 1977; 50 FR 5385, Feb. 8, 1985; 54 FR 33501, Aug. 
15, 1989; 56 FR 50653, Oct. 8, 1991; 58 FR 26523, May 4, 1993; 60 FR 
55659, Nov. 2, 1995; 66 FR 47963, Sept. 17, 2001; 69 FR 62811, Oct. 28, 
2004; 70 FR 32489, June 3, 2005]



Sec. 520.1846  Polyoxyethylene (23) lauryl ether blocks.

    (a) Specifications. Each molasses-based block contains 2.2 percent 
polyoxyethylene (23) lauryl ether.
    (b) Sponsor. See No. 067949 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 2 grams of polyoxyethylene (23) 
lauryl ether per 100 kilograms of body weight per day (1 pound of block 
per 500 kilogram (1,100 pound) animal per day).
    (2) Indications for use. For reduction of the incidence of bloat 
(alfalfa and clover) in pastured cattle.
    (3) Limitations. Administer free-choice to beef cattle and 
nonlactating dairy cattle only. Initially, provide one block per five 
head of cattle. Start treatment 10 to 14 days before exposure to bloat-
producing pastures. Do not allow cattle access to other sources of salt 
while being fed this product. Do not feed this product to animals 
without adequate forage/roughage consumption.

[50 FR 48189, Nov. 22, 1985, as amended at 56 FR 9841, Mar. 8, 1991; 69 
FR 62811, Oct. 28, 2004]



Sec. 520.1855  Ponazuril.

    (a) Specifications. Each gram of paste contains 150 milligrams (mg) 
ponazuril.
    (b) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. 5 mg per kilogram body 
weight, daily for 28 days.
    (2) Indications for use. For the treatment of equine protozoal 
myeloencephalitis caused by Sarcocystis neurona.
    (3) Limitations. Not for use in horses intended for food. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.

[66 FR 43774, Aug. 21, 2001]



Sec. 520.1860  Pradofloxacin.

    (a) Specifications. Each milliliter of suspension contains 25 
milligrams (mg) pradofloxacin.
    (b) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian. Federal law prohibits the 
extralabel use of this drug in food-producing animals.
    (d) Conditions of use in cats--(1) Amount. Administer 3.4 mg/lb (7.5 
mg/kg) body weight once daily for 7 consecutive days.
    (2) Indications for use. For the treatment of skin infections 
(wounds and abscesses) in cats caused by susceptible strains of 
Pasteurella multocida, Streptococcus canis, Staphylococcus aureus,

[[Page 203]]

Staphylococcus felis, and Staphylococcus pseudintermedius.

[77 FR 76863, Dec. 31, 2012]



Sec. 520.1870  Praziquantel tablets.

    (a) Specifications. Each tablet contains:
    (1) 34 milligrams (mg) praziquantel.
    (2) 11.5 or 23 mg praziquantel.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter:
    (1) No. 000859 for use of the product described in paragraph (a)(1) 
of this section, as in paragraph (c)(1) of this section; and for use of 
the product described in paragraph (a)(2) of this section, as in 
paragraph (c)(2) of this section.
    (2) No. 000859 for use of the product described in paragraph (a)(1) 
of this section, as in paragraph (c)(1) of this section.
    (c) Conditions of use--(1) Dogs--(i) Amount. 5 pounds (lb) and 
under, \1/2\ tablet (17 mg); 6 to 10 lb, 1 tablet (34 mg); 11 to 15 lb, 
1\1/2\ tablets (51 mg); 16 to 30 lb, 2 tablets (68 mg); 31 to 45 lb, 3 
tablets (102 mg); 46 to 60 lb, 4 tablets (136 mg); over 60 lb, 5 tablets 
maximum (170 mg). Administer directly by mouth or crumbled and in feed.
    (ii) Indications for use--(A) For removal of canine cestodes 
Dipylidium caninum and Taenia pisiformis.
    (B) For removal of the canine cestode Echinococcus granulosus, and 
for removal and control of the canine cestode Echinococcus 
multilocularis.
    (iii) Limitations--(A) If labeled only for use as in paragraph 
(c)(1)(ii)(A) of this section: Not intended for use in puppies less than 
4 weeks of age. Consult your veterinarian before administering tablets 
to weak or debilitated animals and for assistance in the diagnosis, 
treatment, and control of parasitism.
    (B) If labeled for use as in paragraph (c)(1)(ii)(B) of this 
section: Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (2) Cats--(i) Indications for use. For removal of feline cestodes 
Dipylidium caninum and Taenia taeniaeformis.
    (ii) Dosage. Cats 4 pounds and under, 11.5 mg; 5 to 11 pounds, 23 
mg; over 11 pounds, 34.5 mg.
    (iii) Limitations. Administer directly by mouth or crumbled and in 
feed. Not intended for use in kittens less than 6 weeks of age. For OTC 
use: Consult your veterinarian before administering tablets to weak or 
debilitated animals, and for assistance in the diagnosis, treatment, and 
control of parasitism.

[46 FR 60570, Dec. 11, 1981, as amended at 47 FR 26377, June 18, 1982; 
55 FR 2234, Jan. 23, 1990; 58 FR 7864, Feb. 10, 1993; 58 FR 42853, Aug. 
12, 1993; 68 FR 57351, Oct. 3, 2003; 69 FR 62181, Oct. 25, 2004; 78 FR 
17596, Mar. 22, 2013]



Sec. 520.1871  Praziquantel and pyrantel.

    (a) Specifications. (1) Each tablet contains 13.6 milligrams (mg) 
praziquantel and 54.3 mg pyrantel base (as pyrantel pamoate), 18.2 mg 
praziquantel and 72.6 mg pyrantel base (as pyrantel pamoate), or 27.2 mg 
praziquantel and 108.6 mg pyrantel base (as pyrantel pamoate).
    (2) Each chewable tablet contains 30 mg praziquantel and 30 mg 
pyrantel pamoate or 114 mg praziquantel and 114 mg pyrantel pamoate.
    (b) Sponsors. See sponsors in Sec. 510.600(c) for use as in 
paragraph (d) of this chapter.
    (1) See No. 000859 for use of tablets described in paragraph (a)(1) 
of this section for use as in paragraph (d)(1) of this section.
    (2) See No. 051311 for use of tablets described in paragraph (a)(2) 
of this section for use as in paragraph (d)(2) of this section.
    (c) Special considerations. See Sec. 500.25 of this chapter.
    (d) Conditions of use--(1) Cats--(i) Dosage. Administer a minimum 
dose of 2.27 mg praziquantel and 9.2 mg pyrantel pamoate per pound of 
body weight according to the dosing tables on labeling. May be given 
directly by mouth or in a small amount of food. Do not withhold food 
prior to or after treatment. If reinfection occurs, treatment may be 
repeated.
    (ii) Indications for use. For removal of tapeworms (Dipylidium 
caninum and Taenia taeniaeformis), hookworms (Ancylostoma tubaeforme), 
and large roundworms (Toxocara cati) in cats and kittens.
    (iii) Limitations. Not for use in kittens less than 2 months of age 
or weighing less than 2.0 pounds. Consult your veterinarian before 
giving to sick or pregnant animals.

[[Page 204]]

    (2) Dogs--(i) Amount. Administer a minimum dose of 5 mg praziquantel 
and 5 mg pyrantel pamoate per kilogram body weight (2.27 mg praziquantel 
and 2.27 mg pyrantel pamoate per pound body weight) according to the 
dosing tables on labeling.
    (ii) Indications for use. For the treatment and control of 
roundworms (Toxocara canis and Toxascaris leonina), hookworms 
(Ancylostoma caninum, Ancylostoma braziliense, and Uncinaria 
stenocephala), and tapeworms (Dipylidium caninum and Taenia pisiformis) 
in dogs and puppies.

[58 FR 58652, Nov. 3, 1993, as amended at 72 FR 16270, Apr. 4, 2007; 75 
FR 54018, Sept. 3, 2010]



Sec. 520.1872  Praziquantel, pyrantel pamoate, and febantel tablets.

    (a) Specifications. Each tablet or chewable tablet contains either:
    (1) Tablet No. 1: 22.7 milligrams praziquantel, 22.7 milligrams 
pyrantel base, and 113.4 milligrams febantel; or
    (2) Tablet No. 2: 68 milligrams praziquantel, 68 milligrams pyrantel 
base, and 340.2 milligrams febantel.
    (3) Tablet No. 3: 136 milligrams (mg) praziquantel, 136 mg pyrantel 
base, and 680.4 mg febantel.
    (b) Sponsor. See 000859 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. Administer as a single 
dose directly by mouth or in a small amount of food as follows:

----------------------------------------------------------------------------------------------------------------
                  Weight of animal                                    Number of tablets per dose
----------------------------------------------------------------------------------------------------------------
            Kilograms                   Pounds           Tablet no. 1        Tablet no. 2        Tablet no. 3
----------------------------------------------------------------------------------------------------------------
0.9 to 1.8......................  2 to 4............  1/2...............
2.3 to 3.2......................  5 to 7............  1.................
3.6 to 5.4......................  8 to 12...........  1 1/2.............
5.9 to 8.2......................  13 to 18..........  2.................
8.6 to 11.4.....................  19 to 25..........  2 1/2.............
11.8 to 13.6....................  26 to 30..........  ..................  1.................
14.1 to 20.0....................  31 to 44..........  ..................  1 1/2.............
20.4 to 27.2....................  45 to 60..........  ..................  2.................  1
27.7 to 40.9....................  61 to 90..........  ..................  ..................  1 1/2
41.3 to 54.5....................  91 to 120.........  ..................  ..................  2
----------------------------------------------------------------------------------------------------------------

    (ii) Indications for use. For the removal of tapeworms (Dipylidium 
caninum, Taenia pisiformis, Echinococcus granulosus); hookworms 
(Ancylostoma caninum, Uncinaria stenocephala); ascarids (Toxocara canis, 
Toxascaris leonina); and whipworms (Trichuris vulpis) and for the 
removal and control of tapeworm Echinococcus multilocularis in dogs.
    (iii) Limitations. Do not use in pregnant animals. Do not use in 
dogs weighing less than 0.9 kilogram (2 pounds) or puppies less than 3 
weeks of age. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[59 FR 33908, July 1, 1994, as amended at 61 FR 29651, June 12, 1996; 68 
FR 22293, Apr. 28, 2003; 71 FR 6677, Feb. 9, 2006]



Sec. 520.1880  Prednisolone tablets.

    (a) Specifications. Each tablet contains 5 or 20 milligrams 
prednisolone.
    (b) Sponsor. See No. 061690 in Sec. 510.600(c)(2) of this chapter.
    (c) Special considerations. (1) Clinical and experimental data have 
demonstrated that corticosteroids administered orally or parenterally to 
animals may induce the first stage of parturition when administered 
during the last trimester of pregnancy and may precipitate parturition 
followed by dystocia, fetal death, retained placenta, and metritis.
    (2) Do not use in viral infections. Systemic therapy with 
prednisolone is contraindicated in animals with peptic ulcer, corneal 
ulcer, and Cushingoid syndrome. The presence of diabetes, osteoporosis, 
predisposition to thrombophlebitis, hypertension, congestive heart 
failure, renal insufficiency, and active tuberculosis necessitates 
carefully controlled use. Some of the above conditions occur only rarely 
in dogs but should be kept in mind.
    (3) Anti-inflammatory action of corticosteroids may mask signs of 
infection.
    (d) Conditions of use--(1) Amount. Dogs: 2.5 milligrams per 4.5 
kilograms (10 pounds) body weight per day. Administer total daily dose 
orally in equally divided doses 6 to 10 hours apart until response is 
noted or 7 days have elapsed. When response is attained, dosage should 
be gradually reduced until maintenance level is achieved.
    (2) Indications for use. For use in dogs as an anti-inflammatory 
agent.

[[Page 205]]

    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[57 FR 4718, Feb. 7, 1992, as amended at 60 FR 57832, Nov. 22, 1995; 63 
FR 148, Jan. 5, 1998]



Sec. 520.1900  Primidone tablets.

    (a) Specifications. Each tablet contains 50 or 250 milligrams of 
primidone.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter for 
use of 250 milligram tablets; see No. 000856 in Sec. 510.600(c) of this 
chapter for use of 50 and 250 milligram tablets.
    (c) Conditions of use in dogs--(1) Amount. Twenty-five milligrams of 
primidone per pound of body weight (55 milligrams per kilogram of body 
weight) daily.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (2) Indications for use. For the control of convulsions associated 
with idiopathic epilepsy, epileptiform convulsions, viral encephalitis, 
distemper, and hardpad disease that occurs as a clinically recognizable 
lesion in certain entities in dogs.\1\
    (3) Limitations. The tablets may be administered whole or crushed 
and mixed with the food. When convulsions are frequent, the dosage 
should be divided and administered at intervals. Reduction in dosage 
should be made gradually and never be abruptly discontinued. Do not use 
in feline species, as primidone appears to have a specific neurotoxicity 
in cats. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.\1\

[42 FR 61594, Dec. 6, 1977, as amended at 43 FR 55386, Nov. 28, 1978; 46 
FR 8467, Jan. 27, 1981; 46 FR 57477, Nov. 24, 1981; 53 FR 40727, Oct. 
18, 1988; 56 FR 37473, Aug. 7, 1991; 62 FR 35076, June 30, 1997]



Sec. 520.1920  Prochlorperazine, isopropamide sustained release capsules.

    (a) Specifications. Prochlorperazine, isopropamide sustained release 
capsules contain either:
    (1) 3.33 milligrams of prochlorperazine (as the dimaleate) and 1.67 
milligrams of isopropamide (as the iodide), or
    (2) 10 milligrams of prochlorperazine (as the dimaleate) and 5 
milligrams of isopropamide (as the iodide).
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used for the treatment of 
dogs in which gastrointestinal disturbances are associated with 
emotional stress.
    (2)(i) Capsules described in paragraph (a)(1) of this section are 
administered orally to dogs weighing from 4 to 15 pounds at the rate of 
1 capsule twice daily. These capsules are administered orally to dogs 
weighing from 16 to 30 pounds at the rate of 1 or 2 capsules twice 
daily. For dogs weighing less than 4 pounds, administer orally an 
appropriate fraction of the contents of one of these capsules.
    (ii) Capsules described in paragraph (a)(2) of this section are 
given to dogs weighing 30 pounds and over at the rate of 1 capsule twice 
daily.
    (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 56 FR 50653, Oct. 8, 1991; 60 
FR 55659, Nov. 2, 1995]



Sec. 520.1921  Prochlorperazine, isopropamide, with neomycin 
sustained-release capsules.

    (a) Specifications. Each capsule contains either:
    (1) Capsule No. 1: 3.33 milligrams of prochlorperazine (as the 
dimaleate), 1.67 milligrams of isopropamide (as the iodide), and 25 
milligrams of neomycin base (as the sulfate); or
    (2) Capsule No. 3: 10 milligrams of prochlorperazine (as the 
dimaleate), 5 milligrams of isopropamide (as the iodide), and 75 
milligrams of neomycin base (as the sulfate).
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. Administer capsules orally twice 
daily to dogs as follows:

------------------------------------------------------------------------
                                                      Number of capsules
                                                           per dose
               Animal weight (pounds)                -------------------
                                                       Capsule   Capsule
                                                        No. 1     No. 3
------------------------------------------------------------------------
10 to 20............................................         1
20 to 30............................................         2
Over 30.............................................         3         1

[[Page 206]]

 
Over 60.............................................                   2
------------------------------------------------------------------------

    (2) Indications for use. For treatment of dogs in which infectious 
bacterial gastroenteritis is associated with emotional stress.
    (3) Limitations. Do not continue medication longer than 5 days. 
Overdosage or prolonged administration may produce nephrotoxicity as 
manifested by albuminuria, presence of granular casts and depressed 
urinary output. If it is desirable to administer a vasoconstrictor, 
norepinephrine is the drug of choice. Federal law restricts this drug to 
use by or on the order of a licensed veterinarian.

[49 FR 14103, Apr. 10, 1984, as amended at 56 FR 50653, Oct. 8, 1991; 60 
FR 55659, Nov. 2, 1995]



Sec. 520.1962  Promazine hydrochloride.

    (a)(1) Chemical name. 10-[3-(Dimethylamino)propyl]phenothiazine 
monohydrochloride.
    (2) Specifications. Conforms to N.F. XII.
    (3) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (4) [Reserved]
    (5) Conditions of use. (i) The drug is used for quieting excitable, 
unruly, or intractable horses. It is administered at a dosage level of 
0.45 to 0.9 milligrams of promazine hydrochloride per pound of body 
weight mixed with an amount of feed that will be readily consumed.
    (ii) Do not use in horses intended for food.
    (iii) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (b) [Reserved]

[40 FR 13838, Mar. 27, 1975, as amended at 43 FR 55386, Nov. 28, 1978; 
59 FR 5705, Feb. 8, 1994]



Sec. 520.2002  Propiopromazine hydrochloride.

    (a) Chemical name. 1-Propanone, 1-[10-[3-(dimethylamino) propyl] 
phenothiazine-2-yl]-, monohydrochloride.
    (b) Specifications. The drug is administered in a chewable tablet 
containing 10 to 20 milligrams of propiopromazine hydrochloride.
    (c) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) The drug is intended for oral 
administration to dogs as a tranquilizer. It is used as an aid in 
handling difficult, excited, and unruly dogs, and in controlling 
excessive kennel barking, car sickness, and severe dermatitis. It is 
also indicated for use in minor surgery and prior to routine 
examinations, laboratory procedures, and diagnostic procedures.
    (2) It is administered at the rate of 0.5 to 2 milligrams of 
propiopromazine hydrochloride per pound of body weight once or twice 
daily depending upon the degree of tranquilization desired.

    Note: Not for use with organophosphates and/or procaine 
hydrochloride, as phenothiazine may potentiate the toxicity of 
organophosphates and the activity of procaine hydrochloride. Overdosage 
may produce significant depression.

    (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 46 FR 60570, Dec. 11, 1981; 
61 FR 5506, Feb. 13, 1996]



Sec. 520.2041  Pyrantel pamoate chewable tablets.

    (a) Specifications. Each tablet contains pyrantel pamoate equivalent 
to 22.7 or 113.5 milligrams pyrantel base.
    (b) Sponsor. See Nos. 017135 and 051311 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use--(1) Amount. Provides at least 2.27 milligrams 
pyrantel base per pound body weight for dogs weighing more than 5 
pounds, and at least 4.54 milligrams of pyrantel base per pound body 
weight for dogs weighing 5 pounds or less.
    (2) Indications for use--(i) In dogs and puppies. For removal of 
ascarids (Toxocara canis; Toxascaris leonina) and hookworms (Ancylostoma 
caninum; Uncinaria stenocephala).
    (ii) In puppies and adult dogs and in lactating bitches after 
whelping. To prevent reinfection of Toxocara canis.
    (3) Limitations. Administer to puppies at 2, 3, 4, 6, 8, and 10 
weeks of age. Administer to lactating bitches 2 to 3 weeks after 
whelping. Retreatment of

[[Page 207]]

adult dogs may be necessary at monthly intervals as determined by 
laboratory fecal examinations. Consult your veterinarian for assistance 
in the diagnosis, treatment, and control of parasitism.

[52 FR 37937, Oct. 13, 1987, as amended at 57 FR 48163, Oct. 22, 1992; 
58 FR 44611, Aug. 24, 1993; 66 FR 9650, Feb. 9, 2001; 67 FR 21996, May 
2, 2002]



Sec. 520.2042  Pyrantel pamoate tablets.

    (a) Specifications. Each tablet contains pyrantel pamoate equivalent 
to 22.7, 45.4, or 113.5 milligrams of pyrantel base.
    (b) Sponsor. See No. 017135 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. It is used for dogs as follows:
    (1) Amount. For dogs weighing over 5 pounds, use at least 2.27 
milligrams of pyrantel base per pound of body weight; for dogs weighing 
5 pounds or less, use at least 4.54 milligrams of pyrantel base per 
pound of body weight.
    (2) Indications for use. For removal and control of large roundworms 
(ascarids) (Toxocara canis and Toxascaris leonina), and hookworms 
(Ancylostoma caninum and Uncinaria stenocephala).
    (3) Limitations. Administer orally directly or in a small amount of 
food. To prevent reinfection of T. canis in puppies, lactating bitches 
after whelping, and adult dogs; treat puppies 2, 3, 4, 6, 8, and 10 
weeks of age; treat lactating bitches 2 to 3 weeks after whelping; 
routinely treat adult dogs monthly. Do not withhold food prior to or 
after treatment. The presence of these parasites should be confirmed by 
laboratory fecal examination. A followup fecal examination should be 
conducted 2 to 4 weeks after first treatment regimen to determine the 
need for re-treatment. Consult your veterinarian for assistance in the 
diagnosis, treatment, and control of parasitism.

[43 FR 52700, Nov. 14, 1978, as amended at 49 FR 22073, May 25, 1984; 57 
FR 48163, Oct. 22, 1992; 58 FR 44611, Aug. 24, 1993]



Sec. 520.2043  Pyrantel pamoate suspension.

    (a) Specifications. (1) Each milliliter (mL) contains pyrantel 
pamoate equivalent to 50 milligrams (mg) pyrantel base.
    (2) Each mL contains pyrantel pamoate equivalent to 2.27 or 4.54 mg 
pyrantel base.
    (3) Each mL contains pyrantel pamoate equivalent to 4.54 mg pyrantel 
base.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
uses as in paragraph (d) of this section.
    (1) Nos. 000069, 000859, and 058829 for use of the product described 
in paragraph (a)(1) as in paragraph (d)(1) of this section.
    (2) Nos. 000069, 055246, 058829, and 059130 for use of the products 
described in paragraph (a)(2) as in paragraph (d)(2) of this section.
    (3) No. 023851 for use of the product described in paragraph (a)(3) 
as in paragraph (d)(2) of this section.
    (c) Special considerations. See Sec. 500.25 of this chapter.
    (d) Conditions of use--(1) Horses and ponies. It is used as follows:
    (i) Amount. 3 mg per pound (/lb) body weight as a single dose mixed 
with the usual grain ration, or by stomach tube or dose syringe.
    (ii) Indications for use. For the removal and control of mature 
infections of large strongyles (Strongylus vulgaris, S. edentatus, S. 
equinus); pinworms (Oxyuris equi); large roundworms (Parascaris 
equorum); and small strongyles.
    (iii) Limitations. Do not use in horses intended for human 
consumption. When the drug is for administration by stomach tube, it 
shall be labeled: ``Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.''
    (2) Dogs. It is used as follows:
    (i) Dogs and puppies--(A) Amount. 2.27 mg/lb body weight as a single 
dose in the animal's feed bowl by itself or mixed in a small quantity of 
food.
    (B) Indications for use. For the removal of large roundworms 
(Toxocara canis and Toxascaris leonina) and hookworms (Ancylostoma 
caninum and Uncinaria stenocephala).
    (C) Limitations. Additional treatment may be required and should be 
confirmed by fecal examination within 2 to 4 weeks.

[[Page 208]]

    (ii) Dogs, puppies, and lactating bitches after whelping--(A) 
Amount. 2.27 mg/lb body weight.
    (B) Indications for use. To prevent reinfections of T. canis.
    (C) Limitations. Administer to puppies at 2, 3, 4, 6, 8, and 10 
weeks of age. Administer to lactating bitches 2 to 3 weeks after 
whelping. Adult dogs kept in heavily contaminated quarters may be 
treated at monthly intervals.

[67 FR 43248, June 27, 2002, as amended at 68 FR 54803, Sept. 19, 2003; 
68 FR 55199, Sept. 23, 2003; 68 FR 55825, Sept. 29, 2003; 75 FR 52622, 
Aug. 27, 2010; 76 FR 17337, Mar. 29, 2011; 78 FR 17596, Mar. 22, 2013]



Sec. 520.2044  Pyrantel pamoate paste.

    (a) Specifications--(1) Each milliliter (mL) contains 180 milligrams 
(mg) pyrantel base (as pyrantel pamoate).
    (2) Each mL contains 226 mg pyrantel base (as pyrantel pamoate).
    (3) Each mL contains 171 mg pyrantel base (as pyrantel pamoate).
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter.
    (1) No. 000069 for use of product described in paragraph (a)(1) of 
this section as in paragraph (d)(1)(i) and (d)(2) of this section.
    (2) No. 000859 for use of product described in paragraph (a)(2) of 
this section as in paragraph (d) of this section.
    (3) No. 061623 for use of product described in paragraph (a)(3) of 
this section as in paragraph (d)(1)(i) and (d)(2) of this section.
    (c) Special considerations. See Sec. 500.25 of this chapter.
    (d) Conditions of use. It is used in horses and ponies as follows:
    (1) Amounts and indications for use--(i) 3 mg per pound (/lb) body 
weight as single oral dose for removal and control of infections from 
the following mature parasites: large strongyles (Strongylus vulgaris, 
S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); 
and large roundworms (Parascaris equorum).
    (ii) 6 mg/lb body weight as single oral dose for the removal and 
control of mature infections of tapeworms (Anoplocephala perfoliata).
    (2) Limitations. Do not use in horses intended for human 
consumption.

[70 FR 29447, May 23, 2005, as amended at 76 FR 17337, Mar. 29, 2011; 78 
FR 17596, Mar. 22, 2013]



Sec. 520.2045  Pyrantel tartrate powder; pyrantel tartrate pellets.

    (a) Specifications. (1) Pyrantel tartrate powder horse wormer 
contains 11.3 percent and swine wormer 10.6 percent pyrantel tartrate.
    (2) Pyrantel tartrate pellets colt and horse wormer contains 1.25 
percent pyrantel tartrate.
    (b) Sponsor. (1) See No. 000069 in Sec. 510.600(c) of this chapter 
for conditions of use provided for in paragraphs (d) (1) and (2) of this 
section.
    (2) See No. 061623 in Sec. 510.600(c) of this chapter, for 
conditions of use provided for in paragraph (d)(3) of this section.
    (c) Related tolerances. See Sec. 556.560 of this chapter.
    (d) Conditions of use. It is used in: (1) Horses and ponies:
    (i) For the removal and control of infections from the following 
mature parasites: Large strongyles (Strongylus vulgaris, Strongylus 
edentatus, Strongylus equinus), small strongyles (Trichonema spp., 
Triodontophorus), pinworms (Oxyuris), and large roundworms (Parascaris).
    (ii) It is administered as a single dose at 0.57 gram of pyrantel 
tartrate per 100 pounds of body weight mixed with the usual grain 
ration.
    (iii) It is recommended that severely debilitated animals not be 
treated with this drug. Do not administer by stomach tube or dose 
syringe. The drug should be used immediately after the package is 
opened.
    (iv) Warning: Not for use in horses and ponies to be slaughtered for 
food purposes.
    (2) Swine:
    (i) For the removal and control of large roundworms (Ascaris suum) 
and nodular worm (Oesophagostomum) infections.
    (ii) It is added to feed at 0.4 gram pyrantel tartrate per pound of 
nonpelleted ration. The ration is administered as a single treatment as 
the sole ration at the rate of 1 pound per 40 pounds of animal weight 
for animals up to 200 pounds. Animals 200 pounds and

[[Page 209]]

over are administered 5 pounds of ration per animal.
    (iii) Fast pigs over night for optimum results. Water should be made 
available to animals during fasting and treatment periods. Consult 
veterinarian before using in severely debilitated animals. The drug 
should be used immediately after the package is opened.
    (iv) Warning: Do not treat within 24 hours of slaughter.
    (3) Horses and colts:
    (i) For the removal and control of infections from the following 
mature parasites: Large strongyles (Strongylus vulgaris, Strongylus 
edentatus, Strongylus equinus), small strongyles (Trichonema spp., 
Triodontophorus), pinworms (Oxyuris), and large roundworms (Parascaris).
    (ii) It is administered as a single dose at 12.5 milligrams of 
pyrantel tartrate per 2.2 pounds of body weight mixed with the usual 
grain ration.
    (iii) It is recommended that severely debilitated animals not be 
treated with this drug.
    (iv) Warning: Do not use in horses or colts intended for food.

[40 FR 13838, Mar. 27, 1975, as amended at 59 FR 28769, June 3, 1994; 69 
FR 41427, July 9, 2004; 76 FR 40229, July 8, 2011]



Sec. 520.2075  Robenacoxib.

    (a) Specifications. Each tablet contains 6 milligrams (mg) 
robenacoxib.
    (b) Sponsors. See No. 058198 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in cats--(1) Amount. Administer 0.45 mg per 
pound (/lb) (1 mg/kilogram (kg)) once daily.
    (2) Indications for use. For the control of postoperative pain and 
inflammation associated with orthopedic surgery, ovariohysterectomy, and 
castration in cats weighing at least 5.5 lb (2.5 kg) and at least 6 
months of age; for up to a maximum of 3 days.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[76 FR 18648, Apr. 5, 2011]



Sec. 520.2087  Roxarsone soluble powder.

    (a) Specifications. Each ounce (avoirdupois) of soluble powder 
contains 21.7 grams of roxarsone (monosodium 3-nitro-4-
hydroxyphenylarsonate).
    (b) Sponsor. See No. 046573 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.60 of this chapter.
    (d) NAS/NRC status. These conditions of use are NAS/NRC reviewed and 
found effective. NADA's for these uses need not include effectiveness 
data as specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
    (e) Conditions of use--(1) Growing chickens and growing turkeys--(i) 
Amount. 0.002 percent roxarsone in drinking water (one packet per each 
250 gallons of drinking water).
    (ii) Indications for use. For increased rate of weight gain, 
improved feed efficiency, and improved pigmentation.
    (iii) Limitations. Administer continuously throughout growing 
period. Withdraw 5 days before slaughter. Use as sole source of organic 
arsenic.
    (2) Swine--(i) Amount. 0.01 percent roxarsone in drinking water (one 
packet per each 50 gallons of drinking water); or 30 milliliters of a 
1.55 percent roxarsone solution (one packet per 3 pints of water) per 50 
pounds of body weight as a drench.
    (ii) Indications for use. As an aid in the treatment of swine 
dysentery (hemorrhagic enteritis or bloody scours).
    (iii) Limitations. Administer drinking water continuously for not 
more than 6 days. Administer drench once daily for 1 or 2 days. If no 
improvement is observed, consult a veterinarian. Treatment may be 
repeated after 5 days. Withdraw 5 days before slaughter. Use as sole 
source of organic arsenic.

[46 FR 41039, Aug. 14, 1981, as amended at 55 FR 8460, Mar. 8, 1990; 57 
FR 8577, Mar. 11, 1992; 69 FR 41427, July 9, 2004]



Sec. 520.2088  Roxarsone tablets.

    (a)(1) Specifications. Each tablet contains 36 milligrams of 
roxarsone (3-nitro-4-hydroxyphenylarsonic acid).
    (2) Sponsor. See No. 046573 in Sec. 510.600(c) of this chapter.
    (3) Related tolerances. See Sec. 556.60 of this chapter.
    (4) NAS/NRC status. The weight gain, feed efficiency, and 
pigmentation claims are NAS/NRC reviewed and

[[Page 210]]

found effective. NADA's for these uses need not include effectiveness 
data as specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
    (5) Conditions of use--(i) Growing chickens and growing turkeys--(a) 
Amount. Dissolve 2 tablets in each gallon of drinking water (0.002 
percent roxarsone).
    (b) Indications for use. For increased rate of weight gain, improved 
feed efficiency, and improved pigmentation.
    (c) Limitations. Administer continuously throughout growing period. 
Withdraw 5 days before slaughter. Use as sole source of organic arsenic.
    (ii) Growing chickens--(a) Amount. Dissolve 8 tablets in each gallon 
of drinking water (0.008 percent roxarsone).
    (b) Indications for use. As an aid in the prevention of coccidiosis 
due to Eimeria tenella.
    (c) Limitations. Administer for not more than 10 consecutive days. 
Treatment may be repeated after 5 days off medication. Withdraw 5 days 
before slaughter. Use as sole source of organic arsenic.
    (b)(1) Specifications. Each tablet contains 400 milligrams of 
roxarsone (3-nitro-4-hydroxyphenylarsonic acid).
    (2) Sponsor. See No. 046573 in Sec. 510.600(c) of this chapter.
    (3) Related tolerances. See Sec. 556.60 of this chapter.
    (4) NAS/NRC status. These conditions are NAS/NRC reviewed and found 
effective. NADA's for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
    (5) Conditions of use--(i) Swine--(a) Amount. 1 tablet (400 
milligrams) per gallon of drinking water for no more than 6 days, or 1 
tablet (400 milligrams) per 2 fluid ounces of warm water per 50 pounds 
of body weight as a drench once daily for 1 to 2 days.
    (b) Indications for use. As an aid in the treatment of swine 
dysentery (hemorrhagic enteritis or bloody scours).
    (c) Limitations. Treatment may be repeated after 5 days off 
medication. If no improvement is observed, consult a veterinarian. 
Treated animals must consume enough medicated water to provide a 
therapeutic dose. Withdraw 5 days before slaughter. Use as sole source 
of organic arsenic.
    (ii) [Reserved]
    (c)(1) Specifications. Each tablet contains 72 milligrams of 
roxarsone (3-nitro-4-hydroxyphenylarsonic acid).
    (2) Sponsor. See No. 046573 in Sec. 510.600(c) of this chapter.
    (3) Related tolerances. See Sec. 556.60 of this chapter.
    (4) Conditions of use in growing chickens and growing turkeys--(i) 
Amount. 1 tablet in each gallon of drinking water (0.002 percent 
roxarsone).
    (ii) Indications for use. For improved rate of weight gain, improved 
feed efficiency, and improved pigmentation.
    (iii) Limitations. Administer continuously throughout growing 
period. Do not administer to chickens producing eggs for human 
consumption. Withdraw 5 days before slaughter. Use as sole source of 
organic arsenic. Overdosage or the lack of water intake may result in 
weakness or paralysis of legs.

[46 FR 41040, Aug. 14, 1981, as amended at 46 FR 42448, Aug. 21, 1981; 
47 FR 15238, Apr. 9, 1982; 55 FR 8460, Mar. 8, 1990; 57 FR 8577, Mar. 
11, 1992; 58 FR 65664, Dec. 16, 1993; 65 FR 10705, Feb. 29, 2000]



Sec. 520.2089  Roxarsone liquid.

    (a) Specifications. Each teaspoon (5 milliliters) of solution 
contains 72 milligrams of roxarsone (3-nitro-4-hydroxyphenylarsonic 
acid).
    (b) Sponsor. See No. 046573 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.60 of this chapter.
    (d) Conditions of use in growing chickens and growing turkeys--(1) 
Amount. 1 teaspoon (5 milliliters) to each gallon of drinking water 
(0.002 percent roxarsone).
    (2) Indications for use. For improved rate of weight gain, improved 
feed efficiency, and improved pigmentation.
    (3) Limitations. Administer continuously throughout growing period. 
Do not administer to chickens producing eggs for human consumption. 
Withdraw 5 days before slaughter. Use as sole source of organic arsenic. 
Overdosage or the lack of water intake may result in weakness or 
paralysis of legs.

[58 FR 65665, Dec. 16, 1993, as amended at 65 FR 10705, Feb. 29, 2000]

[[Page 211]]



Sec. 520.2098  Selegiline hydrochloride tablets.

    (a) Specifications. Each tablet contains either 2, 5, 10, 15, or 30 
milligrams of selegiline hydrochloride.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--Dogs--(1) Dosage. 1 milligram per kilogram 
(0.45 milligram per pound) of body weight.
    (i) Indications for use. For control of clinical signs associated 
with uncomplicated pituitary-dependent hyperadrenocorticism in dogs.
    (ii) Limitations. Administer orally once daily. If no improvement in 
clinical signs or physical examination findings after 2 months of 
therapy, increase dose to a maximum of 2 milligrams per kilogram once 
daily. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (2) Dosage. 0.5 to 1.0 milligram per kilogram of body weight once 
daily.
    (i) Indications for use. For the control of clinical signs 
associated with canine cognitive dysfunction syndrome.
    (ii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

[62 FR 34632, June 27, 1997; 62 FR 55159, Oct. 23, 1997, as amended at 
63 FR 29551, June 1, 1998; 64 FR 2122, Jan. 13, 1999]



Sec. 520.2100  Selenium, vitamin E capsules.

    (a) Specifications. The capsules contain 2.19 milligrams of sodium 
selenite (equivalent to 1 milligram of selenium) and 56.2 milligrams of 
vitamin E (68 I.U.) (as d-alpha tocopheryl acid succinate) or 0.548 
milligram of sodium selenite (equivalent to .25 milligram of selenium 
and 14 milligrams of vitamin E (17 I.U.) (as d-alpha tocopheryl acid 
succinate.)
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is intended for use as an aid in 
alleviating and controlling inflammation, pain, and lameness associated 
with certain arthropathies in dogs.
    (2) The capsules are administered orally with the larger capsules 
administered at a dosage level of 1 capsule per 20 pounds of body weight 
to a maximum of 5 capsules with the dosage repeated at 3 day intervals 
until a satisfactory therapeutic response is observed. A maintenance 
dosage is then administered consisting of 1 capsule per 40 pounds of 
body weight, with a minimum of 1 capsule per 40 pounds of body weight, 
with a minimum of 1 capsule, given every 3 days, or 7 days, or longer, 
as required to maintain improvement or an asymptomatic condition. For 
dogs under 20 pounds of body weight, the small capsules are administered 
orally at a dosage level of 1 per 5 pounds of body weight with a minimum 
of 1 capsule which dosage is repeated at 3 day intervals until a 
satisfactory response is observed then a maintenance regimen is 
initiated with 1 capsule per 10 pounds of body weight, minimum of 1 
capsule, every 3 days, or 7 days, or longer as required to maintain 
continued improvement or an asymptomatic condition.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 52 FR 7832, Mar. 13, 1987; 52 
FR 9756, Mar. 26, 1987]



Sec. 520.2123  Spectinomycin oral dosage forms.



Sec. 520.2123a  Spectinomycin tablets.

    (a) Specifications. Each tablet contains spectinomycin 
dihydrochloride pentahydrate equivalent to 100 milligrams (mg) 
spectinomycin.
    (b) Sponsor. See No. 061623 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Administer orally to 
provide 10 mg per pound (lb) of body weight twice daily. Dosage may be 
continued for 4 consecutive days.
    (2) Indications for use. For the treatment of infectious diarrhea 
and gastroenteritis caused by organisms susceptible to spectinomycin.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[73 FR 6607, Feb. 5, 2008]



Sec. 520.2123b  Spectinomycin powder.

    (a) Specifications. Each gram (g) of powder contains spectinomycin 
dihydrochloride pentahydrate equivalent to 0.5 g spectinomycin.

[[Page 212]]

    (b) Sponsor. See No. 061623 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.600 of this chapter.
    (d) Conditions of use in chickens. It is administered in the 
drinking water of growing chickens as follows:
    (1) Indications for use and amounts--(i) For increased rate of 
weight gain and improved feed efficiency in broiler chickens, administer 
0.5 g per gallon of water as the only source of drinking water for the 
first 3 days of life and for 1 day following each vaccination.
    (ii) As an aid in controlling infectious synovitis due to Mycoplasma 
synoviae in broiler chickens, administer 1 g per gallon of water as the 
only source of drinking water for the first 3 to 5 days of life.
    (iii) As an aid in the prevention or control of losses due to CRD 
associated with M. gallisepticum (PPLO) in growing chickens, administer 
2 g per gallon of water as the only source of drinking water for the 
first 3 days of life and for 1 day following each vaccination.
    (2) Limitations. Do not administer to laying chickens. Do not 
administer within 5 days of slaughter.

[73 FR 6607, Feb. 5, 2008]



Sec. 520.2123c  Spectinomycin solution.

    (a) Specifications. Each milliliter of solution contains 
spectinomycin dihydrochloride pentahydrate equivalent to 50 milligrams 
(mg) spectinomycin.
    (b) Sponsors. See Nos. 000856, 000859, and 061623 in Sec. 
510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.600 of this chapter.
    (d) Conditions of use in swine--(1) Amount. Administer 5 mg per 
pound (lb) of body weight orally twice daily for 3 to 5 days.
    (2) Indications for use. For the treatment and control of porcine 
enteric colibacillosis (scours) caused by E. coli susceptible to 
spectinomycin in pigs under 4 weeks of age.
    (3) Limitations. Do not administer to pigs over 15 lb body weight or 
over 4 weeks of age. Do not administer within 21 days of slaughter.

[73 FR 6607, Feb. 5, 2008]



Sec. 520.2130  Spinosad.

    (a) Specifications. Each chewable tablet contains 90, 140, 270, 560, 
810, or 1620 milligrams (mg) spinosad.
    (b) Sponsor. See No. 000986 in Sec. 510.600 of this chapter.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Conditions of use--(1) Dogs--(i) Amount. Administer tablets once 
a month at a recommended minimum dosage of 13.5 mg per pound (30 mg per 
kilogram) of body weight.
    (ii) Indications for use. To kill fleas and for the prevention and 
treatment of flea infestations (Ctenocephalides felis) for 1 month on 
dogs and puppies 14 weeks of age and older and 3.3 pounds of body weight 
or greater.
    (2) Cats--(i) Amount. Administer tablets once a month at a minimum 
dosage of 22.5 mg per pound (50 mg per kilogram) of body weight.
    (ii) Indications for use. To kill fleas and for the prevention and 
treatment of flea infestations (C. felis) for 1 month on cats and 
kittens 14 weeks of age and older and 2 pounds of body weight or 
greater.

[77 FR 60623, Oct. 4, 2012]



Sec. 520.2134  Spinosad and milbemycin.

    (a) Specifications. Each chewable tablet contains 140 milligrams 
(mg) spinosad and 2.3 mg milbemycin oxime, 270 mg spinosad and 4.5 mg 
milbemycin oxime, 560 mg spinosad and 9.3 mg milbemycin oxime, 810 mg 
spinosad and 13.5 mg milbemycin oxime, or 1,620 mg spinosad and 27 mg 
milbemycin oxime.
    (b) Sponsor. See No. 000986 in Sec. 510.600 of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Administer once a month 
at a minimum dosage of 13.5 mg/pound (lb) (30 mg/kilogram (kg)) of body 
weight spinosad and 0.2 mg/lb (0.5 mg/kg) of body weight milbemycin 
oxime.
    (2) Indications for use. To kill fleas; for the prevention and 
treatment of flea infestations (Ctenocephalides felis); for the 
prevention of heartworm disease (Dirofilaria immitis); and for the 
treatment and control of adult hookworm (Ancylostoma caninum), adult 
roundworm (Toxocara canis and

[[Page 213]]

Toxascaris leonina), and adult whipworm (Trichuris vulpis) infections in 
dogs and puppies 8 weeks of age or older and 5 lbs of body weight or 
greater.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[76 FR 12563, Mar. 8, 2011]



Sec. 520.2150  Stanozolol oral dosage forms.



Sec. 520.2150a  Stanozolol tablets.

    (a) Specifications. Each tablet contains 2 milligrams of stanozolol.
    (b) Sponsor. No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) Used as an anabolic steroid treatment in 
dogs and cats.
    (2) Administered orally to cats and small breeds of dogs, \1/2\ to 1 
tablet twice daily for several weeks; to large breeds of dogs, 1 to 2 
tablets twice daily for several weeks. The tablets may be crushed and 
administered in feed.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 46101, Oct. 6, 1975, as amended at 42 FR 36995, July 19, 1977. 
Redesignated at 50 FR 38114, Sept. 20, 1985, and amended at 55 FR 23076, 
June 6, 1990]



Sec. 520.2150b  Stanozolol chewable tablets.

    (a) Specifications. Each chewable tablet contains 2 milligrams of 
stanozolol.
    (b) Sponsor. No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) Used as an anabolic steroid treatment in 
dogs.
    (2) Administered orally to small breeds of dogs, \1/2\ to 1 tablet 
twice daily for several weeks; to large breeds of dogs, 1 to 2 tablets 
twice daily for several weeks.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[50 FR 38114, Sept. 20, 1985, as amended at 55 FR 23076, June 6, 1990]



Sec. 520.2158  Streptomycin/dihydrostreptomycin oral dosage forms.



Sec. 520.2158a  Streptomycin sulfate oral solution.

    (a) Specifications. Solution containing 25 percent streptomycin 
sulfate.
    (b) Sponsor. See Nos. 033008 and 055462 in Sec. 510.600(c) of this 
chapter.
    (c) Related tolerances. See Sec. 556.610 of this chapter.
    (d) Conditions of use. Use in drinking water as follows:
    (1) Calves and swine--(i) Amount. 10 to 15 milligrams per pound (mg/
pound) of body weight (1.0 to 1.5 grams per gallon).
    (ii) Indications for use. Treatment of bacterial enteritis caused by 
Escherichia coli and Salmonella spp. susceptible to streptomycin.
    (iii) Limitations. Calves: Do not administer for more than 5 days. 
Swine: Do not administer for more than 4 days. Prepare fresh solution 
daily. Calves: Withdraw 2 days before slaughter. As sole source of 
streptomycin. Warning: Certain strains of bacteria may develop a 
tolerance for streptomycin. Consult a veterinarian or animal pathologist 
for diagnosis.
    (2) Chickens--(i) Amount. 10 to 15 mg/pound of body weight (0.6 to 
0.9 grams per gallon).
    (ii) Indications for use. Treatment of nonspecific infectious 
enteritis caused by organisms susceptible to streptomycin.
    (iii) Limitations. Chickens: Do not administer for more than 5 days. 
Withdraw 4 days before slaughter. Do not administer to chickens 
producing eggs for human consumption. Prepare fresh solution daily. As 
sole source of streptomycin. Warning: Certain strains of bacteria may 
develop a tolerance for streptomycin. Consult a veterinarian or animal 
pathologist for diagnosis.

[57 FR 37327, Aug. 18, 1992, as amended at 58 FR 47211, Sept. 8, 1993; 
63 FR 51821, Sept. 29, 1998]



Sec. 520.2158b  Dihydrostreptomycin tablets.

    (a) Specifications. Each tablet contains 37.5 milligrams 
dihydrostreptomycin (as the sulfate) with 375 milligrams chlorhexidine 
dihydrochloride.

[[Page 214]]

    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. Sec. 556.120 and 556.200 of this 
chapter.
    (d) Conditions of use. Calves--(1) Amount. 150 milligrams of 
dihydrostreptomycin and 1.5 grams of chlorhexidine dihydrochloride per 
100 pounds of body weight per day.
    (2) Indications for use. Treatment of bacterial scours in calves.
    (3) Limitations. Administer orally once a day for 5 days; withdraw 3 
days before slaughter.

[57 FR 37327, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992]



Sec. 520.2158c  Dihydrostreptomycin oral suspension.

    (a) Specifications. Each milliliter contains 1.25 milligrams 
dihydrostreptomycin (as the sulfate) with 12.5 milligrams chlorhexidine 
dihydrochloride.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. Sec. 556.120 and 556.200 of this 
chapter.
    (d) Conditions of use. Calves--(1) Amount. 150 milligrams of 
dihydrostreptomycin and 1.5 grams of chlorhexidine dihydrochloride per 
100 pounds of body weight per day.
    (2) Indications for use. Treatment of bacterial scours in calves.
    (3) Limitations. Administer orally once a day for 5 days; withdraw 3 
days before slaughter.

[57 FR 37327, Aug. 18, 1992]



Sec. 520.2160  Styrylpyridinium, diethylcarbamazine oral dosage forms.



Sec. 520.2170  Sulfabromomethazine sodium boluses.

    (a) Specifications. Each bolus contains 15 grams of 
sulfabromomethazine sodium.
    (b) Related tolerance. See Sec. 556.620 of this chapter.
    (c) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (d) NAS/NRC status. These conditions of use are NAS/NRC reviewed and 
found effective. NADA's for these uses need not include effectiveness 
data as specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
    (e) Conditions of use. Cattle--(1) Amount. 90 milligrams per pound 
body weight.
    (2) Indications for use. Treatment of necrotic pododermatitis (foot 
rot) and calf diphtheria caused by Fusobacterium necrophorum; 
colibacillosis (scours) caused by Escherichia coli; bacterial pneumonia 
and bovine respiratory disease complex (shipping fever complex) 
associated with Pasteurella spp.; acute metritis and acute mastitis 
caused by Streptococcus spp.
    (3) Limitations. Administer orally; repeat in 48 hours if necessary; 
milk taken from animals within 96 hours (8 milkings) of latest treatment 
must not be used for food; do not administer within 18 days of 
slaughter; discontinue use if hematuria, crystalluria or severe 
depression are noticed; if signs persist after 2 or 3 days consult a 
veterinarian.

[47 FR 30243, July 13, 1982, as amended at 62 FR 63270, Nov. 28, 1997]



Sec. 520.2184  Sodium sulfachloropyrazine monohydrate.

    (a) Chemical name. 2-Sulfamido-6-chloroxyrazine, sodium.
    (b) Sponsor. See Nos. 053501 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.625 of this chapter.
    (d) Conditions of use. It is used in the drinking water of broilers, 
breeder flocks, and replacement chickens as follows:
    (1) Amount. 0.03 percent.
    (2) Indications for use. Treatment of coccidiosis.
    (3) Limitations. Administer in drinking water for 3 days as sole 
source of drinking water and sulfonamide medication; withdraw 4 days 
prior to slaughter; not to be administered to chickens producing eggs 
for human consumption.

[40 FR 13838, Mar. 27, 1975, as amended at 50 FR 41489, Oct. 11, 1985; 
54 FR 12188, Mar. 24, 1989; 55 FR 8460, Mar. 8, 1990; 64 FR 15684, Apr. 
1, 1999; 67 FR 78355, Dec. 24, 2002]



Sec. 520.2200  Sulfachlorpyridazine.

    (a) Specifications.--(1) Sodium sulfachlorpyridazine powder.
    (2) Each bolus contains 2 grams sulfachlorpyridazine.

[[Page 215]]

    (3) Each tablet contains 250 milligrams (mg) sulfachlorpyridazine.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.630 of this chapter.
    (d) Conditions of use. It is used as follows:
    (1) Calves--(i) Amount. Administer 30 to 45 mg sulfachlorpyridazine 
powder per pound (/lb) of body weight per day in milk or milk replacer, 
or in a bolus, in divided doses twice daily for 1 to 5 days.
    (ii) Indications for use. For the treatment of diarrhea caused or 
complicated by Escherichia coli (colibacillosis).
    (iii) Limitations. Treated ruminating calves must not be slaughtered 
for food during treatment or for 7 days after the last treatment. A 
withdrawal period has not been established for this product in 
preruminating calves. Do not use in calves to be processed for veal.
    (2) Swine--(i) Amount. Administer 20 to 35 mg/lb body weight per 
day, in divided doses twice daily for 1 to 5 days:
    (A) In drinking water or
    (B) For individual treatment, in an oral suspension containing 50 mg 
per milliliter.
    (ii) Indications for use. For the treatment of diarrhea caused or 
complicated by E. coli (colibacillosis).
    (iii) Limitations. Treated swine must not be slaughtered for food 
during treatment or for 4 days after the last treatment.
    (3) Dogs--(i) Amount. Administer tablets orally at 500 mg per 10 to 
15 lb of body weight daily, in two or three divided doses.
    (ii) Indications for use. As an aid in the treatment of infectious 
tracheobronchitis and infections caused by E. coli, and in the treatment 
of infections caused by other Gram-positive and Gram-negative organisms 
that are susceptible to sulfonamide therapy.
    (iii) Limitations. Federal law restricts this drug to use only by or 
on the order of a licensed veterinarian.

[75 FR 10166, Mar. 5, 2010]



Sec. 520.2215  Sulfadiazine/pyrimethamine suspension.

    (a) Specifications. Each milliliter (mL) of suspension contains 250 
milligrams (mg) sulfadiazine (as the sodium salt) and 12.5 mg 
pyrimethamine.
    (b) Sponsor. See No. 055246 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. Administer orally 20 mg 
sulfadiazine per kilogram (kg) body weight and 1 mg/kg pyrimethamine 
daily.
    (2) Indications for use. For the treatment of equine protozoal 
myeloencephalitis (EPM) caused by Sarcocystis neurona.
    (3) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[69 FR 70054, Dec. 2, 2004, as amended at 73 FR 53686, Sept. 17, 2008; 
75 FR 69586, Nov. 15, 2010]



Sec. 520.2218  Sulfamerazine, sulfamethazine, and sulfaquinoxaline powder.

    (a) Specifications. Each 195-gram (g) packet of powder contains 78 g 
sulfamerazine, 78 g sulfamethazine, and 39 g sulfaquinoxaline.
    (b) Sponsor. See No. 046573 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. Sec. 556.670 and 556.685 of this 
chapter.
    (d) Conditions of use--(1) Chickens--(i) Amounts and indications for 
use--(A) As an aid in the control of coccidiosis caused by Eimeria 
tenella and E. necatrix susceptible to sulfamerazine, sulfamethazine, 
and sulfaquinoxaline: provide medicated water (0.4 percent solution) for 
2 to 3 days, then plain water for 3 days, then medicated water (0.25 
percent solution) for 2 days. If bloody droppings appear, repeat at 0.25 
percent level for 2 more days. Do not change litter.
    (B) As an aid in the control of acute fowl cholera caused by 
Pasteurella multocida susceptible to sulfamerazine, sulfamethazine, and 
sulfaquinoxaline: provide medicated water (0.4 percent solution) for 2 
to 3 days. If disease recurs, repeat treatment.
    (ii) Limitations. Make fresh solution daily. Do not treat chickens 
within 14 days of slaughter for food. Do not

[[Page 216]]

medicate chickens producing eggs for human consumption.
    (2) Turkeys--(i) Amounts and indications for use--(A) As an aid in 
the control of coccidiosis caused by Eimeria meleagrimitis and E. 
adenoeides susceptible to sulfamerazine, sulfamethazine, and 
sulfaquinoxaline: provide medicated water (0.25 percent solution) for 2 
days, then plain water for 3 days, then medicated water (0.25 percent 
solution) for 2 days, then plain water for 3 days, then medicated water 
(0.25 percent solution) for 2 days. Repeat if necessary. Do not change 
litter.
    (B) As an aid in the control of acute fowl cholera caused by 
Pasteurella multocida susceptible to sulfamerazine, sulfamethazine, and 
sulfaquinoxaline: provide medicated water (0.4 percent solution) for 2 
to 3 days. If disease recurs, repeat treatment.
    (ii) Limitations. Make fresh solution daily. Do not treat turkeys 
within 14 days of slaughter for food. Do not medicate turkeys producing 
eggs for human consumption.

[71 FR 13001, Mar. 14, 2006]



Sec. 520.2220  Sulfadimethoxine oral dosage forms.



Sec. 520.2220a  Sulfadimethoxine oral solution and soluble powder.

    (a) Approvals. (1) For oral solution containing 12.5 percent (3.75 
grams per ounce) sulfadimethoxine, see Nos. 000010, 000069, 000859, 
054925, and 057561 in Sec. 510.600(c).
    (2) For soluble powder, each 107 grams contain the equivalent of 
94.6 grams of sulfadimethoxine (as the sodium salt); see Nos. 000069, 
054925, 057561, 058829, 061623, and 066104 in Sec. 510.600(c) of this 
chapter.
    (b) Special considerations. Federal law prohibits the extralabel use 
of this product in lactating dairy cattle.
    (c) Related tolerances. See Sec. 556.640 of this chapter.
    (d) Conditions of use. The oral solution is administered as a cattle 
drench or diluted as directed to prepare drinking water. The powder is 
used to prepare a drench or drinking water. The concentrations and uses 
of the various solutions are as follows:
    (1) Broiler and replacement chickens only--(i) Amount. 1.875 (0.05 
percent) grams per gallon.
    (ii) Indications for use. Treatment of disease outbreaks of 
coccidiosis, fowl cholera, and infectious coryza.
    (iii) Limitations. Administer for 6 consecutive days; do not 
administer to chickens over 16 weeks of age; as sole source of drinking 
water and sulfonamide medication; as sulfadimethoxine solution or 
sulfadimethoxine soluble sodium salt; withdraw 5 days before slaughter.
    (2) Meat-producing turkeys only--(i) Amount. 0.938 (0.025 percent) 
grams per gallon.
    (ii) Indications for use. Treatment of disease outbreaks of 
coccidiosis and fowl cholera.
    (iii) Limitations. Administer for 6 consecutive days; do not 
administer to turkeys over 24 weeks of age; as sole source of drinking 
water and sulfonamide medication; as sulfadimethoxine solution or 
sulfadimethoxine soluble sodium salt; withdraw 5 days before slaughter.
    (3) Dairy calves, dairy heifers, and beef cattle only--(i) Amount. 
1.18 to 2.36 (0.031 to 0.062 percent) grams per gallon.
    (ii) Indications for use. For the treatment of shipping fever 
complex and bacterial pneumonia associated with Pasteurella spp. 
sensitive to sulfadimethoxine; and calf diphtheria and foot rot 
associated with Fusobacterium necrophorum (Sphaerophorus necrophorus) 
sensitive to sulfadimethoxine.
    (iii) Administer 2.5 grams per 100 pounds of body weight for first 
day, then 1.25 grams per 100 pounds of body weight per day for the next 
4 consecutive days; in drinking water or drench; available as a 
sulfadimethoxine soluble powder or a 12.5 percent sulfadimethoxine 
sodium solution (3.75 grams sulfadimethoxine per fluid ounce); if no 
improvement within 2 to 3 days, reevaluate diagnosis; do not treat 
beyond 5 days; withdraw 7 days before slaughter. A withdrawal period has 
not been established for this product in

[[Page 217]]

preruminating calves. Do not use in calves to be processed for veal.

[40 FR 13838, Mar. 27, 1975, as amended at 58 FR 6092, Jan. 26, 1993; 59 
FR 56000, Nov. 10, 1994; 61 FR 4875, Feb. 9, 1996; 62 FR 8371, Feb. 25, 
1997; 62 FR 23357, Apr. 30, 1997; 62 FR 35076, June 30, 1997; 62 FR 
40932, July 31, 1997; 63 FR 59714, Nov. 5, 1998; 64 FR 18572, Apr. 15, 
1999; 70 FR 73137, Dec. 9, 2005; 71 FR 13542, Mar. 16, 2006; 74 FR 
60156, Nov. 20, 2009; 76 FR 17337, Mar. 29, 2011; 77 FR 56770, Sept. 14, 
2012; 78 FR 17596, Mar. 22, 2013]



Sec. 520.2220b  Sulfadimethoxine tablets and boluses.

    (a) Sponsors. Approval to firms identified in Sec. 510.600(c) of 
this chapter as follows:
    (1) To 000069, approval for use as in paragraphs (d)(1), (d)(2), and 
(d)(3) of this section.
    (2) To 000061, approval for use as in paragraph (d)(2).
    (b) Related tolerances. See Sec. 556.640 of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Cattle--(i) Amount. Administer 2.5 grams 
per 100 pounds body weight for 1 day followed by 1.25 grams per 100 
pounds body weight per day; treat for 4 to 5 days.
    (ii) Indications for use. For the treatment of shipping fever 
complex and bacterial pneumonia associated with Pasteurella spp. 
sensitive to sulfadimethoxine; and calf diphtheria and foot rot 
associated with Fusobacterium necrophorum sensitive to sulfadimethoxine.
    (iii) Limitations. Do not administer within 7 days of slaughter; 
milk that has been taken from animals during treatment and 60 hours (5 
milkings) after the latest treatment must not be used for food. A 
withdrawal period has not been established for this product in 
preruminating calves. Do not use in calves to be processed for veal.
    (2) Dogs and cats--(i) Amount. Administer 25 milligrams per pound of 
body weight on the first day followed by 12.5 milligrams per pound of 
body weight per day until the animal is free of symptoms for 48 hours.
    (ii) Indications for use. Treatment of sulfadimethoxine-susceptible 
bacterial infections.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (3) Beef cattle and nonlactating dairy cattle--(i) Amount. 
Administer one 12.5-gram-sustained-release bolus for the nearest 200 
pounds of body weight, i.e., 62.5 milligrams per pound of body weight. 
Do not repeat treatment for 7 days.
    (ii) Indications for use. Treatment of shipping fever complex and 
bacterial pneumonia associated with organisms such as Pasteurella spp. 
sensitive to sulfadimethoxine; calf diphtheria and foot rot associated 
with Fusobacterium necrophorum sensitive to sulfadimethoxine.
    (iii) Limitations. Do not use in female dairy cattle 20 months of 
age or older. Do not administer within 12 days of slaughter. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 40 FR 43488, Sept. 22, 1975; 
49 FR 36830, Sept. 20, 1984; 59 FR 56000, Nov. 10, 1994; 61 FR 4875, 
Feb. 9, 1996; 62 FR 61625, Nov. 19, 1997; 64 FR 15684, Apr. 1, 1999; 70 
FR 16934, Apr. 4, 2005; 76 FR 17337, Mar. 29, 2011]



Sec. 520.2220c  Sulfadimethoxine oral suspension.

    (a) Chemical name. N'-(2,6-Dimethoxy-4-pyrimidinyl) sulfanilamide.
    (b) Specifications. Each milliliter of the drug contains 50 
milligrams of sulfadimethoxine.
    (c) Sponsor. See Nos. 000061 and 000069 in Sec. 510.600(c) of this 
chapter.
    (1) It is intended for use in the treatment of sulfonamide 
susceptible bacterial infections in dogs and cats and enteritis 
associated with coccidiosis in dogs.
    (2) On the first day of treatment administer an oral dose of 25 
milligrams per pound of body weight, then follow with a daily dosage of 
12.5 milligrams per pound of body weight. Length of treatment will 
depend upon clinical response. Continue treatment until patient is 
asymptomatic for 48 hours. Maintain adequate water intake during the 
treatment period.
    (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 59 FR 56000, Nov. 10, 1994; 
61 FR 4875, Feb. 9, 1996; 62 FR 61625, Nov. 19, 1997]

[[Page 218]]



Sec. 520.2220d  Sulfadimethoxine-ormetoprim tablets.

    (a) Specifications. Each tablet contains 120 milligrams (100 
milligrams of sulfadimethoxine and 20 milligrams of ormetoprim), 240 
milligrams (200 milligrams of sulfadimethoxine and 40 milligrams of 
ormetoprim), 600 milligrams (500 milligrams of sulfadimethoxine and 100 
milligrams of ormetoprim), or 1200 milligrams (1,000 milligrams of 
sulfadimethoxine and 200 milligrams of ormetoprim).
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. On the first day of treatment, 
administer 25 milligrams per pound (55 milligrams per kilogram) of body 
weight. Then follow with a daily dosage of 12.5 milligrams per pound 
(27.5 milligrams per kilogram) of body weight.
    (2) Indications of use. Treatment of skin and soft tissue infections 
(wounds and abscesses) in dogs caused by strains of Staphylococcus 
aureus and Escherichia coli and urinary tract infections caused by 
Escherichia coli, Staphlococcus spp., and Proteus mirabilus susceptible 
to ormetoprim-potentiated sulfadimethoxine.
    (3) Limitations. Continue treatment until patient is asymptomatic 
for 48 hours, but do not exceed a total of 21 consecutive days. Maintain 
adequate water intake during the treatment period. Safety in breeding 
animals has not been established. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.

[54 FR 48593, Nov. 24, 1989, as amended at 59 FR 56000, Nov. 10, 1994; 
61 FR 4875, Feb. 9, 1996; 61 FR 46719, Sept. 5, 1996]



Sec. 520.2240  Sulfaethoxypyridazine.



Sec. 520.2240a  Sulfaethoxypyridazine drinking water.

    (a) Chemical name. N'-(6-Ethoxy-3-pyridazinyl) sulfanilamide.
    (b) Specifications. Melting point range of 180 [deg]C. to 186 
[deg]C.
    (c) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (d) Related tolerances. See Sec. 556.650 of this chapter.
    (e) Conditions of use. It is used as follows:
    (1) Swine--(i) Amount. 1.9 to 3.8 grams per gallon (0.05 percent to 
0.1 percent).
    (ii) Indications for use. Treatment of bacterial scours pneumonia 
enteritis, bronchitis, septicemia accompanying Salmonella cholerasuis 
infection.
    (iii) Limitations. Administer 3.8 grams per gallon for first day 
followed by 1.9 grams per gallon for not less than 3 days nor more than 
9 days as sodium sulfaethoxypyridazine; do not treat within 10 days of 
slaughter; as sole source of sulfonamide; for use by or on the order of 
a licensed veterinarian.
    (2) Cattle--(i) Amount. 2.5 grams per gallon (0.066 percent).
    (ii) Indications for use. Treatment of respiratory infections 
(pneumonia, shipping fever), foot rot, calf scours; as adjunctive 
therapy in septicemia accompanying mastitis and metritis.
    (iii) Limitations. Administer at the rate of 1 gallon per 100 pounds 
of body weight per day for 4 days; as sodium sulfaethoxypyridazine; do 
not treat within 16 days of slaughter; as sole source of sulfonamide; 
for use by or on the order of a licensed veterinarian; milk that has 
been taken from animals during treatment and for 72 hours (6 milkings) 
after latest treatment must not be used for food.

[40 FR 13838, Mar. 27, 1975, as amended at 67 FR 78355, Dec. 24, 2002]



Sec. 520.2240b  Sulfaethoxypyridazine tablets.

    (a) Chemical name. N'-(6-Ethoxy-3-pyridazinyl) sulfanilamide.
    (b) Specifications. Melting point range of 180 [deg]C to 186 [deg]C.
    (c) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (d) Related tolerances. See Sec. 556.650 of this chapter.
    (e) Conditions of use. It is used for cattle as follows:
    (1) Amount. 2.5 or 15 grams per tablet.
    (i) Indications for use. Treatment of respiratory infections 
(pneumonia, shipping fever), foot rot, calf scours; as adjunctive 
therapy in septicemia accompanying mastitis and metritis.
    (ii) Limitations. Administer 25 milligrams per pound of animal 
weight per day for 4 days; do not treat within 16 days of slaughter; as 
sole source of sulfonamide; milk that has been taken from animals during 
treatment and for

[[Page 219]]

72 hours (6 milkings) after the latest treatment must not be used for 
food; for use only by or on the order of a licensed veterinarian.
    (2) Amount. 15-gram controlled release tablets.
    (i) Indications for use. Treatment of foot rot and respiratory 
infections (shipping fever and pneumonia) caused by sulfonamide-
susceptible pathogens (E. coli, streptococci, staphylococci, 
Sphaerophorus necrophorus and Gram-negative rods including Pasteurella); 
for use prophylactically in cattle during periods of stress for reducing 
losses due to sulfonamide sensitive disease conditions.
    (ii) Limitations. Administer 100 milligrams per pound of body 
weight; do not treat within 16 days of slaughter; as sole source of 
sulfonamide; not for use in lactating dairy cows; Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 67 FR 78355, Dec. 24, 2002]



Sec. 520.2260  Sulfamethazine oral dosage forms.



Sec. 520.2260a  Sulfamethazine oblet, tablet, and bolus.

    (a)(1) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter 
for use of 2.5-, 5-, and 15-gram sulfamethazine oblet in beef cattle, 
nonlactating dairy cattle, and horses. See No. 061690 in Sec. 
510.600(c) of this chapter for use of 5-, 15-, and 25-gram tablet in 
beef and nonlactating dairy cattle.
    (2) Related tolerance in edible products. See Sec. 556.670 of this 
chapter.
    (3) Conditions of use--(i) Amount. Administer as a single dose 100 
milligrams of sulfamethazine per pound of body weight the first day and 
50 milligrams per pound of body weight on each following day.
    (ii) Indications for use. For treatment of diseases caused by 
organisms susceptible to sulfamethazine.
    (A) Beef cattle and nonlactating dairy cattle. Treatment of 
bacterial pneumonia and bovine respiratory disease complex (shipping 
fever complex) (Pasteurella spp.), colibacillosis (bacterial scours) 
(Escherichia coli), necrotic pododermatitis (foot rot) (Fusobacterium 
necrophorum), calf diphtheria (Fusobacterium necrophorum), acute 
mastitis (Streptococcus spp.), acute metritis (Streptococcus spp.), 
coccidiosis (Eimeria bovis and Eimeria zurnii).
    (B) Horses. Treatment of bacterial pneumonia (secondary infections 
associated with Pasteurella spp.), strangles (Streptococcus equi), and 
bacterial enteritis (Escherichia coli).
    (iii) Limitations. Administer daily until animal's temperature and 
appearance are normal. If symptoms persist after using for 2 or 3 days 
consult a veterinarian. Fluid intake must be adequate. Treatment should 
continue 24 to 48 hours beyond the remission of disease symptoms, but 
not to exceed 5 consecutive days. Follow dosages carefully. Do not treat 
cattle within 10 days of slaughter. Do not use in female dairy cattle 20 
months of age or older. Use of sulfamethazine in this class of cattle 
may cause milk residues. A withdrawal period has not been established in 
preruminating calves. Do not use in calves to be processed for veal. Do 
not use in horses intended for human consumption.
    (b)(1) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter 
for use of 5-gram sulfamethazine bolus.
    (2) Related tolerances in edible products. See Sec. 556.670 of this 
chapter.
    (3) Conditions of use--(i) Amount. Administer 10 grams (2 boluses) 
of sulfamethazine per 100 pounds of body weight the first day, then 5 
grams (1 bolus) of sulfamethazine per 100 pounds of body weight daily 
for up to 4 additional consecutive days.
    (ii) Indications for use. Ruminating beef and dairy calves. For 
treatment of the following diseases caused by organisms susceptible to 
sulfamethazine: bacterial scours (colibacilloosis) caused by E. coli; 
necrotic pododermatitis (foot rot) and calf diphtheria caused by F. 
necrophorum; bacterial pneumonia associated with Pasteurella spp.; and 
coccidiosis caused by E. bovis and E. zurnii.
    (iii) Limitations. Do not administer for more than 5 consecutive 
days. Do not treat calves within 11 days of slaughter. Do not use in 
calves to be slaughtered under 1 month of age or in calves being fed an 
all milk diet. Do not use in female dairy cattle 20 months of age or 
older; such use may

[[Page 220]]

cause drug residues in milk. Administer with adequate supervision. 
Follows recomended dosages carefully. Fluid intake must be adequate. If 
symptoms persist after 2 or 3 days, consult a veterinarian.

[54 FR 15751, Apr. 19, 1989; 54 FR 19283, May 4, 1989, as amended at 56 
FR 50653, Oct. 8, 1991; 59 FR 22754, May 3, 1994; 61 FR 4875, Feb. 9, 
1996; 64 FR 66383, Nov. 26, 1999; 67 FR 78355, Dec. 24, 2002; 75 FR 
10166, Mar. 5, 2010; 76 FR 17337, Mar. 29, 2011]



Sec. 520.2260b  Sulfamethazine sustained-release boluses.

    (a)(1) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter 
for use of a 22.5-gram sulfamethazine prolonged-release bolus.
    (2) Conditions of use--(i) Amount. Depending on the duration of 
therapeutic levels desired, administer boluses as a single dose as 
follows: 3\1/2\ days--1 bolus (22.5 grams) per 200 pounds of body 
weight; 5 days--1 bolus per 100 pounds of body weight.
    (ii) Indications for use. Beef and nonlactating cattle for sustained 
treatment of shipping fever pneumonia caused or complicated by 
Pasteurella multocida; as an aid in the treatment of foot rot, mastitis, 
pneumonia, metritis, bacterial enteritis, calf diphtheria, and 
septicemia when caused or complicated by bacteria susceptible to 
sulfamethazine.
    (iii) Limitations. Cattle that are acutely ill should be treated 
parenterally with a suitable antibacterial product to obtain immediate 
therapeutic blood levels; do not slaughter animals for food within 16 
days of treatment; do not use in lactating dairy cattle; Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.
    (b)(1) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter 
for use of a 27-gram sulfamethazine sustained-release bolus.
    (2) Conditions of use--(i) Amount. 27 grams (1 bolus) for each 150 
pounds of body weight as a single dose.
    (ii) Indications for use. For nonlactating cattle for the treatment 
of infections caused by organisms sensitive to sulfamethazine such as 
hemorrhagic septicemia (shipping fever complex), bacterial pneumonia, 
foot rot, and calf diphtheria and as an aid in the control of bacterial 
diseases usually associated with shipping and handling of cattle.
    (iii) Limitations. If no response within 2 to 3 days, reevaluate 
therapy; do not crush tablets; treated animals must not be slaughtered 
for food within 28 days after the latest treatment; Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.
    (c)(1) Sponsor. See No. 061623 in Sec. 510.600(c) of this chapter 
for use of a 32.1-gram sustained-release bolus.
    (2) Conditions of use--(i) Amount. 32.1 grams (1 bolus) per 200 
pounds of body weight.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and found effective. 
Applications for these uses need not inlcude effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (ii) Indications for use. For beef and nonlactating dairy cattle for 
the treatment of diseases caused by sulfamethazine-sensitive organisms 
as follows: bacterial pneumonia and bovine respiratory disease complex 
(shipping fever complex) caused by Pasteurella spp., colibacillosis 
(bacterial scours) caused by E. coli, necrotic pododermatitis (foot rot) 
and calf diphtheria caused by Fusobacterium necrophorum, and acute 
mastitis and acute metritis caused by Streptococcus spp.)\1\
    (iii) Limitations. After 72 hours, all animals should be reexamined 
for persistence of observable disease signs. If signs are present, 
consult a veterinarian. It is strongly recommended that a second dose be 
given to provide for an additional 72 hours of therapy, particularly in 
more severe cases. The dosage schedule should be used at each 72-hour 
interval. Animals should not receive more than 2 doses because of the 
possibility of incurring residue violations. This drug, like all 
sulfonamides, may cause toxic reactions and irreparable injury unless 
administered with adequate and continuous supervision; follow dosages 
carefully. Fluid intake must be adequate at all times throughout the 3-
day therapy, Do not use in lactating dairy cattle. Do not treat animals 
within 12 days of slaughter.

[[Page 221]]

    (d)(1) Sponsor. See 000859 in Sec. 510.600(c) of this chapter for 
use of a 22.5-gram sulfamethazine sustained release bolus.
    (2) Conditions of use--(i) Amount. Administer 1 bolus (22.5 grams) 
per 200 pounds of body weight, as a single dose.
    (ii) Indications for use. Beef and nonlactating dairy cattle for the 
prolonged treatment of the following diseases when caused by one or more 
of the listed pathogenic organisms sensitive to sulfamethazine: bovine 
respiratory disease complex (shipping fever complex) (Pasteurella spp.), 
bacterial pneumonia (Pasteurella spp.), necrotic pododermatitis (foot 
rot) (Fusobacterium necrophorum), colibacillosis (bacterial scours) 
(Escherichia coli), calf diphtheria (Fusobacterium necrophorum), acute 
mastitis (Streptococcus spp.) and acute metritis (Streptococcus spp.).
    (iii) Limitations. Cattle that are acutely ill should be treated by 
injection with a suitable antibacterial product to obtain immediate 
therapeutic blood levels; do not slaughter animals for food within 16 
days of treatment; do not use in lactating dairy cattle; if treated 
animals do not respond within 2 to 3 days, consult a veterinarian.
    (e)(1) Sponsor. See No. 061623 in Sec. 510.600(c) of this chapter 
for use of an 8.02-gram sulfamethazine sustained-release bolus.
    (2) Conditions of use--(i) Amount. Administer 2 boluses (8.02 grams 
per bolus) per 100 pounds of body weight, as a single dose.
    (ii) Indications for use. Administer orally to ruminating calves for 
the prolonged treatment of the following diseases when caused by one or 
more of the listed pathogenic organisms sensitive to sulfamethazine: 
bacterial pneumonia (Pasteurella spp.), colibacillosis (bacterial 
scours) (E. coli), and calf diptheria (Fusobacterium necrophorum).
    (iii) Limitations. For use in ruminating replacement calves only; 72 
hours after dosing all animals should be reexamined for persistence of 
disease signs; if signs are present, consult a veterinarian; do not 
slaughter animals for food for at least 12 days after the last dose; 
this product has not been shown to be effective for nonruminating 
calves; exceeding two consecutive doses may cause violative tissue 
residue to remain beyond the withdrawal time; do not use in calves under 
1 month of age or calves being fed an all milk diet.
    (f)(1) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter 
for use of a 30-gram sulfamethazine sustained-release bolus.
    (2) Conditions of use--(i) Amount. Administer at the rate of 1 bolus 
(30 grams per bolus) per 200 pounds of body weight, as a single dose.
    (ii) Indications for use. Administer orally to beef cattle and 
nonlactating dairy cattle for the treatment of the following diseases 
when caused by one or more of the listed pathogenic organisms sensitive 
to sulfamethazine: bovine respiratory disease complex (shipping fever 
complex) associated with Pasteurella spp.; bacterial pneumonia 
associated with Pasteurell spp.; necrotic pododermatitis (foot rot) and 
calf diphtheria caused by Fusobacterium necrophorum; colibacillosis 
(bacterial scours) caused by Escherichia coli; coccidiosis caused by 
Eimeria bovis and E. zurnii; acute mastitis and metritis caused by 
Streptococcus spp.
    (iii) Limitations. For use in beef cattle and nonlactating dairy 
cattle only; if symptoms persist for 2 or 3 days after use, consult a 
veterinarian; do not slaughter animals for food for at least 8 days 
after the last dose; do not use in lactating dairy cattle; do not 
administer more than two consecutive doses.
    (g) Related tolerances. See Sec. 556.670 of this chapter.
    (h)(1) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter 
for use of an 8.25-gram sulfamethazine sustained-release bolus.
    (2) Conditions of use--(i) Amount. Administer at the rate of 1 bolus 
(8.25 grams per bolus) per 50 pounds of body weight, as a single dose. 
If signs of disease are significantly reduced, it is recommended that a 
second dose be given to provide an additional 72 hours of therapy.
    (ii) Indications for use. Administer orally to ruminating beef and 
dairy calves for treatment of the following diseases when caused by one 
or more of the listed pathogenic organisms susceptible to 
sulfamethazine: bacterial pneumonia associated with Pasteurella

[[Page 222]]

spp.; colibacillosis (bacterial scours) caused by Escherichia coli; 
coccidiosis caused by Eimeria bovis and E. zurnii; and calf diphtheria 
caused by Fusobacterium necrophorum.
    (iii) Limitations. Do not use in calves to be slaughtered under 1 
month of age or calves being fed an all milk diet. Do not use in female 
dairy cattle 20 months of age or older. If symptoms persist after 3 
days, consult a veterinarian. Do not administer more than 2 consecutive 
doses. Do not slaughter animals for food for at least 8 days after the 
last dose. Do not crush bolus.

[46 FR 36132, July 14, 1981, as amended at 48 FR 18803, Apr. 26, 1983; 
48 FR 32760, July 19, 1983; 49 FR 29057, July 18, 1984; 50 FR 49372, 
Dec. 2, 1985; 51 FR 30212, Aug. 25, 1986; 53 FR 40727, Oct. 18, 1988; 54 
FR 14341, Apr. 11, 1989; 55 FR 8462, Mar. 8, 1990; 56 FR 50653, Oct. 8, 
1991; 59 FR 22754, May 3, 1994; 61 FR 4875, Feb. 9, 1996; 62 FR 35076, 
June 30, 1997; 66 FR 14073, Mar. 9, 2001; 68 FR 4915, Jan. 31, 2003; 70 
FR 8290, Feb. 18, 2005; 78 FR 17596, Mar. 22, 2013]



Sec. 520.2260c  Sulfamethazine sustained-release tablets.

    (a) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter for 
use of an 8-gram sulfamethazine sustained-release tablet.
    (b) Conditions of use--(1) Amount. 8 grams (1 tablet) per 45 pounds 
of body weight as a single dose.
    (2) Indications for use. In calves for sustained treatment of 
pneumonia caused by Pasteurella spp., colibacillosis (bacterial scours) 
caused by Escherichia coli; and calf diptheria caused by Fusobacterium 
necrophorum.
    (3) Limitations. If there is no response within 2 to 3 days, 
reevaluate therapy. Do not crush tablets. Treated animals must not be 
slaughtered for food within 18 days after the latest treatment. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.

[48 FR 26763, June 10, 1983, as amended at 56 FR 50653, Oct. 8, 1991; 59 
FR 22754, May 3, 1994; 61 FR 4875, Feb. 9, 1996]



Sec. 520.2261  Sulfamethazine sodium oral dosage forms.



Sec. 520.2261a  Sulfamethazine solution.

    (a) Sponsors. See Nos. 000010 and 061623 in Sec. 510.600(c) of this 
chapter for use of a 12.5-percent sulfamethazine sodium solution.
    (b) Related tolerances in edible products. See Sec. 556.670 of this 
chapter.
    (c) Conditions of use--(1) Amount. Administer in drinking water to 
provide: Cattle and swine 112.5 milligrams of sulfamethazine sodium per 
pound of body weight per day on the first day and 56.25 milligrams per 
pound of body weight on subsequent days; Chickens, 61 to 89 milligrams 
of sulfamethazine sodium per pound of body weight per day, and turkeys 
53 to 130 milligrams of sulfamethazine sodium per pound of body weight 
per day, depending upon the dosage, age, and class of chickens or 
turkeys, ambient temperature, and other factors.
    (2) Indications for use. For treatment and control of diseases 
caused by organisms sensitive to sulfamethazine.
    (i) Beef and nonlactating dairy cattle. Treatment of bacterial 
pneumonia and bovine respiratory disease complex (shipping fever 
complex) (Pasteurella spp.), colibacillosis (bacterial scours) 
(Escherichia coli), necrotic pododermatitis (foot rot) (Fusobacterium 
necrophorum), calf diphtheria (Fusobacterium necrophorum), acute 
mastitis (Streptococcus spp.), and acute metritis (Streptococcus spp.).
    (ii) Swine. Treatment of porcine colibacillosis (bacterial scours) 
(Escherichia coli), and bacterial pneumonia (Pasteurella spp.).
    (iii) Chickens and turkeys. In chickens for control of infectious 
coryza (Avibacterium paragallinarum), coccidiosis (Eimeria tenella, 
Eimeria necatrix), acute fowl cholera (Pasteurella multocida), and 
pullorum disease (Salmonella pullorum). In turkeys for control of 
coccidiosis (Eimeria meleagrimitis, Eimeria adenoeides). Medicate as 
follows: Infectious coryza in chickens, medicate for 2 consecutive days; 
acute fowl cholera and pullorum disease, in chickens, medicate for 6 
consecutive days; coccidiosis, in chickens and turkeys, medicate as in 
paragraph (c) of this section, then reduce amount of medication to one-
half for 4 additional days.
    (3) Limitations. Add the required dose to that amount of water that 
will be consumed in 1 day. Consumption should be carefully checked. Have 
only

[[Page 223]]

medicated water available during treatment. Withdraw medication from 
cattle, chickens, and turkeys 10 days prior to slaughter for food. 
Withdraw medication from swine 15 days before slaughter for food. Do not 
medicate chickens or turkeys producing eggs for human consumption. 
Treatment of all diseases should be instituted early. Treatment should 
continue 24 to 48 hours beyond the remission of disease symptoms, but 
not to exceed a total of 5 consecutive days in cattle or swine. 
Medicated cattle, swine, chickens, and turkeys must actually consume 
enough medicated water which provides the recommended dosages. Do not 
use in female dairy cattle 20 months of age or older. Use of 
sulfamethazine in this class of cattle may cause milk residues. A 
withdrawal period has not been established in preruminating calves. Do 
not use in calves to be processed for veal.
    (d) NAS/NRC status. The conditions of use specified in this section 
have been reviewed by NAS/NRC and are found effective. Applications for 
these uses need not include effectiveness data as specified by Sec. 
514.111 of this chapter, but may require bioequivalency and safety 
information.

[47 FR 25322, June 11, 1982, as amended at 47 FR 25735, June 15, 1982; 
67 FR 78355, Dec. 24, 2002; 70 FR 32489, June 3, 2005; 74 FR 36112, July 
22, 2009; 75 FR 10166, Mar. 5, 2010; 76 FR 17337, Mar. 29, 2011]



Sec. 520.2261b  Sulfamethazine powder.

    (a) Specifications. A soluble powder composed of 100 percent 
sulfamethazine sodium.
    (b) Sponsors. See Nos. 000010 and 061623 in Sec. 510.600(c) of this 
chapter.
    (c) Related tolerances. See Sec. 556.670 of this chapter.
    (d) Conditions of use--(1) Chickens--(i) Amount. Administer in 
drinking water to provide 58 to 85 milligrams (mg) per pound (/lb) of 
body weight per day.
    (ii) Indications for use. For control of infectious coryza 
(Haemophilus gallinarum), coccidiosis (Eimeria tenella, E. necatrix), 
acute fowl cholera (Pasteurella multocida), and pullorum disease 
(Salmonella pullorum).
    (iii) Limitations. Add the required dose to that amount of water 
that will be consumed in 1 day. Consumption should be carefully checked. 
Have only medicated water available during treatment. Withdraw 
medication 10 days prior to slaughter for food. Do not medicate chickens 
producing eggs for human consumption. Treatment of all diseases should 
be instituted early. Treatment should continue 24 to 48 hours beyond the 
remission of disease symptoms. Medicated chickens must actually consume 
enough medicated water which provides the recommended dosages.
    (2) Turkeys--(i) Amount. Administer in drinking water to provide 50 
to 124 mg/lb of body weight per day
    (ii) Indications for use. For control of coccidiosis (E. 
meleagrimitis, E. adenoeides).
    (iii) Limitations. Add the required dose to that amount of water 
that will be consumed in 1 day. Consumption should be carefully checked. 
Have only medicated water available during treatment. Withdraw 
medication 10 days prior to slaughter for food. Do not medicate turkeys 
producing eggs for human consumption. Treatment of all diseases should 
be instituted early. Treatment should continue 24 to 48 hours beyond the 
remission of disease symptoms. Medicated turkeys must actually consume 
enough medicated water which provides the recommended dosages.
    (3) Swine--(i) Amount. Administer in drinking water, or as a drench, 
to provide 108 mg/lb of body weight on the first day and 54 mg/lb of 
body weight per day on the second, third, and fourth days of 
administration.
    (ii) Indications for use. For treatment of porcine colibacillosis 
(bacterial scours) (E. coli), and bacterial pneumonia (Pasteurella 
spp.).
    (iii) Limitations. Add the required dose to that amount of water 
that will be consumed in 1 day. Consumption should be carefully checked. 
Have only medicated water available during treatment. Withdraw 
medication 15 days prior to slaughter for food. Treatment of all 
diseases should be instituted early. Treatment should continue 24 to 48 
hours beyond the remission of disease symptoms, but not to exceed a 
total of 5 consecutive days.

[[Page 224]]

Medicated swine must actually consume enough medicated water which 
provides the recommended dosages.
    (4) Cattle--(i) Amount. Administer in drinking water, or as a 
drench, to provide 108 mg/lb of body weight on the first day and 54 mg/
lb of body weight per day on the second, third, and fourth days of 
administration.
    (ii) Indications for use in beef and nonlactating dairy cattle. 
Treatment of bacterial pneumonia and bovine respiratory disease complex 
(shipping fever complex) (Pasteurella spp.), colibacillosis (bacterial 
scours) (E. coli), necrotic pododermatitis (foot rot) (Fusobacterium 
necrophorum), calf diphtheria (F. necrophorum), acute mastitis 
(Streptococcus spp.), and acute metritis (Streptococcus spp.)
    (iii) Limitations. Add the required dose to that amount of water 
that will be consumed in 1 day. Consumption should be carefully checked. 
Have only medicated water available during treatment. Withdraw 
medication 10 days prior to slaughter for food. Treatment of all 
diseases should be instituted early. Treatment should continue 24 to 48 
hours beyond the remission of disease symptoms, but not to exceed a 
total of 5 consecutive days. Medicated cattle must actually consume 
enough medicated water which provides the recommended dosages.

[71 FR 70303, Dec. 4, 2006, as amended at 75 FR 10166, Mar. 5, 2010]



Sec. 520.2280  Sulfamethizole and methenamine mandelate tablets.

    (a) Specifications. Each tablet contains 250 milligrams of 
sulfamethizole and 250 milligrams of methenamine mandelate.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is indicated for the treatment 
of urinary tract infections in dogs and cats such as cystitis, 
nephritis, prostatitis, urethritis, and pyelonephritis. It is also used 
as an aid in the management of complications resulting from surgical 
manipulations of the urinary tract such as removal of calculi from the 
bladder, in ureterostomies, and in instrumentation of the urethra and 
bladder.
    (2) It is administered at a dosage level of one tablet for each 20 
pounds of body weight given three times per day. The drug should be 
given until all signs are alleviated. To reduce the possibility of a 
relapse, it is suggested that therapy be continued for a further period 
of a week to 10 days.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 50 FR 13561, Apr. 5, 1985]



Sec. 520.2325  Sulfaquinoxaline oral dosage forms.



Sec. 520.2325a  Sulfaquinoxaline drinking water.

    (a) Sponsor. See Sec. 510.600(c) of this chapter for identification 
of the sponsors.
    (1) To No. 000859 for use of a 25-percent sulfaquinoxaline soluble 
powder and a 20-percent sulfaquinoxaline sodium solution as provided for 
in paragraph (c) of this section.
    (2) To No. 061623 for use of 3.44- and 12.85-percent 
sulfaquinoxaline sodium solutions as provided for in paragraphs (c)(1), 
(c)(2), (c)(3), (c)(4)(i), and (c)(4)(ii) of this section.
    (3) To No. 046573 for use of a 31.92-percent sulfaquinoxaline 
solution (sodium and potassium salts) as provided for in paragraphs 
(c)(1), (c)(2), (c)(3), (c)(4)(i), and (c)(4)(ii) of this section.
    (4) No. 053501 for use of a 28.62-percent sulfaquinoxaline sodium 
solution as provided in paragraphs (c)(1), (c)(2), and (c)(3) of this 
section.
    (b) Related tolerances. See Sec. 556.685 of this chapter.
    (c) Conditions of use. It is used in drinking water as follows:
    (1) Chickens. (i) As an aid in the control of outbreaks of 
coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. 
maxima, and E. brunetti.
    (ii) Administer at the 0.04 percent level for 2 or 3 days, skip 3 
days then administer at the 0.025 percent level for 2 more days. If 
bloody droppings appear, repeat treatment at the 0.025 percent level for 
2 more days. Do not change litter unless absolutely necessary. Do not 
give flushing mashes.
    (2) Turkeys. (i) As an aid in the control of outbreaks of 
coccidiosis caused

[[Page 225]]

by Eimeria meleagrimitis and E. adenoeides.
    (ii) Administer at the 0.025 percent level for 2 days, skip 3 days, 
give for 2 days, skip 3 days and give for 2 more days. Repeat if 
necessary. Do not change litter unless absolutely necessary. Do not give 
flushing mashes.
    (3) Chickens and turkeys. (i) As an aid in the control of acute fowl 
cholera caused by Pasteurella multocida susceptible to sulfaquinoxaline 
and fowl typhoid caused by Salmonella gallinarum susceptible to 
sulfaquinoxaline.
    (ii) Administer at the 0.04 percent level for 2 or 3 days. Move 
birds to clean ground. If disease recurs, repeat treatment. If cholera 
has become established as the respiratory or chronic form, use feed 
medicated with sulfaquinoxaline. Poultry which have survived typhoid 
outbreaks should not be kept for laying house replacements or breeders 
unless tests show they are not carriers.
    (4) Cattle and calves. (i) For the control and treatment of 
outbreaks of coccidiosis caused by Eimeria bovis or E. zurnii.
    (ii) Administer at the 0.015-percent level for 3 to 5 days in 
drinking water medicated with sulfaquinoxaline solution.
    (iii) In lieu of treatment as provided in paragraph (e)(4)(ii) of 
this section, administer 1 teaspoon of 25-percent sulfaquinoxaline 
soluble powder per day for each 125 pounds of body weight for 3 to 5 
days in drinking water.
    (d) Limitations. Consult a veterinarian or poultry pathologist for 
diagnosis. May cause toxic reactions unless the drug is evenly mixed in 
water at dosages indicated and used according to directions. For control 
of outbreaks of disease, medication should be initiated as soon as the 
diagnosis is determined. Medicated chickens, turkeys, cattle, and calves 
must actually consume enough medicated water which provides a 
recommended dosage of approximately 10 to 45 milligrams per pound per 
day in chickens, 3.5 to 55 milligrams per pound per day in turkeys, and 
approximately 6 milligrams per pound per day in cattle and calves 
depending on the age, class of animal, ambient temperature, and other 
factors. A withdrawal period has not been established for 
sulfaquinoxaline in preruminating calves. Do not use in calves to be 
processed for veal. Not for use in lactating dairy cattle. Do not give 
to chickens, turkeys or cattle within 10 days of slaughter for food. Do 
not medicate chickens or turkeys producing eggs for human consumption. 
Make fresh drinking water daily.

[48 FR 3964, Jan. 28, 1983, as amended at 48 FR 26762, June 10, 1983; 55 
FR 29843, July 23, 1990; 59 FR 28769, June 3, 1994; 59 FR 33197, June 
28, 1994; 61 FR 24443, May 15, 1996; 61 FR 63711, Dec. 2, 1996; 62 FR 
37712, July 15, 1997; 65 FR 10705, Feb. 29, 2000; 69 FR 41427, July 9, 
2004; 69 FR 60547, Oct. 12, 2004; 74 FR 36112, July 22, 2009; 78 FR 
17596, Mar. 22, 2013]



Sec. 520.2325b  Sulfaquinoxaline drench.

    (a)-(b) [Reserved]
    (c) Sponsor. See No. 050749 in Sec. 510.600(c) of this chapter.
    (d) NAS/NRC status. The conditions of use specified in this section 
have been reviewed by NAS/NRC and are found effective. Applications for 
these uses need not include effectiveness data as specified by Sec. 
514.111 of this chapter, but may require bioequivalency information. 
Applications must be accompanied by a written commitment to undertake 
the human safety studies required by FDA.
    (e) Conditions of uses. As a 25-percent sulfaquinoxaline soluble 
powder.
    (1) For the control and treatment of outbreaks of coccidiosis in 
cattle and calves caused by Eimeria bovis or E. zurnii.
    (2) Give one teaspoon of 25 percent sulfaquinoxaline soluble powder 
for each 125 pounds of body weight for 3 to 5 days as a drench.
    (f) Limitations. For control of outbreaks of disease, medication 
should be initiated as soon as the diagnosis is determined. Consult a 
veterinarian for diagnosis. Do not give to cattle within 10 days of 
slaughter for food. Not for use in lactating dairy cattle.

[48 FR 3964, Jan. 28, 1983, as amended at 55 FR 29843, July 23, 1990; 59 
FR 33197, June 28, 1994]



Sec. 520.2330  Sulfisoxazole tablets.

    (a) Specifications. Each tablet contains 260 milligrams (4 grains) 
of sulfisoxazole.

[[Page 226]]

    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. Administer one tablet orally per 
4 pounds of body weight. \1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (2) Indications for use. Use in dogs and cats as an aid in treatment 
of bacterial pneumonia and bacterial enteritis when caused by organisms 
sensitive to sulfisoxazole. \1\
    (3) Limitations. Repeat dosage at 24-hour intervals until 2 to 3 
days after disappearance of clinical symptoms. (Administration of one-
half daily dosage at 12-hour intervals or one-third daily dosage at 8-
hour intervals will provide a more constant blood level.) Provide 
adequate supply of drinking water. If symptoms persist after using this 
preparation for 2 or 3 days, consult a veterinarian. \1\

[43 FR 60895, Dec. 29, 1978]



Sec. 520.2340  Tepoxalin.

    (a) Specifications. Each tablet contains 30, 50, 100, or 200 
milligrams (mg) tepoxalin.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. 10 mg per kilogram (/kg) 
daily; or 20 mg/kg on the initial day of treatment, followed by 10 mg/kg 
daily.
    (2) Indications for use. For the control of pain and inflammation 
associated with osteoarthritis.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[68 FR 34795, June 11, 2003]



Sec. 520.2345  Tetracycline.



Sec. 520.2345a  Tetracycline hydrochloride capsules.

    (a) Specifications. Each capsule contains 50, 100, 125, 250, or 500 
milligrams (mg) tetracycline hydrochloride.
    (b) Sponsor. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (c) of this section:
    (1) No. 000009: 250 mg per capsule.
    (2) No. 000069: 125, 250, or 500 mg per capsule.
    (c) Conditions of use in dogs--(1) Amount. 25 mg per pound of body 
weight per day in divided doses every 6 hours.
    (2) Indications for use. For treatment of infections caused by 
organisms sensitive to tetracycline hydrochloride, such as bacterial 
gastroenteritis due to E. coli and urinary tract infections due to 
Staphylococcus spp. and E. coli.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[70 FR 50182, Aug. 26, 2005, as amended at 73 FR 18442, Apr. 4, 2008]



Sec. 520.2345b  Tetracycline tablets.

    (a) Specifications. Each tablet contains 100, 250, or 500 milligrams 
of tetracycline (as the hydrochloride).
    (b) Sponsor. For 100, 250, or 500 milligrams per tablet, see No. 
000069 in Sec. 510.600(c) of this chapter. For 250 milligrams per 
tablet, see No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. Dogs--(1) Amount. 25 milligrams per pound of 
body weight per day in divided doses every 6 hours.
    (2) Indications for use. Treatment of infections caused by organisms 
sensitive to tetracycline hydrochloride, such as bacterial 
gastroenteritis due to E. coli and urinary tract infections due to 
Staphylococcus spp. and E. coli.
    (3) Limitations. Administer orally; continue treatment until 
symptoms of the disease have subsided and temperature is normal for 48 
hours; not for use in animals raised for food production; Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.

[57 FR 37327, Aug. 18, 1992]



Sec. 520.2345c  Tetracycline boluses.

    (a) Specifications. Each bolus contains 500 milligrams of 
tetracycline (as the hydrochloride).
    (b) Sponsors. See No. 053501 in Sec. 510.600(c) of this chapter for 
use as in paragraph (d)(1) of this section. See No. 000009 in Sec. 
510.600(c) of this chapter for use as in paragraph (d)(2) of this 
section.

[[Page 227]]

    (c) Related tolerances. See Sec. 556.720 of this chapter.
    (d) Conditions of use. Calves--(1) Amount. 10 milligrams per pound 
of body weight per day in divided doses.
    (i) Indications for use. Control and treatment of bacterial 
enteritis (scours) caused by E. coli and bacterial pneumonia caused by 
Pasteurella spp., Hemophilus spp., and Klebsiella spp.
    (ii) Limitations. Administer orally for 3 to 5 days; do not 
slaughter animals for food within 14 days of treatment; use as sole 
source of tetracycline.
    (iii) National Academy of Sciences/National Research Council (NAS/
NRC) status. The conditions of use specified in paragraph (d)(1)(i) of 
this section were NAS/NRC reviewed and found effective. Applications for 
these uses need not include effectiveness data as specified in Sec. 
514.111 of this chapter, but may require bioequivalency and safety 
information.
    (2) Amount. 10 milligrams per pound of body weight per day in two 
divided doses.
    (i) Indications for use. Treatment of bacterial pneumonia caused by 
organisms susceptible to tetracycline, bacterial enteritis caused by E. 
coli, and salmonella organisms susceptible to tetracycline.
    (ii) Limitations. Administer orally for not more than 5 days; do not 
slaughter animals for food within 12 days of treatment; use as sole 
source of tetracycline.

[57 FR 37328, Aug. 18, 1992, as amended at 67 FR 78355, Dec. 24, 2002]



Sec. 520.2345d  Tetracycline powder.

    (a) Specifications. Each pound of powder contains 25, 102.4, or 324 
grams tetracycline hydrochloride.
    (b) Sponsors. See sponsors listed in Sec. 510.600(c) of this 
chapter for conditions of use as in paragraph (d) of this section:
    (1) No. 000069: 25 grams per pound as in paragraphs (d)(3) and 
(d)(4) of this section.
    (2) No. 000010: 25, 102.4, and 324 grams per pound as in paragraph 
(d) of this section.
    (3) No. 046573: 25, 102.4, and 324 grams per pound as in paragraph 
(d) of this section.
    (4) Nos. 054925, 057561, 061623, and 076475: 324 grams per pound as 
in paragraph (d) of this section.
    (c) Related tolerances. See Sec. 556.720 of this chapter.
    (d) Conditions of use. It is administered in drinking water as 
follows:
    (1) Calves--(i) Amount. 10 milligrams per pound of body weight per 
day in divided doses.
    (ii) Indications for use. Control and treatment of bacterial 
enteritis (scours) caused by Escherichia coli and bacterial pneumonia 
(shipping fever complex) associated with Pasteurella spp., 
Actinobacillus pleuropneumoniae (Hemophilus spp.), and Klebsiella spp., 
susceptible to tetracycline.
    (iii) Limitations. Administer for 3 to 5 days; do not slaughter 
animals for food within 4 days of treatment for No. 000010 and within 5 
days of treatment for Nos. 046573, 054925, 057561, 059130, and 061623; 
prepare a fresh solution daily; use as the sole source of tetracycline. 
A withdrawal period has not been established for this product in 
preruminating calves. Do not use in calves to be processed for veal.
    (2) Swine--(i) Amount. 10 milligrams per pound of body weight per 
day in divided doses.
    (ii) Indications for use. Control and treatment of bacterial 
enteritis (scours) caused by E. coli and bacterial pneumonia associated 
with Pasteurella spp., A. pleuropneumoniae (Hemophilus spp.), and 
Klebsiella spp., susceptible to tetracycline.
    (iii) Limitations. Administer for 3 to 5 days; do not slaughter 
animals for food within 7 days of treatment for No. 000010 and within 4 
days of treatment for Nos. 046573, 054925, 057561, 059130, and 061623; 
prepare a fresh solution daily; use as the sole source of tetracycline.
    (3) Chickens--(i) Amount. Chronic respiratory disease: 400 to 800 
milligrams per gallon. Infectious synovitis: 200 to 400 milligrams per 
gallon.
    (ii) Indications for use. Control of chronic respiratory disease 
(CRD or air-sac disease) caused by Mycoplasma gallisepticum and E. coli; 
control of infectious synovitis caused by M. synoviae susceptible to 
tetracycline.
    (iii) Limitations. Administer for 7 to 14 days; do not slaughter for 
food within 4 days of treatment; not for use in

[[Page 228]]

chickens producing eggs for human consumption; prepare a fresh solution 
daily; use as the sole source of tetracycline.
    (4) Turkeys--(i) Amount. For infectious synovitis: 400 milligrams 
per gallon. For complicating bacterial organisms associated with 
bluecomb (transmissible enteritis or coronaviral enteritis): 25 
milligrams per pound of body weight per day.
    (ii) Indications for use. Control of infectious synovitis caused by 
M. synoviae; control of bluecomb complicated by organisms sensitive to 
tetracycline.
    (iii) Limitations. Administer for 7 to 14 days; do not slaughter for 
food within 4 days of treatment; not for use in turkeys producing eggs 
for human consumption; prepare a fresh solution daily; use as the sole 
source of tetracycline.

[59 FR 17693, Apr. 14, 1994, as amended at 59 FR 19133, Apr. 22, 1994; 
62 FR 5319, Feb. 5, 1997; 62 FR 35076, June 30, 1997; 62 FR 46668, Sept. 
4, 1997; 62 FR 55160, Oct. 23, 1997; 64 FR 37673, July 13, 1999; 67 FR 
78355, Dec. 24, 2002; 70 FR 16934, Apr. 4, 2005; 70 FR 67353, Nov. 7, 
2005; 71 FR 13542, Mar. 16, 2006; 75 FR 10166, Mar. 5, 2010; 75 FR 
12981, Mar. 18, 2010; 76 FR 17338, Mar. 29, 2011; 77 FR 20988, Apr. 9, 
2012]



Sec. 520.2345e  Tetracycline oral liquid.

    (a) Specifications. Each milliliter contains the equivalent of 
either 25 or 100 milligrams of tetracycline hydrochloride.
    (b) Sponsor. See No. 000069, in Sec. 510.600(c) of this chapter for 
use of 25 or 100 milligrams per milliliter liquid in dogs as in 
paragraph (c)(1) of this section; see No. 000009 in Sec. 510.600(c) of 
this chapter for use of 100 milligrams per milliliter liquid in dogs and 
cats as in paragraph (c)(2).
    (c) Conditions of use--(1) Dogs--(i) Amount. 25 milligrams per pound 
of body weight per day in divided doses every 6 hours.
    (ii) Indications for use. Treatment of infections caused by 
organisms sensitive to tetracycline hydrochloride, such as bacterial 
gastroenteritis due to Escherichia coli and urinary tract infections due 
to Staphylococcus spp. and E. coli.
    (iii) Limitations. Administer orally; continue treatment until 
symptoms have subsided and the temperature is normal for 48 hours; not 
for use in animals which are raised for food production; Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.
    (iv) National Academy of Sciences/National Research Council (NAS/
NRC) status. These conditions were NAS/NRC reviewed and found effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
    (2) Dogs and cats--(i) Amount. 25 milligrams per pound of body 
weight per day in divided doses every 6 hours.
    (ii) Indications for use. Treatment of infections caused by 
organisms susceptible to tetracycline hydrochloride, such as bacterial 
gastroenteritis due to E. coli and urinary tract infections due to 
Staphylococcus spp. and E. coli.
    (iii) Limitations. Administer orally; continue treatment until the 
temperature has been normal for 48 hours; not for use in food-producing 
animals; Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[57 FR 37329, Aug. 18, 1992]



Sec. 520.2345f  Tetracycline phosphate complex and sodium novobiocin 
capsules.

    (a) Specifications. Each capsule contains the equivalent of 60 
milligrams of tetracycline hydrochloride and 60 milligrams of 
novobiocin.
    (b) Sponsor. No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. Dogs--(1) Amount. 10 milligrams of each 
antibiotic per pound of body weight (1 capsule for each 6 pounds) every 
12 hours.
    (2) Indications for use. Treatment of acute or chronic canine 
respiratory infections such as tonsillitis, bronchitis, and 
tracheobronchitis when caused by pathogens susceptible to tetracycline 
and/or novobiocin, such as Staphylococcus spp. and Escherichia coli.
    (3) Limitations. Continue treatment for at least 48 hours after the 
temperature has returned to normal and all evidence of infection has 
disappeared. As with all antibiotics, appropriate in vitro culturing and 
susceptibility tests of samples taken before treatment

[[Page 229]]

should be conducted. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[57 FR 37329, Aug. 18, 1992]



Sec. 520.2345g  Tetracycline hydrochloride and sodium novobiocin 
tablets.

    (a) Specifications. Each tablet contains the equivalent of 60 
milligrams of tetracycline hydrochloride and 60 milligrams of 
novobiocin, or 180 milligrams of tetracycline hydrochloride and 180 
milligrams of novobiocin.
    (b) Sponsor. No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. Dogs--(1) Amount. 10 milligrams of each 
antibiotic per pound of body weight (one single-strength tablet for each 
6 pounds or one triple-strength tablet for each 18 pounds).
    (2) Indications for use. Treatment of acute or chronic canine 
respiratory infections such as tonsillitis, bronchitis, and 
tracheobronchitis when caused by pathogens susceptible to tetracycline 
and/or novobiocin, such as Staphylococcus spp. and Escherichia coli.
    (3) Limitations. Continue treatment for at least 48 hours after the 
temperature has returned to normal and all evidence of infection has 
disappeared. As with all antibiotics, appropriate in vitro culturing and 
susceptibility tests of samples taken before treatment should be 
conducted. Federal law restricts this drug to use by or on the order of 
a licensed veterinarian.

[57 FR 37329, Aug. 18, 1992]



Sec. 520.2345h  Tetracycline hydrochloride, sodium novobiocin, and 
prednisolone tablets.

    (a) Specifications. Each tablet contains the equivalent of 60 
milligrams of tetracycline hydrochloride, 60 milligrams of novobiocin, 
and 1.5 milligrams of prednisolone or 180 milligrams of tetracycline 
hydrochloride, 180 milligrams of novobiocin, and 4.5 milligrams of 
prednisolone.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. Dogs--(1) Amount. 10 milligrams of each 
antibiotic and 0.25 milligram of prednisolone per pound of body weight 
(one single-strength tablet for each 6 pounds or one triple-strength 
tablet for each 18 pounds) every 12 hours for 48 hours. Treatment is to 
be continued with novobiocin and tetracycline alone at the same dose 
schedule for an additional 3 days or longer as needed.
    (2) Indications for use. Treatment of acute and chronic canine 
respiratory infections such as tonsillitis, bronchitis, and 
tracheobronchitis when caused by pathogens susceptible to tetracycline 
and/or novobiocin, such as Staphylococcus spp. and Escherichia coli, 
when it is necessary to initially reduce the severity of associated 
clinical signs.
    (3) Limitations. As with all antibiotics, appropriate in vitro 
culturing and susceptibility tests of samples taken before treatment 
should be conducted. Administer for 48 hours only. Continue treatment if 
needed with tetracycline/novobiocin alone. The product is 
contraindicated in animals with tuberculosis, hyperadrenocorticalism, or 
peptic ulcers. Clinical and experimental data have demonstrated that 
corticosteroids administered orally or parenterally to animals may 
induce the first stage of parturition when administered during the last 
trimester of pregnancy and may precipitate premature parturition 
followed by dystocia, fetal death, retained placenta, and metritis. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.

[57 FR 37329, Aug. 18, 1992]



Sec. 520.2362  Thenium closylate tablets.

    (a) Chemical name. (N,N-Dimethyl-N-2-phenoxyethyl-N-2'-thenylammo-
nium)-p-chlorobenzene-sulfonate.
    (b) Specifications. Thenium closylate tablets contain thenium 
closylate equivalent to 500 milligrams thenium as base in each tablet.
    (c) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) The tablets are administered orally to 
dogs as a single day treatment of canine ancylostomiasis by the removal 
from the intestines of the adult forms of the species Ancylostoma 
caninum and Uncinaria stenocephala (hookworms). Dogs weighing 10 pounds 
and over are administered 1 tablet as a single dose. Dogs

[[Page 230]]

weighing 5 to 10 pounds are administered one-half tablet twice during a 
single day. All dosages are given for 1 day only. The treatment should 
be repeated after 2 or 3 weeks.
    (2) Suckling puppies or recently weaned puppies weighing less than 5 
pounds should not be treated with the drug. Animals that are severely 
infected, exhibiting evidence of intestinal hemorrhage, debilitation, 
and anemia, should be given supportive treatment.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 41 FR 53477, Dec. 7, 1976; 46 
FR 48642, Oct. 2, 1981; 61 FR 8873, Mar. 6, 1996; 62 FR 61625, Nov. 19, 
1997]



Sec. 520.2380  Thiabendazole oral dosage forms.



Sec. 520.2380a  Thiabendazole top dressing and mineral protein block.

    (a) Chemical name. 2-(4-Thiazolyl)-benzimidazole.
    (b) Specifications. Conforms to N.F. XII.
    (c) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (e) of this section.
    (1) No. 051311 for use as in paragraph (e)(1)(i) of this section.
    (2) No. 050604 for use as in paragraph (e)(1)(ii) of this section.
    (3) No. 012286 for use as in paragraph (e)(2) of this section.
    (d) Related tolerances. See Sec. 556.730 of this chapter.
    (e) Conditions of use. It is used as follows:
    (1) Horses--(i) Route of administration. In feed, as a top dressing.
    (a) Amount. 2 grams per 100 pounds of body weight.
    (b) Indications for use. For control of large strongyles, small 
strongyles, pinworms, and threadworms (including members of the genera 
Strongylus, Cyathostomum, Cylicobrachytus, and related genera, 
Craterostomum, Oesophagodontus, Poteriostomum, Oxyuris, and 
Strongyloides).
    (c) Limitations. Add to the usual feed of horses mixed into that 
amount of the feed normally consumed at one feeding. Warning: Not for 
use in horses intended for food.
    (ii) Route of administration. In feed.
    (a) Amount. 2 grams per 100 pounds of body weight.
    (1) Indications for use. For control of large and small strongyles, 
Strongyloides, and pinworms of the genera Strongylus, Cyathostomum, 
Cylicobrachytus and related genera, Craterostomum, Oesophagodontus, 
Poteriostomum, Oxyuris, and Strongyloides.
    (2) Limitations. Administer in a single dosage mixed with the normal 
grain ration given at one feeding. Warning: Not for use in horses 
intended for food.
    (b) Amount. 4 grams per 100 pounds of body weight.
    (1) Indications for use. For control of ascarids of the genus 
Parascaris.
    (2) Limitations. Administer in a single dosage mixed with the normal 
grain ration given at one feeding. Warning: Not for use in horses 
intended for food.
    (2) Cattle--(i) Route of administration. In feed block.
    (ii) Amount. 3.3 percent block consumed at the recommended level of 
0.11 pound per 100 pounds of body weight per day.
    (iii) Indications for use. For control of infections of 
gastrointestinal roundworms (Trichostrongylus, Haemonchus, Ostertagia 
and Cooperia).
    (iv) Limitations. Administer to cattle on pasture or range 
accustomed to mineral protein block feeding for 3 days. Milk taken from 
animals during treatment and within 96 hours (8 milkings) after the 
latest treatment must not be used for food. Do not treat cattle within 3 
days of slaughter. For a satisfactory diagnosis, a microscopic fecal 
examination should be performed by a veterinarian or diagnostic 
laboratory prior to worming. Animals maintained under conditions of 
constant worm exposure may require re-treatment within 2 to 3 weeks. 
Animals that are severely parasitized, sick, or off feed should be 
isolated and a veterinarian consulted for advice concerning treatment.

[40 FR 13838, Mar. 27, 1975, as amended at 41 FR 9149, Mar. 3, 1976; 62 
FR 63271, Nov. 28, 1997; 70 FR 32489, June 3, 2005; 73 FR 35340, June 
23, 2008]

[[Page 231]]



Sec. 520.2380b  Thiabendazole drench or oral paste.

    (a) Chemical name. 2-(4-Thiazolyl) benzimidazole.
    (b) Specifications. Conforms to N.F. XII.
    (c) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter for 
the sponsor of the usages provided for by paragraph (e) of this section.
    (d) Related tolerances. See Sec. 556.730 of this chapter.
    (e) Conditions of use. It is used as follows:
    (1) Horses. As a single liquid oral dose, administered as a drench 
or by stomach tube; or as an oral paste.
    (i) Amount. 2 grams per 100 pounds of body weight.
    (a) Indications for use. For the control of infections of large 
strongyles (Strongylus vulgaris, Strongylus endentatus), small 
strongyles (Cyathastomum, Cylicobrachytus and related genera, 
Craterostomum, Oesophagodontus, Poteriostomum), pinworms (Oxyuris), and 
threadworms (Strongyloides).
    (b) Limitations. Not for use in horses to be slaughtered for food 
purposes. When administered by stomach tube, for use only by or on the 
order of a licensed veterinarian. When for use as a liquid oral drench 
or an oral paste, consult your veterinarian for assistance in the 
diagnosis, treatment, and control of parasitism.
    (ii) Amount. 4 grams per 100 pounds of body weight.
    (a) Indications for use. For control of infections of ascardis 
(Parascaris).
    (b) Limitations. Not for use in horses to be slaughtered for food 
purposes. When administered by stomach tube, use only by or on the order 
of a licensed veterinarian. When for use as a liquid oral drench or an 
oral paste, consult your veterinarian for assistance in the diagnosis, 
treatment, and control of parasitism.
    (2) Pigs. As an oral paste.
    (i) Amount. 200 milligrams for each 5 to 7 pounds of body weight per 
dose.
    (ii) Indications for use. For control of infections with 
Strongyloides ransomi. These infections are commonly found in 
Southeastern United States.
    (iii) Limitations. Administer to baby pigs (1 to 8 weeks of age). 
Treatment may be repeated in 5 to 7 days if necessary. Before treatment, 
obtain an accurate diagnosis from a veterinarian or diagnostic 
laboratory. Do not treat within 30 days of slaughter.
    (3) Cattle. Orally as a drench and in paste form using a dosing gun 
designed for the product.
    (i) Amount. 3 grams per 100 pounds of body weight.
    (a) Indications for use. Control of infections of gastrointestinal 
roundworms (Trichostrongylus spp., Haemonchus spp., Nematodirus spp., 
Ostertagia spp., and Oesophagostomum radiatum).
    (b) Limitations. For most effective results, severely parasitized 
animals or those constantly exposed to helminth infection should be re-
treated every 2 to 3 weeks. Milk taken from treated animals within 96 
hours (8 milkings) after the latest treatment must not be used for food. 
Do not treat cattle within 3 days of slaughter. For a satisfactory 
diagnosis, a microscopic fecal examination should be performed prior to 
worming.
    (ii) Amount. 5 grams per 100 pounds of body weight.
    (a) Indications for use. Control of infections of Cooperia spp. or 
severe infections of other species in paragraph (e)(3)(i)(a) of this 
section.
    (b) Limitations. For most effective results, severely parasitized 
animals or those constantly exposed to helminth infection should be re-
treated every 2 to 3 weeks. Milk taken from treated animals within 96 
hours (8 milkings) after the latest treatment must not be used for food. 
Do not treat cattle within 3 days of slaughter. For a satisfactory 
diagnosis, a microscopic fecal examination should be performed prior to 
worming.
    (4) Sheep and goats. Orally, as a drench.
    (i) Amount. 2 grams per 100 pounds of body weight.
    (ii) Indications for use. Control of infections of gastrointestinal 
roundworms in sheep and goats. (Trichostrongylus spp., Haemonchus spp., 
Ostertagia spp., Cooperia spp., Nematodirus spp., Bunostomum spp., 
Strongyloides spp., Chabertia spp., and Oesophagostomum spp. ); also 
active

[[Page 232]]

from 3 hours to 3 days following treatment against ova and larvae passed 
by sheep (good activity against Trichostrongylus colubriformis and axei, 
Ostertagia spp., Bunostomum spp., Nematodirus spp., and Strongyloides 
spp.; less effective against Haemonchus contortus and Oesophagostomum 
spp. ).
    (iii) Limitations. As a single oral dose; do not treat animals 
within 30 days of slaughter; milk taken from treated animals within 96 
hours (8 milkings) after the latest treatment must not be used for food; 
in severe infections in sheep, treatment should be repeated in 2 to 3 
weeks.
    (5) Goats. Orally, as a drench.
    (i) Amount. 3 grams per 100 pounds of body weight.
    (ii) Indications for use. Control of severe infections of 
gastrointestinal roundworms (Trichostrongylus spp., Haemonchus spp., 
Ostertagia spp., Cooperia spp., Nematodirus spp., Bunostomum spp., 
Strongyloides spp., Chabertia spp., and Oesophagostomum spp. ).
    (iii) Limitations. As a single oral dose; do not treat animals 
within 30 days of slaughter; milk taken from treated animals within 96 
hours (8 milkings) after the latest treatment must not be used for food; 
treatment should be repeated in 2 to 3 weeks.

[40 FR 13838, Mar. 27, 1975, as amended at 41 FR 9149, Mar. 3, 1976; 41 
FR 47424, Oct. 29, 1976; 62 FR 63271, Nov. 28, 1997]



Sec. 520.2380c  Thiabendazole bolus.

    (a) Chemical name. 2-(4-Thiazolyl) benzimidazole.
    (b) Specifications. Conforms to N.F. XII.
    (c) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (d) Related tolerances. See Sec. 556.730 of this chapter.
    (e) Conditions of use. It is used as follows:
    (1) Cattle. In a bolus.
    (i) Amount. 3 grams per 100 pounds of body weight.
    (a) Indications for use. Control of infections of gastrointestinal 
roundworms (general Trichostrongylus spp., Haemonchus spp., Nematodirus 
spp., Ostertagia spp., and Oesophagostomum radiatum).
    (b) Limitations. As a single oral dose; may repeat once in 2 to 3 
weeks; do not treat animals within 3 days of slaughter; milk taken from 
treated animals within 96 hours (8 milkings) after the latest treatment 
must not be used for food.
    (ii) Amount. 5 grams per 100 pounds of body weight.
    (a) Indications for use. Control of severe infections of 
gastrointestinal roundworms (genera Trichostrongylus spp., Haemonchus 
spp., Nematodirus spp., Ostertagia spp., and Oesophagostomum radiatum). 
Control of infections with Cooperia spp.
    (b) Limitations. As a single oral dose; as a drench or bolus; may 
repeat once in 2 to 3 weeks; do not treat animals within 3 days of 
slaughter; milk taken from treated animals within 96 hours (8 milkings) 
after the latest treatment must not be used for food.
    (2) Sheep and goats. In a bolus.
    (i) Amount. 2 grams per 100 pounds of body weight.
    (ii) Indications for use. Control of infections of gastrointestinal 
roundworms in sheep and goats (general Trichostrongylus spp., Haemonchus 
spp., Ostertagia spp., Cooperia spp., Nematodirus spp., Bunostomum spp., 
Strongyloides spp., Chabertia spp., and Oesophagostomum spp. ); also 
active from 3 hours to 3 days following treatment against ova and larvae 
passed by sheep (good activity against T. colubriformis and axei, 
Ostertagia spp., Bunostomum spp., Nematodirus spp., and Strongyloides 
spp.; less effective against Haemonchus contortus and Oesophagostomum 
spp. ).
    (iii) Limitations. As a single oral dose; do not treat animals 
within 30 days of slaughter; milk taken from treated animals within 96 
hours (8 milkings) after the latest treatment must not be used for food; 
in severe infections in sheep, treatment should be repeated in 2 to 3 
weeks.
    (3) Goats. In a bolus.
    (i) Amount. 3 grams per 100 pounds of body weight.
    (ii) Indications for use. Control of severe infections of 
gastrointestinal roundworms (genera Trichostrongylus spp., Haemonchus 
spp., Ostertagia spp., Cooperia spp., Nematodirus spp., Bunostomum spp., 
Strongyloides spp.,

[[Page 233]]

Chabertia spp., and Oesophagostomum spp. ).
    (iii) Limitations. As a single oral dose; do not treat animals 
within 30 days of slaughter; milk taken from treated animals within 96 
hours (8 milkings) after the latest treatment must not be used for food; 
treatment should be repeated in 2 to 3 weeks.

[40 FR 13838, Mar. 27, 1975, as amended at 41 FR 9149, Mar. 3, 1976; 62 
FR 63271, Nov. 28, 1997]



Sec. 520.2380d  Thiabendazole, piperazine citrate suspension.

    (a) Specifications. Each fluid ounce of suspension contains 2 grams 
of thiabendazole and 2.5 grams of piperazine (from piperazine citrate).
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is administered to horses by stomach 
tube or as a drench at the rate of 1 fluid ounce of suspension per 100 
pounds of body weight for the control of large strongyles, small 
strongyles, pinworms, Strongyloides and ascarids (including members of 
the genera Strongylus spp., Cyathostomum spp., Cylicobrachytus spp. and 
related genera Craterostomum spp., Oesophagodontus spp., Poteriostomum 
spp., Oxyuris spp., Strongyloides spp., and Parascaris spp. ).
    (2) Do not use in horses intended to be used for food purposes.
    (3) For use by or on the order of a licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 62 FR 63271, Nov. 28, 1997]



Sec. 520.2380e  Thiabendazole with trichlorfon.

    (a) Specifications. The drug contains 5 grams of thiabendazole with 
4.5 grams of trichlorfon, or 20 grams of thiabendazole with 18 grams of 
trichlorfon.
    (b) Sponsor. See No. 017135 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) Used for the treatment and control of 
bots (Gasterophilus spp. ), large strongyles (Strongylus spp. ), small 
strongyles (genera Cyathostomum, Cylicobrachytus, Craterostomum, 
Oesophagodontus, Poteriostomum), pinworms (Oxyuris spp., Strongyloides 
spp. ), and ascarids (Parascaris spp. ) in horses.
    (2) Administer 2 grams of thiabendazole with 1.8 grams of 
trichlorfon per 100 pounds of body weight sprinkled on the animals' 
usual daily ration of feed, or may be mixed in 5 to 10 fluid ounces of 
water and administered by stomach tube or drench.
    (3) Do not re-treat more than once every 30 days, preferably every 6 
to 8 weeks.
    (4) Do not treat animals if sick or debilitated; less than 4 months 
of age; or mares in last month of pregnancy.
    (5) Do not administer intravenous anesthetics, especially muscle 
relaxants, within 2 weeks of use.
    (6) Not for animals intended for food use.
    (7) Do not use within a few days before or after treatment with or 
exposure to cholinesterase-inhibiting drugs, pesticides, or chemicals.
    (8) If the label bears directions for administration of the drug by 
stomach tube or drench it shall also bear the statement: Caution; 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.

[40 FR 23071, May 28, 1975, as amended at 48 FR 48229, Oct. 18, 1983]



Sec. 520.2380f  Thiabendazole, piperazine phosphate powder.

    (a) Specifications. Each ounce of water dispersible powder contains 
6.67 grams of thiabendazole and 8.33 grams of piperazine (as piperazine 
phosphate).
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 2 grams of thiabendazole and 2.5 
grams of piperazine (0.3 ounce of powder) per 100 pounds of body weight.
    (2) Indications for use. Treatment of infections of large strongyles 
(genus Strongylus), small strongyles (genera Cyathostomum, 
Cylicobrachytus, and related genera Craterostomum, Oesophagodontus, 
Poteriostomum), pinworms (Oxyuris), threadworms (Strongyloides), and 
ascarids (Parascaris) in horses.
    (3) Limitations. Use a single oral dose. Administer as a drench or 
by stomach tube suspended in 1 pint of warm water; by dose syringe 
suspended in \1/2\ ounce of water for each 100 pounds of body weight; or 
sprinkled over a small amount of daily feed. Not for animals

[[Page 234]]

intended for food use. If the label bears directions for administration 
by stomach tube or drench, it shall also bear the statement ``Caution: 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian;'' if not labeled for use by stomach tube or drench, the 
label shall bear the statement, ``Consult your veterinarian for 
assistance in the diagonosis, treatment, and control of parasitism.''

[46 FR 18963, Mar. 27, 1981, as amended at 46 FR 52330, Oct. 27, 1981; 
62 FR 63271, Nov. 28, 1997]



Sec. 520.2455  Tiamulin.

    (a) Specifications. (1) Each gram of soluble powder contains 450 
milligrams (mg) tiamulin hydrogen fumarate.
    (2) Each milliliter (mL) of solution contains 125 mg (12.5 percent) 
tiamulin hydrogen fumarate.
    (3) Each mL of solution contains 123 mg (12.3 percent) tiamulin 
hydrogen fumarate.
    (b) Sponsors. See sponsor numbers in Sec. 510.600(c) of this 
chapter for use as in paragraph (d) of this section.
    (1) No. 058198 for products described in paragraphs (a)(1) and 
(a)(2) of this section.
    (2) No. 066104 for the product described in paragraph (a)(1) of this 
section.
    (3) No. 000859 for the product described in paragraph (a)(3) of this 
section.
    (c) Related tolerances. See Sec. 556.738 of this chapter.
    (d) Conditions of use in swine--(1) Amounts and indications for use. 
Administer in drinking water for 5 consecutive days:
    (i) 3.5 mg per (/) lb of body weight daily for treatment of swine 
dysentery associated with Brachyspira hyodysenteriae susceptible to 
tiamulin.
    (ii) 10.5 mg/lb of body weight daily for treatment of swine 
pneumonia due to Actinobacillus pleuropneumoniae susceptible to 
tiamulin.
    (2) Limitations. Use as only source of drinking water. Prepare fresh 
medicated water daily. Withdraw medication 3 days before slaughter 
following treatment at 3.5 mg/lb and 7 days before slaughter following 
treatment at 10.5 mg/lb of body weight. Swine being treated with 
tiamulin should not have access to feeds containing polyether ionophores 
(e.g., lasalocid, monensin, narasin, salinomycin, or semduramycin) as 
adverse reactions may occur. The effects of tiamulin on swine 
reproductive performance, pregnancy, and lactation have not been 
determined.

[70 FR 75017, Dec. 19, 2005, as amended at 74 FR 7180, Feb. 13, 2009; 75 
FR 54492, Sept. 8, 2010; 77 FR 56770, Sept. 14, 2012; 78 FR 17596, Mar. 
22, 2013]



Sec. 520.2473  Tioxidazole oral dosage forms.



Sec. 520.2473a  Tioxidazole granules.

    (a) Specifications. Each gram of granules contains 200 milligrams of 
tioxidazole.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Horses--(i) Amount. 5 milligrams per 
pound of body weight as a single dose.
    (ii) Indications for use. Removal of mature large strongyles 
(Strongylus edentatus, S. equinus, and S. vulgaris), mature ascarids 
(Parascaris equorum), mature and immature (4th larval stage) pinworms 
(Oxyuris equi), and mature small strongyles (Triodontophorus spp.).
    (iii) Limitations. For administration with feed: Sprinkle required 
amount of granules on a small amount of the usual grain ration and mix. 
Prepare for each horse individually. Withholding of feed or water not 
necessary. Not for use in horses intended for food. The reproductive 
safety of tioxidazole in breeding animals has not been determined. 
Consult your veterinarian for assistance in the diagnosis, treatment, 
and control of parasitism. It is recommended that this drug be 
administered with caution to sick or debilitated horses.
    (2) [Reserved]

[50 FR 52772, Dec. 26, 1985; 51 FR 2693, Jan. 21, 1986, as amended at 52 
FR 7832, Mar. 13, 1987]



Sec. 520.2473b  Tioxidazole paste.

    (a) Specifications. Each plastic syringe contains 6.25 grams of 
tioxidazole.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.

[[Page 235]]

    (c) Conditions of use--(1) Horses--(i) Amount. 5 milligrams of 
tioxidazole per pound of body weight as a single dose.
    (ii) Indications for use. Removal of mature large strongyles 
(Strongylus edentatus, S. equinus, and S. vulgaris), mature ascarids 
(Parascaris equorum), mature and immature (4th larval stage) pinworms 
(Oxyuris equi), and mature small strongyles (Triodontophorus spp.).
    (iii) Limitations. Administer orally by inserting the nozzle of the 
syringe through the space between front and back teeth and deposit the 
required dose on the base of the tongue. Before dosing, make sure the 
horse's mouth contains no feed. Not for use in horses intended for food. 
The reproductive safety of tioxidazole in breeding animals has not been 
determined. Consult your veterinarian for assistance in the diagnosis, 
treatment, and control of parasitism. It is recommended that this drug 
be administered with caution to sick or debilitated horses.
    (2) [Reserved]

[52 FR 43059, Nov. 9, 1987]



Sec. 520.2475  Toceranib.

    (a) Specifications. Each tablet contains 10, 15, or 50 milligrams 
(mg) toceranib as toceranib phosphate.
    (b) Sponsor. See No. 000009 in Sec. 510.600 of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. Administer an initial 
dose of 3.25 mg per kilogram (1.48 mg per pound) body weight, orally 
every other day.
    (ii) Indications for use. For the treatment of Patnaik grade II or 
III, recurrent, cutaneous mast cell tumors with or without regional 
lymph node involvement.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) [Reserved]

[74 FR 28875, June 18, 2009]



Sec. 520.2483  Triamcinolone.

    (a) Specifications.--(1) Each tablet contains 0.5 milligram (mg) or 
1.5 mg triamcinolone acetonide.
    (2) Each 15 grams of powder contains 10 mg triamcinolone acetonide.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. See Sec. 510.410 of this chapter.
    (d) Conditions of use--(1) Dogs and cats. Use tablets described in 
paragraph (a)(1) of this section as follows:
    (i) Amount. Administer 0.05 mg per pound (/lb) of body weight daily 
by mouth; up to 0.1 mg per pound (/lb) of body weight daily, if response 
to the smaller dose is inadequate. Therapy may be initiated with a 
single injection of triamcinolone acetonide suspension as in Sec. 
522.2483 of this chapter, in which case triamcinolone acetonide tablets 
should be administered beginning 5 to 7 days after the injection.
    (ii) Indications for use. As an anti-inflammatory agent.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Horses. Use oral powder described in paragraph (a)(2) of this 
section as follows:
    (i) Amount. Administer 0.005 to 0.01 mg/lb of body weight twice 
daily, sprinkled (top-dressed) on a small portion of feed. Therapy may 
be initiated with a single injection of triamcinolone acetonide 
suspension as in Sec. 522.2483 of this chapter, in which case 
triamcinolone acetonide oral powder should be administered beginning 3 
or 4 days after the injection.
    (ii) Indications for use. As an anti-inflammatory agent.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian. Do not use in horses intended for 
human consumption.

[75 FR 10166, Mar. 5, 2010]



Sec. 520.2520  Trichlorfon oral dosage forms.



Sec. 520.2520b  Trichlorfon and atropine.

    (a) Chemical name. (1) For trichlorfon: O,O-Dimethyl 2,2,2-
trichloro-1-hydroxyethyl phosphonate.
    (2) For atropine: Atropine N.F.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used for the treatment of 
Syphacia obvelata (pinworm) in laboratory mice.

[[Page 236]]

    (2) It is administered in distilled water as sole source of drinking 
water continuously for 7 to 14 days at 1.67 grams of trichlorfon and 7.7 
milligrams of atropine per liter.
    (3) Prepare fresh solution every 3 days. Do not use simultaneously 
with other drugs, insecticides, pesticides, or chemicals having 
cholinesterase activity, nor within 7 days before or after treatment 
with any other cholinesterase inhibitor.
    (4) Restricted to use by or on the order of a licensed veterinarian.



Sec. 520.2520e  Trichlorfon boluses.

    (a) Specifications. Each bolus contains either 7.3, 10.9, 14.6, or 
18.2 g of trichlorfon.
    (b) Sponsor. See 000856 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. Trichlorfon is a cholinesterase 
inhibitor. Do not use this product on animals simultaneously with, or 
within 2 weeks, before or after treatment with or exposure to, 
neuromuscular depolarizing agents (i.e., succinylcholine) or to 
cholinesterase-inhibiting drugs, pesticides, or chemicals.
    (d) NAS/NRC status. Use of this drug has been NAS/NRC reviewed and 
found effective. Applications for these uses need not include 
effectiveness data as specified by Sec. 514.111 of this chapter.
    (e) Conditions of use--(1) Amount. 18.2 milligrams per pound of body 
weight, except for strongyles use 36.4 milligrams per pound of body 
weight.
    (2) Indications for use. For horses for removal of bots 
(Gastrophilus nasalis, Gastrophilus intestinalis), large strongyles 
(Strongylus vulgaris), small strongyles, large roundworms (ascarids, 
Parascaris equorum), and pinworms (Oxyuris equi).
    (3) Limitations. Do not fast horses before or after treatment. 
Treatment of mares in late pregnancy is not recommended. Surgery or any 
severe stress should be avoided for at least 2 weeks before or after 
treatment. Do not administer to sick, toxic, or debilitated horses. Not 
to be used in horses intended for use as food. Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.

[45 FR 48127, July 18, 1980]



Sec. 520.2520f  Trichlorfon granules.

    (a) Specifications. Each package contains either 18.2 or 36.4 g of 
trichlorfon.
    (b) Sponsor. See 000856 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. Trichlorfon is a cholinesterase 
inhibitor. Do not use this product on animals simultaneously with, or 
within 2 weeks before or after treatment with or exposure to 
neuromuscular depolarizing agents (i.e., succinylcholine) or to 
cholinesterase-inhibiting drugs, pesticides, or chemicals.
    (d) NAS/NRC status. Use of this drug has been NAS/NRC reviewed and 
found effective. Applications for these uses need not include 
effectiveness data as specified by Sec. 514.111 of this chapter.
    (e) Conditions of use--(1) Amount. 18.2 milligrams per pound of body 
weight.
    (2) Indications for use. For horses for removal of bots 
(Gastrophilus nasalis, Gastrophilus intestinalis), large roundworms 
(ascarids, Parascaris equorum), and pinworms (Oxyuris equi).
    (3) Limitations. Do not fast horses before or after treatment. 
Treatment of mares in late pregnancy is not recommended. Surgery or any 
severe stress should be avoided for at least 2 weeks before or after 
treatment. Do not administer to sick, toxic, or debilitated horses. Not 
to be used in horses intended for use as food. Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.

[45 FR 48128, July 18, 1980]



Sec. 520.2520g  Trichlorfon, phenothiazine, and piperazine 
dihydrochloride powder.

    (a) Specifications. Each 54.10 grams (1.91 ounces) of water 
dispersible powder contains 9.10 grams of trichlorfon, 6.25 grams of 
phenothiazine, and the equivalent of 20.0 grams of piperazine base (as 
piperazine dihydrochloride).
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. Labeling shall bear the following 
statements: The drug is a cholinesterase inhibitor. Do not use this 
product in horses simultaneously with, or within 2 weeks before or after 
treatment with, or exposure to, neuromuscular depolarizing

[[Page 237]]

agents (e.g., succinylcholine) or to cholinesterase-inhibiting drugs, 
pesticides, or chemicals.
    (d) Conditions of use--(1) Amount. 18.2 milligrams of trichlorfon, 
12.5 milligrams of phenothiazine, and 40.0 milligrams of piperazine base 
per pound of body weight.
    (2) Indications for use. For horses for removal of bots 
(Gastrophilus nasalis, Gastrophilus intestinalis), large strongyles 
(Strongylus vulgaris), small strongyles, large roundworms (ascarids, 
Parascaris equorum), and pinworms (Oxyuris equi).
    (3) Limitations. Mix powder and vial contents together in warm water 
to form suspension. Administer by stomach tube. Do not fast horses 
before or after treatment. Treatment of mares in late pregnancy is not 
recommended. Surgery or any severe stress should be avoided for at least 
2 weeks before or after treatment. Do not administer to sick, toxic, or 
debilitated horses. Not to be used in horses intended for use as food. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.

[48 FR 2757, Jan. 21, 1983]



Sec. 520.2582  Triflupromazine hydrochloride tablets.

    (a) Specifications. Each tablet contains either 10 milligrams or 25 
milligrams of triflupromazine hydrochloride.
    (b) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used in dogs and cats to 
relieve anxiety and to help control psychomotor overactivity as well as 
to increase the tolerance of animals to pain and pruritus. The drug is 
indicated in various office and clinical procedures which require the 
aid of a tranquilizer, antiemetic, or preanesthetic.\1\
    (2) The drug is administered orally to dogs and cats at a dosage 
level of 1 to 2 milligrams per pound of body weight daily; an initial 
dosage at the 2-milligrams level is suggested followed by daily doses at 
the 1-milligram level. Frequently, the drug may be withdrawn after 4 to 
5 days, with drug effect continuing after withdrawal.\1\
    (3) Do not use in conjunction with organophosphates and/or procaine 
hydrochloride, because phenothiazines may potentiate the toxicity of 
organophosphates and the activity of procaine hydrochloride.\1\
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.\1\

[40 FR 13838, Mar. 27, 1975, as amended at 50 FR 41489, Oct. 11, 1985]



Sec. 520.2598  Trilostane.

    (a) Specifications. Each capsule contains 10, 30, or 60 milligrams 
(mg) trilostane.
    (b) Sponsor. See No. 043264 in Sec. 510.600 of this chapter.
    (c) Conditions of use in dogs--(1) Amount. The starting dose is 1.0 
to 3.0 milligrams per pound (2.2 to 6.7 milligrams per kilogram) once a 
day.
    (2) Indications for use. For treatment of pituitary-dependent 
hyperadrenocorticism. For treatment of hyperadrenocorticism due to 
adrenocortical tumor.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[74 FR 21767, May 11, 2009, as amended at 74 FR 30464, June 26, 2009]



Sec. 520.2604  Trimeprazine tartrate and prednisolone tablets.

    (a) Specifications. Each tablet contains: trimeprazine tartrate, 5 
milligrams; and prednisolone, 2 milligrams.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is administered orally to dogs 
for the relief of itching regardless of cause; reduction of inflammation 
commonly associated with most skin disorders of dogs such as eczema, 
caused by internal disorders, otitis, and dermatitis, allergic, 
parasitic, pustular and nonspecific. It is also used in dogs as 
adjunctive therapy in various cough conditions including treatment of 
``kennel cough'' or tracheobronchitis, bronchitis including allergic 
bronchitis, in tonsillitis, acute upper respiratory infections and 
coughs of nonspecific origin. The product may also be administered to 
dogs suffering from acute or chronic bacterial infections, provided

[[Page 238]]

the infection is controlled by appropriate antibiotic or 
chemotherapeutic agents.\1\
    (2) The drug is administered orally at an initial dosage level of 
\1/2\ tablet twice daily to dogs weighing up to 10 pounds, one tablet 
twice daily to dogs weighing 11 to 20 pounds, two tablets twice daily to 
dogs weighing 21 to 40 pounds, and three tablets twice daily to dogs 
weighing over 40 pounds. After 4 days, the dosage is reduced to 
approximately \1/2\ the initial dosage or to an amount just sufficient 
to maintain remission of symptoms. Dosages in individual cases may vary 
and should be adjusted until proper response is obtained.\1\
    (3) Do not use the drug in cases of viral infections involving 
corneal ulceration or dendritic ulceration of the cornea.\1\
    (4) Clinical and experimental data have demonstrated that 
corticosteroids administered orally or parenterally to animals may 
induce the first stage of parturition when administered during the last 
trimester of pregnancy and may precipitate premature parturition 
followed by dystocia, fetal death, retained placenta, and metritis.\1\
    (5) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.

[40 FR 13838, Mar. 27, 1975, as amended at 56 FR 50653, Oct. 8, 1991; 60 
FR 55659, Nov. 2, 1995]



Sec. 520.2605  Trimeprazine tartrate and prednisolone capsules.

    (a) Specifications. Each capsule contains 3.75 milligrams of 
trimeprazine in sustained released form (as the tartrate) and 1 
milligram of prednisolone (capsule no. 1) or 7.5 milligrams of 
trimeprazine in sustained release form (as the tartrate) and 2 
milligrams of prednisolone (capsule no. 2).
    (b) Sponsor. See 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. Administer either capsule orally 
once daily to dogs as follows:

------------------------------------------------------------------------
                                                     Number of capsules
                                                          per dose
              Animal weight (pounds)               ---------------------
                                                     Capsule    Capsule
                                                      No. 1      No. 2
------------------------------------------------------------------------
Up to 10..........................................          1  .........
11 to 20..........................................          2          1
21 to 40..........................................          4          2
Over 40...........................................          6          3
------------------------------------------------------------------------

    (2) Indications for use. For the relief of itching regardless of 
cause, reduction of inflammation commonly associated with most skin 
disorders of dogs such as eczema caused by internal disorders, otitis, 
and dermatitis (allergic, parasitic, pustular, and nonspecific). It is 
also used in dogs as adjunctive therapy in various cough conditions 
including treatment of ``kennel cough'' or tracheobronchitis, bronchitis 
including allergic bronchitis, tonsillitis, acute upper respiratory 
infections, and coughs of nonspecific origin. The product may also be 
administered to dogs suffering from acute or chronic bacterial 
infections, provided the infection is controlled by appropriate 
antibiotic or chemotherapeutic agents.
    (3) Limitations. After 4 days, reduce dosage to one-half the initial 
dose or to an amount sufficient to maintain remission of symptoms. 
Dosages in individual cases may vary and should be adjusted until proper 
response is obtained. Do not use the drug in cases of viral infections 
involving corneal ulceration or dendritic ulceration of the cornea. 
Clinical and experimental data have demonstrated that corticosteroids 
administered orally or parenterally to animals may induce the first 
stage of parturition when administered during the last trimester of 
pregnancy and may precipitate premature parturition followed by 
dystocia, fetal death, retained placenta, and metritis. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.

[48 FR 19367, Apr. 29, 1983, as amended at 56 FR 50653, Oct. 8, 1991; 60 
FR 55659, Nov. 2, 1995]



Sec. 520.2610  Trimethoprim and sulfadiazine tablets.

    (a) Specifications. Each tablet contains 30 milligrams (5 milligrams 
of trimethoprim and 25 milligrams of sulfadiazine), 120 milligrams (20 
milligrams of trimethoprim and 100 milligrams of sulfadiazine), 480 
milligrams

[[Page 239]]

(80 milligrams of trimethoprim and 400 milligrams of sulfadiazine) or 
960 milligrams (160 milligrams of trimethoprim and 800 milligrams of 
sulfadiazine).
    (b) Sponsor. See Nos. 000061 and 000856 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use. (1) The drug is used in dogs where systemic 
antibacterial action against sensitive organisms is required, either 
alone or as an adjunct to surgery or debridement with associated 
infection. The drug is indicated where control of bacterial infection is 
required during the treatment of acute urinary tract infections, acute 
bacterial complications of distemper, acute respiratory tract 
infections, acute alimentary tract infections, wound infections, and 
abscesses.
    (2) The drug is given orally at 30 milligrams per kilogram of body 
weight per day (14 milligrams per pound per day), or as follows:

------------------------------------------------------------------------
                                                               Number of
                 Animal body weight (pounds)                    tablets
------------------------------------------------------------------------
                              30 mg tablets
------------------------------------------------------------------------
2.2.........................................................           1
4.4.........................................................           2
6.6.........................................................           3
8.8.........................................................           4
------------------------------------------------------------------------
                             120 mg tablets
------------------------------------------------------------------------
Up to 9.....................................................           1
10 to 19....................................................           2
20 to 29....................................................           3
30 to 40....................................................           4
------------------------------------------------------------------------
                             480 mg tablets
------------------------------------------------------------------------
30 to 40....................................................           1
40 to 60....................................................      1\1/2\
60 to 80....................................................           2
80 to 110...................................................           3
Over 110....................................................           4
------------------------------------------------------------------------

    (3) The drug is given once daily. Alternatively, especially in 
severe infections, the initial dose may be followed by one-half the 
recommended daily dose every 12 hours. If no improvement is seen in 3 
days, discontinue therapy and reevaluate diagnosis.
    (4) Administer for 2 to 3 days after symptoms have subsided. Do not 
treat for more than 14 consecutive days.
    (5) During long term treatment, periodic platelet counts and white 
and red blood cell counts are recommended.
    (6) The drug should not be used in patients showing marked liver 
parenchymal damage or blood dyscrasia, nor in those with a history of 
sulfonamide sensitivity.
    (7) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[41 FR 3853, Jan. 27, 1976, as amended at 44 FR 32214, June 5, 1979; 46 
FR 23231, Apr. 24, 1981; 47 FR 36814, Aug. 24, 1982; 50 FR 9800, Mar. 
12, 1985; 50 FR 11852, Mar. 26, 1985; 61 FR 5506, Feb. 13, 1996; 61 FR 
8873, Mar. 6, 1996; 62 FR 61625, Nov. 19, 1997]



Sec. 520.2611  Trimethoprim and sulfadiazine paste.

    (a) Specifications. Each gram (g) of paste contains 67 milligrams 
(mg) trimethoprim and 333 mg sulfadiazine.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter:
    (1) No. 000856 for product administered as in paragraph (c)(1)(i) of 
this section.
    (2) No. 000061 for product administered as in paragraph (c)(1)(ii) 
of this section.
    (c) Conditions of use in horses--(1) Amount. Administer orally as a 
single daily dose for 5 to 7 days:
    (i) 5 g of paste (335 mg trimethoprim and 1,665 mg sulfadiazine) per 
150 pounds (68 kilograms) of body weight per day.
    (ii) 3.75 g of paste (250 mg trimethoprim and 1,250 mg sulfadiazine) 
per 110 pounds (50 kilograms) of body weight per day.
    (2) Indications for use. For use where systemic antibacterial action 
against sensitive organisms is required during treatment of acute 
strangles, respiratory infections, acute urogenital infections, and 
wound infections and abscesses.
    (3) Limitations. Not for use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[71 FR 30802, May 31, 2006]



Sec. 520.2612  Trimethoprim and sulfadiazine oral suspension.

    (a) Specifications. Each milliliter of oral suspension contains 60 
milligrams of drug (10 milligrams of trimethoprim and 50 milligrams of 
sulfadiazine).
    (b) Sponsor. See No. 000061 in Sec. 510.600 of this chapter.
    (c) Conditions of use. Dogs--(1) Dosage. 1 milliliter (10 milligrams 
of

[[Page 240]]

trimethoprim and 50 milligrams of sulfadiazine) per 5 pounds of body 
weight.
    (2) Indications for use. The drug is used in dogs where systemic 
antibacterial action against sensitive organisms is required, either 
alone or as an adjunct to surgery or debridement with associated 
infection. The drug is indicated where control of bacterial infection is 
required during the treatment of acute urinary tract infections, acute 
bacterial complications of distemper, acute respiratory tract 
infections, acute alimentary tract infections, wound infections, and 
abscesses.
    (3) Limitations. For oral use only. Administer the recommended dose 
once daily or one-half the recommended daily dose every 12 hours. 
Administer for 2 to 3 days after symptoms have subsided. If no 
improvement is seen in 3 days, discontinue therapy and reevaluate 
diagnosis. Do not treat for more than 14 consecutive days. During long-
term treatment, a complete blood count is recommended. The drug should 
not be used in patients showing marked liver parenchymal damage or blood 
dyscrasia, nor in those with a history of sulfonamide sensitivity. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.

[50 FR 19168, May 7, 1985, as amended at 61 FR 8873, Mar. 6, 1996; 62 FR 
61625, Nov. 19, 1997]



Sec. 520.2613  Trimethoprim and sulfadiazine powder.

    (a) Specifications. Each gram of powder contains 67 milligrams of 
trimethoprim and 333 milligrams of sulfadiazine.
    (b) Sponsor. See No. 000009 and 058711 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use: Horses--(1) Dosage. 3.75 grams of powder per 
110 pounds (50 kilograms) of body weight per day.
    (2) Indications for use. For control of bacterial infections of 
horses during treatment of acute strangles, respiratory tract 
infections, acute urogenital infections, wound infections, and 
abscesses.
    (3) Limitations. Administer orally in a small amount of feed, as a 
single daily dose, for 5 to 7 days. Continue therapy for 2 to 3 days 
after clinical signs have subsided. If no improvement is seen in 3 to 5 
days, reevaluate diagnosis. A complete blood count should be done 
periodically with prolonged use. Not for use in horses intended for 
food. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[58 FR 36135, July 6, 1993, as amended at 64 FR 68289, Dec. 7, 1999]



Sec. 520.2640  Tylosin.

    (a) Specifications. Each container of soluble powder contains 
tylosin tartrate equivalent to either 100 or 256 grams tylosin base.
    (b) Sponsors. See Nos. 000986, 016592, and 061623 in Sec. 
510.600(c) of this chapter.
    (1) No. 000986 for use of a 100-gram jar as in paragraph (d) of this 
section.
    (2) No. 016592 for use of a 100-gram jar or pouch as in paragraphs 
(d)(1), (d)(2), (d)(3)(i), (d)(3)(ii)(B), (d)(3)(iii), and (d)(4) of 
this section.
    (3) No. 061623 for use of a 100- or 256-gram jar or pouch as in 
paragraphs (d)(1), (d)(2), (d)(3)(i), (d)(3)(ii)(B), (d)(3)(iii), and 
(d)(4) of this section.
    (c) Related tolerances. See Sec. 556.740 of this chapter.
    (d) Conditions of use--(1) Chickens--(i) Amount. 2 grams per gallon 
for 1 to 5 days as the sole source of drinking water. Treated chickens 
should consume enough medicated drinking water to provide 50 milligrams 
(mg) tylosin per pound of body weight per day.
    (ii) Indications for use. For maintaining weight gain and feed 
efficiency in the presence of infectious sinusitis associated with 
Mycoplasma gallisepticum sensitive to tylosin.
    (iii) Limitations. Prepare a fresh solution every 3 days. Do not use 
in layers producing eggs for human consumption. Do not administer within 
24 hours of slaughter.
    (2) Turkeys--(i) Amount. 2 grams per gallon for 2 to 5 days as the 
sole source of drinking water. Treated turkeys should consume enough 
medicated drinking water to provide 60 mg tylosin per pound of body 
weight per day.
    (ii) Indications for use. For maintaining weight gains and feed 
efficiency in the presence of infectious sinusitis associated with 
Mycoplasma gallisepticum sensitive to tylosin.
    (iii) Limitations. Prepare a fresh solution every 3 days. Do not use 
in layers

[[Page 241]]

producing eggs for human consumption. Do not administer within 5 days of 
slaughter.
    (3) Swine--(i) Amount. 250 mg per gallon as the only source of 
drinking water for 3 to 10 days, depending on the severity of the 
condition being treated.
    (ii) Indications for use. (A) For the treatment and control of swine 
dysentery associated with Brachyspira hyodysenteriae when followed 
immediately by tylosin phosphate medicated feed; and for the control of 
porcine proliferative enteropathies (PPE, ileitis) associated with 
Lawsonia intracellularis when followed immediately by tylosin phosphate 
medicated feed.
    (B) For the treatment and control of swine dysentery associated with 
Brachyspira hyodysenteriae.
    (iii) Limitations. Prepare a fresh solution daily. Do not administer 
within 48 hours of slaughter. As indicated in paragraph (d)(3)(ii)(A) of 
this section, follow with tylosin phosphate medicated feed as in Sec. 
558.625(f)(1)(vi)(c) of this chapter.
    (4) Honey bees--(i) Amount. Mix 200 milligrams tylosin in 20 grams 
confectioners'/powdered sugar. Use immediately. Apply (dust) this 
mixture over the top bars of the brood chamber once weekly for 3 weeks.
    (ii) Indications for use. For the control of American foulbrood 
(Paenibacillus larvae).
    (iii) Limitations. The drug should be fed early in the spring or 
fall and consumed by the bees before the main honey flow begins, to 
avoid contamination of production honey. Complete treatments at least 4 
weeks before main honey flow.

[40 FR 13838, Mar. 27, 1975, as amended at 50 FR 49841, Dec. 5, 1985; 59 
FR 14365, Mar. 28, 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, May 9, 
2003; 70 FR 69439, Nov. 16, 2005; 73 FR 76946, Dec. 18, 2008; 75 FR 
76259, Dec. 8, 2010; 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 17, 
2012]



Sec. 520.2645  Tylvalosin.

    (a) Specifications. Granules containing 62.5 percent tylvalosin (w/
w) as tylvalosin tartrate.
    (b) Sponsor. See No. 066916 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.748 of this chapter.
    (d) Conditions of use in swine--(1) Amount. Administer 50 parts per 
million tylvalosin in drinking water for 5 consecutive days.
    (2) Indications for use. For the control of porcine proliferative 
enteropathy (PPE) associated with Lawsonia intracellularis infection in 
groups of swine in buildings experiencing an outbreak of PPE.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[77 FR 55415, Sept. 10, 2012]



PART 522_IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS--
Table of Contents



Sec.
522.23 Acepromazine.
522.44 Sterile sodium acetazolamide.
522.52 Alfaxalone.
522.56 Amikacin.
522.62 Aminopentamide hydrogen sulfate injection.
522.82 Aminopropazine fumarate sterile solution injection.
522.84 Beta-aminopropionitrile fumarate.
522.88 Sterile amoxicillin trihydrate for suspension.
522.90 Ampicillin implantation and injectible dosage forms.
522.90a Ampicillin trihydrate sterile suspension.
522.90b Ampicillin trihydrate.
522.90c Ampicillin sodium.
522.144 Arsenamide sodium aqueous injection.
522.147 Atipamezole.
522.150 Azaperone.
522.161 Betamethasone acetate and betamethasone disodium phosphate 
          aqueous suspension.
522.163 Betamethasone dipropionate and betamethasone sodium phosphate 
          aqueous suspension.
522.204 Boldenone.
522.234 Butamisole hydrochloride.
522.246 Butorphanol.
522.275 N-Butylscopolammonium bromide.
522.300 Carfentanil citrate injection.
522.304 Carprofen.
522.311 Cefovecin.
522.313 Ceftiofur injectable dosage forms.
522.313a Ceftiofur crystalline free acid.
522.313b Ceftiofur hydrochloride.
522.313c Ceftiofur sodium.
522.380 Chloral hydrate, pentobarbital, and magnesium sulfate sterile 
          aqueous solution.
522.390 Chloramphenicol injection.
522.460 Cloprostenol sodium.

[[Page 242]]

522.468 Colistimethate sodium powder for injection.
522.480 Repository corticotropin injection.
522.518 Cupric glycinate injection.
522.522 Danofloxacin.
522.533 Deslorelin.
522.535 Desoxycorticosterone pivalate.
522.536 Detomidine hydrochloride injection.
522.540 Dexamethasone.
522.542 Dexamethasone-21-isonicotinate suspension.
522.558 Dexmedetomidine.
522.563 Diatrizoate meglumine and diatrizoate sodium injection.
522.650 Dihydrostreptomycin sulfate injection.
522.690 Dinoprost solution.
522.723 Diprenorphine hydrochloride injection.
522.770 Doramectin.
522.775 Doxapram.
522.778 Doxycycline hyclate.
522.784 Doxylamine succinate injection.
522.800 Droperidol and fentanyl citrate injection.
522.810 Embutramide, chloroquine, and lidocaine solution.
522.812 Enrofloxacin.
522.814 Eprinomectin.
522.820 Erythromycin.
522.840 Estradiol.
522.842 Estradiol benzoate and testosterone propionate.
522.850 Estradiol valerate and norgestomet in combination.
522.863 Ethylisobutrazine hydrochloride injection.
522.870 Etodolac.
522.883 Etorphine hydrochloride injection.
522.900 Euthanasia solution.
522.914 Fenprostalene solution.
522.930 Firocoxib.
522.955 Florfenicol.
522.956 Florfenicol and flunixin.
522.960 Flumethasone implantation or injectable dosage forms.
522.960a Flumethasone suspension.
522.960b Flumethasone acetate injection.
522.960c Flumethasone solution.
522.970 Flunixin.
522.995 Fluprostenol sodium injection.
522.1002 Follicle stimulating hormone.
522.1004 Fomepizole.
522.1010 Furosemide.
522.1014 Gamithromycin.
522.1020 Gelatin solution.
522.1044 Gentamicin.
522.1066 Glycopyrrolate.
522.1073 Gonadorelin acetate.
522.1075 Gonadorelin diacetate tetrahydrate.
522.1077 Gonadorelin hydrochloride.
522.1079 Serum gonadotropin and chorionic gonadotropin.
522.1081 Chorionic gonadotropin for injection; chorionic gonadotropin 
          suspension.
522.1083 Gonadotropin releasing factor analog-diphtheria toxoid 
          conjugate.
522.1085 Guaifenesin sterile powder.
522.1086 Guaifenesin injection.
522.1125 Hemoglobin glutamer-200 (bovine).
522.1145 Hyaluronate sodium.
522.1150 Hydrochlorothiazide injection.
522.1155 Imidocarb dipropionate sterile powder.
522.1156 Imidocarb dipropionate solution.
522.1160 Insulin.
522.1182 Iron injection.
522.1192 Ivermectin.
522.1193 Ivermectin and clorsulon.
522.1204 Kanamycin sulfate injection.
522.1222 Ketamine hydrochloride injectable dosage forms.
522.1222a Ketamine.
522.1222b Ketamine hydrochloride with promazine hydrochloride and 
          aminopentamide hydrogen sulfate injection.
522.1225 Ketoprofen solution.
522.1228 [Reserved]
522.1244 Levamisole phosphate injection.
522.1260 Lincomycin.
522.1289 Lufenuron suspension.
522.1290 Luprostiol.
522.1315 Maropitant.
522.1335 Medetomidine hydrochloride injection.
522.1350 Melatonin implant.
522.1362 Melarsomine dihydrochloride for injection.
522.1367 Meloxicam.
522.1372 Mepivacaine.
522.1380 Methocarbamol injection.
522.1410 Methylprednisolone.
522.1450 Moxidectin solution.
522.1451 Moxidectin for suspension.
522.1452 Nalorphine hydrochloride injection.
522.1465 Naltrexone hydrochloride injection.
522.1468 Naproxen for injection.
522.1484 Neomycin sulfate sterile solution.
522.1503 Neostigmine methylsulfate injection.
522.1610 Oleate sodium solution.
522.1620 Orgotein for injection.
522.1660 Oxytetracycline injectable dosage forms.
522.1660a Oxytetracycline solution, 200 milligrams/milliliter.
522.1660b Oxytetracycline solution, 300 milligrams/milliliter.
522.1662 Oxytetracycline hydrochloride implantation or injectable dosage 
          forms.
522.1662a Oxytetracycline hydrochloride injection.
522.1662b Oxytetracycline hydrochloride with lidocaine injection.
522.1662 Oxytetracycline and flunixin.
522.1680 Oxytocin injection.
522.1696 Penicillin G procaine implantation and injectable dosage forms.
522.1696a Penicillin G benzathine and penicillin G procaine suspension.

[[Page 243]]

522.1696b Penicillin G procaine aqueous suspension.
522.1696c Penicillin G procaine in oil.
522.1698 Pentazocine lactate injection.
522.1704 Sodium pentobarbital injection.
522.1720 Phenylbutazone injection.
522.1820 Pituitary luteinizing hormone for injection.
522.1850 Polysulfated glycosaminoglycan.
522.1862 Sterile pralidoxime chloride.
522.1870 Praziquantel.
522.1881 Sterile prednisolone acetate aqueous suspension.
522.1883 Prednisolone sodium phosphate.
522.1884 Prednisolone sodium succinate injection.
522.1885 Prednisolone tertiary butylacetate suspension.
522.1890 Sterile prednisone suspension.
522.1920 Prochlorperazine, isopropamide for injection.
522.1940 Progesterone and estradiol benzoate.
522.1962 Promazine hydrochloride.
522.2002 Propiopromazine hydrochloride injection.
522.2005 Propofol.
522.2012 Prostalene solution.
522.2063 Pyrilamine maleate injection.
522.2076 Romifidine.
522.2100 Selenium, vitamin E injection.
522.2112 Sometribove zinc suspension.
522.2120 Spectinomycin dihydrochloride injection.
522.2121 Spectinomycin sulfate.
522.2150 Stanozolol sterile suspension.
522.2200 Sulfachlorpyridazine.
522.2220 Sulfadimethoxine injection.
522.2240 Sulfaethoxypyridazine.
522.2260 Sulfamethazine.
522.2340 Sulfomyxin.
522.2404 Thialbarbitone sodium for injection.
522.2424 Sodium thiamylal for injection.
522.2444 Sodium thiopental implantation or injectable dosage forms.
522.2444a Sodium thiopental for injection.
522.2444b Sodium thiopental, sodium pentobarbital for injection.
522.2460 Tildipirosin.
522.2470 Tiletamine hydrochloride and zolazepam hydrochloride for 
          injection.
522.2471 Tilmicosin.
522.2474 Tolazoline hydrochloride injection.
522.2476 Trenbolone acetate.
522.2477 Trenbolone acetate and estradiol.
522.2478 Trenbolone acetate and estradiol benzoate.
522.2483 Triamcinolone.
522.2582 Triflupromazine hydrochloride injection.
522.2610 Trimethoprim and sulfadiazine.
522.2615 Tripelennamine hydrochloride injection.
522.2630 Tulathromycin.
522.2640 Tylosin.
522.2662 Xylazine.
522.2670 Yohimbine injectable.
522.2680 Zeranol.
522.2690 Zinc gluconate.

    Authority: 21 U.S.C. 360b.

    Source: 40 FR 13858, Mar. 27, 1975, unless otherwise noted.



Sec. 522.23  Acepromazine.

    (a) Specifications. Each milliliter of solution contains 10 
milligrams (mg) acepromazine maleate.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter:
    (1) No. 000010 for use as in paragraphs (d) and (e) of this section.
    (2) No. 000859 for use as in paragraph (d) of this section.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Conditions of use. It is used in dogs, cats, and horses as 
follows:
    (1) Amount. Dogs: 0.25 to 0.5 mg per pound (/lb) of body weight; 
Cats: 0.5 to 1.0 mg/lb of body weight; Horses: 2.0 to 4.0 mg per 100 lbs 
of body weight.
    (2) Indications for use. As a tranquilizer.
    (e) Conditions of use. It is used in dogs as follows:
    (1) Amount. Dogs: 0.25 to 0.5 mg/lb of body weight.
    (2) Indications for use. As an aid in tranquilization and as a 
preanesthetic agent.

[75 FR 10167, Mar. 5, 2010; 78 FR 17597, Mar. 22, 2013]



Sec. 522.44  Sterile sodium acetazolamide.

    (a) Specifications. Sterile sodium acetazolamide contains 
acetazolamide sodium complying with United States Pharmacopeia as a 
sterile powder with directions for reconstituting the product with 
sterile distilled water to furnish a product having a concentration of 
100 milligrams acetazolamide activity per milliliter.
    (b) Sponsor. See No. 010042 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is used as an aid in the treatment of 
dogs with mild congestive heart failure and for rapid reduction of 
intraocular pressure.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.

---------------------------------------------------------------------------

[[Page 244]]

    (2) It is administered intramuscularly or intraperitoneally to dogs 
at a level of 5 to 15 milligrams per pound of body weight daily 
preferably administered in two or more divided doses.\1\
    (3) For use only by or on the order of a licensed veterinarian.\1\



Sec. 522.52  Alfaxalone.

    (a) Specifications. Each milliliter contains 10 milligrams (mg) 
alfaxalone.
    (b) Sponsor. See No. 049480 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in cats and dogs--(1) Amount--(i) Cats--(A) 
Induction of general anesthesia. Administer by intravenous injection 
over approximately 60 seconds or until clinical signs show the onset of 
anesthesia, 2.2 to 9.7 mg/kilogram (kg) for cats that did not receive a 
preanesthetic or 1.0 to 10.8 mg/kg for cats that received a 
preanesthetic.
    (B) Maintenance of general anesthesia following induction. 
Administer an intravenous bolus containing 1.1 to 1.3 mg/kg to provide 
an additional 7 to 8 minutes of anesthesia in preanesthetized cats; a 
dose containing 1.4 to 1.5 mg/kg provides an additional 3 to 5 minutes 
anesthesia in unpreanesthetized cats.
    (ii) Dogs--(A) Induction of general anesthesia. Administer by 
intravenous injection over approximately 60 seconds or until clinical 
signs show the onset of anesthesia, 1.5 to 4.5 mg/kg for dogs that did 
not receive a preanesthetic or 0.2 to 3.5 mg/kg for dogs that received a 
preanesthetic.
    (B) Maintenance of general anesthesia following induction. 
Administer an intravenous bolus containing 1.2 to 1.4 mg/kg to provide 
an additional 6 to 8 minutes of anesthesia in preanesthetized dogs; a 
dose of 1.5 to 2.2 mg/kg provides an additional 6 to 8 minutes of 
anesthesia in unpreanesthetized dogs.
    (2) Indications for use. For the induction and maintenance of 
anesthesia and for induction of anesthesia followed by maintenance with 
an inhalant anesthetic, in dogs and cats.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[77 FR 64717, Oct. 23, 2012]



Sec. 522.56  Amikacin.

    (a) Specifications. Each milliliter of solution contains 50 
milligrams (mg) of amikacin as amikacin sulfate.
    (b) Sponsors. See Nos. 000856 and 000859 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use in dogs--(1) Amount. 5 mg/pound (lb) of body 
weight twice daily by intramuscular or subcutaneous injection.
    (2) Indications for use. For treatment of genitourinary tract 
infections (cystitis) caused by susceptible strains of Escherichia coli 
and Proteus spp. and skin and soft tissue infections caused by 
susceptible strains of Pseudomonas spp. and E. coli.
    (3) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[76 FR 17338, Mar. 29, 2011, as amended at 78 FR 17597, Mar. 22, 2013]



Sec. 522.62  Aminopentamide hydrogen sulfate injection.

    (a) Chemical name. 4-(Dimethylamino)-2,2-diphenylvaleramide hydrogen 
sulfate.
    (b) Specifications. It is sterile and each milliliter of aqueous 
solution contains 0.5 milligram of the drug.
    (c) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) It is intended for use in dogs and cats 
only for the treatment of vomiting and/or diarrhea, nausea, acute 
abdominal visceral spasm, pylorospasm, or hypertrophic gastritis.

    Note: Not for use in animals with glaucoma because of the occurrence 
of mydriasis.

    (2) Dosage is administered by subcutaneous or intramuscular 
injection every 8 to 12 hours, as follows:

------------------------------------------------------------------------
                                                               Dosage in
                 Weight of animal in pounds                   milligrams
------------------------------------------------------------------------
Up to 10....................................................         0.1
11 to 20....................................................         0.2
21 to 50....................................................         0.3
51 to 100...................................................         0.4
Over 100....................................................         0.5
------------------------------------------------------------------------


[[Page 245]]


Dosage may be gradually increased up to a maximum of five times the 
suggested dosage. Following parenteral use dosage may be continued by 
oral administration of tablets.
    (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 53 FR 27851, July 25, 1988]



Sec. 522.82  Aminopropazine fumarate sterile solution injection.

    (a) Specifications. Each milliliter of aminopropazine fumarate 
sterile aqueous solution, veterinary, contains aminopropazine fumarate 
equivalent to 25 milligrams of aminopropazine base.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used for reducing excessive 
smooth muscle contractions, such as occur in urethral spasms associated 
with urolithiasis in cats and dogs and in colic spasms in horses.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (2) It is administered intramuscularly or intravenously to dogs and 
cats at a level of 1 to 2 milligrams per pound of body weight. It is 
administered intramuscularly or intravenously to horses at a level of 
0.25 milligrams per pound of body weight. Dosage can be repeated every 
12 hours, as indicated.\1\
    (3) Not for use in animals intended for food purposes.\1\
    (4) For use only by or on the order of a licensed veterinarian.\1\

[40 FR 13858, Mar. 27, 1975, as amended at 46 FR 48642, Oct. 2, 1981; 61 
FR 8873, Mar. 6, 1996; 62 FR 61625, Nov. 19, 1997]



Sec. 522.84  Beta-aminopropionitrile fumarate.

    (a) Specifications. Each vial contains 7.0 milligrams of beta-
aminopropionitrile fumarate sterile lyophilized powder which is 
reconstituted for injection with 10 milliliters of sterile physiologic 
saline, USP.
    (b) Sponsor. See No. 064146 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Horses--(i) Amount. 7 milligrams (10 
milliliters) intralesionally every other day for 5 treatments beginning 
about 30 days after initial injury.
    (ii) Indications for use. For treatment of tendinitis of the 
superficial digital flexor tendon (SDFT) in the adult horse where there 
is sonographic evidence of fiber tearing.
    (iii) Limitations. Single dose container for intralesional 
injection. Do not use in horses with dermal irritation or open skin 
lesions in the injection area. Do not administer intraarticularly, into 
the tendon sheath, or in the presence of concurrent limb fractures. Do 
not use in breeding animals since the effects on fertility, pregnancy, 
or fetal health have not been determined. Not for use in horses intended 
for food. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (2) [Reserved]

[63 FR 44382, Aug. 19, 1998]



Sec. 522.88  Sterile amoxicillin trihydrate for suspension.

    (a)(1) Specifications. Each vial contains 3 grams of amoxicillin as 
the trihydrate. The powder is reconstituted with sterile water for 
injection USP to a concentration of 100 or 250 milligrams per milliliter 
for use as in paragraph (d) of this section.
    (2) Each vial contains 25 grams of amoxicillin as the trihydrate. 
The powder is reconstituted with sterile water for injection USP to a 
concentration of 250 milligrams per milliliter for use as in paragraph 
(e).
    (b) Sponsor. See 000069 in Sec. 510.600(c) of this chapter.
    (c) Related tolerance. See Sec. 556.38 of this chapter.
    (d) Conditions of use in dogs and cats--(1) Amount. 5 milligrams per 
pound of body weight daily.
    (2) Indications for use--(i) Dogs. Treatment of infections caused by 
susceptible strains of organisms as follows: Respiratory infections 
(tonsillitis, tracheobronchitis) due to Staphylococcus aureus, 
Streptococcus spp., Escherichia coli, and Proteus mirabilis; 
genitourinary infections (cystitis) due to S. aureus, Streptococcus 
spp., E. coli, and P.

[[Page 246]]

mirabilis; gastrointestinal infections (bacterial gastroenteritis) due 
to S. aureus, Streptococcus spp., E. coli, and P. mirabilis; bacterial 
dermatitis due to S. aureus, Streptococcus spp., and P. mirabilis; soft 
tissue infections (abscesses, lacerations, and wounds), due to S. 
aureus, Streptococcus spp., E. coli, and P. mirabilis.
    (ii) Cats. Treatment of infections caused by susceptible strains of 
organisms as follows: Upper respiratory infections due to S. aureus, 
Staphylococcus spp., Streptococcus spp., Hemophilus spp., E. coli, 
Pasteurella spp., and P. mirabilis; genitourinary infections (cystitis) 
due to S. aureus, Streptococcus spp., E. coli, P. mirabilis, and 
Corynebacterium spp.; gastrointestinal infections due to E. coli, 
Proteus spp., Staphylococcus spp., and Streptococcus spp.; skin and soft 
tissue infections (abscesses, lacerations, and wounds) due to S. aureus, 
Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella 
multocida.
    (3) Limitations. For use in dogs and cats only. Administer once 
daily for up to 5 days by intramuscular or subcutaneous injection. 
Continue treatment for 48 hours after the animal has become afebrile or 
asymptomatic. If no improvement is seen within 5 days, review the 
diagnosis and change therapy. As with all antibiotics, appropriate in 
vitro culturing susceptibility testing of samples taken before treatment 
should be conducted. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.
    (e) Condition of use. Cattle--(1) Amount. 3 to 5 milligrams per 
pound of body weight once a day according to the animal being treated, 
the severity of infection, and the animal's response.
    (2) Indications for use. Treatment of diseases due to amoxicillin-
susceptible organisms as follows: Respiratory tract infections (shipping 
fever, pneumonia) due to P. multocida, P. hemolytica, Hemophilus spp., 
Staphylococcus spp., and Streptococcus spp. and acute necrotic 
pododermatitis (foot rot) due to Fusobacterium necrophorum.
    (3) Limitations. Administer once daily for up to 5 days by 
intramuscular or subcutaneous injection. Continue treatment for 48 to 72 
hours after the animal has become afebrile or asymptomatic. Do not 
continue treatment beyond 5 days. Treated animals must not be 
slaughtered for food during treatment and for 25 days after the last 
treatment. As with all antibiotics, appropriate in vitro culturing and 
susceptibility testing of samples taken before treatment should be 
conducted. Milk from treated cows must not be used for human consumption 
during treatment or for 96 hours (8 milkings) after last treatment. 
Maximum volume per injection should not exceed 30 milliliters. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.

[57 FR 37330, Aug. 18, 1992; 60 FR 55659, Nov. 2, 1995]



Sec. 522.90  Ampicillin implantation and injectible dosage forms.



Sec. 522.90a  Ampicillin trihydrate sterile suspension.

    (a) Specifications. Each milliliter contains ampicillin trihydrate 
equivalent to 200 milligrams of ampicillin.
    (1) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (2) Related tolerances. See Sec. 556.40 of this chapter.
    (3) Conditions of use--(i) Calves. (A) Amount. For enteritis: 3 
milligrams per pound of body weight, intramuscularly, once or twice 
daily, for up to 3 days. For pneumonia: 3 milligrams per pound of body 
weight, intramuscularly, twice daily, for up to 3 days.
    (B) Indications for use. Treatment of bacterial enteritis caused by 
Escherichia coli and bacterial pneumonia caused by Pasteurella spp. 
susceptible to ampicillin.
    (C) Limitations. Not for use in other animals raised for food 
production. Treated animals must not be slaughtered for food use during 
treatment or for 9 days after the last treatment. Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.
    (ii) Dogs. (A) Amount. 3 to 6 milligrams per pound of body weight 
intramuscularly, once or twice daily.
    (B) Indications for use. Treatment of respiratory tract infections 
due to E. coli, Pseudomonas spp., Proteus spp., Staphylococcus spp., and 
Streptococcus spp.; tonsillitis due to E. coli,

[[Page 247]]

Pseudomonas spp., Streptococcus spp., and Staphylococcus spp.; 
generalized infections (septicemia) associated with abscesses, 
lacerations, and wounds due to Staphylococcus spp. and Streptococcus 
spp.
    (C) Limitations. Continue treatment at least 48 hours after the 
animal's temperature has returned to normal and other signs of infection 
have subsided. Usual treatment is 3 to 5 days. Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.
    (iii) Cats. (A) Amount. 5 to 10 milligrams per pound of body weight 
intramuscularily or subcutaneously, once or twice daily.
    (B) Indications for use. Treatment of generalized infections 
(septicemia) associated with abscesses, lacerations, and wounds due to 
Staphylococcus spp., Streptococcus spp., and Pasteurella spp.
    (C) Limitations. Continue treatment at least 48 hours after the 
animal's temperature has returned to normal and other signs of infection 
have subsided. Usual treatment is 3 to 5 days. Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.
    (iv) Swine. (A) Amount. 3 milligrams per pound of body weight, 
intramuscularily, once or twice daily, for up to 3 days.
    (B) Indications for use. Treatment of bacterial enteritis 
(colibacillosis) caused by E. coli and bacterial pneumonia caused by 
Pasteurella spp. susceptible to ampicillin.
    (C) Limitations. Treated animals must not be slaughtered for food 
use during treatment or for 15 days after the last treatment. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.
    (b) Specifications. Each milliliter contains ampicillin trihydrate 
equivalent to 150 milligrams of ampicillin.
    (1) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (2) Related tolerances. See Sec. 556.40 of this chapter.
    (3) Conditions of use. Dogs--(i) Amount. 3 to 5 milligrams of 
ampicillin per pound of body weight, once a day for up to 4 days.
    (ii) Indications for use. Treatment of bacterial infections of the 
upper respiratory tract (tonsillitis) due to Streptococcus spp., 
Staphylococcus spp., E. coli, Proteus spp., and Pasteurella spp., and 
soft tissue infections (abscesses, lacerations, and wounds) due to 
Staphylococcus spp., Streptococcus spp., and E. coli, when caused by 
susceptible organisms.
    (iii) Limitations. Administer intramuscularly. If continued 
treatment is indicated, oral dosage is recommended. As with all 
antibiotics, appropriate in vitro culturing and susceptibility tests of 
samples taken before treatment are recommended. Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.

[57 FR 37330, Aug. 18, 1992, as amended at 60 FR 55659, Nov. 2, 1995]



Sec. 522.90b  Ampicillin trihydrate.

    (a) Specifications. Each milliliter of aqueous suspension 
constituted from ampicillin trihydrate powder contains 50, 100, or 250 
milligrams (mg) ampicillin equivalents.
    (b) Sponsors. See Nos. 000010 and 010515 in Sec. 510.600(c) of this 
chapter.
    (c) Related tolerances. See Sec. 556.40 of this chapter.
    (d) Conditions of use--(1) Dogs and cats--(i) Amount. 3 mg/pound 
(lb) of body weight twice daily by subcutaneous or intramuscular 
injection.
    (ii) Indications for use. For treatment of strains of organisms 
susceptible to ampicillin and associated with respiratory tract 
infections, urinary tract infections, gastrointestinal infections, skin 
infections, soft tissue infections, and postsurgical infections.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Cattle--(i) Amount. 2 to 5 mg/lb of body weight once daily by 
intramuscular injection.
    (ii) Indications for use. For treatment of respiratory tract 
infections caused by organisms susceptible to ampicillin, bacterial 
pneumonia (shipping fever, calf pneumonia, and bovine pneumonia) caused 
by Aerobacter spp., Klebsiella spp., Staphylococcus spp., Streptococcus 
spp., Pasteurella multocida, and Escherichia coli.

[[Page 248]]

    (iii) Limitations. Do not treat cattle for more than 7 days. Milk 
from treated cows must not be used for food during treatment and for 48 
hours (4 milkings) after the last treatment. Cattle must not be 
slaughtered for food during treatment and for 144 hours (6 days) after 
the last treatment. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[57 FR 37331, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992; 58 FR 18304, 
Apr. 8, 1993; 63 FR 41420, Aug. 4, 1998; 75 FR 10167, Mar. 5, 2010; 76 
FR 17338, Mar. 29, 2011; 76 FR 53051, Aug. 25, 2011]



Sec. 522.90c  Ampicillin sodium.

    (a) Specifications. Each milliliter of aqueous solution constituted 
from ampicillin sodium powder contains 300 milligrams (mg) ampicillin 
equivalents.
    (b) Sponsors. See Nos. 000069 and 010515 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use in horses--(1) Amount: 3 mg per pound of body 
weight twice daily by intravenous or intramuscular injection.
    (2) Indications for use. For the treatment of respiratory tract 
infections (pneumonia and strangles) due to Staphylococcus spp., 
Streptococcus spp. (including S. equi), Escherichia coli, and Proteus 
mirabilis, and skin and soft tissue infections (abscesses and wounds) 
due to Staphylococcus spp., Streptococcus spp., E. coli, and P. 
mirabilis, when caused by susceptible organisms.
    (3) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[72 FR 45158, Aug. 13, 2007]



Sec. 522.144  Arsenamide sodium aqueous injection.

    (a) Chemical name. [[(p-Carbamoylphenyl) arsylene]dithio diacetic 
acid, sodium salt.
    (b) Specifications. The drug is a sterile aqueous solution and each 
milliliter contains 10.0 milligrams of arsenamide sodium.
    (c) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) For the treatment and prevention of 
canine heartworm disease caused by Dirofilaria immitis.
    (2) It is administered intravenously at 0.1 milliliter per pound of 
body weight (1.0 milliliter for every 10 pounds) twice a day for 2 days. 
For dogs in poor condition, particularly those with evidence of reduced 
liver function, a more conservative dosage schedule of 0.1 milliliter 
per pound of body weight daily for 15 days is recommended.
    (3) Restricted to use only by or on the order of a licensed 
veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 43 FR 27785, June 27, 1978; 
45 FR 56798, Aug. 26, 1980; 55 FR 26683, June 29, 1990]



Sec. 522.147  Atipamezole.

    (a) Specifications. Each milliliter of solution contains 5.0 
milligrams atipamezole hydrochloride.
    (b) Sponsor. See No. 052483 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Inject intramuscularly 
the same volume as that of dexmedetomidine or medetomidine used.
    (2) Indications for use. For reversal of the sedative and analgesic 
effects of dexmedetomidine hydrochloride or medetomidine hydrochloride.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[61 FR 48830, Sept. 17, 1996, as amended at 64 FR 71640, Dec. 22, 1999; 
72 FR 264, Jan. 4, 2007]



Sec. 522.150  Azaperone.

    (a) Specifications. Each milliliter of solution contains 40 
milligrams (mg) azaperone.
    (b) Sponsor. See No. 000986 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Indications for use. For control of 
aggressiveness when mixing or regrouping weanling or feeder pigs 
weighing up to 80 pounds.
    (2) Dosage. 2.2 mg per kilogram (1 mg per pound) by deep 
intramuscular injection.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[74 FR 65689, Dec. 11, 2009, as amended at 77 FR 46613, Aug. 6, 2012]

[[Page 249]]



Sec. 522.161  Betamethasone acetate and betamethasone disodium 
phosphate aqueous suspension.

    (a) Chemical names. Betamethasone acetate: 9-[alpha]-Fluoro-16-
[beta]-methylprednisolone - 21 - acetate 
(C24H31FO6). Betamethasone disodium 
phosphate: 9-[alpha]-Fluoro-16-[beta]-methylprednisolone-21-disodium 
phosphate (C22H28FNa2O8P).
    (b) Specifications. The drug is a sterile aqueous suspension and 
each cubic centimeter contains: 12 milligrams of betamethasone acetate 
(equivalent to 10.8 milligrams of betamethasone), 3.9 milligrams of 
betamethasone disodium phosphate (equivalent to 3 milligrams of 
betamethasone), 2 milligrams of dibasic sodium phosphate, 5 milligrams 
of sodium chloride, 0.1 milligram of disodium EDTA, 0.5 milligram of 
polysorbate 80, 9 milligrams of benzyl alcohol, 5 milligrams of sodium 
carboxymethylcellulose, 1.8 milligrams of methylparaben, 0.2 milligram 
of propylparaben, hydrochloric acid and/or sodium hydroxide to adjust 
pH, and water for injection q.s.
    (c) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. It is used or intended for use by intra-
articular injection of horses for the treatment of various inflammatory 
joint conditions; for example, acute and traumatic lameness involving 
the carpel and fetlock joints. Administer from 2.5 to 5 cubic 
centimeters per dose. Dose may be repeated when necessary depending upon 
the duration of relief obtained. Not for use in horses intended for 
food. For use only by or on the order of a licensed veterinarian.

[40 FR13858, Mar. 27, 1975, as amended at 52 FR 7832, Mar. 13, 1987]



Sec. 522.163  Betamethasone dipropionate and betamethasone sodium 
phosphate aqueous suspension.

    (a) Specifications. Betamethasone dipropionate and betamethasone 
sodium phosphate aqueous suspension is a sterile aqueous suspension. 
Each milliliter of the suspension contains the equivalent of 5 
milligrams of betamethasone as betamethasone dipropionate and 2 
milligrams of betamethasone as betamethasone sodium phosphate.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs. (i) It is used as an aid in the 
control of pruritus associated with dermatoses.
    (ii) It is administered by intramuscular injection at a dosage of 
0.25 to 0.5 milliliter per 20 pounds of body weight, depending on the 
severity of the condition. Frequency of dosage depends on recurrence of 
pruritic symptoms. Dosage may be repeated every 3 weeks or when symptoms 
recur, not to exceed a total of 4 injections.
    (2) Horses. (i) It is used as an aid in the control of inflammation 
associated with various arthropathies.
    (ii) It is administered aseptically by intraarticular injection at a 
dosage of 2.5 to 5 milliliters per joint, depending on the severity of 
the condition and the joint size. Dosage may be repeated upon recurrence 
of clinical signs. Injection into the joint cavity should be preceded by 
withdrawal of synovial fluid.
    (iii) Not for use in horses intended for food.
    (3) Clinical and experimental data. It has been demonstrated that 
corticosteroids administered orally or parenterally to animals may 
induce the first stage of parturition when administered during the last 
trimester of pregnancy and may precipitate premature parturition 
followed by dystocia, fetal death, retained placenta, and metritis.
    (4) Restrictions. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 41 FR 27316, July 2, 1976; 52 
FR 7832, Mar. 13, 1987]



Sec. 522.204  Boldenone.

    (a) Specifications. Each milliliter of solution contains 25 or 50 
milligrams (mg) boldenone undecylenate.
    (b) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. 0.5 mg per pound body 
weight by intramuscular injection. Treatment may be repeated at 3-week 
intervals.
    (2) Indications for use. As an aid for treating debilitated horses 
when an improvement in weight, hair coat, or general physical condition 
is desired.

[[Page 250]]

    (3) Limitations. Do not administer to horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[70 FR 70998, Nov. 25, 2005]



Sec. 522.234  Butamisole hydrochloride.

    (a) Specifications. The drug contains 11 milligrams of butamisole 
per milliliter in a solution consisting of 70 percent propylene glycol, 
4 percent benzyl alcohol and distilled water.
    (b) Sponsor. See Nos. 000859 and 053501 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use. (1) The drug is administered by subcutaneous 
injection to dogs for the treatment of infections with whipworms 
(Trichuris vulpis), and the hookworm (Ancylostoma caninum).
    (2) The drug is administered subcutaneously at the rate of 0.1 
milliliter per pound of body weight. In problem cases, retreatment for 
whipworms may be necessary in approximately 3 months. For hookworms, a 
second injection should be given 21 days after the initial treatment.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[43 FR 15625, Apr. 14, 1978. Redesignated at 43 FR 60883, Dec. 29, 1978, 
and amended at 45 FR 29789, May 6, 1980; 51 FR 19329, May 29, 1986; 67 
FR 63055, Oct. 10, 2002]



Sec. 522.246  Butorphanol.

    (a) Specifications. Each milliliter of solution contains butorphanol 
(as butorphanol tartrate) in the following amounts:
    (1) 0.5 milligrams (mg);
    (2) 2 mg; or
    (3) 10 mg
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter as 
follows:
    (1) No. 000856 for use of the product described in paragraph (a)(1) 
as in paragraph (d)(1) of this section; for use of the product described 
in paragraph (a)(2) as in paragraph (d)(2) of this section; and for use 
of the product described in paragraph (a)(3) as in paragraph (d)(3) of 
this section.
    (2) No. 000859 for use of the product described in paragraph (a)(2) 
as in paragraph (d)(2) of this section.
    (3) Nos. 000061, 000859, and 061690 for use of the product described 
in paragraph (a)(3) as in paragraph (d)(3) of this section.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Conditions of use--(1) Dogs--(i) Amount. Administer 0.025 mg per 
pound of body weight by subcutaneous injection at intervals of 6 to 12 
hours, as required. If necessary, increase dose to a maximum of 0.05 mg 
per pound of body weight. Treatment should not normally be required for 
longer than 7 days.
    (ii) Indications for use. For the relief of chronic nonproductive 
cough associated with tracheo-bronchitis, tracheitis, tonsillitis, 
laryngitis, and pharyngitis associated with inflammatory conditions of 
the upper respiratory tract.
    (2) Cats--(i) Amount. Administer 0.2 mg per pound of body weight by 
subcutaneous injection. Dose may be repeated up to 4 times per day. Do 
not treat for more than 2 days.
    (ii) Indications for use. For the relief of pain in cats caused by 
major or minor trauma, or pain associated with surgical procedures.
    (3) Horses--(i) Amount. Administer 0.05 mg per pound of body weight 
by intravenous injection. Dose may be repeated within 3 to 4 hours. 
Treatment should not exceed 48 hours.
    (ii) Indications for use. For the relief of pain associated with 
colic and postpartum pain in adult horses and yearlings.
    (iii) Limitations. Do not use in horses intended for human 
consumption.

[72 FR 27957, May 18, 2007, as amended at 73 FR 31358, June 2, 2008; 74 
FR 61516, Nov. 25, 2009; 75 FR 22524, Apr. 29, 2010; 77 FR 60302, Oct. 
3, 2012; 78 FR 17597, Mar. 22, 2013]



Sec. 522.275  N-Butylscopolammonium bromide.

    (a) Specifications. Each milliliter of solution contains 20 
milligrams (mg) N-butylscopolammonium bromide.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. 0.3 mg per kilogram of 
body weight (0.14 mg per pound) slowly intravenously.

[[Page 251]]

    (2) Indications for use. For the control of abdominal pain (colic) 
associated with spasmodic colic, flatulent colic, and simple impactions.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[69 FR 35512, June 25, 2004]



Sec. 522.300  Carfentanil citrate injection.

    (a) Specifications. Each milliliter of sterile aqueous solution 
contains 3 milligrams of carfentanil citrate.
    (b) Sponsor. See No. 053923 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 5 to 20 micrograms per kilogram 
(.005 to .020 milligram per kilogram) of body weight.
    (2) Indications for use. For immobilizing free ranging and confined 
members of the family Cervidae (deer, elk, and moose).
    (3) Limitations. Inject into large muscle of neck, shoulder, back, 
or hindquarter. Avoid intrathoracic, intra-abdominal, or subcutaneous 
injection. To reverse effect, use 7 milligrams of diprenorphine for each 
milligram of carefentanil citrate, given intravenously or one-half 
intravenously and one-half intramuscularly or subcutaneously. Do not use 
in domestic animals intended for food. Do not use 30 days before or 
during hunting season. Do not use in animals that display clinical signs 
of severe cardiovascular or respiratory disease. Available data are 
inadequate to recommend use in pregnant animals. Avoid use during 
breeding season. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian. The licensed veterinarian shall be a 
veterinarian engaged in zoo and exotic animal practice, wildlife 
management programs, or research.

[53 FR 40057, Oct. 13, 1988. Redesignated at 73 FR 29685, May 22, 2008]



Sec. 522.304  Carprofen.

    (a) Specifications. Each milliliter of solution contains 50 
milligrams (mg) carprofen.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use in dogs--(1) Amount. 2 mg/lb (4.4 mg/kg) body 
weight once daily or 1 mg/lb (2.2 mg/kg) twice daily, by subcutaneous 
injection. For the control of postoperative pain, administer 
approximately 2 hours before the procedure.
    (2) Conditions of use. For the relief of pain and inflammation 
associated with osteoarthritis and for the control of postoperative pain 
associated with soft tissue and orthopedic surgeries.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[68 FR 26205, May 15, 2003, as amended at 68 FR 34796, June 11, 2003; 68 
FR 49351, Aug. 18, 2003. Redesignated at 73 FR 29685, May 22, 2008]



Sec. 522.311  Cefovecin.

    (a) Specifications. Each milliliter of constituted solution contains 
80 milligrams (mg) cefovecin as the sodium salt.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Conditions of use--(1) Dogs--(i) Amount. Administer 3.6 mg/pound 
(lb) (8 mg/kilograms (kg)) body weight as a single subcutaneous 
injection. A second subcutaneous injection of 3.6 mg/lb (8 mg/kg) may be 
administered if response to therapy is not complete.
    (ii) Indications for use. For the treatment of skin infections 
(secondary superficial pyoderma, abscesses, and wounds) in dogs caused 
by susceptible strains of Staphylococcus intermedius and Streptococcus 
canis (Group G).
    (2) Cats--(i) Amount. Administer 3.6 mg/lb (8 mg/kg) body weight as 
a single, one-time subcutaneous injection.
    (ii) Indications for use. For the treatment of skin infections 
(wounds and abscesses) in cats caused by susceptible strains of 
Pasteurella multocida.

[73 FR 29685, May 22, 2008]

[[Page 252]]



Sec. 522.313  Ceftiofur injectable dosage forms.



Sec. 522.313a  Ceftiofur crystalline free acid.

    (a) Specifications. The product is a suspension of ceftiofur 
crystalline free acid.
    (1) Each milliliter (mL) contains 100 milligrams (mg) ceftiofur 
equivalents.
    (2) Each mL contains 200 mg ceftiofur equivalents.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.113 of this chapter.
    (d) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (e) Conditions of use--(1) Swine. The formulation described in 
paragraph (a)(1) of this section is used as follows:
    (i) Amount. 5.0 mg CE per kilogram (kg) of body weight by 
intramuscular injection in the postauricular region of the neck.
    (ii) Indications for use. For the treatment of swine respiratory 
disease (SRD) associated with Actinobacillus pleuropneumoniae, 
Pasteurella multocida, Haemophilus parasuis, and Streptococcus suis. For 
the control of SRD associated with A. pleuropneumoniae, P. multocida, H. 
parasuis, and S. suis in groups of pigs where SRD has been diagnosed.
    (iii) Limitations. Following label use as a single treatment, a 14-
day pre-slaughter withdrawal period is required.
    (2) Cattle. The formulation described in paragraph (a)(2) of this 
section is used as follows:
    (i) Amount. For subcutaneous (SC) injection in the posterior aspect 
of the ear where it attaches to the head (base of the ear) in lactating 
dairy cattle. For SC injection in the middle third of the posterior 
aspect of the ear or in the base of the ear in beef and non-lactating 
dairy cattle.
    (A) Single-dose regimen: 6.6 mg ceftiofur equivalents per kg of body 
weight as a single injection.
    (B) Two-dose regimen: 6.6 mg ceftiofur equivalents per kg of body 
weight given as two injections in the base of the ear approximately 72 
hours apart.
    (ii) Indications for use--(A) Single-dose regimen: For the treatment 
of bovine respiratory disease (BRD, shipping fever, pneumonia) 
associated with Mannheimia haemolytica, Pasteurella multocida, and 
Histophilus somni in beef, non-lactating dairy, and lactating dairy 
cattle. For the control of respiratory disease in beef and non-lactating 
dairy cattle which are at high risk of developing BRD associated with M. 
haemolytica, P. multocida, and H. somni. For the treatment of bovine 
foot rot (interdigital necrobacillosis) associated with Fusobacterium 
necrophorum and Porphyromonas levii in beef, non-lactating dairy, and 
lactating dairy cattle.
    (B) Two-dose regimen: For the treatment of acute metritis (0-to 10-
days postpartum) associated with bacterial organisms susceptible to 
ceftiofur in lactating dairy cattle.
    (iii) Limitations. Following label use as either a single-dose or 2-
dose regimen, a 13-day pre-slaughter withdrawal period is required after 
the last treatment. A withdrawal period has not been established in 
preruminating calves. Do not use in calves to be processed for veal.
    (3) Horses. The formulation described in paragraph (a)(2) of this 
section is used as follows:
    (i) Amount. Two intramuscular injections, 4 days apart, at a dose of 
3.0 mg/lb (6.6 mg/kg) body weight.
    (ii) Indications for use. For the treatment of lower respiratory 
tract infections in horses caused by susceptible strains of 
Streptococcus equi ssp. zooepidemicus.
    (iii) Limitations. Do not use in horses intended for human 
consumption.

[68 FR 60296, Oct. 22, 2003, as amended at 69 FR 43892, July 23, 2004. 
Redesignated and amended at 71 FR 39546, July 13, 2006; 73 FR 58872, 
Oct. 8, 2008; 75 FR 4692, Jan. 29, 2010; 75 FR 62468, Oct. 12, 2010; 77 
FR 26162, May 3, 2012]



Sec. 522.313b  Ceftiofur hydrochloride.

    (a) Specifications. Each milliliter of ceftiofur hydrochloride 
suspension contains 50 milligrams (mg) ceftiofur equivalents.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.

[[Page 253]]

    (c) Related tolerances. See Sec. 556.113 of this chapter.
    (d) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (e) Conditions of use. (1) Swine--(i) Amount. 3 to 5 mg per kilogram 
(/kg) of body weight by intramuscular injection. Treatment should be 
repeated at 24-hour intervals for a total of 3 consecutive days.
    (ii) Indications for use. For treatment and control of swine 
bacterial respiratory disease (swine bacterial pneumonia) associated 
with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella 
Choleraesuis, and Streptococcus suis.
    (iii) Limitations. Treated swine must not be slaughtered for 4 days 
following the last treatment.
    (2) Cattle--(i) Amount. For bovine respiratory disease and acute 
bovine interdigital necrobacillosis, administer 1.1 to 2.2 mg/kg of body 
weight at 24-hour intervals for 3 to 5 consecutive days. For bovine 
respiratory disease only, 2.2 mg/kg of body weight may be administered 
twice at a 48-hour interval. For acute metritis only, administer 2.2 mg/
kg of body weight at 24-hour intervals for 5 consecutive days. Product 
in peanut oil suspension may be administered by either intramuscular or 
subcutaneous injection. Product in caprylic/capric triglyceride 
suspension may be administered by subcutaneous injection only.
    (ii) Indications for use. For treatment of bovine respiratory 
disease (BRD, shipping fever, pneumonia) associated with Mannheimia 
haemolytica, P. multocida, and Histophilus somni; acute bovine 
interdigital necrobacillosis (foot rot, pododermatitis) associated with 
Fusobacterium necrophorum and Bacteroides melaninogenicus; and acute 
metritis (0 to 14 days post-partum) associated with bacteria susceptible 
to ceftiofur.
    (iii) Limitations. Treated cattle must not be slaughtered for 3 days 
following the last treatment. A withdrawal period has not been 
established in preruminating calves. Do not use in calves to be 
processed for veal.

[61 FR 29479, June 11, 1996, as amended at 63 FR 53578, Oct. 6, 1998; 67 
FR 45901, July 11, 2002; 69 FR 47362, Aug. 5, 2004. Redesignated and 
amended at 71 FR 39544, July 13, 2006; 73 FR 45612, Aug. 6, 2008; 76 FR 
17338, Mar. 29, 2011]



Sec. 522.313c  Ceftiofur sodium.

    (a) Specifications. Each milliliter of aqueous solution constituted 
from ceftiofur sodium powder contains 50 milligrams (mg) ceftiofur 
equivalents.
    (b) Sponsors. See Nos. 000009, 000409, and 068330 in Sec. 
510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.113 of this chapter.
    (d) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (e) Conditions of use--(1) Swine--(i) Amount. 3 to 5 mg per kilogram 
(/kg) body weight by intramuscular injection for 3 consecutive days.
    (ii) Indications for use. For treatment and control of swine 
bacterial respiratory disease (swine bacterial pneumonia) associated 
with Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella 
choleraesuis, and Streptococcus suis.
    (iii) Limitations. Treated pigs must not be slaughtered for 4 days 
following the last treatment.
    (2) Cattle--(i) Amount. 0.5 to 1.0 mg/lb body weight by 
intramuscular or subcutaneous injection for 3 days. Additional 
treatments may be given on days 4 and 5 for animals which do not show 
satisfactory response.
    (ii) Indications for use. For treatment of bovine respiratory 
disease (shipping fever, pneumonia) associated with Mannheimia 
haemolytica, Pasteurella multocida, and Histophilus somni. Also, for the 
treatment of acute bovine interdigital necrobacillosis (foot rot, 
pododermatitis) associated with Fusobacterium necrophorum and 
Bacteroides melaninogenicus.
    (iii) Limitations. Treated cattle must not be slaughtered for 4 days 
following the last treatment.
    (3) Sheep--(i) Amount. 0.5 to 1.0 mg/lb body weight by intramuscular 
injection for 3 days. Additional treatments

[[Page 254]]

may be given on days 4 and 5 for animals which do not show satisfactory 
response.
    (ii) Indications for use. For treatment of sheep respiratory disease 
(sheep pneumonia) associated with Mannheimia haemolytica and Pasteurella 
multocida.
    (4) Goats--(i) Amount. 0.5 to 1.0 mg/lb body weight by intramuscular 
injection for 3 days. Additional treatments may be given on days 4 and 5 
for animals which do not show satisfactory response.
    (ii) Indications for use. For treatment of caprine respiratory 
disease (goat pneumonia) associated with Mannheimia haemolytica and 
Pasteurella multocida.
    (5) Chickens--(i) Amount. 0.08 to 0.20 mg as a single subcutaneous 
injection in the neck.
    (ii) Indications for use. For control of early mortality associated 
with Escherichia coli organisms susceptible to ceftiofur in day-old 
chicks.
    (6) Turkeys--(i) Amount. 0.17 to 0.5 mg as a single subcutaneous 
injection in the neck.
    (ii) Indications for use. For control of early mortality associated 
with E. coli organisms susceptible to ceftiofur in day-old poults.
    (7) Horses--(i) Amount. 2.2 to 4.4 mg/kg (1.0 to 2.0 mg/lb) body 
weight by intramuscular injection. Treatment should be repeated every 24 
hours, continued for 48 hours after clinical signs have disappeared, and 
should not exceed 10 days. A maximum of 10 mL should be administered per 
injection site.
    (ii) Indications for use. For treatment of respiratory infections in 
horses associated with Streptococcus zooepidemicus.
    (iii) Limitations. Do not use in horses intended for human 
consumption.
    (8) Dogs--(i) Amount. 1.0 mg/lb (2.2 mg/kg) body weight by 
subcutaneous injection. Treatment should be repeated at 24-hour 
intervals for 5 to 14 days.
    (ii) Indications for use. For treatment of canine urinary tract 
infections associated with E. coli and Proteus mirabilis.

[53 FR 5369, Feb. 24, 1988, as amended at 55 FR 13768, Apr. 12, 1990; 56 
FR 12119, Mar. 22, 1991; 57 FR 41862, Sept. 14, 1992; 59 FR 41666, Aug. 
15, 1994; 59 FR 54518, Nov. 1, 1994; 60 FR 51719, Oct. 3, 1995; 61 FR 
35130, July 5, 1996; 61 FR 66583, Dec. 18, 1996; 66 FR 21283, Apr. 30, 
2001; 66 FR 32540, June 15, 2001; 69 FR 47362, Aug. 5, 2004. 
Redesignated and amended at 71 FR 39544, July 13, 2006; 74 FR 34236, 
July 15, 2009; 77 FR 29218, May 17, 2012]



Sec. 522.380  Chloral hydrate, pentobarbital, and magnesium sulfate 
sterile aqueous solution.

    (a) [Reserved]
    (b)(1) Specifications. Chloral hydrate, pentobarbital, and magnesium 
sulfate sterile aqueous solution contains 42.5 milligrams of chloral 
hydrate, 8.86 milligrams of pentobarbital, and 21.2 milligrams of 
magnesium sulfate in each milliliter of sterile aqueous solution 
containing water, 33.8 percent propylene glycol, and 14.25 percent ethyl 
alcohol.
    (2) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) It is used for general anesthesia and as 
a sedative-relaxant in cattle and horses.
    (ii) For intravenous use only. The drug is administered at a dosage 
level of 20 to 50 milliliters per 100 pounds of body weight for general 
anesthesia until the desired effect is produced. Cattle usually require 
a lower dosage on the basis of body weight. When used as a sedative-
relaxant, it is administered at a level of one-fourth to one-half of the 
anesthetic dosage level.
    (iii) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 45 FR 16482, Mar. 14, 1980]



Sec. 522.390  Chloramphenicol injection.

    (a) Specifications. Each milliliter contains 100 milligrams of 
chloramphenicol.
    (b) Sponsor. See Nos. 000069 and 000859 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use. Dogs--(1) Amount. 5 to 15 milligrams per 
pound of

[[Page 255]]

body weight, intramuscularly or intravenously, every 6 hours. In severe 
infections, use 4 to 6 hour treatment intervals the first day. If no 
response is obtained in 3 to 5 days, discontinue use and reevaluate 
diagnosis.
    (2) Indications for use. Treatment of infections of the respiratory 
tract, the urinary tract, and enteritis and tonsillitis caused by 
organisms susceptible to chloramphenicol.
    (3) Limitations. Not for use in animals raised for food production. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.

[57 FR 37331, Aug. 18, 1992, as amended at 65 FR 45877, July 26, 2000; 
78 FR 17597, Mar. 22, 2013]



Sec. 522.460  Cloprostenol sodium.

    (a)(1) Specifications. Each milliliter of the aqueous solution 
contains 263 micrograms of cloprostenol sodium (equivalent to 250 
micrograms of cloprostenol) in a sodium citrate, anhydrous citric acid 
and sodium chloride buffer containing 0.1 percent w/v chlorocresol B.P. 
as a bactericide.
    (2) Sponsor. See Nos. 000061 and 068504 in Sec. 510.600(c) of this 
chapter.
    (3) Conditions of use. For intramuscular use in beef and dairy 
cattle to induce luteolysis.
    (i) Amount. 2 milliliters (equivalent to 500 micrograms of 
cloprostenol).
    (ii) Indications. (a) For scheduling estrus and ovulation to control 
the time at which cycling cows or heifers can be bred.
    (1) Single cloprostenol injection. Treat only animals with a mature 
corpus luteum. Estrus should occur in 2 to 5 days, and cattle should be 
inseminated at the usual time relative to the detection of estrus. If 
estrus is not observed, treated animals may be inseminated either once 
at 72 hours post injection or twice at 72 and 96 hours post injection.
    (2) Double cloprostenol injection. Give cattle a second injection 11 
days after the first injection. Estrus should occur 2 to 5 days after 
the second injection, and cattle should be inseminated at the usual time 
relative to the detection of estrus. If estrus is not observed, treated 
animals may be inseminated either once at about 72 hours post injection 
or twice at 72 and 96 hours following the second injection.
    (b) Single cloprostenol injection for terminating unwanted 
pregnancies from mismatings from 1 week after mating until 5 months 
after conception, or for treating unobserved (nondetected) estrus, 
mummified fetus, and luteal cysts.
    (c) Single cloprostenol injection for the treatment of pyometra.
    (iii) Do not administer to pregnant animals where the calf is not to 
be aborted.
    (iv) Women of childbearing age, asthmatics, and persons with 
bronchial and other respiratory problems should exercise extreme caution 
when handling this product. Cloprostenol is readily absorbed through the 
skin and may cause abortion and/or bronchiospasms. Accidental spillage 
on the skin should be washed off immediately with soap and water.
    (v) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (b)(1) Specifications. Each milliliter of sterile aqueous solution 
contains 131.5 micrograms of cloprostenol sodium (equivalent to 125 
micrograms of cloprostenol).
    (2) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (3) Special considerations. Labeling shall bear the statements 
prescribed in paragraphs (a)(3) (iii) and (iv) of this section.
    (4) Conditions of use--(i) Amount. 3 milliliters (equivalent to 375 
micrograms of cloprostenol) intramuscularly per animal as a single dose.
    (ii) Indications for use. To induce abortion in pregnant feedlot 
heifers from 1 week after mating until 4\1/2\ months of gestation.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

[47 FR 4678, Feb. 2, 1982, as amended at 48 FR 15619, Apr. 12, 1983; 49 
FR 5100, Feb. 10, 1984; 49 FR 29957, July 25, 1984; 65 FR 6892, Feb. 11, 
2000; 69 FR 40766, July 7, 2004]



Sec. 522.468  Colistimethate sodium powder for injection.

    (a) Specifications. Each vial contains colistimethate sodium 
equivalent to 10

[[Page 256]]

grams colistin activity and mannitol to be reconstituted with 62.5 
milliliters sterile saline or sterile water for injection. The resulting 
solution contains colistimethate sodium equivalent to 133 milligrams per 
milliliter colistin activity.
    (b) Sponsor. See 046573 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use. (1) 1- to 3-day-old chickens.
    (i) Dosage. 0.2 milligram colistin activity per chicken.
    (ii) Indications for use. Control of early mortality associated with 
Escherichia coli organisms susceptible to colistin.
    (iii) Limitations. For subcutaneous injection in the neck of 1- to 
3-day-old chickens. Not for use in laying hens producing eggs for human 
consumption. Do not use in turkeys. Federal law restricts this drug to 
use by or on the order of a licensed veterinarian.
    (2) [Reserved]

[63 FR 13123, Mar. 18, 1998]



Sec. 522.480  Repository corticotropin injection.

    (a)(1) Specifications. The drug conforms to repository corticotropin 
injection U.S.P. It contains 40 or 80 U.S.C. (I.U.) units per cubic 
centimeter.
    (2) Sponsor. See No. 026637 in Sec. 510.600(c) of this chapter.
    (3) Special considerations. The drug should be refrigerated. With 
prolonged use supplement daily diet with potassium chloride at one gram 
for small animals and from 5 to 10 grams for large animals.
    (4) Conditions of use. (i) It is used as an intramuscular or 
subcutaneous injection in cattle and small animals for stimulation of 
the adrenal cortex where there is a general deficiency of corticotropin 
(ACTH). It is also a therapeutic agent for primary bovine ketosis.
    (ii) It is administered to cattle initially at 200 to 600 units 
followed by a dose daily or every other day of 200 to 300 units and to 
small animals at one unit per pound of body weight to be repeated as 
indicated.
    (iii) For use only by or on the order of a licensed veterinarian.
    (b)(1) Specifications. The drug conforms to respository 
corticotropin injection U.S.P. It contains 40 or 80 U.S.P. units per 
milliliter.
    (2) Sponsor. See No. 061623 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) For intramuscular injection in dogs as a 
diagnostic aid to test for adrenal dysfunction. For intramuscular or 
subcutaneous injection in dogs and cats for stimulation of the adrenal 
cortex where there is a general deficiency of ACTH.
    (ii) For diagnostic use: Administer at one unit per pound of body 
weight intramuscularly. For therapeutic use: Administer at one unit per 
pound of body weight intramuscularly or subcutaneously, initially, to be 
repeated as indicated.
    (iii) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (c) National Academy of Sciences/National Reserach Council (NAS/NRC) 
status. The therapeutic indication for use has been reviewed by NAS/NRC 
and found to be effective. Applications for this use need not include 
effectiveness data as specified in Sec. 514.111 of this chapter, but 
may require bioequivalency and safety information.

[40 FR 13858, Mar. 27, 1985, as amended at 50 FR 40966, Oct. 8, 1985; 53 
FR 45760, Nov. 14, 1988; 68 FR 59881, Oct. 20, 2003; 74 FR 20582, May 5, 
2009]



Sec. 522.518  Cupric glycinate injection.

    (a) Specifications. Each milliliter (mL) of sterile aqueous 
suspension contains 200 milligrams of cupric glycinate (equivalent to 60 
milligrams of copper).
    (b) Sponsor. See No. 049185 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 200 milligrams (1 mL) for calves 
300 pounds and under; 400 milligrams (2 mL) for calves over 300 pounds 
and adult cattle.
    (2) Indications for use. For beef calves and beef cattle for the 
prevention of copper deficiency, or when labeled for veterinary 
prescription use, for the prevention and/or treatment of copper 
deficiency alone or in association with molybdenum toxicity.
    (3) Limitations. For subcutaneous use only; repeat dose in 3 months 
in young

[[Page 257]]

calves, in 6 months in cattle; discontinue use 30 days before treated 
animals are slaughtered for food use; Federal law restricts this drug to 
use by or on the order of a licensed veterinarian.

[46 FR 20159, Apr. 3, 1981, as amended at 52 FR 7832, Mar. 13, 1987; 62 
FR 28630, May 27, 1997]



Sec. 522.522  Danofloxacin.

    (a) Specifications. Each milliliter of solution contains 180 
milligrams (mg) danofloxacin as the mesylate salt.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.169 of this chapter.
    (d) Conditions of use in cattle-- (1) Amount: Administer by 
subcutaneous injection either:
    (i) 6 mg per kilogram (mg/kg) of body weight, repeated in 48 hours; 
or
    (ii) 8 mg/kg of body weight, as a single dose.
    (2) Indications for use. For the treatment of bovine respiratory 
disease (BRD) associated with Mannheimia haemolytica and Pasteurella 
multocida.
    (3) Limitations. Animals intended for human consumption should not 
be slaughtered within 4 days from the last treatment. Do not use in 
cattle intended for dairy production. A withdrawal period has not been 
established for this product in pre-ruminating calves. Do not use in 
calves to be processed for veal. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian. Federal law prohibits the 
extra-label use of this drug in food-producing animals.

[67 FR 78972, Dec. 27, 2002, as amended at 77 FR 4227, Jan. 27, 2012]



Sec. 522.533  Deslorelin.

    (a) Specifications--(1) Each implant contains 2.1 milligrams (mg) 
deslorelin acetate.
    (2) Each milliliter (mL) of suspension contains 1.8 mg deslorelin 
acetate.
    (b) Sponsors. See sponsor numbers in Sec. 510.600(c) of this 
chapter as follows:
    (1) No. 043246 for use of product described in paragraph (a)(1) as 
in paragraph (c)(1) of this section.
    (2) No. 051330 for use of product described in paragraph (a)(2) as 
in paragraph (c)(2) of this section.
    (c) Conditions of use--(1) Horses and ponies--(i) Amount. One 
implant per mare subcutaneously in the neck.
    (ii) Indications for use. For inducing ovulation within 48 hours in 
estrous mares with an ovarian follicle greater than 30 mL in diameter.
    (iii) Limitations. Do not use in horses or ponies intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.
    (2) Horses--(i) Amount. Administer 1.8 mg (1 mL) by intramuscular 
injection in the neck.
    (ii) Indications for use. For inducing ovulation within 48 hours in 
cyclic estrous mares with an ovarian follicle between 30 and 40 mL in 
diameter.
    (iii) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[75 FR 81456, Dec. 28, 2010]



Sec. 522.535  Desoxycorticosterone pivalate.

    (a) Specifications. Each milliliter of sterile aqueous suspension 
contains 25 milligrams of desoxycorticosterone pivalate.
    (b) Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Dogs--(i) Amount. Dosage requirements are 
variable and must be individualized on the basis of the response of the 
patient to therapy. Initial dose of 1 milligram per pound (0.45 
kilogram) of body weight every 25 days, intramuscularly. Usual dose is 
0.75 to 1.0 milligram per pound of body weight every 21 to 30 days.
    (ii) Indications for use. For use as replacement therapy for the 
mineralocorticoid deficit in dogs with primary adrenocortical 
insufficiency.
    (iii) Limitations. For intramuscular use only. Do not use in 
pregnant dogs, dogs suffering from congestive heart disease, severe 
renal disease, or edema. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) [Reserved]

[63 FR 13122, Mar. 18, 1998]

[[Page 258]]



Sec. 522.536  Detomidine hydrochloride injection.

    (a) Specification. Each milliliter of sterile aqueous solution 
contains 10 milligrams of detomidine hydrochloride.
    (b) Sponsor. See 052483 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. For sedation, analgesia, or 
sedation and analgesia: 20 or 40 micrograms per kilogram (0.2 or 0.4 
milliliter per 100 kilogram or 220 pounds) by body weight, depending on 
depth and duration required.
    (2) Indication for use. As a sedative and analgesic to facilitate 
minor surgical and diagnostic procedures in mature horses and yearlings.
    (3) Limitations. For sedation administer intraveneously (IV) or 
intramuscularly (IM); for analgesia by IV; for both sedation and 
analgesia by IV. Do not use in horses with pre-existing atrioventricular 
or sinoauricular block, with severe coronary insufficiency, 
cerebrovascular disease, respiratory disease, or chronic renal failure. 
Do not use in breeding animals. Not for use in horses intended for food. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.

[54 FR 50365, Dec. 6, 1989; 54 FR 51551, Dec. 15, 1989]



Sec. 522.540  Dexamethasone.

    (a)(1) Specifications. Each milliliter of solution contains 2 
milligrams (mg) dexamethasone.
    (2) Sponsors. See sponsors in Sec. 510.600(c) of this chapter:
    (i) Nos. 000061, 000859, and 061623 for use as in paragraph (a)(3) 
of this section.
    (ii) Sponsors. See Nos. 054925 and 058005 for use as in paragraphs 
(a)(3)(i)(C), (a)(3)(i)(D), (a)(3)(ii)(A), and (a)(3)(iii) of this 
section.
    (3) Conditions of use--(i) Amount. The drug is administered 
intravenously or intramuscularly and dosage may be repeated if 
necessary, as follows:
    (A) Dogs. 0.25 to 1 mg.
    (B) Cats. 0.125 to 0.5 mg.
    (C) Horses. 2.5 to 5 mg.
    (D) Cattle. 5 to 20 mg, depending on the severity of the condition.
    (ii) Indications for use. The drug is indicated:
    (A) For the treatment of primary bovine ketosis and as an anti-
inflammatory agent in cattle and horses;
    (B) As an anti-inflammatory agent in dogs and cats.
    (iii) Do not use in horses intended for human food. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.
    (b)(1) Specifications. The drug is a sterile aqueous solution. Each 
milliliter contains either 2.0 milligrams of dexamethasone or 4.0 
milligrams of dexamethasone sodium phosphate (equivalent to 3.0 
milligrams dexamethasone).
    (2) Sponsor. See number in Sec. 510.600(c) of this chapter as 
follows:
    (i) No. 061623 for use of 2.0 milligrams dexamethasone or 4.0 
milligrams dexamethasone sodium phosphate injections.
    (ii) No. 000402 for use of 2.0 milligrams dexamethasone or 4.0 
milligrams dexamethasone sodium phosphate injections.
    (3) Conditions of use. (i) The drug is used in dogs for the 
treatment of inflammatory conditions, as supportive therapy in canine 
posterior paresis, as supportive therapy before or after surgery to 
enhance recovery of poor surgical risks, and as supportive therapy in 
nonspecific dermatosis.
    (ii) The drug is administered intravenously at 0.25 to 1 milligram 
initially. The dose may be repeated for 3 to 5 days or until a response 
is noted. If continued treatment is required, oral therapy may be 
substituted. When therapy is withdrawn after prolonged use, the daily 
dose should be reduced gradually over several days.
    (iii) Clinical and experimental data have demonstrated that 
corticosteroids administered orally or parenterally to animals may 
induce the first stage of parturition when administered during the last 
trimester of pregnancy and may precipitate premature parturition 
followed by dystocia, fetal death, retained placenta, and metritis.
    (iv) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[[Page 259]]

    (c)(1) Specifications. The drug is a sterile aqueous solution. Each 
milliliter contains 2.0 milligrams of dexamethasone or 4.0 milligrams of 
dexamethasone sodium phosphate (equivalent to 3.0 milligrams of 
dexamethasone).
    (2) Sponsor. See Nos. 000402 and 061623 in Sec. 510.600(c) of this 
chapter.
    (3) Conditions of use. (i) The drug is used as a rapid adrenal 
glucocorticoid and/or anti-inflammatory agent in horses.
    (ii) The drug is administered intravenously at a dosage of 2.5 to 
5.0 milligrams. If permanent corticosteroid effect is required, oral 
therapy may be substituted. When therapy is withdrawn after prolonged 
use, the daily dose should be reduced gradually over several days. \1\
    (iii) Clinical and experimental data have demonstrated that 
corticosteroids administered orally or parenterally to animals may 
induce the first stage of parturition when administered during the last 
trimester of pregnancy and may precipitate premature parturition 
followed by dystocia, fetal death, retained placenta, and metritis.
    (iv) Not for use in horses intended for food.
    (v) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (d)(1) Specifications. The drug is a sterile aqueous solution. Each 
milliliter contains 2.0 milligrams of dexamethasone or 4.0 milligrams of 
dexamethasone sodium phosphate (equivalent to 3.0 milligrams of 
dexamethasone).
    (2) Sponsors. See the following numbers in Sec. 510.600(c) of this 
chapter:
    (i) Nos. 000069 and 000859 for intravenous or intramuscular use of 
2.0 milligrams dexamethasone injection.
    (ii) No. 000069 for intravenous use of 2.0 milligrams dexamethasone 
injection.
    (3) Conditions of use. (i) The drug is used as an anti-inflammatory 
agent in dogs, cats, and horses.
    (ii) It is administered intravenously or intramuscularly as follows: 
dogs--0.25 to 1 milligram; cats--0.125 to 0.5 milligram; horses--2.5 to 
5 milligrams.
    (iii) Clinical and experimental data have demonstrated that 
corticosteroids administered orally or by injection to animals may 
induce the first stage of parturition when administered during the last 
trimester of pregnancy and may precipitate premature parturition 
followed by dystocia, fetal death, retained placenta, and metritis.
    (iv) Not for use in horses intended for food.
    (v) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (e)(1) Specifications. The drug is a sterile aqueous solution. Each 
milliliter contains 4.0 milligrams of dexamethasone sodium phosphate 
(equivalent to 3 milligrams of dexamethasone).
    (2) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) The drug is given for glucocorticoid and 
anti-inflammatory effect in dogs and horses.
    (ii) Administer intravenously as follows: Dogs--0.25 to 1 milligram 
initially; may be repeated for 3 to 5 days or until response is noted. 
Horses--2.5 to 5 milligrams. If permanent glucocorticoid effect is 
required, oral therapy may be substituted. When therapy is to be 
withdrawn after prolonged use, the daily dose should be reduced 
gradually over several days.
    (iii) Clinical and experimental data have demonstrated that 
corticosteroids administered orally or by injection may induce the first 
stage of parturition when administered during the last trimester of 
pregnancy and may precipitate premature parturition followed by 
dystocia, fetal death, retained placenta, and metritis.
    (iv) Do not use in viral infections. Anti-inflammatory action of 
corticosteroids may mask signs of infections. Except when used for 
emergency therapy, the product is contraindicated in animals with 
tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers.
    (v) Not for use in horses intended for food.
    (vi) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[41 FR 28265, July 9, 1976]

    Editorial Note: For Federal Register citations affecting Sec. 
522.540, see the List of CFR Sections Affected, which appears in the

[[Page 260]]

Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 522.542  Dexamethasone-21-isonicotinate suspension.

    (a) Specifications. Each milliliter of sterile suspension contains 1 
milligram of dexamethasone-21-isonicotinate.
    (b) Sponsor. No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used in the treatment of 
various inflammatory conditions associated with the musculoskeletal 
system in dogs, cats, and horses.
    (2) It is recommended for intramuscular administration as follows: 
Dogs--0.25 to 1 milligram; cats--0.125 to 0.5 milligram; horses--5 to 20 
milligrams. Dosage may be repeated.
    (3) Clinical and experimental data have demonstrated that 
corticosteriods administered orally or parenterally to animals may 
induce the first stage of parturition when administered during the last 
trimester of pregnancy and may precipitate premature parturition 
following by dystocia, fetal death, retained placenta, and metritis.
    (4) Not for use in horses intended for food.
    (5) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[42 FR 37543, July 22, 1977, as amended at 47 FR 14703, Apr. 6, 1982]



Sec. 522.558  Dexmedetomidine.

    (a) Specifications. Each milliliter of solution contains 0.5 
milligram (mg) of dexmedetomidine hydrochloride.
    (b) Sponsor. See No. 052483 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Indications for use and amount. 
(A) For use as a sedative and analgesic to facilitate clinical 
examinations, clinical procedures, minor surgical procedures, and minor 
dental procedures, administer 375 micrograms ([micro]g) per square meter 
(/m\2\) of body surface area by intravenous injection or 500 [micro]g/
m\2\ of body surface area by intramuscular injection.
    (B) For use as a preanesthetic to general anesthesia, administer 125 
[micro]g/m\2\ of body surface area or 375 [micro]g/m\2\ of body surface 
area by intramuscular injection.
    (ii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Cats--(i) Amount. 40 [micro]g/killogram by intramuscular 
injection.
    (ii) Indications for use. For use as a sedative and analgesic to 
facilitate clinical examinations, clinical procedures, minor surgical 
procedures, and minor dental procedures; and as a preanesthetic to 
general anesthesia.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

[72 FR 263, Jan. 4, 2007, as amended at 72 FR 19797, Apr. 20, 2007; 72 
FR 51365, Sept. 7, 2007; 75 FR 60308, Sept. 30, 2010]



Sec. 522.563  Diatrizoate meglumine and diatrizoate sodium injection.

    (a) Specifications. Diatrizoate meglumine and diatrizoate sodium 
injection contains 34.3 percent diatrizoate meglumine and 35 percent 
diatrizoate sodium, or 66 percent diatrizoate meglumine and 10 percent 
diatrizoate sodium, in sterile aqueous solution.
    (b) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is indicated for use in dogs and cats 
for visualization in excretion urography, including renal angiography, 
uretography, cystography, and urethrography; aortography; 
angiocardiography, peripheral arteriography, and venography; selective 
coronary arteriography; cerebral angiography; lymphography; 
arthrography; discography; and sialography. It is also useful as an aid 
in delineating peritoneal hernias and fistulous tracts.
    (2) For excretion urography administer 0.5 to 1.0 milliliter per 
pound of body weight to a maximum of 30 milliliters intravenously. For 
cystography remove urine, administer 5 to 25 milliliters directly into 
the bladder via catheter. For urethrography administer 1.0 to 5 
milliliters via catheter into the urethra to provide desired contrasts 
delineation. For angiocardiography (including aortography) rapidly 
inject 5 to 10 milliliters directly into the heart via catheter or 
intraventricular puncture. For cerebral angiography rapid injection of 3 
to 10

[[Page 261]]

milliliters via carotid artery. For peripheral arteriography and/or 
venography and selective coronary arteriography rapidly inject 3 to 10 
milliliters intravascularly into the vascular bed to be delineated. For 
lymphography slowly inject 1.0 to 10 milliliters directly into the lymph 
vessel to be delineated. For arthrography slowly inject 1.0 to 5 
milliliters directly into the joint to be delineated. For discography 
slowly inject 0.5 to 1.0 milliliter directly into the disc to be 
delineated. For sialography slowly inject 0.5 to 1.0 milliliter into the 
duct to be delineated. For delineation of fistulous tracts slowly inject 
quantity necessary to fill the tract. For delineation of peritoneal 
hernias inject 0.5 to 1.0 milliliter per pound of body weight directly 
into the peritoneal cavity.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[44 FR 12993, Mar. 9, 1979, as amended at 50 FR 41489, Oct. 11, 1985]



Sec. 522.650  Dihydrostreptomycin sulfate injection.

    (a) Specifications. Each milliliter contains dihydrostreptomycin 
sulfate equivalent to 500 milligrams of dihydrostreptomycin.
    (b) Sponsor. See Nos. 000069 and 055529 in Sec. 510.600(c) of this 
chapter.
    (c) National Academy of Sciences/National Research Council (NAS/NRC) 
status. The conditions of use were NAS/NRC reviewed and found effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter but may require 
bioequivalency and safety information.
    (d) Conditions of use--(1) Amount. 5 milligrams per pound of body 
weight every 12 hours.
    (2) Indications for use. Treatment of leptospirosis in dogs and 
horses due to Leptospira canicola, L. icterohemorrhagiae, and L. pomona; 
in cattle due to L. pomona; and in swine due to L. pomona; and L. 
grippotyphosa.
    (3) Limitations. Administer by deep intramuscular injection only. 
Treatment should be continued for 3 to 5 days or until the urine is free 
of leptospira for at least 72 hours as measured by darkfield microscopic 
examination. Treatment with subtherapeutic dosages, excessive duration 
of therapy, or inappropriate use of this antibiotic may lead to the 
emergence of streptomycin or dihydrostreptomycin resistant organisms. 
Discontinue use 30 days before slaughter for food. Not for use in 
animals producing milk because use of the drug will contaminate the 
milk. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[57 FR 37331, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992]



Sec. 522.690  Dinoprost solution.

    (a) Specifications. Each milliliter (mL) of solution contains 
dinoprost tromethamine equivalent to 5 milligrams (mg) dinoprost.
    (b) Sponsors. See Nos. 000009 and 059130 in Sec. 510.600(c) of this 
chapter.
    (c) Special considerations. (1) Federal law restricts this drug to 
use by or on the order of a licensed veterinarian.
    (2) Women of child-bearing age, asthmatics, and persons with 
bronchial and other respiratory problems should exercise extreme caution 
when handling this product. Dinoprost tromethamine is readily absorbed 
through the skin and can cause abortion and bronchiospasms. Accidental 
spillage on the skin should be washed off immediately with soap and 
water.
    (d) Conditions of use--(1) Horses--(i) Amount. 1 mg per 100 pounds 
of body weight as a single intramuscular injection.
    (ii) Indications. For its luteolytic effect to control timing of 
estrus in estrus cycling mares and in clinically anestrous mares that 
have a corpus luteum.
    (iii) Limitations. Not for use in horses intended for food.
    (2) Cattle--(i) Beef cattle and nonlactating dairy heifers--(A) 
Amount. 25 mg as an intramuscular injection either once or twice at a 
10- to 12-day interval.
    (B) Indications. For its luteolytic effect to control timing of 
estrus and ovulation in estrous cycling cattle that have a corpus 
luteum.
    (ii) Beef cattle and nonlactating dairy heifers--(A) Amount. 25 mg 
as a single intramuscular injection.
    (B) Indications. For treatment of pyometra (chronic endometritis).

[[Page 262]]

    (iii) Nonlactating cattle--(A) Amount. 25 mg as a single 
intramuscular injection during the first 100 days of gestation.
    (B) Indications. For its abortifacient effect in nonlactating 
cattle.
    (iv) Lactating dairy cattle--(A) Amount. 25 mg as a single 
intramuscular injection.
    (B) Indications. For treatment of unobserved (silent) estrus in 
lactating dairy cattle that have a corpus luteum.
    (v) Dinoprost solution as provided by No. 000009 in Sec. 510.600(c) 
of this chapter may be used concurrently with progesterone intravaginal 
inserts as in Sec. 529.1940 of this chapter.
    (3) Swine--(i) Amount. 10 mg as a single intramuscular injection.
    (ii) Indications. For parturition induction in swine when injected 
within 3 days of normal predicted farrowing.

[67 FR 41824, June 20, 2002]



Sec. 522.723  Diprenorphine hydrochloride injection.

    (a) Chemical name. N-(Cyclopropyl-methyl)-6,7,8,14-tetrahydro-7-
alpha-(1-hydroxy - 1 - methylethyl) - 6,14 - endoethanonororipavine 
hydrochloride.
    (b) Specifications. Each milliliter of diprenorphine hydrochloride 
injection, veterinary, contains 2 mg of diprenorphine hydrochloride in 
sterile aqueous solution.
    (c) Sponsors. See No. 053923 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) The drug is used for reversing the 
effects of etorphine hydrochloride injection, veterinary, the use of 
which is provided for in Sec. 522.883, in wild and exotic animals.
    (2) It is administered intramuscularly or intravenously at a 
suitable dosage level depending upon the species.
    (3) For use in wild or exotic animals only. Do not use in domestic 
food-producing animals. Do not use 30 days before, or during, the 
hunting season in free-ranging wild animals that might be used for food.
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian. Distribution is restricted to veterinarians 
engaged in zoo and exotic animal practice, wildlife management programs 
and researchers.

[40 FR 13858, Mar. 27, 1975, as amended at 48 FR 16241, Apr. 15, 1983; 
60 FR 39847, Aug. 4, 1995; 64 FR 15684, Apr. 1, 1999]



Sec. 522.770  Doramectin.

    (a) Specifications. Each milliliter of sterile aqueous solution 
contains 10 milligrams of doramectin.
    (b) Sponsor. See No. 000069 in Sec. 510.600 (c) of this chapter.
    (c) Related tolerances. See Sec. 556.225 of this chapter.
    (d) Conditions of use--(1) Cattle--(i) Amount. 200 micrograms per 
kilogram (10 milligrams per 110 pounds).
    (ii) Indications for use. For treatment and control of 
gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice, 
and mange mites. To control infections and to protect from reinfection 
with Cooperia oncophora and Haemonchus placei for 14 days, Ostertagia 
ostertagi for 21 days, and C. punctata, Oesophagostomum radiatum, and 
Dictyocaulus viviparus for 28 days after treatment.
    (iii) Limitations. Administer as a single subcutaneous or 
intramuscular injection. Do not slaughter cattle within 35 days of 
treatment. Not for use in female dairy cattle 20 months of age or older. 
Do not use in calves to be processed for veal.
    (2) Swine--(i) Amount. 300 micrograms per kilogram (10 milligrams 
per 75 pounds).
    (ii) Indications for use. For treatment and control of 
gastrointestinal roundworms, lungworms, kidney worms, sucking lice, and 
mange mites.
    (iii) Limitations. Administer as a single intramuscular injection. 
Do not slaughter swine within 24 days of treatment. Consult your 
veterinarian for assistance in the diagnosis, treatment, and control of 
parasitism.

[61 FR 53321, Oct. 11, 1996, as amended at 62 FR 44410, Aug. 21, 1997; 
62 FR 62242, Nov. 21, 1997; 63 FR 68183, Dec. 10, 1998; 64 FR 13509, 
Mar. 19, 1999]



Sec. 522.775  Doxapram.

    (a) Specifications. Each milliliter of solution contains 20 
milligrams (mg) doxapram hydrochloride.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.

[[Page 263]]

    (c) Conditions of use--(1) Amount. For intravenous use in dogs and 
cats at a dose of 2\1/2\ to 5 mg per pound (/lb) body weight in 
barbiturate anesthesia, 0.5 mg/lb in inhalation anesthesia; for 
intravenous use in horses at 0.25 mg/lb body weight in barbiturate 
anesthesia, 0.2 mg/lb in inhalation anesthesia, 0.25 mg/lb with chloral 
hydrate with or without magnesium sulfate; for subcutaneous, sublingual, 
or umbilical vein administration in neonate puppies at a dose rate of 1 
to 5 mg; for subcutaneous or sublingual use in neonate kittens at 1 to 2 
mg. Dosage may be repeated in 15 to 20 minutes if necessary.
    (2) Indications for use. Administer to dogs, cats, and horses to 
stimulate respiration during and after general anesthesia; or to speed 
awakening and return of reflexes after anesthesia. Administer to neonate 
dogs and cats to initiate respiration following dystocia or caesarean 
section; or to stimulate respiration following dystocia or caesarean 
section.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[72 FR 261, Jan. 4, 2007, as amended at 75 FR 10167, Mar. 5, 2010; 77 FR 
60302, Oct. 3, 2012]



Sec. 522.778  Doxycycline hyclate.

    (a) Specifications. Doxycycline hyclate solution contains 8.5 
percent doxycycline activity. A syringe of N-methyl-2-pyrrolidone and 
poly (DL-lactide) mixed with a syringe of doxycycline produces 0.5 
milliliter of solution.
    (b) Sponsor. See 000009 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Dogs--(i) Amount. Apply subgingivally to 
periodontal pocket(s) of affected teeth.
    (ii) Indications for use. For treatment and control of periodontal 
disease.
    (iii) Limitations. Do not use in dogs less than 1-year old. Use of 
tetracyclines during tooth development has been associated with 
permanent discoloration of teeth. Do not use in pregnant bitches. Use in 
breeding dogs has not been evaluated. Federal law restricts this drug to 
use by or on the order of a licensed veterinarian.

[63 FR 8349, Feb. 19, 1998, as amended at 65 FR 45878, July 26, 2000]



Sec. 522.784  Doxylamine succinate injection.

    (a) Specifications. Each milliliter of the drug contains 11.36 mg of 
doxylamine succinate.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used in conditions in which 
antihistaminic therapy may be expected to alleviate some signs of 
disease in horses, dogs, and cats. \1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter.
---------------------------------------------------------------------------

    (2) It is administered to horses at a dosage level of 25 mg per 
hundred pounds of body weight. It is administered to dogs and cats at a 
dosage level of 0.5 to 1 mg per pound of body weight. Doses may be 
repeated at 8 to 12 hours, if necessary, to produce desired effect. 
Intravenous route is not recommended for dogs and cats and should be 
injected slowly in horses. Intramuscular and subcutaneous administration 
should be by divided injection sites. \1\
    (3) Not for use in horses intended for food. \1\
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian. \1\

[40 FR 13858, Mar. 27, 1975, as amended at 42 FR 60140, Nov. 25, 1977; 
46 FR 48642, Oct. 2, 1981; 61 FR 8873, Mar. 6, 1996; 62 FR 61625, Nov. 
19, 1997]



Sec. 522.800  Droperidol and fentanyl citrate injection.

    (a) Specifications. Droperidol and fentanyl citrate injection is a 
sterile solution containing 20 milligrams of droperidol and 0.4 
milligram of fentanyl citrate per cubic centimeter.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is used in dogs as an analgesic and 
tranquilizer and for general anesthesia.
    (2) It is administered as follows:

[[Page 264]]

    (i) For analgesia and tranquilization administer according to 
response desired, as follows:
    (a) Intramuscularly at the rate of 1 cubic centimeter per 15 to 20 
pounds of body weight in conjunction with atropine sulfate administered 
at the rate of 0.02 milligram per pound of body weight, or
    (b) Intravenously at the rate of 1 cubic centimeter per 25 to 60 
pounds of body weight in conjunction with atropine sulfate administered 
at the rate of 0.02 milligram per pound of body weight.
    (ii) For general anesthesia administer according to response 
desired, as follows:
    (a) Intramuscularly at the rate of 1 cubic centimeter per 40 pounds 
of body weight in conjunction with atropine sulfate administered at the 
rate of 0.02 milligram per pound of body weight and followed in 10 
minutes by an intravenous administration of sodium pentobarbital at the 
rate of 3 milligrams per pound of body weight, or
    (b) Intravenously at the rate of 1 cubic centimeter per 25 to 60 
pounds of body weight in conjunction with atropine sulfate administered 
at the rate of 0.02 milligram per pound of body weight and followed 
within 15 seconds by an intravenous administration of sodium 
pentobarbital at the rate of 3 milligrams per pound of body weight.
    (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 64 FR 15684, Apr. 1, 1999]



Sec. 522.810  Embutramide, chloroquine, and lidocaine solution.

    (a) Specifications. Each milliliter (mL) of solution contains 135 
milligrams (mg) embutramide; 45 mg chloroquine phosphate, U.S.P.; and 
1.9 mg lidocaine, U.S.P.
    (b) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. One mL per 5 pounds of 
body weight.
    (2) Indications for use. For euthanasia.
    (3) Limitations. Not for use in animals intended for food. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.

[70 FR 36337, June 23, 2005, as amended at 78 FR 17597, Mar. 22, 2013]



Sec. 522.812  Enrofloxacin.

    (a) Specifications. Each milliliter (mL) of solution contains:
    (1) 22.7 milligrams (mg) enrofloxacin or
    (2) 100 mg enrofloxacin.
    (b) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (c) Related tolerance. See Sec. 556.226 of this chapter.
    (d) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian. Federal law prohibits the 
extra-label use of this drug in food-producing animals.
    (e) Conditions of use--(1) Dogs. Use the product described in 
paragraph (a)(1) of this section as follows:
    (i) Amount. 2.5 mg per kilogram (/kg) of body weight (1.13 mg per 
pound) as a single, intramuscular, initial dose followed by use of 
tablets twice daily for 2 to 3 days beyond cessation of clinical signs 
to a maximum of 10 days.
    (ii) Indications for use. For the management of diseases associated 
with bacteria susceptible to enrofloxacin.
    (i) Amount--(A) Single-dose therapy: For treatment of bovine 
respiratory disease (BRD), administer 7.5 to 12.5 mg/kg of body weight 
(3.4 to 5.7 mL per 100 pounds (/100 lb)) once by subcutaneous injection. 
For control of BRD, administer 7.5 mg/kg of body weight (3.4 mL/100 lb) 
once by subcutaneous injection.
    (B) Multiple-day therapy: For treatment of BRD, administer 2.5 to 
5.0 mg/kg of body weight (1.1 to 2.3 mL/100 lb) by subcutaneous 
injection. Treatment should be repeated at 24-hour intervals for 3 days. 
Additional treatments may be given on days 4 and 5 to animals that have 
shown clinical improvement but not total recovery.
    (ii) Indications for use--(A) Single-dose therapy: For the treatment 
of BRD associated with Mannheimia haemolytica, Pasteurella multocida, 
Histophilus somni, and Mycoplasma bovis in beef and non-lactating dairy 
cattle; for the control of BRD in beef and non-lactating dairy cattle at 
high risk of developing BRD

[[Page 265]]

associated with M. haemolytica, P. multocida, H. somni and M. bovis.
    (B) Multiple-day therapy: For the treatment of bovine respiratory 
disease (BRD) associated with Mannheimia haemolytica, Pasteurella 
multocida, and Histophilus somni in beef and non-lactating dairy cattle.
    (iii) Limitations. Animals intended for human consumption must not 
be slaughtered within 28 days from the last treatment. This product is 
not approved for female dairy cattle 20 months of age or older, 
including dry dairy cows. Use in these cattle may cause drug residues in 
milk and/or in calves born to these cows. A withdrawal period has not 
been established for this product in preruminating calves. Do not use in 
calves to be processed for veal.
    (3) Swine. Use the product described in paragraph (a)(2) of this 
section as follows:
    (i) Amount. Administer 7.5 mg/kg of body weight once, by 
subcutaneous injection behind the ear.
    (ii) Indications for use. For the treatment and control of swine 
respiratory disease (SRD) associated with Actinobacillus 
pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, 
Streptococcus suis, Bordetella bronchiseptica, and Mycoplasma 
hyopneumoniae.
    (iii) Limitations. Animals intended for human consumption must not 
be slaughtered within 5 days of receiving a single-injection dose.

[72 FR 10597, Mar. 9, 2007, as amended at 73 FR 17890, Apr. 2, 2008; 73 
FR 21819, Apr. 23, 2008; 76 FR 22611, Apr. 22, 2011; 77 FR 55415, Sept. 
10, 2012; 77 FR 76863, Dec. 31, 2012]



Sec. 522.814  Eprinomectin.

    (a) Specifications. Each milliliter of solution contains 50 
milligrams (mg) eprinomectin.
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. Sec. 500.1410 and 556.227 of this 
chapter.
    (d) Conditions of use in cattle on pasture--(1) Amount. Administer 1 
mg/kilogram of body weight by subcutaneous injection.
    (2) Indications for use. For the treatment and control of the 
following internal and external parasites: Gastrointestinal roundworms 
(adults and fourth-stage larvae) Cooperia oncophora, C. punctata, C. 
surnabada, Trichostrongylus axei, Ostertagia ostertagi (including 
inhibited stage); (adults) Haemonchus placei, Oesophagostomum radiatum, 
O. lyrata, T. colubriformis; lungworms (adults) Dictyocaulus viviparus; 
cattle grubs Hypoderma bovis; mites Sarcoptes scabiei var. bovis. 
Prevents reinfection with C. oncophora, C. punctata, and T. axei for 100 
days following treatment; H. placei, O. radiatum, O. lyrata, and O. 
ostertagi for 120 days following treatment; and D. viviparus for 150 
days following treatment.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian. Animals intended for human consumption 
must not be slaughtered within 48 days of the last treatment. Do not use 
in female dairy cattle 20 months of age or older. Use in lactating dairy 
cows may cause drug residues in milk. A withdrawal period has not been 
established for pre-ruminating calves. Do not use in calves to be 
processed for veal.

[76 FR 72618, Nov. 25, 2011]



Sec. 522.820  Erythromycin.

    (a) Sponsor. See No. 061623 in Sec. 510.600(c) of this chapter.
    (b) Specifications--(1) Each milliliter (mL) of solution contains 
100 milligrams (mg) erythromycin base.
    (2) Each mL of solution contains 200 mg erythromycin base.
    (c) Related tolerances. See Sec. 556.230 of this chapter.
    (d) Conditions of use--(1) Dog. Administer product described in 
paragraph (b)(1) of this section as follows:
    (i) Amount. 3 to 5 mg per pound (/lb) body weight, intramuscularly, 
two to three times daily, for up to 5 days.
    (ii) Indications for use. For the treatment of bacterial pneumonia, 
upper respiratory infections (tonsillitis, bronchitis, tracheitis, 
pharyngitis, pleurisy), endometritis and metritis, and bacterial wound 
infections caused by Staphylococcus spp., Streptococcus spp., and 
Corynebacterium spp., sensitive to erythromycin.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

[[Page 266]]

    (2) Cats. Administer product described in paragraph (b)(1) of this 
section as follows:
    (i) Amount. 3 to 5 mg/lb body weight, intramuscularly, two to three 
times daily, for up to 5 days.
    (ii) Indications for use. For the treatment of bacterial pneumonia, 
upper respiratory infections (rhinitis, bronchitis), secondary 
infections associated with panleukopenia, and bacterial wound infections 
caused by Staphylococcus spp. and Streptococcus spp., susceptible to 
erythromycin.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (3) Cattle. Administer products described in paragraph (b) of this 
section as follows:
    (i) Amount. 4 mg/lb body weight by deep intramuscular injection once 
daily for up to 5 days.
    (ii) Indications for use. For the treatment of bovine respiratory 
disease (shipping fever complex and bacterial pneumonia) associated with 
Pasteurella multocida susceptible to erythromycin.
    (iii) Limitations. Do not use in female dairy cattle over 20 months 
of age. Do not slaughter treated animals within 6 days of last 
treatment. A withdrawal period has not been established for this product 
in pre-ruminating calves. Do not use in calves to be processed for veal. 
To avoid excess trim, do not slaughter within 21 days of last injection.

[72 FR 69142, Dec. 7, 2007]



Sec. 522.840  Estradiol.

    (a) Specifications. Each silicone rubber implant contains 25.7 or 
43.9 milligrams (mg) estradiol and is coated with not less than 0.5 mg 
oxytetracycline powder.
    (b) Sponsor. See No. 000986 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.240 of this chapter.
    (d) Conditions of use. For implantation in steers and heifers as 
follows:
    (1) Amount. Insert one 25.7-mg implant every 200 days; insert one 
43.9-mg implant every 400 days.
    (2) Indications for use. For increased rate of weight gain in 
suckling and pastured growing steers; for improved feed efficiency and 
increased rate of weight gain in confined steers and heifers. No 
additional effectiveness may be expected from reimplanting in less than 
200 days for the 25.7-mg implant or 400 days for the 43.9-mg implant.
    (3) Limitations. For subcutaneous ear implantation in steers and 
heifers only. Safety and effectiveness have not been established in veal 
calves. A withdrawal period has not been established for this product in 
preruminating calves. Do not use in calves to be processed for veal.

[69 FR 67818, Nov. 22, 2004, as amended at 77 FR 31723, May 30, 2012]



Sec. 522.842  Estradiol benzoate and testosterone propionate.

    (a) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (c) of this section.
    (1) No. 000856 for use as in paragraph (c)(1)(i), (c)(2), and (c)(3) 
of this section.
    (2) No. 000986 for use as in paragraph (c) of this section.
    (b) Related tolerances. See Sec. Sec. 556.240 and 556.710 of this 
chapter.
    (c) Conditions of use. For implantation in heifers as follows:
    (1) Amount. (i) 20 milligrams (mg) estradiol benzoate and 200 mg 
testosterone propionate (one implant consisting of 8 pellets, each 
pellet containing 2.5 mg estradiol benzoate and 25 mg testosterone 
propionate) per implant dose.
    (ii) 20 mg estradiol benzoate and 200 mg testosterone propionate 
(one implant consisting of 9 pellets, each of 8 pellets containing 2.5 
mg estradiol benzoate and 25 mg testosterone propionate, and 1 pellet 
containing 29 mg tylosin tartrate) per implant dose.
    (2) Indications for use. For increased rate of weight gain and 
improved feed efficiency.
    (3) Limitations. For heifers weighing 400 pounds or more; for 
subcutaneous ear implantation, one dose per animal; not for use in dairy 
or beef replacement heifers. Safety and effectiveness have not been 
established in veal calves. A withdrawal period has not been established 
for this product in preruminating calves. Do not use in calves to be 
processed for veal.

[69 FR 68252, Nov. 24, 2004, as amended at 77 FR 31723, May 30, 2012]

[[Page 267]]



Sec. 522.850  Estradiol valerate and norgestomet in combination.

    (a) Specifications. The product is a two-component drug consisting 
of the following:
    (1) An implant containing 6.0 milligrams of norgestomet.
    (2) An injectable solution (sesame oil) containing 3.0 milligrams of 
norgestomet and 5.0 milligrams of estradiol valerate per 2 milliliters.
    (b) Sponsor. See 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. One implant and 2 milliliters of 
injection at time of implantation.
    (2) Indications for use. For synchronization of estrus/ovulation in 
cycling beef cattle and non-lactating dairy heifers.
    (3) Limitations. Insert implant subcutaneously in the ear only; then 
immediately inject solution intramuscularly only. Counting the day of 
implantation as day 1, remove the implant on day 10. Collect all 
implants as they are removed and burn them. While animals are restrained 
for artificial insemination, avoid other treatments such as 
vaccinations, dipping, pour-on grub and louse prevention, spraying, etc. 
When inseminating without estrus detection, the entire treated group 
should be started at 48 hours after the last implant has been removed 
and should be completed within 6 hours. Where estrus detection is 
preferred, insemination should be approximately 12 hours after first 
detection of estrus. Those that do not conceive can be re-bred when they 
return to estrus approximately 17 to 25 days after implant removal. Do 
not use in cows producing milk for human consumption.

[47 FR 55477, Dec. 10, 1982, as amended at 48 FR 49656, Oct. 27, 1983; 
51 FR 33592, Sept. 22, 1986; 54 FR 1165, Jan. 12, 1989]



Sec. 522.863  Ethylisobutrazine hydrochloride injection.

    (a) Specifications. The drug is a sterile aqueous solution. Each 
milliliter contains 50 milligrams of ethylisobutrazine hydrochloride.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is used in dogs as a tranquilizer.\1\
    (2) It is administered intramuscularly at a dosage level of 2 to 5 
milligrams of ethylisobutrazine hydrochloride per pound of body weight 
for profound tranquilization. It is administered intravenously at a 
dosage level of 1 to 2 milligrams of ethylisobutrazine hydrochloride per 
pound of body weight to effect.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (3) It is not to be used in conjunction with organophosphates and/or 
procaine hydrochloride because phenothiazines may potentiate the 
toxicity of organophosphates and the activity of procaine 
hydrochloride.\1\
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.\1\

[40 FR 13858, Mar. 27, 1975, as amended at 46 FR 48642, Oct. 2, 1981; 61 
FR 8873, Mar. 6, 1996; 62 FR 61625, Nov. 19, 1997]



Sec. 522.870  Etodolac.

    (a) Specifications. Each milliliter contains 100 milligrams (mg) 
etodolac.
    (b) Sponsor. See No. 000010 in Sec. 510.600 of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Administer 4.5 to 6.8 mg/
pound (10 to 15 mg/kilogram) body weight as a single, dorsoscapular 
subcutaneous injection. If needed, the daily dose of etodolac tablets as 
in Sec. 520.870 of this chapter may be given 24 hours after the 
injection.
    (2) Indications for use. For the control of pain and inflammation 
associated with osteoarthritis.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[72 FR 51365, Sept. 7, 2007, as amended at 75 FR 10167, Mar. 5, 2010]



Sec. 522.883  Etorphine hydrochloride injection.

    (a) Chemical name. 6,7,8,14 - tetrahydro - alpha - methyl - alpha - 
propyl - 6,14 - endo-ethenooripavine-alpha-methanol hydrochloride.

[[Page 268]]

    (b) Specifications. Each milliliter of etorphine hydrochloride 
injection, veterinary, contains 1 mg of etorphine hydrochloride in 
sterile aqueous solution.
    (c) Sponsors. See No. 053923 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) The drug is used for the immobilization 
of wild and exotic animals.
    (2) It is administered intramuscularly by hand syringe or syringe 
dart at a suitable dosage level depending upon the species.
    (3) Do not use the drug unless diprenorphine hydrochloride 
injection, veterinary, as provided for in Sec. 522.723, is available 
for use in reversing the effects of etorphine hydrochloride injection, 
veterinary.
    (4) For use in wild or exotic animals only. Do not use in domestic 
food-producing animals. Do not use 30 days before, or during, the 
hunting season in free-ranging wild animals that might be used for food.
    (5) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian. Distribution is restricted to veterinarians 
engaged in zoo and exotic animal practice, wildlife management programs, 
and researchers.

[40 FR 13858, Mar. 27, 1975, as amended at 48 FR 16241, Apr. 15, 1983; 
61 FR 260, Jan. 4, 1996]



Sec. 522.900  Euthanasia solution.

    (a) Specifications. Each milliliter (mL) of solution contains:
    (1) 390 milligrams (mg) of pentobarbital sodium and 50 mg phenytoin 
sodium.
    (2) 400 mg secobarbital sodium and 25 mg dibucaine hydrochloride.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter:
    (1) Nos. 000061, 051311, and 054925 for use of product described in 
paragraph (a)(1) of this section.
    (2) No. 000856 for use of product described in paragraph (a)(2) of 
this section.
    (c) Special considerations. Product labeling shall bear the 
following warning statements: ``ENVIRONMENTAL HAZARD: This product is 
toxic to wildlife. Birds and mammals feeding on treated animals may be 
killed. Euthanized animals must be properly disposed of by deep burial, 
incineration, or other method in compliance with state and local laws, 
to prevent consumption of carcass material by scavenging wildlife.''
    (d) Conditions of use in dogs--(1) Indications for use. For humane, 
painless, and rapid euthanasia.
    (2) Amount. One mL per 10 pounds of body weight.
    (3) Limitations. Do not use in animals intended for food. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.

[68 FR 42969, July 21, 2003, as amended at 68 FR 55824, Sept. 29, 2003; 
70 FR 8929, Feb. 24, 2005; 71 FR 13542, Mar. 16, 2006]



Sec. 522.914  Fenprostalene solution.

    (a) Specifications--(1) Cattle. Each milliliter of sterile solution 
contains 0.5 milligram of fenprostalene.
    (2) Swine. Each milliliter of sterile solution contains 0.25 
milligram of fenprostalene.
    (b) Sponsor. See 000856 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.277 of this chapter.
    (d) Special considerations. Labeling shall bear the following 
statements: Women of childbearing age, asthmatics, and persons with 
bronchial and other respiratory problems should exercise extreme caution 
when handling this product. It is readily absorbed through the skin and 
may cause abortion and/or bronchiospasms. Accidental spillage on the 
skin should be washed off immediately with soap and water.
    (e) Conditions of use--(1) Cattle--(i) Amount. 1 milligram (2 
milliliters) subcutaneously per animal.
    (ii) Indications for use. For feedlot heifers to induce abortion 
when pregnant 150 days or less. For beef or nonlactating dairy cattle 
for estrus synchronization.
    (iii) Limitations. Subcutaneous use in cattle only. Feedlot heifers 
to induce abortion, single dose. Beef or nonlactating dairy cattle for 
estrus synchronization, a single dose or two doses 11 to 13 days apart. 
Do not use in pregnant animals unless abortion is desired. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.

[[Page 269]]

    (2) Swine--(i) Amount. 0.25 milligram (1 milliliter) subcutaneously 
once per animal.
    (ii) Indications for use. For sows and gilts pregnant at least 112 
days for the induction of parturition.
    (iii) Limitations. Subcutaneous use in swine only. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.

[48 FR 7164, Feb. 18, 1983, as amended at 49 FR 26715, June 29, 1984; 54 
FR 400, Jan. 6, 1989; 61 FR 5506, Feb. 13, 1996]



Sec. 522.930  Firocoxib.

    (a) Specifications. Each milliliter of solution contains 20 
milligrams (mg) firocoxib.
    (b) Sponsors. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. Administer 0.04 mg/
pound (lb) (0.09 mg/kilogram (kg)) of body weight (BW) intravenously, 
once daily, for up to 5 days. If further treatment is needed, firocoxib 
oral paste can be administered at a dosage of 0.045 mg/lb (0.1 mg/kg) of 
BW for up to an additional 9 days of treatment.
    (2) Indications for use. For the control of pain and inflammation 
associated with osteoarthritis.
    (3) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[75 FR 59611, Sept. 28, 2010]



Sec. 522.955  Florfenicol.

    (a) Specifications. Each milliliter (mL) of solution contains:
    (1) 300 milligrams (mg) florfenicol in the inactive vehicles 2-
pyrrolidone and triacetin.
    (2) 300 mg florfenicol in the inactive vehicle n-methyl-2-
pyrrolidone.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter for 
use of product described in paragraph (a)(1) as in paragraph (d)(1)(i) 
and for use of product described in paragraph (a)(2) as in paragraph 
(d)(1)(ii).
    (c) Related tolerance. See Sec. 556.283 of this chapter.
    (d) Conditions of use--(1) Cattle--(i) 300 mg/mL florfenicol in 2-
pyrrolidone and triacetin (inactive vehicles).
    (A) Amount. 40 mg/kilogram (kg) body weight as a single subcutaneous 
injection.
    (B) Indications for use. For treatment of bovine respiratory disease 
(BRD) associated with Mannheimia haemolytica, Pasteurella multocida, 
Histophilus somni, and Mycoplasma bovis in beef and non-lactating dairy 
cattle.
    (C) Limitations. Do not slaughter within 44 days of treatment. Do 
not use in female dairy cattle 20 months of age or older. Use may cause 
milk residues. A withdrawal period has not been established in 
preruminating calves. Do not use in calves to be processed for veal. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.
    (ii) 300 mg/mL florfenicol in n-methyl-2-pyrrolidone (inactive 
vehicle).
    (A)(1) Amount. 20 mg/kg of body weight as an intramuscular 
injection. A second dose should be administered 48 hours later. 
Alternatively, 40 mg/kg of body weight as a single subcutaneous 
injection may be used.
    (2) Indications for use. For treatment of BRD associated with 
Mannheimia (Pasteurella) haemolytica, P. multocida, and Haemophilus 
somnus. For treatment of bovine interdigital phlegmon (foot rot, acute 
interdigital necrobacillosis, infectious pododermatitis) associated with 
Fusobacterium necrophorum and Bacteroides melaninogenicus.
    (B)(1) Amount. 40 mg/kg of body weight as a single subcutaneous 
injection.
    (2) Indications for use. For control of respiratory disease in 
cattle at high risk of developing BRD associated with Mannheimia 
(Pasteurella) haemolytica, P. multocida, and Haemophilus somnus.
    (C) Limitations. Do not slaughter within 28 days of last 
intramuscular treatment or within 38 days of subcutaneous treatment. Do 
not use in female dairy cattle 20 months of age or older. Use may cause 
milk residues. A withdrawal period has not been established in 
preruminating calves. Do not use in calves to be processed for veal. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.
    (2) [Reserved]

[73 FR 21041, Apr. 18, 2008, as amended at 74 FR 66574, Dec. 16, 2009]

[[Page 270]]



Sec. 522.956  Florfenicol and flunixin.

    (a) Specifications. Each milliliter (mL) of solution contains 300 
milligrams (mg) florfenicol and 16.5 mg flunixin (27.37 mg flunixin 
meglumine).
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter for 
use as in paragraph (d) of this section.
    (c) Tolerances. See Sec. Sec. 556.283 and 556.286 of this chapter.
    (d) Conditions for use in cattle--(1) Amount. 40 mg florfenicol/kg 
body weight (BW) and 2.2 mg flunixin/kg BW (equivalent to 2 mL/15 kg BW 
or 6 mL/100 lbs) once, by subcutaneous injection.
    (2) Indications for use. For treatment of bovine respiratory disease 
(BRD) associated with Mannheimia haemolytica, Pasteurella multocida, 
Histophilus somni, and Mycoplasma bovis, and control of BRD-associated 
pyrexia in beef and non-lactating dairy cattle.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian. Animals intended for human consumption 
must not be slaughtered within 38 days of treatment. Do not use in 
female dairy cattle 20 months of age or older. Use of florfenicol in 
this class of cattle may cause milk residues. A withdrawal period has 
not been established in preruminating calves. Do not use in calves to be 
processed for veal.

[75 FR 1275, Jan. 11, 2010, as amended at 75 FR 54018, Sept. 3, 2010]



Sec. 522.960  Flumethasone implantation or injectable dosage forms.



Sec. 522.960a  Flumethasone suspension.

    (a) Chemical name. 6[alpha],9[alpha]-Difluoro-11[beta],17,21 - 
trihydroxy - 16[alpha] - methylpregna - 1,4 - diene - 3,20 - dione.
    (b) Specifications. Flumethasone suspension is sterile and each 
milliliter of the drug contains: 2 milligrams of flumethasone, 20 
milligrams of propylene glycol, 9 milligrams of benzyl alcohol (as 
preservative), 8 milligrams of sodium chloride, 0.02 milligram of 
polysorbate-80, 0.1 milligram of citric acid, and water for injection 
q.s.
    (c) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) It is recommended in the various disease 
states involving synovial structures (joints) of horses where excessive 
synovial fluid of inflammatory origin is present and where permanent 
structural changes do not exist. Such conditions include arthritis, 
carpitis, and osselets.
    (2) The drug is administered intraarticularly at a dosage level of 6 
to 10 milligrams per injection. The dosage level is dependent upon the 
size of the involved synovial structure and the degree of severity of 
the condition under treatment. The dosage is limited to a single 
injection per week in any one synovial structure.
    (3) Clinical and experimental data have demonstrated that 
corticosteroids administered orally and parenterally to animals during 
the last trimester of pregnancy may induce the first stage of 
parturition and may precipitate premature parturition followed by 
dystocia, fetal death, retained placenta, and metritis. The drug is not 
to be used in horses intended for slaughter for food purposes.
    (4) For use only by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975. Redesignated at 44 FR 16011, Mar. 16, 1979, 
as amended at 61 FR 5506, Feb. 13, 1996]



Sec. 522.960b  Flumethasone acetate injection.

    (a) Chemical name. 6-alpha,9-alpha-difluoro - 16 - alpha - 
methylprednisolone 21-acetate.
    (b) Specifications. Flumethasone injection is sterile and contains 
per cubic centimeter: 2 milligrams of flumethasone acetate; 20 
milligrams of propylene glycol; 9 milligrams of benzyl alcohol (as 
preservative); 8 milligrams of sodium chloride; 1 milligram of 
polysorbate 80; 0.1 milligram of citric acid; water for injection q.s.
    (c) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) It is recommended in certain acute and 
chronic canine dermatoses of varying etiology to help control the 
pruritus, irritation, and inflammation associated with these conditions.
    (2) The drug is administered intramuscularly at the following 
recommended daily dosage:

[[Page 271]]



------------------------------------------------------------------------
                                                               Dosage in
                 Weight of animal in pounds                   milligrams
------------------------------------------------------------------------
Up to 10....................................................         1.0
10 to 25....................................................         2.0
25 and over.................................................         4.0
------------------------------------------------------------------------


Dosage should be adjusted according to the weight of the animal, the 
severity of the symptoms, and the response noted. Dosage by injection 
should not exceed 3 days of therapy. With chronic conditions 
intramuscular therapy may be followed by oral administration of 
flumethasone tablets at a daily dose of from 0.0625 to 0.25 milligram 
per animal.
    (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975. Redesignated at 44 FR 16011, Mar. 16, 1979, 
as amended at 61 FR 5507, Feb. 13, 1996]



Sec. 522.960c  Flumethasone solution.

    (a) Specifications. Each milliliter of sterile aqueous solution 
contains 0.5 milligram flumethasone.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. It is used as follows:
    (1) Horses--(i) Amount. 1.25 to 2.5 milligrams daily, intravenously, 
intramuscularly, or intra-articularly.
    (ii) Indications for use. It is used for the treatment of 
musculoskeletal conditions due to inflammation, where permanent 
structural changes do not exist, e.g., bursitis, carpitis, osselets, and 
myositis; and allergic states, e.g., hives, urticaria, and insect bites.
    (iii) Limitations--(a) Clinical and experimental data have 
demonstrated that corticosteroids administered orally or parenterally to 
animals may induce the first stage of parturition when administered 
during the last trimester of pregnancy and may precipitate premature 
parturition followed by dystocia, fetal death, retained placenta, and 
metritis.
    (b) When a long-term therapy is used, the dose should be 
individually adjusted to the minimum maintenance dose. A protein-rich 
diet is useful in dogs and cats on long-term therapy to counteract 
nitrogen loss if it should occur. A small amount of potassium chloride 
daily in the diet will counteract excessive potassium loss if this is 
present.
    (c) It has been demonstrated that corticosteroids, especially at 
high dose levels, may result in delayed wound and fracture healing.
    (d) Flumethasone may be administered to animals with bacterial 
diseases provided appropriate antibacterial therapy is administered 
simultaneously.
    (e) The drug is not to be used in horses intended for slaughter for 
food purposes.
    (f) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (2) Dogs--(i) Amount. 0.0625 to 0.25 milligram daily, intravenously, 
intramuscularly, or subcutaneously; 0.125 to 1.0 milligram daily, 
intralesionally, depending on the size and location of the lesion; 0.166 
to 1.0 milligram daily, intra-articularly, depending on the severity of 
the condition and the size of the involved joint.
    (ii) Indications for use. It is used for the treatment of 
musculoskeletal conditions due to inflamation of muscles or joints and 
accessory structures where permanent structural changes do not exist, 
e.g., arthritis, osteoarthritis, disc syndrome, and myositis (in septic 
arthritis, appropriate antibacterial therapy should be concurrently 
administered); certain acute and chronic dermatoses of varying etiology 
to help control associated pruritus, irritation, and inflammation; 
otitis externa in conjunction with topical medication; allergic states, 
e.g., hives, urticaria, and insect bites; and shock and shock-like 
states by intravenous administration.
    (iii) Limitations. See paragraph (c)(1)(iii) of this section.
    (3) Cats--(i) Amount. 0.03125 to 0.125 milligram daily 
intravenously, intramuscularly, or subcutaneously.
    (ii) Indications for use. It is used for the treatment of certain 
acute and chronic dermatoses of varying etiology to help control 
associated pruritus, irritation, and inflammation.
    (iii) Limitations. See paragraph (c)(1)(iii) of this section.

[44 FR 16011, Mar. 16, 1978, as amended at 61 FR 5507, Feb. 13, 1996]

[[Page 272]]



Sec. 522.970  Flunixin.

    (a) Specifications. Each milliliter of solution contains flunixin 
meglumine equivalent to 50 milligrams (mg) flunixin.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (e) of this section.
    (1) See Nos. 000061, 055529, and 061623 for use as in paragraph (e) 
of this section.
    (2) See No. 000856 for use as in paragraph (e)(1) of this section.
    (3) See Nos. 057561 and 059130 for use as in paragraphs (e)(1) and 
(2) of this section.
    (c) Related tolerances. See Sec. 556.286 of this chapter.
    (d) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (e) Conditions of use--(1) Horses--(i) Amount. 0.5 mg per pound (/
lb) of body weight per day, intravenously or intramuscularly, for up to 
5 days.
    (ii) Indications for use. For alleviation of inflammation and pain 
associated with musculoskeletal disorders, and alleviation of visceral 
pain associated with colic.
    (iii) Limitations. Do not use in horses intended for human 
consumption.
    (2) Cattle--(i) Amounts and indications for use--(A) Administer 1.1 
to 2.2 mg/kilogram (kg) (0.5 to 1.0 mg/lb) of body weight per day 
intravenously, as a single dose or divided into two doses administered 
at 12-hour intervals, for up to 3 days for control of pyrexia associated 
with bovine respiratory disease and endotoxemia or for control of 
inflammation in endotoxemia.
    (B) Administer 2.2 mg/kg (1.0 mg/lb) of body weight once 
intravenously for control of pyrexia associated with acute bovine 
mastitis.
    (ii) Limitations. Cattle must not be slaughtered for human 
consumption within 4 days of last treatment. Milk that has been taken 
during treatment and for 36 hours after the last treatment must not be 
used for food. Do not use in dry dairy cows. A withdrawal period has not 
been established for use in preruminating calves. Do not use in calves 
to be processed for veal.
    (B) For control of pyrexia associated with acute bovine mastitis.
    (iii) Limitations. Do not slaughter for food use within 4 days of 
last treatment. A withdrawal period has not been established for use in 
preruminating calves. Do not use in calves to be processed for veal. For 
Nos. 000061, 055529, 059130, and 061623: Do not use in dry dairy cows. 
Milk that has been taken during treatment and for 36 hours after the 
last treatment must not be used for food. For No. 057561: Not for use in 
lactating or dry dairy cows.
    (3) Swine--(i) Amount. Administer 2.2 mg/kg (1.0 mg/lb) of body 
weight as a single intramuscular injection.
    (ii) Indications for use. For the control of pyrexia associated with 
swine respiratory disease.
    (iii) Limitations. Swine must not be slaughtered for human 
consumption within 12 days of last treatment.

[42 FR 39103, Aug. 2, 1977, as amended at 52 FR 7832, Mar. 13, 1987; 60 
FR 54942, Oct. 27, 1995; 62 FR 22888, Apr. 28, 1997; 63 FR 38749, July 
20, 1998; 67 FR 9400, Mar. 1, 2002; 68 FR 70701, Dec. 19, 2003; 69 FR 
53618, Sept. 2, 2004; 69 FR 60308, Oct. 8, 2004; 70 FR 48868, Aug. 22, 
2005; 70 FR 70998, Nov. 25, 2005; 71 FR 15564, Mar. 29, 2006; 71 FR 
16222, Mar. 31, 2006; 73 FR 2809, Jan. 16, 2008; 73 FR 28037, May 15, 
2008; 74 FR 6994, Feb. 12, 2009; 74 FR 34236, July 15, 2009; 75 FR 
13225, Mar. 19, 2010; 75 FR 76260, Dec. 8, 2010]



Sec. 522.995  Fluprostenol sodium injection.

    (a) Specifications. Each milliliter of sterile aqueous solution 
contains fluprostenol sodium equivalent to 50 micrograms of 
fluprostenol.
    (b) Sponsor. See 000859 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 0.55 microgram fluprostenol per 
kilogram of body weight.
    (2) Indications for use. The drug is used in mares for its 
luteolytic effect to control the timing of estrus in estrous cycling and 
in clinically anestrous mares that have a corpus luteum.
    (3) Limitations. Administer by intramuscular injection only. 
Warning: Not for use in horses intended for food. For veterinary use 
only. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian. Women of childbearing age, asthmatics, and 
persons with bronchial

[[Page 273]]

and other respiratory problems should exercise extreme caution when 
handling this product. In the early stages, women may be unaware of 
their pregnancies. Fluprostenol is readily absorbed through the skin and 
can cause abortion and/or bronchiospasms. Direct contact with the skin 
should therefore be avoided. Accidental spillage on the skin should be 
washed off immediately with soap and water.

[44 FR 52191, Sept. 7, 1979, as amended at 47 FR 22092, May 21, 1982]



Sec. 522.1002  Follicle stimulating hormone.

    (a)(1) Specifications. Each package contains 2 vials. One vial 
contains dry, powdered, porcine pituitary gland equivalent to 75 units 
(NIH-FSH-S1) of follicle stimulating hormone. The other vial contains 10 
milliliters of aqueous diluent.
    (2) Sponsor. See No. 052923 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) Dosage. 12.5 units of follicle 
stimulating hormone twice a day for 3 days (a total of 75 units). To 
effect regression of the corpus luteum, prostaglandin should be given 
with the 5th dose.
    (ii) Indications for use. For induction of superovulation in cows 
for procedures requiring the production of multiple ova at a single 
estrus.
    (iii) Limitations. For intramuscular use in cows that are not 
pregnant and have a normal corpus luteum. Federal law restricts this 
drug to use by or on the order of a licensed veterinarian.
    (b)(1) Specifications. The drug is a lyophilized pituitary extract 
material. Each 10-milliliter vial contains an amount equivalent to 50 
milligrams of standard porcine follicle stimulating hormone and is 
reconstituted for use by addition of 10 milliliters of 0.9 percent 
aqueous sodium chloride solution.
    (2) Sponsor. See 063112 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) Dosage. Cattle and horses, 10-50 
milligrams; sheep and swine, 5-25 milligrams; dogs, 5-15 milligrams.
    (ii) Indications for use. The drug is used as a supplemental source 
of follicle stimulating hormone where there is a general deficiency in 
cattle, horses, sheep, swine, and dogs.
    (iii) Limitations. Administer intramuscularly, subcutaneously, or 
intravenously. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[58 FR 47377, Sept. 9, 1993, as amended at 62 FR 62242, Nov. 21, 1997; 
76 FR 2808, Jan. 18, 2011]



Sec. 522.1004  Fomepizole.

    (a) Specifications. Each vial contains 1.5 grams fomepizole (1.5 
milliliter (mL) of 1.0 gram per mL solution).
    (b) Sponsors. See Nos. 046129 and 063286 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use in dogs--(1) Amount. 20 milligrams per 
kilogram (mg/kg) of body weight intravenously initially, followed by 15 
mg/kg at 12 and 24 hours, and 5 mg/kg at 36 hours.
    (2) Indications for use. As an antidote for ethylene glycol 
(antifreeze) poisoning in dogs who have ingested or are suspected of 
having ingested ethylene glycol.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[61 FR 68147, Dec. 27, 1996, as amended at 71 FR 28266, May 16, 2006; 74 
FR 26952, June 5, 2009; 74 FR 47725, Sept. 17, 2009; 77 FR 26697, May 7, 
2012]



Sec. 522.1010  Furosemide.

    (a) Specifications--(1) Each milliliter (mL) of solution contains 50 
milligrams (mg) furosemide monoethanolamine.
    (2) Each mL of solution contains 50 mg furosemide diethanolamine.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use of products described in paragraph (a) of this section for use as in 
paragraph (d) of this section.
    (1) No. 000010 as described in paragraph (a)(1) of this section for 
use as in paragraphs (d)(1) and (d)(2)(ii) of this section.
    (2) No. 061623 as described in paragraph (a)(2) of this section for 
use as in paragraph (d)(2)(ii) of this section.
    (3) No. 000859 as described in paragraph (a)(2) for use as in 
paragraphs (d)(1), (d)(2)(i), and (d)(3) of this section.
    (4) No. 000061 as described in paragraph (a)(2) for use as in 
paragraphs (d)(1), (d)(2)(iii), and (d)(3) of this section.

[[Page 274]]

    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Conditions of use--(1) Dogs and cats--(i) Amount. 1.25 to 2.5 mg 
per pound (/lb) body weight once or twice daily, intramuscularly or 
intravenously.
    (ii) Indications for use. For the treatment of edema (pulmonary 
congestion, ascites) associated with cardiac insufficiency and acute 
noninflammatory tissue edema.
    (2) Horses--(i) Amount. 250 to 500 mg per animal once or twice 
daily, intramuscularly or intravenously.
    (A) Indications for use. For the treatment of edema (pulmonary 
congestion, ascites) associated with cardiac insufficiency, and acute 
noninflammatory tissue edema.
    (B) Limitations. Do not use in horses intended for food.
    (ii) Amount. 0.5 mg/lb body weight once or twice daily, 
intramuscularly or intravenously.
    (A) Indications for use. For treatment of acute noninflammatory 
tissue edema.
    (B) Limitations. Do not use in horses intended for food.
    (iii) Amount. 250 to 500 mg/animal once or twice daily, 
intramuscularly or intravenously.
    (A) Indications for use. For the treatment of edema (pulmonary 
congestion, ascites) associated with cardiac insufficiency, and acute 
noninflammatory tissue edema.
    (B) Limitations. Do not use in horses intended for human 
consumption.
    (3) Cattle--(i) Amount. 500 mg/animal once daily, intramuscularly or 
intravenously; or 250 mg/animal twice daily at 12-hour intervals, 
intramuscularly or intravenously.
    (ii) Indications for use. For the treatment of physiological 
parturient edema of the mammary gland and associated structures.
    (iii) Limitations. Treatment not to exceed 48 hours post-
parturition. Milk taken during treatment and for 48 hours (four 
milkings) after the last treatment must not be used for food. Cattle 
must not be slaughtered for food within 48 hours following last 
treatment.

[66 FR 47961, Sept. 17, 2001, as amended at 67 FR 18086, Apr. 15, 2002; 
68 FR 59881, Oct. 20, 2003; 69 FR 17585, Apr. 5, 2004; 71 FR 39548, July 
13, 2006; 74 FR 61516, Nov. 25, 2009; 76 FR 17338, Mar. 29, 2011; 78 FR 
17597, Mar. 22, 2013]



Sec. 522.1014  Gamithromycin.

    (a) Specifications. Each milliliter (mL) of solution contains 150 
milligrams (mg) gamithromycin.
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.292 of this chapter.
    (d) Conditions of use--(1) Cattle--(i) Amount. Administer 6 mg/
kilogram of body weight (2 mL per 110 pounds) one time by subcutaneous 
injection in the neck.
    (ii) Indications for use. For the treatment of bovine respiratory 
disease (BRD) associated with Mannheimia haemolytica, Pasteurella 
multocida, Histophilus somni, and Mycoplasma bovis in beef and non-
lactating dairy cattle; and for the control of respiratory disease in 
beef and non-lactating dairy cattle at high risk of developing BRD 
associated with M. haemolytica and P. multocida.
    (iii) Limitations. Cattle intended for human consumption must not be 
slaughtered within 35 days from the last treatment. Do not use in female 
dairy cattle 20 months of age or older. A withdrawal period has not been 
established for this product in preruminating calves. Do not use in 
calves to be processed for veal. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (2) [Reserved]

[76 FR 57906, Sept. 19, 2011, as amended at 77 FR 26162, May 3, 2012]



Sec. 522.1020  Gelatin solution.

    (a) Specifications. It is sterile and each 100 cubic centimeters 
contains 8 grams of gelatin in an 0.85 percent sodium chloride solution.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is used to restore circulatory volume 
and maintain blood pressure in animals being treated for shock.

[[Page 275]]

    (2) The exact dosage to be administered must be determined after 
evaluating the animal's condition and will vary according to the size of 
the animal and the degree of shock. A suggested dosage range for small 
animals such as dogs is 4 to 8 cubic centimeters per pound body weight. 
The suggested dosage range for large animals such as sheep, calves, 
cows, or horses is 2 to 4 cubic centimeters per pound of body weight. It 
is administered intravenously at a rate of 10 cubic centimeters per 
minute in small animals and 20 to 30 cubic centimeters per minute in 
large animals. The solution is administered aseptically and must be 
between 50 to 70 [deg]F. when injected.
    (3) A few animals will exhibit signs of allergic reaction. This 
solution can cause transient reversible nephrosis. This product is not 
intended to replace whole blood in cases of anemia and should not be 
used in the presence of renal dysfunction. Unused portions remaining in 
bottles should be discarded.
    (4) For use only by or on the order of a licensed veterinarian.



Sec. 522.1044  Gentamicin.

    (a) Specifications. Each milliliter of solution contains gentamicin 
sulfate equivalent to 5, 50, or 100 milligrams (mg) gentamicin.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (d) of this section.
    (1) No. 000061 for use of 5 mg per milliliter (/mL) solution in 
swine as in paragraph (d)(4), 50 mg/mL solution in dogs and cats as in 
paragraph (d)(1), 50 mg/mL and 100 mg/mL solution in chickens and 
turkeys as in paragraphs (d)(2) and (d)(3) of this section.
    (2) No. 058005 for use of 5 mg/mL solution in swine as in paragraph 
(d)(4) of this section.
    (3) No. 000010 for use of 50 mg/mL solution in dogs as in paragraph 
(d)(5) of this section.
    (4) No. 000859 for use of 100 mg/mL solution in turkeys as in 
paragraph (d)(2) and in chickens as in paragraph (d)(3) of this section.
    (c) Related tolerances. See Sec. 556.300 of this chapter.
    (d) Conditions of use--(1) Dogs and cats--(i) Amount. Two milligrams 
of gentamicin per pound of body weight, twice daily on the first day, 
once daily thereafter, using a 50 milligram-per-milliliter solution.
    (ii) Indications for use--(a) Dogs. For the treatment of infections 
of urinary tract (cystitis, nephritis), respiratory tract (tonsillitis, 
pneumonia, tracheobronchitis), skin and soft tissue (pyodermatitis, 
wounds, lacerations, peritonitis).
    (b) Cats. For the treatment of infections of urinary tract 
(cystitis, nephritis), respiratory tract (pneumonitis, pneumonia, upper 
respiratory tract infections), skin and soft tissue (wounds, 
lacerations, peritonitis), and as supportive therapy for secondary 
bacterial infections associated with panleucopenia.
    (iii) Limitations. Administer intramuscularly or subcutaneously. If 
response is not noted after 7 days, the antibiotic sensitivity of the 
infecting organism should be retested. Federal law restricts this drug 
to use by or on the order of a licensed veterinarian.
    (2) Turkeys--(i) Amount. One milligram of gentamicin per 0.2 
milliliter dose, using the 50- or 100-milligrams-per-milliliter product 
diluted with sterile saline to a concentration of 5 milligrams-per-
milliliter.
    (ii) Indications for use. As an aid in the prevention of early 
mortality due to Arizona paracolon infections susceptible to gentamicin.
    (iii) Limitations. For 1- to 3-day old turkey poults. Administer 
subcutaneously in the neck. Injected poults must not be slaughtered for 
food for at least 9 weeks after treatment.
    (3) Chickens--(i) Amount. 0.2 milligram of gentamicin per 0.2 
milliliter dose, using the 50- or 100-milligrams-per-milliliter product 
diluted with sterile saline to a concentration of 1.0 milligram-per-
milliliter.
    (ii) Indications for use. In day-old chickens, for prevention of 
early mortality caused by Escherichia coli. Salmonella typhimurium, and 
Pseudomonas aeruginosa that are susceptible to gentamicin.
    (iii) Limitations. For use in day-old chickens only. Administer 
aseptically, injecting the diluted product subcutaneously in the neck. 
Do not slaughter treated animals for food for at least 5 weeks after 
treatment.

[[Page 276]]

    (4) Swine--(i) Amount. 5 milligrams of gentamicin as a single 
intramuscular dose using 5 milligram-per-milliliter solution.
    (ii) Indications for use. In piglets up to 3 days old for treatment 
of porcine colibacillosis caused by strains of E. coli sensitive to 
gentamicin.
    (iii) Limitations. For single intramuscular dose in pigs up to 3 
days of age only. Do not slaughter treated animals for food for at least 
40 days following treatment.
    (5) Dogs--(i) Amount. 2 milligrams of gentamicin per pound of body 
weight, twice daily on the first day, then once daily.
    (ii) Indications for use. For use in the treatment of urinary tract 
infections (cystitis) caused by Proteus mirabilis, Escherichia coli, and 
Staphylococcus aureus.
    (iii) Limitations. Administer intramuscularly or subcutaneously. If 
no improvement is seen after 3 days, treatment should be discontinued 
and the diagnosis reevaluated. Treatment not to exceed 7 days. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.

[43 FR 1942, Jan. 13, 1978, as amended at 48 FR 791, Jan. 7, 1983; 51 FR 
15606, Apr. 25, 1986; 52 FR 7832, Mar. 13, 1987; 53 FR 40727, Oct. 18, 
1988; 60 FR 29985, June 7, 1995; 61 FR 24441, May 15, 1996; 62 FR 45157, 
Aug. 26, 1997; 63 FR 59714, Nov. 5, 1998; 63 FR 68182, Dec. 10, 1998; 65 
FR 45877, July 26, 2000; 71 FR 76901, Dec. 22, 2006; 78 FR 17597, Mar. 
22, 2013]



Sec. 522.1066  Glycopyrrolate.

    (a) Specifications. Each milliliter of solution contains 0.2 
milligram glycopyrrolate.
    (b) Sponsors. See Nos. 000856 and 000859 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use in dogs and cats--(1) Amount. 5 micrograms per 
pound of body weight (0.25 milliliter per 10 pounds of body weight) by 
intravenous, intramuscular, or subcutaneous injection in dogs or by 
intramuscular injection in cats.
    (2) Indications for use. As a preanesthetic agent.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[71 FR 64451, Nov. 2, 2006, as amended at 78 FR 17597, Mar. 22, 2013]



Sec. 522.1073  Gonadorelin acetate.

    (a) Specifications. Each milliliter of solution contains 100 
micrograms ([micro]g) of gonadorelin as gonadorelin acetate.
    (b) Sponsor. See No. 068504 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in cattle--(1) Indications for use and 
amounts.
    (i) For the treatment of ovarian follicular cysts in dairy cattle. 
Administer 100 [micro]g gonadorelin by intramuscular or intravenous 
injection.
    (ii) For use with cloprostenol sodium to synchronize estrous cycles 
to allow for fixed-time artificial insemination in lactating dairy cows 
and beef cows. Administer to each cow 100 [micro]g gonadorelin by 
intramuscular injection, followed 6 to 8 days later by 500 [micro]g 
cloprostenol by intramuscular injection, followed 30 to 72 hours later 
by 100 [micro]g gonadorelin by intramuscular injection.
    (2) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[78 FR 17867, Mar. 25, 2013]



Sec. 522.1075  Gonadorelin diacetate tetrahydrate.

    (a) Specifications. Each milliliter of solution contains 50 
micrograms ([micro]g) of gonadorelin diacetate tetrahydrate.
    (b) Sponsors. See Nos. 000061, 050604, and 059130 in Sec. 
510.600(c) of this chapter.
    (c) Conditions of use in cattle. It is used as follows:
    (1) Amount. 100 [micro]g per cow as a single intramuscular or 
intravenous injection.
    (2) Indications for use. For the treatment of ovarian cysts in dairy 
cattle.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[67 FR 68759, Nov. 13, 2002, as amended at 74 FR 61516, Nov. 25, 2009. 
Redesignated at 78 FR 17867, Mar. 25, 2013]



Sec. 522.1077  Gonadorelin hydrochloride.

    (a) Specifications. Each milliliter sterile aqueous solution 
contains 50 micrograms of gonadorelin (as hydrochloride).
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.

[[Page 277]]

    (c) Conditions of use in cattle--(1) Amount. 100 micrograms per cow 
intramuscularly.
    (2) Indications for use. For the treatment of cystic ovaries 
(ovarian follicular cysts) in cattle to reduce the time to first estrus.
    (3) Limitations. For intramuscular use only. Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.

[54 FR 50235, Dec. 5, 1989, as amended at 78 FR 17867, Mar. 25, 2013]



Sec. 522.1079  Serum gonadotropin and chorionic gonadotropin.

    (a) Specifications. Each dose consists of 400 international units 
(I.U.) serum gonadotropin and 200 I.U. chorionic gonadotropin as a 
freeze-dried powder to be reconstituted with 5 milliliters of sterile 
aqueous diluent.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in swine--(1) Amount. 400 I.U. serum 
gonadotropin with 200 I.U. chorionic gonadotropin per 5 milliliters dose 
per animal.
    (2) Indications for use. (i) Gilts. For induction of fertile estrus 
(heat) in healthy prepuberal (noncycling) gilts.
    (ii) Sows. For induction of estrus in healthy weaned sows 
experiencing delayed return to estrus.
    (3) Limitations. For subcutaneous use only.
    (i) Gilts. For use only in gilts over 5\1/2\ months of age and 
weighing at least 85 kilograms (187 pounds).
    (ii) Sows. Delayed return to estrus is most prevalent after the 
first litter. The effectiveness has not been established after later 
litters. Delayed return to estrus often occurs during periods of adverse 
environmental conditions, and sows mated under such conditions may 
farrow smaller than normal litters.

[55 FR 1405, Jan. 16, 1990, as amended at 58 FR 52222, Oct. 7, 1993; 74 
FR 61516, Nov. 25, 2009]



Sec. 522.1081  Chorionic gonadotropin.

    (a) Specifications. Each vial contains 5,000, 10,000 or 20,000 USP 
units of lyophilized powder for constitution with accompanying diluent 
to a 10-milliliter solution.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (d) of this section.
    (1) Nos. 000402 and 053501 for use as in paragraphs (d)(1)(i)(A), 
(d)(1)(i)(B) and (d)(1)(i)(C) of this section.
    (2) [Reserved]
    (3) No. 000061 for use as in paragraphs (d)(1)(i)(A) and (d)(2) of 
this section.
    (c) Related tolerances. See Sec. 556.304 of this chapter.
    (d) Conditions of use--(1) Cattle--(i) Amount. As a single dose. 
Dosage may be repeated in 14 days if the animal's behavior or 
examination of the ovaries per rectum indicates retreatment.
    (A) 10,000 USP units by intramuscular injection.
    (B) 500 to 2,500 USP units by intrafollicular injection.
    (C) 2,500 to 5,000 USP units by intravenous injection.
    (ii) Indications for use. For parenteral use in cows for treatment 
of nymphomania (frequent or constant heat) due to cystic ovaries.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Finfish--(i) Amount. 50 to 510 IU per pound of body weight for 
males, 67 to 1,816 IU per pound of body weight for females, by 
intramuscular injection. Up to three doses may be administered.
    (ii) Indications for use. An aid in improving spawning function in 
male and female brood finfish.
    (iii) Limitations. In fish intended for human consumption, the total 
dose administered per fish (all injections combined) should not exceed 
25,000 IU chorionic gonadotropin. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.

[74 FR 61516, Nov. 25, 2009, as amended at 76 FR 17778, Mar. 31, 2011; 
77 FR 55414, Sept. 10, 2012]



Sec. 522.1083  Gonadotropin releasing factor analog-diphtheria 
toxoid conjugate.

    (a) Specifications. Each milliliter of solution contains 0.2 
milligrams (mg) gonadotropin releasing factor analog-diphtheria toxoid 
conjugate.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in swine-- (1) Amount. Administer 0.4 mg (2 
milliliter

[[Page 278]]

(mL)) by subcutaneous injection no earlier than 9 weeks of age. A second 
subcutaneous injection of 0.4 mg (2 mL) should be administered at least 
4 weeks after the first dose.
    (2) Indications for use. For the temporary immunological castration 
(suppression of testicular function) and reduction of boar taint in 
intact male pigs intended for slaughter.
    (3) Limitations. Not approved for use in female pigs and barrows. Do 
not use in intact male pigs intended for breeding because of the 
disruption of reproductive function. Federal law restricts this drug to 
use by or on the order of a licensed veterinarian. Pigs should be 
slaughtered no earlier than 3 weeks and no later than 10 weeks after the 
second dose.

[76 FR 27889, May 13, 2011, as amended at 77 FR 4227, Jan. 27, 2012]



Sec. 522.1085  Guaifenesin sterile powder.

    (a) Specifications. It is a sterile powder containing guaifenesin.
    (b) Sponsor. See Nos. 000856 and 037990 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use. (1) It is indicated for intravenous use as a 
muscle relaxant in horses.
    (2) A solution is prepared by dissolving the drug in sterile water 
for injection to make a solution containing 50 milligrams of guaifenesin 
per milliliter of solution. It is administered by rapid intravenous 
infusion at a fixed dosage of 1 milliliter of prepared solution per 
pound of body weight.
    (3) Not to be used in horses intended for food.
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[49 FR 48039, Dec. 10, 1984, as amended at 60 FR 27223, May 23, 1995; 67 
FR 67521, Nov. 6, 2002; 76 FR 53051, Aug. 25, 2011]



Sec. 522.1086  Guaifenesin injection.

    (a) Specifications. Each milliliter of sterile aqueous solution 
contains 50 milligrams of guaifenesin and 50 milligrams of dextrose.
    (b) Sponsor. See Nos. 037990 and 000859 in Sec. 510.600(c) of this 
chapter.
    (c) [Reserved]
    (d) Conditions of use. (1) The drug is used intravenously in horses 
as a skeletal muscle relaxant.
    (2) Administer rapidly at a dosage of 1 milliliter per pound of body 
weight.
    (3) No to be used in horses intended for food.
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[60 FR 27223, May 23, 1995, as amended at 63 FR 29352, May 29, 1998; 78 
FR 17597, Mar. 22, 2013]



Sec. 522.1125  Hemoglobin glutamer-200 (bovine).

    (a) Specifications. Each 125 milliliter bag contains 13 grams per 
deciliter of polymerized hemoglobin of bovine origin in modified 
Lactated Ringer's Solution. It is a sterile, clear, dark purple 
solution.
    (b) Sponsor. See No. 063075 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Amount. One-time dose of 10 to 30 
milliliters per kilogram of body weight administered intravenously at a 
rate of up to 10 milliliters per kilogram per hour.
    (2) Indications for use. For the treatment of anemia in dogs by 
increasing systemic oxygen content (plasma hemoglobin concentration) and 
improving the clinical signs associated with anemia, regardless of the 
cause of anemia (hemolysis, blood loss, or ineffective erythropoiesis).
    (3) Limitations. For intravenous use only. Overdosage or an 
excessive rate of administration (greater than 10 milliliters per 
kilogram per hour) may result in circulatory overload. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.

[63 FR 11598, Mar. 10, 1998, as amended at 65 FR 20732, Apr. 18, 2000]



Sec. 522.1145  Hyaluronate sodium.

    (a)(1) Specifications. Each milliliter of sterile aqueous solution 
contains 10 milligrams of hyaluronate sodium.
    (2) Sponsor. See 000009 in Sec. 510.600(c).
    (3) Conditions of use--(i) Amount. Small and medium-size joints 
(carpal, fetlock)--20 milligrams; larger joint (hock)--40 milligrams.
    (ii) Indications for use. Treatment of joint dysfunction in horses 
due to noninfectious synovitis associated with equine osteoarthritis.

[[Page 279]]

    (iii) Limitations. For intra-articular injection in horses only. 
Treatment may be repeated at weekly intervals for a total of three 
treatments. Do not use in horses intended for human consumption. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.
    (b)(1) Specifications. Each milliliter of sterile aqueous solution 
contains 5 milligrams of hyaluronate sodium.
    (2) Sponsor. See 053501 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use--(i) Amount. Small and medium-size joints 
(carpal, fetlock)--10 milligrams; larger joint (hock)--20 milligrams.
    (ii) Indications for use. Treatment of joint dysfunction in horses 
due to noninfectious synovitis associated with equine osteoarthritis.
    (iii) Limitations. For intraarticular injection in horses only. 
Treatment may be repeated at weekly intervals for a total of four 
treatments. Not for use in horses intended for food. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.
    (c)(1) Specifications. Each milliliter of sterile aqueous solution 
contains 10 milligrams of hyaluronate sodium.
    (2) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use--(i) Amount. Small and medium-size joints 
(carpal, fetlock)--20 milligrams.
    (ii) Indications for use. Treatment of carpal or fetlock joint 
dysfunction in horses due to acute or chronic noninfectious synovitis 
associated with equine osteoarthritis.
    (iii) Limitations. For intraarticular injection in horses only. 
Treatment may be repeated after 1 or more weeks but not to exceed 2 
injections per week for a total of 4 weeks. Not for use in horses 
intended for food. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.
    (d)(1) Specifications. Each milliliter of sterile aqueous solution 
contains 10 milligrams of hyaluronate sodium.
    (2) Sponsor. See 000061 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use--(i) Amount. 50 milligrams in carpal and 
fetlock joints.
    (ii) Indications for use. For treatment of equine carpal and fetlock 
joint dysfunction caused by traumatic and/or degenerative joint disease 
of mild to moderate severity.
    (iii) Limitations. For intraarticular injection in horses only. Not 
for use in horses intended for food. Not intended for use in breeding 
animals. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (e)(1) Specifications. Each milliliter of solution contains:
    (i) 10 milligrams (mg) hyaluronate sodium; or
    (ii) 10 mg hyaluronate sodium with benzyl alcohol as a preservative.
    (2) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use in horses--(i) Amount. 20 mg of the product 
described in paragraph (e)(1)(i) of this section by intra-articular 
injection into the carpus or fetlock; or 40 mg of the product described 
in paragraph (e)(1)(i) or (e)(1)(ii) of this section by slow intravenous 
injection into the jugular vein. Treatment may be repeated at weekly 
intervals for a total of three treatments.
    (ii) Indications for use. For treatment of carpal or fetlock joint 
dysfunction due to noninfectious synovitis associated with equine 
osteoarthritis.
    (iii) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.
    (f)(1) Specifications. Each milliliter of sterile aqueous solution 
contains 11 milligrams of hyaluronate sodium.
    (2) Sponsor. See 060865 in Sec. 510.600(c).
    (3) Conditions of use--(i) Amount. Small and medium-size joints 
(carpal, fetlock)--22 milligrams; larger joint (hock)--44 milligrams.
    (ii) Indications for use. Treatment of joint dysfunction in horses 
due to noninfectious synovitis associated with equine osteoarthritis.
    (iii) Limitations. For intra-articular injection in horses only. 
Treatment may be repeated at weekly intervals for a total of three 
treatments. Do not use in horses intended for human consumption. Federal 
law restricts this

[[Page 280]]

drug to use by or on the order of a licensed veterinarian.

[49 FR 45124, Nov. 15, 1984, as amended at 51 FR 11438, Apr. 3, 1986; 51 
FR 25032, July 10, 1986; 53 FR 19773, May 31, 1988; 53 FR 22297, June 
15, 1988; 56 FR 50814, Oct. 9, 1991; 57 FR 2837, Jan. 24, 1992; 59 FR 
33198, June 28, 1994; 61 FR 59003, Nov. 20, 1996; 63 FR 59216, Nov. 3, 
1998; 71 FR 1689, Jan. 11, 2006; 71 FR 39204, July 12, 2006; 75 FR 1274, 
Jan. 11, 2010; 75 FR 10167, Mar. 5, 2010]



Sec. 522.1150  Hydrochlorothiazide injection.

    (a) Specifications. Each milliliter contains 25 milligrams of 
hydrochlorothiazide.
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 5 to 10 milliliters (125 to 250 
milligrams) intravenously or intramuscularly once or twice a day. After 
onset of diuresis, treatment may be continued with an orally 
administered maintenance dose.
    (2) Indications for use. For use in cattle as an aid in the 
treatment of postparturient udder edema.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (3) Limitations. Animals should be regularly and carefully observed 
for early signs of fluid and electrolyte imbalance. Take appropriate 
countermeasures if this should occur. Milk taken from dairy animals 
during treatment and for 72 hours (6 milkings) after the latest 
treatment must not be used for food. Federal law restricts this drug to 
use by or on the order of a licensed veterinarian.\1\

[43 FR 59058, Dec. 19, 1978, as amended at 62 FR 63271, Nov. 28, 1997]



Sec. 522.1155  Imidocarb dipropionate sterile powder.

    (a) Specifications. Imidocarb dipropionate powder is reconstituted 
with sterile water. Each milliliter of solution contains 100 milligrams 
of imidocarb base.
    (b) Sponsor. No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. The drug is used in horses and zebras as 
follows:
    (1) Amount. For Babesia caballi infections, use intramuscularly 2 
milligrams of imidocarb base per kilogram of body weight, repeating 
dosage once after 24 hours. For Babesia equi infections, use 4 
milligrams of imidocarb base per kilogram of body weight, repeating 
dosage four times at 72-hour intervals.
    (2) Indications for use. For the treatment of babesiosis 
(piroplasmosis) caused by Babesia caballi and Babesia equi.
    (3) Limitations. Administer intramuscularly in the neck region. Do 
not inject intravenously. Do not use for other equidae or for animals of 
other species. Do not use in horses less than 1 year old. Do not use for 
animals in near-term pregnancies. Imidocarb dipropionate is a 
cholinesterase inhibitor. Do not use this product simultaneously with or 
a few days before or after treatment with or exposure to cholinesterase-
inhibiting drugs, pesticides, or chemicals. Do not use in horses 
intended for food. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian. Imidocarb dipropionate is sold only 
under permit issued by the Director of the National Program Planning 
Staff, Veterinary Services, APHIS, USDA, to licensed or full-time State, 
Federal, or military veterinarians.

[43 FR 40455, Sept. 12, 1978, as amended at 46 FR 48642, Oct. 2, 1981; 
61 FR 8873, Mar. 6, 1996; 62 FR 61625, Nov. 19, 1997]



Sec. 522.1156  Imidocarb dipropionate solution.

    (a) Specifications. Each milliliter of injectable solution contains 
120 milligrams of imidocarb.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Dogs--(i) Amount. 6.6 milligrams 
imidocarb per kilogram (3 milligrams per pound) of body weight.
    (ii) Indications for use. Treatment of clinical signs of babesiosis 
and/or demonstrated Babesia organisms in the blood.
    (iii) Limitations. Use subcutaneously or intramuscularly. Not for 
intravenous use. Repeat the dose after 2 weeks for a total of two 
treatments.

[[Page 281]]

Imidocarb is a cholinesterase inhibitor. Do not use simultaneously with 
or a few days before or after treatment with or exposure to 
cholinesterase-inhibiting drugs, pesticides, or chemicals. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.
    (2) [Reserved]

[62 FR 66984, Dec. 23, 1997]



Sec. 522.1160  Insulin.

    (a) Specifications--(1) Each milliliter (mL) of porcine insulin zinc 
suspension contains 40 international units (IU) of insulin.
    (2) Each mL of protamine zinc recombinant human insulin suspension 
contains 40 IU of insulin.
    (b) Sponsors. See sponsors in Sec. 510.600 of this chapter for use 
as in paragraph (c) of this section.
    (1) No. 000061 for use of product described in paragraph (a)(1) of 
this section as in paragraphs (c)(1), (c)(2)(i)(A), (c)(2)(ii), and 
(c)(2)(iii) of this section.
    (2) No. 000010 for use of product described in paragraph (a)(2) of 
this section as in paragraphs (c)(2)(i)(B), (c)(2)(ii), and (c)(2)(iii) 
of this section.
    (c) Conditions of use--(1) Dogs--(i) Amount. Administer an initial 
once-daily dose of 0.5 IU per kilogram of body weight by subcutaneous 
injection concurrently with or right after a meal. Adjust this once-
daily dose at appropriate intervals based on clinical signs, urinalysis 
results, and glucose curve values until adequate glycemic control has 
been attained. Twice-daily therapy should be initiated if the duration 
of insulin action is determined to be inadequate. If twice-daily 
treatment is initiated, the two doses should be 25 percent less than the 
once daily dose required to attain an acceptable nadir.
    (ii) Indications for use. For the reduction of hyperglycemia and 
hyperglycemia-associated clinical signs in dogs with diabetes mellitus.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Cats--(i) Amount--(A) Porcine insulin zinc. Administer an 
initial dose of 1 to 2 IU by subcutaneous injection. Injections should 
be given twice daily at approximately 12-hour intervals. For cats fed 
twice daily, the injections should be concurrent with or right after a 
meal. For cats fed ad libitum, no change in feeding is needed. Adjust 
the dose at appropriate intervals based on clinical signs, urinalysis 
results, and glucose curve values until adequate glycemic control has 
been attained.
    (B) Protamine zinc recombinant human insulin. Administer an initial 
dose of 0.1 to 0.3 IU/pound of body weight (0.2 to 0.7 IU/kilogram) 
every 12 hours. The dose should be given concurrently with or right 
after a meal. Re-evaluate the cat at appropriate intervals and adjust 
the dose based on both clinical signs and glucose nadirs until adequate 
glycemic control has been attained.
    (ii) Indications for use. For the reduction of hyperglycemia and 
hyperglycemia-associated clinical signs in cats with diabetes mellitus.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

[69 FR 25827, May 10, 2004, as amended at 73 FR 21042, Apr. 18, 2008; 74 
FR 61517, Nov. 25, 2009; 74 FR 66048, Dec. 14, 2009]



Sec. 522.1182  Iron injection.

    (a) Specifications. See Sec. 510.440 of this chapter. Each 
milliliter (mL) of solution contains the equivalent of:
    (1) 100 milligrams (mg) of elemental iron derived from:
    (i) Ferric hydroxide;
    (ii) Ferric oxide; or
    (iii) Elemental iron.
    (2) 200 mg of elemental iron derived from ferric hydroxide.
    (b) Sponsors and conditions of use. It is used in baby pigs by 
sponsors in Sec. 510.600(c) of this chapter as follows:
    (1) Nos. 000859 and 042552 for use of product described in paragraph 
(a)(1)(i) of this section as follows:
    (i) For prevention of iron deficiency anemia, inject 100 mg (1 mL) 
by intramuscular injection at 2 to 4 days of age.
    (ii) For treatment of iron deficiency anemia, inject 100 mg (1 mL) 
by intramuscular injection. Dosage may be repeated in approximately 10 
days.
    (2) No. 000856 for use of product described in paragraph (a)(1)(i) 
of this section as follows:

[[Page 282]]

    (i) For the prevention of anemia due to iron deficiency, administer 
an initial intramuscular injection of 100 mg at 2 to 4 days of age. 
Dosage may be repeated in 14 to 21 days.
    (ii) For the treatment of anemia due to iron deficiency, administer 
an intramuscular injection of 200 mg.
    (3) Nos. 000061 and 062408 for use of product described in paragraph 
(a)(1)(i) of this section as follows:
    (i) For the prevention of iron deficiency anemia, administer 
intramuscularly an amount of drug containing 100 to 150 mg of elemental 
iron to animals from 1 to 3 days of age.
    (ii) For the treatment of iron deficiency anemia, administer 
intramuscularly an amount of drug containing 100 to 200 mg of elemental 
iron per animal. Dosage may be repeated in 10 days to 2 weeks.
    (4) Nos. 051311 and 053501 for use of product described in paragraph 
(a)(1)(ii) of this section as follows:
    (i) For prevention of iron deficiency anemia, administer 1 mL by 
intramuscular injection at 2 to 5 days of age. Dosage may be repeated at 
2 weeks of age.
    (ii) For treatment of iron deficiency anemia, administer 1 to 2 mL 
by intramuscular injection at 5 to 28 days of age.
    (5) No. 053501 for use of product described in paragraph (a)(1)(iii) 
of this section as follows:
    (i) For prevention of anemia due to iron deficiency, administer 100 
mg by intramuscular or subcutaneous injection at 2 to 4 days of age.
    (ii) For treatment of anemia due to iron deficiency, administer 100 
mg by intramuscular or subcutaneous injection up to 4 weeks of age.
    (6) Nos. 000859 and 058005 for use of product described in paragraph 
(a)(1)(iii) of this section as follows:
    (i) For prevention of anemia due to iron deficiency, administer 100 
mg by intramuscular injection at 2 to 4 days of age.
    (ii) For treatment of anemia due to iron deficiency, administer 100 
mg by intramuscular injection. Treatment may be repeated in 10 days.
    (7) Nos. 000859 and 042552 for use of product described in paragraph 
(a)(2) of this section as follows:
    (i) For prevention of baby pig anemia due to iron deficiency, 
intramuscularly inject 200 mg of elemental iron (1 mL) at 1 to 3 days of 
age.
    (ii) For treatment of baby pig anemia due to iron deficiency, 
intramuscularly inject 200 mg of elemental iron at the first sign of 
anemia.
    (8) No. 062408 for use of product described in paragraph (a)(2) of 
this section as follows:
    (i) For prevention of iron deficiency anemia, administer 200 mg 
intramuscularly on or before 3 days of age.
    (ii) For treatment of iron deficiency anemia, administer 200 mg 
intramuscularly.

[73 FR 12635, Mar. 10, 2008, as amended at 73 FR 14385, Mar. 18, 2008; 
78 FR 17597, Mar. 22, 2013]



Sec. 522.1192  Ivermectin.

    (a) Specifications--(1) Each milliliter (mL) of solution contains 20 
milligrams (mg) ivermectin.
    (2) Each mL of solution contains 10 mg ivermectin.
    (3) Each mL of solution contains 2.7 mg ivermectin.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (e) of this section.
    (1) No. 050604 for use of the product described in paragraph (a)(1) 
of this section as in paragraph (e)(1) of this section; the product 
described in paragraph (a)(2) of this section as in paragraphs (e)(2), 
(e)(3), (e)(4), and (e)(5) of this section; and the product described in 
paragraph (a)(3) of this section as in paragraphs (e)(3) and (e)(6) of 
this section.
    (2) Nos. 000859 055529, 058005, and 061623 for use of the product 
described in paragraph (a)(2) of this section as in paragraphs (e)(2), 
(e)(3), (e)(4), and (e)(5) of this section.
    (d) Special considerations--(1) See Sec. 500.25 of this chapter.
    (2) Labeling shall bear the following precaution: ``This product 
should not be used in other animal species as severe adverse reactions, 
including fatalities in dogs, may result.''
    (e) Conditions of use--(1) Horses--(i) Amount. 200 micrograms per 
kilogram ([micro]g/kg) of body weight by intramuscular injection.

[[Page 283]]

    (ii) Indications for use. For the treatment and control of large 
strongyles (adult) (Strongylus vulgaris, S. edentatus, Triodontophorus 
spp.), small strongyles (adult and fourth stage larvae) (Cyathostomum 
spp., Cylicocyclus spp., Cylicostephanus spp.), pinworms (adult and 
fourth-stage larvae) (Oxyuris equi), large roundworms (adult) 
(Parascaris equorum), hairworms (adult) (Trichostrongylus axei), large 
mouth stomach worms (adult) (Habronema muscae), neck threadworms 
(microfilariae) (Onchocerca spp.), and stomach bots (Gastrophilus spp.).
    (iii) Limitations. Not for use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.
    (2) Cattle--(i) Amount. 200 [micro]g/kg of body weight by 
subcutaneous injection.
    (ii) Indications for use. For the treatment and control of 
gastrointestinal nematodes (adults and fourth-stage larvae) (Haemonchus 
placei, Ostertagia ostertagi (including inhibited larvae), O. lyrata, 
Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C. 
punctata, C. pectinata, Oesophagostomum radiatum, Nematodirus 
helvetianus (adults only), N. spathiger (adults only), Bunostomum 
phlebotomum); lungworms (adults and fourth-stage larvae) (Dictyocaulus 
viviparus); grubs (parasitic stages) (Hypoderma bovis, H. lineatum); 
sucking lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes 
capillatus); mites (scabies) (Psoroptes ovis (syn. P. communis var. 
bovis), Sarcoptes scabiei var. bovis). For control of infections and to 
protect from reinfection with D. viviparus and O. radiatum for 28 days 
after treatment; O. ostertagi, T. axei, and C. punctata for 21 days 
after treatment; H. placei and C. oncophora for 14 days after treatment.
    (iii) Limitations. Do not treat cattle within 35 days of slaughter. 
Because a withdrawal time in milk has not been established, do not use 
in female dairy cattle of breeding age. A withdrawal period has not been 
established for this product in pre-ruminating calves. Do not use in 
calves to be processed for veal.
    (3) Swine--(i) Amount. 300 [micro]g/kg of body weight by 
subcutaneous injection.
    (ii) Indications for use. For the treatment and control of 
gastrointestinal roundworms (adults and fourth-stage larvae) (large 
roundworm, Ascaris suum; red stomach worm, Hyostrongylus rubidus; 
nodular worm, Oesophagostomum spp.; threadworm, Strongyloides ransomi 
(adults only)); somatic roundworm larvae (threadworm, S. ransomi 
(somatic larvae)); lungworms (Metastrongylus spp. (adults only)); lice 
(H. suis); and mites (S. scabiei var. suis).
    (iii) Limitations. Do not treat swine within 18 days of slaughter.
    (4) American bison--(i) Amount. 200 [micro]g/kg of body weight by 
subcutaneous injection.
    (ii) Indications for use. For the treatment and control of grubs (H. 
bovis).
    (iii) Limitations. Do not slaughter within 56 days of last 
treatment.
    (5) Reindeer--(i) Amount. 200 [micro]g/kg of body weight by 
subcutaneous injection.
    (ii) Indications for use. For the treatment and control of warbles 
(Oedemagena tarandi).
    (iii) Limitations. Do not treat reindeer within 56 days of 
slaughter.
    (6) Ranch-raised foxes--(i) Amount. 200 [micro]g/kg of body weight 
by subcutaneous injection. Repeat in 3 weeks.
    (ii) Indications for use. For treatment and control of ear mites 
(Otodectes cynotis).

[72 FR 27735, May 17, 2007, as amended at 72 FR 62771, Nov. 7, 2007; 74 
FR 9049, Mar. 2, 2009; 75 FR 26647, May 12, 2010; 76 FR 57906, Sept. 19, 
2011; 78 FR 17597, Mar. 22, 2013]



Sec. 522.1193  Ivermectin and clorsulon.

    (a) Specifications. Each milliliter (mL) of solution contains 10 
milligrams (mg) (1 percent) ivermectin and 100 mg (10 percent) 
clorsulon.
    (b) Sponsors. See Nos. 050604, 055529, and 058005 in Sec. 
510.600(c) of this chapter.
    (c) Related tolerances. See Sec. Sec. 556.163 and 556.344 of this 
chapter.
    (d) Special considerations. See Sec. 500.25 of this chapter.
    (e) Conditions of use in cattle--(1) Amount. Administer 1 mL (10 mg 
ivermectin and 100 mg clorsulon) per 50 kilograms (110 pounds) by 
subcutaneous injection.
    (2) Indications for use. For the treatment and control of 
gastrointestinal nematodes (adults and fourth-stage larvae) (Haemonchus 
placei, Ostertagia

[[Page 284]]

ostertagi (including inhibited larvae), O. lyrata, Trichostrongylus 
axei, T. colubriformis, Cooperia oncophora, C. punctata, C. pectinata, 
Oesophagostomum radiatum, Nematodirus helvetianus (adults only), N. 
spathiger (adults only), Bunostomum phlebotomum; lungworms (adults and 
fourth-stage larvae) (Dictyocaulus viviparus); liver flukes (adults 
only) (Fasciola hepatica); grubs (parasitic stages) (Hypoderma bovis, H. 
lineatum); lice (Linognathus vituli, Haematopinus eurysternus, 
Solenopotes capillatus); mites (Psoroptes ovis (syn. P. communis var. 
bovis), Sarcoptes scabiei var. bovis); and for control of infections of 
D. viviparus and O. radiatum for 28 days afer treatment; O. ostertagi, 
T. axei, and C. punctata for 21 days after treatment; and H. placei and 
C. oncophora for 14 days after treatment.
    (3) Limitations. For subcutaneous use only. Not for intravenous or 
intramuscular use. Do not treat cattle within 49 days of slaughter. 
Because a withdrawal time in milk has not been established, do not use 
in female dairy cattle of breeding age. Do not use in other animal 
species because severe adverse reactions, including fatalities in dogs, 
may result. A withdrawal period has not been established for this 
product in preruminating calves. Do not use in calves to be processed 
for veal.

[55 FR 38984, Sept. 24, 1990, as amended at 62 FR 14302, Mar. 26, 1997; 
62 FR 63271, Nov. 28, 1997; 64 FR 26671, May 17, 1999; 69 FR 31735, June 
7, 2004; 72 FR 27734, May 17, 2007; 77 FR 64717, Oct. 23, 2012]



Sec. 522.1204  Kanamycin sulfate injection.

    (a) Specifications. Each milliliter of kanamycin sulfate injection 
veterinary contains either 50 or 200 milligrams of kanamycin.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is used in the treatment of bacterial 
infections due to kanamycin sensitive organisms in dogs and cats.
    (2) It is administered subcutaneously or intramuscularly at 5 
milligrams per pound of body weight per day in equally divided doses at 
12-hour intervals.
    (3) Its label shall bear an appropriate expiration date.
    (4) Restricted to use by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 53 FR 27851, July 25, 1988; 
64 FR 403, Jan. 5, 1999]



Sec. 522.1222  Ketamine hydrochloride injectable dosage forms.



Sec. 522.1222a  Ketamine.

    (a) Specifications. Each milliliter contains ketamine hydrochloride 
equivalent to 100 milligrams (mg) ketamine base activity.
    (b) Sponsors. See Nos. 000010, 000859, 061690, 026637, and 063286 in 
Sec. 510.600(c) of this chapter.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Conditions of use--(1) Cats--(i) Amount. 5 to 15 mg/pound body 
weight intramuscularly, depending on the effect desired.
    (ii) Indications for use. For restraint or as the sole anesthetic 
agent in diagnostic or minor, brief surgical procedures that do not 
require skeletal muscle relaxation.
    (2) Subhuman primates--(i) Amount. 3 to 15 mg/kilogram body weight 
intramuscularly, depending upon the species, general condition, and age 
of the subject.
    (ii) Indications for use. For restraint.

[67 FR 17283, Apr. 10, 2002, as amended at 73 FR 8192, Feb. 13, 2008; 74 
FR 36111, July 22, 2009; 74 FR 66573, Dec. 16, 2009; 75 FR 10167, Mar. 
5, 2010]



Sec. 522.1222b  Ketamine hydrochloride with promazine hydrochloride 
and aminopentamide hydrogen sulfate injection.

    (a) Chemical name. Ketamine hydrochloride, (),-2-(o-chlorophenyl)-2-(methylamino) cyclohexanone 
hydrochloride, with promazine hydrochloride, 10-[3-(dimethylamino) 
propyl] phenothiazine monohydrochloride, and aminopentamide hydrogen 
sulfate.
    (b) Specifications. The drug is a sterile aqueous solution and each 
milliliter contains: Ketamine hydrochloride equivalent to 100 milligrams 
ketamine base activity, 7.5 milligrams of promazine hydrochloride, and 
0.0625 milligram of aminopentamide hydrogen sulfate, with 1:10,000 
benzethonium chloride.

[[Page 285]]

    (c) Sponsor. See Code No. 000856 in Sec. 510.600(c) of this 
chapter.
    (d) Special considerations. Store in a cool place. Protect from 
light. Do not use if precipitate appears.
    (e) Conditions of use. (1) It is used in cats as the sole anesthetic 
agent for ovariohysterectomy and general surgery.
    (2) It is administered intramuscularly at a recommended dose from 15 
to 20 milligrams ketamine base per pound of body weight, depending on 
the effect desired.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 59342, Dec. 23, 1975, as amended at 42 FR 3838, Jan. 21, 1977; 53 
FR 27851, July 25, 1988]



Sec. 522.1225  Ketoprofen solution.

    (a) Specifications. Each milliliter of sterile aqueous solution 
contains 100 milligrams of ketoprofen.
    (b) Sponsor. See 000856 in 21 CFR 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. 1.0 milligram per pound 
of body weight once daily for up to 5 days.
    (2) Indications for use. For alleviation of inflammation and pain 
associated with musculoskeletal disorders in horses.
    (3) Limitations. For intravenous use only. Do not use in breeding 
animals. Effects on fertility, pregnancy, or fetal health have not been 
determined. Not for use in horses intended for food. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.

[55 FR 40653, Oct. 4, 1990]



Sec. 522.1228  [Reserved]



Sec. 522.1244  Levamisole phosphate injection.

    (a) Specifications. Each milliliter of sterile aqueous solution 
contains levamisole phosphate equivalent to 136.5 or 182 milligrams of 
levamisole hydrochloride (13.65 or 18.2 percent).
    (b) Sponsor. See Nos. 000061 and 057561 in Sec. 510.600 of this 
chapter for use of 13.65 percent injection, and see No. 053501 for use 
of 13.65 and 18.2 percent injection.
    (c) Conditions of use--(1) Amount. 2 milliliters per 100 pounds of 
body weight, subcutaneously in the neck.
    (2) Indications for use. (i) The 13.65 percent injection is used as 
an anthelmintic in cattle for treatment of the following parasites: 
stomach worms (Haemonchus, Trichostrongylus, Ostertagia), intestinal 
worms (Trichostrongylus, Cooperia, Nematodirus, Bunostomum, 
Oesophagostomum, Chabertia), and lungworms (Dictyocaulus).
    (ii) The 18.2 percent injection is used as an anthelmintic in cattle 
for treatment of the following parasites: stomach worms (Haemonchus, 
Trichostrongylus, Ostertagia), intestinal worms (Trichostrongylus, 
Cooperia, Nematodirus, Bunostomum, Oesophagostomum) and lungworms 
(Dictyocaulus).
    (3) Limitations. Do not administer more than 10 milliliters per 
site. Cattle that are severely parasitized or maintained under 
conditions of constant helminth exposure may require re-treatment within 
2 to 4 weeks after first treatment. Consult your veterinarian for 
assistance in the diagnosis, treatment, and control of parasitism. 
Consult your veterinarian before using in severely debilitated animals 
or animals under severe stress. Do not administer to cattle within 7 
days of slaughter. Do not administer to dairy animals of breeding age.

[43 FR 20489, May 12, 1978, as amended at 43 FR 29289, July 7, 1978; 43 
FR 60895, Dec. 29, 1978; 47 FR 10807, Mar. 12, 1982; 62 FR 61625, Nov. 
19, 1997; 65 FR 61090, Oct. 16, 2000; 67 FR 63055, Oct. 10, 2002]



Sec. 522.1260  Lincomycin.

    (a) Specifications. Each milliliter of solution contains lincomycin 
hydrochloride monohydrate equivalent to:
    (1) 25, 50, 100, or 300 milligrams (mg) lincomycin.
    (2) 25, 100, or 300 mg lincomycin.
    (3) 300 mg lincomycin.
    (4) 100 or 300 mg lincomycin.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
uses as in paragraph (e) of this section.
    (1) No. 000009 for use of concentrations in paragraph (a)(1) of this 
section as in paragraph (e) of this section.

[[Page 286]]

    (2) Nos. 000859 and 058005 for use of concentrations in paragraph 
(a)(2) of this section as in paragraph (e)(2) of this section.
    (3) No. 046573 for use of concentration in paragraph (a)(3) of this 
section as in paragraph (e)(2) of this section.
    (4) No. 061623 for use of concentrations in paragraph (a)(4) of this 
section as in paragraph (e)(2) of this section.
    (c) Special considerations. When common labeling for use of the drug 
in dogs, cats, and swine is included with the drug, all such uses are 
subject to the labeling requirements of Sec. 201.105 of this chapter.
    (d) Related tolerances. See Sec. 556.360 of this chapter.
    (e) Conditions of use. It is used for animals as follows:
    (1) Dogs and cats--(i) Amount. 5 mg per pound (/lb) of body weight 
twice daily or 10 mg/lb body weight once daily by intramuscular 
injection; 5 to 10 mg/lb body weight one or two times daily by slow 
intravenous injection.
    (ii) Indications for use. Infections caused by Gram-positive 
organisms, particularly streptococci and staphylococci.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Swine--(i) Amount. 5 mg/lb body weight once daily by 
intramuscular injection for 3 to 7 days.
    (ii) Indications for use. Treatment of infectious arthritis and 
mycoplasma pneumonia.
    (iii) Limitations. Do not treat within 48 hours of slaughter.

[40 FR 13858, Mar. 27, 1975, as amended at 50 FR 31351, Aug. 2, 1985; 67 
FR 34388, May 14, 2002; 68 FR 51705, Aug. 28, 2003; 69 FR 11507, Mar. 
11, 2004; 69 FR 47361, Aug. 5, 2004; 71 FR 51996, Sept. 1, 2006; 78 FR 
17597, Mar. 22, 2013 ]



Sec. 522.1289  Lufenuron suspension.

    (a) Specifications. Each milliliter of sterile aqueous suspension 
contains 10 milligrams of lufenuron.
    (b) Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Cats--(i) Amount. 10 milligrams per 
kilogram (4.5 milligrams per pound) of body weight every 6 months, 
subcutaneously.
    (ii) Indications for use. For use in cats 6 weeks of age and older, 
for control of flea populations. Lufenuron controls flea populations by 
preventing the development of flea eggs and does not kill adult fleas. 
Concurrent use of insecticides may be necessary for adequate control of 
adult fleas.
    (iii) Limitations. For subcutaneous use in cats only. The safety of 
this product in reproducing animals has not been established. Do not use 
in dogs. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (2) [Reserved]

[63 FR 29552, June 1, 1998]



Sec. 522.1290  Luprostiol.

    (a) Specifications. Each milliliter of solution contains 7.5 
milligrams (mg) luprostiol.
    (b) Sponsor. See No. 051311 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. Labeling shall bear the following 
statements: Warning: Women of childbearing age, asthmatics, and persons 
with bronchial and other respiratory problems should exercise extreme 
caution when handling this product. In the early stages, women may be 
unaware of their pregnancies. Luprostiol is readily absorbed through the 
skin and can cause abortion and/or bronchiospasms. Direct contact with 
the skin should therefore be avoided. Accidental spillage on the skin 
should be washed off immediately with soap and water.
    (d) Conditions of use in horses--(1) Amount. 7.5 mg by intramuscular 
injection.
    (2) Indications for use. For estrus control and termination of 
pregnancy in mares.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian. Do not use in horses intended for 
human consumption.

[55 FR 1185, Jan. 12, 1990, as amended at 56 FR 50653, Oct. 8, 1991; 60 
FR 55659, Nov. 2, 1995; 61 FR 66582, Dec. 18, 1996; 74 FR 25146, May 27, 
2009]

[[Page 287]]



Sec. 522.1315  Maropitant.

    (a) Specifications. Each milliliter of solution contains 10 
milligrams (mg) maropitant as maropitant citrate.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. Administer 1.0 mg per 
kilogram (mg/kg) of body weight by subcutaneous injection once daily for 
up to 5 consecutive days.
    (ii) Indications for use. For the prevention and treatment of acute 
vomiting.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Cats--(i) Amount. Administer 1.0 mg/kg of body weight by 
subcutaneous injection once daily for up to 5 consecutive days.
    (ii) Indications for use. For the treatment of vomiting.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

[72 FR 9243, Mar. 1, 2007, as amended at 77 FR 39391, July 3, 2012]



Sec. 522.1335  Medetomidine hydrochloride injection.

    (a) Specifications. Each milliliter of sterile aqueous solution 
contains 1.0 milligram of medetomidine hydrochloride.
    (b) Sponsor. See 052483 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 750 micrograms intravenously (IV) 
or 1,000 micrograms intramuscularly per square meter of body surface. 
The IV route is more efficacious for dental care.
    (2) Indications for use. As a sedative and analgesic in dogs over 12 
weeks of age to facilitate clinical examinations, clinical procedures, 
minor surgical procedures not requiring muscle relaxation, and minor 
dental procedures not requiring intubation. The intravenous route of 
administration is more efficacious for dental care.
    (3) Limitations. Do not use in dogs with cardiac disease, 
respiratory disorders, liver or kidney diseases, dogs in shock, dogs 
which are severly debilitated, or dogs which are stressed due to extreme 
heat, cold, or fatigue. Allow agitated dogs to rest quietly before 
administration. Do not repeat dosing in dogs not responding 
satisfactorily to treatment. Do not use in breeding or pregnant animals. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.

[61 FR 21075, May 9, 1996]



Sec. 522.1350  Melatonin implant.

    (a) Specifications. The drug is a silicone rubber elastomer implant 
containing 2.7 milligrams of melatonin.
    (b) Sponsor. See No. 053923 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. One implant per mink.
    (2) Indications for use. For use in healthy male and female kit and 
adult female mink (Mustela vison) to accelerate the fur priming cycle.
    (3) Limitations. For subcutaneous implantation in mink only. Do not 
implant potential breeding stock. Do not use in food-producing animals.

[59 FR 37422, July 22, 1994]



Sec. 522.1362  Melarsomine dihydrochloride for injection.

    (a) Specifications. The drug consists of a vial of lyophilized 
powder containing 50 milligrams of melarsomine dihydrochloride which is 
reconstituted with the provided 2 milliliters of sterile water for 
injection.
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. For asymptomatic to moderate 
(class 1 to class 2) heartworm disease: 2.5 milligrams per kilogram of 
body weight (1.1 milligram per pound) twice, 24 hours apart. The series 
can be repeated in 4 months depending on the response to the first 
treatment and the condition, age, and use of the dog. For severe (class 
3) heartworm disease: Single injection of 2.5 milligrams per kilogram 
followed, approximately 1 month later, by 2.5 milligrams per kilogram 
administered twice, 24 hours apart.
    (2) Indications. Treatment of stabilized, class 1, 2, and 3 
heartworm disease (asymptomatic to mild, moderate, and severe, 
respectively) caused by immature (4 month-old, stage L5) to 
mature adult infections of Dirofilaria immitis in dogs.

[[Page 288]]

    (3) Limitations. Administer only by deep intramuscular injection in 
the lumbar muscles (L3-L5). Use a 23 gauge 1 inch 
needle for dogs less than or equal to 10 kilograms (22 pounds) and a 22 
gauge 1\1/2\ inch needle for dogs greater than 10 kilograms (22 pounds). 
Use alternate sides with each administration. The drug is 
contraindicated in dogs with class 4 (very severe) heartworm disease 
(Caval Sydrome). Not for use in breeding animals and lactating or 
pregnant bitches. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[60 FR 49340, Sept. 25, 1995]



Sec. 522.1367  Meloxicam.

    (a) Specifications. Each milliliter of solution contains 5.0 
milligrams (mg) meloxicam.
    (b) Sponsor. See Nos. 000010, 016729, and 055529 in Sec. 510.600(c) 
of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. Administer 0.09 mg per 
pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) by intravenous 
or subcutaneous injection on the first day of treatment. For treatment 
after day 1, administer meloxicam suspension orally at 0.045 mg/lb (0.1 
mg/kg) body weight once daily as in Sec. 520.1350(c) of this chapter.
    (ii) Indications for use. For the control of pain and inflammation 
associated with osteoarthritis.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Cats--(i) Amount. Administer 0.14 mg/lb (0.3 mg/kg) body weight 
as a single, one-time subcutaneous injection.
    (ii) Indications for use. For the control of postoperative pain and 
inflammation associated with orthopedic surgery, ovariohysterectomy, and 
castration when administered prior to surgery.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

[68 FR 68724, Dec. 10, 2003, as amended at 69 FR 69523, Nov. 30, 2004; 
78 FR 5715, Jan. 28, 2013]



Sec. 522.1372  Mepivacaine.

    (a) Specifications. Each milliliter (mL) of solution contains 20 
milligrams mepivacaine hydrochloride.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. For nerve block, 3 to 5 
mL; for epidural anesthesia, 5 to 20 mL; for intra-articular anesthesia, 
10 to 15 mL; for infiltration, as required; for anesthesia of the 
laryngeal mucosa prior to ventriculectomy, by topical spray, 25 to 40 
mL, by infiltration, 20 to 50 mL.
    (2) Indications for use. For use as a local anesthetic for 
infiltration, nerve block, intra-articular and epidural anesthesia, and 
topical and/or infiltration anesthesia of the laryngeal mucosa prior to 
ventriculectomy.
    (3) Limitations. Not for use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[71 FR 39547, July 13, 2006]



Sec. 522.1380  Methocarbamol injection.

    (a) Specifications. The product is a sterile, pyrogen-free solution, 
each milliliter containing 100 milligrams of methocarbamol, 0.5 
milliliter of polyethylene glycol 300, and water for injection q.s. Its 
pH is 3.5 to 6.0.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount--(i) Dogs and cats. 20 milligrams 
per pound of body weight for moderate conditions, 25 to 100 milligrams 
per pound of body weight for severe conditions (tetanus and strychnine 
poisoning), total cumulative dose not to exceed 150 milligrams per pound 
of body weight.
    (ii) Horses. 2 to 10 milligrams per pound of body weight for 
moderate conditions, 10 to 25 milligrams per pound of body weight for 
severe conditions (tetanus), additional amounts may be needed to relieve 
residual effects and to prevent recurrence of symptoms.
    (2) Indications for use. As an adjunct for treating acute 
inflammatory and traumatic conditions of the skeletal muscles and to 
reduce muscular spasms.
    (3) Limitations. For intravenous use only. For dogs, administer 
rapidly half

[[Page 289]]

the estimated dose, pause until the animal starts to relax, then 
continue administration to effect. For horses, administer rapidly to 
effect. Not for horses intended for food use. Federal law restricts this 
drug to use by or on the order of a licensed veterinarian.

[45 FR 79758, Dec. 2, 1980, as amended at 46 FR 18964, Mar. 27, 1981; 67 
FR 67521, Nov. 6, 2002]



Sec. 522.1410  Methylprednisolone.

    (a) Specifications. Each milliliter of suspension contains 20 or 40 
milligrams (mg) of methylprednisolone acetate.
    (b) Sponsors. See Nos. 000009 and 000010 in Sec. 510.600(c) of this 
chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Dogs--(i) Amount. Administer 2 to 40 mg 
(up to 120 mg in extremely large breeds or dogs with severe involvement) 
by intramuscular injection or up to 20 mg by intrasynovial injection.
    (ii) Indications for use. For treatment of inflammation and related 
disorders; treatment of allergic and dermatologic disorders; and as 
supportive therapy to antibacterial treatment of severe infections.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Cats--(i) Amount. Administer 10 to 20 mg by intramuscular 
injection.
    (ii) Indications for use. For treatment of inflammation and related 
disorders; treatment of allergic and dermatologic disorders; and as 
supportive therapy to antibacterial treatment of severe infections.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (3) Horses--(i) Amount. Administer 200 mg by intramuscular injection 
or 40 to 240 mg by intrasynovial injection.
    (ii) Indications for use. For treatment of inflammation and related 
disorders.
    (iii) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[43 FR 59058, Dec. 19, 1978, as amended at 51 FR 741, Jan. 8, 1986; 53 
FR 40728, Oct. 18, 1988; 62 FR 35076, June 30, 1997; 76 FR 53051, Aug. 
25, 2011]



Sec. 522.1450  Moxidectin solution.

    (a) Specifications. Each milliliter of solution contains 10 
milligrams (mg) moxidectin.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.426 of this chapter.
    (d) Special considerations. See Sec. 500.25 of this chapter.
    (e) Conditions of use in beef and nonlactating dairy cattle-- (1) 
Amount. Administer 0.2 mg/kg of body weight (0.2 mg/2.2 pound) as a 
single, subcutaneous injection.
    (2) Indications for use. For treatment and control of 
gastrointestinal roundworms: Ostertagia ostertagi (adults, fourth-stage 
larvae, and inhibited larvae), Haemonchus placei (adults), 
Trichostrongylus axei (adults and fourth-stage larvae), Trichostrongylus 
colubriformis (adults and fourth-stage larvae), Cooperia oncophora 
(adults), Cooperia pectinata (adults), Cooperia punctata (adults and 
fourth-stage larvae), Cooperia spatulata (adults), Cooperia surnabada 
(adults and fourth-stage larvae), Nematodirus helvetianus (adults), 
Oesophagostomum radiatum (adults and fourth-stage larvae), Trichuris 
spp. (adults); lungworms: Dictyocaulus viviparus (adults and fourth-
stage larvae); grubs: Hypoderma bovis and Hypoderma lineatum; mites: 
Psoroptes ovis (Psoroptes communis var. bovis); lice: Linognathus vituli 
and Solenopotes capillatus; for protection of cattle from reinfection 
with D. viviparus and O. radiatum for 42 days after treatment, with H. 
placei for 35 days after treatment, and with O. ostertagi and T. axei 
for 14 days after treatment.
    (3) Limitations. Do not slaughter cattle within 21 days of 
treatment. Because a withholding time for milk has not been established, 
do not use in female dairy cattle 20 months of age and older. A 
withdrawal period has not been established for pre-ruminating calves. Do 
not use in calves to be processed for veal.

[70 FR 36337, June 23, 2005, as amended at 71 FR 7414, Feb. 13, 2006; 76 
FR 48714, Aug. 9, 2011]

[[Page 290]]



Sec. 522.1451  Moxidectin for suspension.

    (a) Specifications. The drug product consists of two separate vials. 
One contains 10 percent moxidectin microspheres, and the other contains 
a vehicle for constitution of the moxidectin microspheres. Each 
milliliter of constituted, sustained-release suspension contains 3.4 
milligrams (mg) of moxidectin.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use; dogs--(1) Amount. 0.17 mg per kilogram body 
weight (0.0773 mg per pound) as a single subcutaneous injection.
    (2) Indications for use. For prevention of heartworm disease caused 
by Dirofilaria immitis; for treatment of existing larval and adult 
hookworm (Ancylostoma caninum) and Uncinaria stenocephala infections.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[66 FR 35756, July 9, 2001, as amended at 67 FR 57944, Sept. 13, 2002]



Sec. 522.1452  Nalorphine hydrochloride injection.

    (a) Specifications. Each milliliter of aqueous solution contains 5 
milligrams of nalorphine hydrochloride.
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. One milligram per 5 pounds; 
intravenously, intramuscularly, or subcutaneously.
    (2) Indications for use. Respiratory and circulatory depression in 
dogs resulting from overdosage of, or unusual sensitivity to, morphine 
and certain other narcotics. Not for depression due to any other cause.
    (3) Limitations. Successive doses of the drug gradually lose their 
analeptic effect and eventually induce respiratory depression equal to 
that of opiates. Therefore, do not exceed therapeutic dosage. Do not mix 
drug with meperidine solutions because the buffer will cause 
precipitation. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[44 FR 6707, Feb. 2, 1979, as amended at 47 FR 36418, Aug. 20, 1982; 62 
FR 63271, Nov. 28, 1997]



Sec. 522.1465  Naltrexone hydrochloride injection.

    (a) Specifications. Each milliliter of sterile aqueous solution 
contains 50 milligrams of naltrexone hydrochloride.
    (b) Sponsor. See 053923 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in elk and moose--(1) Amount. 100 milligrams 
of naltrexone hydrochloride for each milligram of carfentanil citrate 
administered. One-quarter of the dose should be administered 
intravenously and three-quarters of the dose should be administered 
subcutaneously.
    (2) Indications for use. As an antagonist to carfentanil citrate 
immobilization in free-ranging or confined elk and moose (Cervidae).
    (3) Limitations. Available data are inadequate to recommend use in 
pregnant animals. Avoid using during breeding season. Do not use in 
domestic food-producing animals. Do not use in free-ranging animals for 
45 days before or during hunting season. Federal law restricts this drug 
to use by or on the order of a licensed veterinarian.

[62 FR 5320, Feb. 5, 1997]



Sec. 522.1468  Naproxen for injection.

    (a) Specifications. The drug is a lyophilized powder which is 
reconstituted with sterile water for injection to form a 10 percent 
sterile aqueous solution (100 milligrams per milliliter).
    (b) Sponsor. See 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Dosage. Five milligrams per 
kilogram of body weight intravenously followed by maintenance oral 
therapy of 10 milligrams per kilogram of body weight twice daily for up 
to 14 consecutive days.
    (2) Indications for use. For the relief of inflammation and 
associated pain and lameness exhibited with arthritis, as well as 
myositis and other soft tissue diseases of the musculoskeletal system of 
the horse.
    (3) Limitations. Not for use in horses intended for food. Federal 
law restricts

[[Page 291]]

this drug to use by or on the order of a licensed veterinarian.

[46 FR 26763, May 15, 1981. Redesignated and amended at 51 FR 24525, 
July 7, 1986; 61 FR 5507, Feb. 13, 1996]



Sec. 522.1484  Neomycin sulfate sterile solution.

    (a) Specifications. Each milliliter of sterile aqueous solution 
contains 50 milligrams of neomycin sulfate (equivalent to 35 milligrams 
of neomycin base).\1\
---------------------------------------------------------------------------

    \1\ These claims are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter.
---------------------------------------------------------------------------

    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 5 milligrams per pound of body 
weight daily divided into portions administered every 6 to 8 hours for 3 
to 5 days.\1\
    (2) Indications for use. Administer to dogs and cats for the 
treatment of acute and chronic bacterial infections due to organisms 
susceptible to neomycin.\1\
    (3) Limitations. For intramuscular or intravenous use only. Neomycin 
is not for use parenterally in food-producing animals because of 
prolonged residues in edible tissues. Labeling shall bear an appropriate 
expiration date. For use by or on the order of a licensed 
veterinarian.\1\

[43 FR 48996, Oct. 20, 1978, as amended at 64 FR 403, Jan. 5, 1999]



Sec. 522.1503  Neostigmine methylsulfate injection.

    (a) Specifications. Neostigmine methylsulfate injection contains two 
milligrams of neostigmine methylsulfate in each milliliter of sterile 
aqueous solution.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is intended for use for treating 
rumen atony; initiating peristalsis which causes evacuation of the 
bowel; emptying the urinary bladder; and stimulating skeletal muscle 
contractions. It is a curare antagonist.
    (2) It is administered to cattle and horses at a dosage level of 1 
milligram per 100 pounds of body weight subcutaneously. It is 
administered to sheep at a dosage level of 1 to 1\1/2\ milligrams per 
100 pounds body weight subcutaneously. It is administered to swine at a 
dosage level of 2 to 3 milligrams per 100 pounds body weight 
intramuscularly. These doses may be repeated as indicated.
    (3) The drug is contraindicated in mechanical, intestinal or urinary 
obstruction, late pregnancy, and in animals treated with other 
cholinesterase inhibitors.
    (4) Not for use in animals producing milk, since this use will 
result in contamination of the milk.
    (5) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 62 FR 61625, Nov. 19, 1997]



Sec. 522.1610  Oleate sodium solution.

    (a) Specifications. Each milliliter of sterile aqueous solution 
contains 50 milligrams of sodium oleate.
    (b) Sponsor. See No. 037990 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) It is used in horses to stimulate 
infiltration of cellular blood components that subsequently 
differentiate into fibrous and/or fibrocartilagenous tissue.
    (2) The drug is administered by parenteral injection dependent upon 
the area of response desired. An injection of 1 milliliter will produce 
a response of approximately 15 square centimeters. Do not inject more 
than 2 milliliters per injection site. Regardless of the number of 
injection sites, the total volume used should not exceed 10 milliliters.
    (3) Not for use in horses intended for food.
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[41 FR 27034, July 1, 1976, as amended at 50 FR 40966, Oct. 8, 1985]



Sec. 522.1620  Orgotein for injection.

    (a) Specifications. Orgotein for injection is packaged in a vial 
containing 5 milligrams of orgotein and 10 milligrams of sucrose as 
lyophilized sterile nonpyrogenic powder with directions for dissolving 
the contents of the vial

[[Page 292]]

in 2 milliliters of diluent which is sodium chloride injection, U.S.P.
    (b) Sponsor. See No. 024991 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Horses. (i) It is used in the treatment 
of soft tissue inflammation associated with the musculoskeletal system.
    (ii) It is administered by deep intramuscular injection at a dosage 
level of 5 milligrams every other day for 2 weeks and twice weekly for 2 
to 3 more weeks. Severe cases, both acute and chronic, may benefit more 
from daily therapy initially. Dosage may be continued beyond 5 weeks if 
satisfactory improvement has not been achieved.
    (iii) Not for use in horses intended for food.
    (2) Dogs. (i) It is used for the relief of inflammation associated 
with ankylosing spondylitis, spondylosis, and disc disease. When severe 
nerve damage is present, response will occur much more slowly, if at 
all.
    (ii) It is administered by subcutaneous injection at a dosage level 
of 5 milligrams every day for 6 days, and thereafter, every other day 
for 8 days. In less severe conditions, shorter courses of therapy may be 
indicated.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 41 FR 32583, Aug. 4, 1976]



Sec. 522.1660  Oxytetracycline injectable dosage forms.



Sec. 522.1660a  Oxytetracycline solution, 200 milligrams/milliliter.

    (a) Specifications. Each milliliter of sterile solution contains 200 
milligrams of oxytetracycline base.
    (b) Sponsors. See Nos. 000010, 000069, 000859, 048164, 055529, 
057561, and 061623 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.500 of this chapter.
    (d) Special considerations. When labeled for the treatment of 
anaplasmosis or anthrax, labeling shall also bear the following: 
``Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.''
    (e) Conditions of use--(1) Beef cattle, dairy cattle, and calves 
including prerumenative (veal) calves--(i) Amounts and indications for 
use--(A) 3 to 5 mg per pound of body weight (mg/lb BW) per day (/day) 
intramuscularly, subcutaneously, or intravenously for treatment of 
pneumonia and shipping fever complex associated with Pasteurella spp. 
and Haemophilus spp., foot-rot and diphtheria caused by Fusobacterium 
necrophorum, bacterial enteritis (scours) caused by Escherichia coli, 
wooden tongue caused by Actinobacillus lignieresii, leptospirosis caused 
by Leptospira pomona, wound infections and acute metritis caused by 
Staphylococcus spp. and Streptococcus spp., and anthrax caused by 
Bacillus anthracis.
    (B) 5 mg/lb BW/day intramuscularly or intravenously for treatment of 
anaplasmosis caused by Anaplasma marginale, severe foot-rot, and 
advanced cases of other indicated diseases.
    (C) 9 mg/lb BW intramuscularly or subcutaneously as single dosage 
where retreatment of calves and yearlings for bacterial pneumonia is 
impractical, for treatment of infectious bovine keratoconjunctivitis 
(pinkeye) caused by Moraxella bovis, or where retreatment for 
anaplasmosis is impractical.
    (ii) Limitations. Exceeding the highest recommended level of drug 
per pound of bodyweight per day, administering more than the recommended 
number of treatments, and/or exceeding 10 mL intramuscularly or 
subcutaneously per injection site may result in antibiotic residues 
beyond the withdrawal time. Rapid intravenous administration in cattle 
may result in animal collapse. Oxytetracycline should be administered 
intravenously slowly over a period of at least 5 minutes. Discontinue 
treatment at least 28 days prior to slaughter. Not for use in lactating 
dairy animals.
    (2) Swine--(i) Amounts and indications for use--(A) Sows: 3 mg/lb BW 
intramuscularly once, approximately 8 hours before farrowing or 
immediately after completion of farrowing, as an aid in control of 
infectious enteritis (baby pig scours, colibacillosis) in suckling pigs 
caused by E. coli.
    (B) 3 to 5 mg/lb BW/day intramuscularly for treatment of bacterial 
enteritis (scours, colibacillosis)

[[Page 293]]

caused by E. coli, pneumonia caused by Pasteurella multocida, and 
leptospirosis caused by Leptospira pomona.
    (C) 9 mg/lb BW as a single dosage where retreatment for pneumonia is 
impractical.
    (ii) Limitations. Administer intramuscularly. Do not inject more 
than 5 mL per site in adult swine. Discontinue treatment at least 28 
days prior to slaughter.

[45 FR 16479, Mar. 14, 1980. Redesignated and amended at 69 FR 31879, 
June 8, 2004]

    Editorial Note: For Federal Register citations affecting Sec. 
522.1660a, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 522.1660b  Oxytetracycline solution, 300 milligrams/milliliter.

    (a) Specifications. Each milliliter (mL) of solution contains 300 
milligrams (mg) oxytetracycline base.
    (b) Sponsor. See No. 055529 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.500 of this chapter.
    (d) Special considerations. When labeled for use as in paragraph 
(e)(1)(i)(D) or (e)(1)(i)(E) of this section, labeling shall also bear 
the following: ``Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.''.
    (e) Conditions of use--(1) Beef cattle, nonlactating dairy cattle, 
and calves including preruminating (veal) calves--(i) Amounts and 
indications for use--(A) 3 to 5 mg per pound of bodyweight (mg/lb BW) 
per day (/day) intramuscularly, subcutaneously, or intravenously for 
treatment of pneumonia and shipping fever complex associated with 
Pasteurella spp. and Histophilus spp., foot-rot and diphtheria caused by 
Fusobacterium necrophorum, bacterial enteritis (scours) caused by 
Escherichia coli, wooden tongue caused by Actinobacillus lignieresii, 
leptospirosis caused by Leptospira pomona, wound infections and acute 
metritis caused by Staphylococcus spp. and Streptococcus spp.
    (B) 5 mg/lb BW/day intramuscularly, subcutaneously, or intravenously 
for treatment of severe foot-rot, and advanced cases of other indicated 
diseases.
    (C) 9 mg/lb BW intramuscularly or subcutaneously as single dosage 
where retreatment of calves and yearlings for bacterial pneumonia is 
impractical or for treatment of infectious bovine keratoconjunctivitis 
(pinkeye) caused by Moraxella bovis.
    (D) 9 to 13.6 mg/lb BW intramuscularly or subcutaneously as single 
dosage where retreatment of calves and yearlings for bacterial pneumonia 
is impractical or for treatment of infectious bovine 
keratoconjunctivitis (pinkeye) caused by Moraxella bovis.
    (E) 13.6 mg/lb BW intramuscularly or subcutaneously as a single 
dosage for control of respiratory disease in cattle at high risk of 
developing BRD associated with Mannheimia (Pasteurella) haemolytica.
    (ii) Limitations. Treatment should be continued 24 to 48 hours 
following remission of disease signs, however, not to exceed a total of 
four consecutive days. Do not inject more than 10 mL per site in adult 
cattle, reducing the volume according to age and body size to 1 to 2 mL 
in small calves. Exceeding the highest recommended level of drug/lb BW/
day, administering more than the recommended number of treatments, and/
or exceeding 10 mL intramuscularly or subcutaneously per injection site 
may result in antibiotic residues beyond the withdrawal time. Rapid 
intravenous administration may result in animal collapse. 
Oxytetracycline should be administered intravenously slowly over a 
period of at least 5 minutes. Discontinue treatment at least 28 days 
prior to slaughter. Not for use in lactating dairy animals.
    (2) Swine--(i) Amounts and indications for use--(A) Sows: 3 mg/lb BW 
intramuscularly once, approximately 8 hours before farrowing or 
immediately after completion of farrowing, as an aid in control of 
infectious enteritis (baby pig scours, colibacillosis) in suckling pigs 
caused by E. coli.
    (B) 3 to 5 mg/lb BW/day intramuscularly for treatment of bacterial 
enteritis (scours, colibacillosis) caused by E. coli, pneumonia caused 
by Pasteurella multocida, and leptospirosis caused by Leptospira pomona.

[[Page 294]]

    (C) 9 mg/lb BW as a single dosage where retreatment for pneumonia is 
impractical.
    (ii) Limitations. Administer intramuscularly. Treatment should be 
continued 24 to 48 hours beyond remission of disease signs, however, not 
to exceed a total of 4 consecutive days. Exceeding the highest 
recommended level of drug/lb BW/day, administering more than the 
recommended number of treatments, and/or exceeding 5 mL intramuscularly 
per injection site may result in antibiotic residues beyond the 
withdrawal time. Discontinue treatment at least 28 days prior to 
slaughter.

[68 FR 54805, Sept. 19, 2003. Redesignated and amended at 69 FR 31879, 
June 8, 2004; 73 FR 14926, Mar. 20, 2008]



Sec. 522.1662  Oxytetracycline hydrochloride implantation or 
injectable dosage forms.



Sec. 522.1662a  Oxytetracycline hydrochloride injection.

    (a)(1) Specifications. The drug contains 50 milligrams of 
oxytetracycline hydrochloride in each milliliter of sterile solution.
    (2) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) The drug is intended for use in beef 
cattle, beef calves, nonlactating dairy cattle, and dairy calves for 
treatment of disease conditions caused by one or more of the following 
oxytetracycline sensitive pathogens listed as follows: pneumonia and 
shipping fever complex (Pasteurella spp.; Hemophilis spp.; Klebsiella 
spp. ), bacterial enteritis (scours) (E. coli), foot-rot (Spherophorus 
necrophorus), diphtheria (Spherophorus necrophorus), wooden tongue 
(Actinobacillus lignieresi), leptospirosis (Leptospira pomona), and 
wound infections; acute metritis; traumatic injury (caused by a variety 
of bacterial organisms (such as streptococcal and staphylococcal 
organisms).)
    (ii) It is administered by intramuscular injection of 3 to 5 
milligrams of oxytetracycline hydrochloride per pound of body weight per 
day. Leptospirosis, severe foot-rot and severe forms of the indicated 
diseases should be treated with 5 milligrams per pound of body weight 
per day. Treatment should be continued for 24 to 48 hours following 
remission of disease symptoms; however, not to exceed a total of 4 
consecutive days. Only 2 milliliters of the drug should be injected per 
site in case of calves weighing 100 pounds or less and not more than 10 
milliliters should be injected per site in adult cattle.
    (iii) Discontinue treatment with the drug at least 20 days prior to 
slaughter of the animal. When administered to animals within 30 days of 
slaughter, muscle discoloration may necessitate trimming of injection 
site and surrounding tissues.
    (iv) For use only in beef cattle, beef calves, nonlactating dairy 
cattle, and dairy calves.
    (b)(1) Specifications. Each milliliter of sterile solution contains 
50 or 100 milligrams of oxytetracycline (as oxytetracycline 
hydrochloride).
    (2) Sponsor. See 000010 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use--(i) Beef cattle and nonlactating dairy 
cattle--(a) Amount. Three to 5 milligrams of oxytetracycline per pound 
of body weight per day; 5 milligrams per pound of body weight per day 
for the treatment of anaplasmosis, severe foot-rot, and severe cases of 
other indicated diseases.
    (b) Indications for use. Treatment of diseases due to 
oxytetracycline-susceptible organisms as follows: Pneumonia and shipping 
fever complex associated with Pasteurella spp., Hemophilus spp., and 
Klebsiella spp., foot-rot and diphtheria caused by Spherophorus 
necrophorus, bacterial enteritis (scours) caused by Escherichia coli, 
wooden tongue caused by Actinobacillus lignieresi, leptospirosis caused 
by Leptospira pomona, and wound infections and acute metritis caused by 
Staphylococcus spp. and Streptococcus spp. If labeled for use by or on 
the order of a licensed veterinarian, it may be used for the treatment 
of anaplasmosis caused by Anaplasma marginale.
    (c) Limitations. For 50-milligram-per-milliliter solution, 
administer intramuscularly or intravenously; for 100-milligram-per-
milliliter solution, administer intramuscularly only.

[[Page 295]]

Treatment of all diseases should be instituted early and continue for 24 
to 48 hours beyond remission of disease symptoms, but not to exceed a 
total of 4 consecutive days. Consult your veterinarian if no improvement 
is noted within 48 hours. Do not inject more than 10 milliliters per 
site in adult cattle, reducing the volume according to age and body size 
to 0.5 to 2 milliliters in small calves. Exceeding the highest 
recommended dose of 5 milligrams per pound of body weight, administering 
at recommended levels for more than 4 consecutive days, and/or exceeding 
10 milliliters intramuscularly per injection site may result in 
antibiotic residues beyond the withdrawal time. Discontinue treatment at 
least 18 days prior to slaughter. Not for use in lactating dairy cattle.
    (ii) Swine--(a) Amount. Three to 5 milligrams of oxytetracycline per 
pound of body weight per day. Sows: 3 milligrams of oxytetracycline per 
pound of body weight, approximately 8 hours before farrowing or 
immediately after completion of farrowing.
    (b) Indications for use. For treatment of bacterial enteritis 
(scours, colibacillosis) caused by Escherichia coli, pneumonia caused by 
Pasteurella multocida, and leptospirosis caused by Leptospira pomona. 
Sows: as an aid in control of infectious enteritis (baby pig scours, 
colibacillosis) in suckling pigs caused by Escherichia coli.
    (c) Limitations. Administer intramuscularly. Do not inject more than 
5 milliliters per site. Do not use for more than 4 consecutive days. 
Discontinue treatment at least 26 days before slaughter.
    (c)(1) Specifications. The drug contains 50 or 100 milligrams of 
oxytetracycline hydrochloride in each milliliter of sterile solution.
    (2) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) The drug is intended for use in the 
treatment of disease due to oxytetracycline-susceptible organisms in 
beef cattle and non-lactating dairy cattle. It is indicated in the 
treatment of pneumonia and shipping fever complex associated with 
Pasteurella spp., Hemophilus spp., Klebsiella spp., foot-rot and 
diphtheria caused by Spherophorus necrophorus, bacterial enteritis 
(scours) caused by Escherichia coli, wooden tongue caused by 
Actinobacillus lignieresi, acute metritis, and wound infections caused 
by staphylococcal and streptococcal organisms.
    (ii) It is administered to cattle at a dosage level of 3 to 5 
milligrams per pound of body weight per day. It may be administered 
intramuscularly or intravenously from a 50 milligram per milliliter 
solution. It is administered intravenously from a 100 milligram per 
milliliter solution. Severe foot-rot and the severe forms of the 
indicated diseases should be treated with 5 milligrams per pound of body 
weight. Treatment should be continued 24 to 48 hours following remission 
of disease symptoms, however, not to exceed a total of 4 consecutive 
days. If no improvement is noted within 24 hours, consult a 
veterinarian. When injecting the drug intramuscularly, do not inject 
more than 10 milliliters per site in adult cattle. Reduce the amount 
injected at each site according to the size of the animal. For very 
small calves do not use more than 2 milliliters per injection site.
    (iii) Not for use in lactating dairy cattle. Discontinue treatment 
at least 19 days prior to slaughter. When administered intramuscularly 
within 30 days of slaughter, muscle discoloration may necessitate 
trimming of the injection site and surrounding tissues.
    (d)(1) Specifications. The drug contains 50 milligrams of 
oxytetracycline hydrochloride in each milliliter of sterile solution.
    (2) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) In beef cattle and nonlactating dairy 
cattle as follows:
    (a) It is used for the treatment of pneumonia and shipping fever 
complex associated with Pasteurella spp. and Hemophilus spp.; foot-rot 
and diphtheria caused by Spherophorus necrophorus; bacterial enteritis 
(scours) caused by Escherichia coli; wooden tongue caused by 
Actinobacillus lignieresi; leptospirosis caused by Leptospira pomona; 
wound infections and acute metritis caused by staphylococcal and 
streptococcal organisms.

[[Page 296]]

    (b) Administer by intravenous or intramuscular injection at 3 to 5 
milligrams of oxytetracycline per pound of body weight per day. In the 
treatment of severe foot-rot and severe forms of the indicated diseases, 
a dosage level of 5 milligrams per pound of body weight per day is 
recommended.
    (c) If the labeling of the drug bears the statement ``Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian,'' it may include additional directions for use in beef 
cattle and nonlactating dairy cattle for the treatment of anaplasmosis 
caused by Anaplasma marginale, and anthrax caused by Bacillus anthracis 
in which case the drug is given at 3 to 5 milligrams of oxytetracycline 
per pound of body weight per day for anthrax, and at 5 milligrams per 
pound of body weight per day for anaplasmosis.
    (ii) In swine as follows:
    (a) It is used for the treatment of bacterial enteritis (scours, 
colibacillosis) caused by Escherichia coli; pneumonia caused by 
Pasteurella multocida; and leptospirosis caused by Leptospira pomona. 
Administered to sows as an aid in the control of infectious enteritis 
(baby pig scours, colibacillosis) in suckling pigs caused by Escherichia 
coli.
    (b) Administer by intramuscular injection at 3 to 5 milligrams of 
oxytetracycline per pound of body weight per day to swine. Administered 
to sows at 3 milligrams of oxytetracycline per pound of body weight 
approximately 8 hours before farrowing or immediately after farrowing.
    (iii) In poultry (broilers, turkeys, and breeding chickens) as 
follows:
    (a) It is used for the treatment of air sacculitis (air-sac disease, 
chronic respiratory disease) caused by Mycoplasma gallisepticum and 
Escherichia coli; fowl cholera caused by Pasteurella multocida; 
infectious sinusitis caused by Mycoplasma gallisepticum; and infectious 
synovitis caused by Mycoplasma synoviae.
    (b) Administered subcutaneously to chickens 1 day to 2 weeks of age 
at 6.25 milligrams of oxytetracycline per bird per day diluted with 1 
part of the drug to 3 parts of sterile water; to chickens 2 to 4 weeks 
of age using the same diluted product at 12.5 milligrams of 
oxytetracycline per bird; to chickens 4 to 8 weeks of age without 
dilution at 25 milligrams of oxytetracycline per bird; to chickens 8 
weeks of age (broilers and light pullets) at 50 milligrams of 
oxytetracycline per bird; to adult chickens at 100 milligrams of 
oxytetracycline per bird.
    (c) Administered subcutaneously to turkeys 1 day to 2 weeks of age 
and 2 to 4 weeks of age at the same dosage as chickens; to turkeys 4 to 
6 weeks of age at 50 milligrams of oxytetracycline as the undiluted 
product per bird; to turkeys 6 to 9 weeks of age at 100 milligrams of 
oxytetracycline per bird; to turkeys 9 to 12 weeks of age at 150 
milligrams of oxytetracycline per bird; to turkeys 12 weeks of age and 
older at 200 milligrams of oxytetracycline per bird. In light turkey 
breeds, no more than 25 milligrams per pound of body weight is 
administered. For the treatment of infectious sinusitis in turkeys, \1/
4\ to \1/2\ milliliter of the drug is injected directly into each 
swollen sinus depending upon the age of the bird and the severity of the 
condition. At the time that the sinuses are treated, the drug should 
also be administered subcutaneously to the birds according to the dosage 
schedule given in paragraph (d)(3)(iii)(c) of this section. If refilling 
of the sinuses occurs, the treatment may be repeated in 5 to 7 days.
    (iv) Treatment of all diseases should be instituted early. Treatment 
should continue for 24 to 48 hours beyond the remission of disease 
symptoms, but not exceed a total of 4 consecutive days. If no 
improvement is noted within 24 to 48 hours, diagnosis and therapy should 
be reevaluated.
    (v) When injecting intramuscularly in adult livestock, do not inject 
more than 10 milliliters at any one site. The volume administered per 
injection site should be reduced according to age and body size so that 
1 or 2 milliliters are injected in smaller animals such as small calves 
and young pigs. Intravenous administration is recommended in cattle when 
daily dosage exceeds 50 milliliters.
    (vi) Treatment must be discontinued at least 5 days prior to 
slaughter for chickens and turkeys and at least 22 days prior to 
slaughter for cattle and swine. When administered intramuscularly to 
animals within 30

[[Page 297]]

days of slaughter, muscle discoloration may necessitate trimming of the 
injection site(s) and surrounding tissues during the dressing procedure.
    (vii) Not for use in lactating dairy animals. Do not administer to 
laying hens unless the eggs are used for hatching only.
    (e)(1) Specifications. Each milliliter of sterile solution contains 
100 milligrams of oxytetracycline hydrochloride.
    (2) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use--(i) Beef cattle and nonlactating dairy 
cattle--(a) Amount. 3 to 5 milligrams of oxytetracycline per pound of 
body weight per day; 5 milligrams per pound of body weight per day for 
treatment of anaplasmosis, severe foot-rot, and severe cases of other 
indicated diseases.
    (b) Indications for use. Treatment of diseases due to 
oxytetracycline-susceptible organisms as follows: Pneumonia and shipping 
fever complex associated with Pasteurella spp. and Hemophilus spp., 
foot-rot and diphtheria caused by Fusobacterium necrophorum, bacterial 
enteritis (scours) caused by Escherichia coli, wooden tongue caused by 
Actinobacillus lignieresii, leptospirosis caused by Leptospira pomona, 
and wound infections and acute metritis caused by Staphylococcus spp. 
and Streptococcus spp. If labeled for use by or on the order of a 
licensed veterinarian, it may be used for the treatment of anaplasmosis 
caused by Anaplasma marginale and anthrax caused by Bacillus anthracis.
    (c) Limitations. Administer intramuscularly. Treatment of all 
diseases should be instituted early and continue for 24 to 48 hours 
beyond remission of disease symptoms, but not to exceed a total of 4 
consecutive days. Consult your veterinarian if no improvement is noted 
within 48 hours. Do not inject more than 10 milliliters per site in 
adult cattle, reducing the volume according to age and body size to 1 to 
2 milliliters in small calves. Exceeding the highest recommended dose of 
5 milligrams per pound of body weight, administering at recommended 
levels for more than 4 consecutive days, and/or exceeding 10 milliliters 
intramuscularly per injection site may result in antibiotic residues 
beyond the withdrawal time. Discontinue treatment at least 15 days prior 
to slaughter. Not for use in lactating dairy cattle.
    (ii) Swine--(a) Amount. 3 to 5 milligrams of oxytetracycline per 
pound of body weight per day. Sows: 3 milligrams of oxytetracycline per 
pound of body weight, administered once, approximately 8 hours before 
farrowing or immediately after completion of farrowing.
    (b) Indications for use. For treatment of bacterial enteritis 
(scours, colibacillosis) caused by Escherichia coli, pneumonia caused by 
Pasteurella multocida, and leptospirosis caused by Leptospira pomona. 
Sows: as an aid in control of infections enteritis (baby pig scours, 
colibacillosis) in suckling pigs caused by Escherichia coli.
    (c) Limitations. Administer intramuscularly. Do not inject more than 
5 milliliters per site in adult swine, reducing the volume according to 
age and body size to 1 to 2 milliliters in young pigs. Discontinue 
treatment at least 22 days prior to slaughter.
    (f) [Reserved]
    (g)(1) Specifications. Each milliliter of sterile solution contains 
100 milligrams of oxytetracycline as oxytetracycline hydrochloride.
    (2) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. The drug is used for the treatment of 
diseases due to oxytetracycline-susceptible organisms as follows:
    (i) Beef cattle, beef calves, nonlactating dairy cattle, and dairy 
calves--(a) Amount. 3 to 5 milligrams of oxytetracycline per pound of 
body weight per day.
    (b) Indications for use. For the treatment of pneumonia and shipping 
fever complex associated with Pasteurella spp., Hemophilus spp., or 
Klebsiella spp.
    (c) Limitations. Administer by intramuscular, intravenous, or 
subcutaneous injection. In severe forms of the indicated diseases, 
administer 5 milligrams of oxytetracycline per pound of body weight per 
day. Continue treatment 24 to 48 hours following remission of disease 
symptoms, not to exceed a total of 4 consecutive days. If no improvement 
is noted within 48 hours, consult a veterinarian. Do not

[[Page 298]]

inject more than 10 milliliters per injection site intramuscularly in 
adult cattle; no more than 1 milliliter per site in calves weighing 100 
pounds or less. Do not slaughter cattle for 13 days after intramuscular 
or intravenous treatment, or 2 days after subcutaneous treatment. 
Exceeding the highest recommended dosage or duration of treatment (not 
more than 4 consecutive days) may result in residues beyond the 
withdrawal period. A withdrawal period has not been established for use 
of this product in preruminating calves. Do not use in calves to be 
processed for veal.
    (ii) Swine--(a) Amount. 3 to 5 milligrams of oxytetracycline per 
pound of body weight per day. Sows: Administer once 3 milligrams of 
oxytetracycline per pound of body weight, approximately 8 hours before 
farrowing or immediately after completion of farrowing.
    (b) Indications for use. For treatment of bacterial enteritis 
(scours, colibacillosis) caused by Escherichia coli, pneumonia caused by 
Pasteurella multocida, and leptospirosis caused by Leptospira pomona. 
Sows: As an aid in control of infectious enteritis (baby pig scours, 
colibacillosis) in suckling pigs caused by Escherichia coli.
    (c) Limitations. Administer intramuscularly. If no improvement is 
noted within 24 hours, consult a veterinarian. Do not inject more than 5 
milliliters per site. Discontinue treatment at least 20 days prior to 
slaughter.
    (h)(1) Specifications. Each milliliter of sterile solution contains 
50 or 100 milligrams of oxytetracycline hydrochloride.
    (2) Sponsors. See No. 000010 in Sec. 510.600(c) of this chapter for 
use of 50 and 100 milligrams per milliliter solution; and Nos. 055529 
and 059130 in Sec. 510.600(c) for use of 100 milligrams per milliliter 
solution.
    (3) Conditions of use--(i) Amount. The drug is used in beef cattle, 
beef calves, nonlactating dairy cattle, and dairy calves as follows: 3 
to 5 milligrams of oxytetracycline hydrochloride per pound of body 
weight per day; 5 milligrams per pound of body weight per day for 
treatment of severe forms of the indicated diseases.
    (ii) Indications for use. The drug is used for treatment of 
bacterial pneumonia and shipping fever complex associated with 
Pasteurella spp.; foot-rot and calf diphtheria caused by Spherophorus 
necrophorus; bacterial enterities (scours) caused by Escherichia coli; 
wooden tongue caused by Actinobacillus lignieresi; wound infections, 
acute metrities, and traumatic injury caused by staphylococcal and 
streptococcal organisms.
    (iii) Limitations. Administer 50-milligram-per-milliliter solution 
intramuscularly; administer 100-milligram-per-milliliter solution 
intravenously. Continue treatment 24 to 48 hours following remission of 
disease symptoms, not to exceed a total of 4 consecutive days. If no 
improvement is noted within 24 to 48 hours, consult a veterinarian for 
diagnosis and therapy. When injecting the drug intramuscularly, do no 
inject more than 10 milliliters per site in adult cattle. Reduce the 
volume administered per injection site according to age and body size. 
In calves weighing 100 pounds or less, do no inject more than 2 
milliliters intramuscularly per site. Discontinue treatment at least 22 
days before slaughter. Not for use in lactating dairy animals.
    (i)(1) Specifications. Each milliliter of sterile solution contains 
50 milligrams of oxytetracycline hydrochloride.
    (2) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use--(i) Amount. The drug is used in beef cattle, 
beef calves, nonlactating dairy cattle, and dairy calves as follows: 
Administer 3 to 5 milligrams of the oxytetracycline hydrochloride 
intramuscularly per pound of body weight per day.
    (ii) Indications for use. The drug is used for treatment of 
bacterial pneumonia and shipping fever complex associated with 
Pasteurella spp.; foot-rot and diptheria caused by Spherophorus 
necrophorus; bacterial enteritis (scours) caused by Escherichia coli; 
wooden tongue caused by Actinobacillus lignieresi; wound infections and 
acute metritis caused by staphylococcal and streptococcal organisms 
susceptible to oxytetracycline.
    (iii) Limitations. In severe forms of the indicated diseases, 
administer the

[[Page 299]]

equivalent of 5 milligrams of oxytetracycline hydrochloride per pound of 
body weight per day. Continue treatment 24 to 48 hours following 
remission of disease symptoms, not to exceed a total of 4 consecutive 
days. If no improvement is noted within 24 to 48 hours, consult a 
veterinarian for diagnosis and therapy. In adult livestock, do not 
inject more than 10 milliliters at any one site. Reduce the volume 
administered per injection site according to age and body size. In 
calves weighing 100 pounds or less inject only 2 milliliters per site. 
Discontinue treatment at least 18 days before slaughter. Not for use in 
lactating dairy cattle.
    (j) [Reserved]
    (k)(1) Specifications. Each milliliter of sterile solution contains 
either 50 or 100 milligrams of oxytetracycline hydrochloride.
    (2) Sponsor. See No. 061623 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use in beef cattle and nonlactating dairy cattle--
(i) Amount. 3 to 5 milligrams per pound of body weight daily, 5 
milligrams per pound for anaplasmosis, severe foot rot, and severe forms 
of other diseases.
    (ii) Indications for use. Treatment of diseases due to 
oxytetracycline-susceptible organisms as follows: pneumonia and shipping 
fever complex associated with Pasteurella spp. and Hemophilus spp.; foot 
rot and diphtheria caused by Fusobacterium necrophorum; bacterial 
enteritis (scours) caused by Escherichia coli; wooden tongue caused by 
Actinobacillus lignieresii; leptospirosis caused by Leptospira pomona; 
acute metritis and wound infections caused by staphylococcal and 
streptococcal organisms; if labeled for use by or on the order of a 
licensed veterinarian, it may be used for treatment of anaplasmosis 
caused by Anaplasma marginale and anthrax caused by Bacillus anthracis.
    (iii) Limitations. Administer by intravenous injection. Treatment 
should be continued 24 to 48 hours following remission of disease 
symptoms, but not to exceed a total of 4 consecutive days. If no 
improvement occurs within 24 to 48 hours, reevaluate diagnosis and 
therapy. Discontinue use at least 19 days prior to slaughter. Not for 
use in lactating dairy cattle.

[40 FR 13858, Mar. 27, 1975]

    Editorial Note: For Federal Register citations affecting Sec. 
522.1662a, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 522.1662b  Oxytetracycline hydrochloride with lidocaine injection.

    (a) Specifications. The drug contains 50 or 100 milligrams of 
oxytetracycline hydrochloride and 2 percent lidocaine in each milliliter 
of sterile aqueous solution.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is indicated for use in the 
treatment of diseases of dogs caused by pathogens sensitive to 
oxytetracycline hydrochloride including treatment for the following 
conditions in dogs caused by susceptible microorganisms: Bacterial 
infections of the urinary tract caused by Hemolytic staphylococcus, 
Streptococcus spp., Bacterial pulmonary infections caused by Brucella 
bronchiseptica, Streptococcus pyogenes, Staphylococcus aureus, secondary 
bacterial infections caused by Micrococcus pyogenes var. albus, Brucella 
bronchiseptica, Streptococcus spp.
    (2) The drug is administered intramuscularly at a recommended daily 
dosage to dogs at 5 milligrams per pound of body weight administered in 
divided doses at 6 to 12 hour intervals. Therapy should be continued for 
at least 24 hours after all symptoms have subsided.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 48 FR 30615, July 5, 1983]



Sec. 522.1664  Oxytetracycline and flunixin.

    (a) Specifications. Each milliliter (mL) of solution contains 300 
milligrams (mg) oxytetracycline base as amphoteric oxytetracycline and 
20 mg flunixin base as flunixin meglumine.
    (b) Sponsor. See No. 055529 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. Sec. 556.286 and 556.500 of this 
chapter.
    (d) Conditions of use cattle--(1) Amount. Administer once as an

[[Page 300]]

intramuscular or subcutaneous injection of 1 mL per 22 pounds (lb) body 
weight (BW) (13.6 mg oxytetracycline and 0.9 mg flunixin per lb BW) 
where retreatment of calves and yearlings for bacterial pneumonia is 
impractical due to husbandry conditions, such as cattle on range, or 
where their repeated restraint is inadvisable.
    (2) Indications for use. For the treatment of bacterial pneumonia 
associated with Pasteurella spp. and for the control of associated 
pyrexia in beef and nonlactating dairy cattle.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian. Discontinue treatment at least 21 days 
prior to slaughter of cattle. Do not use in female dairy cattle 20 
months of age or older. Use in this class of cattle may cause milk 
residues. A withdrawal period has not been established in preruminating 
calves. Do not use in calves to be processed for veal. Use of dosages 
other than those indicated may result in residue violations.

[76 FR 3489, Jan. 20, 2011]



Sec. 522.1680  Oxytocin injection.

    (a) Specifications. Each milliliter (mL) of solution contains 20 USP 
units oxytocin.
    (b) Sponsors. See Nos. 000010, 000856, 000859, and 061623 in Sec. 
510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount--(i) Obstetrical. Administer drug 
intravenously, intramuscularly, or subcutaneously under aseptic 
conditions as indicated. The following dosages are recommended and may 
be repeated as conditions require:

------------------------------------------------------------------------
                                          mL             U.S.P. units
------------------------------------------------------------------------
Cats............................  0.25 to 0.5.......  5 to 10.
Dogs............................  0.25 to 1.5.......  5 to 30.
Ewes, Sows......................  1.5 to 2.5........  30 to 50.
Cows, Horses....................  5.0...............  100.
------------------------------------------------------------------------

    (ii) Milk letdown. Intravenous administration is desirable. The 
following dosage is recommended and may be repeated as conditions 
require:

------------------------------------------------------------------------
                                          mL             U.S.P. units
------------------------------------------------------------------------
Cows............................  0.5 to 1.0........  10 to 20.
Sows............................  0.25 to 1.0.......  5 to 20.
------------------------------------------------------------------------

    (2) Indications for use. Oxytocin may be used as a uterine 
contractor to precipitate and accelerate normal parturition and 
postpartum evacuation of uterine debris. In surgery it may be used 
postoperatively following cesarean section to facilitate involution and 
resistance to the large inflow of blood. It will contract smooth muscle 
cells of the mammary gland for milk letdown if the udder is in proper 
physiological state.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[44 FR 63097, Nov. 2, 1979; 45 FR 1019, Jan. 4, 1980, as amended at 52 
FR 18691, May 19, 1987; 52 FR 25212, July 6, 1987; 52 FR 36023, Sept. 
25, 1987; 53 FR 32610, Aug. 26, 1988; 53 FR 40728, Oct. 18, 1988; 54 FR 
41442, Oct. 10, 1989; 55 FR 8462, Mar. 8, 1990; 56 FR 14642, Apr. 11, 
1991, 56 FR 16002, Apr. 19, 1991; 59 FR 31139, June 17, 1994; 62 FR 
35076, June 30, 1997; 62 FR 38906, July 21, 1997; 65 FR 45877, July 26, 
2000; 66 FR 22117, May 3, 2001; 68 FR 36913, June 20, 2003; 77 FR 55414, 
Sept. 10, 2012; 78 FR 17597, Mar. 22, 2013]



Sec. 522.1696  Penicillin G procaine implantation and injectable 
dosage forms.



Sec. 522.1696a  Penicillin G benzathine and penicillin G procaine 
suspension.

    (a) Specifications. Each milliliter of aqueous suspension contains 
penicillin G benzathine and penicillin G procaine, each equivalent to 
150,000 units of penicillin G.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
the conditions of use in paragraph (d) of this section as follows:
    (1) Nos. 000856, 055529, and 061623 for use as in paragraph (d)(1) 
of this section.
    (2) Nos. 000859, 055529, and 061623 for use as in paragraphs 
(d)(2)(i), (d)(2)(ii)(A), and (d)(2)(iii) of this section.
    (3) No. 000856 for use as in paragraphs (d)(2)(i), (d)(2)(ii)(B), 
and (d)(2)(iii) of this section.
    (c) Related tolerances. See Sec. 556.510 of this chapter.
    (d) Conditions of use--(1) Horses, dogs, and beef cattle--(i) 
Amount--(A) Beef cattle. 2 milliliters per 150 pounds of body weight 
intramuscularly or

[[Page 301]]

subcutaneously. Repeat dosage in 48 hours.
    (B) Horses. 2 milliliters per 150 pounds of body weight 
intramuscularly. Repeat dosage in 48 hours.
    (C) Dogs. 1 milliliter per 10 to 25 pounds of body weight 
intramuscularly or subcutaneously. Repeat dosage in 48 hours.
    (ii) Conditions of use. Treatment of bacterial infections 
susceptible to penicillin G.
    (iii) Limitations. Not for use in beef cattle within 30 days of 
slaughter. Do not use in horses intended for human consumption. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.
    (2) Beef cattle--(i) Amount. 2 milliliters per 150 pounds of body 
weight subcutaneously. Repeat dosage in 48 hours.
    (ii) Conditions of use.
    (A) Treatment of bacterial pneumonia (Streptococcus spp., 
Actinomyces pyogenes, Staphylococcus aureus); upper respiratory 
infections such as rhinitis or pharyngitis (A. pyogenes); blackleg 
(Clostridium chauvoei).
    (B) As in paragraph (d)(2)(ii)(A) of this section; and prophylaxis 
of bovine shipping fever in 300- to 500-pound beef calves.
    (iii) Limitations. Not for use within 30 days of slaughter. For Nos. 
055529, 059130, and 061623: A withdrawal period has not been established 
for this product in pre-ruminating calves. Do not use in calves to be 
processed for veal.

[66 FR 711, Jan. 4, 2001, as amended at 68 FR 34534, June 10, 2003; 70 
FR 21947, Apr. 28, 2005; 70 FR 50182, Aug. 26, 2005; 73 FR 16754, Mar. 
31, 2008; 75 FR 54017, Sept. 3, 2010; 77 FR 4897, Feb. 1, 2012; 78 FR 
17597, Mar. 22, 2013]



Sec. 522.1696b  Penicillin G procaine aqueous suspension.

    (a) Specifications. Each milliliter contains penicillin G procaine 
equivalent to 300,000 units of penicillin G.
    (b) Sponsors. See sponsor numbers in Sec. 510.600(c) of this 
chapter as follows:
    (1) Nos. 000859, 053501, and 055529 for use as in paragraph (d) of 
this section.
    (2) No. 061623 for use as in paragraph (d)(2) of this section.
    (c) Related tolerances. See Sec. 556.510 of this chapter.
    (d) Conditions of use--(1) Dogs and cats--(i) Amount. 10,000 units 
per pound body weight daily by intramuscular injection at 24-hour 
intervals. Continue treatment at least 48 hours after symptoms 
disappear.
    (ii) Indications for use. Treatment of infections caused by 
penicillin-sensitive organisms.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Cattle, sheep, swine, and horses--(i) Amount. 3,000 units per 
pound body weight (1 milliliter per 100 pounds body weight) daily by 
intramuscular injection.
    (A) For Nos. 000859, 053501, 055529, and 061623: Continue treatment 
at least 48 hours after symptoms disappear.
    (B) For No. 055529: Continue treatment at least 1 day after symptoms 
disappear (usually 2 or 3 days).
    (ii) Indications for use. Treatment of cattle and sheep for 
bacterial pneumonia (shipping fever) caused by Pasteurella multocida; 
swine for erysipelas caused by Erysipelothrix rhusiopathiae; and horses 
for strangles caused by Streptococcus equi.
    (iii) Limitations. Not for use in horses intended for food. Milk 
that has been taken during treatment and for 48 hours after the last 
treatment must not be used for food.
    (A) For Nos. 053501 and 061623: Do not exceed 7 days of treatment in 
nonlactating dairy and beef cattle, sheep, and swine, or 5 days in 
lactating cattle. Discontinue treatment for the following number of days 
before slaughter: Nonruminating cattle (calves)--7; all other cattle--4; 
sheep--8; and swine--6.
    (B) For Nos. 000859 and 055529: Continue treatment at least 1 day 
after symptoms disappear (usually 2 or 3 days).

[66 FR 712, Jan. 4, 2001, as amended at 68 FR 34534, June 10, 2003; 68 
FR 42589, July 18, 2003; 69 FR 17586, Apr. 5, 2004; 70 FR 16935, Apr. 4, 
2005; 73 FR 14177, Mar. 17, 2008; 75 FR 54017, Sept. 3, 2010; 78 FR 
17597, Mar. 22, 2013]



Sec. 522.1696c  Penicillin G procaine in oil.

    (a) Specifications. Each milliliter contains penicillin G procaine 
equivalent to 300,000 units of penicillin G.

[[Page 302]]

    (b) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (c) National Academy of Sciences/National Research Council (NAS/NRC) 
status. The conditions of use were NAS/NRC reviewed and found effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
    (d) Conditions of use--(1) Amount. Dogs and cats--10,000 units per 
pound of body weight once daily. Horses--3,000 units per pound of body 
weight once daily.
    (2) Indications for use. Treatment of infections of dogs, cats, and 
horses caused by penicillin-susceptible organisms such as Streptococci, 
Staphylococci, and Corynebacteria.
    (3) Limitations. Not for use in food-producing animals. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.

[57 FR 37333, Aug. 18, 1992]



Sec. 522.1698  Pentazocine lactate injection.

    (a) Specifications. Each milliliter of sterile aqueous solution 
contains pentazocine lactate equivalent to 30 milligrams of pentazocine 
base.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Horses--(i) Amount. 0.15 milligram of 
pentazocine base per pound of body weight per day.
    (ii) Indications for use. For symptomatic relief of pain due to 
colic.
    (iii) Limitations. Administer intravenously or intramuscularly. 
Intravenous injections are given slowly in the jugular vein. In cases of 
severe pain, a second dose is recommended intramuscularly 10 to 15 
minutes after the initial dose at the same level. Not for use in horses 
intended for food. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.
    (2) Dogs--(i) Amount. 0.75 to 1.50 milligrams of pentazocine base 
per pound of body weight.
    (ii) Indications for use. For amelioration of pain accompanying 
postoperative recovery, fracture, trauma, and spinal disorders.
    (iii) Limitations. Administer intramuscularly only. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.

[42 FR 31450, June 21, 1977, as amended at 42 FR 36995, July 19, 1977; 
47 FR 5409, Feb. 5, 1982; 55 FR 23076, June 6, 1990]



Sec. 522.1704  Sodium pentobarbital injection.

    (a)(1) Specifications. Sodium pentobarbital injection is sterile and 
contains in each milliliter 64.8 milligrams of sodium pentobarbital.
    (2) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) The drug is indicated for use as a 
general anesthetic in dogs and cats. Although it may be used as a 
general surgical anesthetic for horses, it is usually given at a lower 
dose to cause sedation and hypnosis and may be supplemented with a local 
anesthetic. It may also be used in dogs for the symptomatic treatment of 
strychnine poisoning.
    (ii) The drug is administered intravenously ``to effect''. For 
general surgical anesthesia, the usual dose is 11 to 13 milligrams per 
pound of body weight. For sedation, the usual dose is approximately 2 
milligrams per pound of body weight. For relieving convulsive seizures 
in dogs, when caused by strychnine, the injection should be administered 
intravenously ``to effect''. The drug may be given intraperitoneally if 
desired. However, the results of such injections are less uniform. When 
given intraperitoneally, it is administered at the same dosage level as 
for intravenous administration. The dose must be reduced for animals 
showing under-nourishment, toxemia, shock and similar conditions.
    (iii) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (b) [Reserved]

[40 FR 13858, Mar. 27, 1975, as amended at 45 FR 83483, Dec. 19, 1980; 
52 FR 25212, July 6, 1987; 62 FR 61625, Nov. 19, 1997; 66 FR 23588, May 
9, 2001]



Sec. 522.1720  Phenylbutazone injection.

    (a) Specifications. The drug contains 100 or 200 milligrams of 
phenylbutazone in each milliliter of sterile aqueous solution.
    (b) Sponsors. (1) Approval for use of the 200 milligrams per 
milliliter drug

[[Page 303]]

in dogs and horses: See sponsor Nos. 000061, 000856, 000859, and 061623 
in Sec. 510.600(c) of this chapter.
    (2) Approval for use of the 200 milligrams per milliliter drug for 
use in horses: See sponsor Nos. 000010 and 058005 in Sec. 510.600(c) of 
this chapter.
    (3) Approval for use of the 100 milligrams per milliliter drug in 
dogs and horses: See sponsor No. 000856 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use for dogs. (1) It is used for the relief of 
inflammatory conditions associated with the musculoskeletal system.
    (2) It is administered intravenously at a dosage level of 10 
milligrams per pound of body weight daily in 3 divided doses, not to 
exceed 800 milligrams daily regardless of weight. Limit intravenous 
administration to 2 successive days. Oral medication may follow.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (d) Conditions of use for horses. (1) It is used for the relief of 
inflammatory conditions associated with the musculoskeletal system.
    (2) It is administered intravenously at a dosage level of 1 to 2 
grams per 1,000 pounds of body weight daily in 3 divided doses, not to 
exceed 4 grams daily. Limit intravenous administration to not more than 
5 successive days.
    (3) Not for use in animals intended for food.
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13858, Mar. 27, 1975]

    Editorial Note: For Federal Register citations affecting Sec. 
522.1720, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 522.1820  Pituitary luteinizing hormone for injection.

    (a) Specifications. The drug is a lyophilized pituitary extract. 
Each 6-milliliter vial contains an amount equivalent to 25 milligrams of 
standard pituitary luteinizing hormone and is reconstituted for use by 
addition of 5 milliliters of 0.9 percent aqueous sodium chloride 
solution.
    (b) Sponsor. No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is an aid in the treatment of 
breeding disorders related to pituitary hypofunction in cattle, horses, 
swine, sheep, and dogs.
    (2) Preferably given by intravenous injection, it may be 
administered subcutaneously; dosage is as follows: Cattle and horses, 25 
mg; swine, 5 mg; sheep, 2.5 mg, and dogs, 1.0 mg. Treatment may be 
repeated in 1 to 4 weeks, or as indicated.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 52 FR 7832, Mar. 13, 1987]



Sec. 522.1850  Polysulfated glycosaminoglycan.

    (a) Specifications. (1) Each 1-milliliter (mL) ampule of solution 
contains 250 milligrams (mg) polysulfated glycosaminoglycan.
    (2) Each mL of solution packaged in 5-mL ampules or 20-, 30-, or 50-
mL vials contains 100 mg polysulfated glycosaminoglycan.
    (b) Sponsor. See No. 010797 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Conditions of use--(1) Horses--(i) Indications for use. For the 
treatment of noninfectious degenerative and/or traumatic joint 
dysfunction and associated lameness of the carpal and hock joints in 
horses.
    (ii) Amount--(A) Intra-articular use (carpal): 250 mg once a week 
for 5 weeks.
    (B) Intramuscular use (carpal and hock): 500 mg every 4 days for 28 
days.
    (iii) Limitations. Do not use in horses intended for human 
consumption.
    (2) Dogs--(i) Indications for use. For control of signs associated 
with noninfectious degenerative and/or traumatic arthritis of canine 
synovial joints.
    (ii) Amount. 2 mg per pound of body weight by intramuscular 
injection twice weekly for up to 4 weeks (maximum of 8 injections).

[72 FR 56896, Oct. 5, 2007, as amended at 74 FR 67816, Dec. 21, 2009]

[[Page 304]]



Sec. 522.1862  Sterile pralidoxime chloride.

    (a) Chemical name. 2-Formyl-1-methylpyridinium chloride oxime.
    (b) Specifications. Sterile pralidoxime chloride is packaged in 
vials. Each vial contains 1 gram of sterile pralidoxime chloride powder 
and includes directions for mixing this gram with 20 cubic centimeters 
of sterile water for injection prior to use.
    (c) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) It is used in horses, dogs, and cats as 
an antidote in the treatment of poisoning due to those pesticides and 
chemicals of the organophosphate class which have anticholinesterase 
activity in horses, dogs, and cats.
    (2) It is administered as soon as possible after exposure to the 
poison. Before administration of the sterile pralidoxime chloride, 
atropine is administered intravenously at a dosage rate of 0.05 
milligram per pound of body weight, followed by administration of an 
additional 0.15 milligram of atropine per pound of body weight 
administered intramuscularly. Then the appropriate dosage of sterile 
pralidoxime chloride is administered slowly intravenously. The dosage 
rate for sterile pralidoxime chloride when administered to horses is 2 
grams per horse. When administered to dogs and cats, it is 25 milligrams 
per pound of body weight. For small dogs and cats, sterile pralidoxime 
chloride may be administered either intraperitoneally or 
intramuscularly. A mild degree of atropinization should be maintained 
for at least 48 hours. Following severe poisoning, a second dose of 
sterile pralidoxime chloride may be given after 1 hour if muscle 
weakness has not been relieved.
    (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 49 FR 32061, Aug. 10, 1984]



Sec. 522.1870  Praziquantel.

    (a) Specification. Each milliliter contains 56.8 milligrams of 
praziquantel.
    (b) Sponsors. See Nos. 000859 and 061623 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. For dogs 5 pounds and 
under, 0.3 milliliter (17.0 milligrams); for 6 to 10 pounds, 0.5 
milliliter (28.4 milligrams); for 11 to 25 pounds, 1.0 milliliter (56.8 
milligrams); if over 25 Pounds, 0.2 milliliter (11.4 milligrams) per 5 
pounds body weight to a maximum of 3 milliliters (170.4 milligrams).
    (ii) Indications for use. For removal of canine cestodes Dipylidium 
caninum, Taenia pisiformis, and Echinococcus granulosus, and removal and 
control of canine cestode Echinococcus multilocularis.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Cats--(i) Amount. For cats under 5 pounds, 0.2 milliliter (11.4 
milligrams); 5 to 10 pounds, 0.4 milliliter (22.7 milligrams); 11 pounds 
and over, 0.6 milliliter (34.1 milligrams) maximum.
    (ii) Indications for use. For removal of feline cestodes Dipylidium 
caninum and Taenia taeniaeformis.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

[46 FR 10464, Feb. 3, 1981, as amended at 47 FR 6617, Feb. 16, 1982; 58 
FR 42853, Aug. 12, 1993; 67 FR 79853, Dec. 31, 2002; 78 FR 17868, Mar. 
25, 2013]



Sec. 522.1881  Sterile prednisolone acetate aqueous suspension.

    (a) Specifications. Each milliliter of sterile aqueous suspension 
contains 25 milligrams of prednisolone acetate.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) NAS/NRC status. The conditions of use are NAS/NRC reviewed and 
found effective. Applications for these uses need not include 
effectiveness data as specified in Sec. 514.111 of this chapter but may 
require bioequivalency and safety information.
    (d) Conditions of use. (1) The drug is indicated in the treatment of 
dogs, cats, and horses for conditions requiring an anti-inflammatory 
agent. The drug is indicated for the treatment of acute musculoskeletal 
inflammations such as bursitis, carpitis, and spondylitis. The drug is 
indicated as supportive therapy in nonspecific dermatosis such as summer 
eczema and

[[Page 305]]

atopy. The drug may be used as supportive therapy pre- and post-
operatively and for various stress conditions when corticosteroids are 
required while the animal is being treated for a specific condition.
    (2) The drug is administered to horses intra-articularly at a dosage 
level of 50 to 100 milligrams. The dose may be repeated when necessary. 
If no response is noted after 3 or 4 days, the possibility must be 
considered that the condition is unresponsive to prednisolone therapy. 
The drug is administered to dogs and cats intramuscularly at a dosage 
level of 10 to 50 milligrams. The dosage may be repeated when necessary. 
If the condition is of a chronic nature, an oral corticosteroid may be 
given as a maintenance dosage. The drug may be given intra-articularly 
to dogs and cats at a dosage level of 5 to 25 milligrams. The dose may 
be repeated when necessary after 7 days for two or three doses.
    (3) The labeling shall comply with the requirements of Sec. 510.410 
of this chapter for corticosteroids.
    (4) Not for use in horses intended for food.
    (5) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[52 FR 23032, June 17, 1987]



Sec. 522.1883  Prednisolone sodium phosphate.

    (a) Specifications. Each milliliter of solution contains 20 
milligrams (mg) prednisolone sodium phosphate (equivalent to 14.88 mg of 
prednisolone).
    (b) Sponsor. See No. 061623 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Administer intravenously 
in a dosage of 2\1/2\ to 5 mg per pound of body weight, initially for 
shock and shock-like states, followed by equal maintenance doses at 1-, 
3-, 6-, or 10-hour intervals as determined by the condition of the 
animal.
    (2) Indications for use. Administer when a rapid adrenal 
glucocorticoid and/or anti-inflammatory effect is necessary.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[68 FR 59881, Oct. 20, 2003]



Sec. 522.1884  Prednisolone sodium succinate injection.

    (a) Chemical name. 11 beta, 17, 21-Trihydroxypregna-1, 4-diene-3, 
20-dione 21-succinate sodium salt.
    (b) Specifications. Each milliliter of prednisolone sodium succinate 
injection contains: Prednisolone sodium succinate equivalent in activity 
to 10, 20, or 50 milligrams of prednisolone.
    (c) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter for 
products containing 10, 20, and 50 milligrams equivalent prednisolone 
activity per milliliter for use in horses, dogs, and cats as provided in 
paragraphs (d)(1), (2) (i), (ii), and (iii) of this section.
    (d) Conditions of use. (1) The drug is intended for the treatment of 
horses, dogs, and cats.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and found effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (2)(i) The dosage for horses is 50 to 100 milligrams as an initial 
dose given intravenously over a period of one-half to 1 minute, or 
intramuscularly, and may be repeated in inflammatory, allergic, or other 
stress conditions at intervals of 12, 24, or 48 hours, depending upon 
the size of the animal, the severity of the condition and the response 
to treatment. \1\
    (ii) In dogs, the drug is administered intravenously at a range of 
2.5 to 5 milligrams per pound of body weight as an initial dose followed 
by maintenance doses at 1, 3, 6, or 10 hour intervals, as determined by 
the condition of the animal, for treatment of shock.
    (iii) In dogs and cats, the drug may be given intramuscularly for 
treatment of inflammatory, allergic and less severe stress conditions, 
where immediate effect is not required, at 1 to 5 milligrams ranging 
upward to 30 to 50 milligrams in large breeds of dogs. Dosage may be 
repeated in 12 to 24 hours

[[Page 306]]

and continued for 3 to 5 days if necessary. If permanent corticosteroid 
effect is required oral therapy with prednisolone tablets may be 
substituted.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian. \1\

[40 FR 13858, Mar. 27, 1975, as amended at 46 FR 13215, Feb. 20, 1981; 
46 FR 33513, June 30, 1981; 52 FR 25212, July 6, 1987; 66 FR 23588, May 
9, 2001]



Sec. 522.1885  Prednisolone tertiary butylacetate suspension.

    (a) Specifications. Prednisolone tertiary butylacetate (Pregna-1,4-
diene-3, 20-dione-11B, 17[alpha] 21-triol 21-(3,3, dimethyl butyrate) 
suspension contains 20 milligrams of prednisolone tertiary butylacetate 
per milliliter. It is sterile.
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is used as an anti-inflammatory agent 
in horses, dogs, and cats.\1\
    (2) It is administered to horses intramuscularly at a dosage level 
of 100 to 300 milligrams and intrasynovially at a dosage level of 50 to 
100 milligrams. It is administered intramuscularly to dogs and cats at a 
dosage level of 1 milligram per 5 pounds of body weight and 
intrasynovially at a dosage level of 10 to 20 milligrams. Intramuscular 
retreatment of horses in 24 to 48 hours may be necessary, depending on 
the general condition of the animal and the severity and duration of the 
disease.\1\
    (3) Clinical and experimental data have demonstrated that 
corticosteroids administered orally or parenterally to animals may 
induce the first stage of parturition when administered late in 
pregnancy and may precipitate premature parturition followed by 
dystocia, fetal death, retained placenta, and metritis.\1\
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.\1\

[40 FR 13858, Mar. 27, 1975, as amended at 62 FR 63271, Nov. 28, 1997]



Sec. 522.1890  Sterile prednisone suspension.

    (a) [Reserved]
    (b)(1) Specifications. Each milliliter of sterile aqueous suspension 
contains 10 to 40 milligrams of prednisone.
    (2) Sponsor. See 000061 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use--(i) Amount. Administer intramuscularly as 
follows:
    (a) Horses. 100 to 400 milligrams, repeating if necessary. If no 
response is observed after 3 to 4 days of therapy, reevaluate 
diagnosis.\1\
    (b) Dogs and cats. 0.25 to 1.0 milligram per pound of body weight 
for 3 to 5 days or until a response is noted. Treatment may be continued 
with an orally administered dose.\1\
    (ii) Indications for use. It is used for conditions requiring an 
anti-inflammatory agent.\1\
    (iii) Limitations. \1\ Do not use in viral infections. Except in 
emergency therapy, do not use in animals with tuberculosis, chronic 
nephritis, or Cushings's disease. With infections, use appropriate 
antibacterial therapy with and for at least 3 days after discontinuance 
of use and disappearance of all signs of infection. Clinical and 
experimental data have demonstrated that corticosteroids administered 
orally or parenterally to animals may induce the first stage of 
parturition when administered during the last trimester of pregnancy and 
may precipitate premature parturition followed by dystocia, fetal death, 
retained placenta, and metritis. Not for use in horses intended for 
food. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.

[45 FR 13446, Feb. 29, 1980, as amended at 50 FR 6160, Feb. 14, 1985; 52 
FR 7832, Mar. 13, 1987]



Sec. 522.1920  Prochlorperazine, isopropamide for injection.

    (a) Specifications. Prochlorperazine, isopropamide for injection, 
veterinary, contains in each milliliter, 6 milligrams of 
prochlorperazine edisylate (equivalent to 4 milligrams 
prochlorperazine), and 0.38 milligrams of isopropamide iodide 
(equivalent to

[[Page 307]]

0.28 milligrams of isopropamide) in buffered aqueous solution.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used in dogs and cats in 
which gastrointestinal disturbances are associated with emotional 
stress.
    (2) Dosage is administered by subcutaneous injection twice daily as 
follows:

------------------------------------------------------------------------
                                                              Dosage in
                 Weight of animal in pounds                  Milliliters
------------------------------------------------------------------------
Up to 4....................................................         0.25
5 to 14....................................................        0.5-1
15 to 30...................................................          2-3
30 to 45...................................................          3-4
45 to 60...................................................          4-5
Over 60....................................................            6
------------------------------------------------------------------------


Following the last injection, administer prochlorperazine and 
isopropamide sustained release capsules as indicated.
    (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 56 FR 50653, Oct. 8, 1991; 60 
FR 55659, Nov. 2, 1995]



Sec. 522.1940  Progesterone and estradiol benzoate.

    (a) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (c) of this section:
    (1) No. 000856 for use as in paragraphs (c)(1)(i)(A), (c)(1)(ii), 
(c)(1)(iii), (c)(2)(i)(A), (c)(2)(ii), (c)(2)(iii), and (c)(3) of this 
section.
    (2) No. 000986 for use as in paragraphs (c)(1) and (c)(2) of this 
section.
    (b) Related tolerances. See Sec. Sec. 556.240 and 556.540 of this 
chapter.
    (c) Conditions of use in cattle. It is used for implantation as 
follows:
    (1) Suckling beef calves--(i) Amount--(A) 100 milligrams (mg) 
progesterone and 10 mg estradiol benzoate (one implant consisting of 4 
pellets, each pellet containing 25 mg progesterone and 2.5 mg estradiol 
benzoate) per implant dose.
    (B) 100 mg progesterone and 10 mg estradiol benzoate (one implant 
consisting of 5 pellets, each of 4 pellets containing 25 mg progesterone 
and 2.5 mg estradiol benzoate, and 1 pellet containing 29 mg tylosin 
tartrate) per implant dose.
    (ii) Indications for use. For increased rate of weight gain.
    (iii) Limitations. For use in suckling beef calves (at least 45 days 
of age) up to 400 pounds (lb) of body weight. For subcutaneous ear 
implantation, one dose per animal. Do not use in bull calves intended 
for reproduction. Safety and effectiveness have not been established in 
veal calves. A withdrawal period has not been established for this 
product in preruminating calves. Do not use in calves to be processed 
for veal.
    (2) Steers--(i) Amount--(A) 200 mg progesterone and 20 mg estradiol 
benzoate (one implant consisting of 8 pellets, each pellet containing 25 
mg progesterone and 2.5 mg estradiol benzoate) per implant dose.
    (B) 200 mg progesterone and 20 mg estradiol benzoate (one implant 
consisting of 9 pellets, each of 8 pellets containing 25 mg progesterone 
and 2.5 mg estradiol benzoate, and 1 pellet containing 29 mg tylosin 
tartrate) per implant dose.
    (ii) Indications for use. For increased rate of weight gain and 
improved feed efficiency.
    (iii) Limitations. For animals weighing 400 lb or more; for 
subcutaneous ear implantation, one dose per animal. Safety and 
effectiveness have not been established in veal calves. A withdrawal 
period has not been established for this product in preruminating 
calves. Do not use in calves to be processed for veal.
    (3) Steers fed in confinement for slaughter--(i) Amount. Reimplant 
200 mg progesterone and 20 mg estradiol benzoate on approximately day 70 
following an initial implant of 100 mg progesterone and 10 mg estradiol 
benzoate or 200 mg progesterone and 20 mg estradiol benzoate.
    (ii) Indications for use. For additional improvement in rate of 
weight gain.
    (iii) Limitations. For subcutaneous ear implantation. Safety and 
effectiveness have not been established in veal calves. A withdrawal 
period has not been established for this product in preruminating 
calves. Do not use in calves to be processed for veal.

[69 FR 70055, Dec. 2, 2004, as amended at 77 FR 31723, May 30, 2012]

[[Page 308]]



Sec. 522.1962  Promazine hydrochloride.

    (a) Specifications. Each milliliter of solution contains 50 
milligrams (mg) promazine hydrochloride.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (c) of this section:
    (1) No. 000856 for use as in paragraphs (c)(1)(i)(A), (c)(1)(ii)(A), 
(c)(1)(iii), and (c)(2) of this section.
    (2) No. 061623 for use as in paragraphs (c)(1)(i)(B), (c)(1)(ii)(B), 
and (c)(1)(iii) of this section.
    (c) Conditions of use--(1) Horses--(i) Amount--(A) 0.2 to 0.5 
milligrams per pounds (mg/lb) body weight intramuscularly or 
intravenously every 4 to 6 hours.
    (B) 0.2 to 0.5 mg/lb body weight intravenously as required.
    (ii) Indications for use--(A) For use as a tranquilizer, 
preanesthetic, or for minor operative procedures in conjunction with 
local anesthesia; and as adjunctive therapy for tetanus.
    (B) For use as a tranquilizer and preanesthetic.
    (iii) Limitations. Not for use in horses intended for food. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.
    (2) Dogs and cats--(i) Amount. 1 to 2 mg/lb body weight 
intramuscularly or intravenously every 4 to 6 hours.
    (ii) Indications for use. For use as a tranquilizer, preanesthetic, 
for minor operative procedures in conjunction with local anesthesia, as 
adjunctive therapy for tetanus, and as an antiemetic prior to worming; 
or to prevent motion sickness in dogs.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

[46 FR 18962, Mar. 27, 1981, as amended at 68 FR 59881, Oct. 20, 2003; 
70 FR 50183, Aug. 26, 2005]



Sec. 522.2002  Propiopromazine hydrochloride injection.

    (a) Chemical name. 1-Propanone, 1-[10-[3-(dimethylamino) propyl] 
phenothiazine-2-yl]-, monohydrochloride.
    (b) Specifications. Propiopromazine hydrochloride injection contains 
5 or 10 milligrams of the drug in each milliliter of sterile aqueous 
solution.
    (c) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (d) Conditions of use. (1) It is administered either intravenously 
or intramuscularly to dogs and cats for tranquilization at a dosage 
level of 0.05-0.5 milligram per pound of body weight and is also 
administered intravenously to dogs and cats as a preanesthetic at a 
dosage level of 0.25 milligram per pound of body weight.
    (2) It is not to be used in conjunction with organophosphates and/or 
procaine hydrochloride since phenothiazines may potentiate the toxicity 
of organophosphates and the activity of procaine hydrochloride.
    (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 46 FR 60570, Dec. 11, 1981; 
61 FR 5507, Feb. 13, 1996]



Sec. 522.2005  Propofol.

    (a) Specifications. Each milliliter of emulsion contains 10 
milligrams (mg) propofol.
    (b) Sponsors. See sponsor numbers in Sec. 510.600(c) of this 
chapter.
    (1) No. 000859 for use as in paragraphs (c)(1), (c)(2)(i), and 
(c)(3) of this section.
    (2) No. 000044 for use as in paragraphs (c)(1), (c)(2)(i), and 
(c)(3) of this section.
    (3) No. 000856 for use as in paragraphs (c)(1), (c)(2)(ii), and 
(c)(3) of this section.
    (c) Conditions of use in dogs and cats--(1) Amount. Administer by 
intravenous injection according to label directions. The use of 
preanesthetic medication reduces propofol dose requirements.
    (2) Indications for use--(i) As a single injection to provide 
general anesthesia for short procedures; for induction and maintenance 
of general anesthesia using incremental doses to effect; for induction 
of general anesthesia where maintenance is provided by inhalant 
anesthetics.
    (ii) For the induction and maintenance of anesthesia and for 
induction of anesthesia followed by maintenance with an inhalant 
anesthetic.

[75 FR 20269, Apr. 19, 2010, as amended at 75 FR 38700, July 6, 2010; 78 
FR 17868, Mar. 25, 2013]

[[Page 309]]



Sec. 522.2012  Prostalene solution.

    (a) Specifications. Each milliliter of sterile solution contains 1 
milligram of prostalene.
    (b) Sponsor. No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--Horses. (1) It is used in mares for the 
control of estrus.
    (2) It is administered at a dose of 5 micrograms per kilogram of 
body weight as a single subcutaneous injection.
    (3) Not for use in horses intended for food.
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[41 FR 26854, June 30, 1976, as amended at 61 FR 5507, Feb. 13, 1996]



Sec. 522.2063  Pyrilamine maleate injection.

    (a) Specifications. The drug is a sterile aqueous solution with each 
milliliter containing 20 milligrams of pyrilamine maleate.
    (b) Sponsors. See No. 000061 in Sec. 510.600(c) of this chapter for 
uses in paragraph (c)(2)(i) of this section; see No. 061623 in Sec. 
510.600(c) of this chapter for uses in paragraph (c)(2)(ii) of this 
section.
    (c) Conditions of use. (1) It is intended for treating horses in 
conditions in which antihistaminic therapy may be expected to lead to 
alleviation of some signs of disease.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and found effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (2)(i) It is administered intramuscularly, subcutaneously, or 
intravenously. Local injection at the site of insect bites may be 
indicated in severe cases. Intravenous injections must be given slowly 
to avoid symptoms of overdosage. Dosage may be repeated every 6 to 12 
hours whenever necessary. Horses, 40 to 60 milligrams per 100 pounds 
body weight; foals, 20 milligrams per 100 pounds body weight.\1\
    (ii) It is administered intravenously. Intravenous injections must 
be given slowly to avoid symptoms of overdosage. Dosage may be repeated 
every 6 to 12 hours if necessary. Horses, 40 to 60 milligrams per 100 
pounds body weight; foals, 20 milligrams per 100 pounds body weight.\1\
    (3) Do not use in horses intended for food purposes.\1\
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.\1\

[40 FR 13858, Mar. 27, 1975; 41 FR 9150, Mar. 3, 1976, as amended at 42 
FR 13549, Mar. 11, 1977; 42 FR 61256, Dec. 2, 1977; 51 FR 41477, Nov. 
17, 1986; 52 FR 7832, Mar. 13, 1987; 54 FR 1164, Jan. 12, 1989; 68 FR 
59881, Oct. 20, 2003]



Sec. 522.2076  Romifidine.

    (a) Specifications. Each milliliter of solution contains 10 
milligrams (mg) romifidine hydrochloride.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. 40 to 120 micrograms 
per kilogram of body weight (mcg/kg BW) intravenously for sedation and 
analgesia; 100 mcg/kg BW intravenously as a preanesthetic.
    (2) Indications for use. For use as a sedative and analgesic to 
facilitate handling, clinical examinations, clinical procedures, and 
minor surgical procedures in adult horses; and for use as a 
preanesthetic prior to the induction of general anesthesia in adult 
horses.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian. Not for horses intended for human 
consumption.

[69 FR 47363, Aug. 5, 2004]



Sec. 522.2100  Selenium, vitamin E injection.

    (a)(1) Specifications. The drug is an emulsion containing in each 
milliliter, 5.48 milligrams sodium selenite (equivalent to 2.5 
milligrams selenium), 50 milligrams of vitamin E (68 I.U.) (as d-alpha 
tocopheryl acetate).
    (2) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) The drug is intended for use for the 
prevention and treatment of selenium-tocopherol deficiency syndrome in 
horses.
    (ii) The drug is administered by intravenous or deep intramuscular 
injection in divided doses in 2 or more sites

[[Page 310]]

in the gluteal or cervical muscles at a dosage level of 1 milliliter per 
100 pounds of body weight and may be repeated at 5 to 10 day intervals.
    (iii) Do not use in horses intended for food.
    (iv) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (b)(1) Specifications. The drug contains in each milliliter 2.19 
milligrams of sodium selenite (equivalent to 1 milligram of selenium), 
50 milligrams of vitamin E (68 I.U.) (as d-alpha tocopheryl acetate).
    (2) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) The drug is intended for use as an aid in 
alleviating and controlling inflammation, pain and lameness associated 
with certain arthropathies in dogs.
    (ii) The drug is administered subcutaneously or intramuscularly in 
divided doses in 2 or more sites at a dosage level of 1 milliliter per 
20 pounds of body weight with a minimum dosage of \1/4\ milliliter and a 
maximum dosage of 5 milliliters. The dosage is repeated at 3 day 
intervals until a satisfactory therapeutic response is observed. A 
maintenance regimen is then initiated which consists of 1 milliliter per 
40 pounds of body weight with a minimum dosage of \1/4\ milliliter which 
is repeated every 3 days or 7 days, or longer, as required to maintain 
continued improvement or an asymptomatic condition; or the drug may be 
used in capsule form for oral maintenance therapy.
    (iii) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (c)(1) Specifications. Each milliliter contains 2.19 milligrams of 
selenite sodium (equivalent to 1 milligram selenium), 50 milligrams 
vitamin E (68 U.S.P. units).
    (2) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use--(i) Dosage. Calves: 2.5 to 3.75 milliliters 
per 100 pounds of body weight. Lambs 2 weeks of age or older: 1 
milliliter per 40 pounds, minimum 1 milliliter. Ewes: 2.5 milliliters 
per 100 pounds. Sows: 1 milliliter per 40 pounds. Weanling pigs: 1 
milliliter per 40 pounds, minimum 1 milliliter.
    (ii) Indications for use. Calves, lambs, and ewes: prevention and 
treatment of white muscle disease (selenium-tocopherol deficiency 
syndrome). Sows and weanling pigs: an aid in the prevention and 
treatment of selenium-tocopherol deficiency.
    (iii) Limitations. For subcutaneous or intramuscular use. Not for 
use in newborn pigs. Do not use in pregnant ewes. Calves: Discontinue 
use 30 days before treated calves are slaughtered for human consumption. 
Lambs, ewes, sows, or pigs: Discontinue use 14 days before treated 
lambs, ewes, sows, or pigs are slaughtered for human consumption. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.
    (d)(1) Specifications. Each milliliter contains 10.95 milligrams 
selenite sodium (equivalent to 5 milligrams selenium), 50 milligrams 
vitamin E (68 U.S.P. units).
    (2) Sponsor. See Nos. 000061 and 000856 in Sec. 510.600(c) of this 
chapter.
    (3) Conditions of use--(i) Dosage. Breeding beef cows: 1 milliliter 
per 200 pounds of body weight during the middle third of gestation, and 
30 days before calving. Weanling calves: 1 milliliter per 200 pounds of 
body weight.
    (ii) Indications for use. Weanling calves and breeding beef cows: 
For the prevention and treatment of selenium-tocopherol deficiency 
syndrome.
    (iii) Limitations. For subcutaneous or intramuscular use. 
Discontinue use 30 days before treated cattle are slaughtered for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.
    (e)(1) Specifications. Each milliliter contains 0.55 milligram 
selenite sodium (equivalent to 0.25 milligram selenium), 50 milligrams 
(68 U.S.P. units) vitamin E.
    (2) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use--(i) Dosage. Newborn lambs: 1 milliliter. 
Lambs 2 weeks of age or older: 4 milliliters. Baby pigs: 1 milliliter 
(or treat the sow during the last week of pregnancy).
    (ii) Indications for use. Lambs: for prevention and treatment of 
white muscle disease (selenium-tocopherol deficiency

[[Page 311]]

syndrome). Baby pigs: an aid in the prevention and treatment of 
selenium-tocopherol deficiency.
    (iii) Limitations. For subcutaneous or intramuscular use only. 
Discontinue use 14 days before treated animals are slaughtered for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 52 FR 7832, Mar. 13, 1987; 57 
FR 21209, May 19, 1992; 58 FR 57556, Oct. 26, 1993; 60 FR 57833, Nov. 
22, 1995; 64 FR 27916, May 24, 1999]



Sec. 522.2112  Sometribove zinc suspension.

    (a) Specifications. Each single-dose syringe contains 500 milligrams 
(mg) sometribove zinc in a prolonged-release suspension.
    (b) Sponsor. See No. 000986 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. Inject 500 mg every 14 days 
starting during the 9th or 10th week (57 to 70 days) after calving and 
continue until the end of lactation.
    (2) Indications for use. To increase production of marketable milk 
in healthy lactating dairy cows.
    (3) Limitations. Use in lactating dairy cows only. Safety to 
replacement bulls born to treated dairy cows has not been established. 
Inject subcutaneously. Avoid injections within 2 weeks of expected 
slaughter to minimize injection site blemishes on carcass. There is no 
milk discard or preslaughter withdrawal period. Use may reduce pregnancy 
rates and increase days open. Treated cows are at an increased risk for 
mastitis and higher milk somatic cell counts. Use care to differentiate 
increased body temperature due to use of this product from an increased 
body temperature that may occur due to illness. Cows treated with this 
product may have more enlarged hocks and disorders of the foot region. 
Use may reduce hemoglobin and hematocrit values during treatment. Human 
warning: Avoid prolonged or repeated contact with eyes and skin.

[58 FR 59947, Nov. 12, 1993, as amended at 67 FR 18085, Apr. 15, 2002; 
68 FR 62006, Oct. 31, 2003; 74 FR 53164, Oct. 16, 2009]



Sec. 522.2120  Spectinomycin dihydrochloride injection.

    (a) Specifications. The spectinomycin dihydrochloride pentahydrate 
used in manufacturing the drug is the antibiotic substance produced by 
the growth of Streptomyces flavopersicus (var. Abbott) or the same 
antibiotic substance produced by any other means. Each milliliter of the 
drug contains the following amount of spectinomycin activity from 
spectinomycin dihydrochloride pentahydrate:
    (1) 5 milligrams when used as provided in paragraph (d)(1) of this 
section.
    (2) [Reserved]
    (3) 100 milligrams when used as provided in paragraphs (d) (2), (3), 
and (4) of this section.
    (b) Sponsor. In Sec. 510.600 of this chapter, see No. 000859 for 
conditions of use as in paragraph (d) of this section, and see No. 
000009 for conditions of use as in paragraph (d)(2) and (d)(4) of this 
section.
    (c) Special considerations. The quantity of spectinomycin referred 
to in this section refers to the equivalent weight of base activity for 
the drug.
    (d) Conditions of use. It is administered as spectinomycin 
dihydrochloride pentahydrate as follows:
    (1) Subcutaneously in the treatment of 1-to-3-day-old turkey poults 
at the rate of 1 to 2 milligrams per poult as an aid in the prevention 
of mortality associated with Arizona group infection.
    (2) Subcutaneously in the treatment of 1-to-3-day old:
    (i) Turkey poults at the rate of 5 milligrams per poult as an aid in 
the control of chronic respiratory disease (CRD) associated with E. 
coli.
    (ii) Baby chicks at the rate of 2.5 to 5 milligrams per chick as an 
aid in the control of mortality and to lessen severity of infections 
caused by M. synoviae, S. typhimurium, S. infantis, and E. coli.
    (3) Intramuscularly in the treatment of dogs:
    (i) At a dosage level of 2.5 milligrams to 5.0 milligrams per pound 
of body weight twice daily. Treatment may be continued for 4 days. For 
treatment of infections caused by gram-negative and

[[Page 312]]

gram-positive organisms susceptible to spectinomycin.
    (ii) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (4) Administer single injection of 0.1 milliliter (10 milligrams) 
subcutaneously in nape of neck of 1- to 3-day-old turkey poults as an 
aid in control of airsacculitis associated with M. meleagridis sensitive 
to spectinomycin.

[40 FR 13858, Mar. 27, 1975, as amended at 43 FR 9273, Mar. 7, 1978; 46 
FR 18964, Mar. 27, 1981; 47 FR 14149, Apr. 2, 1982; 61 FR 5507, Feb. 13, 
1996; 61 FR 31028, June 19, 1996; 65 FR 45877, July 26, 2000; 66 FR 
22118, May 3, 2001]



Sec. 522.2121  Spectinomycin sulfate.

    (a) Specifications. Each milliliter of solution contains 
spectinomycin sulfate tetrahydrate equivalent to 100 milligrams (mg) 
spectinomycin.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.600 of this chapter.
    (d) Conditions of use in cattle--(1) Amount. 10 to 15 mg per 
kilogram of body weight at 24-hour intervals for 3 to 5 consecutive 
days.
    (2) Indications for use. For the treatment of bovine respiratory 
disease (pneumonia) associated with Mannheimia haemolytica, Pasteurella 
multocida, and Histophilus somni.
    (3) Limitations. Do not slaughter within 11 days of last treatment. 
Do not use in female dairy cattle 20 months of age or older. Use in this 
class of cattle may cause residues in milk. A withdrawal period has not 
been established for this product in preruminating calves. Do not use in 
calves to be processed for veal. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.

[72 FR 31178, June 6, 2007]



Sec. 522.2150  Stanozolol sterile suspension.

    (a) Specifications. Each milliliter of sterile suspension contains 
50 milligrams of stanozolol.
    (b) Sponsor. No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) Used as an anabolic steroid treatment in 
dogs, cats, and horses.
    (2) Administered to dogs and cats by deep intramuscular injection in 
the thigh at weekly intervals, for several weeks. For cats and small 
breeds of dogs, 25 milligrams. For larger dogs, 50 milligrams.
    (3) Administered to horses by deep intramuscular injection in the 
gluteal region at weekly intervals, for not more than 4 weeks; 25 
milligrams per 100 pounds of body weight.
    (4) Not for use in horses intended for food.
    (5) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 46101, Oct. 6, 1975, as amended at 42 FR 36995, July 19, 1977; 55 
FR 23076, June 6, 1990]



Sec. 522.2200  Sulfachlorpyridazine.

    (a) Specifications. Each milliliter of solution contains sodium 
sulfachlorpyridazine equivalent to 200 milligrams (mg) 
sulfachlorpyridazine.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.630 of this chapter.
    (d) Conditions of use in calves. It is used as follows:
    (1) Amount. Administer 30 to 45 mg per pound (/lb) of body weight in 
divided doses by twice daily injection for 1 to 5 days.
    (2) Indications for use. For the treatment of diarrhea caused or 
complicated by Escherichia coli (colibacillosis).
    (3) Limitations. Treated calves must not be slaughtered for food 
during treatment or for 5 days after the last treatment. A withdrawal 
period has not been established for this product in preruminating 
calves. Do not use in calves to be processed for veal.

[75 FR 10167, Mar. 5, 2010]



Sec. 522.2220  Sulfadimethoxine injection.

    (a)(1) Specifications. Sulfadimethoxine injection containing 400 
milligrams per milliliter.
    (2) Sponsor. (i) See No. 000069 in Sec. 510.600(c) of this chapter 
for conditions of use as in paragraphs (a)(3)(i) through (a)(3)(iii) of 
this section.
    (ii) See No. 057561 for conditions of use as in paragraph (a)(3) of 
this section.

[[Page 313]]

    (iii) See No. 000859 for use as in paragraph (a)(3)(iii) of this 
section.
    (3) Conditions of use. (i) It is used or intended for use in dogs 
and cats as follows:
    (a) For the treatment of respiratory, genitourinary tract, enteric, 
and soft tissue infections when caused by Streptococci, Staphylococci, 
Escherichia, Salmonella, Klebsiella, Proteus, or Shigella organisms 
sensitive to sulfadimethoxine, and in the treatment of canine bacterial 
enteritis associated with coccidiosis and canine Salmonellosis.
    (b) It is administered by intravenous or subcutaneous injection at 
an initial dose of 55 milligrams per kilogram of body weight followed by 
27.5 milligrams per kilogram of body weight every 24 hours.
    (c) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (ii) It is used or intended for use in horses as follows:
    (a) For the treatment of respiratory disease caused by Streptococcus 
equi (strangles).
    (b) It is administered by intravenous injection at an initial dose 
of 55 milligrams per kilogram of body weight followed by 27.5 milligrams 
per kilogram of body weight every 24 hours until the patient is 
asymptomatic for 48 hours.
    (c) Not for use in horses intended for food.
    (d) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (iii) It is used or intended for use in cattle as follows:
    (a) For the treatment of shipping fever complex, bacterial 
pneumonia, calf diphtheria, and foot-rot.
    (b) It is administered by intravenous injection at an initial dose 
of 25 milligrams per pound of body weight followed by 12.5 milligrams 
per pound of body weight every 24 hours until the animal is asymptomatic 
for 48 hours.
    (c) Milk taken from animals during treatment and for 60 hours (5 
milkings) after the latest treatment must not be used for food. Do not 
administer within 5 days of slaughter. A withdrawal period has not been 
established for this product in preruminating calves. Do not use in 
calves to be processed for veal.
    (d) Tissue damage may result from perivascular infiltration.
    (b) [Reserved]
    (c)(1) Specifications. Sulfadimethoxine containing 100 milligrams 
per milliliter.
    (2) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (3) Conditions of use. (i) It is used or intended for use in the 
treatment of sulfadimethoxine-susceptible bacterial infections in dogs.
    (ii) It is administered by subcutaneous, intramuscular, or 
intravenous injection at an initial dose of 25 milligrams per pound of 
body weight followed by 12.5 milligrams per pound of body weight every 
24 hours thereafter. Continue treatment until the animal is free from 
symptoms for 48 hours.
    (iii) For use by or on the order of a licensed veterinarian.
    (d) Related tolerances. See Sec. 556.640 of this chapter.

[40 FR 13858, Mar. 27, 1975, as amended at 40 FR 34112, Aug. 14, 1975; 
40 FR 42007, Sept. 10, 1975; 50 FR 254, Jan. 3, 1985; 53 FR 40728, Oct. 
18, 1988; 54 FR 30205, July 19, 1989; 58 FR 38972, July 21, 1993; 59 FR 
56000, Nov. 10, 1994; 61 FR 4875, Feb. 9, 1996; 62 FR 23128, Apr. 29, 
1997; 62 FR 35076, June 30, 1997; 70 FR 16935, Apr. 4, 2005; 78 FR 
17597, Mar. 22, 2013]



Sec. 522.2240  Sulfaethoxypyridazine.

    (a) Chemical name. N\1\-(6-Ethoxy-3-pyridazinyl) sulfanilamide.
    (b) Specifications. Melting point range of 180 [deg]C to 186 [deg]C.
    (c) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (d) Related tolerances. See Sec. 556.650 of this chapter.
    (e) Conditions of use. It is used for injection into cattle as 
follows:
    (1) Amount. 2.5 grams per 100 pounds of body weight per day.
    (2) Indications for use. Treatment of respiratory infection 
(pneumonia, shipping fever), foot rot, calf scours; as adjunctive 
therapy in septicemia accompanying mastitis and metritis.
    (3) Limitations. Administer intravenously for not more than 4 days; 
or first treatment may be followed by 3 days of treatment with 
sulfaethoxypyridazine in drinking water or tablets in accordance with 
Sec. Sec. 520.2240a(e) and 520.2240b(e) of this

[[Page 314]]

chapter; as sodium sulfaethoxypyridazine; do not treat within 16 days of 
slaughter; as sole source of sulfonamide; milk that has been taken from 
animals during treatment and for 72 hours (6 milkings) after the latest 
treatment must not be used for food. Federal law restricts this drug to 
use by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 41 FR 11011, Mar. 15, 1976; 
67 FR 78355, Dec. 24, 2002; 76 FR 17027, Mar. 28, 2011]



Sec. 522.2260  Sulfamethazine.

    (a) Specifications. Each milliliter (mL) of solution contains 250 
milligrams (mg) sulfamethazine sodium.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.670 of this chapter.
    (d) Conditions of use in cattle--(1) Amount. Initially administer 20 
mL for each 50 pounds (lb) of body weight (100 mg/lb) by intravenous 
injection, followed by 20 mL per 100 lb of body weight (50 mg/lb) by 
intravenous injection, daily thereafter. Treatment should not exceed a 
total of 5 consecutive days.
    (2) Indications for use. For cattle for treatment of bacterial 
pneumonia and bovine respiratory disease complex (shipping fever 
complex) (Pasteurella spp.), colibacillosis (bacterial scours) 
(Escherichia coli), necrotic pododermatitis (foot rot) (Fusobacterium 
necrophorum), calf diphtheria (Fusobacterium necrophorum), acute 
mastitis and acute metritis (Streptococcus spp.) when caused by one or 
more pathogenic organisms sensitive to sulfamethazine.
    (3) Limitations. Withdraw medication from cattle 10 days prior to 
slaughter. Do not use in female dairy cattle 20 months of age or older. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.

[46 FR 62055, Dec. 22, 1981, as amended at 67 FR 78355, Dec. 24, 2002; 
75 FR 10167, Mar. 5, 2010; 76 FR 53051, Aug. 25, 2011]



Sec. 522.2340  Sulfomyxin.

    (a) Specifications. Sulfomyxin for injection is sterile. It is 
derived from the antibiotic substance produced by the growth of Bacillus 
polymyxa or is the same substance produced by any other means.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. The quantities of antibiotic in 
paragraph (e) of this section refer to the activity of the appropriate 
standard.
    (d) Related tolerances. See Sec. 556.700 of this chapter.
    (e) Conditions of use. (1) It is used or intended for use in 
chickens and turkeys as an aid in the treatment of disease caused or 
complicated by E. coli, such as colibacillosis and complicated chronic 
respiratory disease.
    (2) It is administered by subcutaneous injection as follows:

------------------------------------------------------------------------
                                                    Antibiotic activity
                                                 -----------------------
              Age of birds in days                 Chickens     Turkeys
                                                    (units)     (units)
------------------------------------------------------------------------
1 to 14.........................................      12,500      12,500
15 to 28........................................      25,000      25,000
29 to 63........................................      50,000      50,000
Over 63.........................................      50,000     100,000
------------------------------------------------------------------------

    (3) A second injection may be given 3 days later if symptoms 
persist.
    (4) Not for use in laying hens; do not treat chickens within 5 days 
of slaughter; do not treat turkeys within 7 days of slaughter.



Sec. 522.2404  Thialbarbitone sodium for injection.

    (a) Specifications. Thialbarbitone sodium for injection when 
reconstituted with sterile distilled water provides 94 milligrams of 
thialbarbitone sodium per milliliter of solution.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is administered as a general 
anesthetic in surgical procedures on dogs, cats, swine, sheep, cattle, 
and horses. The drug is used for procedures of relatively short 
duration. However, the period of anesthesia can be lengthened by slower 
initial injection and supplemental administration during surgery.
    (2) It is administered intravenously. The drug is injected slowly to 
dogs, cats, cattle, sheep, and swine. For horses, it is recommended that 
a pre-anesthetic sedation be administered to the horse 30 minutes before 
the drug is administered. The drug is then injected

[[Page 315]]

rapidly and completely. The drug is used at the following dosage levels:

------------------------------------------------------------------------
                                                               Dosage in
               Species                  Weight of animal in   milligrams
                                              pounds           per pound
------------------------------------------------------------------------
Dog.................................  Over 50...............        14.1
 Do.................................  30-50.................        18.8
 Do.................................  10-30.................        23.5
 Do.................................  Under 10..............        28.2
Cat.................................  ......................   31.3-37.6
Horse...............................  ......................     6.3-7.8
Cattle and swine....................  ......................     6.7-9.4
Calves and sheep....................  ......................    9.4-11.8
------------------------------------------------------------------------

    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.



Sec. 522.2424  Sodium thiamylal for injection.

    (a) Specifications. The drug is a sterile dry powder. It is 
reconstituted aseptically with sterile distilled water, water for 
injection, or sodium chloride injection, to a desired concentration of 
0.5 to 4 percent sodium thiamylal.
    (b) Sponsors. See code Nos. 000010 and 000856 in Sec. 510.500(c) of 
this chapter.
    (c) Conditions of use. (1) It is used as an ultra-short-acting 
anesthetic in dogs, cats, swine, horses, and cattle.
    (2) When diluted aseptically to the desired concentration and 
administered intravenously to effect, the average single dose is:
    (i) Dogs and cats: 8 milligrams per pound of body weight (when used 
with a preanesthetic, generally one-half the normal dose).
    (ii) Swine: 40 milligrams per 5 pounds of body weight.
    (iii) Horses: Light anesthesia, 1 gram per 500 pounds to 1,100 
pounds of body weight; deep anethesia, 1 gram per 300 pounds of body 
weight (40 milligrams per 12 pounds of body weight).
    (iv) Cattle: Short duration, 20 milligrams per 5 pounds of body 
weight; longer duration, 40 milligrams per 7 pounds of body weight.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (4) NAS/NRC status: The conditions of use specified in this 
paragraph are NAS/NRC reviewed and found effective. Applications for 
these uses need not include effectiveness data as specified in Sec. 
514.111 of this chapter, but may require bioequivalency and safety 
information.

[40 FR 25812, June 19, 1975, as amended at 49 FR 8434, Mar. 7, 1984; 53 
FR 23390, June 22, 1988; 53 FR 40728, Oct. 18, 1988; 62 FR 35076, June 
30, 1997]



Sec. 522.2444  Sodium thiopental implantation or injectable dosage 
forms.



Sec. 522.2444a  Sodium thiopental for injection.

    (a) Specifications. The drug contains sodium thiopental sterile 
powder for dilution with sterile water for injection.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is used as an anesthetic for 
intravenous administration to dogs and cats during short to moderately 
long surgical and other procedures. It is also used to induce anesthesia 
in dogs and cats which then have surgical anesthesia maintained by use 
of a volatile anesthetic.
    (2) It is administered as follows:
    (i) For brief anesthesia (6 to 10 minutes) a dosage of 6 to 9 
milligrams per pound of body weight is suggested.
    (ii) To obtain anesthesia of 15 to 25 minutes duration the suggested 
dosage is 10 to 12 milligrams per pound of body weight.
    (iii) Use of a preanesthetic tranquilizer or morphine will decrease 
the dosage of sodium thiopental required, provide for smoother induction 
and smoother recovery, and sometimes prolong the recovery period. If 
morphine is used as a preanesthetic agent the dose of the barbiturate 
can be reduced as much as 40 to 50 percent. When a tranquilizer is 
administered the barbiturate dosage can be reduced 10 to 25 percent.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.



Sec. 522.2444b  Sodium thiopental, sodium pentobarbital for injection.

    (a) Specifications. Each gram of the drug contains 750 milligrams of 
sodium thiopental and 250 milligrams of sodium pentobarbital sterile 
powder for dilution with sterile water for injection.
    (b) Sponsor. See No. 061623 in Sec. 510.600(c) of this chapter.

[[Page 316]]

    (c) Conditions of use. (1) It is used as an anesthetic for 
intravenous administration to dogs and cats during short to moderately 
long surgical procedures.
    (2) It is administered as follows:
    (i) For total anesthesia, it is given at approximately 10 to 12 
milligrams per pound of body weight over a period of 3.5 to 5 minutes.
    (ii) When preanesthetic medication is used, it is important to wait 
at least an hour before administering thiopental and sodium 
pentobarbital for injection, and the dosage necessary for anesthesia is 
reduced. Usually \1/2\ to \2/3\ the normal amount is adequate.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 47 FR 14149, Apr. 2, 1982; 66 
FR 14073, Mar. 9, 2001; 68 FR 4915, Jan. 31, 2003]



Sec. 522.2460  Tildipirosin.

    (a) Specifications. Each milliliter of solution contains:
    (1) 180 milligrams (mg) tildipirosin.
    (2) [Reserved]
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.733 of this chapter.
    (d) Conditions of use--(1) Cattle--(i) Amount. Administer 4 mg/kg of 
bodyweight one time by subcutaneous injection in the neck.
    (ii) Indications for use. For the treatment of bovine respiratory 
disease (BRD) associated with Mannheimia haemolytica, Pasteurella 
multocida, and Histophilus somni in beef and non-lactating dairy cattle; 
and for the control of respiratory disease in beef and non-lactating 
dairy cattle at high risk of developing BRD associated with M. 
haemolytica, P. multocida, and H. somni.
    (iii) Limitations. Cattle intended for human consumption must not be 
slaughtered within 21 days from the last treatment. Do not use in female 
dairy cattle 20 months of age or older. A withdrawal period has not been 
established for this product in preruminating calves. Do not use in 
calves to be processed for veal. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (2) [Reserved]

[77 FR 39391, July 3, 2012]



Sec. 522.2470  Tiletamine hydrochloride and zolazepam hydrochloride 
for injection.

    (a) Specifications. Tiletamine hydrochloride and zolazepam 
hydrochloride for injection when reconstituted with sterile distilled 
water provides tiletamine hydrochloride and zolazepam hydrochloride 
equivalent to 50 milligrams of tiletamine base and 50 milligrams of 
zolazepam base per milliliter of solution.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Indications for use. It is used for 
restraint or for anesthesia combined with muscle relaxation in cats and 
in dogs for restraint and minor procedures of short duration (30 
minutes) requiring mild to moderate analgesia.
    (2) Amount. Expressed as milligrams of the drug combination:
    (i) In healthy dogs: An initial intramuscular dosage of 3 to 4.5 
milligrams per pound of body weight for diagnostic purposes; 4.5 to 6 
milligrams per pound of body weight for minor procedures of short 
duration such as repair of lacerations and wounds, castrations, and 
other procedures requiring mild to moderate analgesia. Supplemental 
doses when required should be less than the initial dose and the total 
dose given should not exceed 12 milligrams per pound of body weight. The 
maximum total safe dose is 13.6 milligrams per pound of body weight.
    (ii) In healthy cats: An initial intramuscular dosage of 4.4 to 5.4 
milligrams per pound of body weight is recommended for such procedures 
as dentistry, treatment of abscesses, foreign body removal, and related 
types of surgery; 4.8 to 5.7 milligrams per pound of body weight for 
minor procedures requiring mild to moderate analgesia, such as repair of 
lacerations, castrations, and other procedures of short duration. 
Initial dosages of 6.5 to 7.2 milligrams per pound of body weight are 
recommended for ovariohysterectomy and onychectomy. When supplemental 
doses are required, such individual supplemental doses should be given 
in increments that are less than the initial dose and the total dose 
given (initial dose plus supplemental doses) should not exceed the 
maximum allowable

[[Page 317]]

safe dose of 32.7 milligrams per pound of body weight.
    (3) Limitations. Discard unused reconstituted solution after 48 
hours. Not for use in dogs and cats with pancreatic disease, or with 
severe cardiac or pulmonary dysfunction. Not for use in pregnant 
animals. Not for use in cats suffering with renal insufficiency. The 
dosage should be reduced in geriatric dogs and cats. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.

[47 FR 15328, Apr. 9, 1982, as amended at 51 FR 24142, July 2, 1986; 67 
FR 67521, Nov. 6, 2002]



Sec. 522.2471  Tilmicosin.

    (a) Specifications. Each milliliter of solution contains 300 
milligrams (mg) tilmicosin base as tilmicosin phosphate.
    (b) Sponsor. See No. 000986 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.735 of this chapter.
    (d) Special considerations. (1) Not for human use. Use of this 
antibiotic in humans may prove fatal. Do not use in automatically 
powered syringes.
    (2) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.
    (e) Conditions of use--(1) Cattle--(i) Amount. 10 to 20 milligrams 
per kilograms (mg/kg) of body weight as a single subcutaneous injection.
    (ii) Indications for use. For the treatment of bovine respiratory 
disease (BRD) associated with Mannheimia haemolytica, Pasteurella 
multocida, and Histophilus somni. For the control of respiratory disease 
in cattle at high risk of developing BRD associated with M. haemolytica.
    (iii) Limitations. Do not use in female dairy cattle 20 months of 
age or older. Use of this antibiotic in this class of cattle may cause 
milk residues. Do not slaughter within 42 days of last treatment.
    (2) Sheep--(i) Amount. 10 mg/kg body weight as a single subcutaneous 
injection.
    (ii) Indications for use. For the treatment of ovine respiratory 
disease (ORD) associated with Mannheimia (P.) haemolytica.
    (iii) Limitations. Do not slaughter within 28 days of last 
treatment.

[67 FR 72367, Dec. 5, 2002, as amended at 75 FR 9334, Mar. 2, 2010]



Sec. 522.2474  Tolazoline hydrochloride injection.

    (a) Specifications. Each milliliter of sterile aqueous solution 
contains tolazoline hydrochloride equivalent to 100 milligrams of base 
activity.
    (b) Sponsor. See No. 061690 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. It is used as follows:
    (1) Horses--(i) Amount. Administer slowly by intravenous injection 4 
milligrams per kilogram of body weight or 1.8 milligrams per pound (4 
milliliters per 100 kilograms or 4 milliliters per 220 pounds).
    (ii) Indications for use. For use in horses when it is desirable to 
reverse the effects of sedation and analgesia caused by xylazine.
    (iii) Limitations. The safety of Tolazine\TM\ has not been 
established in pregnant mares, lactating mares, horses intended for 
breeding, foals, or horses with metabolically unstable conditions. The 
safety of Tolazine\TM\ has not been evaluated for reversing xylazine 
used as a preanesthetic to a general anesthetic. This drug is for use in 
horses only and not for use in food-producing animals. Users with 
cardiovascular disease (for example, hypertension or ischemic heart 
disease) should take special precautions to avoid accidental exposure to 
this product.

Accidental spillage on the skin should be washed off immediately with 
soap and water. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.
    (2) [Reserved]

[61 FR 25785, May 23, 1996]



Sec. 522.2476  Trenbolone acetate.

    (a) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (d) of this section.
    (1) No. 021641 for use as in paragraph (c) of this section.
    (2) No. 000061 for use as in paragraphs (c)(1)(i)(A), (c)(1)(ii), 
(c)(1)(iii),

[[Page 318]]

(c)(2)(i)(A), (c)(2)(ii), and (c)(2)(iii) of this section.
    (b) Related tolerances. See Sec. 556.739 of this chapter.
    (c) Conditions of use--(1) Steers fed in confinement for slaughter--
(i) Amount. Use 126 days prior to slaughter; should be reimplanted once 
after 63 days.
    (A) 140 milligrams (mg) trenbolone acetate (one implant consisting 
of 7 pellets, each pellet containing 20 mg trenbolone acetate) per 
implant dose.
    (B) 140 mg trenbolone acetate (one implant consisting of 8 pellets, 
each of 7 pellets containing 20 milligrams trenbolone acetate, and 1 
pellet containing 29 mg tylosin tartrate) per implant dose.
    (ii) Indications for use. For improved feed efficiency.
    (iii) Limitations. Implant subcutaneously in ear only. Do not use in 
animals intended for subsequent breeding or in dairy animals. Safety and 
effectiveness have not been established in veal calves. A withdrawal 
period has not been established for this product in preruminating 
calves. Do not use in calves to be processed for veal.
    (2) Heifers fed in confinement for slaughter--(i) Amount. Use last 
63 days prior to slaughter.
    (A) 200 mg trenbolone acetate (one implant consisting of 10 pellets, 
each pellet containing 20 mg trenbolone acetate) per implant dose.
    (B) 200 mg of trenbolone acetate (one implant consisting of 11 
pellets, each of 10 pellets containing 20 mg of trenbolone acetate, and 
1 pellet containing 29 mg of tylosin tartrate) per implant dose.
    (ii) Indications for use. For increased rate of weight gain and 
improved feed efficiency.
    (iii) Limitations. Implant subcutaneously in ear only. Do not use in 
animals intended for subsequent breeding or in dairy animals. Safety and 
effectiveness have not been established in veal calves. A withdrawal 
period has not been established for this product in preruminating 
calves. Do not use in calves to be processed for veal.

[66 FR 47961, Sept. 17, 2001, as amended at 69 FR 70056, Dec. 2, 2004; 
74 FR 61517, Nov. 25, 2009]

    Editorial Note: At 77 FR 31723, May 30, 2012, Sec. 522.2476 was 
amended in paragraph (b)(l) by removing ``021641'' and in its place 
adding ``000986''; however, the amendment could not be incorporated 
because (b)(1) doesn't exist.



Sec. 522.2477  Trenbolone acetate and estradiol.

    (a) [Reserved]
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
uses as in paragraph (d) of this section.
    (1) No. 000986 for use as in paragraphs (d)(1)(i)(A), (d)(1)(i)(B), 
(d)(1)(i)(C), (d)(1)(i)(D), (d)(1)(i)(E), (d)(1)(i)(F), (d)(1)(ii), 
(d)(1)(iii), (d)(2), and (d)(3) of this section.
    (2) No. 000061 for use as in paragraphs (d)(1)(i)(A), (d)(1)(i)(C), 
(d)(1)(i)(D), (d)(1)(i)(G), (d)(1)(ii), (d)(1)(iii), (d)(2)(i)(A), 
(d)(2)(i)(C), (d)(2)(i)(D), (d)(2)(ii), (d)(2)(iii), (d)(3)(i)(A), 
(d)(3)(ii), and (d)(3)(iii) of this section.
    (3) No. 000856 for use as in paragraphs (d)(1)(i)(A), (d)(1)(i)(D), 
(d)(1)(ii), (d)(1)(iii), (d)(3)(i)(A), (d)(3)(ii), and (d)(3)(iii) of 
this section.
    (d) Conditions of use--(1) Steers fed in confinement for slaughter--
(i) Amount. (A) 120 milligrams (mg) trenbolone acetate and 24 mg 
estradiol (one implant consisting of 6 pellets, each pellet containing 
20 mg trenbolone acetate and 4 mg estradiol) per implant dose.
    (B) 120 mg trenbolone acetate and 24 mg estradiol (one implant 
consisting of 7 pellets, each of 6 pellets containing 20 mg trenbolone 
acetate and 4 mg estradiol, and 1 pellet containing 29 mg tylosin 
tartrate) per implant dose.
    (C) 200 mg trenbolone acetate and 20 mg estradiol (one implant 
consisting of 10 pellets, each pellet containing 20 mg trenbolone 
acetate and 2 mg estradiol) per implant dose.
    (D) 80 mg trenbolone acetate and 16 mg estradiol (one implant 
consisting of 4 pellets, each pellet containing 20 mg trenbolone acetate 
and 4 mg estradiol) per implant dose.
    (E) 200 mg trenbolone acetate and 20 mg estradiol (one implant 
consisting of 11 pellets, each of 10 pellets containing 20 mg trenbolone 
acetate and 2 mg estradiol, and 1 pellet containing 29 mg tylosin 
tartrate) per implant dose.
    (F) 80 mg trenbolone acetate and 16 mg estradiol (one implant 
consisting of 5 pellets, each of 4 pellets containing 20

[[Page 319]]

mg trenbolone acetate and 4 mg estradiol, and 1 pellet containing 29 mg 
tylosin tartrate) per implant dose.
    (G) 200 milligram (mg) trenbolone acetate and 40 mg estradiol (one 
implant consisting of 10 pellets, each pellet containing 20 mg 
trenbolone acetate and 4 mg estradiol) per implant dose.
    (ii) Indications for use. For increased rate of weight gain and 
improved feed efficiency.
    (iii) Limitations. Implant subcutaneously in ear only. Do not use in 
animals intended for subsequent breeding or in dairy animals. Safety and 
effectiveness have not been established in veal calves. A withdrawal 
period has not been established for this product in preruminating 
calves. Do not use in calves to be processed for veal.
    (2) Heifers fed in confinement for slaughter--(i) Amount. (A) 140 mg 
trenbolone acetate and 14 mg estradiol (one implant consisting of 7 
pellets, each pellet containing 20 mg trenbolone acetate and 2 mg 
estradiol) per implant dose for use as in paragraph (d)(2)(ii)(A) of 
this section.
    (B) 140 mg trenbolone acetate and 14 mg estradiol (one implant 
consisting of 8 pellets, each of 7 pellets containing 20 mg trenbolone 
acetate and 2 mg estradiol, and 1 pellet containing 29 mg tylosin 
tartrate) per implant dose for use as in paragraphs (d)(2)(ii)(A) of 
this section.
    (C) 80 mg trenbolone acetate and 8 mg estradiol (one implant 
consisting of 4 pellets, each pellet containing 20 mg trenbolone acetate 
and 2 mg estradiol) per implant dose for use as in paragraph 
(d)(2)(ii)(B) of this section.
    (D) 200 mg trenbolone acetate and 20 mg estradiol (one implant 
consisting of 10 pellets, each pellet containing 20 mg trenbolone 
acetate and 2 mg estradiol) per implant dose for use as in paragraph 
(d)(2)(ii)(A) of this section.
    (E) 80 mg trenbolone acetate and 8 mg estradiol (one implant 
consisting of 5 pellets, each of 4 pellets containing 20 mg trenbolone 
acetate and 2 mg

estradiol, and 1 pellet containing 29 mg tylosin tartrate) per implant 
dose for use as in paragraph (d)(2)(ii)(B) of this section.
    (F) 200 mg trenbolone acetate and 20 mg estradiol (one implant 
consisting of 11 pellets, each of 10 pellets containing 20 mg trenbolone 
acetate and 2 mg estradiol, and 1 pellet containing 29 mg tylosin 
tartrate) per implant dose.
    (ii) Indications for use. (A) For increased rate of weight gain and 
improved feed efficiency.
    (B) For increased rate of weight gain.
    (iii) Limitations. Implant subcutaneously in ear only. Do not use in 
animals intended for subsequent breeding or in dairy animals. Safety and 
effectiveness have not been established in veal calves. A withdrawal 
period has not been established for this product in preruminating 
calves. Do not use in calves to be processed for veal.
    (3) Pasture cattle (slaughter, stocker, and feeder steers and 
heifers)--(i) Amount. (A) 40 mg trenbolone acetate and 8 mg estradiol 
(one implant consisting of 2 pellets, each pellet containing 20 mg 
trenbolone acetate and 4 mg estradiol) per implant dose.
    (B) 40 mg trenbolone acetate and 8 mg estradiol (one implant 
consisting of 3 pellets, each of 2 pellets containing 20 mg trenbolone 
acetate and 4 mg estradiol, and 1 pellet containing 29 mg tylosin 
tartrate) per implant dose.
    (ii) Indications for use. For increased rate of weight gain.
    (iii) Limitations. Implant subcutaneously in ear only. Do not use in 
animals intended for subsequent breeding or in dairy animals. Safety and 
effectiveness have not been established in veal calves. A withdrawal 
period has not been established for this product in preruminating 
calves. Do not use in calves to be processed for veal.

[60 FR 4376, Jan. 23, 1995]

    Editorial Note: For Federal Register citations affecting Sec. 
522.2477, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 522.2478  Trenbolone acetate and estradiol benzoate.

    (a) Specifications. Each implant dose consists of:
    (1) 8 pellets, each pellet containing 25 milligrams (mg) trenbolone 
acetate and 3.5 mg estradiol benzoate.

[[Page 320]]

    (2) 4 pellets, each pellet containing 25 mg trenbolone acetate and 
3.5 mg estradiol benzoate.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. Sec. 556.240 and 556.739 of this 
chapter.
    (d) Conditions of use--(1) Steers fed in confinement for slaughter. 
(i) For an implant as described in paragraph (a)(1) of this section:
    (A) Amount. 200 mg trenbolone acetate and 28 mg estradiol benzoate.
    (B) Indications for use. For increased rate of weight gain and 
improved feed efficiency.
    (C) Limitations. Implant subcutaneously in ear only. Safety and 
effectiveness have not been established in veal calves. A withdrawal 
period has not been established for this product in preruminating 
calves. Do not use in calves to be processed for veal.
    (ii) For an implant as described in paragraph (a)(2) of this 
section:
    (A) Amount. 100 mg trenbolone acetate and 14 mg estradiol benzoate.
    (B) Indications for use. For increased rate of weight gain.
    (C) Limitations. Implant subcutaneously in ear only. Safety and 
effectiveness have not been established in veal calves. A withdrawal 
period has not been established for this product in preruminating 
calves. Do not use in calves to be processed for veal.
    (2) Heifers fed in confinement for slaughter--(i) Amount. 200 mg 
trenbolone acetate and 28 mg estradiol benzoate (as described in 
paragraph (a)(1) of this section).
    (ii) Indications for use. For increased rate of weight gain.
    (iii) Limitations. Implant subcutaneously in ear only. Not for 
subsequent breeding dairy or beef replacement heifers. Safety and 
effectiveness have not been established in veal calves. A withdrawal 
period has not been established for this product in preruminating 
calves. Do not use in calves to be processed for veal.

[67 FR 78972, Dec. 27, 2002, as amended at 69 FR 67818, Nov. 22, 2004]



Sec. 522.2483  Triamcinolone.

    (a) Specifications. Each milliliter of suspension contains 2 or 6 
milligrams (mg) triamcinolone acetonide.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs and cats--(i) Amount--(A) 
Intramuscular or subcutaneous. For inflammatory, arthritic, or allergic 
disorders, administer 0.05 to 0.1 mg per pound (/lb) of body weight as a 
single injection. For dermatologic disorders, administer 0.1 mg per 
pound (/lb) of body weight as a single injection. If symptoms recur, the 
dose may be repeated, or oral corticosteroid therapy may be instituted.
    (B) Intralesional. Administer 1.2 to 1.8 mg, divided in several 
injections around the lesion, spaced 0.5 to 2.5 centimeters apart, 
depending on lesion size. At any one site, the dose injected should not 
exceed 0.6 mg. and should be well into the cutis to prevent rupture of 
the epidermis. When treating animals with multiple lesions, do not 
exceed a total dose of 6 mg.
    (C) Intra-articular and intrasynovial. Administer 1 to 3 mg as a 
single injection, depending on the size of the joint and severity of 
symptoms. After 3 or 4 days, repeat dosage if indicated. If initial 
results are inadequate or too transient, dosage may be increased, not to 
exceed 3 mg.
    (ii) Indications for use. For the treatment of inflammation and 
related disorders, and the management and treatment of acute arthritis 
and allergic and dermatologic disorders.
    (iii) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.
    (2) Horses--(i) Amount--(A) Intramuscular or subcutaneous. 
Administer 0.01 to 0.02 mg/lb of body weight as a single injection. 
Usual dose is 12 to 20 mg.
    (B) Intra-articular and intrasynovial. Administer 6 to 18 mg as a 
single injection, depending on the size of the joint and severity of 
symptoms. After 3 or 4 days, repeat dosage if indicated. If initial 
results are inadequate or too transient, dosage may be increased, not to 
exceed 18 mg.
    (ii) Indications for use. For the treatment of inflammation and 
related disorders.

[[Page 321]]

    (iii) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[75 FR 10167, Mar. 5, 2010]



Sec. 522.2582  Triflupromazine hydrochloride injection.

    (a) Specifications. Triflupromazine hydrochloride injection contains 
20 milligrams of triflupromazine hydrochloride in each milliliter of 
sterile aqueous solution.
    (b) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used in dogs, cats, and 
horses to relieve anxiety and to help control psychomotor overactivity 
as well as to increase the tolerance of animals to pain and pruritus. 
The drug is indicated in various office and clinical procedures which 
require the aid of a tranquilizer, antiemetic, or preanesthetic.\1\
    (2) The drug is administered to dogs either intravenously at a 
dosage level of 0.5 to 1 milligram per pound of body weight daily, or 
intramuscularly at a dosage level of 1 to 2 milligrams per pound of body 
weight daily. It is administered to cats intramuscularly at a dosage 
level of 2 to 4 milligrams per pound of body weight daily. It is 
administered to horses intravenously or intramuscularly at a dosage 
level of 10 to 15 milligrams per 100 pounds of body weight daily to a 
maximum dose of 100 milligrams. \1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and are deemed effective. 
Applications for these uses need not include the effectiveness data 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (3) Not for use in horses intended for food. \1\
    (4) Do not use in conjunction with organophosphates and/or procaine 
hydrochloride, because phenothiazines may potentitate the toxicity of 
organophosphates and the activity of procaine hydrochloride. \1\
    (5) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.\1\

[40 FR 13858, Mar. 27, 1975, as amended at 50 FR 41490, Oct. 11, 1985]



Sec. 522.2610  Trimethoprim and sulfadiazine.

    (a) Specifications. Each milliliter (mL) contains:
    (1) 40 milligrams (mg) trimethoprim suspended in a solution 
containing 200 mg sulfadiazine; or
    (2) 80 mg trimethoprim suspended in a solution containing 400 mg 
sulfadiazine (as the sodium salt).
    (b) Sponsors. See Nos. 000061 and 000856 in Sec. 510.600(c) of this 
chapter.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Conditions of use--(1) Dogs--(i) Amount. 1 mL of the product 
described in paragraph (a)(1) of this section (40 mg trimethoprim and 
200 mg sulfadiazine) per 20 pounds (9 kilograms) of body weight per day 
by subcutaneous injection.
    (ii) Indications for use. For the treatment of acute urinary tract 
infections, acute bacterial complications of distemper, acute 
respiratory tract infections, acute alimentary tract infections, and 
acute septicemia due to Streptococcus zooepidemicus.
    (2) Horses--(i) Amount. 2 mL of the product described in paragraph 
(a)(2) of this section (160 mg trimethoprim and 800 mg sulfadiazine) per 
100 pounds (45 kilograms) of body weight per day by intravenous 
injection as single, daily dose for 5 to 7 days. The daily dose may also 
be halved and given morning and evening.
    (ii) Indications for use. For use where systemic antibacterial 
action against sensitive organisms is required during treatment of acute 
strangles, respiratory tract infections, acute urogenital infections, 
and wound infections and abscesses.
    (iii) Limitations. Not for use in horses intended for human 
consumption.

[71 FR 30803, May 31, 2006]



Sec. 522.2615  Tripelennamine hydrochloride injection.

    (a) Specifications. Each milliliter of aqueous solution contains 20 
milligrams of tripelennamine hydrochloride.
    (b) Sponsor. See Nos. 000859 and 053501 in Sec. 510.600(c) of this 
chapter.
    (c) Related tolerances. See Sec. 556.741 of this chapter.

[[Page 322]]

    (d) Conditions of use--(1) Amount--(i) Dogs, cats, and horses. For 
intramuscular use only at a dose of 0.5 milligram per pound of body 
weight.
    (ii) Cattle. Administer intravenously or intramuscularly at a dose 
of 0.5 milligram per pound of body weight.
    (2) Indications for use. For use in treating conditions in which 
antihistaminic therapy may be expected to lead to alleviation of some 
signs of disease.
    (3) Limitations. Do not use in horses intended for food purposes. 
Treated cattle must not be slaughtered for food during treatment and for 
4 days following the last treatment. Milk that has been taken during 
treatment and for 24 hours (two milkings) after the last treatment must 
not be used for food. A withdrawal period has not been established for 
this product in preruminating calves. Do not use in calves to be 
processed for veal. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[51 FR 44450, Dec. 10, 1986, as amended at 61 FR 29480, June 11, 1996; 
62 FR 4164, Jan. 29, 1997; 78 FR 17597, Mar. 22, 2013]



Sec. 522.2630  Tulathromycin.

    (a) Specifications. Each milliliter of solution contains 100 
milligrams (mg) tulathromycin.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.745 of this chapter.
    (d) Conditions of use--(1) Beef and nonlactating dairy cattle--(i) 
Amount. 2.5 mg per kilogram (/kg) body weight as a single subcutaneous 
injection in the neck.
    (ii) Indications for use. For the treatment of bovine respiratory 
disease (BRD) associated with Mannheimia haemolytica, Pasteurella 
multocida, Histophilus somni, and Mycoplasma bovis. For the control of 
respiratory disease in cattle at high risk of developing BRD associated 
with M. haemolytica, P. multocida, H. somni, and M. bovis. For the 
treatment of infectious bovine keratoconjunctivitis associated with 
Moraxella bovis. For the treatment of bovine foot rot (interdigital 
necrobacillosis) associated with Fusobacterium necrophorum and 
Porphyromonas levii.
    (iii) Limitations. Cattle intended for human consumption must not be 
slaughtered within 18 days from the last treatment. Do not use in female 
dairy cattle 20 months of age or older. A withdrawal period has not been 
established for this product in preruminating calves. Do not use in 
calves to be processed for veal. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (2) Swine--(i) Amount. 2.5 mg/kg body weight as a single 
intramuscular injection in the neck.
    (ii) Indications for use. For the treatment of swine respiratory 
disease (SRD) associated with Actinobacillus pleuropneumoniae, P. 
multocida, Bordetella bronchiseptica, Haemophilus parasuis, and 
Mycoplasma hyopneumoniae; and for the control of SRD associated with A. 
pleuropneumoniae, P. multocida, and M. hyopneumoniae in groups of pigs 
where SRD has been diagnosed.
    (iii) Limitations. Swine intended for human consumption must not be 
slaughtered within 5 days from the last treatment. Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.

[70 FR 39918, July 12, 2005, as amended at 71 FR 57416, Sept. 29, 2006; 
72 FR 54540, Sept. 26, 2007; 73 FR 6018, Feb. 1, 2008; 73 FR 58872, Oct. 
8, 2008; 74 FR 53165, Oct. 16, 2009]



Sec. 522.2640  Tylosin.

    (a) Specifications. Each milliliter of sterile solution of 50 
percent propylene glycol with 4 percent benzyl alcohol contains 50 to 
200 milligrams of tylosin activity (as tylosin base). Tylosin conforms 
to the appropriate antibiotic standard. Tylosin contains at least 95 
percent tylosin as a combination of tylosin A, tylosin B, tylosin C, and 
tylosin D of which at least 80 percent is tylosin A as determined by a 
method entitled ``Determination of Factor Content in Tylosin by High 
Performance Liquid Chromatography,'' which is incorporated by reference. 
Copies are available from the Division of Dockets Management (HFA-305), 
Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 
20852, or at the National Archives and Records Administration (NARA). 
For information on the availability of this material at

[[Page 323]]

NARA, call 202-741-6030, or go to: http://www.archives.gov/federal--
register/code--of--federal--regulations/ibr--locations.html.
    (b) Sponsors. (1) See No. 000986 in Sec. 510.600(c) of this chapter 
for use in paragraphs (e)(1), (2), and (3) of this section.
    (2) See No. 000010 in Sec. 510.600(c) of this chapter for use as in 
paragraphs (e)(1) and (2) of this section.
    (c) [Reserved]
    (d) Related tolerances. See Sec. 556.740 of this chapter.
    (e) Conditions of use--(1) Beef cattle and nonlactating dairy 
cattle--(i) Amount. 8 milligrams per pound of body weight once daily.
    (ii) Indications for use. Treatment of bovine respiratory complex 
(shipping fever, pneumonia) usually associated with Pasteurella 
multocida and Arcanobacterium pyogenes; foot rot (necrotic 
pododermatitis) and calf diphtheria caused by Fusobacterium necrophorum 
and metritis caused by Arcanobacterium pyogenes.
    (iii) Limitations. Administer intramuscularly for not more than 5 
consecutive days. Continue treatment 24 hours after symptoms disappear. 
Do not inject more than 10 milliliters per site. Do not use in lactating 
dairy cattle. Use a 50-milligram-per-milliliter solution for calves 
weighing less than 200 pounds. Do not administer within 21 days of 
slaughter. A withdrawal period has not been established for this product 
in preruminating calves. Do not use in calves to be processed for veal.
    (2) Swine--(i) Amount. 4 milligrams per pound of body weight twice 
daily.
    (ii) Indications for use. Treatment of swine arthritis caused by 
Mycoplasma hyosynoviae; swine pneumonia caused by Pasteurella spp.; 
swine erysipelas caused by Erysipelothrix rhusiopathiae; swine dysentery 
associated with Treponema hyodysenteriae when followed by appropriate 
medication in the drinking water and/or feed.
    (iii) Limitations. Administer intramuscularly for not more than 3 
consecutive days. Continue treatment 24 hours after symptoms disappear. 
Do not inject more than 5 milliliters per site. Do not administer within 
14 days of slaughter. If tylosin medicated drinking water is used as 
followup treatment for swine dysentery, the animal should thereafter 
receive feed containing 40 to 100 grams of tylosin per ton for 2 weeks 
to assure depletion of tissue residues.
    (3) Dogs and cats--(i) Amount. 3 to 5 milligrams per pound of body 
weight at 12- to 24-hour intervals.
    (ii) Indications for use--(a) Dogs. Treatment of upper respiratory 
infections such as bronchitis, tracheobronchitis, tracheitis, 
laryngitis, tonsillitis, and pneumonia caused by Staphylococci spp., 
hemolytic Streptococci spp., and Pasteurella multocida.
    (b) Cats. Treatment of upper respiratory infections when caused by 
Staphylococci spp. and hemolytic Streptococci spp. and for feline 
pneumonitis when caused by tylosin susceptible organisms.
    (iii) Limitations. For intramuscular use only. If there is no 
response to therapy in 5 days, diagnosis and treatment should be 
reassessed. Use a 50-milligram-per-milliliter solution only. Dogs and 
cats receiving a dose of less than 50 milligrams (1 milliliter) should 
be dosed with a tuberculin syringe. Federal law restricts this drug to 
use by or on the order of a licensed veterinarian.

[46 FR 48643, Oct. 2, 1981, as amended at 47 FR 9398, Mar. 5, 1982; 50 
FR 49841, Dec. 5, 1985; 50 FR 50292, Dec. 10, 1985; 53 FR 40728, Oct. 
18, 1988; 59 FR 14365, Mar. 28, 1994; 62 FR 35077, June 30, 1997; 68 FR 
24879, May 9, 2003; 70 FR 16935, Apr. 4, 2005. Redesignated and amended 
at 74 FR 11644, Mar. 19, 2009]



Sec. 522.2662  Xylazine.

    (a) Specifications. Each milliliter (mL) of solution contains 
xylazine hydrochloride equivalent to:
    (1) 20 milligrams (mg) xylazine.
    (2) 100 mg xylazine.
    (3) 300 mg xylazine.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
uses as in paragraph (d) of this section.
    (1) No. 000010 for use of product described in paragraph (a)(2) of 
this section as in paragraph (d)(2) of this section.
    (2) No. 000010 for use of product described in paragraph (a)(2) of 
this section as in paragraphs (d)(2), (d)(3)(i),

[[Page 324]]

(d)(3)(ii)(A), and (d)(3)(iii) of this section.
    (3) Nos. 000859 and 061651 for use of product described in paragraph 
(a)(1) of this section as in paragraph (d)(1); and product described in 
paragraph (a)(2) of this section as in paragraphs (d)(2), (d)(3)(i), 
(d)(3)(ii)(A), and (d)(3)(iii) of this section.
    (4) No. 061690 for use of product described in paragraph (a)(1) of 
this section as in paragraph (d)(1) of this section; product described 
in paragraph (a)(2) of this section as in paragraphs (d)(2), (d)(3)(i), 
(d)(3)(ii)(A), and (d)(3)(iii) of this section; and product described in 
paragraph (a)(3) of this section as in paragraphs (d)(3)(i), 
(d)(3)(ii)(B), and (d)(3)(iii) of this section.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Conditions of use--(1) Dogs and cats--(i) Amount. 0.5 mg/pound 
(lb) intravenously or 1.0 mg/lb subcutaneously.
    (ii) Indications for use. To produce sedation, as an analgesic, and 
as a preanesthetic to local or general anesthesia.
    (2) Horses--(i) Amount. 0.5 mg/lb intravenously or 1.0 mg/lb 
intramuscularly.
    (ii) Indications for use. To produce sedation, as an analgesic, and 
as a preanesthetic to local or general anesthesia.
    (iii) Limitations. Not for use in horses intended for food.
    (3) Elk and deer--(i) Amount. Administer intramuscularly, by hand 
syringe, or by syringe dart, in the heavy muscles of the croup or 
shoulder as follows:
    (A) Elk (Cervus canadensis): 0.25 to 0.5 mg/lb.
    (B) Mule deer (Odocoileus hemionus), sika deer (Cervus nippon), and 
white-tailed deer (Odocoileus virginianus): 1 to 2 mg/lb.
    (C) Fallow deer (Dama dama): 2 to 4 mg/lb.
    (ii) Indications for use. (A) To produce sedation, as an analgesic, 
and as a preanesthetic to local anesthesia.
    (B) To produce sedation, accompanied by a shorter period of 
analgesia. May be used to calm and facilitate handling of fractious 
animals for diagnostic procedures, for minor surgical procedures, for 
therapeutic medication for sedation and relief of pain following injury 
or surgery, and as a preanesthetic to local anesthetic. At the 
recommended dosages, can be used in conjunction with local anesthetics, 
such as procaine or lidocaine.
    (iii) Limitations. Do not use in domestic food-producing animals. Do 
not use in Cervidae less than 15 days before or during the hunting 
season.

[68 FR 26206, May 15, 2003, as amended at 75 FR 10167, Mar. 5, 2010]



Sec. 522.2670  Yohimbine injectable.

    (a) Specifications. Each milliliter of sterile aqueous solution 
contains either 2 or 5 milligrams of yohimbine (as hydrochloride).
    (b) Sponsor. See 061690 in Sec. 510.600(c) of this chapter for use 
of 2 milligrams per milliliter solution in dogs.
    (1) Amount. 0.05 milligram per pound (0.11 milligram per kilogram) 
of body weight.
    (2) Indications for use. To reverse the effects of xylazine in dogs.
    (3) Limitations. For intravenous use in dogs only. Not for use in 
food-producing animals. Safety of use in pregnant dogs or in dogs 
intended for breeding has not been established. Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.
    (c) Sponsor. See 053923 in Sec. 510.600(c) of this chapter for use 
of 5 milligrams per milliliter solution in deer and elk.
    (1) Amount. 0.2 to 0.3 milligram per kilogram of body weight.
    (2) Indications for use. As an antagonist to xylazine sedation in 
free ranging or confined members of the family Cervidae (deer and elk).
    (3) Limitations. For intravenous use only. Do not use in domestic 
food-producing animals. Do not use for 30 days before or during hunting 
season. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[58 FR 8543, Feb. 16, 1993, as amended at 60 FR 57832, Nov. 22, 1995]



Sec. 522.2680  Zeranol.

    (a) Specifications. Each pellet contains 12, 18, or 20 milligrams 
(mg) zeranol.
    (b) Sponsor. See 000061 in Sec. 510.600(c) of this chapter.

[[Page 325]]

    (c) Related tolerances. See Sec. 556.760 of this chapter.
    (d) Conditions of use--(1) Beef cattle--(i) Amount. 36 mg zeranol 
(one implant consisting of 3 pellets, each pellet containing 12 mg 
zeranol) per implant dose.
    (ii) Indications for use--(A) For increased rate of weight gain and 
improved feed conversion in weaned beef calves, growing beef cattle, 
feedlot steers, and feedlot heifers.
    (B) For increased rate of weight gain in suckling calves.
    (iii) Limitations. Implant subcutaneously in ear only. Do not use in 
bulls intended for reproduction or in dairy animals. Do not use before 1 
month of age or after weaning in heifers intended for reproduction. 
Safety and effectiveness have not been established in veal calves. A 
withdrawal period has not been established for this product in 
preruminating calves. Do not use in calves to be processed for veal.
    (2) Feedlot lambs--(i) Amount. 12 mg zeranol (one implant consisting 
of 1 pellet containing 12 mg zeranol) per implant dose.
    (ii) Indications for use. For increased rate of weight gain and 
improved feed conversion.
    (iii) Limitations. Implant subcutaneously in ear only. Do not use in 
breeding animals. Do not implant animals within 40 days of slaughter. 
Safety and effectiveness have not been established in veal calves. A 
withdrawal period has not been established for this product in 
preruminating calves. Do not use in calves to be processed for veal.
    (3) Steers fed in confinement for slaughter--(i) Amount. 72 mg 
zeranol (one implant consisting of 6 pellets, each pellet containing 12 
mg zeranol) per implant dose.
    (ii) Indications for use. For increased rate of weight gain and 
improved feed efficiency.
    (iii) Limitations. Implant subcutaneously in ear only. Safety and 
effectiveness have not been established in veal calves. A withdrawal 
period has not been established for this product in preruminating 
calves. Do not use in calves to be processed for veal.
    (4) Pasture cattle (slaughter, stocker, feeder steers, and 
heifers)--(i) Amount. 138 mg zeranol (one implant consisting of 7 
pellets, each of 6 pellets containing 20 mg zeranol and a seventh pellet 
containing 18 mg zeranol) per implant dose.
    (ii) Indications for use. For increased rate of weight gain.
    (iii) Limitations. Implant subcutaneously in ear only. Safety and 
effectiveness have not been established in veal calves. A withdrawal 
period has not been established for this product in preruminating 
calves. Do not use in calves to be processed for veal.

[59 FR 19639, Apr. 25, 1994; 60 FR 26360, May 17, 1995, as amended at 62 
FR 61625, Nov. 19, 1997; 64 FR 46840, Aug. 27, 1999; 67 FR 6867, Feb. 
14, 2002; 70 FR 6764, Feb. 9, 2005]



Sec. 522.2690  Zinc gluconate.

    (a) Specifications. Each milliliter of solution contains 13.1 
milligrams zinc as zinc gluconate neutralized to pH 7.0 with L-arginine.
    (b) Sponsor. See No. 076175 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. The volume injected into 
each testicle is based on testicular width as determined by measuring 
each testicle at its widest point using a metric scale (millimeter) 
caliper.
    (2) Indications for use. Intratesticular injection for chemical 
sterilization of 3- to 10-month-old male dogs.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[68 FR 26995, May 19, 2003, as amended at 76 FR 79064, Dec. 21, 2011]



PART 524_OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS--Table of Contents



Sec.
524.86 Amitraz liquid.
524.154 Bacitracin or bacitracin zinc-neomycin sulfate-polymyxin B 
          sulfate ophthalmic ointment.
524.155 Bacitracin zinc-polymyxin B sulfate-neomycin sulfate-
          hydrocortisone or hydrocortisone acetate ophthalmic ointment.
524.390 Chloramphenicol ophthalmic ointment.
524.402 Chlorhexidine.
524.450 Clotrimazole cream.

[[Page 326]]

524.463 Copper naphthenate.
524.575 Cyclosporine ophthalmic ointment.
524.590 Diclofenac.
524.660 Dimethyl sulfoxide ophthalmic and topical dosage forms.
524.660a Dimethyl sulfoxide solution.
524.660b Dimethyl sulfoxide gel.
524.770 Doramectin.
524.775 Emodepside and praziquantel.
524.802 Enrofloxacin, silver sulfadiazine emulsion.
524.814 Eprinomectin.
524.900 Famphur.
524.920 Fenthion.
524.916 Fentanyl.
524.960 Flumethasone, neomycin sulfate, and polymyxin B sulfate 
          ophthalmic solutions.
524.981 Fluocinolone acetonide ophthalmic and topical dosage forms.
524.981a Fluocinolone acetonide cream.
524.981b Fluocinolone acetonide solution.
524.981c Fluocinolone acetonide, neomycin sulfate cream.
524.981d Fluocinolone acetonide, dimethyl sulfoxide solution.
524.981e Fluocinolone acetonide, dimethyl sulfoxide otic solution.
524.1005 Furazolidone aerosol powder.
524.1044 Gentamicin sulfate ophthalmic and topical dosage forms.
524.1044a Gentamicin ophthalmic solution.
524.1044b Gentamicin sulfate, betamethasone valerate otic solution.
524.1044c Gentamicin sulfate ophthalmic ointment.
524.1044d Gentamicin sulfate, betamethasone valerate ointment.
524.1044e Gentamicin sulfate spray.
524.1044f Gentamicinand betamethasone spray.
524.1044g Gentamicin sulfate, betamethasone valerate, clotrimazole 
          ointment.
524.1044h Gentamicin sulfate, mometasone furoate, clotrimazole otic 
          suspension.
524.1044i Gentamicin and betamethasone ophthalmic solution.
524.1132 Hydrocortisone aceponate, miconazole nitrate, gentamicin 
          sulfate otic suspension.
524.1140 Imidacloprid and ivermectin.
524.1146 Imidacloprid and moxidectin.
524.1193 Ivermectin topical solution.
524.1195 Ivermectin otic suspension.
524.1200 Kanamycin ophthalmic and topical dosage forms.
524.1200a Kanamycin ophthalmic ointment.
524.1200b Kanamycin ophthalmic aqueous solution.
524.1204 Kanamycin sulfate, calcium amphomycin, and hydrocortisone 
          acetate.
524.1240 Levamisole.
524.1376 2-Mercaptobenzothiazole solution.
524.1443 Miconazole.
524.1445 Miconazole, polymixin B, and prednisolone suspension.
524.1446 Milbemycin oxime solution.
524.1450 Moxidectin.
524.1465 Mupirocin.
524.1484 Neomycin sulfate ophthalmic and topical dosage forms.
524.1484b Neomycin sulfate, isoflupredone acetate, tetracaine 
          hydrochloride, and myristyl-gamma-picolinium chloride, topical 
          powder.
524.1484c Neomycin sulfate, isoflupredone acetate, tetracaine 
          hydrochloride ointment.
524.1484d Neomycin sulfate, hydrocortisone acetate, tetracaine 
          hydrochloride ear ointment.
524.1484e Neomycin sulfate and polymyxin B sulfate ophthalmic solution.
524.1484f Neomycin sulfate, prednisolone acetate, tetracaine 
          hydrochloride eardrops.
524.1484g Neomycin sulfate-thiabendazole-dexamethasone solution.
524.1484h Neomycin, penicillin, polymyxin, hydrocortisone suspension.
524.1484i Neomycin sulfate, hydrocortisone acetate, sterile ointment.
524.1580 Nitrofurazone ophthalmic and topical dosage forms.
524.1580a [Reserved]
524.1580b Nitrofurazone ointment.
524.1580c Nitrofurazone soluble powder.
524.1580d [Reserved]
524.1580e Nitrofurazone ointment with butacaine sulfate.
524.1600 Nystatin ophthalmic and topical dosage forms.
524.1600a Nystatin, neomycin, thiostrepton, and triamcinolone acetonide 
          ointment.
524.1600b Nystatin, neomycin, thiostrepton, and triamcinolone acetonide 
          ophthalmic ointment.
524.1610 Orbifloxacin, mometasone furoate monohydrate, and posaconazole 
          suspension.
524.1662 Oxytetracycline hydrochloride ophthalmic and topical dosage 
          forms.
524.1662a Oxytetracycline hydrochloride and hydrocortisone spray.
524.1662b Oxytetracycline hydrochloride, polymyxin B sulfate ophthalmic 
          ointment.
524.1742 N-(Mercaptomethyl) phthalimide S-(O,O-dimethyl 
          phosphorodithioate) emulsifiable liquid.
524.1881 Prednisolone acetate ophthalmic and topical dosage forms.
524.1881a [Reserved]
524.1881b Prednisolone acetate-neomycin sulfate sterile suspension.
524.1883 Prednisolone sodium phosphate-neomycin sulfate ophthalmic 
          ointment.
524.1982 Proparacaine hydrochloride ophthalmic solution.
524.2098 Selamectin.
524.2101 Selenium disulfide suspension.
524.2350 Tolnaftate cream.

[[Page 327]]

524.2482 Triamcinolone spray.
524.2483 Triamcinolone cream.
524.2620 Liquid crystalline trypsin, Peru balsam, castor oil.

    Authority: 21 U.S.C. 360b.

    Source: 40 FR 13873, Mar. 27, 1975, unless otherwise noted.



Sec. 524.86  Amitraz liquid.

    (a) Specifications. Amitraz liquid contains 19.9 percent amitraz in 
an organic solvent.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Indications for use. For dogs for the 
treatment of generalized demodicosis (Demodex canis).
    (2) Amount. One 10.6 milliliter bottle per 2 gallons of warm water 
(250 parts per million) for each treatment, for a total of 3 to 6 
treatments, 14 days apart.
    (3) Limitations. Continue treatment until no viable mites are found 
in skin scrapings at 2 successive treatments, or until 6 treatments have 
been applied. Do not use for treatment of localized demodicosis or 
scabies. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[47 FR 18589, Apr. 30, 1982]



Sec. 524.154  Bacitracin or bacitracin zinc-neomycin sulfate-polymyxin 
B sulfate ophthalmic ointment.

    (a) Sponsor. To firms identified in Sec. 510.600(c) of this chapter 
as follows:
    (1) To 000009; each gram contains 500 units of bacitracin, 3.5 
milligrams of neomycin, and 10,000 units of polymyxin B.
    (2) To 000061 and 043264; each gram contains 400 units of bacitracin 
zinc, 3.5 milligrams of neomycin, and 10,000 units of polymyxin B 
sulfate.
    (b) Conditions of use. Dogs and Cats--(1) Amount. Apply a thin film 
over the cornea 3 or 4 times daily.
    (2) Indications for use. Treatment of superficial bacterial 
infections of the eyelid and conjunctiva of dogs and cats when due to 
susceptible organisms.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[57 FR 37333, Aug. 18, 1992, as amended at 61 FR 8873, Mar. 6, 1996; 62 
FR 61625, Nov. 19, 1997; 77 FR 64717, Oct. 23, 2012]



Sec. 524.155  Bacitracin zinc-polymyxin B sulfate-neomycin sulfate-
hydrocortisone or hydrocortisone acetate ophthalmic ointment.

    (a) Sponsor. To firms identified in Sec. 510.600(c) of this chapter 
as follows:
    (1) To 000061; each gram of ointment contains 400 units of 
bacitracin zinc, 10,000 units of polymyxin B sulfate, 5 milligrams of 
neomycin sulfate (equivalent to 3.5 milligrams of neomycin base), and 10 
milligrams of hydrocortisone.
    (2) To 043264; each gram of ointment contains 400 units of 
bacitracin zinc, 10,000 units of polymyxin B sulfate, 5 milligrams of 
neomycin sulfate (equivalent to 3.5 milligrams of neomycin base), and 10 
milligrams of hydrocortisone acetate.
    (b) Conditions of use. Dogs and cats--(1) Amount. Apply a thin film 
over the cornea three or four times daily.
    (2) Indications for use. For treating acute or chronic 
conjunctivitis caused by susceptible organisms.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[57 FR 37333, Aug. 18, 1992, as amended at 61 FR 8873, Mar. 6, 1996; 62 
FR 61626, Nov. 19, 1997; 77 FR 64717, Oct. 23, 2012]



Sec. 524.390  Chloramphenicol ophthalmic ointment.

    (a) Specifications. Each gram contains 10 milligrams 
chloramphenicol.
    (b) Sponsors. See Nos. 000856 and 043264 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use in dogs and cats--(1) Amount. Apply every 3 
hours around the clock for 48 hours, after which night instillations may 
be omitted.
    (2) Indications for use. For treatment of bacterial conjunctivitis 
caused by pathogens susceptible to chloramphenicol.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[77 FR 4897, Feb. 1, 2012, as amended at 77 FR 64717, Oct. 23, 2012]



Sec. 524.402  Chlorhexidine.

    (a) Specifications. Each gram of ointment contains 10 milligrams 
chlorhexidine acetate.
    (b) Sponsors. See Nos. 000856 and 058829 in Sec. 510.600(c) of this 
chapter.

[[Page 328]]

    (c) Conditions of use in dogs, cats, and horses--(1) Indications for 
use. For use as a topical antiseptic ointment for surface wounds.
    (2) Limitations. Do not use in horses intended for human 
consumption.

[72 FR 265, Jan. 4, 2007]



Sec. 524.450  Clotrimazole cream.

    (a) Specifications. Each gram of cream contains 10 milligrams of 
clotrimazole.
    (b) Sponsor. See 000859 in Sec. 510.600(c).
    (c) Conditions of use--(1) Amount. Apply \1/4\-inch ribbon of cream 
per square inch of lesion once daily for 2 to 4 weeks.
    (2) Indications of use. For the treatment of fungal infections of 
dogs and cats caused by Microsporum canis and Trichophyton 
mentagrophytes.
    (3) Limitations. Wash hands thoroughly after use to avoid spread of 
infection. Federal law restricts this drug to use by or on the order of 
a licensed veterinarian.

[40 FR 48128, July 18, 1980]



Sec. 524.463  Copper naphthenate.

    (a) Amount. The drug is a 37.5 percent solution of copper 
naphthenate.
    (b) Sponsors. See Nos. 000856, 017135, and 058829 in Sec. 
510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. Apply daily to affected 
hooves until fully healed.
    (2) Indications for use. As an aid in treating horses and ponies for 
thrush caused by organisms susceptible to copper naphthenate.
    (3) Limitations. Use on horses and ponies only. Avoid contact around 
eyes. Do not contaminate feed. Do not use in horses intended for human 
consumption.

[47 FR 4250, Jan. 29, 1982, as amended at 68 FR 55825, Sept. 29, 2003; 
71 FR 38074, July 5, 2006]



Sec. 524.575  Cyclosporine ophthalmic ointment.

    (a) Specifications. Each gram of ointment contains 2 milligrams of 
cyclosporine.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. Apply a 1/4-inch strip of 
ointment to the affected eye(s) every 12 hours.
    (2) Indications for use. For management of chronic 
keratoconjunctivitis sicca (KCS) and chronic superficial keratitis (CSK) 
in dogs.
    (3) Limitations. Place ointment directly on cornea or into the 
conjunctival sac. Safety of use in puppies, pregnant or breeding animals 
has not been determined. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

[60 FR 48651, Sept. 20, 1995, as amended at 62 FR 48940, Sept. 18, 1997]



Sec. 524.590  Diclofenac.

    (a) Specifications. Each gram of cream contains 10 milligrams 
diclofenac sodium.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. Apply a 5-inch (5[sec]) 
ribbon of cream twice daily over the affected joint for up to 10 days 
and rub thoroughly into the hair covering the joint until it disappears.
    (2) Indications for use in horses. For the control of pain and 
inflammation associated with osteoarthritis in tarsal, carpal, 
metacarpophalangeal, metatarsophalangeal, and proximal interphalangeal 
(hock, knee, fetlock and pastern) joints.
    (3) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[69 FR 40767, July 7, 2004, as amended at 74 FR 26782, June 4, 2009; 74 
FR 47436, Sept. 16, 2009]



Sec. 524.660  Dimethyl sulfoxide ophthalmic and topical dosage forms.



Sec. 524.660a  Dimethyl sulfoxide solution.

    (a) Specifications. Dimethyl sulfoxide contains 90 percent of 
dimethyl sulfoxide and 10 percent of water.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is used or intended for use as a 
topical application to reduce acute swelling due to trauma:
    (i) In horses administered 2 or 3 times daily in an amount not to 
exceed 100 milliliters per day. Total duration of therapy should not 
exceed 30 days.

[[Page 329]]

    (ii) In dogs administered 3 or 4 times daily in an amount not to 
exceed 20 milliliters per day. Total duration of therapy should not 
exceed 14 days.
    (2) Not for use in horses and dogs intended for breeding purposes 
nor in horses slaughtered for food. Other topical medications should 
only be used when the dimethyl sulfoxide treated area is thoroughly dry. 
Do not administer by any other route.
    (3) For use by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 61 FR 5507, Feb. 13, 1996]



Sec. 524.660b  Dimethyl sulfoxide gel.

    (a) Specifications. Dimethyl sulfoxide gel, veterinary contains 90 
percent dimethyl sulfoxide in an aqueous gel.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Indications for use. For use on horses 
and dogs as a topical application to reduce acute swelling due to 
trauma.
    (2) Amount--(i) Horses. Administer 2 or 3 times daily in an amount 
not to exceed 100 grams per day. Total duration of therapy should not 
exceed 30 days.
    (ii) Dogs. Administer 3 or 4 times daily in an amount not to exceed 
20 grams per day. Total duration of therapy should not exceed 14 days.
    (3) Limitations. Do not use in horses and dogs intended for breeding 
purposes or in horses slaughtered for food. Restricted to topical use on 
horses and dogs only. Due to rapid penetrating ability of dimethyl 
sulfoxide, rubber gloves should be worn when applying the drug. No other 
medications should be present on the skin prior to application of the 
drug. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 48 FR 56205, Dec. 20, 1983; 
61 FR 5507, Feb. 13, 1996]



Sec. 524.770  Doramectin.

    (a) Specifications. Each milliliter (mL) of solution contains 5 
milligrams (mg) doramectin.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.225 of this chapter.
    (d) Special considerations. See Sec. 500.25 of this chapter.
    (e) Conditions of use in cattle--(1) Amount. Administer topically as 
a single dose 0.5 mg (1 mL) per kilogram (1 mL per 22 pounds) body 
weight.
    (2) Indications for use. For treatment and control of 
gastrointestinal roundworms: Ostertagia ostertagi (adults and fourth-
stage larvae), Ostertagia ostertagi (inhibited fourth-stage larvae), 
Ostertagia lyrata (adults), Haemonchus placei (adults and fourth-stage 
larvae), Trichostrongylus axei (adults and fourth-stage larvae), 
Trichostrongylus colubriformis (adults and fourth-stage larvae), 
Cooperia oncophora (adults and fourth-stage larvae), Cooperia punctata 
(adults and fourth-stage larvae), Cooperia pectinata (adults), Cooperia 
surnabada (adults), Bunostomum phlebotomum (adults), Oesophagostomum 
radiatum (adults and fourth-stage larvae), Trichuris spp. (adults); 
lungworms: Dictyocaulus viviparus (adults and fourth-stage larvae); 
eyeworms: Thelazia gulosa (adults), Thelazia skrjabini (adults); grubs: 
Hypoderma bovis and Hypoderma lineatum; sucking lice: Linognathus 
vituli, Haematopinus eurysternus, and Solenopotes capillatus; biting 
lice: Bovicola (Damalinia) bovis; mange mites: Chorioptes bovis and 
Sarcoptes scabiei; horn flies: Haematobia irritans; and to control 
infections and to protect from reinfection with Cooperia oncophora, 
Dictyocaulus viviparus, Ostertagia ostertagi, and Oesophagostomum 
radiatum for 28 days; and with Cooperia punctata and Haemonchus placei 
for 35 days after treatment; and to control infestations and to protect 
from reinfestation with Linognathus vituli for 42 days and with Bovicola 
(Damalinia) bovis for 77 days after treatment.
    (3) Limitations. Do not slaughter cattle within 45 days of latest 
treatment. Not for use in female dairy cattle 20 months of age or older. 
Do not use in calves to be processed for veal.

[69 FR 48392, Aug. 10, 2004, as amended at 70 FR 43046, July 26, 2005]

[[Page 330]]



Sec. 524.775  Emodepside and praziquantel.

    (a) Specifications. Each milliliter of solution contains 21.4 
milligrams (mg) emodepside and 85.7 mg praziquantel.
    (b) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in cats--(1) Amount. The recommended minimum 
dose is 1.36 mg/pound (lb) (3 mg/kilogram (kg)) emodepside and 5.45 mg/
lb (12 mg/kg) praziquantel applied as a single topical dose.
    (2) Indications for use. For the treatment and control of hookworm 
infections caused by Ancylostoma tubaeforme (adults, immature adults, 
and fourth stage larvae), roundworm infections caused by Toxocara cati 
(adults and fourth stage larvae), and tapeworm infections caused by 
Dipylidium caninum (adults) and Taenia taeniaeformis (adults).
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[72 FR 42291, Aug. 2, 2007]



Sec. 524.802  Enrofloxacin, silver sulfadiazine emulsion.

    (a) Specifications. Each milliliter contains 5 milligrams (mg) 
enrofloxacin and 10 mg silver sulfadiazine.
    (b) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--Dogs--(1) Amount. 5 to 10 drops for dogs 
weighing 35 pounds (lb) or less and 10 to 15 drops for dogs weighing 
more than 35 lb; applied twice daily for up to 14 days.
    (2) Indications for use. For the treatment of otitis externa in 
dogs.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian. Federal law prohibits the extra-label 
use of this drug in food-producing animals.

[65 FR 66620, Nov. 7, 2000]



Sec. 524.814  Eprinomectin.

    (a) Specifications. Each milliliter (mL) contains 5 milligrams (mg) 
of eprinomectin.
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.227 of this chapter.
    (d) Special considerations. See Sec. 500.25 of this chapter.
    (e) Conditions of use in cattle--(1) Amount. Apply 5 mg (1 mL) per 
10 kilograms (kg) of body weight (500 micrograms/kg) applied topically 
along backbone from withers to tailhead.
    (2) Indications for use. For treatment and control of 
gastrointestinal roundworms (Haemonchus placei (adult and L4), 
Ostertagia ostertagi (adult and L4, including inhibited L4), 
Trichostrongylus axei (adult and L4), T. colubriformis (adult and L4), 
T. longispicularis (adult), Cooperia oncophora (adult and L4), C. 
punctata (adult and L4), C. surnabada (adult and L4), Nematodirus 
helvetianus (adult and L4), Bunostomum phlebotomum (adult and L4), 
Oesophagostomum radiatum (adult and L4), Strongyloides papillosus 
(adults), Trichuris spp. (adults)); lungworms (Dictyocaulus viviparus, 
adult and L4); cattle grubs (all parasitic stages Hypoderma lineatum, H. 
bovis); lice (Damalinia bovis, Linognathus vituli, Haematopinus 
eurysternus, Solenopotes capillatus); mange mites (Chorioptes bovis, 
Sarcoptes scabiei); and horn flies (Haematobia irritans). Controls and 
protects from reinfection of D. viviparus for 21 days after treatment 
and H. irritans for 7 days after treatment.
    (3) Limitations. A withdrawal period has not been established for 
preruminating calves. Do not use in calves to be processed for veal.

[76 FR 72619, Nov. 25, 2011]



Sec. 524.900  Famphur.

    (a) Chemical name. O,O- Dimethyl O-[p-(dimethylsulfamoyl)phenyl] 
phosphorothioate.
    (b) Specifications. The drug is in liquid form containing 13.2 
percent famphur.
    (c) Sponsor. See Nos. 000061 and 051311 in Sec. 510.600(c) of this 
chapter.
    (d) Special considerations. Do not use on animals simultaneously or 
within a few days before or after treatment with or exposure to 
cholinesterase-inhibiting drugs, pesticides, or chemicals.
    (e) Related tolerances. See Sec. 556.273 of this chapter.
    (f) Conditions of use. (1) The drug is used as a pour-on formulation 
for the control of cattle grubs and to reduce cattle lice infestations.

[[Page 331]]

    (2) It is used at the rate of 1 ounce per 200 pounds body weight, 
not to exceed a total dosage of 4 ounces, applied from the shoulder to 
the tail head as a single treatment. It is applied as soon as possible 
after heel fly activity ceases. Do not use on lactating dairy cows or 
dry dairy cows within 21 days of freshening, calves less than 3 months 
old, animals stressed from castration, over-excitement or dehorning, 
sick or convalescent animals. Animals may become dehydrated and under 
stress following shipment. Do not treat until they are in good 
condition. Brahman and Brahman crossbreeds are less tolerant of 
cholinesterase-inhibiting insecticides than other breeds. Do not treat 
Brahman bulls.
    (3) Do not slaughter within 35 days after treatment. Swine should be 
eliminated from area where run-off occurs.

[40 FR 13873, Mar. 27, 1975, as amended at 49 FR 34352, Aug. 30, 1984; 
57 FR 7652, Mar. 4, 1992; 59 FR 28769, June 3, 1994; 62 FR 55161, Oct. 
23, 1997; 62 FR 61626, Nov. 19, 1997; 69 FR 41427, July 9, 2004]



Sec. 524.916  Fentanyl.

    (a) Specifications. Each milliliter of solution contains 50 
milligrams (mg) fentanyl.
    (b) Sponsor. See No. 050929 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Dogs--(i) Amount. 1.2 mg/lb (2.7 mg/kg) 
applied topically to the dorsal scapular area 2 to 4 hours prior to 
surgery.
    (ii) Indications for use. For the control of postoperative pain 
associated with surgical procedures in dogs.
    (iii) Limitations. Fentanyl is a Class II controlled substance. 
Observe all ``black-box warnings'' on product labeling. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.
    (2) [Reserved]

[77 FR 47512, Aug. 9, 2012]



Sec. 524.920  Fenthion.

    (a) Chemical name. O,O-Dimethyl O-[4-(methylthio)-m- tolyl] 
phosphorothioate.
    (b) Specifications. (1) The drug is in a liquid form containing 3 
percent of fenthion.
    (2) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (3) Special considerations. Do not use on animals simultaneously or 
within a few days before or after treatment with or exposure to 
cholinesterase-inhibiting drugs, pesticides, or chemicals.
    (4) Related tolerances. See 40 CFR 180.214.
    (5) Conditions of use. (i) The drug is used as a pour-on formulation 
for the control of grubs and lice in beef and nonlactating cattle.
    (ii) It is used at the rate of one-half fluid ounce per 100 pounds 
of body weight placed on the backline of the animal. Only one 
application per season should be made for grub control and this will 
also provide initial control of lice. A second application for lice 
control may be made if animals become reinfested, but no sooner than 35 
days after the first treatment. Proper timing of treatment is important 
for grub control; cattle should be treated as soon as possible after 
heel-fly activity ceases. Cattle should not be slaughtered within 35 
days following a single treatment. If a second application is made for 
lice control, cattle should not be slaughtered within 45 days of the 
second treatment. The drug must not be used within 28 days of freshening 
of dairy cattle. If freshening should occur within 28 days after 
treatment, do not use milk as human food for the balance of the 28-day 
interval. Do not treat lactating dairy cattle; calves less than 3 months 
old; or sick, convalescent, or stressed livestock. Do not treat cattle 
for 10 days before or after shipping, weaning, or dehorning or after 
exposure to contagious infectious diseases.
    (c) Specifications. (1) The drug is in a liquid form containing 20 
percent fenthion.
    (2) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (3) Special considerations. Do not use on animals simultaneously or 
within a few days before or after treatment with or exposure to 
cholinesterase-inhibiting drugs, pesticides, or chemicals.
    (4) Related tolerances. See 40 CFR 180.214.
    (5) Conditions of use. (i) The drug is used for control of cattle 
grubs and as an aid in controlling lice on beef cattle and on dairy 
cattle not of breeding age.

[[Page 332]]

    (ii) It is applied as a single application placed on the backline of 
animals as follows:

------------------------------------------------------------------------
                                                               Dosage
                     Weight of animal                      (milliliters)
------------------------------------------------------------------------
150 to 300 lb............................................             4
301 to 600 lb............................................             8
601 to 900 lb............................................            12
901 to 1,200 lb..........................................            16
Over 1,200 lb............................................            20
------------------------------------------------------------------------


For most effective results, cattle should be treated as soon as possible 
after heel-fly activity ceases. Host-parasite reactions such as bloat, 
salivation, staggering and paralysis may sometimes occur when cattle are 
treated while the common cattle grub (Hypoderma lineatum) is in the 
gullet, or while the northern cattle grub (H. bovis) is in the area of 
the spinal cord. Cattle should be treated before these stages of grub 
development. Consult your veterinarian, extension livestock specialist, 
or extension entomologist regarding the timing of treatment. If it is 
impossible to determine the area from which the cattle came and/or exact 
stage of the grubs, it is recommended that the cattle receive only a 
maintenance ration of low-energy feed during the treatment period. This 
lessens the likelihood of severe bloat which may occur in cattle on full 
feed when the common grub is killed while in the gullet. A second 
application is required for animals heavily infested with lice or for 
those which become reinfested. A second application should be made no 
sooner than 35 days after the first treatment.
    (iii) Do not treat dairy cattle of breeding age; calves less than 3 
months old; sick, convalescent, or severely stressed livestock.
    (iv) Do not treat cattle for 10 days before or after shipping, 
weaning, dehorning, or after exposure to contagious or infectious 
diseases.
    (v) Do not slaughter within 45 days of treatment.
    (d) Specifications. (1) The drug is a solution containing either 5.6 
or 13.8 percent fenthion. Each concentration is available in 2 volumes 
which are contained in single-dose applicators.
    (2) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (3) Special considerations. Fenthion is a cholinesterase inhibitor. 
Do not use this product on dogs simultaneously with or within 14 days 
before or after treatment with or exposure to cholinesterase-inhibiting 
drugs, pesticides, or chemicals. Do not use with flea or tick collars.
    (4) Conditions of use--(i) Amount. Four to 8 milligrams per kilogram 
of body weight.
    (ii) Indications for use. For flea control on dogs only.
    (iii) Limitations. Apply the contents of the proper size, single-
dose tube directly to one spot on the dog's skin. Frequency of repeat 
treatments depends upon rate of flea reinfestations. Do not use more 
often than once every 2 weeks. Treatment at 2-week intervals is not to 
exceed 6 months. Do not use on puppies under 10 weeks of age. Do not use 
on sick, stressed, or convalescing dogs. Safe use in breeding males has 
not been established. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 41 FR 16656, Apr. 21, 1976; 
42 FR 58741, Nov. 11, 1977; 45 FR 62425, Sept. 19, 1980; 50 FR 19169, 
May 7, 1985]



Sec. 524.960  Flumethasone, neomycin sulfate, and polymyxin B 
sulfate ophthalmic solutions.

    (a) Specifications. Each milliliter of ophthalmic preparation 
contains 0.10 milligram flumethasone, 5.0 milligrams neomycin sulfate 
(3.5 milligrams neomycin base), and 10,000 units of polymyxin B sulfate, 
with or without hydroxypropyl methylcellulose.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount--(i) Preparation containing 
hydroxypropyl methylcellulose. Dogs: 1 to 2 drops per eye, every 6 
hours.
    (ii) Preparation without hydroxyproply methylcellulose. Dogs and 
cats: 2 to 3 drops per eye, every 4 hours.
    (2) Indications for use. Treatment of the inflammation, edema, and 
secondary bacterial infections associated with topical ophthalmological 
conditions of the eye such as corneal injuries, incipient pannus, 
superficial keratitis, conjunctivitis, acute

[[Page 333]]

nongranulomatous anterior uveitis, kerato- conjunctivitis, and 
blepharitis.
    (3) Limitations. (i) In treating ophthalmological conditions 
associated with bacterial infections, the drug is contraindicated in 
those cases in which microorganisms are not susceptible to the 
antibiotics incorporated in the drug.
    (ii) The drug is contraindicated in infectious tuberculous lesions 
of the eye, early acute stages of viral diseases of the cornea and 
conjunctiva, herpes simplex lesions of the eye, and fungal infections of 
the conjunctiva and eyelids.
    (iii) The usual precautions and contraindications for 
corticosteroids and adrenocorticoids are applicable with this drug. 
Corticosteroids may inhibit essential inflammatory responses intrinsic 
to the fundamental healing mechanism. Adrenocorticoid compounds have 
been reported to cause an increase in intraocular pressure. Intraocular 
pressure should be checked frequently. Ocular reexaminations should be 
made at frequent intervals during long-term therapy.
    (iv) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[44 FR 16012, Mar. 16, 1979, as amended at 61 FR 5507, Feb. 13, 1996]



Sec. 524.981  Fluocinolone acetonide ophthalmic and topical dosage 
forms.



Sec. 524.981a  Fluocinolone acetonide cream.

    (a) Specifications. The drug contains 0.025 percent fluocinolone 
acetonide.
    (b) Sponsor. See No. 099207 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is indicated for the relief of 
pruritus and inflammation associated with certain superficial acute and 
chronic dermatoses in dogs. It is used in the treatment of allergic and 
acute moist dermatitis and for the relief of superficial inflammation 
caused by chemical and physical abrasions and burns.
    (2) A small amount is applied to the affected area two or three 
times daily.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 62 FR 40932, July 31, 1997]



Sec. 524.981b  Fluocinolone acetonide solution.

    (a) Specifications. The drug contains 0.01 percent fluocinolone 
acetonide in propylene glycol with citric acid.
    (b) Sponsor. See No. 099207 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is indicated for the relief of 
pruritus and inflammation associated with otitis externa and certain 
superficial acute and chronic dermatoses in the dog. It is also 
indicated for the relief of pruritus and inflammation associated with 
acute otitis externa and certain superficial acute and chronic 
dermatoses in the cat.
    (2) A small amount of solution is applied to the affected area 2 or 
3 times daily.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 62 FR 40932, July 31, 1997]



Sec. 524.981c  Fluocinolone acetonide, neomycin sulfate cream.

    (a) Specifications. The drug contains 0.025 percent fluocinolone 
acetonide and 0.5 percent neomycin sulfate (0.35 percent neomycin base).
    (b) Sponsor. See No. 099207 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used in the relief of 
pruritus and inflammation associated with superficial acute and chronic 
dermatoses in dogs. It is used in the treatment of such conditions as 
allergic and acute moist dermatoses and nonspecific dermatoses in dogs. 
It is used in the treatment of wound infections in dogs and cats.
    (2) A small amount is applied to the infected area two or three 
times daily.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 62 FR 40932, July 31, 1997]

[[Page 334]]



Sec. 524.981d  Fluocinolone acetonide, dimethyl sulfoxide solution.

    (a) Specifications. Each milliliter of solution contains 0.01 
percent fluocinolone acetonide and 20 percent dimethyl sulfoxide with 
propylene glycol and citric acid.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used in dogs for the relief 
of impaction commonly present in apparently normal anal sacs, for the 
reversal of inflammatory changes associated with abnormal anal sacs, and 
to counteract the offensive odor of anal sac secretions.
    (2) It is administered by instillation of 1 to 2 milliliters into 
each anal sac following expression of anal sac contents. It may be 
necessary to repeat treatment at 60-day intervals to maintain an odor-
free state. The total dosage used should not exceed 2 milliliters per 
anal sac per treatment.
    (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 61 FR 5507, Feb. 13, 1996]



Sec. 524.981e  Fluocinolone acetonide, dimethyl sulfoxide otic solution.

    (a) Specifications. Each milliliter of solution contains 0.01 
percent of fluocinolone acetonide in 60 percent dimethyl sulfoxide with 
propylene glycol and citric acid.
    (b) Sponsor. See No. 000033 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used in dogs for the relief 
of pruritis and inflammation associated with acute and chronic otitis.
    (2) It is administered at 4 to 6 drops (0.2 milliliter) twice daily 
into the ear canal for a maximum period of 14 days. The total dosage 
used should not exceed 17 milliliters. The ear canal should be cleansed 
by some appropriate method prior to instillation of the solution and the 
ear should be massaged gently following instillation.
    (3) There should be careful initial evaluation and followup of 
infected ears. Incomplete response or exacerbation of corticosteroid-
responsive lesions may be due to the presence of an infection which 
requires identification or antibiotic sensitivity testing, and the use 
of the appropriate antimicrobial agent. As with any corticosteroid, 
animals with a generalized infection should not be treated with this 
product without proper supportive antimicrobial therapy. Preparations 
with dimethyl sulfoxide should not be used in pregnant animals. For use 
by or on the order of a licensed veterinarian.



Sec. 524.1005  Furazolidone aerosol powder.

    (a) Specifications. The product contains either 4 or 10 percent 
furazolidone in inert dispersing agent and propellant.
    (b) Sponsors. (1) See No. 053501 in Sec. 510.600(c) of this chapter 
for use as in paragraphs (c)(1), (c)(2)(i), (c)(2)(ii), and (c)(3) of 
this section.
    (2) See No. 017135 for use of the 4 percent product as in paragraph 
(c)(2)(iv) of this section.
    (c) Conditions of use--(1) Amount. Hold container about 6 to 12 
inches from the eye or affected area and apply only enough powder to 
impart a light yellow color.
    (2) Indications of use--(i) Dogs. For treatment or prevention of 
bacterial infection of superficial wounds, abrasions, lacerations, and 
pyogenic dermatitis.
    (ii) Horses. For treatment or prevention of bacterial infection of 
superficial wounds, abrasions, lacerations, and following firing (heat 
or electrocautery).
    (iii) [Reserved]
    (iv) Horses and ponies. For treatment or prevention of bacterial 
infection of superficial wounds, abrasions, and lacerations caused by 
Staphylococcus aureus, Streptococcus spp. and Proteus spp. sensitive to 
furazolidone.
    (3) Limitations. For topical application in horses, ponies, and 
dogs: Clean affected area thoroughly, apply drug once or twice daily, 
and repeat treatment as required. Use only as recommended by a 
veterinarian in treatment of puncture wounds, wounds requiring surgical 
debridement or suturing, those of a chronic nature involving proud 
flesh, generalized and chronic infections of the skin, and those skin 
conditions associated with intense itching. If redness, irritation, or 
swelling persists or increases, discontinue

[[Page 335]]

use and consult a veterinarian. Not for use in horses intended for food.

[45 FR 49543, July 25, 1980, as amended at 50 FR 30153, July 24, 1985; 
56 FR 50653, Oct. 8, 1991; 57 FR 31314, July 15, 1992; 60 FR 55659, Nov. 
2, 1995; 65 FR 41588, July 6, 2000]



Sec. 524.1044  Gentamicin sulfate ophthalmic and topical dosage forms.



Sec. 524.1044a  Gentamicin ophthalmic solution.

    (a) Specifications. Each milliliter of sterile aqueous solution 
contains gentamicin sulfate equivalent to 3 milligrams of gentamicin.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used in dogs and cats for the 
topical treatment of infections of the conjunctiva caused by susceptible 
bacteria.
    (2) Administer 1 or 2 drops into the conjunctival sac 2 to 4 times a 
day.
    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[41 FR 14189, Apr. 2, 1976, as amended at 52 FR 7832, Mar. 13, 1987]



Sec. 524.1044b  Gentamicin sulfate, betamethasone valerate otic solution.

    (a) Specifications. Each milliliter of solution contains gentamicin 
sulfate equivalent to 3 milligrams (mg) gentamicin base and 
betamethasone valerate equivalent to 1 mg betamethasone alcohol.
    (b) Sponsors. See Nos. 000061 and 054925 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use--(1) Amounts and indications for use--(i) For 
the treatment of acute and chronic otitis externa caused by bacteria 
sensitive to gentamicin in dogs, instill three to eight drops of 
solution into the ear canal twice daily for 7 to 14 days.
    (ii) For the treatment of infected superficial lesions caused by 
bacteria sensitive to gentamicin in dogs and cats, apply a sufficient 
amount of the drug to cover the treatment area twice daily for 7 to 14 
days.
    (2) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[71 FR 13542, Mar. 16, 2006]



Sec. 524.1044c  Gentamicin sulfate ophthalmic ointment.

    (a) Specifications. Each gram of ointment contains gentamicin 
sulfate equivalent to 3 milligrams of gentamicin.
    (b) Sponsors. See Nos. 000061 and 043264 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use in dogs and cats--(1) Amount. Apply 
approximately a 1/2-inch strip to the affected eye 2 to 4 times a day.
    (2) Indications for use. For treatment of conjunctivitis caused by 
susceptible bacteria.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[69 FR 47363, Aug. 5, 2004, as amended at 77 FR 64717, Oct. 23, 2012]



Sec. 524.1044d  Gentamicin sulfate, betamethasone valerate ointment.

    (a) Specifications. Each gram of ointment contains gentamicin 
sulfate equivalent to 3 milligrams of gentamicin base and betamethasone 
valerate equivalent to 1 milligram of betamethasone.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used or indicated for use in 
dogs in the treatment of acute and chronic canine otitis externa and 
canine infected superficial lesions caused by bacteria sensitive to 
gentamicin.
    (2)(i) For the treatment of acute and chronic canine otitis externa 
the drug is administered by instillation of 3 to 8 drops into the ear 
canal twice daily for 7 days. The external ear and ear canal should be 
properly cleaned and dried before treatment. Remove foreign material, 
debris, crusted exudates, etc., with suitable nonirritating solutions. 
Excessive hair should be clipped from the treatment area of the external 
ear.
    (ii) For the treatment of canine infected superficial lesions, the 
lesion and adjacent area should be properly cleaned before treatment. 
Excessive hair should be removed. A sufficient amount of the drug should 
be applied to cover the treatment area. The drug should be administered 
twice daily for 7 to 14 days.
    (3) If hypersensitivity to any of the components occurs, treatment 
should

[[Page 336]]

be discontinued and appropriate therapy instituted. Concomitant use of 
drugs known to induce ototoxicity should be avoided. Observe patients 
for signs of adrenocorticoid overdosage. The antibiotic susceptibility 
of the pathogenic organism should be determined prior to use of this 
preparation. Administration of recommended doses beyond 7 days may 
result in delayed wound healing. Animals treated longer than 7 days 
should be monitored closely.
    (4) For use by or on the order of a licensed veterinarian.

[47 FR 26378, June 18, 1982, as amended at 52 FR 7832, Mar. 13, 1987]



Sec. 524.1044e  Gentamicin sulfate spray.

    (a) Specification. Each milliliter of sterile aqueous solution 
contains gentamicin sulfate equivalent to 1.07 milligrams of gentamicin.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is indicated for the treatment 
of pink eye in cattle (infectious bovine keratoconjunctivitis) caused by 
Moraxella bovis.
    (2) One actuation of the sprayer delivers 0.7 milliliter containing 
0.75 milligram gentamicin. The sprayer should be held upright 3 to 6 
inches from the affected eye, with the opening directed towards the eye, 
and pumped once. It is advisable to treat once a day for up to 3 days.
    (3) Conditions other than bacterial infections of the bovine eye and 
infectious keratoconjunctivitis caused by Moraxella bovis may produce 
similar signs. If conditions persists or increases, discontinue use and 
consult veterinarian.

[48 FR 41157, Sept. 14, 1983, as amended 52 FR 7833, Mar. 13, 1987]



Sec. 524.1044f  Gentamicin and betamethasone spray.

    (a) Specifications. Each milliliter of spray contains gentamicin 
sulfate equivalent to 0.57 milligram (mg) gentamicin base and 
betamethasone valerate equivalent to 0.284 mg betamethasone.
    (b) Sponsors. See Nos. 000061, 054925, 058005, 058829, and 065531 in 
Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Hold bottle upright 3 to 
6 inches from the lesion and depress the sprayer head twice. Administer 
two spray actuations two to four times daily for 7 days.
    (2) Indications for use. For the treatment of infected superficial 
lesions caused by bacteria susceptible to gentamicin.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[71 FR 13542, Mar. 16, 2006, as amended at 72 FR 5929, Feb. 8, 2007; 74 
FR 22822, May 15, 2009; 77 FR 3598, Jan. 25, 2012]



Sec. 524.1044g  Gentamicin sulfate, betamethasone valerate, clotrimazole 
ointment.

    (a) Specifications. Each gram (g) of ointment contains gentamicin 
sulfate equivalent to 3 milligrams (mg) gentamicin base, betamethasone 
valerate equivalent to 1 mg betamethasone, and 10 mg clotrimazole.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
uses as in paragraph (c) of this section.
    (1) No. 000061 for use of 7.5- or 15-gram (g) tubes, 12.5-, 30-, or 
215-g bottles.
    (2) No. 054925 for use of 7.5- or 15-g tubes; 10-, 15-, 25-, or 215-
g bottles.
    (3) No. 000859 for use of 10-, 20-, 40-, or 215-g bottles.
    (3) No. 059130 for use of 10-, 20-, or 215-g bottles.
    (4) No. 025463 for use of 7.5- or 15-g tubes, or 215-g bottles.
    (c) Conditions of use in dogs--(1) Amount. Instill ointment twice 
daily into the ear canal for 7 consecutive days.
    (i) From 7.5- or 15-g tubes; 10-, 12.5-, 15-, 25-, or 30-g bottles: 
4 drops for dogs weighing less than 30 pounds (lb) or 8 drops for dogs 
weighing 30 lb or more.
    (ii) From 20-, 40-, or 215-g bottles: 2 drops for dogs weighing less 
than 30 lb or 4 drops for dogs weighing 30 lb or more.
    (ii) From 20- or 215-g bottles: 2 drops for dogs weighing less than 
30 lb or 4 drops for dogs weighing 30 lb or more.

[[Page 337]]

    (2) Indications for use. For the treatment of acute and chronic 
canine otitis externa associated with yeast (Malassezia pachydermatis, 
formerly Pityrosporum canis) and/or bacteria susceptible to gentamicin.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[58 FR 38973, July 21, 1993, as amended at 63 FR 31932, June 11, 1998; 
68 FR 42970, July 21, 2003; 70 FR 8291, Feb. 18, 2005; 71 FR 13542, Mar. 
16, 2006; 71 FR 16481, Apr. 3, 2006; 71 FR 38261, July 6, 2006; 71 FR 
56867, Sept. 28, 2006; 78 FR 17597, Mar. 22, 2013]



Sec. 524.1044h  Gentamicin sulfate, mometasone furoate, clotrimazole 
otic suspension.

    (a) Specifications. Each gram contains gentamicin sulfate, United 
States Pharmacopeia (USP) equivalent to 3 milligram (mg) gentamicin 
base, mometasone furoate monohydrate equivalent to 1 mg mometasone, and 
10 mg clotrimazole, USP.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. For dogs weighing less 
than 30 pounds (lb), instill 4 drops from the 7.5-, 15-, or 30-gram (g) 
bottle into the ear canal (2 drops from the 215-g bottle) or, for dogs 
weighing 30 lb or more, instill 8 drops from the 7.5-, 15-, or 30-g 
bottle into the ear canal (4 drops from the 215-g bottle), once or twice 
daily for 7 days.
    (2) Indications for use. For the treatment of otitis externa caused 
by susceptible strains of yeast (Malassezia pachydermatis) and bacteria 
(Pseudomonas spp. [including P. aeruginosa], coagulase-positive 
staphylococci, Enterococcus faecalis, Proteus mirabilis, and beta-
hemolytic streptococci).

[66 FR 712, Jan. 4, 2001, as amended at 68 FR 15370, Mar. 31, 2003; 70 
FR 36338, June 23, 2005]



Sec. 524.1044i  Gentamicin and betamethasone ophthalmic solution.

    (a) Specifications. Each milliliter (mL) of solution contains 
gentamicin sulfate equivalent to 3 milligrams (mg) of gentamicin base 
and 1 mg betamethasone acetate equivalent to 0.89 mg betamethasone 
alcohol.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Instill one or two drops 
of solution in the conjunctival sac three or four times a day.
    (2) Indications for use. For treatment of external bacterial 
infections of the eye (conjunctiva and cornea).
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[75 FR 54492, Sept. 8, 2010]



Sec. 524.1132  Hydrocortisone aceponate, miconazole nitrate, gentamicin 
sulfate otic suspension.

    (a) Specifications. Each milliliter (mL) of suspension contains 1.11 
milligrams (mg) of hydrocortisone aceponate, 15.1 mg of miconazole 
nitrate, and 1,505 micrograms of gentamicin sulfate.
    (b) Sponsor. See No.051311 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Instill 1.0 mL in the 
affected ear once daily for 5 days.
    (2) Indications for use. For the treatment of otitis externa in dogs 
associated with susceptible strains of yeast (Malassezia pachydermatis) 
and bacteria (Staphylococcus pseudintermedius).
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[76 FR 78150, Dec. 16, 2011]



Sec. 524.1140  Imidacloprid and ivermectin.

    (a) Specifications. The product is available in unit applicator 
tubes containing 0.4, 1.0, 2.5, or 4.0 milliliters (mL). Each mL of 
solution contains 100 milligrams (mg) imidacloprid and 800 micrograms 
([micro]g) ivermectin.
    (b) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (c) Conditions of Use in Dogs--(1) Amount. The recommended minimum 
dosage is 4.5 mg/pound (lb) (10 mg/kilogram (kg)) of imidacloprid and 
36.4 [micro]g/lb (80 [micro]g/kg) of ivermectin, topically once a month.
    (2) Indications for Use. For the prevention of heartworm disease 
caused by Dirofilaria immitis; kills adult fleas and is indicated for 
the treatment of flea infestations (Ctenocephalides felis).

[[Page 338]]

    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[67 FR 78685, Dec. 26, 2002]



Sec. 524.1146  Imidacloprid and moxidectin.

    (a) Specifications--(1) Each milliliter of solution contains 100 
milligrams (mg) imidacloprid and 25 mg moxidectin for use as in 
paragraph (d)(1) of this section.
    (2) Each milliliter of solution contains 100 mg imidacloprid and 10 
mg moxidectin for use as in paragraph (d)(2) of this section.
    (b) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Conditions of use--(1) Dogs--(i) Amount. Topically apply 4.5 mg/
lb body weight (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) 
moxidectin, once a month.
    (ii) Indications for use. For the prevention of heartworm disease 
caused by Dirofilaria immitis; and the treatment and control of 
intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms 
(Ancylostoma caninum and Uncinaria stenocephala), and whipworms 
(Trichuris vulpis); kills adult fleas and treats flea infestations 
(Ctenocephalides felis).
    (2) Cats--(i) Amount. Topically apply 4.5 mg/lb body weight (10 mg/
kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month.
    (ii) Indications for use. For the prevention of heartworm disease 
caused by Dirofilaria immitis; for the treatment and control of ear mite 
(Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), 
and hookworms (Ancylostoma tubaeforme); kills adult fleas and treats 
flea infestations (Ctenocephalides felis).

[72 FR 10597, Mar. 9, 2007]



Sec. 524.1193  Ivermectin topical solution.

    (a) Specifications. Each milliliter (mL) of solution contains 5 
milligrams of ivermectin.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (e) of this section.
    (1) Nos. 050604, 055529, 058829, 061623 for use as in paragraphs 
(e)(1), (e)(2)(i), (e)(2)(iii), and (e)(3) of this section.
    (2) Nos. 000859, 054925, and 066916 for use as in paragraphs (e)(1), 
(e)(2)(i), (e)(2)(ii), and (e)(3) of this section.
    (c) Related tolerances. See Sec. 556.344 of this chapter.
    (d) Special considerations. See Sec. 500.25 of this chapter.
    (e) Conditions of use in cattle--(1) Amount. One mL per 22 pounds 
(0.5 milligram per kilogram) of body weight applied topically to the 
back of the animal.
    (2) Indications for use--(i) It is used for the treatment and 
control of: Gastrointestinal roundworms (adults and fourth-stage larvae) 
Ostertagia ostertagi (including inhibited stage), Haemonchus placei, 
Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C. 
punctata, C. surnabada, Oesophagostomum radiatum; (adults) Strongyloides 
papillosus, Trichuris spp.; lungworms (adults and fourth-stage larvae) 
Dictyocaulus viviparus; cattle grubs (parasitic stages) Hypoderma bovis, 
H. lineatum; mites Sarcoptes scabiei var. bovis; lice Linognathus 
vituli, Haematopinus eurysternus, Damalinia bovis, Solenoptes 
capillatus; and horn flies Haematobia irritans.
    (ii) It controls infections and prevents reinfection with O. 
ostertagi, O. radiatum, H. placei, T. axei, C. punctata, and C. 
oncophora for 14 days after treatment.
    (iii) It controls infections and prevents reinfection with O. 
radiatum and D. viviparus for 28 days after treatment, C. punctata and 
T. axei for 21 days after treatment, O. ostertagi, H. placei, C. 
oncophora, and C. surnabada for 14 days after treatment, and D. bovis 
for 56 days after treatment.
    (3) Limitations. Do not treat cattle within 48 days of slaughter. 
Because a withdrawal time in milk has not been established, do not use 
in female dairy cattle of breeding age. A withdrawal period has not been 
established for this product on preruminating calves. Do

[[Page 339]]

not use on calves to be processed for veal.

[55 FR 50551, Dec. 7, 1990, as amended at 62 FR 38908, July 21, 1997; 62 
FR 63271, Nov. 28, 1997; 63 FR 44385, Aug. 19, 1998; 66 FR 13236, Mar. 
5, 2001; 66 FR 63165, Dec. 5, 2001; 68 FR 3817, Jan. 27, 2003; 68 FR 
4713, Jan. 30, 2003; 69 FR 501, Jan. 6, 2004; 69 FR 62181, Oct. 25, 
2004; 71 FR 13542, Mar. 16, 2006; 72 FR 6464, Feb. 12, 2007; 74 FR 
36112, July 22, 2009; 75 FR 26648, May 12, 2010; 76 FR 81807, Dec. 29, 
2011; 78 FR 17597, Mar. 22, 2013]



Sec. 524.1195  Ivermectin otic suspension.

    (a) Specifications. Each tube contains 0.5 milliliter (mL) of a 0.01 
percent suspension of ivermectin.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. Administer the contents of one 
0.5-mL tube topically into each external ear canal.
    (2) Indications for use. For the treatment of adult ear mite 
(Otodectes cynotis) infestations in cats and kittens 4 weeks of age and 
older. Effectiveness against eggs and immature stages has not been 
proven.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[66 FR 7578, Jan. 24, 2001, as amended at 74 FR 26782, June 4, 2009]



Sec. 524.1200  Kanamycin ophthalmic and topical dosage forms.



Sec. 524.1200a  Kanamycin ophthalmic ointment.

    (a) Specifications. The drug, which is in a suitable and harmless 
ointment base, contains 3.5 milligrams of kanamycin activity (as the 
sulfate) per gram of ointment.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. It is indicated for use in dogs in various 
eye infections due to kanamycin sensitive bacteria. It is used treating 
conditions such as conjunctivitis, blepharitis, dacryocystitis, 
keratitis, and corneal ulcerations and as a prophylactic in traumatic 
conditions, removal of foreign bodies, and intraocular surgery. Apply a 
thin film to the affected eye three or four times daily or more 
frequently if deemed advisable. Treatment should be continued for at 
least 48 hours after the eye appears normal. For use only by or on the 
order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 53 FR 27851, July 25, 1988; 
64 FR 404, Jan. 5, 1999]



Sec. 524.1200b  Kanamycin ophthalmic aqueous solution.

    (a) Specifications. The drug, which is in an aqueous solution 
including suitable and harmless preservatives and buffer substances, 
contains 10 milligrams of kanamycin activity (as the sulfate) per 
milliliter of solution.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. It is indicated for use in dogs in various 
eye infections due to kanamycin sensitive bacteria. It is used in 
treating conditions such as conjunctivities, blepharitis, 
dacryocystitis, keratitis, and corneal ulcerations and as a prophylactic 
in traumatic conditions, removal of foreign bodies, and intraocular 
surgery. Instill a few drops into the affected eye every 3 hours or more 
frequently if deemed advisable. Administer as frequently as possible for 
the first 48 hours, after which the frequency of applications may be 
decreased. Treatment should be continued for at least 48 hours after the 
eye appears normal. For use only by or on the order of a licensed 
veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 53 FR 27851, July 25, 1988; 
64 FR 404, Jan. 5, 1999]



Sec. 524.1204  Kanamycin sulfate, calcium amphomycin, and hydrocortisone 
acetate.

    (a) Specifications. (1) Calcium amphomycin is the calcium salt of 
amphomycin. It conforms to the following specifications:
    (i) Its potency is not less than 863 micrograms of amphomycin per 
milligram;
    (ii) Its moisture content is not more than 10 percent; and
    (iii) Its pH in a 2-percent aqueous suspension is 6.0 to 7.5.
    (2) The drug is in a water-miscible ointment or cream base and each 
gram of ointment or cream contains: 5.0 milligrams of kanamycin activity 
as the sulfate, 5.0 milligrams of amphomycin activity as the calcium 
salt, and 10.0 milligrams of hydrocortisone acetate.

[[Page 340]]

    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is indicated for use in dogs in the 
following conditions associated with bacterial infections caused by 
organisms susceptible to one or both antibiotics: Acute otitis externa, 
furunculosis, folliculitis, pruritus, anal gland infections, erythema, 
decubital ulcer, superficial wounds, and superficial abscesses.
    (2) The ointment should be applied to the affected areas of the skin 
at least twice daily. In severe or widespread lesions it may be 
desirable to apply the ointment more than twice daily. After some 
improvement is observed, treatment can usually be reduced to once daily. 
Before application, hair in the affected area should be closely clipped 
and the area should be thoroughly cleansed of crusts, scales, dirt, or 
other detritus. When treating infections of the anal gland, the drug 
should be introduced into the orifice of the gland and not through any 
fistulous tract. If no response is evident in 7 days, diagnosis and 
therapy should be reevaluated.
    (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 53 FR 12512, Apr. 15, 1988; 
53 FR 27851, July 25, 1988; 64 FR 404, Jan. 5, 1999]



Sec. 524.1240  Levamisole.

    (a) Specifications. The drug contains 200 milligrams of levamisole 
per milliliter of diethylene glycol monobutyl ether (DGME) solution.
    (b) Sponsor. See 000061 and 053501 in Sec. 510.600(c) of this 
chapter.
    (c) Related tolerances. See Sec. 556.350 of this chapter.
    (d) Conditions of use. Cattle--(1) Amount. 2.5 milliliters per 110 
pounds (10 milligrams of levamisole per kilogram) of body weight as a 
single dose topically to the back of the animal.
    (2) Indications for use. Anthelmintic effective against stomach 
worms (Haemonchus, Trichostrongylus, Ostertagia), intestinal worms 
(Trichostrongylus, Cooperia, Nematodirus, Bunostomum, Oesophagostomum, 
Chabertia), and lungworms (Dictyocaulus).
    (3) Limitations. Conditions of constant helminth exposure may 
require retreatment within 2 to 4 weeks after the first treatment. 
Cattle must not be slaughtered within 9 days following last treatment. 
Do not administer to dairy animals of breeding age. Do not treat animals 
before dipping or prior to exposure to heavy rain. Consult your 
veterinarian for assistance in the diagnosis, treatment, and control of 
parasitism, and before using in severely debilitated animals.

[52 FR 10887, Apr. 6, 1987, as amended at 53 FR 7504, Mar. 9, 1988; 62 
FR 61626, Nov. 19, 1997; 67 FR 78355, Dec. 24, 2002]



Sec. 524.1376  2-Mercaptobenzothiazole solution.

    (a) Specifications. The drug contains 1.3 percent 2-
mercaptobenzothiazole in a suitable solvent.
    (b) Sponsor. See 017135 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. Apply twice daily to affected 
area.
    (2) Indications for use. For dogs as an aid in the treatment of hot 
spots (moist dermatitis) and as first aid for scrapes and abrasions.
    (3) Limitations. Clip hair from affected area before applying. If no 
improvement is seen within 1 week, consult a veterinarian.

[48 FR 15618, Apr. 12, 1983, as amended at 65 FR 50913, Aug. 22, 2000; 
68 FR 33381, June 4, 2003]



Sec. 524.1443  Miconazole.

    (a) Specifications--(1) Each gram of cream contains miconazole 
nitrate equivalent to 20 milligrams miconazole base.
    (2) Each gram of lotion or spray contains miconazole nitrate 
equivalent to 1 percent miconazole base.
    (b) Sponsors. See Sec. 510.600(c) of this chapter for use as in 
paragraph (c) of this section:
    (1) No. 000061 for use of cream, lotion, and spray;
    (2) Nos. 054925 and 058829 for use of lotion and spray.
    (c) Conditions of use in dogs and cats--(1) Amount. Apply once daily 
by rubbing into or spraying a light covering on the infected site and 
the immediate surrounding vicinity. Continue treatment for 2 to 4 weeks 
until infection is completely eradicated as determined

[[Page 341]]

by appropriate laboratory examination.
    (2) Indications for use. For topical treatment of infections caused 
by Microsporum canis, Microsporum gypseum, and Trichophyton 
mentagrophytes.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[71 FR 13542, Mar. 16, 2006]



Sec. 524.1445  Miconazole, polymixin B, and prednisolone suspension.

    (a) Specifications. Each milliliter of suspension contains 23 
milligrams (mg) miconazole nitrate, 0.5293 mg polymixin B sulfate, and 5 
mg prednisolone acetate.
    (b) Sponsor. See No. 000986 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Instill five drops in the 
ear canal twice daily for 7 consecutive days.
    (2) Indications for use. For the treatment of canine otitis externa 
associated with susceptible strains of yeast (Malassezia pachydermatis) 
and bacteria (Staphylococcus pseudintermedius).
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[ 75 FR 4693, Jan. 29, 2010, as amended at 77 FR 46613, Aug. 6, 2012]



Sec. 524.1446  Milbemycin oxime solution.

    (a) Specifications. Each tube contains 0.25 milliliter of a 0.1 
percent solution of milbemycin oxime.
    (b) Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. One tube administered topically 
into each external ear canal.
    (2) Indications for use. For the treatment of ear mite (Otodectes 
cynotis) infestations in cats and kittens 4 weeks of age and older. 
Effectiveness is maintained throughout the life cycle of the ear mite.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[65 FR 13905, Mar. 15, 2000, as amended at 66 FR 13849, Mar. 8, 2001]



Sec. 524.1450  Moxidectin.

    (a) Specifications. Each milliliter contains 5 milligrams (mg) 
moxidectin (0.5 percent solution).
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.426 of this chapter.
    (d) Special considerations. See Sec. 500.25 of this chapter.
    (e) Conditions of use-(1) Amount. Administer topically 0.5 mg per 
kilogram of body weight.
    (2) Indications for use. Beef and dairy cattle: For treatment and 
control of internal and external parasites: gastrointestinal roundworms 
(Ostertagia ostertagi (adult and L4, including inhibited larvae), 
Haemonchus placei (adult and L4), Trichostrongylus axei (adult and L4), 
T. colubriformis (adult and L4), Cooperia oncophora (adult and L4), C. 
pectinata (adult), C. punctata (adult and L4), C. spatulata (adult), C. 
surnabada (adult and L4), Bunostomum phlebotomum (adult), 
Oesophagostomum radiatum (adult and L4), Nematodirus helvetianus (adult 
and L4)); lungworms (Dictyocaulus viviparus, adult and L4); cattle grubs 
(Hypoderma bovis, H. lineatum); mites (Chorioptes bovis, Psoroptes ovis 
(P. communis var. bovis)); lice (Linognathus vituli, Haematopinus 
eurysternus, Solenopotes capillatus, Bovicola(Damalinia) bovis); and 
horn flies (Haematobia irritans). To control infections and to protect 
from reinfection with H. placei for 14 days after treatment, O. radiatum 
and O. ostertagi for 28 days after treatment, and D. viviparus for 42 
days after treatment.
    (3) Limitations. A withdrawal period has not been established for 
this product on preruminating calves. Do not use on calves to be 
processed for veal.

[63 FR 14036, Mar. 24, 1998, as amended at 65 FR 36617, June 9, 2000; 66 
FR 46370, Sept. 5, 2001. Redesignated at 76 FR 48715, Aug. 9, 2011]



Sec. 524.1465  Mupirocin.

    (a) Specifications. Each gram of ointment contains 20 milligrams 
mupirocin.
    (b) Sponsors. See Nos. 000069, 025463, and 051672 in Sec. 
510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Apply twice daily. 
Treatment should not exceed 30 days.

[[Page 342]]

    (2) Indications for use. For the topical treatment of bacterial 
infections of the skin, including superficial pyoderma, caused by 
susceptible strains of Staphylococcus aureus and S. intermedius.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[72 FR 18119, Apr. 11, 2007, as amended at 75 FR 79296, Dec. 20, 2010]



Sec. 524.1484  Neomycin sulfate ophthalmic and topical dosage forms.



Sec. 524.1484b  Neomycin sulfate, isoflupredone acetate, tetracaine 
hydrochloride, and myristyl-gamma-picolinium chloride, topical powder.

    (a) Specifications. The product contains 5 milligrams of neomycin 
sulfate, equivalent to 3.5 milligrams of neomycin base, 1 milligram of 
isoflupredone acetate, 5 milligrams of tetracaine hydrochloride and .2 
milligram of myristyl-gamma-picolinium chloride in each gram of the 
product in a special adherent powder base.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is used in horses, dogs, and cats in 
the treatment or adjunctive therapy of certain ear and skin conditions 
when such conditions are caused by or associated with neomycin-
susceptible organisms and/or allergy. In addition the product is 
indicated as superficial dressing applied to minor cuts, wounds, 
lacerations, abrasions, and for postsurgical application where reduction 
of pain and inflammatory response is deemed desirable. The product may 
be used as a dusting powder following amputation of tails, claws, and 
dew-claws and following ear trimming, castrating, and such surgical 
procedures as ovariohysterectomies. The product may also be used in the 
treatment of acute otitis externa in dogs, acute moist dermatitis and 
interdigital dermatitis in dogs.
    (2) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 43 FR 18172, Apr. 28, 1978]



Sec. 524.1484c  Neomycin sulfate, isoflupredone acetate, tetracaine 
hydrochloride ointment.

    (a) Specifications. The drug contains 5 milligrams of neomycin 
sulfate (equivalent to 3.5 milligrams of neomycin base), 1 milligram of 
isoflupredone acetate, and 5 milligrams of tetracaine hydrochloride in 
each gram of ointment.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is used in treating such conditions as 
acute otitis externa in dogs and to a lesser degree, chronic otitis 
externa in dogs. It also is effective in treating anal gland infections 
and moist dermatitis in the dog and is a useful dressing for minor cuts, 
lacerations, abrasions, and post-surgical therapy in the horse, cat, and 
dog. It may also be used following amputation of dewclaws, tails and 
claws, following ear trimming and castrating operations.
    (2) In treatment of otitis externa and other inflammatory conditions 
of the external ear canal, a quantity of ointment sufficient to fill the 
external ear canal may be applied one to three times daily. When used on 
the skin or mucous membranes, the affected area should be cleansed, and 
a small amount of the ointment applied and spread or rubbed in gently. 
The involved area may be treated one to three times a day and these 
daily applications continued in accordance with the clinical response.
    (3) Tetracaine and neomycin have the potential to sensitize. Care 
should be taken to observe animals being treated for evidence of 
hypersensitivity or allergy to the drug. If such signs are noted, 
therapy with the drug should be stopped. Treatment should be limited to 
the period when local anesthesia is essential to control self-inflicted 
trauma.
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 43 FR 18172, Apr. 28, 1978]



Sec. 524.1484d  Neomycin sulfate, hydrocortisone acetate, tetracaine 
hydrochloride ear ointment.

    (a) Specifications. The product contains 5 milligrams of neomycin 
sulfate,

[[Page 343]]

equivalent to 3.5 milligrams of neomycin base, 5 milligrams of 
hydrocortisone acetate, and 5 milligrams of tetracaine hydrochloride in 
each gram of ointment.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is indicated for treating acute otitis 
externa and, to a lesser degree, chronic otitis externa in dogs and 
cats. In treatment of ear canker and other inflammatory conditions of 
the external ear canal, a quantity of ointment sufficient to fill the 
external ear canal may be applied one to three times daily.\1\
    (2) Tetracaine and neomycin have the potential to sensitize. Care 
should be taken to observe animals being treated for evidence of 
hypersensitivity or allergy to the product. If such signs are noted, 
therapy with the product should be stopped. Incomplete response or 
exacerbation of corticosteroid responsive lesions may be due to the 
presence of nonsusceptible organisms or to prolonged use of antibiotic-
containing preparations resulting in overgrowth of nonsusceptible 
organisms, particularly Monilia.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.\1\

[40 FR 13873, Mar. 27, 1975, as amended at 49 FR 21922, May 24, 1984]



Sec. 524.1484e  Neomycin sulfate and polymyxin B sulfate ophthalmic 
solution.

    (a) Specifications. Each milliliter of the ophthalmic preparation 
contains 5.0 milligrams neomycin sulfate (3.5 milligrams neomycin base), 
and 10,000 Units of polymyxin B sulfate.
    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is recommended for the treatment 
of bacterial infections associated with topical ophthalmological 
conditions such as corneal injuries, superficial keratitis, 
conjunctivitis, keratocon- junctivities, and blepharitis in the dog.
    (2) The recommended dosage is 1 to 2 drops per eye every 6 hours.
    (3) In treating ophthalmological conditions associated with 
bacterial infections the drug is contraindicated in those cases in which 
microorganisms are nonsusceptible to the antibiotics incorporated in the 
drug.
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 61 FR 5507, Feb. 13, 1996]



Sec. 524.1484f  Neomycin sulfate, prednisolone acetate, tetracaine 
hydrochloride eardrops.

    (a) Specifications. The product contains 5 milligrams of neomycin 
sulfate equivalent to 3.5 milligrams of neomycin base, 2.5 milligrams of 
prednisolone acetate, and 5 milligrams of tetracaine hydrochloride in 
each milliliter of sterile suspension.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) It is useful in treating such conditions 
as acute otitis externa and, to a lesser degree, chronic otitis externa 
in dogs and cats. It is indicated as treatment or adjunctive therapy of 
certain ear conditions in dogs and cats caused by or associated with 
neomycin-susceptible organisms and/or allergy. In otitis externa, 2 to 6 
drops may be placed in the external ear canal two or three times 
daily.\1\
    (2) Incomplete response or exacerbation of corticosteroid responsive 
lesions may be due to the presence of nonsusceptible organisms or to 
prolonged use of antibiotic-containing preparations resulting in 
overgrowth of nonsusceptible organisms, particularly Monilia. Thus, if 
improvement is not noted within 2 or 3 days, or if redness, irritation, 
or swelling persists or increases, the diagnosis should be redetermined 
and appropriate therapeutic measures initiated. Tetracaine and neomycin 
have the potential to sensitize. Care should be taken to observe animals 
being treated for evidence of hypersensitivity or allergy. If such signs 
are noted, therapy should be stopped.\1\

[[Page 344]]

    (3) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------



Sec. 524.1484g  Neomycin sulfate-thiabendazole-dexamethasone solution.

    (a) Specifications. Each cubic centimeter of neomycin sulfate-
thiabendazole-dexamethasone solution contains: 40 milligrams of 
thiabendazole, 3.2 milligrams of neomycin (from neomycin sulfate), and 1 
milligram of dexamethasone.
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is recommended for use as an aid 
in the treatment of bacterial, mycotic, and inflammatory dermatoses and 
otitis externa in dogs and cats.
    (2) In treating dermatoses affecting areas other than the ear, the 
surface of the lesions should be well moistened (two to four drops per 
square inch) twice daily. In treating otitis externa, five to 15 drops 
of the drug should be instilled in the ear twice daily. The drug is 
limited to 7 days maximum duration of administration.
    (3) For use only by or on order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 62 FR 63271, Nov. 28, 1997]



Sec. 524.1484h  Neomycin, penicillin, polymyxin, hydrocortisone 
suspension.

    (a) Specifications. Each milliliter of suspension contains 25 
milligrams of neomycin sulfate equivalent to 17.5 milligrams of 
neomycin, 10,000 international units of penicillin G procaine, 5,000 
international units of polymyxin B sulfate, 2 milligrams of 
hydrocortisone acetate, and 1.25 milligrams of hydrocortisone sodium 
succinate.
    (b) Sponsor. See 000009 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. The labeling shall state: This 
medication contains penicillin. Allergic reactions in humans are known 
to occur from topical exposure to penicillin.
    (d) Conditions of use--dogs--(1) Amount. Rub a small amount into the 
involved area 1 to 3 times a day. After definite improvement, it may be 
applied once a day or every other day.
    (2) Indications for use. Treatment of summer eczema, atopic 
dermatitis, interdigital eczema, and otitis externa caused by bacteria 
susceptible to neomycin, penicillin, and polymyxin B.
    (3) Limitations. For use in dogs only. Shake drug thoroughly and 
clean lesion before using. If redness, irritation, or swelling persists 
or increases, discontinue use and reevaluate diagnosis. Federal law 
restricts this drug to use by or on the order of a licensed 
veterinarian.

[59 FR 5105, Feb. 3, 1994]



Sec. 524.1484i  Neomycin sulfate, hydrocortisone acetate, sterile 
ointment.

    (a) Specifications. The drug contains 5 milligrams of neomycin 
sulfate, equivalent to 3.5 milligrams of neomycin base, and 5 milligrams 
of hydrocortisone acetate in each gram of ointment.\1\
    (b) Sponsor. No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. Apply three or four times daily 
into the conjunctival sac. With improvement, frequency may be reduced to 
two or three times daily. For treatment of ear canker and other 
inflammatory conditions of the external ear canal, fill external ear 
canal one to three times daily.\1\
    (2) Indications for use. For treating infections, allergic, and 
traumatic keratitis, conjunctivitis, acute otitis externa and, to a 
lesser degree, chronic otitis externa in dogs and cats.\1\
    (3) Limitations. All topical ophthalmic preparations containing 
corticosteroids, with or without an antimicrobial agent, are 
contraindicated in the initial treatment of corneal ulcers. They should 
not be used until infection is under control and corneal regeneration is 
well underway. Incomplete response or exacerbation of corticosteroid 
responsive lesions may be due to the presence of nonsusceptible 
organisms or to prolonged use on antibiotic-containing preparations 
resulting in overgrowth of nonsusceptible

[[Page 345]]

organisms, particularly Monilia. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.\1\

[43 FR 40456, Sept. 12, 1978]



Sec. 524.1580  Nitrofurazone ophthalmic and topical dosage forms.



Sec. 524.1580a  [Reserved]



Sec. 524.1580b  Nitrofurazone ointment.

    (a) Specifications. The drug contains 0.2 percent nitrofurazone in a 
water-soluble base.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter.
    (1) See Nos. 000010, 000069, 050749, 054925, 058005, and 061623 for 
use on dogs, cats, or horses.
    (2) See No. 017135 for use on dogs and horses.
    (3) See Nos. 017153 and 058829 for use on horses.
    (c) [Reserved]
    (d) Conditions of use--(1) Amount. Apply directly on the lesion with 
a spatula or first place on a piece of gauze. The preparation should 
remain on the lesion for at least 24 hours. Use of a bandage is 
optional.
    (2) Indications for use. For prevention or treatment of surface 
bacterial infections of wounds, burns, and cutaneous ulcers of dogs, 
cats, or horses.
    (3) Limitations. For use only on dogs, cats, and horses. Do not use 
in horses intended for human consumption. Federal law prohibits the use 
of this product in food-producing animals. In case of deep or puncture 
wounds or serious burns, use only as recommended by veterinarian. If 
redness, irritation, or swelling persists or increases, discontinue use; 
consult veterinarian.

[46 FR 43402, June 27, 1980]

    Editorial Note: For Federal Register citations affecting Sec. 
524.1580b, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 524.1580c  Nitrofurazone soluble powder.

    (a) Specifications. The drug contains 0.2 percent nitrofurazone in a 
water-soluble base.
    (b) Sponsor. See Nos. 000010 and 000069 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use--(1) Amount. Apply several times daily to the 
lesion or affected area from the plastic squeeze bottle.
    (2) Indications for use. For prevention or treatment of surface 
bacterial infections of wounds, burns, skin ulcers, and abscesses after 
incision. \1\
    (3) Limitations. In case of deep or puncture wounds or serious 
burns, use only as recommended by veterinarian. If redness, irritation, 
or swelling persists or increases, discontinue use; consult 
veterinarian. For use only on dogs, cats, and horses (not for food use). 
\1\

[45 FR 43402, June 27, 1980, as amended at 47 FR 43368, Oct. 1, 1982; 48 
FR 28984, June 24, 1983; 53 FR 40728, Oct. 18, 1988; 54 FR 30542, July 
21, 1989; 56 FR 50653, Oct. 8, 1991; 59 FR 33197, June 28, 1994; 60 FR 
55659, Nov. 2, 1995; 62 FR 35077, June 30, 1997; 76 FR 17778, Mar. 31, 
2011]



Sec. 524.1580d  [Reserved]



Sec. 524.1580e  Nitrofurazone ointment with butacaine sulfate.

    (a) Specifications. The drug contains 0.2 percent nitrofurazone and 
0.5 percent butacaine sulfate in a water-soluble base.
    (b) Sponsor. See No. 054925 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Indications for use. For prevention or 
treatment of surface bacterial infections of ears, wounds, burns, and 
cutaneous ulcers of dogs, cats, and horses.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (2) Limitations. Apply directly on the lesion with a spatula or 
first place on a piece of gauze. Use of a bandage is optional. The 
preparation should remain on the lesion for at least 24 hours. The 
dressing may be changed several times daily or left on the lesion for a 
longer period. For use only on dogs, cats, and horses (not for food 
use). In case of deep or puncture wounds or serious burns, use only as 
recommended by a veterinarian. If redness, irritation, or

[[Page 346]]

swelling persists or increases, discontinue use; consult 
---------------------------------------------------------------------------
veterinarian.\1\

[49 FR 9417, Mar. 13, 1984, as amended at 71 FR 13542, Mar. 16, 2006]



Sec. 524.1600  Nystatin ophthalmic and topical dosage forms.



Sec. 524.1600a  Nystatin, neomycin, thiostrepton, and triamcinolone 
acetonide ointment.

    (a) Specifications. Each milliliter of petrolatum base or each gram 
of vanishing cream base ointment contains: 100,000 units of nystatin; 
neomycin sulfate equivalent to 2.5 milligrams of neomycin base; 2,500 
units of thiostrepton; and 1.0 milligram of triamcinolone acetonide.
    (b) Sponsors. For petrolatum base ointments see 000069, 000856, 
025463, 053501, and 054925 in Sec. 510.600(c) of this chapter. For 
vanishing cream base ointments see Nos. 025463, 053501, and 054925.
    (c) Conditions of use--(1) Amount. (i) For topical dermatological 
use: Clean affected areas and remove any encrusted discharge or exudate, 
and apply sparingly either ointment in a thin film.
    (ii) For otic use: Clean ear canal of impacted cerumen, remove any 
foreign bodies such as grass awns and ticks, and instill three to five 
drops of petrolatum base ointment. Preliminary use of a local anesthetic 
may be advisable.
    (iii) For infected anal glands and cystic areas: Drain gland or cyst 
and fill with petrolatum base ointment.
    (2) Indications for use. (i) Topically: Use either ointment in dogs 
and cats for anti-inflammatory, antipruritic, antifungal, and 
antibacterial treatment of superficial bacterial infections, and for 
dermatologic disorders characterized by inflammation and dry or 
exudative dermatitis, particularly associated with bacterial or candidal 
(Candida albicans) infections.
    (ii) Otitis, cysts, and anal gland infections: Use petrolatum base 
ointment in dogs and cats for the treatment of acute and chronic otitis 
and interdigital cysts, and in dogs for anal gland infections.
    (3) Limitations. For mild inflammations, use once daily to once a 
week. For severe conditions, apply initially two to three times daily, 
decreasing frequency as improvement occurs. Not intended for treatment 
of deep abscesses or deep-seated infections. Not for ophthalmic use. 
Federal law restricts this drug to use by or on the order of a licensed 
veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 43 FR 29770, July 11, 1978; 
50 FR 41490, Oct. 11, 1985; 53 FR 39257, Oct. 6, 1988; 54 FR 5431, Feb. 
3, 1989; 54 FR 48090, Nov. 21, 1989; 56 FR 50653, Oct. 8, 1991; 60 FR 
55660, Nov. 2, 1995; 61 FR 63712, Dec. 2, 1996; 64 FR 42831, Aug. 6, 
1999; 67 FR 67521, Nov. 6, 2002; 68 FR 55201, Sept. 23, 2003; 70 FR 
50183, Aug. 26, 2005; 71 FR 13542, Mar. 16, 2006]



Sec. 524.1600b  Nystatin, neomycin, thiostrepton, and triamcinolone 
acetonide ophthalmic ointment.

    (a) Specifications. Each cubic centimeter of ointment contains: 
100,000 units of nystatin, neomycin sulfate equivalent to 2.5 milligrams 
of neomycin base, 2,500 units of thiostrepton, and 1.0 milligram of 
triamcinolone acetonide.
    (b) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is recommended for ophthalmic 
use as an anti-inflammatory, antipruritic, antifungal (Candida 
albicans), and antibacterial ointment for local therapy in keratitis and 
conjunctivitis in cats and dogs and for infectious kerato-conjunctivitis 
(pink eye) in cattle.
    (2) It is to be administered as follows:
    (i) For conjunctivitis and keratitis: Apply one drop of ointment to 
the affected eye(s) two or three times daily. Treatment may be continued 
for up to 2 weeks if necessary.
    (ii) For bovine infectious kerato-conjunctivitis: Apply small line 
of ointment to the affected eye(s) once daily. Treatment may be 
continued for up to 2 weeks if necessary.
    (iii) Frequency of administration is dependent on the severity of 
the condition. For mild inflammations, applications may range from once 
daily to once a week; for severe conditions the drug may be applied as 
often as two to three times daily. Frequency of treatment may be 
decreased as improvement occurs.

[[Page 347]]

    (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 50 FR 41490, Oct. 11, 1985]



Sec. 524.1610  Orbifloxacin, mometasone furoate monohydrate, and 
posaconazole suspension.

    (a) Specifications. Each gram of suspension contains 10 milligrams 
(mg) orbifloxacin, mometasone furoate monohydrate equivalent to 1 mg 
mometasone furoate, and 1 mg posaconazole.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. For dogs weighing less 
than 30 lbs. instill 4 drops once daily into the ear canal. For dogs 
weighing 30 lbs. or more, instill 8 drops into the ear canal. Therapy 
should continue for 7 consecutive days.
    (2) Indications for use. For the treatment of otitis externa 
associated with susceptible strains of yeast (Malassezia pachydermatis) 
and bacteria (coagulase-positive staphylococci, Pseudomonas aeruginosa, 
and Enterococcus faecalis).
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[75 FR 16346, Apr. 1, 2010]



Sec. 524.1662  Oxytetracycline hydrochloride ophthalmic and topical 
dosage forms.



Sec. 524.1662a  Oxytetracycline hydrochloride and hydrocortisone spray.

    (a) Specifications. Each 3-ounce unit of oxytetracycline 
hydrochloride and hydrocortisone spray contains 300 milligrams of 
oxytetracycline hydrochloride and 100 milligrams of hydrocortisone with 
an inert freon propellant such that a 1-second spray treatment will 
deliver approximately 2.5 milligrams of oxytetracycline hydrochloride 
and 0.8 milligram of hydrocortisone.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is indicated for relief of 
discomfort and continued treatment of many allergic, infectious, and 
traumatic skin conditions. The indications include prevention of 
bacterial infections in superficial wounds, cuts, and abrasions, 
treatment of allergic dermatoses, including urticaria, eczemas, insect 
bites, and cutaneous drug reactions, infections associated with minor 
burns and wounds, and nonspecific pruritus in dogs and cats.
    (2) A small quantity should be sprayed on the affected surface by 
holding the container about 6 inches from the area to be treated and 
pressing the nozzle for 1 or 2 seconds. Only sufficient spray to coat 
the skin thinly is necessary. The application of small amounts at 
frequent intervals will give best results. Before treating animals with 
long or matted hair, it may be necessary to clip the affected area or 
spread the hairs to allow the medication to contact the skin surface. 
Relief may be noted following the first or second treatment; however, 
treatment should not be discontinued too soon after the initial 
favorable response has been obtained.
    (3) Keep away from eyes or other mucous membranes; avoid inhaling; 
use with adequate ventilation; in case of deep or puncture wounds or 
serious burns, consult a veterinarian.



Sec. 524.1662b  Oxytetracycline hydrochloride, polymyxin B sulfate 
ophthalmic ointment.

    (a) Specifications. Each gram of the ointment contains 
oxytetracycline hydrochloride equivalent to 5 milligrams of 
oxytetracycline and 10,000 units of polymyxin B sulfate.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is used for the prophylaxis and 
local treatment of superficial ocular infections due to oxytetracycline- 
and polymyxin-sensitive organisms. These infections include the 
following: Ocular infections due to streptococci, rickettsiae, E. coli, 
and A. aerogenes (such as conjunctivitis, keratitis, pinkeye, corneal 
ulcer, and blepharitis in dogs, cats, cattle, sheep, and horses); ocular 
infections due to secondary bacterial complications associated with 
distemper in dogs; and ocular infections due to bacterial inflammatory 
conditions which may occur secondary to other infectious diseases in 
dogs, cats, cattle, sheep, and horses.

[[Page 348]]

    (2) It is administered topically to the eye two to four times daily.
    (3) Allergic reactions may occasionally occur. Treatment should be 
discontinued if reactions are severe. If new infections due to 
nonsensitive bacteria or fungi appear during therapy, appropriate 
measures should be taken.



Sec. 524.1742  N-(Mercaptomethyl) phthalimide S-(O,O-dimethyl 
phosphorodithioate) emulsifiable liquid.

    (a) Specifications. The emulsifiable liquid contains 11.6 percent N-
(mercaptomethyl) phthalimide S-(O,O- dimethyl phosphorodithioate).
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Methods of application. Methods of 
application to control the following conditions on beef cattle:

------------------------------------------------------------------------
                                              Dilution rate (gal. drug:
         To control/method of use                  gal. of water)
------------------------------------------------------------------------
Grubs:
  Dip.....................................  1:60
  Pour-on.................................  1:2
  Spray...................................  1:49
Lice:
  Dip.....................................  1:60
  Pour-on.................................  1:2 or 1:5
  Spray...................................  1:49 or 1:100
Hornflies:
  Dip.....................................  1:60
  Spray...................................  1:49 or 1:100
Cattle Ticks:
  Dip.....................................  1:60 or 1:240
  Spray...................................  1:49
Southern cattle ticks:
  Dip.....................................  1:60 or 1:240
  Spray...................................  1:49
Scabies mites:............................
  Dip.....................................  1:60
Lone Star Ticks:
  Dip.....................................  1:60
  Spray...................................  1:49 or 1:100
------------------------------------------------------------------------

    (i) Dip vat procedure. (a) Prior to charging vat, empty old contents 
and thoroughly clean the vat. Dip vats should be calibrated to maintain 
an accurate dilution. Add water, then drug to the vat according to the 
dilution rate indicated in the table. Add super phosphate at a rate of 
100 pounds per 1,000 gallons of vat solution. Super phosphate is added 
to control the pH of the solution and ensure vat stability. Super 
phosphate is usually available at most fertilizer dealers as 0-45-0 or 
0-46-0. Stir the dip thoroughly, preferably with a compressed air 
device; however, any form of thorough mixing is adequate. Re-stir vat 
contents prior to each use. During the dipping operation, each time the 
dip's volume is reduced by \1/8\ to \1/4\ of its initial volume, 
replenish with water and add the drug at a rate of 1 gallon for each 50 
or 200 gallons water added--depending on dilution rate 1:60 or 1:240. 
Also add super phosphate as necessary to maintain pH between 4.5 and 
6.5. Stir well and resume dipping. Repeat replenishment process as 
necessary. For evaportion, add additional water accordingly. For added 
water due to rainfall, merely replenish dip with the product according 
to directions. If overflow occurs, either analyze for drug concentration 
and adjust accordingly or dispose of vat contents and recharge. Check pH 
after each addition of water or super phosphate to assure proper pH 
controls.
    (b) Dip maintenance. (1) With use of dip vat tester, dipping may 
continue as long as the drug concentration is maintained between 0.15 
and 0.25 percent, and the dip is not too foul for satisfactory use as 
indicated by foul odor or excessive darkening (i.e., color changes from 
beige to very dark brown).
    (2) Without use of dip vat tester, vat should be emptied, cleaned, 
and recharged each time one of the following occurs: When the dip has 
been charged for 120 days; when the dip becomes too foul for 
satisfactory use, within the 120-day limit; if the number of animals 
dipped equals twice the number of gallons of the initial dip volume, 
within the 120-day limit.
    (ii) Spray method. To prepare the spray, mix drug with water 
according to table and stir thoroughly. Apply the fresh mixture as a 
high-pressure spray, taking care to wet the skin, not just the hair. 
Apply to the point of ``runoff,'' about 1 gallon of diluted spray per 
adult animal. Lesser amounts will permit runoff for younger animals.
    (iii) Pour-on method. Dilute the drug with water according to table 
by slowly adding water to the product while stirring. Apply 1 ounce of 
the diluted mixture per 100 pounds of body weight (to a maximum of 8 
ounces per head) down the center line of the back.
    (2) Timing of applications for cattle grub control. For optimum 
cattle grub control, it is important to treat as

[[Page 349]]

soon as possible after the heel fly season, before the grub larvae reach 
the gullet or spinal canal, as the rapid kill of large numbers of larvae 
in these tissues may cause toxic side effects, such as bloat, 
salivation, staggering, and paralysis.
    (3) Treatment regimens. (i) Control of scabies mites requires two 
treatments, 10 to 14 days apart.
    (ii) Control of Lone Star Ticks and hornflies requires two 
treatments, 7 days apart.
    (4) Warnings. The drug is a cholinesterase inhibitor. Do not use 
this drug on animals simultaneously or within a few days before or after 
treatment with or exposure to cholinesterase-inhibiting drugs, 
pesticides, or chemicals. Do not apply within 21 days of slaughter. For 
use on beef cattle only. Do not treat sick, convalescent, or stressed 
cattle, or calves less than 3 months old except in Federal or State 
eradication programs where immediate treatment of all animals in an 
infested herd is mandatory. Be sure free access to drinking water is 
available to cattle prior to dipping. Do not dip excessively thirsty 
animals. Do not dip animals when overheated. Repeat treatment as 
necessary but not more often than every 7 to 10 days. Treatment for 
lice, ticks, hornflies, and scabies mites may be made any time of the 
year except when cattle grub larvae are in the gullet or spinal canal. 
Treatment for lice, ticks, and scabies mites may be made any time 7 to 
10 days following treatment for grubs. Do not treat grubs when the grub 
larvae are in the gullet or spinal canal. Do not get in eyes, on skin, 
or on clothing. Do not breathe spray mist. Wear rubber gloves, goggles, 
and protective clothing. In case of skin contact, wash immediately with 
soap and water; for eyes, flush with water. Wash all contaminated 
clothing with soap and hot water before re-use.
    (d) Related tolerances. See 40 CFR 180.261.

[40 FR 13873, Mar. 27, 1975, as amended at 46 FR 27914, May 22, 1981; 48 
FR 39607, Sept. 1, 1983; 54 FR 51021, Dec. 12, 1989; 61 FR 8873, Mar. 6, 
1996; 62 FR 61626, Nov. 19, 1997; 63 FR 5255, Feb. 2, 1998]



Sec. 524.1881  Prednisolone acetate ophthalmic and topical dosage forms.



Sec. 524.1881a  [Reserved]



Sec. 524.1881b  Prednisolone acetate-neomycin sulfate sterile 
suspension.

    (a) Specifications. Prednisolone acetate-neomycin sulfate sterile 
suspension contains 2.5 milligrams of prednisolone acetate and 5 
milligrams of neomycin sulfate (equivalent to 3.5 milligrams of neomycin 
base) in each milliliter of sterile suspension.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is indicated for treating 
infectious, allergic and traumatic keratitis and conjunctivitis, acute 
otitis externa, and chronic otitis externa in dogs and cats.
    (2) For beginning treatment of acute ocular inflammations 1 or 2 
drops may be placed in the conjunctival sac 3 to 6 times during a 24 
hour period. When improvement occurs, the dosage may be reduced to 1 
drop 2 to 4 times daily. In otitis externa, 2 to 6 drops may be placed 
in the external ear canal 2 or 3 times daily.
    (3) All topical ophthalmic preparations containing corticosteroids 
with or without an anti-microbial agent are contraindicated in the 
initial treatment of corneal ulcers. They should not be used until 
infection is under control and corneal regeneration is well underway.
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.



Sec. 524.1883  Prednisolone sodium phosphate-neomycin sulfate 
ophthalmic ointment.

    (a) Specifications. Prednisolone sodium phosphate-neomycin sulfate 
ophthalmic ointment contains prednisolone sodium phosphate equivalent to 
2.5 milligrams prednisolone 21-phosphate and 5 milligrams neomycin 
sulfate (equivalent to 3.5 milligrams neomycin base) in each gram of 
ointment.
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is recommended for use in 
superficial ocular inflammations or infections limited to the 
conjunctiva or the anterior segment of the eye of cats and dogs,

[[Page 350]]

such as those associated with allergic reactions or gross irritants.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (2) A small quantity of the ointment should be expressed into the 
conjunctival sac 4 times a day (at intervals of 1 to 8 hours) for a few 
days until there is a favorable response, then the frequency of 
application may be reduced to twice daily as long as the condition 
remains under control. Treatment may require from a few days to several 
weeks.\1\
    (3) All topical ophthalmic preparations containing corticosteroids 
with or without an antimicrobial agent are contraindicated in the 
initial treatment of corneal ulcers. They should not be used until the 
infection is under control and corneal regeneration is well underway.\1\
    (4) For use only by or on the order of a licensed veterinarian.\1\

[40 FR 13873, Mar. 27, 1975, as amended at 62 FR 63271, Nov. 28, 1997]



Sec. 524.1982  Proparacaine hydrochloride ophthalmic solution.

    (a) Specifications. The drug is an aqueous solution containing 0.5 
percent proparacaine hydrochloride, 2.45 percent glycerin as a 
stabilizer, and 0.2 percent chlorobutanol (choral derivative) and 
1:10,000 benzalkonium chloride as preservatives.
    (b) Sponsor. See No. 053501 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. The longterm toxicity of proparacaine is 
unknown. Prolonged use may possibly delay wound healing.
    (d) Conditions of use. (1) The drug is indicated for use as a 
topical ophthalmic anesthetic in animals. It is used as an anesthetic in 
cauterization of corneal ulcers, removal of foreign bodies and sutures 
from the cornea, and measurement of intraocular pressure (tonometry) 
when glaucoma is suspected. Local applications may also be used as an 
aid in the removal of foreign bodies from the nose and ear canal, as an 
accessory in the examination and treatment of painful otitis, in minor 
surgery, and prior to catheterization.
    (2) It is administered as follows:
    (i) For removal of sutures: Instill one to two drops 2 or 3 minutes 
before removal of stitches.
    (ii) For removal of foreign bodies from eye, ear, and nose: For 
ophthalmic use, instill three to five drops in the eye prior to 
examination; for otic use, instill five to 10 drops in the ear; for 
nasal use, instill five to 10 drops in each nostril every 3 minutes for 
three doses.
    (iii) For tonometry: Instill one to two drops immediately before 
measurement.
    (iv) As an aid in treatment of otitis: Instill two drops into the 
ear every 5 minutes for three doses.
    (v) For minor surgery: Instill one or more drops as required.
    (vi) For catheterization: Instill two to three drops with a blunt 
20-gauge needle immediately before inserting catheter.
    (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13873, Mar. 27, 1975, as amended at 50 FR 41490, Oct. 11, 1985]



Sec. 524.2098  Selamectin.

    (a) Specifications. Each milliliter contains 60 or 120 milligrams of 
selamectin.
    (b) Sponsor. See 000069 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use--(1) Amount. 2.7 milligrams of selamectin, 
topically, per pound (6 milligrams per kilogram) of body weight.
    (2) Indications for use. Kills adult fleas and prevents flea eggs 
from hatching for 1 month, and it is indicated for the prevention and 
control of flea infestations (Ctenocephalides felis), prevention of 
heartworm disease caused by Dirofilaria immitis, and treatment and 
control of ear mite (Otodectes cynotis) infestations in dogs and cats. 
Treatment and control of sarcoptic mange (Sarcoptes scabiei) and control 
of tick (Dermacentor variabilis) infestations in dogs. Treatment and 
control of intestinal hookworm (Ancylostoma tubaeforme) and roundworm 
(Toxocara cati) infections in cats. For dogs 6

[[Page 351]]

weeks of age and older, and cats 8 weeks of age and older.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[64 FR 37401, July 12, 1999, as amended at 64 FR 48707, Sept. 8, 1999; 
65 FR 45282, July 21, 2000; 74 FR 19878, Apr. 30, 2009]



Sec. 524.2101  Selenium disulfide suspension.

    (a) Specifications. The product contains 0.9-percent weight in 
weight (w/w) selenium disulfide (1-percent weight in volume (w/v)).
    (b) Sponsors. See Nos. 000061, 017135, and 050604 in Sec. 
510.600(c) of this chapter.
    (c) Conditions of use on dogs--(1) Indications for use. For use as a 
cleansing shampoo and as an agent for removing skin debris associated 
with dry eczema, seborrhea, and nonspecific dermatoses.
    (2) Amount. One to 2 ounces per application.
    (3) Limitations. Use carefully around scrotum and eyes, covering 
scrotum with petrolatum. Allow the shampoo to remain for 5 to 15 minutes 
before thorough rinsing. Repeat treatment once or twice a week. If 
conditions persist or if rash or irritation develops, discontinue use 
and consult a veterinarian.

[47 FR 53351, Nov. 26, 1982, as amended at 48 FR 32762, July 19, 1983; 
54 FR 36962, Sept. 6, 1989; 56 FR 9623, Mar. 7, 1991; 58 FR 41025, Aug. 
2, 1993; 63 FR 26981, May 15, 1998; 70 FR 50183, Aug. 26, 2005]



Sec. 524.2350  Tolnaftate cream.

    (a) Specifications. The drug contains 1 percent tolnaftate (2-
naphthyl-N-methyl-N-(3-tolyl) thionocarbamate) in an anhydrous cream 
base.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. (1) The drug is indicated for treatment of 
ringworm lesions due to Microsporum canis and Microsporum gypseum in 
dogs and cats.
    (2) A small amount of the cream is applied to the affected areas 
once or twice a day for 2 to 4 weeks. The areas to be treated are first 
cleared of exudate and the hair clipped if the areas are not already 
denuded. The cream is massaged into each lesion and immediate 
surrounding area until the cream is no longer visible.
    (3) If no response is seen after 2 weeks of treatment with the drug 
the diagnosis should be reviewed.
    (4) Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[43 FR 29289, July 7, 1978, as amended at 52 FR 7833, Mar. 13, 1987]



Sec. 524.2482  Triamcinolone spray.

    (a) Specifications. Each milliliter of solution contains 0.15 
milligrams triamcinolone acetonide.
    (b) Sponsor. See No. 051311 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Apply sufficient pump 
sprays to uniformly and thoroughly wet the affected areas while avoiding 
run off of excess product. Administer twice daily for 7 days, then once 
daily for 7 days, then every other day for an additional 14 days (28 
days total).
    (2) Indications for use. For the control of pruritus associated with 
allergic dermatitis.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[68 FR 4916, Jan. 31, 2003, as amended at 78 FR 17868, Mar. 25, 2013]



Sec. 524.2483  Triamcinolone cream.

    (a) Specifications. The vanishing cream contains 0.1 percent 
triamcinolone acetonide.
    (b) Sponsor. See Nos. 000010 and 054925 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use in dogs--(1) Amount. Rub into affected areas 
two to four times daily for 4 to 10 days.
    (2) Indications for use. For topical treatment of allergic 
dermatitis and summer eczema.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[71 FR 13542, Mar. 16, 2006, as amended at 73 FR 79318, Dec. 29, 2008. 
Redesignated and amended at 75 FR 10168, Mar. 5, 2010; 77 FR 60302, Oct. 
3, 2012]



Sec. 524.2620  Liquid crystalline trypsin, Peru balsam, castor oil.

    (a)(1) Specifications. The drug is a liquid for direct application 
or an aerosol preparation formulated so that each

[[Page 352]]

gram delivered to the wound site contains 0.12 milligram of crystalline 
trypsin, 87.0 milligrams of Peru balsam, and 788.0 milligrams of castor 
oil.
    (2) Sponsor. See No. 051079 in Sec. 510.600(c) of this chapter.
    (b)(1) Specifications. The drug is a liquid for direct application 
or an aerosol preparation formulated so that each gram delivered to the 
wound site contains 0.1 milligram of crystalline trypsin, 72.5 
milligrams of Peru balsam, and 800 milligrams of castor oil.
    (2) Sponsor. See No. 017135 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. The drug is used as an aid in the treatment 
of external wounds and assists healing by facilitating the removal of 
necrotic tissue, exudate and organic debris.

[40 FR 13873, Mar. 27, 1975, as amended at 41 FR 56307, Dec. 28, 1976; 
50 FR 9800, Mar. 12, 1985; 54 FR 25565, June 16, 1989; 56 FR 37474, Aug. 
7, 1991; 66 FR 46369, Sept. 5, 2001; 72 FR 36595, July 5, 2007]



PART 526_INTRAMAMMARY DOSAGE FORM NEW ANIMAL DRUGS--Table of Contents



Sec.
526.88 Amoxicillin trihydrate for intramammary infusion.
526.313 Ceftiofur.
526.363 Cephapirin benzathine.
526.365 Cephapirin sodium.
526.464 Cloxacillin intramammary dosage forms.
526.464a Cloxacillin benzathine.
526.464b Cloxacillin benzathine for intramammary infusion, sterile.
526.464c Cloxacillin sodium for intramammary infusion, sterile.
526.464d Cloxacillin sodium for intramammary infusion.
526.820 Erythromycin.
526.1130 Hetacillin potassium for intramammary infusion.
526.1590 Novobiocin oil suspension.
526.1696 Penicillin intramammary dosage forms.
526.1696a Penicillin G procaine.
526.1696b Penicillin G procaine-dihydrostreptomycin in soybean oil for 
          intramammary infusion (dry cows).
526.1696c Penicillin G procaine-dihydrostreptomycin sulfate for 
          intramammary infusion (dry cows).
526.1696d Penicillin G procaine-novobiocin for intramammary infusion.
526.1810 Pirlimycin.

    Authority: 21 U.S.C. 360b.



Sec. 526.88  Amoxicillin trihydrate for intramammary infusion.

    (a) Specifications. Each single dose syringe contains amoxicillin 
trihydrate equivalent to 62.5 milligrams of amoxicillin.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.38 of this chapter.
    (d) Conditions of use--Lactating cows--(1) Amount. One syringe 
(equivalent to 62.5 milligrams amoxicillin) per quarter.
    (2) Indications for use. For the treatment of subclinical infectious 
bovine mastitis due to Streptococcus agalactiae and Straphylococcus 
aureus (penicillin sensitive).
    (3) Limitations. Administer after milking. Clean and disinfect the 
teat. Use one syringe per infected quarter every 12 hours for a maximum 
of 3 doses. Do not use milk taken from treated animals for food purposes 
within 60 hours (5 milkings) after last treatment. Do not slaughter 
treated animals for food purposes within 12 days after the last 
treatment. Federal law restricts this drug to use by or on the order of 
a licensed veterinarian.

[57 FR 37334, Aug. 18, 1992, as amended at 60 FR 55660, Nov. 2, 1995; 68 
FR 44878, July 31, 2003]



Sec. 526.313  Ceftiofur.

    (a) Specifications. Each single-use, 10-milliliter syringe of 
ceftiofur hydrochloride suspension contains 125 milligrams (mg) or 500 
mg ceftiofur equivalents.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.113 of this chapter.
    (d) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (e) Conditions of use in cattle--(1) Lactating cows--(i) Amount. 
Infuse 125 mg per affected quarter. Repeat treatment in 24 hours. Once 
daily treatment may be repeated for up to 8 consecutive days.
    (ii) Indications for use. For the treatment of clinical mastitis in 
lactating dairy cattle associated with coagulase-negative staphylococci, 
Streptococcus dysgalactiae, and Escherichia coli.

[[Page 353]]

    (iii) Limitations. Milk taken from cows during treatment (a maximum 
of eight daily infusions) and for 72 hours after the last treatment must 
not be used for human consumption. Following label use for up to 8 
consecutive days, a 2-day pre-slaughter withdrawal period is required.
    (2) Dry cows--(i) Amount. Infuse 500 mg per affected quarter at the 
time of dry off.
    (ii) Indications for use. For the treatment of subclinical mastitis 
in dairy cattle at the time of dry off associated with Staphylococcus 
aureus, Streptococcus dysgalactiae, and Streptococcus uberis.
    (iii) Limitations. Milk taken from cows completing a 30-day dry off 
period may be used for food with no milk discard due to ceftiofur 
residues. Following intramammary infusion, a 16-day pre-slaughter 
withdrawal period is required for treated cows. Following label use, no 
preslaughter withdrawal period is required for neonatal calves from 
treated cows regardless of colostrum consumption.

[70 FR 9516, Feb. 28, 2005, as amended at 70 FR 20048, Apr. 18, 2005. 
Redesignated and amended at 71 FR 39545, July 13, 2006]



Sec. 526.363  Cephapirin benzathine.

    (a) Specifications. Each 10 milliliter disposable syringe contains 
300 milligrams of cephapirin activity (as cephapirin benzathine) in a 
peanut-oil gel.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.115 of this chapter.
    (d) Conditions of use--(1) Amount. Infuse the contents of one 
syringe into each quarter.
    (2) Indications for use. Use in dry cows for treatment of mastitis 
caused by susceptible strains of Streptococcus agalactiae and 
Staphylococcus aureus, including penicillin-resistant strains.
    (3) Limitations. Infuse each quarter following last milking, but no 
later than 30 days before calving. Milk from treated cows must not be 
used for food during the first 72 hours after calving. Animals infused 
with this product must not be slaughtered for food until 42 days after 
the latest infusion. For use in dry cows only.

[43 FR 37174, Aug. 22, 1978, as amended at 53 FR 27851, July 25, 1988; 
73 FR 12262, Mar. 7, 2008; 75 FR 10168, Mar. 5, 2010; 76 FR 17338, Mar. 
29, 2011]



Sec. 526.365  Cephapirin sodium.

    (a) Specifications. Each 10-milliliter dose contains 200 milligrams 
of cephapirin sodium activity in a peanut-oil gel.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.115 of this chapter.
    (d) Conditions of use in lactating cows--(1) Amount. Infuse one dose 
into each infected quarter immediately after the quarter has been 
completely milked out. Do not milk out for 12 hours. Repeat once only in 
12 hours.
    (2) Indications for use. For the treatment of mastitis in lactating 
cows caused by susceptible strains of Streptococcus agalactiae and 
Staphylococcus aureus including strains resistant to penicillin.
    (3) Limitations. If improvement is not noted within 48 hours after 
treatment, consult your veterinarian. Milk that has been taken from 
animals during treatment and for 96 hours after the last treatment must 
not be used for food. Treated animals must not be slaughtered for food 
until 4 days after the last treatment.

[40 FR 57455, Dec. 10, 1975, as amended at 53 FR 27852, July 25, 1988. 
Redesignated at 63 FR 8349, Feb. 19, 1998; 65 FR 20733, Apr. 18, 2000; 
73 FR 3181, Jan. 17, 2008; 75 FR 10168, Mar. 5, 2010]



Sec. 526.464  Cloxacillin intramammary dosage forms.



Sec. 526.464a  Cloxacillin benzathine.

    (a) Specifications. Each dose contains cloxacillin benzathine 
equivalent to 500 milligrams of cloxacillin.
    (b) Related tolerances. See Sec. 556.165 of this chapter.
    (c) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter for 
use in dairy cows.
    (1) Amount. Administer aseptically into each quarter immediately 
after last milking.

[[Page 354]]

    (2) Indications for use. For the treatment of mastitis caused by 
Staphylococcus aureus and Streptococcus agalactiae including penicillin 
resistant strains in dairy cows during the dry period.
    (3) Limitations. For use in dry cows only. Not to be used within 30 
days of calving. Animals infused with this product must not be 
slaughtered for food use for 30 days after the latest infusion. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.
    (d) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter for 
use in dairy cows.
    (1) Amount. Administer one dose in each quarter immediately after 
last milking.
    (2) Indications for use. Treatment and prophylaxis of bovine 
mastitis in nonlactating cows due to S. agalactiae and S. aureus.
    (3) Limitations. For use in dry cows only. Not to be used within 4 
weeks (28 days) of calving. Animals infused with this product must not 
be slaughtered for food use for 4 weeks (28 days) after the latest 
infusion. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[57 FR 37334, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992, as amended at 
60 FR 55660, Nov. 2, 1995; 75 FR 10168, Mar. 5, 2010; 75 FR 71017, Nov. 
22, 2010]



Sec. 526.464b  Cloxacillin benzathine for intramammary infusion, sterile.

    (a) Specifications. Each 6 milliliter dose contains cloxacillin 
benzathine equivalent to 500 milligrams of cloxacillin.
    (b) Related tolerances. See Sec. 556.165 of this chapter.
    (c) Sponsor. See No. 055529 in Sec. 510.600(c) of this chapter.
    (1) Amount. 6 milliliters per infected quarter aseptically 
immediately after last milking at the time of drying-off of the cow.
    (2) Indications for use. Treatment of mastitis caused by 
Staphylococcus aureus and Streptococus agalactiae in dairy cows at the 
time of drying-off of the cow.
    (3) Limitations. For use in dry cows only. Not to be used within 30 
days of calving. Milk taken from treated cows prior to 72 hours (6 
milkings) after calving must not be used for human food. Animals infused 
with this product must not be slaughtered for food from the time of 
infusion until 72 hours after calving. Federal law restricts this drug 
to use by or on the order of a licensed veterinarian.
    (d) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (1) Amount. One dose per infected quarter immediately after last 
milking.
    (2) Indications for use. Treatment and prophylaxis of bovine 
mastitis in nonlactating cows due to Streptococcus agalactiae and 
Staphylococcus aureus.
    (3) Limitations. For use in dry cows only. Not to be used within 4 
weeks (28 days) of calving. Animals infused with this product must not 
be slaughtered for food use for 4 weeks (28 days) after the latest 
infusion. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[57 FR 37334, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992, as amended at 
58 FR 61016, Nov. 19, 1993; 60 FR 55660, Nov. 2, 1995; 68 FR 44878, July 
31, 2003]



Sec. 526.464c  Cloxacillin sodium for intramammary infusion, sterile.

    (a) Specifications. Each milliliter contains cloxacillin sodium 
equivalent to 20.0 milligrams of cloxacillin.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.165 of this chapter.
    (d) Conditions of use. Lactating cows--(1) Amount. 10 milliliters 
(one dose of 200 milligrams) per infected quarter.
    (2) Indications for use. Treatment of mastitis in lactating cows due 
to Streptococcus agalactiae and Staphylococcus aureus, nonpenicillinase-
producing strains.
    (3) Limitations. Administer after milking, cleaning, and 
disinfecting, and as early as possible after detection. Treatment should 
be repeated at 12-hour intervals for a total of three doses. Milk taken 
from treated animals within 48 hours (four milkings) after the latest 
treatment should not be used for food. Treated animals should not be 
slaughtered for food within 10 days after the latest treatment. Federal 
law

[[Page 355]]

restricts this drug to use by or on the order of a licensed 
veterinarian.

[57 FR 37335, Aug. 18, 1992, as amended at 60 FR 55660, Nov. 2, 1995; 68 
FR 44878, July 31, 2003]



Sec. 526.464d  Cloxacillin sodium for intramammary infusion.

    (a) Specifications. Each milliliter contains cloxacillin sodium 
equivalent 20.0 milligrams of cloxacillin.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.165 of this chapter.
    (d) Conditions for use. Lactating cows--(1) Amount. 10 milliliters 
(one dose of 200 milligrams) per infected quarter.
    (2) Indications for use. Treatment of mastitis in lactating cows due 
to Streptococcus agalactiae and Staphylococcus aureus, nonpenicillinase-
producing strains.
    (3) Limitations. Administer after milking, cleaning, and 
disinfecting, and as early as possible after detection. Treatment should 
be repeated at 12-hour intervals for a total of three doses. Milk taken 
from treated animals within 48 hours (4 milkings) after the latest 
treatment should not be used for food. Treated animals should not be 
slaughtered for food within 10 days after the latest treatment. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.

[57 FR 37335, Aug. 18, 1992, as amended at 60 FR 55660, Nov. 2, 1995]



Sec. 526.820  Erythromycin.

    (a) Specifications. (1) Each 6-milliliter, single-dose, disposable 
syringe contains 300 milligrams of erythromycin (as the base), 0.45 
milligram of butylated hydroxyanisole, and 0.45 milligram of butylated 
hydroxytoluene.
    (2) Each 12-milliliter, single-dose, disposable syringe contains 600 
milligrams of erythromycin (as the base), 0.90 milligram of butylated 
hydroxyanisole, and 0.90 milligram of butylated hydroxytoluene.
    (3) The vehicle is triglyceride of saturated fatty acids from 
coconut oil.
    (4) The drug may or may not be sterile.
    (b) Sponsor. See No. 061623 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. (i) Lactating cows: After 
milking, cleaning, and disinfecting, infuse contents of a single 6-
milliliter syringe into each infected quarter; repeat procedure at 12-
hour intervals for a maximum of 3 consecutive infusions.
    (ii) Dry cows: After milking, cleaning, and disinfecting, infuse 
contents of a single 12-milliliter syringe into each infected quarter at 
the time of drying off.
    (2) Indications for use. Treatment of mastitis due to Staphylococcus 
aureus, Streptococcus agalactiae, Streptococcus dysgalactiae, and 
Streptococcus uberis in lactating or dry cows.
    (3) Limitations. Milk taken from animals during treatment and for 36 
hours (3 milkings) after the latest treatment must not be used for food.

[47 FR 15772, Apr. 13, 1982, as amended at 66 FR 14074, Mar. 9, 2001; 68 
FR 4915, Jan. 31, 2003]



Sec. 526.1130  Hetacillin potassium for intramammary infusion.

    (a) Specifications. Each 10 milliliter syringe contains hetacillin 
potassium equivalent of 62.5 milligrams of ampicillin.
    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use. Lactating cows--(1) Amount. 10 milliliters of 
hetacillin potassium equivalent to 62.5 milligrams ampicillin into each 
infected quarter. Repeat at 24-hour intervals until a maximum of three 
treatments has been given.
    (2) Indications for use. Treating acute, chronic, or subclinical 
bovine mastitis in lactating cows caused by susceptible strains of 
Streptococcus agalactiae, Streptococcus dysgalactiae, Staphylococcus 
aureus, and Escherichia coli.
    (3) Limitations. Milk that has been taken from animals during 
treatment and for 72 hours (6 milkings) after the latest treatment must 
not be used for food. Treated animals must not be slaughtered for food 
until 10 days after the latest treatment. Federal law restricts this 
drug to use by or on the order of a licensed veterinarian.

[57 FR 37335, Aug. 18, 1992, as amended at 75 FR 10168, Mar. 5, 2010]

[[Page 356]]



Sec. 526.1590  Novobiocin oil suspension.

    (a)(1) Specifications. Each 10 milliliters of oil suspension 
contains the equivalent of 400 milligrams of novobiocin (present as 
sodium novobiocin).
    (2) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (3) Related tolerances. See Sec. 556.460 of this chapter.
    (4) Conditions of use--(i) Amount. Ten milliliters (equivalent to 
400 milligrams of novobiocin) infused in each quarter.
    (ii) Indications for use. It is used in dry cows for the treatment 
of mastitis caused by susceptible strains of Staphylococcus aureus and 
Streptococcus agalactiae.
    (iii) Limitations. Infuse each quarter at the time of drying off, 
but not less than 30 days prior to calving. Do not slaughter treated 
animals for food use for 30 days following udder infusion. For udder 
installation for the treatment of mastitis in dry cows only.
    (b)(1) Specifications. Each 10 milliliters of oil suspension 
contains the equivalent of 150 milligrams of novobiocin (present as 
sodium novobiocin).
    (2) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (3) Related tolerances. See Sec. 556.460 of this chapter.
    (4) Conditions of use--(i) Amount. Infuse 10 milliliters (equivalent 
to 150 milligrams of novobiocin) in each quarter after milking. Repeat 
treatment once after 24 hours.
    (ii) Indications for use. Use in lactating cows for treatment of 
mastitis caused by susceptible strains of Staphylococcus aureus.
    (iii) Limitations. Do not milk for at least 6 hours after treatment; 
afterwards, milk at regular intervals. Milk taken from treated animals 
within 72 hours (6 milkings) after latest treatment must not be used for 
food. Do not slaughter treated animals for food for 15 days following 
latest treatment. If redness, swelling, or abnormal milk persists or 
increases after treatment, discontinue use and consult a veterinarian. 
For udder instillation in lactating cattle only. Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.

[43 FR 10554, Mar. 14, 1978]



Sec. 526.1696  Penicillin intramammary dosage forms.



Sec. 526.1696a  Penicillin G procaine.

    (a) Specifications. Each 10-milliliter single-dose syringe contains 
penicillin G procaine equivalent to 100,000 units of penicillin G.
    (b) Related tolerances. See Sec. 556.510 of this chapter.
    (c) Sponsors. See Nos. 010515 and 061623 in Sec. 510.600(c) of this 
chapter.
    (d) Conditions of use in lactating cows--(1) Amount. Infuse one 10-
milliliter dose into each infected quarter. Treatment may be repeated at 
12-hour intervals for not more than three doses, as indicated by 
clinical response.
    (2) Indications for use. For the treatment of mastitis caused by 
Streptococcus agalactiae, S. dysgalactiae, and S. uberus in lactating 
cows.
    (3) Limitations. Milk that has been taken from animals during 
treatment and for 60 hours after the latest treatment must not be used 
for food. Animals must not be slaughtered for food during treatment or 
within 3 days after the latest treatment.
    (e) Conditions of use in dry cows--(1) Amount. Infuse one 10-
milliliter dose into each infected quarter at time of drying-off.
    (2) Indications of use. For the treatment of mastitis caused by 
Streptococcus agalactiae in dry cows.
    (3) Limitations. Discard all milk for 72 hours (6 milkings) 
following calving, or later as indicated by the marketable quality of 
the milk. Animals must not be slaughtered for food within 14 days 
postinfusion.

[73 FR 18442, Apr. 4, 2008, as amended at 74 FR 18990, Apr. 27, 2009]



Sec. 526.1696b  Penicillin G procaine-dihydrostreptomycin in soybean 
oil for intramammary infusion (dry cows).

    (a) Specifications. Each 10 milliliters of suspension contains 
penicillin G procaine equivalent to 200,000 units of penicillin G and 
dihydrostreptomycin sulfate equivalent to 300 milligrams of 
dihydrostreptomycin.

[[Page 357]]

    (b) Sponsor. See No. 000010 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. Sec. 556.200 and 556.510 of this 
chapter.
    (d) Conditions of use. Dairy cows--(1) Amount. One syringe into each 
quarter at the last milking prior to drying off.
    (2) Indications for use. Intramammary treatment of subclinical 
mastitis in dairy cows at the time of drying off, specifically against 
infections caused by Staphylococcus aureus and Streptococcus agalactiae.
    (3) Limitations. Not to be used within 6 weeks of calving. For use 
in dry cows only. Milk taken from cows within 24 hours (2 milkings) 
after calving must not be used for food. Animals infused with this drug 
must not be slaughtered for food within 60 days of treatment nor within 
24 hours after calving.

[57 FR 37336, Aug. 18, 1992]



Sec. 526.1696c  Penicillin G procaine-dihydrostreptomycin sulfate 
for intramammary infusion (dry cows).

    (a) Specifications. Each 10 milliliters of suspension contains 
penicillin G procaine equivalent to 1 million units of penicillin G and 
dihydrostreptomycin sulfate equivalent to 1 gram of dihydrostreptomycin.
    (b) Sponsor. See No. 033392 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. Sec. 556.200 and 556.510 of this 
chapter.
    (d) Conditions of use. Dairy cows--(1) Amount. One syringe per 
quarter at the last milking prior to drying off.
    (2) Indications for use. Intramammary use to reduce the frequency of 
existing infection and to prevent new infections with Staphylococcus 
aureus in dry cows.
    (3) Limitations. Not to be used within 6 weeks of freshening. Not 
for use in lactating cows. Milk taken from animals within 96 hours (8 
milkings) after calving must not be used for feed. Animals infused with 
this drug must not be slaughtered for food within 60 days from the time 
of infusion nor within 96 hours after calving. Federal law restricts 
this drug to use by or on the order of a licensed veterinarian.

[57 FR 37336, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992]



Sec. 526.1696d  Penicillin G procaine-novobiocin for intramammary 
infusion.

    (a) Specifications. For lactating cattle: each 10-milliliter dose 
contains 100,000 units of penicillin G procaine and 150 milligrams of 
novobiocin as novobiocin sodium. For dry cows: 200,000 units of 
penicillin G procaine and 400 milligrams of novobiocin as novobiocin 
sodium.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Lactating cows--(i) Amount. 10 
milliliters in each infected quarter after milking. Repeat once after 24 
hours.
    (ii) Indications for use. Treating lactating cows for mastitis 
caused by susceptible strains of Staphylococcus aureus, Streptococcus 
agalactiae, Streptococcus dysgalactiae, and Streptococcus uberis.
    (iii) Limitations. For udder instillation in lactating cattle only. 
Do not milk for at least 6 hours after treatment; thereafter, milk at 
regular intervals. Milk taken from treated animals within 72 hours (6 
milkings) after the latest treatment must not be used for food. Treated 
animals must not be slaughtered for food for 15 days following the 
latest treatment. If redness, swelling, or abnormal milk persists, 
discontinue use and consult a veterinarian.
    (2) Dry cows--(i) Amount. 10 milliliters in each quarter at time of 
drying off.
    (ii) Indications for use. Treatment of subclinical mastitis caused 
by susceptible strains of Staphylococcus aureus and Streptococcus 
agalactiae.
    (iii) Limitations. For udder instillation in dry cows only. Do not 
use less than 30 days prior to calving. Milk from treated cows must not 
be used for food during the first 72 hours after calving. Treated 
animals must not be slaughtered for food for 30 days following udder 
infusion.

[57 FR 37336, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992]



Sec. 526.1810  Pirlimycin.

    (a) Specifications. Each 10-milliliter syringe contains 50 
milligrams (mg) pirlimycin (as pirlimycin hydrochloride).

[[Page 358]]

    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.515 of this chapter.
    (d) Conditions of use in cattle--(1) Amount. Infuse 50 mg into each 
infected quarter. Repeat treatment after 24 hours. Daily treatment may 
be repeated at 24-hour intervals for up to 8 consecutive days.
    (2) Indications for use. For the treatment of clinical and 
subclinical mastitis in lactating dairy cattle associated with 
Staphylococcus species such as Staphylococcus aureus and Streptococcus 
species such as Streptococcus agalactiae, Streptococcus dysgalactiae, 
and Streptococcus uberis.
    (3) Limitations. Milk taken from animals during treatment and for 36 
hours following the last treatment must not be used for food regardless 
of treatment duration. Following infusion twice at a 24-hour interval, 
treated animals must not be slaughtered for 9 days. Following any 
extended duration of therapy (infusion longer than twice at a 24-hour 
interval, up to 8 consecutive days), animals must not be slaughtered for 
21 days. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.

[58 FR 58486, Nov. 2, 1993, as amended at 65 FR 61091, Oct. 16, 2000; 73 
FR 811, Jan. 4, 2008]



PART 528_NEW ANIMAL DRUGS IN GENETICALLY ENGINEERED ANIMALS--Table of 
Contents



    Authority: 21 U.S.C. 360b.

    Source: 74 FR 6823, Feb. 11, 2009, unless otherwise noted.



Sec. 528.1070  Bc6 recombinant deoxyribonucleic acid construct.

    (a) Specifications and indications for use. Five copies of a human 
Bc6 recombinant deoxyribonucleic acid (rDNA) construct located at the 
GTC 155-92 site in a specific hemizygous diploid line of dairy breeds of 
domestic goats (Capra aegagrus hircus) directing the expression of the 
human gene for antithrombin (which is intended for the treatment of 
humans) in the mammary gland of goats derived from lineage progenitor 
155-92.
    (b) Sponsor. See No. 042976 in Sec. 510.600 of this chapter.
    (c) Limitations. Food or feed from GTC-155-92 goats is not permitted 
in the food or feed supply.



PART 529_CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS--Table of Contents



Sec.
529.40 Albuterol.
529.56 Amikacin.
529.400 Chlorhexidine tablets and suspension.
529.536 Detomidine.
529.1030 Formalin.
529.1044 Gentamicin sulfate in certain other dosage forms.
529.1044a Gentamicin sulfate intrauterine solution.
529.1044b Gentamicin sulfate solution.
529.1115 Halothane.
529.1150 Hydrogen peroxide.
529.1186 Isoflurane.
529.1350 Meloxicam.
529.1660 Oxytetracycline.
529.1940 Progesterone intravaginal inserts.
529.2150 Sevoflurane.
529.2464 Ticarcillin powder.
529.2503 Tricaine methanesulfonate.
529.2620 Triptorelin.

    Authority: 21 U.S.C. 360b.

    Source: 40 FR 13881, Mar. 27, 1975, unless otherwise noted.



Sec. 529.40  Albuterol.

    (a) Specifications. A net weight of 6.7 grams of formulated 
albuterol sulfate is supplied in a pressurized aluminum canister within 
an actuator system equipped with a detachable nasal delivery bulb.
    (b) Approvals. See No. 000010 in Sec. 510.600(c) of this chapter 
for uses as in paragraph (d) of this section.
    (c) Special considerations. Federal law restricts this drug to use 
by or on the order of a licensed veterinarian.
    (d) Conditions of use--(1) Amount. Each valve actuation (puff) of 
the device delivers 120 micrograms (mcg) of albuterol sulfate. One dose 
is three (3) puffs, totaling 360 mcg.
    (2) Indications for use. For the immediate relief of bronchospasm 
and bronchoconstriction associated with reversible airway obstruction in 
horses.

[[Page 359]]

    (3) Limitations. Not for use in horses intended for food.

[67 FR 7072, Feb. 15, 2002]



Sec. 529.56  Amikacin.

    (a) Specifications. Each milliliter (mL) of solution contains 250 
milligrams of amikacin as amikacin sulfate.
    (b) Sponsors. See Nos. 000856 and 000859 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use in horses--(1) Amount. Administer 2 grams (8 
mL) diluted with 200 mL of sterile physiological saline by intrauterine 
infusion daily for 3 consecutive days.
    (2) Indications for use. For treating genital tract infections 
(endometritis, metritis, and pyometra) in mares caused by susceptible 
organisms including Escherichia coli, Pseudomonas spp., and Klebsiella 
spp.
    (3) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[76 FR 17339, Mar. 29, 2011, as amended at 78 FR 17597, Mar. 22, 2013]



Sec. 529.400  Chlorhexidine tablets and suspension.

    (a) Specification. Each tablet and each 28-milliliter syringe of 
suspension contain 1 gram of chlorhexidine dihydrochloride.\1\
---------------------------------------------------------------------------

    \1\ These conditions are NAS/NRC reviewed and deemed effective. 
Applications for these uses need not include effectiveness data as 
specified by Sec. 514.111 of this chapter, but may require 
bioequivalency and safety information.
---------------------------------------------------------------------------

    (b) Sponsor. See No. 000856 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. Place 1 or 2 tablets deep in each 
uterine horn; or infuse a solution of 1 tablet disolved in an 
appropriate amount of clean boiled water; or infuse one syringe of 
suspension into the uterus.\1\
    (2) Indications for use. For prevention or treatment of metritis and 
vaginitis in cows and mares when caused by pathogens sensitive to 
chlorhexidine dihydrochloride.\1\
    (3) Limitations. Prior to administration, remove any unattached 
placental membranes, any excess uterine fluid or debris, and carefully 
clean external genitalia. Use a clean, sterile inseminating pipette for 
administrating solutions and suspensions. Treatment may be repeated in 
48 to 72 hours.\1\

[43 FR 10705, Feb. 23, 1979]



Sec. 529.536  Detomidine.

    (a) Specifications. Each milliliter of gel contains 7.6 milligrams 
(mg) of detomidine hydrochloride.
    (b) Sponsor. See No. 052483 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in horses--(1) Amount. Administer 0.018 mg per 
pound (mg/lb) (0.040 mg/kilogram (kg) sublingually.
    (2) Indications for use. For sedation and restraint.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian. Do not use in horses intended for 
human consumption.

[75 FR 21163, Apr. 23, 2010, as amended at 76 FR 16533, Mar. 24, 2011]



Sec. 529.1030  Formalin.

    (a) Specifications. Formalin is an aqueous solution containing 
approximately 37 percent by weight of formaldehyde gas, U.S.P.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
uses as in paragraph (d) of this section.
    (1) Nos. 049968, 050378, and 067188 for use as in paragraphs 
(d)(1)(iii), (d)(1)(iv), (d)(1)(v), (d)(2)(iii), (d)(2)(iv), (d)(2)(v), 
and (d)(3).
    (2) No. 051212 for use as in paragraphs (d)(1)(i), (d)(1)(ii), 
(d)(2)(i), (d)(2)(ii), and (d)(3).
    (c) [Reserved]
    (d) Conditions of use. It is added to environmental water as 
follows:
    (1) Indications for use. (i) Select finfish. For control of external 
protozoa Ichthyophthirius spp., Chilodonella spp., Ichthyobodo spp., 
Ambiphrya spp., Epistylis spp., and Trichodina spp., and monogenetic 
trematodes Cleidodiscus spp., Gyrodactylus spp., and Dactylogyrus spp., 
on salmon, trout, catfish, largemouth bass, and bluegill.
    (ii) Select finfish eggs. For control of fungi of the family 
Saprolegniaceae on salmon, trout, and esocid eggs.
    (iii) Penaeid shrimp. For control of external protozoan parasites 
Bodo spp., Epistylis spp., and Zoothamnium spp.

[[Page 360]]

    (iv) All finfish. For control of external protozoa Ichthyophthirius 
spp., Chilodonella spp., Ichthyobodo spp., Ambiphrya spp., Epistylis 
spp., and Trichodina spp., and monogenetic trematodes Cleidodiscus spp., 
Gyrodactylus spp., and Dactylogyrus spp.
    (v) All finfish eggs: For control of fungi of the family 
Saprolegniaceae.
    (2) Amount. The drug concentrations required are as follows:
    (i) For control of external parasites on select finfish:

------------------------------------------------------------------------
                                          Concentration of formalin
                                           (microliters per liter)
                                   -------------------------------------
               Fish                  Tanks and raceways
                                      (for up to 1 hour    Earthen ponds
                                           daily)         (indefinitely)
------------------------------------------------------------------------
Salmon and trout:
    Above 50 [deg]F...............  Up to 170...........          15-25
    Below 50 [deg]F...............  Up to 250...........          15-25
    Catfish, largemouth bass, and   Up to 250...........      \1\ 15-25
     bluegill.
------------------------------------------------------------------------
\1\ Use the lower concentrations when pond is heavily loaded with fish
  or phytoplankton.

    (ii) For control of fungi of the Saprolegniaceae on salmon, trout, 
and esocid eggs: Apply in constant flow water supply of incubating 
facilities for 15 minutes. Concentration of formalin used is 1,000 to 
2,000 microliters per liter.
    (iii) For control of external protozoan parasites on shrimp:

------------------------------------------------------------------------
                                  Concentration of formalin (microliters
                                                per liter)
                                 ---------------------------------------
             Shrimp               Tanks and raceways
                                    (up to 4 hours       Earthen ponds
                                        daily)        (single treatment)
------------------------------------------------------------------------
Penaeid Shrimp..................  50 to 100 \1\.....  25 \2\
------------------------------------------------------------------------
\1\ Treat for up to 4 hours daily. Treatment may be repeated daily until
  parasite control is achieved. Use the lower concentration when the
  tanks and raceways are heavily loaded.
\2\ Single treatment. Treatment may be repeated in 5 to 10 days if
  needed.

    (iv) For control of external parasites on all finfish:

------------------------------------------------------------------------
                         Administer in tanks and
                           raceways for up to 1    Administer in earthen
    Aquatic species       hour (microliter/liter    ponds indefinitely
                           or part per million      ([micro]L/L or ppm)
                           ([micro]L/L or ppm))
------------------------------------------------------------------------
Salmon and trout:
Above 50 [deg]F          Up to 170                15 to 25 \1,2\
Below 50 [deg]F          Up to 250                15 to 25 \1,2\
All other finfish        Up to 250                15 to 25 \1,2\
------------------------------------------------------------------------
\1\ Use the lower concentration when ponds, tanks, or raceways are
  heavily loaded with phytoplankton or fish to avoid oxygen depletion
  due to the biological oxygen demand by decay of dead phytoplankton.
  Alternatively, a higher concentration may be used if dissolved oxygen
  is strictly monitored.
\2\ Although the indicated concentrations are considered safe for cold
  and warm water finfish, a small number of each lot or pond to be
  treated should always be used to check for any unusual sensitivity to
  formalin before proceeding.

    (v) For control of fungi of the family Saprolegniaceae on all 
finfish eggs: Eggs of all finfish except Acipenseriformes, 1,000 to 
2,000 [micro]L/L (ppm) for 15 minutes; eggs of Acipenseriformes, up to 
1,500 [micro]L/L (ppm) for 15 minutes.
    (3) Limitations. Fish tanks and raceways may be treated daily until 
parasite control is achieved. Pond treatment may be repeated in 5 to 10 
days if needed. However, pond treatments for Ichthyophthirius should be 
made at 2-day intervals until control is achieved. Egg tanks may be 
treated as often as necessary to prevent growth of fungi. Do not use 
formalin which has been subjected to temperatures below 40 [deg]F, or 
allowed to freeze. Do not treat ponds containing striped bass. 
Treatments in tanks should never exceed 1 hour even if fish show no 
signs of stress. Do not apply formalin to ponds with water warmer than 
27 [deg]C (80 [deg]F), when a heavy bloom of phytoplankton is present, 
or when the concentration of dissolved oxygen is less than 5 milligrams 
per liter.

[51 FR 11441, Apr. 3, 1986, as amended at 58 FR 59169, Nov. 8, 1993; 59 
FR 60076, Nov. 22, 1994; 63 FR 38304, July 16, 1998; 68 FR 5563; Feb. 4, 
2003; 72 FR 45158, Aug. 13, 2007; 76 FR 17339, Mar. 29, 2011]



Sec. 529.1044  Gentamicin sulfate in certain other dosage forms.



Sec. 529.1044a  Gentamicin sulfate intrauterine solution.

    (a) Specifications. Each milliliter of solution contains 50 or 100 
milligrams gentamicin sulfate.
    (b) Sponsors. See Nos. 000010, 000061, 000856, 000859 057561, 
058005, and 061623 in Sec. 510.600(c) of this chapter.

[[Page 361]]

    (c) Conditions of use in horses--(1) Amount. Infuse 2 to 2.5 grams 
per day for 3 to 5 days during estrus.
    (2) Indications for use. For control of bacterial infections of the 
uterus (metritis) and as an aid in improving conception in mares with 
uterine infections caused by bacteria sensitive to gentamicin.
    (3) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[71 FR 51727, Aug. 31, 2006, as amended at 78 FR 17597, Mar. 22, 2013]



Sec. 529.1044b  Gentamicin sulfate solution.

    (a) Specifications. Each milliliter of solution contains gentamicin 
sulfate equivalent to 50 milligrams of gentamicin base.
    (b) Sponsors. See Nos. 000061 and 054925 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use. (1) The drug is recommended as an aid in the 
reduction or elimination of the following microorganisms from turkey-
hatching eggs: Arizona hinshawii (paracolon), Salmonella st. paul, and 
Mycoplasma meleagridis.
    (2) The drug is added to clean water to provide a dip solution with 
a gentamicin concentration of 250 to 1,000 parts per million. A 
concentration of 500 parts per million is recommended. Clean eggs should 
be held submerged in the gentamicin solution under a vacuum of about 
27.5 to 38 centimeters of mercury for 5 minutes followed by additional 
soaking in gentamicin solution for approximately 10 minutes at 
atmospheric pressure. Eggs can also be treated by warming them for 3 to 
6 hours at approximately 100 [deg]F. then immediately submerging them in 
gentamicin solution maintained at about 40 [deg]F., keeping the eggs 
submerged for 10 to 15 minutes.
    (3) For use in the dipping treatment of turkey-hatching eggs only. 
Eggs which have been dipped in the drug shall not be used for food.

[40 FR 13881, Mar. 27, 1975, as amended at 52 FR 7833, Mar. 13, 1987; 62 
FR 22889, Apr. 28, 1997; 71 FR 13543, Mar. 16, 2006]



Sec. 529.1115  Halothane.

    (a) Specifications. The drug is a colorless, odorless, nonflammable, 
nonexplosive, heavy liquid containing 0.01 percent thymol as a 
preservative.
    (b) Sponsor. See 000856 and 012164 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use--(1) Amount. Two to 5 percent of inhaled 
atmosphere for induction of anesthesia; 0.5 to 2 percent for maintenance 
of anesthesia.\1\
---------------------------------------------------------------------------

    \1\ These conditions have been reviewed by FDA and found effective. 
NADA's for similar products for these conditions of use need not include 
effectiveness data as specified by Sec. 514.111 of this chapter, but 
may require bioequivalency and safety information.
---------------------------------------------------------------------------

    (2) Indications for use. For nonfood animals for the induction and 
maintenance of anesthesia.\1\
    (3) Limitations. Administered by inhalation. May be administered 
with either oxygen or a mixture of oxygen and nitrous oxide. Place drug 
vaporizer between the gas supply and breathing bag to prevent 
overdosage. Not recommended for obstetrical anesthesia except when 
uterine relaxation is required. Do not use in pregnant animals; 
information on possible adverse effects on fetal development is not 
available. Operating rooms should have adequate ventilation to prevent 
accumulation of anesthetic gases. Not for use in animals intended for 
food. Federal law restricts this drug to use by or on the order of a 
licensed veterinarian.\1\

[46 FR 27915, May 22, 1981, as amended at 62 FR 29014, May 29, 1997]



Sec. 529.1150  Hydrogen peroxide.

    (a) Specifications. Each milliliter of solution contains 396.1 
milligrams (mg) hydrogen peroxide (a 35% w/w solution).
    (b) Sponsor. See No. 061088 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in finfish--(1) Amount--(i) Freshwater-reared 
finfish eggs: 500 to 1,000 mg per liter (/L) of culture water for 15 
minutes in a continuous flow system once per day on consecutive or 
alternate days until hatch for all coldwater and coolwater species of 
freshwater-reared finfish eggs or 750 to 1,000 mg/L for 15 minutes in a 
continuous flow system once per day on consecutive or alternate days

[[Page 362]]

until hatch for all warmwater species of freshwater-reared finfish eggs.
    (ii) Freshwater-reared salmonids: 100 mg/L for 30 minutes or 50 to 
100 mg/L for 60 minutes once per day on alternate days for three 
treatments in a continuous flow water supply or as a static bath.
    (iii) Coolwater species of freshwater-reared finfish fingerlings and 
adults (except northern pike & paddlefish) and channel catfish 
fingerlings and adults: 50 to 75 mg/L for 60 minutes once per day on 
alternate days for three treatments in continuous flow water supply or 
as a static bath. Coolwater species of freshwater-reared finfish fry 
(except northern pike, pallid sturgeon & paddlefish) and channel catfish 
fry: 50 mg/L for 60 minutes once per day on alternate days for three 
treatments in continuous flow water supply or as a static bath.
    (2) Indications for use. For control of mortality in freshwater-
reared finfish eggs due to saprolegniasis; for control of mortality in 
freshwater-reared salmonids due to bacterial gill disease associated 
with Flavobacterium branchiophilum; and for control of mortality in 
freshwater-reared coolwater finfish and channel catfish due to external 
columnaris disease associated with Flavobacterium columnare (Flexibacter 
columnaris).
    (3) Limitations. Initial bioassay on a small number is recommended 
before treating the entire group. Eggs: Some strains of rainbow trout 
eggs are sensitive to hydrogen peroxide treatment at a time during 
incubation concurrent with blastopore formation through closure, about 
70 to 140 Daily Temperature Units, [deg]C. Consider withholding 
treatment or using an alternate therapeutant during that sensitive time 
to reduce egg mortalities due to drug toxicity. Finfish: Use with 
caution on walleye. Preharvest withdrawal time: zero days.

[72 FR 5330, Feb. 6, 2007]



Sec. 529.1186  Isoflurane.

    (a) Specifications. The drug is a clear, colorless, stable liquid.
    (b) Sponsors. See Nos. 000044, 010019, 012164, 065085, and 066794 in 
Sec. 510.600(c) of this chapter.
    (c) Conditions of use. Administer by inhalation:
    (1) Amount--(i) Horses: For induction of surgical anesthesia: 3 to 5 
percent isoflurane (with oxygen) for 5 to 10 minutes. For maintenance of 
surgical anesthesia: 1.5 to 1.8 percent isoflurane (with oxygen).
    (ii) Dogs: For induction of surgical anesthesia: 2 to 2.5 percent 
isoflurane (with oxygen) for 5 to 10 minutes. For maintenance of 
surgical anesthesia: 1.5 to 1.8 percent isoflurane (with oxygen).
    (2) Indications for use. For induction and maintenance of general 
anesthesia in horses and dogs.
    (3) Limitations. Do not use in horses intended for human 
consumption. Federal law restricts this drug to use by or on the order 
of a licensed veterinarian.

[51 FR 594, Jan. 7, 1986, as amended at 54 FR 23472, June 1, 1989; 58 FR 
17346, Apr. 2, 1993; 59 FR 44315, Aug. 29, 1994; 60 FR 40456, Aug. 9, 
1995; 63 FR 8122, Feb. 18, 1998; 63 FR 24106, May 1, 1998; 66 FR 17510, 
Apr. 2, 2001; 71 FR 43967, Aug. 3, 2006; 74 FR 68530, Dec. 28, 2009; 76 
FR 16533, Mar. 24, 2011; 78 FR 14669, Mar. 7, 2013; 78 FR 17868, Mar. 
25, 2013]



Sec. 529.1350  Meloxicam.

    (a) Specifications. Each milliliter of solution contains 5 
milligrams (mg) meloxicam.
    (b) Sponsor. See No. 000074 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in dogs--(1) Amount. Administer 0.1 mg per 
kilogram of body weight once daily using the metered dose pump.
    (2) Indications for use. For the control of pain and inflammation 
associated with osteoarthritis in dogs.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[77 FR 76863, Dec. 31, 2012]



Sec. 529.1660  Oxytetracycline.

    (a) Specifications--(1) Each gram of powder contains 366 milligrams 
(mg) oxytetracycline hydrochloride.
    (2) Each gram of powder contains 753 mg oxytetracycline 
hydrochloride.
    (b) Sponsors. See sponsors in Sec. 510.600(c) of this chapter for 
use of products described in paragraph (a) of this section as in 
paragraph (d) of this section.

[[Page 363]]

    (1) Nos. 046573 and 061623 for use of product in paragraph (a)(1) of 
this section.
    (2) Nos. 000069, 048164, and 059130 for use of product described in 
paragraph (a)(2) of this section.
    (c) Related tolerances. See Sec. 556.500 of this chapter.
    (d) Conditions of use in finfish--(1) Amount. Immerse fish in a 
solution containing 200 to 700 mg oxytetracycline hydrochloride 
(buffered) per liter of water for 2 to 6 hours.
    (2) Indications for use. For skeletal marking of finfish fry and 
fingerlings.

[69 FR 6557, Feb. 11, 2004, as amended at 69 FR 61999, Oct. 22, 2004; 70 
FR 41140, July 18, 2005; 72 FR 26289, May 9, 2007; 76 FR 17026, Mar. 28, 
2011]



Sec. 529.1940  Progesterone intravaginal inserts.

    (a) Specifications. Each insert contains:
    (1) 1.38 grams (g) progesterone in molded silicone over a nylon 
spine.
    (2) 0.3 g progesterone in molded silicone over a flexible nylon 
spine.
    (b) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter for 
use of the product described in paragraph (a)(1) of this section as in 
paragraph (e)(1) of this section; and the product described in paragraph 
(a)(2) of this section as in paragraph (e)(2) of this section.
    (c) Related tolerances. See Sec. 556.540(a) of this chapter.
    (d) Special considerations--(1) Cows and ewes. Product labeling 
shall bear the following warnings: ``Avoid contact with skin by wearing 
protective gloves when handling inserts. Store removed inserts in a 
sealable container until they can be disposed of in accordance with 
applicable local, state, and Federal regulations.''
    (2) Cows. This product is approved with the concurrent use of 
dinoprost solution when used for indications listed in paragraphs 
(e)(1)(ii)(A) and (e)(1)(ii)(B) of this section. See Sec. 522.690(c) of 
this chapter.
    (e) Conditions of use--(1) Cows--(i) Amount. Administer one 
intravaginal insert per animal for 7 days. When used for indications 
listed in paragraph (e)(1)(ii)(A) of this section, administer 25 
milligrams (mg) dinoprost (5 milliliters (mL) of 5 mg/mL solution as in 
Sec. 522.690(a) of this chapter) as a single intramuscular injection 1 
day prior to insert removal (Day 6). When used for indications listed in 
paragraph (e)(1)(ii)(B) of this section, administer 25 mg dinoprost as a 
single intramuscular injection on the day of insert removal (Day 7).
    (ii) Indications for use--(A) For synchronization of estrus in 
suckled beef cows and replacement beef and dairy heifers; for 
advancement of first postpartum estrus in suckled beef cows; and for 
advancement of first pubertal estrus in replacement beef heifers.
    (B) For synchronization of estrus in lactating dairy cows.
    (C) For synchronization of the return to estrus in lactating dairy 
cows inseminated at the immediately preceding estrus.
    (iii) Limitations. Do not use in beef or dairy heifers of 
insufficient size or age for breeding or in animals with abnormal, 
immature, or infected genital tracts. Do not use in beef cows that are 
fewer than 20 days postpartum. Do not use an insert more than once. To 
prevent the potential transmission of venereal and bloodborne diseases, 
the inserts should be disposed after a single use. Administration of 
vaginal inserts for periods greater than 7 days may result in reduced 
fertility. Dinoprost solution provided by No. 000009 in Sec. 510.600(c) 
of this chapter.
    (2) Ewes--(i) Amount. Administer one intravaginal insert per animal 
for 5 days.
    (ii) Indications for use. For induction of estrus in ewes (sheep) 
during seasonal anestrus.
    (iii) Limitations. Do not use in animals with abnormal, immature, or 
infected genital tracts; or in ewes that have never lambed. Do not use 
an insert more than once. To prevent the potential transmission of 
venereal and bloodborne diseases, the inserts should be disposed after a 
single use.

[74 FR 59074, Nov. 17, 2009, as amended at 75 FR 63085, Oct. 14, 2010]



Sec. 529.2150  Sevoflurane.

    (a) Specifications. Sevoflurane liquid.
    (b) Sponsors. See Nos. 000044, 012164, and 066794 in Sec. 
510.600(c) of this chapter.

[[Page 364]]

    (c) Conditions of use--(1) Amount. For induction of surgical 
anesthesia: up to 7 percent sevoflurane. For maintenance of surgical 
anesthesia: 3.7 to 4 percent sevoflurane with oxygen in the absence of 
premedication and 3.3 to 3.6 percent in the presence of premedication.
    (2) Indications for use. For induction and maintenance of general 
anesthesia in dogs.
    (3) Limitations. Federal law restricts this drug to use by or on the 
order of a licensed veterinarian.

[64 FR 71640, Dec. 22, 1999, as amended at 73 FR 25508, May 7, 2008; 74 
FR 10484, Mar. 11, 2009, 75 FR 1021, Jan. 8, 2010; 76 FR 16533, Mar. 24, 
2011; 78 FR 17868, Mar. 25, 2013]



Sec. 529.2464  Ticarcillin powder.

    (a) Specifications. Each vial contains ticarcillin disodium 
equivalent to 6 grams of ticarcillin to be reconstituted with 25 
milliliters of sterile water for injection or sterile physiological 
saline.
    (b) Sponsor. See No. 000069 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--(1) Amount. 6 grams per day, intrauterine, 
for 3 consecutive days during estrus.
    (2) Indications for use. Horses. Intrauterine treatment of 
endometritis caused by beta-hemolytic streptococci.
    (3) Limitations. For intrauterine use in horses only. Infuse 
aseptically. Not for use in horses raised for food production. Federal 
law restricts this drug to use by or on the order of a licensed 
veterinarian.

[57 FR 37336, Aug. 18, 1992, as amended at 60 FR 55660, Nov. 2, 1995]



Sec. 529.2503  Tricaine methanesulfonate.

    (a) Chemical name. Ethyl-m-amino-benzoate methanesulfonate.
    (b) Sponsor. See Nos. 050378 and 051212 in Sec. 510.600(c) of this 
chapter.
    (c) Conditions of use. (1) It is used for the temporary 
immobilization of fish, amphibians, and other aquatic coldblooded 
animals (poikilotherms) as an aid in handling during manual spawning 
(fish stripping), weighing, measuring, marking, surgical operations, 
transport, photography, and research.
    (2) It is used as follows:
    (i) For fish the drug is added to ambient water at a concentration 
of from 15 to 330 milligrams per liter depending upon the degree of 
anesthetization or sedation desired, the species and size of the fish, 
and the temperature and softness of the water. Preliminary tests of 
solutions must be made with small numbers of fish to determine the 
desired rates of sedation or anesthesia and the appropriate exposure 
times for the specific lots of fish under prevailing conditions.
    (ii) For amphibians and other aquatic coldblooded animals, the drug 
is added to ambient water in concentrations of from 1:1000 to 1:20,000 
depending upon species and stage of development.
    (iii) Do not use within 21 days of harvesting fish for food. Use in 
fish intended for food should be restricted to Ictaluridae, Salmonidae, 
Esocidae, and Percidae, and water temperature should exceed 10 [deg]C. 
(50 [deg]F.). In other fish and in cold-blooded animals, the drug should 
be limited to hatchery or laboratory use.

[40 FR 13881, Mar. 27, 1975, as amended at 49 FR 5748, Feb. 15, 1984; 51 
FR 11439, Apr. 3, 1986; 63 FR 7702, Feb. 17, 1998]



Sec. 529.2620  Triptorelin.

    (a) Specifications. Each milliliter of gel contains 100 micrograms 
(mcg) triptorelin as triptorelin acetate.
    (b) Sponsor. See No. 051233 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use in swine--(1) Amount. Administer 200 mcg 
intravaginally approximately 96 hours after weaning.
    (2) Indications for use. For the synchronization of time of 
insemination in weaned sows to facilitate a single fixed-time artificial 
insemination.
    (3) Limitations. Not approved for use in gilts. Safety and 
effectiveness have not been evaluated in these animals. Should not be 
used in sows with obvious reproductive tract abnormalities.

[77 FR 64717, Oct. 23, 2012]



PART 530_EXTRALABEL DRUG USE IN ANIMALS--Table of Contents



                      Subpart A_General Provisions

Sec.
530.1 Scope.
530.2 Purpose.
530.3 Definitions.
530.4 Advertising and promotion.

[[Page 365]]

530.5 Veterinary records.

 Subpart B_Rules and Provisions for Extralabel Uses of Drugs in Animals

530.10 Provision permitting extralabel use of animal drugs.
530.11 Limitations.
530.12 Labeling.
530.13 Extralabel use from compounding of approved new animal and 
          approved human drugs.

 Subpart C_Specific Provisions Relating to Extralabel Use of Animal and 
                  Human Drugs in Food-Producing Animals

530.20 Conditions for permitted extralabel animal and human drug use in 
          food-producing animals.
530.21 Prohibitions for food-producing animals.
530.22 Safe levels and analytical methods for food-producing animals.
530.23 Procedure for setting and announcing safe levels.
530.24 Procedure for announcing analytical methods for drug residue 
          quantification.
530.25 Orders prohibiting extralabel uses for drugs in food-producing 
          animals.

   Subpart D_Extralabel Use of Human and Animal Drugs in Animals Not 
                     Intended for Human Consumption

530.30 Extralabel drug use in nonfood animals.

 Subpart E_Safe Levels for Extralabel Use of Drugs in Animals and Drugs 
                Prohibited From Extralabel Use in Animals

530.40 Safe levels and availability of analytical methods.
530.41 Drugs prohibited for extralabel use in animals.

    Authority: 15 U.S.C. 1453, 1454, 1455; 21 U.S.C. 321, 331, 351, 352, 
353, 355, 357, 360b, 371, 379e.

    Source: 61 FR 57743, Nov. 7, 1996, unless otherwise noted.



                      Subpart A_General Provisions



Sec. 530.1  Scope.

    This part applies to the extralabel use in an animal of any approved 
new animal drug or approved new human drug by or on the lawful order of 
a licensed veterinarian within the context of a valid veterinary-client-
patient relationship.



Sec. 530.2  Purpose.

    The purpose of this part is to establish conditions for extralabel 
use or intended extralabel use in animals by or on the lawful order of 
licensed veterinarians of Food and Drug Administration approved new 
animal drugs and approved new human drugs. Such use is limited to 
treatment modalities when the health of an animal is threatened or 
suffering or death may result from failure to treat. This section 
implements the Animal Medicinal Drug Use Clarification Act of 1994 (the 
AMDUCA) (Pub. L. 103-396).



Sec. 530.3  Definitions.

    (a) Extralabel use means actual use or intended use of a drug in an 
animal in a manner that is not in accordance with the approved labeling. 
This includes, but is not limited to, use in species not listed in the 
labeling, use for indications (disease or other conditions) not listed 
in the labeling, use at dosage levels, frequencies, or routes of 
administration other than those stated in the labeling, and deviation 
from the labeled withdrawal time based on these different uses.
    (b) FDA means the U.S. Food and Drug Administration.
    (c) The phrase a reasonable probability that a drug's use may 
present a risk to the public health means that FDA has reason to believe 
that use of a drug may be likely to cause a potential adverse event.
    (d) The phrase use of a drug may present a risk to the public health 
means that FDA has information that indicates that use of a drug may 
cause an adverse event.
    (e) The phrase use of a drug presents a risk to the public health 
means that FDA has evidence that demonstrates that the use of a drug has 
caused or likely will cause an adverse event.
    (f) A residue means any compound present in edible tissues that 
results from the use of a drug, and includes the drug, its metabolites, 
and any other substance formed in or on food because of the drug's use.
    (g) A safe level is a conservative estimate of a drug residue level 
in edible animal tissue derived from food safety data or other 
scientific information. Concentrations of residues in tissue

[[Page 366]]

below the safe level will not raise human food safety concerns. A safe 
level is not a safe concentration or a tolerance and does not indicate 
that an approval exists for the drug in that species or category of 
animal from which the food is derived.
    (h) Veterinarian means a person licensed by a State or Territory to 
practice veterinary medicine.
    (i) A valid veterinarian-client-patient relationship is one in 
which:
    (1) A veterinarian has assumed the responsibility for making medical 
judgments regarding the health of (an) animal(s) and the need for 
medical treatment, and the client (the owner of the animal or animals or 
other caretaker) has agreed to follow the instructions of the 
veterinarian;
    (2) There is sufficient knowledge of the animal(s) by the 
veterinarian to initiate at least a general or preliminary diagnosis of 
the medical condition of the animal(s); and
    (3) The practicing veterinarian is readily available for followup in 
case of adverse reactions or failure of the regimen of therapy. Such a 
relationship can exist only when the veterinarian has recently seen and 
is personally acquainted with the keeping and care of the animal(s) by 
virtue of examination of the animal(s), and/or by medically appropriate 
and timely visits to the premises where the animal(s) are kept.



Sec. 530.4  Advertising and promotion.

    Nothing in this part shall be construed as permitting the 
advertising or promotion of extralabel uses in animals of approved new 
animal drugs or approved human drugs.



Sec. 530.5  Veterinary records.

    (a) As a condition of extralabel use permitted under this part, to 
permit FDA to ascertain any extralabel use or intended extralabel use of 
drugs that the agency has determined may present a risk to the public 
health, veterinarians shall maintain the following records of extralabel 
uses. Such records shall be legible, documented in an accurate and 
timely manner, and be readily accessible to permit prompt retrieval of 
information. Such records shall be adequate to substantiate the 
identification of the animals and shall be maintained either as 
individual records or, in food animal practices, on a group, herd, 
flock, or per-client basis. Records shall be adequate to provide the 
following information:
    (1) The established name of the drug and its active ingredient, or 
if formulated from more than one ingredient, the established name of 
each ingredient;
    (2) The condition treated;
    (3) The species of the treated animal(s);
    (4) The dosage administered;
    (5) The duration of treatment;
    (6) The numbers of animals treated; and
    (7) The specified withdrawal, withholding, or discard time(s), if 
applicable, for meat, milk, eggs, or any food which might be derived 
from any food animals treated.
    (b) A veterinarian shall keep all required records for 2 years or as 
otherwise required by Federal or State law, whichever is greater.
    (c) Any person who is in charge, control, or custody of such records 
shall, upon request of a person designated by FDA, permit such person 
designated by FDA to, at all reasonable times, have access to, permit 
copying, and verify such records.



 Subpart B_Rules and Provisions for Extralabel Uses of Drugs in Animals



Sec. 530.10  Provision permitting extralabel use of animal drugs.

    An approved new animal drug or human drug intended to be used for an 
extralabel purpose in an animal is not unsafe under section 512 of the 
act and is exempt from the labeling requirements of section 502(f) of 
the act if such use is:
    (a) By or on the lawful written or oral order of a licensed 
veterinarian within the context of a valid veterinarian-client-patient 
relationship; and
    (b) In compliance with this part.



Sec. 530.11  Limitations.

    In addition to uses which do not comply with the provision set forth 
in Sec. 530.10, the following specific extralabel uses are not 
permitted and result in the drug being deemed unsafe

[[Page 367]]

within the meaning of section 512 of the act:
    (a) Extralabel use in an animal of an approved new animal drug or 
human drug by a lay person (except when under the supervision of a 
licensed veterinarian);
    (b) Extralabel use of an approved new animal drug or human drug in 
or on an animal feed;
    (c) Extralabel use resulting in any residue which may present a risk 
to the public health; and
    (d) Extralabel use resulting in any residue above an established 
safe level, safe concentration or tolerance.



Sec. 530.12  Labeling.

    Any human or animal drug prescribed and dispensed for extralabel use 
by a veterinarian or dispensed by a pharmacist on the order of a 
veterinarian shall bear or be accompanied by labeling information 
adequate to assure the safe and proper use of the product. Such 
information shall include the following:
    (a) The name and address of the prescribing veterinarian. If the 
drug is dispensed by a pharmacy on the order of a veterinarian, the 
labeling shall include the name of the prescribing veterinarian and the 
name and address of the dispensing pharmacy, and may include the address 
of the prescribing veterinarian;
    (b) The established name of the drug or, if formulated from more 
than one active ingredient, the established name of each ingredient;
    (c) Any directions for use specified by the veterinarian, including 
the class/species or identification of the animal or herd, flock, pen, 
lot, or other group of animals being treated, in which the drug is 
intended to be used; the dosage, frequency, and route of administration; 
and the duration of therapy;
    (d) Any cautionary statements; and
    (e) The veterinarian's specified withdrawal, withholding, or discard 
time for meat, milk, eggs, or any other food which might be derived from 
the treated animal or animals.



Sec. 530.13  Extralabel use from compounding of approved new animal 
and approved human drugs.

    (a) This part applies to compounding of a product from approved 
animal or human drugs by a veterinarian or a pharmacist on the order of 
a veterinarian within the practice of veterinary medicine. Nothing in 
this part shall be construed as permitting compounding from bulk drugs.
    (b) Extralabel use from compounding of approved new animal or human 
drugs is permitted if:
    (1) All relevant portions of this part have been complied with;
    (2) There is no approved new animal or approved new human drug that, 
when used as labeled or in conformity with criteria established in this 
part, will, in the available dosage form and concentration, 
appropriately treat the condition diagnosed. Compounding from a human 
drug for use in food-producing animals will not be permitted if an 
approved animal drug can be used for the compounding;
    (3) The compounding is performed by a licensed pharmacist or 
veterinarian within the scope of a professional practice;
    (4) Adequate procedures and processes are followed that ensure the 
safety and effectiveness of the compounded product;
    (5) The scale of the compounding operation is commensurate with the 
established need for compounded products (e.g., similar to that of 
comparable practices); and
    (6) All relevant State laws relating to the compounding of drugs for 
use in animals are followed.
    (c) Guidance on the subject of compounding may be found in guidance 
documents issued by FDA.



 Subpart C_Specific Provisions Relating to Extralabel Use of Animal and 
                  Human Drugs in Food-Producing Animals



Sec. 530.20  Conditions for permitted extralabel animal and human drug 
use in food-producing animals.

    (a) The following conditions must be met for a permitted extralabel 
use in food-producing animals of approved new animal and human drugs:

[[Page 368]]

    (1) There is no approved new animal drug that is labeled for such 
use and that contains the same active ingredient which is in the 
required dosage form and concentration, except where a veterinarian 
finds, within the context of a valid veterinarian-client-patient 
relationship, that the approved new animal drug is clinically 
ineffective for its intended use.
    (2) Prior to prescribing or dispensing an approved new animal or 
human drug for an extralabel use in food animals, the veterinarian must:
    (i) Make a careful diagnosis and evaluation of the conditions for 
which the drug is to be used;
    (ii) Establish a substantially extended withdrawal period prior to 
marketing of milk, meat, eggs, or other edible products supported by 
appropriate scientific information, if applicable;
    (iii) Institute procedures to assure that the identity of the 
treated animal or animals is carefully maintained; and
    (iv) Take appropriate measures to assure that assigned timeframes 
for withdrawal are met and no illegal drug residues occur in any food-
producing animal subjected to extralabel treatment.
    (b) The following additional conditions must be met for a permitted 
extralabel use of in food-producing animals an approved human drug, or 
of an animal drug approved only for use in animals not intended for 
human consumption:
    (1) Such use must be accomplished in accordance with an appropriate 
medical rationale; and
    (2) If scientific information on the human food safety aspect of the 
use of the drug in food-producing animals is not available, the 
veterinarian must take appropriate measures to assure that the animal 
and its food products will not enter the human food supply.
    (c) Extralabel use of an approved human drug in a food-producing 
animal is not permitted under this part if an animal drug approved for 
use in food-producing animals can be used in an extralabel manner for 
the particular use.



Sec. 530.21  Prohibitions for food-producing animals.

    (a) FDA may prohibit the extralabel use of an approved new animal or 
human drug or class of drugs in food-producing animals if FDA determines 
that:
    (1) An acceptable analytical method needs to be established and such 
method has not been established or cannot be established; or
    (2) The extralabel use of the drug or class of drugs presents a risk 
to the public health.
    (b) A prohibition may be a general ban on the extralabel use of the 
drug or class of drugs or may be limited to a specific species, 
indication, dosage form, route of administration, or combination of 
factors.



Sec. 530.22  Safe levels and analytical methods for food-producing 
animals.

    (a) FDA may establish a safe level for extralabel use of an approved 
human drug or an approved new animal drug when the agency finds that 
there is a reasonable probability that an extralabel use may present a 
risk to the public health. FDA may:
    (1) Establish a finite safe level based on residue and metabolism 
information from available sources;
    (2) Establish a safe level based on the lowest level that can be 
measured by a practical analytical method; or
    (3) Establish a safe level based on other appropriate scientific, 
technical, or regulatory criteria.
    (b) FDA may require the development of an acceptable analytical 
method for the quantification of residues above any safe level 
established under this part. If FDA requires the development of such an 
acceptable analytical method, the agency will publish notice of that 
requirement in the Federal Register.
    (c) The extralabel use of an animal drug or human drug that results 
in residues exceeding a safe level established under this part is an 
unsafe use of such drug.
    (d) If the agency establishes a safe level for a particular species 
or category of animals and a tolerance or safe concentration is later 
established through an approval for that particular species or category 
of animals, for that species or category of animals, the safe level is 
superseded by the tolerance or

[[Page 369]]

safe concentration for that species or category of animals.



Sec. 530.23  Procedure for setting and announcing safe levels.

    (a) FDA may issue an order establishing a safe level for a residue 
of an extralabel use of an approved human drug or an approved animal 
drug. The agency will publish in the Federal Register a notice of the 
order. The notice will include:
    (1) A statement setting forth the agency's finding that there is a 
reasonable probability that extralabel use in animals of the human drug 
or animal drug may present a risk to the public health;
    (2) A statement of the basis for that finding; and
    (3) A request for public comments.
    (b) A current listing of those drugs for which a safe level for 
extralabel drug use in food-producing animals has been established, the 
specific safe levels, and the availability, if any, of a specific 
analytical method or methods for drug residue detection will be codified 
in Sec. 530.40.



Sec. 530.24  Procedure for announcing analytical methods for drug 
residue quantification.

    (a) FDA may issue an order announcing a specific analytical method 
or methods for the quantification of extralabel use drug residues above 
the safe levels established under Sec. 530.22 for extralabel use of an 
approved human drug or an approved animal drug. The agency will publish 
in the Federal Register a notice of the order, including the name of the 
specific analytical method or methods and the drug or drugs for which 
the method is applicable.
    (b) Copies of analytical methods for the quantification of 
extralabel use drug residues above the safe levels established under 
Sec. 530.22 will be available upon request from the Communications and 
Education Branch (HFV-12), Division of Program Communication and 
Administrative Management, Center for Veterinary Medicine, 7500 Standish 
Pl., Rockville, MD 20855. When an analytical method for the detection of 
extralabel use drug residues above the safe levels established under 
Sec. 530.22 is developed, and that method is acceptable to the agency, 
FDA will incorporate that method by reference.



Sec. 530.25  Orders prohibiting extralabel uses for drugs in 
food-producing animals.

    (a) FDA may issue an order prohibiting extralabel use of an approved 
new animal or human drug in food-producing animals if the agency finds, 
after providing an opportunity for public comment, that:
    (1) An acceptable analytical method required under Sec. 530.22 has 
not been developed, submitted, and found to be acceptable by FDA or that 
such method cannot be established; or
    (2) The extralabel use in animals presents a risk to the public 
health.
    (b) After making a determination that the analytical method required 
under Sec. 530.22 has not been developed and submitted, or that such 
method cannot be established, or that an extralabel use in animals of a 
particular human drug or animal drug presents a risk to the public 
health, FDA will publish in the Federal Register, with a 90-day delayed 
effective date, an order of prohibition for an extralabel use of a drug 
in food-producing animals. Such order shall state that an acceptable 
analytical method required under Sec. 530.22 has not been developed, 
submitted, and found to be acceptable by FDA; that such method cannot be 
established; or that the extralabel use in animals presents a risk to 
the public health; and shall:
    (1) Specify the nature and extent of the order of prohibition and 
the reasons for the prohibition;
    (2) Request public comments; and
    (3) Provide a period of not less than 60 days for comments.
    (c) The order of prohibition will become effective 90 days after 
date of publication of the order unless FDA publishes a notice in the 
Federal Register prior to that date, that revokes the order of 
prohibition, modifies it, or extends the period of public comment.
    (d) The agency may publish an order of prohibition with a shorter 
comment period and/or delayed effective date than specified in paragraph 
(b) of this section in exceptional circumstances (e.g., where there is 
immediate risk to

[[Page 370]]

the public health), provided that the order of prohibition states that 
the comment period and/or effective date have been abbreviated because 
there are exceptional circumstances, and the order of prohibition sets 
forth the agency's rationale for taking such action.
    (e) If FDA publishes a notice in the Federal Register modifying an 
order of prohibition, the agency will specify in the modified order of 
prohibition the nature and extent of the modified prohibition, the 
reasons for it, and the agency's response to any comments on the 
original order of prohibition.
    (f) A current listing of drugs prohibited for extralabel use in 
animals will be codified in Sec. 530.41.
    (g) After the submission of appropriate information (i.e., adequate 
data, an acceptable method, approval of a new animal drug application 
for the prohibited extralabel use, or information demonstrating that the 
prohibition was based on incorrect data), FDA may, by publication of an 
appropriate notice in the Federal Register, remove a drug from the list 
of human and animal drugs prohibited for extralabel use in animals, or 
may modify a prohibition.
    (h) FDA may prohibit extralabel use of a drug in food-producing 
animals without establishing a safe level.



   Subpart D_Extralabel Use of Human and Animal Drugs in Animals Not 
                     Intended for Human Consumption



Sec. 530.30  Extralabel drug use in nonfood animals.

    (a) Because extralabel use of animal and human drugs in nonfood-
producing animals does not ordinarily pose a threat to the public 
health, extralabel use of animal and human drugs is permitted in 
nonfood-producing animal practice except when the public health is 
threatened. In addition, the provisions of Sec. 530.20(a)(1) will apply 
to the use of an approved animal drug.
    (b) If FDA determines that an extralabel drug use in animals not 
intended for human consumption presents a risk to the public health, the 
agency may publish in the Federal Register a notice prohibiting such use 
following the procedures in Sec. 530.25. The prohibited extralabel drug 
use will be codified in Sec. 530.41.



 Subpart E_Safe Levels for Extralabel Use of Drugs in Animals and Drugs 
                Prohibited From Extralabel Use in Animals



Sec. 530.40  Safe levels and availability of analytical methods.

    (a) In accordance with Sec. 530.22, the following safe levels for 
extralabel use of an approved animal drug or human drug have been 
established: [Reserved]
    (b) In accordance with Sec. 530.22, the following analytical 
methods have been accepted by FDA: [Reserved]



Sec. 530.41  Drugs prohibited for extralabel use in animals.

    (a) The following drugs, families of drugs, and substances are 
prohibited for extralabel animal and human drug uses in food-producing 
animals.
    (1) Chloramphenicol;
    (2) Clenbuterol;
    (3) Diethylstilbestrol (DES);
    (4) Dimetridazole;
    (5) Ipronidazole;
    (6) Other nitroimidazoles;
    (7) Furazolidone.
    (8) Nitrofurazone.
    (9) Sulfonamide drugs in lactating dairy cattle (except approved use 
of sulfadimethoxine, sulfabromomethazine, and sulfaethoxypyridazine);
    (10) Fluoroquinolones; and
    (11) Glycopeptides.
    (12) Phenylbutazone in female dairy cattle 20 months of age or 
older.
    (13) Cephalosporins (not including cephapirin) in cattle, swine, 
chickens, or turkeys:
    (i) For disease prevention purposes;
    (ii) At unapproved doses, frequencies, durations, or routes of 
administration; or
    (iii) If the drug is not approved for that species and production 
class.
    (b) The following drugs, families of drugs, and substances are 
prohibited for extralabel animal and human drug uses in nonfood-
producing animals: [Reserved]
    (c) [Reserved]

[[Page 371]]

    (d) The following drugs, or classes of drugs, that are approved for 
treating or preventing influenza A, are prohibited from extralabel use 
in chickens, turkeys, and ducks:
    (1) Adamantanes.
    (2) Neuraminidase inhibitors.

[62 FR 27947, May 22, 1997, as amended at 67 FR 5471, Feb. 6, 2002; 68 
FR 9530, Feb. 28, 2003; 68 FR 14134, Mar. 24, 2003; 71 FR 14377, Mar. 
22, 2006; 77 FR 745, Jan. 6, 2012]



PART 556_TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD--Table 
of Contents



                      Subpart A_General Provisions

Sec.
556.1 General considerations; tolerances for residues of new animal 
          drugs in food.

     Subpart B_Specific Tolerances for Residues of New Animal Drugs

556.34 Albendazole.
556.36 Altrenogest.
556.38 Amoxicillin.
556.40 Ampicillin.
556.50 Amprolium.
556.52 Apramycin.
556.60 Arsenic.
556.70 Bacitracin.
556.100 Carbadox.
556.110 Carbomycin.
556.113 Ceftiofur.
556.115 Cephapirin.
556.120 Chlorhexidine.
556.150 Chlortetracycline.
556.160 Clopidol.
556.163 Clorsulon.
556.165 Cloxacillin.
556.167 Colistimethate.
556.169 Danofloxacin.
556.170 Decoquinate.
556.180 Dichlorvos.
556.185 Diclazuril.
556.200 Dihydrostreptomycin.
556.225 Doramectin.
556.226 Enrofloxacin.
556.227 Eprinomectin.
556.230 Erythromycin.
556.240 Estradiol and related esters.
556.260 Ethopabate.
556.273 Famphur.
556.275 Fenbendazole.
556.277 Fenprostalene.
556.283 Florfenicol.
556.286 Flunixin.
556.292 Gamithromycin.
556.300 Gentamicin sulfate.
556.304 Gonadotropin.
556.308 Halofuginone hydrobromide.
556.310 Haloxon.
556.330 Hygromycin B.
556.344 Ivermectin.
556.346 Laidlomycin.
556.347 Lasalocid.
556.350 Levamisole hydrochloride.
556.360 Lincomycin.
556.375 Maduramicin ammonium.
556.380 Melengestrol acetate.
556.410 Metoserpate hydrochloride.
556.420 Monensin.
556.425 Morantel tartrate.
556.426 Moxidectin.
556.428 Narasin.
556.430 Neomycin.
556.440 Nequinate.
556.445 Nicarbazin.
556.460 Novobiocin.
556.470 Nystatin.
556.480 Oleandomycin.
556.490 Ormetoprim.
556.495 Oxfendazole.
556.500 Oxytetracycline.
556.510 Penicillin.
556.513 Piperazine.
556.515 Pirlimycin.
556.540 Progesterone.
556.560 Pyrantel tartrate.
556.570 Ractopamine.
556.580 Robenidine hydrochloride.
556.592 Salinomycin.
556.597 Semduramicin.
556.600 Spectinomycin.
556.610 Streptomycin.
556.620 Sulfabromomethazine sodium.
556.625 Sodium sulfachloropyrazine monohydrate.
556.630 Sulfachlorpyridazine.
556.640 Sulfadimethoxine.
556.650 Sulfaethoxypyridazine.
556.660 Sulfamerazine.
556.670 Sulfamethazine.
556.685 Sulfaquinoxaline.
556.690 Sulfathiazole.
556.700 Sulfomyxin.
556.710 Testosterone propionate.
556.720 Tetracycline.
556.730 Thiabendazole.
556.733 Tildipirosin.
556.735 Tilmicosin.
556.738 Tiamulin.
556.739 Trenbolone.
556.740 Tylosin.
556.741 Tripelennamine.
556.745 Tulathromycin.
556.748 Tylvalosin.
556.750 Virginiamycin.
556.760 Zeranol.
556.765 Zilpaterol.
556.770 Zoalene.

    Authority: 21 U.S.C. 342, 360b, 371.

    Source: 40 FR 13942, Mar. 27, 1975, unless otherwise noted.

[[Page 372]]



                      Subpart A_General Provisions



Sec. 556.1  General considerations; tolerances for residues of new 
animal drugs in food.

    (a) Tolerances established in this part are based upon residues of 
drugs in edible products of food-producing animals treated with such 
drugs. Consideration of an appropriate tolerance for a drug shall result 
in a conclusion either that:
    (1) Finite residues will be present in the edible products--in which 
case a finite tolerance is required; or
    (2) It is not possible to determine whether finite residues will be 
incurred but there is reasonable expectation that they may be present--
in which case a tolerance for negligible residue is required; or
    (3) The drug induces cancer when ingested by man or animal or, after 
tests which are appropriate for the evaluation of the safety of such 
drug, has been shown to induce cancer in man or animal; however, such 
drug will not adversely affect the animals for which it is intended, and 
no residue of such drug will be found by prescribed methods of analysis 
in any edible portion of such animals after slaughter or in any food 
yielded by or derived from the living animal--in which case the accepted 
method of analysis shall be published or cited, if previously published 
and available elsewhere, in this part; or
    (4) It may or may not be possible to determine whether finite 
residues will be incurred but there is no reasonable expectation that 
they may be present--in which case the establishment of a tolerance is 
not required; or
    (5) The drug is such that it may be metabolized and/or assimilated 
in such form that any possible residue would be indistinguishable from 
normal tissue constituents--in which case the establishment of a 
tolerance is not required.
    (b) No tolerance established pursuant to paragraph (a)(1) of this 
section will be set at any level higher than that reflected by the 
permitted use of the drug.
    (c) Any tolerance required pursuant to this section will, in 
addition to the toxicological considerations, be conditioned on the 
availability of a practicable analytical method to determine the 
quantity of residue. Such method must be sensitive to and reliable at 
the established tolerance level or, in certain instances, may be 
sensitive at a higher level where such level is also deemed satisfactory 
and safe in light of the toxicity of the drug residue and of the 
unlikelihood of such residue's exceeding the tolerance.



     Subpart B_Specific Tolerances for Residues of New Animal Drugs



Sec. 556.34  Albendazole.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
albendazole is 5 micrograms per kilogram of body weight per day.
    (b) Tolerances. The tolerances for albendazole 2-aminosulfone 
(marker residue) are:
    (1) Cattle--(i) Liver (target tissue): 0.2 parts per million (ppm).
    (ii) Muscle: 0.05 ppm.
    (2) Sheep--(i) Liver (target tissue): 0.25 ppm.
    (ii) Muscle: 0.05 ppm.
    (3) Goat--(i) Liver (target tissue): 0.25 ppm.
    (ii) [Reserved]
    (c) Related conditions of use. See Sec. 520.45 of this chapter.

[64 FR 1504, Jan. 11, 1999, as amended at 73 FR 11027, Feb. 29, 2008]



Sec. 556.36  Altrenogest.

    (a) Acceptable Daily Intake (ADI). The ADI for total residues of 
altrenogest is 0.04 micrograms per kilogram of body weight per day.
    (b) Tolerances--(1) Swine--(i) Liver (the target tissue). The 
tolerance for altrenogest (the marker residue) is 4 parts per billion 
(ppb).
    (ii) Muscle. The tolerance for altrenogest (the marker residue) is 1 
ppb.
    (2) [Reserved]

[68 FR 62007, Oct. 31, 2003]



Sec. 556.38  Amoxicillin.

    A tolerance of 0.01 part per million is established for negligible 
residues of amoxicillin in milk and in the uncooked edible tissues of 
cattle.

[49 FR 45422, Nov. 16, 1984]

[[Page 373]]



Sec. 556.40  Ampicillin.

    A tolerance of 0.01 p/m is established for negligible residues of 
ampicillin in the uncooked edible tissues of swine and cattle and in 
milk.



Sec. 556.50  Amprolium.

    Tolerances are established as follows for residues of amprolium (1-
(4-amino-2-n- propyl-5-pyrimidinylmethyl)-2-picolinium chloride 
hydrochloride):
    (a) In the edible tissues and in eggs of chickens and turkeys:
    (1) 1 part per million in uncooked liver and kidney.
    (2) 0.5 part per million in uncooked muscle tissue.
    (3) In eggs:
    (i) 8 parts per million in egg yolks.
    (ii) 4 parts per million in whole eggs.
    (b) In the edible tissues of calves:
    (1) 2.0 parts per million in uncooked fat.
    (2) 0.5 part per million in uncooked muscle tissue, liver, and 
kidney.
    (c) In the edible tissues of pheasants:
    (1) 1 part per million in uncooked liver.
    (2) 0.5 part per million in uncooked muscle.

[40 FR 13942, Mar. 27, 1975, as amended at 50 FR 18472, May 1, 1985]



Sec. 556.52  Apramycin.

    A tolerance of 0.1 part per million is established for parent 
apramycin (marker residue) in kidney (target tissue) of swine. The 
acceptable daily intake (ADI) for total residues of apramycin is 25 
micrograms per kilogram of body weight per day.

[62 FR 40933, July 31, 1997]



Sec. 556.60  Arsenic.

    Tolerances for total residues of combined arsenic (calculated as As) 
in food are established as follows:
    (a) In edible tissues and in eggs of chickens and turkeys:
    (1) 0.5 part per million in uncooked muscle tissue.
    (2) 2 parts per million in uncooked edible by-products.
    (3) 0.5 part per million in eggs.
    (b) In edible tissues of swine:
    (1) 2 parts per million in uncooked liver and kidney.
    (2) 0.5 part per million in uncooked muscle tissue and by-products 
other than liver and kidney.



Sec. 556.70  Bacitracin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
bacitracin is 0.05 milligram per kilogram of body weight per day.
    (b) Tolerances. The tolerance for residues of bacitracin from zinc 
bacitracin or bacitracin methylene disalicylate in uncooked edible 
tissues of cattle, swine, chickens, turkeys, pheasants, and quail, and 
in milk and eggs is 0.5 part per million.

[65 FR 70791, Nov. 28, 2000]



Sec. 556.100  Carbadox.

    A tolerance of 30 parts per billion is established for residues of 
quinoxaline-2-carboxylic acid (marker residue) in liver (target tissue) 
of swine.

[63 FR 13337, Mar. 19, 1998]



Sec. 556.110  Carbomycin.

    A tolerance of zero is established for residues of carbomycin in the 
uncooked edible tissues of chickens.



Sec. 556.113  Ceftiofur.

    (a) Acceptable daily intake and acceptable single-dose intake--(1) 
Acceptable daily intake (ADI). The ADI for total residues of ceftiofur 
is 30 micrograms per kilogram of body weight per day.
    (2) Acceptable single-dose intake (ASDI). The ASDI total residues of 
ceftiofur is 0.830 milligrams per kilogram of body weight. The ASDI is 
the amount of total residues of ceftiofur that may safely be consumed in 
a single meal. The ASDI is used to derive the tolerance for residues of 
desfuroylceftiofur at the injection site.
    (b) Tolerances--(1) Poultry, and sheep. A tolerance for residues of 
ceftiofur in edible tissue is not required.
    (2) Swine. The tolerances for desfuroylceftiofur (marker residue) 
are:
    (i) Kidney (target tissue). 0.25 parts per million (ppm).
    (ii)Liver. 3 ppm.
    (iii) Muscle. 2 ppm.
    (3) Cattle. The tolerances for desfuroylceftiofur (marker residue) 
are:

[[Page 374]]

    (i) Kidney (target tissue). 0.4 ppm.
    (ii) Liver. 2 ppm.
    (iii)Muscle. 1 ppm.
    (iv) Milk. 0.1 ppm.

[63 FR 53579, Oct. 6, 1998, as amended at 68 FR 60296, Oct. 22, 2003; 69 
FR 43892, July 23, 2004; 71 FR 39546, July 13, 2006]



Sec. 556.115  Cephapirin.

    A tolerance of 0.02 parts per million (ppm) is established for 
residues of cephapirin in the milk and 0.1 ppm in the uncooked edible 
tissues of dairy cattle.

[40 FR 57454, Dec. 10, 1975]



Sec. 556.120  Chlorhexidine.

    A tolerance of zero is established for residues of chlorhexidine in 
the uncooked edible tissues of calves.



Sec. 556.150  Chlortetracycline.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
tetracyclines including chlortetracycline, oxytetracycline, and 
tetracycline is 25 micrograms per kilogram of body weight per day.
    (b) Tolerances. (1) Tolerances are established for the sum of 
tetracycline residues in tissues of beef cattle, nonlactating dairy 
cows, calves, swine, sheep, chickens, turkeys, and ducks, of 2 parts per 
million (ppm) in muscle, 6 ppm in liver, and 12 ppm in fat and kidney.
    (2) A tolerance is established for residues of chlortetracycline in 
eggs of 0.4 ppm.

[63 FR 52158, Sept. 30, 1998, as amended at 63 FR 57246, Oct. 27, 1998]



Sec. 556.160  Clopidol.

    Tolerances for residues of clopidol (3,5-dichloro-2,6-dimethyl-4-
pyridinol) in food are established as follows:
    (a) In cereal grains, vegetables, and fruits: 0.2 part per million.
    (b) In chickens and turkeys:
    (1) 15 parts per million in uncooked liver and kidney.
    (2) 5 parts per million in uncooked muscle.
    (c) In cattle, sheep, and goats:
    (1) 3 parts per million in uncooked kidney.
    (2) 1.5 parts per million in uncooked liver.
    (3) 0.2 part per million in uncooked muscle.
    (d) In swine: 0.2 part per million in uncooked edible tissues.
    (e) In milk: 0.02 part per million (negligible residue).



Sec. 556.163  Clorsulon.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
clorsulon is 8 micrograms per kilogram of body weight per day.
    (b) Tolerances--(1) Cattle--(i) Kidney (the target tissue). The 
tolerance for parent clorsulon (the marker residue) is 1.0 part per 
million.
    (ii) Muscle. The tolerance for parent clorsulon (the marker residue) 
is 0.1 part per million.
    (2) [Reserved]

[66 FR 35544, July 6, 2001]



Sec. 556.165  Cloxacillin.

    A tolerance of 0.01 part per million is established for negligible 
residues of cloxacillin in the uncooked edible tissues of cattle and in 
milk.

[40 FR 28792, July 9, 1975]



Sec. 556.167  Colistimethate.

    A tolerance for residues of colistimethate in the edible tissues of 
chickens is not required.

[63 FR 13123, Mar. 18, 1998]



Sec. 556.169  Danofloxacin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
danofloxacin is 2.4 micrograms per kilogram of body weight per day.
    (b) Tolerances--(1) Cattle--(i) Liver (the target tissue). The 
tolerance for parent danofloxacin (the marker residue) is 0.2 part per 
million (ppm).
    (ii) Muscle. The tolerance for parent danofloxacin (the marker 
residue) is 0.2 ppm.
    (2) [Reserved]

[67 FR 78973, Dec. 27, 2002]



Sec. 556.170  Decoquinate.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
decoquinate is 75 micrograms per kilogram of body weight per day.
    (b) Tolerances. Tolerances are established for residues of 
decoquinate in

[[Page 375]]

the uncooked, edible tissues of chickens, cattle, and goats as follows:
    (1) 1 part per million (ppm) in skeletal muscle.
    (2) 2 ppm in other tissues.

[64 FR 10103, Mar. 2, 1999]



Sec. 556.180  Dichlorvos.

    A tolerance of 0.1 part per million is established for negligible 
residues of dichlorvos (2,2-dichlorovinyl dimethyl phosphate) in the 
edible tissues of swine.



Sec. 556.185  Diclazuril.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
diclazuril is 25 micrograms per kilogram of body weight per day.
    (b) Tolerances--(1) Chickens--(i) Liver. The tolerance for parent 
diclazuril (the marker residue) is 3 parts per million (ppm).
    (ii) Muscle. The tolerance for parent diclazuril (the marker 
residue) is 0.5 ppm.
    (iii) Skin/fat. The tolerance for parent diclazuril (the marker 
residue) is 1 ppm.
    (2) Turkeys--(i) Liver. The tolerance for parent diclazuril (the 
marker residue) is 3 ppm.
    (ii) Muscle. The tolerance for parent diclazuril (the marker 
residue) is 0.5 ppm.
    (iii) Skin/fat. The tolerance for parent diclazuril (the marker 
residue) is 1 ppm.

[64 FR 35923, July 2, 1999. Redesignated and amended at 66 FR 62917, 
Dec. 4, 2001]



Sec. 556.200  Dihydrostreptomycin.

    Tolerances are established for residues of dihydrostreptomycin in 
uncooked, edible tissues of cattle and swine of 2.0 parts per million 
(ppm) in kidney and 0.5 ppm in other tissues, and 0.125 ppm in milk.

[59 FR 41977, Aug. 16, 1994]



Sec. 556.225  Doramectin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
doramectin is 0.75 microgram per kilogram of body weight per day.
    (b) Tolerances--(1) Cattle. A tolerance of 100 parts per billion is 
established for parent doramectin (marker residue) in liver (target 
tissue) and of 30 parts per billion for parent doramectin in muscle.
    (2) Swine. A tolerance is established for parent doramectin (marker 
residue) in liver (target tissue) of 160 parts per billion.

[63 FR 68184, Dec. 10, 1998]



Sec. 556.226  Enrofloxacin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
enrofloxacin is 3 micrograms per kilogram of body weight per day.
    (b) Tolerances. The tolerances for enrofloxacin are:
    (1) Cattle--(i) Liver (target tissue). 0.1 part per million (ppm) 
desethylene ciprofloxacin (the marker residue).
    (ii) [Reserved]
    (2) Swine--(i) Liver (target tissue). 0.5 ppm enrofloxacin (the 
marker residue).
    (ii) [Reserved]
    (c) Related conditions of use. See Sec. 522.812 of this chapter.

[73 FR 21819, Apr. 23, 2008]



Sec. 556.227  Eprinomectin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
eprinomectin is 10 micrograms per kilogram of body weight per day.
    (b) Tolerances. The tolerances for eprinomectin B1a 
(marker residue) are:
    (1) Cattle--(i) Liver (target tissue): 1.5 parts per million.
    (ii) Muscle: 100 parts per billion (ppb).
    (iii) Milk: 12 ppb.
    (2) [Reserved]
    (c) Related conditions of use. See Sec. Sec. 522.814 and 524.814 of 
this chapter.

[63 FR 59715, Nov. 5, 1998, as amended at 76 FR 72619, Nov. 25, 2011]



Sec. 556.230  Erythromycin.

    Tolerances for residues of erythromycin in food are established as 
follows:
    (a) 0.1 part per million in uncooked edible tissues of beef cattle 
and swine.
    (b) Zero in milk.
    (c) 0.025 part per million in uncooked eggs.
    (d) 0.125 part per million (negligible residue) in uncooked edible 
tissues of chickens and turkeys.

[40 FR 13942, Mar. 27, 1975, as amended at 58 FR 43795, Aug. 18, 1993]

[[Page 376]]



Sec. 556.240  Estradiol and related esters.

    No residues of estradiol, resulting from the use of estradiol or any 
of the related esters, are permitted in excess of the following 
increments above the concentrations of estradiol naturally present in 
untreated animals:
    (a) In uncooked edible tissues of heifers, steers, and calves:
    (1) 120 parts per trillion for muscle.
    (2) 480 parts per trillion for fat.
    (3) 360 parts per trillion for kidney.
    (4) 240 parts per trillion for liver.
    (b) [Reserved]

[49 FR 13873, Apr. 9, 1984, as amended at 56 FR 67175, Dec. 30, 1991; 76 
FR 16291, Mar. 23, 2011]



Sec. 556.260  Ethopabate.

    Tolerance for residues of ethopabate converted to metaphenetidine 
are established in the edible tissues of chickens as follows:
    (a) 1.5 parts per million in uncooked liver and kidney.
    (b) 0.5 part per million in uncooked muscle.



Sec. 556.273  Famphur.

    Tolerances are established for residues of famphur including its 
oxygen analog in or on meat, fat, or meat byproducts of cattle at 0.1 
part per million.

[62 FR 55161, Oct. 23, 1997]



Sec. 556.275  Fenbendazole.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
fenbendazole is 40 micrograms per kilogram of body weight per day.
    (b) Tolerances--(1) Cattle--(i) Liver (the target tissue). The 
tolerance for parent fenbendazole (the marker residue) is 0.8 part per 
million (ppm).
    (ii) Muscle. The tolerance for parent fenbendazole (the marker 
residue) is 0.4 ppm.
    (iii) Milk. The tolerance for fenbendazole sulfoxide metabolite (the 
marker residue in cattle milk) is 0.6 ppm.
    (2) Swine--(i) Liver (the target tissue). The tolerance for parent 
fenbendazole (the marker residue) is 6 ppm.
    (ii) Muscle. The tolerance for parent fenbendazole (the marker 
residue) is 2 ppm.
    (3) Turkeys--(i) Liver (the target tissue). The tolerance for 
fenbendazole sulfone (the marker residue) is 6 ppm.
    (ii) Muscle. The tolerance for fenbendazole sulfone (the marker 
residue) is 2 ppm.
    (4) Goats--(i) Liver (the target tissue). The tolerance for parent 
fenbendazole (the marker residue) is 0.8 ppm.
    (ii) Muscle. The tolerance for parent fenbendazole (the marker 
residue) is 0.4 ppm.

[65 FR 20733, Apr. 18, 2000, as amended at 65 FR 41588, July 6, 2000; 65 
FR 50914, Aug. 22, 2000]



Sec. 556.277  Fenprostalene.

    A tolerance for marker residue of fenprostalene in cattle is not 
needed. The safe concentrations for the total residues of fenprostalene 
in the uncooked edible tissues of cattle are 10 parts per billion in 
muscle, 20 parts per billion in liver, 30 parts per billion in kidney, 
40 parts per billion in fat, and 100 parts per billion in the injection 
site. As used in this section ``tolerance'' refers to a concentration of 
a marker residue in the target tissue selected to monitor for total 
residues of the drug in the target animal, and ``safe concentrations'' 
refer to the concentrations of total residues considered safe in edible 
tissues.

[49 FR 26716, June 29, 1984]



Sec. 556.283  Florfenicol.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
florfenicol is 10 micrograms per kilogram of body weight per day.
    (b) Tolerances--(1) Cattle--(i) Liver (the target tissue). The 
tolerance for florfenicol amine (the marker residue) is 3.7 parts per 
million (ppm).
    (ii) Muscle. The tolerance for florfenicol amine (the marker 
residue) is 0.3 ppm.
    (2) Swine--(i) Liver (the target tissue). The tolerance for parent 
florfenicol (the marker residue) is 2.5 ppm.
    (ii) Muscle. The tolerance for parent florfenicol (the marker 
residue) is 0.2 ppm.
    (3) Catfish. The tolerance for florfenicol amine (the marker 
residue) in muscle (the target tissue) is 1 ppm.

[[Page 377]]

    (4) Salmonids. The tolerance for florfenicol amine (the marker 
residue) in muscle/skin (the target tissues) is 1 ppm.
    (c) Related conditions of use. See Sec. Sec. 520.955, 522.955, 
522.956, and 558.261 of this chapter.

[76 FR 16291, Mar. 23, 2011]



Sec. 556.286  Flunixin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
flunixin is 0.72 micrograms per kilogram of body weight per day.
    (b) Tolerances--(1) Cattle. The tolerance for flunixin free acid 
(the marker residue) is:
    (i) Liver (the target tissue). 125 parts per billion (ppb).
    (ii) Muscle. 25 ppb.
    (iii) Milk: 2 ppb 5-hydroxy flunixin.
    (2) Swine. The tolerance for flunixin free acid (the marker residue) 
is:
    (i) Liver (the target tissue). 30 ppb.
    (ii) Muscle. 25 ppb.
    (c) Related conditions of use. See Sec. Sec. 522.956 and 522.970 of 
this chapter.

[63 FR 38750, July 20, 1998, as amended at 69 FR 60309, Oct. 8, 2004; 70 
FR 70999, Nov. 25, 2005; 76 FR 16291, Mar. 23, 2011]



Sec. 556.292  Gamithromycin.

    (a) Acceptable Daily Intake (ADI). The ADI for total residues of 
gamithromycin is 10 micrograms per kilogram of body weight per day.
    (b) Tolerances. The tolerances for gamithromycin (the marker 
residue) are:
    (1) Cattle--(i) Liver (the target tissue): 500 parts per billion 
(ppb).
    (ii) Muscle. 150 ppb.
    (2) [Reserved]
    (c) Related conditions of use. See Sec. 522.1014 of this chapter.

[76 FR 57907, Sept. 19, 2011]



Sec. 556.300  Gentamicin sulfate.

    (a) A tolerance of 0.1 part per million is established for 
negligible residues of gentamicin sulfate in the uncooked edible tissues 
of chickens and turkeys.
    (b) Tolerances are established for total residues of gentamicin in 
edible tissues of swine as follows: 0.1 part per million in muscle, 0.3 
part per million in liver, and 0.4 part per million in fat and kidney. A 
microbiological determinative procedure and an HPLC confirmatory 
procedure for gentamicin have been developed to assay gentamicin in 
kidney at 0.4 ppm. Since residues of gentamicin as the parent compound 
and total residues are equal, the marker (parent drug) residue 
concentration of 0.4 ppm in kidney corresponds to 0.4 ppm of total 
residue.

[48 FR 791, Jan. 7, 1983, as amended at 61 FR 24441, May 15, 1996]



Sec. 556.304  Gonadotropin.

    (a) Acceptable daily intake (ADI). The ADI for residues of total 
gonadotropins (human chorionic gonadotropin and pregnant mare serum 
gonadotropin) is 42.25 I.U. per kilogram of body weight per day.
    (b) Tolerances. A tolerance for residues of gonadotropin in uncooked 
edible tissues of cattle or of fish is not required.

[64 FR 48545, Sept. 7, 1999]



Sec. 556.308  Halofuginone hydrobromide.

    The marker residue selected to monitor for total residues of 
halofuginone hydrobromide in broilers and turkeys is parent halofuginone 
hydrobromide and the target tissue selected is liver. A tolerance is 
established in broilers of 0.16 part per million and in turkeys of 0.13 
part per million for parent halofuginone hydrobromide in liver. These 
marker residue concentrations in liver correspond to total residue 
concentrations of 0.3 part per million in liver. The safe concentrations 
for total residues of halofuginone hydrobromide in the uncooked edible 
tissues of broilers and turkeys are 0.1 part per million in muscle, 0.3 
part per million in liver, and 0.2 part per million in skin with 
adhering fat. As used in this section, ``tolerance'' refers to a 
concentration of a marker residue in the target tissue selected to 
monitor for total residues of the drug in the target animal, and ``safe 
concentrations'' refers to the concentrations of total residues 
considered safe in edible tissues.

[54 FR 28052, July 5, 1989, as amended at 56 FR 8711, Mar. 1, 1991; 57 
FR 21209, May 19, 1992]

[[Page 378]]



Sec. 556.310  Haloxon.

    A tolerance of 0.1 part per million is established for negligible 
residues of haloxon (3-chloro-7-hydroxy-4-methyl-coumarin bis(2-
chloroethyl) phosphate) in the edible tissues of cattle.

[40 FR 13942, Mar. 27, 1975, as amended at 45 FR 10333, Feb. 15, 1980]



Sec. 556.330  Hygromycin B.

    A tolerance of zero is established for residues of hygromycin B in 
or on eggs and the uncooked edible tissues of swine and poultry.



Sec. 556.344  Ivermectin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
ivermectin is 1 microgram per kilogram of body weight per day.
    (b) Tolerances--(1) Liver. A tolerance is established for 22,23-
dihydroavermectin B1a (marker residue) in liver (target 
tissue) as follows:
    (i) Cattle. 100 parts per billion.
    (ii) Swine. 20 parts per billion.
    (iii) Sheep. 30 parts per billion.
    (iv) Reindeer. 15 parts per billion.
    (v) American bison. 15 parts per billion.
    (2) Muscle. Muscle residues are not indicative of the safety of 
other edible tissues. A tolerance is established for 22,23-
dihydroavermectin B1a (marker residue) in muscle as follows:
    (i) Swine. 20 parts per billion.
    (ii) Cattle. 10 parts per billion.

[63 FR 54352, Oct. 9, 1998, as amended at 64 FR 26671, May 17, 1999]



Sec. 556.346  Laidlomycin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
laidlomycin is 7.5 micrograms per kilogram of body weight per day.
    (b) Tolerance. The tolerance for parent laidlomycin (the marker 
residue) in the liver (the target tissue) of cattle is 0.2 part per 
million (ppm).

[68 FR 42590, July 18, 2003]



Sec. 556.347  Lasalocid.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
lasalocid is 10 micrograms per kilogram of body weight per day.
    (b) Tolerances--(1) Cattle. The tolerance for parent lasalocid (the 
marker residue) in liver (the target tissue) is 0.7 part per million 
(ppm).
    (2) Chickens--(i) Skin with adhering fat (the target tissue). The 
tolerance for parent lasalocid (the marker residue) is 1.2 ppm.
    (ii) Liver. The tolerance for parent lasalocid (the marker residue) 
is 0.4 ppm.
    (3) Turkeys--(i) Liver (the target tissue). The tolerance for parent 
lasalocid (the marker residue) is 0.4 ppm.
    (ii) Skin with adhering fat. The tolerance for parent lasalocid (the 
marker residue) is 0.4 ppm.
    (4) Rabbits. The tolerance for parent lasalocid (the marker residue) 
in liver (the target tissue) is 0.7 ppm.
    (5) Sheep. The tolerance for parent lasalocid (the marker residue) 
in liver (the target tissue) is 1.0 ppm.

[66 FR 19854, Apr. 18, 2001]



Sec. 556.350  Levamisole hydrochloride.

    A tolerance of 0.1 part per million is established for negligible 
residues of levamisole hydrochloride in the edible tissues of cattle, 
sheep, and swine.



Sec. 556.360  Lincomycin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
lincomycin is 25 micrograms per kilogram of body weight per day.
    (b) Chickens. A tolerance for residues of lincomycin in chickens is 
not required.
    (c) Swine. Tolerances for lincomycin of 0.6 part per million in 
liver and 0.1 part per million in muscle are established.

[64 FR 13342, Mar. 18, 1999]



Sec. 556.375  Maduramicin ammonium.

    A tolerance is established for residues of maduramicin ammonium in 
chickens as follows:
    (a) A tolerance for maduramicin ammonium (marker residue) in 
chickens is 0.38 parts per million in fat (target tissue). A tolerance 
refers to the concentration of marker residues in the target tissue used 
to monitor for total drug residues in the target animals.
    (b) The safe concentrations for total maduramicin ammonium residues 
in

[[Page 379]]

uncooked edible chicken tissues are: 0.24 parts per million in muscle; 
0.72 parts per million in liver; 0.48 parts per million in skin; and 
0.48 parts per million in fat. A safe concentration refers to the total 
residue concentration considered safe in edible tissues.

[54 FR 5229, Feb. 2, 1989]



Sec. 556.380  Melengestrol acetate.

    A tolerance of 25 parts per billion is established for residues of 
the parent compound, melengestrol acetate, in fat of cattle.

[59 FR 41241, Aug. 11, 1994]



Sec. 556.410  Metoserpate hydrochloride.

    A tolerance of 0.02 part per million is established for negligible 
residues of metoserpate hydrochloride (methyl-o- methyl-18-epireserpate 
hydrochloride) in uncooked edible tissues of chickens.



Sec. 556.420  Monensin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
monensin is 12.5 micrograms per kilogram of body weight per day.
    (b) Tolerances. The tolerances for residues of monensin are:
    (1) Cattle--(i) Liver. 0.10 part per million (ppm).
    (ii) Muscle, kidney, and fat. 0.05 ppm.
    (iii) Milk. Not required.
    (2) Goats--(i) Edible tissues. 0.05 ppm.
    (ii) [Reserved]
    (3) Chickens, turkeys, and quail. A tolerance for residues of 
monensin in chickens, turkeys, and quail is not required.
    (c) Related conditions of use. See Sec. Sec. 520.1448 and 558.355 
of this chapter.

[64 FR 5159, Feb. 3, 1999, as amended at 69 FR 68783, Nov. 26, 2004; 72 
FR 56897, Oct. 5, 2007]



Sec. 556.425  Morantel tartrate.

    A tolerance of 0.7 part per million is established for N-methyl-1,3-
propanediamine (MAPA, marker residue) in the liver (target tissue) of 
cattle and goats. A tolerance for residues of morantel tartrate in milk 
is not required.

[59 FR 17922, Apr. 15, 1994]



Sec. 556.426  Moxidectin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
moxidectin is 4 micrograms per kilogram of body weight per day.
    (b) Tolerances--(1) Cattle--(i) Fat (the target tissue). The 
tolerance for parent moxidectin (the marker residue) is 900 parts per 
billion (ppb).
    (ii) Liver. The tolerance for parent moxidectin (the marker residue) 
is 200 ppb.
    (iii) Muscle. The tolerance for parent moxidectin (the marker 
residue) is 50 ppb.
    (iv) Milk. The tolerance for parent moxidectin (the marker residue) 
is 40 ppb.
    (2) Sheep--(i) Fat (the target tissue). The tolerance for parent 
moxidectin (the marker residue) is 900 parts per billion (ppb).
    (ii) Liver. The tolerance for parent moxidectin (the marker residue) 
is 200 ppb.
    (iii) Muscle. The tolerance for parent moxidectin (the marker 
residue) is 50 ppb.
    (c) Related conditions of use. See Sec. Sec. 520.1454 and 522.1450 
of this chapter.

[65 FR 36617, June 9, 2000, as amended at 65 FR 76930, Dec. 8, 2000; 70 
FR 36338, June 23, 2005; 70 FR 76163, Dec. 23, 2005]



Sec. 556.428  Narasin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
narasin is 5 micrograms per kilogram of body weight per day.
    (b) Tolerances--(1) Chickens (abdominal fat). The tolerance for 
parent narasin (the marker residue) is 480 parts per billion.
    (2) [Reserved]

[66 FR 23589, May 9, 2001]



Sec. 556.430  Neomycin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
neomycin is 6 micrograms per kilogram of body weight per day.
    (b) Tolerances. Tolerances are established for residues of parent 
neomycin in uncooked edible tissues as follows:
    (1) Cattle, swine, sheep, and goats. 7.2 parts per million (ppm) in 
kidney (target tissue) and fat, 3.6 ppm in liver, and 1.2 ppm in muscle.

[[Page 380]]

    (2) Turkeys. 7.2 ppm in skin with adhearing fat, 3.6 ppm in liver, 
and 1.2 ppm in muscle.
    (3) Milk. A tolerance is established for residues of parent neomycin 
of 0.15 ppm.

[64 FR 31498, June 11, 1999]



Sec. 556.440  Nequinate.

    A tolerance of 0.1 part per million is established for negligible 
residues of nequinate in the uncooked edible tissues of chickens.



Sec. 556.445  Nicarbazin.

    A tolerance of 4 parts per million is established for residues of 
nicarbazin in uncooked chicken muscle, liver, skin, and kidney.

[42 FR 56729, Oct. 28, 1977]



Sec. 556.460  Novobiocin.

    Tolerances for residues of novobiocin are established at 0.1 part 
per million in milk from dairy animals and 1 part per million in the 
uncooked edible tissues of cattle, chickens, turkeys, and ducks.

[47 FR 18590, Apr. 30, 1982]



Sec. 556.470  Nystatin.

    A tolerance of zero is established for residues of nystatin in or on 
eggs and the uncooked edible tissues of swine and poultry.



Sec. 556.480  Oleandomycin.

    Tolerances are established for negligible residues of oleandomycin 
in uncooked edible tissues of chickens, turkeys, and swine at 0.15 part 
per million.



Sec. 556.490  Ormetoprim.

    (a) [Reserved]
    (b) Tolerances. A tolerance of 0.1 part per million (ppm) is 
established for negligible residues of ormetoprim in uncooked edible 
tissues of chickens, turkeys, ducks, salmonids, catfish, and chukar 
partridges.

[64 FR 26672, May 17, 1999]



Sec. 556.495  Oxfendazole.

    Cattle: A tolerance is established for total oxfendazole residues in 
edible cattle tissues based on a marker residue concentration of 0.8 
part per million (ppm) fenbendazole in the target liver tissue. A 
fenbendazole concentration of 0.8 ppm in liver corresponds to a total 
safe concentration of oxfendazole residues of 1.7 ppm in liver. The safe 
concentrations of total oxfendazole residues in other uncooked edible 
cattle tissues are: muscle, 0.84 ppm; kidney, 2.5 ppm; and fat, 3.3 ppm. 
A tolerance refers to the concentration of marker residue in the target 
tissue selected to monitor for total drug residue in the target animal. 
A safe concentration is the total residue considered safe in edible 
tissue.

[55 FR 46943, Nov. 8, 1990]



Sec. 556.500  Oxytetracycline.

    (a) Acceptable daily intake (ADI). The ADI for total tetracycline 
residues (chlortetracycline, oxytetracycline, and tetracycline) is 25 
micrograms per kilogram of body weight per day.
    (b) Beef cattle, dairy cattle, calves, swine, sheep, chickens, 
turkeys, finfish, and lobster. Tolerances are established for the sum of 
residues of the tetracyclines including chlortetracycline, 
oxytetracycline, and tetracycline, in tissues and milk as follows:
    (1) 2 parts per million (ppm) in muscle.
    (2) 6 ppm in liver.
    (3) 12 ppm in fat and kidney.
    (4) 0.3 ppm in milk.

[63 FR 57246, Oct. 27, 1998, as amended at 66 FR 46370, Sept. 5, 2001; 
69 FR 6557, Feb. 11, 2004]



Sec. 556.510  Penicillin.

    Tolerances are established for residues of penicillin and the salts 
of penicillin in food as follows:
    (a) 0.05 part per million (negligible residue) in the uncooked 
edible tissues of cattle.
    (b) Zero in the uncooked edible tissues of chickens, pheasants, 
quail, swine, and sheep; in eggs; and in milk or in any processed food 
in which such milk has been used.
    (c) 0.01 part per million in the uncooked edible tissues of turkeys.

[40 FR 13942, Mar. 27, 1975, as amended at 43 FR 32749, July 28, 1978]

[[Page 381]]



Sec. 556.513  Piperazine.

    A tolerance of 0.1 part per million piperazine base is established 
for edible tissues of poultry and swine.

[64 FR 23019, Apr. 29, 1999]



Sec. 556.515  Pirlimycin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
pirlimycin is 0.01 milligrams per kilogram of body weight per day.
    (b) Tolerances--(1) Cattle--(i) Liver (the target tissue). The 
tolerance for parent pirlimycin (the marker residue) is 0.5 part per 
million (ppm).
    (ii) Muscle. The tolerance for parent pirlimycin (the marker 
residue) is 0.3 ppm.
    (iii) Milk. The tolerance for parent pirlimycin (the marker residue 
in cattle milk) is 0.4 ppm.
    (2) [Reserved]

[65 FR 61091, Oct. 16, 2000]



Sec. 556.540  Progesterone.

    (a) [Reserved]
    (b) Tolerances. Residues of progesterone are not permitted in excess 
of the following increments above the concentrations of progesterone 
naturally present in untreated animals:
    (1) Cattle and sheep--(i) Muscle: 5 parts per billion (ppb).
    (ii) Liver: 15 ppb.
    (iii) Kidney: 30 ppb.
    (iv) Fat: 30 ppb.
    (2) [Reserved]
    (c) Related conditions of use. See Sec. Sec. 522.1940 and 529.1940 
of this chapter.

[76 FR 57907, Sept. 19, 2011]



Sec. 556.560  Pyrantel tartrate.

    Tolerances are established for residues of pyrantel tartrate in 
edible tissues of swine as follows:
    (a) 10 parts per million in liver and kidney.
    (b) 1 part per million in muscle.



Sec. 556.570  Ractopamine.

    (a) Acceptable Daily Intake (ADI). The ADI for total residues of 
ractopamine hydrochloride is 1.25 micrograms per kilogram of body weight 
per day.
    (b) Tolerances--(1) Cattle--(i) Liver (the target tissue). The 
tolerance for ractopamine hydrochloride (the marker residue) is 0.09 
parts per million (ppm).
    (ii) Muscle. The tolerance for ractopamine hydrochloride (the marker 
residue) is 0.03 ppm.
    (2) Swine--(i) Liver (the target tissue). The tolerance for 
ractopamine hydrochloride (the marker residue) is 0.15 ppm.
    (ii) Muscle. The tolerance for ractopamine hydrochloride (the marker 
residue) is 0.05 ppm.
    (3) Turkeys--(i) Liver (the target tissue). The tolerance for 
ractopamine (the marker residue) is 0.45 ppm.
    (ii) Muscle. The tolerance for ractopamine (the marker residue) is 
0.1 ppm.

[68 FR 54659, Sept. 18, 2003, as amended at 73 FR 72715, Dec. 1, 2008]



Sec. 556.580  Robenidine hydrochloride.

    Tolerances are established for residues of robenidine hydrochloride 
in edible tissues of chickens as follows:
    (a) 0.2 part per million in skin and fat.
    (b) 0.1 part per million (negligible residue) in edible tissues 
other than skin and fat.



Sec. 556.592  Salinomycin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
salinomycin is 0.005 milligram per kilogram of body weight per day.
    (b) [Reserved]

[65 FR 70791, Nov. 28, 2000]



Sec. 556.597  Semduramicin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
semduramicin is 180 micrograms per kilogram of body weight per day.
    (b) Tolerances--(1) Broiler chickens. Tolerances are established for 
residues of parent semduramicin in uncooked edible tissues of 400 parts 
per billion (ppb) in liver and 130 ppb in muscle.
    (2) [Reserved]

[64 FR 48296, Sept. 3, 1999]



Sec. 556.600  Spectinomycin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
spectinomycin is 25 micrograms per kilogram of body weight per day.

[[Page 382]]

    (b) Chickens and turkeys. A tolerance of 0.1 part per million (ppm) 
for negligible residues of spectinomycin in uncooked edible tissues of 
chickens and turkeys is established.
    (c) Cattle. A tolerance of 4 ppm for parent spectinomycin (marker 
residue) in kidney (target tissue) is established. A tolerance of 0.25 
ppm for parent spectinomycin in cattle muscle is established.

[63 FR 24107, May 1, 1998; 63 FR 38304, July 16, 1998]



Sec. 556.610  Streptomycin.

    Tolerances are established for residues of streptomycin in uncooked, 
edible tissues of chickens, swine, and calves of 2.0 parts per million 
(ppm) in kidney and 0.5 ppm in other tissues.

[58 FR 47211, Sept. 8, 1993]



Sec. 556.620  Sulfabromomethazine sodium.

    Tolerances for residues of sulfabromomethazine sodium in food are 
established as follows:
    (a) In the uncooked edible tissues of cattle at 0.1 part per million 
(negligible residue).
    (b) In milk at 0.01 part per million (negligible residue).

[47 FR 30244, July 13, 1982]



Sec. 556.625  Sodium sulfachloropyrazine monohydrate.

    A tolerance of zero is established for residues of sodium 
sulfachloropyrazine monohydrate in the uncooked edible tissues of 
chickens.



Sec. 556.630  Sulfachlorpyridazine.

    A tolerance of 0.1 part per million is established for negligible 
residues of sulfachlorpyridazine in uncooked edible tissues of calves 
and swine.



Sec. 556.640  Sulfadimethoxine.

    (a) [Reserved]
    (b) Tolerances. (1) A tolerance of 0.1 part per million (ppm) is 
established for negligible residues of sulfadimethoxine in uncooked 
edible tissues of chickens, turkeys, cattle, ducks, salmonids, catfish, 
and chukar partridges.
    (2) A tolerance of 0.01 ppm is established for negligible residues 
of sulfadimethoxine in milk.

[64 FR 26672, May 17, 1999]



Sec. 556.650  Sulfaethoxypyridazine.

    Tolerances for residues of sulfaethoxypyridazine in food are 
established as follows:
    (a) Zero in the uncooked edible tissues of swine and in milk.
    (b) 0.1 part per million (negligible residue) in uncooked edible 
tissues of cattle.



Sec. 556.660  Sulfamerazine.

    A tolerance of zero is established for residues of sulfamerazine 
(N\1\-[4-methyl-2-pyrimidinyl]sulfanilamide) in the uncooked edible 
tissues of trout.



Sec. 556.670  Sulfamethazine.

    A tolerance of 0.1 part per million is established for negligible 
residues of sulfamethazine in the uncooked edible tissues of chickens, 
turkeys, cattle, and swine.

[47 FR 25323, June 11, 1982]



Sec. 556.685  Sulfaquinoxaline.

    A tolerance of 0.1 part per million is established for negligible 
residues of sulfaquinoxaline in the uncooked edible tissues of chickens, 
turkeys, calves, and cattle.

[61 FR 24443, May 15, 1996]



Sec. 556.690  Sulfathiazole.

    A tolerance of 0.1 part per million is established for negligible 
residues of sulfathiazole in the uncooked edible tissues of swine.



Sec. 556.700  Sulfomyxin.

    A tolerance of zero is established for residues of sulfomyxin (N-
sulfomethyl-polymyxin B sodium salt) in uncooked edible tissues from 
chickens and turkeys.



Sec. 556.710  Testosterone propionate.

    No residues of testosterone, resulting from the use of testosterone 
propionate, are permitted in excess of the following increments above 
the concentrations of testosterone naturally present in untreated 
animals:

[[Page 383]]

    (a) In uncooked edible tissues of heifers:
    (1) 0.64 part per billion in muscle.
    (2) 2.6 parts per billion in fat.
    (3) 1.9 parts per billion in kidney.
    (4) 1.3 parts per billion in liver.
    (b) [Reserved]

[52 FR 27683, July 23, 1987]



Sec. 556.720  Tetracycline.

    (a) Acceptable daily intake (ADI). The ADI for total tetracycline 
residues (chlortetracycline, oxytetracycline, and tetracycline) is 25 
micrograms per kilogram of body weight per day.
    (b) Tolerances. Tolerances are established for the sum of 
tetracycline residues in tissues of calves, swine, sheep, chickens, and 
turkeys, of 2 parts per million (ppm) in muscle, 6 ppm in liver, and 12 
ppm in fat and kidney.

[63 FR 57246, Oct. 27, 1998]



Sec. 556.730  Thiabendazole.

    Tolerances are established at 0.1 part per million for negligible 
residues of thiabendazole in uncooked edible tissues of cattle, goats, 
sheep, pheasants, and swine, and at 0.05 part per million for negligible 
residues in milk.

[40 FR 13942, Mar. 27, 1975, as amended at 49 FR 29958, July 25, 1984]



Sec. 556.733  Tildipirosin.

    (a) Acceptable Daily Intake (ADI). The ADI for total residues of 
tildipirosin is 10 micrograms per kilogram of body weight per day.
    (b) Tolerances. The tolerances for tildipirosin (the marker residue) 
are:
    (1) Cattle--(i) Liver (the target tissue): 10 parts per million.
    (ii) [Reserved]
    (2) [Reserved]
    (c) Related conditions of use. See Sec. 522.2460 of this chapter.

[77 FR 39391, July 3, 2012]



Sec. 556.735  Tilmicosin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
tilmicosin is 25 micrograms per kilogram of body weight per day.
    (b) Tolerances--(1) Cattle--(i) Liver (the target tissue). The 
tolerance for parent tilmicosin (the marker residue) is 1.2 parts per 
million (ppm).
    (ii) Muscle. The tolerance for parent tilmicosin (the marker 
residue) is 0.1 ppm.
    (2) Swine--(i) Liver (the target tissue). The tolerance for parent 
tilmicosin (the marker residue) is 7.5 ppm.
    (ii) Muscle. The tolerance for parent tilmicosin (the marker 
residue) is 0.1 ppm.
    (3) Sheep--(i) Liver (the target tissue). The tolerance for parent 
tilmicosin (the marker residue) is 1.2 ppm.
    (ii) Muscle. The tolerance for parent tilmicosin (the marker 
residue) is 0.1 ppm.

[64 FR 13679, Mar. 22, 1999, as amended at 67 FR 72368, Dec. 5, 2002]



Sec. 556.738  Tiamulin.

    A tolerance of 0.6 part per million is established for 8-alpha-
hydroxymutilin (marker compound) in liver (target tissue) of swine.

[62 FR 12086, Mar. 14, 1997]



Sec. 556.739  Trenbolone.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
trenbolone is 0.4 microgram per kilogram of body weight per day.
    (b) Tolerances. A tolerance for total trenbolone residues in 
uncooked edible tissues of cattle is not needed.

[64 FR 18574, Apr. 15, 1999]



Sec. 556.740  Tylosin.

    Tolerances are established for residues of tylosin in edible 
products of animals as follows:
    (a) In chickens and turkeys: 0.2 part per million (negligible 
residue) in uncooked fat, muscle, liver, and kidney.
    (b) In cattle: 0.2 part per million (negligible residue) in uncooked 
fat, muscle, liver, and kidney.
    (c) In swine: 0.2 part per million (negligible residue) in uncooked 
fat, muscle, liver, and kidney.
    (d) In milk: 0.05 part per million (negligible residue).
    (e) In eggs: 0.2 part per million (negligible residue).



Sec. 556.741  Tripelennamine.

    A tolerance of 200 parts per billion (ppb) is established for 
residues of

[[Page 384]]

tripelennamine in uncooked edible tissues of cattle and 20 ppb in milk.

[62 FR 4164, Jan. 29, 1997]



Sec. 556.745  Tulathromycin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
tulathromycin is 15 micrograms per kilogram of body weight per day.
    (b) Tolerances--(1) Cattle--(i) Liver (the target tissue). The 
tolerance for CP-60,300 (the marker residue) is 5.5 parts per million 
(ppm).
    (ii) [Reserved]
    (2) Swine--(i) Kidney (the target tissue). The tolerance for CP-
60,300 (the marker residue) is 15 ppm.
    (ii) [Reserved]
    (c) Related conditions of use. See Sec. 522.2630 of this chapter.

[70 FR 39918, July 12, 2005]



Sec. 556.748  Tylvalosin.

    (a) Acceptable Daily Intake (ADI). The ADI for total residues of 
tylvalosin is 47.7 micrograms per kilogram of body weight per day.
    (b) Tolerances. A tolerance for tylvalosin in edible tissues of 
swine is not required.
    (c) Related conditions of use. See Sec. 520.2645 of this chapter.

[77 FR 55415, Sept. 10, 2012]



Sec. 556.750  Virginiamycin.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
virginiamycin is 250 micrograms per kilogram of body weight per day.
    (b) Tolerances--(1) Swine. Tolerances are established for residues 
of virginiamycin in uncooked edible tissues of 0.4 part per million 
(ppm) in kidney, skin, and fat, 0.3 ppm in liver, and 0.1 ppm in muscle.
    (2) Broiler chickens and cattle. A tolerance for residues of 
virginiamycin is not required.

[64 FR 48296, Sept. 3, 1999]



Sec. 556.760  Zeranol.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
zeranol is 0.00125 milligrams per kilogram of body weight per day.
    (b) Tolerances. The tolerances for residues of zeranol in edible 
tissues are:
    (1) Cattle. A tolerance is not needed.
    (2) Sheep. 20 parts per billion.
    (c) Related conditions of use. See Sec. 522.2680 of this chapter.

[40 FR 13942, Mar. 27, 1975, as amended at 54 FR 31950, Aug. 3, 1989; 67 
FR 6867, Feb. 14, 2002; 70 FR 15759, Mar. 29, 2005]



Sec. 556.765  Zilpaterol.

    (a) Acceptable daily intake (ADI). The ADI for total residues of 
zilpaterol is 0.083 micrograms per kilogram of body weight per day.
    (b) Tolerances--(1) Cattle--(i) Liver (the target tissue). The 
tolerance for zilpaterol freebase (the marker residue) is 12 parts per 
billion (ppb).
    (ii) [Reserved]
    (2) [Reserved]

[71 FR 53005, Sept. 8, 2006]



Sec. 556.770  Zoalene.

    Tolerances are established for residues of zoalene (3,5-dinitro-o- 
toluamide) and its metabolite 3-amino-5-nitro-o-toluamide in food as 
follows:
    (a) In edible tissues of chickens:
    (1) 6 parts per million in uncooked liver and kidney.
    (2) 3 parts per million in uncooked muscle tissue.
    (3) 2 parts per million in uncooked fat.
    (b) In edible tissues of turkeys: 3 parts per million in uncooked 
muscle tissue and liver.



PART 558_NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS--Table of Contents



                      Subpart A_General Provisions

Sec.
558.3 Definitions and general considerations applicable to this part.
558.4 Requirement of a medicated feed mill license.
558.5 Requirements for liquid medicated feed.
558.6 Veterinary feed directive drugs.
558.15 Antibiotic, nitrofuran, and sulfonamide drugs in the feed of 
          animals.

       Subpart B_Specific New Animal Drugs For Use in Animal Feeds

558.55 Amprolium.
558.58 Amprolium and ethopabate.
558.59 Apramycin.
558.62 Arsanilic acid.
558.76 Bacitracin methylene disalicylate.

[[Page 385]]

558.78 Bacitracin zinc.
558.95 Bambermycins.
558.105 [Reserved]
558.115 Carbadox.
558.120 Carbarsone (not U.S.P.).
558.128 Chlortetracycline.
558.140 Chlortetracycline and sulfamethazine.
558.145 Chlortetracycline, procaine penicillin, and sulfamethazine.
558.155 Chlortetracycline, sulfathiazole, penicillin.
558.175 Clopidol.
558.185 Coumaphos.
558.195 Decoquinate.
558.198 Diclazuril.
558.205 Dichlorvos.
558.235 Efrotomycin.
558.248 Erythromycin thiocyanate.
558.254 Famphur.
558.258 Fenbendazole.
558.261 Florfenicol.
558.265 Halofuginone hydrobromide.
558.274 Hygromycin B.
558.295 Iodinated casein.
558.300 Ivermectin.
558.305 Laidlomycin.
558.311 Lasalocid.
558.325 Lincomycin.
558.340 Maduramicin ammonium.
558.342 Melengestrol.
558.348 Mibolerone.
558.355 Monensin.
558.360 Morantel tartrate.
558.363 Narasin.
558.364 Neomycin sulfate.
558.365 Nequinate.
558.366 Nicarbazin.
558.369 Nitarsone.
558.415 Novobiocin.
558.430 Nystatin.
558.435 Oleandomycin.
558.450 Oxytetracycline.
558.455 Oxytetracycline and neomycin.
558.460 Penicillin.
558.464 Poloxalene.
558.465 Poloxalene free-choice liquid Type C feed.
558.485 Pyrantel.
558.500 Ractopamine.
558.515 Robenidine hydrochloride.
558.530 Roxarsone.
558.550 Salinomycin.
558.555 Semduramicin.
558.575 Sulfadimethoxine, ormetoprim.
558.582 Sulfamerazine.
558.586 Sulfaquinoxaline.
558.600 Tiamulin.
558.615 Thiabendazole.
558.618 Tilmicosin.
558.625 Tylosin.
558.630 Tylosin and sulfamethazine.
558.635 Virginiamycin.
558.665 Zilpaterol.
558.680 Zoalene.

    Authority: 21 U.S.C. 360b, 371.

    Source: 40 FR 13959, Mar. 27, 1975, unless otherwise noted.



                      Subpart A_General Provisions



Sec. 558.3  Definitions and general considerations applicable to 
this part.

    (a) Regulations in this part provide for approved uses of drugs and 
combinations of drugs in animal feeds. Approved combinations of such 
drugs are specifically identified or incorporated by cross-reference. 
Unless specifically provided for by the regulations, a combination of 
two or more drugs is not approved.
    (b) The following definitions apply to terms used in this part:
    (1) New animal drugs approved for use in animal feed are placed in 
two categories as follows:
    (i) Category I--These drugs require no withdrawal period at the 
lowest use level in each species for which they are approved.
    (ii) Category II--These drugs require a withdrawal period at the 
lowest use level for at least one species for which they are approved, 
or are regulated on a ``no-residue'' basis or with a zero tolerance 
because of a carcinogenic concern regardless of whether a withdrawal 
period is required, or are a veterinary feed directive drug.
    (2) A ``Type A medicated article'' is intended solely for use in the 
manufacture of another Type A medicated article or a Type B or Type C 
medicated feed. It consists of a new animal drug(s), with or without 
carrier (e.g., calcium carbonate, rice hull, corn, gluten) with or 
without inactive ingredients. The manufacture of a Type A medicated 
article requires an application approved under Sec. 514.105 of this 
chapter or an index listing granted under Sec. 516.151 of this chapter.
    (3) A ``Type B medicated feed'' is intended solely for the 
manufacture of other medicated feeds (Type B or Type C). It contains a 
substantial quantity of nutrients including vitamins and/or minerals 
and/or other nutritional ingredients in an amount not less than 25 
percent of the weight. It is manufactured by diluting a Type A medicated 
article or another Type B medicated feed. The maximum concentration of 
animal drug(s) in a Type B medicated

[[Page 386]]

feed is 200 times the highest continuous use level for Category I drugs 
and 100 times the highest continuous use level for Category II drugs. 
The term ``highest continuous use level'' means the highest dosage at 
which the drug is approved for continuous use (14 days or more), or, if 
the drug is not approved for continuous use, it means the highest level 
used for disease prevention or control. If the drug is approved for 
multiple species at different use levels, the highest approved level of 
use would govern under this definition. The manufacture of a Type B 
medicated feed from a Category II, Type A medicated article requires a 
medicated feed mill license application approved under Sec. 515.20 of 
this chapter.
    (4) A ``Type C medicated feed'' is intended as the complete feed for 
the animal or may be fed ``top dressed'' (added on top of usual ration) 
on or offered ``free-choice'' (e.g., supplement) in conjunction with 
other animal feed. It contains a substantial quantity of nutrients 
including vitamins, minerals, and/or other nutritional ingredients. It 
is manufactured by diluting a Type A medicated article or a Type B 
medicated feed. A Type C medicated feed may be further diluted to 
produce another Type C medicated feed. The manufacture of a Type C 
medicated feed from a Category II, Type A medicated article requires a 
medicated feed mill license application approved under Sec. 515.20 of 
this chapter.
    (5) A Type B or Type C medicated feed manufactured from a drug 
component (bulk or ``drum-run'' (dried crude fermentation product)) 
requires an application approved under Sec. 514.105 of this chapter or 
an index listing granted under Sec. 516.151 of this chapter.
    (6) A ``veterinary feed directive (VFD) drug'' is a new animal drug 
approved under section 512(b) of the Federal Food, Drug, and Cosmetic 
Act (the act) or listed in the index under section 572 of the act for 
use in or on animal feed. Use of a VFD drug must be under the 
professional supervision of a licensed veterinarian.
    (7) A ``veterinary feed directive'' is a written statement issued by 
a licensed veterinarian in the course of the veterinarian's professional 
practice that orders the use of a VFD drug in or on an animal feed. This 
written statement authorizes the client (the owner of the animal or 
animals or other caretaker) to obtain and use the VFD drug in or on an 
animal feed to treat the client's animals only in accordance with the 
directions for use approved or indexed by the Food and Drug 
Administration (FDA). A veterinarian may issue a VFD only if a valid 
veterinarian-client-patient relationship exists, as defined in Sec. 
530.3(i) of this chapter.
    (8) A ``medicated feed'' means a Type B medicated feed as defined in 
paragraph (b)(3) of this section or a Type C medicated feed as defined 
in paragraph (b)(4) of this section.
    (9) For the purposes of this part, a ``distributor'' means any 
person who distributes a medicated feed containing a VFD drug to another 
distributor or to the client-recipient of the VFD.
    (10) An ``animal production facility'' is a location where animals 
are raised for any purpose, but does not include the specific location 
where medicated feed is made.
    (11) An ``acknowledgment letter'' is a written communication 
provided to a distributor by a consignee who is not the ultimate user of 
medicated feed containing a VFD drug. An acknowledgment letter affirms 
that the consignee will not ship such medicated animal feed to an animal 
production facility that does not have a VFD, and will not ship such 
feed to another distributor without receiving a similar written 
acknowledgment letter.

[51 FR 7392, Mar. 3, 1986, as amended at 52 FR 2682, Jan. 26, 1987; 54 
FR 51386, Dec. 15, 1989; 56 FR 19268, Apr. 26, 1991; 64 FR 63206, Nov. 
19, 1999; 65 FR 76929, Dec. 8, 2000; 72 FR 69130, Dec. 6, 2007]



Sec. 558.4  Requirement of a medicated feed mill license.

    (a) A feed manufacturing facility must possess a medicated feed mill 
license in order to manufacture a Type B or Type C medicated feed from a 
Category II, Type A medicated article.
    (b) The manufacture of the following types of feed are exempt from 
the required license, unless otherwise specified:

[[Page 387]]

    (1) Type B or Type C medicated feed using Category I, Type A 
medicated articles or Category I, Type B or Type C medicated feeds; and
    (2) Type B or Type C medicated feed using Category II, Type B or 
Type C medicated feeds.
    (c) The use of Type B and Type C medicated feeds shall also conform 
to the conditions of use provided for in subpart B of this part and in 
Sec. 558.15 of this chapter.
    (d) This paragraph identifies each drug by category, the maximum 
level of drug in Type B medicated feeds, and the assay limits for the 
drug in Type A medicated articles and Type B and Type C medicated feeds, 
as follows:

                                                   Category I
----------------------------------------------------------------------------------------------------------------
                                            Assay
                                            limits                                 Assay limits percent \1\ type
                  Drug                   percent \1\     Type B maximum (200x)                B/C \2\
                                            type A
----------------------------------------------------------------------------------------------------------------
Amprolium with Ethopabate..............       94-114  22.75 g/lb (5.0%).........  80-120.
Bacitracin methylene disalicylate......       85-115  25.0 g/lb (5.5%)..........  70-130.
Bacitracin zinc........................       84-115  5.0 g/lb (1.1%)...........  70-130.
Bambermycins...........................       90-110  800 g/ton (0.09%).........  80-120/70-130.
Chlortetracycline......................       85-115  40.0 g/lb (8.8%)..........  80-115/70-130.
Coumaphos..............................       95-115  6.0 g/lb (1.3%)...........  80-120.
Decoquinate............................       90-105  2.72 g/lb (0.6%)..........  80-120.
Dichlorvos.............................      100-115  33.0 g/lb (7.3%)..........  90-120/80-130.
Diclazuril.............................       90-110  182 g/t (0.02%)...........  85-115/70-120.
Efrotomycin............................       94-113  1.45 g/lb (0.32%).........  80-120.
Erythromycin (thiocyanate salt)........       85-115  9.25 g/lb (2.04%).........  <20g/ton 70-115/150-50:20g/ton 75-125.
Iodinated casein.......................       85-115  20.0 g/lb (4.4%)..........  75-125.
Laidlomycin propionate potassium.......       90-110  1 g/lb (0.22%)............  90-115/85-115.
Lasalocid..............................       95-115  40.0 g/lb (8.8%)..........  Type B (cattle and sheep): 80-
                                                                                   120; Type C (all): 75-125.
Lincomycin.............................       90-115  20.0 g/lb (4.4%)..........  80-130.
Melengestrol acetate...................       90-110  10.0 g/ton (0.0011%)......  70-120.
Monensin...............................       85-115  40.0 g/lb (8.8%)..........  Chickens, turkeys, and quail:
                                                                                   75-125; Cattle: 5-10 g/ton 80-
                                                                                   120; Cattle: 10-30 g/ton 85-
                                                                                   115; Goats: 20 g/ton 85-115;
                                                                                   Liq. feed: 80-120.
Narasin................................       90-110  7.2 g/lb (1.6%)...........  85-115/75-125.
Nequinate..............................       95-112  1.83 g/lb (0.4%)..........  80-120.
Niclosamide............................       85-120  225g/lb (49.5%)...........  80-120.
Nystatin...............................       85-125  5.0 g/lb (1.1%)...........  75-125.
Oleandomycin...........................       85-120  1.125 g/lb (0.25%)........  <11.25 g/ton 70-130; 11.25 g/ton 75-125.
Oxytetracycline........................       90-120  20.0 g/lb (4.4%)..........  75-125/65-135.
Penicillin.............................       80-120  10.0 g/lb (2.2%)..........  65-135.
Poloxalene.............................       90-110  54.48 g/lb (12.0%)........  Liq. feed: 85-115.
Ractopamine............................       85-105  2.46 g/lb (0.54%).........  80-110/75-125.
Salinomycin............................       95-115  6.0 g/lb (1.3%)...........  80-120.
Semduramicin (as semduramicin sodium)..       90-110  2.27 g/lb (0.50%).........  80-110
Semduramicin (as semduramicin sodium          90-110  2.27 g/lb (0.50%).........  80-120
 biomass).
Tylosin................................       80-120  10.0 g/lb (2.2%)..........  75-125.
Virginiamycin..........................       85-115  10.0 g/lb (2.2%)..........  70-130.
Zoalene................................       92-104  11.35 g/lb (2.5%).........  85-115.
----------------------------------------------------------------------------------------------------------------
\1\ Percent of labeled amount.
\2\ Values given represent ranges for either Type B or Type C medicated feeds. For those drugs that have two
  range limits, the first set is for a Type B medicated feed and the second set is for a Type C medicated feed.
  These values (ranges) have been assigned in order to provide for the possibility of dilution of a Type B
  medicated feed with lower assay limits to make Type C medicated feed.


                                                   Category II
----------------------------------------------------------------------------------------------------------------
                                            Assay
                                            limits                                 Assay limits percent \1\ Type
                  Drug                   percent \1\     Type B maximum (100x)                B/C \2\
                                            Type A
----------------------------------------------------------------------------------------------------------------
Amprolium..............................       94-114  11.35 g/lb (2.5%).........  80-120.
Apramycin..............................       88-112  7.5 g/lb (1.65%)..........  80-120.
Arsanilic acid.........................       90-110  4.5 g/lb (1.0%)...........  85-115/75-125.
Carbadox...............................       90-110  2.5 g/lb (0.55%)..........  75-125.
Carbarsone.............................       93-102  17.0 g/lb (3.74%).........  85-115.
Clopidol...............................       94-106  11.4 g/lb (2.5%)..........  90-115/80-120.

[[Page 388]]

 
Famphur................................      100-110  5.5 g/lb (1.21%)..........  90-115/80-120.
Fenbendazole...........................       93-113  8.87 g/lb (1.96%).........  75-125
Florfenicol............................       90-110  9.1 g/lb (2.0%)...........  Swine feed: 85-115
                                                                                  Catfish feed: 80-110
                                                                                  Salmonid feed: 80-110
Halofuginone hydrobromide..............       90-115  272.0 g/ton (.03%)........  75-125.
Hygromycin B...........................       90-110  1,200 g/ton (0.13%).......  75-125.
Ivermectin.............................       95-105  1,180 g/ton (0.13%).......  80-110.
Maduramicin ammonium...................       90-110  545 g/ton (.06%)..........  80-120.
Morantel tartrate......................       90-110  66.0 g/lb (14.52%)........  85-115.
Neomycin...............................       80-120  7.0 g/lb (1.54%)..........  70-125.
  Oxytetracycline......................       80-120  10.0 g/lb (2.2%)..........  65-135.
Neomycin sulfate.......................       80-120  100 g/lb (22.0%)..........  70-125.
Nicarbazin (granular)..................       90-110  5.675 g/lb (1.25%)........  85-115/75-125
  Narasin..............................       90-110  5.675 g/lb (1.25%)........  85-115/75-125
Nicarbazin (powder)....................       98-106  5.675 g/lb (1.25%)........  85-115/80-120
Nitarsone..............................       90-110  8.5 g/lb (1.87%)..........  85-120.
  Sulfanitran..........................       85-115  13.6 g/lb (3.0%)..........  75-125.
  Roxarsone............................       90-110  2.275 g/lb (0.5%).........  85-120.
Novobiocin.............................       85-115  17.5 g/lb (3.85%).........  80-120.
Pyrantel tartrate......................       90-110  36 g/lb (7.9%)............  75-125.
Robenidine.............................       95-115  1.5 g/lb (0.33%)..........  80-120.
Ronnel.................................       85-115  27.2 g/lb (6.0%)..........  80-120.
Roxarsone..............................       90-110  2.275 g/lb (0.5%).........  85-120.
Roxarsone..............................       90-110  2.275 g/lb (0.5%).........  85-120.
  Aklomide.............................       90-110  11.35 g/lb (2.5%).........  85-120.
Roxarsone..............................       90-110  2.275 g/lb (0.5%).........  85-120.
  Clopidol.............................       94-106  11.35 g/lb (2.5%).........  80-120.
  Bacitracin methylene disalicylate....       85-115  5.0 g/lb (1.1%)...........  70-130.
Roxarsone..............................       90-110  2.275 g/lb (0.5%).........  85-120.
  Monensin.............................       90-110  5.5 g/lb (1.2%)...........  75-125.
Sulfadimethoxine.......................       90-110  5.675 g/lb (1.25%)........  85-115/75-125.
  Ormetoprim (5/3).....................       90-110  3.405 g/lb (0.75%)........  85-115.
  Ormetoprim (5/1).....................       90-110  17.0 g/lb (3.75%).........  85-115.
Sulfaethoxypyridazine..................       95-105  50.0 g/lb (11.0%).........  85-115.
Sulfamerazine..........................       85-115  18.6 g/lb (4.0%)..........  85-115.
Sulfamethazine.........................       85-115  10.0 g/lb (2.2%)..........  80-120.
  Chlortetracycline....................       85-115  10.0 g/lb (2.2%)..........  85-125/70-130.
  Penicillin...........................       85-115  5.0 g/lb (1.1%)...........  85-125/70-130.
Sulfamethazine.........................       85-115  10.0 g/lb (2.2%)..........  80-120.
  Chlortetracycline....................       85-115  10.0 g/lb (2.2%)..........  85-125/70-130.
Sulfamethazine.........................       85-115  10.0 g/lb (2.2%)..........  80-120.
  Tylosin..............................       80-120  10.0 g/lb (2.2%)..........  75-125.
  Aklomide.............................       90-110  11.2 g/lb (2.5%)..........  85-120.
  Aklomide.............................       90-110  11.2 g/lb (2.5%)..........  85-120.
  Roxarsone............................       90-110  2.715 g/lb (0.60%)........  85-120.
  Aklomide.............................       90-110  11.2 g/lb (2.5%)..........  85-120.
  Roxarsone............................       90-110  2.27 g/lb (0.5%)..........  85-120.
Sulfaquinoxaline.......................       98-106  11.2 g/lb (2.5%)..........  85-115.
Sulfathiazole..........................       85-115  10.0 g/lb (2.2%)..........  80-120.
  Chlortetracycline....................       85-125  10.0g/lb (2.2%)...........  70-130.
  Penicillin...........................       80-120  5.0 g/lb (1.1%)...........  70-130.
Thiabendazole..........................       94-106  45.4 g/lb (10.0%).........  7% 85-115; <7% 90-
                                                                                   110.
Tiamulin hydrogen fumarate.............       90-115  10 g/lb...................  90-115/70-130
Tilmicosin.............................       90-110  37.9 g/lb (8.35%).........  85-115.
Zilpaterol.............................       90-110  680 g/t (0.075%)..........  80-110/75-115
----------------------------------------------------------------------------------------------------------------
\1\ Percent of labeled amount.
\2\ Values given represent ranges for either Type B or Type C medicated feeds. For those drugs that have two
  range limit, the first set is for a Type B medicated feed and the second set is for a Type C medicated feed.
  These values (ranges) have been assigned in order to provide for the possibility of dilution of a Type B
  medicated feed with lower assay limits to make a Type C medicated feed.

    (e) When drugs from both categories are in combination, the Category 
II requirements will apply to the combination drug product.

[51 FR 7392, Mar. 3, 1986]

[[Page 389]]


    Editorial Note: For Federal Register citations affecting Sec. 
558.4, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.5  Requirements for liquid medicated feed.

    (a) What types of liquid medicated feeds are covered by this 
section? This section covers the following types of liquid medicated 
feed:
    (1) Type B feed that is intended for further manufacture of other 
medicated feeds (Sec. 558.3(b)(3)) or:
    (2) Type C feed that is intended for the following:
    (i) Further manufacture of another Type C feed, or
    (ii) Top-dressing (adding on top of the usual ration) (Sec. 
558.3(b)(4)).
    (b) How is liquid free-choice medicated feed regulated? Liquid free-
choice medicated feed is covered by this section and by Sec. 510.455.
    (c) What is required for new animal drugs intended for use in liquid 
feed? Any new animal drug intended for use in liquid feed must be 
approved for such use under section 512 of the Federal Food, Drug, and 
Cosmetic Act (the act) or index listed under section 572 of the act. 
Such approvals under section 512 of the act must be:
    (1) An original NADA,
    (2) A supplemental NADA, or
    (3) An abbreviated NADA.
    (d) What are the approval requirements under section 512 of the act 
for new animal drugs intended for use in liquid feed? An approval under 
section 512 of the act for a new animal drug intended for use in liquid 
feed must contain the following information:
    (1) Data, or a reference to data in a master file (MF), that shows 
the relevant ranges of conditions under which the drug will be 
chemically stable in liquid feed under field use conditions; and
    (2) Data, or a reference to data in an MF, that shows that the drug 
is physically stable in liquid feed under field conditions; or
    (3) Feed labeling with recirculation or agitation directions as 
follows:
    (i) For liquid feeds stored in recirculating tank systems: 
Recirculate immediately prior to use for not less than 10 minutes, 
moving not less than 1 percent of the tank contents per minute from the 
bottom of the tank to the top. Recirculate daily as described even when 
not used.
    (ii) For liquid feeds stored in mechanical, air, or other agitation-
type tank systems: Agitate immediately prior to use for not less than 10 
minutes, creating a turbulence at the bottom of the tank that is visible 
at the top. Agitate daily as described even when not used.
    (e) How are chemical and physical stability data to be submitted? 
The data must be submitted as follows:
    (1) Directly in the NADA,
    (2) By a sponsor, or
    (3) To an MF that a sponsor may then reference in its NADA with 
written consent of the MF holder.
    (f) What will be stated in the published approval for a new animal 
drug intended for use in liquid feed? The approval of a new animal drug 
intended for use in liquid feed as published in this subchapter will 
include the following requirements:
    (1) The formula and/or specifications of the liquid medicated feed, 
where the owner of this information requests such publication; and/or
    (2) A statement that the approval has been granted for a proprietary 
formula and/or specifications.
    (g) When is a medicated feed mill license required for the 
manufacture of a liquid medicated feed? An approved medicated feed mill 
license is required for the manufacture of the following types of feeds:
    (1) All liquid medicated feeds that contain a Category II drug, and
    (2) Liquid medicated feeds that contain a Category I drug and use a 
proprietary formula and/or specifications.
    (h) What measures are in place to prevent certain drugs, approved 
for use in animal feed or drinking water but not in liquid medicated 
feed, from being diverted to use in liquid feeds? Any product containing 
any form of bacitracin, oxytetracycline, or chlortetracycline, intended 
for oral administration via animal feed and/or drinking water, and not 
approved for use in a liquid medicated feed must include in its labeling 
the following statement: ``FOR USE IN ------ ONLY. NOT FOR USE IN LIQUID 
MEDICATED FEEDS.'' The blank

[[Page 390]]

may be filled in with the words: ``DRY FEEDS'', ``DRINKING WATER'', or 
``DRY FEEDS AND DRINKING WATER''.
    (i) Can the labeling provisions of paragraph (h) of this section be 
waived, and how can I apply for a waiver? (1) The labeling provisions of 
paragraph (h) of this section may be waived if there is evidence to 
indicate that it is unlikely a new animal drug would be used in the 
manufacture of a liquid medicated feed.
    (2) To obtain a waiver, you must submit a letter requesting a waiver 
to the Office of New Animal Drug Evaluation (HFV-100), Center for 
Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., 
Rockville, MD 20855.
    (3) The letter must include a copy of the product label; a 
description of the formulation; and information to establish that the 
physical, chemical, or other properties of the new animal drug are such 
that diversion to use in liquid medicated feed is unlikely.
    (j) What else do I need to know about the labeling provisions of 
paragraph (h) of this section? The labeling provisions of paragraph (h) 
of this section may be implemented without prior approval as provided 
for in Sec. 514.8(c)(3) of this chapter.

[69 FR 30197, May 27, 2004, as amended at 71 FR 74785, Dec. 13, 2006; 72 
FR 69131, Dec. 6, 2007]



Sec. 558.6  Veterinary feed directive drugs.

    (a) What conditions must I meet if I am a veterinarian issuing a 
veterinary feed directive (VFD)?
    (1) You must be appropriately licensed.
    (2) You must issue a VFD only within the confines of a valid 
veterinarian-client-patient relationship (see definition at Sec. 
530.3(i) of this chapter).
    (3) You must complete the VFD in writing and sign it or it will be 
invalid.
    (4) You must include all of the following information in the VFD or 
it will be invalid:
    (i) You and your client's name, address and telephone and, if the 
VFD is faxed, facsimile number.
    (ii) Identification and number of animals to be treated/fed the 
medicated feed, including identification of the species of animals, and 
the location of the animals.
    (iii) Date of treatment, and, if different, date of prescribing the 
VFD drug.
    (iv) Approved or index listed indications for use.
    (v) Name of the animal drug.
    (vi) Level of animal drug in the feed, and the amount of feed 
required to treat the animals in paragraph (a)(4)(ii) of this section.
    (vii) Feeding instructions with the withdrawal time.
    (viii) Any special instructions and cautionary statements necessary 
for use of the drug in conformance with the approval.
    (ix) Expiration date of the VFD.
    (x) Number of refills (reorders) if necessary and permitted by the 
approval.
    (xi) Your license number and the name of the State issuing the 
license.
    (xii) The statement: ``Extra-label use, (i.e., use of this VFD feed 
in a manner other than as provided for in the VFD drug approval) is 
strictly prohibited.''
    (xiii) Any other information required by the VFD drug approval 
regulation.
    (5) You must produce the VFD in triplicate.
    (6) You must issue a VFD only for the approved or indexed conditions 
and indications for use of the VFD drug.
    (b) What must I do with the VFD if I am a veterinarian?
    (1) You must give the original VFD to the feed distributor (directly 
or through the client).
    (2) You must keep one copy of the VFD.
    (3) You must give the client a copy of the VFD.
    (4) You may send a VFD to the client or distributor by facsimile or 
other electronic means provided you assure that the distributor receives 
the original signed VFD within 5 working days of receipt of the 
facsimile or other electronic order.
    (5) You may not transmit a VFD by telephone.
    (c) What are the VFD recordkeeping requirements?
    (1) The VFD feed distributor must keep the VFD original for 2 years 
from the date of issuance. The veterinarian and the client must keep 
their copies for the same period of time.

[[Page 391]]

    (2) All involved parties must make the VFD available for inspection 
and copying by FDA.
    (3) All involved parties (the VFD feed distributor, the 
veterinarian, and the client) must keep VFD's transmitted by facsimile 
or other electronic means for a period of 2 years from date of issuance.
    (4) All involved parties must have a copy of the VFD before 
distribution of a VFD feed to the ultimate user.
    (d) What are the notification requirements if I am a distributor of 
animal feed containing a VFD drug?
    (1) You must notify FDA only once, by letter, that you intend to 
distribute animal feed containing a VFD drug.
    (i) The notification letter must include the complete name and 
address of each business site from which distribution will occur.
    (ii) A responsible person from your firm must sign and date the 
notification letter.
    (iii) You must submit the notification letter to the Center for 
Veterinary Medicine, Division of Animal Feeds (HFV-220), 7500 Standish 
Pl., Rockville, MD 20855, prior to beginning your first distribution.
    (iv) You must notify the Center for Veterinary Medicine at the above 
address within 30 days of any change in name or business address.
    (2) If you are a distributor who ships an animal feed containing a 
VFD drug to another consignee-distributor in the absence of a valid VFD, 
you must obtain an ``acknowledgment letter,'' as defined in Sec. 
558.3(b)(11), from the consignee-distributor. The letter must include a 
statement affirming that the consignee-distributor has complied with 
``distributor notification'' requirements of paragraph (d)(1) of this 
section.
    (e) What are the additional recordkeeping requirements if I am a 
distributor?
    (1) You must keep records of receipt and distribution of all 
medicated animal feed containing a VFD drug.
    (2) You must keep these records for 2 years from date of receipt and 
distribution.
    (3) You must make records available for inspection and copying by 
FDA.
    (f) What cautionary statements are required for VFD drugs and animal 
feeds containing VFD drugs? All labeling and advertising must 
prominently and conspicuously display the following cautionary 
statement: ``Caution: Federal law limits this drug to use under the 
professional supervision of a licensed veterinarian. Animal feed bearing 
or containing this veterinary feed directive drug shall be fed to 
animals only by or upon a lawful veterinary feed directive issued by a 
licensed veterinarian in the course of the veterinarian's professional 
practice.''

[65 FR 76929, Dec. 8, 2000, as amended at 72 FR 69131, Dec. 6, 2007]



Sec. 558.15  Antibiotic, nitrofuran, and sulfonamide drugs in the 
feed of animals.

    (a) The Commissioner of Food and Drugs will propose to revoke 
currently approved subtherapeutic (increased rate of gain, disease 
prevention. etc.) uses in animal feed of antibiotic and sulfonamide 
drugs whether granted by approval of new animal drug applications, 
master files and/or antibiotic or food additive regulations, by no later 
than April 20, 1975, or the nitrofuran drugs by no later than September 
5, 1975, unless data are submitted which resolve conclusively the issues 
concerning their safety to man and animals and their effectiveness under 
specific criteria established by the Food and Drug Administration based 
on the guidelines included in the report of the FDA task force on the 
use of antibiotics in animal feeds. All persons or firms previously 
marketing identical, related, or similar products except the nitrofuran 
drugs not the subject of an approved new animal drug application must 
submit a new animal drug application by July 19, 1973, or by December 4, 
1973, in the case of nitrofuran drugs, if marketing is to continue 
during the interim. New animal drug entities with antibacterial activity 
not previously marketed, now pending approval or submitted for approval 
prior to, on, or following the effective date of this publication, shall 
satisfy such criteria prior to approval.
    (b) Any person interested in developing data which will support 
retaining

[[Page 392]]

approval for such uses of such antibiotic, nitrofuran, and sulfonamide 
drugs pursuant to section 512(l) of the Federal Food, Drug, and Cosmetic 
Act shall submit to the Commissioner the following:
    (1) By July 19, 1973, records and reports of completed, ongoing, or 
planned studies, including protocols, on the tetracyclines, 
streptomycin, dihydrostreptomycin, penicillin, and the sulfonamides; for 
all other antibiotics by October 17, 1973; and for the nitrofuran drugs 
by March 4, 1974. The Food and Drug Administration encourages sponsors 
to consult with the Center for Veterinary Medicine on protocol design 
and plans for future studies.
    (2) By April 20, 1974, data from completed studies on the 
tetracyclines, streptomycin, dihydrostreptomycin, the sulfonamides, and 
penicillin assessing the effect of the subtherapeutic use of the drug in 
feed on the salmonella reservoir in the target animal as compared to 
that in nonmedicated controls. Failure to complete the salmonella 
studies for any of these drugs by that time will be grounds for 
proceeding to immediately withdraw approval.
    (3) By April 20, 1975, data satisfying all other specified criteria 
for safety and effectiveness, including the effect on the salmonella 
reservoir for any antibiotic or sulfonamide drugs and by September 5, 
1975, for the nitrofuran drugs, approved for subtherapeutic use in 
animal feeds. Drug efficacy data shall be submitted for any feed-use 
combination product containing such drug and any feed-use single 
ingredient antibiotic, nitrofuran, or sulfonamide not reviewed by the 
National Academy of Sciences--National Research Council, Drug Efficacy 
Study covering drugs marketed between 1938 and 1962.
    (4) Progress reports on studies underway every January 1 and July 1 
until completion.
    (c) Failure on the part of any sponsor to comply with any of the 
provisions of paragraph (b) of this section for any of the antibacterial 
drugs included in paragraph (b)(1) of this section, or interim results 
indicating a health hazard, will be considered as grounds for 
immediately proceeding to withdraw approval of that drug for use in 
animal feeds under section 512(l) of the act in the case of failure to 
submit required records and reports and under section 512(e) where new 
information shows that such drug is not shown to be safe.
    (d) Criteria based upon the guidelines laid down by the task force 
may be obtained from the Food and Drug Administration, Center for 
Veterinary Medicine, 7500 Standish Pl., Rockville, MD 20855.
    (e) Reports as specified in this section shall be submitted to: Food 
and Drug Administration, Center for Veterinary Medicine, Office of New 
Animal Drug Evaluation (HFV-100), 7500 Standish Pl., Rockville, MD 
20855.
    (f) Following the completion of the requirements of paragraphs (a) 
and (b) of this section and the studies provided for therein:
    (1) Those antibiotic, nitrofuran, and sulfonamide drugs which fail 
to meet the prescribed criteria for subtherapeutic uses but which are 
found to be effective for the therapeutic purposes will be permitted in 
feed only for high-level, short-term therapeutic use and only by or on 
the order of a licensed veterinarian.
    (2) Animal feeds containing antibacterial drugs permitted to remain 
in use for subtherapeutic purposes shall be labeled to include a 
statement of the quantity of such drugs.
    (g) The submission of applications and data required by paragraphs 
(a) and (b) of this section is not required for the continued 
manufacture of any Type A medicated article which is produced solely 
from a Type A article that is in compliance with the requirements of 
this section: Provided, That the Type A medicated article contains no 
drug ingredient whose use in or on animal feed requires an approved 
application pursuant to section 512(m) of the act and/or where the Type 
A article is approved by regulation in this part.
    (1) The following antibacterial Type A articles manufactured by the 
designated sponsors are eligible for interim marketing based on their 
compliance with the requirements of this section:

[[Page 393]]



----------------------------------------------------------------------------------------------------------------
                                                                                                Indications for
          Drug sponsor              Type A article          Species            Use levels             use
----------------------------------------------------------------------------------------------------------------
Fermenta Animal Health Co......  Bacitracin           Chicken turkeys,     Sec. 558.76.......  Sec. 558.76.
                                  methylene            swine, and cattle.
                                  disalicylate.
----------------------------------------------------------------------------------------------------------------

    (2) [Reserved]

[51 FR 8811, Mar. 14, 1986; 51 FR 11014, Apr. 1, 1986, as amended at 51 
FR 28547, Aug. 8, 1986; 53 FR 20843, June 7, 1988; 54 FR 37098, Sept. 7, 
1989; 54 FR 51386, Dec. 15, 1989; 55 FR 8460, 8462, Mar. 8, 1990; 56 FR 
41912, Aug. 23, 1991; 56 FR 64702, Dec. 12, 1991; 57 FR 6476, Feb. 25, 
1992; 57 FR 8577, Mar. 11, 1992; 57 FR 14639, Apr. 22, 1992; 58 FR 
17515, Apr. 5, 1993; 58 FR 30119, May 26, 1993; 61 FR 51589, Oct. 3, 
1996; 64 FR 992, Jan. 7, 1999; 64 FR 37673, July 13, 1999; 71 FR 16221, 
Mar. 31, 2006; 75 FR 16002, Mar. 31, 2010]



       Subpart B_Specific New Animal Drugs for Use in Animal Feeds



Sec. 558.55  Amprolium.

    (a) Approvals. Type A medicated articles: 25 percent to No. 016592 
in Sec. 510.600(c) of this chapter for use as in paragraph (d) of this 
section.
    (b) Special considerations. Do not use in Type B or Type C medicated 
feeds containing bentonite.
    (c) Related tolerances. See Sec. 556.50 of this chapter.
    (d) Conditions of use--(1) Cattle. It is used as follows:

------------------------------------------------------------------------
  Amprolium in
  Grams per Ton    Indications for Use        Limitations        Sponsor
------------------------------------------------------------------------
(i) 113.5 to 11,  Calves: As an aid in   Top-dress on or mix      050604
 350; to provide   the prevention of      in the daily ration.
 5 milligrams      coccidiosis caused     Feed for 21 days
 (mg) per          by Eimeria bovis and   during periods of
 kilogram of       E. zurnii.             exposure or when
 body weight per                          experience indicates
 day                                      that coccidiosis is
                                          likely to be a
                                          hazard; as sole
                                          source of amprolium.
                                          Withdraw 24 hours
                                          before slaughter. A
                                          withdrawal period
                                          has not been
                                          established for this
                                          product in
                                          preruminating
                                          calves. Do not use
                                          in calves to be
                                          processed for veal.
------------------------------------------------------------------------
(ii) 113.5 to     Calves: As an aid in   Top-dress on or mix      050604
 11, 350; to       the treatment of       in the daily ration.
 provide 10 mg     coccidiosis caused     Feed for 5 days; as
 per kilogram of   by Eimeria bovis and   sole source of
 body weight per   E. zurnii.             amprolium. Withdraw
 day                                      24 hours before
                                          slaughter. A
                                          withdrawal period
                                          has not been
                                          established for this
                                          product in
                                          preruminating
                                          calves. Do not use
                                          in calves to be
                                          processed for veal.
                                          For a satisfactory
                                          diagnosis, a
                                          microscopic
                                          examination of the
                                          feces should be done
                                          by a veterinarian or
                                          diagnostic
                                          laboratory before
                                          treatment; when
                                          treating outbreaks,
                                          the drug should be
                                          administered
                                          promptly after
                                          diagnosis is
                                          determined.
------------------------------------------------------------------------

    (i) Amount. 227 milligrams per 100 pounds (5 milligrams per 
kilogram) body weight per day.
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by Eimeria bovis and E. zurnii.
    (b) Limitations. Administer from a Type B feed containing from 0.05 
to 1.25 percent amprolium with the usual amount of feed consumed in 1 
day; feed for 21 days during periods of exposure or when experience 
indicates that coccidiosis is likely to be a hazard; withdraw 24 hours 
before slaughter; as sole source of amprolium. A withdrawal period has 
not been established for this product in preruminating calves. Do not 
use in calves to be processed for veal.
    (ii) Amount. 454 milligrams per 100 pounds (10 milligrams per 
kilogram) body weight per day.
    (a) Indications for use. As an aid in the treatment of coccidiosis 
caused by Eimeria bovis and E. zurnii.

[[Page 394]]

    (b) Limitations. Administer from a Type B feed containing from 0.05 
to 1.25 percent amprolium with the usual amount of feed consumed in 1 
day; feed for 5 days; for a satisfactory diagnosis, a microscopic 
examination of the feces should be done by a veterinarian or diagnostic 
laboratory before treatment; when treating outbreaks, the drug should be 
administered promptly after diagnosis is determined; withdraw 24 hours 
before slaughter; as sole source of amprolium. A withdrawal period has 
not been established for this product in preruminating calves. Do not 
use in calves to be processed for veal.
    (2) Chickens and turkeys. It is used as follows:

----------------------------------------------------------------------------------------------------------------
                               Combination in grams per
 Amprolium in grams per ton              ton                Indications for use       Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 36.3 to 113.5 (0.004%    ...........................  Replacement chickens;     Feed as follows--
 to 0.0125%).                                              development of active
                                                           immunity to
                                                           coccidiosis.
----------------------------------------------------------------------------------------------------------------


----------------------------------------------------------------------------------------------------------------
                                                     Up to 5 weeks of    From 5 to 8 weeks
                Growing conditions                         age                 of age        Over 8 weeks of age
----------------------------------------------------------------------------------------------------------------
                                                             Amprolium            Amprolium            Amprolium
                                                         grams per ton        grams per ton        grams per ton
 
Severe exposure to coccidiosis                         113.5 (0.0125%)           72.6-113.5           36.3-113.5
                                                                           (0.008%-0.0125%)     (0.004%-0.0125%)
Moderate exposure to coccidiosis                            72.6-113.5           54.5-113.5           36.3-113.5
                                                      (0.008%-0.0125%)     (0.006%-0.0125%)     (0.004%-0.0125%)
Slight exposure to coccidiosis                              36.3-113.5           36.3-113.5           36.3-113.5
                                                      (0.004%-0.0125%)     (0.004%-0.0125%)     (0.004%-0.0125%)
 
----------------------------------------------------------------------------------------------------------------


----------------------------------------------------------------------------------------------------------------
                                Combination in grams
 Amprolium in grams per ton           per ton            Indications for use         Limitations        Sponsor
----------------------------------------------------------------------------------------------------------------
                              Arsanilic acid 90        Replacement chickens;   Withdraw 5 d before
                               (0.01%).                 development of active   slaughter; as sole
                                                        immunity to             source of organic
                                                        coccidiosis; growth     arsenic; feed
                                                        promotion and feed      according to subtable
                                                        efficiency; improving   in item (i).
                                                        pigmentation.
 
 
                              Arsanilic acid 90        Replacement chickens;   Withdraw 5 d before
                               (0.01%) plus             development of active   slaughter; as sole
                               erythromycin 4.6 to      immunity to             source of organic
                               18.5.                    coccidiosis; growth     arsenic. Feed
                                                        promotion and feed      according to subtable
                                                        efficiency; improving   in item (i).
                                                        pigmentation.
                              Arsanilic acid 90        1. Replacement          Feed for 2 d before
                               (0.01%) plus             chickens; development   stress and 3 to 6 d
                               erythromycin 92.5.       of active immunity to   after stress;
                                                        coccidiosis; growth     withdraw 5 d before
                                                        promotion and feed      slaughter; as sole
                                                        efficiency; improving   source of organic
                                                        pigmentation; as an     arsenic. Feed
                                                        aid in the prevention   according to subtable
                                                        of chronic              in item (i).
                                                        respiratory disease
                                                        during periods of
                                                        stress.
                                                       2. Replacement          Feed for 7 to 14 d;
                                                        chickens; development   withdraw 5 d before
                                                        of active immunity to   slaughter; as sole
                                                        coccidiosis; growth     source of organic
                                                        promotion and feed      arsenic. Feed
                                                        efficiency; improving   according to subtable
                                                        pigmentation; as an     in item (i).
                                                        aid in the prevention
                                                        of infectious coryza.
(i) 36.3 to 113.5 (0.004% to  Arsanilic acid 90        Replacement chickens;   Feed for 5 to 8 d; do   .........
 0.0125%).                     (0.01%) plus             development of active   not use in birds
                               erythromycin 185.        immunity to             producing eggs for
                                                        coccidiosis; growth     food purposes;
                                                        promotion and feed      withdraw 5 d before
                                                        efficiency; improving   slaughter; as sole
                                                        pigmentation; as an     source of organic
                                                        aid in the prevention   arsenic. Feed
                                                        and reduction of        according to subtable
                                                        lesions and in          in item (i).
                                                        lowering severity of
                                                        chronic respiratory
                                                        disease.

[[Page 395]]

 
                              Bacitracin 100 to 200..  Replacement chickens;   As bacitracin           .........
                                                        development of active   methylene
                                                        immunity to             disalicylate or
                                                        coccidiosis;            bacitracin zinc. Feed
                                                        treatment of chronic    according to subtable
                                                        respiratory disease     in item (i).
                                                        (air-sac infection)
                                                        and blue comb
                                                        (nonspecific
                                                        infectious enteritis).
                              Bacitracin methylene     Replacement chickens;   Feed according to          046573
                               disalicylate 4 to 50.    development of active   subtable in item (i);
                                                        immunity to             bacitracin methylene
                                                        coccidiosis,            disalicylate as
                                                        increased rate of       provided by 046573 in
                                                        weight gain, and        Sec. 510.600(c) of
                                                        improved feed           this chapter.
                                                        efficiency..
                              Bacitracin methylene     Replacement chickens;   Feed according to          046573
                               disalicylate 50 plus     development of active   subtable in entry
                               roxarsone 22.7 to 45.4.  immunity to             (i); bacitracin
                                                        coccidiosis; as an      methylene
                                                        aid in the control of   disalicylate and
                                                        necrotic enteritis      roxarsone as provided
                                                        caused or complicated   by 046573 in Sec.
                                                        by Clostridium spp.     510.600(c) of this
                                                        or other organisms      chapter.
                                                        susceptible to
                                                        bacitracin; increased
                                                        rate of weight gain,
                                                        improved feed
                                                        efficiency, and
                                                        improved pigmentation.
                              Chlortetracycline 100    Chickens; development   Do not feed to          .........
                               to 200.                  of active immunity to   chickens producing
                                                        coccidiosis; control    eggs for human
                                                        of infectious           consumption. Feed for
                                                        synovitis caused by     7 to 14 d.
                                                        Mycoplasma synoviae
                                                        susceptible to
                                                        chlortetracycline.
                              Chlortetracycline 200    Chickens; development   Do not feed to          .........
                               to 400.                  of active immunity to   chickens producing
                                                        coccidiosis; control    eggs for human
                                                        of chronic              consumption. Feed for
                                                        respiratory disease     7 to 14 d.
                                                        (CRD) and air sac
                                                        infection caused by
                                                        M. gallisepticum and
                                                        E. coli susceptible
                                                        to chlortetracycline.
                              Erythromycin 4.6 to      Replacement chickens;   As erythromycin         .........
                               18.5.                    development of active   thiocyanate. Feed
                                                        immunity to             according to subtable
                                                        coccidiosis; growth     in item (i).
                                                        promotion and feed
                                                        efficiency.
                              Erythromycin 92.5......  1. Replacement          Feed for 7 to 14 d;     .........
                                                        chickens; development   withdraw 24 h before
                                                        of active immunity to   slaughter. Feed
                                                        coccidiosis; as an      according to subtable
                                                        aid in the prevention   in item (i).
                                                        of infectious coryza.
                                                       2. Replacement          Feed for 2 d before     .........
                                                        chickens; development   stress and 3 to 6 d
                                                        of active immunity to   after stress;
                                                        coccidiosis; as an      withdraw 24 h before
                                                        aid in the prevention   slaughter. Feed
                                                        of chronic              according to subtable
                                                        respiratory disease     in item (i).
                                                        during periods of
                                                        stress.
                              Erythromycin 185.......  Replacement chickens;   Feed for 5 to 8 d; do   .........
                                                        development of active   not use in birds
                                                        immunity to             producing eggs for
                                                        coccidiosis; as an      food purposes;
                                                        aid in the prevention   withdraw 48 h before
                                                        and reduction of        slaughter. Feed
                                                        lesions and in          according to subtable
                                                        lowering severity of    in item (i).
                                                        chronic respiratory
                                                        disease.
                              Hygromycin B 8 to 12...  Replacement chickens;   Feed according to       .........
                                                        development of active   subtable in item (i).
                                                        immunity to
                                                        coccidiosis; control
                                                        of infestation of
                                                        large round worms
                                                        (Ascaris galli),
                                                        cecal worms
                                                        (Heterakis gallinae),
                                                        and capillary worms
                                                        (Capillaria
                                                        obsignata).
                              Penicillin 2.4 to 50...  Replacement chickens;   As procaine             .........
                                                        development of active   penicillin. Feed
                                                        immunity to             according to subtable
                                                        coccidiosis; growth     in item (i).
                                                        promotion and feed
                                                        efficiency.

[[Page 396]]

 
                              Roxarsone 22.7 to 45.4   Replacement chickens;   Withdraw 5 d before     .........
                               (0.0025% to 0.005%).     development of active   slaughter; as sole
                                                        immunity to             source of organic
                                                        coccidiosis; growth     arsenic. Feed
                                                        promotion, and feed     according to subtable
                                                        efficiency; improving   in item (i).
                                                        pigmentation.
(ii) 72.6 to 113.5 (0.008%    .......................  Broiler chickens;       Feed according to       .........
 to 0.0125%).                                           prevention of           subtable in item (i).
                                                        coccidiosis caused by
                                                        Eimeria tenella only.
                              Arsanilic acid 90        ......do..............  ......do..............
                               (0.01%).
                              Bacitracin 100 to 200..  Broiler chickens;       As bacitracin
                                                        prevention of           methylene
                                                        coccidiosis caused by   disalicylate, or zinc
                                                        E. tenella only;        bacitracin.
                                                        treatment of chronic
                                                        respiratory disease
                                                        (air-sac infection)
                                                        and blue comb
                                                        (nonspecific
                                                        infectious enteritis).
                              Chlortetracycline 100    Chickens; prevention    Do not feed to
                               to 200.                  of coccidiosis caused   chickens producing
                                                        by E. tenella only;     eggs for human
                                                        control of infectious   consumption. Feed for
                                                        synovitis caused by     7 to 14 d.
                                                        M. synoviae
                                                        susceptible to
                                                        chlortetracycline.
                              Chlortetracycline 200    Chickens; prevention    Do not feed to
                               to 400.                  of coccidiosis caused   chickens producing
                                                        by E. tenella only;     eggs for human
                                                        control of chronic      consumption. Feed for
                                                        respiratory disease     7 to 14 d.
                                                        (CRD) and air sac
                                                        infection caused by
                                                        M. gallisepticum and
                                                        E. coli susceptible
                                                        to chlortetracycline.
                              Hygromycin B 8 to 12...  Broiler chickens;       Feed according to
                                                        prevention of           subtable in item (i).
                                                        coccidiosis caused by
                                                        Eimeria tenella only;
                                                        control of
                                                        infestation of large
                                                        round worms
                                                        (Heterakis gallinae),
                                                        and capillary worms
                                                        (Capillaria
                                                        obsignata).
                              Penicillin 2.4 to 50...  Broiler chickens;       As procaine penicillin
                                                        prevention of
                                                        coccidiosis caused by
                                                        E. tenella only;
                                                        growth promotion and
                                                        feed efficiency.
                              Roxarsone 22.7 to 45.4   Broiler chickens;       Withdraw 5 d before
                               (0.0025% to 0.005%).     prevention of           slaughter; as sole
                                                        coccidiosis caused by   source of organic
                                                        E. tenella only;        arsenic.
                                                        growth promotion and
                                                        feed efficiency;
                                                        improving
                                                        pigmentation.
(iii) 113.5 (0.0125%).......  .......................  1. Laying chickens;     ......................
                                                        prevention of
                                                        coccidiosis.
                                                       2. Laying chickens;     For moderate outbreaks
                                                        treatment of            of coccidiosis;
                                                        coccidiosis.            administer for 2
                                                                                weeks.
                              Bambermycins 1 to 3      Broiler chickens; as    Feed continuously as       016592
                               plus roxarsone 22.8 to   an aid in the           the sole ration; as
                               34.1 (0.0025% to         prevention of           sole source of
                               0.00375%).               coccidiosis; for        amprolium and organic
                                                        increased rate of       arsenic; roxarsone as
                                                        weight gain, improved   provided by No.
                                                        feed efficiency, and    053501 in Sec.
                                                        improved pigmentation.  510.600(c) of this
                                                                                chapter, bambermycins
                                                                                by No. 016592;
                                                                                withdraw 5 d before
                                                                                slaughter.
                              Bambermycins 1 to 4....  Growing turkeys;        Feed continuously as       016592
                                                        prevention of           the sole source of
                                                        coccidiosis;            amprolium;
                                                        increased rate of       bambermycins as
                                                        weight gain and         provided by No.
                                                        improved feed           016592 in Sec.
                                                        efficiency.             510.600(c) of this
                                                                                chapter.
(iv) 113.5 to 227 (0.0125%    .......................  1. Broiler chickens
 to 0.025%).                                            and replacement
                                                        chickens where
                                                        immunity to
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis.
                                                       2. Turkeys; prevention
                                                        of coccidiosis.

[[Page 397]]

 
                              Arsanilic acid 90        1. Broiler chickens     ......do..............
                               (0.01%).                 and replacement
                                                        chickens where
                                                        immunity to
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency;
                                                        improving
                                                        pigmentation.
                                                       2. Turkeys; prevention  ......do..............
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency;
                                                        improving
                                                        pigmentation.
                              Arsanilic acid 90        1. Broiler chickens     Feed for 2 d before
                               (0.01%) plus             and replacement         stress and 3 to 6 d
                               erythromycin 92.5.       chickens where          after stress;
                                                        immunity to             withdraw 5 d before
                                                        coccidiosis is not      slaughter; as sole
                                                        desired; prevention     source of organic
                                                        of coccidiosis;         arsenic.
                                                        growth promotion and
                                                        feed efficiency;
                                                        improving
                                                        pigmentation; as an
                                                        aid in the prevention
                                                        of chronic
                                                        respiratory disease
                                                        during periods of
                                                        stress.
                                                       2. Broiler chickens     Feed for 7 to 14 d;
                                                        and replacement         withdraw 5 d before
                                                        chickens where          slaughter; as sole
                                                        immunity to             source of organic
                                                        coccidiosis is not      arsenic.
                                                        desired; prevention
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency;
                                                        improving
                                                        pigmentation; as an
                                                        aid in the prevention
                                                        of infectious coryza.
                              Arsanilic acid 90        Broiler chickens and    Feed for 5 to 8 d; do
                               (0.01%) plus             replacement chickens    not use in birds
                               erythromycin 185.        where immunity to       producing eggs for
                                                        coccidiosis is not      food purposes;
                                                        desired; prevention     withdraw 5 d before
                                                        of coccidiosis;         slaughter; as sole
                                                        growth promotion and    source of organic
                                                        feed efficiency;        arsenic.
                                                        improving
                                                        pigmentation; as an
                                                        aid in the prevention
                                                        and reduction of
                                                        lesions and in
                                                        lowering severity of
                                                        chronic respiratory
                                                        disease.
                              Arsanilic acid 90        Broiler chickens and    Withdraw 5 d before
                               (0.01%) plus             replacement chickens    slaughter; as sole
                               erythromycin 4.6 to      where immunity to       source of organic
                               18.5.                    coccidiosis is not      arsenic.
                                                        desired; prevention
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency;
                                                        improved pigmentation.
                              Bacitracin 4 to 50.....  1. Broiler chickens     As bacitracin                 \1\
                                                        and replacement         methylene                 012769
                                                        chickens where          disalicylate or
                                                        immunity to             bacitracin zinc.
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency.
                                                       2. Turkeys; prevention  ......do..............
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency.
                              Bacitracin 100 to 200..  1. Broiler chickens     ......do..............
                                                        and replacement
                                                        chickens where
                                                        immunity to
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis;
                                                        treatment of chronic
                                                        respiratory disease
                                                        (air-sac infection),
                                                        blue comb
                                                        (nonspecific
                                                        infectious enteritis).
                                                       2. Broiler chickens     As bacitracin zinc....
                                                        and replacement
                                                        chickens where
                                                        immunity to
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis;
                                                        treatment of chronic
                                                        ry disease (air-sac
                                                        infection), blue comb
                                                        (nonspecific
                                                        infectious enteritis).

[[Page 398]]

 
                              Bacitracin 100 to 500..  Turkeys; prevention of  As bacitracin zinc....
                                                        coccidiosis;
                                                        treatment of
                                                        infectious sinusitis,
                                                        blue comb (mud fever).
                              Bacitracin plus          ......do..............  Feed contains 50% to
                               penicillin 100 to 500                            75% of bacitracin but
                               (of combination).                                not more than 125 g
                                                                                penicillin; as
                                                                                procaine penicillin;
                                                                                as bacitracin zinc.
                              Carbarsone 227 to 340.5  Turkeys; aid in         Feed continuously 2        016592
                                                        prevention of           weeks before
                                                        coccidiosis (Eimeria    coccidiosis and
                                                        adenoeides, E.          blackhead are
                                                        meleagrimitis, and E.   expected and continue
                                                        gallopavonis) and       as long as prevention
                                                        blackhead.              is needed; withdraw 5
                                                                                days before
                                                                                slaughter; use as
                                                                                sole source of
                                                                                amprolium and organic
                                                                                arsenic; do not use
                                                                                as a treatment for
                                                                                outbreaks of
                                                                                coccidiosis;
                                                                                carbarsone by 046573
                                                                                in Sec. 510.600(c)
                                                                                of this chapter.
                              Chlortetracycline 100    Chickens where          Do not feed to
                               to 200.                  immunity to             chickens producing
                                                        coccidiosis is not      eggs for human
                                                        desired; prevention     consumption. Feed for
                                                        of coccidiosis;         7 to 14 d.
                                                        control of infectious
                                                        synovitis caused by
                                                        M. synoviae
                                                        susceptible to
                                                        chlortetracycline.
                              Chlortetracycline 200    Chickens where          Do not feed to
                               to 400.                  immunity to             chickens producing
                                                        coccidiosis is not      eggs for human
                                                        desired; control of     consumption. Feed for
                                                        chronic respiratory     7 to 14 d.
                                                        disease (CRD) and air
                                                        sac infection caused
                                                        by M. gallisepticum
                                                        and E. coli
                                                        susceptible to
                                                        chlortetracycline.
                              Erythromycin 4.6 to      Broiler chickens and    As erythromycin
                               18.5.                    replacement chickens    thiocyanate.
                                                        where immunity to
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency.
                              Erythromycin 92.5......  1. Broiler chickens     Feed for 2 d before
                                                        and replacement         stress and 3 to 6 d
                                                        chickens where          after stress;
                                                        immunity to             withdraw 24 h before
                                                        coccidiosis is not      slaughter.
                                                        desired; prevention
                                                        of coccidiosis; as an
                                                        aid in the prevention
                                                        of chronic
                                                        respiratory disease
                                                        during periods of
                                                        stress.
                                                       2. Broiler chickens     Feed for 7 to 14 d;
                                                        and replacement         withdraw 24 h before
                                                        chickens where          slaughter.
                                                        immunity to
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis; as an
                                                        aid in the prevention
                                                        of infectious coryza.
                              Erythromycin 185.......  Broiler chickens and    Feed for 5 to 8 d, do
                                                        replacement chickens    not use in birds
                                                        where immunity to       producing eggs for
                                                        coccidiosis is not      food purposes;
                                                        desired; prevention     withdraw 48 h before
                                                        of coccidiosis; as an   slaughter.
                                                        aid in the prevention
                                                        and reduction of
                                                        lesions and in
                                                        lowering severity of
                                                        chronic respiratory
                                                        disease.
                              Hygromycin B 8 to 12...  Broiler chickens and    Feed according to
                                                        replacement chickens    subtable in item (i).
                                                        where immunity to
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis;
                                                        control of
                                                        infestation of large
                                                        round worms
                                                        (Heterakis gallinae)
                                                        and capillary worms
                                                        (Capillaria
                                                        obsignata).

[[Page 399]]

 
                              Penicillin 2.4 to 50...  1. Broiler chickens     As procaine penicillin
                                                        and replacement
                                                        chickens where
                                                        immunity to
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency.
                                                       2. Turkeys; prevention  ......do..............
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency.
                              Roxarsone 22.7 to 45.4   1. Broiler chickens     Withdraw 5 d before
                               (0.0025% to 0.005%).     and replacement         slaughter; as sole
                                                        chickens where          source of organic
                                                        immunity to             arsenic.
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency;
                                                        improving
                                                        pigmentation.
                                                       2. Turkeys; prevention  ......do..............
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency;
                                                        improving
                                                        pigmentation.
(v) 227 (0.025%)............  .......................  Laying chickens;        For severe outbreaks    .........
                                                        treatment of            of coccidiosis;
                                                        coccidiosis.            administer for 2
                                                                                weeks.
----------------------------------------------------------------------------------------------------------------
\1\ Bacitracin zinc in Sec. 510.600(c) of this chapter.

    (3) Pheasants. It is used as follows:
    (i) Amount. 0.0175 percent (159 grams per ton).
    (ii) Indications for use. For the prevention of coccidiosis in 
growing pheasants caused by Eimeria colchici, E. duodenalis, and E. 
phasiani.
    (iii) Limitations. Feed continuously as sole ration. Use as sole 
source of amprolium. Fertility, hatchability, and other reproductive 
data are not available on amprolium in breeding pheasants. Do not use in 
feeds containing bentonite.

[41 FR 10985, Mar. 15, 1976]

    Editorial Note: For Federal Register citations affecting Sec. 
558.55, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.58  Amprolium and ethopabate.

    (a) Specifications. Type A medicated articles containing:
    (1) 25 percent amprolium and 8 percent ethopabate or 5 percent 
amprolium and 1.6 percent ethopabate;
    (2) 25 percent amprolium and 0.8 percent ethopabate or 5 percent 
amprolium and 0.16 percent ethopabate.
    (b) Approvals. See No. 016592 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. Do not use in Type B or Type C medicated 
feeds containing bentonite.
    (d) Related tolerances. See Sec. Sec. 556.50 and 556.260 of this 
chapter.
    (e) Conditions of use. (1) It is used for chickens as follows:

----------------------------------------------------------------------------------------------------------------
 Amprolium and ethopabate in    Combination in grams
        grams per ton                 per ton            Indications for use         Limitations        Sponsor
----------------------------------------------------------------------------------------------------------------
(i) Amprolium 113.5 (0.0125   .......................  Broiler chickens as an  Not for laying hens;       016592
 pct) and ethopabate 3.6                                aid in the prevention   as sole source of
 (0.0004 pct).                                          of coccidiosis.         amprolium.

[[Page 400]]

 
                              Bambermycins, 1 to 3;    Broiler chickens: As    Feed continuously as       016592
                               plus roxarsone, 22.8     an aid in the           the sole ration; as
                               to 34.1.                 prevention of           sole source of
                                                        coccidiosis; and for    amprolium and organic
                                                        increased rate of       arsenic; withdraw 5 d
                                                        weight gain, improved   before slaughter;
                                                        feed efficiency, and    roxarsone provided by
                                                        improved pigmentation.  No. 046573,
                                                                                bambermycins by No.
                                                                                016592 in Sec.
                                                                                510.600(c) of this
                                                                                chapter.
(ii) Amprolium 113.5          Bambermycins 2 to 3      Broiler chickens; as    Feed continuously as       016592
 (0.0125%) and ethopabate      plus roxarsone 22.8 to   an aid in the           the sole ration; as
 3.6 (0.0004%).                34.1 (0.0025% to         prevention of           sole source of
                               0.00375%).               coccidiosis; for        amprolium and organic
                                                        increased rate of       arsenic; amprolium
                                                        weight gain, improved   and ethopabate as
                                                        feed efficiency, and    provided by No.
                                                        pigmentation.           016592 in Sec.
                                                                                510.600(c) of this
                                                                                chapter, roxarsone by
                                                                                No. 046573,
                                                                                bambermycins by No.
                                                                                016592; withdraw 5 d
                                                                                before slaughter.
                              Lincomycin 2 to 4......  Broiler chickens; for   Not for laying
                                                        increase in rate of     chickens; as
                                                        weight gain; improved   lincomycin
                                                        feed efficiency; as     hydrochloride
                                                        an aid in the           monohydrate; as sole
                                                        prevention of           source of amprolium.
                                                        coccidiosis.
                              Lincomycin 2 to 4 plus   Broiler chickens; for   Not for laying
                               roxarsone 45.4           increase in rate of     chickens; as
                               (0.005%).                weight gain; improved   lincomycin
                                                        feed efficiency and     hydrochloride
                                                        pigmentation; as an     monohydrate; withdraw
                                                        aid in the prevention   5 d before slaughter;
                                                        of coccidiosis.         as sole source of
                                                                                amprolium and organic
                                                                                arsenic.
                              Roxarsone 45.4 (0.005    Broiler chickens; to    Do not feed to laying
                               pct).                    aid in prevention of    chickens; withdraw 5
                                                        coccidiosis where       d before slaughter;
                                                        severe exposure to      as sole source of
                                                        coccidiosis from        amprolium; do not use
                                                        Eimeria acervulina,     as a treatment for
                                                        E. maxima, and E.       outbreaks of
                                                        brunetti is likely to   coccidiosis; feed as
                                                        occur; for increased    sole ration from time
                                                        rate of weight gain     chickens are placed
                                                        in broiler chickens     on litter until the
                                                        raised in floor pens.   past the time when
                                                                                coccidiosis is
                                                                                ordinarily a hazard;
                                                                                roxarsone as provided
                                                                                by No. 046573 in Sec.
                                                                                  510.600(c) of this
                                                                                chapter; combinations
                                                                                as provided by No.
                                                                                016592.
(iii) Amprolium 113.5         .......................  Broiler chickens and    Not for chickens over
 (0.0125%) and ethopabate                               replacement chickens    16 weeks of age.
 36.3 (0.004%).                                         where immunity to
                                                        coccidiosis is not
                                                        desired; as an aid in
                                                        the prevention of
                                                        coccidiosis where
                                                        severe exposure to
                                                        coccidiosis from
                                                        Eimeria acervulina,
                                                        E. maxima, and E.
                                                        brunetti is likely to
                                                        occur.
                              Arsanilic acid 90 (0.01  Broiler chickens and    Not for laying hens;       061133
                               pct) plus erythromycin   replacement chickens    withdraw 5 d before
                               4.6 to 18.5.             where immunity to       slaughter; as sole
                                                        coccidiosis is not      source of organic
                                                        desired; prevention     arsenic; as
                                                        of coccidiosis;         erythromycin
                                                        growth promotion and    thiocyanate.
                                                        feed efficiency;
                                                        improve pigmentation.

[[Page 401]]

 
                              Bacitracin 4 to 50.....  1. Broiler chickens     Not for chickens over
                                                        and replacement         16 weeks of age; do
                                                        chickens where          not feed to laying
                                                        immunity to             chickens; as sole
                                                        coccidiosis is not      source of amprolium;
                                                        desired; to aid in      not for use as a
                                                        prevention of           treatment for
                                                        coccidiosis where       outbreaks of
                                                        severe exposure to      coccidiosis; as
                                                        coccidiosis from        bacitracin methylene
                                                        Eimeria acervulina,     disalicylate as
                                                        E. maxima, and E.       provided by No.
                                                        brunetti is likely to   046573 or bacitracin
                                                        occur; for increased    zinc as provided by
                                                        rate of weight gain     No. 046573 in Sec.
                                                        in broiler chickens     510.600(c) of this
                                                        raised in floor pens.   chapter; feed as the
                                                                                sole ration from the
                                                                                time chickens are
                                                                                placed on litter
                                                                                until past the time
                                                                                when coccidiosis is
                                                                                ordinarily a hazard;
                                                                                combination as
                                                                                provided by No.
                                                                                016592 in Sec.
                                                                                510.600(c) of this
                                                                                chapter.
                              .......................  2. Broiler chickens;    Not for chickens over      046573
                                                        as an aid in            16 weeks of age; do
                                                        prevention of           not feed to laying
                                                        coccidiosis where       chickens; as sole
                                                        severe exposure to      source of amprolium;
                                                        coccidiosis from        not for use as a
                                                        Eimeria acervulina,     treatment for
                                                        E. maxima, and E.       coccidiosis;
                                                        brunetti is likely to   bacitracin zinc as
                                                        occur; improved feed    provided by No.
                                                        efficiency.             046573 in Sec.
                                                                                510.600(c) of this
                                                                                chapter; feed as the
                                                                                sole ration from the
                                                                                time chickens are
                                                                                placed on litter
                                                                                until market weight;
                                                                                combination as
                                                                                provided by No.
                                                                                046573.
                              Bacitracin 5 to 35 plus  Broiler chickens; for   Do not feed to laying
                               roxarsone 34             increased rate of       chickens; withdraw 5
                               (0.00375%).              weight gain and as an   d before slaughter;
                                                        aid in the prevention   as sole source of
                                                        of coccidiosis where    amprolium and organic
                                                        severe exposure to      arsenic; do not use
                                                        coccidiosis from        as a treatment for
                                                        Eimeria acervulina,     outbreaks of
                                                        E. maxima, and E.       coccidiosis; feed as
                                                        brunetti is likely to   the sole ration from
                                                        occur in broiler        time chickens are
                                                        chickens raised in      placed on litter
                                                        floor pens.             until past the time
                                                                                when coccidiosis is
                                                                                ordinarily a hazard;
                                                                                amprolium and
                                                                                ethopabate as
                                                                                provided by No.
                                                                                016592 in Sec.
                                                                                510.600(c) of this
                                                                                chapter; bacitracin
                                                                                methylene
                                                                                disalicylate as
                                                                                provided by No.
                                                                                046573 or bacitracin
                                                                                zinc as provided by
                                                                                No. 046573 in Sec.
                                                                                510.600(c) of this
                                                                                chapter; roxarsone as
                                                                                provided by No.
                                                                                046573 in Sec.
                                                                                510.600(c) of this
                                                                                chapter; combination
                                                                                as provided by No.
                                                                                016592 in Sec.
                                                                                510.600(c) of this
                                                                                chapter.

[[Page 402]]

 
                              Bacitracin 20 to 35      Broiler chickens; for   Do not feed to laying
                               plus roxarsone 34        increased rate of       chickens; withdraw 5
                               (0.00375%).              weight gain, improved   d before slaughter;
                                                        feed efficiency, and    as sole source of
                                                        as an aid in the        amprolium and organic
                                                        prevention of           arsenic; do not use
                                                        coccidiosis where       as a treatment for
                                                        severe exposure to      outbreaks of
                                                        coccidiosis from        coccidiosis; feed as
                                                        Eimeria acervulina,     the sole ration from
                                                        E. maxima, and E.       time chickens are
                                                        brunetti is likely to   placed on litter
                                                        occur in broiler        until past the time
                                                        chickens raised in      when coccidiosis is
                                                        floor pens.             ordinarily a hazard;
                                                                                amprolium and
                                                                                ethopabate as
                                                                                provided by No.
                                                                                016592 in Sec.
                                                                                510.600(c) of this
                                                                                chapter; bacitracin
                                                                                methylene
                                                                                disalicylate as
                                                                                provided by No.
                                                                                046573 in Sec.
                                                                                510.600(c) of this
                                                                                chapter; roxarsone as
                                                                                provided by No.
                                                                                046573 in Sec.
                                                                                510.600(c) of this
                                                                                chapter; combination
                                                                                as provided by No.
                                                                                016592 in Sec.
                                                                                510.600(c) of this
                                                                                chapter.
                              Bacitracin 10 to 50      Broiler chickens; as    Do not feed to laying      046573
                               plus roxarsone 15.4 to   an aid in prevention    chickens; withdraw 5
                               45.4 (0.0017% to         of coccidiosis where    d before slaughter;
                               0.005%).                 severe exposure to      as sole source of
                                                        coccidiosis from        amprolium and organic
                                                        Eimeria acervulina,     arsenic; do not use
                                                        E. maxima, and E.       as a treatment for
                                                        brunetti is likely to   outbreaks of
                                                        occur; improved feed    coccidiosis; feed as
                                                        efficiency.             the sole ration from
                                                                                time chicks are
                                                                                placed on litter
                                                                                until past the time
                                                                                when coccidiosis is
                                                                                ordinarily a hazard;
                                                                                amprolium and
                                                                                ethopabate as
                                                                                provided by No.
                                                                                016592 in Sec.
                                                                                510.600(c) of this
                                                                                chapter; bacitracin
                                                                                zinc as provided by
                                                                                No. 046573 roxarsone
                                                                                as provided by No.
                                                                                046573 combination as
                                                                                provided by No.
                                                                                046573.
                              Bacitracin 10 plus       Broiler chickens; as    ......do..............     063238
                               roxarsone 30 to 45.4     an aid in prevention
                               (0.0033% to 0.005%).     of coccidiosis where
                                                        severe exposure to
                                                        coccidiosis from E.
                                                        acervulina, E.
                                                        maxima, and E.
                                                        brunetti is likely to
                                                        occur; improved feed
                                                        efficiency and
                                                        improved pigmentation.
                              Bambermycins 1 to 3....  Broiler chickens; as    Feed continuously as       016592
                                                        an aid in the           the sole ration; as
                                                        prevention of           sole source of
                                                        coccidiosis where       amprolium; amprolium,
                                                        severe exposure to      ethopabate as
                                                        coccidiosis from        provided by No.
                                                        Eimeria acervulina,     016592 in Sec.
                                                        E. maxima, and E.       510.600(c) of this
                                                        brunetti is likely to   chapter, bambermycins
                                                        occur; for increased    as provided by No.
                                                        rate of weight gain,    016592 in Sec.
                                                        and improved feed       510.600(c) of this
                                                        efficiency.             chapter.
                              Bambermycins 1 to 3      Broiler chickens; as    Feed continuously as       016592
                               plus roxarsone 22.8 to   an aid in the           the sole ration; as
                               34.1 (0.0025% to         prevention of           sole source of
                               0.00375%).               coccidiosis where       amprolium and organic
                                                        severe exposure to      arsenic; amprolium
                                                        coccidiosis from        and ethopabate as
                                                        Eimeria acervulina,     provided by No.
                                                        E. maxima, and E.       016592 in Sec.
                                                        brunetti is likely to   510.600(c) of this
                                                        occur; for increased    chapter, roxarsone by
                                                        rate of weight gain;    No. 046573
                                                        improved feed           bambermycins by No.
                                                        efficiency, and         016592. Withdraw 5
                                                        improved pigmentation.  days before slaughter.
                              Erythromycin 4.6 to      Broiler chickens and    Not for laying hens;
                               18.5.                    replacement chickens    withdraw 24 hours
                                                        where immunity to       before slaughter;
                                                        coccidiosis is not      erythromycin
                                                        desired; prevention     thiocyanate.
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency.

[[Page 403]]

 
                              Virginiamycin, 15......  Broiler chickens, as    Feed continuously as       000069
                                                        an aid in the           sole ration, do not
                                                        prevention of           feed to laying hens,
                                                        coccidiosis where       not for chickens over
                                                        severe exposure to      16 weeks of age, as
                                                        Eimeria acervulina,     sole source of
                                                        E. brunetti, and E.     amprolium, amprolium
                                                        maxima is likely to     and ethopabate as
                                                        occur, for increased    provided by 016592 in
                                                        rate of weight gain     Sec. 510.600(c),
                                                        and improved feed       virginiamycin as
                                                        efficiency.             provided by 066104.
                              Virginiamycin, 5 to 15.  Broiler chickens, as    ......do..............
                                                        an aid in the
                                                        prevention of
                                                        coccidiosis where
                                                        severe exposure to
                                                        Eimeria acervulina,
                                                        E. brunetti, and E.
                                                        maxima is likely to
                                                        occur, for increased
                                                        rate of weight gain.
(iv) Amprolium 113.5 to 227   .......................  For broiler chickens    Not for laying hens...
 (0.0125% to 0.025%) and                                and replacement
 ethopabate 3.6 (0.0004%).                              chickens where
                                                        immunity to
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis.
                              Arsanilic acid 90        Broiler chickens and    As sole source of
                               (0.01%).                 replacement chickens    organic arsenic;
                                                        where immunity to       withdraw 5 d before
                                                        coccidiosis is not      slaughter; not for
                                                        desired; prevention     laying hens.
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency;
                                                        improving
                                                        pigmentation.
                              Arsanilic acid 90        1. For broiler          Feed for 2 d before
                               (0.01%) plus             chickens and            stress and 3 to 6 d
                               erythromycin 92.5.       replacement chickens    after stress;
                                                        where immunity to       withdraw 5 d before
                                                        coccidiosis is not      slaughter; as sole
                                                        desired; prevention     source of organic
                                                        of coccidiosis; as an   arsenic; not for
                                                        aid in the prevention   laying hens.
                                                        of chronic
                                                        respiratory disease
                                                        during periods of
                                                        stress; growth
                                                        promotion and feed
                                                        efficiency; improving
                                                        pigmentation.
                                                       2. For broiler          Feed for 7 to 14 d;
                                                        chickens and            withdraw 5 d before
                                                        replacement chickens    slaughter; as sole
                                                        where immunity to       source of organic
                                                        coccidiosis is not      arsenic; not for
                                                        desired; prevention     laying hens.
                                                        of coccidiosis; as an
                                                        aid in the prevention
                                                        of infectious coryza;
                                                        growth promotion and
                                                        feed efficiency;
                                                        improving
                                                        pigmentation.
                              Arsanilic acid 90        For broiler chickens    Feed for 5 to 8 d; do
                               (0.01%) plus             and replacement         not use in birds
                               erythromycin 185.        chickens where          producing eggs for
                                                        immunity to             food purposes;
                                                        coccidiosis is not      withdraw 5 d before
                                                        desired; prevention     slaughter; as sole
                                                        of coccidiosis; as an   source of organic
                                                        aid in the prevention   arsenic.
                                                        and reduction of
                                                        lesions and in
                                                        lowering severity of
                                                        chronic respiratory
                                                        disease; growth
                                                        promotion and feed
                                                        efficiency; improving
                                                        pigmentation.
                              Bacitracin 4 to 50.....  For broiler chickens    As bacitracin
                                                        and replacement         methylene
                                                        chickens where          disalicylate; not for
                                                        immunity to             laying hens.
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency.
                              Bacitracin 100 to 200..  1. Broiler chickens     ......do..............
                                                        and replacement
                                                        chickens where
                                                        immunity to
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis;
                                                        treatment of chronic
                                                        respiratory disease
                                                        (air-sac infection)
                                                        and blue comb
                                                        (nonspecific
                                                        infectious enteritis).

[[Page 404]]

 
                                                       2. For broiler          As zinc bacitracin,
                                                        chickens and            not for laying hens.
                                                        replacement chickens
                                                        where immunity to
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis;
                                                        treatment of chronic
                                                        respiratory disease
                                                        (air-sac infection),
                                                        blue comb
                                                        (nonspecific
                                                        infectious enteritis).
                              Bacitracin 4 to 50 plus  Broiler chickens and    As bacitracin
                               roxarsone 22.7 to 45.4   replacement chickens    methylene
                               (0.0025% to 0.005%).     where immunity to       disalicylate; not for
                                                        coccidiosis is not      laying hens; as sole
                                                        desired; prevention     source of organic
                                                        of coccidiosis;         arsenic; withdraw 5 d
                                                        growth promotion and    before slaughter.
                                                        feed efficiency;
                                                        improving
                                                        pigmentation.
                              Chlortetracycline 100    For chickens where      Do not feed to
                               to 200.                  immunity to             chickens producing
                                                        coccidiosis is not      eggs for human
                                                        desired; prevention     consumption. Feed for
                                                        of coccidiosis;         7 to 14 d.
                                                        control of infectious
                                                        synovitis caused by
                                                        Mycoplasma synoviae
                                                        susceptible to
                                                        chlortetracycline.
                              Chlortetracycline 200    For chickens where      In low calcium feed
                               to 400.                  immunity to             containing 0.8%
                                                        coccidiosis is not      dietary calcium and
                                                        desired; prevention     1.5% sodium sulfate;
                                                        of coccidiosis;         feed continuously as
                                                        control of chronic      sole ration for 7 to
                                                        respiratory disease     14 d; do not feed to
                                                        (CRD) and air sac       chickens producing
                                                        infection caused by     eggs for human
                                                        M. gallisepticum and    consumption.
                                                        E. coli susceptible
                                                        to chlortetracycline.
                              Erythromycin 92.5......  1. For broiler          Feed for 2 d before
                                                        chickens and for        stress and 3 to 6 d
                                                        replacement chickens    after stress;
                                                        where immunity to       withdraw 24 h before
                                                        coccidiosis is not      slaughter; not for
                                                        desired; prevention     laying hens.
                                                        of coccidiosis; as an
                                                        aid in the prevention
                                                        of chronic
                                                        respiratory disease
                                                        during periods of
                                                        stress.
                                                       2. For broiler          Feed for 7 to 14 d;
                                                        chickens and            withdraw 24 h before
                                                        replacement chickens    slaughter; not for
                                                        where immunity to       laying hens.
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis; as an
                                                        aid in the prevention
                                                        of infectious coryza.
                              Erythromycin 185.......  For broiler chickens    Feed for 5 to 8 d; do
                                                        and replacement         not use in birds
                                                        chickens where          producing eggs for
                                                        immunity to             food purposes;
                                                        coccidiosis is not      withdraw 48 h before
                                                        desired; prevention     slaughter.
                                                        of coccidiosis; as an
                                                        aid in the prevention
                                                        and reduction of
                                                        lesions and in
                                                        lowering severity of
                                                        chronic respiratory
                                                        disease.
                              Penicillin 2.4 to 50...  For broiler chickens    Not for laying hens;
                                                        and replacement         as procaine
                                                        chickens where          penicillin.
                                                        immunity to
                                                        coccidiosis is not
                                                        desired; prevention
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency;
                                                        improving
                                                        pigmentation.
                              Roxarsone 22.7 to 45.4   Broiler chickens and    As sole source of       .........
                               (0.0025% to 0.005%).     replacement chickens    organic arsenic;
                                                        where immunity to       withdraw 5 d before
                                                        coccidiosis is not      slaughter; not for
                                                        desired; prevention     laying hens.
                                                        of coccidiosis;
                                                        growth promotion and
                                                        feed efficiency;
                                                        improving
                                                        pigmentation.
----------------------------------------------------------------------------------------------------------------

    (2) [Reserved]

[41 FR 10990, Mar. 15, 1976]

[[Page 405]]


    Editorial Note: For Federal Register citations affecting Sec. 
558.58, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.59  Apramycin.

    (a) Approvals. Type A articles to sponsors identified in Sec. 
510.600(c) of this chapter as follows:
    (1) 000986 for 75 grams apramycin (as apramycin sulfate) per pound 
for use as in paragraph (d)(1) of this section.
    (2) [Reserved]
    (b) [Reserved]
    (c) Related tolerances. See Sec. 556.52 of this chapter.
    (d) Conditions of use--(1) Swine--(i) Amount. 150 grams per ton.
    (ii) Indications for use. For control of porcine colibacillosis 
(weanling pig scours) caused by susceptible strains of Escherichia coli.
    (iii) Limitations. Use for 14 days. Withdraw 28 days before 
slaughter.
    (2) [Reserved]

[51 FR 9190, Mar. 18, 1986]



Sec. 558.62  Arsanilic acid.

    (a) Approvals. Type A medicated articles to sponsors in Sec. 
510.600(c) of this chapter as follows:
    (1) To 015565: 20, 50, and 100 percent for use as in the table in 
paragraph (c)(1), entry (ii), item 1; entry (ii), item 2; entry (iv); 
entry (vi); and entry (vii) of this section.
    (2) To 015565: 20 percent for use as in paragraph (c)(1), entry (i); 
entry (ii), item 3 of this section.
    (3) To 061133: 90 grams per pound arsanilic acid and 4.6 grams per 
pound erythromycin equivalents as erythromycin thiocyanate for use as in 
paragraph (c)(1), entry (iii); 90 grams per pound arsanilic acid and 
9.25 grams per pound erythromycin equivalents as erythromycin 
thiocyanate for use as in paragraph (c)(1), entry (v).
    (b) Related tolerances. See Sec. 556.60 of this chapter.
    (c) Conditions of use. (1) It is used as follows:

----------------------------------------------------------------------------------------------------------------
 Arsanilic acid in grams per    Combination in grams
             ton                      per ton            Indications for use         Limitations        Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 45 to 90................  .......................  1. Growing chickens:    Withdraw 5 days before     015565
                                                        For growth promotion    slaughter; as sole
                                                        and feed efficiency;    source of organic
                                                        improving               arsenic.
                                                        pigmentation.
                              .......................  2. Growing turkeys:     .......do.............     015565
                                                        For growth promotion
                                                        and feed efficiency;
                                                        improving
                                                        pigmentation.
                              .......................  3. Growing swine: For   .......do.............     015565
                                                        increased rate of
                                                        weight gain and
                                                        improved feed
                                                        efficiency.
(ii) 90.....................  .......................  Swine: As an aid in     .......do.............     015565
                                                        control of swine
                                                        dysentery
                                                        (hemorrhagic
                                                        enteritis, bloody
                                                        dysentery).
(iii).......................  Erythromycin 4.6.......  Chickens; growth        As erythromycin            012487
                                                        promotion and feed      thiocyanate; withdraw
                                                        efficiency; improving   5 days before
                                                        pigmentation.           slaughter; as sole
                                                                                source of organic
                                                                                arsenic.
(iv)........................  Erythromycin 4.6 to      Chickens; growth        As erythromycin             15565
                               18.5.                    promotion and feed      thiocyanate; withdraw
                                                        efficiency; improving   5 days before
                                                        pigmentation.           slaughter; as sole
                                                                                source of organic
                                                                                arsenic.
(v).........................  Erythromycin 9.25......  Chickens; growth        As erythromycin            012487
                                                        promotion and feed      thiocyanate; withdraw
                                                        efficiency; improving   5 days before
                                                        pigmentation.           slaughter; as sole
                                                                                source of organic
                                                                                arsenic.
(vi)........................  Erythromycin 92.5......  1. Chickens; as an aid  As erythromycin            015565
                                                        in the prevention of    thiocyanate; feed for
                                                        chronic respiratory     2 days before stress
                                                        disease during          and 3 to 6 days after
                                                        periods of stress;      stress; withdraw 5
                                                        growth promotion and    days before
                                                        feed efficiency;        slaughter; as sole
                                                        improving               source of organic
                                                        pigmentation.           arsenic.

[[Page 406]]

 
                                                       2. Chickens; as an aid  As erythromycin            015565
                                                        in the prevention of    thiocyanate; feed for
                                                        infectious coryza;      7 to 14 days;
                                                        growth promotion and    withdraw 5 days
                                                        feed efficiency;        before slaughter; as
                                                        improving               sole source of
                                                        pigmentation.           organic arsenic.
(vii).......................  Erythromycin 185.......  Chickens; as an aid in  As erythromycin             15565
                                                        the prevention and      thiocyanate; feed for
                                                        reduction of lesions    5 to 8 days; do not
                                                        and in lowering         use in birds
                                                        severity of chronic     producing eggs for
                                                        respiratory disease;    food purposes;
                                                        growth promotion and    withdraw 5 days
                                                        feed efficiency;        before slaughter; as
                                                        improving               sole source of
                                                        pigmentation.           organic arsenic.
----------------------------------------------------------------------------------------------------------------

    (2) Arsanilic acid may be used in accordance with the provisions of 
this section in the combinations provided as follows:
    (i) Amprolium in accordance with Sec. 558.55.
    (ii) Amprolium and ethopabate in accordance with Sec. 558.58.
    (iii) Bacitracin zinc in accordance with Sec. 558.78.
    (iv) Bacitracin and zoalene in accordance with Sec. 558.680.
    (v) Zoalene in accordance with Sec. 558.680.

[41 FR 10992, Mar. 15, 1976, as amended at 42 FR 18617, Apr. 8, 1977; 51 
FR 7395, Mar. 3, 1986; 51 FR 33897, Sept. 24, 1986; 54 FR 18281, Apr. 
28, 1989; 56 FR 19268, Apr. 26, 1991; 60 FR 39847, Aug. 4, 1995; 66 FR 
14074, Mar. 9, 2001; 66 FR 57873, Nov. 19, 2001]



Sec. 558.76  Bacitracin methylene disalicylate.

    (a) Approvals. Type A medicated articles: 10, 25, 30, 40, 50, 60, or 
75 grams per pound to 046573 in Sec. 510.600(c) of this chapter.
    (b) Special considerations. The quantities of antibiotics are 
expressed in terms of the equivalent amount of antibiotic standard.
    (c) Related tolerances. See Sec. 556.70 of this chapter.
    (d) Conditions of use. (1) It is used as follows:

----------------------------------------------------------------------------------------------------------------
    Bacitracin methylene
  disalicylate in grams per     Combination in grams     Indications for use         Limitations        Sponsor
             ton                      per ton
----------------------------------------------------------------------------------------------------------------
(i) 4 to 50.................  .......................  Chickens, turkeys, and  ......................     046573
                                                        pheasants; increased
                                                        rate of weight gain
                                                        and improved feed
                                                        efficiency \1\.
(ii) 5 to 20................  .......................  Quail not over 5 weeks  ......................     046573
                                                        of age; increased
                                                        rate of weight gain
                                                        and improved feed
                                                        efficiency \1\.
(iii) 10 to 25..............  .......................  Chickens; for           For first 7 months of      046573
                                                        increased egg           production.
                                                        production and
                                                        improved feed
                                                        efficiency for egg
                                                        production.
(iv) 10 to 30...............  .......................  Swine: for increased    For growing and            046573
                                                        rate of weight gain     finishing swine.
                                                        and improved feed
                                                        efficiency.
                              Chlortetracycline        Swine; for increased    Feed for not more than     046573
                               approximately 400,       rate of weight gain     14 days; bacitracin       048164
                               varying with body        and improved feed       methylene
                               weight and food          efficiency; for         disalicylate provided
                               consumption to provide   treatment of            by No. 046573;
                               10 milligrams per        bacterial enteritis     chlortetracycline
                               pound of body weight     caused by Escherichia   provided by Nos.
                               per day.                 coli and Salmonella     046573 and 048164 in
                                                        choleraesuis and        Sec. 510.600(c) of
                                                        bacterial pneumonia     this chapter.
                                                        caused by Pasteurella
                                                        multocida susceptible
                                                        to chlortetracycline.
                                                       Swine; for control of   Feed for not more than     046573
                                                        porcine proliferative   14 days;
                                                        enteropathies           chlortetracycline and
                                                        (ileitis) caused by     BMD as provided by
                                                        Lawsonia                046573 in Sec.
                                                        intracellularis         510.600(c) of this
                                                        susceptible to          chapter.
                                                        chlortetracycline.

[[Page 407]]

 
(v) [Reserved]
(vi) 50.....................  .......................  Broiler chickens; as    ......................     046573
                                                        an aid in the
                                                        prevention of
                                                        necrotic enteritis
                                                        caused or complicated
                                                        by Clostridium spp.
                                                        or other organisms
                                                        susceptible to
                                                        bacitracin.
                                                       Replacement chickens;   Feed continuously as       046573
                                                        as an aid in the        sole ration.
                                                        prevention of
                                                        necrotic enteritis
                                                        caused or complicated
                                                        by Clostridium spp.
                                                        or other organisms
                                                        susceptible to
                                                        bacitracin
(vii)-(viii) [Reserved]
(ix) 100 to 200.............  .......................  Broiler chickens; as    ......................     046573
                                                        an aid in the control
                                                        of necrotic enteritis
                                                        caused or complicated
                                                        by Clostridium spp.
                                                        or other organisms
                                                        susceptible to
                                                        bacitracin.
                                                       Replacement chickens;   Feed continuously as       046573
                                                        as an aid in the        sole ration. Start at
                                                        control of necrotic     first clinical signs
                                                        enteritis caused or     of disease, vary
                                                        complicated by          dosage based on
                                                        Clostridium spp. or     severity of
                                                        other organisms         infection, administer
                                                        susceptible to          continuously for 5 to
                                                        bacitracin              7 days or as long as
                                                                                clinical signs
                                                                                persist, then reduce
                                                                                medication to
                                                                                prevention level (50
                                                                                g/t).
(x) 200.....................  .......................  Turkeys; as an aid in   ......................     046573
                                                        the control of
                                                        transmissible
                                                        enteritis in growing
                                                        turkeys complicated
                                                        by organisms
                                                        susceptible to
                                                        bacitracin methylene
                                                        disalicylate.
                                                       Quail; for the          From Type A medicated      046573
                                                        prevention of           articles containing
                                                        ulcerative enteritis    25, 40, or 50 grams
                                                        in growing quail due    of bacitracin
                                                        to Clostridium          methylene
                                                        colinum susceptible     disalicylate. Feed
                                                        to bacitracin           continuously as the
                                                        methylene               sole ration.
                                                        disalicylate
(xi) 250....................  .......................  1. Growing/Finishing    As the sole ration.        046573
                                                        Swine: For control of   Not for use in swine
                                                        swine dysentery         weighing more than
                                                        associated with         250 pounds. Diagnosis
                                                        Treponema               should be confirmed
                                                        hyodysenteriae on       by a veterinarian
                                                        premises with a         when results are not
                                                        history of swine        satisfactory.
                                                        dysentery but where
                                                        signs of the disease
                                                        have not yet
                                                        occurred; or
                                                        following an approved
                                                        treatment of the
                                                        disease condition.
                                                       2. Pregnant sows: For   As the sole ration.     .........
                                                        control of              Feed to sows from 14
                                                        clostridial enteritis   days before through
                                                        caused by C.            21 days after
                                                        perfringens in          farrowing on premises
                                                        suckling piglets.       with a history of
                                                                                clostridial scours.
                                                                                Diagnosis should be
                                                                                confirmed by a
                                                                                veterinarian when
                                                                                results are not
                                                                                satisfactory.
----------------------------------------------------------------------------------------------------------------
\1\ These conditions are NAS/NRC reviewed and found effective. Applications for these uses may not require
  effectiveness data as specified by Sec. 514.111 of this chapter, but may require bioequivalency and safety
  information.

    (2) It is used as bacitracin methylene disalicylate in feed for 
animals as follows:
    (i) Amount. 70 milligrams per head per day.
    (a) Indications for use. Feedlot beef cattle; reduction in the 
number of liver condemnations due to abscesses.
    (b) Limitations. Administer continuously throughout the feeding 
period.
    (ii) Amount. 250 milligrams per head per day.
    (a) Indications for use. Feedlot beef cattle; reduction in the 
number of liver condemnations due to abscesses.

[[Page 408]]

    (b) Limitations. Administer continuously for 5 days then discontinue 
for subsequent 25 days, repeat the pattern during the feeding period.
    (3) Bacitracin methylene disalicylate may also be used with:
    (i) Amprolium as in Sec. 558.55.
    (ii) Amprolium and ethopabate as in Sec. 558.58.
    (iii) Carbarsone (not USP) as in Sec. 558.120.
    (iv) Decoquinate alone and with roxarsone as in Sec. 558.195.
    (v) Diclazuril alone and with roxarsone as in Sec. 558.198.
    (vi) Fenbendazole as in Sec. 558.258.
    (vii) Halofuginone hydrobromide alone and with roxarsone as in Sec. 
558.265.
    (viii) Hygromycin B as in Sec. 588.274.
    (ix) Ivermectin as in Sec. 558.300.
    (x) Lasalocid sodium alone and with roxarsone as in Sec. 558.311.
    (xi) Monensin alone and with roxarsone as in Sec. 588.355.
    (xii) Narasin alone and with roxarsone as in Sec. 558.363.
    (xiii) Nicarbazin alone or with narasin or roxarsone or with narasin 
and roxarsone as in Sec. 558.366.
    (xiv) Nitarsone as in Sec. 558.369.
    (xv) Robenidine alone and with roxarsone as in Sec. 558.515.
    (xvi) Salinomycin alone and with roxarsone as in Sec. 558.550.
    (xvii) Semduramicin alone and with roxarsone as in Sec. 558.555.
    (xviii) Zoalene alone and with arsanilic acid or roxarsone as in 
Sec. 558.680.

[41 FR 10993, Mar. 15, 1976]

    Editorial Note: For Federal Register citations affecting Sec. 
558.76, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.78  Bacitracin zinc.

    (a) Specifications. Type A medicated articles containing bacitracin 
zinc equivalent to 10, 25, 40, or 50 grams per pound bacitracin.
    (b) Approvals. See No. 046573 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.70 of this chapter.
    (d) Conditions of use. (1) It is used as follows:

----------------------------------------------------------------------------------------------------------------
Bacitracin zinc in grams per   Combinations in grams
             ton                      per ton            Indications for use         Limitations        Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 4 to 50.................  .......................  Chickens: for           Growing chickens......     046573
                                                        increased rate of
                                                        weight gain and
                                                        improved feed
                                                        efficiency.
(ii) 4 to 50................  .......................  Turkeys and pheasants:  Growing turkeys and        046573
                                                        for increased rate of   pheasants.
                                                        weight gain and
                                                        improved feed
                                                        efficiency.
(iii) 5 to 20...............  .......................  Quail; for increased    Growing quail; feed as     046573
                                                        rate of weight gain     the Type C feed to
                                                        and improved feed       starting quail
                                                        efficiency.             through 5 weeks of
                                                                                age.
(iv) 10 to 25...............  .......................  Laying chickens;        ......................     046573
                                                        improved feed
                                                        efficiency and
                                                        increased egg
                                                        production.
(v) 10 to 50................  .......................  Swine; increased rate   Growing and finishing      046573
                                                        of weight gain and      swine.
                                                        improved feed
                                                        efficiency.
(vi) 20.....................  .......................  Growing-finishing       In Type C feed........     046573
                                                        swine; increased rate
                                                        of weight gain.
(vii) 20 to 40..............  .......................  Growing-finishing       ......do..............     046573
                                                        swine; improved feed
                                                        efficiency.
----------------------------------------------------------------------------------------------------------------

    (2) It is used in feed for growing cattle at 35 to 70 milligrams per 
head per day as follows:
    (i) To aid in stimulating growth and improving feed efficiency.
    (ii) For increased rate of weight gain and improved feed efficiency; 
see sponsor 046573.
    (3) It may be used as approved in combination with:
    (i) Amprolium alone and with roxarsone as in Sec. 558.55.
    (ii) Amprolium and ethopabate alone and with roxarsone as in Sec. 
558.58.
    (iii) Carbarsone as in Sec. 558.120.
    (iv) Clopidol alone and with roxarsone as in Sec. 558.175.
    (v) Decoquinate alone and with roxarsone as in Sec. 558.195.

[[Page 409]]

    (vi) Hygromycin B alone and with penicillin as in Sec. 558.274.
    (vii) Lasalocid sodium alone or with roxarsone as in Sec. 558.311.
    (viii) Monensin alone and with roxarsone as in Sec. 558.355.
    (ix) Naracin as in Sec. 558.363.
    (x) Nitarsone as in Sec. 558.369.
    (xi) Robenidine as in Sec. 558.515.
    (xii) Salinomycin alone and with roxarsone as in Sec. 558.550.
    (xiii) Zoalene alone and with arsanilic acid or roxarsone as in 
Sec. 558.680.

[41 FR 10994, Mar. 15, 1976]

    Editorial Note: For Federal Register citations affecting Sec. 
558.78, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.95  Bambermycins.

    (a) Approvals. To sponsors identified by drug labeler codes in Sec. 
510.600(c) of this chapter for use of bambermycins Type A medicated 
articles as bambermycins activity per pound in paragraph (d) of this 
section as follows:
    (1) To 016592: 2, 4, and 10 grams for use as in paragraphs (d)(1), 
(d)(2), (d)(3), and (d)(4) of this section.
    (2) To 016592: 0.4 gram for use as in paragraph (d)(2) of this 
section.
    (3) [Reserved]
    (4) To Nos. 012286, 016968, and 017790: 0.4 and 2 grams for use as 
in paragraph (d)(2) and 2 grams for use as in paragraph (d)(3) of this 
section.
    (5) To 016592: 10 grams to make 40 to 800 grams per ton Type B feed 
for use as in paragraph (d)(4) of this section.
    (b) Special considerations. (1) Bambermycins liquid Type B feeds may 
be manufactured from dry bambermycins Type A articles. The liquid Type B 
feeds must have a pH of 3.8 to 7.5, moisture content of 30 to 45 
percent.
    (2) The expiration date for the liquid Type B feed is 8 weeks after 
date of manufacture. The expiration date for the dry Type C feed made 
from the liquid Type B feed is 1 week after date of manufacture.
    (c) [Reserved]
    (d) Conditions of use--(1) Broiler chickens. It is used as follows:
    (i) Amount per ton. 1 to 2 grams.
    (a) Indications for use. For increased rate of weight gain and 
improved feed efficiency.
    (b) Limitations. Feed continuously as the sole ration.
    (ii) [Reserved]
    (2) Growing-finishing swine. It is used as follows:
    (i) Amount per ton. 2 grams.
    (a) Indications for use. For increased rate of weight gain and 
improved feed efficiency.
    (b) Limitations. Feed continuously as sole ration.
    (ii) Amount per ton. 2 to 4 grams.
    (a) Indications for use. For increased rate of weight gain.
    (b) Limitations. Feed continuously as sole ration.
    (3) Growing turkeys. It is used as follows:
    (i) Amount per ton. 1 to 2 grams.
    (a) Indications for use. For improved feed efficiency.
    (b) Limitations. Feed continuously as the sole ration.
    (ii) Amount per ton. 2 grams.
    (a) Indications for use. For increased rate of weight gain and 
improved feed efficiency.
    (b) Limitations. Feed continuously as sole ration.
    (4) Cattle--(i) Amount per ton. 1 to 4 grams.
    (a) Indications for use. For increased rate of weight gain and 
improved feed efficiency.
    (b) Limitations. Feed only to cattle being fed in confinement for 
slaughter. Feed continuously in a Type C medicated feed at a rate of 10 
to 20 milligrams of bambermycins per head per day. Liquid Type B feeds 
containing bambermycins may be used in the preparation of dry complete 
ration Type C feeds.
    (ii) Amount per ton. 2 to 40 grams.
    (a) Indications for use. For increased rate of weight gain.
    (b) Limitations. Feed continuously to pasture cattle (slaughter, 
stocker, and feeder cattle, and dairy and beef replacement heifers) at a 
rate of 10 to 40 milligrams of bambermycins per head per day in at least 
1 pound and not more than 10 pounds of Type C medicated feed. Daily 
bambermycins intakes in excess of 20 mg/head/day have

[[Page 410]]

not been shown to be more effective than 20 mg/head/day.
    (iii) Used as a free-choice Type C medicated loose mineral feed for 
pasture cattle (slaughter, stocker, and feeder cattle, and dairy and 
beef replacement heifers) as follows:
    (a) Specifications.

------------------------------------------------------------------------
                                  International Feed
           Ingredient                     No.               Percent
------------------------------------------------------------------------
Deflorinated phosphate (20.5%     6-01-080..........  42.50
 calcium, 18.5% phosphorus).
Sodium chloride (salt)..........  6-04-152..........  20.10
Calcium carbonate (38% calcium).  6-01-069..........  15.24
Corn distillers dried grains w/   5-28-236..........  9.57
 solubles.
Magnesium oxide.................  6-02-756..........  5.15
Vitamin and trace mineral premix  ..................  3.72
 *.
Mineral oil.....................  ..................  1.00
Yeast (primary dehydrated yeast)  7-05-533..........  0.75
Bambermycins Type A article (10   ..................  0.60
 g/lb).
Iron oxide......................  6-02-431..........  0.50
Magnesium sulfate (67%).........  6-02-758..........  0.32
Selenium premix (270 mg/lb) *...  ..................  0.21
Copper sulfate..................  6-01-720..........  0.18
Potassium sulfate (0.33%).......  6-06-098..........  0.16
------------------------------------------------------------------------
*Content of vitamin/trace mineral premix may be varied. However, they
  should be comparable to those used for other free-choice feeds.
  Formulation modifications require FDA approval prior to marketing.
  Selenium must comply with 21 CFR 573.920. Ethylenediamine
  dihydroiodide (EDDI) should comply with FDA Compliance Policy Guides
  Sec. 651.100 (CPG 7125.18).

    (b) Amount per ton. 120 grams.
    (c)Indications for use. For increased rate of weight gain.
    (d) Limitations. For free-choice feeding to pasture cattle 
(slaughter, stocker, and feeder cattle, and dairy and beef replacement 
heifers). Feed a nonmedicated commercial mineral product for 6 weeks to 
stabilize consumption between 2.66 and 10.66 ounces per head per day. 
Feed continuously to provide 10 to 40 milligrams bambermycins per head 
per day. Daily bambermycins intakes in excess of 20 mg/head/day have not 
been shown to be more effective than 20 mg/head/day.
    (iv) Use free-choice Type C medicated feeds for pasture cattle 
(slaughter, stocker, and feeder cattle, and dairy and beef replacement 
heifers) as follows:
    (a) Amount. Feed continuously to provide 10 to 40 milligrams of 
bambermycins per head per day.
    (b) Indications for use. For increased rate of weight gain.
    (c) Limitations. Each use in a free-choice Type C medicated feed 
must be the subject of an approved new animal drug application (NADA) or 
supplemental NADA as required by 21 CFR 510.455. Daily bambermycins 
intakes in excess of 20 mg/head/day have not been shown to be more 
effective than 20 mg/head/day.
    (5) Bambermycins may also be used in combination with:
    (i) Amprolium alone or with roxarsone as in Sec. 558.55.
    (ii) Amprolium and ethopabate alone or with roxarsone as in Sec. 
558.58.
    (iii) Diclazuril as in Sec. 558.198.
    (iv) Halofuginone as in Sec. 558.265.
    (v) Lasalocid alone or with roxarsone as in Sec. 558.311.
    (vi) Monensin alone or with roxarsone as in Sec. 558.355.
    (vii) Narasin alone or with nicarbazin or roxarsone as in Sec. 
558.363.
    (viii) Nicarbazin as in Sec. 558.366.
    (ix) Salinomycin alone or with roxarsone as in Sec. 558.550.
    (x) Zoalene alone or with roxarsone as in Sec. 558.680.

[40 FR 13959, Mar. 27, 1975]

    Editorial Note: For Federal Register citations affecting Sec. 
558.95, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.105  [Reserved]



Sec. 558.115  Carbadox.

    (a) Approvals. Type A medicated articles: 2.2. percent (10 grams per 
pound) to 066104 in Sec. 510.600(c) of this chapter.
    (b) Related tolerances. See Sec. 556.100 of this chapter.
    (c) Special considerations. Do not use in Type B or Type C medicated 
feeds containing bentonite.
    (d) Conditions of use. It is used for swine as follows:

[[Page 411]]

    (1) Amount per ton. 10-25 grams (0.0011-0.00275 percent).
    (i) Indications for use. For increase in rate of weight gain and 
improvement of feed efficiency.
    (ii) Limitations. Not for use in pregnant swine or swine intended 
for breeding purposes. Do not feed to swine within 42 days of slaughter.
    (2) Amount per ton. 50 grams (0.0055 percent).
    (i) Indications for use. For control of swine dysentery (vibrionic 
dysentery, bloody scours, or hemorrhagic dysentery); control of 
bacterial swine enteritis (salmonellosis or necrotic enteritis caused by 
Salmonella choleraesuis); increased rate of weight gain and improved 
feed efficiency.
    (ii) Limitations. Not for use in pregnant swine or swine intended 
for breeding purposes. Do not feed to swine within 42 days of slaughter.
    (3) Amount per ton. Carbadox 50 grams (0.0055 percent) plus pyrantel 
tartrate, 96 grams (0.0106 percent).
    (i) Indications for use. For control of swine dysentery (vibrionic 
dysentery, bloody scours, or hemorrhagic dysentery); control of 
bacterial swine enteritis (salmonellosis or necrotic enteritis caused by 
Salmonella choleraesuis); aid in the prevention of migration and 
establishment of large roundworm (Ascaris suum) infections; aid in the 
prevention of establishment of nodular worm (Oesophagostomum) 
infections.
    (ii) Limitations. Do not feed to swine over 75 pounds; do not feed 
within 10 weeks of slaughter; consult a veterinarian before feeding to 
severely debilitated animals; feed continuously as sole ration. Do not 
use in complete feeds containing less than 15 percent crude protein.
    (4) Amount. Carbadox, 10 to 25 grams per ton of feed; plus 
oxytetracycline, 10 milligrams per pound of body weight.
    (i) Indications for use. For treatment of bacterial enteritis caused 
by Escherichia coli and S. choleraesuis susceptible to oxytetracycline, 
for treatment of bacterial pneumonia caused by Pasteurella multocida 
susceptible to oxytetracycline; and for increased rate of weight gain 
and improved feed efficiency.
    (ii) Limitations. Feed continuously for 7 to 14 days. Not for use in 
pregnant swine or swine intended for breeding purposes. Do not feed to 
swine within 42 days of slaughter.

[40 FR 13959, Mar. 27, 1975, as amended at 40 FR 45164, Oct. 1, 1975; 40 
FR 57798, Dec. 12, 1975; 42 FR 761, Jan. 4, 1977; 51 FR 7396, Mar. 3, 
1986; 63 FR 59216, Nov. 3, 1998; 66 FR 47963, Sept. 17, 2001; 69 FR 
51173, Aug. 18, 2004]



Sec. 558.120  Carbarsone (not U.S.P.).

    (a) Approvals. Type A medicated articles: (1) 37.5 percent to 046573 
in Sec. 510.600(c) of this chapter.
    (2) 25 percent carbarsone and 5 grams per pound bacitracin (as 
bacitracin methylene disalicylate) to 046573 in Sec. 510.600(c) of this 
chapter.
    (b) Related tolerances. See Sec. 556.60 of this chapter.
    (c) [Reserved]
    (d) Conditions of use. (1) It is used for turkeys as follows:
    (i) Grams per ton. 227 to 340.5 (0.025 to 0.0375 percent).
    (a) Indications for use. As an aid in the prevention of blackhead.
    (b) Limitations. Feed continuously beginning 2 weeks before 
blackhead is expected and continue as long as prevention is needed; 
withdraw 5 days before slaughter; as sole source of organic arsenic.
    (ii) Grams per ton. 227 to 340.5 (0.025 to 0.0375 percent) 
carbarsone plus 10 grams per ton bacitracin from bacitracin methylene 
disalicylate.
    (a) Indications for use. As an aid in the prevention of blackhead; 
for increased rate of weight gain.
    (b) Limitations. Feed continuously beginning 2 weeks before 
blackhead is expected and continue as long as prevention is needed; 
withdraw 5 days before slaughter; as sole source of organic arsenic.
    (iii) Grams per ton. 227 to 340.5 (0.025 to 0.0375 percent) 
carbarsone plus 4 to 45 grams per ton bacitracin from bacitracin zinc.
    (a) Indications for use. As an aid in the prevention of blackhead, 
increased rate of weight gain, and improved feed efficiency.
    (b) Limitations. Feed continuously as sole ration. Withdraw 5 days 
before slaughter. As sole source of organic arsenic; as bacitracin zinc 
provided by No. 046573 in Sec. 510.600(c) of this chapter.

[[Page 412]]

    (iv) Grams per ton. 227 carbarsone, plus 1 or 4 grams per ton 
bambermycins.
    (a) Indications for use. As an aid in the prevention of blackhead; 
and for increased rate of weight gain (4 grams per ton bambermycins) or 
improved feed efficiency (1 gram per ton bambermycins).
    (b) Limitations. Feed continuously 2 weeks before blackhead is 
expected and continue as long as prevention is needed. Withdraw 5 days 
before slaughter. As sole source of organic arsenic. Bambermycins 
provided by No. 046573 in Sec. 510.600(c) of this chapter.
    (2) Carbarsone (not U.S.P.) may be used in accordance with the 
provisions of this section in the combinations provided as follows:
    (i) Zoalene in accordance with Sec. 558.680.
    (ii) Amprolium as in Sec. 558.55.

[41 FR 10995, Mar. 15, 1976, as amended at 42 FR 18617, Apr. 8, 1977; 46 
FR 46797, Sept. 22, 1981; 48 FR 2758, Jan. 21, 1983; 51 FR 7396, Mar. 3, 
1986; 52 FR 2687, Jan. 26, 1987; 53 FR 20843, June 7, 1988; 57 FR 7652, 
Mar. 4, 1992; 61 FR 515, Jan. 8, 1996; 61 FR 18082, Apr. 24, 1996; 62 FR 
61011, Nov. 14, 1997; 63 FR 27845, May 21, 1998; 66 FR 46706, Sept. 7, 
2001; 71 FR 27956, May 15, 2006]



Sec. 558.128  Chlortetracycline.

    (a) Specifications. Type A medicated articles containing either 
chlortetracycline calcium complex equivalent to chlortetracycline 
hydrochloride or, for products intended for use in milk replacer, 
chlortetracycline hydrochloride.
    (b) Approvals. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (e) of this section.
    (1) Nos. 046573, 048164, and 066104: 50 to 100 grams per pound (g/
lb) of Type A medicated article.
    (2) No. 012286: 50, 90, or 100 grams per pound of Type A medicated 
article.
    (c) Related tolerances. See Sec. 556.150 of this chapter.
    (d) Special considerations. (1) In milk replacers or starter feed; 
include on labeling the warning: ``A withdrawal period has not been 
established for this product in preruminating calves. Do not use in 
calves to be processed for veal.''
    (2) Manufacture for use in free-choice feeds as in paragraph 
(e)(4)(iii) of this section must conform to Sec. 510.455 of this 
chapter.
    (3) When manufactured for use as in paragraph (e)(5)(iv) of this 
section, include on labeling the warning: ``Psittacosis, avian 
chlamydiosis, or ornithosis is a reportable communicable disease, 
transmissible between wild and domestic birds, other animals, and man. 
Contact appropriate public health and regulatory officials.''
    (e) Conditions of use--(1) Chickens. It is used as follows:

----------------------------------------------------------------------------------------------------------------
        Chlortetracycline amount               Indications for use                Limitations            Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 10 to 50 g/ton......................  Chickens: For increased rate   .............................   046573.
                                           of weight gain and improved   .............................  ........
                                           feed efficiency.              Do not feed to chickens         012286,
                                                                          producing eggs for human       046573,
                                                                          consumption.                   048164,
                                                                                                         066104.
(ii) 100 to 200 g/ton...................  Chickens: For control of       1. Feed continuously for 7 to   046573.
                                           infectious synovitis caused    14 d..                        ........
                                           by Mycoplasma synoviae        .............................   012286,
                                           susceptible to                2. Feed continuously for 7 to   046573,
                                           chlortetracycline.             14 d; do not feed to           048164,
                                                                          chickens producing eggs for    066104.
                                                                          human consumption.
(iii) 200 to 400 g/ton..................  Chickens: For the control of   1. Feed continuously for 7 to   046573.
                                           chronic respiratory disease    14 d..                        ........
                                           (CRD) and air sac infection   .............................   012286,
                                           caused by M. gallisepticum    2. Feed continuously for 7 to   046573,
                                           and Escherichia coli           14 d; do not feed to           048164,
                                           susceptible to                 chickens producing eggs for    066104.
                                           chlortetracycline.             human consumption.

[[Page 413]]

 
(iv) 500 g/ton..........................  Chickens: For the reduction    1. Feed for 5 d; 0-day          046573.
                                           of mortality due to E. coli    withdrawal time when          ........
                                           infections susceptible to      formulated from AUREOMYCIN    ........
                                           chlortetracycline.             Type A medicated articles or  ........
                                                                          Type B medicated feeds under   012286,
                                                                          NADA 48-761..                  046573,
                                                                         2. Feed for 5 d; withdraw 24    048164,
                                                                          h prior to slaughter; do not   066104.
                                                                          feed to chickens producing
                                                                          eggs for human consumption.
----------------------------------------------------------------------------------------------------------------

    (2) Turkeys. It is used as follows:

----------------------------------------------------------------------------------------------------------------
        Chlortetracycline amount                Indications for use               Limitations           Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 10 to 50 g/ton......................  Growing turkeys: For increased  Do not feed to turkeys         012286,
                                           rate of weight gain and         producing eggs for human      046573,
                                           improved feed efficiency.       consumption.                  048164,
                                                                                                         066104.
(ii) 200 g/ton..........................  Turkeys: For control of         Feed continuously for 7 to     012286,
                                           infectious synovitis caused     14 d; do not feed to          046573,
                                           by M. synoviae susceptible to   turkeys producing eggs for    048164,
                                           chlortetracycline.              human consumption.            066104.
(iii) 400 g/ton.........................  1. Turkeys: For control of      Feed continuously for 7 to     012286,
                                           hexamitiasis caused by          14 d; do not feed to          046573,
                                           Hexamita meleagridis            turkeys producing eggs for    048164,
                                           susceptible to                  human consumption.            066104.
                                           chlortetracycline.
                                          ..............................  ...........................  .........
                                          2. Turkey poults not over 4                                    012286,
                                           weeks of age: For reduction                                   046573,
                                           of mortality due to                                           048164,
                                           paratyphoid caused by                                         066104.
                                           Salmonella typhimurium
                                           susceptible to
                                           chlortetracycline.
(iv) 25 mg/lb of body weight............  Turkeys: For control of         Feed continuously for 7 to     012286,
                                           complicating bacterial          14 d; do not feed to          046573,
                                           organisms associated with       turkeys producing eggs for    048164,
                                           bluecomb (transmissible         human consumption.            066104.
                                           enteritis; coronaviral
                                           enteritis) susceptible to
                                           chlortetracycline.
----------------------------------------------------------------------------------------------------------------

    (3) Swine. It is used as follows:

----------------------------------------------------------------------------------------------------------------
        Chlortetracycline amount                Indications for use               Limitations           Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 10 to 50 g/ton......................  Growing swine: For increased    ...........................    012286,
                                           rate of weight gain and                                       046573,
                                           improved feed efficiency.                                     048164,
                                                                                                         066104.
(ii) 50 to 100 g/ton....................  Swine: For reducing the         ...........................    012286,
                                           incidence of cervical                                         046573,
                                           lymphadenitis (jowl                                           048164,
                                           abscesses) caused by Group E.                                 066104.
                                           Streptococci susceptible to
                                           chlortetracycline.
(iii) 400 g/ton.........................  Breeding swine: For the         Feed continuously for not      012286,
                                           control of leptospirosis        more than 14 d.               046573,
                                           (reducing the incidence of                                    048164,
                                           abortion and shedding of                                      066104.
                                           leptospirae) caused by
                                           Leptospira pomona susceptible
                                           to chlortetracycline.
(iv) 10 mg/lb of body weight............  1. Swine: For the treatment of  Feed approximately 400 g/t,    012286,
                                           bacterial enteritis caused by   varying with body weight      046573,
                                           E. coli and S. choleraesuis     and feed consumption to       048164,
                                           and bacterial pneumonia         provide 10 mg/lb per day.     066104.
                                           caused by Pasteurella           Feed for not more than 14
                                           multocida susceptible to        d; withdraw 5 d prior to
                                           chlortetracycline.              slaughter for sponsor
                                                                           012286.
                                          ..............................  ...........................  .........
                                          2. Swine: For the control of    Feed for not more than 14 d    046573.
                                           porcine proliferative
                                           enteropathies (ileitis)
                                           caused by Lawsonia
                                           intracellularis susceptible
                                           to chlortetracycline.
----------------------------------------------------------------------------------------------------------------

    (4) Cattle. It is used as follows:

[[Page 414]]



----------------------------------------------------------------------------------------------------------------
        Chlortetracycline amount                Indications for use               Limitations           Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 0.1 mg/lb of body weight daily......  Calves (up to 250 lb): For      See paragraph (d)(1) of        012286,
                                           increased rate of weight gain   this section.                 046573,
                                           and improved feed efficiency.                                 048164,
                                                                                                         066104.
(ii) 0.5 mg/lb of body weight daily.....  Beef cattle (over 700 lb);      Withdraw 48 h prior to         012286,
                                           control of active infection     slaughter. To sponsor Nos.    046573,
                                           of anaplasmosis caused by       046573 and 048164: zero       048164,
                                           Anaplasma marginale             withdrawal time.              066104.
                                           susceptible to
                                           chlortetracycline.
(iii) 0.5 to 2.0 mg/lb of body weight     Beef cattle and nonlactating    In free-choice cattle feeds    046573.
 daily.                                    dairy cattle: As an aid in      such as feed blocks or
                                           the control of active           salt-mineral mixes
                                           infection of anaplsmosis        manufactured from approved
                                           caused by A. marginale          Type A articles. See
                                           susceptible to                  paragraph (d)(2) of this
                                           chlortetracycline.              section.
(iv) 10 mg/lb of body weight daily......  1. Calves, beef and             Feed approximately 400 g/      012286,
                                           nonlactating dairy cattle;      ton, varying with body        048164,
                                           treatment of bacterial          weight and feed               066104.
                                           enteritis caused by E. coli     consumption to provide 10
                                           and bacterial pneumonia         mg/lb per day. Treat for
                                           caused by P. multocida          not more than 5 d; in feed
                                           organisms susceptible to        including milk replacers;
                                           chlortetracycline.              withdraw 10 d prior to
                                                                           slaughter. To sponsor No.
                                                                           048164: zero withdrawal
                                                                           time. See paragraph (d)(1)
                                                                           of this section.
                                           2. Calves (up to 250 lb): For  See paragraph (d)(1) of        012286,
                                           the treatment of bacterial      this section.                 046573,
                                           enteritis caused by E. coli                                   048164,
                                           susceptible to                                                066104.
                                           chlortetracycline.
(v) 500 to 4,000 g/ton..................  Calves, beef and nonlactating   Feed continuously for not      046573.
                                           dairy cattle; treatment of      more than 5 days to
                                           bacterial enteritis caused by   provide 10 mg/lb body
                                           E. coli and bacterial           weight per day. To sponsor
                                           pneumonia caused by P.          No. 046573 under NADA 046-
                                           multocida organisms             699: 24-h withdrawal time.
                                           susceptible to                  To sponsor No. 046573
                                           chlortetracycline.              under NADA 048-761: zero
                                                                           withdrawal time.
(vi) 4,000 to 20,000 g/ton..............  Calves, beef and nonlactating   As a top dress, varying        046573.
                                           dairy cattle; treatment of      with body weight and feed
                                           bacterial enteritis caused by   consumption, to provide 10
                                           E. coli and bacterial           mg/lb per day. Treat for
                                           pneumonia caused by P.          not more than 5 days. See
                                           multocida organisms             paragraph (d)(1) of this
                                           susceptible to                  section.
                                           chlortetracycline.
(vii) 25 to 70 mg/head/day..............  Calves (250 to 400 lb): For     See paragraph (d)(1) of        012286,
                                           increased rate of weight gain   this section.                 046573,
                                           and improved feed efficiency.                                 048164,
                                                                                                         066104.
(viii) 70 mg/head/day...................  Growing cattle (over 400 lb):   See paragraph (d)(1) of        012286,
                                           For increased rate of weight    this section.                 046573,
                                           gain, improved feed                                           048164,
                                           efficiency, and reduction of                                  066104.
                                           liver condemnation due to
                                           liver abscesses.
(ix) 350 mg/head/day....................  1. Beef cattle: For control of  Withdraw 48 h prior to         012286,
                                           bacterial pneumonia             slaughter. To sponsor No.     046573,
                                           associated with shipping        046573 under NADA 046-699:    048164,
                                           fever complex caused by         48-h withdrawal time. To      066104.
                                           Pasteurella spp. susceptible    sponsor No. 046573 under
                                           to chlortetracycline.           NADA 048-761 and No.
                                                                           048164: zero withdrawal
                                                                           time.
                                           2. Beef cattle (under 700      Withdraw 48 h prior to         012286,
                                           lb): For control of active      slaughter. To sponsor No.     046573,
                                           infection of anaplasmosis       046573 under NADA 046-699:    048164,
                                           caused by A. marginale          48-h withdrawal time. To      066104.
                                           susceptible to                  sponsor No. 046573 under
                                           chlortetracycline.              NADA 048-761 and No.
                                                                           048164: zero withdrawal
                                                                           time.
----------------------------------------------------------------------------------------------------------------

    (5) Minor species. It is used as follows:

----------------------------------------------------------------------------------------------------------------
        Chlortetracycline amount                Indications for use               Limitations           Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 20 to 50 g/ton......................  Growing sheep; increased rate   ...........................    046573,
                                           of weight gain and improved                                   048164,
                                           feed efficiency.                                              066104.
(ii) 80 mg/head/day.....................  Breeding sheep; reducing the    ...........................    046573,
                                           incidence of (vibrionic)                                      048164,
                                           abortion caused by                                            066104.
                                           Campylobacter fetus infection
                                           susceptible to
                                           chlortetracycline.

[[Page 415]]

 
(iii) 200 to 400 g/ton..................  Ducks: For the control and      Feed in complete ration to     046573.
                                           treatment of fowl cholera       provide from 8 to 28 mg/lb
                                           caused by P. multocida          of body weight per day
                                           susceptible to                  depending upon age and
                                           chlortetracycline.              severity of disease, for
                                                                           not more than 21 d. Do not
                                                                           feed to ducks producing
                                                                           eggs for human consumption.
(iv) 10 mg/g of finished feed daily.....  Psittacine birds (cockatoos,    Feed continuously for 45 d;    046573.
                                           macaws, and parrots)            each bird should consume
                                           suspected or known to be        daily an amount of
                                           infected with psittacosis       medicated feed equal to
                                           caused by Chlamydia psittaci    one fifth of its body
                                           sensitive to                    weight..
                                           chlortetracycline.             ...........................
                                                                          See paragraph (d)(3) of
                                                                           this section.
----------------------------------------------------------------------------------------------------------------

    (6) It is used as a free-choice, loose mineral Type C feed as 
follows:
    (i) Specifications.

------------------------------------------------------------------------
         Ingredient                Percent        International Feed No.
------------------------------------------------------------------------
Dicalcium Phosphate          46.20               6-26-335
Sodium Chloride (Salt)       15.00               6-04-152
Magnesium Oxide              10.67               6-02-756
Cottonseed Meal              10.00               5-01-625
Trace Mineral/Vitamin        3.80                .......................
 Premix\1\
Calcium Carbonate            3.50                6-01-069
Dried Cane Molasses          3.00                4-04-695
Potassium Chloride           2.00                6-03-755
Mineral Oil                  2.00                8-03-123
Iron Oxide                   0.50                6-02-431
Chlortetracycline Type A     3.33                .......................
 medicated article (90 gram/
 lb)
------------------------------------------------------------------------
\1\Content of vitamin and trace mineral premixes may be varied. However,
  they should be comparable to those used for other free-choice feeds.
  Formulation modifications require FDA approval prior to marketing.
  Selenium must comply with 21 CFR 573.920. Ethylenediamine
  dihydroiodide (EDDI) should comply with FDA Compliance Policy Guides
  Sec. 651.100 (CPG 7125.18).

    (ii) Amount. 6,000 grams per ton.
    (iii) Indications for use. Beef and nonlactating dairy cattle: As an 
aid in the control of active infection of anaplasmosis caused by 
Anaplasma marginale susceptible to chlortetracycline.
    (iv) Limitations. Feed continuously on a free-choice basis at a rate 
of 0.5 to 2.0 mg chlortetracycline per head per day.
    (v) Sponsor. See No. 046573 in Sec. 510.600(c) of this chapter.
    (7) Chlortetracycline. It may be used in accordance with this 
section in combinations as follows:
    (i) Amprolium in accordance with Sec. 558.55.
    (ii) Amprolium plus ethopabate in accordance with Sec. 558.58.
    (iii) Bacitracin methylene disalicylate in accordance with Sec. 
558.76.
    (iv) Clopidol in accordance with Sec. 558.175.
    (v) Decoquinate in accordance with Sec. 558.195.
    (vi) Hygromycin B in accordance with Sec. 558.274.
    (vii) Laidlomycin in accordance with Sec. 558.305.
    (viii) Lasalocid in accordance with Sec. 558.311.
    (ix) Monensin in accordance with Sec. 558.355.
    (x) Robenidine hydrochloride in accordance with Sec. 558.515.
    (xi) Roxarsone in accordance with Sec. 558.530.
    (xii) Salinomycin alone or with roxarsone in accordance with Sec. 
558.550.
    (xiii) Tiamulin in accordance with Sec. 558.600.
    (xiv) Zoalene in accordance with Sec. 558.680.

[41 FR 10995, Mar. 15, 1976]

    Editorial Note: For Federal Register citations affecting Sec. 
558.128, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.140  Chlortetracycline and sulfamethazine.

    (a) Approvals. Type A medicated articles: 35 grams of 
chlortetracycline per pound with 7.7 percent (35 grams) of 
sulfamethazine to Nos. 046573 and 048164 in Sec. 510.600(c) of this 
chapter.
    (b) Related tolerances. See Sec. Sec. 556.150 and 556.670 of this 
chapter.
    (c) It is used in feed for beef cattle as follows:
    (1) Amount per head per day. Chlortetracycline, 350 milligrams plus 
sulfamethazine, 350 milligrams.
    (2) Indications for use. Aid in the maintenance of weight gains in 
the presence of respiratory disease such as shipping fever.

[[Page 416]]

    (3) Limitations. Feed for 28 days; withdraw 7 days prior to 
slaughter.

[61 FR 35954, July 9, 1996, as amended at 64 FR 15684, Apr. 1, 1999; 66 
FR 46706, Sept. 7, 2001; 68 FR 22294, Apr. 28, 2003; 69 FR 62407, Oct. 
26, 2004]



Sec. 558.145  Chlortetracycline, procaine penicillin, and 
sulfamethazine.

    (a) Approvals. Type A medicated articles: (1) 20 grams of 
chlortetracycline per pound, 4.4 percent (20 grams) of sulfamethazine, 
and procaine penicillin equivalent in activity to 10 grams of penicillin 
per pound to 046573 in Sec. 510.600(c) of this chapter.
    (2) 40 grams of chlortetracycline per pound, 8.8 percent of 
sulfamethazine, and penicillin procaine equivalent in activity to 20 
grams of penicillin per pound to 046573 and 048164 in Sec. 510.600(c) 
of this chapter.
    (b) Specifications. (1) The antibiotic substance refers to the 
antibiotic or feed-grade antibiotic.
    (2) The antibiotic activities are expressed in terms of the 
appropriate antibiotic standards.
    (3) Type C medicated feed contains in each ton, 100 grams of 
chlortetracycline, 50 grams of penicillin as procaine penicillin, and 
100 grams of sulfamethazine.
    (c) Related tolerances. See Sec. Sec. 556.150, 556.510, and 556.670 
of this chapter.
    (d) Conditions of use. (1) It is administered to swine in a Type C 
feed for reduction of the incidence of cervical abscesses; treatment of 
bacterial swine enteritis (salmonellosis or necrotic enteritis caused by 
Salmonella choleraesuis and vibrionic dysentery); prevention of these 
diseases during times of stress; maintenance of weight gains in the 
presence of atrophic rhinitis; growth promotion and increased feed 
efficiency in swine weighing up to 75 pounds.
    (2) Withdraw 15 days prior to slaughter.

[40 FR 13959, Mar. 27, 1975, as amended at 43 FR 19385, May 5, 1978; 47 
FR 39814, Sept. 10, 1982; 48 FR 30615, July 5, 1983; 51 FR 7396, Mar. 3, 
1986; 52 FR 2684, Jan. 26, 1987; 56 FR 14019, Apr. 5, 1991; 61 FR 18082, 
Apr. 24, 1996; 62 FR 14300, Mar. 26, 1997; 63 FR 27845, May 21, 1998; 66 
FR 46706, Sept. 7, 2001; 68 FR 47237, Aug. 8, 2003; 69 FR 62407, Oct. 
26, 2004]



Sec. 558.155  Chlortetracycline, sulfathiazole, penicillin.

    (a) Approvals. Type A medicated articles: (1) 20 grams of 
chlortetracycline hydrochloride, 4.4 percent (20 grams) sulfathiazole, 
and procaine penicillin equivalent to 10 grams of penicillin per pound 
to No. 046573 in Sec. 510.600(c) of this chapter.
    (2) 40 grams of chlortetracycline hydrochloride, 8.8 percent (40 
grams) sulfathiazole and procaine penicillin equivalent in activity to 
20 grams of penicillin per pound to No. 046573 in Sec. 510.600(c) of 
this chapter.
    (b) Specifications. (1) The antibiotic substance refers to the 
antibiotic or feed-grade antibiotic.
    (2) The antibiotic activities are expressed in terms of the 
appropriate antibiotic standards.
    (c) Related tolerances. See Sec. Sec. 556.150, 556.510, and 556.690 
of this chapter.
    (d) Conditions of use. It is used for swine as follows:
    (1) Amount per ton. Chlortetracycline, 100 grams plus penicillin, 50 
grams plus sulfathiazole, 100 grams.
    (2) Indications for use. For reduction of incidence of cervical 
abscesses. Treatment of bacterial enteritis (salmonellosis or necrotic 
enteritis caused by Salmonella choleraesuis and vibrionic dysentery). 
Maintenance of weight gains in the presence of atrophic rhinitis. Swine 
10 pounds of body weight to 6 weeks post-weaning: Increased rate of 
weight gain and improved feed efficiency. Swine 6 to 16 weeks post-
weaning: Increased rate of weight gain.
    (3) Limitations. For swine raised in confinement (dry-lot) or on 
limited pasture. Feed as sole ration. Withdraw 7 days prior to 
slaughter.

[[Page 417]]



      Minimum Amount of Type C Feed Which the Animal Should Consume
------------------------------------------------------------------------
                                                              Minimum
                                            Approximate    desired daily
              Type of feed                body weight in  feed intake in
                                              pounds          pounds
------------------------------------------------------------------------
Prestarter (up to 6 weeks postweaning)..              20               1
Starter (up to 6 weeks postweaning).....              50          1\1/2\
Grower (6-16 weeks postweaning).........              80               2
Finisher (6-16 weeks postweaning).......             150               3
------------------------------------------------------------------------


[40 FR 13959, Mar. 27, 1975, as amended at 51 FR 7397, Mar. 3, 1986; 51 
FR 28547, Aug. 8, 1986; 52 FR 2684, Jan. 26, 1987; 61 FR 2415, Jan. 26, 
1996; 62 FR 35077, June 30, 1997; 62 FR 67725, Dec. 30, 1997; 63 FR 
11599, Mar. 10, 1998; 66 FR 46706, Sept. 7, 2001; 67 FR 21171, Apr. 30, 
2002]



Sec. 558.175  Clopidol.

    (a) Specifications. Type A medicated article containing 25 percent 
clopidol.
    (b) Approvals. See No. 016592 in Sec. 510.600(c) of this chapter.
    (c) [Reserved]
    (d) Conditions of use. It is used as follows:

----------------------------------------------------------------------------------------------------------------
                                   Combination in grams
    Clopidol in grams per ton             per ton          Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(1) 113.5........................  ....................  Broiler chickens and re- Do not feed to          016592
                                                          placement chickens       chickens over 16
                                                          intended for use as      weeks of age.
                                                          caged layers: As an
                                                          aid in the prevention
                                                          of coccidiosis caused
                                                          by E. tenella, E.
                                                          necatrix, E.
                                                          acervulina, E. maxima,
                                                          E. brunetti, and E.
                                                          mivati.
(2) 113.5........................  Bacitracin methylene  Broiler chickens: As in  Feed continuously       016592
                                    disalicylate 4 to     paragraph (d)(1) of      as the sole ration
                                    50.                   this section; for        from the time
                                                          increased rate of        chicks are placed
                                                          weight gain.             in floor pens
                                                                                   until slaughter.
                                                                                   Do not feed to
                                                                                   chickens over 16
                                                                                   weeks of age;
                                                                                   bacitracin
                                                                                   methylene
                                                                                   disalicylate as
                                                                                   provided by No.
                                                                                   046573 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
(3) 113.5........................  Bacitracin 4 to 25    Broiler chickens: As in  Do not feed to         046573,
                                    plus roxarsone 45.4.  paragraph (d)(1) of      chickens over 16       016592
                                                          this section; for        weeks of age;
                                                          growth promotion, feed   withdraw 5 days
                                                          efficiency; improved     before slaughter;
                                                          pigmentation, and        as sole source of
                                                          increased rate of        organic arsenic;
                                                          weight gain.             as bacitracin
                                                                                   methylene
                                                                                   disalicylate or
                                                                                   bacitracin zinc
                                                                                   provided by No.
                                                                                   046573 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
(4) 113.5........................  Bacitracin zinc 5 to  Broiler chickens: As in  Feed continuously      046573,
                                    25.                   paragraph (d)(1) of      as sole ration;        016592
                                                          this section; for        bacitracin zinc as
                                                          increased rate of        provided by No.
                                                          weight gain and          046573 in Sec.
                                                          improved feed            510.600(c) of this
                                                          efficiency.              chapter.
(5) 113.5........................  Chlortetracycline     Broiler and replacement  Feed continuously       016592
                                    100 to 200.           chickens: As in          as sole ration
                                                          paragraph (d)(1) of      from the time
                                                          this section; for        chicks are placed
                                                          control of infectious    in floor pens for
                                                          synovitis caused by      7 to 14 days.
                                                          Mycoplasma synoviae
                                                          susceptible to
                                                          chlortetracycline.
(6) 113.5........................  Lincomycin 2 to 4...  Broiler chickens: As in  Do not feed to          000009
                                                          paragraph (d)(1) of      chickens over 16
                                                          this section; for        weeks of age; as
                                                          increased rate of        lincomycin
                                                          weight gain and          hydrochloride
                                                          improved feed            monohydrate.
                                                          efficiency.
(7) 113.5........................  Roxarsone 45.4......  Broiler and replacement  Do not feed to          016592
                                                          chickens intended for    chickens over 16
                                                          use as caged layers:     weeks of age;
                                                          As in paragraph (d)(1)   withdraw 5 days
                                                          of this section; for     before slaughter;
                                                          growth promotion, feed   as sole source of
                                                          efficiency; and          organic arsenic.
                                                          improved pigmentation.

[[Page 418]]

 
(8) 227..........................  ....................  Broiler and replacement  Feed continuously       016592
                                                          chickens intended for    as the sole
                                                          use as caged layers:     ration; feed up to
                                                          As in paragraph (d)(1)   16 weeks of age if
                                                          of this section.         intended for use
                                                                                   as caged layers;
                                                                                   withdraw 5 days
                                                                                   before slaughter
                                                                                   if given at the
                                                                                   level of 0.025
                                                                                   percent in feed or
                                                                                   reduce level to
                                                                                   0.0125 percent 5
                                                                                   days before
                                                                                   slaughter.
(9) 113.5 or 227.................  ....................  Turkeys: As an aid in    For turkeys grown       016592
                                                          the prevention of        for meat purposes
                                                          leucocytozoonosis        only; feed
                                                          caused by                continuously as
                                                          Leucocytozoon smithi.    the sole ration at
                                                                                   0.0125 or 0.025
                                                                                   percent clopidol
                                                                                   depending on
                                                                                   management
                                                                                   practices, degree
                                                                                   of exposure, and
                                                                                   amount of feed
                                                                                   eaten; withdraw 5
                                                                                   days before
                                                                                   slaughter.
----------------------------------------------------------------------------------------------------------------


[68 FR 17882, Apr. 14, 2003, as amended at 72 FR 60551, Oct. 25, 2007; 
74 FR 61028, Nov. 23, 2009]



Sec. 558.185  Coumaphos.

    (a) Specifications. Type A medicated articles containing 1.12, 2.0, 
11.2, or 50 percent coumaphos.
    (b) Approvals. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (e) of this section.
    (1) No. 000859 for use of Type A medicated articles containing 1.12, 
2.0, 11.2, or 50 percent coumaphos as in paragraphs (e)(2) and (e)(3) of 
this section.
    (2) No. 051311 for use of Type A medicated articles containing 1.12 
percent coumaphos as in paragraph (e)(1) of this section.
    (c) Related tolerances. See 40 CFR 180.189.
    (d) Special considerations. Labeling shall bear the following 
caution statement: ``The active ingredient coumaphos is a cholinesterase 
inhibitor. Do not use this product on animals simultaneously or within a 
few days before or after treatment with or exposure to cholinesterase-
inhibiting drugs, pesticides, or chemicals.'' Also, see Sec. 500.25 of 
this chapter.
    (e) Conditions of use--(1) Beef and dairy cattle--(i) Amount. 0.0002 
lb. (0.091 gram) per 100 lb. body weight per day for 6 consecutive days. 
Should conditions warrant, repeat treatment at 30-day intervals.
    (ii) Indications for use. Control of gastrointestinal roundworms 
(Haemonchus spp., Ostertagia spp., Cooperia spp., Nematodirus spp., 
Trichostrongylus spp.).
    (iii) Limitations. Feed in the normal grain ration to which the 
animals are accustomed, but not in rations containing more than 0.1 
percent coumaphos. Do not feed to animals less than 3 months old. Do not 
feed to sick animals or animals under stress, such as those just 
shipped, dehorned, castrated, or weaned within the last 3 weeks. Do not 
feed in conjunction with oral drenches or with feeds containing 
phenothiazine.
    (2) Laying chickens--(i) Amount. Coumaphos 27.2 grams per ton (0.003 
percent).
    (ii) Indications for use. For control of capillary worm (Capillaria 
obsignata) and as an aid in control of common round worm (Ascaridia 
galli) and cecal worm (Heterakis gallinae).
    (iii) Limitations. In Type C feed; administer continuously as the 
total feed ration for 14 days; when reinfection occurs, treatment may be 
repeated but not sooner than 3 weeks after the end of the previous 
treatment; do not feed to chickens within 10 days of vaccination or 
other conditions of stress; treatment of colored breeds of commercial 
layers should be avoided while in production since these breeds appear 
to be more sensitive to coumaphos than white breeds; as sole medication; 
medications in general should be avoided while birds are approaching 
peak production; such interruption of normal feeding practices may upset 
the flock and lower egg production; diagnosis by

[[Page 419]]

competent personnel is essential; flock condition and production records 
should be carefully evaluated prior to treatment.
    (3) Replacement pullets--(i) Amount. Coumaphos 36.3 grams per ton 
(0.004 percent).
    (ii) Indications for use. For control of capillary worm (Capillaria 
obsignata) and as an aid in control of common roundworm (Ascaridia 
galli) and cecal worm (Heterakis gallinae).
    (iii) Limitations. In Type C feed; administer before the onset of 
production; diagnosis by competent personnel is essential; administer 
continuously as total feed ration for from 10 to 14 days; do not feed to 
chickens under 8 weeks of age nor within 10 days of vaccination or other 
conditions of stress; if birds are maintained on contaminated litter or 
exposed to infected birds, a second 10 to 14 day treatment is 
recommended but not sooner than 3 weeks after the end of the previous 
treatment; as sole medication; if reinfection occurs after production 
begins, repeat treatment as recommended for laying flocks.

[40 FR 13959, Mar. 27, 1975, as amended at 42 FR 1463, Jan. 7, 1977; 51 
FR 7397, Mar. 3, 1986; 52 FR 2684, Jan. 26, 1987; 61 FR 34729, July 3, 
1996; 69 FR 70056, Dec. 2, 2004; 70 FR 32489, June 3, 2005; 75 FR 24394, 
May 5, 2010]



Sec. 558.195  Decoquinate.

    (a) Specifications. Type A medicated article containing 6 percent 
decoquinate.
    (b) Approvals. See No. 046573 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.170 of this chapter.
    (d) Special considerations. (1) Bentonite should not be used in 
decoquinate feeds.
    (2) Type A medicated articles may be used to manufacture dry or 
liquid Type B cattle (including veal calf), sheep, and goat feeds as in 
paragraphs (e)(2) and (e)(3) of this section.
    (3) Type C cattle feeds may be manufactured from decoquinate liquid 
Type B feeds having a pH between 5.0 to 6.5 and containing a suspending 
agent to maintain a viscosity of not less than 500 centipoises.
    (e) Conditions of use. It is used as follows:
    (1) Chickens.

----------------------------------------------------------------------------------------------------------------
                                   Combination in grams/
     Decoquinate in grams/ton               ton            Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 27.2.........................  ....................  Broiler chickens: For    Do not feed to          046573
                                                          prevention of            laying chickens.
                                                          coccidiosis caused by
                                                          Eimeria tenella, E.
                                                          necatrix, E. mivati,
                                                          E. acervulina, E.
                                                          maxima, and E.
                                                          brunetti.
(ii) 27.2........................  Bacitracin methylene  Broiler chickens: As in  Feed continuously       046573
                                    disalicylate 4 to     paragraph (e)(1)(i) of   as sole ration; do
                                    50.                   this section; and for    not feed to laying
                                                          increased rate of        chickens.
                                                          weight gain and          Bacitracin
                                                          improved feed            methylene
                                                          efficiency.              disalicylate as
                                                                                   provided by No.
                                                                                   046573 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
(iii) 27.2.......................  Bacitracin zinc 10    Broiler chickens: As in  Feed continuously       046573
                                    to 50.                paragraph (e)(1)(ii)     as sole ration; do
                                                          of this section.         not feed to laying
                                                                                   chickens.
                                                                                   Bacitracin zinc as
                                                                                   provided by No.
                                                                                   046573 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
(iv) 27.2........................  Bacitracin zinc 12    Broiler chickens: As in  Do not feed to          046573
                                    to 50 plus            paragraph (e)(1)(ii)     laying chickens;
                                    roxarsone 11 to 45.   of this section.         withdraw 5 days
                                                                                   before slaughter;
                                                                                   as sole source of
                                                                                   organic arsenic.
                                   ....................  .......................  Bacitracin zinc and  .........
                                                                                   roxarsone as
                                                                                   provided by No.
                                                                                   046573 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.

[[Page 420]]

 
(v) 27.2.........................  Bacitracin methylene  Broiler chickens: As in  Feed continuously       046573
                                    disalicylate 50 and   paragraph (e)(1)(ii)     as sole ration; do
                                    roxarsone 22.7 to     of this section; as an   not feed to laying
                                    45.4.                 aid in the prevention    chickens; withdraw
                                                          of necrotic enteritis    5 days before
                                                          caused or complicated    slaughter. Not for
                                                          by Clostridium spp. or   use in breeder
                                                          other organisms          chickens. Use as
                                                          susceptible to           sole source of
                                                          bacitracin; and for      organic arsenic.
                                                          improved pigmentation.   Poultry should
                                                                                   have access to
                                                                                   drinking water at
                                                                                   all times. Drug
                                                                                   overdosage or lack
                                                                                   of drinking water
                                                                                   may result in leg
                                                                                   weakness or
                                                                                   paralysis..
                                                                                  Bacitracin
                                                                                   methylene
                                                                                   disalicylate and
                                                                                   roxarsone as
                                                                                   provided by No.
                                                                                   046573 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
(vi) 27.2........................  Chlortetracycline     Chickens: As in          Feed continuously       046573
                                    100 to 200.           paragraph (e)(1)(i) of   for 7 to 14 days;
                                                          this section; control    do not feed to
                                                          of infectious            chickens producing
                                                          synovitis caused by      eggs for human
                                                          Mycoplasma synoviae      consumption.
                                                          susceptible to
                                                          chlortetracycline.
(vii) 27.2.......................  Chlortetracycline     Chickens: As in          As in paragraph         046573
                                    200 to 400.           paragraph (e)(1)(i) of   (e)(1)(vi) of this
                                                          this section; and for    section.
                                                          control of chronic
                                                          respiratory disease
                                                          (CRD) and air sac
                                                          infection caused by M.
                                                          gallisepticum and
                                                          Escherichia coli
                                                          susceptible to
                                                          chlortetracycline.
(viii) 27.2......................  Lincomycin 2........  Broiler chickens: As in  Feed as sole            000009
                                                          paragraph (e)(1)(ii)     ration; do not         046573
                                                          of this section.         feed to laying
                                                                                   chickens;
                                                                                   lincomycin
                                                                                   provided by No.
                                                                                   000009 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
(ix) 27.2........................  Roxarsone 45.4......  Broiler chickens: As in  Do not feed to          046573
                                                          paragraph (e)(1)(ii)     laying chickens;
                                                          of this section; and     withdraw 5 days
                                                          for improving            before slaughter;
                                                          pigmentation.            as sole source of
                                                                                   organic arsenic.
----------------------------------------------------------------------------------------------------------------

    (2) Cattle.

----------------------------------------------------------------------------------------------------------------
                                   Combination in grams/
     Decoquinate in grams/ton               ton            Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 12.9 to 90.8.................  ....................  Cattle (including        Feed Type C feed or     046573
                                                          ruminating and           milk replacer to
                                                          nonruminating calves     provide 22.7
                                                          and veal calves): For    milligrams (mg)
                                                          prevention of            per 100 pounds
                                                          coccidiosis caused by    (lb) of body
                                                          Eimeria bovis and E.     weight (0.5 mg/kg)
                                                          zuernii.                 per day. Feed at
                                                                                   least 28 days
                                                                                   during periods of
                                                                                   exposure to
                                                                                   coccidiosis or
                                                                                   when it is likely
                                                                                   to be a hazard. Do
                                                                                   not feed to cows
                                                                                   producing milk for
                                                                                   food. See
                                                                                   paragraph (d)(3)
                                                                                   of this section.

[[Page 421]]

 
(ii) 12.9 to 90.8................  Chlortetracycline     Calves, beef, and        Feed Type C feed to     046573
                                    500 to 4,000.         nonlactating dairy       provide 22.7 mg
                                                          cattle: As in            decoquinate and 1
                                                          paragraph (e)(2)(i) of   gram
                                                          this section; for        chlortetracycline
                                                          treatment of bacterial   per 100 lb body
                                                          enteritis caused by      weight per day for
                                                          Escherichia coli; and    not more than 5
                                                          for treatment of         days. When
                                                          bacterial pneumonia      consumed, feed
                                                          caused by Pasteurella    22.7 mg
                                                          multocida organisms      decoquinate per
                                                          susceptible to           100 lb body weight/
                                                          chlortetracycline.       day for a total of
                                                                                   28 days to prevent
                                                                                   coccidiosis.
                                                                                   Withdraw 24 hours
                                                                                   prior to slaughter
                                                                                   when manufactured
                                                                                   from CTC
                                                                                   (chlortetracycline
                                                                                   ) Type A medicated
                                                                                   articles under
                                                                                   NADA 141-147. Zero
                                                                                   withdrawal time
                                                                                   when manufactured
                                                                                   from AUREOMYCIN
                                                                                   (chlortetracycline
                                                                                   ) Type A medicated
                                                                                   articles under
                                                                                   NADA 141-185. A
                                                                                   withdrawal period
                                                                                   has not been
                                                                                   established for
                                                                                   this product in
                                                                                   preruminating
                                                                                   calves. Do not use
                                                                                   in calves to be
                                                                                   processed for
                                                                                   veal. Do not feed
                                                                                   to animals
                                                                                   producing milk for
                                                                                   food.
                                                                                   Chlortetracycline
                                                                                   as provided by No.
                                                                                   046573 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
(iii) 12.9 to 90.8...............  Monensin 5 to 30....  Cattle fed in            Feed only to cattle     046573
                                                          confinement for          fed in confinement
                                                          slaughter: As in         for slaughter.
                                                          paragraph (e)(2)(i) of   Feed continuously
                                                          this section; and for    as the sole ration
                                                          improved feed            to provide 22.7 mg
                                                          efficiency.              of decoquinate per
                                                                                   100 lb body weight
                                                                                   per day and 50 to
                                                                                   360 mg of monensin
                                                                                   per head per day.
                                                                                   Feed at least 28
                                                                                   days during period
                                                                                   of exposure to
                                                                                   coccidiosis or
                                                                                   when it is likely
                                                                                   to be a hazard. Do
                                                                                   not feed to
                                                                                   animals producing
                                                                                   milk for food. Do
                                                                                   not feed to
                                                                                   lactating dairy
                                                                                   cattle. Also see
                                                                                   paragraph (d)(1)
                                                                                   of this section
                                                                                   and Sec.
                                                                                   558.355(d)(8).
                                                                                   Monensin as
                                                                                   provided by No.
                                                                                   000986 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.

[[Page 422]]

 
(iv) 13.6 to 27.2................  Chlortetracycline     Calves, beef and         Feed Type C feed to     046573
                                    approximately 400     nonlactating dairy       provide 22.7 mg        048164
                                    (varying with body    cattle: As in            decoquinate and 1
                                    weight and feed       paragraph (e)(2)(i) of   gram (g)
                                    consumption to        this section; for        chlortetracycline
                                    provide 10 mg/lb of   treatment of bacterial   per 100 lb body
                                    body weight per       enteritis caused by E.   weight (0.5 mg/kg)
                                    day).                 coli; and for            per day for not
                                                          treatment of bacterial   more than 5 days.
                                                          pneumonia caused by      Type C feed may be
                                                          Pasteurella multocida    prepared from Type
                                                          organisms susceptible    B feed containing
                                                          to chlortetracycline.    535.8 to 5,440 g/
                                                                                   ton decoquinate
                                                                                   and 6,700 to
                                                                                   80,000 g/ton
                                                                                   chlortetracycline.
                                                                                   When consumed,
                                                                                   feed 22.7 mg
                                                                                   decoquinate per
                                                                                   100 lb body weight/
                                                                                   day for a total of
                                                                                   28 days to prevent
                                                                                   coccidiosis.
                                                                                   Withdraw 24 hours
                                                                                   prior to slaughter
                                                                                   when manufactured
                                                                                   from
                                                                                   chlortetracycline
                                                                                   Type A medicated
                                                                                   articles under
                                                                                   NADA 141-147 and
                                                                                   ANADA 200-359.
                                                                                   Zero withdrawal
                                                                                   time when
                                                                                   manufactured from
                                                                                   AUREOMYCIN
                                                                                   (chlortetracycline
                                                                                   ) Type A medicated
                                                                                   articles under
                                                                                   NADA 141-185. Do
                                                                                   not feed to calves
                                                                                   to be processed
                                                                                   for veal. Do not
                                                                                   feed to animals
                                                                                   producing milk for
                                                                                   food.
                                                                                   Chlortetracycline
                                                                                   as provided by
                                                                                   Nos. 046573 and
                                                                                   048164 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
(v) 13.6 to 27.2.................  Monensin 5 to 30      Cattle fed in            Feed only to cattle     046573
                                    plus tylosin 8 to     confinement for          fed in confinement
                                    10.                   slaughter: As in         for slaughter.
                                                          paragraph (e)(2)(i) of   Feed continuously
                                                          this section; for        as the sole ration
                                                          improved feed            to provide 22.7 mg
                                                          efficiency; and for      of decoquinate per
                                                          reduction of incidence   100 lb body weight
                                                          of liver abscesses       per day, 50 to 360
                                                          caused by                mg of monensin per
                                                          Fusobacterium            head per day, and
                                                          necrophorum and          60 to 90 mg of
                                                          Actinomyces              tylosin per head
                                                          (Corynebacterium)        per day. Feed at
                                                          pyogenes.                least 28 days
                                                                                   during period of
                                                                                   exposure to
                                                                                   coccidiosis or
                                                                                   when it is likely
                                                                                   to be a hazard. Do
                                                                                   not feed to
                                                                                   animals producing
                                                                                   milk for food.
                                                                                   Also see paragraph
                                                                                   (d)(1) of this
                                                                                   section and Sec.
                                                                                   558.355(d)(8).
                                                                                   Monensin and
                                                                                   tylosin as
                                                                                   provided by No.
                                                                                   000986 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
(vi) 90.9 to 535.7...............  ....................  Cattle (including        Feed Type C             046573
                                                          ruminating and           medicated feed
                                                          nonruminating calves     supplements as a
                                                          and veal calves): As     top dress or mix
                                                          in paragraph (e)(2)(i)   into the daily
                                                          of this section.         ration to provide
                                                                                   22.7 mg per 100 lb
                                                                                   of body weight
                                                                                   (0.5 mg/kg) per
                                                                                   day. Feed at least
                                                                                   28 days during
                                                                                   periods of
                                                                                   exposure to
                                                                                   coccidiosis or
                                                                                   when it is likely
                                                                                   to be a hazard. Do
                                                                                   not feed to cows
                                                                                   producing milk for
                                                                                   food. See
                                                                                   paragraph (d)(3)
                                                                                   of this section.

[[Page 423]]

 
(vii) 90.9 to 535.7..............  Chlortetracycline     Calves, beef, and        Feed Type C             046573
                                    4,000 to 20,000.      nonlactating dairy       medicated feed
                                                          cattle: As in            supplements as a
                                                          paragraph (e)(2)(i) of   top dress or mix
                                                          this section; for        into the daily
                                                          treatment of bacterial   ration to provide
                                                          enteritis caused by      22.7 mg
                                                          Escherichia coli; and    decoquinate and 1
                                                          for treatment of         gram
                                                          bacterial pneumonia      chlortetracycline
                                                          caused by Pasteurella    per 100 lb body
                                                          multocida organisms      weight per day for
                                                          susceptible to           not more than 5
                                                          chlortetracycline.       days. When
                                                                                   consumed, feed
                                                                                   22.7 mg
                                                                                   decoquinate per
                                                                                   100 lb body weight
                                                                                   per day for a
                                                                                   total of 28 days
                                                                                   to prevent
                                                                                   coccidiosis.
                                                                                   Withdraw 24 hours
                                                                                   prior to slaughter
                                                                                   when manufactured
                                                                                   from CTC
                                                                                   (chlortetracycline
                                                                                   ) Type A medicated
                                                                                   articles under
                                                                                   NADA 141-147. Zero
                                                                                   withdrawal time
                                                                                   when manufactured
                                                                                   from AUREOMYCIN
                                                                                   (chlortetracycline
                                                                                   ) Type A medicated
                                                                                   articles under
                                                                                   NADA 141-185. A
                                                                                   withdrawal period
                                                                                   has not been
                                                                                   established for
                                                                                   this product in
                                                                                   preruminating
                                                                                   calves. Do not use
                                                                                   in calves to be
                                                                                   processed for
                                                                                   veal. Do not feed
                                                                                   to animals
                                                                                   producing milk for
                                                                                   food.
                                                                                   Chlortetracycline
                                                                                   as provided by No.
                                                                                   046573 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
----------------------------------------------------------------------------------------------------------------

    (3) Minor species.

----------------------------------------------------------------------------------------------------------------
                                   Combination in grams/
     Decoquinate in grams/ton               ton            Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 12.9 to 90.8.................  ....................  1. Young sheep: For the  Feed Type C feed or     046573
                                                          prevention of            milk replacer at a
                                                          coccidiosis caused by    rate to provide
                                                          Eimeria ovinoidalis,     22.7 mg per 100 lb
                                                          E. crandallis, E.        of body weight
                                                          parva, and E.            (0.5 mg per kg)
                                                          bakuensis.               per day; feed for
                                                                                   at least 28 days
                                                                                   during periods of
                                                                                   exposure to
                                                                                   coccidiosis or
                                                                                   when it is likely
                                                                                   to be a hazard. Do
                                                                                   not feed to sheep
                                                                                   producing milk for
                                                                                   food.
                                   ....................  2. Young goats: For the  Feed Type C feed or
                                                          prevention of            milk replacer at a
                                                          coccidiosis caused by    rate to provide
                                                          E. christenseni and E.   22.7 mg per 100 lb
                                                          ninakohlyakimovae.       of body weight
                                                                                   (0.5 mg per kg)
                                                                                   per day; feed for
                                                                                   at least 28 days
                                                                                   during periods of
                                                                                   exposure to
                                                                                   coccidiosis or
                                                                                   when it is likely
                                                                                   to be a hazard. Do
                                                                                   not feed to goats
                                                                                   producing milk for
                                                                                   food.
(ii) 90.9 to 535.7...............  ....................  1. Young sheep: As in    Feed Type C             046573
                                                          item 1 of paragraph      medicated feed
                                                          (e)(3)(i) of this        supplements as a
                                                          section.                 top dress or mix
                                                                                   into the daily
                                                                                   ration to provide
                                                                                   22.7 mg per 100
                                                                                   lbs of body weight
                                                                                   (0.5 mg per kg)
                                                                                   per day; feed for
                                                                                   at least 28 days
                                                                                   during periods of
                                                                                   exposure to
                                                                                   coccidiosis or
                                                                                   when it is likely
                                                                                   to be a hazard. Do
                                                                                   not feed to sheep
                                                                                   producing milk for
                                                                                   food.

[[Page 424]]

 
                                   ....................  2. Young goats: As in    Feed Type C          .........
                                                          item 2 of paragraph      medicated feed
                                                          (e)(3)(i) of this        supplements as a
                                                          section.                 top dress or mix
                                                                                   into the daily
                                                                                   ration to provide
                                                                                   22.7 mg per 100
                                                                                   lbs of body weight
                                                                                   (0.5 mg per kg)
                                                                                   per day; feed for
                                                                                   at least 28 days
                                                                                   during periods of
                                                                                   exposure to
                                                                                   coccidiosis or
                                                                                   when it is likely
                                                                                   to be a hazard. Do
                                                                                   not feed to goats
                                                                                   producing milk for
                                                                                   food.
----------------------------------------------------------------------------------------------------------------


[67 FR 72370, Dec. 5, 2002; 68 FR 15372, Mar. 31, 2003; 69 FR 26499, May 
13, 2004; 69 FR 52816, Aug. 30, 2004; 69 FR 62407, Oct. 26, 2004; 69 FR 
67264, Nov. 17, 2004; 70 FR 2567, Jan. 14, 2005]



Sec. 558.198  Diclazuril.

    (a) Specifications. Type A medicated article containing 0.2 percent 
diclazuril.
    (b) Approvals. See No. 016592 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.185 of this chapter.
    (d) Conditions of use. (1) Chickens. For chickens it is used as 
follows:

----------------------------------------------------------------------------------------------------------------
                                    Combination grams/
       Diclazuril grams/ton                 ton            Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 0.91 (1 part per million       ....................  Broiler chickens: For    Feed continuously.      016592
 (ppm)).                                                  the prevention of        Not for use in
                                                          coccidiosis caused by    hens producing
                                                          Eimeria tenella, E.      eggs for human
                                                          necatrix, E.             food.
                                                          acervulina, E.
                                                          brunetti, E. mitis
                                                          (mivati), and E.
                                                          maxima. Because
                                                          diclazuril is
                                                          effective against E.
                                                          maxima later in its
                                                          life cycle,
                                                          subclinical intestinal
                                                          lesions may be present
                                                          for a short time after
                                                          infection. Diclazuril
                                                          was shown in studies
                                                          to reduce lesion
                                                          scores and improve
                                                          performance and health
                                                          of birds challenged
                                                          with E. maxima.
(ii) 0.91 (1 ppm)................  Bacitracin methylene  Broiler chickens: As in  As in item (i) of       016592
                                    disalicylate 4 to     item (i) of this         this table.
                                    50.                   table; for increased     Bacitracin
                                                          rate of weight gain      methylene
                                                          and improved feed        disalicylate
                                                          efficiency.              provided by 046573.
(iii) 0.91 (1 ppm)...............  Bacitracin methylene  Broiler chickens: As in  Feed continuously       016592
                                    disalicylate 50       item (i) of this         as the sole ration
                                    plus roxarsone 22.7   table; as an aid in      throughout growing
                                    to 45.4.              the prevention of        period. Use as
                                                          necrotic enteritis       sole source of
                                                          caused or complicated    organic arsenic;
                                                          by Clostridium spp. or   drug overdose or
                                                          other organisms          lack of water may
                                                          susceptible to           result in leg
                                                          bacitracin; for          weakness. Not for
                                                          increased rate of        use in hens
                                                          weight gain, improved    producing eggs for
                                                          feed efficiency, and     human consumption.
                                                          improved pigmentation.   Withdraw 5 days
                                                                                   before slaughter.
                                                                                   Bacitracin
                                                                                   methylene
                                                                                   disalicylate and
                                                                                   roxarsone provided
                                                                                   by No. 046573 in
                                                                                   Sec. 510.600(c)
                                                                                   of this chapter.

[[Page 425]]

 
(iv) 0.91 (1 ppm)................  Bacitracin methylene  Broiler chickens: As in  Feed continuously       016592
                                    disalicylate 100 to   item (i) of this         as the sole ration
                                    200 plus roxarsone    table; as an aid in      throughout growing
                                    22.7 to 45.4.         the control of           period. Start at
                                                          necrotic enteritis       first clinical
                                                          caused or complicated    signs of disease;
                                                          by Clostridium spp. or   vary dosage of
                                                          other organisms          bacitracin based
                                                          susceptible to           on severity of
                                                          bacitracin; for          infection;
                                                          increased rate of        administer
                                                          weight gain, improved    continuously for 5
                                                          feed efficiency, and     to 7 days or as
                                                          improved pigmentation.   long as clinical
                                                                                   signs persist,
                                                                                   then reduce
                                                                                   bacitracin to
                                                                                   prevention level
                                                                                   (50 grams per ton
                                                                                   (g/ton). Use as
                                                                                   sole source of
                                                                                   organic arsenic;
                                                                                   drug overdose or
                                                                                   lack of water may
                                                                                   result in leg
                                                                                   weakness. Not for
                                                                                   use in hens
                                                                                   producing eggs for
                                                                                   human consumption.
                                                                                   Withdraw 5 days
                                                                                   before slaughter.
                                                                                   Bacitracin
                                                                                   methylene
                                                                                   disalicylate and
                                                                                   roxarsone provided
                                                                                   by No. 046573 in
                                                                                   Sec. 510.600(c)
                                                                                   of this chapter.
(v) 0.91 (1 ppm).................  Bambermycins 1 to 2.  Broiler chickens: As in  As in item (i) of       016592
                                                          item (i) of this         this table.
                                                          table); for increased    Bambermycins
                                                          rate of weight gain      provided by 057926.
                                                          and improved feed
                                                          efficiency.
(vi) 0.91(1 ppm).................  Roxarsone 22.7 to     Broiler chickens: As in  Feed continuously       046573
                                    45.4.                 item (i) of this         as the sole ration
                                                          table; for increased     throughout growing
                                                          rate of weight gain,     period. Use as
                                                          improved feed            sole source of
                                                          efficiency, and          organic arsenic;
                                                          improved pigmentation.   drug overdose or
                                                                                   lack of water may
                                                                                   result in leg
                                                                                   weakness. Not for
                                                                                   use in hens
                                                                                   producing eggs for
                                                                                   human consumption.
                                                                                   Withdraw 5 days
                                                                                   before slaughter..
                                                                                  Roxarsone provided
                                                                                   by No. 046573 in
                                                                                   Sec. 510.600(c)
                                                                                   of this chapter.
(vii) 0.91 (1 ppm)...............  Virginiamycin 5.....  Broiler chickens: As in  As in item (i) of       016592
                                                          item (i) of this         this table;
                                                          table; for increased     Virginiamycin
                                                          rate of weight gain      provided by 066104.
                                                          and improved feed
                                                          efficiency.
(viii) 0.91 (1 ppm)..............  Virginiamycin 5 to    Broiler chickens: As in  As in item (i) of       016592
                                    15.                   item (i) of this         this table.
                                                          table; for increased     Virginiamycin
                                                          rate of weight gain.     provided by 066104.
----------------------------------------------------------------------------------------------------------------

    (2) Turkeys. For turkeys it is used as follows:

----------------------------------------------------------------------------------------------------------------
                                    Combination grams/
       Diclazuril grams/ton                 ton            Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 0.91 (1 ppm).................  ....................  Growing turkeys: For     Feed continuously       016592
                                                          the prevention of        as the sole
                                                          coccidiosis caused by    ration. Do not
                                                          E. adenoeides, E.        feed to breeding
                                                          gallopavonis and E.      turkeys. Not for
                                                          meleagrimitis.           use in hens
                                                                                   producing eggs for
                                                                                   human consumption.
(ii) 0.91 (1 ppm)................  Bacitracin methylene  Growing turkeys: As in   As in paragraph         016592
                                    disalicylate 4 to     paragraph (d)(2)(i) of   (d)(2)(i) of this
                                    50.                   this section; for        section.
                                                          increased rate of        Bacitracin
                                                          weight gain and          methylene
                                                          improved feed            disalicylate
                                                          efficiency.              provided by No.
                                                                                   046573 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
(iii) 0.91 (1 ppm)...............  Bambermycins 1 to 2.  Growing turkeys: As in   As in paragraph         016592
                                                          paragraph (d)(2)(i) of   (d)(2)(i) of this
                                                          this section; for        section.
                                                          improved feed            Bambermycins
                                                          efficiency.              provided by No.
                                                                                   057926 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
(iv) 0.91 (1 ppm)................  Bambermycins 2......  Growing turkeys: As in   As in paragraph         016592
                                                          paragraph (d)(2)(i) of   (d)(2)(i) of this
                                                          this section; for        section.
                                                          increased rate of        Bambermycins
                                                          weight gain and          provided by No.
                                                          improved feed            057926 in Sec.
                                                          efficiency.              510.600(c) of this
                                                                                   chapter.
----------------------------------------------------------------------------------------------------------------


[[Page 426]]


[64 FR 35923, July 2, 1999, as amended at 65 FR 50134, Aug. 17, 2000; 66 
FR 47962, 47963, Sept. 17, 2001; 66 FR 62917, Dec. 4, 2001; 67 FR 34830, 
May 16, 2002; 67 FR 47257, July 18, 2002; 67 FR 48549, July 25, 2002; 69 
FR 9947, Mar. 3, 2004; 72 FR 60552, Oct. 25, 2007]



Sec. 558.205  Dichlorvos.

    (a) Approvals. Type A medicated articles: 3.1 and 9.6 percent to 
000010 in Sec. 510.600(c) of this chapter.
    (b) Special considerations. (1) Dichlorvos is to be included in meal 
or mash or mixed with feed in crumble form only after the crumble feed 
has been manufactured. Do not mix in feeds to be pelleted nor with 
pelleted feed. Do not soak the feed or administer as wet mash. Feed must 
be dry when administered. Do not use in animals other than swine. Do not 
allow fowl access to feed containing this preparation or to feces from 
treated animals.
    (2) Dichlorvos is a cholinesterase inhibitor. Do not use this 
product in animals simultaneously or within a few days before or after 
treatment with or exposure to cholinesterase-inhibiting drugs, 
pesticides, or chemicals. If human or animal poisoning should occur, 
immediately consult a physician or a veterinarian. Atropine is 
antidotal.
    (3) Labeling for Type A articles and Type B feeds must include a 
statement that containers or materials used in packaging such Type A 
articles and Type B feeds are not to be reused and all such packaging 
materials must be destroyed after the product has been used.
    (c) Related tolerances. See Sec. 556.180 of this chapter.
    (d) Conditions of use. It is used in feed for swine as follows:
    (1) Amount per ton. Dichlorvos, 348 grams (0.0384 percent).
    (i) Indications for use. For the removal and control of mature, 
immature, and/or fourth-stage larvae of the whipworm (Trichuris suis), 
nodular worm (Oesophagostomum sp. ), large roundworm (Ascaris suum) and 
the thick stomach worm (Ascarops strongylina) of the gastrointestinal 
tract.
    (ii) Limitations. For swine up to 70 pounds body weight, feed as 
sole ration for 2 consecutive days. For swine from 70 pounds to market 
weight, feed as sole ration at the rate of 8.4 pounds of feed per head 
until the medicated feed has been consumed. For boars, open or bred 
gilts, and sows, feed as sole ration at the rate of 4.2 pounds per head 
per day for 2 consecutive days.
    (2) Amount per ton. Dichlorvos, 479 grams (0.0528 percent).
    (i) Indications for use. For the removal and control of mature, 
immature, and/or fourth-stage larvae of the whipworm (Trichuris suis), 
nodular worm (Oesophagostomum sp. ), large roundworm (Ascaris suum), and 
the thick stomach worm (Ascarops strongylina) of the gastrointestinal 
tract.
    (ii) Limitations. For boars, open or bred gilts, and sows, feed as 
sole ration at the rate of 6 pounds per head for one feeding.
    (3) Amount per ton. Dichlorvos, 334-500 grams (0.0366-0.0550 
percent).
    (i) Indications for use. An aid in improving litter production 
efficiency by increasing pigs born alive, birth weights, survival to 
market, and rate of weight gain. Treatment also removes and controls 
mature, immature and/or fourth stage larvae of whipworm (Trichuris 
suis), nodular worm (Oesophagostomum supp. ) large roundworm (Ascaris 
suum), and the thick stomach worm (Ascarops strongylina) occurring in 
the gastrointestinal tract of the sow or gilt.
    (ii) Limitations. For pregnant swine; mix into a gestation feed to 
provide 1,000 milligrams per head daily during last 30 days of 
gestation.

[40 FR 13959, Mar. 27, 1975, as amended at 40 FR 50258, Oct. 29, 1975; 
48 FR 46515, Oct. 13, 1983; 51 FR 7397, Mar. 3, 1986; 51 FR 28547, Aug. 
8, 1986; 52 FR 2684, Jan. 26, 1987; 62 FR 35077, June 30, 1997]



Sec. 558.235  Efrotomycin.

    (a) Approvals. Type A medicated article: 14.5 grams per pound to 
050604 in Sec. 510.600(c) of this chapter.
    (b) Conditions of use--(1) Swine--(i) Amount. 3.6 grams per ton.
    (A) Indications for use. For improved feed efficiency.

[[Page 427]]

    (B) Limitations. Feed continuously as sole ration. Not to be used in 
swine weighing more than 250 pounds.
    (ii) Amount. 3.6 to 14.5 grams per ton.
    (A) Indications for use. For increased rate of weight gain.
    (B) Limitations. Feed continuously as sole ration. Not to be used in 
swine weighing more than 250 pounds.
    (2) [Reserved]

[57 FR 38442, Aug. 25, 1992, as amended at 62 FR 63271, Nov. 28, 1997]



Sec. 558.248  Erythromycin thiocyanate.

    (a) Approvals. Type A medicated articles: (1) 2.2 percent to 061623 
in Sec. 510.600(c) of this chapter for use as in paragraph (d) of this 
section.
    (2) 5 and 10 percent to 061623 for use in paragraphs (d)(1)(i) and 
(ii) of this section.
    (b) Special considerations. The levels of antibiotic are expressed 
in terms of erythromycin master standard. One gram of erythromycin 
thiocyanate is equivalent to 0.925 gram of erythromycin master standard.
    (c) Related tolerances. See Sec. 556.230 of this chapter.
    (d) Condition of use. (1) It is used as follows:

----------------------------------------------------------------------------------------------------------------
Erythromycin thiocyanate in grams  Combination in grams
             per ton                      per ton          Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 4.6 to 18.5..................  ....................  Chickens; growth         ...................          ,
                                                          promotion and feed                              061623
                                                          efficiency.
(ii) 9.25 to 18.5................  ....................  Turkeys; growth          For turkeys not              ,
                                                          promotion and feed       over 12 weeks of       061623
                                                          efficiency.              age.
(iii) 9.25 to 64.75..............  ....................  Swine; increase in       Starter ration for      061623
                                                          weight gain, improved    animals up to 35
                                                          feed efficiency in       lb body weight.
                                                          starter pigs (9.25 to
                                                          64.75) and grower-
                                                          finishing pigs (9.25).
(iv) 18.5........................  ....................  Laying chickens; aids    ...................     061623
                                                          in increasing egg
                                                          production.
(v) 92.5.........................  ....................  1. Chickens; as an aid   Feed for 2 d before     061623
                                                          in the prevention of     stress and 3 to 6
                                                          chronic respiratory      d after stress;
                                                          disease during periods   withdraw 24 h
                                                          of stress.               before slaughter.
                                                         2. Chickens; as an aid   Feed for 7 to 14 d;
                                                          in the prevention of     withdraw 24 h
                                                          infectious coryza.       before slaughter.
                                                         3. Turkeys; as an aid    Feed for 2 d before
                                                          in the prevention of     stress and 3 to 6
                                                          chronic respiratory      d after stress.
                                                          disease during periods
                                                          of stress.
(vi) 185.........................  ....................  1. Chickens; as an aid   Feed for 5 to 8 d;      061623
                                                          in the prevention and    do not use in
                                                          reduction of lesions     birds producing
                                                          and in lowering          eggs for food
                                                          severity of chronic      purposes; withdraw
                                                          respiratory disease.     48 h before
                                                                                   slaughter.
                                                         2. Turkeys; as an aid    Feed for 5 to 8 d;      061623
                                                          in the prevention and    do not use in
                                                          reduction of lesions     birds producing
                                                          and in lowering          eggs for food
                                                          severity of chronic      purposes.
                                                          respiratory disease.
----------------------------------------------------------------------------------------------------------------

    (2) In feed for feedlot beef cattle at 37 milligrams per head per 
day as an aid in stimulating growth and improving feed efficiency.
    (3) Erythromycin thiocyanate may be used in accordance with the 
provisions of this section in the combinations provided as follows:
    (i) Amprolium in accordance with Sec. 558.55.
    (ii) Amprolium and ethopabate in accordance with Sec. 558.58.
    (iii) Arsanilic acid in accordance with Sec. 558.62.
    (iv) Zoalene in accordance with Sec. 558.680.

[41 FR 10999, Mar. 15, 1976, as amended at 45 FR 56799, Aug. 26, 1980; 
49 FR 31281, Aug. 6, 1984; 51 FR 7397, Mar. 3, 1986; 52 FR 2684, Jan. 
26, 1987; 54 FR 12189, Mar. 24, 1989; 66 FR 14074, Mar. 9, 2001; 68 FR 
4915, Jan. 31, 2003]



Sec. 558.254  Famphur.

    (a) Approvals. Type A medicated articles: 13.2 and 33.3 percent to 
000061 in Sec. 510.600(c) of this chapter.
    (b) Special considerations. Famphur is a cholinesterase inhibitor. 
Do not use this product in animals simultaneously or within a few days 
before or after

[[Page 428]]

treatment with or exposure to cholinesterase-inhibiting drugs, 
pesticides, or chemicals.
    (c) Related tolerances. See Sec. 556.273 of this chapter.
    (d) Conditions of use. It is used in the feed for cattle as follows:
    (1) Amount. 1.1 milligrams per pound body weight per day.
    (i) Indications for use. For control of grubs and as an aid in 
control of sucking lice.
    (ii) Limitations. For beef cattle and nonlactating dairy cows; feed 
for 30 days; withdraw from dry dairy cows and heifers 21 days prior to 
freshening; withdraw 4 days prior to slaughter.
    (2) Amount. 2.3 milligrams per pound body weight per day.
    (i) Indications for use. For control of grubs.
    (ii) Limitations. For beef cattle and nonlactating dairy cows; feed 
for 10 days; withdraw from dry dairy cows and heifers 21 days prior to 
freshening; withdraw 4 days prior to slaughter.

[41 FR 11000, Mar. 15, 1976, as amended at 51 FR 7397, Mar. 3, 1986; 57 
FR 7652, Mar. 4, 1992; 62 FR 55161, Oct. 23, 1997; 62 FR 61626, Nov. 19, 
1997]



Sec. 558.258  Fenbendazole.

    (a) Specifications. Type A medicated articles: 4 percent (18.1 grams 
per pound (g/lb)), 8 percent (36.2 g/lb), and 20 percent (90.7 g/lb) 
fenbendazole.
    (b) Approvals. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.275 of this chapter.
    (d) Special considerations. See Sec. 500.25 of this chapter.
    (e) Conditions of use--(1) Turkeys.

----------------------------------------------------------------------------------------------------------------
 Amount fenbendazole in grams per  Combination in grams
               ton                        per ton          Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
14.5 (16 parts per million)......  ....................  Growing turkeys: For     Feed continuously       000061
                                                          the removal and          as the sole ration
                                                          control of               for 6 days. For
                                                          gastrointestinal         growing turkeys
                                                          worms: roundworms,       only.
                                                          adult and larvae
                                                          (Ascaridia
                                                          dissimilis); cecal
                                                          worms, adult and
                                                          larvae (Heterakis
                                                          gallinarum), an
                                                          important vector of
                                                          Histomonas meleagridis
                                                          (Blackhead).
----------------------------------------------------------------------------------------------------------------

    (2) Swine.

----------------------------------------------------------------------------------------------------------------
 Amount fenbendazole in grams per  Combination in grams
               ton                        per ton          Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 10 to 300 (to provide 9        ....................  For the removal and      Feed as sole ration     000061
 milligrams per kilogram (mg/kg)                          control of: Adult
 of body weight) given over a 3-                          stage lungworms
 to 12-day period.                                        (Metastrongylus apri
                                                          and M. pudendotectus);
                                                          adult and larvae (L3,
                                                          4 stages--liver, lung,
                                                          intestinal forms)
                                                          large roundworms
                                                          (Ascaris suum); adult
                                                          stage nodular worms
                                                          (Oesophagostomum
                                                          dentatum, O.
                                                          quadrispinulatum);
                                                          adult stage small
                                                          stomach worms
                                                          (Hyostrongylus
                                                          rubidus); adult and
                                                          larvae (L2, 3, 4
                                                          stages--intestinal
                                                          mucosal forms)
                                                          whipworms (Trichuris
                                                          suis); adult and
                                                          larvae kidney worms
                                                          (Stephanurus dentatus).
(ii) 10 to 80 (to provide 9 mg/kg  Lincomycin 20.......  As in paragraph          Feed as sole            000061
 of body weight).                                         (e)(2)(i) of this        ration. Do not
                                                          section; for increased   feed to swine that
                                                          rate of gain in          weigh more than
                                                          growing-finishing        250 pounds (lbs);
                                                          swine.                   lincomycin as
                                                                                   provided by 000009
                                                                                   in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.

[[Page 429]]

 
(iii) 10 to 80 (to provide 9 mg/   Lincomycin 40.......  As in paragraph          Feed as sole            000061
 kg of body weight).                                      (e)(2)(i) of this        ration. Do not
                                                          section; for control     feed to swine that
                                                          of swine dysentery in    weigh more than
                                                          animals on premises      250 lbs.;
                                                          with a history of        lincomycin as
                                                          swine dysentery, but     provided by 000009
                                                          where symptoms have      in Sec.
                                                          not yet occurred.        510.600(c) of this
                                                                                   chapter.
(iv) 10 to 80 (to provide 9 mg/kg  Lincomycin 100......  As in paragraph          Feed as sole            000061
 of body weight).                                         (e)(2)(i) of this        ration. Do not use
                                                          section; for the         within 6 days of
                                                          treatment of swine       slaughter. Do not
                                                          dysentery.               feed to swine that
                                                                                   weigh more than
                                                                                   250 lbs.;
                                                                                   lincomycin as
                                                                                   provided by 000009
                                                                                   in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
(v) 10 to 80 (to provide 9 mg/kg   Lincomycin 200......  As in paragraph          Feed as sole            000061
 of body weight).                                         (e)(2)(i) of this        ration. Do not use
                                                          section; for reduction   within 6 days of
                                                          in the severity of       slaughter. Do not
                                                          swine mycoplasmal        feed to swine that
                                                          pneumonia caused by      weigh more than
                                                          Mycoplasma               250 pound (lb);
                                                          hyopneumoniae.           lincomycin as
                                                                                   provided by 000009
                                                                                   in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
(vi) 10 to 300 (to provide 9 mg/   Bacitracin methylene  Growing/finishing        Feed as sole            046573
 kg of body weight).                disalicylate 10 to    swine: As in paragraph   ration. Under
                                    30.                   (e)(2)(i) of this        conditions of
                                                          section; for increased   continued exposure
                                                          rate of weight gain      to parasites,
                                                          and improved feed        retreatment may be
                                                          efficiency.              needed after 4 to
                                                                                   6 weeks.
                                                                                   Bacitracin
                                                                                   methylene
                                                                                   disalicylate as
                                                                                   provided by 046573
                                                                                   in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
(vii) 10 to 300 (to provide 9 mg/  Bacitracin methylene  1. Growing/finishing     1. Growing/             046573
 kg of body weight).                disalicylate 250.     swine: As in paragraph   finishing swine:
                                                          (e)(2)(i) of this        Feed as sole
                                                          section; for control     ration. Not for
                                                          of swine dysentery       use in growing and
                                                          associated with          finishing swine
                                                          Treponema                that weigh more
                                                          hyodysenteriae on        than 250 lbs.
                                                          premises with a          Diagnosis of swine
                                                          history of swine         dysentery should
                                                          dysentery, but where     be confirmed by a
                                                          signs of disease have    veterinarian when
                                                          not yet occurred; or     results are not
                                                          following an approved    satisfactory.
                                                          treatment of the         Under conditions
                                                          disease condition.       of continued
                                                                                   exposure to
                                                                                   parasites,
                                                                                   retreatment may be
                                                                                   needed after 4 to
                                                                                   6 weeks.
                                                                                   Bacitracin
                                                                                   methylene
                                                                                   disalicylate as
                                                                                   provided by 046573
                                                                                   in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
                                   ....................  2. Pregnant sows: As in  2. Pregnant sows:    .........
                                                          paragraph (e)(2)(i) of   Feed as sole
                                                          this section; for        ration. Diagnosis
                                                          control of clostridial   of clostridial
                                                          enteritis in suckling    enteritis should
                                                          pigs caused by           be confirmed by a
                                                          Clostridium              veterinarian when
                                                          perfringens.             results are not
                                                                                   satisfactory.
                                                                                   Under conditions
                                                                                   of continued
                                                                                   exposure to
                                                                                   parasites,
                                                                                   retreatment may be
                                                                                   needed after 4 to
                                                                                   6 weeks.
                                                                                   Bacitracin
                                                                                   methylene
                                                                                   disalicylate as
                                                                                   provided by 046573
                                                                                   in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
----------------------------------------------------------------------------------------------------------------

    (3) Cattle.

[[Page 430]]



------------------------------------------------------------------------
     Amount      Indications for
  fenbendazole         use            Limitations           Sponsor
------------------------------------------------------------------------
(i) 5 mg/kg      Dairy and beef   Feed as the sole    000061
 body weight      cattle: For      ration or as a
 (2.27 mg/lb)     the removal      top dress for one
                  and control      day. Retreatment
                  of: Lungworms    may be needed
                  (Dictyocaulus    after 4 to 6
                  viviparus);      weeks. Cattle
                  Stomach worms:   must not be
                  barberpole       slaughtered
                  worms            within 13 days
                  (Haemonchus      following last
                  contortus),      treatment. For
                  brown stomach    dairy cattle the
                  worms            milk discard time
                  (Ostertagia      is zero hours. A
                  ostertagi),      withdrawal period
                  small stomach    has not been
                  worms            established for
                  (Trichostrongy   this product in
                  lus axei);       pre-ruminating
                  Intestinal       calves. Do not
                  worms:           use in calves to
                  hookworms        be processed for
                  (Bunostomum      veal.
                  phlebotomum),
                  thread-necked
                  intestinal
                  worms
                  (Nematodirus
                  helvetianus),
                  small
                  intestinal
                  worms
                  (Cooperia
                  oncophora and
                  C. punctata);
                  Bankrupt worms
                  (Trichostrongy
                  lus
                  colubriformis)
                  ; and Nodular
                  worms
                  (Oesophagostom
                  um radiatum)
(ii) [Reserved]  ...............  ..................  ..................
------------------------------------------------------------------------

    (iii) Free-choice feeds--(A) Amount. 5 mg/kg body weight (2.27 mg/
lb), including the following formulations:

----------------------------------------------------------------------------------------------------------------
              Ingredient\1\                             Percent                     International Feed No.
----------------------------------------------------------------------------------------------------------------
(1) Free-choice, dry Type C feed:         ..................................  ..................................
 Salt (sodium chloride)                                                59.00                            6-04-152
 Monosodium phosphate                                                  31.16                            6-04-288
 Dried cane molasses                                                    3.12                            4-04-695
 Zinc sulfate                                                           0.76                            6-05-556
 Copper sulfate                                                         0.45                            6-01-720
 Fenbendazole 20% Type A article                                        5.51                                 n/a
(2) Free-choice, dry Type C feed:         ..................................  ..................................
 Salt (sodium chloride)                                                35.93                            6-04-152
 Dicalcium phosphate (18.5% P)                                         32.44                            6-00-080
 Calcium carbonate (38% Ca)                                            15.93                            6-01-069
 Magnesium oxide (56% Mg)                                              10.14                            6-02-756
 Zinc sulfate                                                           1.47                            6-05-556
 Mineral oil                                                            1.00                            8-03-123
 Dried cane molasses (46% sugars)                                       0.98                            4-04-695
 Potassium iodide                                                       0.01                            6-03-759
 Fenbendazole 20% Type A article                                        2.10                                 n/a
(3) Free-choice, liquid Type C feed:      ..................................  ..................................
 Cane molasses\2\                                                     80.902                            4-13-251
 Water                                                                  9.36                                 n/a
 Urea solution, 55%                                                     7.05                            5-05-707
 Phosphoric acid 75% (feed grade)                                       2.00                            6-03-707
 Xantham gum                                                            0.20                            8-15-818
 Trace minerals                                                         0.20                                 n/a
 Vitamin premix                                                         0.01                                 n/a
 Fenbendazole 20% Type A article                                       0.278                                 n/a
----------------------------------------------------------------------------------------------------------------
\1\The content of any added vitamin and trace mineral may be varied; however, they should be comparable to those
  used by the manufacturer for other free-choice cattle feeds. Formulation modifications require FDA approval
  prior to marketing. Selenium is not approved for the free-choice formulations described in paragraph
  (e)(3)(iii) of this section. Free-choice cattle feeds containing selenium must comply with published
  regulations (see 21 CFR 573.920).
\2\The percentage of cane molasses and water in the formulation may be adjusted as needed in order to bring the
  brix value of the molasses to the industry standard of 79.5 brix.


[[Page 431]]

    (B) Indications for use. As in paragraph (e)(3)(i) of this section.
    (C) Limitations. Feed a total of 5 mg of fenbendazole per kg (2.27 
mg/lb) of body weight to cattle over a 3- to 6-day period. Retreatment 
may be needed after 4 to 6 weeks. Cattle must not be slaughtered within 
13 days following last treatment. For dairy cattle the milk discard time 
is zero hours. A withdrawal period has not been established for this 
product in pre-ruminating calves. Do not use in calves to be processed 
for veal.
    (4) Horses.

----------------------------------------------------------------------------------------------------------------
 Amount fenbendazole in grams per ton         Indications for use                Limitations            Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 4,540.............................  5 mg/kg body weight (2.27 mg/   Feed at the rate of 0. 1lb of     000061
                                         lb) for the control of large    feed per 100 lb of body
                                         strongyles (Strongylus          weight to provide 2.27 mg
                                         edentatus, S. equinus, S.       fenbendazole/lb of body
                                         vulgaris, Triodontophorus       weight in a 1-day treatment
                                         spp.), small strongyles         or 0.2 lb of feed per 100 lb
                                         (Cyathostomum spp.,             of body weight to provide
                                         Cylicocyclus spp.,              4.54 mg fenbendazole/lb of
                                         Cylicostephanus spp.), and      body weight in a 1-day
                                         pinworms (Oxyuris equi); 10     treatment. All horses must
                                         mg/kg body weight (4.54 mg/     be eating normally to ensure
                                         lb) for the control of          that each animal consumes an
                                         ascarids (Parascaris equorum).  adequate amount of the
                                                                         medicated feed. Regular
                                                                         deworming at intervals of 6
                                                                         to 8 weeks may be required
                                                                         due to the possibility of
                                                                         reinfection. Do not use in
                                                                         horses intended for human
                                                                         consumption.
(ii) [Reserved].......................  ..............................  .............................  .........
----------------------------------------------------------------------------------------------------------------

    (5) Zoo and wildlife animals.

----------------------------------------------------------------------------------------------------------------
          Species/Class             Amount fenbendazole    Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) Feral swine (Sus scrofa).....  3 mg/kg/day for 3     For the removal and      Use as complete         000061
                                    days.                 control of kidney worm   feed. Prior
                                                          (Stephanurus             withdrawal of feed
                                                          dentatus), roundworm     or water is not
                                                          (Ascaris suum),          necessary.
                                                          nodular worm             Retreatment may be
                                                          (Oesophagostomum         required in 6
                                                          dentatum).               weeks. Do not use
                                                                                   14 days before or
                                                                                   during the hunting
                                                                                   season.
(ii) Ruminants (subfamily          2.5 mg/kg/day for 3   For the removal and      Use as complete         000061
 Antilopinae, Hippotraginae,        days.                 control of small         feed. Prior
 Caprinae).                                               stomach worm             withdrawal of feed
                                                          (Trichostrongylus        or water is not
                                                          spp.), thread necked     necessary.
                                                          intestinal worm          Retreatment may be
                                                          (Nematodirus spp.),      required in 6
                                                          barberpole worm          weeks. Do not use
                                                          (Haemonchus spp.),       14 days before or
                                                          whipworm (Trichuris      during the hunting
                                                          spp.).                   season.
(iii) Rocky mountain bighorn       10 mg/kg/day for 3    For the removal and      Use as complete         000061
 sheep (Ovis c. canadensis).        days.                 control of               feed. Prior
                                                          Protostrongylus spp.     withdrawal of feed
                                                                                   or water is not
                                                                                   necessary.
                                                                                   Retreatment may be
                                                                                   required in 6
                                                                                   weeks. Do not use
                                                                                   14 days before or
                                                                                   during the hunting
                                                                                   season.
----------------------------------------------------------------------------------------------------------------


[66 FR 58935, Nov. 26, 2001, as amended at 68 FR 34534, June 10, 2003; 
72 FR 66046, Nov. 27, 2007; 73 FR 58873, Oct. 8, 2008; 74 FR 61517, Nov. 
25, 2009]



Sec. 558.261  Florfenicol.

    (a) Specifications. Type A medicated articles containing florfenicol 
in the following concentrations:
    (1) 40 grams per kilogram for use as in paragraph (e)(1) of this 
section.
    (2) 500 grams per kilogram for use as in paragraph (e)(2) of this 
section.
    (b) Sponsor. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Special considerations--(1) Federal law limits this drug to use 
under the professional supervision of a licensed veterinarian. See Sec. 
558.6 of this chapter for additional requirements.

[[Page 432]]

    (2) The expiration date of veterinary feed directives (VFDs) for 
florfenicol medicated feeds:
    (i) For freshwater-reared finfish, must not exceed 15 days from the 
date of issuance.
    (ii) For swine must not exceed 90 days from the date of issuance.
    (3) VFDs for florfenicol shall not be refilled.
    (d) Related tolerances. See Sec. 556.283 of this chapter.
    (e) Conditions of use--(1) Swine--

------------------------------------------------------------------------
 Florfenicol in grams/ton of
            feed               Indications for use       Limitations
------------------------------------------------------------------------
182.........................  For the control of    Feed continuously as
                               swine respiratory     a sole ration for 5
                               disease (SRD)         consecutive days.
                               associated with       The safety of
                               Actinobacillus        florfenicol on
                               pleuropneumoniae,     swine reproductive
                               Pasteurella           performance,
                               multocida,            pregnancy, and
                               Streptococcus suis,   lactation have not
                               and Bordetella        been determined.
                               bronchiseptica in     Feeds containing
                               groups of swine in    florfenicol must be
                               buildings             withdrawn 13 days
                               experiencing an       prior to slaughter.
                               outbreak of SRD.
------------------------------------------------------------------------

    (2) Fish--

------------------------------------------------------------------------
 Florfenicol in grams/ton of
            feed               Indications for use       Limitations
------------------------------------------------------------------------
(i) 182 to 2,724............  Catfish: For the      Feed as a sole
                               control of            ration for 10
                               mortality due to      consecutive days to
                               enteric septicemia    deliver 10 to 15
                               of catfish            milligrams (mg)
                               associated with       florfenicol per
                               Edwardsiella          kilogram (kg) of
                               ictaluri.             fish. Feed
                                                     containing
                                                     florfenicol shall
                                                     not be fed for more
                                                     than 10 days.
                                                     Following
                                                     administration,
                                                     fish should be
                                                     reevaluated by a
                                                     licensed
                                                     veterinarian before
                                                     initiating a
                                                     further course of
                                                     therapy. A dose-
                                                     related decrease in
                                                     hematopoietic/
                                                     lymphopoietic
                                                     tissue may occur.
                                                     The time required
                                                     for hematopoietic/
                                                     lymphopoietic
                                                     tissues to
                                                     regenerate was not
                                                     evaluated. The
                                                     effects of
                                                     florfenicol on
                                                     reproductive
                                                     performance have
                                                     not been
                                                     determined. Feeds
                                                     containing
                                                     florfenicol must be
                                                     withdrawn 15 days
                                                     prior to slaughter.
------------------------------------------------------------------------
(ii) 182 to 1,816...........  Freshwater-reared     Feed as a sole
                               salmonids: For the    ration for 10
                               control of            consecutive days to
                               mortality due to      deliver 10 mg
                               coldwater disease     florfenicol per kg
                               associated with       of fish. Feed
                               Flavobacterium        containing
                               psychrophilum and     florfenicol shall
                               furunculosis          not be fed for more
                               associated with       than 10 days.
                               Aeromonas             Following
                               salmonicida.          administration,
                                                     fish should be
                                                     reevaluated by a
                                                     licensed
                                                     veterinarian before
                                                     initiating a
                                                     further course of
                                                     therapy. The
                                                     effects of
                                                     florfenicol on
                                                     reproductive
                                                     performance have
                                                     not been
                                                     determined. Feeds
                                                     containing
                                                     florfenicol must be
                                                     withdrawn 15 days
                                                     prior to slaughter.
------------------------------------------------------------------------
(iii) 182 to 2,724..........  Freshwater-reared     Feed as a sole
                               finfish: For the      ration for 10
                               control of            consecutive days to
                               mortality due to      deliver 10 to 15 mg
                               columnaris disease    florfenicol per kg
                               associated with       of fish for
                               Flavobacterium        freshwater-reared
                               columnare.            warmwater finfish
                                                     and 10 mg
                                                     florfenicol per kg
                                                     of fish for other
                                                     freshwater-reared
                                                     finfish. Feed
                                                     containing
                                                     florfenicol shall
                                                     not be fed for more
                                                     than 10 days.
                                                     Following
                                                     administration,
                                                     fish should be
                                                     reevaluated by a
                                                     licensed
                                                     veterinarian before
                                                     initiating a
                                                     further course of
                                                     therapy. For
                                                     catfish, a dose-
                                                     related decrease in
                                                     hematopoietic/
                                                     lymphopoietic
                                                     tissue may occur.
                                                     The time required
                                                     for hematopoietic/
                                                     lymphopoietic
                                                     tissues to
                                                     regenerate was not
                                                     evaluated. The
                                                     effects of
                                                     florfenicol on
                                                     reproductive
                                                     performance have
                                                     not been
                                                     determined. Feeds
                                                     containing
                                                     florfenicol must be
                                                     withdrawn 15 days
                                                     prior to slaughter.
------------------------------------------------------------------------

[[Page 433]]

 
(iv) 273 to 2,724...........  Freshwater-reared     Feed as a sole
                               warmwater finfish:    ration for 10
                               For the control of    consecutive days to
                               mortality due to      deliver 15 mg
                               streptococcal         florfenicol per kg
                               septicemia            of fish. Feed
                               associated with       containing
                               Streptococcus iniae.  florfenicol shall
                                                     not be fed for more
                                                     than 10 days.
                                                     Following
                                                     administration,
                                                     fish should be
                                                     reevaluated by a
                                                     licensed
                                                     veterinarian before
                                                     initiating a
                                                     further course of
                                                     therapy. For
                                                     catfish, a dose-
                                                     related decrease in
                                                     hematopoietic/
                                                     lymphopoietic
                                                     tissue may occur.
                                                     The time required
                                                     for hematopoietic/
                                                     lymphopoietic
                                                     tissues to
                                                     regenerate was not
                                                     evaluated. The
                                                     effects of
                                                     florfenicol on
                                                     reproductive
                                                     performance have
                                                     not been
                                                     determined. Feeds
                                                     containing
                                                     florfenicol must be
                                                     withdrawn 15 days
                                                     prior to slaughter.
------------------------------------------------------------------------


[70 FR 70047, Nov. 21, 2005, as amended at 71 FR 70304, Dec. 4, 2006; 72 
FR 19798, Apr. 20, 2007; 72 FR 65885, Nov. 26, 2007; 77 FR 32012, May 
31, 2012]



Sec. 558.265  Halofuginone hydrobromide.

    (a) Specifications. Type A medicated articles containing 6 grams of 
halofuginone hydrobromide per kilogram.
    (b) Approvals. See No. 016592 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.308 of this chapter.
    (d) Conditions of use. (1) It is used in feed for broiler chickens 
as follows:
    (i) Amount. 2.72 grams per ton.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and 
E. maxima.
    (B) Limitations. Feed continuously as sole ration; withdraw 4 days 
before slaughter; do not feed to layers; avoid contact with skin, eyes, 
or clothing; keep out of lakes, ponds, or streams.
    (ii) Amount per ton. Halofuginone 2.72 grams (0.0003 percent) plus 
bambermycins 1 to 2 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and 
E. maxima; for increased rate of weight gain and improved feed 
efficiency.
    (B) Limitations. Feed continuously as sole ration; withdraw 5 days 
before slaughter; do not feed to layers.
    (iii) Amount per ton. Halofuginone 2.72 grams (0.0003 percent) plus 
virginiamycin 5 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and 
E. maxima; for increased rate of weight gain and improved feed 
efficiency.
    (B) Limitations. Feed continuously as sole ration; withdraw 6 days 
before slaughter; do not feed to layers.
    (iv) Amount per ton. Halofuginone 2.72 grams (0.0003 percent) plus 
virginiamycin 5 to 15 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mevati, and 
E. maxima; for increased rate of weight gain.
    (B) Limitations. Feed continuously as sole ration; withdraw 6 days 
before slaughter; do not feed to layers.
    (v) Amount per ton. Halofuginone hydrobromide 2.72 grams (0.0003 
percent) plus bacitracin methylene disalicylate 10 to 50 grams and 
roxarsone 22.7 to 45.4 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and 
E. maxima; for increased rate of weight gain; and for improved feed 
efficiency.
    (B) Limitations. Feed continuously as sole ration; withdraw 5 days 
before slaughter; use as sole source of organic arsenic; do not feed to 
layers; avoid contact with skin, eyes, or clothing; keep out of lakes, 
ponds, or streams.
    (vi) Amount per ton. Halofuginone 2.72 grams (0.0003 percent) plus 
bacitracin methylene disalicylate 10 to 50 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mevati, E. 
maxima and for improved feed efficiency.

[[Page 434]]

    (B) Limitations. Feed continuously as sole ration; withdraw 5 days 
before slaughter; do not feed to layers; avoid contact with skin, eyes, 
or clothing; keep out of lakes, ponds, or streams.
    (vii) Amount per ton. Halofuginone 2.72 grams (0.0003 percent) plus 
lincomycin 2 to 4 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and 
E. maxima and for improved feed efficiency.
    (B) Limitations. Feed continuously as sole ration; withdraw 4 days 
before slaughter; do not feed to layers; avoid contact with skin, eyes, 
or clothing; keep out of lakes, ponds, or streams.
    (viii) Amount per ton. Halofuginone hydrobromide, 2.72 grams plus 
roxarsone, 22.7 to 45.4 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and 
E. maxima; for increased rate of weight gain, improved feed efficiency, 
and improved pigmentation.
    (B) Limitations. Feed continuously as sole ration to replacement 
cage laying chickens until 20 weeks of age. Feed continuously as sole 
ration to replacement broiler breeder chickens until 16 weeks of age. 
Use as the sole source of organic arsenic; drug overdose or lack of 
water intake may result in leg weakness or paralysis. Do not feed to 
laying chickens or waterfowl. Withdraw 5 days before slaughter.
    (2) It is used in feed for turkeys as follows:
    (i) Amount per ton. 1.36 to 2.72 grams.
    (A) Indications for use. For the prevention of coccidiosis in 
growing turkeys caused by Eimeria adenoeides, E. meleagrimitis, and E. 
gallopavonis.
    (B) Limitations. Feed continuously as sole ration; withdraw 7 days 
before slaughter; do not feed to layers or water fowl; avoid contact 
with skin, eyes, or clothing; keep out of lakes, ponds, or streams.
    (ii) Amount per ton. Halofuginone hydrobromide 1.36 to 2.72 grams 
plus bacitracin methylene disalicylate 10 to 50 grams.
    (A) Indications for use. For prevention of coccidiosis caused by 
Eimeria adenoeides, E. meleagrimitis., and E. gallopavonis, and for 
increased rate of weight gain in growing turkeys.
    (B) Limitations. Feed continuously as sole ration. Withdraw 7 days 
before slaughter. Do not feed to laying chickens or water fowl. Keep out 
of lakes, ponds, and streams. Halofuginone is toxic to fish and aquatic 
life. Halofuginone is an irritant to eyes and skin. Avoid contact with 
skin, eyes, or clothing.
    (iii) Amount per ton. 1.36 to 2.72 grams of halofuginone 
hydrobromide plus 2 grams of bambermycins.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria adenoides, E. meleagrimitis, and E. gallopavonis, and for 
increased rate of weight gain in growing turkeys.
    (B) Limitations. Feed continuously as sole ration. Withdraw 7 days 
before slaughter. Do not feed to laying chickens or waterfowl. 
Halofuginone hydrobromide is toxic to fish and other aquatic life. Keep 
out of lakes, ponds, and streams. Halofuginone hydrobromide is an eye 
and skin irritant. Avoid contact with skin, eyes, and clothing.
    (3) It is used in feed for replacement cage laying chickens and 
replacement broiler breeder chickens as follows:
    (i) Amount per ton. 2.72 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. mivati/E. 
mitis, and E. brunetti.
    (B) Limitations. Feed continuously as sole ration to replacement 
cage laying chickens until 20 weeks of age. Feed continuously as sole 
ration to replacement broiler breeder chickens until 16 weeks of age. 
Withdraw 4 days before slaughter. Do not feed to laying chickens or 
water fowl. Halofuginone hydrobromide is toxic to fish and aquatic life. 
Keep out of lakes, ponds, and streams. Halofuginone hydrobromide is an 
irritant to eyes and skin. Avoid contact with skin, eyes, and clothing.
    (ii) Amount per ton. Halofuginone hydrobromide, 2.72 grams plus 
roxarsone, 22.7 to 45.4 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and 
E. maxima; for

[[Page 435]]

increased rate of weight gain, improved feed efficiency, and improved 
pigmentation.
    (B) Limitations. Feed continuously as sole ration to replacement 
cage laying chickens until 20 weeks of age. Feed continuously as sole 
ration to replacement broiler breeder chickens until 16 weeks of age. 
Use as the sole source of organic arsenic; drug overdose or lack of 
water intake may result in leg weakness or paralysis. Do not feed to 
laying chickens or waterfowl. Withdraw 5 days before slaughter.

[50 FR 33719, Aug. 21, 1985, as amended at 50 FR 42518, Oct. 21, 1985; 
51 FR 7397, Mar. 3, 1986; 51 FR 11439, Apr. 3, 1986; 51 FR 14989, Apr. 
22, 1986; 51 FR 23737, July 1, 1986; 53 FR 1018, Jan. 15, 1988; 53 FR 
11065, Apr. 5, 1988; 54 FR 11519, Mar. 21, 1989; 54 FR 28052, July 5, 
1989; 59 FR 51498, Oct. 12, 1994; 61 FR 21076, May 9, 1996; 61 FR 24694, 
May 16, 1996; 64 FR 42597, Aug. 5, 1999; 65 FR 45712, July 25, 2000; 66 
FR 47962, Sept. 17, 2001; 71 FR 27956, May 15, 2006]



Sec. 558.274  Hygromycin B.

    (a) Approvals. (1) Type A medicated articles: 2.4 and 8 grams per 
pound to 000986 in Sec. 510.600(c) of this chapter for use as in 
paragraph (c) of this section.
    (2) 2.4 grams per pound to No. 051311 in Sec. 510.600(c) of this 
chapter for use in swine feed as in paragraph (c)(1)(ii) of this 
section.
    (3) [Reserved]
    (4) 0.6 gram per pound to 017790 and 043733 in Sec. 510.600(c) of 
this chapter for use in chickens as in paragraph (c)(1)(i) of this 
section and in swine as in paragraph (c)(1)(ii) of this section.
    (5)-(7) [Reserved]
    (8) 0.6 and 1.6 grams per pound granted to 046573 in Sec. 
510.600(c) of this chapter for use in chickens as in paragraph (c)(1)(i) 
and in swine as in paragraph (c)(1)(ii) of this section.
    (b) Related tolerances. See Sec. 556.330 of this chapter.
    (c) Conditions of use. (1) It may be used as follows:

----------------------------------------------------------------------------------------------------------------
                                   Combination in grams
  Hygromycin B in grams per ton           per ton          Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 8 to 12......................  ....................  Chickens: control of     Withdraw 3 days        000986,
                                                          infestation of large     before slaughter.     017790,
                                                          roundworms (Ascaris                            043733,
                                                          galli), cecal worms                             046573
                                                          (Heterakis gallinae),
                                                          and capillary worms
                                                          (Capillaria obsignata).
                                   Bacitracin 100......  Chickens; control of     As bacitracin
                                                          infestation of large     methylene
                                                          roundworms (Ascaris      disalicylate or
                                                          galli), cecal worms      zinc bacitracin;
                                                          (Heterakis gallinae),    withdraw 3 days
                                                          and capillary worms      before slaughter.
                                                          (Capillaria
                                                          obsignata); treatment
                                                          of chronic respiratory
                                                          disease (airsac
                                                          infection), blue comb
                                                          (nonspecific
                                                          infectious enteritis).
                                   Bacitracin plus       1. Chickens; control of  Feed containing not
                                    penicillin (100 to    infestation of large     less than 25% of
                                    200 of combination).  roundworms (Ascaris      penicillin plus
                                                          galli), cecal worms      not less than 50%
                                                          (Heterakis gallinae),    of bacitracin; as
                                                          and capillary worms      procaine
                                                          (Capillaria              penicillin plus
                                                          obsignata); treatment    bacitracin
                                                          of chronic respiratory   methylene
                                                          disease (airsac          disalicylate;
                                                          infection), blue comb    withdraw 3 days
                                                          (nonspecific             before slaughter.
                                                          infectious enteritis).
                                                         2. Chickens; control of  Combination
                                                          infestation of large     containing not
                                                          roundworms (Ascaris      less than 50% nor
                                                          galli), cecal worms      more than 75% of
                                                          (Heterakis gallinae),    bacitracin, except
                                                          and capillary worms      that it contains
                                                          (Capillaria              not more than 125
                                                          obsignata); treatment    g of penicillin;
                                                          of chronic respiratory   as procaine
                                                          disease (airsac          penicillin plus
                                                          infection), blue comb    zinc bacitracin;
                                                          (nonspecific             withdraw 3 days
                                                          infectious enteritis).   before slaughter.
                                                         3. Chickens, control of  Combination
                                                          infestation of large     containing 50% to
                                                          roundworms (Ascaris      75% bacitracin,
                                                          galli), cecal worms      but not more than
                                                          (Heterakis gallinae),    125 g of
                                                          and capillary worms      penicillin, as
                                                          (Capillaria              procaine
                                                          obsignata); treatment    penicillin;
                                                          of chronic respiratory   withdraw 3 days
                                                          disease (airsac          before slaughter..
                                                          infection), blue comb
                                                          (nonspecific
                                                          infectious enteritis).

[[Page 436]]

 
                                   Chlortetracycline     Chickens; control of     Do not feed to
                                    100 to 200.           infestation of large     chickens producing
                                                          roundworms (Ascaris      eggs for human
                                                          galli), cecal worms      consumption; feed
                                                          (Heterakis gallinae),    for 7 to 14 days;
                                                          and capillary worms      withdraw 3 days
                                                          (Capillaria              before slaughter.
                                                          obsignata); control of
                                                          infectious synovitis
                                                          caused by Mycoplasma
                                                          synoviae susceptible
                                                          to chlortetracycline.
                                   Chlortetracycline     Chickens; control of     ......do...........
                                    200 to 400.           infestation of large
                                                          roundworms (Ascaris
                                                          galli), cecal worms
                                                          (H. Gallinae), and
                                                          capillary worms
                                                          (Capillaria
                                                          obsignata); control of
                                                          chronic respiratory
                                                          disease (CRD) and air
                                                          sac infection caused
                                                          by Mycoplasma
                                                          gallisepticum and
                                                          Escherichia coli
                                                          susceptible to
                                                          chlortetracycline.
                                   Penicillin 100......  Chickens; control of     As procaine
                                                          infestation of large     penicillin;
                                                          roundworms (Ascaris      withdraw 3 days
                                                          galli), cecal worms      before slaughter.
                                                          (Heterakis gallinae),
                                                          and capillary worms
                                                          (Capillaria
                                                          obsignata); treatment
                                                          of chronic respiratory
                                                          disease (airsac
                                                          infection), blue comb
                                                          (nonspecific
                                                          infectious enteritis).
                                   Tylosin 4 to 50.....  Chickens: Control of     As tylosin              000986
                                                          infestations of large    phosphate;
                                                          roundworms (Ascaris      withdraw 3 days
                                                          galli), cecal worms      before slaughter.
                                                          (Heterakis gallinae),
                                                          and capillary worms
                                                          (Capillaria
                                                          obsignata); growth
                                                          promotion and feed
                                                          efficiency.
(ii) 12..........................  ....................  Swine: control of        Withdraw 15 days       000986,
                                                          infestation of large     before slaughter.     012286,
                                                          roundworms (Ascaris                            017790,
                                                          suis), nodular worms                           043733,
                                                          (Oesophagostomum                               046573,
                                                          dentatum), and                                  051311
                                                          whipworms (Trichuris
                                                          suis).
                                   Chlortetracycline     Swine; control of        Withdraw 15 d
                                    400.                  infestation of large     before slaughter..
                                                          roundworms (Ascaris
                                                          suis), nodular worms
                                                          (Oesophagostomum
                                                          dentatum) and
                                                          whipworms (Trichuris
                                                          suis); treatment of
                                                          bacterial enteritis
                                                          caused by E. coli and
                                                          Salmonella
                                                          choleraesuis and
                                                          bacterial pneumonia
                                                          caused by P. multocida
                                                          susceptible to
                                                          chlortetracycline.
                                   Tylosin 10 to 100...  Swine: Control of        As tylosin              000986
                                                          infestations of large    phosphate;
                                                          roundworms (Ascaris      withdraw 15 days
                                                          suis), nodular worms     prior to
                                                          (Oesophagostomum         slaughter; feed
                                                          dentatum), and           continuously as
                                                          whipworms (Trichuris     follows:.
                                                          suis); growth           Animal wt.(lbs.):..
                                                          promotion and feed       Up to 40........20
                                                          efficiency.              to 100\1\.
                                                                                   41 to
                                                                                   100........20 to
                                                                                   40\1\.
                                                                                   101 to market
                                                                                   wt........10 to
                                                                                   20\1\.
----------------------------------------------------------------------------------------------------------------
\1\ Amount of Tylosin (g/t).

    (2) Hygromycin B may also be used in combination with:
    (i) Amprolium in accordance with Sec. 558.55.
    (ii) Zoalene in accordance with Sec. 558.680.

[41 FR 11000, Mar. 15, 1976]

    Editorial Note: For Federal Register citations affecting Sec. 
558.274, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.295  Iodinated casein.

    (a) Approvals. See 017762 in Sec. 510.600(c) of this chapter.
    (b) NAS/NRC status. The use of this drug is NAS/NRC reviewed and 
found effective. Applications for these uses

[[Page 437]]

need not include efficacy data as required by Sec. 514.111 of this 
chapter but may require bioequivalency or safety data.
    (c) Conditions of use--(1) Ducks--(i) Amount per ton. 100 to 200 
grams.
    (ii) Indications for use. For increased rate of weight gain and 
improved feathering in growing ducks.
    (2) Dairy cows--(i) Amount per pound. \1/2\ to 1\1/2\ grams per 100 
lb of body weight.
    (ii) Indications for use. For increased milk production in dairy 
cows.
    (iii) Limitations. This drug is effective for limited periods of 
time, and the effectiveness is limited to the declining phase of 
lactation. Administration must be accompanied with increased feed 
intake; administration may increase heat sensitivity of the animal.

[45 FR 41631, June 20, 1980]



Sec. 558.300  Ivermectin.

    (a) Specifications. Type A medicated article containing 2.72 grams 
ivermectin per pound (g/lb).
    (b) Sponsor. See No. 050604 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.344 of this chapter.
    (d) Special considerations. See Sec. 500.25 of this chapter.
    (e) Conditions of use in swine. It is used in feed as follows:

----------------------------------------------------------------------------------------------------------------
Ivermectin in g/ Combination in g/ton
  ton of feed           of feed              Indications for use                 Limitations            Sponsor
----------------------------------------------------------------------------------------------------------------
(1) 1.8 (to      ....................  Weaned, growing-finishing       Feed as the only feed for 7        050604
 provide 0.1                            swine: For treatment and        consecutive days. Withdraw 5
 milligram per                          control of gastrointestinal     days before slaughter
 kilogram (mg/                          roundworms (Ascaris suum,
 kg) of body                            adults and fourth-stage
 weight per                             larvae; Ascarops strongylina,
 day)                                   adults; Hyostrongylus
                                        rubidus, adults and fourth-
                                        stage larvae; Oesophagostomum
                                        spp., adults and fourth-stage
                                        larvae); kidneyworms
                                        (Stephanurus dentatus, adults
                                        and fourth-stage larvae);
                                        lungworms (Metastrongylus
                                        spp., adults); threadworms
                                        (Strongyloides ransomi,
                                        adults and somatic larvae);
                                        lice (Haematopinus suis); and
                                        mange mites (Sarcoptes
                                        scabiei var. suis)
----------------------------------------------------------------------------------------------------------------
(2) 1.8 (to      Bacitracin methylene  Weaned, growing-finishing       For use in swine feed only.        050604
 provide 0.1 mg/  disalicylate, 10 to   swine: As in paragraph (e)(1)   Feed as the only feed for 7
 kg of body       30                    of this section; and for        consecutive days. Withdraw 5
 weight per                             increased rate of weight gain   days before slaughter
 day)                                   and improved feed efficiency
----------------------------------------------------------------------------------------------------------------
(3) 1.8 (to      Bacitracin methylene  Weaned, growing-finishing       For use in swine feed only.        050604
 provide 0.1 mg/  disalicylate, 250     swine: As in paragraph (e)(1)   Feed as the only feed for 7
 kg of body                             of this section; and for        consecutive days. Withdraw 5
 weight per                             control of swine dysentery      days before slaughter
 day)                                   associated with Treponema
                                        hyodysenteriae on premises
                                        with a history of swine
                                        dysentery, but where symptoms
                                        have not yet occurred, or
                                        following an approved
                                        treatment of disease
                                        condition
----------------------------------------------------------------------------------------------------------------

[[Page 438]]

 
(4) 1.8 (to      Lincomycin, 20        Weaned, growing-finishing       Feed as the only feed for 7        050604
 provide 0.1 mg/                        swine: For treatment and        consecutive days. Not to be
 kg of body                             control of gastrointestinal     fed to swine that weigh more
 weight per                             roundworms (Ascaris suum,       than 250 lbs. Withdraw 5 days
 day)                                   adults and fourth-stage         before slaughter. Also see
                                        larvae; Ascarops strongylina,   paragraphs (c)(1) and (c)(2)
                                        adults; Hyostrongylus           in Sec. 558.325 of this
                                        rubidus, adults and fourth-     chapter
                                        stage larvae; Oesophagostomum
                                        spp., adults and fourth-stage
                                        larvae); kidneyworms
                                        (Stephanurus dentatus, adults
                                        and fourth-stage larvae);
                                        lungworms (Metastrongylus
                                        spp., adults); lice
                                        (Haematopinus suis); and
                                        mange mites (Sarcoptes
                                        scabiei var. suis); and for
                                        increased rate of weight gain
----------------------------------------------------------------------------------------------------------------
(5) 1.8 (to      Lincomycin, 40        Weaned, growing-finishing       Feed as the only feed for 7        050604
 provide 0.1 mg/                        swine: As in paragraph (e)(4)   consecutive days. Not to be
 kg of body                             of this section; and for        fed to swine that weigh more
 weight per                             control of swine dysentery on   than 250 lbs. Also see
 day)                                   premises with a history of      paragraphs (c)(1) and (c)(2)
                                        swine dysentery, but where      in Sec. 558.325 of this
                                        symptoms have not yet           chapter. Withdraw 5 days
                                        occurred                        before slaughter. A separate
                                                                        feed containing 40 g/ton
                                                                        lincomycin may be continued
                                                                        to complete the lincomycin
                                                                        treatment
----------------------------------------------------------------------------------------------------------------
(6) 1.8 (to      Lincomycin, 100       Weaned, growing-finishing       Feed as the only feed for 7        050604
 provide 0.1 mg/                        swine: As in paragraph (e)(4)   consecutive days followed by
 kg of body                             of this section; and for        a separate feed containing
 weight per                             treatment of swine dysentery    100 g/ton lincomycin for an
 day)                                                                   additional 14 days to
                                                                        complete the lincomycin
                                                                        treatment. Withdraw 6 days
                                                                        before slaughter. Not to be
                                                                        fed to swine that weigh more
                                                                        than 250 lbs. Also see
                                                                        paragraphs (c)(1) and (c)(2)
                                                                        in Sec. 558.325 of this
                                                                        chapter
----------------------------------------------------------------------------------------------------------------
(7) 1.8 (to      Lincomycin, 200       Weaned, growing-finishing       Feed as the only feed for 7        050604
 provide 0.1 mg/                        swine: As in paragraph (e)(4)   consecutive days followed by
 kg of body                             of this section; and for        a separate feed containing
 weight per                             reduction in severity of        200 g/ton lincomycin for an
 day)                                   swine mycoplasmal pneumonia     additional 14 days to
                                        caused by Mycoplasma            complete the lincomycin
                                        hyopneumoniae                   treatment. Withdraw 6 days
                                                                        before slaughter. Not to be
                                                                        fed to swine that weigh more
                                                                        than 250 lbs. Also see
                                                                        paragraphs (c)(1) and (c)(2)
                                                                        in Sec. 558.325 of this
                                                                        chapter
----------------------------------------------------------------------------------------------------------------

[[Page 439]]

 
(8) 1.8 to 11.8  ....................  Adult and breeding swine: For   Feed as the only feed for 7        050604
 (to provide                            treatment and control of        consecutive days. Withdraw 5
 0.1 mg/kg of                           gastrointestinal roundworms     days before slaughter
 body weight                            (Ascaris suum, adults and
 per day)                               fourth-stage larvae; Ascarops
                                        strongylina, adults;
                                        Hyostrongylus rubidus, adults
                                        and fourth-stage larvae;
                                        Oesophagostomum spp., adults
                                        and fourth-stage larvae);
                                        kidneyworms (Stephanurus
                                        dentatus, adults and fourth-
                                        stage larvae); lungworms
                                        (Metastrongylus spp.,
                                        adults); threadworms
                                        (Strongyloides ransomi,
                                        adults and somatic larvae,
                                        and prevention of
                                        transmission of infective
                                        larvae to piglets, via the
                                        colostrum or milk, when fed
                                        during gestation); lice
                                        (Haematopinus suis); and
                                        mange mites (Sarcoptes
                                        scabiei var. suis)
----------------------------------------------------------------------------------------------------------------
(9) 1.8 to 11.8  Bacitracin methylene  Pregnant sows: As in paragraph  Feed as the only feed for 7        050604
 (to provide      disalicylate, 250     (e)(8) of this section; and     consecutive days. Withdraw 5
 0.1 mg/kg of                           for control of clostridial      days before slaughter. Feed
 body weight                            enteritis caused by             bacitracin methylene
 per day)                               Clostridium perfringens in      disalicylate Type C medicated
                                        suckling piglets                feed to sows from 14 days
                                                                        before through 21 days after
                                                                        farrowing on premises with a
                                                                        history of clostridial scours
----------------------------------------------------------------------------------------------------------------
(10) 18.2 to     ....................  Adult and breeding swine: As    Top dress on daily ration for      050604
 120 (to                                in paragraph (e)(8) of this     individual treatment for 7
 provide 0.1 mg/                        section                         consecutive days. Withdraw 5
 kg of body                                                             days before slaughter
 weight per
 day)
----------------------------------------------------------------------------------------------------------------


[72 FR 37437, July 10, 2007]



Sec. 558.305  Laidlomycin.

    (a) Specifications. Type A medicated articles containing 50 grams 
laidlomycin propionate potassium per pound.
    (b) Approvals. See No. 046573 in Sec. 510.600(c) of this chapter.
    (c) Tolerances. See Sec. 556.346 of this chapter.
    (d) Special considerations. (1) Laidlomycin liquid Type B feeds may 
be manufactured from dry laidlomycin Type A articles. The liquid Type B 
feeds must have a pH of 6.0 to 8.0, dry matter of 62 to 75 percent, and 
bear appropriate mixing directions as follows:
    (i) For liquid feeds stored in recirculating tank systems: 
Recirculate immediately prior to use for no less than 10 minutes, moving 
not less than 1 percent of the tank contents per minute from the bottom 
of the tank to the top. Recirculate daily as described even when not 
used.
    (ii) For liquid feeds stored in mechanical, air, or other agitation 
type tank systems: Agitate immediately prior to use for not less than 10 
minutes, creating a turbulence at the bottom of the tank that is visible 
at the top. Agitate daily as described even when not used.
    (2) The expiration date for the liquid Type B feed is 21 days after 
date of manufacture. The expiration date for the dry Type C feed made 
from the liquid Type B feed is 7 days after date of manufacture.
    (3) Labeling for all Type B feeds (liquid and dry) and Type C feeds 
containing laidlomycin shall bear the following statements:
    (i) Do not allow horses or other equines access to feeds containing 
laidlomycin propionate potassium.

[[Page 440]]

    (ii) The safety of laidlomycin propionate potassium in unapproved 
species has not been established.
    (iii) Not for use in animals intended for breeding.
    (e) Conditions of use. It is used in cattle being fed in confinement 
for slaughter as follows:

----------------------------------------------------------------------------------------------------------------
                                   Combination in grams
   Laidlomycin in grams per ton           per ton          Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(1) 5............................  ....................  For improved feed        Feed continuously       046573
                                                          efficiency and           in a Type C feed
                                                          increased rate of        at a rate of 30 to
                                                          weight gain.             75 mg/head/day.
(2) 5............................  Chlortetracycline10   For improved feed        Feed continuously       046573
                                    mg/lb body weight.    efficiency and           at a rate of 30 to
                                                          increased rate of        75 mg laidlomycin
                                                          weight gain; and for     propionate
                                                          treatment of bacterial   potassium per head
                                                          enteritis caused by      per day for not
                                                          Echerichia coli and      more than 5 days.
                                                          bacterial pneumonia      A withdrawal
                                                          caused by Pasteurella    period has not
                                                          multocida organisms      been established
                                                          susceptible to           for this product
                                                          chlortetracycline.       in pre-ruminating
                                                                                   calves. Do not use
                                                                                   in calves to be
                                                                                   processed for veal.
(3) 5............................  Chlortetracycline     For improved feed        Feed continuously       046573
                                    350 mg/head/day.      efficiency and           at a rate of 30 to
                                                          increased rate of        75 mg laidlomycin
                                                          weight gain; and for     propionate
                                                          control of bacterial     potassium per head
                                                          pneumonia associated     per day. A
                                                          with shipping fever      withdrawal period
                                                          complex caused by        has not been
                                                          Pasteurella spp.         established for
                                                          susceptible to           this product in
                                                          chlortetracycline.       pre-ruminating
                                                                                   calves. Do not use
                                                                                   in calves to be
                                                                                   processed for veal.
(4) 5 to 10......................  ....................  For improved feed        Feed continuously       046573
                                                          efficiency.              in a Type C feed
                                                                                   at a rate of 30 to
                                                                                   150 milligrams/
                                                                                   head/day.
(5) 5 to 10......................  Chlortetracycline 10  For improved feed        Feed continuously       046573
                                    mg/pound body         efficiency; and for      at a rate of 30 to
                                    weight.               treatment of bacterial   150 mg laidlomycin
                                                          enteritis caused by E.   propionate
                                                          coli and bacterial       potassium per head
                                                          pneumonia caused by P.   per day for not
                                                          multocida organisms      more than 5 days.
                                                          susceptible to           A withdrawal
                                                          chlortetracycline.       period has not
                                                                                   been established
                                                                                   for this product
                                                                                   in pre-ruminating
                                                                                   calves. Do not use
                                                                                   in calves to be
                                                                                   processed for veal.
(6) 5 to 10......................  Chlortetracycline     For improved feed        Feed continuously       046573
                                    350 mg/head/day.      efficiency; and for      at a rate of 30 to
                                                          control of bacterial     150 mg laidlomycin
                                                          pneumonia associated     propionate
                                                          with shipping fever      potassium per head
                                                          complex caused by        per day. A
                                                          Pasteurella spp.         withdrawal period
                                                          susceptible to           has not been
                                                          chlortetracycline.       established for
                                                                                   this product in
                                                                                   pre-ruminating
                                                                                   calves. Do not use
                                                                                   in calves to be
                                                                                   processed for veal.
-------------------------------------------------------------------------      ---------------------------------


[59 FR 18297, Apr. 18, 1994, as amended at 60 FR 53509, Oct. 16, 1995; 
62 FR 9929, Mar. 5, 1997; 63 FR 27845, May 21, 1998; 66 FR 46706, Sept. 
7, 2001; 68 FR 13839, Mar. 21, 2003; 68 FR 42590, July 18, 2003; 69 FR 
30198, May 27, 2004]



Sec. 558.311  Lasalocid.

    (a) Specifications. A minimum of 90 percent of lasalocid activity is 
derived from lasalocid A.
    (b) Approvals. Type A medicated articles approved for sponsors 
identified in Sec. 510.600(c) of this chapter for use as in paragraph 
(e) of this section as follows:
    (1) 3.0, 3.3, 3.8, 4.0, 4.3, 4.4, 5.0, 5.1, 5.5, 5.7, 6.0, 6.3, 6.7, 
7.2, 7.5, 8.0, 8.3, 10.0, 12.5, 15, 20, and 50 percent activity to No. 
046573 for use as in paragraphs (e)(1) (i), (ii), (iii), (iv), and (x) 
of this section.
    (2) 15 percent activity to No. 066104 as provided by No. 046573 for 
use as in paragraph (e)(1)(v) of this section.
    (3) 15, 20, 33.1, and 50 percent activity to No. 046573 for use in 
cattle feeds as in paragraphs (e)(1)(vi), (vii), (ix), (xi), (xii), and 
(xv) of this section, and for use in sheep as in paragraph (e)(1)(viii) 
of this section.

[[Page 441]]

    (4) 15 percent activity to No. 046573 for use in Type C rabbit feeds 
as in paragraph (e)(1)(xvi) of this section and for use in ruminant 
free-choice Type C feeds as in paragraphs (e)(2), (e)(3), and (e)(4) of 
this section.
    (5) 15 and 20 percent activity to Nos. 012286 and 017800 for use in 
free-choice mineral feeds for cattle as in paragraph (e)(1)(xviii) of 
this section.
    (6) 20 percent activity as a liquid Type A article to No. 046573 for 
use in cattle feeds as in paragraphs (e)(1)(vi), (e)(1)(vii), 
(e)(1)(ix), (e)(1)(xi), (e)(1)(xii), and (e)(3) of this section, and for 
use in sheep feeds as in paragraph (e)(1)(viii) of this section.
    (7) 20 percent activity to No. 046573 for use as follows:
    (i) Chukar partridges as in paragraph (e)(1)(xiii).
    (ii) Turkeys as in paragraph (e)(1)(xiv).
    (iii) Rabbits as in paragraph (e)(1)(xvi).
    (8) [Reserved]
    (9) 15 percent activity to No. 068287 for use in free-choice protein 
blocks for cattle as in paragraphs (e)(1)(xix) of this section.
    (c) Related tolerance. See Sec. 556.347 of this chapter.
    (d) Special considerations. (1) Type C cattle and sheep feeds may be 
manufactured from lasalocid liquid Type B feeds which have a pH of 4.0 
to 8.0 and bear appropriate mixing directions as follows:
    (i) For liquid feeds stored in recirculating tank systems: 
Recirculate immediately prior to use for no less than 10 minutes, moving 
not less than 1 percent of the tank contents per minute from the bottom 
of the tank to the top. Recirculate daily as described even when not 
used.
    (ii) For liquid feeds stored in mechanical, air, or other agitation-
type tank systems: Agitate immediately prior to use for not less than 10 
minutes, creating a turbulence at the bottom of the tank that is visible 
at the top. Agitate daily as described even when not used.
    (2) A physically stable lasalocid liquid feed will not be subject to 
the requirements for mixing directions prescribed in paragraph (d)(1) of 
this section provided it has a pH of 4.0 to 8.0 and contains a 
suspending agent(s) sufficient to maintain a viscosity of not less than 
300 centipoises per second for 3 months.
    (3) If a manufacturer is unable to meet the requirements of 
paragraph (d)(1) or (d)(2) of this section, the manufacturer may secure 
approval of a positionally stable liquid feed by:
    (i) Either filing a new animal drug application for the product or 
establishing a master file containing data to support the stability of 
its product;
    (ii) Authorizing the agency to reference and rely upon the data in 
the master file to support approval of a supplemental new animal drug 
application to establish physical stability; and
    (iii) Requesting the sponsor of an approved new animal drug 
application to file a supplement to provide for use of its lasalocid 
Type A article in the manufacture of the liquid feed specified in the 
appropriate master file. If the data demonstrate the stability of the 
liquid feed described in the master file, the supplemental new animal 
drug application will be approved. The approval will provide a basis for 
the individual liquid feed manufacturer to manufacture under a medicated 
feed license the liquid mediated feed described in the master file. A 
manufacturer who seeks to market a physically unstable lasalocid liquid 
feed with mixing directions different from the standard directions 
established in paragraph (d)(1) of this section may also follow this 
procedure.
    (4) If adequate information is submitted to show that a particular 
liquid feed containing lasalocid is stable outside the pH of 4.0 to 8.0, 
the pH restriction described in paragraphs (d)(1) and (d)(2) of this 
section may be waived.
    (5) Required label statements:
    (i) For liquid Type B feed (cattle and sheep): Mix thoroughly with 
grain and/or roughage prior to feeding. Feeding undiluted, mixing 
errors, or inadequate mixing (recirculation or agitation) may result in 
an excess lasalocid concentration which could be fatal to cattle and 
sheep. Do not allow horses or other equines access to Type A articles or 
Type B feeds containing lasalocid as ingestion may be fatal. Safety of 
lasalocid for use in unapproved species has not been established.

[[Page 442]]

    (ii) For Type A articles or Type B feeds (cattle and sheep): Feeding 
undiluted or mixing errors may result in an excess lasalocid 
concentration which could be fatal to cattle and sheep. Do not allow 
horses or other equines access to Type A articles or Type B feeds 
containing lasalocid as ingestion may be fatal. Safety of lasalocid for 
use in unapproved species has not been established.
    (iii) For Type A articles, Type B or Type C feeds (cattle): A 
withdrawal period has not been established for this product in 
preruminating calves. Do not use in calves to be processed for veal.
    (6) Lasalocid Type A medicated articles containing lasalocid dried 
fermentation residue are for use in cattle and sheep feed only.
    (7) Each use in a free-choice Type C cattle feed as in paragraphs 
(e)(1)(xii) and (e)(1)(xviii) of this section must be the subject of an 
approved NADA or supplemental NADA as provided in Sec. 510.455 of this 
chapter.
    (e)(1) Conditions of use. It is used as follows:

----------------------------------------------------------------------------------------------------------------
   Lasalocid sodium activity in    Combination in grams
          grams per ton                   per ton          Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 68 (0.0075 pct) to 113         ....................  For the prevention of    For broiler or          046573
 (0.0125 pct).                                            coccidiosis caused by    fryer chickens
                                                          Eimeria tenella, E.      only; feed
                                                          necatrix, E.             continuously as
                                                          acervulina, E.           the sole ration.
                                                          brunetti, E. mivati,
                                                          and E. maxima.
(ii) 68 (0.0075 pct) to 113        Roxarsone 45.4        Broiler or fryer         For broiler or          046573
 (0.0125 pct).                      (0.005 pct).          chickens; for the        fryer chickens
                                                          prevention of            only; feed
                                                          coccidiosis caused by    continuously as
                                                          Eimeria tenella, E.      the sole ration;
                                                          necatrix, E.             as sole source of
                                                          acervulina, E.           organic arsenic;
                                                          brunetti, E. mivati,     withdraw 5 d
                                                          and E. maxima and as     before slaughter;
                                                          an aid in the            roxarsone provided
                                                          reduction of lesions     by Nos. 046573 and
                                                          due to E. tenella.       011526 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
                                   Roxarsone 45.4 plus   For prevention of        For broiler             046573
                                    bambermycins 1        coccidiosis caused by    chickens only;
                                    (0.00011 pct).        Eimeria tenella, E.      feed continuously
                                                          necatrix, E.             as sole ration;
                                                          acervulina, E.           withdraw 5 days
                                                          brunetti, E. mivati,     before slaughter;
                                                          and E. maxima; as an     roxarsone provided
                                                          aid in the reduction     by Nos. 046573 and
                                                          of lesions due to E.     011526 in Sec.
                                                          tenella; and for         510.600(c) of this
                                                          increased rate of        chapter,
                                                          weight gain.             bambermycins
                                                                                   provided by No.
                                                                                   016592.
                                   Bambermycins 1 to 2.  Broiler chickens: For    Feed continuously       016592
                                                          prevention of            as sole ration.
                                                          coccidiosis caused by    Bambermycins
                                                          Eimeria tenella, E.      provided by No.
                                                          necatrix, E.             016592 in Sec.
                                                          acervulina, E.           510.600(c) of this
                                                          brunetti, E. mivati,     chapter.
                                                          and E. maxima; and for
                                                          increased rate of
                                                          weight gain and
                                                          improved feed
                                                          efficiency.
                                   Roxarsone 45.4 plus   For prevention of        For broiler             046573
                                    lincomycin 2.0.       coccidiosis caused by    chickens only;
                                                          Eimeria tenella, E.      feed continuously
                                                          necatrix, E.             as sole ration;
                                                          acervulina, E.           withdraw 5 days
                                                          brunetti, E. mivati,     before slaughter;
                                                          and E. maxima; as an     roxarsone provided
                                                          aid in the reduction     by Nos. 046573 and
                                                          of lesions due to E.     011526 in Sec.
                                                          tenella; and for         510.600(c) of this
                                                          increased rate of        chapter,
                                                          weight gain and          lincomycin
                                                          improved feed            provided by No.
                                                          efficiency.              000009.
                                   Roxarsone 45.4 plus   For prevention of        For broiler or          046573
                                    bacitracin 10 to 25.  coccidiosis caused by    fryer chickens
                                                          Eimeria tenella, E.      only; feed
                                                          necatrix, E.             continuously as
                                                          acervulina, E.           the sole ration;
                                                          brunetti, E. mivati,     withdraw 5 days
                                                          and E. maxima; as an     before slaughter;
                                                          aid in the reduction     roxarsone provided
                                                          of lesions due to E.     by Nos. 046573 and
                                                          tenella; and for         011526 in Sec.
                                                          increased rate of        510.600(c) of this
                                                          weight gain.             chapter,
                                                                                   bacitracin
                                                                                   methylene
                                                                                   disalicylate
                                                                                   provided by No.
                                                                                   046573 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.

[[Page 443]]

 
                                   Roxarsone 45.4 plus   For prevention of        For broiler             046573
                                    bacitracin 10 or 30.  coccidiosis caused by    chickens only;
                                                          E. tenella, E.           feed continuously
                                                          necatrix, E.             as sole ration;
                                                          acervulina, E.           withdraw 5 days
                                                          brunetti, E. mivati      before slaughter;
                                                          and E. maxima; as an     roxarsone provided
                                                          aid in the reduction     by Nos. 046573 and
                                                          of lesions due to E.     011526 in Sec.
                                                          tenella; and for         510.600(c) of this
                                                          increased rate of        chapter,
                                                          weight gain (10 grams    bacitracin zinc
                                                          per ton) or improved     provided by No.
                                                          feed efficiency (30      000004.
                                                          grams per ton).
                                   Roxarsone 45.5 plus   Prevention of            Feed continuously       046573
                                    bacitracin            coccidiosis caused by    as sole ration; as
                                    methylene             Eimeria necatrix, E.     sole source of
                                    disalicylate 50.      tenella, E.              organic arsenic;
                                                          acervulina, E.           withdraw 5 days
                                                          brunetti; E. mivati,     before slaughter.
                                                          and E. maxima;
                                                          reduction of lesions
                                                          due to E. tenella;
                                                          prevention of necrotic
                                                          enteritis caused or
                                                          complicated by
                                                          Clostridium spp. or
                                                          other susceptible
                                                          organisms.
(iii) 68 (0.0075 pct)............  Lincomycin 2          Broiler or fryer         For broiler and         046573
                                    (0.00022 pct).        chickens; for the        fryer chickens
                                                          prevention of            only; feed
                                                          coccidiosis caused by    continuously as
                                                          Eimeria mivati, E.       sole ration;
                                                          brunetti, E. tenella,    withdraw 5 d
                                                          E. acervulina, E.        before slaughter;
                                                          maxima, and E.           Type C feed must
                                                          necatrix; for            be used within 4
                                                          increased rate of        weeks of
                                                          weight gain and          manufacture; as
                                                          improved feed            lincomycin
                                                          efficiency.              hydrochloride
                                                                                   monohydrate.
(iv) 68 (0.0075 percent).........  Bacitracin 10 to 50.  For prevention of        For broiler or          046573
                                                          coccidiosis caused by    fryer chickens
                                                          Eimeria tenella, E.      only; feed
                                                          necatrix, E.             continuously as
                                                          acervulina, E.           the sole ration;
                                                          brunetti, E. mivati,     bacitracin
                                                          and E. maxima, and for   methylene
                                                          increased rate of        disalicylate
                                                          weight gain and          provided by No.
                                                          improved feed            046573 in Sec.
                                                          efficiency.              510.600(c) of this
                                                                                   chapter.
(v) 68 (0.0075 pct) to 113         Virginiamycin 20....  For prevention of        For broiler and         046573
 (0.0125 pct).                                            coccidiosis caused by    fryer chickens
                                                          Eimeria tenella E.       only; feed
                                                          necatrix, E.             continuously as
                                                          acervulina, E.           sole ration; do
                                                          brunetti, E. mivati,     not feed to laying
                                                          and E. maxima, and for   chickens;
                                                          increased rate of        lasalocid sodium
                                                          weight gain and          provided by No.
                                                          improved feed            046573 in Sec.
                                                          efficiency.              510.600(c) of this
                                                                                   chapter.
(vi) 10 (0.0011 pct) to 30         ....................  Cattle; for improved     In Type C feeds;        046573
 (0.0033 pct).                                            feed efficiency.         for cattle fed in
                                                                                   confinement for
                                                                                   slaughter only;
                                                                                   feed continuously
                                                                                   in complete feed
                                                                                   to provide not
                                                                                   less than 100 mg
                                                                                   nor more than 360
                                                                                   mg of lasalocid
                                                                                   sodium activity
                                                                                   per head per day.
                                   Oxytetracycline 7.5.  Cattle: for improved     In Type C feeds,        046573
                                                          feed efficiency and      for beef cattle
                                                          reduction of incidence   fed in confinement
                                                          and severity of liver    for slaughter;
                                                          abscesses.               feed continuously
                                                                                   at 100 to 360 mg/
                                                                                   head/day lasalocid
                                                                                   and 75 mg/head/day
                                                                                   oxytetracycline.
                                                                                   As monoalkyl (C8-
                                                                                   C18) trimethyl
                                                                                   ammonium
                                                                                   oxytetracycline.
(vii) 25 (0.0027 pct) to 30        ....................  Cattle; for improved     In Type C feeds;        046573
 (0.0033 pct).                                            feed efficiency and      for cattle fed in
                                                          increased rate of        confinement for
                                                          weight gain.             slaughter only;
                                                                                   feed continuously
                                                                                   in complete feed
                                                                                   to provide not
                                                                                   less than 250 mg
                                                                                   nor more than 360
                                                                                   mg of lasalocid
                                                                                   sodium activity
                                                                                   per head per day.
                                   Oxytetracycline 7.5.  Cattle: for improved     In Type C feeds,        046573
                                                          feed efficiency,         for beef cattle
                                                          increased rate of        fed in confinement
                                                          weight gain, and         for slaughter;
                                                          reduction of incidence   feed continuously
                                                          and severity of liver    at 250 to 360 mg/
                                                          abscesses.               head/day lasalocid
                                                                                   and 75 mg/head/day
                                                                                   oxytetracycline.
                                                                                   As monoalkyl (C8-
                                                                                   C18) trimethyl
                                                                                   ammonium
                                                                                   oxytetracycline.

[[Page 444]]

 
(viii) 20 (0.0022 pct) to 30       ....................  Sheep; for the           In Type C feeds;        046573
 (0.0033 pct).                                            prevention of            for sheep
                                                          coccidiosis caused by    maintained in
                                                          Eimeria ovina, E.        confinement; feed
                                                          crandallis, E.           continuously in
                                                          ovinoidalis (E.          complete feed to
                                                          ninakohlyakimovae), E.   provide not less
                                                          parva, and E.            than 15 mg nor
                                                          intricata.               more than 70 mg of
                                                                                   lasalocid sodium
                                                                                   activity per head
                                                                                   per day depending
                                                                                   on body weight.
(ix).............................  ....................  Pasture cattle           Feed continuously       046573
                                                          (slaughter, stocker,     at a rate of not
                                                          feeder cattle, and       less than 60 mg or
                                                          dairy and beef           more than 300 mg
                                                          replacement heifers):    of lasalocid per
                                                          for increased rate of    head per day when
                                                          weight gain. Intakes     on pasture; the
                                                          of lasalocid in excess   drug must be
                                                          of 200 mg/head/day       contained in at
                                                          have not been shown to   least 1 pound of
                                                          be more effective than   feed.
                                                          200 mg/head/day.
(x) 68 (0.0075 pct) to 113         Bacitracin 4 to 50..  Broiler chickens; for    For broiler             046573
 (0.0125 pct).                                            prevention of            chickens only;
                                                          coccidiosis caused by    feed continuously
                                                          Eimeria tenella, E.      as the sole
                                                          necatrix, E.             ration; bacitracin
                                                          acervulina, E.           methylene
                                                          brunetti, E. mivati,     disalicylate
                                                          and E. maxima; and for   provided by No.
                                                          improved feed            046573 in Sec.
                                                          efficiency.              510.600(c) of this
                                                                                   chapter.
(xi) 68 (0.0075 pct) to 113        Bacitracin zinc 4 to  Broiler chickens. For    Feed continuously       046573
 (0.0125 pct).                      50.                   prevention of            as sole ration.
                                                          coccidiosis caused by    Bacitracin zinc
                                                          Eimeria tenella, E.      and lasalocid
                                                          necatrix, E.             sodium as provided
                                                          acervulina, E.           by No. 046573 in
                                                          brunetti, E. mivati,     Sec. 510.600(c)
                                                          and E. maxima, and for   of this chapter.
                                                          increased rate of
                                                          weight gain and
                                                          improved feed
                                                          efficiency.
(xii)............................  ....................  Pasture cattle           Feed continuously       046573
                                                          (slaughter, stocker,     on a free-choice
                                                          feeder cattle, and       basis at a rate of
                                                          dairy and beef           not less than 60
                                                          replacement heifers):    mg or more than
                                                          For increased rate of    300 mg of
                                                          weight gain. Intakes     lasalocid per head
                                                          of lasalocid in excess   per day.
                                                          of 200 mg/head/day
                                                          have not been shown to
                                                          be more effective than
                                                          200 mg/head/day.
(xiii)...........................  ....................  Cattle; for control of   For cattle; hand        046573
                                                          coccidiosis caused by    feed at a rate of
                                                          Eimeria bovis and        1 mg of lasalocid
                                                          Eimeria zuernii.         per 2.2 pounds
                                                                                   body weight per
                                                                                   day to cattle
                                                                                   weighing up to 800
                                                                                   pounds with a
                                                                                   maximum of 360 mg
                                                                                   of lasalocid per
                                                                                   head per day.
(xiv) 113 (0.0125 pct)...........  ....................  Chukar partridges; for   Feed continuously       046573
                                                          prevention of            as sole ration up
                                                          coccidiosis caused by    to 8 weeks of age.
                                                          Eimeria legionensis.
(xv) 68 (0.0075 pct) to 113        ....................  Growing turkeys; for     Feed continuously       046573
 (0.0125 pct).                                            prevention of            as sole ration.
                                                          coccidiosis caused by
                                                          E. meleagrimitis, E.
                                                          gallopavonis, and E.
                                                          adenoeides..
                                   Bacitracin 4 to 50..  Growing turkeys; for     Feed continuously       046573
                                                          prevention of            as sole ration.
                                                          coccidiosis caused by
                                                          E. meleagrimitis, E.
                                                          gallopavonis, and E.
                                                          adenoeides; for
                                                          increased rate of
                                                          weight gain and
                                                          improved feed
                                                          efficiency.
                                   Bacitracin methylene  Growing turkeys; for     Feed continuously       046573
                                    disalicylate 4 to     prevention of            as sole ration.
                                    50.                   coccidiosis caused by    Bacitracin
                                                          E. meleagrimitis, E.     methylene
                                                          gallopavonis, and E.     disalicylate as
                                                          adenoeides; for          provided by No.
                                                          increased rate of        046573 in Sec.
                                                          weight gain and          510.600(c) of this
                                                          improved feed            chapter.
                                                          efficiency.
                                   Roxarsone 22.7 to     Growing turkeys: For     Feed continuously       046573
                                    45.4.                 prevention of            as the sole
                                                          coccidiosis caused by    ration. Roxarsone
                                                          E. meleagrimitis, E.     provided by No.
                                                          gallopavonis, and E.     046573 in Sec.
                                                          adenoeides, increased    510.600(c) in this
                                                          rate of weight gain,     chapter.
                                                          improved feed
                                                          efficiency, and
                                                          improved pigmentation.

[[Page 445]]

 
                                   Virginiamycin 10 to   Growing turkeys; for     Feed continuously       046573
                                    20.                   prevention of            as sole ration. As
                                                          coccidiosis caused by    lasalocid sodium
                                                          E. meleagrimitis, E.     provided by 063238
                                                          gallopavonis, and E.     and virginiamycin
                                                          adenoeides, and for      provided by 066104.
                                                          increased rate of
                                                          weight gain and
                                                          improved feed
                                                          efficiency.
(xvi)............................  ....................  Replacement calves; for  In milk replacer        046573
                                                          control of coccidiosis   powder; hand feed
                                                          caused by E. bovis and   at a rate of 1 mg
                                                          E. zuernii.              of lasalocid per
                                                                                   2.2 lb body weight
                                                                                   per day; include
                                                                                   on labeling
                                                                                   warning: ``A
                                                                                   withdrawal period
                                                                                   has not been
                                                                                   established for
                                                                                   lasalocid in pre-
                                                                                   ruminating calves.
                                                                                   Do not use in
                                                                                   calves to be
                                                                                   processed for
                                                                                   veal''.
(xvii) 113 (0.0125 pct)..........  ....................  Rabbits; for prevention  Feed continuously       046573
                                                          of coccidiosis caused    as sole ration up
                                                          by Eimeria stiedae.      to 6\1/2\ weeks of
                                                                                   age.
(xviii) 1440.....................  ....................  Pasture cattle           Feed continuously       021930
                                                          (slaughter, stocker,     on a free-choice       017800
                                                          feeder cattle, and       basis at a rate of
                                                          dairy and beef           not less than 60
                                                          replacement heifers):    mg nor more than
                                                          For increased rate of    200 mg of
                                                          weight gain.             lasalocid per head
                                                                                   per day.
(xix) 300........................  ....................  Pasture cattle           Feed continuously       068287
                                                          (slaughter, stocker,     on a free-choice
                                                          feeder cattle, and       basis at a rate of
                                                          dairy and beef           not less than 60
                                                          replacement heifers):    mg nor more than
                                                          for increased rate of    200 mg of
                                                          weight gain.             lasalocid per head
                                                                                   per day.
(xx) 10 to 30....................  Chlortetracycline 25  1. Cattle fed in         Feed continuously       046573
                                    to 100.               confinement for          in complete feed
                                                          slaughter: For           at a rate of 350
                                                          improved feed            mg
                                                          efficiency; and for      chlortetracycline
                                                          control of bacterial     and not less than
                                                          pneumonia associated     100 mg nor more
                                                          with shipping fever      than 360 mg of
                                                          complex caused by        lasalocid sodium
                                                          Pasteurella spp.         activity per head
                                                          susceptible to           per day.
                                                          chlortetracycline.
                                   ....................  2. Cattle under 700      Feed continuously       046573
                                                          pounds fed in            in complete feed
                                                          confinement for          at a rate of 350
                                                          slaughter: For           mg
                                                          improved feed            chlortetracycline
                                                          efficiency; and for      and not less than
                                                          control of active        100 mg nor more
                                                          infection of             than 360 mg of
                                                          anaplasmosis caused by   lasalocid sodium
                                                          Anaplasma marginale      activity per head
                                                          susceptible to           per day.
                                                          chlortetracycline.
(xxi) 10 to 30...................  Chlortetracycline     Cattle fed in            Feed continuously       046573
                                    500 to 2000.          confinement for          in complete feed
                                                          slaughter: For           for not more than
                                                          improved feed            5 days to provide
                                                          efficiency; and for      10 mg
                                                          treatment of bacterial   chlortetracycline
                                                          enteritis caused by E.   per lb body weight
                                                          coli and bacterial       per day and not
                                                          pneumonia caused by P.   less than 100 mg
                                                          multocida organisms      nor more than 360
                                                          susceptible to           mg of lasalocid
                                                          chlortetracycline.       sodium activity
                                                                                   per head per day.
(xxii) 25 to 30..................  Chlortetracycline 25  1. Cattle fed in         Feed continuously       046573
                                    to 42.2.              confinement for          in complete feed
                                                          slaughter: For           at a rate of 350
                                                          increased rate of        mg
                                                          weight gain and          chlortetracycline
                                                          improved feed            and not less than
                                                          efficiency; and for      250 mg nor more
                                                          control of bacterial     than 360 mg of
                                                          pneumonia associated     lasalocid sodium
                                                          with shipping fever      activity per head
                                                          complex caused by        per day.
                                                          Pasteurella spp.
                                                          susceptible to
                                                          chlortetracycline.
                                   ....................  2. Cattle under 700      Feed continuously       046573
                                                          pounds fed in            in complete feed
                                                          confinement for          at a rate of 350
                                                          slaughter: For           mg
                                                          increased rate of        chlortetracycline
                                                          weight gain and          and not less than
                                                          improved feed            250 mg nor more
                                                          efficiency; and for      than 360 mg of
                                                          control of active        lasalocid sodium
                                                          infection of             activity per head
                                                          anaplasmosis caused by   per day.
                                                          Anaplasma marginale
                                                          susceptible to
                                                          chlortetracycline.

[[Page 446]]

 
(xxiii) 25 to 30.................  Chlortetracycline     Cattle fed in            Feed continuously       046573
                                    500 to 1200.          confinement for          in complete feed
                                                          slaughter: For           for not more than
                                                          increased rate of        5 days to provide
                                                          weight gain and          10 mg
                                                          improved feed            chlortetracycline
                                                          efficiency; and for      per lb body weight
                                                          treatment of bacterial   per day and not
                                                          enteritis caused by E.   less than 250 mg
                                                          coli and bacterial       nor more than 360
                                                          pneumonia caused by P.   mg of lasalocid
                                                          multocida organisms      sodium activity
                                                          susceptible to           per head per day.
                                                          chlortetracycline.
(xxiv) 30 to 181.8...............  Chlortetracycline 25  1. Beef cattle under     Hand feed               046573
                                    to 2800.              700 pounds: For          continuously at a
                                                          control of coccidiosis   rate of 350 mg
                                                          caused by Eimeria        chlortetracycline
                                                          bovis and E. zuernii;    per head per day
                                                          and for control of       and 1 mg lasalocid
                                                          active infection of      per 2.2 lb body
                                                          anaplasmosis caused by   weight per day
                                                          Anaplasma marginale      with a maximum of
                                                          susceptible to           360 mg lasalocid
                                                          chlortetracycline.       per head per day.
                                   ....................  2. Beef cattle up to     Hand feed               046573
                                                          800 pounds: For          continuously at a
                                                          control of coccidiosis   rate of 350 mg
                                                          caused by Eimeria        chlortetracycline
                                                          bovis and E. zuernii;    per head per day
                                                          and for control of       and 1 mg lasalocid
                                                          bacterial pneumonia      per 2.2 lb body
                                                          associated with          weight per day
                                                          shipping fever complex   with a maximum of
                                                          caused by Pasteurella    360 mg lasalocid
                                                          spp. susceptible to      per head per day.
                                                          chlortetracycline.
(xxv) 30 to 181.8................  Chlortetracycline     Cattle up to 800         Hand feed               046573
                                    500 to 4000.          pounds: For control of   continuously for
                                                          coccidiosis caused by    not more than 5
                                                          Eimeria bovis and E.     days to provide 10
                                                          zuernii; and for         mg
                                                          treatment of bacterial   chlortetracycline
                                                          enteritis caused by E.   per lb body weight
                                                          coli and bacterial       per day and 1 mg
                                                          pneumonia caused by P.   lasalocid per 2.2
                                                          multocida organisms      lb body weight per
                                                          susceptible to           day with a maximum
                                                          chlortetracycline.       of 360 mg
                                                                                   lasalocid per head
                                                                                   per day.
(xxvi) 30 to 600.................  Chlortetracycline 25  1. Pasture cattle        Hand feed               046573
                                    to 700.               (slaughter, stocker,     continuously at a
                                                          feeder cattle, and       rate of 350 mg
                                                          beef replacement         chlortetracycline
                                                          heifers): for            and not less than
                                                          increased rate of        60 mg or more than
                                                          weight gain; and for     300 mg lasalocid
                                                          control of bacterial     per head daily in
                                                          pneumonia associated     at least 1 lb of
                                                          with shipping fever      feed. Intakes of
                                                          complex caused by        lasalocid in
                                                          Pasteurella spp.         excess of 200 mg/
                                                          susceptible to           head/day have not
                                                          chlortetracycline.       been shown to be
                                                                                   more effective
                                                                                   than 200 mg/head/
                                                                                   day.
                                   ....................  2. Pasture cattle under  Hand feed               046573
                                                          700 pounds (slaughter,   continuously at a
                                                          stocker, feeder          rate of 350 mg
                                                          cattle, and beef         chlortetracycline
                                                          replacement heifers):    and not less than
                                                          for increased rate of    60 mg or more than
                                                          weight gain; and for     300 mg lasalocid
                                                          control of active        per head daily in
                                                          infection of             at least 1 lb of
                                                          anaplasmosis caused by   feed. Intakes of
                                                          Anaplasma marginale      lasalocid in
                                                          susceptible to           excess of 200 mg/
                                                          chlortetracycline.       head/day have not
                                                                                   been shown to be
                                                                                   more effective
                                                                                   than 200 mg/head/
                                                                                   day.
(xxvii) 30 to 600................  Chlortetracycline 25  Pasture cattle over 700  Hand feed               046573
                                    to 1100.              pounds (slaughter,       continuously at a
                                                          stocker, feeder          rate of 0.5 mg
                                                          cattle, and beef         chlortetracycline
                                                          replacement heifers):    per lb body weight
                                                          For increased rate of    per day and not
                                                          weight gain; and for     less than 60 mg or
                                                          control of active        more than 300 mg
                                                          infection of             lasalocid per head
                                                          anaplasmosis caused by   daily in at least
                                                          Anaplasma marginale      1 lb of feed.
                                                          susceptible to           Intakes of
                                                          chlortetracycline.       lasalocid in
                                                                                   excess of 200 mg/
                                                                                   head/day have not
                                                                                   been shown to be
                                                                                   more effective
                                                                                   than 200 mg/head/
                                                                                   day.

[[Page 447]]

 
(xxviii) 30 to 600...............  Chlortetracycline     Pasture cattle           Hand feed               046573
                                    500 to 4000.          (slaughter, stocker,     continuously for
                                                          feeder cattle, and       not more than 5
                                                          dairy and beef           days to provide 10
                                                          replacement heifers):    mg
                                                          For increased rate of    chlortetracycline
                                                          weight gain; and for     per lb body weight
                                                          treatment of bacterial   per day and not
                                                          enteritis caused by E.   less than 60 mg or
                                                          coli and bacterial       more than 300 mg
                                                          pneumonia caused by P.   lasalocid per head
                                                          multocida organisms      daily in at least
                                                          susceptible to           1 lb of feed.
                                                          chlortetracycline.       Intakes of
                                                                                   lasalocid in
                                                                                   excess of 200 mg/
                                                                                   head/day have not
                                                                                   been shown to be
                                                                                   more effective
                                                                                   than 200 mg/head/
                                                                                   day.
----------------------------------------------------------------------------------------------------------------

    (2) It is used as a free-choice mineral Type C feed as follows:
    (i) Specifications.

------------------------------------------------------------------------
            Ingredient               Percent    International feed No.
------------------------------------------------------------------------
Defluorinated phosphate (20.5% Ca,     35.9   6-01-080
 18.5% P).
Sodium chloride (salt)............     20.0   6-04-152
Calcium carbonate (38% Ca)........     18.0   6-01-069
Cottonseed meal...................     10.0   5-01-621
Potassium chloride................      3.0   6-03-755
Selenium premix (0.02 percent           3.0   ..........................
 Se)\1\.
Dried cane molasses (46% sugars)..      2.5   4-04-695
Magnesium sulfate.................      1.7   6-02-758
Vitamin premix\1\.................      1.4   ..........................
Magnesium oxide (58% Mg)..........      1.2   6-02-756
Potassium sulfate.................      1.2   6-06-098
Trace mineral premix\1\...........      1.04  ..........................
Lasalocid Type A medicated article      1.06  ..........................
 (68 g/lb)\2\.
------------------------------------------------------------------------
\1\ Content of the vitamin and trace mineral premixes may be varied;
  however, they should be comparable to those used by the firm for other
  free-choice feeds. Formulation modifications require FDA approval
  prior to marketing. Selenium must comply with 21 CFR 573.920.
  Ethylenediamine dihydroiodide (EDDI) should comply with FDA Compliance
  Policy Guides Sec. 651.100 (CPG 7125.18).
\2\ To provide 1,440 g lasalocid per ton, use 21.2 lbs (1.06%) of a
  lasalocid Type A medicated article containing 68 g/lb. If using a
  lasalocid Type A medicated article containing 90.7 g/lb, use 15.88 lbs
  per ton (0.794%), adding molasses.

    (ii) Amount. 1,440 grams per ton.
    (iii) Indications for use. Pasture cattle (slaughter, stocker, 
feeder cattle, and dairy and beef replacement heifers): for increased 
rate of weight gain. Intakes of lasalocid in excess of 200 mg/head/day 
have not been shown to be more effective than 200 mg/head/day.
    (iv) Limitations. For pasture cattle (slaughter, stocker, feeder 
cattle, and dairy and beef replacement heifers); feed continuously on a 
free-choice basis at a rate of 60 to 300 milligrams lasalocid per head 
per day.
    (v) Sponsor. See No. 046573 in Sec. 510.600(c) of this chapter.
    (3) It is used as a ruminant free-choice liquid Type C feed as 
follows:
    (i) Specifications.

------------------------------------------------------------------------
            Ingredient               Percent     International feed No.
------------------------------------------------------------------------
Cane molasses....................      55.167  4-13-241
Condensed molasses fermentation        24.0    .........................
 solubles.
50% Urea Solution (23% N)........      12.0    .........................
Ammonium polyphosphate solution..       1.0    6-08-42
Phosphoric acid (54%)............       3.0    6-03-707
Xanthan gum......................       0.05   8-15-818
Water............................       4.0    .........................
Trace mineral premix\1\..........       0.5    .........................
Vitamin premix\1\................       0.2    .........................
Lasalocid Type A medicated              0.083  .........................
 article (90.7 g/lb)\2\.
------------------------------------------------------------------------
\1\ Content of the vitamin and trace mineral premixes may be varied;
  however, they should be comparable to those used by the firm for other
  free-choice feeds. Formulation modifications require FDA approval
  prior to marketing. Selenium must comply with 21 CFR 573.920.
  Ethylenediamine dihydroiodide (EDDI) should comply with FDA Compliance
  Policy Guides Sec. 651.100 (CPG 7125.18).

[[Page 448]]

 
\2\ To provide 150 gm lasalocid per ton, use 1.652 lb (0.083%) of a
  lasalocid liquid Type A medicated article containing 90.7 g/lb. If
  using a dry lasalocid Type A medicated article containing 68 g/lb,
  use, use 2.206 lbs per ton (0.111%), replacing molasses. If using a
  dry lasalocid Type A medicated article containing 90.7 g/lb, use 1.652
  lbs per ton (0.083%), adding molasses.

    (ii) Amount. 150 grams per ton.
    (iii) Indications for use. Pasture cattle (slaughter, stocker, 
feeder cattle, and dairy and beef replacement heifers): for increased 
rate of weight gain. Intakes of lasalocid in excess of 200 mg/head/day 
have not been shown to be more effective than 200 mg/head/day.
    (iv) Limitations. For pasture cattle (slaughter, stocker, feeder 
cattle, and dairy and beef replacement heifers). Feed continuously on a 
free-choice basis at a rate of 60 to 300 milligrams lasalocid per head 
per day.
    (v) Sponsor. See No. 046573 in Sec. 510.600(c) of this chapter.
    (4) It is used as a free-choice, loose mineral Type C feed as 
follows:
    (i) Specifications.

------------------------------------------------------------------------
            Ingredient               Percent    International feed No.
------------------------------------------------------------------------
Monocalcium phosphate (21% P).....    57.70   6-01-082
Salt..............................    17.55   6-04-152
Distillers dried grains w/             5.40   5-28-236
 solubles.
Dried cane molasses (46% Sugars)..     5.20   4-04-695
Potassium chloride................     4.90   6-03-755
Trace mineral/vitamin premix\1\...     3.35   ..........................
Calcium carbonate (38% Ca)........     2.95   6-01-069
Mineral oil.......................     1.05   8-03-123
Magnesium oxide (58% Mg)..........     1.00   6-02-756
Iron oxide (52% Fe)...............     0.10   6-02-431
Lasalocid Type A medicated article     0.80   ..........................
 (68 g/lb)\2\.
------------------------------------------------------------------------
\1\ Content of the vitamin and trace mineral premixes may be varied;
  however, they should be comparable to those used by the firm for other
  free-choice feeds. Formulation modifications require FDA approval
  prior to marketing. Selenium must comply with 21 CFR 573.920.
  Ethylenediamine dihydroiodide (EDDI) should comply with FDA Compliance
  Policy Guides Sec. 651.100 (CPG 7125.18).
\2\ To provide 1,088 g lasalocid per ton, use 16 lbs (0.80%) of a
  lasalocid Type A medicated article containing 68 g/lb. If using a
  lasalocid Type A medicated article containing 90.7 g/lb, use 12 lbs
  per ton (0.6%), adding molasses.

    (ii) Amount. 1,088 grams per ton.
    (iii) Indications for use. Pasture cattle (slaughter, stocker, 
feeder cattle, and dairy and beef replacement heifers): For increased 
rate of weight gain. Intakes of lasalocid in excess of 200 mg/head/day 
have not been shown to be more effective than 200 mg/head/day.
    (iv) Limitations. Feed continuously on a free-choice basis at a rate 
of 60 to 300 mg lasalocid per head per day.
    (v) Sponsor. See No. 046573 in Sec. 510.600(c) of this chapter.
    (5) Additional combinations. Lasalocid may be used in accordance 
with the provisions of this section in combination as follows:
    (i) Melengestrol acetate alone or in combination with tylosin in 
accordance with Sec. 558.342.
    (ii) [Reserved]

[41 FR 44382, Oct. 8, 1976]

    Editorial Note: For Federal Register citations affecting Sec. 
558.311, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.325  Lincomycin.

    (a) Approvals. Type A articles and Type B feeds approved for 
sponsors in Sec. 510.600(c) of this chapter for specific uses as in 
paragraph (d) of this section as follows:
    (1) No. 000009 for 20 and 50 grams per pound.
    (2) No. 051311 for 2.5 and 8 grams per pound.
    (b) Related tolerances. See Sec. 556.360 of this chapter.
    (c) Special considerations--(1) Labeling of Type A medicated 
articles and Type B and Type C medicated feeds containing lincomycin 
shall bear the following directions: ``CAUTION: Do not allow rabbits, 
hamsters, guinea pigs, horses, or ruminants access to feeds containing 
lincomycin. Ingestion by these species may result in severe 
gastrointestinal effects.''
    (2) Labeling of Type A medicated articles and Type B and Type C 
medicated feeds containing lincomycin intended for use in swine shall 
bear the

[[Page 449]]

following directions: ``CAUTION: Occasionally, swine fed lincomycin may 
within the first 2 days after the onset of treatment develop diarrhea 
and/or swelling of the anus. On rare occasions, some pigs may show 
reddening of the skin and irritable behavior. These conditions have been 
self-correcting within 5 to 8 days without discontinuing the lincomycin 
treatment.''
    (3) Labeling of Type A medicated articles and single-ingredient Type 
B and Type C medicated feeds containing lincomycin intended for use in 
swine shall bear the following directions:
    (i) No. 000009: ``CAUTION: The effects of lincomycin on swine 
reproductive performance, pregnancy, and lactation have not been 
determined. Not for use in swine intended for breeding when lincomycin 
is fed at 20 grams per ton of complete feed.''
    (ii) No. 051311:``CAUTION: Not to be fed to swine that weigh more 
than 250 lb.''
    (d) Conditions of use--(1) Chickens. It is used in feed as follows:

----------------------------------------------------------------------------------------------------------------
           Lincomycin grams/ton                 Indications for use               Limitations           Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 2....................................  Broilers: For control of      As lincomycin hydrochloride      000009
                                            necrotic enteritis caused     monohydrate.
                                            by Clostridium spp. or
                                            other susceptible organisms.
(ii) 2 to 4..............................  Broilers: For increased rate  As lincomycin hydrochloride      000009
                                            of weight gain and improved   monohydrate.
                                            feed efficiency.
----------------------------------------------------------------------------------------------------------------

    (2) Swine. It is used in feed as follows:

----------------------------------------------------------------------------------------------------------------
           Lincomycin grams/ton                 Indications for use               Limitations           Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 20...................................  Growing-finishing swine: For  Feed as sole ration.........     000009
                                            increased rate of weight
                                            gain.
(ii) 40..................................  1. For control of swine       Feed as sole ration; for use     000009
                                            dysentery.                    in swine on premises with a     051311
                                                                          history of swine dysentery
                                                                          but where symptoms have not
                                                                          yet occurred, or following
                                                                          use of lincomycin at 100
                                                                          grams (g)/ton for treatment
                                                                          of swine dysentery.
                                           2. For control of porcine     Feed as sole ration, or          000009
                                            proliferative enteropathies   following use of lincomycin
                                            (ileitis) caused by           at 100 g/ton for control of
                                            Lawsonia intracellularis.     porcine proliferative
                                                                          enteropathies (ileitis).
(iii) 100................................  1. For treatment of swine     Feed as sole ration for 3        000009
                                            dysentery.                    weeks or until signs of         051311
                                                                          disease disappear.
                                           2. For control of porcine     Feed as sole ration for 3        000009
                                            proliferative enteropathies   weeks or until signs of
                                            (ileitis) caused by           disease disappear.
                                            Lawsonia intracellularis.
(iv) 200.................................  For reduction in the          Feed as sole ration for 3        000009
                                            severity of swine             weeks.                          051311
                                            mycoplasmal pneumonia
                                            caused by Mycoplasma
                                            hyopneumoniae.
----------------------------------------------------------------------------------------------------------------

    (3) Lincomycin may also be used in combination with:
    (i) Amprolium and ethopabate or amprolium and ethopabate with 
roxarsone in accordance with Sec. 558.58.
    (ii) Clopidol in accordance with Sec. 558.175.
    (iii) Decoquinate in accordance with Sec. 558.195.
    (iv) Fenbendazole as provided in Sec. 558.258.
    (v) Halofuginone in accordance with Sec. 558.265.
    (vi) Ivermectin as in Sec. 558.300.
    (vii) Lasalocid alone or with roxarsone in accordance with Sec. 
558.311.
    (viii) Monensin alone or with roxarsone in accordance with Sec. 
558.355.
    (ix) Nicarbazin alone or with narasin or roxarsone as in Sec. 
558.366.
    (x) Pyrantel as in Sec. 558.485.
    (xi) Robenidine in accordance with Sec. 558.515.
    (xii) Roxarsone in accordance with Sec. 558.530.
    (xiii) Salinomycin with or without roxarsone as in Sec. 558.550.

[[Page 450]]

    (xiv) Zoalene in accordance with Sec. 558.680.

[40 FR 13959, Mar. 27, 1975]

    Editorial Note: For Federal Register citations affecting Sec. 
558.325, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.340  Maduramicin ammonium.

    (a) Approvals. Type A medicated articles: 4.54 grams per pound to 
046573 in Sec. 510.600(c) of this chapter.
    (b) Tolerances. See Sec. 556.375 of this chapter.
    (c) Conditions of use--(1) Amount. 4.54 to 5.45 grams per ton (5 to 
6 parts per million) (1 to 1.2 pounds per ton).
    (i) Indications for use. For prevention of coccidiosis caused by 
Eimeria acervulina, E. tenella, E. brunetti, E. maxima, E. necatrix, and 
E. mivati.
    (ii) Limitations. For broiler chickens only. Feed continuously as 
sole ration. Do not feed to laying hens. Withdraw 5 days before 
slaughter.
    (2) [Reserved]

[54 FR 5229, Feb. 2, 1989, as amended at 54 FR 26732, June 26, 1989; 54 
FR 32635, Aug. 9, 1989; 54 FR 33885, Aug. 17, 1989; 55 FR 23, Jan. 2, 
1990; 55 FR 8460, Mar. 8, 1990; 55 FR 49616, Nov. 30, 1990; 59 FR 8134, 
Feb. 18, 1994; 61 FR 18082, Apr. 24, 1996; 63 FR 27845, May 21, 1998; 66 
FR 46706, Sept. 7, 2001]



Sec. 558.342  Melengestrol.

    (a) Specifications. (1) Dry Type A medicated articles containing 100 
or 200 milligrams (mg) melengestrol acetate per pound.
    (2) Liquid Type A medicated article containing 500 mg melengestrol 
acetate per pound.
    (b) Approvals. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (e) of this section.
    (1) No. 000009 for use of products described in paragraph (a) of 
this section.
    (2) No. 000986 for use of product described in paragraph (a)(2) of 
this section.
    (c) Related tolerances. See Sec. 556.380 of this chapter.
    (d) Special considerations. (1) Type B or C medicated feeds may be 
manufactured from melengestrol acetate liquid Type A articles or Type B 
or C medicated feeds which have a pH of 4.0 to 8.0 and bear appropriate 
mixing directions as follows:
    (i) For liquid feeds stored in recirculating tank systems: 
Recirculate immediately prior to use for no less than 10 minutes, moving 
not less than 1 percent of the tank contents per minute from the bottom 
of the tank to the top. Recirculate daily as described even when not 
used.
    (ii) For liquid feeds stored in mechanical, air, or other agitation 
type tank systems: Agitate immediately prior to use for not less than 10 
minutes, creating a turbulence at the bottom of the tank that is visible 
at the top. Agitate daily as described even when not used.
    (2) A physically stable melengestrol acetate liquid Type B or C feed 
will not be subject to the requirements for mixing directions prescribed 
in paragraph (d)(1) of this section provided it has a pH of 4.0 to 8.0 
and contains a suspending agent(s) sufficient to maintain a viscosity of 
not less than 300 centipoises per second for 3 months.
    (3) Combination Type B or C medicated feeds containing lasalocid 
must be labeled in accordance with Sec. 558.311(d)(5) of this chapter.
    (4) Liquid combination Type B or C medicated feeds containing 
melengestrol acetate and lasalocid must be manufactured in accordance 
with Sec. 558.311(d) of this chapter.
    (5) Combination Type B or C medicated feeds containing monensin must 
be labeled in accordance with Sec. 558.355(d) of this chapter.
    (6) Liquid combination Type B or C medicated feeds containing 
melengestrol acetate and monensin must be manufactured in accordance 
with Sec. 558.355(f)(3)(i) of this chapter.
    (7) Liquid combination Type B or C medicated feeds containing 
melengestrol acetate and tylosin must be manufactured in accordance with 
Sec. 558.625(c) of this chapter.
    (8) Liquid melengestrol acetate may not be mixed with 
oxytetracycline in a common liquid feed supplement.
    (e) Conditions of use--(1) Cattle.

[[Page 451]]



----------------------------------------------------------------------------------------------------------------
 Melengestrol acetate in mg/head/   Combination in mg/
               day                       head/day          Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 0.25 to 0.5..................  ....................  Heifers fed in           Administer 0.5 to      000009,
                                                          confinement for          2.0 pounds (lb)/       000986
                                                          slaughter: For           head/day of
                                                          increased rate of        medicated feed
                                                          weight gain, improved    containing 0.125
                                                          feed efficiency, and     to 1.0 mg
                                                          suppression of estrus    melengestrol
                                                          (heat).                  acetate/lb to
                                                                                   provide 0.25 to
                                                                                   0.5 mg
                                                                                   melengestrol
                                                                                   acetate/head/day.
(ii) 0.5.........................  ....................  Heifers intended for     Administer 0.5 to      000009,
                                                          breeding: For            2.0 lb/head/day of     000986
                                                          suppression of estrus    Type C feed
                                                          (heat).                  containing 0.25 to
                                                                                   1.0 mg
                                                                                   melengestrol
                                                                                   acetate/lb to
                                                                                   provide 0.5 mg
                                                                                   melengestrol
                                                                                   acetate/head/day.
                                                                                   Do not exceed 24
                                                                                   days of feeding.
(iii) 0.25 to 0.5................  Lasalocid 100 to 360  Heifers fed in           Add at the rate of     000009,
                                                          confinement for          0.5 to 2.0 lb/head/    000986
                                                          slaughter: As in         day a medicated
                                                          paragraph (e)(1)(i) of   feed (liquid or
                                                          this section.            dry) containing
                                                                                   0.125 to 1.0 mg
                                                                                   melengestrol
                                                                                   acetate/lb to a
                                                                                   feed containing 10
                                                                                   to 30 grams (g) of
                                                                                   lasalocid per ton;
                                                                                   or add at the rate
                                                                                   of 0.5 to 2.0 lb/
                                                                                   head/day a
                                                                                   medicated feed
                                                                                   (liquid or dry)
                                                                                   containing 0.125
                                                                                   to 1.0 mg
                                                                                   melengestrol
                                                                                   acetate plus 50 to
                                                                                   720 mg lasalocid/
                                                                                   lb to a ration of
                                                                                   nonmedicated feed
                                                                                   to provide 0.25 to
                                                                                   0.5 mg
                                                                                   melengestrol
                                                                                   acetate and 100 to
                                                                                   360 mg lasalocid/
                                                                                   head/day..
                                                                                  Lasalocid provided
                                                                                   by No. 046573 in
                                                                                   Sec. 510.600(c)
                                                                                   of this chapter.
(iv) 0.25 to 0.5.................  Lasalocid 100 to 360  Heifers fed in           To administer 0.25
                                    plus tylosin 90.      confinement for          to 0.5 mg
                                                          slaughter: As in         melengestrol
                                                          paragraph (e)(1)(i) of   acetate plus 100
                                                          this section; and for    to 360 mg
                                                          reduced incidence of     lasalocid plus 90
                                                          liver abscesses caused   mg tylosin/head/
                                                          by Fusobacterium         day:.
                                                          necrophorum and         1. Add 0.5 to 2.0
                                                          Actinomyces              lb/head/day of a
                                                          (Corynebacterium)        liquid or dry
                                                          pyogenes.                medicated feed
                                                                                   containing 0.125
                                                                                   to 1.0 mg
                                                                                   melengestrol
                                                                                   acetate/lb to a
                                                                                   medicated feed
                                                                                   containing 10 to
                                                                                   30 g lasalocid and
                                                                                   8 to 10 g tylosin
                                                                                   per ton; or.
                                                                                  2. Add 0.5 to 2.0
                                                                                   lb/head/day of a
                                                                                   liquid or dry
                                                                                   medicated feed
                                                                                   containing 0.125
                                                                                   to 1.0 mg
                                                                                   melengestrol
                                                                                   acetate plus 50 to
                                                                                   720 mg lasalocid/
                                                                                   lb to 4.5 to 18 lb
                                                                                   of a dry medicated
                                                                                   feed containing 10
                                                                                   to 40 g tylosin
                                                                                   per ton; or.
                                                                                  3. Add 0.5 to 2.0
                                                                                   lb/head/day of a
                                                                                   dry pelleted
                                                                                   medicated feed
                                                                                   containing 0.125
                                                                                   to 1.0 mg
                                                                                   melengestrol
                                                                                   acetate (from a
                                                                                   dry Type A
                                                                                   article), 50 to
                                                                                   720 mg lasalocid,
                                                                                   and 45 to 180 mg
                                                                                   tylosin/lb to a
                                                                                   ration of
                                                                                   nonmedicated feed..
                                                                                  Lasalocid provided
                                                                                   by No. 046573 and
                                                                                   tylosin as tylosin
                                                                                   phosphate by No.
                                                                                   000986 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter..
                                                                                  021641, 000986.....
(v) [Reserved]...................
 (vi)-(vii) [Reserved]...........

[[Page 452]]

 
(viii) 0.25 to 0.5...............  Oxytetracycline 75..  Heifers fed in           Add at the rate of      000009
                                                          confinement for          0.5 to 2.0 lb/head/
                                                          slaughter: As in         day a medicated
                                                          paragraph (e)(1)(i) of   feed (liquid or
                                                          this section; and for    dry) containing
                                                          reduction of liver       0.125 to 1.0 mg
                                                          condemnation due to      melengestrol
                                                          liver abscesses.         acetate/lb per
                                                                                   pound to a feed
                                                                                   containing 6 to 10
                                                                                   g oxytetracycline
                                                                                   per ton; or add at
                                                                                   the rate of 0.5 to
                                                                                   2.0 lb/head/day a
                                                                                   dry medicated feed
                                                                                   containing 0.125
                                                                                   to 1.0 mg
                                                                                   melengestrol
                                                                                   acetate plus 37.5
                                                                                   to 150 mg
                                                                                   oxytetracycline/lb
                                                                                   to provide 0.25 to
                                                                                   0.5 mg
                                                                                   melengestrol
                                                                                   acetate and 75 mg
                                                                                   oxytetracycline/
                                                                                   head/day..
                                                                                  Oxytetracycline as
                                                                                   provided by No.
                                                                                   066104 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
(ix) 0.25 to 0.5.................  Tylosin 60 to 90....  Heifers fed in           To administer 0.25      000009
                                                          confinement for          to 0.5 mg              000986
                                                          slaughter: As in         melengestrol
                                                          paragraph (e)(1)(i) of   acetate with 60 to
                                                          this section; and for    90 mg tylosin/head/
                                                          reduced incidence of     day:.
                                                          liver abscesses caused  1. Add 0.5 to 2.0
                                                          by F. necrophorum and    lb/head/day of a
                                                          Actinomyces              liquid or dry
                                                          (Corynebacterium)        medicated feed
                                                          pyogenes.                containing 0.125
                                                                                   to 1.0 mg
                                                                                   melengestrol
                                                                                   acetate/lb to a
                                                                                   medicated feed
                                                                                   containing 8 to 10
                                                                                   g tylosin per ton;
                                                                                   or.
                                                                                  2. Add 0.5 to 2.0
                                                                                   lb/head/day of a
                                                                                   liquid or dry
                                                                                   medicated feed
                                                                                   containing 0.125
                                                                                   to 1.0 mg
                                                                                   melengestrol
                                                                                   acetate/lb to 4.5
                                                                                   to 18 pounds of a
                                                                                   dry medicated feed
                                                                                   containing 10 to
                                                                                   40 g tylosin per
                                                                                   ton; or.
                                                                                  3. Add 0.5 to 2.0
                                                                                   lb/head/day of a
                                                                                   liquid or dry
                                                                                   medicated feed
                                                                                   containing 0.125
                                                                                   to 1.0 mg
                                                                                   melengestrol
                                                                                   acetate (from a
                                                                                   dry Type A
                                                                                   article) plus 45
                                                                                   to 180 mg tylosin/
                                                                                   lb to a ration of
                                                                                   nonmedicated feed..
                                                                                  Tylosin as tylosin
                                                                                   phosphate provided
                                                                                   by No. 000986 in
                                                                                   Sec. 510.600(c)
                                                                                   of this chapter.
(x) 0.25 to 0.5..................  Monensin 50 to 480..  Heifers fed in           Add at the rate of      000009
                                                          confinement for          0.5 to 2.0 lb/head/    000986
                                                          slaughter: As in         day a medicated
                                                          paragraph (e)(1)(i) of   feed (liquid or
                                                          this section; and for    dry) containing
                                                          the prevention and       0.125 to 1.0 mg
                                                          control of coccidiosis   melengestrol
                                                          due to Eimeria bovis     acetate/lb to a
                                                          and E. zuernii.          feed containing 10
                                                                                   to 40 g of
                                                                                   monensin per ton
                                                                                   to provide 0.25 to
                                                                                   0.5 mg
                                                                                   melengestrol
                                                                                   acetate/head/day
                                                                                   and 0.14 to 0.42
                                                                                   mg monensin/lb
                                                                                   body weight,
                                                                                   depending on
                                                                                   severity of
                                                                                   coccidiosis
                                                                                   challenge, up to
                                                                                   480 mg monensin/
                                                                                   head/day..
                                                                                  ...................
                                                                                  Monensin provided
                                                                                   by No. 000986 in
                                                                                   Sec. 510.600(c)
                                                                                   of this chapter.

[[Page 453]]

 
(xi) 0.25 to 0.5.................  Monensin 50 to 480,   Heifers fed in           Feed continuously       000009
                                    plus tylosin 60 to    confinement for          as sole ration         016592
                                    90.                   slaughter: As in         (liquid or dry) at
                                                          paragraph (e)(1)(i) of   a rate of 0.5 to
                                                          this section; for the    2.0 lb/head/day to
                                                          prevention and control   provide 0.25 to
                                                          of coccidiosis due to    0.5 mg/head/day
                                                          Eimeria bovis and E.     melengestrol
                                                          zuernii; and for         acetate; 0.14 to
                                                          reduction of incidence   0.42 mg monensin/
                                                          of liver abscesses       lb body weight/
                                                          caused by                day, depending on
                                                          Fusobacterium            the severity of
                                                          necrophorum and          the coccidiosis
                                                          Arcanobacterium          challenge, up to
                                                          pyogenes.                480 mg/head/day;
                                                                                   and 60 to 90 mg/
                                                                                   head/day tylosin.
                                                                                   The melengestrol
                                                                                   acetate portion of
                                                                                   this Type C
                                                                                   medicated feed
                                                                                   must be mixed into
                                                                                   a complete feed
                                                                                   containing 10 to
                                                                                   40 g/ton monensin
                                                                                   and 8 to 10 g/ton
                                                                                   tylosin in the
                                                                                   amount of complete
                                                                                   feed consumed by
                                                                                   an animal per day..
                                                                                  ...................
                                                                                  Monensin provided
                                                                                   by No. 000986 and
                                                                                   tylosin provided
                                                                                   by Nos. 000986 and
                                                                                   016592 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
----------------------------------------------------------------------------------------------------------------

    (2) Melengestrol may also be used with:
    (i) Ractopamine as in Sec. 558.500 of this chapter.
    (ii) Zilpaterol as in Sec. 558.665 of this chapter.

[42 FR 28535, June 3, 1977]

    Editorial Note: For Federal Register citations effecting Sec. 
558.342, see the List of CFR Section Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.348  Mibolerone.

    (a) Approvals. To No. 000009 in Sec. 510.600(c) of this chapter for 
a canned dog food, each 6\1/2\ ounce can containing 30 or 60 micrograms 
of mibolerone.
    (b) Conditions of use--(1) Amount. 30 micrograms for animals 
weighing up to 25 pounds; 60 micrograms for animals weighing 26 to 50 
pounds; 120 micrograms for animals weighing 51 to 100 pounds; 180 
micrograms for animals weighing over 100 pounds, or German Shepherds or 
German Shepherd mix weighing 30 to 80 pounds.
    (2) Indications for use. For the prevention of estrus (heat) in 
adult female dogs not intended primarily for breeding purposes.
    (3) Limitations. Administer daily at least 30 days before expected 
initiation of heat and continue as long as desired, but for not more 
than 12 months. Mibolerone should not be used in bitches before first 
estrous period or in purebred Bedlington terriers. It is not intended 
for animals being used primarily for breeding purposes. Use orally in 
adult female dogs only. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian.

[47 FR 6617, Feb. 16, 1982]



Sec. 558.355  Monensin.

    (a) Specifications. Type A medicated articles containing monensin, 
USP.
    (b) Approvals. Approvals for Type A medicated articles containing 
the specified levels of monensin activity granted to firms identified by 
sponsor numbers in Sec. 510.600(c) of this chapter for the conditions 
of use indicated in paragraph (f) of this section are as follows:
    (1) To No. 000986: 36.3 (for export only), 44, 45, 60, or 90.7 grams 
per pound for use as in paragraphs (f)(1)(i) and (f)(4) of this section.
    (2) To 000986: 110 grams per lb., paragraphs (f)(1) (i), (iii), 
(iv), (v), (ix), and (x).
    (3) To 000986: 44 grams per lb. with 18 grams per lb. of roxarsone, 
110 grams per lb. with 45 grams per lb. of roxarsone, paragraph 
(f)(1)(ii).

[[Page 454]]

    (4) To No. 000986: 45, 60, or 90.7 grams per pound for use as in 
paragraph (f)(2) of this section.
    (5) To 066104: 45 and 60 grams per pound, as monensin sodium 
provided by No. 000986, paragraphs (f)(1)(xiii), (xx), and (xxi) of this 
section.
    (6) To No. 000986: 45, 60, or 90.7 grams per pound for use as in 
paragraph (f)(5) of this section.
    (7) To 000986: 20, 30, 45, 60, 80, and 90.7 grams per pound, as 
monensin sodium, paragraph (f)(3) of this section.
    (8) To 046573: 45 and 60 grams per pound, as monensin sodium 
provided by No. 000986, paragraph (f)(1)(xiv) of this section.
    (9) To 046573: 45 and 60 grams per pound, as monensin sodium 
provided by No. 000986, paragraphs (f)(1)(xv) and (xvi) of this section.
    (10) To 016592: 45 and 60 grams per pound, as monensin sodium, 
paragraph (f)(1)(xvii) of this section.
    (11) To 046573: 45 and 60 grams per pound, as monensin sodium 
provided by No. 000986, paragraphs (f)(1)(xiv), (xviii), (xix), (xxiii), 
(xxiv), (xxv), (xxvi), and (xxvii) of this section.
    (12) To 066104: 45 and 60 grams per pound, as monensin sodium 
provided by No. 000986, paragraph (f)(1)(xxii) of this section.
    (13) To No. 012286: 60 and 80 grams per pound, paragraph (f)(3)(v) 
of this section.
    (14) To 000986: 60, 80, and 90.7 grams per pound, as monensin 
sodium, paragraph (f)(6) of this section.
    (c) [Reserved]
    (d) Special considerations. (1) Type C chicken feed containing 
monensin as the mycelial cake shall bear an expiration date of 90 days 
after its date of manufacture.
    (2)-(3) [Reserved]
    (4) Liquid Type B feeds shall bear an expiration date of 8 weeks 
after its date of manufacture.
    (5) All Type A medicated articles containing monensin shall bear the 
following warning statement: When mixing and handling monensin Type A 
medicated articles, use protective clothing, impervious gloves, and a 
dust mask. Operators should wash thoroughly with soap and water after 
handling. If accidental eye contact occurs, immediately rinse thoroughly 
with water.
    (6) All formulations containing monensin shall bear the following 
caution statement: Do not allow horses or other equines access to feed 
containing monensin. Ingestion of monensin by horses has been fatal.
    (7) Type A medicated articles containing monensin intended for use 
in cattle and goats shall bear, in addition to the caution statement in 
paragraph (d)(6) of this section, the following statements:
    (i) Monensin medicated cattle and goat feeds are safe for use in 
cattle and goats only. Consumption by unapproved species may result in 
toxic reactions.
    (ii) Feeding undiluted or mixing errors resulting in high 
concentrations of monensin has been fatal to cattle and could be fatal 
to goats.
    (iii) Must be thoroughly mixed in feeds before use.
    (iv) Do not feed undiluted.
    (v) Do not exceed the levels of monensin recommended in the feeding 
directions, as reduced average daily gains may result.
    (vi) Do not feed to lactating goats.
    (vii) If feed refusals containing monensin are fed to other groups 
of cattle, the concentration of monensin in the refusals and amount of 
refusals fed should be taken into consideration to prevent monensin 
overdosing (see paragraphs (d)(10)(i) and (d)(10)(ii) of this section).
    (viii) A withdrawal period has not been established for this product 
in pre-ruminating calves. Do not use in calves to be processed for veal.
    (ix) You may notice the following: Reduced voluntary feed intake in 
dairy cows fed monensin. This reduction increases with higher doses of 
monensin fed. Rule out monensin as the cause of reduced feed intake 
before attributing to other causes such as illness, feed management, or 
the environment. Reduced milk fat percentage in dairy cows fed monensin. 
This reduction increases with higher doses of monensin fed. Increased 
incidence of cystic ovaries and metritis in dairy cows fed monensin. 
Reduced conception rates, increased services per animal, and extended 
days open and corresponding

[[Page 455]]

calving intervals in dairy cows fed monensin. Have a comprehensive and 
ongoing nutritional, reproductive, and herd health program in place when 
feeding monensin to dairy cows.
    (x) Inadequate mixing (recirculation or agitation) of monensin 
liquid Type B or Type C medicated feeds has resulted in increased 
monensin concentration which has been fatal to cattle and could be fatal 
to goats.
    (8) Type A medicated articles containing monensin intended for use 
in chickens, turkeys, and quail shall bear the following statements:
    (i) Do not allow horses, other equines, mature turkeys, or guinea 
fowl access to feed containing monensin. Ingestion of monensin by horses 
and guinea fowl has been fatal.
    (ii) Must be thoroughly mixed in feeds before use.
    (iii) Do not feed undiluted.
    (iv) Do not feed to laying chickens.
    (v) Do not feed to chickens over 16 weeks of age.
    (vi) For replacement chickens intended for use as cage layers only.
    (vii) Some strains of turkey coccidia may be monensin tolerant or 
resistant. Monensin may interfere with development of immunity to turkey 
coccidiosis.
    (viii) In the absence of coccidiosis in broiler chickens the use of 
monensin with no withdrawal period may limit feed intake resulting in 
reduced weight gain.
    (9) Type B feeds containing monensin shall bear the statements 
specified in the following paragraphs of this section when intended for 
use in:
    (i) Cattle (as described in paragraphs (f)(3)(i) through (f)(3)(xii) 
of this section): See paragraphs (d)(6), (d)(7)(i) through (d)(7)(v), 
(d)(7)(vii), and (d)(7)(viii) of this section.
    (ii) Dairy cows (as described in paragraphs (f)(3)(xiii) and 
(f)(3)(xiv) of this section): See paragraphs (d)(6), (d)(7)(i) through 
(d)(7)(iv), (d)(7)(vii), (d)(7)(viii), and (d)(7)(ix) of this section.
    (iii) Goats: See paragraphs (d)(6) and (d)(7)(i) through (d)(7)(vi) 
of this section.
    (iv) Chickens: See paragraphs (d)(8)(i) through (d)(8)(vi), and 
(d)(8)(viii) of this section.
    (v) Turkeys: See paragraphs (d)(8)(i), (d)(8)(ii), (d)(8)(iii), and 
(d)(8)(vii) of this section.
    (vi) Quail: See paragraphs (d)(8)(i), (d)(8)(ii), and (d)(8)(iii) of 
this section.
    (10) Type C feeds containing monensin shall bear the statements 
specified in the following paragraphs of this section when intended for 
use in:
    (i) Cattle (as described in paragraphs (f)(3)(i) through (f)(3)(xii) 
of this section): See paragraphs (d)(6), (d)(7)(i), (d)(7)(v), 
(d)(7)(vii), and (d)(7)(viii) of this section. Paragraph (d)(7)(vii) of 
this section does not apply to free-choice Type C medicated feeds as 
defined in Sec. 510.455 of this chapter.
    (ii) Dairy cows (as described in paragraphs (f)(3)(xiii) and 
(f)(3)(xiv) of this section): See paragraphs (d)(6), (d)(7)(i), 
(d)(7)(vii), (d)(7)(viii), and (d)(7)(ix) of this section. Paragraph 
(d)(7)(vii) of this section does not apply to free-choice Type C 
medicated feeds as defined in Sec. 510.455 of this chapter.
    (iii) Goats: See paragraphs (d)(6), (d)(7)(i), (d)(7)(v), and 
(d)(7)(vi) of this section.
    (iv) Chickens: See paragraphs (d)(8)(i), (d)(8)(iv), (d)(8)(v), 
(d)(8)(vi), and (d)(8)(viii) of this section.
    (v) Turkeys: See paragraphs (d)(8)(i) and (d)(8)(vii) of this 
section.
    (vi) Quail: See paragraph (d)(8)(i) of this section.
    (11) Type B and Type C liquid feeds requiring recirculation or 
agitation that contain monensin and are intended for use in cattle 
(including dairy cows) and goats shall bear the caution statement 
specified in paragraph (d)(7)(x) of this section.
    (12) Mixing directions for liquid feeds requiring recirculation or 
agitation:
    (i) For liquid feeds stored in recirculating tank systems: 
Recirculate immediately prior to use for not less than 10 minutes, 
moving not less than 1 percent of the tank contents per minute from the 
bottom of the tank to the top. Recirculate daily as described even when 
not used.
    (ii) For liquid feeds stored in mechanical, air, or other agitation-
type tank systems: Agitate immediately prior to use for not less than 10 
minutes, creating a turbulence at the bottom of the tank that is visible 
at the

[[Page 456]]

top. Agitate daily as described even when not used.
    (e) Related tolerances. See Sec. 556.420 of this chapter.
    (f) Conditions of use. It is used as follows:
    (1) Broiler chickens--(i) Amount per ton. Monensin, 90-110 grams.
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima.
    (b) Limitations. Feed only to cattle being fed in confinement for 
slaughter. Feed continuously as sole ration at the rate of 50 to 480 
milligrams of monensin and 60 to 90 milligrams of tylosin per head per 
day. Combination drug liquid Type B medicated feeds may be used to 
manufacture dry Type C medicated feeds as in Sec. 558.625(c) of this 
chapter.
    (ii) Amount per ton. Monensin, 90-110 grams, plus roxarsone 45.4 
grams (0.005 percent).
    (a) Indications for use. Growth promotion and feed efficiency, 
improving pigmentation; as an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati 
and E. maxima.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as the sole ration; withdraw 5 days before slaughter; as sole source of 
organic arsenic; as monensin or monensin sodium.
    (iii) Amount per ton. Monensin, 90-110 grams plus bacitracin, 5-25 
grams.
    (a) Indications for use. For increased rate of weight gain and 
improved feed efficiency; as an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as sole ration; in the absence of coccidiosis, the use of monensin with 
no withdrawal period may limit feed intake resulting in reduced weight 
gain; as bacitracin methylene disalicylate provided by No. 046573 in 
Sec. 510.600(c) of this chapter; as monensin sodium.
    (iv) Amount per ton. Monensin, 90-110 grams plus bacitracin, 10 
grams.
    (a) Indications for use. For increased rate of weight gain and 
improved feed efficiency; as an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as sole ration; in the absence of coccidiosis, the use of monensin with 
no withdrawal period may limit feed intake resulting in reduced weight 
gain; as zinc bacitracin provided by No. 046573 in Sec. 510.600(c) of 
this chapter; as monensin sodium.
    (v) Amount per ton. Monensin, 90-110 grams plus bacitracin, 10-30 
grams.
    (a) Indications for use. For improved feed efficiency; as an aid in 
the prevention of coccidiosis caused by E. necatrix, E. tenella, E. 
acervulina, E. brunetti, E. mivati, and E. maxima.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as sole ration; in the absence of coccidiosis, the use of monensin with 
no withdrawal period may limit feed intake resulting in reduced weight 
gain; as zinc bacitracin provided by No. 046573 in Sec. 510.600(c) of 
this chapter; as monensin sodium.
    (vi) Amount per ton. Monensin, 90 to 110 grams; plus bambermycins, 1 
to 2 grams.
    (a) Indications for use. For increased rate of weight gain and 
improved feed efficiency; and as an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella,E. acervulina, E. brunetti, E. mivati, 
and E. maxima.
    (b) Limitations. Feed continuously as sole ration; do not feed to 
laying chickens. Bambermycins provided by No. 016592 in Sec. 510.600(c) 
of this chapter.
    (vii) Amount per ton. Monensin, 90 to 110 grams; plus bambermycins, 
1 gram; plus roxarsone, 22.7 to 45.4 grams
    (a) Indications for use. For increased rate of weight gain and 
improved feed efficiency; and as an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima.
    (b) Limitations. Feed continuously as sole ration; use as sole 
source of organic arsenic; withdraw 5 d before slaughter; do not feed to 
laying chickens. Bambermycins provided by No. 016592 in Sec. 510.600(c) 
of this chapter; roxarsone provided by No. 046573.
    (viii) Amount per ton. Monensin, 90 to 110 grams plus 
oxytetracycline, 200 grams.

[[Page 457]]

    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima; and for the control of complicated chronic 
respiratory disease (CRD or air-sac infection) caused by Mycoplasma 
gallisepticum and Escherichia coli.
    (b) Limitations. In the absence of coccidiosis, the use of monensin 
with no withdrawal period may limit feed intake resulting in reduced 
weight gain; do not feed to laying chickens; feed continuously as sole 
ration; as monensin sodium.
    (ix) Amount per ton. Monensin, 90-110 grams plus lincomycin, 2 
grams.
    (a) Indications for use. For increase in rate of weight gain and 
improved feed efficiency; as an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima.
    (b) Limitations. Do not feed to laying chickens; to be fed as a sole 
ration; in the absence of coccidiosis, the use of monensin with no 
withdrawal period may limit feed intake resulting in reduced weight 
gain; as monensin sodium.
    (x) Amount per ton. Monensin, 90-110 grams plus lincomycin, 2 grams 
and roxarsone, 15-45 grams.
    (a) Indications for use. For increase in rate of weight gain; as an 
aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, 
E. acervulina, E. brunetti, E. mivati, and E. maxima.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as the sole ration; withdraw 5 days before slaughter; as sole source of 
organic arsenic; as roxarsone provided by No. 046573, Sec. 510.600(c) 
of this chapter; as monensin sodium provided by No. 000986, Sec. 
510.600(c) of this chapter; as lincomycin provided by No. 000009, Sec. 
510.600(c) of this chapter; as a combination provided by No. 000009, 
Sec. 510.600(c) of this chapter.
    (xi) Amount per ton. Monensin, 90 to 110 grams, plus lincomycin, 2 
grams and roxarsone, 15 to 30 grams.
    (a) Indications for use. For increase in rate of weight gain, 
improved feed efficiency, improved pigmentation, and as an aid in the 
prevention of coccidiosis caused by E. necatrix, E. tenella, E. 
acervulina, E. brunetti, E. mivati and E. maxima.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as the sole ration; withdraw 5 days before slaughter; as sole source of 
organic arsenic; as roxarsone provided by No. 046573 in Sec. 510.600(c) 
of this chapter; as monensin sodium provided by No. 000986 in Sec. 
510.600(c) of this chapter; as lincomycin provided by No. 000009 in 
Sec. 510.600(c) of this chapter; as a combination provided by No. 
000009 in Sec. 510.600(c) of this chapter.
    (xii) Amount per ton. Monensin, 90 to 110 grams, plus bacitracin 
methylene disalicylate, 10 to 25 grams, and roxarsone, 11.3 to 45.4 
grams.
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. 
maxima, and E. mivati; for increased rate of weight gain and for 
improved feed efficiency.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as sole ration; withdraw 5 days before slaughter; as sole source of 
organic arsenic; as monensin sodium provided by No. 000986 in Sec. 
510.600 of this chapter; as bacitracin methylene disalicylate provided 
by No. 046573 in Sec. 510.600 of this chapter; as roxarsone provided by 
No. 011526 or 046573 in Sec. 510.600 of this chapter.
    (xiii) Amount per ton. Monensin, 90 to 110 grams, plus 5 grams 
virginiamycin.
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. 
maxima, and E. mivati; for increased rate of weight gain and improved 
feed efficiency.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as sole ration; as monensin sodium provided by No. 000986 in Sec. 
510.600 of this chapter; virginiamycin provided by No. 066104 in Sec. 
510.600 of this chapter.
    (xiv) Amount per ton. Monensin, 90 to 110 grams, plus 500 grams 
chlortetracycline.
    (a) Indications for use. As an aid in the reduction of mortality due 
to Escherichia coli infections susceptible to such treatment. As an aid 
in the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, 
E. acervulina, E. brunetti, E. mivati, and E. maxima.

[[Page 458]]

    (b) Limitations. Do not feed to laying chickens; feed for 5 days as 
the sole ration; withdraw 24 hours before slaughter; in the absence of 
coccidiosis, the use of monensin with no withdrawal period may limit 
feed intake resulting in reduced weight gain; not to be fed continuously 
for more than 5 days; as monensin sodium; as chlortetracycline 
hydrochloride provided by Nos. 046573 and 048164 in Sec. 510.600(c) of 
this chapter.
    (xv) Amount per ton. Monensin, 90 to 110 grams, plus bacitracin 
zinc, 10 grams, and roxarsone, 15 grams (0.0017 percent).
    (a) Indications for use. For increase in rate of weight gain; for 
the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. 
acervulina, E. maxima, E. brunetti, and E. mivati.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as the sole ration; withdraw 5 days before slaughter; as sole source of 
organic arsenic; feed must be used within 4 weeks of manufacture; as 
monensin sodium; as bacitracin zinc provided by No. 046573 in Sec. 
510.600(c) of this chapter; as roxarsone provided by No. 046573 in Sec. 
510.600(c) of this chapter.
    (xvi) Amount per ton. Monensin, 90 to 110 grams, plus bacitracin 
zinc, 4 to 50 grams, and roxarsone, 15 to 45.4 grams (0.0017 percent to 
0.005 percent).
    (a) Indications for use. For improved feed efficiency; for improved 
pigmentation by enhancing carotenoid and xanthophyll utilization; for 
the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. 
acervulina, E. maxima, E. brunetti, and E. mivati.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as the sole ration; withdraw 5 days before slaughter; as sole source of 
organic arsenic; feed must be used within 4 weeks of manufacture; as 
monensin sodium; as bacitracin zinc provided by No. 046573 in Sec. 
510.600(c) of this chapter; as roxarsone provided by No. 046573 in Sec. 
510.600(c) of this chapter.
    (xvii) Amount per ton. Bambermycins, 1 to 2 grams plus monensin, 90 
to 110 grams plus roxarsone, 22.7 to 45.4 grams.
    (a) Indications for use. For increased rate of weight gain; and as 
an aid in prevention of coccidiosis caused by E. necatrix, E. tenella, 
E. acervulina, E. brunetti, E. mivati, and E. maxima.
    (b) Limitations. Feed continuously as sole ration; use as sole 
source of organic arsenic; withdraw 5 d before slaughter; do not feed to 
laying chickens. Bambermycins provided by No. 016592 in Sec. 510.600(c) 
of this chapter; roxarsone provided by No. 046573.
    (xviii) Amount per ton. Monensin, 90 to 110 grams, plus bacitracin 
methylene disalicylate, 50 grams, and roxarsone, 22.7 to 34.0 grams 
(0.0025 percent to .00375 percent).
    (a) Indications for use. For increase in rate of weight gain and 
improved feed efficiency; as an aid in the prevention of coccidiosis 
caused by Eimeria necatrix, E. tenella, E. acervulina, E. maxima, E. 
brunetti, and E. mivati; as an aid in the prevention of necrotic 
enteritis caused or complicated by Clostridium spp or other organisms 
susceptible to bacitracin methylene disalicylate.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as the sole ration; withdraw 5 days before slaughter; as sole source of 
organic arsenic; as monensin sodium provided by No. 000986 in Sec. 
510.600(c) of this chapter; as bacitracin methylene disalicylate 
provided by No. 046573 in Sec. 510.600(c) of this chapter; as roxarsone 
provided by No. 046573 in Sec. 510.600(c) of this chapter.
    (xix) Amount per ton. Monensin, 90 to 110 grams, plus bacitracin 
methylene disalicylate, 50 grams, and roxarsone, 22.7 to 45.4 grams 
(0.0025 percent to .005 percent).
    (a) Indications for use. For increased rate of weight gain; as an 
aid in the prevention of necrotic enteritis caused or complicated by 
Clostridium spp or other organisms susceptible to bacitracin methylene 
disalicylate; as an aid in the prevention of coccidiosis caused by 
Eimeria necatrix, E. tenella, E. acervulina, E. maxima, E. brunetti, and 
E. mivati.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as the sole ration; withdraw 5 days before slaughter; as sole source of 
organic arsenic; as monensin sodium provided by No. 000986 in Sec. 
510.600(c) of this chapter; as bacitracin methylene disalicylate 
provided by No. 046573 in Sec. 510.600(c) of this

[[Page 459]]

chapter; as roxarsone provided by No. 046573 in Sec. 510.600(c) of this 
chapter.
    (xx) Amount per ton. Monensin, 90 to 110 grams, plus virginiamycin, 
5 to 15 grams, and roxarsone, 22.7 grams (0.0025 percent).
    (a) Indications for use. For incease in rate of weight gain; as an 
aid in the prevention of coccidiosis caused by Eimeria necatrix, E. 
tenella, E. acervulina, E. maxima, E. brunetti, and E. mivati.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as the sole ration; withdraw 5 days before slaughter; as sole source of 
organic arsenic; as monensin sodium provided by No. 000986 in Sec. 
510.600(c) of this chapter; as virginiamycin provided by No. 066104 in 
Sec. 510.600(c) of this chapter; roxarsone provided by Nos. 046753 and 
011526 in Sec. 510.600(c) of this chapter.
    (xxi) Amount per ton. Monensin, 90 to 110 grams, plus virginiamycin, 
5 to 15 grams.
    (a) Indications for use. For increase in rate of weight gain; as an 
aid in the prevention of coccidiosis caused by Eimeria necatrix, E. 
tenella, E. acervulina, E. maxima, E. brunetti, and E. mivati.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as sole ration; as monensin sodium provided by No. 000986 in Sec. 
510.600 of this chapter; virginiamycin provided by No. 066104 in Sec. 
510.600 of this chapter.
    (xxii) Amount per ton. Monensin, 90 to 110 grams plus 
oxytetracycline, 500 grams.
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. 
Mivati, and E. maxima; as an aid in the reduction of mortality due to 
air-sacculities (air-sac infection) caused by Escherichia coli sensitive 
to oxytetracycline.
    (b) Limitations. Feed for 5 days as sole ration. Do not feed to 
laying chickens. Withdraw 24 hours before slaughter. As monensin sodium 
provided by No. 000986 in Sec. 510.600(c) of this chapter. As mono-
alkyl (C8-C18) trimethylammonium oxytetracycline 
provided by No. 066104 in Sec. 510.600(c) of this chapter.
    (xxiii) Amount per ton. Monensin, 90 to 110 grams, plus bacitracin 
zinc, 4 to 50 grams, and roxarsone, 22.7 to 45.4 grams (0.0025 percent 
to 0.005 percent).
    (a) Indications for use. For improved feed efficiency; as an aid in 
the prevention of coccidiosis caused by Eimeria necatrix, E. tenella, E. 
acervulina, E. maxima, E. brunetti, and E. mivati.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as the sole ration; withdraw 5 days before slaughter; as sole source of 
organic arsenic; as monensin sodium provided by No. 000986 in Sec. 
510.600(c) of this chapter; as bacitracin zinc provided by No. 046573 in 
Sec. 510.600(c) of this chapter; as roxarsone provided by No. 046573 in 
Sec. 510.600(c) of this chapter.
    (xxiv) Amount per ton. Monensin, 90 to 110 grams, plus bacitracin 
methylene disalicylate, 4 to 50 grams.
    (xxv) Amount per ton. Monensin, 90 to 110 grams plus bacitracin, 4 
to 50 grams.
    (a) Indications for use. For increased rate of weight gain and 
improved feed efficiency; as an aid in the prevention of coccidiosis 
caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima.
    (b) Limitations. Do not feed to laying chickens; feed continuously 
as sole ration; in the absence of coccidiosis, the use of monensin with 
no withdrawal period may limit feed intake resulting in reduced weight 
gain; as bacitracin zinc provided by No. 046573 in Sec. 510.600(c) of 
this chapter, as monensin sodium.
    (xxvi) Amount per ton. Monensin 90 to 110 grams plus bacitracin 100 
to 200 grams and roxarsone 22.7 to 34.0 grams.
    (a) Indications for use. As an aid in the control of necrotic 
enteritis caused or complicated by Clostridium spp. or other organisms 
susceptible to bacitracin methylene disalicylate; as an aid in the 
prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. 
acervulina, E. maxima, E. brunetti, and E. mivati; for increased rate of 
weight gain and improved feed efficiency.
    (b) Limitations. For broiler chickens only. Feed continuously as 
sole ration. Use as sole source of organic arsenic. Withdraw 5 days 
before slaughter. Do not feed to laying hens. To control necrotic 
enteritis, start medication at

[[Page 460]]

first clinical signs of disease. The dosage range permitted provides for 
different levels based on the severity of infection. Use continuously 
for 5 to 7 days or as long as clinical signs persist, then reduce dosage 
to prevention level. Animals should have access to drinking water at all 
times. Drug overdosage or lack of water may result in leg weakness. As 
roxarsone and bacitracin methylene disalicylate provided by No. 046573 
in Sec. 510.600(c) of this chapter.
    (xxvii) Amount per ton. Monensin 90 to 110 grams plus bacitracin 100 
to 200 grams and roxarsone 22.7 to 45.4 grams.
    (a) Indications for use. As an aid in the control of necrotic 
enteritis caused or complicated by Clostridium spp. or other organisms 
susceptible to bacitracin methylene disalicylate; as an aid in the 
prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. 
acervulina, E. maxima, E. brunetti, and E. mivati; for increased rate of 
weight gain.
    (b) Limitations. For broiler chickens only. Feed continuously as 
sole ration. Use as sole source of organic arsenic. Withdraw 5 days 
before slaughter. Do not feed to laying hens. To control necrotic 
enteritis, start medication at first clinical signs of disease. The 
dosage range permitted provides for different levels based on the 
severity of infection. Use continuously for 5 to 7 days or as long as 
clinical signs persist, then reduce dosage to prevention level. Animals 
should have access to drinking water at all times. Drug overdosage or 
lack of water may result in leg weakness. As roxarsone and bacitracin 
methylene disalicylate provided by No. 046573 in Sec. 510.600(c) of 
this chapter.
    (xxviii) Amount per ton. Monensin, 90 to 110 grams, plus tylosin 
phosphate, 4 to 50 grams.
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima, for increased rate of weight gain, and improved 
feed efficiency.
    (b) Limitations. Feed continuously as sole ration. In the absence of 
coccidiosis, the use of monensin with no withdrawal period may limit 
feed intake resulting in reduced weight gain. Do not feed to laying 
chickens. As monensin sodium and tylosin phosphate provided by No. 
000986 in Sec. 510.600(c) of this chapter.
    (xxix) Amount per ton. Monensin, 90 to 110 grams; plus bacitracin 
methylene disalicylate, 50 grams.
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima; and as an aid in the prevention of necrotic 
enteritis caused or complicated by Clostridium spp. or other organisms 
susceptible to bacitracin.
    (b) Limitations. Feed continuously as sole ration. Do not feed to 
chickens over 16 weeks of age. Do not feed to laying chickens. As 
monensin sodium provided by 000986; bacitracin methylene disalicylate as 
provided by 046573 in Sec. 510.600(c) of this chapter.
    (xxx) Amount per ton. Monensin, 90 to 110 grams; plus bacitracin 
methylene disalicylate, 100 to 200 grams.
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima; and as an aid in the control of necrotic 
enteritis caused or complicated by Clostridium spp. or other organisms 
susceptible to bacitracin.
    (b) Limitations. Feed continuously as sole ration. Do not feed to 
chickens over 16 weeks of age. Do not feed to laying chickens. To 
control necrotic enteritis, start medication at first clinical signs of 
disease; vary dosage based on the severity of infection; administer 
continuously for 5 to 7 days or as long as clinical signs persist, then 
reduce bacitracin to prevention level (50 grams per ton). As monensin 
sodium provided by 000986; bacitracin methylene disalicylate as provided 
by 046573 in Sec. 510.600(c) of this chapter.
    (2) Turkeys--(i) Amount per ton. Monensin, 54 to 90 grams.
    (a) Indications for use. For the prevention of coccidiosis in 
turkeys caused by E. adenoeides, E. meleagrimitis, and E. gallopavonis.
    (b) Limitations. For growing turkeys only; as monensin sodium; feed 
continuously as sole ration. Do not allow horses, other equines, mature 
turkeys, or guinea fowl access to feed containing monensin. Ingestion of 
monensin by horses and guinea fowl has been fatal. Some strains of 
turkey

[[Page 461]]

coccidia may be monensin tolerant or resistant. Monensin may interfere 
with development of immunity to turkey coccidiosis.
    (ii) Amount per ton. Monensin, 54 to 90 grams, and bacitracin 
methylene disalicylate, 4 to 50 grams.
    (a) Indications for use. For prevention of coccidiosis caused by 
Eimeria adenoeides, E. meleagrimitis, and E. gallopavonis, for increased 
rate of weight gain, and for improved feed efficiency.
    (b) Limitations. For growing turkeys only; as monensin sodium; feed 
continuously as sole ration. Do not allow horses, other equines, mature 
turkeys or guinea fowl access to feed containing monensin. Ingestion of 
monensin by horses and guinea fowl has been fatal. Some strains of 
turkey coccidia may be monensin tolerant or resistant. Monensin may 
interfere with development of immunity to turkey coccidiosis. Bacitracin 
methylene disalicylate as provided by No. 046573 in Sec. 510.600(c) of 
this chapter.
    (iii) Amount per ton. Monensin, 54 to 90 grams, and bacitracin 
methylene disalicylate, 200 grams.
    (a) Indications for use. For the prevention of coccidiosis caused by 
Eimeria adenoides, E. meleagrimitis, and E. gallopavonis, and as an aid 
in the control of transmissible enteritis complicated by organisms 
susceptible to bacitracin methylene disalicylate.
    (b) Limitations. For growing turkeys only; as monensin sodium; feed 
continuously as sole ration. Do not allow horses, other equines, mature 
turkeys or guinea fowl access to feed containing monensin. Ingestion of 
monensin by horses and guinea fowl has been fatal. Some strains of 
turkey coccidia may be monensin tolerant or resistant. Monensin may 
interfere with development of immunity to turkey coccidiosis. Bacitracin 
methylene disalicylate as provided by No. 046573 in Sec. 510.600(c) of 
this chapter.
    (iv) Amount per ton. Monensin, 54 to 90 grams, with virginiamycin, 
10 to 20 grams.
    (a) Indications for use. For the prevention of coccidiosis caused by 
Eimeria adenoeides, E. meleagrimitis, and E. gallopavonis, and for 
increased rate of weight gain and improved feed efficiency in growing 
turkeys.
    (b) Limitations. For growing turkeys only. Feed continuously as sole 
ration. Do not allow horses, other equines, mature turkeys, or guinea 
fowl access to feed containing monensin. Ingestion of monensin by 
horses, mature turkeys, and guinea fowl has been fatal. Some strains of 
turkey coccidia may be monensin tolerant or resistant. Monensin may 
interfere with development of immunity to turkey coccidiosis. 
Virginiamycin as provided by No. 066104 in Sec. 510.600(c) of this 
chapter.
    (v) Amount per ton. Monensin, 54 to 90 grams, plus bambermycins, 1 
to 2 grams.
    (a) Indications for use. For the prevention of coccidiosis in 
turkeys caused by E. adenoeides, E. meleagrimitis, and E. gallopavonis, 
and for improved feed efficiency in growing turkeys.
    (b) Limitations. For growing turkeys only. Feed continuously as sole 
ration. Some strains of turkey coccidia may be monensin tolerant or 
resistant. Monensin may interfere with development of immunity to turkey 
coccidiosis. Bambermycins as provided by No. 016592 in Sec. 510.600(c) 
of this chapter.
    (vi) Amount per ton. Monensin, 54 to 90 grams, plus bambermycins, 2 
grams.
    (a) Indications for use. For the prevention of coccidiosis in 
turkeys caused by E. adenoeides, E. meleagrimitis, and E. gallopavonis, 
and for increased rate of weight gain and improved feed efficiency in 
growing turkeys.
    (b) Limitations. For growing turkeys only. Feed continuously as sole 
ration. Some strains of turkey coccidia may be monensin tolerant or 
resistant. Monensin may interfere with development of immunity to turkey 
coccidiosis. Bambermycins as provided by No. 016592 in Sec. 510.600(c) 
of this chapter.
    (3) Cattle--(i) Amount per ton. Monensin, 5-40 grams.
    (a) Indications for use. Improved feed efficiency.
    (b) Limitations. (1) Feed only to cattle being fed in confinement 
for slaughter. Feed continuously in complete feed at a rate of 50 to 480 
milligrams of monensin per head per day. No additional improvement in 
feed efficiency has been shown from feeding monensin at levels greater 
than 30 grams per ton

[[Page 462]]

(360 milligrams per head per day). Complete feeds may be manufactured 
from monensin liquid Type B feeds. The liquid Type B feeds have a pH of 
4.3 to 7.1 and their labels must bear appropriate mixing directions as 
defined in paragraph (d)(12) of this section. The liquid feed must bear 
caution statement as follows: Inadequate mixing, (recirculation or 
agitation), of liquid feeds has resulted in increased monensin 
concentration which has been fatal to cattle.
    (2) An approved physically stable monensin liquid feed will not be 
subject to the requirements for mixing directions defined in paragraph 
(d)(12) of this section. A manufacturer may secure approval of a 
physically stable liquid feed by:
    (i) Either filing an NADA for the product or by establishing a 
master file containing data to support the stability of its product;
    (ii) Authorizing the agency to reference and rely upon the data in 
the master file to support approval of a supplemental NADA to establish 
physical stability; and
    (iii) Requesting No. 000986 in Sec. 510.600(c) of this chapter to 
file a supplemental NADA to provide for the use of its monensin Type A 
article in the manufacture of the liquid feed specified in the 
appropriate master file. If the data demonstrate the stability of the 
liquid feed described in the master file, the agency will approve the 
supplemental NADA. The approval will provide a basis for the individual 
liquid feed manufacturer to manufacture the liquid medicated feed under 
a medicated feed mill license described in the master file. A 
manufacturer who seeks to market a physically unstable monensin liquid 
feed with mixing directions different from the standard established in 
paragraph (d)(12) of this section may also follow this procedure.
    (ii) Amount per ton. Monensin, 5 to 40 grams; plus tylosin, 8 to 10 
grams.
    (a) Indications for use. Cattle fed in confinement for slaughter: 
For improved feed efficiency; and reduction of incidence of liver 
abscesses caused by Fusobacterium necrophorum and Arcanobacterium 
(Actinomyces) pyogenes.
    (b) Limitations. Feed only to cattle being fed in confinement for 
slaughter. Feed continuously as sole ration at the rate of 50 to 480 
milligrams of monensin and 60 to 90 milligrams of tylosin per head per 
day. Combination drug liquid Type B medicated feeds may be used to 
manufacture dry Type C medicated feeds and shall conform to mixing 
instructions as in 558.625(c) of this chapter.
    (iii) Amount per ton. Monensin, 25 to 400 grams.
    (a) Indications for use. Growing cattle on pasture or in dry lot 
(stocker and feeder cattle and dairy and beef replacement heifers): For 
increased rate of weight gain; for prevention and control of coccidiosis 
due to Eimeria bovis and E. zuernii.
    (b) Limitations. For increased rate of weight gain, feed at a rate 
of 50 to 200 milligrams monensin per head per day in not less than 1 
pound of feed or, after the 5th day, feed at a rate of 400 milligrams 
per head per day every other day in not less than 2 pounds of feed. For 
prevention and control of coccidiosis, feed at a rate of 0.14 to 0.42 
milligram per pound of body weight per day, depending on severity of 
challenge, up to 200 milligrams per head per day. During first 5 days of 
feeding, cattle should receive no more than 100 milligrams per day in 
not less than 1 pound of feed.
    (iv) Amount. Monensin at concentrations in free-choice Type C 
medicated feeds to provide 50 to 200 mg per head per day.
    (a) Indications for use. Growing cattle on pasture or in dry lot 
(stocker and feeder cattle and dairy and beef replacement heifers): For 
increased rate of weight gain; for prevention and control of coccidiosis 
due to Eimeria bovis and E. zuernii.
    (b) Limitations. During the first 5 days of feeding, cattle should 
receive no more than 100 milligrams per day. Do not feed additional salt 
or minerals. Do not mix with grain or other feeds. Monensin is toxic to 
cattle when consumed at higher than approved levels. Stressed and/or 
feed- and/or water-deprived cattle should be adapted to the pasture and 
to unmedicated supplement before using the monensin medicated 
supplement. The product's effectiveness in cull cows and bulls has not 
been established. See paragraph (d) of

[[Page 463]]

this section for other required label warnings.
    (v) [Reserved]
    (vi) Amount per ton. Monensin, 25 to 400 grams.
    (a) Indications for use. For improved feed efficiency; for 
prevention and control of coccidiosis due to E. bovis and E. zuernii.
    (b) Limitations. Feed to mature reproducing beef cows. Feed as 
supplemental feed, either hand-fed in a minimum of 1 pound of feed or 
mixed in a total ration. For improved feed efficiency, feed continuously 
at a rate of 50 to 200 milligrams monensin per head per day. For 
prevention and control of coccidiosis, feed at a rate of 0.14 to 0.42 
milligram per pound of body weight per day, depending upon severity of 
challenge, up to a maximum of 200 milligrams per head per day. During 
first 5 days of feeding, cattle should receive no more than 100 
milligrams per head per day.
    (vii) Amount per ton. Monensin, 10 to 40 grams.
    (a) Indications for use. For prevention and control of coccidiosis 
due to E. bovis and E. zuernii.
    (b) Limitations. For cattle fed in confinement for slaughter, feed 
at a rate of 0.14 to 0.42 milligram per pound of body weight per day, 
depending upon the severity of challenge, up to maximum of 480 
milligrams per head per day.
    (ix) Amount. To 000986: To make liquid Type B medicated feed 
containing 400 grams per ton monensin sodium with 150 grams per ton 
tylosin phosphate used to make a dry Type C medicated feed containing 
21.4 to 26.8 grams per ton monensin plus 8 to 10 grams per ton tylosin.
    (a) Indications for use. Improved feed efficiency; for reduction of 
incidence of liver abscesses caused by Fusobacterium necrophorum and 
Actinomyces (Corynebacterium) pyogenes.
    (b) Limitations. Feed only to cattle being fed in confinement for 
slaughter. Feed continuously at the rate of 8.2 to 10.2 kilograms (18 to 
22.5 pounds) of Type C medicated feed per head per day to supply 240 
milligrams of monensin and 90 milligrams of tylosin per head per day; as 
monensin sodium; as tylosin phosphate. Do not allow horses or other 
equines access to feeds containing monensin. Ingestion of monensin by 
equines has been fatal. Safe use in unapproved species and breeding 
cattle has not been established. The liquid medicated feed must bear 
expiration date of 14 days after date of manufacture. The mixing 
directions for this liquid medicated feed stored in recirculation or 
agitation tank systems are as defined in paragraph (d)(12) of this 
section.
    (x) Amount per ton. 1,620 grams monensin, USP.
    (a) Indications for use. Growing cattle on pasture or in dry lot 
(stocker and feeder cattle and dairy and beef replacement heifers): For 
increased rate of weight gain; for prevention and control of coccidiosis 
due to Eimeria bovis and E. zuernii.
    (b) Specifications. Use as free-choice Type C medicated feed 
formulated as mineral granules as follows:

------------------------------------------------------------------------
                                                      International feed
           Ingredient                   Percent               No.
------------------------------------------------------------------------
Monocalcium phosphate (21%                     29.49            6-01-082
 phosphorus, 15% calcium).......
Sodium chloride (salt)..........               24.37            6-04-152
Dried cane molasses.............               20.0             4-04-695
Ground limestone (33% calcium)                 13.75            6-02-632
 or calcium carbonate (38%
 calcium).......................
Cane molasses...................                3.0             4-04-696
Processed grain by-products (as                 5.0
 approved by AAFCO).............
Vitamin/trace mineral premix \1\                2.5
Monensin Type A article, 90.7                   0.89
 grams per pound................
Antidusting oil.................                1.0
------------------------------------------------------------------------
\1\ Content of the vitamin/trace mineral premix may be varied. However,
  they should be comparable to those used for other free-choice feeds.
  Formulation modifications require FDA approval prior to marketing. The
  amount of selenium and ethylenediamine dihydroiodide (EDDI) must
  comply with the published requirements. (For selenium see 21 CFR
  573.920; for EDDI see 51 FR 11483 (April 3, 1986).)

    (c) Limitations. Feed at a rate of 50 to 200 milligrams per head per 
day. During the first 5 days of feeding, cattle should receive no more 
than 100 milligrams per day. Do not feed additional salt or minerals. Do 
not mix with grain

[[Page 464]]

or other feeds. Monensin is toxic to cattle when consumed at higher than 
approved levels. Stressed and/or feed- and/or water-deprived cattle 
should be adapted to the pasture and to unmedicated mineral supplement 
before using the monensin mineral supplement. The product's 
effectiveness in cull cows and bulls has not been established.
    (xi) Amount per ton. Monensin, 10 to 200 grams.
    (a) Indications for use. For prevention and control of coccidiosis 
due to E. bovis and E. zuernii.
    (b) Limitations. For calves excluding veal calves. Feed at a rate of 
0.14 to 1.0 milligram monensin per pound of body weight per day, 
depending upon the severity of challenge, up to maximum of 200 
milligrams per head per day.
    (xii) Amount per ton. Monensin, 10 to 40 grams; plus tylosin, 8 to 
10 grams.
    (a) Indications for use. Cattle fed in confinement for slaughter: 
For prevention and control of coccidiosis due to E. bovis and E. 
zuernii; and reduction of incidence of liver abscesses caused by 
Fusobacterium necrophorum and Arcanobacterium (Actinomyces) pyogenes.
    (b) Limitations. Feed only to cattle being fed in confinement for 
slaughter. For prevention and control of coccidiosis, feed at a rate of 
0.14 to 0.42 milligrams monensin per pound of body weight per day, 
depending upon the severity of challenge, up to maximum of 480 
milligrams per head per day; and 60 to 90 milligrams of tylosin per head 
per day.
    (xiii) Amount per ton. Monensin, 11 to 22 grams.
    (A) Indications for use. For increased milk production efficiency 
(production of marketable solids-corrected milk per unit of feed intake) 
in dairy cows.
    (B) Limitations. Feed continuously to dry and lactating dairy cows 
in a total mixed ration (``complete feed''). See special labeling 
considerations in paragraph (d) of this section.
    (xiv) Amount per ton. Monensin, 11 to 400 grams.
    (A) Indications for use. For increased milk production efficiency 
(production of marketable solids-corrected milk per unit of feed intake) 
in dairy cows.
    (B) Limitations. Feed continuously to dry and lactating dairy cows 
in a component feeding system (including top dress). The Type C 
medicated feed must be fed in a minimum of 1 lb of feed to provide 185 
to 660 mg/head/day monensin to lactating cows or 115 to 410 mg/head/day 
monensin to dry cows. See special labeling considerations in paragraph 
(d) of this section.
    (4) Replacement chickens intended for use as cage layers--(i) Amount 
per ton. Monensin, 90 to 110 grams.
    (i)(a) Indications for use. As an aid in the prevention of 
coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. 
brunetti, E. mivati, and E. maxima.
    (ii) Amount per ton. Monensin, 90 to 110 grams; plus bacitracin 
methylene disalicylate, 4 to 50 grams.
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima; for increased rate of weight gain, and improved 
feed efficiency.
    (b) Limitations. Feed continuously as sole ration. Do not feed to 
chickens over 16 weeks of age. Do not feed to laying chickens. As 
monensin sodium provided by 000986; bacitracin methylene disalicylate as 
provided by 046573 in Sec. 510.600(c) of this chapter.
    (iii) Amount per ton. Monensin, 90 to 110 grams; plus bacitracin 
methylene disalicylate, 50 grams.
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima; and as an aid in the prevention of necrotic 
enteritis caused or complicated by Clostridium spp. or other organisms 
susceptible to bacitracin.
    (b) Limitations. Feed continuously as sole ration. Do not feed to 
chickens over 16 weeks of age. Do not feed to laying chickens. As 
monensin sodium provided by 000986; bacitracin methylene disalicylate as 
provided by 046573 in Sec. 510.600(c) of this chapter.
    (iv) Limitations. Do not feed to laying chickens; feed continuously 
as sole ration; as monensin sodium; do not feed to chickens over 16 
weeks of age.
    (v) Amount per ton. Monensin, 90 to 110 grams; plus bacitracin 
methylene disalicylate, 100 to 200 grams.
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella, E. acervulina, E.

[[Page 465]]

brunetti, E. mivati, and E. maxima; and as an aid in the control of 
necrotic enteritis caused or complicated by Clostridium spp. or other 
organisms susceptible to bacitracin.
    (b) Limitations. Feed continuously as sole ration. Do not feed to 
chickens over 16 weeks of age. Do not feed to laying chickens. To 
control necrotic enteritis, start medication at first clinical signs of 
disease; vary dosage based on the severity of infection; administer 
continuously for 5 to 7 days or as long as clinical signs persist, then 
reduce bacitracin to prevention level (50 grams per ton). As monensin 
sodium provided by 000986; bacitracin methylene disalicylate as provided 
by 046573 in Sec. 510.600(c) of this chapter.
    (vi) Amount per ton. Monensin, 90 to 110 grams; bacitracin methylene 
disalicylate, 50 grams; plus roxarsone, 22.7 to 45.4 grams.
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima; as an aid in the prevention of necrotic enteritis 
caused or complicated by Clostridium spp. or other organisms susceptible 
to bacitracin; and for increased rate of weight gain, improved feed 
efficiency, and improved pigmentation.
    (b) Limitations. Feed continuously as sole ration. Do not feed to 
laying chickens. Use as sole source of organic arsenic. Do not feed to 
chickens over 16 weeks of age. Poultry should have access to drinking 
water at all times. Drug overdosage or lack of water may result in leg 
weakness or paralysis. Withdraw 5 days before slaughter. As monensin 
sodium provided by 000986; bacitracin methylene disalicylate and 
roxarsone as provided by 046573 in Sec. 510.600(c) of this chapter.
    (vii) Amount per ton. Monensin, 90 to 110 grams; bacitracin 
methylene disalicylate, 100 to 200 grams; plus roxarsone, 22.7 to 45.4 
grams.
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima; as an aid in the control of necrotic enteritis 
caused or complicated by Clostridium spp. or other organisms susceptible 
to bacitracin; and for increased rate of weight gain, improved feed 
efficiency, and improved pigmentation.
    (b) Limitations. Feed continuously as sole ration. To control 
necrotic enteritis, start medication at first clinical signs of disease; 
vary bacitracin dosage based on the severity of infection; administer 
continuously for 5 to 7 days or as long as clinical signs persist, then 
reduce bacitracin to prevention level (50 grams/ton). Do not feed to 
laying chickens. Use as sole source of organic arsenic. Do not feed to 
chickens over 16 weeks of age. Poultry should have access to drinking 
water at all times. Drug overdosage or lack of water may result in leg 
weakness or paralysis. Withdraw 5 days before slaughter. As monensin 
sodium provided by 000986; bacitracin methylene disalicylate and 
roxarsone as provided by 046573 in Sec. 510.600(c) of this chapter.
    (iv) Amount per ton. Monensin, 90 to 110 grams, plus roxarsone, 22.7 
to 45.4 grams.
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima, and for increased rate of weight gain, improved 
feed efficiency, and improved pigmentation.
    (b) Limitations. Feed continuously as sole ration. Use as sole 
source of organic arsenic. Withdraw 5 days before slaughter. Do not feed 
to laying chickens. Do not feed to chickens over 16 weeks of age. 
Poultry should have access to drinking water at all times. Drug 
overdosage or lack of water may result in leg weakness or paralysis. As 
monensin sodium provided by 000986; roxarsone as provided by 046573 in 
Sec. 510.600(c) of this chapter.
    (5) Bobwhite quail--(i) Amount per ton. Monensin, 73 grams.
    (ii) Indications for use. For the prevention of coccidiosis in 
growing bobwhite quail caused by Eimeria dispersa and E. Lettyae.
    (iii) Limitations. Feed continuously as the sole ration; do not 
allow horses, other equines, mature turkeys, or guinea fowl access to 
feed containing monensin.
    (6) Goats--(i) Amount per ton. Monensin, 20 grams.
    (a) Indications for use. For the prevention of coccidiosis caused by 
Eimeria

[[Page 466]]

crandallis, E. christenseni, and E. ninakohlyakimovae.
    (b) Limitations. (1) Feed continuously. Feed only to goats being fed 
in confinement. Do not feed to lactating goats. Type C feeds may be 
manufactured from monensin liquid Type B feeds. The liquid Type B feeds 
have a pH of 4.3 to 7.1 and their labels must bear appropriate mixing 
directions, as defined in paragraph (d)(12) of this section. See special 
labeling considerations in paragraph (d) of this section.
    (2) An approved physically stable monensin liquid feed will not be 
subject to the requirements for mixing directions defined in paragraph 
(d)12) of this section. A manufacturer may secure approval of a 
physically stable liquid feed by:
    (i) Either filing an NADA for the product or by establishing a 
master file containing data to support the stability of its product;
    (ii) Authorizing the agency to reference and rely upon the data in 
the master file to support approval of a supplemental NADA to establish 
physical stability; and
    (iii) Requesting No. 000986 in Sec. 510.600(c) of this chapter to 
file a supplemental NADA to provide for the use of its monensin Type A 
article in the manufacture of the liquid feed specified in the 
appropriate master file. If the data demonstrate the stability of the 
liquid feed described in the master file, the agency will approve the 
supplemental NADA. The approval will provide a basis for the individual 
liquid feed manufacturer to manufacture the liquid medicated feed under 
a medicated feed mill license described in the master file. A 
manufacturer who seeks to market a physically unstable monensin liquid 
feed with mixing directions different from the standard established in 
paragraph (d)(12) of this section may also follow this procedure.
    (ii) [Reserved]
    (7) Free-choice feeds--(i) Amount. 150 milligrams per pound of 
protein-mineral block (0.033 percent).
    (a) [Reserved]
    (b) Conditions of use--(1) Indications for use. For increased rate 
of weight gain; and for prevention and control of coccidiosis caused by 
Eimeria bovis and E. zuernii in pasture cattle (slaughter, stocker, 
feeder, and dairy and beef replacement heifers) which may require 
supplemental feed.
    (2) Limitations. Provide 50 to 200 milligrams of monensin (0.34 to 
1.33 pounds of block) per head per day, at least 1 block per 10 to 12 
head of cattle. Roughage must be available at all times. Do not allow 
animals access to other protein blocks, salt or mineral, while being fed 
this product. The effectiveness of this block in cull cows and bulls has 
not been established. See paragraph (d)(10)(i) of this section.
    (ii) Amount. 400 milligrams per pound of protein-mineral block 
(0.088 percent).
    (a) Sponsor. See No. 067949 in Sec. 510.600(c) of this chapter.
    (b) Conditions of use--(1) Indications for use. For increased rate 
of weight gain in pasture cattle (slaughter, stocker, feeder, and dairy 
and beef replacement heifers).
    (2) Limitations. Provide 80 to 200 milligrams of monensin (0.2 to 
0.5 pounds of block) per head per day, at least 1 block per 5 head of 
cattle. Feed blocks continuously. Do not feed salt or minerals 
containing salt. The effectiveness of this block in cull cows and bulls 
has not been established. See paragraph (d)(10)(i) of this section.
    (iii) Amount. 175 milligrams per pound of protein-mineral block 
(0.038 percent).
    (a) Sponsor. See No. 066071 in Sec. 510.600(c) of this chapter.
    (b) Conditions of use--(1) Indications for use. For increased rate 
of weight gain in pasture cattle (slaughter, stocker, and feeder).
    (2) Limitations. Provide 40 to 200 milligrams of monensin (0.25 to 
1.13 pounds or 4 to 18 ounces of block) per head per day, at least 1 
block per 4 head of cattle. Do not allow cattle access to salt or 
mineral while being fed this product. Ingestion by cattle of monensin at 
levels of 600 milligrams per head per day and higher has been fatal. The 
effectiveness of this block in cull cows and bulls has not been 
established. See paragraph (d)(10)(i) of this section.
    (iv) Amount. 400 milligrams per pound of block (0.088 percent).
    (a) Sponsor. See No. 051267 in Sec. 510.600(c) of this chapter.

[[Page 467]]

    (b) Conditions of use--(1) Indications for use. For increased rate 
of weight gain in pasture cattle (slaughter, stocker, feeder, and dairy 
and beef replacement heifers).
    (2) Limitations. Provide 50 to 200 milligrams of monensin (2 to 8 
ounces of block) per head per day, at least 1 block per 5 head of 
cattle. Feed blocks continuously. Do not feed salt or mineral 
supplements in addition to the blocks. Ingestion by cattle of monensin 
at levels of 600 milligrams per head per day and higher has been fatal. 
The effectiveness of this block in cull cows and bulls has not been 
established. See paragraph (d)(10)(i) of this section.
    (8) Monensin may also be used in combination with:
    (i) Decoquinate alone or with tylosin as in Sec. 558.195.
    (ii) Melengestrol acetate alone or with tylosin as in Sec. 558.342.
    (iii) Ractopamine alone or in combination as in Sec. 558.500.
    (iv) Tilmicosin alone or in combination as in Sec. 558.618.
    (v) Zilpaterol alone or in combination as in Sec. 558.665.

[40 FR 13959, Mar. 27, 1975]

    Editorial Note: For Federal Register citations affecting Sec. 
558.355, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.360  Morantel tartrate.

    (a) Approvals. Type A medicated articles: 88 grams per pound to 
066104 in Sec. 510.600(c) of this chapter.
    (b) Related tolerances. See Sec. 556.425 of this chapter.
    (c) Special considerations. (1) Do not use in Type B or Type C 
medicated feeds containing bentonite.
    (2) Consult your veterinarian before using in severely debilitated 
animals and for assistance in the diagnosis, treatment, and control of 
parasitism.
    (d) Conditions of use--(1) Amount. 0.44 to 4.4 grams of morantel 
tartrate per pound of feed.
    (2) Indications for use--(i) Cattle. For removal and control of 
mature gastrointestinal nematode infections of cattle including stomach 
worms (Haemonchus spp., Ostertagia spp., Trichostrongylus spp.), worms 
of the small intestine (Cooperia spp., Trichostrongylus spp., 
Nematodirus spp.), and worms of the large intestine (Oesophagostomum 
radiatum).
    (ii) Goats. For removal and control of mature gastrointestinal 
nematode infections of goats including Haemonchus contortus, Ostertagia 
(Teladorsagia) circumcincta, and Trichostrongylus axei.
    (3) Limitations. Feed as a single therapeutic treatment at 0.44 gram 
of morantel tartrate per 100 pounds of body weight. Fresh water should 
be available at all times. When medicated feed is consumed, resume 
normal feeding. Conditions of constant worm exposure may require 
retreatment in 2 to 4 weeks. Do not treat cattle within 14 days of 
slaughter; do not treat goats within 30 days of slaughter.

[46 FR 50950, Oct. 16, 1981, as amended at 47 FR 53352, Nov. 26, 1982; 
51 FR 7399, Mar. 3, 1986; 51 FR 9005, Mar. 17, 1986; 52 FR 11642, Apr. 
10, 1987; 59 FR 17922, Apr. 15, 1994; 66 FR 47963, Sept. 17, 2001]



Sec. 558.363  Narasin.

    (a) Approvals. Type A medicated articles containing specified levels 
of narasin approved for sponsors identified in Sec. 510.600(c) of this 
chapter for use as in paragraph (d) of this section are as follows:
    (1) To 000986: 36, 45, 54, 72, and 90 grams per pound, paragraph 
(d)(1)(i) of this section.
    (2) To 000986: 36, 45, 54, 72, and 90 grams per pound, with 10, 20, 
50, and 80 percent roxarsone, paragraph (d)(1)(ii) of this section.
    (3) To 000986: 36 grams per pound, with 36 grams per pound 
nicarbazin, paragraph (d)(1)(iii) of this section.
    (4) To 016592: 36, 45, 54, 72, and 90 grams per pound, with 2 and 10 
grams per pound bambermycins, paragraph (d)(1)(iv) of this section.
    (5) To 016592: 45 grams per pound, with 4 and 10 grams per pound 
bambermycins, and 45.4, 90, and 227 grams per pound roxarsone, paragraph 
(d)(1)(vii) of this section.
    (6) To 046573: 45 grams per pound with 10, 25, 30, 40, 50, 60, or 75 
grams per pound bacitracin methylene disalicylate and 45.4, 90, or 227 
grams per pound roxarsone, paragraphs (d)(1)(viii) and (d)(1)(ix) of 
this section.
    (7) To 046573: 36, 45, 54, 72, or 90 grams per pound, with 10, 25, 
40, or 50 grams

[[Page 468]]

per pound bacitracin zinc, paragraph (d)(1)(x) of this section.
    (8) To 000986: 45.4 grams per pound for use as in paragraph (d)(2) 
of this section.
    (b) Tolerances. See Sec. 556.428 of this chapter.
    (c) Special considerations. An expiration date of 2 months (8 weeks) 
is required for narasin Type C medicated swine feeds.
    (d) Conditions of use. It is used as follows:
    (1) Broiler chickens--(i) Amount per ton. Narasin, 54 to 90 grams.
    (A) Indications for use. For prevention of coccidiosis caused by 
Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and 
E. maxima.
    (B) Limitations. For broiler chickens only. Feed continuously as 
sole ration. Do not allow adult turkeys, horses, or other equines access 
to narasin formulations. Ingestion of narasin by these species has been 
fatal.
    (ii) Amount per ton. Narasin, 54 to 72 grams, plus roxarsone 45.4 
grams (0.005 percent).
    (A) Indications for use. For the prevention of coccidiosis in 
broiler chickens caused by Eimeria tenella, E. necatrix, E. acervulina, 
E. maxima, E. brunetti, and E. mivati including some field strains of E. 
tenella which are more susceptible to roxarsone combined with narasin 
than to narasin alone.
    (B) Limitations. For broiler chickens only; feed continuously as the 
sole ration; do not feed to laying chickens; may be fatal if 
accidentally fed to adult turkeys or to horses; withdraw 5 days before 
slaughter; as sole source of organic arsenic; not approved for use with 
pellet binders.
    (iii) Amount per ton. Narasin, 27 to 45 grams, plus nicarbazin, 27 
to 45 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and 
E. maxima.
    (B) Limitations. For broiler chickens only. Feed continuously as the 
sole ration. Do not feed to laying hens. Do not allow adult turkeys, 
horses, or other equines access to formulations containing narasin. 
Ingestion of narasin by these animals has been fatal. Withdraw 5 days 
before slaughter. The 2 drugs can be combined only at a 1:1 ratio for 
the 27 to 45 grams per ton range. Only granular nicarbazin as provided 
by No. 000986 in Sec. 510.600(c) of this chapter may be used in the 
combination.
    (iv) Amount per ton. Narasin, 54 to 72 grams, plus bambermycins, 1 
to 2 grams.
    (A) Indications for use. For prevention of coccidiosis caused by 
Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and 
E. maxima, and for increased rate of weight gain and improved feed 
efficiency.
    (B) Limitations. For broiler chickens only. Feed continuously as the 
sole ration. May be fatal if fed to adult turkeys, horses, or other 
equines. Narasin as provided by No. 000986; bambermycins by No. 016592 
in Sec. 510.600(c) of this chapter.
    (v) Amount per ton. Narasin 54 to 72 grams, roxarsone 22.7 to 45.4 
grams, and bacitracin methylene disalicylate 10 to 50 grams.
    (A) Indications for use. For prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, for increased rate of weight gain, and for improved feed 
efficiency.
    (B) Limitations. For broiler chickens only. Feed continuously as 
sole ration. Withdraw 5 days before slaughter. Do not feed to laying 
hens. Use as sole source of organic arsenic. Drug overdose or lack of 
water may result in leg weakness. Do not allow adult turkeys, horses, or 
other equines access to narasin formulations. Ingestion of narasin by 
these species has been fatal. Narasin as provided by 000986, roxarsone 
by 046573, bacitracin methylene disalicylate by 046573 in Sec. 
510.600(c) of this chapter.
    (vi) Amount per ton. Narasin 54 to 72 grams, and bacitracin 
methylene disalicylate 10 to 50 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria acervulina, E. brunetti, E. maxima, E. mivati, E. necatrix, and 
E. tenella, for increased rate of weight gain, and for improved feed 
efficiency.
    (B) Limitations. For broiler chickens only. Feed continuously as 
sole ration. Do not feed to laying hens. Do not allow adult turkeys, 
horses, or other

[[Page 469]]

equines access to narasin formulations. Ingestion of narasin by these 
species has been fatal. Narasin as provided by 000986, bacitracin 
methylene disalicylate by 046573 in Sec. 510.600(c) of this chapter.
    (vii) Amount per ton. Narasin 54 to 72 grams, bambermycins 1 to 2 
grams, and roxarsone 22.7 to 45.4 grams.
    (A) Indications for use. For prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. mivati, E. acervulina, E. maxima, and 
E. brunetti, and for increased rate of weight gain, improved feed 
efficiency, and improved pigmentation in broiler chickens.
    (B) Limitations. For broiler chickens only. Feed continuously as 
sole ration. Do not feed to laying hens. Do not allow adult turkeys or 
horses or other equines access to formulations containing narasin. 
Ingestion of narasin by these animals has been fatal. Use as sole source 
of organic arsenic. Poultry should have access to drinking water at all 
times. Drug overdosage or lack of water intake may result in leg 
weakness or paralysis. Withdraw 5 days before slaughter. Narasin as 
provided by 000986 in Sec. 510.600(c) of this chapter, bambermycins by 
016592, and roxarsone by 046573.
    (viii) Amount per ton. Narasin, 54 to 72 grams, and bacitracin 
methylene disalicylate, 50 grams, with roxarsone, 22.7 to 45.4 grams.
    (A) Indications for use. For prevention of coccidiosis caused by 
Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and 
E. maxima, as an aid in the prevention of necrotic enteritis caused or 
complicated by Clostridium spp. or other organisms susceptible to 
bacitracin, and for increased rate of weight gain, improved feed 
efficiency, and improved pigmentation.
    (B) Limitations. For broiler chickens only. Feed continuously as 
sole ration. Withdraw 5 days before slaughter. Do not feed to laying 
hens. Do not allow adult turkeys, horses, or other equines access to 
narasin formulations. Ingestion of narasin by these species has been 
fatal. Use as sole source of organic arsenic. Poultry should have access 
to drinking water at all times. Drug overdose or lack of water intake 
may result in leg weakness or paralysis. Narasin as provided by 000986, 
bacitracin methylene disalicylate and roxarsone by 046573 in Sec. 
510.600(c) of this chapter.
    (ix) Amount per ton. Narasin, 54 to 72 grams, and bacitracin 
methylene disalicylate, 100 to 200 grams, with roxarsone, 22.7 to 45.4 
grams.
    (A) Indications for use. For prevention of coccidiosis caused by 
Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and 
E. maxima, as an aid in the control of necrotic enteritis caused or 
complicated by Clostridium spp. or other organisms susceptible to 
bacitracin, and for increased rate of weight gain, improved feed 
efficiency, and improved pigmentation.
    (B) Limitations. For broiler chickens only. Feed continuously as 
sole ration. Withdraw 5 days before slaughter. Do not feed to laying 
hens. Do not allow adult turkeys, horses, or other equines access to 
narasin formulations. Ingestion of narasin by these species has been 
fatal. Use as sole source of organic arsenic. Poultry should have access 
to drinking water at all times. Drug overdose or lack of water intake 
may result in leg weakness or paralysis. Narasin as provided by 000986, 
bacitracin methylene disalicylate and roxarsone by 046573 in Sec. 
510.600(c) of this chapter.
    (x) Amount per ton. Narasin, 54 to 72 grams and bacitracin zinc, 4 
to 50 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and 
E. maxima, and for increased rate of weight gain and improved feed 
efficiency.
    (B) Limitations. For broiler chickens only. Feed continuously as 
sole ration. Do not allow adult turkeys, horses, or other equines access 
to formulations containing narasin. Ingestion of narasin by these 
species has been fatal. Narasin as provided by 000986, bacitracin zinc 
by 046573 in Sec. 510.600(c) of this chapter.
    (xi) Amount per ton. Narasin, 54 to 72 grams, plus tylosin, 4 to 50 
grams.
    (A) Indications for use. As an aid in the prevention of coccidiosis 
caused by Eimeria necatrix, E. tenella, E. acervulina, E. brunetti, E. 
mivati, and E. maxima, for increased rate of weight gain, and improved 
feed efficiency.

[[Page 470]]

    (B) Limitations. For broiler chickens only. Feed continuously as 
sole ration. Do not allow adult turkeys, horses, or other equines access 
to formulations containing narasin. Ingestion of narasin by these 
species has been fatal. Narasin and tylosin as provided by 000986 in 
Sec. 510.600(c) of this chapter.
    (2) Growing-finishing swine--(i) Amount per ton. Narasin, 13.6 to 
27.2 grams.
    (A) Indications for use. For increased rate of weight gain when fed 
for at least 4 weeks.
    (B) Limitations. Feed continuously for at least 4 weeks to swine 
during the growing-finishing period as the sole ration. No increased 
benefit in rate of weight gain has been shown when narasin 
concentrations in the diet are greater than 13.6 g/ton. Effectiveness 
has not been demonstrated when fed for durations less than 4 weeks. Do 
not allow adult turkeys, horses, or other equines access to narasin 
formulations. Ingestion of narasin by these species has been fatal. Not 
approved for use in breeding animals because safety and effectiveness 
have not been evaluated in these animals. Swine being fed with narasin 
should not have access to feeds containing pleuromutilins (e.g., 
tiamulin) as adverse reactions may occur. If signs of toxicity occur, 
discontinue use.
    (ii) Amount per ton. Narasin, 18.1 to 27.2 grams.
    (A) Indications for use. For increased rate of weight gain and 
improved feed efficiency when fed for at least 4 weeks.
    (B) Limitations. Feed continuously for at least 4 weeks to swine 
during the growing-finishing period as the sole ration. No increased 
benefit in rate of weight gain has been shown when narasin 
concentrations in the diet are greater than 13.6 g/ton. Effectiveness 
has not been demonstrated when fed for durations less than 4 weeks. Do 
not allow adult turkeys, horses, or other equines access to narasin 
formulations. Ingestion of narasin by these species has been fatal. Not 
approved for use in breeding animals because safety and effectiveness 
have not been evaluated in these animals. Swine being fed with narasin 
should not have access to feeds containing pleuromutilins (e.g., 
tiamulin) as adverse reactions may occur. If signs of toxicity occur, 
discontinue use.
    (3) Narasin may also be used for broilers in combination with:
    (i) Nicarbazin with lincomycin as in Sec. 558.366.
    (ii) Nicarbazin and bacitracin methylene disalicylate as in Sec. 
558.366.
    (iii) Bacitracin methylene disalicylate, nicarbazin, and roxarsone 
as in Sec. 558.366.
    (iv) Nicarbazin and roxarsone as in Sec. 558.366.

[51 FR 29098, Aug. 14, 1986]

    Editorial Note: For Federal Register citations affecting Sec. 
558.363, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.364  Neomycin sulfate.

    (a) Approvals. Type A medicated article: 325 grams per pound to 
000009 in Sec. 510.600(c) of this chapter.
    (b) Related tolerances. See Sec. 556.430 of this chapter.
    (c) [Reserved]
    (d) Conditions of use. Neomycin sulfate is used as follows:

[[Page 471]]



----------------------------------------------------------------------------------------------------------------
         Neomycin Sulfate               Combination        Indications for Use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(1) 250 to 2,250 grams per ton (g/ ....................  Cattle, swine, sheep,    To provide 10           000009
 t) of dry type C feed.                                   and goats. For           milligrams (mg) of
                                                          treatment and control    neomycin sulfate
                                                          of colibacillosis        per pound of body
                                                          (bacterial enteritis)    weight per day for
                                                          caused by Escherichia    a maximum of 14
                                                          coli susceptible to      days. The
                                                          neomycin.                concentration of
                                                                                   neomycin sulfate
                                                                                   required in
                                                                                   medicated feed
                                                                                   must be adjusted
                                                                                   to compensate for
                                                                                   variation in age
                                                                                   and weight of
                                                                                   animal, the nature
                                                                                   and severity of
                                                                                   disease signs, and
                                                                                   environmental
                                                                                   temperature and
                                                                                   humidity, each of
                                                                                   which affects feed
                                                                                   consumption. If
                                                                                   symptoms persist
                                                                                   after using for 2
                                                                                   or 3 days, consult
                                                                                   a veterinarian.
                                                                                   Treatment should
                                                                                   continue 24 to 48
                                                                                   hours beyond
                                                                                   remission of
                                                                                   disease symptoms.
                                                                                   Discontinue
                                                                                   treatment prior to
                                                                                   slaughter as
                                                                                   follows: Cattle 1
                                                                                   day, swine 3 days,
                                                                                   sheep 2 days, and
                                                                                   goats 3 days. A
                                                                                   withdrawal period
                                                                                   has not been
                                                                                   established for
                                                                                   use in
                                                                                   preruminating
                                                                                   calves. Do not use
                                                                                   in calves to be
                                                                                   processed for
                                                                                   veal. A milk
                                                                                   discard time has
                                                                                   not been
                                                                                   established for
                                                                                   use in lactating
                                                                                   dairy cattle or
                                                                                   lactating dairy
                                                                                   goats. Do not use
                                                                                   in female dairy
                                                                                   cattle 20 months
                                                                                   of age or older or
                                                                                   female dairy goats
                                                                                   12 months of age
                                                                                   or older. For use
                                                                                   in dry feeds only.
                                                                                   Not for use in
                                                                                   liquid feed
                                                                                   supplements.
(2) 400 to 2,000 g/t of type C     ....................  Do.....................  To provide 10 mg of     000009
 milk replacer.                                                                    neomycin sulfate
                                                                                   per pound of body
                                                                                   weight per day for
                                                                                   a maximum of 14
                                                                                   days. Amount
                                                                                   consumed will vary
                                                                                   depending on
                                                                                   animal's
                                                                                   consumption and
                                                                                   weight. If
                                                                                   symptoms persist
                                                                                   after using for 2
                                                                                   or 3 days, consult
                                                                                   a veterinarian.
                                                                                   Treatment should
                                                                                   continue 24 to 48
                                                                                   hours beyond
                                                                                   remission of
                                                                                   disease symptoms.
                                                                                   Discontinue
                                                                                   treatment prior to
                                                                                   slaughter as
                                                                                   follows: Cattle 1
                                                                                   day, swine 3 days,
                                                                                   sheep 2 days, and
                                                                                   goats 3 days. A
                                                                                   withdrawal period
                                                                                   has not been
                                                                                   established for
                                                                                   use in
                                                                                   preruminating
                                                                                   calves. Do not use
                                                                                   in calves to be
                                                                                   processed for
                                                                                   veal. A milk
                                                                                   discard time has
                                                                                   not been
                                                                                   established for
                                                                                   use in lactating
                                                                                   dairy cattle or
                                                                                   lactating dairy
                                                                                   goats. Do not use
                                                                                   in female dairy
                                                                                   cattle 20 months
                                                                                   of age or older or
                                                                                   female dairy goats
                                                                                   12 months of age
                                                                                   or older. For use
                                                                                   in milk replacers
                                                                                   only.
----------------------------------------------------------------------------------------------------------------


[64 FR 70576, Dec. 17, 1999, as amended at 65 FR 45881, July 26, 2000]

[[Page 472]]



Sec. 558.365  Nequinate.

    (a) Approvals. Type A medicated articles: 4 percent to No. 051311 in 
Sec. 510.600(c) of this chapter.
    (b) Related tolerances. See Sec. 556.440 of this chapter.
    (c) Special considerations. Do not use in Type B or Type C medicated 
feeds containing bentonite.
    (d) Conditions of use. It is used as follows:
    (1) Broiler or fryer chickens--(i) Amount per ton. Nequinate, 18.16 
grams.
    (ii) Indications for use. An aid in the prevention of coccidiosis 
caused by E. tenella, E. necatrix, E. acervulina, E. maxima, E. 
brunetti, and E. mivati.
    (iii) Limitations. Feed continuously as the sole ration.
    (2) Roaster chickens or replacement chickens for caged layers--(i) 
Amount per ton. Nequinate, 18.16 grams (0.002 percent).
    (ii) Indications for use. An aid in the prevention of coccidiosis 
caused by E. tenella, E. necatrix, E. acervulina, E. maxima, E. 
brunetti, and E. mivati.
    (iii) Limitations. Feed continuously as the sole ration; do not feed 
to chickens over 16 weeks of age.

[40 FR 13959, Mar. 27, 1975, as amended at 51 FR 7399, Mar. 3, 1986; 52 
FR 2685, Jan. 26, 1987; 66 FR 45167, Aug. 28, 2001; 70 FR 32489, June 3, 
2005]



Sec. 558.366  Nicarbazin.

    (a) Specifications. Type A medicated articles containing 25 percent 
nicarbazin.
    (b) Approvals. See Nos. 000986, 060728, and 066104 in Sec. 
510.600(c) of this chapter for use as in paragraph (d) of this section.
    (c) Related tolerances. See Sec. 556.445 of this chapter.
    (d) Conditons of use. It is used in chicken feed as follows:

----------------------------------------------------------------------------------------------------------------
                                   Combination in grams
   Nicarbazin in grams per ton            per ton          Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
27 to 45.........................  Narasin 27 to 45....  Broiler chickens;        Sec. 000986
                                                          prevention of            558.363(d)(1)(iii).
                                                          coccidiosis caused by
                                                          Eimeria tenella, E.
                                                          necatrix, E.
                                                          acervulina, E. maxima,
                                                          E. brunetti, E. mivati.
                                   Narasin 27 to 45 and  Broiler chickens;        Feed continuously       000986
                                    bacitracin            prevention of            as sole ration.
                                    methylene             coccidiosis caused by    Withdraw 5 days
                                    disalicylate 4 to     Eimeria tenella, E.      before slaughter.
                                    50.                   necatrix, E.             Do not allow
                                                          acervulina, E. maxima,   turkeys, horses,
                                                          E. brunetti, E.          or other equines
                                                          mivati; for increased    access to
                                                          rate of weight gain      formulations
                                                          and improved feed        containing
                                                          efficiency.              narasin. Ingestion
                                                                                   of narasin by
                                                                                   these species has
                                                                                   been fatal. Do not
                                                                                   feed to laying
                                                                                   hens. Narasin and
                                                                                   nicarbazin as
                                                                                   provided by
                                                                                   000986, bacitracin
                                                                                   methylene
                                                                                   disalicylate by
                                                                                   046573.
                                   Narasin 27 to 45 and  Broiler chickens: For    Feed continuously       046573
                                    bacitracin            prevention of            as sole ration. Do
                                    methylene             coccidiosis caused by    not feed to laying
                                    disalicylate 50.      Eimeria tenella, E.      hens. Withdraw 5
                                                          necatrix, E.             days before
                                                          acervulina, E. maxima,   slaughter. Do not
                                                          E. brunetti, and E.      allow turkeys,
                                                          mivati; as an aid in     horses or other
                                                          the prevention of        equines access to
                                                          necrotic enteritis       formulations
                                                          caused or complicated    containing
                                                          by Clostridium spp. or   narasin. Ingestion
                                                          other organisms          of narasin by
                                                          susceptible to           these species has
                                                          bacitracin.              been fatal.
                                                                                   Narasin and
                                                                                   nicarbazin as
                                                                                   provided by No.
                                                                                   000986, bacitracin
                                                                                   methylene
                                                                                   disalicylate by
                                                                                   No. 046573 in Sec.
                                                                                     510.600(c) of
                                                                                   this chapter.

[[Page 473]]

 
                                   Narasin 27 to 45 and  Broiler chickens: For    To control necrotic     046573
                                    bacitracin            prevention of            enteritis, start
                                    methylene             coccidiosis caused by    medication at
                                    disalicylate 100 to   Eimeria tenella, E.      first clinical
                                    200.                  necatrix, E.             signs of disease;
                                                          acervulina, E. maxima,   vary dosage based
                                                          E. brunetti, and E.      on the severity of
                                                          mivati; as an aid in     infection;
                                                          the control of           administer
                                                          necrotic enteritis       continuously for 5
                                                          caused or complicated    to 7 days or as
                                                          by Clostridium spp. or   long as clinical
                                                          other organisms          signs persist,
                                                          susceptible to           then reduce
                                                          bacitracin.              bacitracin to
                                                                                   prevention level
                                                                                   (50 g/ton). Do not
                                                                                   feed to laying
                                                                                   hens. Withdraw 5
                                                                                   days before
                                                                                   slaughter. Do not
                                                                                   allow turkeys,
                                                                                   horses or other
                                                                                   equines access to
                                                                                   formulations
                                                                                   containing
                                                                                   narasin. Ingestion
                                                                                   of narasin by
                                                                                   these species has
                                                                                   been fatal.
                                                                                   Narasin and
                                                                                   nicarbazin as
                                                                                   provided by No.
                                                                                   000986, bacitracin
                                                                                   methylene
                                                                                   disalicylate by
                                                                                   No. 046573 in Sec.
                                                                                     510.600(c) of
                                                                                   this chapter.
                                   Narasin 27 to 45,     Broiler chickens;        Feed continuously       046573
                                    bacitracin            prevention of            as sole ration.
                                    methylene             coccidiosis caused by    Withdraw 5 days
                                    disalicylate 50,      Eimeria tenella, E.      before slaughter.
                                    and roxarsone 22.7    necatrix, E.             Do not allow
                                    to 45.4..             acervulina, E. maxima,   turkeys, horses or
                                                          E. brunetti, and E.      other equines
                                                          mivati, as an aid in     access to
                                                          the prevention of        formulations
                                                          necrotic enteritis       containing
                                                          caused or complicated    narasin. Ingestion
                                                          by Clostridium spp. or   of narasin by
                                                          other organisms          these species has
                                                          susceptible to           been fatal. Do not
                                                          bacitracin, for          feed to laying
                                                          increased rate of        hens. Use as sole
                                                          weight gain, improved    source of organic
                                                          feed efficiency, and     arsenic. Narasin
                                                          improved pigmentation.   and nicarbazin as
                                                                                   provided by
                                                                                   000986, bacitracin
                                                                                   methylene
                                                                                   disalicylate and
                                                                                   roxarsone by
                                                                                   046573.
                                   Narasin 27 to 45,     Broiler chickens: As an  Feed continuously       000986
                                    and bambermycins 1    aid in preventing        as sole ration
                                    to 2.                 outbreaks of cecal       from time chicks
                                                          (Eimeria tenella) and    are placed on
                                                          intestinal (E.           litter until past
                                                          acervulina, E. maxima,   the time when
                                                          E. necatrix, and E.      coccidiosis is
                                                          brunetti) coccidiosis;   ordinarily a
                                                          and for increased rate   hazard; do not use
                                                          of weight gain and       as a treatment for
                                                          improved feed            coccidiosis; do
                                                          efficiency.              not use in
                                                                                   flushing mashes;
                                                                                   do not feed to
                                                                                   laying hens;
                                                                                   withdraw 4 days
                                                                                   before slaughter.
                                                                                   Bambermycins
                                                                                   provided by No.
                                                                                   016592; nicarbazin
                                                                                   and narasin by No.
                                                                                   066104 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
                                   Narasin 27 to 45 and  Broiler chickens;        Feed continuously       000986
                                    Lincomycin 2 to 4.    prevention of            as sole ration.
                                                          coccidiosis caused by    Withdraw 5 days
                                                          Eimeria tenella, E.      before slaughter.
                                                          necatrix, E.             Do not allow
                                                          acervulina, E. maxima,   turkeys, horses,
                                                          E. brunetti, E.          or other equines
                                                          mivati; for increased    access to
                                                          rate of weight gain      formulations
                                                          and improved feed        containing
                                                          efficiency.              narasin. Ingestion
                                                                                   of narasin by
                                                                                   these species has
                                                                                   been fatal. Do not
                                                                                   feed to laying
                                                                                   hens. Do not allow
                                                                                   rabbits, hamsters,
                                                                                   guinea pigs,
                                                                                   horses, or
                                                                                   ruminants access
                                                                                   to feeds
                                                                                   containing
                                                                                   lincomycin.
                                                                                   Ingestion by these
                                                                                   species may result
                                                                                   in severe
                                                                                   gastrointestinal
                                                                                   effects. Narasin
                                                                                   and nicarbazin as
                                                                                   provided by
                                                                                   000986, lincomycin
                                                                                   by 000009.

[[Page 474]]

 
                                   Narasin 27 to 45 and  Broiler chickens; for    Feed continuously       000986
                                    roxarsone 22.7 to     prevention of            as sole ration.
                                    45.4.                 coccidiosis caused by    Use as sole source
                                                          Eimeria tenella, E.      of organic
                                                          necatrix, E.             arsenic. Withdraw
                                                          acervulina, E. maxima,   5 days before
                                                          E. brunetti, and E.      slaughter. Do not
                                                          mivati; for increased    allow turkeys,
                                                          rate of weight gain,     horses or other
                                                          improved feed            equines access to
                                                          efficiency, and          formulations
                                                          improved pigmentation.   containing
                                                                                   narasin. Ingestion
                                                                                   of narasin by
                                                                                   these species has
                                                                                   been fatal. Do not
                                                                                   feed to laying
                                                                                   hens. Use as sole
                                                                                   source of organic
                                                                                   arsenic. Narasin
                                                                                   and nicarbazin as
                                                                                   provided by
                                                                                   000986, roxarsone
                                                                                   by 046573.
90.8 to 181.6 (0.01 to 0.02 pct).  ....................  Broiler chickens: As an  Feed continuously       066104
                                                          aid in preventing        as sole ration
                                                          outbreaks of cecal       from time chicks
                                                          (Eimeria tenella) and    are placed on
                                                          intestinal (E.           litter until past
                                                          acervulina, E. maxima,   the time when
                                                          E. necatrix, and E.      coccidiosis is
                                                          brunetti) coccidiosis.   ordinarily a
                                                                                   hazard. Do not use
                                                                                   as a treatment for
                                                                                   coccidiosis. Do
                                                                                   not feed to laying
                                                                                   hens. Withdraw 4
                                                                                   days before
                                                                                   slaughter for use
                                                                                   levels at or below
                                                                                   113.5 g/ton.
                                                                                   Withdraw 5 days
                                                                                   before slaughter
                                                                                   for use levels
                                                                                   above 113.5 g/ton.
                                   Bacitracin methylene  Broiler chickens: As an  Feed continuously       066104
                                    disalicylate 4 to     aid in preventing        as sole ration
                                    50 and roxarsone      outbreaks of cecal       from time chicks
                                    22.7 to 45.4.         (Eimeria tenella) and    are placed on
                                                          intestinal (E.           litter until past
                                                          acervulina, E. maxima,   the time when
                                                          E. necatrix, and E.      coccidiosis is
                                                          brunetti) coccidiosis;   ordinarily a
                                                          and for increased rate   hazard; do not use
                                                          of weight gain and       as a treatment for
                                                          improved feed            outbreaks of
                                                          efficiency.              coccidiosis.
                                                                                   Discontinue
                                                                                   medication 5 days
                                                                                   before marketing
                                                                                   the birds for
                                                                                   human consumption
                                                                                   to allow for
                                                                                   elimination of the
                                                                                   drug from edible
                                                                                   tissue. Do not
                                                                                   feed to laying
                                                                                   hens in
                                                                                   production.
                                                                                   Nicarbazin as
                                                                                   provided by No.
                                                                                   066104; bacitracin
                                                                                   methylene
                                                                                   disalicylate and
                                                                                   roxarsone by No.
                                                                                   046573 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
                                   Bacitracin methylene  Broiler chickens: As an  Feed continuously       066104
                                    disalicylate 30.      aid in preventing        as sole ration
                                                          outbreaks of cecal       from time chicks
                                                          (Eimeria tenella) and    are placed on
                                                          intestinal (E.           litter until past
                                                          acervulina, E. maxima,   the time when
                                                          E. necatrix, and E.      coccidiosis is
                                                          brunetti) coccidiosis;   ordinarily a
                                                          and for increased rate   hazard. Do not use
                                                          of weight gain and       as a treatment for
                                                          improved feed            coccidiosis. Do
                                                          efficiency.              not feed to laying
                                                                                   hens. Withdraw 4
                                                                                   days before
                                                                                   slaughter for use
                                                                                   levels at or below
                                                                                   113.5 g/ton.
                                                                                   Withdraw 5 days
                                                                                   before slaughter
                                                                                   for use levels
                                                                                   above 113.5 g/ton.

[[Page 475]]

 
                                   Penicillin 2.4 to 50  Broiler chickens: As an  Feed continuously       066104
                                                          aid in preventing        as sole ration
                                                          outbreaks of cecal       from time chicks
                                                          (Eimeria tenella) and    are placed on
                                                          intestinal (E.           litter until past
                                                          acervulina, E. maxima,   the time when
                                                          E. necatrix, and E.      coccidiosis is
                                                          brunetti) coccidiosis,   ordinarily a
                                                          and for increased rate   hazard; do not use
                                                          of weight gain and       as a treatment for
                                                          improved feed            outbreaks of
                                                          efficiency.              coccidiosis. Do
                                                                                   not use in
                                                                                   flushing mashes.
                                                                                   Do not feed to
                                                                                   chickens producing
                                                                                   eggs for human
                                                                                   consumption.
                                                                                   Discontinue
                                                                                   medication 5 days
                                                                                   before marketing
                                                                                   the birds for
                                                                                   human consumption
                                                                                   to allow for
                                                                                   elimination of the
                                                                                   drug from edible
                                                                                   tissue. Penicillin
                                                                                   as procaine
                                                                                   penicillin G.
                                                                                   Nicarbazin and
                                                                                   penicillin as
                                                                                   provided by No.
                                                                                   066104 in Sec.
                                                                                   510.600(c) of this
                                                                                   chapter.
                                   Penicillin 2.4 to 50  Broiler chickens: As an  Feed continuously       066104
                                    and roxarsone 22.7    aid in preventing        as sole ration
                                    to 45.4.              outbreaks of cecal       from time chicks
                                                          (Eimeria tenella) and    are placed on
                                                          intestinal (E.           litter until past
                                                          acervulina, E. maxima,   the time when
                                                          E. necatrix, and E.      coccidiosis is
                                                          brunetti) coccidiosis,   ordinarily a
                                                          and for increased rate   hazard; do not use
                                                          of weight gain and       as a treatment for
                                                          improved feed            outbreaks of
                                                          efficiency, and          coccidiosis. Feed
                                                          improved pigmentation.   as the sole source
                                                                                   of organic
                                                                                   arsenic; drug
                                                                                   overdose or lack
                                                                                   of water may
                                                                                   result in leg
                                                                                   weakness; do not
                                                                                   use in flushing
                                                                                   mashes.
                                                                                   Discontinue
                                                                                   medication 5 days
                                                                                   before marketing
                                                                                   the birds for
                                                                                   human consumption
                                                                                   to allow for
                                                                                   elimination of the
                                                                                   drug from edible
                                                                                   tissue. Do not
                                                                                   feed to laying
                                                                                   hens in
                                                                                   production.
                                                                                   Penicillin as
                                                                                   procaine
                                                                                   penicillin G.
                                                                                   Nicarbazin and
                                                                                   penicillin as
                                                                                   provided by No.
                                                                                   066104; roxarsone
                                                                                   by No. 046573 in
                                                                                   Sec. 510.600(c)
                                                                                   of this chapter.
113.5 (0.0125 pct)...............  ....................  Chickens; aid in         Feed continuously       000986
                                                          preventing outbreaks     as sole ration         060728
                                                          of cecal (Eimeria        from time chicks
                                                          tenella) and             are placed on
                                                          intestinal (E.           litter until past
                                                          acervulina, E. maxima,   the time when
                                                          E. necatrix, and E.      coccidiosis is
                                                          brunetti) coccidiosis.   ordinarily a
                                                                                   hazard; do not use
                                                                                   as a treatment for
                                                                                   coccidiosis; do
                                                                                   not use in
                                                                                   flushing mashes;
                                                                                   do not feed to
                                                                                   laying hens;
                                                                                   withdraw 4 days
                                                                                   before slaughter.
                                   Bacitracin methylene  Broiler chickens; aid    Feed continuously       046573
                                    disalicylate 4 to     in preventing            as sole ration
                                    50.                   outbreaks of cecal       from time chicks
                                                          (Eimeria tenella) and    are placed on
                                                          intestinal (E.           litter until past
                                                          acervulina, E. maxima,   the time when
                                                          E. necatrix, and E.      coccidiosis is
                                                          brunetti) coccidiosis;   ordinarily a
                                                          for increased rate of    hazard; do not use
                                                          weight gain and          as a treatment for
                                                          improved feed            outbreaks of
                                                          efficiency.              coccidiosis; do
                                                                                   not use in
                                                                                   flushing mashes;
                                                                                   do not feed to
                                                                                   laying hens;
                                                                                   withdraw 4 days
                                                                                   before slaughter.
                                   Bacitracin methylene  Broiler chickens; aid    ......do...........     060728
                                    disalicylate 30.      in preventing
                                                          outbreaks of cecal
                                                          (Eimeria tenella) and
                                                          intestinal (E.
                                                          acervulina, E. maxima,
                                                          E. necatrix, and E.
                                                          brunetti) coccidiosis;
                                                          for increased rate of
                                                          weight gain and
                                                          improved feed
                                                          efficiency.

[[Page 476]]

 
                                   Bacitracin methylene  Broiler chickens; aid    Feed continuously       046573
                                    disalicylate 50.      in preventing            as sole ration
                                                          outbreaks of cecal       from time chicks
                                                          (Eimeria tenella) and    are placed on
                                                          intestinal (E.           litter until past
                                                          acervulina, E. maxima,   the time when
                                                          E. necatrix, and E.      coccidiosis is
                                                          brunetti) coccidiosis;   ordinarily a
                                                          as an aid in the         hazard; do not use
                                                          prevention of necrotic   as a treatment for
                                                          enteritis caused or      outbreaks of
                                                          complicated by           coccidiosis; do
                                                          Clostridium spp. or      not use in
                                                          other organisms          flushing mashes;
                                                          susceptible to           do not feed to
                                                          bacitracin.              laying hens;
                                                                                   withdraw 4 days
                                                                                   before slaughter.
                                   Bacitracin zinc 4 to  Broiler chickens; aid    For broiler             066104
                                    50.                   in preventing            chickens only.         046573
                                                          outbreaks of cecal       Feed continuously
                                                          (Eimeria tenella) and    as sole ration
                                                          intestinal (E.           from time chicks
                                                          acervulina, E. maxima,   are placed on
                                                          E. necatrix, and E.      litter until past
                                                          brunetti) coccidiosis,   the time when
                                                          and for increased rate   coccidiosis is
                                                          of weight gain and       ordinarily a
                                                          improved feed            hazard.
                                                          efficiency.              Discontinue
                                                                                   medication 4 days
                                                                                   before marketing
                                                                                   the birds for
                                                                                   human consumption
                                                                                   to allow for
                                                                                   elimination of the
                                                                                   drug from edible
                                                                                   tissue. Do not
                                                                                   feed to laying
                                                                                   hens in
                                                                                   production.
                                                                                   Nicarbazin as
                                                                                   provided by
                                                                                   066104, bacitracin
                                                                                   zinc by 046573.
                                   Bambermycins 1 to 2.  Broiler chickens; aid    Feed continuously       057926
                                                          in preventing            as sole ration
                                                          outbreaks of cecal       from time chicks
                                                          (Eimeria tenella) and    are placed on
                                                          intestinal (E.           litter until past
                                                          acervulina, E. maxima,   the time when
                                                          E. necatrix, and E.      coccidiosis is
                                                          brunetti) coccidiosis,   ordinarily a
                                                          for increased rate of    hazard; do not use
                                                          weight gain and          as a treatment for
                                                          improved feed            coccidiosis; do
                                                          efficiency.              not use in
                                                                                   flushing mashes;
                                                                                   do not feed to
                                                                                   laying hens;
                                                                                   withdraw 4 days
                                                                                   before slaughter.
                                                                                   Nicarbazin as
                                                                                   provided by 066104.
                                   Bambermycins 1 to 2.  Broiler chickens: For    Feed continuously       016592
                                                          prevention of            as sole ration.
                                                          coccidiosis caused by    Bambermycins
                                                          Eimeria tenella, E.      provided by No.
                                                          necatrix, E.             016592 in Sec.
                                                          acervulina, E.           510.600(c) of this
                                                          brunetti, E. mivati,     chapter.
                                                          and E. maxima; and for
                                                          increased rate of
                                                          weight gain and
                                                          improved feed
                                                          efficiency.
                                   Lincomycin 2          Broiler chickens; aid    Feed continuously       060728
                                    (0.00044 pct).        in preventing            as sole ration         066104
                                                          outbreaks of secal       from time chicks
                                                          (Eimeria tenella) and    are placed on
                                                          intestinal (E.           litter until past
                                                          acervulina, E. maxima,   the time when
                                                          E. necatrix, and E.      coccidiosis is
                                                          brunetti) coccidiosis;   ordinarily a
                                                          for increased rate of    hazard; do not use
                                                          weight gain.             as a treatment for
                                                                                   coccidiosis; do
                                                                                   not use in
                                                                                   flushing mashes;
                                                                                   do not feed to
                                                                                   laying hens;
                                                                                   withdraw 4 days
                                                                                   before slaughter.
                                   Roxarsone 22.7        ......do...............  Feed continuously       060728
                                    (0.0025).                                      as sole ration         066104
                                                                                   from time chicks
                                                                                   are placed on
                                                                                   litter until past
                                                                                   the time when
                                                                                   coccidiosis is
                                                                                   ordinarily a
                                                                                   hazard; as sole
                                                                                   source of organic
                                                                                   arsenic; do not
                                                                                   use a treatment
                                                                                   for coccidiosis;
                                                                                   do not use in
                                                                                   flushing mashes;
                                                                                   do not feed to
                                                                                   laying hens;
                                                                                   withdraw 5 days
                                                                                   before slaughter.
                                   Roxarsone 22.7        ......do...............  ......do...........     060728
                                    (0.0025) plus                                                         066104
                                    lincomycin 2
                                    (0.0004).
----------------------------------------------------------------------------------------------------------------


[[Page 477]]


[42 FR 56729, Oct. 28, 1977; 43 FR 1942, Jan. 13, 1978, as amended at 44 
FR 40887, July 13, 1979; 50 FR 13562, Apr. 5, 1985; 51 FR 7399, Mar. 3, 
1986; 54 FR 1928, Jan. 18, 1989; 60 FR 29483, June 5, 1995; 61 FR 1832, 
Jan. 24, 1996; 61 FR 14021, Mar. 29, 1996; 61 FR 14483, Apr. 2, 1996; 62 
FR 29011, May 29, 1997; 63 FR 13124, Mar. 18, 1998; 63 FR 57248, Oct. 
27, 1998; 64 FR 4966, Feb. 2, 1999; 64 FR 18574, Apr. 15, 1999; 64 FR 
20164, Apr. 26, 1999; 64 FR 49384, Sept. 13, 1999; 65 FR 11889, Mar. 7, 
2000; 66 FR 46706, Sept. 7, 2001; 66 FR 47962, Sept. 17, 2001; 66 FR 
63500, Dec. 7, 2001; 67 FR 30327, May 6, 2002; 71 FR 16224, Mar. 31, 
2006; 71 FR 27957, May 15, 2006; 73 FR 15884, Mar. 26, 2008; 75 FR 7555, 
Feb. 22, 2010]



Sec. 558.369  Nitarsone.

    (a) Approvals. Type A medicated articles: 50 percent to 046573 in 
Sec. 510.600(c) of this chapter.
    (b) Related tolerances. See Sec. 556.60 of this chapter.
    (c) [Reserved]
    (d) Conditions of use. It is used as follows:
    (1) Chickens and turkeys--(i) Amount. Nitarsone, 0.01875 percent.
    (ii) Indications for use. As an aid in the prevention of blackhead.
    (iii) Limitations. Early medication is essential to prevent spread 
of disease. Adequate drinking water must be provided near feeder at all 
times. The drug is not effective in preventing blackhead in birds 
infected more than 4 or 5 days. Discontinue use 5 days before 
slaughtering animals for human consumption to allow elimination of the 
drug from edible tissues. The drug is dangerous for ducks, geese, and 
dogs. Overdosage or lack of water may result in leg weakness or 
paralysis. Use as sole source of arsenic.
    (2) Turkeys--(i) Amount. Nitarsone 0.01875 percent, plus bacitracin 
methylene disalicylate or bacitracin zinc 4 to 50 grams per ton.
    (ii) Indications for use. As an aid in the prevention of blackhead, 
and for increased rate of weight gain and improved feed efficiency.
    (iii) Limitations. For growing turkeys. Feed continuously as sole 
ration. Early medication is essential to prevent spread of disease. 
Adequate drinking water must be provided near feeders at all times. 
Overdosage or lack of water may result in leg weakness or paralysis. The 
drug is not effective in preventing blackhead in birds infected more 
than 4 or 5 days. Discontinue use 5 days before slaughtering animals for 
human consumption to allow elimination of the drug from edible tissues. 
The drug is dangerous for ducks, geese, and dogs. Use as sole source of 
arsenic.

[46 FR 47535, Sept. 29, 1981, as amended at 47 FR 14152, Apr. 2, 1982; 
51 FR 7399, Mar. 3, 1986; 52 FR 2686, Jan. 26, 1987; 55 FR 8460, Mar. 8, 
1990; 57 FR 8578, Mar. 11, 1992; 63 FR 39028, July 21, 1998; 71 FR 
16223, Mar. 31, 2006]



Sec. 558.415  Novobiocin.

    (a) Approvals. Type A medicated articles: 25 grams of activity per 
pound to 000009 in Sec. 510.600(c) of this chapter. Type B medicated 
feeds: 17.5 grams per pound to 000009 in Sec. 510.600(c) of this 
chapter.
    (b) Related tolerances. See Sec. 556.460 of this chapter.
    (c) Conditions of use. It is used in animal feeds as follows:
    (1) Chickens--(i) Amount. Novobiocin, 6-7 mgs. per lb. body weight 
per day.
    (a) Indications for use. Aid in the treatment of breast blisters 
associated with staphylococcal infections susceptible to novobiocin.
    (b) Limitations. Administer, as sole ration, feed which contains not 
less than 200 grams of novobiocin activity per ton of feed; not for 
laying chickens; feed 5 to 7 days; withdraw 4 days before slaughter.
    (ii) Amount. Novobiocin, 10-14 mgs. per lb. body weight per day.
    (a) Indications for use. Treatment of staphylococcal synovitis and 
generalized staphylococcal infections susceptible to novobiocin.
    (b) Limitations. Administer, as sole ration, feed which contains not 
less than 350 grams of novobiocin activity per ton of feed; not for 
laying chickens; feed 5 to 7 days; withdraw 4 days before slaughter.
    (2) Turkeys--(i) Amount. Novobiocin, 4-5 mgs. per lb. body weight 
per day.
    (a) Indications for use. Aid in the treatment of breast blisters 
associated with staphylococcal infections susceptible to novobiocin.

[[Page 478]]

    (b) Limitations. Administer, as sole ration, feed which contains not 
less than 200 grams of novobiocin activity per ton of feed; not for 
laying turkeys; feed 5 to 7 days; withdraw 4 days before slaughter.
    (ii) Amount. Novobiocin, 5-8 mgs. per lb. body weight per day.
    (a) Indications for use. Aid in the control of recurring outbreaks 
of fowl cholera caused by strains of Pasteurella multocida susceptible 
to novobiocin following initial treatment with 7-8 mgs. per pound body 
weight per day.
    (b) Limitations. Administer, as sole ration, feed which contains not 
less than 200 grams of novobiocin activity per ton of feed; feed 5 to 7 
days; not for laying turkeys; withdraw 4 days before slaughter.
    (iii) Amount. Novobiocin, 7-8 mgs. per lb. body weight per day.
    (a) Indications for use. Treatment of staphylococcal synovitis and 
generalized staphylococcal infection susceptible to novobiocin; 
treatment of acute outbreaks of fowl cholera caused by strains of 
Pasteurella multocida susceptible to novobiocin.
    (b) Limitations. Administer, as sole ration, feed which contains not 
less than 350 grams of novobiocin activity per ton of feed; feed 5 to 7 
days; not for laying turkeys; withdraw 4 days before slaughter.
    (3) Mink--(i) Amount. 20 mgs. per lb. body weight per day.
    (ii) Indications for use. For treatment of generalized infections, 
abscesses, or urinary infections caused by staphylococcal or other 
novobiocin sensitive organisms.
    (iii) Limitations. Administer, as sole ration, feed which contains 
not less than 200 grams of novobiocin activity per ton of feed; feed for 
7 days.
    (4) Ducks--(i) Amount. Novobiocin, 350 grams per ton.
    (ii) Indications for use. Control of infectious serositis and fowl 
cholera in ducks caused by Pasteurella anatipestifer and P. multocida, 
susceptible to novobiocin.
    (iii) Limitations. Administer, as sole ration, for 5 to 7 days, 
continue medication for 14 days if necessary, repeat if reinfection 
occurs; discontinue use at least 3 days before slaughter; not for use in 
laying ducks.

[40 FR 13959, Mar. 27, 1975, as amended at 45 FR 42263, June 24, 1980; 
51 FR 7399, Mar. 3, 1986; 52 FR 36402, Sept. 29, 1987]



Sec. 558.430  Nystatin.

    (a) Approvals. Type A medicated articles: 20 grams of activity per 
pound to 046573 in Sec. 510.600(c) of this chapter.
    (b) Related tolerances. See Sec. 556.470 of this chapter.
    (c) Conditions of use. It is used for chickens and turkeys as 
follows:
    (1) Amount. 50 grams per ton.
    (i) Indications for use. Chickens and turkeys; aid in control of 
crop mycosis and mycotic diarrhea (Candida albicans).
    (ii) Limitations. Growing and laying chickens; growing turkeys.
    (2) Amount. 100 grams per ton.
    (i) Indications for use. Chickens and turkeys; treatment of crop 
mycosis and mycotic diarrhea (Candida albicans).
    (ii) Limitations. Growing and laying chickens; growing turkeys; to 
be fed for 7 to 10 days.

[41 FR 11002, Mar. 15, 1976, as amended at 51 FR 7399, Mar. 3, 1986; 52 
FR 2686, Jan. 26, 1987; 53 FR 40729, Oct. 18, 1988; 55 FR 8461, Mar. 8, 
1990; 57 FR 8578, Mar. 11, 1992]



Sec. 558.435  Oleandomycin.

    (a) Approvals. Type A medicated articles: 5 grams of activity per 
pound to 066104 in Sec. 510.600(c) of this chapter.
    (b) Related tolerances. See Sec. 556.480 of this chapter.
    (c) Special considerations. Do not use bentonite in Type B or Type C 
medicated feeds containing oleandomycin. Oleandomycin refers to 
oleandomycin or feed-grade oleandomycin.
    (d) Conditions of use. It is used in animal feed as follows:
    (1) Chickens and turkeys--(i) Amount per ton. Oleandomycin, 1 to 2 
grams.
    (ii) Indications for use. For increased rate of weight gain and 
improved feed efficiency for broiler chickens and growing turkeys.
    (2) Swine--(i) Amount per ton. Oleandomycin, 5 to 11.25 grams.

[[Page 479]]

    (ii) Indications for use. For increased rate of weight gain and 
improved feed efficiency in growing-finishing swine.

[40 FR 13959, Mar. 27, 1975, as amended at 44 FR 40283, July 10, 1979; 
51 FR 7399, Mar. 3, 1986; 52 FR 2686, Jan. 26, 1987; 66 FR 47963, Sept. 
17, 2001]



Sec. 558.450  Oxytetracycline.

    (a) Approvals. Type A medicated articles:
    (1) 10, 20, 30, 50, 100, and 200 grams per pound to No. 066104 in 
Sec. 510.600(c) of this chapter.
    (2) 50, 100, and 200 grams per pound to No. 048164 in Sec. 
510.600(c) of this chapter.
    (b) Special considerations. (1) In accordance with Sec. 558.5 
labeling shall bear the statement: ``FOR USE IN DRY ANIMAL FEED ONLY. 
NOT FOR USE IN LIQUID FEED SUPPLEMENTS.''
    (2) The articles in paragraph (a)(1) of this section contain an 
amount of mono-alkyl (C8-C18) trimethylammonium 
oxytetracycline expressed in terms of an equivalent amount of 
oxytetracycline hydrochloride or an amount of oxytetracycline dihydrate 
base expressed in terms of an equivalent amount of oxytetracycline 
hydrochloride.
    (3) 50-, 100-, and 200-gram per pound articles in paragraph (a)(2) 
of this section contain oxytetracycline dihydrate expressed in terms of 
an equivalent amount of oxytetracycline hydrochloride. Another 100-gram 
per pound article in paragraph (a)(2) of this section contains 
oxytetracycline hydrochloride.
    (c) Related tolerances. See Sec. 556.500 of this chapter.
    (d) Conditions of use--(1) Chickens--

----------------------------------------------------------------------------------------------------------------
          Oxytetracycline amount                Indications for use               Limitations           Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 10 to 50 grams per ton (g/ton).......  Chickens: For increased rate  Feed continuously; do not       066104,
                                            of weight gain and improved   feed to chickens producing      048164
                                            feed efficiency.              eggs for human consumption.
----------------------------------------------------------------------------------------------------------------
(ii) 100 to 200 g/ton....................  Chickens: For control of      Feed continuously for 7 to      066104,
                                            infectious synovitis caused   14 days (d); do not feed to     048164
                                            by Mycoplasma synoviae and    chickens producing eggs for
                                            control of fowl cholera       human consumption; in low
                                            caused by Pasteurella         calcium feeds, withdraw 3 d
                                            multocida susceptible to      before slaughter.
                                            oxytetracycline.
----------------------------------------------------------------------------------------------------------------
(iii) 400 g/ton..........................  Chickens: For control of      Feed continuously for 7 to      066104,
                                            chronic respiratory disease   14 d; do not feed to            048164
                                            (CRD) and air sac infection   chickens producing eggs for
                                            caused by Mycoplasma          human consumption; in low
                                            gallisepticum and             calcium feeds, withdraw 3 d
                                            Escherichia coli              before slaughter.
                                            susceptible to
                                            oxytetracycline.
----------------------------------------------------------------------------------------------------------------
(iv) 500 g/ton...........................  Chickens: For reduction of    Feed continuously for 5 d;      066104,
                                            mortality due to air          do not feed to chickens         048164
                                            sacculitis (air sac           producing eggs for human
                                            infection) caused by E.       consumption; withdraw 24
                                            coli susceptible to           hours before slaughter; in
                                            oxytetracycline.              low calcium feeds, withdraw
                                                                          3 d before slaughter.
----------------------------------------------------------------------------------------------------------------

    (2) Turkeys--

----------------------------------------------------------------------------------------------------------------
       Oxytetracycline amount           Indications for use           Limitations                 Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 10 to 50 g/ton..................  Growing turkeys: For     Feed continuously; do not  066104,
                                       increased rate of        feed to turkeys           048164
                                       weight gain and          producing eggs for human
                                       improved feed            consumption.
                                       efficiency.
----------------------------------------------------------------------------------------------------------------
(ii) 100 g/ton......................  Turkeys: For control of  Feed continuously for 7    066104,
                                       hexamitiasis caused by   to 14 d; do not feed to   048164
                                       Hexamita meleagridis     turkeys producing eggs
                                       susceptible to           for human consumption.
                                       oxytetracycline.
----------------------------------------------------------------------------------------------------------------

[[Page 480]]

 
(iii) 200 g/ton.....................  Turkeys: For control of  Feed continuously for 7    066104,
                                       infectious synovitis     to 14 d; for No. 066104   048164
                                       caused by M. synoviae    withdraw 5 d before
                                       susceptible to           slaughter; for No.
                                       oxytetracycline.         048164 zero-day
                                                                withdrawal time; do not
                                                                feed to turkeys
                                                                producing eggs for human
                                                                consumption.
----------------------------------------------------------------------------------------------------------------
(iv) 25 milligrams/pound (mg/lb) of   Turkeys: For control of  Feed continuously for 7    066104,
 body weight daily.                    complicating bacterial   to 14 d; for No. 066104   048164
                                       organisms associated     withdraw 5 d before
                                       with bluecomb            slaughter; for No.
                                       (transmissible           048164 zero-day
                                       enteritis; coronaviral   withdrawal time; do not
                                       enteritis) susceptible   feed to turkeys
                                       to oxytetracycline.      producing eggs for human
                                                                consumption.
----------------------------------------------------------------------------------------------------------------

    (3) Swine--

----------------------------------------------------------------------------------------------------------------
       Oxytetracycline amount           Indications for use           Limitations                 Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 10 to 50 g/ton..................  Swine: For increased     Feed continuously........  066104,
                                       rate of weight gain                                048164
                                       and improved feed
                                       efficiency.
----------------------------------------------------------------------------------------------------------------
(ii) 10 mg/lb of body weight daily..  1. Swine: For treatment  Feed continuously for 7    066104,
                                       of bacterial enteritis   to 14 d.                  048164
                                       caused by E. coli and
                                       Salmonella
                                       choleraesuis
                                       susceptible to
                                       oxytetracycline and
                                       treatment of bacterial
                                       pneumonia caused by P.
                                       multocida susceptible
                                       to oxytetracycline.
                                      2. Breeding swine: For   Feed continuously for 14   066104,
                                       control and treatment    d.                        048164
                                       of leptospirosis
                                       (reducing the
                                       incidence of abortion
                                       and shedding of
                                       leptospirae) caused by
                                       Leptospira pomona
                                       susceptible to
                                       oxytetracycline.
----------------------------------------------------------------------------------------------------------------

    (4) Cattle--

----------------------------------------------------------------------------------------------------------------
       Oxytetracycline amount           Indications for use           Limitations                 Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 0.05 to 0.1 mg/lb of body weight  Calves (up to 250 lb):   Feed continuously in milk  066104,
 daily.                                For increased rate of    replacer or starter feed. 048164
                                       weight gain and
                                       improved feed
                                       efficiency.
----------------------------------------------------------------------------------------------------------------
(ii) 10 mg/lb of body weight daily..  1. Calves and beef and   Feed continuously for 7    066104,
                                       nonlactating dairy       to 14 d; for No. 048164,  048164
                                       cattle: For treatment    withdraw 5 d before
                                       of bacterial enteritis   slaughter; for No.
                                       caused by E. coli and    066104, zero-day
                                       bacterial pneumonia      withdrawal time.
                                       (shipping fever
                                       complex) caused by P.
                                       multocida susceptible
                                       to oxytetracycline.

[[Page 481]]

 
                                      2. Calves: For           Feed continuously for 7    066104,
                                       treatment of bacterial   to 14 d in milk replacer  048164
                                       enteritis caused by E.   or starter feed; for No.
                                       coli susceptible to      048164, withdraw 5 d
                                       oxytetracycline.         before slaughter; for
                                                                No. 066104, zero-day
                                                                withdrawal time.
----------------------------------------------------------------------------------------------------------------
(iii) 25 mg/head/day................  Calves (250 to 400 lb):  Feed continuously........  066104,
                                       For increased rate of                              048164
                                       weight gain and
                                       improved feed
                                       efficiency.
----------------------------------------------------------------------------------------------------------------
(iv) 75 mg/head/day.................  Growing cattle (over     Feed continuously........  066104,
                                       400 lb): For increased                             048164
                                       rate of weight gain,
                                       improved feed
                                       efficiency, and
                                       reduction of liver
                                       condemnation due to
                                       liver abscesses.
----------------------------------------------------------------------------------------------------------------
(v) 0.5 to 2.0 g/head/day...........  Cattle: For prevention   Feed 3 to 5 d before and   066104,
                                       and treatment of the     after arrival in          048164
                                       early stages of          feedlots.
                                       shipping fever complex.
----------------------------------------------------------------------------------------------------------------

    (5) Minor species--

----------------------------------------------------------------------------------------------------------------
       Oxytetracycline amount           Indications for use           Limitations                 Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 10 to 20 g/ton..................  Sheep: For increased     Feed continuously........  066104,
                                       rate of weight gain                                048164
                                       and improved feed
                                       efficiency.
----------------------------------------------------------------------------------------------------------------
(ii) 10 mg/lb of body weight daily..  Sheep: For treatment of  Feed continuously for 7    066104,
                                       bacterial enteritis      to 14 d; withdraw 5 d     048164
                                       caused by E. coli and    before slaughter.
                                       bacterial pneumonia
                                       caused by P. multocida
                                       susceptible to
                                       oxytetracycline.
----------------------------------------------------------------------------------------------------------------
(iii) 200 mg/colony.................  Honey bees: For control  Remove at least 6 weeks    066104,
                                       of American foulbrood    prior to main honey flow. 048164
                                       caused by
                                       Paenibacillus larvae
                                       and European foulbrood
                                       caused by
                                       Streptococcus pluton
                                       susceptible to
                                       oxytetracycline.
----------------------------------------------------------------------------------------------------------------
(iv) 250 mg/kilogram of fish/day      Pacific salmon: For      For salmon not over 30 g   066104
 (11.35 g/100 lb of fish/day).         marking of skeletal      body weight; administer
                                       tissue.                  as sole ration for 4
                                                                consecutive days; fish
                                                                not to be liberated for
                                                                at least 7 d following
                                                                the last administration
                                                                of medicated feed.
----------------------------------------------------------------------------------------------------------------

[[Page 482]]

 
(v) 2.5 to 3.75 g/100 lb of fish/day  1. Salmonids: For        Administer in mixed        066104
                                       control of ulcer         ration for 10 d; do not
                                       disease caused by        liberate fish or
                                       Hemophilus piscium,      slaughter fish for food
                                       furunculosis caused by   for 21 d following the
                                       Aeromonas salmonicida,   last administration of
                                       bacterial hemorrhagic    medicated feed.
                                       septicemia caused by
                                       A. liquefaciens, and
                                       pseudomonas disease.
                                      2. Catfish: For control  Administer in mixed        066104
                                       of bacterial             ration for 10 d; do not
                                       hemorrhagic septicemia   liberate fish or
                                       caused by A.             slaughter fish for food
                                       liquefaciens and         for 21 d following the
                                       pseudomonas disease.     last administration of
                                                                medicated feed; do not
                                                                administer when water
                                                                temperature is below
                                                                16.7 [deg]C (62 [deg]F).
----------------------------------------------------------------------------------------------------------------
(vi) 3.75 g/100 lb of fish/day......  1. Freshwater-reared     Administer in mixed        066104
                                       salmonids: For control   ration for 10 d; do not
                                       of mortality due to      liberate fish or
                                       coldwater disease        slaughter fish for food
                                       associated with          for 21 d following the
                                       Flavobacterium           last administration of
                                       psychrophilum.           medicated feed.
                                      2. Freshwater-reared     Administer in mixed        066104
                                       Oncorhynchus mykiss:     ration for 10 d; do not
                                       For control of           liberate fish or
                                       mortality due to         slaughter fish for food
                                       columnaris disease       for 21 d following the
                                       associated with          last administration of
                                       Flavobacterium           medicated feed.
                                       columnare.
----------------------------------------------------------------------------------------------------------------
(vii) 1 g/lb of medicated feed......  Lobsters: For control    Administer as sole ration  066104
                                       of gaffkemia caused by   for 5 consecutive days;
                                       Aerococcus viridans.     withdraw medicated feed
                                                                30 d before harvesting
                                                                lobsters.
----------------------------------------------------------------------------------------------------------------

    (6) Oxytetracycline may be used in accordance with the provisions of 
this section in the combinations as follows:
    (i) Carbadox as in Sec. 558.115.
    (ii) Lasalocid as in Sec. 558.311.
    (iii) Melengestrol acetate as in Sec. 558.342.
    (iv) Robenidine hydrochloride as in Sec. 558.515.
    (v) Salinomycin as in Sec. 558.550.

[61 FR 51590, Oct. 3, 1996, as amended at 63 FR 41192, Aug. 3, 1998; 66 
FR 32740, June 18, 2001; 66 FR 45167, Aug. 28, 2001; 66 FR 47963, Sept. 
17, 2001; 67 FR 51081, Aug. 7, 2002; 69 FR 28821, May 19, 2004; 69 FR 
51173, Aug. 18, 2004; 69 FR 62407, Oct. 26, 2004; 71 FR 27958, May 15, 
2006; 71 FR 44887, Aug. 8, 2006; 71 FR 53006, Sept. 8, 2006; 72 FR 
70774, Dec. 13, 2007; 73 FR 45875, Aug. 7, 2008]



Sec. 558.455  Oxytetracycline and neomycin.

    (a) Specifications. Type A medicated articles containing 
oxytetracycline equivalent to 50 grams per pound (g/lb) oxytetracycline 
hydrochloride and 50 g/lb neomycin sulfate or oxytetracycline equivalent 
to 100 g/lb oxytetracycline hydrochloride and 100 g/lb neomycin sulfate.
    (b) Sponsors. See Nos. 048164 and 066104 in Sec. 510.600(c) of this 
chapter.
    (c) Related tolerances. See Sec. Sec. 556.430 and 556.500 of this 
chapter.
    (d) Special considerations. Cattle feeds shall bear the following 
warning statement: ``Use of more than one product containing neomycin or 
failure to follow withdrawal times may result in illegal drug 
residues.''
    (e) Indications for use--(1) Chickens. It is used in feed as 
follows:

[[Page 483]]



----------------------------------------------------------------------------------------------------------------
   Oxytetracycline and neomycin sulfate
     amount in grams per ton of feed            Indications for use               Limitations           Sponsors
----------------------------------------------------------------------------------------------------------------
(i) 10 to 50.............................  Chickens: For increased rate  Feed continuously; do not        048164
                                            of weight gain and improved   feed to chickens producing      066104
                                            feed efficiency.              eggs for human consumption;
                                                                          in low calcium feeds
                                                                          withdraw 3 days before
                                                                          slaughter.
----------------------------------------------------------------------------------------------------------------
(ii) 100 to 200..........................  Chickens: For control of      Feed continuously for 7 to       048164
                                            infectious synovitis caused   14 d; do not feed to            066104
                                            by Mycoplasma synoviae;       chickens producing eggs for
                                            control of fowl cholera       human consumption; in low
                                            caused by Pasteurella         calcium feed, withdraw 3 d
                                            multocida susceptible to      before slaughter.
                                            oxytetracycline.
----------------------------------------------------------------------------------------------------------------
(iii) 400................................  Chickens: For control of      Feed continuously for 7 to       048164
                                            chronic respiratory disease   14 d; do not feed to            066104
                                            (CRD) and air sac infection   chickens producing eggs for
                                            caused by M. gallisepticum    human consumption; in low
                                            and Escherichia coli          calcium feeds, withdraw 3 d
                                            susceptible to                before slaughter.
                                            oxytetracycline.
----------------------------------------------------------------------------------------------------------------
(iv) 500.................................  Chickens: For reduction of    Feed continuously for 5 d;       048164
                                            mortality due to air          do not feed to chickens         066104
                                            sacculitis (air-sac-          producing eggs for human
                                            infection) caused by E.       consumption; withdraw 24
                                            coli susceptible to           hours before slaughter; in
                                            oxytetracycline.              low calcium feeds withdraw
                                                                          3 d before slaughter.
----------------------------------------------------------------------------------------------------------------

    (2) Turkeys. It is used in feed as follows:

----------------------------------------------------------------------------------------------------------------
   Oxytetracycline and neomycin sulfate
                  amount                        Indications for use               Limitations           Sponsors
----------------------------------------------------------------------------------------------------------------
(i) 10 to 50 grams per ton (g/ton) of      Growing turkeys: For          Feed continuously; do not        048164
 feed.                                      increased rate of weight      feed to turkeys producing       066104
                                            gain and improved feed        eggs for human consumption.
                                            efficiency.
----------------------------------------------------------------------------------------------------------------
(ii) 100 g/ton of feed...................  Turkeys: For control of       Feed continuously for 7 to       048164
                                            hexamitiasis caused by        14 d; do not feed to            066104
                                            Hexamita meleagridis          turkeys producing eggs for
                                            susceptible to                human consumption.
                                            oxytetracycline.
----------------------------------------------------------------------------------------------------------------
(iii) 200 g/ton of feed..................  Turkeys: For control of       Feed continuously for 7 to       048164
                                            infectious synovitis caused   14 d; withdraw 5 d before       066104
                                            by M. synoviae susceptible    slaughter; do not feed to
                                            to oxytetracycline.           turkeys producing eggs for
                                                                          human consumption.
----------------------------------------------------------------------------------------------------------------
(iv) To provide 25 milligrams per pound    Turkeys: For control of       Feed continuously for 7 to       048164
 (mg/lb) of body weight daily.              complicating bacterial        14 d; withdraw 5 d before       066104
                                            organisms associated with     slaughter; do not feed to
                                            bluecomb (transmissible       turkeys producing eggs for
                                            enteritis; coronaviral        human consumption.
                                            enteritis) susceptible to
                                            oxytetracycline.
----------------------------------------------------------------------------------------------------------------

    (3) Swine. It is used in feed as follows:

----------------------------------------------------------------------------------------------------------------
   Oxytetracycline and neomycin sulfate
                  amount                        Indications for use               Limitations           Sponsors
----------------------------------------------------------------------------------------------------------------
(i) 10 to 50 g/ton of feed...............  Swine: For increased rate of  Feed continuously...........     048164
                                            weight gain and improved                                      066104
                                            feed efficiency.
----------------------------------------------------------------------------------------------------------------
(ii) To provide 10 mg/lb of body weight    1. Swine: For treatment of    Feed continuously for 7 to       048164
 daily.                                     bacterial enteritis caused    14 d; withdraw 5 d before       066104
                                            by E. coli and Salmonella     slaughter.
                                            choleraesuis and treatment
                                            of bacterial pneumonia
                                            caused by P. multocida
                                            susceptible to
                                            oxytetracycline; treatment
                                            and control of
                                            colibacillosis (bacterial
                                            enteritis) caused by E.
                                            coli susceptible to
                                            neomycin.
                                           2. Breeding swine: For        Feed continuously for not        048164
                                            control and treatment of      more than 14 d; withdraw 5      066104
                                            leptospirosis (reducing the   d before slaughter.
                                            incidence of abortion and
                                            shedding of leptospirae)
                                            caused by Leptospira pomona
                                            susceptible to
                                            oxytetracycline.
----------------------------------------------------------------------------------------------------------------

    (4) Cattle and sheep. It is used in feed as follows:

[[Page 484]]



----------------------------------------------------------------------------------------------------------------
   Oxytetracycline and neomycin sulfate
                  amount                        Indications for use               Limitations           Sponsors
----------------------------------------------------------------------------------------------------------------
(i) 10 to 20 g/ton of feed...............  Sheep: For increased rate of  Feed continuously...........     048164
                                            weight gain and improved                                      066104
                                            feed efficiency.
----------------------------------------------------------------------------------------------------------------
(ii) To provide 0.05 to 0.1 mg/lb of body  Calves (up to 250 lb): For    Feed continuously; in milk       048164
 weight daily.                              increased rate of weight      replacers or starter feed.      066104
                                            gain and improved feed
                                            efficiency.
----------------------------------------------------------------------------------------------------------------
(iii) To provide 10 mg/lb of body weight   1. Calves and beef and        Feed continuously for 7 to       048164
 daily.                                     nonlactating dairy cattle:    14 d; in feed or milk           066104
                                            For treatment of bacterial    replacers. If symptoms
                                            enteritis caused by E. coli   persist after using for 2
                                            and bacterial pneumonia       or 3 days, consult a
                                            (shipping fever complex)      veterinarian. Treatment
                                            caused by P. multocida        should continue 24 to 48
                                            susceptible to                hours beyond remission of
                                            oxytetracycline; treatment    disease symptoms. A
                                            and control of                withdrawal period has not
                                            colibacillosis (bacterial     been established for use in
                                            enteritis) caused by E.       preruminating calves. Do
                                            coli susceptible to           not use in calves to be
                                            neomycin.                     processed for veal. A milk
                                                                          discard time has not been
                                                                          established for use in
                                                                          lactating dairy cattle. Do
                                                                          not use in female dairy
                                                                          cattle 20 months of age or
                                                                          older. Withdraw 5 d before
                                                                          slaughter.
                                           2. Calves (up to 250 lb):     Feed continuously for 7 to       048164
                                            For treatment of bacterial    14 d; in milk replacers or      066104
                                            enteritis caused by E. coli   starter feed. If symptoms
                                            susceptible to                persist after using for 2
                                            oxytetracycline; treatment    or 3 days, consult a
                                            and control of                veterinarian. Treatment
                                            colibacillosis (bacterial     should continue 24 to 48
                                            enteritis) caused by E.       hours beyond remission of
                                            coli susceptible to           disease symptoms. A
                                            neomycin.                     withdrawal period has not
                                                                          been established for use in
                                                                          preruminating calves. Do
                                                                          not use in calves to be
                                                                          processed for veal. A milk
                                                                          discard time has not been
                                                                          established for use in
                                                                          lactating dairy cattle. Do
                                                                          not use in female dairy
                                                                          cattle 20 months of age or
                                                                          older. Withdraw 5 d before
                                                                          slaughter.
                                           3. Sheep: For treatment of    Feed continuously for 7 to       048164
                                            bacterial enteritis caused    14 d. If symptoms persist       066104
                                            by E. coli and bacterial      after using for 2 or 3
                                            pneumonia caused by P.        days, consult a
                                            multocida susceptible to      veterinarian. Treatment
                                            oxytetracycline; treatment    should continue 24 to 48
                                            and control of                hours beyond remission of
                                            colibacillosis (bacterial     disease symptoms. Withdraw
                                            enteritis) caused by E.       5 d before slaughter.
                                            coli susceptible to
                                            neomycin.
----------------------------------------------------------------------------------------------------------------
(iv) To provide 25 mg/head/day...........  Calves (250 to 400 lb): For   Feed continuously...........     048164
                                            increased rate of weight                                      066104
                                            gain and improved feed
                                            efficiency.
----------------------------------------------------------------------------------------------------------------
(v) To provide 75 mg/head/day............  Growing cattle (over 400      Feed continuously...........     048164
                                            lb): For increased rate of                                    066104
                                            weight gain; improved feed
                                            efficiency, and reduction
                                            of liver condemnation due
                                            to liver abscesses.
----------------------------------------------------------------------------------------------------------------
(vi) To provide 0.5 to 2.0 g/head/ day...  Cattle: For prevention and    Feed 3 to 5 d before and         048164
                                            treatment of the early        after arrival in feedlots.      066104
                                            stages of shipping fever      A withdrawal period has not
                                            complex.                      been established for use in
                                                                          preruminating calves. Do
                                                                          not use in calves to be
                                                                          processed for veal. A milk
                                                                          discard time has not been
                                                                          established for use in
                                                                          lactating dairy cattle. Do
                                                                          not use in female dairy
                                                                          cattle 20 months of age or
                                                                          older.
----------------------------------------------------------------------------------------------------------------


[71 FR 16225, Mar. 31, 2006, as amended at 74 FR 40724, Aug. 13, 2009]



Sec. 558.460  Penicillin.

    (a) Specifications. As penicillin procaine G or feed grade 
penicillin procaine.
    (b) Sponsors. Type A medicated articles: To 066104, 100 and 227 
grams per pound. To 046573, 100 and 227 grams per pound.
    (c) Related tolerances. See Sec. 556.510 of this chapter.
    (d) Conditions of use. (1) It is used as follows:

[[Page 485]]



----------------------------------------------------------------------------------------------------------------
                                   Combination in grams
   Penicillin in grams per ton            per ton          Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 2.4 to 50....................  ....................  Chickens, turkeys, and   Do not feed to         000069,
                                                          pheasants; for           poultry producing     046573.
                                                          increased rate of        eggs for human
                                                          weight gain and          consumption.
                                                          improved feed
                                                          efficiency.
(ii) 5 to 20.....................  ....................  Quail; for increased     Quail; not over 5          Do.
                                                          rate of weight gain      weeks of age.
                                                          and improved feed
                                                          efficiency.
(iii) 10 to 50...................  ....................  Swine; for increased     ...................        Do.
                                                          rate of weight gain
                                                          and improved feed
                                                          efficiency.
----------------------------------------------------------------------------------------------------------------

    (2) Penicillin may be used in accordance with the provisions of this 
section in the combinations provided as follows:
    (i) Amprolium in accordance with Sec. 558.55.
    (ii) Amprolium plus ethopatbate in accordance with Sec. 558.58.
    (iii) Hygromycin B in accordance with Sec. 558.274.
    (iv) Nicarbazin alone or with roxarsone as in Sec. 558.366.
    (v) Roxarsone and zoalene in accordance with Sec. 558.680.
    (vi) Zoalene in accordance with Sec. 558.680.

[41 FR 11004, Mar. 15, 1976, as amended at 42 FR 18618, Apr. 8, 1977; 42 
FR 36995, July 19, 1977; 47 FR 42103, Sept. 24, 1982; 51 FR 7399, Mar. 
3, 1986; 52 FR 2686, Jan. 26, 1987; 58 FR 30120, May 26, 1993; 60 FR 
39847, Aug. 4, 1995; 63 FR 36179, July 2, 1998; 65 FR 45880, July 26, 
2000; 66 FR 47963, Sept. 17, 2001; 71 FR 16227, Mar. 31, 2006]



Sec. 558.464  Poloxalene.

    (a) Approvals. (1) Dry Type A medicated articles: 53 percent to 
000069 in Sec. 510.600(c) of this chapter.
    (2) Liquid Type A medicated articles: 99.5 percent to 000069 in 
Sec. 510.600(c) of this chapter.
    (b) Conditions of use. (1) For prevention of legume (alfalfa, 
clover) and wheat pasture bloat in cattle.
    (2) Poloxalene dry Type A article and liquid Type A article must be 
thoroughly blended and evenly distributed in feed prior to use. This may 
be accomplished by adding the Type A article to a small quantity of 
feed, mixing thoroughly, then adding this mixture to the remaining feed 
and again mixing thoroughly. Dosage is 1 gram of poloxalene per 100 
pounds of body weight daily and continued during exposure to bloat 
producing conditions. If bloating conditions are severe, the dose is 
doubled. Treatment should be started 2 to 3 days before exposure to 
bloat-producing conditions. Repeat dosage if animals are exposed to 
bloat-producing conditions more than 12 hours after the last treatment. 
Do not exceed the higher dosage levels in any 24-hour period.

[40 FR 39857, Aug. 29, 1975, as amended at 51 FR 7399, Mar. 3, 1986; 52 
FR 2686, Jan. 26, 1987; 56 FR 50654, Oct. 8, 1991; 60 FR 55660, Nov. 2, 
1995]



Sec. 558.465  Poloxalene free-choice liquid Type C feed.

    (a) Approvals. Type A medicated articles: 99.5 percent to 066104 in 
Sec. 510.600(c) of this chapter.
    (b) Conditions of use. (1) For control of legume (alfalfa, clover) 
and wheat pasture bloat in cattle, use 7.5 grams of poloxalene per pound 
of liquid Type C feed (1.65 percent weight/weight). Each animal must 
consume 0.2 pound of Type C feed per 100 pounds of body weight daily for 
adequate protection.
    (2) For control of legume (alfalfa, clover) bloat in cattle grazing 
of prebloom legumes, use 10.00 grams of poloxalene per pound of liquid 
Type C feed (2.2 percent weight/weight). Each animal must consume 0.15 
pound of Type C feed per 100 pounds of body weight daily for adequate 
protection. If consumption exceeds 0.2 pound of Type C feed per 100 
pounds of body weight daily, cattle should be changed to a Type C feed 
containing 7.5 grams of poloxalene per pound.
    (3) Poloxalene liquid Type A article must be thoroughly blended and 
evenly distributed into a liquid Type C feed and offered to cattle in a 
covered liquid Type C feed feeder with lick wheels. The formula for the 
liquid Type C feed, on a weight/weight basis, is as follows: Ammonium 
polyphosphate 2.66 percent, phosphoric acid (75 percent) 3.37 percent, 
sulfuric acid 1.00 percent, water 10.00 percent, and molasses sufficient 
to make 100.00 percent, vitamins A and

[[Page 486]]

D and/or trace minerals may be added. One free-turning lick wheel per 25 
head of cattle must be provided.
    (4) The medicated liquid Type C feed must be introduced at least 2 
to 5 days before legume consumption to accustom the cattle to the 
medicated liquid Type C feed and to lick wheel feedings. If the 
medicated liquid wheel Type C feed feeding is interrupted, this 2- to 5-
day introductory feeding should be repeated.

[40 FR 13959, Mar. 27, 1975, as amended at 42 FR 21281, Apr. 26, 1977; 
51 FR 7399, Mar. 3, 1986; 52 FR 2686, Jan. 26, 1987; 56 FR 50654, Oct. 
8, 1991; 60 FR 55660, Nov. 2, 1995; 66 FR 47963, Sept. 17, 2001]



Sec. 558.485  Pyrantel.

    (a) Specifications. Type A medicated articles containing 9.6, 19.2, 
48, or 80 grams per pound pyrantel tartrate.
    (b) Approvals. See sponsors in Sec. 510.600(c) of this chapter for 
uses as in paragraph (e) of this section:
    (1) No. 066104: 9.6, 19.2, 48, and 80 grams per pound for use as in 
paragraph (e)(1) of this section.
    (2) [Reserved]
    (3) Nos. 016968, and 017790: 9.6 and 19.2 grams per pound for use as 
in paragraphs (e)(1)(i) through (e)(1)(iii) of this section.
    (4) [Reserved]
    (5) No. 051311: 19.2 and 48 grams per pound for use as in paragraphs 
(e)(1)(i) through (e)(1)(iii) of this section.
    (6) No. 034936: 9.6 and 19.2 grams per pound for use as in 
paragraphs (e)(1)(i) and (e)(1)(ii) of this section.
    (7) Nos. 000069 and 017135: 48 grams per pound for use as in 
paragraph (e)(2) of this section.
    (c) Related tolerances. See Sec. 556.560 of this chapter.
    (d) Special considerations. (1) See Sec. 500.25 of this chapter. 
Consult a veterinarian before using in severely debilitated animals.
    (2) Do not mix in Type B or Type C medicated feeds containing 
bentonite.
    (e) Conditions of use. It is used as follows:
    (1) Swine--(i) Amount per ton. 96 grams (0.0106 percent).
    (A) Indications for use. Aid in the prevention of migration and 
establishment of large roundworm (Ascaris suum) infections; aid in the 
prevention of establishment of nodular worm (Oesophagostomum) 
infections.
    (B) Limitations. Feed continuously as the sole ration in a Type C 
feed; withdraw 24 hours prior to slaughter.
    (ii) Amount per ton. 96 grams (0.0106 percent).
    (A) Indications for use. For the removal and control of large 
roundworm (Ascaris suum) infections.
    (B) Limitations. Feed for 3 days as the sole ration in a Type C 
feed; withdraw 24 hours prior to slaughter.
    (iii) Amount per ton. 800 grams (0.0881 percent).
    (A) Indications for use. For the removal and control of large 
roundworm (Ascaris suum) and nodular worm (Oesophagostomum) infections.
    (B) Limitations. As sole ration for a single therapeutic treatment 
in Type C feed; feed at the rate of 1 lb of feed per 40 lb of body 
weight for animals up to 200 lb, and 5 lb of feed per head for animals 
200 lb or over; withdraw 24 hours prior to slaughter.
    (iv) Amount per ton. Pyrantel tartrate, 96 grams (0.0106 percent) 
and carbadox, 50 grams (0.0055 percent).
    (A) Indications for use. For control of swine dysentery (vibrionic 
dysentery, bloody scours or hemorrhagic dysentery); control of bacterial 
swine enteritis (salmonellosis or necrotic enteritis caused by 
Salmonella choleraesuis); aid in the prevention of migration and 
establishment of large roundworm (Ascaris suum) infections; aid in the 
prevention of establishment of nodular worm (Oesophagostomum) 
infections.
    (B) Limitations. Do not feed to swine weighing over 75 pounds; do 
not feed within 10 weeks of slaughter; consult a veterinarian before 
feeding to severely debilitated animals; feed continuously as sole 
ration. Do not use in Type C feeds containing less than 15 percent crude 
protein.
    (v) Amount per ton. Pyrantel tartrate, 96 grams (0.0106 percent) and 
tylosin, 40 to 100 grams, as tylosin phosphate.
    (A) Indications for use. For prevention of swine dysentery 
(vibrionic); aid in the prevention of migration and establishment of 
large roundworms (Ascaris suum) infections; aid in the prevention of 
establishment of nodular worm (Oesophagostomum spp. ) infections.

[[Page 487]]

    (B) Limitations. Use 100 grams tylosin per ton for at least 3 weeks 
followed by 40 grams tylosin per ton until market weight; withdraw 24 
hours before slaughter. Consult your veterinarian before feeding to 
severely debilitated animals and for assistance in the diagnosis, 
treatment, and control of parasitism.
    (vi) Amount per ton. Pyrantel tartrate, 96 grams (0.0106 percent) 
and tylosin 40 to 100 grams, as tylosin phosphate.
    (A) Indications for use. Treatment and control of swine dysentery 
(vibrionic); aid in the prevention of migration and establishment of 
large roundworm (Ascaris suum) infections; aid in the prevention of 
establishment of nodular worm (Oesophagostomum spp. ) infections.
    (B) Limitations. Administer tylosin in feed as tylosin phosphate 
after treatment with tylosin in drinking water as tylosin base; 0.25 
grams per gallon in drinking water for 3 to 10 days, 40 to 100 grams 
tylosin per ton in feed for 2 to 6 weeks; withdraw 24 hours before 
slaughter. Consult your veterinarian before feeding to severely 
debilitated animals and for assistance in the diagnosis, treatment, and 
control of parasitism.
    (vii) Amount per ton. Pyrantel tartrate, 96 grams (0.0106 percent) 
and lincomycin, 40 grams, as lincomycin hydrochloride monohydrate.
    (A) Indications for use. For control of swine dysentery; aid in the 
prevention of migration and establishment of large roundworm (Ascaris 
suum) infections; aid in the prevention of establishment of nodular worm 
(Oesophagostomum spp.) infections.
    (B) Limitations. Feed as sole ration; for use in swine on premises 
with a history of swine dysentery but where symptoms have not yet 
occurred; not to be fed to swine that weigh more than 250 pounds; 
withdraw 6 days before slaughter. Consult your veterinarian before 
feeding to severely debilitated animals and for assistance in the 
diagnosis, treatment, and control of parasitism.
    (viii) Amount per ton. Pyrantel tartrate, 96 grams (0.0106 percent) 
and lincomycin, 100 grams, then 40 grams, as lincomycin hydrochloride 
monohydrate.
    (A) Indications for use. For treatment and control of swine 
dysentery; aid in the prevention of migration and establishment of large 
roundworm (Ascaris suum) infections; aid in the prevention of 
establishment of nodular worm (Oesophagostomum spp.) infections.
    (B) Limitations. Feed 100 grams per ton for 3 weeks or until signs 
of disease disappear, followed by 40 grams per ton; feed as sole ration; 
not to be fed to swine that weigh more than 250 pounds; withdraw 6 days 
before slaughter. Consult your veterinarian before feeding to severely 
debilitated animals and for assistance in the diagnosis, treatment, and 
control of parasitism.
    (ix) Amount per ton. Pyrantel tartrate, 96 grams (0.0106 percent) 
and lincomycin, 100 grams, as lincomycin hydrochloride monohydrate.
    (A) Indications for use. For treatment of swine dysentery; aid in 
the prevention of migration and establishment of large roundworm 
(Ascaris suum) infections; aid in the prevention of establishment of 
nodular worm (Oesophagostomum spp.) infections.
    (B) Limitations. Feed 100 grams per ton 3 weeks or until signs of 
disease disappear, followed by 40 grams per ton; feed as sole ration; 
not to be fed to swine that weigh more than 250 pounds; withdraw 6 days 
before slaughter. Consult your veterinarian before feeding to severely 
debilitated animals and for assistance in the diagnosis, treatment, and 
control of parasitism.
    (x) Amount per ton. Pyrantel tartrate, 96 grams (0.0106 percent) and 
lincomycin, 100 or 40 grams.
    (A) Indications for use. For treatment and/or control of swine 
dysentery; for removal and control of large roundworm (Ascaris suum) 
infections.
    (B) Limitations. Administer in accordance with paragraph (c)(2)(i), 
(c)(2)(ii), or (c)(2)(iii) of Sec. 558.325 and paragraph (e)(1)(ii)(B) 
of this section.
    (xi) Amount per ton. Pyrantel tartrate, 800 grams (0.0881 percent) 
and lincomycin, 100 or 40 grams.
    (A) Indications for use. For treatment and/or control of swine 
dysentery; for removal and control of large roundworm (Ascaris suum) and 
nodular

[[Page 488]]

worm (Oesophagostomum spp.) infections.
    (B) Limitations. Administer in accordance with paragraph (c)(2)(i), 
(c)(2)(ii), or (c)(2)(iii) of Sec. 558.325 and paragraph (e)(1)(iii)(B) 
of this section.
    (xii) Amount per ton. Pyrantel tartrate, 96 grams (0.0106 percent) 
and lincomycin, 200 grams as lincomycin hydrochloride monohydrate.
    (A) Indications for use. For the reduction in severity of swine 
mycoplasma pneumonia caused by Mycoplasma hyopneumoniae; aid in the 
prevention of migration and establishment of large roundworms (Ascaris 
suum) infections; aid in the prevention of establishment of nodular worm 
(Oesophagostomum spp.) infections.
    (B) Limitations. Feed as sole ration for 21 days; not to be fed to 
swine that weigh more than 250 pounds; withdraw 6 days before slaughter; 
consult your veterinarian before feeding to severely debilitated animals 
and for assistance in the diagnosis, treatment, and control of 
parasitism.
    (C) Sponsor. See No. 000009 in Sec. 510.600(c) of this chapter.
    (2) Horses--(i) Amount. Feed continuously at the rate of 1.2 
milligrams per pound (2.64 milligrams per kilogram) of body weight.
    (A) Indications for use. Prevention of Strongylus vulgaris larval 
infections; control of adult large strongyles (S. vulgaris, and S. 
edentatus), adult and 4th stage larvae small strongyles (Cyathostomum 
spp., Cylicocyclus spp., Cylicostephanus spp., Cylicodontophorus spp., 
Poteriostomum spp., and Triodontophorus spp.), adult and 4th stage 
larvae pinworms (Oxyuris equi), and adult and 4th stage larvae ascarids 
(Parascaris equorum).
    (B) Limitations. Administer either as a top-dress (not to exceed 
20,000 grams per ton) or mixed in the horse's daily grain ration (not to 
exceed 1,200 grams per ton) during the time that the animal is at risk 
of exposure to internal parasites. Not for use in horses intended for 
food. Consult your veterinarian before using in severely debilitated 
animals and for assistance in the diagnosis, treatment, and control of 
parasitism.
    (ii) [Reserved]

[40 FR 13959, Mar. 27, 1975]

    Editorial Note: For Federal Register citations affecting Sec. 
558.485, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.500  Ractopamine.

    (a) Specifications. Type A medicated articles containing 9 or 45 
grams of ractopamine hydrochloride per pound.
    (b) Approvals. See No. 000986 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.570 of this chapter.
    (d) Special considerations. (1) Labeling of Type B and Type C feeds 
shall bear the following: ``Not for animals intended for breeding.''
    (2) Labeling of Type B and Type C swine feeds shall bear the 
following:
    (i) ``No increased benefit has been shown when ractopamine 
concentrations in the diet are greater than 4.5 g/ton.''
    (ii) ``Ractopamine may increase the number of injured and/or 
fatigued pigs during marketing.''
    (3) Labeling of Type B and Type C tom turkey feeds shall bear the 
following: ``No increased benefit has been shown when ractopamine 
concentrations in the diet are greater than 4.6 g/ton.''
    (4) Tylosin in combinations as tylosin phosphate.
    (5) Ractopamine liquid Type B cattle feeds may be manufactured from 
dry ractopamine Type A articles. The liquid Type B feeds must be 
maintained at a pH of 4.5 to 7.5 or, if in combination with monensin 
and/or tylosin, at a pH of 4.5 to 6.0. Mixing directions for liquid Type 
B feeds requiring recirculation or agitation: Recirculate immediately 
prior to use for not less than 10 minutes, moving not less than 1 
percent of the tank contents per minute from the bottom of the tank to 
the top. Recirculate daily as described even when not used.
    (e) Conditions of use--(1) Swine--

[[Page 489]]



----------------------------------------------------------------------------------------------------------------
                                   Combination in grams/
     Ractopamine in grams/ton               ton            Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 4.5 to 9.....................  ....................  For increased rate of    Feed continuously       000986
                                                          weight gain, improved    as sole ration.
                                                          feed efficiency, and
                                                          increased carcass
                                                          leanness in finishing
                                                          swine, weighing not
                                                          less than 150 lbs, fed
                                                          a complete ration
                                                          containing at least
                                                          16% crude protein for
                                                          the last 45 to 90 lbs
                                                          of gain prior to
                                                          slaughter.
(ii) 4.5 to 9....................  Tylosin.............  Finishing swine: As in   Feed 100 grams per      000986
                                   40 or 100...........   paragraph (e)(1)(i) of   tons (g/ton)
                                                          this section; and for    continuously as
                                                          control of swine         sole ration for at
                                                          dysentery associated     least 3 weeks
                                                          with Brachyspira         followed by 40 g/
                                                          hyodysenteriae and       ton until market
                                                          porcine proliferative    weight.
                                                          enteropathies (PPE,
                                                          ileitis) associated
                                                          with Lawsonia
                                                          intracellularis.
(iii) 4.5 to 9...................  Tylosin.............  Finishing swine: As in   Feed continuously       000986
                                   100.................   paragraph (e)(1)(i) of   as sole ration for
                                                          this section; and for    21 days.
                                                          control of porcine
                                                          proliferative
                                                          enteropathies (PPE,
                                                          ileitis) associated
                                                          with L.
                                                          intracellularis.
(iv) 4.5 to 9....................  Tylosin.............  Finishing swine: As in   Feed continuously       000986
                                   40 to 100...........   paragraph (e)(1)(i) of   as sole ration for
                                                          this section; for        2 to 6 weeks,
                                                          treatment and control    immediately after
                                                          of swine dysentery       treatment with
                                                          associated with B.       tylosin tartrate
                                                          hyodysenteriae and for   in drinking water
                                                          control of porcine       as in Sec.
                                                          proliferative            520.2640(d)(3) of
                                                          enteropathies (PPE,      this chapter.
                                                          ileitis) associated
                                                          with L.
                                                          intracellularis.
----------------------------------------------------------------------------------------------------------------

    (2) Cattle--

----------------------------------------------------------------------------------------------------------------
                                   Combination in grams/
     Ractopamine in grams/ton               ton            Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 8.2 to 24.6..................  ....................  Cattle fed in            Feed continuously       000986
                                                          confinement for          as sole ration
                                                          slaughter: For           during the last 28
                                                          increased rate of        to 42 days on feed.
                                                          weight gain and
                                                          improved feed
                                                          efficiency during the
                                                          last 28 to 42 days on
                                                          feed.
(ii) 8.2 to 24.6.................  Monensin 10 to 40 to  Cattle fed in            As in paragraph         000986
                                    provide 0.14 to       confinement for          (e)(2)(i) of this
                                    0.42 mg monensin/lb   slaughter: As in         section; see
                                    of body weight,       paragraph (e)(2)(i) of   paragraph Sec.
                                    depending on          this section; for        Sec. 558.355(d)
                                    severity of           prevention and control   of this chapter.
                                    coccidiosis           of coccidiosis due to
                                    challenge, up to      Eimeria bovis and E
                                    480 mg/head/day.      zuernii.
(iii) [Reserved].................
(iv) 8.2 to 24.6.................  Monensin 10 to 40 to  Cattle fed in            As in paragraph         000986
                                    provide 0.14 to       confinement for          (e)(2)(i) of this
                                    0.42 mg monensin/lb   slaughter: As in         section; see Sec.
                                    of body weight,       paragraph (e)(2)(i) of   Sec. 558.355(d)
                                    depending on          this section; for        and 558.625(c) of
                                    severity of           prevention and control   this chapter.
                                    coccidiosis           of coccidiosis due to
                                    challenge, up to      Eimeria bovis and E.
                                    480 mg/head/day,      zuernii; and for
                                    plus tylosin 8 to     reduction of incidence
                                    10.                   of liver abscesses
                                                          caused by
                                                          Fusobacterium
                                                          necrophorum and
                                                          Arcanobacterium
                                                          (Actinomyces) pyogenes.
(v) [Reserved]...................
(vi) 9.8 to 24.6.................  ....................  Cattle fed in            Feed continuously       000986
                                                          confinement for          as sole ration
                                                          slaughter: For           during the last 28
                                                          increased rate of        to 42 days on
                                                          weight gain, improved    feed. Not for
                                                          feed efficiency, and     animals intended
                                                          increased carcass        for breeding.
                                                          leanness during the
                                                          last 28 to 42 days on
                                                          feed.

[[Page 490]]

 
(vii) 9.8 to 24.6................  Monensin 10 to 40 to  Cattle fed in            As in paragraph         000986
                                    provide 0.14 to       confinement for          (e)(2)(vi) of this
                                    0.42 mg monensin/lb   slaughter: As in         section; see
                                    of body weight,       paragraph (e)(2)(vi)     paragraph Sec.
                                    depending on          of this section; for     Sec. 558.355(d)
                                    severity of           prevention and control   of this chapter.
                                    coccidiosis           of coccidiosis due to
                                    challenge, up to      Eimeria bovis and E
                                    480 mg/head/day.      zuernii.
(viii) 9.8 to 24.6...............  Monensin 10 to 40 to  Heifers fed in           As in paragraph         000986
                                    provide 0.14 to       confinement for          (e)(2)(vi) of this
                                    0.42 mg monensin/lb   slaughter: As in         section; see Sec.
                                    of body weight,       paragraph (e)(2)(vi)     Sec. 558.342(d)
                                    depending on          of this section; for     and 558.355(d) of
                                    severity of           prevention and control   this chapter.
                                    coccidiosis           of coccidiosis due to    Melengestrol
                                    challenge, up to      Eimeria bovis and E.     acetate as
                                    480 mg/head/day,      zuernii; and for         provided by No.
                                    plus melengestrol     suppression of estrus    000009 or 021641
                                    acetate to provide    (heat).                  in Sec.
                                    0.25 to 0.5 mg/head/                           510.600(c) of this
                                    day.                                           chapter.
(ix) 9.8 to 24.6.................  Monensin 10 to 40 to  Cattle fed in            As in paragraph         000986
                                    provide 0.14 to       confinement for          (e)(2)(vi) of this
                                    0.42 mg monensin/lb   slaughter: As in         section; see Sec.
                                    of body weight,       paragraph (e)(2)(vi)     Sec. 558.355(d)
                                    depending on          of this section; for     and 558.625(c) of
                                    severity of           prevention and control   this chapter.
                                    coccidiosis           of coccidiosis due to
                                    challenge, up to      Eimeria bovis and E.
                                    480 mg/head/day,      zuernii; and for
                                    plus tylosin 8 to     reduction of incidence
                                    10.                   of liver abscesses
                                                          caused by
                                                          Fusobacterium
                                                          necrophorum and
                                                          Arcanobacterium
                                                          (Actinomyces) pyogenes.
(x) 9.8 to 24.6..................  Monensin 10 to 40 to  Heifers fed in           As in paragraph         000986
                                    provide 0.14 to       confinement for          (e)(2)(vi) of this
                                    0.42 mg monensin/lb   slaughter: As in         section; see
                                    of body weight,       paragraph (e)(2)(vi)     paragraphs Sec.
                                    depending on          of this section; for     Sec. 558.342(d),
                                    severity of           prevention and control   558.355(d) and
                                    coccidiosis           of coccidiosis due to    558.625(c) of this
                                    challenge, up to      Eimeria bovis and E.     chapter.
                                    480 mg/head/day,      zuernii; for reduction   Melengestrol
                                    plus tylosin 8 to     of incidence of liver    acetate as
                                    10, plus              abscesses caused by      provided by Nos.
                                    melengestrol          Fusobacterium            000009 and 021641
                                    acetate to provide    necrophorum and          in Sec.
                                    0.25 to 0.5 mg/head/  Arcanobacterium          510.600(c) of this
                                    day.                  (Actinomyces)            chapter.
                                                          pyogenes; and for
                                                          suppression of estrus
                                                          (heat).
(xi) Not to exceed 800; to         ....................  Cattle fed in            Top dress in a          000986
 provide 70 to 400 mg/head/day.                           confinement for          minimum of 1.0 lb
                                                          slaughter: As in         of medicated feed.
                                                          paragraph (e)(2)(i) of
                                                          this section.
(xii) Not to exceed 800; to        Monensin 10 to 40 to  Cattle fed in            Top dress               000986
 provide 70 to 400 mg/head/day.     provide 0.14 to       confinement for          ractopamine in a
                                    0.42 mg monensin/lb   slaughter: As in         minimum of 1.0 lb
                                    of body weight,       paragraph (e)(2)(i) of   of medicated feed
                                    depending on          this section; for        during the last 28
                                    severity of           prevention and control   to 42 days on
                                    coccidiosis           of coccidiosis due to    feed. Not for
                                    challenge, up to      Eimeria bovis and E.     animals intended
                                    480 mg/head/day.      zuernii.                 for breeding. See
                                                                                   Sec. 558.355(d).
(xiii) Not to exceed 800; to       Monensin 10 to 40 to  Cattle fed in            Top dress               000986
 provide 70 to 400 mg/head/day.     provide 0.14 to       confinement for          ractopamine in a
                                    0.42 mg monensin/lb   slaughter: As in         minimum of 1.0 lb
                                    of body weight,       paragraph (e)(2)(i) of   of medicated feed
                                    depending on          this section; for        during the last 28
                                    severity of           prevention and control   to 42 days on
                                    coccidiosis           of coccidiosis due to    feed. Not for
                                    challenge, up to      Eimeria bovis and E.     animals intended
                                    480 mg/head/day,      zuernii; and for         for breeding. See
                                    plus tylosin 8 to     reduction of incidence   Sec. Sec.
                                    10.                   of liver abscesses       558.355(d) and
                                                          caused by                558.625(c).
                                                          Fusobacterium
                                                          necrophorum and
                                                          Arcanobacterium
                                                          (Actinomyces) pyogenes.
----------------------------------------------------------------------------------------------------------------


[[Page 491]]

    (3) Turkeys--

----------------------------------------------------------------------------------------------------------------
                                   Combination in grams/
     Ractopamine in grams/ton               ton            Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 4.6 to 11.8 (5 to 13 ppm)....  ....................  Finishing hen turkeys:   Feed continuously       000986
                                                          For increased rate of    as sole ration
                                                          weight gain and          during the last 7
                                                          improved feed            to 14 days prior
                                                          efficiency when fed      to slaughter.
                                                          for the last 7 to 14
                                                          days prior to
                                                          slaughter.
----------------------------------------------------------------------------------------------------------------
(ii) 4.6 to 11.8 (5 to 13 ppm)...  ....................  Finishing tom turkeys:   Feed continuously       000986
                                                          For increased rate of    as sole ration
                                                          weight gain and          during the last 14
                                                          improved feed            days prior to
                                                          efficiency when fed      slaughter. Feeding
                                                          for the last 14 days     ractopamine to tom
                                                          prior to slaughter.      turkeys during
                                                                                   periods of
                                                                                   excessive heat can
                                                                                   result in
                                                                                   increased
                                                                                   mortality.
(iii) 4.6 to 11.8 (5 to 13 ppm)..  Monensin 54 to 90...  Finishing hen turkeys:   Feed continuously       000986
                                                          As in paragraph          as sole ration
                                                          (e)(3)(i) of this        during the last 7
                                                          section; and for the     to 14 days prior
                                                          prevention of            to slaughter. See
                                                          coccidiosis in growing   Sec. 558.355(d).
                                                          turkeys caused by
                                                          Eimeria adenoeides, E.
                                                          meleagrimitis and E.
                                                          gallopavonis.
(iv) 4.6 to 11.8 (5 to 13 ppm)...  Monensin 54 to 90...  Finishing tom turkeys:   Feed continuously       000986
                                                          As in paragraph          as sole ration
                                                          (e)(3)(ii) of this       during the last 14
                                                          section; and for the     days prior to
                                                          prevention of            slaughter. Feeding
                                                          coccidiosis in growing   ractopamine to tom
                                                          turkeys caused by        turkeys during
                                                          Eimeria adenoeides, E.   periods of
                                                          meleagrimitis and E.     excessive heat can
                                                          gallopavonis.            result in
                                                                                   increased
                                                                                   mortality. See
                                                                                   Sec. 558.355(d).
----------------------------------------------------------------------------------------------------------------


[67 FR 71820, Dec. 3, 2002, as amended at 68 FR 54659, Sept. 18, 2003; 
69 FR 12068, Mar. 15, 2004; 69 FR 51174, Aug. 18, 2004; 71 FR 31074, 
June 1, 2006; 71 FR 67301, Nov. 21, 2006; 72 FR 10358, Mar. 8, 2007; 72 
FR 41619, July 31, 2007; 72 FR 56897, Oct. 5, 2007; 72 FR 62571, Nov. 6, 
2007; 72 FR 65667, Nov. 23, 2007; 72 FR 70777, Dec. 13, 2007; 73 FR 
72715, Dec. 1, 2008; 73 FR 75323, Dec. 11, 2008; 74 FR 66914, Dec. 17, 
2009; 75 FR 1276, Jan. 11, 2010; 75 FR 5888, Feb. 5, 2010; 75 FR 20917, 
Apr. 22, 2010; 75 FR 54018, Sept. 3, 2010; 77 FR 31724, May 30, 2012]



Sec. 558.515  Robenidine hydrochloride.

    (a) Approvals. Type A medicated articles: 30 grams per pound to 
046573 in Sec. 510.600(c) of this chapter.
    (b) Special considerations. Type C feed containing robenidine 
hydrochloride must be fed within 50 days from the date of manufacture. 
Do not use in Type B or Type C medicated feeds containing bentonite.
    (c) Related tolerances. See Sec. 556.580 of this chapter.
    (d) Conditions of use. It is used in feed for chickens as follows:

----------------------------------------------------------------------------------------------------------------
Robenidine hydrochloride in grams/ Combination in grams/
               ton                          ton            Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
30 (0.0033 pct)..................  ....................  For broiler and fryer    Feed continuously       046573
                                                          chickens: As an aid in   as sole ration. Do
                                                          the prevention of        not feed to
                                                          coccidiosis caused by    layers. Withdraw 5
                                                          E. mivati, E.            days prior to
                                                          brunetti, E. tenella,    slaughter.
                                                          E. acervulina, E.
                                                          maxima, and E.
                                                          necatrix.
                                   Bacitracin (as        For broiler and fryer    Feed continuously       046573
                                    bacitracin            chickens: As an aid in   as sole ration. Do
                                    methylene             the prevention of        not feed to laying
                                    disalicylate) 4 to    coccidiosis caused by    chickens. Withdraw
                                    30.                   E. mivati, E.            5 days prior to
                                                          brunetti, E. tenella,    slaughter.
                                                          E. acervulina, E.
                                                          maxima, and E.
                                                          necatrix. For
                                                          increased rate of
                                                          weight gain.
                                   Bacitracin (as        For broiler and fryer    Feed continuously       046573
                                    bacitracin            chickens: As an aid in   as sole ration. Do
                                    methylene             the prevention of        not feed to laying
                                    disalicylate) 27 to   coccidiosis caused by    chickens. Withdraw
                                    50.                   E. mivati, E.            5 days prior to
                                                          brunetti, E. tenella,    slaughter.
                                                          E. acervulina, E.
                                                          maxima, and E.
                                                          necatrix. For improved
                                                          feed efficiency.

[[Page 492]]

 
                                   Bacitracin (as        For broiler and fryer    Feed continuously       046573
                                    bacitracin            chickens: As an aid in   as sole ration. Do
                                    methylene             the prevention of        not feed to laying
                                    disalicylate) 50.     necrotic enteritis       hens. Withdraw 5
                                                          caused or complicated    days before
                                                          by Clostridium spp. or   slaughter.
                                                          other organisms
                                                          susceptible to
                                                          bacitracin.
                                   Bacitracin (as        For broiler and fryer    To control a            046573
                                    bacitracin            chickens: As an aid in   necrotic enteritis
                                    methylene             the control of           outbreak, start
                                    disalicylate) 100     necrotic enteritis       medication at
                                    to 200.               caused or complicated    first clinical
                                                          by Clostridium spp. or   signs of disease;
                                                          other organisms          administer
                                                          susceptible to           continuously for 5
                                                          bacitracin.              to 7 days or as
                                                                                   long as clinical
                                                                                   signs persist,
                                                                                   then reduce
                                                                                   bacitracin
                                                                                   methylene
                                                                                   disalicylate to
                                                                                   prevention level
                                                                                   (50 g/ton). Do not
                                                                                   feed to laying
                                                                                   hens. Withdraw 5
                                                                                   days before
                                                                                   slaughter.
                                   Bacitracin (as        For broiler chickens:    Feed continuously       046573
                                    bacitracin            As an aid in the         as sole ration.
                                    methylene             prevention of            Use as the sole
                                    disalicylate) 50      coccidiosis caused by    source of organic
                                    and roxarsone 22.7    E. mivati, E.            arsenic; poultry
                                    to 45.4.              brunetti, E. tenella,    should have access
                                                          E. acervulina, E.        to water at all
                                                          maxima, and E.           times; drug
                                                          necatrix. As an aid in   overdose or lack
                                                          the prevention of        of water intake
                                                          necrotic enteritis       may result in leg
                                                          caused or complicated    weakness or
                                                          by Clostridium spp. or   paralysis. Do not
                                                          other organisms          feed to laying
                                                          susceptible to           chickens. Withdraw
                                                          bacitracin. For          5 days prior to
                                                          increased rate of        slaughter.
                                                          weight gain, improved
                                                          feed efficiency, and
                                                          improved pigmentation.
                                   Bacitracin (as        For broiler chickens:    To control necrotic     046573
                                    bacitracin            As an aid in the         enteritis, start
                                    methylene             prevention of            medication at
                                    disalicylate) 100     coccidiosis caused by    first clinical
                                    to 200 and            E. mivati, E.            signs of disease;
                                    roxarsone 22.7 to     brunetti, E. tenella,    vary bacitracin
                                    45.4.                 E. acervulina, E.        dosage based on
                                                          maxima, and E.           the severity of
                                                          necatrix. As an aid in   infection;
                                                          the control of           administer
                                                          necrotic enteritis       continuously for 5
                                                          caused or complicated    to 7 days or as
                                                          by Clostridium spp. or   long as clinical
                                                          other organisms          signs persist,
                                                          susceptible to           then reduce
                                                          bacitracin. For          bacitracin to
                                                          increased rate of        prevention level
                                                          weight gain, improved    (50 g/ton). Use as
                                                          feed efficiency, and     the sole source of
                                                          improved pigmentation.   organic arsenic;
                                                                                   poultry should
                                                                                   have access to
                                                                                   water at all
                                                                                   times; drug
                                                                                   overdose or lack
                                                                                   of water intake
                                                                                   may result in leg
                                                                                   weakness or
                                                                                   paralysis. Do not
                                                                                   feed to laying
                                                                                   chickens. Withdraw
                                                                                   5 days prior to
                                                                                   slaughter.
                                   Bacitracin (as        For broiler and fryer    Feed continuously       046573
                                    bacitracin zinc) 4    chickens: As an aid in   as sole ration. Do     046573
                                    to 30.                the prevention of        not feed to laying
                                                          coccidiosis caused by    chickens. Withdraw
                                                          E. mivati, E.            5 days prior to
                                                          brunetti, E. tenella,    slaughter.
                                                          E. acervulina, E.
                                                          maxima, and E.
                                                          necatrix. For
                                                          increased rate of
                                                          weight gain.
                                   Bacitracin (as        For broiler and fryer    Feed continuously       046573
                                    bacitracin zinc) 27   chickens: As an aid in   as sole ration. Do     046573
                                    to 50.                the prevention of        not feed to laying
                                                          coccidiosis caused by    chickens. Withdraw
                                                          E. mivati, E.            5 days prior to
                                                          brunetti, E. tenella,    slaughter.
                                                          E. acervulina, E.
                                                          maxima, and E.
                                                          necatrix. For improved
                                                          feed efficiency.
                                   Chlortetracycline     For broiler and fryer    Feed continuously
                                    100 to 200.           chickens: As an aid in   as sole ration up
                                                          the prevention of        to 14 days. Do not
                                                          coccidiosis caused by    feed to chickens
                                                          E. mivati, E.            producing eggs for
                                                          brunetti, E. tenella,    human consumption.
                                                          E. acervulina, E.        Withdraw 5 days
                                                          maxima, and E.           prior to
                                                          necatrix. For control    slaughter..
                                                          of infectious
                                                          synovitis caused by
                                                          Mycoplasma synoviae
                                                          susceptible to
                                                          chlortetracycline.

[[Page 493]]

 
                                   Chlortetracycline     For broiler and fryer    Feed continuously
                                    200 to 400.           chickens: As an aid in   as sole ration up
                                                          the prevention of        to 14 days. Do not
                                                          coccidiosis caused by    feed to chickens
                                                          E. mivati, E.            producing eggs for
                                                          brunetti, E. tenella,    human consumption.
                                                          E. acervulina, E.        Withdraw 5 days
                                                          maxima, and E.           prior to
                                                          necatrix. For control    slaughter..
                                                          of chronic respiratory
                                                          disease (CRD) and air
                                                          sac infection caused
                                                          by M. gallisepticum
                                                          and E. coli
                                                          susceptible to
                                                          chlortetracycline.
                                   Chlortetracycline     For broiler and fryer    Feed continuously       046573
                                    500.                  chickens: As an aid in   as sole ration up
                                                          the prevention of        to 5 days. Do not
                                                          coccidiosis caused by    feed to chickens
                                                          E. mivati, E.            producing eggs for
                                                          brunetti, E. tenella,    human consumption.
                                                          E. acervulina, E.        Withdraw 5 days
                                                          maxima, and E.           prior to slaughter.
                                                          necatrix. As an aid in
                                                          the reduction of
                                                          mortality due to E.
                                                          coli susceptible to
                                                          chlortetracycline.
                                   Lincomycin 2........  For broiler and fryer    Feed continuously       000009
                                                          chickens: As an aid in   as the sole
                                                          the prevention of        ration. Do not
                                                          coccidiosis caused by    feed to laying
                                                          E. mivati, E.            hens. Withdraw 5
                                                          brunetti, E. tenella,    days before
                                                          E. acervulina, E.        slaughter.
                                                          maxima, and E.
                                                          necatrix. For increase
                                                          in rate of weight gain
                                                          and improved feed
                                                          efficiency.
                                   Oxytetracycline 400.  For broiler chickens:    Feed continuously       066104
                                                          As an aid in the         for 7 to 14 days.
                                                          prevention of            Do not feed to
                                                          coccidiosis caused by    chickens producing
                                                          E. mivati, E.            eggs for human
                                                          brunetti, E. tenella,    consumption.
                                                          E. acervulina, E.        Withdraw 5 days
                                                          maxima, and E.           before slaughter.
                                                          necatrix. For control
                                                          of CRD and air sac
                                                          infection caused by
                                                          Mycoplasma
                                                          gallisepticum and E.
                                                          coli susceptible to
                                                          oxytetracycline.
                                   Roxarsone 22.5 to     For broiler and fryer    Feed continuously       046573
                                    45.4 (0.005           chickens: As an aid in   as the sole
                                    percent).             the prevention of        ration. Use as
                                                          coccidiosis caused by    sole source of
                                                          E. mivati, E.            organic arsenic.
                                                          brunetti, E. tenella,    Do not feed to
                                                          E. acervulina, E.        layers. Withdraw 5
                                                          maxima, and E.           days prior to
                                                          necatrix. For            slaughter.
                                                          increased rate of
                                                          weight gain.
----------------------------------------------------------------------------------------------------------------


[40 FR 13959, Mar. 27, 1975]

    Editorial Note: For Federal Register citations affecting Sec. 
558.515, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.530  Roxarsone.

    (a) Specifications. Type A medicated articles containing 10, 20, 50, 
or 80 percent roxarsone.
    (b) Approvals. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (d) of this section.
    (1) No. 046573 for use of 10, 20, and 50 percent Type A medicated 
articles as in paragraph (d)(1)(i) of this section.
    (2) No. 046573 for use of 10, 20, 50, and 80 percent Type A 
medicated articles as in paragraphs (d)(1) through (d)(3) of this 
section.
    (c) Related tolerances. See Sec. 556.60 of this chapter.
    (d) Conditions of use--(1) Chickens. It is used in chicken feed as 
follows:

[[Page 494]]



------------------------------------------------------------------------
Roxarsone in   Combinations
  grams per    in grams per    Indications     Limitations     Sponsor
     ton            ton          for use
------------------------------------------------------------------------
(i) 22.7 to   ..............  Growing        Feed                 046573
 45.4                          chickens:      continuously
                               For            throughout
                               increased      growing
                               rate of        period;
                               weight gain,   withdraw 5
                               improved       days before
                               feed           slaughter; as
                               efficiency,    sole source
                               and improved   of organic
                               pigmentation   arsenic; drug
                                              overdose or
                                              lack of water
                                              may result in
                                              weakness or
                                              paralysis of
                                              the legs
------------------------------------------------------------------------
(ii) 22.7 to  Chlortetracycl  Growing        As in           ...........
 45.4          ine 10 to 50    chickens: As   paragraph
                               in paragraph   (d)(1)(i) of
                               (d)(1)(i) of   this section.
                               this section   Chlortetracyc
                                              line as
                                              provided by
                                              No. 046573 in
                                              Sec.
                                              510.600(c) of
                                              this chapter
------------------------------------------------------------------------
(iii) 22.7    Chlortetracycl  Growing        As in           ...........
 to 45.4       ine 100 to      chickens: As   paragraph
               200             in paragraph   (d)(1)(i) of
                               (d)(1)(i) of   this section
                               this           except feed
                               section; and   continuously
                               for control    for 7 to 14
                               of             days.
                               infectious     Chlortetracyc
                               synovitis      line as
                               caused by      provided by
                               Mycoplasma     No. 046573 in
                               synoviae       Sec.
                               susceptible    510.600(c) of
                               to             this chapter
                               chlortetracy
                               cline
------------------------------------------------------------------------
(iv) 22.7 to  Chlortetracycl  Growing        As in           ...........
 45.4          ine 200 to      chickens: As   paragraph
               400             in paragraph   (d)(1)(i) of
                               (d)(1)(i) of   this section
                               this           except feed
                               section; and   continuously
                               for control    for 7 to 14
                               of chronic     days.
                               respiratory    Chlortetracyc
                               disease        line as
                               (CRD) and      provided by
                               air sac        No. 046573 in
                               infection      Sec.
                               caused by M.   510.600(c) of
                               gallisepticu   this chapter
                               m and
                               Escherichia
                               coli
                               susceptible
                               to
                               chlortetracy
                               cline
------------------------------------------------------------------------
(v) 22.7 to   Chlortetracycl  Growing        As in           ...........
 45.4          ine 500         chickens: As   paragraph
                               in paragraph   (d)(1)(i) of
                               (d)(1)(i) of   this section
                               this           except feed
                               section; and   continuously
                               for            for 5 days.
                               reduction of   Chlortetracyc
                               mortality      line as
                               due to E.      provided by
                               coli           No. 046573 in
                               infections     Sec.
                               susceptible    510.600(c) of
                               to             this chapter
                               chlortetracy
                               cline
------------------------------------------------------------------------

    (2) Turkeys. It is used in turkey feed as follows:

------------------------------------------------------------------------
Roxarsone in   Combinations
  grams per    in grams per    Indications     Limitations     Sponsor
     ton            ton          for use
------------------------------------------------------------------------
(i) 22.7 to   ..............  Growing        Feed                 046573
 45.4                          turkeys: For   continuously
                               increased      throughout
                               rate of        growing
                               weight gain,   period;
                               improved       withdraw 5
                               feed           days before
                               efficiency,    slaughter; as
                               and improved   sole source
                               pigmentation   of organic
                                              arsenic; drug
                                              overdose or
                                              lack of water
                                              may result in
                                              weakness or
                                              paralysis of
                                              the legs
------------------------------------------------------------------------
(ii) 22.7 to  Chlortetracycl  Growing        As in           ...........
 45.4          ine 10 to 50    turkeys: As    paragraph
                               in paragraph   (d)(2)(i) of
                               (d)(2)(i) of   this section.
                               this section   Chlortetracyc
                                              line as
                                              provided by
                                              No. 046573 in
                                              Sec.
                                              510.600(c) of
                                              this chapter
------------------------------------------------------------------------
(iii) 22.7    Chlortetracycl  Growing        As in           ...........
 to 45.4       ine 200         turkeys: As    paragraph
                               in paragraph   (d)(2)(i) of
                               (d)(2)(i) of   this section
                               this           except feed
                               section; and   continuously
                               for control    for 7 to 14
                               of             days.
                               infectious     Chlortetracyc
                               synovitis      line as
                               caused by      provided by
                               Mycoplasma     No. 046573 in
                               synoviae       Sec.
                               susceptible    510.600(c) of
                               to             this chapter
                               chlortetracy
                               cline
------------------------------------------------------------------------

[[Page 495]]

 
(iv) 22.7 to  Chlortetracycl  1. Growing     As in           ...........
 45.4          ine 400         turkeys: As    paragraph
                               in paragraph   (d)(2)(i) of
                               (d)(2)(i) of   this section
                               this           except feed
                               section; and   continuously
                               for control    for 7 to 14
                               of             days.
                               hexamitiasis   Chlortetracyc
                               caused by      line as
                               Hexamita       provided by
                               meleagrides    No. 046573 in
                               susceptible    Sec.
                               to             510.600(c) of
                               chlortetracy   this chapter
                               cline.
                              2. Turkey
                               poults not
                               over 4 weeks
                               of age:
                               Reduction of
                               mortality
                               due to
                               paratyphoid
                               caused by
                               Salmonella
                               typhimurium
                               susceptible
                               to
                               chlortetracy
                               cline
------------------------------------------------------------------------
(v) 22.7 to   Chlortetracycl  Growing        As in           ...........
 45.4          ine 25 mg/lb    turkeys: As    paragraph
               body weight     in paragraph   (d)(2)(i) of
               daily           (d)(2)(i) of   this section
                               this           except feed
                               section; and   continuously
                               for control    for 7 to 14
                               of             days.
                               complicating   Chlortetracyc
                               bacterial      line as
                               organisms      provided by
                               associated     No. 046573 in
                               with           Sec.
                               bluecomb       510.600(c) of
                               (transmissib   this chapter
                               le
                               enteritis,
                               coronaviral
                               enteritis)
                               susceptible
                               to
                               chlortetracy
                               cline
------------------------------------------------------------------------

    (3) Swine. It is used in swine feed as follows:

------------------------------------------------------------------------
Roxarsone in   Combinations
  grams per    in grams per    Indications     Limitations     Sponsor
     ton            ton          for use
------------------------------------------------------------------------
(i) 22.7 to   ..............  Growing and    Feed                 046573
 34.1                          finishing      continuously
                               swine: For     throughout
                               increased      growing
                               rate of        period;
                               weight gain    withdraw 5
                               and improved   days before
                               feed           slaughter; as
                               efficiency     sole source
                                              of organic
                                              arsenic
------------------------------------------------------------------------
(ii) 22.7 to  Chlortetracycl  Growing and    Feed for not    ...........
 34.1          ine 400 (to     finishing      more than 14
               administer 10   swine: As in   days;
               mg/lb body      paragraph      withdraw 5
               weight)         (d)(3)(i) of   days before
                               this           slaughter; as
                               section; and   sole source
                               for            of organic
                               treatment of   arsenic
                               bacterial
                               enteritis
                               caused by E.
                               coli and S.
                               choleraesuis
                               and
                               bacterial
                               pneumonia
                               caused by
                               Pasteurella
                               multocida
                               susceptible
                               to
                               chlortetracy
                               cline
------------------------------------------------------------------------
(iii) 181.5   ..............  Growing and    Feed for not         046573
                               finishing      more than 6
                               swine: For     consecutive
                               the            days; if
                               treatment of   improvement
                               swine          is not
                               dysentery      observed,
                                              consult a
                                              veterinarian;
                                              withdraw 5
                                              days before
                                              slaughter; as
                                              a sole source
                                              of organic
                                              arsenic;
                                              animals must
                                              consume
                                              enough
                                              medicated
                                              feed to
                                              provide a
                                              therapeutic
                                              dose
------------------------------------------------------------------------
(iv) 181.5    Chlortetracycl  Growing and    Feed for not    ...........
               ine 10 to 50    finishing      more than 6
                               swine: As in   consecutive
                               paragraph      days; if
                               (d)(3)(i) of   improvement
                               this           is not
                               section; and   observed,
                               for            consult a
                               treatment of   veterinarian;
                               swine          withdraw 5
                               dysentery      days before
                                              slaughter; as
                                              a sole source
                                              of organic
                                              arsenic;
                                              animals must
                                              consume
                                              enough
                                              medicated
                                              feed to
                                              provide a
                                              therapeutic
                                              dose
------------------------------------------------------------------------
(v) 181.5     Chlortetracycl  Growing and    Feed for not    ...........
               ine 400 (to     finishing      more than 6
               administer 10   swine: As in   consecutive
               mg/lb body      paragraph      days; if
               weight)         (d)(3)(iii)    improvement
                               of this        is not
                               section; and   observed,
                               for            consult a
                               treatment of   veterinarian;
                               bacterial      withdraw 5
                               enteritis      days before
                               caused by E.   slaughter; as
                               coli and S.    a sole source
                               choleraesuis   of organic
                               and            arsenic;
                               bacterial      animals must
                               pneumonia      consume
                               caused by P.   enough
                               multocida      medicated
                               susceptible    feed to
                               to             provide a
                               chlortetracy   therapeutic
                               cline          dose
------------------------------------------------------------------------


[[Page 496]]

    (4) Permitted combinations. It may be used in accordance with this 
section in combination with:
    (i) [Reserved]
    (ii) Amprolium as in Sec. 558.55.
    (iii) Amprolium and ethopabate as in Sec. 558.58.
    (iv) Bacitracin methylene disalicylate as in Sec. 558.76.
    (v) Bacitracin zinc as in Sec. 558.78.
    (vi) Bambermycins and bambermycins plus certain anticoccidials as in 
Sec. 558.95.
    (vii) Chlortetracycline as in Sec. 558.128.
    (viii) Clopidol as in Sec. 558.175.
    (ix) Decoquinate alone or in combination as in Sec. 558.195.
    (x) Diclazuril alone or in combination as in Sec. 558.198.
    (xi) Halofuginone alone or in combination as in Sec. 558.265.
    (xii) Lasalocid alone or in combination as in Sec. 558.311.
    (xiii) Monensin alone or in combination as in Sec. 558.355.
    (xiv) Narasin alone or in combination as in Sec. 558.363.
    (xv) Nequinate as in Sec. 558.365.
    (xvi) Nicarbazin alone or in combination as in Sec. 558.366.
    (xvii) [Reserved]
    (xviii) Penicillin and zoalene as in Sec. 558.680.
    (xix) Robenidine hydrochloride as in Sec. 558.515.
    (xx) Salinomycin alone or in combination as in Sec. 558.550.
    (xxi) Semduramicin alone or in combination as in Sec. 558.555.
    (xxii) Sulfadimethoxine, ormetoprim as in Sec. 558.575.
    (xxiii) Zoalene alone or in combination as in Sec. 558.680.

[46 FR 52331, Oct. 27, 1981]

    Editorial Note: For Federal Register citations affecting Sec. 
558.530, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.550  Salinomycin.

    (a) Specifications. Type A medicated articles containing 30 or 60 
grams of salinomycin activity per pound (as salinomycin sodium biomass).
    (b) Approvals. See sponsors in Sec. 510.600(c) of this chapter for 
use as in paragraph (d) of this section:
    (1) No. 046573 for use as in paragraph (d) of this section.
    (2) No. 016592 for use as in paragraphs (d)(1)(i), (d)(1)(iii) 
through (d)(1)(xvi), (d)(1)(xxiii) and (d)(1)(xxiv), (d)(2)(i), 
(d)(3)(i), and (d)(4) of this section.
    (3) No. 048164 for use as in paragraphs (d)(1)(xv) and (d)(1)(xvi) 
of this section.
    (c) [Reserved]
    (d) Conditions of use. (1) Broilers: It is used as follows:
    (i)(a) Amount per ton. Salinomycin 40 to 60 grams.
    (b) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati.
    (c) Limitations. Feed continuously as sole ration. Do not feed to 
layers. Not approved for use with pellet binders. May be fatal if 
accidentally fed to adult turkeys or horses.
    (ii)(a) Amount per ton. Salinomycin 40 to 60 grams and roxarsone 
45.4 grams.
    (b) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, including some field strains of E. tenella which are more 
susceptible to roxarsone combined with salinomycin than to salinomycin 
alone.
    (c) Limitations. Feed continuously as sole ration. Use as sole 
source of organic arsenic. Not approved for use with pellet binders. Do 
not feed to layers. May be fatal if accidentally fed to adult turkeys or 
horses. Withdraw 5 days before slaughter. Roxarsone as provided by No. 
011526 or 046573 in Sec. 510.600(c) of this chapter.
    (iii)(a) Amount per ton. Salinomycin 40 to 60 grams and bacitracin 
methylene disalicylate 4 to 30 grams.
    (b) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati for incresed rate of weight gain and improved feed efficiency.
    (c) Limitation. Feed continuously as sole ration. Not approved for 
use with pellet binders. Do not feed to layers. May be fatal if 
accidentially fed to adult turkeys or horses. Bacitracin methylene 
disalicylate as provided by No. 046573 in Sec. 510.600(c) of this 
chapter.
    (iv)(a) Amount per ton. Salinomycin 40 to 60 grams with roxarsone 
45.4

[[Page 497]]

grams and bacitracin methylene disalicylate 4 to 50 grams.
    (b) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, including some field strains of E. tenella which are more 
susceptible to roxarsone combined with salinomycin than to salinomycin 
alone; for increased rate of weight gain.
    (c) Limitations. Feed continuously as sole ration. Use as sole 
source of organic arsenic. Not approved for use with pellet binders. Do 
not feed to layers. May be fatal if accidentally fed to adult turkeys or 
horses. Withdraw 5 days before slaughter. Roxarsone and bacitracin as 
provided by No. 046573 in Sec. 510.600(c) of this chapter.
    (v)(a) Amount per ton. Salinomycin 40 to 60 grams per ton with 
roxarsone 22.7 to 45.4 grams per ton.
    (b) Indications for use. For the prevention of coccidiosis caused by 
Eimera tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and 
E. maxima and for improved feed efficiency.
    (c) Limitations. Feed continuously as sole ration. Use as sole 
source of organic arsenic. Not approved for use with pellet binders. Do 
not feed to layers. May be fatal if accidently fed to adult turkeys or 
to horses. Withdraw 5 days before slaughter. Roxarsone as provided by 
No. 046573 in Sec. 510.600(c) of this chapter.
    (vi)(a) Amount per ton. Salinomycin 40 to 60 grams and bacitracin 
methylene disalicylate 4 to 50 grams.
    (b) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, and for improved feed efficiency.
    (c) Limitations. Feed continuously as sole ration. Not approved for 
use with pellet binders. Do not feed to layers. May be fatal if 
accidentally fed to adult turkeys or horses. Bacitracin MD as provided 
by No. 046573 in Sec. 510.600(c) of this chapter.
    (vii)(a) Amount per ton. Salinomycin 40 to 60 grams and bacitracin 
zinc 10 to 50 grams.
    (b) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, and for increased rate of weight gain.
    (c) Limitations. Feed continuously as sole ration. Not approved for 
use with pellet binders. Do not feed to layers. May be fatal if 
accidentally fed to adult turkeys or horses. Bacitracin zinc as provided 
by No. 046573 in Sec. 510.600(c) of this chapter.
    (viii)(a) Amount per ton. Salinomycin 40 to 60 grams with roxarsone 
45.4 grams and bacitracin zinc 4 to 50 grams.
    (b) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, including some field strains of E. tenella which are more 
susceptible to roxarsone combined with salinomycin than to salinomycin 
alone; for increased rate of weight gain and improved feed efficiency.
    (c) Limitations. See paragraph (d)(1)(iv)(c) of this section.
    (ix)(a) Amount per ton. Salinomycin 40 to 60 grams with roxarsone 
34.1 grams and bacitracin zinc 10 to 50 grams.
    (b) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, and for increased rate of weight gain and improved feed 
efficiency.
    (c) Limitations. Feed continuously as sole ration. Use as sole 
source of organic arsenic. Do not feed to layers. May be fatal if 
accidentally fed to adult turkeys or horses. Withdraw 5 days before 
slaughter. Roxarsone as provided by No. 046573 and bacitracin as 
provided by No. 046573 in Sec. 510.600(c) of this chapter.
    (x)(a) Amount per ton. Salinomycin 40 to 60 grams and virginiamycin 
5 grams.
    (b) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, and for increased rate of weight gain and improved feed 
efficiency.
    (c) Limitations. Feed continuously as sole ration. Not approved for 
use with pellet binders. Do not feed to layers or to chickens over 16 
weeks of age. May

[[Page 498]]

be fatal if accidentally fed to adult turkeys or horses. Virginiamycin 
as provided by No. 066104 in Sec. 510.600(c) of this chapter.
    (xi)(a) Amount per ton. Salinomycin 40 to 60 grams and virginiamycin 
5 to 15 grams.
    (b) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, and for increased rate of weight gain.
    (c) Limitations. See paragraph (d)(1)(x)(c) of this section.
    (xii) (a) Amount per ton. Salinomycin 40 to 60 grams, virginiamycin 
5 grams, and roxarsone 45.4 grams.
    (b) Indications for use. For prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, including some field strains of E. tenella which are more 
susceptible to roxarsone combined with salinomycin than to salinomycin 
alone, and for improved feed efficiency.
    (c) Limitations. Feed continuously as sole ration. Withdraw 5 days 
prior to slaughter. Use as sole source of organic arsenic. Not approved 
for use with pellet binders. Do not feed to layers. May be fatal if 
accidentally fed to adult turkeys or horses. Virginiamycin as provided 
by No. 066104 in Sec. 510.600(c) of this chapter. Roxarsone as provided 
by No. 046573 in Sec. 510.600(c) of this chapter.
    (xiii)(a) Amount per ton. Salinomycin 40 to 60 grams and lincomycin 
2 to 4 grams.
    (b) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati and for improved feed efficiency.
    (c) Limitations. Feed continuously as sole ration. Not approved for 
use with pellet binders. Do not feed to layers. Do not allow horses, 
adult turkeys, guinea pigs, rabbits, hamsters, or ruminants access to 
this feed. Ingestion by these species may result in severe 
gastrointestinal effects or may be fatal. Lincomycin hydrochloride 
monohydrate as provided by No. 000009 in Sec. 510.600(c) of this 
chapter.
    (xiv)(a) Amount per ton. Salinomycin 40 to 60 grams, roxarsone 45.4 
grams, and lincomycin 2 grams.
    (b) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, including some field strains of E. tenella that are more 
susceptible to roxarsone combined with salinomycin than to salinomycin 
alone, and for improved feed efficiency.
    (c) Limitations. Feed continuously as sole ration. Not approved for 
use with pellet binders. Drug overdose or lack of water may result in 
leg weakness. Do not feed to layers. Do not allow horses, adult turkeys, 
guinea pigs, rabbits, hamsters, or ruminants access to this feed. 
Ingestion by these species may result in severe gastrointestinal effects 
or may be fatal. Withdraw 5 days before slaughter. Lincomycin 
hydrochloride monohydrate as provided by No. 000009 in Sec. 510.600(c) 
of this chapter. Roxarsone as provided by No. 046573 in Sec. 510.600(c) 
of this chapter.
    (xv)(a) Amount per ton. Salinomycin 40 to 60 grams, 
chlortetracycline 500 grams, and roxarsone 45.4 grams.
    (b) Indications for use. For prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, including some field strains of E. tenella which are more 
susceptible to roxarsone combined with salinomycin than to salinomycin 
alone, and as an aid in the reduction of mortality due to E. coli 
infections susceptible to such treatment.
    (c) Limitations. Do not feed to layers. In feeds containing 0.8 
percent dietary calcium, not to be fed for more than 5 days. Not 
approved for use with pellet binders. Withdraw 5 days before slaughter. 
May be fatal if accidentally fed to adult turkeys or to horses. 
Chlortetracycline as provided by Nos. 046573 and 048164; roxarsone as 
provided by No. 046573; and salinomycin as provided by Nos. 046573 and 
016592 in Sec. 510.600(c) of this chapter.
    (xvi)(a) Amount per ton. Salinomycin 40 to 60 grams and 
chlortetracycline 500 grams.
    (b) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E., necatrix, E. acervulina, E. maxima, E. brunetti, 
and E. mivati, and as an aid in the reduction of mortality due to E. 
coli infections susceptible to such treatment.

[[Page 499]]

    (c) Limitations. Do not feed to layers. In feeds containing 0.8 
percent dietary calcium. Not to be fed for more than 5 days. Not 
approved for use with pellet binders. Withdraw 24 hours before 
slaughter. May be fatal if accidentally fed to adult turkeys or horses. 
Chlortetracycline as provided by Nos. 046573 and 048164; salinomycin as 
provided by Nos. 046573 and 016592 in Sec. 510.600(c) of this chapter.
    (xvii)(A) Amount per ton. Salinomycin 40 to 60 grams with roxarsone 
34.1 or 45.4 grams and bacitracin methylene disalicylate 4 to 50 grams.
    (B) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, including some field strains of E. tenella that are more 
susceptible to roxarsone combined with salinomycin than to salinomycin 
alone; for increased rate of weight gain. Use of 34.1 or 45.4 grams per 
ton roxarsone is indicated to meet the E. tenella challenge which varies 
with environmental and management conditions.
    (C) Limitations. Feed continuously as sole ration. Use as sole 
source of organic arsenic. Not approved for use with pellet binders. Do 
not feed to laying chickens. May be fatal if accidentally fed to adult 
turkeys or horses. Poultry should have access to drinking water at all 
times. Overdosage or lack of water may result in leg weakness or 
paralysis. Withdraw 5 days before slaughter. Salinomycin as provided by 
No. 046573 in Sec. 510.600(c) of this chapter. Roxarsone and bacitracin 
as provided by No. 046573 in Sec. 510.600(c) of this chapter.
    (xviii)(A) Amount per ton. Salinomycin, 40 to 60 grams; bacitracin 
methylene disalicylate, 50 grams; and roxarsone, 22.7 to 45.4 grams.
    (B) Indications for use. For the prevention of coccidiosis caused by 
E. tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. 
maxima, as an aid in the prevention of necrotic enteritis caused or 
complicated by Clostridium spp. or other organisms susceptible to 
bacitracin, for increased rate of weight gain, improved feed efficiency, 
and improved pigmentation.
    (C) Limitations. Feed continuously as sole ration. Do not feed to 
laying chickens. Use as sole source of organic arsenic. Poultry should 
have access to drinking water at all times. Drug overdosage or lack of 
water intake may result in leg weakness or paralysis. May be fatal if 
fed to adult turkeys or to horses. Withdraw 5 days before slaughter. 
Salinomycin as provided by Nos. 046573; bacitracin methylene 
disalicylate and roxarsone as provided by No. 046573 in Sec. 510.600(c) 
of this chapter.
    (xix)(A) Amount per ton. Salinomycin, 40 to 60 grams; bacitracin 
methylene disalicylate, 100 to 200 grams; and roxarsone, 22.7 to 45.4 
grams.
    (B) Indications for use. For the prevention of coccidiosis caused by 
E. tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. 
maxima, as an aid in the control of necrotic enteritis caused or 
complicated by Clostridium spp. or other organisms susceptible to 
bacitracin, for increased rate of weight gain, improved feed efficiency, 
and improved pigmentation.
    (C) Limitations. Feed continuously as sole ration. To control 
necrotic enteritis, start medication at first clinical signs of disease; 
vary dosage based on the severity of infection; administer continuously 
for 5 to 7 days or as long as clinical signs persist, then reduce 
bacitracin to prevention level (50 g/ton). Do not feed to laying 
chickens. Use as sole source of organic arsenic. Poultry should have 
access to drinking water at all times. Drug overdosage or lack of water 
intake may result in leg weakness or paralysis. May be fatal if fed to 
adult turkeys or to horses. Withdraw 5 days before slaughter. 
Salinomycin as provided by No. 046573; bacitracin methylene disalicylate 
and roxarsone as provided by No. 046573 in Sec. 510.600(c) of this 
chapter.
    (xx)(A) Amount per ton. Salinomycin, 40 to 60 grams; and bacitracin 
methylene disalicylate, 50 grams.
    (B) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, and as an aid in the prevention of necrotic enteritis caused 
or complicated by Clostridium spp. or other organisms susceptible to 
bacitracin.
    (C) Limitations. Feed continuously as sole ration. Do not feed to 
laying chickens. May be fatal if fed to adult

[[Page 500]]

turkeys or to horses. Salinomycin as provided by 046573; bacitracin 
methylene disalicylate as provided by 046573 in Sec. 510.600(c) in this 
chapter.
    (xxi)(A) Amount per ton. Salinomycin, 40 to 60 grams; and bacitracin 
methylene disalicylate, 100 to 200 grams.
    (B) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, and as an aid in the control of necrotic enteritis caused or 
complicated by Clostridium spp. or other organisms susceptible to 
bacitracin.
    (C) Limitations. Feed continuously as sole ration. To control 
necrotic enteritis, start medication at first clinical signs of disease; 
vary dosage based on the severity of infection; administer continuously 
for 5 to 7 days or as long as clinical signs persist, then reduce 
bacitracin to prevention level (50 grams per ton). Do not feed to laying 
chickens. May be fatal if fed to adult turkeys or to horses. Salinomycin 
as provided by 046573; bacitracin methylene disalicylate as provided by 
046573 in Sec. 510.600(c) in this chapter.
    (xxii) Amount per ton. Salinomycin, 40 to 60 grams; plus tylosin, 4 
to 50 grams.
    (A) Indications for use. As an aid in the prevention of coccidiosis 
caused by Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. 
brunetti, and E. mivati, and for increased rate of weight gain and 
improved feed efficiency.
    (B) Limitations. For broiler chickens only. Feed continuously as 
sole ration. Do not feed to laying hens. Not approved for use with 
pellet binders. May be fatal if accidentally fed to adult turkeys or 
horses. Salinomycin as provided by 046573; tylosin phosphate as provided 
by 000986 in Sec. 510.600(c) of this chapter.
    (xxiii) Amount per ton. Salinomycin, 40 to 60 grams; plus 
bambermycins, 1 to 3 grams.
    (a) Indications for use. Broiler chickens: For prevention of 
coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. 
maxima, E. brunetti, and E. mivati; and for improved feed efficiency.
    (b) Limitations. Feed continuously as sole ration. Do not feed to 
laying chickens; not approved for use with pellet binders; may be fatal 
if accidentally fed to adult turkeys or horses. Salinomycin as provided 
by Nos. 046573 and 016592; bambermycins by No. 016592 in Sec. 
510.600(c) of this chapter.
    (xxiv) Amount per ton. Salinomycin, 40 to 60 grams; plus 
bambermycins, 1 to 2 grams; plus roxarsone, 45.4 grams.
    (a) Indications for use. Broiler chickens: For prevention of 
coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. 
maxima, E. brunetti, and E. mivati, including some field strains of E. 
tenella that are more susceptible to roxarsone combined with salinomycin 
than salinomycin alone; and for improved feed efficiency.
    (b) Limitations. Feed continuously as sole ration. Do not feed to 
laying chickens; as sole source or organic arsenic; withdraw 5 days 
before slaughter; not approved for use with pellet binders; may be fatal 
if accidentally fed to adult turkeys or horses; Salinomycin as provided 
by Nos. 046573and 016592; bambermycins by No. 016592; roxarsone by No. 
046573 in Sec. 510.600(c) of this chapter.
    (2) Quail--(i)(a) Amount per ton. Salinomycin 50 grams.
    (b) Indications for use. For the prevention of coccidiosis caused by 
E. dispersa and E. lettyae.
    (c) Limitations. Feed continuously as sole ration. Not approved for 
use with pellet binders. May be fatal if accidentally fed to adult 
turkeys or horses.
    (ii) [Reserved]
    (3) Roaster and replacement (breeder and layer) chickens: It is used 
as follows:
    (i)(A) Amount per ton. Salinomycin 40 to 60 grams.
    (B) Indications for use. For prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati.
    (C) Limitations. Feed continuously as sole ration. Do not feed to 
laying hens producing eggs for human consumption. Not approved for use 
with pellet binders. May be fatal if accidentally fed to horses or adult 
turkeys.
    (ii) Amount per ton. Salinomycin, 40 to 60 grams, and bacitracin 
methylene disalicylate, 4 to 50 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E.

[[Page 501]]

maxima, E. brunetti, and E. mivati, and for increased rate of weight 
gain and improved feed efficiency.
    (B) Limitations. Feed continuously as sole ration. Discontinue use 
prior to sexual maturity. Do not feed to laying chickens. May be fatal 
if fed to adult turkeys or to horses. Salinomycin as provided by 046573; 
bacitracin methylene disalicylate as provided by 046573 in Sec. 
510.600(c) of this chapter.
    (iii) Amount per ton. Salinomycin, 40 to 60 grams, and bacitracin 
methylene disalicylate, 50 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, and as an aid in the prevention of necrotic enteritis caused 
or complicated by Clostridium spp. or other organisms susceptible to 
bacitracin.
    (B) Limitations. Feed continuously as sole ration. Discontinue use 
prior to sexual maturity. Do not feed to laying chickens. May be fatal 
if fed to adult turkeys or to horses. Salinomycin as provided by 046573; 
bacitracin methylene disalicylate as provided by 046573 in Sec. 
510.600(c) of this chapter.
    (iv)(A) Amount per ton. Salinomycin, 40 to 60 grams; bacitracin 
methylene disalicylate, 50 grams; and roxarsone, 22.7 to 45.4 grams.
    (B) Indications for use. For the prevention of coccidiosis caused by 
E. tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. 
maxima, as an aid in the prevention of necrotic enteritis caused or 
complicated by Clostridium spp. or other organisms susceptible to 
bacitracin, for increased rate of weight gain, improved feed efficiency, 
and improved pigmentation.
    (C) Limitations. Feed continuously as sole ration. Discontinue use 
prior to sexual maturity. Do not feed to laying chickens. Use as sole 
source of organic arsenic. Poultry should have access to drinking water 
at all times. Drug overdosage or lack of water intake may result in leg 
weakness or paralysis. May be fatal if fed to adult turkeys or to 
horses. Withdraw 5 days before slaughter. Salinomycin as provided by No. 
046573; bacitracin methylene disalicylate and roxarsone as provided by 
No. 046573 in Sec. 510.600(c).
    (v) Amount per ton. Salinomycin, 40 to 60 grams, and bacitracin 
methylene disalicylate, 100 to 200 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati, and as an aid in the control of necrotic enteritis caused or 
complicated by Clostridium spp. or other organisms susceptible to 
bacitracin.
    (B) Limitations. Feed continuously as sole ration. To control 
necrotic enteritis, start medication at first clinical signs of disease; 
vary dosage based on the severity of infection; administer continuously 
for 5 to 7 days or as long as clinical signs persist, then reduce 
bacitracin to prevention level (50 grams per ton). Discontinue use prior 
to sexual maturity. Do not feed to laying chickens. May be fatal if fed 
to adult turkeys or to horses. Salinomycin as provided by 046573; 
bacitracin methylene disalicylate as provided by 046573 in Sec. 
510.600(c) of this chapter.
    (vi)(A) Amount per ton. Salinomycin, 40 to 60 grams; bacitracin 
methylene disalicylate, 100 to 200 grams; and roxarsone, 22.7 to 45.4 
grams.
    (B) Indications for use. For the prevention of coccidiosis caused by 
E. tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. 
maxima, as an aid in the control of necrotic enteritis caused or 
complicated by Clostridium spp. or other organisms susceptible to 
bacitracin, for increased rate of weight gain, improved feed efficiency, 
and improved pigmentation.
    (C) Limitations. Feed continuously as sole ration. To control 
necrotic enteritis, start medication at first clinical signs of disease; 
vary dosage based on the severity of infection; administer continuously 
for 5 to 7 days or as long as clinical signs persist, then reduce 
bacitracin to prevention level (50 g/ton). Discontinue use prior to 
sexual maturity. Do not feed to laying chickens. Use as sole source of 
organic arsenic. Poultry should have access to drinking water at all 
times. Drug overdosage or lack of water intake may result in leg 
weakness or paralysis. May be fatal if fed to adult turkeys or to 
horses. Withdraw 5 days before slaughter. Salinomycin as provided by No.

[[Page 502]]

046573; bacitracin methylene disalicylate and roxarsone as provided by 
No. 046573 in Sec. 510.600(c).
    (vii) Amount per ton. Salinomycin, 40 to 60 grams; and roxarsone, 
22.7 to 45.4 grams.
    (A) Indications for use. For the prevention of coccidiosis caused by 
Eimeria tenella,E. necatrix,E. acervulina,E. brunetti,E. mivati, andE. 
maxima, and for increased rate of weight gain, improved feed efficiency, 
and improved pigmentation.
    (B) Limitations. Feed continuously as sole ration. Discontinue use 
prior to sexual maturity. Do not feed to laying chickens. Use as sole 
source of organic arsenic. Poultry should have access to drinking water 
at all times. Drug overdosage or lack of water intake may result in leg 
weakness or paralysis. May be fatal if fed to adult turkeys or to 
horses. Withdraw 5 days before slaughter. Salinomycin as provided by No. 
046573 and roxarsone as provided by No. 046573 in Sec. 510.600(c) of 
this chapter.
    (4) Chickens: It is used in chicken feed as follows:
    (i) Amount per ton. Salinomycin, 40 to 60 grams; plus 
oxytetracycline, 500 grams.
    (a) Indications for use. For prevention of coccidiosis caused by 
Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and 
E. mivati; and for reduction of mortality due to air sacculitis (air-
sac-infection) caused by Escherichia coli susceptible to 
oxytetracycline.
    (b) Limitations. Feed continuously for 5 days; do not feed to 
chickens producing eggs for human consumption; withdraw 24 hours before 
slaughter; in low calcium feeds withdraw 3 d before slaughter. 
Salinomycin as provided by Nos. 046573 and 016592; oxytetracycline as 
provided by No. 066104 in Sec. 510.600(c) of this chapter.
    (ii) [Reserved]

[48 FR 30616, July 5, 1983]

    Editorial Note: For Federal Register citations affecting Sec. 
558.550, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.555  Semduramicin.

    (a) Specifications. Type A medicated article containing:
    (1) 22.7 grams (g) per pound (lb) (50 g/kilogram (kg)) semduramicin 
(as semduramicin sodium).
    (2) 22.7 g/lb (50 g/kg) semduramicin (as semduramicin sodium 
biomass).
    (b) Approvals. See No. 066104 in Sec. 510.600(c) of this chapter 
for use of product described in paragraph (a)(1) as in paragraph (d) of 
this section; for use of product described in paragraph (a)(2) as in 
paragraph (e) of this section.
    (c) Related tolerances. See Sec. 556.597 of this chapter.
    (d) Conditions of use in chickens. It is used in chicken feed as 
follows:

------------------------------------------------------------------------
 Semduramicin    Combinations
 in grams per    in grams per   Indications    Limitations     Sponsor
      ton            ton          for use
------------------------------------------------------------------------
(1) 22.7 (25    .............  Broiler       Do not feed to       066104
 ppm)                           chickens:     laying hens
                                For the
                                prevention
                                of
                                coccidiosis
                                caused by
                                Eimeria
                                acervulina,
                                E.
                                brunetti,
                                E. maxima,
                                E. mivati/
                                E. mitis,
                                E.
                                necatrix,
                                and E.
                                tenella
------------------------------------------------------------------------
(2) 22.7        Bacitracin     Broiler       Feed                 066104
                 methylene      chickens:     continuously
                 disalicylate   As in         as sole
                 10 to 50       paragraph     ration. Do
                                (d)(1) of     not feed to
                                this          laying hens.
                                section;      Bacitracin
                                for           methylene
                                improved      disalicylate
                                feed          as provided
                                efficiency    by No. 046573
                                              in Sec.
                                              510.600(c) of
                                              this chapter
------------------------------------------------------------------------

[[Page 503]]

 
(3) 22.7        Bacitracin     Broiler       Feed                 066104
                 methylene      chickens:     continuously
                 disalicylate   As in         as sole
                 10 to 50       paragraph     ration. Use
                 plus           (d)(4) of     feed within 2
                 roxarsone      this          weeks of
                 45.4           section;      production.
                                for           Do not feed
                                improved      to laying
                                feed          hens. Use as
                                efficiency    sole source
                                              of organic
                                              arsenic.
                                              Poultry
                                              should have
                                              access to
                                              drinking
                                              water at all
                                              times. Drug
                                              overdosage or
                                              lack of water
                                              intake may
                                              result in leg
                                              weakness or
                                              paralysis.
                                              Withdraw 5
                                              days before
                                              slaughter.
                                              Bacitracin
                                              methylene
                                              disalicylate
                                              and roxarsone
                                              as provided
                                              by No. 046573
                                              in Sec.
                                              510.600(c) of
                                              this chapter
------------------------------------------------------------------------
(4) 22.7        Roxarsone      Broiler       Feed                 066104
                 45.4           chickens:     continuously
                                For the       as sole
                                prevention    ration. For
                                of            broiler
                                coccidiosis   chickens
                                caused by     only. Do not
                                Eimeria       feed to
                                acervulina,   laying hens.
                                E.            Use as sole
                                brunetti,     source of
                                E. maxima,    organic
                                E. mivati/    arsenic.
                                E. mitis,     Withdraw 5
                                E.            days before
                                necatrix,     slaughter.
                                and E.        Roxarsone as
                                tenella,      provided by
                                including     No. 046573 in
                                some field    Sec.
                                strains of    510.600(c) of
                                E. tenella    this chapter
                                that are
                                more
                                susceptible
                                to
                                semduramici
                                n combined
                                with
                                roxarsone
                                than
                                semduramici
                                n alone
------------------------------------------------------------------------
(5) 22.7        Virginiamycin  Broiler       Feed                 066104
                 5              chickens:     continuously
                                As in         as sole
                                paragraph     ration. Do
                                (d)(1) of     not feed to
                                this          laying hens.
                                section;      Virginiamycin
                                for           as provided
                                increased     by No. 066104
                                rate of       in Sec.
                                weight gain   510.600(c) of
                                and           this chapter
                                improved
                                feed
                                efficiency
------------------------------------------------------------------------
(6) 22.7        Virginiamycin  Broiler       Feed                 066104
                 5 to 15        chickens:     continuously
                                As in         as sole
                                paragraph     ration. Do
                                (d)(1) of     not feed to
                                this          laying hens.
                                section;      Virginiamycin
                                for           as provided
                                increased     by No. 066104
                                rate of       in Sec.
                                weight gain   510.600(c) of
                                              this chapter
------------------------------------------------------------------------
(7) 22.7        Virginiamycin  Broiler       Feed                 066104
                 20             chickens:     continuously
                                As in         as sole
                                paragraph     ration. Do
                                (d)(1) of     not feed to
                                this          laying hens.
                                section;      Virginiamycin
                                for           as provided
                                prevention    by No. 066104
                                of necrotic   in Sec.
                                enteritis     510.600(c) of
                                caused by     this chapter
                                Clostridium
                                perfringens
                                susceptible
                                to
                                virginiamyc
                                in
------------------------------------------------------------------------
(8) 22.7        Virginiamycin  Broiler       Feed                 066104
                 20 plus        chickens:     continuously
                 roxarsone      As in         as sole
                 22.7 to 45.4   paragraph     ration
                                (d)(1) of     throughout
                                this          growing
                                section;      period. Do
                                for           not feed to
                                prevention    laying hens.
                                of necrotic   Use as sole
                                enteritis     source of
                                caused by     organic
                                Clostridium   arsenic.
                                perfringens   Poultry
                                susceptible   should have
                                to            access to
                                virginiamyc   drinking
                                in; for       water at all
                                increased     times. Drug
                                rate of       overdose or
                                weight gain   lack of water
                                and           may result in
                                improved      leg weakness.
                                feed          Roxarsone as
                                efficiency;   in Sec.
                                and for       558.530(b)(1)
                                improved      of this
                                pigmentatio   chapter
                                n             provided by
                                              No. 046573 in
                                              Sec.
                                              510.600(c) of
                                              this chapter;
                                              semduramicin
                                              and
                                              virginiamycin
                                              as provided
                                              by No. 066104
------------------------------------------------------------------------

    (e) Conditions of use in chickens. It is used in chicken feed as 
follows:

[[Page 504]]



------------------------------------------------------------------------
 Semduramicin    Combination
 in grams per    in grams per   Indications    Limitations     Sponsor
      ton            ton          for use
------------------------------------------------------------------------
(1) 22.7 (25    .............  Broiler       Do not feed to       066104
 ppm)                           chickens:     laying hens
                                For the
                                prevention
                                of
                                coccidiosis
                                caused by
                                Eimeria
                                tenella, E.
                                acervulina,
                                E. maxima,
                                E.
                                brunetti,
                                E.
                                necatrix,
                                and E.
                                mitis
------------------------------------------------------------------------
(2) 22.7        Virginiamycin  Broiler       Feed                 066104
                 5              chickens:     continuously
                                As in         as sole
                                paragraph     ration.
                                (e)(1) of     Withdraw 1
                                this          day before
                                section;      slaughter. Do
                                for           not feed to
                                increased     laying hens.
                                rate of       Virginiamycin
                                weight gain   provided by
                                and           No. 066104 in
                                improved      Sec.
                                feed          510.600(c) of
                                efficiency    this chapter
(3) 22.7        Virginiamycin  Broiler       Feed                 066104
                 5 to 15        chickens:     continuously
                                As in         as sole
                                paragraph     ration.
                                (e)(1) of     Withdraw 1
                                this          day before
                                section;      slaughter. Do
                                for           not feed to
                                increased     laying hens.
                                rate of       Virginiamycin
                                weight gain   provided by
                                              No. 066104 in
                                              Sec.
                                              510.600(c) of
                                              this chapter
(4) 22.7        Virginiamycin  Broiler       Feed                 066104
                 20             chickens:     continuously
                                As in         as sole
                                paragraph     ration.
                                (e)(1) of     Withdraw 1
                                this          day before
                                section;      slaughter. Do
                                for           not feed to
                                prevention    laying hens.
                                of necrotic   Virginiamycin
                                enteritis     provided by
                                caused by     No. 066104 in
                                C.            Sec.
                                perfringens   510.600(c) of
                                susceptible   this chapter
                                to
                                virginiamyc
                                in
------------------------------------------------------------------------


[59 FR 17477, Apr. 13, 1994, as amended at 60 FR 57928, Nov. 24, 1995; 
61 FR 29481, June 11, 1996; 61 FR 43451, Aug. 23, 1996; 61 FR 66584, 
Dec. 18, 1996; 62 FR 66985, Dec. 23, 1997; 64 FR 48296, Sept. 3, 1999; 
66 FR 47964, Sept. 17, 2001; 69 FR 13221, Mar. 22, 2004; 70 FR 41961, 
July 21, 2005; 73 FR 812, Jan. 4, 2008; 74 FR 41631, Aug. 18, 2009]



Sec. 558.575  Sulfadimethoxine, ormetoprim.

    (a) Approvals. Type A medicated articles to sponsors as identified 
in Sec. 510.600(c) of this chapter for uses as in paragraph (d) of this 
section as follows:
    (1) 25 percent sufadimethoxine and 15 percent ormetoprim to 046573 
for use for poultry as in paragraphs (d)(1), (d)(2), (d)(3), (d)(4), and 
(d)(7) of this section.
    (2) 25 percent sulfadimethoxine and 5 percent ormetoprim to No. 
015331 for use for fish as in paragraphs (d)(5) and (d)(6) of this 
section.
    (b) Related tolerances. See Sec. Sec. 556.490 and 556.640 of this 
chapter.
    (c) [Reserved]
    (d) Conditions -of use. It is used in feeds for animals as follows:
    (1) Broiler chickens--(i) Amount per ton. Sulfadimethoxine, 113.5 
grams (0.0125 percent) plus ormetoprim, 68.1 grams (0.0075 percent).
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by all Eimeria species known to be pathogenic to chickens, 
namely, E. tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, 
and E. maxima, and bacterial infections due to H. gallinarum (infectious 
coryza), E. coli (colibacillosis) and P. multocida (fowl cholera).
    (b) Limitations. Feed as sole ration; withdraw 5 days before 
slaughter.
    (ii) Amount per ton. Sulfadimethoxine, 113.5 grams (0.0125 percent) 
plus ormetoprim, 68.1 grams (0.0075 percent) plus roxarsone, 22.7 grams 
(0.0025 percent).
    (a) Indications for use. As an aid in the prevention of coccidiosis 
caused by all Eimeria species known to be pathogenic to chickens, namely 
E. tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. 
maxima, and bacterial infections due to H. gallinarum (infectious 
coryza), E. coli, (colibacillosis); and P. multocida (fowl cholera); 
growth promotion and feed efficiency; improving pigmentation.
    (b) Limitations. Withdraw 5 days before slaughter; as sole source of 
organic arsenic.
    (2) Replacement chickens--(i) Amount per ton. Sulfadimethoxine, 
113.5 grams (0.0125 percent) plus ormetoprim, 68.1 grams (0.0075 
percent).
    (ii) Indications for use. As an aid in the prevention of coccidiosis 
caused by

[[Page 505]]

all Eimeria species known to be pathogenic to chickens, namely E. 
tenella, E. necatrix, E. acervulina, E. brunetti, E. mivati, and E. 
maxima, and bacterial infections due to H. galmaxima, and bacterial 
infections due to H. gallinarum (infectious coryza), E. coli 
(colibacillosis) and P. multocida (fowl cholera).
    (iii) Limitations. Feed as a sole ration; do not feed to chickens 
over 16 weeks (112 days) of age; withdraw 5 days before slaughter.
    (3) Turkeys--(i) Amount per ton. Sulfadimethoxine, 56.75 grams 
(0.00625 percent) plus ormetoprim, 34.05 grams (0.00375 percent).
    (ii) Indications for use. As an aid in the prevention of coccidiosis 
caused by all Eimeria species known to be pathogenic to turkeys, namely, 
E. adenoeides, E. gallopavonis, and E. meleagrimitis and bacterial 
infection due to P. multocida (fowl cholera).
    (iii) Limitations. Do not feed to turkeys producing eggs for food; 
withdraw 5 days before slaughter.
    (4) Ducks--(i) Amount per ton. Sulfadimethoxine, 227 grams (0.025 
percent) plus ormetoprim, 136.2 grams (0.015 percent).
    (a) Indications for use. As an aid in the control of bacterial 
infections due to P. multocida (fowl cholera) in ducks, including 
breeding ducks.
    (b) Limitations. Feed as sole ration for 7 days; withdraw 5 days 
before slaughter; medication should be started at the first signs of 
infection; do not feed to ducks producing eggs for food.
    (ii) Amount per ton. Sulfadimethoxine, 454 grams (0.05 percent) plus 
ormetoprim, 272.4 grams (0.03 percent).
    (a) Indications for use. As an aid in the control of bacterial 
infections due to E. coli, Riemerella anatipestifer, and severe 
challenge of P. multocida (fowl cholera) in ducks.
    (b) Limitations. Feed as a sole ration for 7 days; withdraw 5 days 
before slaughter; medication should be started at the first signs of 
infection; not for breeding ducks; do not feed to ducks producing eggs 
for food.
    (5) Salmonids--(i) Amount. 50 milligrams of active ingredients per 
kilogram of body weight per day.
    (ii) Indications of use. For the control of furunculosis in 
salmonids (trout and salmon) caused by Aeromonas salmonicida strains 
susceptible to sulfadimethoxine and ormetoprim combination.
    (iii) Limitations. Administer for 5 consecutive days; withdraw 42 
days before release as stocker fish or slaughter.
    (6) Catfish--(i) Amount. 50 milligrams of active ingredients per 
kilogram of body weight per day.
    (ii) Indications for use. For control of enteric septicemia of 
catfish caused by Edwardsiella ictaluri strains susceptible to 
sulfadimethoxine and ormetoprim combination.
    (iii) Limitations. Administer for 5 consecutive days; withdraw 3 
days before slaughter or release as stocker fish.
    (7) Chukar partridges--(i) Amount per ton. Sulfadimethoxine 113.5 
grams (0.0125 percent) plus ormetoprim 68.1 grams (0.0075 percent).
    (ii) Indications for use. For prevention of coccidiosis caused by 
Eimeria kofoidi and E. legionensis.
    (iii) Limitations. Feed continuously to young birds up to 8 weeks of 
age as sole ration.

[40 FR 13959, Mar. 27, 1975, as amended at 42 FR 13550, Mar. 11, 1977; 
49 FR 33442, Aug. 23, 1984; 49 FR 46371, Nov. 26, 1984; 51 FR 7400, Mar. 
3, 1986; 51 FR 18884, May 23, 1986; 52 FR 2686, Jan. 26, 1987; 54 FR 
1686, Jan. 17, 1989; 63 FR 27846, May 21, 1998; 64 FR 26672, May 17, 
1999; 64 FR 43910, Aug. 12, 1999; 66 FR 46707, Sept. 7, 2001; 70 FR 
52292, Sept. 2, 2005]



Sec. 558.582  Sulfamerazine.

    (a) Approvals. Type A medicated articles: 99 percent to 046573 in 
Sec. 510.600(c) of this chapter.
    (b) Related tolerances. See Sec. 556.660 of this chapter.
    (c) Conditions of use. It is used in fish feed for rainbow trout, 
brook trout, and brown trout as follows:
    (1) Amount. 10 grams of sulfamerazine per 100 pounds of fish per 
day.
    (2) Indications for use. Control of furunculosis.
    (3) Limitations. Treat for not more than 14 days; do not treat 
within 3

[[Page 506]]

weeks of marketing or stocking in stream open to fishing.

[41 FR 11005, Mar. 15, 1976, as amended at 51 FR 7400, Mar. 3, 1986; 61 
FR 18082, Apr. 24, 1996; 63 FR 27846, May 21, 1998; 66 FR 46707, Sept. 
7, 2001]



Sec. 558.586  Sulfaquinoxaline.

    (a) Specifications. Type A medicated articles containing 40 percent 
sulfaquinoxaline.
    (b) Approvals. See No. 000859 in Sec. 510.600(c) of this chapter.
    (c) Special considerations. (1) For control of outbreaks of disease, 
medication should be initiated as soon as the diagnosis is determined. 
Medicated chickens, turkeys, and rabbits must actually consume enough 
medicated feed which provides a recommended dose of approximately 3.5 to 
60 milligrams per pound per day in chickens, 2.5 to 100 milligrams per 
pound per day in turkeys, and 2.8 to 68 milligrams per pound per day in 
rabbits depending upon age and class of animal, ambient temperature, and 
other factors. Consult a veterinarian or poultry pathologist for 
diagnosis.
    (2) [Reserved]
    (d) Conditions of use. It is used as follows:
    (1) Chickens--(i) Amount. 0.015 percent.
    (a) Indications for use. As an aid in preventing outbreaks of 
coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. 
maxima, and E. brunetti under average conditions of exposure.
    (b) Limitations. Feed continuously from the time birds are placed on 
litter and continue past the age when coccidiosis is ordinarily a 
hazard. If death losses exceed 0.5 percent in a 2-day period, obtain a 
laboratory diagnosis. If coccidiosis is the cause, use the 
sulfaquinoxaline levels recommended for control of outbreaks, returning 
to the original dosage schedule after the outbreak has subsided. Losses 
may result from intercurrent disease, other conditions affecting drug 
intake, or variant strains of coccidia species which can contribute to 
the virulence of coccidiosis under field conditions. Do not treat 
chickens within 10 days of slaughter. Do not medicate chickens producing 
eggs for human consumption.
    (ii) Amount. 0.0175 percent.
    (a) Indications for use. As an aid in preventing outbreaks of 
coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. 
maxima, and E. brunetti where excessive exposure to coccidia is 
increased due to overcrowding or other management factors.
    (b) Limitations. Feed continuously from the time birds are placed on 
litter and continue past the age when coccidiosis is ordinarily a 
hazard. If death losses exceed 0.5 percent in a 2-day period, obtain a 
laboratory diagnosis. If coccidiosis is the cause, use the 
sulfaquinoxaline levels recommended for control of outbreaks, returning 
to the original dosage schedule after the outbreak has subsided. Losses 
may result from intercurrent disease, other conditions affecting drug 
intake, or variant strains of coccidia species which can contribute to 
the virulence of coccidiosis under field conditions. Do not treat 
chickens within 10 days of slaughter. Do not medicate chickens producing 
eggs for human consumption.
    (iii) Amount. 0.1 to 0.05 percent.
    (a) Indications for use. As an aid in controlling outbreaks of 
coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. 
maxima, and E. brunetti.
    (b) Limitations. Feed at 0.1 percent level for first 48 to 72 hours. 
Skip 3 days; 0.05 percent for 2 days, skip 3 days; 0.05 percent for 2 
days. If bloody droppings recur, give 0.05 percent for another 2 days. 
Do not treat chickens within 10 days of slaughter. Do not medicate 
chickens producing eggs for human consumption.
    (2) Turkeys--(i) Amount. 0.0175 percent.
    (a) Indications for use. As an aid in preventing outbreaks of 
coccidiosis caused by Eimeria meleagrimitis and E. adenoeides.
    (b) Limitations. Feed 0.0175 percent continuously during time birds 
are closely confined. May be continued for week to 10 days after flock 
is transferred to range to reduce danger of an outbreak following moving 
of the flock. Do not treat turkeys within 10 days of slaughter. Do not 
medicate turkeys producing eggs for human consumption.
    (ii) Amount. 0.05 percent.

[[Page 507]]

    (a) Indications for use. As an aid in controlling outbreaks of 
coccidiosis caused by Eimeria meleagrimitis, and E. adenoeides.
    (b) Limitations. Feed 0.05 percent for 2 days. Follow with 3 days on 
regular feed and 2 more days on 0.05 percent sulfaquinoxaline feed. 
Again follow with 3 days on regular feed and 2 more days on 0.05 percent 
sulfaquinoxaline feed. Continue this schedule if necessary till all 
signs of the outbreaks have subsided. Do not treat turkeys within 10 
days of slaughter. Do not medicate turkeys producing eggs for human 
consumption.
    (3) Chickens and turkeys--(i) Amount. 0.05 or 0.1 percent.
    (a) Indications for use. As an aid in the control of acute fowl 
cholera caused by Pasteurella multocida susceptible to sulfaquinoxaline 
and fowl typhoid caused by Salmonella gallinarum susceptible to 
sulfaquinoxaline.
    (b) Limitations. Feed 0.1 percent for 48 to 72 hours. Mortality 
should be brought under control. After medication, move birds to clean 
ground or to a clean house. If disease recurs, use 0.05 percent in feed 
again for 2 days. Do not treat chickens or turkeys within 10 days of 
slaughter for food. Do not medicate chickens or turkeys producing eggs 
for human consumption.
    (ii) [Reserved]
    (4) Rabbits--(i) Amount. 0.025 percent.
    $(a) Indications for use. As an aid in preventing coccidiosis caused 
by Eimeria stiedae.
    $(b) Limitations. Treatment to be started after weaning. Feed 
continuously for 30 days or feed medicated feed for 2 days out of every 
week until marketing. Do not treat within 10 days of slaughter.
    (ii) Amount. 0.1 percent.
    (a) Indications for use. As an aid in controlling outbreaks of 
coccidiosis caused by Eimeria stiedae.
    $(b) Limitations. Feed for 2 weeks. Do not treat within 10 days of 
slaughter.

[48 FR 3965, Jan. 28, 1983, as amended at 51 FR 7400, Mar. 3, 1986; 52 
FR 2686, Jan. 26, 1987; 55 FR 29843, July 23, 1990; 59 FR 33197, June 
28, 1994; 69 FR 60547, Oct. 12, 2004; 78 FR 17597, Mar. 22, 2013]



Sec. 558.600  Tiamulin.

    (a) Specifications. Type A article containing 363.2 grams of 
tiamulin hydrogen fumarate per pound.
    (b) Approvals. See No. 058198 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.738 of this chapter.
    (d) Special considerations--(1) Swine being treated with tiamulin 
should not have access to feeds containing polyether ionophores (e.g., 
lasalocid, monensin, narasin, salinomycin, or semduramycin) as adverse 
reactions may occur. If signs of toxicity occur, discontinue use.
    (2) The effects of tiamulin on swine reproductive performance, 
pregnancy, and lactation have not been determined.
    (3) Use as sole source of tiamulin.
    (e) Conditions of use--(1) Swine. It is used as follows:

----------------------------------------------------------------------------------------------------------------
  Tiamulin hydrogen fumarate in    Combination in grams
          grams per ton                   per ton          Indications for use        Limitations       Sponsor
----------------------------------------------------------------------------------------------------------------
(i) [Reserved]...................  ....................  .......................  ...................
(ii) 35..........................  ....................  1. For control of swine  Feed continuously       058198
                                                          dysentery associated     as sole ration on
                                                          with Brachyspira         premises with a
                                                          (formerly Serpulina or   history of swine
                                                          Treponema)               dysentery but
                                                          hyodysenteriae           where signs of
                                                          susceptible to           disease have not
                                                          tiamulin.                yet occurred or
                                                                                   following approved
                                                                                   treatment of
                                                                                   disease. Withdraw
                                                                                   2 days before
                                                                                   slaughter.
                                   ....................  2. For control of        Feed continuously       058198
                                                          porcine proliferative    as the sole ration
                                                          enteropathies            for not less than
                                                          (ileitis) associated     10 days. Withdraw
                                                          with Lawsonia            2 days before
                                                          intracellularis.         slaughter.

[[Page 508]]

 
(iii) 35.........................  Chlortetracycline,    For treatment of swine   Feed continuously      048164,
                                    approximately 400     bacterial enteritis      as sole ration for     058198
                                    (varying with body    caused by Escherichia    14 days. Use as
                                    weight and feed       coli and Salmonella      only source of
                                    consumption to        choleraesuis and         chlortetracycline.
                                    provide 10            bacterial pneumonia      Withdraw 2 days
                                    milligrams of         caused by Pasteurella    before slaughter.
                                    chlortetracycline     multocida susceptible   As
                                    per pound of body     to chlortetracycline,    chlortetracycline
                                    weight daily).        and control of swine     calcium complex,
                                                          dysentery associated     Type A medicated
                                                          with Brachyspira         articles
                                                          (formerly Serpulina or   containing the
                                                          Treponema)               equivalent of 50
                                                          hyodysenteriae           to 100 grams per
                                                          susceptible to           pound of
                                                          tiamulin.                chlortetracycline
                                                                                   hydrochloride
                                                                                   provided by 046573
                                                                                   and 048164 in Sec.
                                                                                     510.600(c) of
                                                                                   this chapter.
(iv) 200.........................  ....................  For treatment of swine   Feed continuously       058198
                                                          dysentery associated     as the sole feed
                                                          with Brachyspira         for 14 consecutive
                                                          (formerly Serpulina or   days. Withdraw
                                                          Treponema)               feed 7 days before
                                                          hyodysenteriae           slaughter.
                                                          susceptible to
                                                          tiamulin.
----------------------------------------------------------------------------------------------------------------

    (2) [Reserved]

[67 FR 7268, Feb. 19, 2002, as amended at 69 FR 62407, Oct. 26, 2004; 70 
FR 75018, Dec. 19, 2005; 74 FR 6, Jan. 2, 2009; 77 FR 24139, Apr. 23, 
2012]



Sec. 558.615  Thiabendazole.

    (a) Approvals. Dry Type A medicated articles: 22, 44.1, 66.1, and 
88.2 percent to 050604 in Sec. 510.600(c) of this chapter. The 66.1 
percent Type A is solely for the manufacture of cane molasses liquid 
Type B feed which is mixed in dry feeds. The 88.2 percent Type A is used 
solely for the manufacture of an aqueous slurry for adding to a Type C 
dry cattle feed.
    (b) Special considerations. Do not use in Type B or Type C medicated 
feed containing bentonite.
    (c) Related tolerances. See Sec. 556.730 of this chapter.
    (d) Conditions of use. It is used in feed for animals as follows:
    (1) Cattle--(i) Amount. 3 grams per 100 lb. body weight.
    (a) Indications for use. Control of infections of gastrointestinal 
roundworms (Trichostrongylus spp., Haemonchus spp., Ostertagia spp., 
Nematodirus spp., Oesophagostomum radiatum).
    (b) Limitations. Use 3 grams per 100 lb. body weight at a single 
dose; may repeat once in 2 to 3 weeks; do not treat animals within 3 
days of slaughter; milk taken from treated animals within 96 hours (8 
milkings) after the latest treatment must not be used for food.
    (ii) Amount. 5 grams per 100 lb. body weight.
    (a) Indications for use. Control of severe infections of 
gastrointestinal roundworms (Trichostrongylus spp., Haemonchus spp., 
Ostertagia spp., Nematodirus spp., Oesophagostomum radiatum); control of 
infections of Cooperia spp.
    (b) Limitations. 5 grams per 100 lb. body weight at a single dose or 
divided into 3 equal doses, administered 1 dose each day, on succeeding 
days; may repeat once in 2 to 3 weeks; do not treat animals within 3 
days of slaughter; milk taken from treated animals within 96 hours (8 
milkings) after the latest treatment must not be used for food.
    (2) Goats--(i) Amount. 3 grams per 100 lb. body weight.
    (ii) Indications for use. Control of severe infections of 
gastrointestinal roundworms (Trichostrongylus spp., Haemonchus spp., 
Ostertagia spp., Cooperia spp., Nematodirus spp., Bunostomum spp., 
Strongyloides spp., Chabertia spp., and Oesophagostomum spp. ).
    (iii) Limitations. 3 grams per 100 lb. body weight at a single dose; 
do not treat animals within 30 days of slaughter; milk taken from 
treated animals within 96 hours (8 milkings) after the latest treatment 
must not be used for food.
    (3) Sheep and goats--(i) Amount. 2 grams per 100 lb. body weight.
    (ii) Indications for use. Control of infections of gastrointestinal

[[Page 509]]

roundworms (Trichostrongylus spp., Haemonchus spp., Ostertagia spp., 
Cooperia spp.; Nematodirus spp., Bunostomum spp., Strongyloides spp., 
Chabertia spp., and Oesophagostomum spp. ); also active against ova and 
larvae passed by sheep from 3 hours to 3 days after the feed is consumed 
(good activity against ova and larvae of T. colubriformis and axei, 
Ostertagia spp., Nematodirus spp., Strongyloides spp.; less effective 
against those of Haemonchus contortus and Oesophagostomum spp. ).
    (iii) Limitations. Use 2 grams per 100 lb. body weight at a single 
dose; do not treat animals within 30 days of slaughter; milk taken from 
treated animals within 96 hours (8 milkings) after the latest treatment 
must not be used for food.
    (4) For swine--(i) Amount. 45.4-908 grams per ton (0.005-0.1 
percent).
    (ii) Indications for use. Aid in the prevention of infections of 
large roundworms (genus Ascaris).
    (iii) Limitations. Administer continuously feed containing 0.05-0.1 
percent thiabendazole per ton for 2 weeks followed by feed containing 
0.005-0.02 percent thiabendazole per ton for 8-14 weeks; do not treat 
animals within 30 days of slaughter.
    (5) Pheasants--(i) Amount. 454 grams per ton (0.05 percent) 
continuously for 2 weeks (14 days).
    (ii) Indications for use. For the treatment of gapeworms (Syngamus 
trachea) in pheasants.
    (iii) Limitations. Do not use treated pheasants for food for 21 days 
after last day of treatment. Fertility, hatchability, and other 
reproductive data are not available on use in breeding animals.

[40 FR 13959, Mar. 27, 1975, as amended at 47 FR 49641, Nov. 2, 1982; 49 
FR 29958, July 25, 1984; 51 FR 7400, Mar. 3, 1986; 52 FR 2686, Jan. 26, 
1987; 62 FR 63271, Nov. 28, 1997]



Sec. 558.618  Tilmicosin.

    (a) Specifications. Type A medicated article containing 90.7 grams 
(g) per pound tilmicosin as tilmicosin phosphate (200 g per kilogram).
    (b) Approvals. See No. 000986 in Sec. 510.600(c) of this chapter.
    (c) Special considerations--(1) Tilmicosin medicated feeds are 
restricted to use under a veterinary feed directive (VFD). See Sec. 
558.6 of this chapter for required label statements and other 
limitations.
    (2) VFDs for tilmicosin phosphate shall not be refilled.
    (3) Labeling of tilmicosin Type B or Type C medicated feeds must 
bear the following warnings:
    (i) Do not allow horses or other equines access to feeds containing 
tilmicosin.
    (ii) [Reserved]
    (4) Special considerations for use of tilmicosin medicated swine 
feeds include the following:
    (i) The expiration date of VFDs for tilmicosin must not exceed 90 
days from the time of issuance.
    (ii) Labeling of tilmicosin Type B or Type C medicated feeds for 
swine must bear the following warning: ``Do not use in any feeds 
containing bentonite. Bentonite in feeds may affect the efficacy of 
tilmicosin.''
    (iii) Feed containing tilmicosin shall not be fed to pigs for more 
than 21 days during each phase of production without ceasing 
administration for reevaluation of antimicrobial use by a licensed 
veterinarian before reinitiating a further course of therapy with an 
appropriate antimicrobial.
    (5) Special consideration for use of tilmicosin medicated cattle 
feeds include the following:
    (i) The expiration date of VFDs for cattle must not exceed 45 days 
from the time of issuance.
    (ii) Labeling of tilmicosin Type B or Type C medicated feeds for 
cattle must bear the following warning: ``Do not use in any feeds 
containing bentonite, cottonseed meal, or cottonseed hulls. Bentonite, 
cottonseed meal, or cottonseed hulls in feeds may affect the efficacy of 
tilmicosin.''
    (iii) To assure both food safety and responsible use in cattle, 
administration of feed containing tilmicosin to cattle experiencing an 
outbreak of BRD must be initiated during the first 45 days of the 
production period, shall not exceed a single 14-consecutive-day 
treatment, should not occur concurrent with or following administration 
of an injectable macrolide, and should not occur within 3 days following 
administration of a nonmacrolide injectable BRD therapy. Tilmicosin

[[Page 510]]

medicated feed treatment has not been evaluated in cattle with severe 
clinical disease. Cattle with severe clinical illness should be 
evaluated for individual treatment with an alternative non-macrolide 
therapy.
    (d) Related tolerances. See Sec. 556.735 of this chapter.
    (e) Conditions of use. It is used in feed as follows:
    (1) Swine--

----------------------------------------------------------------------------------------------------------------
 Tilmicosin  phosphate  in
         grams/ton            Combination in grams/ton    Indications for use        Limitations        Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 181 to 363.............  ..........................  Swine: For the         Feed continuously as      000986
                                                          control of swine       the sole ration for
                                                          respiratory disease    21-day period,
                                                          associated with        beginning
                                                          Actinobacillus         approximately 7 days
                                                          pleuropneumoniae and   before an
                                                          Pasteurella            anticipated disease
                                                          multocida.             outbreak. The safety
                                                                                 of tilmicosin has
                                                                                 not been established
                                                                                 in male swine
                                                                                 intended for
                                                                                 breeding purposes.
                                                                                 Swine intended for
                                                                                 human consumption
                                                                                 must not be
                                                                                 slaughtered within 7
                                                                                 days of the last
                                                                                 treatment with this
                                                                                 drug product.
(ii) [Reserved]............  ..........................  .....................  .....................     000986
----------------------------------------------------------------------------------------------------------------

    (2) Cattle--

----------------------------------------------------------------------------------------------------------------
 Tilmicosin  phosphate  in
         grams/ton           Combination in grams/ton    Indications for use         Limitations        Sponsor
----------------------------------------------------------------------------------------------------------------
(i) 568 to 757............  ..........................  Beef and nonlactating  Feed continuously for      000986
                                                         dairy cattle: For      14 days to provide
                                                         the control of         12.5 milligrams/
                                                         bovine respiratory     kilogram/head/day.
                                                         disease (BRD)          The safety of
                                                         associated with        tilmicosin has not
                                                         Mannheimia             been established in
                                                         haemolytica,           cattle intended for
                                                         Pasteurella            breeding purposes.
                                                         multocida, and         This drug product is
                                                         Histophilus somni in   not approved for use
                                                         groups of beef and     in female dairy
                                                         nonlactating dairy     cattle 20 months of
                                                         cattle, where active   age or older. Use in
                                                         BRD has been           these cattle may
                                                         diagnosed in at        cause drug residues
                                                         least 10 percent of    in milk. This drug
                                                         the animals in the     product is not
                                                         group.                 approved for use in
                                                                                calves intended to be
                                                                                processed for veal. A
                                                                                withdrawal period has
                                                                                not been established
                                                                                in preruminating
                                                                                calves. Cattle
                                                                                intended for human
                                                                                consumption must not
                                                                                be slaughtered within
                                                                                28 days of the last
                                                                                treatment with this
                                                                                drug product.
(ii) 568 to 757...........  Monensin, 5 to 40.........  Cattle fed in          Feed continuously for      000986
                                                         confinement for        14 days to provide
                                                         slaughter: For         12.5 milligrams
                                                         improved feed          tilmicosin/kilogram/
                                                         efficiency; and for    head/day. The safety
                                                         the control of         of tilmicosin has not
                                                         bovine respiratory     been established in
                                                         disease (BRD)          cattle intended for
                                                         associated with        breeding purposes.
                                                         Mannheimia             This drug product is
                                                         haemolytica,           not approved for use
                                                         Pasteurella            in female dairy
                                                         multocida, and         cattle 20 months of
                                                         Histophilus somni in   age or older. Use in
                                                         groups of cattle fed   these cattle may
                                                         in confinement for     cause drug residues
                                                         slaughter, where       in milk. This drug
                                                         active BRD has been    product is not
                                                         diagnosed in at        approved for use in
                                                         least 10 percent of    calves intended to be
                                                         the animals in the     processed for veal. A
                                                         group.                 withdrawal period has
                                                                                not been established
                                                                                in pre-ruminating
                                                                                calves. Cattle
                                                                                intended for human
                                                                                consumption must not
                                                                                be slaughtered within
                                                                                28 days of the last
                                                                                treatment with this
                                                                                drug product. See
                                                                                Sec. 558.355(d) of
                                                                                this chapter.

[[Page 511]]

 
(iii) 568 to 757..........  Monensin, 10 to 40........  Cattle fed in          Feed continuously for      000986
                                                         confinement for        14 days to provide
                                                         slaughter: For         12.5 milligrams
                                                         prevention and         tilmicosin/kilogram/
                                                         control of             head/day. The safety
                                                         coccidiosis due to     of tilmicosin has not
                                                         Eimeria bovis and E.   been established in
                                                         zuernii; and for the   cattle intended for
                                                         control of bovine      breeding purposes.
                                                         respiratory disease    This drug product is
                                                         (BRD) associated       not approved for use
                                                         with Mannheimia        in female dairy
                                                         haemolytica,           cattle 20 months of
                                                         Pasteurella            age or older. Use in
                                                         multocida, and         these cattle may
                                                         Histophilus somni in   cause drug residues
                                                         groups of cattle fed   in milk. This drug
                                                         in confinement for     product is not
                                                         slaughter, where       approved for use in
                                                         active BRD has been    calves intended to be
                                                         diagnosed in at        processed for veal. A
                                                         least 10 percent of    withdrawal period has
                                                         the animals in the     not been established
                                                         group.                 in pre-ruminating
                                                                                calves. Cattle
                                                                                intended for human
                                                                                consumption must not
                                                                                be slaughtered within
                                                                                28 days of the last
                                                                                treatment with this
                                                                                drug product. See
                                                                                Sec. 558.355(d) of
                                                                                this chapter.
----------------------------------------------------------------------------------------------------------------


[61 FR 68148, Dec. 27, 1996; 62 FR 15391, Apr. 1, 1997, as amended at 64 
FR 13679, Mar. 22, 1999; 65 FR 76930, Dec. 8, 2000; 67 FR 21997, May 2, 
2002; 69 FR 78306, Dec. 30, 2004; 76 FR 76894, Dec. 9, 2011; 77 FR 
60623, Oct. 4, 2012]



Sec. 558.625  Tylosin.

    (a) Specifications. Type A medicated articles containing tylosin 
phosphate.
    (b) Approvals. Type A medicated article levels of tylosin granted to 
firms as sponsor(s) and identified by drug listing numbers in Sec. 
510.600(c) of this chapter for the specific usage indicated in paragraph 
(f) of this section.
    (1) To 000986: 10, 40, 100 grams per pound, paragraphs (f)(1) (i) 
through (vi) of this section.
    (2)-(4) [Reserved]
    (5) To No. 051311: 0.4, 0.8, 1, and 8 grams per pound, paragraph 
(f)(1)(vi)(a) of this section; 10 and 40 grams per pound, paragraphs 
(f)(1) (i) through (vi) of this section.
    (6)-(8) [Reserved]
    (9)-(13) [Reserved]
    (14) To 016968: 1, 2, 4, 8, and 10 grams per pound, paragraphs 
(f)(1) (i), (iii), (iv), and (vi) of this section; 20, 25, 40, and 100 
grams per pound, paragraphs (f)(1) (i) through (vi) of this section.
    (15)-(24) [Reserved]
    (25) To 066104: 4, 8, and 10 grams per pound, paragraph 
(f)(1)(vi)(a) of this section; 20 and 40 grams per pound, paragraphs 
(f)(1) (i) through (vi) of this section.
    (26)-(32) [Reserved]
    (33) To 034936: 0.8 and 2 grams per pound, paragraph (f)(1)(vi)(a) 
of this section; 4, 8, and 10 grams per pound, paragraphs (f)(1)(i), 
(iii), (iv), and (vi) of this section; 40 grams per pound, paragraphs 
(f)(1) (i) through (vi) of this section; 100 grams per pound, paragraphs 
(f)(1) (i), (ii), (iii), (iv), and (vi) of this section.
    (34) [Reserved]
    (35)-(38) [Reserved]
    (39) To 061623: 10 grams per pound, paragraph (f)(1)(vi)(a) of this 
section.
    (40)-(47) [Reserved]
    (48) To 017790: 5, 10, 20, and 40 grams per pound, paragraphs (f)(1) 
(i) through (vi) of this section.
    (49)-(53) [Reserved]
    (54) To 046573: 5, 10, 20, and 40 grams per pound, paragraphs (f)(1) 
(i) through (vi) of this section.
    (55)-(56) [Reserved]
    (57) To 028459: 0.4 and 10 grams per pound; paragraph (f)(1)(vi)(a) 
of this section.
    (58)-(62) [Reserved]
    (63)-(77) [Reserved]
    (78) To 050972: 0.36, 0.4, 0.72, and 0.8 gram per pound, paragraph 
(f)(1)(vi)(a) of this section; 1 gram per pound, paragraphs (f)(1)(vi) 
(a), (b), and (d) of this section.
    (79)-(80) [Reserved]
    (81)-(82) [Reserved]
    (83) To 046573: 5-, 10-, 20-, and 40-grams per pound, paragraphs 
(f)(1) (i) through (vi) of this section.
    (84) [Reserved]

[[Page 512]]

    (85) To 047126: 10, 40, and 100 grams per pound, paragraphs (f)(1) 
(i) through (vi) of this section.
    (86)-(88) [Reserved]
    (89) To 048164: 5, 10, 20, and 40 grams per pound, paragraph (f)(1) 
(i) through (vi) of this section.
    (90) No. 016592: 100 grams per pound for use as in paragraph (f) of 
this section.
    (c) Special considerations. (1) Type C medicated feeds for cattle 
may be manufactured from tylosin liquid Type B medicated feeds which 
have a pH between 4.5 and 6.0 and which bear appropriate mixing 
directions as follows:
    (i) For liquid feeds stored in recirculating tank systems: 
Recirculate immediately prior to use for not less than 10 minutes, 
moving not less than 1 percent of the tank contents per minute from the 
bottom of the tank to the top. Recirculate daily as described even when 
not used.
    (ii) For liquid feeds stored in mechanical, air, or other agitation-
type tank systems: Agitate immediately prior to use for not less than 10 
minutes, creating a turbulence at the bottom of the tank that is visible 
at the top. Agitate daily as described even when not used.
    (2) Tylosin liquid Type B medicated feeds used to make Type C 
medicated feeds for cattle may be manufactured from tylosin Type A 
medicated articles according to the following mixing directions:
    (i) [Reserved]
    (ii) Maintain a pH between 4.5 and 6.0.
    (3) Tylosin liquid Type B medicated feeds must bear an expiration 
date of 31 days after the date of manufacture.
    (d) [Reserved]
    (e) Related tolerances. See Sec. 556.740 of this chapter.
    (f) Conditions of use. (1) It is used in animal feeds as follows:
    (i) For beef cattle--(a) Amount per ton. 8-10 grams.
    (b) Indications for use. For reduction of incidence of liver 
abscesses caused by Fusobacterium necrophorum and Arcanobacterium 
(Actinomyces) pyogenes.
    (c) Limitations. As tylosin phosphate; each animal must receive not 
more than 90 milligrams per day and not less than 60 milligrams per day; 
feed continuously as sole ration.
    (ii) Broiler chickens--(a) Amount per ton. Tylosin, 800-1000 grams.
    (b) Indications for use. To aid in the control of chronic 
respiratory disease caused by Mycoplasma gallisepticum.
    (c) Limitations. As tylosin phosphate; withdraw 5 days before 
slaughter; administer in feed to chickens 0 to 5 days of age, follow 
with second administration in feed for 24-48 hours at 3 to 5 weeks of 
age.
    (iii) Chickens--(a) Amount per ton. Tylosin, 4-50 grams.
    (1) Indications for use. For increased rate of weight gain and 
improved feed efficiency.
    (2) Limitations. As tylosin phosphate.
    (iv) Laying chickens--(a) Amount per ton. Tylosin, 20-50 grams.
    (b) Indications for use. For improved feed efficiency.
    (c) Limitations. As tylosin phosphate.
    (v) Replacement chickens--(a) Amount per ton. Tylosin, 1,000 grams.
    (b) Indications for use. To aid in the control of chronic 
respiratory disease caused by Mycoplasma gallisepticum.
    (c) Limitations. As tylosin phosphate; withdraw 5 days before 
slaughter; administer in feed to chickens 0 to 5 days of age, follow 
with second administration in feed for 24 to 48 hours at 3 to 5 weeks of 
age.
    (vi) Swine--(a) Amount per ton. Tylosin, 10-100 grams.
    (1) Indications for use. For increased rate of weight gain and 
improved feed efficiency.
    (2) Limitations. As tylosin phosphate; continuous use as follows: 
Grams per ton: 20-100, prestarter or starter; 20-40, grower; 10-20, 
finisher.
    (b) Amount per ton. Tylosin, 40 or 100 grams.
    (1) Indications for use. For control of swine dysentery associated 
with Brachyspira hyodysenteriae, and for control of porcine 
proliferative enteropathies (ileitis) associated with Lawsonia 
intracellularis.
    (2) Limitations. Use 100 grams per ton for at least 3 weeks followed 
by 40 grams per ton until market weight; as tylosin phosphate.
    (c) Amount per ton. Tylosin, 40-100 grams.

[[Page 513]]

    (1) Indications for use. For the treatment and control of swine 
dysentery associated with Brachyspira hyodysenteriae and for the control 
of porcine proliferative enteropathies (PPE, ileitis) associated with 
Lawsonia intracellularis.
    (2) Limitations. Administer as tylosin phosphate in feed for 2 to 6 
weeks, immediately after treatment with tylosin tartrate in drinking 
water as in Sec. 520.2640(d)(3) of this chapter.
    (d) Amount per ton. Tylosin, 100 grams.
    (1) Indications for use. Maintaining weight gains and feed 
efficiency in presence of atrophic rhinitis.
    (2) Limitations. As tylosin phosphate.
    (vi) Pyrantel tartrate in accordance with Sec. 558.485.
    (e) Amount per ton. Tylosin 100 grams.
    (1) Indications for use. For the control of porcine proliferative 
enteropathies (PPE, ileitis) associated with Lawsonia intracellularis.
    (2) Limitations. As tylosin phosphate, administer for 21 days.
    (2) Tylosin may also be used in combination with:
    (i) Decoquinate and monensin as in Sec. 558.195.
    (ii) Hygromycin B as in Sec. 558.274.
    (iii) Melengestrol acetate alone or in combination with certain 
ionophores as in Sec. 558.342.
    (iv) Monensin as in Sec. 558.355.
    (v) Narasin as in Sec. 558.363.
    (vi) Pyrantel tartrate as in Sec. 558.485.
    (vii) Ractopamine alone or in combination as in Sec. 558.500.
    (viii) Salinomycin as in Sec. 558.550.
    (ix) Zilpaterol alone or in combination as in Sec. 558.665.

[40 FR 13959, Mar. 27, 1975]

    Editorial Note: For Federal Register citations affecting Sec. 
558.625, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.



Sec. 558.630  Tylosin and sulfamethazine.

    (a) Specifications. Type A medicated articles containing equal 
amounts of tylosin phosphate and sulfamethazine, available in 
concentrations of 4, 5, 10, 20, or 40 grams each, per pound.
    (b) Approvals. See sponsor numbers in Sec. 510.600(c) of this 
chapter for use as in paragraph (e) of this section.
    (1) No. 000986: 10 or 40 grams per pound each for use as in 
paragraph (e)(2)(i) of this section.
    (2) [Reserved]
    (3) No. 051311: 40 grams per pound each for use as in paragraph 
(e)(2)(ii) of this section.
    (4) [Reserved]
    (5) Nos. 000986, 012286, 034936, and 046573: 5, 10, 20, or 40 grams 
per pound each for use as in paragraph (e)(2)(ii) of this section.
    (6) No. 000986: 40 grams per pound each for use as in paragraph 
(e)(2)(iii) of this section.
    (c) Special considerations. Labeling shall bear the statement: ``Do 
not use in medicated feeds containing in excess of 2% bentonite.''
    (d) Related tolerances. See Sec. Sec. 556.670 and 556.740 of this 
chapter.
    (e) Conditions of use. It is used in feed for swine as follows:
    (1) Amount per ton. 100 grams tylosin and 100 grams sulfamethazine.
    (2) Indications for use-(i) Maintaining weight gains and feed 
efficiency in the presence of atrophic rhinitis; lowering the incidence 
and severity of Bordetella bronchiseptica rhinitis; prevention of swine 
dysentery (vibrionic); control of swine pneumonias caused by bacterial 
pathogens (Pasteurella multocida and/or Corynebacterium pyogenes); for 
reducing the incidence of cervical lymphadenitis (jowl abscesses) caused 
by Group E Streptococci. Only the sulfamethazine portion of this 
combination is active in controlling jowl abscesses.
    (ii) Maintaining weight gains and feed efficiency in the presence of 
atrophic rhinitis; lowering the incidence and severity of Bordetella 
bronchiseptica rhinitis; prevention of swine dysentery (vibrionic); 
control of swine pneumonias caused by bacterial pathogens (Pasteurella 
multocida and/or Corynebacterium pyogenes).
    (iii) For maintaining weight gains and feed efficiency in the 
presence of atrophic rhinitis; lowering the incidence and severity of 
Bordetella bronchiseptica rhinitis; prevention of swine dysentery 
associated with Brachyspira hyodysenteriae; and control of swine 
pneumonias caused by bacterial pathogens (Pasteurella multocida and/or 
Arcanobacterium pyogenes).

[[Page 514]]

    (3) Limitations. Withdraw 15 days before swine are slaughtered.

[73 FR 34185, June 17, 2008, as amended at 73 FR 35341, June 23, 2008; 
75 FR 55677, Sept. 14, 2010; 76 FR 17778, Mar. 31, 2011; 77 FR 4897, 
Feb. 1, 2012; 78 FR 14669, Mar. 7, 2013]



Sec. 558.635  Virginiamycin.

    (a) Approvals. Type A medicated articles. (1) 1.1 percent activity 
(5 grams per pound), 2.2 percent activity (10 grams per pound), 4.4 
percent activity (20 grams per pound), 11 percent activity (50 grams per 
pound), and 50 percent activity (227 grams per pound) used as in 
paragraph (d) of this section; and 30 percent activity (136.2 grams per 
pound) for the manufacture of Type C medicated feed for cattle used as 
in paragraph (d)(3); to 066104 in Sec. 510.600(c) of this chapter.
    (2) 2.2 percent activity (10 grams per pound) to 046573, 016968, and 
017790 in Sec. 510.600(c) of this chapter for use as in paragraphs 
(d)(1)(iv) and (d)(1)(v) of this section.
    (b) Related tolerances. See Sec. 556.750 of this chapter.
    (c) Special considerations. (1) Not for use in breeding swine over 
120 pounds.
    (2) Dilute Type A article with at least 10 pounds of a feed 
ingredient prior to final mixing in 1 ton of Type C feed.
    (d) Conditions of use--(1) Swine. It is used as follows:
    (i) 100 grams per ton for 2 weeks, for treatment of swine dysentery 
in nonbreeding swine over 120 pounds.
    (ii) 100 grams per ton for 2 weeks, 50 grams per ton thereafter, for 
treatment and control of swine dysentery in swine up to 120 pounds.
    (iii) 25 grams per ton, as an aid in control of dysentery in swine 
up to 120 pounds. For use in animals or on premises with a history of 
swine dysentery but where symptoms have not yet occurred.
    (iv) 10 grams per ton from weaning up to 120 pounds for increased 
rate of weight gain and improved feed efficiency, followed by 5 grams 
per ton to market weight for increased rate of weight gain and improved 
feed efficiency. For continuous use from weaning to market weight.
    (v) 10 grams per ton from weaning up to 120 pounds for increased 
rate of weight gain and improved feed efficiency, followed by 5 to 10 
grams per ton to market weight for increased rate of weight gain. For 
continuous use from weaning to market weight.
    (2) Poultry. It is used as follows:
    (i) 5 to 15 grams per ton for increased rate of weight gain, for use 
in broiler chickens, not for use in layers.
    (ii) 5 grams per ton for increased rate of weight gain and improved 
feed efficiency in broiler chickens, not for use in layers.
    (iii) 20 grams per ton for prevention of necrotic enteritis caused 
by Clostridium perfringens susceptible to virginiamycin in broiler 
chickens; not for use in layers.
    (iv) 10 to 20 grams per ton for increased rate of weight gain and 
improved feed efficiency in growing turkeys.
    (3) Cattle. It is used as follows:
    (i) 16.0 to 22.5 grams per ton to provide 100 to 340 milligrams per 
head per day for increased rate of weight gain.
    (ii) 13.5 to 16.0 grams per ton to provide 85 to 240 milligrams per 
head per day for reduction of incidence of liver abscesses.
    (iii) 11.0 to 16.0 grams per ton to provide 70 to 240 milligrams per 
head per day for improved feed efficiency.
    (iv) Feed continuously as sole ration to cattle fed in confinement 
for slaughter. Not for use in animals intended for breeding.
    (4) Virginiamycin may be used in combination with:
    (i) Amprolium and ethopabate as in Sec. 558.58.
    (ii) Diclazuril as in Sec. 558.198.
    (iii) Halofuginone as in Sec. 558.265.
    (iv) Lasalocid as in Sec. 558.311.
    (v) Monensin alone or with roxarsone as in Sec. 558.355.
    (vi) Salinomycin alone or with roxarsone as in Sec. 558.550.
    (vii) Semduramicin alone or with roxarsone as in Sec. 558.555.

[40 FR 13959, Mar. 27, 1975]

    Editorial Note: For Federal Register citations affecting Sec. 
558.635, see the List of CFR Sections Affected, which appears in the 
Finding Aids section of the printed volume and at www.fdsys.gov.

[[Page 515]]



Sec. 558.665  Zilpaterol.

    (a) Specifications. Type A medicated articles containing 21.77 grams 
(g) zilpaterol hydrochloride per pound.
    (b) Approvals. See No. 000061 in Sec. 510.600(c) of this chapter.
    (c) Tolerances. See Sec. 556.765 of this chapter.
    (d)Special considerations--(1) Labeling of Type B and Type C cattle 
feeds shall bear the following:
    (i) Do not allow horses or other equines access to feed containing 
zilpaterol.
    (ii) Not for use in animals intended for breeding.
    (iii) Do not use in veal calves.
    (2) Type B Liquid Feeds can be manufactured containing 68 to 680 g 
zilpaterol hydrochloride/ton. The liquid Type B feeds must be maintained 
at a pH of 3.8 to 7.5. For liquid feeds stored in recirculating tank 
systems: Recirculate immediately prior to use for not less than 10 
minutes, moving not less than 1 percent of the tank contents per minute 
from the bottom of the tank to the top. Recirculate daily as described 
even when not used. For liquid feeds stored in mechanical, air or other 
agitation-type tank systems: Agitate immediately prior to use for not 
less than 10 minutes, creating a turbulence at the bottom of the tank 
that is visible at the top. Agitate daily as described even when not 
used.
    (e) Conditions of use in cattle. It is administered in feed as 
follows:

----------------------------------------------------------------------------------------------------------------
                           Combination in grams/
 Zilpaterol in grams/ton            ton              Indications for use          Limitations          Sponsor
----------------------------------------------------------------------------------------------------------------
(1) 6.8 to provide 60 to  .......................  Cattle fed in            Feed continuously as          000061
 90 mg/head/day                                     confinement for          the sole ration during
                                                    slaughter: For           the last 20 to 40 days
                                                    increased rate of        on feed. Withdrawal
                                                    weight gain, improved    period: 3 days
                                                    feed efficiency, and
                                                    increased carcass
                                                    leanness in cattle fed
                                                    in confinement for
                                                    slaughter during the
                                                    last 20 to 40 days on
                                                    feed
----------------------------------------------------------------------------------------------------------------
(2) 6.8 to provide 60 to  Melengestrol acetate to  Heifers fed in           As in paragraph (e)(1)        000061
 90 mg/head/day            provide 0.25 to 0.5 mg/  confinement for          of this section; see         000986
                            head/day                slaughter: As in         paragraph Sec. Sec.
                                                    paragraph (e)(1) of      558.342(d) of this
                                                    this section; and for    chapter. Melengestrol
                                                    suppression of estrus    acetate as provided by
                                                    (heat)                   Nos. 000009 or 021641
                                                                             in Sec. 510.600(c)
                                                                             of this chapter
----------------------------------------------------------------------------------------------------------------
(3) 6.8 to provide 60 to  Monensin 10 to 40        Cattle fed in            As in paragraph (e)(1)        000061
 90 mg/head/day                                     confinement for          of this section; see
                                                    slaughter: As in         paragraph Sec.
                                                    paragraph (e)(1) of      558.355(d) of this
                                                    this section; and for    chapter. Monensin as
                                                    prevention and control   provided by No. 000986
                                                    of coccidiosis due to    in Sec. 510.600(c)
                                                    Eimeria bovis and E.     of this chapter
                                                    zuernii
----------------------------------------------------------------------------------------------------------------
(4) 6.8 to provide 60 to  Melengestrol acetate to  Heifers fed in           As in paragraph (e)(1)        000061
 90 mg/head/day            provide 0.25 to 0.5 mg/  confinement for          of this section; see         000986
                            head/day                slaughter: As in         Sec. Sec.
                                                    paragraph (e)(1) of      558.342(d) and
                                                    this section; for        558.355(d) of this
                                                    prevention and control   chapter. Monensin as
                                                    of coccidiosis due to    provided by No.
                                                    Eimeria bovis and E.     000986; melengestrol
                                                    zuernii; and for         acetate as provided by
                                                    suppression of estrus    Nos. 000009 or 021641
                                                    (heat)                   in Sec. 510.600(c)
                                                                             of this chapter
----------------------------------------------------------------------------------------------------------------

[[Page 516]]

 
(5) 6.8 to provide 60 to  Monensin 10 to 40, plus  Cattle fed in            As in paragraph (e)(1)        000061
 90 mg/head/day            tylosin 8 to 10          confinement for          of this section; see
                                                    slaughter: As in         Sec. Sec.
                                                    paragraph (e)(1) of      558.355(d) and
                                                    this section; for        558.625(c) of this
                                                    prevention and control   chapter. Monensin and
                                                    of coccidiosis due to    tylosin as provided by
                                                    Eimeria bovis and E.     No. 000986 in Sec.
                                                    zuernii; and for         510.600(c) of this
                                                    reduction of incidence   chapter
                                                    of liver abscesses
                                                    caused by
                                                    Fusobacterium
                                                    necrophorum and
                                                    Arcanobacterium
                                                    (Actinomyces) pyogenes
----------------------------------------------------------------------------------------------------------------
(6) 6.8 to provide 60 to  Monensin 10 to 40, plus  Heifers fed in           As in paragraph (e)(1)        000061
 90 mg/head/day            tylosin 8 to 10, plus    confinement for          of this section; see         000986
                           melengestrol acetate     slaughter: As in         Sec. Sec.
                           to provide 0.25 to 0.5   paragraph (e)(1) of      558.342(d),
                           mg/ head/day             this section; for        558.355(d), and
                                                    prevention and control   558.625(c) of this
                                                    of coccidiosis due to    chapter. Monensin and
                                                    Eimeria bovis and E.     tylosin as provided by
                                                    zuernii; for reduction   No. 000986;
                                                    of incidence of liver    melengestrol acetate
                                                    abscesses caused by      as provided by Nos.
                                                    Fusobacterium            000009 or 021641 in
                                                    necrophorum and          Sec. 510.600(c) of
                                                    Arcanobacterium          this chapter
                                                    (Actinomyces)
                                                    pyogenes; and for
                                                    suppression of estrus
                                                    (heat)
----------------------------------------------------------------------------------------------------------------


[71 FR 53006, Sept. 8, 2006, as amended at 72 FR 9245, Mar. 1, 2007; 72 
FR 6019, Feb. 1, 2008; 73 FR 14385, Mar. 18, 2008; 73 FR 16755, Mar. 31, 
2008; 73 FR 18959, Apr. 8, 2008; 73 FR 19432, Apr. 10, 2008; 74 FR 
61517, Nov. 25, 2009; 75 FR 11451, Mar. 11, 2010; 77 FR 31724, May 30, 
2012]



Sec. 558.680  Zoalene.

    (a) Specifications. Type A medicated article containing 25 percent 
zoalene.
    (b) Approvals. See No. 046573 in Sec. 510.600(c) of this chapter.
    (c) Related tolerances. See Sec. 556.770 of this chapter.
    (d) Conditions of use--(1) Chickens and turkeys:

----------------------------------------------------------------------------------------------------------------
                                        Combination in grams/
         Zoalene in grams/ton                    ton              Indications for use          Limitations
----------------------------------------------------------------------------------------------------------------
(i) 36.3-113.5 (0.004-0.0125%).......  .......................  Replacement chickens;    Grower ration not to be
                                                                 development of active    fed to birds over 14
                                                                 immunity to              weeks of age; as
                                                                 coccidiosis.             follows:
----------------------------------------------------------------------------------------------------------------


------------------------------------------------------------------------
                                    Starter ration       Grower ration
       Growing conditions            Grams per ton       Grams per ton
------------------------------------------------------------------------
Severe exposure.................  113.5 (0.0125%)...  75.4-113.5
                                                       (0.0083%-0.0125%)
Light to moderate exposure......  75.4-113.5          36.3-75.4 (0.004%-
                                   (0.0083%-0.0125%).  0.0083%)
------------------------------------------------------------------------


----------------------------------------------------------------------------------------------------------------
                                        Combination in grams/
         Zoalene in grams/ton                    ton              Indications for use          Limitations
----------------------------------------------------------------------------------------------------------------
                                       Arsanilic acid 90        Replacement chickens;    Grower ration not to be
                                        (0.01%).                 development of active    fed to birds over 14
                                                                 immunity to              weeks of age; withdraw
                                                                 coccidiosis; growth      5 d before slaughter;
                                                                 promotion and feed       as sole source of
                                                                 efficiency; improving    organic arsenic; feed
                                                                 pigmentation.            as in subtable in item
                                                                                          (i).

[[Page 517]]

 
                                       Arsanilic acid 90        Replacement chickens;    As erythromycin
                                        (0.01%) plus             growth promotion and     thiocyanate; grower
                                        erythromycin 4.6 to      feed efficiency;         ration not to be fed
                                        18.5.                    development of active    to birds over 14 weeks
                                                                 immunity to              of age; withdraw 5 d
                                                                 coccidiosis; improving   before slaughter; as
                                                                 pigmentation.            sole source of organic
                                                                                          arsenic; feed as in
                                                                                          subtable item (i).
                                       Arsanilic acid 90        1. Replacement           Feed for 2 d before
                                        (0.01%) plus             chickens; as an aid in   stress and 3 to 6 d
                                        erythromycin 92.5.       the prevention of        after stress; as
                                                                 chronic respiratory      erythromycin
                                                                 disease during periods   thiocyanate; grower
                                                                 of stress; development   ration not to be fed
                                                                 of active immunity to    to birds over 14 weeks
                                                                 coccidiosis; growth      of age; withdraw 5 d
                                                                 promotion and feed       before slaughter; as
                                                                 efficiency; improving    sole source of organic
                                                                 pigmentation.            arsenic arsenic; feed
                                                                                          as in subtable in item
                                                                                          (i).
                                       .......................  2. Replacement           Feed for 7 to 14 d; as
                                                                 chickens; as an aid in   erythromycin
                                                                 the prevention of        thiocyanate; grower
                                                                 infectious coryza;       ration not to be fed
                                                                 development of active    to birds over 14 weeks
                                                                 immunity to              of age; withdraw 5 d
                                                                 coccidiosis; growth      before slaughter; as
                                                                 promotion and feed       sole source of organic
                                                                 efficiency; improving    arsenic; feed as in
                                                                 pigmentation.            subtable in item (i).
                                       Arsanilic acid 90        Replacement chickens;    Feed for 5 to 8 d; do
                                        (0.01%) plus             as an aid in the         not use in birds
                                        erythromycin 185.        prevention and           producing eggs for
                                                                 reduction of lesions     food purposes;
                                                                 and in lowering          withdraw 5 d before
                                                                 severity of chronic      slaughter; as
                                                                 respiratory disease;     erythromycin
                                                                 growth promotion and     thiocyanate; as sole
                                                                 feed efficiency;         source of organic
                                                                 improving pigmentation   arsenic; feed as in
                                                                 and development of       subtable in item (i).
                                                                 active immunity to
                                                                 coccidiosis.
                                       Arsanilic acid 90        Replacement chickens;    As procaine penicillin;
                                        (0.01%) plus             growth promotion and     grower ration not to
                                        penicillin 2.4 to 50.    feed efficiency;         be fed to birds over
                                                                 development of active    14 weeks of age;
                                                                 immunity to              withdraw 5 d before
                                                                 coccidiosis; improving   slaughter; as sole
                                                                 pigmentation.            source of organic
                                                                                          arsenic; feed as in
                                                                                          subtable in item (i).
                                       Bacitracin 4 to 50.....  Replacement chickens:    Feed as in subtable in
                                                                 For development of       Sec.
                                                                 active immunity to       558.680(d)(1)(i);
                                                                 coccidiosis; for         grower ration not to
                                                                 increased rate of        be fed to birds over
                                                                 weight gain, improved    14 weeks of age. As
                                                                 feed efficiency.         bacitracin methylene
                                                                                          disalicylate provided
                                                                                          by No. 046573 in Sec.
                                                                                           510.600(c) of this
                                                                                          chapter.
                                       Bacitracin methylene     Replacement chickens:    Feed as in subtable in
                                        disalicylate 4 to 50     For development of       Sec.
                                        plus roxarsone 22.7 to   active immunity to       558.680(d)(1)(i);
                                        45.4.                    coccidiosis; for         grower ration not to
                                                                 increased rate of        be fed to birds over
                                                                 weight gain, improved    14 weeks of age.
                                                                 feed efficiency, and     Discontinue use 5 days
                                                                 improved pigmentation.   before slaughter; as
                                                                                          sole source of organic
                                                                                          arsenic; drug overdose
                                                                                          or lack of water may
                                                                                          result in leg
                                                                                          weakness. As
                                                                                          bacitracin methylene
                                                                                          disalicylate and
                                                                                          roxarsone provided by
                                                                                          No. 046573 in Sec.
                                                                                          510.600(c) of this
                                                                                          chapter.
                                       Bacitracin methylene...  Replacement chickens;    Feed continuously as
                                        disalicylate 50.......   development of active    sole ration as in
                                                                 immunity to              subtable in this item
                                                                 coccidiosis; as an aid   (i); grower ration not
                                                                 in the prevention of     to be fed to birds
                                                                 necrotic enteritis       over 14 weeks of age.
                                                                 caused or complicated    Bacitracin methylene
                                                                 by Clostridium spp. or   disalicylate as
                                                                 other organisms          provided by 046573 in
                                                                 susceptible to           Sec. 510.600(c) of
                                                                 bacitracin.              this chapter.

[[Page 518]]

 
                                       Bacitracin methylene     Replacement chickens;    Feed continuously as
                                        disalicylate 100 to      development of active    sole ration as in
                                        200.                     immunity to              subtable in this item
                                                                 coccidiosis; as an aid   (i). To control
                                                                 in the control of        necrotic enteritis,
                                                                 necrotic enteritis       start medication at
                                                                 caused or complicated    first clinical signs
                                                                 by Clostridium spp. or   of disease; vary
                                                                 other organisms          bacitracin dosage
                                                                 susceptible to           based on the severity
                                                                 bacitracin.              of infection;
                                                                                          administer
                                                                                          continuously for 5 to
                                                                                          7 days or as long as
                                                                                          clinical signs
                                                                                          persist, then reduce
                                                                                          bacitracin to
                                                                                          prevention level (50
                                                                                          grams/ton). Bacitracin
                                                                                          methylene disalicylate
                                                                                          as provided by 046573
                                                                                          in Sec. 510.600(c)
                                                                                          of this chapter.
                                       Bacitracin 100 to 500..  Replacement chickens;    As bacitracin zinc;
                                                                 treatment of chronic     grower ration not to
                                                                 respiratory disease      be fed to birds over
                                                                 (air-sac infection);     14 weeks of age; feed
                                                                 blue comb (nonspecific   as in subtable in item
                                                                 infectious enteritis);   (i).
                                                                 development of active
                                                                 immunity to
                                                                 coccidiosis.
 
                                       Chlortetracycline 100    Replacement chickens;    Do not feed to chickens
                                        to 200.                  development of active    producing eggs for
                                                                 immunity to              human consumption;
                                                                 coccidiosis; control     grower ration not to
                                                                 of infectious            be fed to birds over
                                                                 synovitis caused by      14 weeks of age; feed
                                                                 Mycoplasma synoviae      as in subtable in item
                                                                 susceptible to           (i).
                                                                 chlortetracycline.
                                       Chlortetracycline 200    Replacement chickens;    Do not feed to chickens
                                        to 400.                  development of active    producing eggs for
                                                                 immunity to              human consumption;
                                                                 coccidiosis; control     grower ration not to
                                                                 of chronic respiratory   be fed to birds over
                                                                 disease (CRD) and air    14 weeks of age; feed
                                                                 sac infection caused     as in subtable in item
                                                                 by M. gallisepticum      (i).
                                                                 and Escherichia coli
                                                                 susceptible to
                                                                 chlortetracycline.
                                       Erythromycin 4.6 to      Replacement chickens;    As erythromycin
                                        18.5.                    growth promotion and     thiocyanate; grower
                                                                 feed efficiency;         ration not to be fed
                                                                 development of active    to birds over 14 weeks
                                                                 immunity to              of age; feed as in
                                                                 coccidiosis.             subtable in item (i).
                                       Erythromycin 92.5......  1. Replacement           Feed for 2 d before
                                                                 chickens, as an aid in   stress and 3 to 6
                                                                 the prevention of        after stress; withdraw
                                                                 chronic respiratory      24 hours (h) before
                                                                 disease during periods   slaughter; as
                                                                 of stress; development   erythromycin
                                                                 of active immunity to    thiocyanate; grower
                                                                 coccidiosis.             ration not to be fed
                                                                                          to birds over 14 weeks
                                                                                          of age; feed as in
                                                                                          subtable in item (i).
                                       .......................  2. Replacement           Feed for 7 to 14 d;
                                                                 chickens; as an aid in   withdraw 24 h before
                                                                 the prevention of        slaughter; as
                                                                 infectious coryza;       erythromycin
                                                                 development of active    thiocyanate; grower
                                                                 immunity to              ration not to be fed
                                                                 coccidiosis.             to birds over 14 weeks
                                                                                          of age; feed as in
                                                                                          subtable in item (i).
                                       Erythromycin 185.......  Replacement chickens;    Feed for 5 to 8 d; do
                                                                 as an aid in the         not use in birds
                                                                 prevention and           producing eggs for
                                                                 reduction of lesions     food purposes;
                                                                 and in lowering          withdraw 48 h before
                                                                 severity of chronic      slaughter; grower
                                                                 respiratory disease;     ration not to be fed
                                                                 development of active    to birds over 14 weeks
                                                                 immunity to              of age; feed as in
                                                                 coccidiosis.             subtable in item (i).
                                       Hygromycin B 8 to 12...  Replacement chickens;    Grower ration not to be
                                                                 development of active    fed to birds over 14
                                                                 immunity to              weeks of age; feed as
                                                                 coccidiosis; control     in subtable in item
                                                                 of infestation of        (i).
                                                                 large round worms
                                                                 (Ascaris galli) cecal
                                                                 worms (Heterakis
                                                                 gallinae) and
                                                                 capillary worms
                                                                 (Capillaria obsignate).
                                       Penicillin 2.4 to 50...  Replacement chickens;    As procaine penicillin;
                                                                 growth promotion and     grower ration not to
                                                                 feed efficiency;         be fed to birds over
                                                                 development of active    14 weeks of age; feed
                                                                 immunity to              as in subtable in item
                                                                 coccidiosis.             (i).

[[Page 519]]

 
                                       Penicillin 2.4 to 50     Replacement chickens;    As procaine penicillin;
                                        plus roxarsone 22.7 to   growth promotion and     grower ration not to
                                        45.4 (0.0025% to         feed efficiency;         be fed to birds over
                                        0.005%).                 development of active    14 weeks of age;
                                                                 immunity to              withdraw 5 d before
                                                                 coccidiosis; improving   slaughter; as sole
                                                                 pigmentation.            source of organic
                                                                                          arsenic; feed as in
                                                                                          subtable in item (i).
                                       Roxarsone 22.7 to 45.5   Replacement chickens;    Grower ration not to be
                                        (0.0025% to 0.005%).     development of active    fed to birds over 14
                                                                 immunity to              weeks of age; withdraw
                                                                 coccidiosis; growth      5 d before slaughter;
                                                                 promotion and feed       as sole source of
                                                                 efficiency; improving    organic arsenic; feed
                                                                 pigmentation.            as in subtable in item
                                                                                          (i).
(ii) 113.5 (0.0125%).................  .......................  Broiler chickens;
                                                                 prevention and control
                                                                 of coccidiosis..
                                       Arsanilic acid 90        Broiler chickens;        Withdraw 5 d before
                                        (0.01%).                 growth promotion and     slaughter; as sole
                                                                 feed efficiency;         source of organic
                                                                 prevention and control   arsenic.
                                                                 of coccidiosis;
                                                                 improving pigmentation.
                                       Arsanilic acid 90        Broiler chickens;        As erythromycin
                                        (0.01%) plus             growth prevention and    thiocyanate; withdraw
                                        erythromycin 4.6 to      control of               5 d before slaughter;
                                        18.5.                    coccidiosis; improving   as sole source of
                                                                 pigmentation.            organic arsenic.
                                       Arsanilic acid 90        1. Broiler chickens; as   Do.
                                        (0.01%) plus             an aid in the
                                        erythromycin 92.5.       prevention of chronic
                                                                 respiratory disease
                                                                 during periods of
                                                                 stress; growth
                                                                 promotion and feed
                                                                 efficiency; improving
                                                                 pigmentation; control
                                                                 of coccidiosis.
                                       .......................  2. Broiler chickens;      Do.
                                                                 prevention and control
                                                                 of coccidiosis; growth
                                                                 promotion and feed
                                                                 efficiency; improving
                                                                 pigmentation; as an
                                                                 aid in the prevention
                                                                 of infectious coryza.
                                       Arsanilic acid 90        Broiler chickens; as an  Feed for 5 to 8 d; do
                                        (0.01%) plus             aid in the prevention    not use in birds
                                        erythromycin 185.        and reduction of         producing eggs for
                                                                 lesions and in           food purposes; as
                                                                 lowering severity of     erythromycin
                                                                 chronic respiratory      thiocyanate; withdraw
                                                                 disease; prevention      5 d before slaughter;
                                                                 and control of           as sole source of
                                                                 coccidiosis; growth      organic arsenic.
                                                                 promotion and feed
                                                                 efficiency; improving
                                                                 pigmentation.
                                       Arsanilic acid 90        Broiler chickens;        As procaine penicillin;
                                        (0.01%) plus             growth promotion and     withdraw 5 d before
                                        penicillin 2.4 to 50.    feed efficiency;         slaughter; as sole
                                                                 prevention and control   source of organic
                                                                 of coccidiosis;          arsenic.
                                                                 improving pigmentation.
                                       Arsanilic acid 90        Broiler chickens;        Withdraw 5 d before
                                        (0.01%) plus             prevention and control   slaughter; as sole
                                        bacitracin 4 to 50.      of coccidiosis;          source of organic
                                                                 improving                arsenic; as bacitracin
                                                                 pigmentation; growth     methylene
                                                                 promotion and feed       disalicylate.
                                                                 efficiency.
                                       Bacitracin 4 to 50.....  Broiler chickens;        As bacitracin methylene
                                                                 growth promotion and     disalicylate or zinc
                                                                 feed efficiency;         bacitracin.
                                                                 prevention and control
                                                                 of coccidiosis.
                                       Bacitracin 4 to 50 plus  Broiler chickens;        As bacitracin methylene
                                        roxarsone 22.7 to 45.4   growth promotion and     disalicylate or zinc
                                        (0.0025 to 0.005%).      feed efficiency;         bacitracin; withdraw 5
                                                                 prevention and control   d before slaughter; as
                                                                 of coccidiosis;          sole source of organic
                                                                 improving pigmentation.  arsenic.
                                       Bacitracin methylene     Broiler chickens;        Feed continuously as
                                        disalicylate 50.         prevention and control   sole ration.
                                                                 of coccidiosis; as an    Bacitracin methylene
                                                                 aid in the prevention    disalicylate as
                                                                 of necrotic enteritis    provided by 046573 in
                                                                 caused or complicated    Sec. 510.600(c) of
                                                                 by Clostridium spp. or   this chapter.
                                                                 other organisms
                                                                 susceptible to
                                                                 bacitracin.

[[Page 520]]

 
                                       Bacitracin methylene     Broiler chickens;        Feed continuously as
                                        disalicylate 100 to      prevention and control   sole ration. To
                                        200.                     of coccidiosis; as an    control necrotic
                                                                 aid in the control of    enteritis, start
                                                                 necrotic enteritis       medication at first
                                                                 caused or complicated    clinical signs of
                                                                 by Clostridium spp. or   disease; vary
                                                                 other organisms          bacitracin dosage
                                                                 susceptible to           based on the severity
                                                                 bacitracin.              of infection;
                                                                                          administer
                                                                                          continuously for 5 to
                                                                                          7 days or as long as
                                                                                          clinical signs
                                                                                          persist, then reduce
                                                                                          bacitracin to
                                                                                          prevention level (50
                                                                                          grams/ton). Bacitracin
                                                                                          methylene disalicylate
                                                                                          as provided by 046573
                                                                                          in Sec. 510.600(c)
                                                                                          of this chapter.
                                       Bacitracin 100 to 500..  Broiler chickens;        As zinc bacitrain.
                                                                 treatment of chronic
                                                                 respiratory disease
                                                                 (air-sac infection);
                                                                 blue comb (nonspecific
                                                                 infectious enteritis);
                                                                 prevention and control
                                                                 of coccidiosis.
                                       Bambermycins 1.........  Broiler chickens: As an  Feed continuously as
                                                                 aid in the prevention    sole ration. Do not
                                                                 and control of           feed to chickens over
                                                                 coccidiosis; and for     14 weeks of age.
                                                                 increased rate of        Bambermycins as
                                                                 weight gain and          provided by No. 016592
                                                                 improved feed            in Sec. 510.600(c)
                                                                 efficiency.              of this chapter.
                                       Bambermycins 1 plus      Broiler chickens: As an  Feed continuously as
                                        roxarsone 22.7.          aid in the prevention    sole ration. Do not
                                                                 and control of           feed to chickens over
                                                                 coccidiosis; and for     14 weeks of age; feed
                                                                 increased rate of        as sole source of
                                                                 weight gain and          organic arsenic;
                                                                 improved feed            withdraw 5 days before
                                                                 efficiency.              slaughter.
                                                                                          Bambermycins as
                                                                                          provided by No.
                                                                                          016592, roxarsone by
                                                                                          No. 046573 in Sec.
                                                                                          510.600(c) of this
                                                                                          chapter.
                                       Chlortetracycline 100    Broiler chickens;        Do not feed to chickens
                                        to 200.                  prevention and control   producing eggs for
                                                                 of coccidiosis;          human consumption;
                                                                 control of infectious    feed continuously for
                                                                 synovitis caused by M.   7 to 14 d.
                                                                 synoviae susceptible
                                                                 to chlortetracycline.
                                       Chlortetracycline 200    Broiler chickens;        Do not feed to chickens
                                        to 400.                  prevention and control   producing eggs for
                                                                 of coccidiosis;          human consumption;
                                                                 control of chronic       feed continuously for
                                                                 respiratory disease      7 to 14 d.
                                                                 (CRD) and air sac
                                                                 infection caused by M.
                                                                 gallisepticum and E.
                                                                 coli susceptible to
                                                                 chlortetracycline.
                                       Erythromycin 4.6 to      Broiler chickens;        As erythromycin
                                        18.5.                    growth promotion and     thiocyanate.
                                                                 feed efficiency;
                                                                 prevention and control
                                                                 of coccidiosis.
                                       Erythromycin 92.5......  1. Broiler chickens; as  Feed for 2 d before
                                                                 an aid in the            stress and 3 to 6 d
                                                                 prevention of chronic    after stress; withdraw
                                                                 respiratory disease      24 h before slaughter;
                                                                 during period of         as erythromycin
                                                                 stress; prevention and   thiocyanate.
                                                                 control of coccidiosis.
                                       .......................  2. Broiler chicken; as   Feed for 7 to 14 d;
                                                                 an aid in the            withdraw 24 h before
                                                                 prevention of            slaughter; as
                                                                 infectious coryza;       erythromycin
                                                                 prevention and control   thiocyanate.
                                                                 of coccidiosis.
                                       Erythromycin 185.......  Broiler chickens; as an  Feed for 5 to 8 d; do
                                                                 aid in the prevention    not use in birds
                                                                 and reduction of         producing eggs for
                                                                 lesions and in           food purposes;
                                                                 lowering severity of     withdraw 48 h before
                                                                 chronic respiratory      slaughter; as
                                                                 disease; prevention      erythromycin
                                                                 and control of           thiocyanate.
                                                                 coccidiosis.
                                       Hygromycin B 8 to 12...  Broiler chickens;        .......................
                                                                 prevention and control
                                                                 of coccidiosis;
                                                                 control of infestation
                                                                 of large round worms
                                                                 (Ascaris galli) cecal
                                                                 worms (Heterakis
                                                                 gallinae) and
                                                                 capillary worms
                                                                 (Capillaria obsignate).

[[Page 521]]

 
                                       Lincomycin 2...........  Broiler chickens;        Do not feed to laying
                                                                 increase in rate of      chickens; to be fed as
                                                                 weight gain; improved    the sole ration; as
                                                                 feed efficiency; as an   lincomycin
                                                                 aid in the prevention    hydrochloride
                                                                 and control of           monohydrate provided
                                                                 coccidiosis.             by No. 000009 in Sec.
                                                                                           510.600(c) of this
                                                                                          chapter.
                                       Penicillin 2.4 to 50...  Broiler chickens;        As procaine penicillin.
                                                                 growth promotion and
                                                                 feed efficiency;
                                                                 prevention and control
                                                                 of coccidiosis.
                                       Penicillin 2.4 to 50     Broiler chickens;        Withdraw 5 d before
                                        plus roxarsone 22.7 to   prevention and control   slaughter; as sole
                                        45.4 (0.0025 to          of coccidiosis; growth   source of organic
                                        0.005%).                 promotion and feed       arsenic; as procaine
                                                                 efficiency; improving    penicillin.
                                                                 pigmentation.
                                       Roxarsone 22.7 to 45.4   Broiler chickens;        Withdraw 5 d before
                                        (0.0025 to 0.005%).      prevention and control   slaugher; as sole
                                                                 of coccidiosis; growth   source of organic
                                                                 promotion and feed       arsenic.
                                                                 efficiency; improving
                                                                 pigmentation.
(iii) 113.5 to 170.3 (0.0125 to        .......................  Turkeys; prevention and  For turkeys grown for
 0.01875%).                                                      control of coccidiosis.  meat purposes only.
                                       Arsanilic acid            do....................   Do.
                                        90(0.01%).
                                       Bacitracin methylene     Turkeys; prevention and  For turkeys grown for
                                        disalicylate 4-50.       control of               meat purposes only,
                                                                 coccidiosis, and         not to be fed to
                                                                 increased rate of        laying birds, feed
                                                                 weight gain and          continuously as sole
                                                                 improved feed            ration until 14 to 16
                                                                 efficiency.              weeks of age.
                                       Carbarsone (not U.S.P.)  Turkeys; prevention and  For turkeys grown for
                                        277 to 340.5 (0.025%     control of               meat purposes only;
                                        to 0.0375%).             coccidiosis; aid in      feed continuously
                                                                 the prevention of        beginning 2 weeks
                                                                 blackhead.               before blackhead and
                                                                                          coccidiosis are
                                                                                          expected and continue
                                                                                          as long as prevention
                                                                                          of blackhead and
                                                                                          prevention and control
                                                                                          of coccidiosis is
                                                                                          needed; withdraw 5 d
                                                                                          before slaughter; as
                                                                                          sole source of organic
                                                                                          arsenic.
                                       Roxarsone 22.7 to 45.4   Turkeys; growth          Withdraw 5 d before
                                        (0.0025% to 0.005%).     promotion and feed       slaughter; as sole
                                                                 efficiency; improving    source of organic
                                                                 pigmentation.            arsenic.
----------------------------------------------------------------------------------------------------------------

    (2) Zoalene may also be used in combination with roxarsone as in 
Sec. 558.530.

[41 FR 11005, Mar. 15, 1976, as amended at 42 FR 18618, Apr. 8, 1977; 42 
FR 20817, Apr. 22, 1977; 42 FR 36995, July 19, 1977; 51 FR 7401, Mar. 3, 
1986; 52 FR 2686, Jan. 26, 1987; 55 FR 8461, Mar. 8, 1990; 57 FR 8403, 
Mar. 10, 1992; 57 FR 8578, Mar. 11, 1992; 61 FR 35957, July 9, 1996; 63 
FR 38750, July 20, 1998; 67 FR 6868, Feb. 14, 2002; 71 FR 16223, Mar. 
31, 2006; 71 FR 27958, May 15, 2006; 76 FR 17027, Mar. 28, 2011]

                           PART 564 [RESERVED]



PART 570_FOOD ADDITIVES--Table of Contents



                      Subpart A_General Provisions

Sec.
570.3 Definitions.
570.6 Opinion letters on food additive status.
570.13 Indirect food additives resulting from packaging materials prior 
          sanctioned for animal feed and pet food.
570.14 Indirect food additives resulting from packaging materials for 
          animal feed and pet food.
570.15 Adoption of regulation on initiative of Commissioner.
570.17 Exemption for investigational use and procedure for obtaining 
          authorization to market edible products from experimental 
          animals.
570.18 Tolerances for related food additives.
570.19 Pesticide chemicals in processed foods.

                     Subpart B_Food Additive Safety

570.20 General principles for evaluating the safety of food additives.
570.30 Eligibility for classification as generally recognized as safe 
          (GRAS).
570.35 Affirmation of generally recognized as safe (GRAS) status.
570.38 Determination of food additive status.

    Authority: 21 U.S.C. 321, 341, 342, 346a, 348, 371.

    Source: 41 FR 38644, Sept. 10, 1976, unless otherwise noted.

[[Page 522]]



                      Subpart A_General Provisions



Sec. 570.3  Definitions.

    (a) Secretary means the Secretary of Health and Human Services.
    (b) Department means the Department of Health and Human Services.
    (c) Commissioner means the Commissioner of Food and Drugs.
    (d) As used in this part, the term act means the Federal Food, Drug, 
and Cosmetic Act approved June 25, 1936 (52 Stat. 1040 et seq., as 
amended; 21 U.S.C. 301-392).
    (e) Food additives includes all substances not exempted by section 
201(s) of the act, the intended use of which results or may reasonably 
be expected to result, directly or indirectly, either in their becoming 
a component of food or otherwise affecting the characteristics of food. 
A material used in the production of containers and packages is subject 
to the definition if it may reasonably be expected to become a 
component, or to affect the characteristics, directly or indirectly, of 
food packed in the container. Affecting the characteristics of food does 
not include such physical effects, as protecting contents of packages, 
preserving shape, and preventing moisture loss. If there is no migration 
of a packaging component from the package to the food, it does not 
become a component of the food and thus is not a food additive. A 
substance that does not become a component of food, but that is used, 
for example, in preparing an ingredient of the food to give a different 
flavor, texture, or other characteristic in the food, may be a food 
additive.
    (f) Common use in food means a substantial history of consumption of 
a substance by a significant number of animals in the United States.
    (g) The word substance in the definition of the term food additive 
includes a food or feed or a component of a food or feed consisting of 
one or more ingredients.
    (h) Scientific procedures include those human, animal, analytical, 
and other scientific studies, whether published or unpublished, 
appropriate to establish the safety of a substance.
    (i) Safe or safety means that there is a reasonable certainty in the 
minds of competent scientists that the substance is not harmful under 
the intended conditions of use. It is impossible in the present state of 
scientific knowledge to establish with complete certainty the absolute 
harmlessness of the use of any substance. Safety may be determined by 
scientific procedures or by general recognition of safety. In 
determining safety, the following factors shall be considered:
    (1) The probable consumption of the substance and of any substance 
formed in or on food because of its use;
    (2) The cumulative effect of the substance in the diet, taking into 
account any chemically or pharmacologically related substance or 
substances in such diet;
    (3) Safety factors which, in the opinion of experts qualified by 
scientific training and experience to evaluate the safety of food and 
food ingredients, are generally recognized as appropriate.
    (j) The term nonperishable processed food means any processed food 
not subject to rapid decay or deterioration that would render it unfit 
for consumption. Not included are hermetically sealed foods and other 
processed foods requiring refrigeration.
    (k) General recognition of safety shall be determined in accordance 
with Sec. 570.30.
    (l) Prior sanction means an explicit approval granted with respect 
to use of a substance in food prior to September 6, 1958, by the Food 
Drug and Administration or the United States Department of Agriculture 
pursuant to the Federal Food, Drug, and Cosmetic Act, the Poultry 
Products Inspection Act, or the Meat Inspection Act.
    (m) Food includes human food, substances migrating to food from 
food-contact articles, pet food, and animal feed.

[41 FR 38644, Sept. 10, 1976, as amended at 42 FR 55206, Oct. 14, 1977]



Sec. 570.6  Opinion letters on food additive status.

    (a) Over the years the Food and Drug Administration has given 
informal written opinions to inquirers as to the safety of articles 
intended for use as components of, or in contact with, food. Prior to 
the enactment of the Food Additives Amendment of 1958 (Pub. L. 85-929, 
Sept. 6, 1958), these

[[Page 523]]

opinions were given pursuant to section 402(a)(1) of the Federal Food, 
Drug, and Cosmetic Act, which reads in part: ``A food shall be deemed to 
be adulterated if it bears or contains any poisonous or deleterious 
substance which may render it injurious to health''.
    (b) Since enactment of the Food Additives Amendment, the Food and 
Drug Administration has advised such inquirers that an article:
    (1) Is a food additive within the meaning of section 201(s) of the 
act; or
    (2) Is generally recognized as safe (GRAS); or
    (3) Has prior sanction or approval under that amendment; or
    (4) Is not a food additive under the conditions of intended use.
    (c) In the interest of the public health, such articles which have 
been considered in the past by the Food and Drug Administration to be 
safe under the provisions of section 402(a)(1), or to be generally 
recognized as safe for their intended use, or to have prior sanction or 
approval, or not to be food additives under the conditions of intended 
use, must be reexamined in the light of current scientific information 
and current principles for evaluating the safety of food additives if 
their use is to be continued.
    (d) Because of the time span involved, copies of many of the letters 
in which the Food and Drug Administration has expressed an informal 
opinion concerning the status of such articles may no longer be in the 
file of the Food and Drug Administration. In the absence of information 
concerning the names and uses made of all the articles referred to in 
such letters, their safety of use cannot be reexamined. For this reason 
all food additive status opinions of the kind described in paragraph (c) 
of this section given by the Food and Drug Administration are hereby 
revoked.
    (e) The prior opinions of the kind described in paragraph (c) of 
this section will be replaced by qualified and current opinions if the 
recipient of each such letter forwards a copy of each to the Department 
of Health and Human Services, Food and Drug Administration, Center for 
Veterinary Medicine, Office of Surveillance and Compliance (HFV-200), 
7500 Standish Pl., Rockville, MD 20855, along with a copy of his letter 
of inquiry, on or before July 23, 1970.
    (f) This section does not apply to food additive status opinion 
letters pertaining to articles that were considered by the Food and Drug 
Administration to be food additives nor to articles included in 
regulations in this Subchapter E if the articles are used in accordance 
with the requirements of such regulations.

[41 FR 38644, Sept. 10, 1976, as amended at 54 FR 18281, Apr. 28, 1989; 
57 FR 6476, Feb. 25, 1992]



Sec. 570.13  Indirect food additives resulting from packaging 
materials prior sanctioned for animal feed and pet food.

    Regulations providing for the use of food packaging materials as 
prior sanctioned in part 181 of this chapter are incorporated in 
Subchapter E as applicable to packaging materials used for animal feed 
and pet food.

[42 FR 14091, Mar. 15, 1977]



Sec. 570.14  Indirect food additives resulting from packaging materials 
for animal feed and pet food.

    Regulations providing for the use of food packaging materials in 
parts 174 through 179 of this chapter are incorporated in Subchapter E 
as applicable to packaging materials used for animal feed and pet food.

[42 FR 14091, Mar. 15, 1977]



Sec. 570.15  Adoption of regulation on initiative of Commissioner.

    (a) The Commissioner upon his own initiative may propose the 
issuance of a regulation prescribing, with respect to any particular use 
of a food additive, the conditions under which such additive may be 
safely used. Notice of such proposal shall be published in the Federal 
Register and shall state the reasons for the proposal.
    (b) Action upon a proposal made by the Commissioner shall proceed as 
provided in part 10 of this chapter.

[41 FR 38644, Sept. 10, 1976, as amended at 42 FR 4717, Jan. 25, 1977; 
42 FR 15675, Mar. 22, 1977]

[[Page 524]]



Sec. 570.17  Exemption for investigational use and procedure for 
obtaining authorization to market edible products from experimental 

animals.

    A food additive or food containing a food additive intended for 
investigational use by qualified experts shall be exempt from the 
requirements of section 409 of the act under the following conditions:
    (a) If intended for investigational use in vitro or in laboratory 
research animals, it bears a label which states prominently, in addition 
to the other information required by the act, the warning:

    Caution. Contains a new food additive for investigational use only 
in laboratory research animals or for tests in vitro. Not for use in 
humans.

    (b) If intended for use in animals other than laboratory research 
animals and if the edible products of the animals are to be marketed as 
food, permission for the marketing of the edible products as food has 
been requested by the sponsor, and authorization has been granted by the 
Food and Drug Administration in accordance with Sec. 511.1 of this 
chapter or by the Department of Agriculture in accordance with 9 CFR 
309.17, and it bears a label which states prominently, in addition to 
the other information required by the act, the warning:

    Caution. Contains a new food additive for use only in 
investigational animals. Not for use in humans.
    Edible products of investigational animals are not to be used for 
food unless authorization has been granted by the U.S. Food and Drug 
Administration or by the U.S. Department of Agriculture.

    (c) If intended for nonclinical laboratory studies in food-producing 
animals, the study is conducted in compliance with the regulations set 
forth in part 58 of this chapter.

[41 FR 38644, Sept. 10, 1976, as amended at 43 FR 60023, Dec. 22, 1978]



Sec. 570.18  Tolerances for related food additives.

    (a) Food additives that cause similar or related pharmacological 
effects will be regarded as a class, and in the absence of evidence to 
the contrary, as having additive toxic effects and will be considered as 
related food additives.
    (b) Tolerances established for such related food additives may limit 
the amount of a common component that may be present, or may limit the 
amount of biological activity (such as cholinesterase inhibition) that 
may be present or may limit the total amount of related food additives 
that may be present.
    (c) Where food additives from two or more chemicals in the same 
class are present in or on a food, the tolerance for the total of such 
additives shall be the same as that for the additive having the lowest 
numerical tolerance in this class, unless there are available methods 
that permit quantitative determination of the amount of each food 
additive present or unless it is shown that a higher tolerance is 
reasonably required for the combined additives to accomplish the 
physical or technical effect for which such combined additives are 
intended and that the higher tolerance will be safe.
    (d) Where residues from two or more additives in the same class are 
present in or on a food and there are available methods that permit 
quantitative determination of each residue, the quantity of combined 
residues that are within the tolerance may be determined as follows:
    (1) Determine the quantity of each residue present.
    (2) Divide the quantity of each residue by the tolerance that would 
apply if it occurred alone, and multiply by 100 to determine the 
percentage of the permitted amount of residue present.
    (3) Add the percentages so obtained for all residues present.
    (4) The sum of the percentages shall not exceed 100 percent.



Sec. 570.19  Pesticide chemicals in processed foods.

    When pesticide chemical residues occur in processed foods due to the 
use of raw agricultural commodities that bore or contained a pesticide 
chemical in conformity with an exemption granted or a tolerance 
prescribed under section 408 of the act, the processed food will not be 
regarded as adulterated so long as good manufacturing practice has been 
followed in removing

[[Page 525]]

any residue from the raw agricultural commodity in the processing (such 
as by peeling or washing) and so long as the concentration of the 
residue in the processed food when ready to eat is not greater than the 
tolerance prescribed for the raw agricultural commodity. But when the 
concentration of residue in the processed food when ready to eat is 
higher than the tolerance prescribed for the raw agricultural commodity, 
the processed food is adulterated unless the higher concentration is 
permitted by a tolerance obtained under section 409 of the act. For 
example, if fruit bearing a residue of 7 parts per million of DDT 
permitted on the raw agricultural commodity is dried and a residue in 
excess of 7 parts per million of DDT results on the dried fruit, the 
dehydrated fruit is adulterated unless the higher tolerance for DDT is 
authorized by the regulations in this part. Food that is itself ready to 
eat, and which contains a higher residue than allowed for the raw 
agricultural commodity, may not be legalized by blending or mixing with 
other foods to reduce the residue in the mixed food below the tolerance 
prescribed for the raw agricultural commodity.



                     Subpart B_Food Additive Safety



Sec. 570.20  General principles for evaluating the safety of food 
additives.

    (a) In reaching a decision on any petition filed under section 409 
of the act, the Commissioner will give full consideration to the 
specific biological properties of the compound and the adequacy of the 
methods employed to demonstrate safety for the proposed use, and the 
Commissioner will be guided by the principles and procedures for 
establishing the safety of food additives stated in current publications 
of the National Academy of Sciences-National Research Council. A 
petition will not be denied, however, by reason of the petitioner's 
having followed procedures other than those outlined in the publications 
of the National Academy of Sciences-National Research Council if, from 
available evidence, the Commissioner finds that the procedures used give 
results as reliable as, or more reliable than, those reasonably to be 
expected from the use of the outlined procedures. In reaching a 
decision, the Commissioner will give due weight to the anticipated 
levels and patterns of consumption of the additive specified or 
reasonably inferable. For the purposes of this section, the principles 
for evaluating safety of additives set forth in the above-mentioned 
publications will apply to any substance that may properly be classified 
as a food additive as defined in section 201(s) of the act.
    (b) Upon written request describing the proposed use of an additive 
and the proposed experiments to determine its safety, the Commissioner 
will advise a person who wishes to establish the safety of a food 
additive whether he believes the experiments planned will yield data 
adequate for an evaluation of the safety of the additive.



Sec. 570.30  Eligibility for classification as generally recognized 
as safe (GRAS).

    (a) General recognition of safety may be based only on the views of 
experts qualified by scientific training and experience to evaluate the 
safety of substances directly or indirectly added to food. The basis of 
such views may be either (1) scientific procedures or (2) in the case of 
a substance used in food prior to January 1, 1958, through experience 
based on common use in food. General recognition of safety requires 
common knowledge about the substance throughout the scientific community 
knowledgeable about the safety of substances directly or indirectly 
added to food.
    (b) General recognition of safety based upon scientific procedures 
shall require the same quantity and quality of scientific evidence as is 
required to obtain approval of a food additive regulation for the 
ingredient. General recognition of safety through scientific procedures 
shall ordinarily be based upon published studies which may be 
corroborated by unpublished studies and other data and information.
    (c) General recognition of safety through experience based on common 
use in food prior to January 1, 1958, may be determined without the 
quantity or quality of scientific procedures required for approval of a 
food additive

[[Page 526]]

regulation. General recognition of safety through experience based on 
common use in food prior to January 1, 1958, shall ordinarily be based 
upon generally available data and information. An ingredient not in 
common use in food prior to January 1, 1958, may achieve general 
recognition of safety only through scientific procedures.
    (d) The food ingredients listed as GRAS in part 582 of this chapter 
do not include all substances that are generally recognized as safe for 
their intended use in food. Because of the large number of substances 
the intended use of which results or may reasonably be expected to 
result, directly or indirectly, in their becoming a component or 
otherwise affecting the characteristics of food, it is impracticable to 
list all such substances that are GRAS. A food ingredient of natural 
biological origin that has been widely consumed for its nutrient 
properties in the United States prior to January 1, 1958, without known 
detrimental effects, which is subject only to conventional processing as 
practiced prior to January 1, 1958, and for which no known safety hazard 
exists, will ordinarily be regarded as GRAS without specific inclusion 
in part 582 of this chapter.
    (e) A food ingredient that is not GRAS or subject to a prior 
sanction requires a food additive regulation promulgated under section 
409 of the act before it may be directly or indirectly added to food.
    (f) A food ingredient that is listed as GRAS in part 582 of this 
chapter shall be regarded as GRAS only if, in addition to all the 
requirements in the applicable regulation, it also meets all of the 
following requirements:
    (1) It complies with any applicable specifications, or in the 
absence of such specifications, shall be of a purity suitable for its 
intended use.
    (2) It performs an appropriate function in the food or food-contact 
article in which it is used.
    (3) It is used at a level no higher than necessary to achieve its 
intended purpose in that food or, if used as a component of a food-
contact article, at a level no higher than necessary to achieve its 
intended purpose in that article.
    (g) New information may at any time require reconsideration of the 
GRAS status of a food ingredient. Any change in status shall be 
accomplished pursuant to Sec. 570.38.
    (h) If a substance is affirmed as GRAS pursuant to Sec. 570.35 and 
listed in a regulation with no limitation other than good manufacturing 
practice, it shall be regarded as GRAS if its conditions of use are not 
significantly different from those reported in the regulation as the 
basis on which the GRAS status of the substance was affirmed. If the 
conditions of use are significantly different, such use of the substance 
may not be GRAS. In such case a manufacturer may not rely on the 
regulation as authorizing the use but must independently establish that 
the use is GRAS or must use the substance in accordance with a food 
additive regulation.
    (i) If an ingredient is affirmed as GRAS pursuant to Sec. 570.35 
and listed in a regulation with specific limitation(s), it may be used 
in food only within such limitation(s) (including the category of 
food(s), the functional use(s) of the ingredient, and the level(s) of 
use). Any use of such and ingredient not in full compliance with each 
such established limitation shall require a food additive regulation.
    (j) Pursuant to Sec. 570.35, a food ingredient may be affirmed as 
GRAS and listed in a regulation for a specific use(s) without a general 
evaluation of use of the ingredient. In addition to the use(s) specified 
in the regulation, other uses of such an ingredient may also be GRAS. 
Any affirmation of GRAS status for a specific use(s), without a general 
evaluation of use of the ingredient, is subject to reconsideration upon 
such evaluation.

[42 FR 55206, Oct. 14, 1977]



Sec. 570.35  Affirmation of generally recognized as safe (GRAS) status.

    (a) The Commissioner, either on his initiative or on the petition of 
an interested person, may affirm the GRAS status of substances that 
directly or indirectly become components of food.
    (b)(1) If the Commissioner proposes on his own initiative that a 
substance is entitled to affirmation as GRAS, he

[[Page 527]]

will place all of the data and information on which he relies on public 
file in the office of the Division of Dockets Management and will 
publish in the Federal Register a notice giving the name of the 
substance, its proposed uses, and any limitations proposed for purposes 
other than safety.
    (2) The Federal Register notice will allow a period of 60 days 
during which any interested person may review the data and information 
and/or file comments with the Division of Dockets Management. Copies of 
all comments received shall be made available for examination in the 
Division of Dockets Management's office.
    (3) The Commissioner will evaluate all comments received. If he 
concludes that there is convincing evidence that the substance is GRAS 
as defined in Sec. 570.3(k), he will publish a notice in the Federal 
Register listing the substance in this subchapter E as GRAS.
    (4) If, after evaluation of the comments, the Commissioner concludes 
that there is a lack of convincing evidence that the substance is GRAS 
and that it should be considered a food additive subject to section 409 
of the act, he shall publish a notice thereof in the Federal Register in 
accordance with Sec. 570.38.
    (c)(1) Persons seeking the affirmation of GRAS status of substances 
as provided for in Sec. 570.30(e), except those subject to the NAS-NRC 
GRAS list survey (36 FR 20546), shall submit a petition for GRAS 
affirmation pursuant to part 10 of this chapter. Such petition shall 
contain information to establish that the GRAS criteria as set forth in 
Sec. 570.30(b) have been met, in the following form:
    (i) Description of the substance, including:
    (a) Common or usual name.
    (b) Chemical name.
    (c) Chemical Abstract Service (CAS) registry number.
    (d) Empirical formula.
    (e) Structural formula.
    (f) Specifications for food grade material, including arsenic and 
heavy metals. (Recommendation for any change in the Food Chemicals Codex 
monograph should be included where applicable.)
    (g) Quantitative compositions.
    (h) Manufacturing process (excluding any trade secrets).
    (ii) Use of the substance, including:
    (a) Date when use began.
    (b) Information and reports or other data on past uses in food.
    (c) Foods in which used, and levels of use in such foods, and for 
what purposes.
    (iii) Methods for detecting the substance in food, including:
    (a) References to qualitative and quantitative methods for 
determining the substance(s) in food, including the type of analytical 
procedures used.
    (b) Sensitivity and reproducibility of such method(s).
    (iv) Information to establish the safety and functionality of the 
substance in food. Published scientific literature, evidence that the 
substance is identical to a GRAS counterpart of natural biological 
origin, and other data may be submitted to support safety. Any adverse 
information or consumer complaints shall be included. Complete 
bibliographic references shall be provided where a copy of the article 
is not provided.
    (v) A statement signed by the person responsible for the petition 
that to the best of his knowledge it is a representative and balanced 
submission that includes unfavorable information, as well as favorable 
information, known to him pertinent to the evaluation of the safety and 
functionality of the substance.
    (vi) If nonclinical laboratory studies are involved, additional 
information and data submitted in support of filed petitions shall 
include, with respect to each nonclinical study, either a statement that 
the study was conducted in compliance with the requirements set forth in 
part 58 of this chapter, or, if the study was not conducted in 
compliance with such regulations, a brief statement of the reason for 
the noncompliance.
    (vii) [Reserved]
    (viii) A claim for categorical exclusion under Sec. 25.30 or 25.32 
of this chapter or an environmental assessment under Sec. 25.40 of this 
chapter.
    (2) Within 30 days after the date of filing the petition, the 
Commissioner will place the petition on public file in the Division of 
Dockets Management

[[Page 528]]

and will publish a notice of filing in the Federal Register giving the 
name of the petitioner and a brief description of the petition including 
the name of the substance, its proposed use, and any limitations 
proposed for reasons other than safety. A copy of the notice will be 
mailed to the petitioner at the time the original is sent to the Federal 
Register.
    (3) The notice of filing in the Federal Register will allow a period 
of 60 days during which any interested person may review the petition 
and/or file comments with the Division of Dockets Management. Copies of 
all comments received shall be made available for examination in the 
Division of Dockets Management.
    (4) The Commissioner will evaluate the petition and all available 
information including all comments received. If the petition and such 
information provide convincing evidence that the substance is GRAS as 
defined in Sec. 570.3, he will publish an order in the Federal Register 
listing the substance in this subchapter E as GRAS.
    (5) If, after evaluation of the petition and all available 
information, the Commissioner concludes that there is a lack of 
convincing evidence that the substance is GRAS and that it should be 
considered a food additive subject to section 409 of the act, he shall 
publish a notice thereof in the Federal Register in accordance with 
Sec. 570.38.
    (6) The notice of filing in the Federal Register will request 
submission of proof of any applicable prior sanction for use of the 
ingredient under conditions different from those proposed to be 
determined to be GRAS. The failure of any person to come forward with 
proof of such an applicable prior sanction in response to the notice of 
filing will constitute a waiver of the right to assert or rely on such 
sanction at any later time. The notice of filing will also constitute a 
proposal to establish a regulation under this subchapter E, 
incorporating the same provisions, in the event that such a regulation 
is determined to be appropriate as a result of submission of proof of 
such an applicable prior sanction in response to the notice of filing.

[41 FR 38644, Sept. 10, 1976, as amended at 42 FR 4717, Jan. 25, 1977; 
42 FR 15675, Mar. 22, 1977; 42 FR 55207, Oct. 10, 1977; 50 FR 7517, Feb. 
22, 1985; 50 FR 16668, Apr. 26, 1985; 54 FR 18281, Apr. 28, 1989; 62 FR 
40600, July 29, 1997]



Sec. 570.38  Determination of food additive status.

    (a) The Commissioner may, in accordance with Sec. 570.35 (b)(4) or 
(c)(5), publish a notice in the Federal Register determining that a 
substance is not GRAS and is a food additive subject to section 409 of 
the act.
    (b)(1) The Commissioner, on his own initiative or on the petition of 
any interested person, pursuant to part 10 of this chapter, may issue a 
notice in the Federal Register proposing to determine that a substance 
is not GRAS and is a food additive subject to section 409 of the act. 
Any petition shall include all relevant data and information of the type 
described in Sec. 571.130(b) of this chapter. The Commissioner will 
place all of the data and information on which he relies on public file 
in the Division of Dockets Management and will include in the Federal 
Register notice the name of the substance, its known uses, and a summary 
of the basis for the determination.
    (2) The Federal Register notice will allow a period of 60 days 
during which any interested person may review the data and information 
and/or file comments with the Division of Dockets Management. Copies of 
all comments shall be made available for examination in the Division of 
Dockets Management.
    (3) The Commissioner will evaluate all comments received. If he 
concludes that there is a lack of convincing evidence that the substance 
is GRAS or is otherwise exempt from the definition of a food additive in 
section 201(s) of the act, he will publish a notice thereof in the 
Federal Register. If he concludes that there is convincing evidence that 
the substance is GRAS, he will publish an order in the Federal Register 
listing the substance in this subchapter E as GRAS.

[[Page 529]]

    (c) A Federal Register notice determining that a substance is a food 
additive shall provide for the use of the additive in food or food-
contact surfaces as follows:
    (1) It may promulgate a food additive regulation governing use of 
the additive.
    (2) It may promulgate an interim food additive regulation governing 
use of the additive.
    (3) It may require discontinuation of the use of the additive.
    (4) It may adopt any combination of the above three approaches for 
different uses or levels of use of the additive.
    (d) If the Commissioner of Food and Drugs is aware of any prior 
sanction for use of the substance, he will concurrently propose a 
separate regulation covering such use of the ingredient under this 
subchapter E. If the Commissioner is unaware of any such applicable 
prior sanction, the proposed regulation will so state and will require 
any person who intends to assert or rely on such sanction to submit 
proof of its existence. Any regulation promulgated pursuant to this 
section constitutes a determination that excluded uses would result in 
adulteration of the food in violation of section 402 of the act, and the 
failure of any person to come forward with proof of such an applicable 
prior sanction in response to the proposal will constitute a waiver of 
the right to assert or rely on such sanction at any later time. The 
notice will also constitute a proposal to establish a regulation under 
this subchapter E., incorporating the same provisions, in the event that 
such a regulation is determined to be appropriate as a result of 
submission of proof of such an applicable prior sanction in response to 
the proposal.

[41 FR 38644, Sept. 10, 1976, as amended at 42 FR 4717, Jan. 25, 1977; 
42 FR 15675, Mar. 22, 1977; 42 FR 55207, Oct. 14, 1977; 54 FR 18281, 
Apr. 28, 1989]



PART 571_FOOD ADDITIVE PETITIONS--Table of Contents



                      Subpart A_General Provisions

Sec.
571.1 Petitions.
571.6 Amendment of petition.
571.7 Withdrawal of petition without prejudice.

            Subpart B_Administrative Actions on Applications

571.100 Regulation based on petition.
571.102 Effective date of regulation.
571.110 Procedure for objections and hearings.
571.115 Application of the cancer clause of section 409 of the act.
571.130 Procedure for amending and repealing tolerances or exemptions 
          from tolerances.

    Authority: 21 U.S.C. 321, 342, 348, 371; 42 U.S.C. 241.

    Source: 41 FR 38647, Sept. 10, 1976, unless otherwise noted.



                      Subpart A_General Provisions



Sec. 571.1  Petitions.

    (a) Petitions to be filed with the Commissioner under the provisions 
of section 409(b) of the act shall be submitted in triplicate. If any 
part of the material submitted is in a foreign language, it shall be 
accompanied by an accurate and complete English translation. The 
petition shall state petitioner's post office address to which published 
notices or orders issued or objections filed pursuant to section 409 of 
the act may be sent.
    (b) Pertinent information may be incorporated in, and will be 
considered as part of, a petition on the basis of specific reference to 
such information submitted to and retained in the files of the Food and 
Drug Administration. However, any reference to unpublished information 
furnished by a person other than the applicant will not be considered 
unless use of such information is authorized in a written statement 
signed by the person who submitted it. Any reference to published 
information offered in support of a food-additive petition should be 
accompanied by reprints or photostatic copies of such references.
    (c) Petitions shall include the following data and be submitted in 
the following form:

                                                                  (Date)
Name of petitioner______________________________________________________
Post office address_____________________________________________________
Date____________________________________________________________________

[[Page 530]]

Name of food additive and proposed use__________________________________

Food and Drug Administration
Center for Veterinary Medicine,
Director, Division of Animal Feeds (HFV-220), 7500 Standish Pl., 
          Rockville, MD 20855.

    Dear Sirs: The undersigned, --------

submits this petition pursuant to section 409(b)(1) of the Federal Food, 
Drug, and

Cosmetic Act with respect to____________________________________________

(Name of the food additive and proposed use)
    Attached hereto, in triplicate, and constituting a part of this 
petition, are the following:
    A. The name and all pertinent information concerning the food 
additive, including chemical identity and composition of the food 
additive, its physical, chemical, and biological properties, and 
specifications prescribing the minimum content of the desired 
component(s) and identifying and limiting the reaction byproducts and 
other impurities. Where such information is not available, a statement 
as to the reasons why it is not should be submitted.
    When the chemical identity and composition of the food additive is 
not known, the petition shall contain information in sufficient detail 
to permit evaluation regarding the method of manufacture and the 
analytical controls used during the various stages of manufacturing, 
processing, or packing of the food additive which are relied upon to 
establish that it is a substance of reproducible composition. 
Alternative methods and controls and variations in methods and controls 
within reasonable limits that do not affect the characteristics of the 
substance or the reliability of the controls may be specified.
    If the food additive is a mixture of chemicals, the petition shall 
supply a list of all substances used in the synthesis, extraction, or 
other method of preparation, regardless of whether they undergo chemical 
change in the process. Each substance should be identified by its common 
English name and complete chemical name, using structural formulas when 
necessary for specific identification. If any proprietary preparation is 
used as a component, the proprietary name should be followed by a 
complete quantitative statement of composition. Reasonable alternatives 
for any listed substance may be specified.
    If the petitioner does not himself perform all the manufacturing, 
processing, and packing operations for a food additive, the petition 
shall identify each person who will perform a part of such operations 
and designate the part.
    The petition shall include stability data, and, if the data indicate 
that it is needed to ensure the identity, strength, quality, or purity 
of the additive, the expiration date that will be employed.
    B. The amount of the food additive proposed for use and the purposes 
for which it is proposed, together with all directions, recommendations, 
and suggestions regarding the proposed use, as well as specimens of the 
labeling proposed for the food additive and any labeling that will be 
required by applicable provisions of the Federal Food, Drug, and 
Cosmetic Act on the finished food by reason of the use of the food 
additive. If the additive results or may reasonably be expected to 
result from the use of packaging material, the petitioner shall show how 
this may occur and what residues may reasonably be anticipated.
    (Typewritten or other draft-labeling copy will be accepted for 
consideration of the petition, provided a statement is made that final 
printed labeling identical in content to the draft copy will be 
submitted as soon as available and prior to the marketing of the food 
additive.
    If the food additive is one for which a tolerance limitation is 
required to assure its safety, the level of use proposed should be no 
higher than the amount reasonably required to accomplish the intended 
physical or other technical effect, even though the safety data may 
support a higher tolerance.)
    C. Data establishing that the food additive will have the intended 
physical or other technical effect or that it may reasonably be expected 
to become a component, or to affect the characteristics, directly or 
indirectly, of food and the amount necessary to accomplish this. These 
data should include information in sufficient detail to permit 
evaluation with control data.
    D. A description of practicable methods to determine the amount of 
the food additive in the raw, processed, and/or finished food and of any 
substance formed in or on such food because of its use. The test 
proposed shall be one that can be used for food-control purposes and 
that can be applied with consistent results by any properly equipped and 
trained laboratory personnel.
    E. Full reports of investigations made with respect to the safety of 
the food additive.
    (A petition may be regarded as incomplete unless it includes full 
reports of adequate tests reasonably applicable to show whether or not 
the food additive will be safe for its intended use. The reports 
ordinarily should include detailed data derived from appropriate animal 
and other biological experiments in which the methods used and the 
results obtained are clearly set forth. The petition shall not omit 
without explanation any reports of investigations that would bias an 
evaluation of the safety of the food additive.)
    F. Proposed tolerances for the food additive, if tolerances are 
required in order to ensure its safety. A petitioner may include a 
proposed regulation.

[[Page 531]]

    G. If submitting petition to modify an existing regulation issued 
pursuant to section 409(c)(1)(A) of the act, full information on each 
proposed change that is to be made in the original regulation must be 
submitted. The petition may omit statements made in the original 
petition concerning which no change is proposed. A supplemental petition 
must be submitted for any change beyond the variations provided for in 
the original petition and the regulation issued on the basis of the 
original petition.
    H. The petitioner is required to submit either a claim for 
categorical exclusion under Sec. 25.30 or Sec. 25.32 of this chapter 
or an environmental assessment under Sec. 25.40 of this chapter.
Yours very truly,
     Petitioner --------
     By --------
                                                    (Indicate authority)

    (d) The petitioner will be notified of the date on which his 
petition is filed, and an incomplete petition, or one that has not been 
submitted in triplicate, will usually be retained but not filed as a 
petition under section 409 of the act. The petitioner will be notified 
in what respects his petition is incomplete.
    (e) The petition must be signed by the petitioner or by his attorney 
or agent, or (if a corporation) by an authorized official.
    (f) The data specified under the several lettered headings should be 
submitted on separate sheets or sets of sheets, suitably identified. If 
such data have already been submitted with an earlier application, the 
present petition may incorporate it by specific reference to the 
earlier. If part of the data have been submitted by the manufacturer of 
the food additive as a master file, the petitioner may refer to the 
master file if and to the extent he obtains the manufacturer's written 
permission to do so. The manufacturer may authorize specific reference 
to the data without disclosure to the petitioner. Nothing herein shall 
prevent reference to published data.
    (g) A petition shall be retained but shall not be filed if any of 
the data prescribed by section 409(b) of the act are lacking or are not 
set forth so as to be readily understood.
    (h)(1) The following data and information in a food additive 
petition are available for public disclosure, unless extraordinary 
circumstances are shown, after the notice of filing of the petition is 
published in the Federal Register or, if the petition is not promptly 
filed because of deficiencies in it, after the petitioner is informed 
that it will not be filed because of the deficiencies involved:
    (i) All safety and functionality data and information submitted with 
or incorporated by reference in the petition.
    (ii) A protocol for a test or study, unless it is shown to fall 
within the exemption established for trade secrets and confidential 
commercial information in Sec. 20.61 of this chapter.
    (iii) Adverse reaction reports, product experience reports, consumer 
complaints, and other similar data and information, after deletion of:
    (a) Names and any information that would identify the person using 
the product.
    (b) Names and any information that would identify any third party 
involved with the report, such as a physician or hospital or other 
institution.
    (iv) A list of all ingredients contained in a food additive, whether 
or not it is in descending order of predominance. A particular 
ingredient or group of ingredients shall be deleted from any such list 
prior to public disclosure if it is shown to fall within the exemption 
established in Sec. 20.61 of this chapter, and a notation shall be made 
that any such ingredient list is incomplete.
    (v) An assay method or other analytical method, unless it serves no 
regulatory or compliance purpose and is shown to fall within the 
exemption established in Sec. 20.61 of this chapter.
    (2) The following data and information in a food additive petition 
are not available for public disclosure unless they have been previously 
disclosed to the public as defined in Sec. 20.81 of this chapter or 
they relate to a product or ingredient that has been abandoned and they 
no longer represent a trade secret or confidential commercial or 
financial information as defined in Sec. 20.61 of this chapter:
    (i) Manufacturing methods or processes, including quality control 
procedures.
    (ii) Production, sales, distribution, and similar data and 
information, except that any compilation of such data and information 
aggregated and prepared in a way that does not reveal

[[Page 532]]

data or information which is not available for public disclosure under 
this provision is available for public disclosure.
    (iii) Quantitative or semiquantitative formulas.
    (3) All correspondence and written summaries of oral discussions 
relating to a food additive petition are available for public disclosure 
in accordance with the provisions of part 20 of this chapter when the 
food additive regulation is published in the Federal Register.
    (4) For purposes of this regulation, safety and functionality data 
include all studies and tests of a food additive on animals and humans 
and all studies and tests on a food additive for identity, stability, 
purity, potency, performance, and usefulness.
    (i)(1) Within 15 days after receipt, the Commissioner will notify 
the petitioner of acceptance or nonacceptance of a petition, and if not 
accepted the reasons therefor. If accepted, the date of the notification 
letter sent to petitioner becomes the date of filing for the purposes of 
section 409(b)(5) of the act. If the petitioner desires, he may 
supplement a deficient petition after being notified regarding 
deficiencies. If the supplementary material or explanation of the 
petition is deemed acceptable, petitioner shall be notified. The date of 
such notification becomes the date of filing. If the petitioner does not 
wish to supplement or explain the petition and requests in writing that 
it be filed as submitted, the petition shall be filed and the petitioner 
so notified. The date of such notification becomes the date of filing.
    (2) The Commissioner will publish in the Federal Register within 30 
days from the date of filing of such petition, a notice of the filing, 
the name of the petitioner, and a brief description of the proposal in 
general terms. In the case of a food additive which becomes a component 
of food by migration from packaging material, the notice shall include 
the name of the migratory substance, and where it is different from that 
of one of the original components, the name of the parent component, the 
maximum quantity of the migratory substance that is proposed for use in 
food, and the physical or other technical effect which the migratory 
substance or its parent component is intended to have in the packaging 
material. A copy of the notice will be mailed to the petitioner when the 
original is forwarded to the Federal Register for publication.
    (j) The Commissioner may request a full description of the methods 
used in, and the facilities and controls used for, the production of the 
food additive, or a sample of the food additive, articles used as 
components thereof, or of the food in which the additive is proposed to 
be used, at any time while a petition is under consideration. The 
Commissioner shall specify in the request for a sample of the food 
additive, or articles used as components thereof, or of the food in or 
on which the additive is proposed to be used, a quantity deemed adequate 
to permit tests of analytical methods to determine quantities of the 
food additive present in foods for which it is intended to be used or 
adequate for any study or investigation reasonably required with respect 
to the safety of the food additive or the physical or technical effect 
it produces. The date used for computing the 90-day limit for the 
purposes of section 409(c)(2) of the act shall be moved forward 1 day 
for each day after the mailing date of the request taken by the 
petitioner to submit the sample. If the information or sample is 
requested a reasonable time in advance of the 180 days, but is not 
submitted within such 180 days after filing of the petition, the 
petition will be considered withdrawn without prejudice.
    (k) If nonclinical laboratory studies are involved, petitions filed 
with the Commissioner under section 409(b) of the act shall include, 
with respect to each study, either a statement that the study was 
conducted in compliance with the requirements set forth in part 58 of 
this chapter, or, if the study was not conducted in compliance with such 
regulations, a brief statement of the reason for the noncompliance.

[41 FR 38647, Sept. 10, 1976, as amended at 42 FR 15675, Mar. 22, 1977; 
50 FR 7518, Feb. 22, 1985; 50 FR 16668, Apr. 26, 1985; 52 FR 8583, Mar. 
19, 1987; 57 FR 6476, Feb. 25, 1992; 62 FR 40600, July 29, 1997]

[[Page 533]]



Sec. 571.6  Amendment of petition.

    After a petition has been filed, the petitioner may submit 
additional information or data in support thereof. In such cases, if the 
Commissioner determines that the additional information or data amounts 
to a substantive amendment, the petition as amended will be given a new 
filing date, and the time limitation will begin to run anew. If 
nonclinical laboratory studies are involved, additional information and 
data submitted in support of filed petitions shall include, with respect 
to each such study, either a statement that the study was conducted in 
compliance with the requirements set forth in part 58 of this chapter, 
or, if the study was not conducted in compliance with such regulations, 
a brief statement of the reason or the noncompliance.

[41 FR 38647, Sept. 10, 1976, as amended at 50 FR 7518, Feb. 22, 1985; 
50 FR 16668, Apr. 26, 1985]



Sec. 571.7  Withdrawal of petition without prejudice.

    (a) In some cases the Commissioner will notify the petitioner that 
the petition, while technically complete, is inadequate to justify the 
establishment of a regulation or the regulation requested by petitioner. 
This may be due to the fact that the data are not sufficiently clear or 
complete. In such cases, the petitioner may withdraw the petition 
pending its clarification or the obtaining of additional data. This 
withdrawal will be without prejudice to a future filing. Upon refiling, 
the time limitation will begin to run anew from the date of refiling.
    (b) At any time before the order provided for in Sec. 571.100(a) 
has been forwarded to the Federal Register for publication, the 
petitioner may withdraw the petition without prejudice to a future 
filing. Upon refiling the time limitation will begin to run anew.



            Subpart B_Administrative Actions on Applications



Sec. 571.100  Regulation based on petition.

    (a) The Commissioner will forward for publication in the Federal 
Register, within 90 days after filing of the petition (or within 180 
days if the time is extended as provided for in section 409(c)(2) of the 
act), a regulation prescribing the conditions under which the food 
additive may be safely used (including, but not limited to, 
specifications as to the particular food or classes of food in or on 
which such additive may be used, the maximum quantity that may be used 
or permitted to remain in or on such food, the manner in which such 
additive may be added to or used in or on such food, and any directions 
or other labeling or packaging requirements for such additive deemed 
necessary by him to assure the safety of such use), and prior to the 
forwarding of the order to the Federal Register for publication shall 
notify the petitioner of such order and the reasons for such action; or 
by order deny the petition, and shall notify the petitioner of such 
order and of the reasons for such action.
    (b) If the Commissioner determines that additional time is needed to 
study and investigate the petition, he shall by written notice to the 
petitioner extend the 90-day period for not more than 180 days after the 
filing of the petition.



Sec. 571.102  Effective date of regulation.

    A regulation published in accordance with Sec. 571.100(a) shall 
become effective upon publication in the Federal Register.



Sec. 571.110  Procedure for objections and hearings.

    Objections and hearings relating to food additive regulations under 
section 409(c), (d), or (h) of the act shall be governed by part 12 of 
this chapter.

[42 FR 4717, Jan. 25, 1977, as amended at 42 FR 15676, Mar. 22, 1977]



Sec. 571.115  Application of the cancer clause of section 409 of the act.

    Food additives intended for use as an ingredient in food for animals 
that are raised for food production and that have the potential to 
contaminate human food with residues whose consumption could present a 
risk of cancer

[[Page 534]]

to people must satisfy the requirements of subpart E of part 500 of this 
chapter.

[52 FR 49588, Dec. 31, 1987]



Sec. 571.130  Procedure for amending and repealing tolerances or 
exemptions from tolerances.

    (a) The Commissioner, on his own initiative or on the petition of 
any interested person, pursuant to part 10 of this chapter, may propose 
the issuance of a regulation amending or repealing a regulation 
pertaining to a food additive or granting or repealing an exception for 
such additive.
    (b) Any such petition shall include an assertion of facts, supported 
by data, showing that new information exists with respect to the food 
additive or that new uses have been developed or old uses abandoned, 
that new data are available as to toxicity of the chemical, or that 
experience with the existing regulation or exemption may justify its 
amendment or repeal. New data shall be furnished in the form specified 
in Sec. 571.1 for submitting petitions.

[42 FR 4717, Jan. 25, 1977; 42 FR 15676, Mar. 22, 1977]



PART 573_FOOD ADDITIVES PERMITTED IN FEED AND DRINKING WATER OF 
ANIMALS--Table of Contents



Subpart A [Reserved]

                     Subpart B_Food Additive Listing

Sec.
573.120 Acrylamide-acrylic acid resin.
573.130 Aminoglycoside 3'-phospho- transferase II.
573.140 Ammoniated cottonseed meal.
573.160 Ammoniated rice hulls.
573.170 Ammonium formate.
573.180 Anhydrous ammonia.
573.200 Condensed animal protein hydrolysate.
573.220 Feed-grade biuret.
573.225 1,3-Butylene glycol.
573.240 Calcium periodate.
573.260 Calcium silicate.
573.280 Feed-grade calcium stearate and sodium stearate.
573.300 Choline xanthate.
573.310 Crambe meal, heat toasted.
573.320 Diammonium phosphate.
573.340 Diatomaceous earth.
573.360 Disodium EDTA.
573.380 Ethoxyquin in animal feeds.
573.400 Ethoxyquin in certain dehydrated forage crops.
573.420 Ethyl cellulose.
573.440 Ethylene dichloride.
573.450 Fermented ammoniated condensed whey.
573.460 Formaldehyde.
573.480 Formic acid.
573.500 Condensed, extracted glutamic acid fermentation product.
573.520 Hemicellulose extract.
573.530 Hydrogenated corn syrup.
573.540 Hydrolyzed leather meal.
573.560 Iron ammonium citrate.
573.580 Iron-choline citrate complex.
573.600 Lignin sulfonates.
573.620 Menadione dimethylpyrimidinol bisulfite.
573.625 Menadione nicotinamide bisulfite.
573.637 Methyl esters of conjugated linoleic acid (cis-9, trans-11 and 
          trans-10, cis-12-octadecadienoic acids).
573.640 Methyl esters of higher fatty acids.
573.660 Methyl glucoside-coconut oil ester.
573.680 Mineral oil.
573.685 Natamycin.
573.700 Sodium nitrite.
573.720 Petrolatum.
573.740 Odorless light petroleum hydrocarbons.
573.750 Pichia pastoris dried yeast.
573.760 Poloxalene.
573.780 Polyethylene.
573.800 Polyethylene glycol (400) mono- and dioleate.
573.820 Polyoxyethylene glycol (400) mono- and dioleates.
573.840 Polysorbate 60.
573.860 Polysorbate 80.
573.870 Poly(2-vinylpyridine-co-styrene).
573.880 Normal propyl alcohol.
573.900 Pyrophyllite.
573.914 Salts of volatile fatty acids.
573.920 Selenium.
573.940 Silicon dioxide.
573.960 Sorbitan monostearate.
573.980 Taurine.
573.1000 Verxite.
573.1010 Xanthan gum.
573.1020 Yellow prussiate of soda.

    Authority: 21 U.S.C. 321, 342, 348.

    Source: 41 FR 38652, Sept. 10, 1976, unless otherwise noted.

Subpart A [Reserved]



                     Subpart B_Food Additive Listing



Sec. 573.120  Acrylamide-acrylic acid resin.

    Acrylamide-acrylic acid resin (hydrolized polyacrylamide), only for

[[Page 535]]

the purposes of this section as described below, may be safely used in 
accordance with the following prescribed conditions:
    (a) The additive is produced by polymerization of acrylamide with 
partial hydrolysis, or by copolymerization of acrylamide and acrylic 
acid with the greater part of the polymer being composed of acrylamide 
units.
    (b) The additive meets the following specifications:
    (1) A minimum molecular weight of 3 million.
    (2) Viscosity range: 3,000 to 6,000 centipoises at 77 [deg]F in a 1 
percent aqueous solution as determined by LVF Brookfield Viscometer or 
equivalent using a number 6 spindle at 20 r.p.m.
    (3) Residual acrylamide: Not more than 0.05 percent.
    (c) It is used as a thickener and suspending agent in nonmedicated 
aqueous suspensions intended for addition to animal feeds.

[41 FR 38652, Sept. 10, 1976, as amended at 45 FR 38058, June 6, 1980]



Sec. 573.130  Aminoglycoside 3'-phospho- transferase II.

    The food additive aminoglycoside 3'-phosphotransferase II may be 
safely used in the development of genetically modified cotton, oilseed 
rape, and tomatoes in accordance with the following prescribed 
conditions:
    (a) The food additive is the enzyme aminoglycoside 3'-
phosphotransferase II (CAS Reg. No. 58943-39-8) which catalyzes the 
phosphorylation of certain aminoglycoside antibiotics, including 
kanamycin, neomycin, and gentamicin.
    (b) Aminoglycoside 3'-phosphotransferase II is encoded by the kan\r\ 
gene originally isolated from transposon Tn5 of the bacterium 
Escherichia coli.
    (c) The level of the additive does not exceed the amount reasonably 
required for selection of plant cells carrying the kan\r\ gene along 
with the genetic material of interest.

[59 FR 26711, May 23, 1994]



Sec. 573.140  Ammoniated cottonseed meal.

    The food additive ammoniated cottonseed meal may be safely used in 
accordance with the following conditions:
    (a) The food additive is the product obtained by the treatment of 
cottonseed meal with anhydrous ammonia until a pressure of 50 pounds per 
square inch gauge is reached.
    (b) It is used or intended for use in the feed of ruminants as a 
source of protein and/or as a source of nonprotein nitrogen in an amount 
not to exceed 20 percent of the total ration.
    (c) To assure safe use, the label and labeling of the additive and 
of any feed additive supplement, concentrate, or premix prepared 
therefrom shall bear, in addition to the other information required by 
the act, the following:
    (1) The name of the additive.
    (2) The maximum percentage of equivalent crude protein from the 
nonprotein nitrogen.
    (3) Directions for use to provide not more than 20 percent of the 
additive in the total ration.
    (4) A statement:
    (i) That not more than one-third of the total protein in the feed 
should come from nonprotein nitrogen sources.
    (ii) That the additive is not to be given to debilitated or starved 
animals.
    (iii) ``Warning--This feed should be used only in accordance with 
directions furnished on the label.''

[41 FR 38652, Sept. 10, 1976, as amended at 42 FR 52397, Sept. 30, 1977]



Sec. 573.160  Ammoniated rice hulls.

    The food additive ammoniated rice hulls may be safely used in 
accordance with the following prescribed conditions:
    (a) The food additive is the product obtained by the treatment of 
ground rice hulls with monocalcium phosphate and anhydrous ammonia at a 
temperature of 350 [deg]F and a pressure of 175 pounds per square inch.
    (b) It is used or intended for use in the feed of beef cattle as a 
source of crude fiber and as the sole source of nonprotein nitrogen in 
an amount not to exceed 20 percent of the total ration.
    (c) To assure safe use of the additive, the label and labeling of 
the additive and of any feed additive supplement, feed additive 
concentrate, or feed additive premix prepared therefrom, shall contain, 
in addition to other information required by the act, the following:

[[Page 536]]

    (1) The name of the additive.
    (2) The maximum percentage of equivalent crude protein from the 
nonprotein nitrogen.
    (3) Directions for use to provide not more than 20 percent of the 
additive in the total ration, and a prominent statement: ``Warning--This 
feed should be used only in accordance with the directions furnished on 
the label.''



Sec. 573.170  Ammonium formate.

    The food additive, partially ammonium formate, may be safely used in 
the manufacture of complete swine feeds in accordance with the following 
prescribed conditions:
    (a) The additive is manufactured by the reaction of 99.5 percent 
ammonia gas and 99 percent formic acid in a continuous loop reactor to 
produce a solution made up of 37 percent ammonium salt of formic acid 
and 62 percent formic acid.
    (b) The additive is used or intended for use as a feed acidifying 
agent, to lower the pH, in complete swine feeds at levels not to exceed 
1.2 percent of the complete feed.
    (c) To assure safe use of the additive, in addition to the other 
information required by the Federal Food, Drug, and Cosmetic Act (the 
act), the label and labeling shall contain:
    (1) The name of the additive.
    (2) Adequate directions for use including a statement that ammonium 
formate must be uniformly applied and thoroughly mixed into complete 
swine feeds and that the complete swine feeds so treated shall be 
labeled as containing ammonium formate.
    (d) To assure safe use of the additive, in addition to the other 
information required by the act and paragraph (c) of this section, the 
label and labeling shall contain:
    (1) Appropriate warnings and safety precautions concerning ammonium 
formate (37 percent ammonium salt of formic acid and 62 percent formic 
acid).
    (2) Statements identifying ammonium formate in formic acid (37 
percent ammonium salt of formic acid and 62 percent formic acid) as a 
corrosive and possible severe irritant.
    (3) Information about emergency aid in case of accidental exposure 
as follows:
    (i) Statements reflecting requirements of applicable sections of the 
Superfund Amendments and Reauthorization Act (SARA), and the 
Occupational Safety and Health Administration's (OSHA) human safety 
guidance regulations.
    (ii) Contact address and telephone number for reporting adverse 
reactions or to request a copy of the Material Safety Data Sheet (MSDS).

[75 FR 41725, July 19, 2010]



Sec. 573.180  Anhydrous ammonia.

    (a) The food additive anhydrous ammonia is applied directly to corn 
plant material and thoroughly blended prior to ensiling. It is used or 
intended for use as a source of nonprotein nitrogen in cattle feed in 
accordance with paragraphs (a)(1), (2), or (3) as follows:
    (1)(i) The food additive anhydrous ammonia is applied as a component 
of an aqueous premix containing 16 to 17 percent ammonia, with molasses, 
minerals, and not less than 83 percent crude protein. The premix is a 
source of nonprotein nitrogen and minerals.
    (ii) In addition to the requirements of paragraph (b) of this 
section, the labeling shall bear an expiration date of not more than 10 
weeks after date of manufacture; a statement that additional protein 
should not be fed to lactating dairy cows producing less than 32 pounds 
of milk per day nor beef cattle consuming less than 1 percent of body 
weight daily in shelled corn; and a warning not to use additional trace 
mineral supplementation with treated silage.
    (2)(i) The food additive anhydrous ammonia is applied directly to 
corn plant material for use in dairy or beef cattle rations.
    (ii) The anhydrous ammonia is applied at a rate not to exceed the 
equivalent of 0.35 percent of the corn plant material.
    (iii) It is applied to corn plant material containing 30 to 35 
percent dry matter.
    (iv) It is applied so that 75 to 85 percent of the additive is 
liquid at ambient pressure.
    (3)(i) The food additive anhydrous ammonia is applied after being 
diluted to a 15 to 30 percent aqueous ammonia solution (by weight).

[[Page 537]]

    (ii) The anhydrous ammonia solution is applied at a rate not to 
exceed anhydrous ammonia equivalent to 0.3 percent of the corn plant 
material.
    (iii) It is applied to corn plant material containing 28 to 38 
percent dry matter.
    (iv) The silage treated with aqueous ammonia is to be fed to dairy 
cattle only.
    (b) Its labeling shall bear, in addition to the other requirements 
of the act, the name of the additive, the concentration of ammonia, the 
maximum percentage of equivalent crude protein from nonprotein nitrogen, 
and directions for use consistent with this section.

[44 FR 40284, July 10, 1979]



Sec. 573.200  Condensed animal protein hydrolysate.

    (a) Identity. The condensed animal protein hydrolysate is produced 
from the meat byproducts scraped from cured (salted) hides taken from 
cattle slaughtered for food consumption. The meat byproduct is 
hydrolyzed with heat and phosphoric acid.
    (b) Specifications. The additive shall conform to the following 
percent-by-weight specifications:

Moisture, not less than 45 percent nor more than 50 percent.
Protein, not less than 24 percent.
Salt (NaCl), not more than 15 percent.
Phosphorus, not less than 2.25 percent.

    (c) Uses. It is used or intended for use as a source of animal 
protein, phosphorus, and salt (NaCl) as follows:
    (1) In poultry and swine feed in an amount not to exceed 5 percent 
by weight of the feed.
    (2) In feed concentrates for cattle in an amount not to exceed 10 
percent by weight of the concentrate.
    (d) Labeling. The label and labeling shall bear, in addition to the 
other information required by the act:
    (1) The name of the additive, condensed animal protein hydrolysate.
    (2) Adequate directions for use including maximum quantities 
permitted for each species and a guaranteed analysis of the additive.



Sec. 573.220  Feed-grade biuret.

    The food additive feed grade biuret may be safely used in ruminant 
feed in accordance with the following prescribed conditions:
    (a) The food additive is the product resulting from the controlled 
pyrolysis of urea conforming to the following specifications:

------------------------------------------------------------------------
                                                      Percent
------------------------------------------------------------------------
Biuret...................................  55 minimum.
Urea.....................................  15 maximum.
Cyanuric acid and triuret................  30 maximum.
Mineral oil..............................  0.5 maximum.
Total nitrogen (equivalent to 218.75 pct   35 minimum.
 crude protein).
------------------------------------------------------------------------

    (b) It is used in ruminant feeds as a source of nonprotein nitrogen.
    (c) To assure safe use of the additive:
    (1) The label and labeling of the additive and that of any feed 
additive supplement, feed additive concentrate, feed additive premix, or 
complete feed prepared therefrom shall contain, in addition to other 
information required by the act, the following:
    (i) The name of the additive.
    (ii) The maximum percentage of equivalent crude protein from 
nonprotein nitrogen.
    (2) The label shall recommend that the diet be balanced to provide 
adequate nutrients when equivalent crude protein from all forms of 
nonprotein nitrogen exceed one-third of the total crude protein in the 
total daily ration.

[41 FR 38652, Sept. 10, 1976, as amended at 68 FR 27904, May 22, 2003]



Sec. 573.225  1,3-Butylene glycol.

    The food additive 1,3-butylene glycol (1,3-butanediol) may be safely 
used in accordance with the following prescribed conditions:
    (a) It complies with the specifications in Sec. 173.220(a) of this 
chapter.
    (b) It is intended for use in swine feed as a source of energy.
    (c) It is to be thoroughly mixed into feed at levels not to exceed 9 
percent of the dry matter of the total ration.
    (d) 1,3-Butylene glycol should be mixed in feed with equipment 
adapted for the addition of liquids, and the feed should be mixed not 
less than 5 minutes after its addition.

[53 FR 40061, Oct. 13, 1988]

[[Page 538]]



Sec. 573.240  Calcium periodate.

    The food additive calcium periodate may be safely used in accordance 
with the following prescribed conditions:
    (a) The additive is produced by reacting calcium iodate with calcium 
hydroxide or calcium oxide to form a substance consisting of not less 
than 60 percent by weight of penta calcium orthoperiodate containing 28 
to 31 percent by weight of iodine.
    (b) It is used or intended for use in salt for livestock as a source 
of iodine.



Sec. 573.260  Calcium silicate.

    Calcium silicate, including synthetic calcium silicate, may be 
safely used as an anticaking agent in animal feed, provided that the 
amount of calcium silicate does not exceed 2 percent.



Sec. 573.280  Feed-grade calcium stearate and sodium stearate.

    Feed-grade calcium stearate and sodium stearate may be safely used 
in an animal feed in accordance with the following prescribed 
conditions:
    (a) Feed-grade calcium stearate and sodium stearate are the calcium 
or sodium salts of a fatty acid mixture that is predominately stearic 
acid. Associated fatty acids, including palmitic acid and minor amounts 
of lauric, myristic, pentadecanoic, margaric, arachidic, and other fatty 
acids may be contained in the mixture, but such associated fatty acids 
in aggregate do not exceed 35 percent by weight of the mixture. The 
fatty acids may be derived from feed-grade fats or oils.
    (b) The additives meet the following specifications:
    (1) Unsaponifiable matter does not exceed 2 percent.
    (2) They are free of chick-edema factor.
    (c) The additives are manufactured so that in aqueous solution they 
are exposed for 1 hour or longer to temperature in excess of 180 [deg]F.
    (d) They are used as anticaking agents in animal feeds in accordance 
with current good manufacturing practices.

[63 FR 8573, Feb. 20, 1998]



Sec. 573.300  Choline xanthate.

    Choline xanthate may be safely used as a component of animal feed as 
an added source of choline to supplement the diets of poultry, 
ruminants, and swine in accordance with good feeding practice.



Sec. 573.310  Crambe meal, heat toasted.

    (a) The additive is the seed meal of Crambe abyssinica obtained 
after the removal of oil from the seed and hull. The oil may be removed 
by pre-press solvent extraction or by solvent extraction alone. The 
resulting seed meal is heat toasted.
    (b) The additive conforms to the following percent-by-weight 
specifications: moisture, not more than 11 percent; oil, not more than 4 
percent; crude protein, not less than 24 percent; crude fiber, not more 
than 26 percent; glucosinolate calculated as epi-progoitrin, not more 
than 4 percent; goitrin, not more than 0.1 percent; nitrile calculated 
as 1-cyano-2-hydroxy-3-butene, not more than 1.4 percent. At least 50 
percent of the nitrogen shall be soluble in 0.5 M sodium chloride. 
Myrosinase enzyme activity shall be absent.
    (c) The additive is used or intended for use in the feed of feedlot 
cattle as a source of protein in an amount not to exceed 4.2 percent of 
the total ration.

[46 FR 30082, June 5, 1981]



Sec. 573.320  Diammonium phosphate.

    The food additive diammonium phosphate may be safely used in 
ruminant feed in accordance with the following prescribed conditions:
    (a) The food additive is the product resulting from the 
neutralization of feeding-phosphoric-acid or defluorinated wet-process 
phosphoric acid with anhydrous ammonia. It contains not less than 106.25 
percent equivalent crude protein (nitrogen x 6.25) and 20 percent 
phosphorus. It contains not more than the following:

1 part fluorine to 100 parts phosphorus.
75 parts per million or arsenic (as As).
30 parts per million of heavy metals, as lead (Pb).

    (b) It is used in ruminant feeds as a source of phosphorus and 
nitrogen in an amount that supplies not more than

[[Page 539]]

2 percent of equivalent crude protein in the total daily ration.
    (c) To assure safe use of the additive, the label and labeling of 
the additive and that of any feed additive supplement, feed additive 
concentrate, feed additive premix, or complete feed prepared therefrom 
shall contain, in addition to other information required by the act, the 
following:
    (1) The name of the additive.
    (2) The maximum percentage of equivalent crude protein from the 
nonprotein nitrogen.
    (3) If the feed additive premix, feed additive concentrate, or feed 
additive supplement contains more than 2 percent equivalent crude 
protein from diammonium phosphate, adequate directions for use and a 
prominent statement, ``Warning--This feed should be used only in 
accordance with directions furnished on the label.''



Sec. 573.340  Diatomaceous earth.

    (a) Identity. The additive consists of siliceous skeletal material 
derived from various species of diatoms.
    (b) Specifications. The additive shall conform to the following 
specifications:

Lead, not more than 15 parts per million.
Arsenic (as As), not more than 20 parts per million
Fluorine, not more than 600 parts per million.

    (c) Uses. It is used or intended for use as an inert carrier or 
anticaking agent in animal feeds in an amount not to exceed 2 percent by 
weight of the total ration.



Sec. 573.360  Disodium EDTA.

    The food additive disodium EDTA (disodium ethylenediaminetetraace- 
tate) may be safely used in animal feeds, in accordance with the 
following prescribed conditions:
    (a) The food additive contains a minimum of 99 percent disodium 
ethylenediaminetetraacetate dihydrate 
(C10H14O8N2Na2 
[middot] 2H2O).
    (b) It is used to solubilize trace minerals in aqueous solutions, 
which are then added to animal feeds.
    (c) It is used or intended for use in an amount not to exceed 240 
parts per million of the additive in finished feed.
    (d) To assure safe use of the additive the label and labeling shall 
bear:
    (1) The name of the additive; and
    (2) Adequate mixing directions to ensure that the chelated trace-
mineral mix is uniformly blended throughout the feed.



Sec. 573.380  Ethoxyquin in animal feeds.

    Ethoxyquin (1,2-dihydro-6-ethoxy-2,2,4-trimethylquinoline) may be 
safely used in animal feeds, when incorporated therein in accordance 
with the following prescribed conditions.
    (a) It is intended for use only: (1) As a chemical preservative for 
retarding oxidation of carotene, xanthophylls, and vitamins A and E in 
animal feed and fish food and, (2) as an aid in preventing the 
development of organic peroxides in canned pet food.
    (b) The maximum quantity of the additive permitted to be used and to 
remain in or on the treated article shall not exceed 150 parts per 
million.
    (c) To assure safe use of the additive, the label and labeling of 
the food additive container and that of any intermediate premixes 
prepared therefrom shall contain, in addition to other information 
required by the act:
    (1) The name of the additive, ethoxyquin.
    (2) A statement of the concentration or strength contained therein.
    (3) Adequate use directions to provide for a finished article with 
the proper concentration of the additive as provided in paragraph (b) of 
this section, whether or not intermediate premixes are to be used.
    (d) The label of any animal feed containing the additive shall, in 
addition to the other information required by the act, bear the 
statement ``Ethoxyquin, a preservative'' or ``Ethoxyquin added to retard 
the oxidative destruction of carotene, xanthophylls, and vitamins A and 
E.''



Sec. 573.400  Ethoxyquin in certain dehydrated forage crops.

    Ethoxyquin (1,2-dihydro-6-ethoxy-2,2,4-trimethylquinoline) may be 
safely used in the dehydrated forage crops listed in paragraph (a) of 
this section when incorporated therein in accordance with the conditions 
prescribed in this section:

[[Page 540]]

    (a) It may be added to dehydrated forage prepared from:

Alfalfa...................................  Medicago sativa.
Barley....................................  Hordeum vulgare.
Clovers:
  Alsike clover...........................  Trifolium hybridum.
  Crimson clover..........................  Trifolium incarnatum.
  Red clover..............................  Trifolium pratense.
  White clover (including Ladino).........  Trifolium repens.
  White sweetclover.......................  Melilotus alba.
  Yellow sweetclover......................  Melilotus officinalis.
Coastal Bermudagrass......................  Cynodon dactylon.
Corn......................................  Zea mays.
Fescue....................................  Festuca sp.
Oats......................................  Avena sativa.
Orchardgrass..............................  Dactylis glomerata.
Reed canarygrass..........................  Pharlaris arundinacea.
Ryegrass (annual and perennial)...........  Elymus sp. and Lolium
                                             perenne.
Sorghums..................................  Sorghum vulgare vars,
                                             feterita, shallu, kaoliang,
                                             broomcorn.
Sudan grass...............................  Sorghum vulgare sudanense.
Wheat.....................................  Triticum aestivum.
 


or any mixture of such forage crops, for use only as an animal feed.
    (b) Such additive is used only as a chemical preservative for the 
purpose of retarding oxidative destruction of naturally occurring 
carotenes and vitamin E in the forage crops.
    (c) It is added to the dehydrated forage crops in an oil mixture 
containing only suitable animal or suitable vegetable oil, prior to 
grinding and mixing.
    (d) The maximum quantity of the additive permitted to be used and to 
remain in or on the dehydrated forage crop shall not exceed 150 parts 
per million.
    (e) To assure the safe use of the additive, the label of the market 
package shall contain, in addition to other information required by the 
act:
    (1) The name of the additive as specified in this section.
    (2) Directions for the incorporation of the additive in the forage 
crops, as specified in paragraph (c) of this section, with the directive 
that only suitable animal or suitable vegetable oils are to be used in 
the oil mix.
    (f) The label of any dehydrated forage crops treated with the 
additive or the label of an animal-feed supplement containing such 
treated forage crops, shall, in addition to other information required 
by the act, bear the following statements:
    (1) ``Ethoxyquin, a preservative,'' or ``Ethoxyquin added to retard 
the oxidative destruction of carotene and vitamin E.''
    (2) The statement ``For use in animal feed only.''



Sec. 573.420  Ethyl cellulose.

    The food additive ethyl cellulose may be safely used in animal feed 
in accordance with the following prescribed conditions:
    (a) The food additive is a cellulose ether containing ethoxy 
(OC2H5) groups attached by an ether linkage and 
containing on an anhydrous basis not more than 2.6 ethoxy groups per 
anhydroglucose unit.
    (b) It is used or intended for use as a binder or filler in dry 
vitamin preparations to be incorporated into animal feed.



Sec. 573.440  Ethylene dichloride.

    The food additive ethylene dichloride may be safely used in the 
manufacture of animal feeds in accordance with the following prescribed 
conditions:
    (a) It is used as a solvent in the extraction processing of animal 
byproducts for use in animal feeds.
    (b) The maximum quantity of the additive permitted to remain in or 
on the extracted byproducts shall not exceed 300 parts per million.
    (c) The extracted animal byproduct is added as a source of protein 
to a total ration at levels consistent with good feeding practices, but 
in no event at levels exceeding 13 percent of the total ration.



Sec. 573.450  Fermented ammoniated condensed whey.

    (a) Identity. The product is produced by the Lactobacillus 
bulgaricus fermentation of whey with the addition of ammonia.
    (b) Specifications. The product contains 35 to 55 percent crude 
protein and not more than 42 percent equivalent crude protein from 
nonprotein nitrogen sources.
    (c) Uses. The product is used as a source of protein and nonprotein 
nitrogen for cattle.
    (d) Limitations. (1) Store in a closed vented tank equipped for 
agitation. Agitate 5 minutes before using. Do not store at temperature 
above 110 [deg]F (43 [deg]C).
    (2) The maximum level of use of fermented ammoniated condensed whey

[[Page 541]]

and equivalent crude protein from all other added forms of nonprotein 
nitrogen shall not exceed 30 percent of the dietary crude protein.
    (3) The additive may be used as follows:
    (i) Mixed with grain, roughage, or grain and roughage prior to 
feeding.
    (ii) As a component of free-choice liquid feeds, used to supplement 
the diets of cattle fed other sources of nutrients, fermented ammoniated 
condensed whey shall not exceed 80 percent of the free-choice liquid 
feed.
    (e) Labeling. The label shall bear, in addition to other information 
required by the act:
    (1) The name of the additive.
    (2) The maximum percentage of equivalent crude protein from 
nonprotein nitrogen.
    (3) Adequate directions for use in accordance with the provisions in 
paragraph (d) of this section.

[43 FR 33708, July 1, 1978, as amended at 46 FR 49115, Oct. 6, 1981]



Sec. 573.460  Formaldehyde.

    The food additive formaldehyde may be safely used in the manufacture 
of animal feeds in accordance with the following conditions:
    (a) The additive is used, or intended for use, to improve the 
handling characteristics of fat by producing a dry, free-flowing 
product, as follows:
    (1) For animal fat in combination with certain oilseed meals, as a 
component of dry, nonpelletted feeds for beef and nonlactating dairy 
cattle.
    (i) An aqueous blend of soybean and sunflower meals in a ratio of 
3:1, respectively, is mixed with animal fat such that the oilseed meals 
and animal fat are in a ratio of 3:2. The feed ingredients are those 
defined by the ``Official Publication'' of the Association of American 
Feed Control Officials, Inc., 2003 ed., pp. 303, 308, and 309, which is 
incorporated by reference. The Director of the Office of the Federal 
Register approves this incorporation by reference in accordance with 5 
U.S.C. 552(a) and 1 CFR part 51. You may obtain copies from the 
Assistant Secretary-Treasurer, Association of American Feed Control 
Officials Inc., P.O. Box 478, Oxford, IN 47971, or you may examine a 
copy at the Division of Dockets Management, Food and Drug 
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, or at 
the National Archives and Records Administration (NARA). For information 
on the availability of this material at NARA, call 202-741-6030, or go 
to: http://www.archives.gov/federal--register/code--of--federal--
regulations/ibr--locations.html.
    (ii) Formaldehyde (37 percent solution) is added to the mixture at a 
level of 4 percent of the dry matter weight of the oilseed meals and 
animal fat. This mixture, upon drying, contains not more than 1 percent 
formaldehyde and not more than 12 percent moisture.
    (iii) To assure the safe use of the additive, in addition to the 
other information required by the Federal Food, Drug, and Cosmetic Act 
(the act), the label and labeling of the dried mixture shall bear:
    (A) The name of the additive.
    (B) Adequate directions for use providing that the feed as consumed 
does not contain more than 25 percent of the mixture.
    (2) For soybean and canola seeds and/or meals to which there may be 
added vegetable oil as a component of dry, nonpelleted feeds for beef 
and dairy cattle, including lactating dairy cattle.
    (i) An aqueous blend of oilseed and/or meals, with or without added 
vegetable oil, in a ratio such that, on a dry matter basis, the final 
protein level will be 25 to 35 percent and the fat content will be 20 to 
45 percent. The feed ingredients are those defined by the ``Official 
Publication'' of the Association of American Feed Control Officials, 
Inc., 2003 ed., pp. 301, 307, 308, and 309, which is incorporated by 
reference. The Director of the Office of the Federal Register approves 
this incorporation by reference in accordance with 5 U.S.C. 552(a) and 1 
CFR part 51. You may obtain copies from the Assistant Secretary-
Treasurer, Association of American Feed Control Officials Inc., P.O. Box 
478, Oxford, IN 47971, or you may examine a copy at the Division of 
Dockets Management, Food and Drug Administration, 5630 Fishers lane, rm. 
1061, Rockville, MD 20852, or at the National Archives and Records 
Administration (NARA). For information on the availability of this 
material at

[[Page 542]]

NARA, call 202-741-6030, or go to: http://www.archives.gov/federal--
register/code--of--federal--regulations/ibr--locations.html.
    (ii) Formaldehyde (37 percent solution) is added to the mixture at a 
level of 2.7 percent of the dry matter weight basis of the oilseeds and/
or meals and the vegetable oil. This mixture, upon drying, contains not 
more than 0.5 percent formaldehyde and not more than 12 percent 
moisture.
    (iii) To assure the safe use of the additive, in addition to the 
other information required by the act, the label and labeling of the 
dried mixture shall bear:
    (A) The name of the additive.
    (B) The statement, ``This supplement is not to exceed 12.5% of the 
total ration. Dietary calcium and magnesium levels should be considered 
when supplementing the diet with fat.''
    (C) The minimum and maximum levels of crude fat must be guaranteed 
and must be between -5 percent and +5 percent of the analyzed fat 
content for each batch.
    (b)(1) The food additive is formaldehyde (CAS No. 50-00-0; 37 
percent aqueous solution). It is used at a rate of 5.4 pounds (2.5 
kilograms) per ton of animal feed or feed ingredient. It is an 
antimicrobial agent used to maintain complete animal feeds or feed 
ingredients Salmonella negative for up to 21 days.
    (2) To assure safe use of the additive, in addition to the other 
information required by the Act, the label and labeling shall contain:
    (i) The name of the additive.
    (ii) A statement that formaldehyde solution which has been stored 
below 40 [deg]F or allowed to freeze should not be applied to complete 
animal feeds or feed ingredients.
    (iii) Adequate directions for use including a statement that 
formaldehyde should be uniformly sprayed on and thoroughly mixed into 
the complete animal feeds or feed ingredients and that the complete 
animal feeds or feed ingredients so treated shall be labeled as 
containing formaldehyde. The label must prominently display the 
statement: ``Treated with formaldehyde to maintain feed Salmonella 
negative. Use within 21 days.''
    (iv) The labeling for feed or feed ingredients to which formaldehyde 
has been added under the provisions of paragraph (b)(1) of this section 
is required to carry the following statement: ``Treated with 
formaldehyde to maintain feed Salmonella negative. Use within 21 days.''
    (3) To assure safe use of the additive, in addition to the other 
information required by the Act, the label and labeling shall contain:
    (i) Appropriate warnings and safety precautions concerning 
formaldehyde.
    (ii) Statements identifying formaldehyde as a poison with potentials 
for adverse respiratory effects.
    (iii) Information about emergency aid in case of accidental 
inhalation.
    (iv) Statements reflecting requirements of applicable sections of 
the Superfund Amendments and Reauthorization Act (SARA), and the 
Occupational Safety and Health Administration's (OSHA) human safety 
guidance regulations.
    (v) Contact address and phone number for reporting adverse reactions 
or to request a copy of the Materials Safety Data Sheet (MSDS).

[41 FR 38652, Sept. 10, 1976, as amended at 54 FR 18281, Apr. 28, 1989; 
61 FR 15704, Apr. 9, 1996; 63 FR 53580, Oct. 6, 1998; 68 FR 65633, Nov. 
21, 2003]



Sec. 573.480  Formic acid.

    The food additive, formic acid, may be safely used in accordance 
with the following conditions:
    (a) The additive is used as a preservative in hay crop silage in an 
amount not to exceed 2.25 percent of the silage on a dry weight basis or 
0.45 percent when direct cut, as follows:
    (1) The top foot of silage stored should not contain formic acid and
    (2) Silage should not be fed to livestock within 4 weeks of 
treatment.
    (b) The additive is used or intended for use as a feed acidifying 
agent, to lower the pH, in complete swine feeds at levels not to exceed 
1.2 percent of the complete feed.
    (1) The additive consists of not less than 85 percent formic acid 
(CAS 64-18-6).
    (2) The additive meets the following specifications:

[[Page 543]]

    (i) Free methyl alcohol not to exceed 1,000 parts per million (ppm);
    (ii) Methyl formate not to exceed 1,000 ppm; and
    (iii) Moisture not to exceed 15 percent.
    (3) To assure safe use of the additive, in addition to the other 
information required by the Federal Food, Drug and Cosmetic Act, the 
label and labeling shall contain:
    (i) The name of the additive.
    (ii) Adequate directions for use including a statement that formic 
acid must be uniformly applied and thoroughly mixed into complete swine 
feeds and that the complete swine feeds so treated shall be labeled as 
containing formic acid.
    (4) To assure safe use of the additive, in addition to the other 
information required by the Federal Food, Drug, and Cosmetic Act and 
paragraph (b)(3) of this section, the label and labeling shall contain:
    (i) Appropriate warnings and safety precautions concerning formic 
acid (85 percent formic acid).
    (ii) Statements identifying formic acid (85 percent formic acid) as 
a corrosive and possible severe irritant.
    (iii) Information about emergency aid in case of accidental 
exposure.
    (A) Statements reflecting requirements of applicable sections of the 
Superfund Amendments and Reauthorization Act (SARA), and the 
Occupational Safety and Health Administration's (OSHA) human safety 
guidance regulations.
    (B) Contact address and telephone number for reporting adverse 
reactions or to request a copy of the Material Safety Data Sheet (MSDS).

[76 FR 7106, Feb. 9, 2011]



Sec. 573.500  Condensed, extracted glutamic acid fermentation product.

    Condensed, extracted glutamic acid fermentation product may be 
safely used in animal feed under the following conditions:
    (a) The additive is a concentrated mixture of the liquor remaining 
from the extraction of glutamic acid, combined with the cells of 
Corynebacterium lilium used to produce the glutamic acid.
    (b) It is used or intended for use as follows:
    (1) In poultry feed as a source of protein in an amount not to 
exceed 5 percent of the total ration.
    (2) In cattle feed as a source of protein in an amount not to exceed 
10 percent of the feed.
    (c) In order to assure safe use, the label and labeling of the 
additive shall bear, in addition to the other information required by 
the Act, the following:
    (1) The name of the additive.
    (2) A statement of the concentration of the additive contained in 
any mixture.
    (3) Adequate directions for use.



Sec. 573.520  Hemicellulose extract.

    Hemicellulose extract may be safely used in animal feed when 
incorporated therein in accordance with the following conditions:
    (a) The additive is produced from the aqueous extract obtained by 
the treatment of wood with water at elevated temperatures (325 degrees-
535 degrees F) and pressure (80 to 900 pounds per square inch) and 
contains primarily pentose and hexose sugars.
    (b) The additive may be used in a liquid or dry state with the 
liquid product containing not less than 55 percent carbohydrate and the 
dry product containing not less than 84 percent carbohydrate.
    (c) The additive is used as a source of metabolizable energy in 
animal feed in accordance with good manufacturing and feeding practices.

[41 FR 38652, Sept. 10, 1976, as amended at 43 FR 11181, Mar. 17, 1978]



Sec. 573.530  Hydrogenated corn syrup.

    (a) Identity. The product is produced by hydrogenation of corn syrup 
over a nickel catalyst.
    (b) Specifications. The product contains 70 percent hydrogenated 
corn syrup and a maximum of 0.5 percent reducing sugars.
    (c) Uses. The product is used as a humectant and plasticizer in 
preparation of soft-moist dog and cat foods.
    (d) Limitations. The product is preferably stored in a closed, 
stainless steel or aluminum container. The level of use of the product 
shall not exceed

[[Page 544]]

15 percent of the total weight of the pet food formulation.
    (e) Labeling. The labeling shall bear, in addition to other 
information required by the Act:
    (1) The name of the additive.
    (2) Adequate directions for use in accordance with the provisions in 
paragraph (d) of this section.

[45 FR 22920, Apr. 4, 1980]



Sec. 573.540  Hydrolyzed leather meal.

    (a) Identity. Hydrolyzed leather meal is produced from leather 
scraps that are treated with steam for not less than 33 minutes at a 
pressure of not less than 125 pounds per square inch.
    (b) Specifications. The additive shall conform to the following 
percent-by-weight specifications:

Moisture, not less than 5 percent nor more than 10 percent.
Crude protein, not less than 60 percent.
Crude fat, not less than 5 percent.
Crude fiber, not more than 6 percent.
Chromium, not more than 2.75 percent.

    (c) Use. It is used or intended for use as a source of protein in 
swine feeds in an amount not to exceed 1.0 percent by weight of the 
finished feed.
    (d) Labeling. The labels and labeling shall bear, in addition to the 
other information required by the Act:
    (1) The name of the additive, hydrolyzed leather meal.
    (2) Adequate directions to provide finished feeds complying with 
paragraph (c) of this section.



Sec. 573.560  Iron ammonium citrate.

    Iron ammonium citrate may be safely used in animal feed in 
accordance with the following prescribed conditions:
    (a) The additive is the chemical green ferric ammonium citrate.
    (b) The additive is used or intended for use as an anticaking agent 
in salt for animal consumption so that the level of iron ammonium 
citrate does not exceed 25 parts per million (0.0025 percent) in the 
finished salt.
    (c) To assure safe use of the additive the label or labeling of the 
additive shall bear, in addition to the other information required by 
the Act:
    (1) The name of the additive.
    (2) Adequate directions to provide a final product that complies 
with the limitations prescribed in paragraph (b) of this section.



Sec. 573.580  Iron-choline citrate complex.

    Iron-choline citrate complex made by reacting approximately 
equimolecular quantities of ferric hydroxide, choline, and citric acid 
may be safely used as a source of iron in animal feed.



Sec. 573.600  Lignin sulfonates.

    Lignin sulfonates may be safely used in animal feeds in accordance 
with the following prescribed conditions:
    (a) For the purpose of this section, the food additive is either 
one, or a combination of, the ammonium, calcium, magnesium, or sodium 
salts of the extract of spent sulfite liquor derived from the sulfite 
digestion of wood or of abaca (Musa textilis) or of sisal (Agave 
sisalana) in either a liquid form (moisture not to exceed 50 percent by 
weight) or dry form (moisture not to exceed 6 percent by weight).
    (b) It is used or intended for use in an amount calculated on a dry 
weight basis, as follows:
    (1) As a pelleting aid in the liquid or dry form in an amount not to 
exceed 4 percent of the finished pellets.
    (2) As a binding aid in the liquid form in the flaking of feed 
grains in an amount not to exceed 4 percent of the flaked grain.
    (3) As a surfactant in molasses used in feeds, as liquid lignin 
sulfonate, in an amount not to exceed 11 percent of the molasses.
    (4) As a source of metabolizable energy, in the liquid or dry form, 
in an amount not to exceed 4 percent of the finished feed.



Sec. 573.620  Menadione dimethylpyrimidinol bisulfite.

    The food additive, menadione dimethylpyrimidinol bisulfite, may be 
safely used in accordance with the following conditions:
    (a) The additive is the 2-hydroxy-4,6-dimethylpyrimidinol salt of 
menadione 
(C17H18O6N2
S).
    (b) The additive is used or intended for use as a nutritional 
supplement for the prevention of vitamin K deficiency as follows:

[[Page 545]]

    (1) In chicken and turkey feed at a level not to exceed 2 grams per 
ton of complete feed.
    (2) In the feed of growing and finishing swine at a level not to 
exceed 10 grams per ton of feed.
    (c) To assure safe use, the label and labeling of the additive shall 
bear adequate directions for use.



Sec. 573.625  Menadione nicotinamide bisulfite.

    The food additive may be safely used as follows:
    (a) The additive is 1,2,3,4-tetrahydro-2-methyl-1,4-dioxo-2-
naphthalene sulfonic acid with 3-pyridine carboxylic acid amine (CAS No. 
73581-79-0).
    (b) The additive is used or intended for use as a nutritional 
supplement for both the prevention of vitamin K deficiency and as a 
source of supplemental niacin as follows:
    (1) In chicken and turkey feeds at a level not to exceed 2 grams per 
ton of complete feed.
    (2) In growing and finishing swine feeds at a level not to exceed 10 
grams per ton of complete feed.
    (c) To assure safe use, the label and labeling of the additive shall 
bear adequate directions for use.

[64 FR 46840, Aug. 27, 1999]



Sec. 573.637  Methyl esters of conjugated linoleic acid (cis-9, 
trans-11 and trans-10, cis-12-octadecadienoic acids).

    The food additive, methyl esters of conjugated linoleic acid (cis-9, 
trans-11 and trans-10, cis-12 octadecadienoic acids), may be safely used 
in swine feed in accordance with the prescribed conditions:
    (a) The food additive is manufactured by the reaction of refined 
sunflower oil with methanol to produce fatty acid methyl esters, which 
then undergo conjugation to yield methyl esters of octadecadienoic acid. 
The additive consists of not less than 28 percent methyl ester of cis-9, 
trans-11-octadecadienoic acid, and not less than 28 percent methyl ester 
of trans-10, cis-12-octadecadienoic acid with the sum of the other 
methyl esters of octadecadienoic acid not to exceed 4 percent. The 
additive shall contain not less than 35 percent of other fatty acid 
esters composed of oleic acid, palmitic acid, stearic acid, linoleic 
acid, and other associated acid esters.
    (b) The additive is used or intended for use in the feed of growing 
and finishing swine as a source of fatty acids at levels not to exceed 
0.6% in the finished feed.
    (c) The additive meets the following specifications:
    (1) Free methyl alcohol not to exceed 0.015%.
    (2) Insoluble impurities not to exceed 0.1%.
    (3) Moisture not to exceed 0.5%.
    (4) Unsaponifiable matter not to exceed 1.0%.
    (d) To assure safe use of the additive, in addition to the other 
information required by the act:
    (1) The label and labeling of the additive and any feed premix shall 
bear the following:
    (i) The name of the additive.
    (ii) A statement to indicate that methyl esters of conjugated 
linoleic acid (cis-9, trans-11 and trans-10, cis-12 octadecadienoic 
acids) must not be added to vitamin or mineral premixes.
    (2) The label and labeling of the additive, any feed premix, or 
complete feed prepared therefrom shall bear adequate directions for use.

[73 FR 64198, Oct. 29, 2008]



Sec. 573.640  Methyl esters of higher fatty acids.

    The food additive methyl esters of higher fatty acids may be safely 
used in animal feeds in accordance with the following prescribed 
conditions:
    (a) The food additive is manufactured by reaction of methyl alcohol 
with feed-grade fats or oils and consists of not less than 70 percent 
methyl esters of the following straight-chain monocarboxylic acids: 
Docosahexanoic acid, eicosapentanoic acid, linoleic acid, myristic acid, 
oleic acid, palmitic acid, palmitoleic acid, and stearic acid, and 
lesser amounts of the associated acid esters.
    (b) The food additive meets the following specifications:
    (1) Free methyl alcohol not to exceed 150 parts per million.
    (2) Unsaponifiable matter not to exceed 2 percent.

[[Page 546]]

    (3) It is free of chick-edema factor or other factors toxic to 
chicks, as evidenced during the bioassay method for determining the 
chick-edema factor as prescribed in paragraph (b)(4)(ii) of this 
section.
    (4) For the purposes of this section:
    (i) Unsaponifiable matter shall be determined by the method 
described in Section 28.081, ``Unsaponifiable Residue (20)--Official 
Final Action'' of the ``Official Methods of Analysis of the Association 
of Official Analytical Chemists,'' 13th Ed., 1980, p. 451, which is 
incorporated by reference. Copies are available from the AOAC 
INTERNATIONAL, 481 North Frederick Ave., suite 500, Gaithersburg, MD 
20877, or available for inspection at the National Archives and Records 
Administration (NARA). For information on the availability of this 
material at NARA, call 202-741-6030, or go to: http://www.archives.gov/
federal--register/code--of--federal--regulations/ibr--locations.html.
    (ii) The chick-edema factor bioassay method described under ``26. 
Oils, Fats, and Waxes'' in the Journal of the Association of Official 
Agricultural Chemists, Vol. 44, Page 146 (1961), or the method described 
under ``Chick-Edema Factor--Bioassay Method (34)--Official Final 
Action'' in Sec. Sec. 28.113-28.117, ``Official Methods of Analysis of 
the Association of Official Analytical Chemists,'' 12th Ed., 1975, pp. 
509-511, which is incorporated by reference, shall be employed. (Copies 
of the methods are available from the AOAC INTERNATIONAL, 481 North 
Frederick Ave., suite 500, Gaithersburg, MD 20877, or available for 
inspectionat the National Archives and Records Administration (NARA). 
For information on the availability of this material at NARA, call 202-
741-6030, or go to: http://www.archives.gov/federal--register/code--of--
federal--regulations/ibr--locations.html. ) The presence of chick-edema 
factor shall be determined by a comparison between the mean log of the 
pericardial fluid volumes of a test group and of a concurrent negative 
control group. The significance of the difference in pericardial fluid 
volumes between the test group and the negative control group is 
determined by calculating a ``t'' value according to the formula:
[GRAPHIC] [TIFF OMITTED] TR01JA93.412

where:

xt and xc are the means of the logs of the pericardial fluid volumes of 
          the test and control groups, respectively;
nt and nc are the number of chicks in the respective groups;
st\2\ and sc\2\ are the variances of the test and control groups, 
          respectively.
The variances are calculated as follows:
[GRAPHIC] [TIFF OMITTED] TR01JA93.413

where:

[Sigma]x is the sum of the logs of the pericardial fluid volumes;
[Sigma]x\2\ is the sum of the squares of the logs of the pericardial 
          fluid volumes for either the test t or control c group data.


The test sample is judged to contain chick-edema factor if the 
calculated ``t'' exceeds +1.3 and the mean log of the pericardial fluid 
volume obtained from the negative control group multiplied by 100 is 
less than 1.1461.
    (iii) ``Other factors toxic to chicks'' referred to in paragraph 
(b)(3) of this section shall be determined during the course of the 
bioassay test described in paragraph (b)(4)(ii) of this section, on the 
basis of chick deaths or other abnormalities not attributable to chick-
edema factor or to the experimental conditions of the test.
    (c) It is used or intended for use as a supplementary source of fat 
for animal feed.
    (d) To assure safe use of the additive, in addition to the other 
information required by the act:
    (1) The label and labeling of the additive, and any feed additive 
supplement, feed additive concentrate, feed additive premix, or complete 
feed prepared therefrom shall bear:
    (i) The name of the additive.
    (ii) The designation ``feed grade'' in juxtaposition with the name 
and equally as prominent.
    (2) The label or labeling of the additive and any feed additive 
supplement, feed additive concentrate, feed additive premix, or complete 
feed prepared

[[Page 547]]

therefrom shall bear adequate directions for use.

[41 FR 38652, Sept. 10, 1976, as amended at 47 FR 9397, Mar. 5, 1982; 54 
FR 18281, Apr. 28, 1989; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 
8, 2005]



Sec. 573.660  Methyl glucoside-coconut oil ester.

    Methyl glucoside-coconut oil ester may be safely used in accordance 
with the following conditions:
    (a) The additive meets the specifications prescribed in Sec. 
172.816 of this chapter.
    (b) It is used as a surfactant in molasses intended for use in 
animal feed at a level not to exceed 320 parts per million.



Sec. 573.680  Mineral oil.

    Mineral oil may be safely used in animal feed, subject to the 
provisions of this section.
    (a) Mineral oil, for the purpose of this section, is that complying 
with the definition and specifications contained in Sec. 172.878 (a) 
and (b) or in Sec. 178.3620(b)(1) (i) and (ii) of this chapter.
    (b) It is used in animal feeds for the following purposes:
    (1) To reduce dustiness of feeds or mineral supplements.
    (2) To serve as a lubricant in the preparation of pellets, cubes, or 
blocks and to improve resistance to moisture of such pellets, cubes, or 
blocks.
    (3) To prevent the segregation of trace minerals in mineralized 
salt.
    (4) To serve as a diluent carrier in the manufacture of feed grade 
biuret in accordance with good manufacturing practice.
    (5) For the removal of water from substances intended as ingredients 
of animal feed.
    (c) The quantity of mineral oil used in animal feed shall not exceed 
3.0 percent in mineral supplements, nor shall it exceed 0.06 percent of 
the total ration when present in feed or feed concentrates.

[41 FR 38652, Sept. 10, 1976, as amended at 47 FR 41106, Sept. 17, 1982]



Sec. 573.685  Natamycin.

    The food additive natamycin (CAS No. 7681-93-8) may be safely used 
in broiler chicken feeds in accordance with the following 
specifications:
    (a) The additive is a stereoisomer of 22-[(3-amino-3,6,dideoxy-
[beta]-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-
trioxatricyclo[22.3.1.0\5\, \7\] octacosa-8,14,16,18,20-pentaene-25-
carboxylic acid with the empirical formula 
C33H47NO13.
    (b) The additive shall conform to U.S.P. specifications.
    (c) The additive (as part of a premix composed of calcium carbonate, 
natamycin, and lactose) is used for retarding the growth of Aspergillus 
parasiticus in broiler chicken feeds for up to 14 days after the 
addition of natamycin.
    (d) Each pound (454 grams (g)) of the premix shall contain 434 (g) 
of calcium carbonate, 10 g of natamycin activity, and 10 g of lactose. 
The premix shall be mixed into broiler chicken feed at the rate of 1 
pound (0.454 kilograms (kg)) per ton (908 kg) of feed to provide 
natamycin at a level of 11 parts per million (ppm). The premix shall be 
thoroughly mixed into the dry components of the broiler chicken feed 
before adding the liquid components. Broiler feeds to which the 
natamycin premix is added shall be used within 4 weeks of addition of 
the premix.
    (e) To assure the safe use of the additive, the label or labeling of 
the additive shall bear, in addition to other information required by 
the Federal Food, Drug, and Cosmetic Act, the following:
    (1) The name and CAS number of the additive, and its purpose.
    (2) A listing of ingredients consisting of calcium carbonate, the 
additive, and lactose and their proportions in the premix as prescribed 
under paragraph (d) of this section.
    (3) Adequate directions for use to ensure a broiler chicken feed 
that is in compliance with the limitations prescribed in paragraph (d) 
of this section.
    (4) An appropriate cautionary statement: ``Caution: Store in a 
tightly-closed, light-resistant container in a cool, dry place.''
    (5) An expiration date of 1 year from the date of manufacture.
    (6) A contact address and telephone number for reporting adverse 
reactions experienced by users, or to request a

[[Page 548]]

copy of the Material Safety Data Sheet for natamycin.

[69 FR 19321, Apr. 13, 2004]



Sec. 573.700  Sodium nitrite.

    Sodium nitrite may be safely used in canned pet food containing meat 
and fish in accordance with the following prescribed conditions:
    (a) It is used or intended for use alone as a preservative and color 
fixative in canned pet food containing fish, meat, and fish and meat 
byproducts so that the level of sodium nitrite does not exceed 20 parts 
per million.
    (b) To assure safe use of the additive, in addition to the other 
information required by the act:
    (1) The label of the additive shall bear:
    (i) The name of the additive.
    (ii) A statement of the concentration of the additive in any 
mixture.
    (2) The label or labeling shall bear adequate directions to provide 
a final product that complies with the limitations prescribed in 
paragraph (a) of this section.



Sec. 573.720  Petrolatum.

    Petrolatum may be safely used in or on animal feed, subject to the 
following prescribed conditions:
    (a) Petrolatum complies with the specifications set forth in the 
U.S. Pharmacopeia XVI for white petrolatum or in The National Formulary 
XII for yellow petrolatum.
    (b) Petrolatum meets the following ultraviolet absorbance limits 
when subjected to the analytical procedure described in Sec. 172.886(b) 
of this chapter.

    Ultraviolet absorbance per centimeter path length:

------------------------------------------------------------------------
                        Millimicrons                            Maximum
------------------------------------------------------------------------
280 to 289..................................................        0.25
290 to 299..................................................         .20
300 to 359..................................................         .14
360 to 400..................................................         .04
------------------------------------------------------------------------

    (c) It is used in animal feed for the following purposes:
    (1) To reduce dustiness of feeds or mineral supplements.
    (2) To serve as a lubricant in the preparation of pellets, cubes, or 
blocks, and to improve resistance to moisture of such pellets, cubes, or 
blocks.
    (d) The quantity of petrolatum present in animal feeds from the uses 
specified in paragraph (c) of this section shall not exceed 3 percent in 
mineral supplements nor shall it exceed 0.06 percent of the total ration 
when present in feed or feed concentrates.
    (e) When used in combination with technical white mineral oil for 
the uses described in paragraph (c) of this section, the total quantity 
of combined petrolatum and technical white mineral oil shall not exceed 
the limits prescribed in paragraph (d) of this section.
    (f) Petrolatum may contain any antioxidant permitted in food by 
regulations issued in accordance with section 409 of the act, in an 
amount not greater than that required to produce its intended effect.



Sec. 573.740  Odorless light petroleum hydrocarbons.

    Odorless light petroleum hydrocarbons complying with Sec. 
172.884(a) and (b) of this chapter may be safely used in an amount not 
in excess of that required as a component of insecticide formulations 
used in compliance with regulations issued in this part.



Sec. 573.750  Pichia pastoris dried yeast.

    (a) Identity. The food additive Pichia pastoris dried yeast may be 
used in feed formulations of broiler chickens as a source of protein not 
to exceed 10 percent by weight of the total formulation.
    (b) Specifications. The additive shall conform to the following 
percent-by-weight specifications:
    (1) Crude protein, not less than 60 percent.
    (2) Crude fat, not less than 2 percent.
    (3) Crude fiber, not more than 2 percent.
    (4) Ash, not more than 13 percent.
    (5) Moisture, not more than 6 percent.
    (c) Use. To ensure safe use, the labeling of the additive and any 
feed additive supplement, concentrate, or premix prepared therefrom 
shall bear, in addition to other required information, the name of the 
additive, directions for use to provide not more than 10 percent by 
weight of the total ration, and the statement ``Caution: Not to be used 
in

[[Page 549]]

layers or other poultry intended for breeding.''

[58 FR 59170, Nov. 8, 1993]



Sec. 573.760  Poloxalene.

    The food additive poloxalene may be safely used in accordance with 
the following prescribed conditions:
    (a) The additive consists of polyoxy-propylene-polyoxyethylene 
glycol non-ionic block polymer meeting the following specifications:
    (1) Molecular weight range: 2,850-3,150.
    (2) Hydroxyl number: 35.7-39.4.
    (3) Cloud point (10 percent solution): 42 [deg]C-46 [deg]C.
    (4) Structural formula:
    [GRAPHIC] [TIFF OMITTED] TR01JA93.414
    
    (b) In feed as a surfactant for the flaking of feed grains when 
added to liquid grain conditioner in an amount not to exceed 1.0 percent 
of the conditioner. The conditioner is added to the feed at a rate of 1 
quart per ton of feed.
    (c) The label and labeling shall bear, in addition to the other 
information required by the Act:
    (1) The name of the additive.
    (2) Adequate directions and warnings for use.



Sec. 573.780  Polyethylene.

    (a) Identity. Polyethylene consists of basic polymers manufactured 
by the catalytic polymerization of ethylene.
    (b) Specifications. (1) For the purposes of this section, 
polyethylene shall meet the specifications in item 2.1 of Sec. 
177.1520(c) of this chapter.
    (2) The polyethylene is designed in a pellet form in a configuration 
presenting maximum angular surface having the following dimensions in 
centimeters:

0.9 0.1 x 0.8 0.1 x 1.2 
          0.1

    (c) Use. It is used as a replacement for roughage in feedlot rations 
for finishing slaughter cattle.
    (d) Labeling. The labels and labeling shall bear in addition to the 
other information required by the Act:
    (1) The name of the additive ``polyethylene roughage replacement.''
    (2) Adequate directions for use which shall provide for the 
administration of one-half pound of polyethylene pellets per head per 
day for 6 successive days. All natural roughage should be removed for a 
minimum of 12 hours prior to administration of polyethylene roughage 
replacement. Roughage replacement must be adequately mixed in the ration 
for uniform distribution.

[41 FR 38652, Sept. 10, 1976, as amended at 54 FR 18282, Apr. 28, 1989]



Sec. 573.800  Polyethylene glycol (400) mono- and dioleate.

    (a) The food additive polyethylene glycol (400) mono- and dioleate 
meets the following specifications: Saponification number, 80-88; acid 
number, 5.0 maximum; and average molecular weight range, 640-680.
    (b) It is used as a processing aid in the production of animal feeds 
when present as a result of its addition to molasses in an amount not to 
exceed 250 parts per million of the molasses.



Sec. 573.820  Polyoxyethylene glycol (400) mono- and dioleates.

    The food additive polyoxyethylene glycol (400) mono- and dioleates 
may be safely used as an emulsifier in calf-milk replacer formulations.



Sec. 573.840  Polysorbate 60.

    The food additive polysorbate 60 (polyoxyethylene (20) sorbitan 
monostearate) may be safely used in animal feeds in accordance with the 
following prescribed conditions:
    (a) It is used alone or in combination with sorbitan monostearate as 
an emulsifier in mineral premixes and dietary supplements for animal 
feeds.
    (b) It is used as an emulsifier in milk-replacer formulations for 
calves.



Sec. 573.860  Polysorbate 80.

    The food additive polysorbate 80 (polyoxyethylene (20) sorbitan 
monooleate) may be safely used as an emulsifier in milk-replacer 
formulations for calves.



Sec. 573.870  Poly(2-vinylpyridine-co-styrene).

    The food additive poly(2-vinylpyridine-co-styrene) may be safely 
used as nutrient protectant in feed

[[Page 550]]

for beef cattle and dairy cattle and replacement dairy heifers when used 
in accordance with the following conditions:
    (a) The additive meets the following specifications:

------------------------------------------------------------------------
            Component/property                       Limitation
------------------------------------------------------------------------
Inherent viscosity........................  1.0-1.6 deciliter per
                                             gram.\1\
Styrene moiety............................  40 percent maximum.
2-Vinylpyridine moiety....................  90 percent maximum.
Residual styrene..........................  200 parts per billion
                                             maximum.
Residual 2-vinylstyrene...................  200 parts per billion
                                             maximum.
Heavy metals such as lead.................  10 parts per million
                                             maximum.
Arsenic...................................  3 parts per million maximum.
------------------------------------------------------------------------
\1\ Inherent viscosity of a 0.25 percent (weight/volume) solution in
  dimethylformamide.

    (b) The additive is used in the manufacture of rumen-stable, 
abomasum-dispersible nutrient(s) for beef cattle and dairy cattle and 
replacement dairy heifers such that the maximum use of the additive from 
all sources does not exceed 5.1 grams per head per day. The additive may 
be used to protect the following nutrients:
    (1) Methionine. The resulting product must contain a maximum of 10 
percent poly(2-vinylpyridine-co-styrene) by weight and a minimum of 55 
percent methionine by weight. The coated methionine must be established 
through in vitro tests to be at least 90 percent rumen-stable, of which 
at least 90 percent is subsequently dispersible under abomasal 
conditions.
    (2) Methionine and lysine. The resulting product must contain a 
maximum of 10 percent poly(2-vinylpyridine-co-styrene) by weight and a 
minimum of a combined total of 55 percent methionine and lysine by 
weight. The coated methionine and lysine must be established through in 
vitro tests to be at least 90 percent rumen-stable, of which at least 90 
percent is subsequently dispersible under abomasal conditions.
    (c) Label and labeling. To ensure safe use of the additive, the 
label and labeling of the additive and of any feed additive supplement, 
feed additive concentrate, feed additive premix, or liquid feed 
supplement prepared therefrom, shall bear, in addition to the other 
information required by the Federal Food, Drug, and Cosmetic Act, the 
following:
    (1) The name of the additive.
    (2) A statement of the concentration of poly(2-vinylpyridine-co-
styrene) in any product or mixture.
    (3) Adequate directions for the use of the rumen-stable, abomasum-
dispersible nutrient(s) products.
    (4) The following statement: ``Warning: Maximum use of poly(2-
vinylpyridine-co-styrene) from all sources is not to exceed 5.1 grams 
per head per day.''

[57 FR 7875, Mar. 5, 1992, as amended at 57 FR 24187, June 8, 1992; 61 
FR 11547, Mar. 21, 1996; 70 FR 13100, Mar. 18, 2005]



Sec. 573.880  Normal propyl alcohol.

    Normal propyl alcohol may be safely used in feeds and feed 
supplements for cattle as a source of metabolizable energy. It is 
incorporated in the feed or feed supplement in an amount which provides 
not more than 54.5 grams of the additive per head per day.



Sec. 573.900  Pyrophyllite.

    Pyrophyllite (aluminum silicate monohydrate) may be safely used as 
the sole anticaking aid, blending agent, pelleting aid, or carrier in 
animal feed when incorporated therein in an amount not to exceed 2 
percent in complete animal feed.



Sec. 573.914  Salts of volatile fatty acids.

    (a) Identity. The food additive is a blend containing the ammonium 
or calcium salt of isobutyric acid and the ammonium or calcium salts of 
a mixture of 5-carbon acids--isovaleric, 2-methylbutyric, and n-valeric.
    (b) Specifications. The additive contains ammonium or calcium salts 
of volatile fatty acids and shall conform to the following 
specifications:
    (1) Ammonium salts:

------------------------------------------------------------------------
                Components                             Amount
------------------------------------------------------------------------
Ammonium salts of mixed 5-carbon acids (as  48 to 54 percent.
 identified in paragraph (a) of this
 section).
Ammonium salt of isobutyric acid..........  22 to 26 percent.
Water.....................................  28 percent maximum.
Ammonia...................................  0.3 percent maximum.
Arsenic...................................  3 parts per million maximum.
Heavy metals such as lead.................  10 parts per million
                                             maximum.
------------------------------------------------------------------------

    (2) Calcium salts:

[[Page 551]]



------------------------------------------------------------------------
                Components                             Amount
------------------------------------------------------------------------
Calcium salts of mixed 5-carbon acids (as   58 to 72 percent.
 identified in paragraph (a) of this
 section).
Calcium salt of isobutyric acid...........  26 to 34 percent.
Calcium hydroxide.........................  3 percent maximum.
Water.....................................  14 percent maximum.
Arsenic...................................  3 parts per million maximum.
Heavy metals such as lead.................  10 parts per million
                                             maximum.
------------------------------------------------------------------------

    (c) Use. The additive is used or intended for use as a source of 
energy in dairy cattle feed.
    (d) Labeling. The label and labeling of the additive in any feed, 
feed supplement, feed concentrate, feed premix, or liquid feed 
supplement prepared therefrom shall bear, in addition to other 
information required by the act, the following:
    (1) The name of the additive.
    (2) Adequate directions for use, including statements expressing 
maximum use levels. For ammonium salts of volatile fatty acids, the 
statements: ``Not to exceed 160 grams per head per day thoroughly mixed 
in dairy cattle feed as a source of energy.'' For calcium salts of 
volatile fatty acids, the statement: ``Not to exceed 135 grams per head 
per day thoroughly mixed in dairy cattle feed as a source of energy.''

[49 FR 45125, Nov. 15, 1984; 50 FR 8606, Mar. 4, 1985, as amended at 70 
FR 13100, Mar. 18, 2005]



Sec. 573.920  Selenium.

    (a) Public Law 103-354 enacted October 13, 1994 (the 1994 Act), 
states that FDA shall not implement or enforce the final rule issued on 
September 13, 1993 (58 FR 47962), in which FDA stayed the 1987 
amendments and any modification of such rule issued after enactment of 
the 1994 Act; unless the Commissioner of Food and Drugs makes a 
determination that:
    (1) Selenium additives are not essential at levels authorized in the 
absence of such final rule, to maintain animal nutrition and protect 
animal health;
    (2) selenium at such levels is not safe to the animals consuming the 
additive;
    (3) selenium at such levels is not safe to individuals consuming 
edible portions of animals that receive the additive;
    (4) selenium at such levels does not achieve its intended effect of 
promoting normal growth and reproduction of livestock and poultry; and
    (5) the manufacture and use of selenium at such levels cannot 
reasonably be controlled by adherence to current good manufacturing 
practice requirements.
    (6) Paragraphs (b) through (g) of this section provide the currently 
acceptable levels of selenium supplementation.
    (b) The food additive selenium is a nutrient administered in animal 
feed as sodium selenite or sodium selenate or in a controlled-release 
sodium selenite bolus, as provided in paragraphs (f) and (g) of this 
section, or as selenium yeast, as provided in paragraph (h) of this 
section.
    (c) It is added to feed as follows:
    (1) In complete feed for chickens, swine, turkeys, sheep, cattle, 
and ducks at a level not to exceed 0.3 part per million.
    (2) In feed supplements for limit feeding as follows:
    (i) Sheep: At a level not to exceed an intake of 0.7 milligram per 
head per day.
    (ii) Beef cattle: At a level not to exceed an intake of 3 milligrams 
per head per day.
    (3) In salt-mineral mixtures for free-choice feeding as follows:
    (i) Sheep: Up to 90 parts per million in a mixture for free-choice 
feeding at a rate not to exceed an intake of 0.7 milligram per head per 
day.
    (ii) Beef cattle: Up to 120 parts per million in a mixture for free-
choice feeding at a rate not to exceed an intake of 3 milligrams per 
head per day.
    (d) The additive shall be incorporated into feed as follows:
    (1) It shall be incorporated into each ton of complete feed by 
adding no less than 1 pound of a premix containing no more than 272.4 
milligrams of added selenium per pound.
    (2) It shall be incorporated into each ton of salt-mineral mixture 
for sheep or beef cattle from a premix containing no more than 4.5 grams 
of added selenium per pound.
    (e) The premix manufacturer shall follow good manufacturing 
practices in the production of selenium premixes.

[[Page 552]]

Inventory, production, and distribution records must provide a complete 
and accurate history of product production. Production controls must 
assure products to be what they are purported and labeled. Production 
controls shall include analysis sufficient to adequately monitor 
quality.
    (f) The label or labeling of any selenium premix shall bear adequate 
directions and cautions for use including this statement: ``Caution: 
Follow label directions. The addition to feed of higher levels of this 
premix containing selenium is not permitted.''
    (g) The additive is orally administered to beef and dairy cattle as 
an osmotically controlled, constant release bolus containing sodium 
selenite. Each bolus contains 360 milligrams of selenium as sodium 
selenite, and delivers 3 milligrams of selenium per day for 120 days. To 
ensure safe use of the additive:
    (1) The osmotically controlled, constant release bolus is for use 
only in beef and dairy cattle more than 3 months of age or over 200 
pounds body weight.
    (2) Only one bolus containing 360 milligrams of selenium as sodium 
selenite is administered orally to each animal in 120 days.
    (3) The labeling shall bear the following: ``This bolus delivers the 
maximum daily allowable amount of selenium and shall be the sole source 
of supplementation. Do not use in areas containing excess selenium. Do 
not rebolus within 4 months.''
    (h) Selenium yeast is a dried, non-viable yeast (Saccharomyces 
cerevisiae) cultivated in a fed-batch fermentation which provides 
incremental amounts of cane molasses and selenium salts in a manner 
which minimizes the detrimental effects of selenium salts on the growth 
rate of the yeast and allows for optimal incorporation of inorganic 
selenium into cellular organic material. Residual inorganic selenium is 
eliminated in a rigorous washing process and must not exceed 2 percent 
of the total selenium content in the final selenium yeast product.
    (1) Selenium, as selenium yeast, is added to feed as follows:
    (i) In complete feed for chickens, turkeys, swine, beef cattle, and 
dairy cattle at a level not to exceed 0.3 part per million.
    (ii) In feed supplements for limit feeding for beef cattle at a 
level not to exceed an intake of 3 milligrams per head per day.
    (iii) In salt-mineral mixtures for free-choice feeding for beef 
cattle up to 120 parts per million in a mixture for free-choice feeding 
at a rate not to exceed an intake of 3 milligrams per head per day.
    (2) Guaranteed organic selenium content from selenium yeast must be 
declared on the selenium yeast product label.
    (3) The additive, as selenium yeast, shall be incorporated into feed 
as follows:
    (i) It shall be incorporated into each ton of complete feed by 
adding no less than 1 pound of a premix containing no more than 272.4 
milligrams of added selenium per pound.
    (ii) It shall be incorporated into each ton of salt-mineral mixture 
for beef cattle from a premix containing no more than 4.5 grams of added 
selenium per pound.
    (4) Usage of this additive must conform to the requirements of 
paragraphs (e) and (f) of this section.

[52 FR 10888, Apr. 6, 1987; 52 FR 21001, June 4, 1987, as amended at 54 
FR 14215, Apr. 10, 1989; 54 FR 15874, Apr. 19, 1989; 60 FR 53703, Oct. 
17, 1995; 65 FR 35824, June 6, 2000; 65 FR 53167, Sept. 1, 2000; 67 FR 
46851, July 17, 2002; 68 FR 52340, Sept. 3, 2003; 72 FR 39561, July 19, 
2007]

    Effective Date Note: At 58 FR 47973, Sept. 13, 1993, the amendments 
to Sec. 573.920 that were published at 52 FR 10887, Apr. 6, 1987; 52 FR 
21001, June 4, 1987; and 54 FR 14214, Apr. 10, 1989 were stayed until 
further notice. At 59 FR 45973, Sept. 6, 1994, the stay was confirmed.



Sec. 573.940  Silicon dioxide.

    The food additive silicon dioxide may be safely used in animal feed 
in accordance with the following conditions:
    (a) The food additive is manufactured by vapor phase hydrolysis or 
by other means whereby the particle size is such as to accomplish the 
intended effect.
    (b) It is used or intended for use in feed components as an 
anticaking agent, and/or grinding aid, as follows:

[[Page 553]]



------------------------------------------------------------------------
                                                             Limitations
                       Feed component                         (percent)
------------------------------------------------------------------------
BHT (butylated hydroxytoluene).............................            2
Methionine hydroxy analog and its calcium salts............            1
Piperazine, piperazine salts...............................          0.8
Sodium propionate..........................................            1
Urea.......................................................            1
Vitamins...................................................            3
------------------------------------------------------------------------

    (c) It is used in feed as an anticaking agent in an amount not to 
exceed that reasonably required to accomplish its intended effect and in 
no case in an amount to exceed 2 percent by weight of the finished feed.



Sec. 573.960  Sorbitan monostearate.

    The food additive sorbitan monostearate may be safely used alone or 
in combination with polysorbate 60 as an emulsifier in mineral premixes 
and dietary supplements for animal feeds.



Sec. 573.980  Taurine.

    The food additive taurine (2-amino-ethanesulfonic acid) may be 
safely used in feed in accordance with the following prescribed 
conditions:
    (a) It is used as a nutritional supplement in the feed of growing 
chickens.
    (b) It is added to complete feeds so that the total taurine content 
does not exceed 0.054 percent of the feed.
    (c) To assure safe use of the additive, the label and labeling shall 
bear in addition to the other information required by the Act:
    (1) The name of the additive.
    (2) The quantity of the additive contained therein.
    (3) Adequate directions for use.



Sec. 573.1000  Verxite.

    The food additive verxite may be safely used in animal feed in 
accordance with the following prescribed conditions:
    (a) The additive is a magnesium-aluminum-iron silicate conforming to 
one of the following:
    (1)(i) Verxite granules: The additive contains a minimum of 98 
percent of hydrobiotite; it is thermally expanded and has a bulk density 
of from 5 to 9 pounds per cubic foot.
    (ii) It is used or intended for use:
    (a) In poultry feed at a level not to exceed 5 percent of the weight 
of the finished feed as a nonnutritive bulking agent for restricting 
calorie intake in pullet replacement feeds.
    (b) As an anticaking or blending agent, pelleting aid, or 
nonnutritive carrier for the incorporation of nutrients in poultry, 
swine, dog, or ruminant feeds, in an amount not to exceed that necessary 
to accomplish its intended effect and in no case to exceed 1.5 percent 
of the dog feed or 5 percent of the final feed for other animals.
    (2)(i) Verxite flakes: The additive contains a minimum of 98 percent 
of hydrobiotite; it has a bulk density of from 20 to 30 pounds per cubic 
foot.
    (ii) It is used or intended for use as an anticaking or blending 
agent in ruminant feeds in an amount not to exceed that necessary to 
accomplish its intended effect and in no case to exceed 1 percent by 
weight of the final feed for ruminants.
    (3)(i) Verxite grits: The additive contains a minimum of 80 percent 
of hydrobiotite; it has a bulk density of from 40 to 50 pounds per cubic 
foot.
    (ii) It is used or intended for use as a partial roughage 
replacement in ruminant feeds in an amount not to exceed that necessary 
to accomplish its intended effect and in no case to exceed 1 percent by 
weight of the final feed.
    (b) To assure safe use of the additive, the label of any feed 
additive supplement, feed additive concentrate, feed additive premix, or 
complete feed prepared therefrom shall bear, in addition to the other 
information required by the Act, the name of the additive (verxite 
granules, verxite flakes, or verxite grits), adequate directions for 
use, and, when the additive is present in excess of 1 percent, a 
statement of the quantity of the additive contained therein and the term 
``nonnutritive'' in juxtaposition therewith.



Sec. 573.1010  Xanthan gum.

    The food additive xanthan gum may be safely used in animal feed as 
follows:
    (a) The food additive is xanthan gum as defined in Sec. 172.695 of 
this chapter and meets all of the specifications thereof.
    (b) It is used or intended for use as a stabilizer, emulsifier, 
thickener, suspending agent, or bodying agent in animal feed as follows:

[[Page 554]]

    (1) In calf milk replacers at a maximum use level of 0.1 percent, as 
fed.
    (2) In liquid feed supplements for ruminant animals at a maximum use 
level of 0.25 percent (5 pounds per ton).
    (c) To assure safe use of the additive:
    (1) The label of its container shall bear, in addition to other 
information required by the act, the name of the additive.
    (2) The label or labeling of the additive container shall bear 
adequate directions for use.

[49 FR 44630, Nov. 8, 1984]



Sec. 573.1020  Yellow prussiate of soda.

    Yellow prussiate of soda (sodium ferrocyanide decahydrate: 
Na4Fe(Cn)6[deg]-10H2O) may be safely 
used as an anticaking agent in salt for animal consumption at a level 
not to exceed 13 parts per million. The additive contains a minimum of 
99.0 percent by weight of sodium ferrocyanide decahydrate.

[41 FR 38657, Sept. 10, 1976; 41 FR 48100, Nov. 2, 1976]



PART 579_IRRADIATION IN THE PRODUCTION, PROCESSING, AND HANDLING OF 
ANIMAL FEED AND PET FOOD--Table of Contents



                      Subpart A_General Provisions

Sec.
579.12 Incorporation of regulations in part 179.

                Subpart B_Radiation and Radiation Sources

579.22 Ionizing radiation for treatment of animal diets.
579.40 Ionizing radiation for the treatment of poultry feed and poultry 
          feed ingredients.

    Authority: 21 U.S.C. 321, 342, 343, 348, 371.



                      Subpart A_General Provisions



Sec. 579.12  Incorporation of regulations in part 179.

    Regulations providing for irradiation in the production, processing, 
and handling of food in part 179 of this chapter are incorporated in 
subchapter E as applicable to use in the production, processing, 
handling, and labeling of animal feed and pet food, except where 
specifically provided for in this part.

[51 FR 5993, Feb. 19, 1986]



                Subpart B_Radiation and Radiation Sources



Sec. 579.22  Ionizing radiation for treatment of animal diets.

    Ionizing radiation for treatment of complete diets for animals may 
be safely used under the following conditions:
    (a) Energy sources. Ionizing radiation is limited to:
    (1) Gamma rays for sealed units of the radionuclides cobalt-60 or 
cesium-137.
    (2) Electrons generated from machine sources at energy levels not to 
exceed 10 million electron volts.
    (b) Uses. (1) The ionizing radiation is used or intended for use in 
single treatment as follows:

------------------------------------------------------------------------
      Food for irradiation            Limitations             Use
------------------------------------------------------------------------
Bagged complete diets, packaged   Absorbed dose: Not  Microbial
 feeds, feed ingredients, bulk     to exceed 50        disinfection,
 feeds, animal treats and chews.   kiloGrays. Feeds    control or
                                   and feed            elimination
                                   ingredients
                                   treated by
                                   irradiation
                                   should be
                                   formulated to
                                   account for
                                   nutritional loss.
------------------------------------------------------------------------

    (2) If an irradiated feed ingredient is less than 5 percent of the 
final product, the final product can be irradiated without being 
considered to be re-irradiated.

[51 FR 5993, Feb. 19, 1986; 51 FR 8315, Mar. 11, 1986, as amended at 58 
FR 18148, Apr. 8, 1993; 66 FR 18540, Apr. 10, 2001]



Sec. 579.40  Ionizing radiation for the treatment of poultry feed and 
poultry feed ingredients.

    Ionizing radiation for the treatment of complete poultry diets and 
poultry feed ingredients may be safely used as follows:
    (a) Energy sources. Ionizing radiation is limited to gamma rays from 
sealed units of cobalt-60.
    (b) Limitation. The ionizing radiation is used for feed or feed 
ingredients that do not contain drugs.

[[Page 555]]

    (c) Use. Ionizing radiation is used as a single treatment for 
rendering complete poultry diets or poultry feed ingredients salmonella 
negative as follows:
    (1) Minimum dose 2.0 kiloGrays (kGy) (0.2 megarad (Mrad)); maximum 
dose 25 kGy (2.5 megarads Mrad). The absorbed dose of irradiation is to 
be based on initial concentration of salmonella using the relationship 
that 1.0 kGy (0.1 Mrad) reduces salmonella concentration by one log 
cycle (one decimal reduction).
    (2) Feeds treated by irradiation should be formulated to account for 
nutritional loss.
    (3) If an irradiated feed ingredient is less than 5 percent of the 
final product, the final product can be irradiated without being 
considered to be reirradiated.

[60 FR 50099, Sept. 28, 1995]



PART 582_SUBSTANCES GENERALLY RECOGNIZED AS SAFE--Table of Contents



                      Subpart A_General Provisions

Sec.
582.1 Substances that are generally recognized as safe.
582.10 Spices and other natural seasonings and flavorings.
582.20 Essential oils, oleoresins (solvent-free), and natural 
          extractives (including distillates).
582.30 Natural substances used in conjunction with spices and other 
          natural seasonings and flavorings.
582.40 Natural extractives (solvent-free) used in conjunction with 
          spices, seasonings, and flavorings.
582.50 Certain other spices, seasonings, essential oils, oleoresins, and 
          natural extracts.
582.60 Synthetic flavoring substances and adjuvants.
582.80 Trace minerals added to animal feeds.
582.99 Adjuvants for pesticide chemicals.

                Subpart B_General Purpose Food Additives

582.1005 Acetic acid.
582.1009 Adipic acid.
582.1033 Citric acid.
582.1057 Hydrochloric acid.
582.1061 Lactic acid.
582.1069 Malic acid.
582.1073 Phosphoric acid.
582.1077 Potassium acid tartrate.
582.1087 Sodium acid pyrophosphate.
582.1091 Succinic acid.
582.1095 Sulfuric acid.
582.1099 Tartaric acid.
582.1125 Aluminum sulfate.
582.1127 Aluminum ammonium sulfate.
582.1129 Aluminum potassium sulfate.
582.1131 Aluminum sodium sulfate.
582.1135 Ammonium bicarbonate.
582.1137 Ammonium carbonate.
582.1139 Ammonium hydroxide.
582.1141 Ammonium phosphate.
582.1143 Ammonium sulfate.
582.1155 Bentonite.
582.1165 Butane.
582.1191 Calcium carbonate.
582.1193 Calcium chloride.
582.1195 Calcium citrate.
582.1199 Calcium gluconate.
582.1205 Calcium hydroxide.
582.1207 Calcium lactate.
582.1210 Calcium oxide.
582.1217 Calcium phosphate.
582.1235 Caramel.
582.1240 Carbon dioxide.
582.1275 Dextrans.
582.1320 Glycerin.
582.1324 Glyceryl monostearate.
582.1355 Helium.
582.1366 Hydrogen peroxide.
582.1400 Lecithin.
582.1425 Magnesium carbonate.
582.1428 Magnesium hydroxide.
582.1431 Magnesium oxide.
582.1480 Methylcellulose.
582.1500 Monoammonium glutamate.
582.1516 Monopotassium glutamate.
582.1540 Nitrogen.
582.1585 Papain.
582.1613 Potassium bicarbonate.
582.1619 Potassium carbonate.
582.1625 Potassium citrate.
582.1631 Potassium hydroxide.
582.1643 Potassium sulfate.
582.1655 Propane.
582.1666 Propylene glycol.
582.1685 Rennet.
582.1711 Silica aerogel.
582.1721 Sodium acetate.
582.1736 Sodium bicarbonate.
582.1742 Sodium carbonate.
582.1745 Sodium carboxymethylcellulose.
582.1748 Sodium caseinate.
582.1751 Sodium citrate.
582.1763 Sodium hydroxide.
582.1775 Sodium pectinate.
582.1778 Sodium phosphate.
582.1781 Sodium aluminum phosphate.
582.1792 Sodium sesquicarbonate.
582.1804 Sodium potassium tartrate.
582.1810 Sodium tripolyphosphate.
582.1901 Triacetin.
582.1973 Beeswax.
582.1975 Bleached beeswax.
582.1978 Carnauba wax.

                       Subpart C_Anticaking Agents

582.2122 Aluminum calcium silicate.

[[Page 556]]

582.2227 Calcium silicate.
582.2437 Magnesium silicate.
582.2727 Sodium aluminosilicate.
582.2729 Hydrated sodium calcium aluminosilicate.
582.2906 Tricalcium silicate.

                    Subpart D_Chemical Preservatives

582.3013 Ascorbic acid.
582.3021 Benzoic acid.
582.3041 Erythorbic acid.
582.3081 Propionic acid.
582.3089 Sorbic acid.
582.3109 Thiodipropionic acid.
582.3149 Ascorbyl palmitate.
582.3169 Butylated hydroxyanisole.
582.3173 Butylated hydroxytoluene.
582.3189 Calcium ascorbate.
582.3221 Calcium propionate.
582.3225 Calcium sorbate.
582.3280 Dilauryl thiodipropionate.
582.3336 Gum guaiac.
582.3490 Methylparaben.
582.3616 Potassium bisulfite.
582.3637 Potassium metabisulfite.
582.3640 Potassium sorbate.
582.3660 Propyl gallate.
582.3670 Propylparaben.
582.3731 Sodium ascorbate.
582.3733 Sodium benzoate.
582.3739 Sodium bisulfite.
582.3766 Sodium metabisulfite.
582.3784 Sodium propionate.
582.3795 Sodium sorbate.
582.3798 Sodium sulfite.
582.3845 Stannous chloride.
582.3862 Sulfur dioxide.
582.3890 Tocopherols.

                      Subpart E_Emulsifying Agents

582.4101 Diacetyl tartaric acid esters of mono- and diglycerides of 
          edible fats or oils, or edible fat-forming fatty acids.
582.4505 Mono- and diglycerides of edible fats or oils, or edible fat-
          forming acids.
582.4521 Monosodium phosphate derivatives of mono- and diglycerides of 
          edible fats or oils, or edible fat-forming fatty acids.
582.4666 Propylene glycol.

             Subpart F_Nutrients and/or Dietary Supplements

582.5013 Ascorbic acid.
582.5017 Aspartic acid.
582.5049 Aminoacetic acid.
582.5065 Linoleic acid.
582.5118 Alanine.
582.5145 Arginine.
582.5159 Biotin.
582.5191 Calcium carbonate.
582.5195 Calcium citrate.
582.5201 Calcium glycerophosphate.
582.5210 Calcium oxide.
582.5212 Calcium pantothenate.
582.5217 Calcium phosphate.
582.5223 Calcium pyrophosphate.
582.5230 Calcium sulfate.
582.5245 Carotene.
582.5250 Choline bitartrate.
582.5252 Choline chloride.
582.5260 Copper gluconate.
582.5271 Cysteine.
582.5273 Cystine.
582.5301 Ferric phosphate.
582.5304 Ferric pyrophosphate.
582.5306 Ferric sodium pyrophosphate.
582.5308 Ferrous gluconate.
582.5311 Ferrous lactate.
582.5315 Ferrous sulfate.
582.5361 Histidine.
582.5370 Inositol.
582.5375 Iron reduced.
582.5381 Isoleucine.
582.5406 Leucine.
582.5411 Lysine.
582.5431 Magnesium oxide.
582.5434 Magnesium phosphate.
582.5443 Magnesium sulfate.
582.5446 Manganese chloride.
582.5449 Manganese citrate.
582.5452 Manganese gluconate.
582.5455 Manganese glycerophosphate.
582.5458 Manganese hypophosphite.
582.5461 Manganese sulfate.
582.5464 Manganous oxide.
582.5470 Mannitol.
582.5475 Methionine.
582.5477 Methionine hydroxy analog and its calcium salts.
582.5530 Niacin.
582.5535 Niacinamide.
582.5580 D-Pantothenyl alcohol.
582.5590 Phenylalanine.
582.5622 Potassium chloride.
582.5628 Potassium glycerophosphate.
582.5634 Potassium iodide.
582.5650 Proline.
582.5676 Pyridoxine hydrochloride.
582.5695 Riboflavin.
582.5697 Riboflavin-5-phosphate.
582.5701 Serine.
582.5772 Sodium pantothenate.
582.5778 Sodium phosphate.
582.5835 Sorbitol.
582.5875 Thiamine hydrochloride.
582.5878 Thiamine mononitrate.
582.5881 Threonine.
582.5890 Tocopherols.
582.5892 a-Tocopherol acetate.
582.5915 Tryptophane.
582.5920 Tyrosine.
582.5925 Valine.
582.5930 Vitamin A.
582.5933 Vitamin A acetate.
582.5936 Vitamin A palmitate.
582.5945 Vitamin B12.
582.5950 Vitamin D2.
582.5953 Vitamin D3.
582.5985 Zinc chloride.
582.5988 Zinc gluconate.
582.5991 Zinc oxide.

[[Page 557]]

582.5994 Zinc stearate.
582.5997 Zinc sulfate.

                         Subpart G_Sequestrants

582.6033 Citric acid.
582.6085 Sodium acid phosphate.
582.6099 Tartaric acid.
582.6185 Calcium acetate.
582.6193 Calcium chloride.
582.6195 Calcium citrate.
582.6197 Calcium diacetate.
582.6199 Calcium gluconate.
582.6203 Calcium hexametaphosphate.
582.6215 Monobasic calcium phosphate.
582.6219 Calcium phytate.
582.6285 Dipotassium phosphate.
582.6290 Disodium phosphate.
582.6386 Isopropyl citrate.
582.6511 Monoisopropyl citrate.
582.6625 Potassium citrate.
582.6751 Sodium citrate.
582.6754 Sodium diacetate.
582.6757 Sodium gluconate.
582.6760 Sodium hexametaphosphate.
582.6769 Sodium metaphosphate.
582.6778 Sodium phosphate.
582.6787 Sodium pyrophosphate.
582.6789 Tetra sodium pyrophosphate.
582.6801 Sodium tartrate.
582.6804 Sodium potassium tartrate.
582.6807 Sodium thiosulfate.
582.6810 Sodium tripolyphosphate.
582.6851 Stearyl citrate.

                          Subpart H_Stabilizers

582.7115 Agar-agar.
582.7133 Ammonium alginate.
582.7187 Calcium alginate.
582.7255 Chondrus extract.
582.7330 Gum arabic.
582.7333 Gum ghatti.
582.7339 Guar gum.
582.7343 Locust bean gum.
582.7349 Sterculia gum.
582.7351 Gum tragacanth.
582.7610 Potassium alginate.
582.7724 Sodium alginate.

    Authority: 21 U.S.C. 321, 342, 348, 371.

    Source: 41 FR 38657, Sept. 10, 1976, unless otherwise noted.



                      Subpart A_General Provisions



Sec. 582.1  Substances that are generally recognized as safe.

    (a) It is impracticable to list all substances that are generally 
recognized as safe for their intended use. However, by way of 
illustration, the Commissioner regards such common food ingredients as 
salt, pepper, sugar, vinegar, baking powder, and monosodium glutamate as 
safe for their intended use. The lists in subparts B through H of this 
part include additional substances that, when used for the purposes 
indicated, in accordance with good manufacturing or feeding practice, 
are regarded by the Commissioner as generally recognized as safe for 
such uses.
    (b) For the purposes of this section, good manufacturing or feeding 
practice shall be defined to include the following restrictions:
    (1) The quantity of a substance added to animal food does not exceed 
the amount reasonably required to accomplish its intended physical, 
nutritional, or other technical effect in food; and
    (2) The quantity of a substance that becomes a component of animal 
food as a result of its use in the manufacturing, processing, or 
packaging of food, and which is not intended to accomplish any physical 
or other technical effect in the food itself, shall be reduced to the 
extent reasonably possible.
    (3) The substance is of appropriate grade and is prepared and 
handled as a food ingredient. Upon request the Commissioner will offer 
an opinion, based on specifications and intended use, as to whether or 
not a particular grade or lot of the substance is of suitable purity for 
use in food and would generally be regarded as safe for the purpose 
intended, by experts qualified to evaluate its safety.
    (c) The inclusion of substances in the list of nutrients does not 
constitute a finding on the part of the Department that the substance is 
useful as a supplement to the diet for animals.
    (d) Substances that are generally recognized as safe for their 
intended use within the meaning of section 409 of the Act are listed in 
subparts B through H of this part. When the status of a substance has 
been reevaluated and affirmed as GRAS or deleted from subparts B through 
H of this part, an appropriate explanation will be noted, e.g., 
``affirmed as GRAS,'' ``food additive regulation,'' ``interim food 
additive regulation,'' or ``prohibited from use in food,'' with a 
reference to the appropriate new regulation. Such notation will apply 
only to the specific use covered by the review, e.g., direct animal food 
use and/or indirect animal

[[Page 558]]

food use and/or animal feed use and will not affect its status for other 
uses not specified in the referenced regulation, pending a specific 
review of such other uses.



Sec. 582.10  Spices and other natural seasonings and flavorings.

    Spices and other natural seasonings and flavorings that are 
generally recognized as safe for their intended use, within the meaning 
of section 409 of the act, are as follows:

------------------------------------------------------------------------
              Common name                 Botanical name of plant source
------------------------------------------------------------------------
Alfalfa herb and seed..................  Medicago sativa L.
Allspice...............................  Pimenta officinalis Lindl.
Ambrette seed..........................  Hibiscus abelmoschus L.
Angelica...............................  Angelica archangelica L. or
                                          other spp. of Angelica.
Angelica root..........................   Do.
Angelica seed..........................   Do.
Angostura (cusparia bark)..............  Galipea officinalis Hancock.
Anise..................................  Pimpinella anisum L.
Anise, star............................  Illicium verum Hook. f.
Balm (lemon balm)......................  Melissa officinalis L.
Basil, bush............................  Ocimum minimum L.
Basil, sweet...........................  Ocimum basilicum L.
Bay....................................  Laurus nobilis L.
Calendula..............................  Calendula officinalis L.
Camomile (chamomile), English or Roman.  Anthemis nobilis L.
Camomile (chamomile), German or          Matricaria chamomilla L.
 Hungarian.
Capers.................................  Capparis spinosa L.
Capsicum...............................  Capsicum frutescens L. or
                                          Capsicum annuum L.
Caraway................................  Carum carvi L.
Caraway, black (black cumin)...........  Nigella sativa L.
Cardamom (cardamon)....................  Elettaria cardamomum Maton.
Cassia, Chinese........................  Cinnamomum cassia Blume.
Cassia, Padang or Batavia..............  Cinnamomum burmanni Blume.
Cassia, Saigon.........................  Cinnamomum loureirii Nees.
Cayenne pepper.........................  Capsicum frutescens L. or
                                          Capsicum annuum L.
Celery seed............................  Apium graveolens L.
Chervil................................  Anthriscus cerefolium (L.)
                                          Hoffm.
Chives.................................  Allium schoenoprasum L.
Cinnamon, Ceylon.......................  Cinnamomum zeylanicum Nees.
Cinnamon, Chinese......................  Cinnamomum cassia Blume.
Cinnamon, Saigon.......................  Cinnamomum loureirii Nees.
Clary (clary sage).....................  Salvia sclarea L.
Clover.................................  Trifolium spp.
Cloves.................................  Eugenia caryophyllata Thunb.
Coriander..............................  Coriandrum sativum L.
Cumin (cummin).........................  Cuminum cyminum L.
Cumin, black (black caraway)...........  Nigella sativa L.
Dill...................................  Anethum graveolens L.
Elder flowers..........................  Sambucus canadensis L.
Fennel, common.........................  Foeniculum vulgare Mill.
Fennel, sweet (finocchio, Florence       Foeniculum vulgare Mill. var.
 fennel).                                 duice (DC.) Alex.
Fenugreek..............................  Trigonella foenum-graecum L.
Galanga (galangal).....................  Alpina officinarum Hance.
Garlic.................................  Allium sativum L.
Geranium...............................  Pelargonium spp.
Ginger.................................  Zingiber officinale Rosc.
Glycyrrhiza............................  Glycyrrhiza glabra L. and other
                                          spp. of Glycyrrhiza.
Grains of paradise.....................  Amomum melegueta Rosc.
Horehound (hoarhound)..................  Marrubium vulgare L.
Horseradish............................  Armoracia lapathifolia Gilib.
Hyssop.................................  Hyssopus officinalis L.
Lavender...............................  Lavandula officinalis Chaix.
Licorice...............................  Glycyrrhiza glabra L. and other
                                          spp. of Glycyrrhiza.
Linden flowers.........................  Tilia spp.
Mace...................................  Myristica fragrans Houtt.
Marigold, pot..........................  Calendula officinalis L.
Marjoram, pot..........................  Majorana onites (L.) Benth.
Marjoram, sweet........................  Majorana hortensis Moench.
Mustard, black or brown................  Brassica nigra (L.) Koch.
Mustard, brown.........................  Brassica juncea (L.) Coss.
Mustard, white or yellow...............  Brassica hirta Moench.
Nutmeg.................................  Myristica fragrans Houtt.
Oregano (oreganum, Mexican oregano,      Lippia spp.
 Mexican sage, origan).
Paprika................................  Capsicum annuum L.

[[Page 559]]

 
Parsley................................  Petroselinum crispum (Mill.)
                                          Mansf.
Pepper, black..........................  Piper nigrum L.
Pepper, cayenne........................  Capsicum frutescens L. or
                                          Capsicum annuum L.
Pepper, red............................   Do.
Pepper, white..........................  Piper nigrum L.
Peppermint.............................  Mentha piperita L.
Poppy seed.............................  Papaver somniferum L.
Pot marigold...........................  Calendula officinalis L.
Pot marjoram...........................  Majorana onites (L.) Benth.
Rosemary...............................  Rosmarinus officinalis L.
Rue....................................  Ruta graveolens L.
Saffron................................  Crocus sativus L.
Sage...................................  Salvia officinalis L.
Sage, Greek............................  Salvia triloba L.
Savory, summer.........................  Satureia hortensis L.
                                          (Satureja).
Savory, winter.........................  Satureia montana L. (Satureja).
Sesame.................................  Sesamum indicum L.
Spearmint..............................  Mentha spicata L.
Star anise.............................  Illicium verum Hook. f.
Tarragon...............................  Artemisia dracunculus L.
Thyme..................................  Thymus vulgaris L.
Thyme, wild or creeping................  Thymus serpyllum L.
Turmeric...............................  Curcuma longa L.
Vanilla................................  Vanilla planifolia Andr. or
                                          Vanilla tahitensis J. W.
                                          Moore.
Zedoary................................  Curcuma zedoaria Rosc.
------------------------------------------------------------------------



Sec. 582.20  Essential oils, oleoresins (solvent-free), and natural 
extractives (including distillates).

    Essential oils, oleoresins (solvent-free), and natural extractives 
(including distillates) that are generally recognized as safe for their 
intended use, within the meaning of section 409 of the act, are as 
follows:

------------------------------------------------------------------------
              Common name                 Botanical name of plant source
------------------------------------------------------------------------
Alfalfa................................  Medicago sativa L.
Allspice...............................  Pimenta officinalis Lindl.
Almond, bitter (free from prussic acid)  Prunus amygdalus Batsch, Prunus
                                          armeniaca L. or Prunus persica
                                          (L.) Batsch.
Ambrette (seed)........................  Hibiscus moschatus Moench.
Angelica root..........................  Angelica archangelica L.
Angelica seed..........................   Do.
Angelica stem..........................   Do.
Angostura (cusparia bark)..............  Galipea officinalis Hancock.
Anise..................................  Pimpinella anisum L.
Asafetida..............................  Ferula assa-foetida L. and
                                          related spp. of Ferula.
Balm (lemon balm)......................  Melissa officinalis L.
Balsam of Peru.........................  Myroxylon pereirae Klotzsch.
Basil..................................  Ocimum basilicum L.
Bay leaves.............................  Laurus nobilis L.
Bay (myrcia oil).......................  Pimenta racemosa (Mill.) J. W.
                                          Moore.
Bergamot (bergamot orange).............  Citrus aurantium L. subsp.
                                          bergamia Wright et Arn.
Bitter almond (free from prussic acid).  Prunus amygdalus Batsch, Prunus
                                          armeniaca L., or Prunus
                                          persica (L.) Batsch.
Bois de rose...........................  Aniba rosaeodora Ducke.
Cacao..................................  Theobroma cacao L.
Camomile (chamomile) flowers, Hungarian  Matricaria chamomilla L.
Camomile (chamomile) flowers, Roman or   Anthemis nobilis L.
 English.
Cananga................................  Cananga odorata Hook. f. and
                                          Thoms.
Capsicum...............................  Capsicum frutescens L. and
                                          Capsicum annuum L.
Caraway................................  Carum carvi L.
Cardamom seed (cardamon)...............  Elettaria cardamomum Maton.
Carob bean.............................  Ceratonia siliqua L.
Carrot.................................  Daucus carota L.
Cascarilla bark........................  Croton eluteria Benn.
Cassia bark, Chinese...................  Cinnamomum cassia Blume.
Cassia bark, Padang or Batavia.........  Cinnamomum burmanni Blume.
Cassia bark, Saigon....................  Cinnamomum loureirii Nees.
Celery seed............................  Apium graveolens L.
Cherry, wild, bark.....................  Prunus serotina Ehrh.
Chervil................................  Anthriscus cerefolium (L.)
                                          Hoffm.

[[Page 560]]

 
Chicory................................  Cichorium intybus L.
Cinnamon bark, Ceylon..................  Cinnamomum zeylanicum Nees.
Cinnamon bark, Chinese.................  Cinnamomum cassia Blume.
Cinnamon bark, Saigon..................  Cinnamomum loureirii Nees.
Cinnamon leaf, Ceylon..................  Cinnamomum zeylanicum Nees.
Cinnamon leaf, Chinese.................  Cinnamomum cassia Blume.
Cinnamon leaf, Saigon..................  Cinnamomum loureirii Nees.
Citronella.............................  Cymbopogon nardus Rendle.
Citrus peels...........................  Citrus spp.
Clary (clary sage).....................  Salvia sclarea L.
Clove bud..............................  Eugenia caryophyllata Thunb.
Clove leaf.............................   Do.
Clove stem.............................   Do.
Clover.................................  Trifolium spp.
Coca (decocainized)....................  Erythroxylum coca Lam. and
                                          other spp. of Erythroxylum.
Coffee.................................  Coffea spp.
Cola nut...............................  Cola acuminata Schott and
                                          Endl., and other spp. of Cola.
Coriander..............................  Coriandrum sativum L.
Corn silk..............................  Zea mays L.
Cumin (cummin).........................  Cuminum cyminum L.
Curacao orange peel (orange, bitter      Citrus aurantium L.
 peel).
Cusparia bark..........................  Galipea officinalis Hancock.
Dandelion..............................  Taraxacum officinale Weber and
                                          T. laevigatum DC.
Dandelion root.........................   Do.
Dill...................................  Anethum graveolens L.
Dog grass (quackgrass, triticum).......  Agropyron repens (L.) Beauv.
Elder flowers..........................  Sambucus canadensis L. and S.
                                          nigra L.
Estragole (esdragol, esdragon,           Artemisia dracunculus L.
 tarragon).
Estragon (tarragon)....................   Do.
Fennel, sweet..........................  Foeniculum vulgare Mill.
Fenugreek..............................  Trigonella foenum-graecum L.
Galanga (galangal).....................  Alpinia officinarum Hance.
Garlic.................................  Allium sativum L.
Geranium...............................  Pelargonium spp.
Geranium, East Indian..................  Cymbopogon martini Stapf.
Geranium, rose.........................  Pelargonium graveolens L'Her.
Ginger.................................  Zingiber officinale Rosc.
Glycyrrhiza............................  Glycyrrhiza glabra L. and other
                                          spp. of Glycyrrhiza.
Glycyrrhizin, ammoniated...............   Do.
Grapefruit.............................  Citrus paradisi Macf.
Guava..................................  Psidium spp.
Hickory bark...........................  Carya spp.
Horehound (hoarhound)..................  Marrubium vulgare L.
Hops...................................  Humulus lupulus L.
Horsemint..............................  Monarda punctata L.
Hyssop.................................  Hyssopus officinalis L.
Immortelle.............................  Helichrysum augustifolium DC.
Jasmine................................  Jaminum officinale L. and other
                                          spp. of Jasminum.
Juniper (berries)......................  Juniperus communis L.
Kola nut...............................  Cola acuminata Schott and
                                          Endl., and other spp. of Cola.
Laurel berries.........................  Laurus nobilis L.
Laurel leaves..........................  Laurus spp.
Lavender...............................  Lavandula officinalis Chaix.
Lavender, spike........................  Lavandula latifolia Vill.
Lavandin...............................  Hybrids between Lavandula
                                          officinalis Chaix and
                                          Lavandula latifolin Vill.
Lemon..................................  Citrus limon (L.) Burm. f.
Lemon balm (see balm).
Lemon grass............................  Cymbopogon citratus DC. and
                                          Cymbopogon flexuosus Stapf.
Lemon peel.............................  Citrus limon (L.) Burm. f.
Licorice...............................  Glycyrrhiza glabra L. and other
                                          spp. of Glycyrrhiza.
Lime...................................  Citrus aurantifolia Swingle.
Linden flowers.........................  Tilia spp.
Locust bean............................  Ceratonia siliqua L.
Lupulin................................  Humulus lupulus L.
Mace...................................  Myristica fragrans Houtt.
Malt (extract).........................  Hordeum vulgare L., or other
                                          grains.
Mandarin...............................  Citrus reticulata Blanco.
Marjoram, sweet........................  Majorana hortensis Moench.
Mate 1.................................  Ilex paraguariensis St. Hil.
Melissa (see balm).
Menthol................................  Mentha spp.
Menthyl acetate........................   Do.
Molasses (extract).....................  Saccharum officinarum L.

[[Page 561]]

 
Mustard................................  Brassica spp.
Naringin...............................  Citrus paradisi Macf.
Neroli, bigarade.......................  Citrus aurantium L.
Nutmeg.................................  Myristica fragrans Houtt.
Onion..................................  Allium cepa L.
Orange, bitter, flowers................  Citrus aurantium L.
Orange, bitter, peel...................   Do.
Orange leaf............................  Citrus sinensis (L.) Osbeck.
Orange, sweet..........................   Do.
Orange, sweet, flowers.................   Do.
Orange, sweet, peel....................   Do.
Origanum...............................  Origanum spp.
Palmarosa..............................  Cymbopogon martini Stapf.
Paprika................................  Capsicum annuum L.
Parsley................................  Petroselinum crispum (Mill.)
                                          Mansf.
Pepper, black..........................  Piper nigrum L.
Pepper, white..........................  Piper nigrum L.
Peppermint.............................  Mentha piperita L.
Peruvian balsam........................  Myroxylon pereirae Klotzsch.
Petitgrain.............................  Citrus aurantium L.
Petitgrain lemon.......................  Citrus limon (L.) Burm. f.
Petitgrain mandarin or tangerine.......  Citrus reticulata Blanco.
Pimenta................................  Pimenta officinalis Lindl.
Pimenta leaf...........................  Primenta officinalis Lindl.
Pipsissewa leaves......................  Chimaphila umbellata Nutt.
Pomegranate............................  Punica granatum L.
Prickly ash bark.......................  Xanthoxylum (or Zanthoxylum)
                                          Americanum Mill. or
                                          Xanthoxylum clava-herculis L.
Rose absolute..........................  Rosa alba L., Rosa centifolia
                                          L., Rosa damascena Mill., Rosa
                                          gallica L., and vars. of these
                                          spp.
Rose (otto of roses, attar of roses)...   Do.
Rose buds..............................   Do.
Rose flowers...........................   Do.
Rose fruit (hips)......................   Do.
Rose geranium..........................  Pelargonium graveolens L'Her.
Rose leaves............................  Rosa spp.
Rosemary...............................  Rosmarinus officinalis L.
Rue....................................  Ruta graveolens L.
Saffron................................  Crocus sativus L.
Sage...................................  Salvia officinalis L.
Sage, Greek............................  Salvia triloba L.
Sage, Spanish..........................  Salvia lavandulaefolia Vahl.
St. John's bread.......................  Ceratonia siliqua L.
Savory, summer.........................  Satureia hortensis L.
Savory, winter.........................  Satureia montana L.
Schinus molle..........................  Schinus molle L.
Sloe berries (blackthorn berries)......  Prunus spinosa L.
Spearmint..............................  Mentha spicata L.
Spike lavender.........................  Lavandula latifolia Vill.
Tamarind...............................  Tamarindus indica L.
Tangerine..............................  Citrus reticulata Blanco.
Tannic acid............................  Nutgalls of Quercus infectoria
                                          Oliver and related spp. of
                                          Quercus. Also in many other
                                          plants.
Tarragon...............................  Artemisia dracunculus L.
Tea....................................  Thea sinensis L.
Thyme..................................  Thymus vulgaris L. and Thymus
                                          zygis var. gracilis Boiss.
Thyme, white...........................   Do.
Thyme, wild or creeping................  Thymus serpyllum L.
Triticum (see dog grass).
Tuberose...............................  Polianthes tuberosa L.
Turmeric...............................  Curcuma longa L.
Vanilla................................  Vanilla planifolia Andr. or
                                          Vanilla tahitensis J. W.
                                          Moore.
Violet flowers.........................  Viola odorata L.
Violet leaves..........................   Do.
Violet leaves absolute.................   Do.
Wild cherry bark.......................  Prunus serotina Ehrh.
Ylang-ylang............................  Cananga odorata Hook. f. and
                                          Thoms.
Zedoary bark...........................  Curcuma zedoaria Rosc.
------------------------------------------------------------------------


[[Page 562]]



Sec. 582.30  Natural substances used in conjunction with spices and 
other natural seasonings and flavorings.

    Natural substances used in conjunction with spices and other natural 
seasonings and flavorings that are generally recognized as safe for 
their intended use, within the meaning of section 409 of the act, are as 
follows:

------------------------------------------------------------------------
              Common name                 Botanical name of plant source
------------------------------------------------------------------------
Algae, brown (kelp)....................  Laminaria spp. and Nereocystis
                                          spp.
Algae, red.............................  Porphyra spp. and Rhodymenia
                                          palmata (L.) Grev.
Dulse..................................  Rhodymenia palmata (L.)
------------------------------------------------------------------------



Sec. 582.40  Natural extractives (solvent-free) used in conjunction 
with spices, seasonings, and flavorings.

    Natural extractives (solvent-free) used in conjunction with spices, 
seasonings, and flavorings that are generally recognized as safe for 
their intended use, within the meaning of section 409 of the act, are as 
follows:

------------------------------------------------------------------------
              Common name                 Botanical name of plant source
------------------------------------------------------------------------
Algae, brown...........................  Laminaria spp. and Nereocystis
                                          spp.
Algae, red.............................  Porphyra spp. and Rhodymenia
                                          palmata (L.) Grev.
Apricot kernel (persic oil)............  Prunus armeniaca L.
Dulse..................................  Rhodymenia palmata (L.) Grev.
Kelp (see algae, brown).
Peach kernel (persic oil)..............  Prunus persica Sieb. et Zucc.
Peanut stearine........................  Arachis hypogaea L.
Persic oil (see apricot kernel and
 peach kernel).
Quince seed............................  Cydonia oblonga Miller.
------------------------------------------------------------------------



Sec. 582.50  Certain other spices, seasonings, essential oils, 
oleoresins, and natural extracts.

    Certain other spices, seasonings, essential oils, oleoresins, and 
natural extracts that are generally recognized as safe for their 
intended use, within the meaning of section 409 of the act, are as 
follows:

------------------------------------------------------------------------
              Common name                           Derivation
------------------------------------------------------------------------
Ambergris..............................  Physeter macrocephalus L.
Castoreum..............................  Castor fiber L. and C.
                                          canadensis Kuhl.
Civet (zibeth, zibet, zibetum).........  Civet cats, Viverra civetta
                                          Schreber and Viverra zibetha
                                          Schreber.
Cognac oil, white and green............  Ethyl oenanthate, so-called.
Musk (Tonquin musk)....................  Musk deer, Moschus moschiferus
                                          L.
------------------------------------------------------------------------



Sec. 582.60  Synthetic flavoring substances and adjuvants.

    Synthetic flavoring substances and adjuvants that are generally 
recognized as safe for their intended use, within the meaning of section 
409 of the act, are as follows:

Acetaldehyde (ethanal).
Acetoin (acetyl methylcarbinol).
Aconitic acid (equisetic acid, citridic acid, achilleic acid).
Anethole (parapropenyl anisole).
Benzaldehyde (benzoic aldehyde).
N-Butyric acid (butanoic acid).
d- or l-Carvone (carvol).
Cinnamaldehyde (cinnamic aldehyde).
Citral (2,6-dimethyloctadien-2,6-al-8, geranial, neral).
Decanal (N-decylaldhehyde, capraldehyde, capric aldehyde, 
caprinaldehyde, aldehyde C-10).
Diacetyl (2,3-butandeione). Ethyl acetate. Ethyl butyrate.
3-Methyl-3-phenyl glycidic acid ethyl ester (ethyl-methyl-phenyl-
glycidate, so-called strawberry aldehyde, C-16 aldehyde).
Ethyl vanillin.
Eugenol.
Geranoil (3,7-dimethyl-2,6 and 3,6-octadien-1-ol).
Geranyl acetate (geraniol acetate).

[[Page 563]]

Glycerol (glyceryl) tributyrate (tributyrin, butyrin).
Limonene (d-, l-, and dl-).
Linalool (linalol, 3,7-dimethyl-1,6-octadien-3-ol).
Linalyl acetate (bergamol).
1-Malic acid.
Methyl anthranilate (methyl-2-aminobenzoate).
Piperonal (3,4-methylenedioxy-benzaldehyde, heliotropin).
Vanillin.



Sec. 582.80  Trace minerals added to animal feeds.

    These substances added to animal feeds as nutritional dietary 
supplements are generally recognized as safe when added at levels 
consistent with good feeding practice. \1\
---------------------------------------------------------------------------

    \1\ All substances listed may be in anhydrous or hydrated form.

------------------------------------------------------------------------
                Element                         Source compounds
------------------------------------------------------------------------
Cobalt................................  Cobalt acetate.
                                        Cobalt carbonate.
                                        Cobalt chloride.
                                        Cobalt oxide.
                                        Cobalt sulfate.
Copper................................  Copper carbonate.
                                        Copper chloride.
                                        Copper gluconate.
                                        Copper hydroxide.
                                        Copper orthophosphate.
                                        Copper oxide.
                                        Copper pyrophosphate.
                                        Copper sulfate.
Iodine................................  Calcium iodate.
                                        Calcium iodobehenate.
                                        Cuprous iodide.
                                        3,5-Diiodosalicylic acid.
                                        Ethylenediamine dihydroiodide.
                                        Potassium iodate.
                                        Potassium iodide.
                                        Sodium iodate.
                                        Sodium iodide.
                                        Thymol iodide.
Iron..................................  Iron ammonium citrate.
                                        Iron carbonate.
                                        Iron chloride.
                                        Iron gluconate.
                                        Iron oxide.
                                        Iron phosphate.
                                        Iron pyrophosphate.
                                        Iron sulfate.
                                        Reduced iron.
Manganese.............................  Manganese acetate.
                                        Manganese carbonate.
                                        Manganese citrate (soluble).
                                        Manganese chloride.
                                        Manganese gluconate.
                                        Manganese orthophosphate.
                                        Manganese phosphate (dibasic).
                                        Manganese sulfate.
                                        Manganous oxide.
Zinc..................................  Zinc acetate.
                                        Zinc carbonate.
                                        Zinc chloride.
                                        Zinc oxide.
                                        Zinc sulfate.
------------------------------------------------------------------------



Sec. 582.99  Adjuvants for pesticide chemicals.

    Adjuvants, identified and used in accordance with 40 CFR 180.1001(c) 
and (d), which are added to pesticide use dilutions by a grower or 
applicator prior to application to the raw agricultural commodity, are 
exempt from the requirement of tolerances under section 409 of the act.



                Subpart B_General Purpose Food Additives



Sec. 582.1005  Acetic acid.

    (a) Product. Acetic acid.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1009  Adipic acid.

    (a) Product. Adipic acid.
    (b) [Reserved]
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used as a buffer and neutralizing 
agent in accordance with good manufacturing or feeding practice.



Sec. 582.1033  Citric acid.

    (a) Product. Citric acid.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1057  Hydrochloric acid.

    (a) Product. Hydrochloric acid.
    (b) [Reserved]
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used as a buffer and neutralizing 
agent in accordance with good manufacturing or feeding practice.



Sec. 582.1061  Lactic acid.

    (a) Product. Lactic acid.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1069  Malic acid.

    (a) Product. Malic acid.

[[Page 564]]

    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1073  Phosphoric acid.

    (a) Product. Phosphoric acid.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1077  Potassium acid tartrate.

    (a) Product. Potassium acid tartrate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1087  Sodium acid pyrophosphate.

    (a) Product. Sodium acid pyrophosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1091  Succinic acid.

    (a) Product. Succinic acid.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1095  Sulfuric acid.

    (a) Product. Sulfuric acid.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1099  Tartaric acid.

    (a) Product. Tartaric acid.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1125  Aluminum sulfate.

    (a) Product. Aluminum sulfate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1127  Aluminum ammonium sulfate.

    (a) Product. Aluminum ammonium sulfate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1129  Aluminum potassium sulfate.

    (a) Product. Aluminum potassium sulfate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1131  Aluminum sodium sulfate.

    (a) Product. Aluminum sodium sulfate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1135  Ammonium bicarbonate.

    (a) Product. Ammonium bicarbonate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1137  Ammonium carbonate.

    (a) Product. Ammonium carbonate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1139  Ammonium hydroxide.

    (a) Product. Ammonium hydroxide.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1141  Ammonium phosphate.

    (a) Product. Ammonium phosphate (mono- and dibasic).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1143  Ammonium sulfate.

    (a) Product. Ammonium sulfate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.

[[Page 565]]



Sec. 582.1155  Bentonite.

    (a) Product. Bentonite.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1165  Butane.

    (a) Product. Butane.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1191  Calcium carbonate.

    (a) Product. Calcium carbonate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1193  Calcium chloride.

    (a) Product. Calcium chloride.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1195  Calcium citrate.

    (a) Product. Calcium citrate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1199  Calcium gluconate.

    (a) Product. Calcium gluconate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1205  Calcium hydroxide.

    (a) Product. Calcium hydroxide.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1207  Calcium lactate.

    (a) Product. Calcium lactate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1210  Calcium oxide.

    (a) Product. Calcium oxide.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1217  Calcium phosphate.

    (a) Product. Calcium phosphate (mono-, di-, and tribasic).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1235  Caramel.

    (a) Product. Caramel.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1240  Carbon dioxide.

    (a) Product. Carbon dioxide.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1275  Dextrans.

    (a) Product. Dextrans of average molecular weight below 100,000.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1320  Glycerin.

    (a) Product. Glycerin.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1324  Glyceryl monostearate.

    (a) Product. Glyceryl monostearate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1355  Helium.

    (a) Product. Helium.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1366  Hydrogen peroxide.

    (a) Product. Hydrogen peroxide.

[[Page 566]]

    (b) [Reserved]
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used as a bleaching agent in 
accordance with good manufacturing or feeding practice.



Sec. 582.1400  Lecithin.

    (a) Product. Lecithin.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1425  Magnesium carbonate.

    (a) Product. Magnesium carbonate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1428  Magnesium hydroxide.

    (a) Product. Magnesium hydroxide.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1431  Magnesium oxide.

    (a) Product. Magnesium oxide.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1480  Methylcellulose.

    (a) Product. U.S.P. methylcellulose, except that the methoxy content 
shall not be less than 27.5 percent and not more than 31.5 percent on a 
dry-weight basis.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1500  Monoammonium glutamate.

    (a) Product. Monoammonium glutamate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1516  Monopotassium glutamate.

    (a) Product. Monopotassium glutamate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1540  Nitrogen.

    (a) Product. Nitrogen.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1585  Papain.

    (a) Product. Papain.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1613  Potassium bicarbonate.

    (a) Product. Potassium bicarbonate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1619  Potassium carbonate.

    (a) Product. Potassium carbonate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1625  Potassium citrate.

    (a) Product. Potassium citrate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1631  Potassium hydroxide.

    (a) Product. Potassium hydroxide.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1643  Potassium sulfate.

    (a) Product. Potassium sulfate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1655  Propane.

    (a) Product. Propane.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.

[[Page 567]]



Sec. 582.1666  Propylene glycol.

    (a) Product. Propylene glycol.
    (b) Conditions of use. This substance is generally recognized as 
safe (except in cat food) when used in accordance with good 
manufacturing or feeding practice.

[41 FR 38657, Sept. 10, 1976, as amended at 61 FR 19544, May 2, 1996]



Sec. 582.1685  Rennet.

    (a) Product. Rennet (rennin).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1711  Silica aerogel.

    (a) Product. Silica aerogel as a finely powdered microcellular 
silica foam having a minimum silica content of 89.5 percent.
    (b) [Reserved]
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used as a component of antifoaming 
agents in accordance with good manufacturing or feeding practice.



Sec. 582.1721  Sodium acetate.

    (a) Product. Sodium acetate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1736  Sodium bicarbonate.

    (a) Product. Sodium bicarbonate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1742  Sodium carbonate.

    (a) Product. Sodium carbonate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1745  Sodium carboxymethylcellulose.

    (a) Product. Sodium carboxymethyl- cellulose is the sodium salt of 
carboxymethylcellulose not less than 99.5 percent on a dry-weight basis, 
with maximum substitution of 0.95 carboxymethyl groups per 
anhydroglucose unit, and with a minimum viscosity of 25 centipoises for 
2 percent by weight aqueous solution at 25 [deg]C.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1748  Sodium caseinate.

    (a) Product. Sodium caseinate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1751  Sodium citrate.

    (a) Product. Sodium citrate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1763  Sodium hydroxide.

    (a) Product. Sodium hydroxide.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1775  Sodium pectinate.

    (a) Product. Sodium pectinate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1778  Sodium phosphate.

    (a) Product. Sodium phosphate (mono-, di-, and tribasic).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1781  Sodium aluminum phosphate.

    (a) Product. Sodium aluminum phosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1792  Sodium sesquicarbonate.

    (a) Product. Sodium sesquicarbonate.
    (b) Conditions of use. This substance is generally recognized as 
safe when

[[Page 568]]

used in accordance with good manufacturing or feeding practice.



Sec. 582.1804  Sodium potassium tartrate.

    (a) Product. Sodium potassium tartrate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1810  Sodium tripolyphosphate.

    (a) Product. Sodium tripolyphosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1901  Triacetin.

    (a) Product. Triacetin (glyceryl triacetate).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1973  Beeswax.

    (a) Product. Beeswax (yellow wax).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1975  Bleached beeswax.

    (a) Product. Bleached beeswax (white wax).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.1978  Carnauba wax.

    (a) Product. Carnauba wax.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



                       Subpart C_Anticaking Agents



Sec. 582.2122  Aluminum calcium silicate.

    (a) Product. Aluminum calcium silicate.
    (b) Tolerance. 2 percent.
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used in table salt in accordance with 
good manufacturing or feeding practice.



Sec. 582.2227  Calcium silicate.

    (a) Product. Calcium silicate.
    (b) Tolerance. 2 percent and 5 percent.
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used at levels not exceeding 2 percent 
in table salt and 5 percent in baking powder in accordance with good 
manufacturing or feeding practice.



Sec. 582.2437  Magnesium silicate.

    (a) Product. Magnesium silicate.
    (b) Tolerance. 2 percent.
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used in table salt in accordance with 
good manufacturing or feeding practice.



Sec. 582.2727  Sodium aluminosilicate.

    (a) Product. Sodium aluminosilicate (sodium silicoaluminate).
    (b) Tolerance. This substance is generally recognized as safe for 
use at a level not exceeding 2 percent in accordance with good 
manufacturing or feeding practice.



Sec. 582.2729  Hydrated sodium calcium aluminosilicate.

    (a) Product. Hydrated sodium calcium aluminosilicate (sodium calcium 
silicoaluminate).
    (b) Tolerance. This substance is generally recognized as safe for 
use at a level not exceeding 2 percent in accordance with good 
manufacturing or feeding practice.



Sec. 582.2906  Tricalcium silicate.

    (a) Product. Tricalcium silicate.
    (b) Tolerance. 2 percent.
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used in table salt in accordance with 
good manufacturing or feeding practice.



                    Subpart D_Chemical Preservatives



Sec. 582.3013  Ascorbic acid.

    (a) Product. Ascorbic acid.

[[Page 569]]

    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.3021  Benzoic acid.

    (a) Product. Benzoic acid.
    (b) Tolerance. This substance is generally recognized as safe for 
use at a level not exceeding 0.1 percent in accordance with good 
manufacturing or feeding practice.



Sec. 582.3041  Erythorbic acid.

    (a) Product. Erythorbic acid.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.3081  Propionic acid.

    (a) Product. Propionic acid.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.3089  Sorbic acid.

    (a) Product. Sorbic acid.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.3109  Thiodipropionic acid.

    (a) Product. Thiodipropionic acid.
    (b) Tolerance. This substance is generally recognized as safe for 
use in food when the total content of antioxidants is not over 0.02 
percent of fat or oil content including essential (volatile) oil content 
of the food, provided the substance is used in accordance with good 
manufacturing or feeding practice.



Sec. 582.3149  Ascorbyl palmitate.

    (a) Product. Ascorbyl palmitate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.3169  Butylated hydroxyanisole.

    (a) Product. Butylated hydroxyanisole.
    (b) Tolerance. This substance is generally recognized as safe for 
use in food when the total content of antioxidants is not over 0.02 
percent of fat or oil content, including essential (volatile) oil 
content of food provided the substance is used in accordance with good 
manufacturing or feeding practice.



Sec. 582.3173  Butylated hydroxytoluene.

    (a) Product. Butylated hydroxytol- uene.
    (b) Tolerance. This substance is generally recognized as safe for 
use in food when the total content of antioxidants is not over 0.02 
percent of fat or oil content, including essential (volatile) oil 
content of food provided the substance is used in accordance with good 
manufacturing or feeding practice.



Sec. 582.3189  Calcium ascorbate.

    (a) Product. Calcium ascorbate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.3221  Calcium propionate.

    (a) Product. Calcium propionate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.3225  Calcium sorbate.

    (a) Product. Calcium sorbate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.3280  Dilauryl thiodipropionate.

    (a) Product. Dilauryl thiodipropionate.
    (b) Tolerance. This substance is generally recognized as safe for 
use in food when the total content of antioxidants is not over 0.02 
percent of fat or oil content, including essential (volatile) oil 
content of the food, provided the substance is used in accordance with 
good manufacturing or feeding practice.



Sec. 582.3336  Gum guaiac.

    (a) Product. Gum guaiac.
    (b) Tolerance. 0.1 percent (equivalent antioxidant activity 0.01 
percent).
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used in edible fats

[[Page 570]]

or oils in accordance with good manufacturing or feeding practice.



Sec. 582.3490  Methylparaben.

    (a) Product. Methylparaben (methyl p-hydroxybenzoate).
    (b) Tolerance. This substance is generally recognized as safe for 
use at a level not exceeding 0.1 percent in accordance with good 
manufacturing or feeding practice.



Sec. 582.3616  Potassium bisulfite.

    (a) Product. Potassium bisulfite.
    (b) [Reserved]
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used in accordance with good 
manufacturing or feeding practice, except that it is not used in meats 
or in food recognized as source of vitamin B1.



Sec. 582.3637  Potassium metabisulfite.

    (a) Product. Potassium metabisulfite.
    (b) [Reserved]
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used in accordance with good 
manufacturing or feeding practice, except that it is not used in meats 
or in food recognized as source of vitamin B1.



Sec. 582.3640  Potassium sorbate.

    (a) Product. Potassium sorbate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.3660  Propyl gallate.

    (a) Product. Propyl gallate.
    (b) Tolerance. This substance is generally recognized as safe for 
use in food when the total content of antioxidants is not over 0.02 
percent of fat or oil content, including essential (volatile) oil 
content of the food, provided the substance is used in accordance with 
good manufacturing or feeding practice.



Sec. 582.3670  Propylparaben.

    (a) Product. Propylparaben (propyl p-hydroxybenzoate).
    (b) Tolerance. This substance is generally recognized as safe for 
use at a level not exceeding 0.1 percent in accordance with good 
manufacturing or feeding practice.



Sec. 582.3731  Sodium ascorbate.

    (a) Product. Sodium ascorbate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.3733  Sodium benzoate.

    (a) Product. Sodium benzoate.
    (b) Tolerance. This substance is generally recognized as safe for 
use at a level not exceeding 0.1 percent in accordance with good 
manufacturing or feeding practice.



Sec. 582.3739  Sodium bisulfite.

    (a) Product. Sodium bisulfite.
    (b) [Reserved]
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used in accordance with good 
manufacturing or feeding practice, except that it is not used in meats 
or in food recognized as source of vitamin B1.



Sec. 582.3766  Sodium metabisulfite.

    (a) Product. Sodium metabisulfite.
    (b) [Reserved]
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used in accordance with good 
manufacturing or feeding practice, except that it is not used in meats 
or in food recognized as source of vitamin B1.



Sec. 582.3784  Sodium propionate.

    (a) Product. Sodium propionate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.3795  Sodium sorbate.

    (a) Product. Sodium sorbate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.3798  Sodium sulfite.

    (a) Product. Sodium sulfite.
    (b) [Reserved]

[[Page 571]]

    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used in accordance with good 
manufacturing or feeding practice, except that it is not used in meats 
or in food recognized as source of vitamin B1.



Sec. 582.3845  Stannous chloride.

    (a) Product. Stannous chloride.
    (b) Tolerance. This substance is generally recognized as safe for 
use at a level not exceeding 0.0015 percent calculated as tin in 
accordance with good manufacturing or feeding practice.



Sec. 582.3862  Sulfur dioxide.

    (a) Product. Sulfur dioxide.
    (b) [Reserved]
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used in accordance with good 
manufacturing or feeding practice, except that it is not used in meats 
or in food recognized as source of vitamin B1.



Sec. 582.3890  Tocopherols.

    (a) Product. Tocopherols.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



                      Subpart E_Emulsifying Agents



Sec. 582.4101  Diacetyl tartaric acid esters of mono- and diglycerides 
of edible fats or oils, or edible fat-forming fatty acids.

    (a) Product. Diacetyl tartaric acid esters of mono- and diglycerides 
of edible fats or oils, or edible fat-forming fatty acids.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.4505  Mono- and diglycerides of edible fats or oils, or 
edible fat-forming acids.

    (a) Product. Mono- and diglycerides of edible fats or oils, or 
edible fat-forming acids.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.4521  Monosodium phosphate derivatives of mono- and 
diglycerides of edible fats or oils, or edible fat-forming fatty acids.

    (a) Product. Monosodium phosphate derivatives of mono- and 
diglycerides of edible fats or oils, or edible fat-forming fatty acids.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.4666  Propylene glycol.

    (a) Product. Propylene glycol.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



           Subpart F_Nutrients and/or Dietary Supplements \1\



Sec. 582.5013  Ascorbic acid.

    (a) Product. Ascorbic acid.
---------------------------------------------------------------------------

    \1\ Amino acids listed in this subpart may be free hydrochloride 
salt, hydrated, or anhydrous form, where applicable.
---------------------------------------------------------------------------

    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5017  Aspartic acid.

    (a) Product. Aspartic acid (L- and DL-forms).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5049  Aminoacetic acid.

    (a) Product. Glycine (aminoacetic acid).
    (b) [Reserved]
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used in animal feeds in accordance 
with good manufacturing or feeding practice.



Sec. 582.5065  Linoleic acid.

    (a) Product. Linoleic acid prepared from edible fats and oils and 
free from chick-edema factor.
    (b) Conditions of use. This substance is generally recognized as 
safe when

[[Page 572]]

used in accordance with good manufacturing or feeding practice.



Sec. 582.5118  Alanine.

    (a) Product. Alanine (L- and DL-forms).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5145  Arginine.

    (a) Product. Arginine (L- and DL-forms).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5159  Biotin.

    (a) Product. Biotin.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5191  Calcium carbonate.

    (a) Product. Calcium carbonate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5195  Calcium citrate.

    (a) Product. Calcium citrate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5201  Calcium glycerophosphate.

    (a) Product. Calcium glycerophosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5210  Calcium oxide.

    (a) Product. Calcium oxide.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5212  Calcium pantothenate.

    (a) Product. Calcium pantothenate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5217  Calcium phosphate.

    (a) Product. Calcium phosphate (mono-, di-, and tribasic).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5223  Calcium pyrophosphate.

    (a) Product. Calcium pyrophosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5230  Calcium sulfate.

    (a) Product. Calcium sulfate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5245  Carotene.

    (a) Product. Carotene.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5250  Choline bitartrate.

    (a) Product. Choline bitartrate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5252  Choline chloride.

    (a) Product. Choline chloride.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5260  Copper gluconate.

    (a) Product. Copper gluconate.
    (b) Tolerance. This substance is generally recognized as safe for 
use at a level not exceeding 0.005 percent in accordance with good 
manufacturing or feeding practice.



Sec. 582.5271  Cysteine.

    (a) Product. Cysteine (L-forms).

[[Page 573]]

    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5273  Cystine.

    (a) Product. Cystine (L- and DL-forms).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5301  Ferric phosphate.

    (a) Product. Ferric phosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5304  Ferric pyrophosphate.

    (a) Product. Ferric pyrophosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5306  Ferric sodium pyrophosphate.

    (a) Product. Ferric sodium pyrophosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5308  Ferrous gluconate.

    (a) Product. Ferrous gluconate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5311  Ferrous lactate.

    (a) Product. Ferrous lactate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5315  Ferrous sulfate.

    (a) Product. Ferrous sulfate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5361  Histidine.

    (a) Product. Histidine (L- and DL-forms).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5370  Inositol.

    (a) Product. Inositol.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5375  Iron reduced.

    (a) Product. Iron reduced.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5381  Isoleucine.

    (a) Product. Isoleucine (L- and DL-forms).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5406  Leucine.

    (a) Product. Leucine (L- and DL-forms).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5411  Lysine.

    (a) Product. Lysine (L- and DL-forms).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5431  Magnesium oxide.

    (a) Product. Magnesium oxide.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5434  Magnesium phosphate.

    (a) Product. Magnesium phosphate (di- and tribasic).
    (b) Conditions of use. This substance is generally recognized as 
safe when

[[Page 574]]

used in accordance with good manufacturing or feeding practice.



Sec. 582.5443  Magnesium sulfate.

    (a) Product. Magnesium sulfate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5446  Manganese chloride.

    (a) Product. Manganese chloride.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5449  Manganese citrate.

    (a) Product. Manganese citrate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5452  Manganese gluconate.

    (a) Product. Manganese gluconate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5455  Manganese glycerophosphate.

    (a) Product. Manganese glycerophosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5458  Manganese hypophosphite.

    (a) Product. Manganese hypophosphite.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5461  Manganese sulfate.

    (a) Product. Manganese sulfate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5464  Manganous oxide.

    (a) Product. Manganous oxide.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5470  Mannitol.

    (a) Product. Mannitol.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5475  Methionine.

    (a) Product. Methionine.
    (b) [Reserved]
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used in animal feeds in accordance 
with good manufacturing or feeding practice.



Sec. 582.5477  Methionine hydroxy analog and its calcium salts.

    (a) Product. Methionine hydroxy analog and its calcium salts.
    (b) [Reserved]
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used in animal feeds in accordance 
with good manufacturing or feeding practice.



Sec. 582.5530  Niacin.

    (a) Product. Niacin.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5535  Niacinamide.

    (a) Product. Niacinamide.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5580  D-Pantothenyl alcohol.

    (a) Product. D-Pantothenyl alcohol.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5590  Phenylalanine.

    (a) Product. Phenylalanine (L- and DL-forms).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.

[[Page 575]]



Sec. 582.5622  Potassium chloride.

    (a) Product. Potassium chloride.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5628  Potassium glycerophosphate.

    (a) Product. Potassium glycerophosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5634  Potassium iodide.

    (a) Product. Potassium iodide.
    (b) Tolerance. 0.01 percent.
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used in table salt as a source of 
dietary iodine in accordance with good manufacturing or feeding 
practice.



Sec. 582.5650  Proline.

    (a) Product. Proline (L- and DL-forms).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5676  Pyridoxine hydrochloride.

    (a) Product. Pyridoxine hydrochloride.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5695  Riboflavin.

    (a) Product. Riboflavin.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5697  Riboflavin-5-phosphate.

    (a) Product. Riboflavin-5-phosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5701  Serine.

    (a) Product. Serine (L- and DL-forms).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5772  Sodium pantothenate.

    (a) Product. Sodium pantothenate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5778  Sodium phosphate.

    (a) Product. Sodium phosphate (mono-, di-, and tribasic).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5835  Sorbitol.

    (a) Product. Sorbitol.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5875  Thiamine hydrochloride.

    (a) Product. Thiamine hydrochloride.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5878  Thiamine mononitrate.

    (a) Product. Thiamine mononitrate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5881  Threonine.

    (a) Product. Threonine (L- and DL-forms).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5890  Tocopherols.

    (a) Product. Tocopherols.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5892  a-Tocopherol acetate.

    (a) Product. a-Tocopherol acetate.

[[Page 576]]

    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5915  Tryptophane.

    (a) Product. Tryptophane (L- and DL-forms).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5920  Tyrosine.

    (a) Product. Tyrosine (L- and DL-forms).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5925  Valine.

    (a) Product. Valine (L- and DL-forms).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5930  Vitamin A.

    (a) Product. Vitamin A.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5933  Vitamin A acetate.

    (a) Product. Vitamin A acetate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5936  Vitamin A palmitate.

    (a) Product. Vitamin A palmitate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5945  Vitamin B 12.

    (a) Product. Vitamin B12.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5950  Vitamin D 2.

    (a) Product. Vitamin D2.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5953  Vitamin D 3.

    (a) Product. Vitamin D3.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5985  Zinc chloride.

    (a) Product. Zinc chloride.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5988  Zinc gluconate.

    (a) Product. Zinc gluconate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5991  Zinc oxide.

    (a) Product. Zinc oxide.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5994  Zinc stearate.

    (a) Product. Zinc stearate prepared from stearic acid free from 
chick-edema factor.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.5997  Zinc sulfate.

    (a) Product. Zinc sulfate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



                       Subpart G_Sequestrants \2\



Sec. 582.6033  Citric acid.

    (a) Product. Citric acid.
---------------------------------------------------------------------------

    \2\ For the purpose of this subpart, no attempt has been made to 
designate those sequestrants that may also function as chemical 
preservatives.

---------------------------------------------------------------------------

[[Page 577]]

    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6085  Sodium acid phosphate.

    (a) Product. Sodium acid phosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6099  Tartaric acid.

    (a) Product. Tartaric acid.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6185  Calcium acetate.

    (a) Product. Calcium acetate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6193  Calcium chloride.

    (a) Product. Calcium chloride.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6195  Calcium citrate.

    (a) Product. Calcium citrate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6197  Calcium diacetate.

    (a) Product. Calcium diacetate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6199  Calcium gluconate.

    (a) Product. Calcium gluconate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6203  Calcium hexametaphosphate.

    (a) Product. Calcium hexametaphosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6215  Monobasic calcium phosphate.

    (a) Product. Monobasic calcium phosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6219  Calcium phytate.

    (a) Product. Calcium phytate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6285  Dipotassium phosphate.

    (a) Product. Dipotassium phosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6290  Disodium phosphate.

    (a) Product. Disodium phosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6386  Isopropyl citrate.

    (a) Product. Isopropyl citrate.
    (b) Tolerance. This substance is generally recognized as safe for 
use at a level not exceeding 0.02 percent in accordance with good 
manufacturing or feeding practice.



Sec. 582.6511  Monoisopropyl citrate.

    (a) Product. Monoisopropyl citrate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6625  Potassium citrate.

    (a) Product. Potassium citrate.
    (b) Conditions of use. This substance is generally recognized as 
safe when

[[Page 578]]

used in accordance with good manufacturing or feeding practice.

[41 FR 38657, Sept. 10, 1976. Redesignated at 42 FR 14091, Mar. 15, 
1977]



Sec. 582.6751  Sodium citrate.

    (a) Product. Sodium citrate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.

[41 FR 38657, Sept. 10, 1976. Redesignated at 42 FR 14091, Mar. 15, 
1977]



Sec. 582.6754  Sodium diacetate.

    (a) Product. Sodium diacetate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6757  Sodium gluconate.

    (a) Product. Sodium gluconate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6760  Sodium hexametaphosphate.

    (a) Product. Sodium hexametaphosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6769  Sodium metaphosphate.

    (a) Product. Sodium metaphosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6778  Sodium phosphate.

    (a) Product. Sodium phosphate (mono-, di-, and tribasic).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6787  Sodium pyrophosphate.

    (a) Product. Sodium pyrophosphate.
    (b) Condition of use. This substance is generally recognized as safe 
when used in accordance with good manufacturing or feeding practice.



Sec. 582.6789  Tetra sodium pyrophosphate.

    (a) Product. Tetra sodium pyrophosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6801  Sodium tartrate.

    (a) Product. Sodium tartrate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6804  Sodium potassium tartrate.

    (a) Product. Sodium potassium tartrate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6807  Sodium thiosulfate.

    (a) Product. Sodium thiosulfate.
    (b) Tolerance. 0.1 percent.
    (c) Limitations, restrictions, or explanation. This substance is 
generally recognized as safe when used in salt in accordance with good 
manufacturing or feeding practice.



Sec. 582.6810  Sodium tripolyphosphate.

    (a) Product. Sodium tripolyphosphate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.6851  Stearyl citrate.

    (a) Product. Stearyl citrate.
    (b) Tolerance. This substance is generally recognized as safe for 
use at a level not exceeding 0.15 percent in accordance with good 
manufacturing or feeding practice.



                          Subpart H_Stabilizers



Sec. 582.7115  Agar-agar.

    (a) Product. Agar-agar.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.

[[Page 579]]



Sec. 582.7133  Ammonium alginate.

    (a) Product. Ammonium alginate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.7187  Calcium alginate.

    (a) Product. Calcium alginate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.7255  Chondrus extract.

    (a) Product. Chondrus extract (carrageenin).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.7330  Gum arabic.

    (a) Product. Acacia (gum arabic).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.7333  Gum ghatti.

    (a) Product. Gum ghatti.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.7339  Guar gum.

    (a) Product. Guar gum.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.7343  Locust bean gum.

    (a) Product. Locust (carob) bean gum.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.7349  Sterculia gum.

    (a) Product. Sterculia gum (karaya gum).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.7351  Gum tragacanth.

    (a) Product. Tragacanth (gum tragacanth).
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.7610  Potassium alginate.

    (a) Product. Potassium alginate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



Sec. 582.7724  Sodium alginate.

    (a) Product. Sodium alginate.
    (b) Conditions of use. This substance is generally recognized as 
safe when used in accordance with good manufacturing or feeding 
practice.



PART 584_FOOD SUBSTANCES AFFIRMED AS GENERALLY RECOGNIZED AS SAFE 
IN FEED AND DRINKING WATER OF ANIMALS--Table of Contents



Subpart A [Reserved]

        Subpart B_Listing of Specific Substances Affirmed as GRAS

Sec.
584.200 Ethyl alcohol containing ethyl acetate.
584.700 Hydrophobic silicas.
584.725 25-Hydroxyvitamin D3.

    Authority: 21 U.S.C. 321, 342, 348, 371.

Subpart A [Reserved]



        Subpart B_Listing of Specific Substances Affirmed as GRAS



Sec. 584.200  Ethyl alcohol containing ethyl acetate.

    The feed additive ethyl alcohol containing ethyl acetate meets the 
requirement of 27 CFR 21.62, being not less than 92.5 percent ethyl 
alcohol, each 100 gallons having had added the equivalent of 4.25 
gallons of 100 percent ethyl acetate. It is used in accordance with good 
feeding practices in ruminant feed supplements as a source of added 
energy.

[46 FR 52333, Oct. 27, 1981, as amended at 72 FR 41620, July 31, 2007]

[[Page 580]]



Sec. 584.700  Hydrophobic silicas.

    (a) Product. Amorphous fumed hydrophobic silica or precipitated 
hydrophobic silica (CAS Reg. No. 68611-0944-099, silane, 
dichlorodimethyl-, reaction products with silica).
    (b) Conditions of use. An anticaking/free-flow agent in vitamin 
preparations for animal feed.
    (c) Limitations. Not to exceed 5 percent in the vitamin preparation. 
It shall be used in accordance with good manufacturing or feeding 
practices. It must be of purity suitable for intended use, and it must 
comply with the following specifications:
    (i) Amorphous fumed hydrophobic silica: Not less than 99.0 percent 
silicon dioxide after ignition. Not more than 3 ppm arsenic. Not more 
than 0.003 percent heavy metals (as lead). Not more than 10 ppm lead. 
Not more than 2.5 percent loss on drying. Not more than 2 percent loss 
on ignition after drying. Not more than 1 percent insoluble substances. 
Not more than 50 parts per million dichlorodimethylsilane.
    (ii) Precipated hydrophobic silica: Not less than 94.0 percent 
silicon dioxide after ignition. Not more than 3 ppm arsenic. Not more 
than 0.003 percent heavy metals (as lead). Not more than 10 ppm lead. 
Not more than 7 percent loss on drying. Not more than 8.5 percent loss 
on ignition after drying. Not more than 5 percent soluble ionizable 
salts (as sodium sulfate). Not more than 1 percent insoluble substances. 
Not more than 50 parts per million dichlorodimethylsilane.

[61 FR 43453, Aug. 23, 1996]



Sec. 584.725  25-Hydroxyvitamin D3.

    (a) Product. 25-Hydroxyvitamin D3 (9,10-secocholesta-
5,7,10(19)-triene-3[beta], 25-diol).
    (b) Conditions of use. This substance is generally recognized as 
safe as a source of vitamin D3 activity in feed or drinking 
water of broiler chickens when used in accordance with the limitations 
in paragraph (c) of this section.
    (c) Limitations. (1) Not to exceed 69 parts per billion (ppb) in 
feed or 34.5 ppb in drinking water. It shall be used in accordance with 
good manufacturing and feeding practices.
    (2) The product must comply with the following specifications:
    (i) Not less than 94.0 percent 25-hydroxyvitamin D3.
    (ii) Not more than 1 percent of any individual sterol.
    (iii) Not more than 5 percent water.
    (iv) Not more than 20 parts per million (ppm) lead.
    (v) Not more than 20 ppm aluminum.
    (vi) Not more than 1.0 percent solvents and non-detectable levels of 
2', 4', 5', 7'-tetraiodofluorescin.
    (3) Product labeling shall bear the following:
    (i) A statement to indicate that the maximum use level of 25-
hydroxyvitamin D3 must not exceed 69 ppb in feed or 34.5 ppb 
in drinking water.
    (ii) Adequate use directions to ensure that 25-hydroxyvitamin 
D3 (and all premixes) is uniformly blended throughout the 
feed or drinking water.
    (iii) An expiration date on all premix labeling.
    (iv) A statement on all premix labeling (feed and drinking water 
forms) that 25-hydroxyvitamin D3 should not be used 
simultaneously in both feed and water.

[72 FR 12564, Mar. 16, 2007]



PART 589_SUBSTANCES PROHIBITED FROM USE IN ANIMAL FOOD OR FEED--Table 
of Contents



                      Subpart A_General Provisions

Sec.
589.1 Substances prohibited from use in animal food or feed.

 Subpart B_Listing of Specific Substances Prohibited From Use in Animal 
                              Food or Feed

589.1000 Gentian violet.
589.1001 Propylene glycol in or on cat food.
589.2000 Animal proteins prohibited in ruminant feed.
589.2001 Cattle materials prohibited in animal food or feed to prevent 
          the transmission of bovine spongiform encephalopathy.

    Authority: 21 U.S.C. 321, 342, 343, 348, 371.

[[Page 581]]



                      Subpart A_General Provisions



Sec. 589.1  Substances prohibited from use in animal food or feed.

    (a) The substances listed in this part have been prohibited from use 
in animal food or feed by the Food and Drug Administration because of a 
determination that they present a potential risk to the public health or 
have not been shown by adequate scientific data to be safe for use in 
such food or feed. Use of any of these substances in violation of this 
part causes the animal food or feed involved to be adulterated and in 
violation of the Act.
    (b) This part includes only a partial list of substances prohibited 
from use in animal food or feed; it is for easy reference purposes and 
is not a complete list of substances that may not lawfully be used in 
such animal food or feed. No substance may be used in animal food or 
feed unless it meets all applicable requirements of the Act.
    (c) The Food and Drug Administration either on its own initiative or 
on behalf of any interested person who has submitted a petition, may 
publish a proposal to establish, amend, or repeal a regulation under 
this part on the basis of new scientific evaluation or information. Any 
such petition shall include an adequate scientific basis to support the 
petition, shall be the form set forth in Sec. 571.1 of this chapter, 
and will be published in the Federal Register for comment if it contains 
reasonable ground.

[45 FR 28319, Apr. 29, 1980]



 Subpart B_Listing of Specific Substances Prohibited From Use in Animal 
                              Food or Feed



Sec. 589.1000  Gentian violet.

    The Food and Drug Administration has determined that gentian violet 
has not been shown by adequate scientific data to be safe for use in 
animal feed. Use of gentian violet in animal feed causes the feed to be 
adulterated and in violation of the Federal Food, Drug, and Cosmetic Act 
(the act), in the absence of a regulation providing for its safe use as 
a food additive under section 409 of the act, unless it is subject to an 
effective notice of claimed investigational exemption for a food 
additive under Sec. 570.17 of this chapter, or unless the substance is 
intended for use as a new animal drug and is subject to an approved 
application under section 512 of the act, or an index listing under 
section 572 of the act, or an effective notice of claimed 
investigational exemption for a new animal drug under part 511 of this 
chapter or Sec. 516.125 of this chapter.

[72 FR 69131, Dec. 6, 2007]



Sec. 589.1001  Propylene glycol in or on cat food.

    The Food and Drug Administration has determined that propylene 
glycol in or on cat food has not been shown by adequate scientific data 
to be safe for use. Use of propylene glycol in or on cat food causes the 
feed to be adulterated and in violation of the Federal Food, Drug, and 
Cosmetic Act (the act), in the absence of a regulation providing for its 
safe use as a food additive under section 409 of the act, unless it is 
subject to an effective notice of claimed investigational exemption for 
a food additive under Sec. 570.17 of this chapter, or unless the 
substance is intended for use as a new animal drug and is subject to an 
approved application under section 512 of the act or an effective notice 
of claimed investigational exemption for a new animal drug under part 
511 of this chapter.

[61 FR 19544, May 2, 1996]



Sec. 589.2000  Animal proteins prohibited in ruminant feed.

    (a) Definitions--(1) Protein derived from mammalian tissues means 
any protein-containing portion of mammalian animals, excluding: Blood 
and blood products; gelatin; tallow containing no more than 0.15 percent 
insoluble impurities and tallow derivatives as specified in Sec. 
589.2001; inspected meat products which have been cooked and offered for 
human food and further heat processed for feed (such as plate waste and 
used cellulosic food casings); milk products (milk and milk proteins); 
and any product whose only mammalian protein consists entirely of 
porcine or equine protein.

[[Page 582]]

    (2) Renderer means any firm or individual that processes slaughter 
byproducts, animals unfit for human consumption, or meat scraps. The 
term includes persons who collect such materials and subject them to 
minimal processing, or distribute them to firms other than renderers (as 
defined here) whose intended use for the products may include animal 
feed. The term includes renderers that also blend animal protein 
products.
    (3) Blender means any firm or individual which obtains processed 
animal protein from more than one source or from more than one species, 
and subsequently mixes (blends) or redistributes an animal protein 
product.
    (4) Feed manufacturer includes manufacturers of complete and 
intermediate feeds intended for animals, and includes on-farm in 
addition to off-farm feed manufacturing and mixing operations.
    (5) Nonmammalian protein includes proteins from nonmammalian 
animals.
    (6) Distributor includes persons who distribute or transport feeds 
or feed ingredients intended for animals.
    (7) Ruminant includes any member of the order of animals which has a 
stomach with four chambers (rumen, reticulum, omasum, and abomasum) 
through which feed passes in digestion. The order includes, but is not 
limited to, cattle, buffalo, sheep, goats, deer, elk, and antelopes.
    (b) Food additive status. The Food and Drug Administration has 
determined that protein derived from mammalian tissues for use in 
ruminant feed is a food additive subject to section 409 of the Federal 
Food, Drug, and Cosmetic Act (the act). The use or intended use in 
ruminant feed of any material that contains protein derived from 
mammalian tissues causes the feed to be adulterated and in violation of 
the act, unless it is the subject of an effective notice of claimed 
investigational exemption for a food additive under Sec. 570.17 of this 
chapter.
    (c) Requirements for renderers that are not included in paragraph 
(e) of this section. (1) Renderers that manufacture products that 
contain or may contain protein derived from mammalian tissues and that 
are intended for use in animal feed shall take the following measures to 
ensure that materials identified in paragraph (b) of this section are 
not used in the feed of ruminants:
    (i) Label the materials as follows: ``Do not feed to cattle or other 
ruminants''; and
    (ii) Maintain records sufficient to track the materials throughout 
their receipt, processing, and distribution, and make the copies 
available for inspection and copying by the Food and Drug 
Administration.
    (2) Renderers described in paragraph (c)(1) of this section will be 
exempted from the requirements of paragraphs (c)(1)(i) and (c)(1)(ii) of 
this section if they:
    (i) Use exclusively a manufacturing method that has been validated 
by the Food and Drug Administration to deactivate the agent that causes 
transmissible spongiform encephalopathy (TSE) and whose design has been 
made available to the public;
    (ii) Use routinely a test method that has been validated by the Food 
and Drug Administration to detect the presence of the agent that causes 
TSE's and whose design has been made available to the public. Renderers 
whose products test positive for agents that cause TSE's must comply 
with paragraphs (c)(1)(i) and (c)(1)(ii) of this section. Records of the 
test results shall be made available for inspection by the Food and Drug 
Administration; or
    (iii) Use exclusively a method for controlling the manufacturing 
process that minimizes the risk of the TSE agent entering the product 
and whose design has been made available to the public and validated by 
the Food and Drug Administration.
    (3) Renderers described in paragraph (c)(1) of this section will be 
exempted from the requirements of paragraph (c)(1)(ii) of this section 
if they use a permanent method, approved by FDA, to make a mark 
indicating that the product contains or may contain protein derived from 
mammalian tissue. If the marking is by the use of an agent that cannot 
be detected on visual inspection, the renderer must use an agent whose 
presence can be detected by a method that has been validated by the Food 
and Drug Administration and

[[Page 583]]

whose design has been made available to the public.
    (4) Renderers shall comply with all applicable requirements under 
Sec. 589.2001.
    (d) Requirements for protein blenders, feed manufacturers, and 
distributors that are not included in paragraph (e) of this section. (1) 
Protein blenders, feed manufacturers, and distributors that manufacture, 
blend, process, and distribute products that contain or may contain 
protein derived from mammalian tissues shall comply with paragraph 
(c)(1) of this section.
    (2) Protein blenders, feed manufacturers, and distributors, shall be 
exempt from paragraphs (d)(1) of this section if they:
    (i) Purchase animal products from renderers that certified 
compliance with paragraph (c)(2) of this section or purchase such 
materials from parties that certify that the materials were purchased 
from renderers that certified compliance with paragraph (c)(2) of this 
section; or
    (ii) Comply with the requirements of paragraph (c)(2) of this 
section where appropriate.
    (3) Protein blenders, feed manufacturers, and distributors, shall be 
exempt from paragraph (c)(1)(ii) of this section if they:
    (i) Purchase animal protein products that are marked in accordance 
with paragraph (c)(3) of this section or purchase such materials from 
renderers that certified compliance with paragraph (c)(3) of this 
section, or purchase such materials from parties that certify that the 
materials were purchased from renderers that certified compliance with 
paragraph (c)(3) of this section; or
    (ii) Comply with the requirements of paragraph (c)(3) of this 
section where appropriate.
    (4) Pet food products that are sold or are intended for sale at 
retail and feeds for nonruminant laboratory animals are exempt from the 
labeling requirements in paragraphs (c) and (d) of this section. 
However, if the pet food products or feeds for nonruminant laboratory 
animals are sold or are intended for sale as distressed or salvage 
items, then such products shall be labeled in accordance with paragraph 
(c) or (d) of this section, as appropriate.
    (5) Copies of certifications as described in paragraphs (d)(2) and 
(d)(3) of this section, shall be made available for inspection and 
copying by the Food and Drug Administration.
    (e) Requirements for persons that intend to separate mammalian and 
nonmammalian materials. (1) Renderers, protein blenders, feed 
manufacturers, distributors, and others that manufacture, process, blend 
and distribute both products that contain or may contain protein derived 
from mammalian tissues or feeds containing such products, and protein 
products from other animal tissues or feeds containing such products, 
and that intend to keep those products separate shall:
    (i) Comply with paragraphs (c)(1) or (d)(1) of this section as 
appropriate except that the labeling requirement shall apply only to 
products that contain or may contain protein derived from mammalian 
tissues or feeds containing such products;
    (ii) In the case of a renderer, obtain nonmammalian or pure porcine 
or pure equine materials only from single-species slaughter facilities;
    (iii) Provide for measures to avoid commingling or cross-
contamination;
    (A) Maintain separate equipment or facilities for the manufacture, 
processing, or blending of such materials; or
    (B) Use clean-out procedures or other means adequate to prevent 
carry-over of products that contain or may contain protein derived from 
mammalian tissues into animal protein or feeds that may be used for 
ruminants; and
    (iv) Maintain written procedures specifying the clean-out procedures 
or other means, and specifying the procedures for separating products 
that contain or may contain protein derived from mammalian tissue from 
all other protein products from the time of receipt until the time of 
shipment.
    (2) Renderers, blenders, feed manufacturers, and distributors will 
be exempted from applicable requirements of paragraph (e)(1) of this 
section, if they meet the criteria for exemption under paragraphs (c)(2) 
or (c)(3) of this section, and (d)(2) or (d)(3) of this section.

[[Page 584]]

    (3) Renderers shall comply with all applicable requirements under 
Sec. 589.2001.
    (f) Requirements for establishments and individuals that are 
responsible for feeding ruminant animals. Establishments and individuals 
that are responsible for feeding ruminant animals shall maintain copies 
of purchase invoices and labeling for all feeds containing animal 
protein products received, and make the copies available for inspection 
and copying by the Food and Drug Administration.
    (g) Adulteration and misbranding. (1) Animal protein products, and 
feeds containing such products, that are not in compliance with 
paragraphs (c) through (f) of this section, excluding labeling 
requirements, will be deemed adulterated under section 402(a)(2)(C) or 
402(a)(4) of the act.
    (2) Animal protein products, and feeds containing such products, 
that are not in compliance with the labeling requirements of paragraphs 
(c) through (f) of this section will be deemed misbranded under section 
403(a)(1) or 403(f) of the act.
    (h) Inspection; records retention. (1) Records that are to be made 
available for inspection and copying, as required by this section, shall 
be kept for a minimum of 1 year.
    (2) Written procedures required by this section shall be made 
available for inspection and copying by the Food and Drug 
Administration.

[62 FR 30976, June 5, 1997, as amended at 73 FR 22756, Apr. 25, 2008]

    Effective Date Note: At 62 FR 30976, June 5, 1997, Sec. 589.2000 
was added. Paragraph (e)(1)(iv) of this section contains information 
collection and recordkeeping requirements and will not become effective 
until approval has been given by the Office of Management and Budget.



Sec. 589.2001  Cattle materials prohibited in animal food or feed to 
prevent the transmission of bovine spongiform encephalopathy.

    (a) Purpose--The purpose of this section is to prohibit the use of 
certain cattle origin materials in the food or feed of all animals to 
further reduce the risk of the spread of bovine spongiform 
encephalopathy (BSE) within the United States.
    (b) Definitions--(1) Cattle materials prohibited in animal feed 
include:
    (i) The entire carcass of BSE-positive cattle;
    (ii) The brains and spinal cords of cattle 30 months of age and 
older;
    (iii) The entire carcass of cattle not inspected and passed for 
human consumption as defined in paragraph (b)(2) of this section that 
are 30 months of age or older from which brains and spinal cords were 
not effectively removed or otherwise effectively excluded from animal 
feed;
    (iv) Mechanically separated beef as defined in paragraph (b)(3) of 
this section that is derived from materials specified in paragraphs 
(b)(1)(i), (b)(1)(ii), and (b)(1)(iii) of this section; and
    (v) Tallow as defined in paragraph (b)(5) of this section that is 
derived from materials specified in paragraphs (b)(1)(i), (b)(1)(ii), 
and (b)(1)(iii) of this section.
    (vi) Cattle materials prohibited in animal feed do not include:
    (A) Tallow derivatives as defined in paragraph (b)(6) of this 
section;
    (B) Tallow as defined in paragraph (b)(5) of this section that is 
derived from materials specified in paragraphs (b)(1)(ii) and 
(b)(1)(iii) of this section and that contains no more than 0.15 percent 
insoluble impurities. Insoluble impurities must be measured by the 
method entitled ``Insoluble Impurities'' (AOCS Method Ca 3a-46), 
American Oil Chemists' Society (AOCS), 5th Edition, 1997, incorporated 
by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51, or 
another method equivalent in accuracy, precision, and sensitivity to 
AOCS Official Method Ca 3a-46. You may obtain copies of the method from 
the AOCS (http://www.aocs.org), 2211 W. Bradley Ave., Champaign, IL 
61821. Copies may be examined at the Center for Food Safety and Applied 
Nutrition's Library, 5100 Paint Branch Pkwy., College Park, MD 20740, or 
at the National Archives and Records Administration (NARA). For 
information on the availability of this material at NARA, call 202-741-
6030, or go to: http://www.archives.gov/federal--register/code--of--
federal--regulations/ibr--locations.html.

[[Page 585]]

    (C) Materials as defined in paragraphs (b)(1)(ii), (b)(1)(iii), 
(b)(1)(iv) (other than mechanically separated beef from the carcass of a 
BSE-positive cattle), and (b)(1)(v) of this section from cattle from a 
country that has been designated under paragraph (f) of this section.
    (2) Cattle not inspected and passed for human consumption means 
cattle that did not pass antemortem inspection by the appropriate 
regulatory authority. This term includes nonambulatory disabled cattle. 
Nonambulatory disabled cattle are cattle that cannot rise from a 
recumbent position or that cannot walk, including, but not limited to, 
those with broken appendages, severed tendons or ligaments, nerve 
paralysis, fractured vertebral column, or metabolic conditions.
    (3) Mechanically separated beef means a finely comminuted meat food 
product, resulting from the mechanical separation and removal of most of 
the bone from attached skeletal muscle of cattle carcasses and parts of 
carcasses.
    (4) Renderer means any firm or individual that processes slaughter 
byproducts, animals unfit for human consumption, or meat scraps. The 
term includes persons who collect such materials and subject them to 
minimal processing, or distribute them to firms other than renderers (as 
defined in this paragraph) whose intended use for the products may 
include animal feed, industrial use, or other uses. The term includes 
renderers that also blend animal protein products.
    (5) Tallow means the rendered fat of cattle obtained by pressing or 
by applying any other extraction process to tissues derived directly 
from discrete adipose tissue masses or to other carcass parts and 
tissues.
    (6) Tallow derivative means any product obtained through initial 
hydrolysis, saponification, or trans-esterification of tallow; chemical 
conversion of material obtained by hydrolysis, saponification, or trans-
esterification may be applied to obtain the desired product.
    (c) Requirements. (1) No animal feed or feed ingredient shall be 
manufactured from, processed with, or otherwise contain, cattle 
materials prohibited in animal feed as defined in paragraph (b)(1) of 
this section.
    (2) Renderers that receive, manufacture, process, blend, or 
distribute cattle materials prohibited in animal feed as defined in 
paragraph (b)(1) of this section, or products that contain or may 
contain cattle materials prohibited in animal feed, shall take the 
following measures to ensure that materials prohibited as defined in 
paragraph (b)(1) of this section are not introduced into animal feed:
    (i) Exclude from use in animal feed the entire carcass of cattle not 
inspected and passed for human consumption as defined in paragraph 
(b)(2) of this section if:
    (A) The brain and spinal cord are not effectively removed from such 
cattle or the brain and spinal cord from such cattle are not otherwise 
effectively excluded from animal feed; and
    (B) Such cattle are 30 months of age or older.
    (ii) If renderers remove brain and spinal cord from cattle not 
inspected and passed for human consumption, or separate such animals 
based on whether or not they are 30 months of age or older, renderers 
must maintain adequate written procedures specifying how these processes 
are carried out.
    (iii) Once cattle materials prohibited in animal feed have been 
separated from other cattle materials, provide for measures to avoid 
cross-contamination;
    (A) Use separate equipment while handling cattle materials 
prohibited in animal feed; or
    (B) Use separate containers that adequately prevent contact with 
animal feed, animal feed ingredients, or equipment surfaces;
    (iv) Label the cattle materials prohibited in animal feed and 
products that contain or may contain cattle materials prohibited in 
animal feed in a conspicuous manner as follows: ``Do not feed to 
animals'';
    (v) Mark the cattle materials prohibited in animal feed and products 
that contain or may contain cattle materials prohibited in animal feed 
with an agent that can be readily detected on visual inspection; and
    (vi) Establish and maintain records sufficient to track cattle 
materials

[[Page 586]]

prohibited in animal feed to ensure such material is not introduced into 
animal feed, and make the records available for inspection and copying 
by the Food and Drug Administration.
    (3) Renderers that receive, manufacture, process, blend, or 
distribute any cattle materials shall take the following measures to 
ensure that materials prohibited as defined in paragraph (b)(1) of this 
section are not used in animal feed:
    (i) Establish and maintain records sufficient to demonstrate that 
material rendered for use in animal feed was not manufactured from, 
processed with, or does not otherwise contain, cattle materials 
prohibited in animal feed and make copies of all records available for 
inspection and copying by the Food and Drug Administration. With respect 
to cattle materials obtained from establishments which have segregated 
cattle materials prohibited in animal feed, such records must 
demonstrate that establishments supplying cattle materials to the 
renderers have adequate procedures in place to effectively exclude 
cattle materials prohibited in animal feed; and these records shall be 
considered sufficient to meet this requirement if they include either:
    (A) Certification or other documentation from the supplier that 
material supplied to the renderer does not include cattle materials 
prohibited in animal feed; such certification or documentation is 
acceptable, provided that it includes a description of the segregation 
procedures used, documentation that the supplier confirms that its 
segregation procedures are in place prior to supplying any cattle 
material to the renderer, and records of the renderer's periodic review 
of the suppliers' certification or other documentation; or
    (B) Documentation of another method acceptable to FDA, such as 
third-party certification, for verifying that suppliers have effectively 
excluded cattle materials prohibited in animal feed.
    (ii) Comply with all applicable requirements under Sec. 589.2000 
regarding animal proteins prohibited in ruminant feed.
    (d) Adulteration and misbranding. (1) Failure of a renderer to 
comply with the requirements in paragraphs (c)(2)(i) through 
(c)(2)(iii), (c)(2)(v) and (c)(2)(vi), or (c)(3)(i) of this section will 
render the animal feed or feed ingredients adulterated under section 
402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the act).
    (2) Animal feed or feed ingredients that are not in compliance with 
paragraph (c)(1) of this section are adulterated under section 
402(a)(2), 402(a)(3), or 402(a)(5) of the act.
    (3) Animal feed or feed ingredients that are not in compliance with 
the labeling requirements of paragraph (c)(2)(iv) of this section are 
misbranded under section 403(a)(1) or 403(f) of the act.
    (4) Failure of a renderer to comply with the requirements in 
paragraph (e) of this section will render the animal feed or feed 
ingredients adulterated under section 402(a)(4) of the act.
    (e) Inspection; records retention. Records required to be made 
available for inspection and copying by the Food and Drug 
Administration, as required by this section, shall be kept for a minimum 
of 1 year.
    (f) Process for designating countries. A country seeking designation 
must send a written request to the Director, Office of the Center 
Director, Center for Veterinary Medicine, at the address designated in 
Sec. 5.1100 of this chapter. The request shall include information 
about that country's BSE case history, risk factors, measures to prevent 
the introduction and transmission of BSE, and any other information 
relevant to determining whether the cattle materials from the requesting 
country do or do not meet the definitions set forth in paragraph (b)(1) 
of this section. FDA shall respond in writing to any such request and 
may impose conditions in granting any such request. Any grant by FDA of 
such a request under this paragraph will be subject to future review by 
FDA and may be revoked if FDA determines that the granted request is no 
longer appropriate.

[73 FR 22756, Apr. 25, 2008]

                        PARTS 590	599 [RESERVED]

[[Page 587]]



                              FINDING AIDS




  --------------------------------------------------------------------

  A list of CFR titles, subtitles, chapters, subchapters and parts and 
an alphabetical list of agencies publishing in the CFR are included in 
the CFR Index and Finding Aids volume to the Code of Federal Regulations 
which is published separately and revised annually.

  Table of CFR Titles and Chapters
  Alphabetical List of Agencies Appearing in the CFR
  List of CFR Sections Affected

[[Page 589]]



                    Table of CFR Titles and Chapters




                      (Revised as of April 1, 2013)

                      Title 1--General Provisions

 Chapter I  Administrative Committee of the Federal Register 
                (Parts 1--49)
Chapter II  Office of the Federal Register (Parts 50--299)
  Chapter 
       III  Administrative Conference of the United States (Parts 
                300--399)
Chapter IV  Miscellaneous Agencies (Parts 400--500)

                    Title 2--Grants and Agreements

            Subtitle A--Office of Management and Budget Guidance 
                for Grants and Agreements
 Chapter I  Office of Management and Budget Governmentwide 
                Guidance for Grants and Agreements (Parts 2--199)
Chapter II  Office of Management and Budget Circulars and Guidance 
                (200--299)
            Subtitle B--Federal Agency Regulations for Grants and 
                Agreements
  Chapter 
       III  Department of Health and Human Services (Parts 300-- 
                399)
Chapter IV  Department of Agriculture (Parts 400--499)
Chapter VI  Department of State (Parts 600--699)
  Chapter 
       VII  Agency for International Development (Parts 700--799)
  Chapter 
      VIII  Department of Veterans Affairs (Parts 800--899)
Chapter IX  Department of Energy (Parts 900--999)
Chapter XI  Department of Defense (Parts 1100--1199)
  Chapter 
       XII  Department of Transportation (Parts 1200--1299)
  Chapter 
      XIII  Department of Commerce (Parts 1300--1399)
  Chapter 
       XIV  Department of the Interior (Parts 1400--1499)
Chapter XV  Environmental Protection Agency (Parts 1500--1599)
  Chapter 
     XVIII  National Aeronautics and Space Administration (Parts 
                1800--1899)
Chapter XX  United States Nuclear Regulatory Commission (Parts 
                2000--2099)
  Chapter 
      XXII  Corporation for National and Community Service (Parts 
                2200--2299)
  Chapter 
     XXIII  Social Security Administration (Parts 2300--2399)
  Chapter 
      XXIV  Housing and Urban Development (Parts 2400--2499)
  Chapter 
       XXV  National Science Foundation (Parts 2500--2599)
  Chapter 
      XXVI  National Archives and Records Administration (Parts 
                2600--2699)

[[Page 590]]

  Chapter 
     XXVII  Small Business Administration (Parts 2700--2799)
  Chapter 
    XXVIII  Department of Justice (Parts 2800--2899)
  Chapter 
       XXX  Department of Homeland Security (Parts 3000--3099)
  Chapter 
      XXXI  Institute of Museum and Library Services (Parts 3100--
                3199)
  Chapter 
     XXXII  National Endowment for the Arts (Parts 3200--3299)
  Chapter 
    XXXIII  National Endowment for the Humanities (Parts 3300--
                3399)
  Chapter 
     XXXIV  Department of Education (Parts 3400--3499)
  Chapter 
      XXXV  Export-Import Bank of the United States (Parts 3500--
                3599)
  Chapter 
    XXXVII  Peace Corps (Parts 3700--3799)
  Chapter 
     LVIII  Election Assistance Commission (Parts 5800--5899)

                        Title 3--The President

 Chapter I  Executive Office of the President (Parts 100--199)

                           Title 4--Accounts

 Chapter I  Government Accountability Office (Parts 1--199)
Chapter II  Recovery Accountability and Transparency Board (Parts 
                200--299)

                   Title 5--Administrative Personnel

 Chapter I  Office of Personnel Management (Parts 1--1199)
Chapter II  Merit Systems Protection Board (Parts 1200--1299)
  Chapter 
       III  Office of Management and Budget (Parts 1300--1399)
 Chapter V  The International Organizations Employees Loyalty 
                Board (Parts 1500--1599)
Chapter VI  Federal Retirement Thrift Investment Board (Parts 
                1600--1699)
  Chapter 
      VIII  Office of Special Counsel (Parts 1800--1899)
Chapter IX  Appalachian Regional Commission (Parts 1900--1999)
Chapter XI  Armed Forces Retirement Home (Parts 2100--2199)
  Chapter 
       XIV  Federal Labor Relations Authority, General Counsel of 
                the Federal Labor Relations Authority and Federal 
                Service Impasses Panel (Parts 2400--2499)
Chapter XV  Office of Administration, Executive Office of the 
                President (Parts 2500--2599)
  Chapter 
       XVI  Office of Government Ethics (Parts 2600--2699)
  Chapter 
       XXI  Department of the Treasury (Parts 3100--3199)
  Chapter 
      XXII  Federal Deposit Insurance Corporation (Parts 3200--
                3299)

[[Page 591]]

  Chapter 
     XXIII  Department of Energy (Parts 3300--3399)
  Chapter 
      XXIV  Federal Energy Regulatory Commission (Parts 3400--
                3499)
  Chapter 
       XXV  Department of the Interior (Parts 3500--3599)
  Chapter 
      XXVI  Department of Defense (Parts 3600-- 3699)
  Chapter 
    XXVIII  Department of Justice (Parts 3800--3899)
  Chapter 
      XXIX  Federal Communications Commission (Parts 3900--3999)
  Chapter 
       XXX  Farm Credit System Insurance Corporation (Parts 4000--
                4099)
  Chapter 
      XXXI  Farm Credit Administration (Parts 4100--4199)
  Chapter 
    XXXIII  Overseas Private Investment Corporation (Parts 4300--
                4399)
  Chapter 
     XXXIV  Securities and Exchange Commission (Parts 4400--4499)
  Chapter 
      XXXV  Office of Personnel Management (Parts 4500--4599)
  Chapter 
    XXXVII  Federal Election Commission (Parts 4700--4799)
Chapter XL  Interstate Commerce Commission (Parts 5000--5099)
  Chapter 
       XLI  Commodity Futures Trading Commission (Parts 5100--
                5199)
  Chapter 
      XLII  Department of Labor (Parts 5200--5299)
  Chapter 
     XLIII  National Science Foundation (Parts 5300--5399)
  Chapter 
       XLV  Department of Health and Human Services (Parts 5500--
                5599)
  Chapter 
      XLVI  Postal Rate Commission (Parts 5600--5699)
  Chapter 
     XLVII  Federal Trade Commission (Parts 5700--5799)
  Chapter 
    XLVIII  Nuclear Regulatory Commission (Parts 5800--5899)
  Chapter 
      XLIX  Federal Labor Relations Authority (Parts 5900--5999)
 Chapter L  Department of Transportation (Parts 6000--6099)
  Chapter 
       LII  Export-Import Bank of the United States (Parts 6200--
                6299)
  Chapter 
      LIII  Department of Education (Parts 6300--6399)
  Chapter 
       LIV  Environmental Protection Agency (Parts 6400--6499)
Chapter LV  National Endowment for the Arts (Parts 6500--6599)
  Chapter 
       LVI  National Endowment for the Humanities (Parts 6600--
                6699)
  Chapter 
      LVII  General Services Administration (Parts 6700--6799)
  Chapter 
     LVIII  Board of Governors of the Federal Reserve System 
                (Parts 6800--6899)
  Chapter 
       LIX  National Aeronautics and Space Administration (Parts 
                6900--6999)
Chapter LX  United States Postal Service (Parts 7000--7099)
  Chapter 
       LXI  National Labor Relations Board (Parts 7100--7199)
  Chapter 
      LXII  Equal Employment Opportunity Commission (Parts 7200--
                7299)
  Chapter 
     LXIII  Inter-American Foundation (Parts 7300--7399)
  Chapter 
      LXIV  Merit Systems Protection Board (Parts 7400--7499)
  Chapter 
       LXV  Department of Housing and Urban Development (Parts 
                7500--7599)

[[Page 592]]

  Chapter 
      LXVI  National Archives and Records Administration (Parts 
                7600--7699)
  Chapter 
     LXVII  Institute of Museum and Library Services (Parts 7700--
                7799)
  Chapter 
    LXVIII  Commission on Civil Rights (Parts 7800--7899)
  Chapter 
      LXIX  Tennessee Valley Authority (Parts 7900--7999)
  Chapter 
       LXX  Court Services and Offender Supervision Agency for the 
                District of Columbia (Parts 8000--8099)
  Chapter 
      LXXI  Consumer Product Safety Commission (Parts 8100--8199)
  Chapter 
    LXXIII  Department of Agriculture (Parts 8300--8399)
  Chapter 
     LXXIV  Federal Mine Safety and Health Review Commission 
                (Parts 8400--8499)
  Chapter 
     LXXVI  Federal Retirement Thrift Investment Board (Parts 
                8600--8699)
  Chapter 
    LXXVII  Office of Management and Budget (Parts 8700--8799)
  Chapter 
      LXXX  Federal Housing Finance Agency (Parts 9000--9099)
  Chapter 
    LXXXII  Special Inspector General for Iraq Reconstruction 
                (Parts 9200--9299)
  Chapter 
   LXXXIII  Special Inspector General for Afghanistan 
                Reconstruction (Parts 9300--9399)
  Chapter 
    LXXXIV  Bureau of Consumer Financial Protection (Parts 9400--
                9499)
  Chapter 
     XCVII  Department of Homeland Security Human Resources 
                Management System (Department of Homeland 
                Security--Office of Personnel Management) (Parts 
                9700--9799)
  Chapter 
     XCVII  Council of the Inspectors General on Integrity and 
                Efficiency (Parts 9800--9899)

                      Title 6--Domestic Security

 Chapter I  Department of Homeland Security, Office of the 
                Secretary (Parts 1--99)

                         Title 7--Agriculture

            Subtitle A--Office of the Secretary of Agriculture 
                (Parts 0--26)
            Subtitle B--Regulations of the Department of 
                Agriculture
 Chapter I  Agricultural Marketing Service (Standards, 
                Inspections, Marketing Practices), Department of 
                Agriculture (Parts 27--209)
Chapter II  Food and Nutrition Service, Department of Agriculture 
                (Parts 210--299)
  Chapter 
       III  Animal and Plant Health Inspection Service, Department 
                of Agriculture (Parts 300--399)
Chapter IV  Federal Crop Insurance Corporation, Department of 
                Agriculture (Parts 400--499)

[[Page 593]]

 Chapter V  Agricultural Research Service, Department of 
                Agriculture (Parts 500--599)
Chapter VI  Natural Resources Conservation Service, Department of 
                Agriculture (Parts 600--699)
  Chapter 
       VII  Farm Service Agency, Department of Agriculture (Parts 
                700--799)
  Chapter 
      VIII  Grain Inspection, Packers and Stockyards 
                Administration (Federal Grain Inspection Service), 
                Department of Agriculture (Parts 800--899)
Chapter IX  Agricultural Marketing Service (Marketing Agreements 
                and Orders; Fruits, Vegetables, Nuts), Department 
                of Agriculture (Parts 900--999)
 Chapter X  Agricultural Marketing Service (Marketing Agreements 
                and Orders; Milk), Department of Agriculture 
                (Parts 1000--1199)
Chapter XI  Agricultural Marketing Service (Marketing Agreements 
                and Orders; Miscellaneous Commodities), Department 
                of Agriculture (Parts 1200--1299)
  Chapter 
       XIV  Commodity Credit Corporation, Department of 
                Agriculture (Parts 1400--1499)
Chapter XV  Foreign Agricultural Service, Department of 
                Agriculture (Parts 1500--1599)
  Chapter 
       XVI  Rural Telephone Bank, Department of Agriculture (Parts 
                1600--1699)
  Chapter 
      XVII  Rural Utilities Service, Department of Agriculture 
                (Parts 1700--1799)
  Chapter 
     XVIII  Rural Housing Service, Rural Business-Cooperative 
                Service, Rural Utilities Service, and Farm Service 
                Agency, Department of Agriculture (Parts 1800--
                2099)
Chapter XX  Local Television Loan Guarantee Board (Parts 2200--
                2299)
  Chapter 
       XXV  Office of Advocacy and Outreach, Department of 
                Agriculture (Parts 2500--2599)
  Chapter 
      XXVI  Office of Inspector General, Department of Agriculture 
                (Parts 2600--2699)
  Chapter 
     XXVII  Office of Information Resources Management, Department 
                of Agriculture (Parts 2700--2799)
  Chapter 
    XXVIII  Office of Operations, Department of Agriculture (Parts 
                2800--2899)
  Chapter 
      XXIX  Office of Energy Policy and New Uses, Department of 
                Agriculture (Parts 2900--2999)
  Chapter 
       XXX  Office of the Chief Financial Officer, Department of 
                Agriculture (Parts 3000--3099)
  Chapter 
      XXXI  Office of Environmental Quality, Department of 
                Agriculture (Parts 3100--3199)
  Chapter 
     XXXII  Office of Procurement and Property Management, 
                Department of Agriculture (Parts 3200--3299)
  Chapter 
    XXXIII  Office of Transportation, Department of Agriculture 
                (Parts 3300--3399)
  Chapter 
     XXXIV  National Institute of Food and Agriculture (Parts 
                3400--3499)
  Chapter 
      XXXV  Rural Housing Service, Department of Agriculture 
                (Parts 3500--3599)

[[Page 594]]

  Chapter 
     XXXVI  National Agricultural Statistics Service, Department 
                of Agriculture (Parts 3600--3699)
  Chapter 
    XXXVII  Economic Research Service, Department of Agriculture 
                (Parts 3700--3799)
  Chapter 
   XXXVIII  World Agricultural Outlook Board, Department of 
                Agriculture (Parts 3800--3899)
  Chapter 
       XLI  [Reserved]
  Chapter 
      XLII  Rural Business-Cooperative Service and Rural Utilities 
                Service, Department of Agriculture (Parts 4200--
                4299)

                    Title 8--Aliens and Nationality

 Chapter I  Department of Homeland Security (Immigration and 
                Naturalization) (Parts 1--499)
 Chapter V  Executive Office for Immigration Review, Department of 
                Justice (Parts 1000--1399)

                 Title 9--Animals and Animal Products

 Chapter I  Animal and Plant Health Inspection Service, Department 
                of Agriculture (Parts 1--199)
Chapter II  Grain Inspection, Packers and Stockyards 
                Administration (Packers and Stockyards Programs), 
                Department of Agriculture (Parts 200--299)
  Chapter 
       III  Food Safety and Inspection Service, Department of 
                Agriculture (Parts 300--599)

                           Title 10--Energy

 Chapter I  Nuclear Regulatory Commission (Parts 0--199)
Chapter II  Department of Energy (Parts 200--699)
  Chapter 
       III  Department of Energy (Parts 700--999)
 Chapter X  Department of Energy (General Provisions) (Parts 
                1000--1099)
  Chapter 
      XIII  Nuclear Waste Technical Review Board (Parts 1300--
                1399)
  Chapter 
      XVII  Defense Nuclear Facilities Safety Board (Parts 1700--
                1799)
  Chapter 
     XVIII  Northeast Interstate Low-Level Radioactive Waste 
                Commission (Parts 1800--1899)

                      Title 11--Federal Elections

 Chapter I  Federal Election Commission (Parts 1--9099)
Chapter II  Election Assistance Commission (Parts 9400--9499)

                      Title 12--Banks and Banking

 Chapter I  Comptroller of the Currency, Department of the 
                Treasury (Parts 1--199)
Chapter II  Federal Reserve System (Parts 200--299)
  Chapter 
       III  Federal Deposit Insurance Corporation (Parts 300--399)

[[Page 595]]

Chapter IV  Export-Import Bank of the United States (Parts 400--
                499)
 Chapter V  Office of Thrift Supervision, Department of the 
                Treasury (Parts 500--599)
Chapter VI  Farm Credit Administration (Parts 600--699)
  Chapter 
       VII  National Credit Union Administration (Parts 700--799)
  Chapter 
      VIII  Federal Financing Bank (Parts 800--899)
Chapter IX  Federal Housing Finance Board (Parts 900--999)
 Chapter X  Bureau of Consumer Financial Protection (Parts 1000--
                1099)
Chapter XI  Federal Financial Institutions Examination Council 
                (Parts 1100--1199)
  Chapter 
       XII  Federal Housing Finance Agency (Parts 1200--1299)
  Chapter 
      XIII  Financial Stability Oversight Council (Parts 1300--
                1399)
  Chapter 
       XIV  Farm Credit System Insurance Corporation (Parts 1400--
                1499)
Chapter XV  Department of the Treasury (Parts 1500--1599)
  Chapter 
       XVI  Office of Financial Research (Parts 1600--1699)
  Chapter 
      XVII  Office of Federal Housing Enterprise Oversight, 
                Department of Housing and Urban Development (Parts 
                1700--1799)
  Chapter 
     XVIII  Community Development Financial Institutions Fund, 
                Department of the Treasury (Parts 1800--1899)

               Title 13--Business Credit and Assistance

 Chapter I  Small Business Administration (Parts 1--199)
  Chapter 
       III  Economic Development Administration, Department of 
                Commerce (Parts 300--399)
Chapter IV  Emergency Steel Guarantee Loan Board (Parts 400--499)
 Chapter V  Emergency Oil and Gas Guaranteed Loan Board (Parts 
                500--599)

                    Title 14--Aeronautics and Space

 Chapter I  Federal Aviation Administration, Department of 
                Transportation (Parts 1--199)
Chapter II  Office of the Secretary, Department of Transportation 
                (Aviation Proceedings) (Parts 200--399)
  Chapter 
       III  Commercial Space Transportation, Federal Aviation 
                Administration, Department of Transportation 
                (Parts 400--1199)
 Chapter V  National Aeronautics and Space Administration (Parts 
                1200--1299)
Chapter VI  Air Transportation System Stabilization (Parts 1300--
                1399)

                 Title 15--Commerce and Foreign Trade

            Subtitle A--Office of the Secretary of Commerce (Parts 
                0--29)
            Subtitle B--Regulations Relating to Commerce and 
                Foreign Trade
 Chapter I  Bureau of the Census, Department of Commerce (Parts 
                30--199)

[[Page 596]]

Chapter II  National Institute of Standards and Technology, 
                Department of Commerce (Parts 200--299)
  Chapter 
       III  International Trade Administration, Department of 
                Commerce (Parts 300--399)
Chapter IV  Foreign-Trade Zones Board, Department of Commerce 
                (Parts 400--499)
  Chapter 
       VII  Bureau of Industry and Security, Department of 
                Commerce (Parts 700--799)
  Chapter 
      VIII  Bureau of Economic Analysis, Department of Commerce 
                (Parts 800--899)
Chapter IX  National Oceanic and Atmospheric Administration, 
                Department of Commerce (Parts 900--999)
Chapter XI  Technology Administration, Department of Commerce 
                (Parts 1100--1199)
  Chapter 
      XIII  East-West Foreign Trade Board (Parts 1300--1399)
  Chapter 
       XIV  Minority Business Development Agency (Parts 1400--
                1499)
            Subtitle C--Regulations Relating to Foreign Trade 
                Agreements
Chapter XX  Office of the United States Trade Representative 
                (Parts 2000--2099)
            Subtitle D--Regulations Relating to Telecommunications 
                and Information
  Chapter 
     XXIII  National Telecommunications and Information 
                Administration, Department of Commerce (Parts 
                2300--2399)

                    Title 16--Commercial Practices

 Chapter I  Federal Trade Commission (Parts 0--999)
Chapter II  Consumer Product Safety Commission (Parts 1000--1799)

             Title 17--Commodity and Securities Exchanges

 Chapter I  Commodity Futures Trading Commission (Parts 1--199)
Chapter II  Securities and Exchange Commission (Parts 200--399)
Chapter IV  Department of the Treasury (Parts 400--499)

          Title 18--Conservation of Power and Water Resources

 Chapter I  Federal Energy Regulatory Commission, Department of 
                Energy (Parts 1--399)
  Chapter 
       III  Delaware River Basin Commission (Parts 400--499)
Chapter VI  Water Resources Council (Parts 700--799)
  Chapter 
      VIII  Susquehanna River Basin Commission (Parts 800--899)
  Chapter 
      XIII  Tennessee Valley Authority (Parts 1300--1399)

                       Title 19--Customs Duties

 Chapter I  U.S. Customs and Border Protection, Department of 
                Homeland Security; Department of the Treasury 
                (Parts 0--199)

[[Page 597]]

Chapter II  United States International Trade Commission (Parts 
                200--299)
  Chapter 
       III  International Trade Administration, Department of 
                Commerce (Parts 300--399)
Chapter IV  U.S. Immigration and Customs Enforcement, Department 
                of Homeland Security (Parts 400--599)

                     Title 20--Employees' Benefits

 Chapter I  Office of Workers' Compensation Programs, Department 
                of Labor (Parts 1--199)
Chapter II  Railroad Retirement Board (Parts 200--399)
  Chapter 
       III  Social Security Administration (Parts 400--499)
Chapter IV  Employees' Compensation Appeals Board, Department of 
                Labor (Parts 500--599)
 Chapter V  Employment and Training Administration, Department of 
                Labor (Parts 600--699)
Chapter VI  Office of Workers' Compensation Programs, Department 
                of Labor (Parts 700--799)
  Chapter 
       VII  Benefits Review Board, Department of Labor (Parts 
                800--899)
  Chapter 
      VIII  Joint Board for the Enrollment of Actuaries (Parts 
                900--999)
Chapter IX  Office of the Assistant Secretary for Veterans' 
                Employment and Training Service, Department of 
                Labor (Parts 1000--1099)

                       Title 21--Food and Drugs

 Chapter I  Food and Drug Administration, Department of Health and 
                Human Services (Parts 1--1299)
Chapter II  Drug Enforcement Administration, Department of Justice 
                (Parts 1300--1399)
  Chapter 
       III  Office of National Drug Control Policy (Parts 1400--
                1499)

                      Title 22--Foreign Relations

 Chapter I  Department of State (Parts 1--199)
Chapter II  Agency for International Development (Parts 200--299)
  Chapter 
       III  Peace Corps (Parts 300--399)
Chapter IV  International Joint Commission, United States and 
                Canada (Parts 400--499)
 Chapter V  Broadcasting Board of Governors (Parts 500--599)
  Chapter 
       VII  Overseas Private Investment Corporation (Parts 700--
                799)
Chapter IX  Foreign Service Grievance Board (Parts 900--999)
 Chapter X  Inter-American Foundation (Parts 1000--1099)
Chapter XI  International Boundary and Water Commission, United 
                States and Mexico, United States Section (Parts 
                1100--1199)
  Chapter 
       XII  United States International Development Cooperation 
                Agency (Parts 1200--1299)
  Chapter 
      XIII  Millennium Challenge Corporation (Parts 1300--1399)

[[Page 598]]

  Chapter 
       XIV  Foreign Service Labor Relations Board; Federal Labor 
                Relations Authority; General Counsel of the 
                Federal Labor Relations Authority; and the Foreign 
                Service Impasse Disputes Panel (Parts 1400--1499)
Chapter XV  African Development Foundation (Parts 1500--1599)
  Chapter 
       XVI  Japan-United States Friendship Commission (Parts 
                1600--1699)
  Chapter 
      XVII  United States Institute of Peace (Parts 1700--1799)

                          Title 23--Highways

 Chapter I  Federal Highway Administration, Department of 
                Transportation (Parts 1--999)
Chapter II  National Highway Traffic Safety Administration and 
                Federal Highway Administration, Department of 
                Transportation (Parts 1200--1299)
  Chapter 
       III  National Highway Traffic Safety Administration, 
                Department of Transportation (Parts 1300--1399)

                Title 24--Housing and Urban Development

            Subtitle A--Office of the Secretary, Department of 
                Housing and Urban Development (Parts 0--99)
            Subtitle B--Regulations Relating to Housing and Urban 
                Development
 Chapter I  Office of Assistant Secretary for Equal Opportunity, 
                Department of Housing and Urban Development (Parts 
                100--199)
Chapter II  Office of Assistant Secretary for Housing-Federal 
                Housing Commissioner, Department of Housing and 
                Urban Development (Parts 200--299)
  Chapter 
       III  Government National Mortgage Association, Department 
                of Housing and Urban Development (Parts 300--399)
Chapter IV  Office of Housing and Office of Multifamily Housing 
                Assistance Restructuring, Department of Housing 
                and Urban Development (Parts 400--499)
 Chapter V  Office of Assistant Secretary for Community Planning 
                and Development, Department of Housing and Urban 
                Development (Parts 500--599)
Chapter VI  Office of Assistant Secretary for Community Planning 
                and Development, Department of Housing and Urban 
                Development (Parts 600--699) [Reserved]
  Chapter 
       VII  Office of the Secretary, Department of Housing and 
                Urban Development (Housing Assistance Programs and 
                Public and Indian Housing Programs) (Parts 700--
                799)
  Chapter 
      VIII  Office of the Assistant Secretary for Housing--Federal 
                Housing Commissioner, Department of Housing and 
                Urban Development (Section 8 Housing Assistance 
                Programs, Section 202 Direct Loan Program, Section 
                202 Supportive Housing for the Elderly Program and 
                Section 811 Supportive Housing for Persons With 
                Disabilities Program) (Parts 800--899)
Chapter IX  Office of Assistant Secretary for Public and Indian 
                Housing, Department of Housing and Urban 
                Development (Parts 900--1699)

[[Page 599]]

 Chapter X  Office of Assistant Secretary for Housing--Federal 
                Housing Commissioner, Department of Housing and 
                Urban Development (Interstate Land Sales 
                Registration Program) (Parts 1700--1799)
  Chapter 
       XII  Office of Inspector General, Department of Housing and 
                Urban Development (Parts 2000--2099)
Chapter XV  Emergency Mortgage Insurance and Loan Programs, 
                Department of Housing and Urban Development (Parts 
                2700--2799)
Chapter XX  Office of Assistant Secretary for Housing--Federal 
                Housing Commissioner, Department of Housing and 
                Urban Development (Parts 3200--3899)
  Chapter 
      XXIV  Board of Directors of the HOPE for Homeowners Program 
                (Parts 4000--4099)
  Chapter 
       XXV  Neighborhood Reinvestment Corporation (Parts 4100--
                4199)

                           Title 25--Indians

 Chapter I  Bureau of Indian Affairs, Department of the Interior 
                (Parts 1--299)
Chapter II  Indian Arts and Crafts Board, Department of the 
                Interior (Parts 300--399)
  Chapter 
       III  National Indian Gaming Commission, Department of the 
                Interior (Parts 500--599)
Chapter IV  Office of Navajo and Hopi Indian Relocation (Parts 
                700--799)
 Chapter V  Bureau of Indian Affairs, Department of the Interior, 
                and Indian Health Service, Department of Health 
                and Human Services (Part 900)
Chapter VI  Office of the Assistant Secretary-Indian Affairs, 
                Department of the Interior (Parts 1000--1199)
  Chapter 
       VII  Office of the Special Trustee for American Indians, 
                Department of the Interior (Parts 1200--1299)

                      Title 26--Internal Revenue

 Chapter I  Internal Revenue Service, Department of the Treasury 
                (Parts 1--End)

           Title 27--Alcohol, Tobacco Products and Firearms

 Chapter I  Alcohol and Tobacco Tax and Trade Bureau, Department 
                of the Treasury (Parts 1--399)
Chapter II  Bureau of Alcohol, Tobacco, Firearms, and Explosives, 
                Department of Justice (Parts 400--699)

                   Title 28--Judicial Administration

 Chapter I  Department of Justice (Parts 0--299)
  Chapter 
       III  Federal Prison Industries, Inc., Department of Justice 
                (Parts 300--399)
 Chapter V  Bureau of Prisons, Department of Justice (Parts 500--
                599)

[[Page 600]]

Chapter VI  Offices of Independent Counsel, Department of Justice 
                (Parts 600--699)
  Chapter 
       VII  Office of Independent Counsel (Parts 700--799)
  Chapter 
      VIII  Court Services and Offender Supervision Agency for the 
                District of Columbia (Parts 800--899)
Chapter IX  National Crime Prevention and Privacy Compact Council 
                (Parts 900--999)
Chapter XI  Department of Justice and Department of State (Parts 
                1100--1199)

                            Title 29--Labor

            Subtitle A--Office of the Secretary of Labor (Parts 
                0--99)
            Subtitle B--Regulations Relating to Labor
 Chapter I  National Labor Relations Board (Parts 100--199)
Chapter II  Office of Labor-Management Standards, Department of 
                Labor (Parts 200--299)
  Chapter 
       III  National Railroad Adjustment Board (Parts 300--399)
Chapter IV  Office of Labor-Management Standards, Department of 
                Labor (Parts 400--499)
 Chapter V  Wage and Hour Division, Department of Labor (Parts 
                500--899)
Chapter IX  Construction Industry Collective Bargaining Commission 
                (Parts 900--999)
 Chapter X  National Mediation Board (Parts 1200--1299)
  Chapter 
       XII  Federal Mediation and Conciliation Service (Parts 
                1400--1499)
  Chapter 
       XIV  Equal Employment Opportunity Commission (Parts 1600--
                1699)
  Chapter 
      XVII  Occupational Safety and Health Administration, 
                Department of Labor (Parts 1900--1999)
Chapter XX  Occupational Safety and Health Review Commission 
                (Parts 2200--2499)
  Chapter 
       XXV  Employee Benefits Security Administration, Department 
                of Labor (Parts 2500--2599)
  Chapter 
     XXVII  Federal Mine Safety and Health Review Commission 
                (Parts 2700--2799)
Chapter XL  Pension Benefit Guaranty Corporation (Parts 4000--
                4999)

                      Title 30--Mineral Resources

 Chapter I  Mine Safety and Health Administration, Department of 
                Labor (Parts 1--199)
Chapter II  Bureau of Safety and Environmental Enforcement, 
                Department of the Interior (Parts 200--299)
Chapter IV  Geological Survey, Department of the Interior (Parts 
                400--499)
 Chapter V  Bureau of Ocean Energy Management, Department of the 
                Interior (Parts 500--599)
  Chapter 
       VII  Office of Surface Mining Reclamation and Enforcement, 
                Department of the Interior (Parts 700--999)
  Chapter 
       XII  Office of Natural Resources Revenue, Department of the 
                Interior (Parts 1200--1299)

[[Page 601]]

                 Title 31--Money and Finance: Treasury

            Subtitle A--Office of the Secretary of the Treasury 
                (Parts 0--50)
            Subtitle B--Regulations Relating to Money and Finance
 Chapter I  Monetary Offices, Department of the Treasury (Parts 
                51--199)
Chapter II  Fiscal Service, Department of the Treasury (Parts 
                200--399)
Chapter IV  Secret Service, Department of the Treasury (Parts 
                400--499)
 Chapter V  Office of Foreign Assets Control, Department of the 
                Treasury (Parts 500--599)
Chapter VI  Bureau of Engraving and Printing, Department of the 
                Treasury (Parts 600--699)
  Chapter 
       VII  Federal Law Enforcement Training Center, Department of 
                the Treasury (Parts 700--799)
  Chapter 
      VIII  Office of International Investment, Department of the 
                Treasury (Parts 800--899)
Chapter IX  Federal Claims Collection Standards (Department of the 
                Treasury--Department of Justice) (Parts 900--999)
 Chapter X  Financial Crimes Enforcement Network, Department of 
                the Treasury (Parts 1000--1099)

                      Title 32--National Defense

            Subtitle A--Department of Defense
 Chapter I  Office of the Secretary of Defense (Parts 1--399)
 Chapter V  Department of the Army (Parts 400--699)
Chapter VI  Department of the Navy (Parts 700--799)
  Chapter 
       VII  Department of the Air Force (Parts 800--1099)
            Subtitle B--Other Regulations Relating to National 
                Defense
  Chapter 
       XII  Defense Logistics Agency (Parts 1200--1299)
  Chapter 
       XVI  Selective Service System (Parts 1600--1699)
  Chapter 
      XVII  Office of the Director of National Intelligence (Parts 
                1700--1799)
  Chapter 
     XVIII  National Counterintelligence Center (Parts 1800--1899)
  Chapter 
       XIX  Central Intelligence Agency (Parts 1900--1999)
Chapter XX  Information Security Oversight Office, National 
                Archives and Records Administration (Parts 2000--
                2099)
  Chapter 
       XXI  National Security Council (Parts 2100--2199)
  Chapter 
      XXIV  Office of Science and Technology Policy (Parts 2400--
                2499)
  Chapter 
     XXVII  Office for Micronesian Status Negotiations (Parts 
                2700--2799)
  Chapter 
    XXVIII  Office of the Vice President of the United States 
                (Parts 2800--2899)

               Title 33--Navigation and Navigable Waters

 Chapter I  Coast Guard, Department of Homeland Security (Parts 
                1--199)
Chapter II  Corps of Engineers, Department of the Army (Parts 
                200--399)

[[Page 602]]

Chapter IV  Saint Lawrence Seaway Development Corporation, 
                Department of Transportation (Parts 400--499)

                          Title 34--Education

            Subtitle A--Office of the Secretary, Department of 
                Education (Parts 1--99)
            Subtitle B--Regulations of the Offices of the 
                Department of Education
 Chapter I  Office for Civil Rights, Department of Education 
                (Parts 100--199)
Chapter II  Office of Elementary and Secondary Education, 
                Department of Education (Parts 200--299)
  Chapter 
       III  Office of Special Education and Rehabilitative 
                Services, Department of Education (Parts 300--399)
Chapter IV  Office of Vocational and Adult Education, Department 
                of Education (Parts 400--499)
 Chapter V  Office of Bilingual Education and Minority Languages 
                Affairs, Department of Education (Parts 500--599)
Chapter VI  Office of Postsecondary Education, Department of 
                Education (Parts 600--699)
  Chapter 
       VII  Office of Educational Research and Improvement, 
                Department of Education (799--799) [Reserved]
Chapter XI  National Institute for Literacy (Parts 1100--1199)
            Subtitle C--Regulations Relating to Education
  Chapter 
       XII  National Council on Disability (Parts 1200--1299)

                          Title 35 [Reserved]

             Title 36--Parks, Forests, and Public Property

 Chapter I  National Park Service, Department of the Interior 
                (Parts 1--199)
Chapter II  Forest Service, Department of Agriculture (Parts 200--
                299)
  Chapter 
       III  Corps of Engineers, Department of the Army (Parts 
                300--399)
Chapter IV  American Battle Monuments Commission (Parts 400--499)
 Chapter V  Smithsonian Institution (Parts 500--599)
Chapter VI  [Reserved]
  Chapter 
       VII  Library of Congress (Parts 700--799)
  Chapter 
      VIII  Advisory Council on Historic Preservation (Parts 800--
                899)
Chapter IX  Pennsylvania Avenue Development Corporation (Parts 
                900--999)
 Chapter X  Presidio Trust (Parts 1000--1099)
Chapter XI  Architectural and Transportation Barriers Compliance 
                Board (Parts 1100--1199)
  Chapter 
       XII  National Archives and Records Administration (Parts 
                1200--1299)
Chapter XV  Oklahoma City National Memorial Trust (Parts 1500--
                1599)
  Chapter 
       XVI  Morris K. Udall Scholarship and Excellence in National 
                Environmental Policy Foundation (Parts 1600--1699)

[[Page 603]]

             Title 37--Patents, Trademarks, and Copyrights

 Chapter I  United States Patent and Trademark Office, Department 
                of Commerce (Parts 1--199)
Chapter II  Copyright Office, Library of Congress (Parts 200--299)
  Chapter 
       III  Copyright Royalty Board, Library of Congress (Parts 
                300--399)
Chapter IV  Assistant Secretary for Technology Policy, Department 
                of Commerce (Parts 400--599)

           Title 38--Pensions, Bonuses, and Veterans' Relief

 Chapter I  Department of Veterans Affairs (Parts 0--199)
Chapter II  Armed Forces Retirement Home (Parts 200--299)

                       Title 39--Postal Service

 Chapter I  United States Postal Service (Parts 1--999)
  Chapter 
       III  Postal Regulatory Commission (Parts 3000--3099)

                  Title 40--Protection of Environment

 Chapter I  Environmental Protection Agency (Parts 1--1099)
Chapter IV  Environmental Protection Agency and Department of 
                Justice (Parts 1400--1499)
 Chapter V  Council on Environmental Quality (Parts 1500--1599)
Chapter VI  Chemical Safety and Hazard Investigation Board (Parts 
                1600--1699)
  Chapter 
       VII  Environmental Protection Agency and Department of 
                Defense; Uniform National Discharge Standards for 
                Vessels of the Armed Forces (Parts 1700--1799)

          Title 41--Public Contracts and Property Management

            Subtitle A--Federal Procurement Regulations System 
                [Note]
            Subtitle B--Other Provisions Relating to Public 
                Contracts
Chapter 50  Public Contracts, Department of Labor (Parts 50-1--50-
                999)
Chapter 51  Committee for Purchase From People Who Are Blind or 
                Severely Disabled (Parts 51-1--51-99)
Chapter 60  Office of Federal Contract Compliance Programs, Equal 
                Employment Opportunity, Department of Labor (Parts 
                60-1--60-999)
Chapter 61  Office of the Assistant Secretary for Veterans' 
                Employment and Training Service, Department of 
                Labor (Parts 61-1--61-999)
 Chapters 
   62--100  [Reserved]
            Subtitle C--Federal Property Management Regulations 
                System
  Chapter 
       101  Federal Property Management Regulations (Parts 101-1--
                101-99)
  Chapter 
       102  Federal Management Regulation (Parts 102-1--102-299)
 Chapters 
       103  104 [Reserved]

[[Page 604]]

  Chapter 
       105  General Services Administration (Parts 105-1--105-999)
  Chapter 
       109  Department of Energy Property Management Regulations 
                (Parts 109-1--109-99)
  Chapter 
       114  Department of the Interior (Parts 114-1--114-99)
  Chapter 
       115  Environmental Protection Agency (Parts 115-1--115-99)
  Chapter 
       128  Department of Justice (Parts 128-1--128-99)
 Chapters 
  129--200  [Reserved]
            Subtitle D--Other Provisions Relating to Property 
                Management [Reserved]
            Subtitle E--Federal Information Resources Management 
                Regulations System [Reserved]
            Subtitle F--Federal Travel Regulation System
  Chapter 
       300  General (Parts 300-1--300-99)
  Chapter 
       301  Temporary Duty (TDY) Travel Allowances (Parts 301-1--
                301-99)
  Chapter 
       302  Relocation Allowances (Parts 302-1--302-99)
  Chapter 
       303  Payment of Expenses Connected with the Death of 
                Certain Employees (Part 303-1--303-99)
  Chapter 
       304  Payment of Travel Expenses from a Non-Federal Source 
                (Parts 304-1--304-99)

                        Title 42--Public Health

 Chapter I  Public Health Service, Department of Health and Human 
                Services (Parts 1--199)
Chapter IV  Centers for Medicare & Medicaid Services, Department 
                of Health and Human Services (Parts 400--599)
 Chapter V  Office of Inspector General-Health Care, Department of 
                Health and Human Services (Parts 1000--1999)

                   Title 43--Public Lands: Interior

            Subtitle A--Office of the Secretary of the Interior 
                (Parts 1--199)
            Subtitle B--Regulations Relating to Public Lands
 Chapter I  Bureau of Reclamation, Department of the Interior 
                (Parts 400--999)
Chapter II  Bureau of Land Management, Department of the Interior 
                (Parts 1000--9999)
  Chapter 
       III  Utah Reclamation Mitigation and Conservation 
                Commission (Parts 10000--10099)

             Title 44--Emergency Management and Assistance

 Chapter I  Federal Emergency Management Agency, Department of 
                Homeland Security (Parts 0--399)
Chapter IV  Department of Commerce and Department of 
                Transportation (Parts 400--499)

[[Page 605]]

                       Title 45--Public Welfare

            Subtitle A--Department of Health and Human Services 
                (Parts 1--199)158 I18[Reserved]
            Subtitle B--Regulations Relating to Public Welfare
Chapter II  Office of Family Assistance (Assistance Programs), 
                Administration for Children and Families, 
                Department of Health and Human Services (Parts 
                200--299)
  Chapter 
       III  Office of Child Support Enforcement (Child Support 
                Enforcement Program), Administration for Children 
                and Families, Department of Health and Human 
                Services (Parts 300--399)
Chapter IV  Office of Refugee Resettlement, Administration for 
                Children and Families, Department of Health and 
                Human Services (Parts 400--499)
 Chapter V  Foreign Claims Settlement Commission of the United 
                States, Department of Justice (Parts 500--599)
Chapter VI  National Science Foundation (Parts 600--699)
  Chapter 
       VII  Commission on Civil Rights (Parts 700--799)
  Chapter 
      VIII  Office of Personnel Management (Parts 800--899)
 Chapter X  Office of Community Services, Administration for 
                Children and Families, Department of Health and 
                Human Services (Parts 1000--1099)
Chapter XI  National Foundation on the Arts and the Humanities 
                (Parts 1100--1199)
  Chapter 
       XII  Corporation for National and Community Service (Parts 
                1200--1299)
  Chapter 
      XIII  Office of Human Development Services, Department of 
                Health and Human Services (Parts 1300--1399)
  Chapter 
       XVI  Legal Services Corporation (Parts 1600--1699)
  Chapter 
      XVII  National Commission on Libraries and Information 
                Science (Parts 1700--1799)
  Chapter 
     XVIII  Harry S. Truman Scholarship Foundation (Parts 1800--
                1899)
  Chapter 
       XXI  Commission on Fine Arts (Parts 2100--2199)
  Chapter 
     XXIII  Arctic Research Commission (Part 2301)
  Chapter 
      XXIV  James Madison Memorial Fellowship Foundation (Parts 
                2400--2499)
  Chapter 
       XXV  Corporation for National and Community Service (Parts 
                2500--2599)

                          Title 46--Shipping

 Chapter I  Coast Guard, Department of Homeland Security (Parts 
                1--199)
Chapter II  Maritime Administration, Department of Transportation 
                (Parts 200--399)
  Chapter 
       III  Coast Guard (Great Lakes Pilotage), Department of 
                Homeland Security (Parts 400--499)
Chapter IV  Federal Maritime Commission (Parts 500--599)

[[Page 606]]

                      Title 47--Telecommunication

 Chapter I  Federal Communications Commission (Parts 0--199)
Chapter II  Office of Science and Technology Policy and National 
                Security Council (Parts 200--299)
  Chapter 
       III  National Telecommunications and Information 
                Administration, Department of Commerce (Parts 
                300--399)
Chapter IV  National Telecommunications and Information 
                Administration, Department of Commerce, and 
                National Highway Traffic Safety Administration, 
                Department of Transportation (Parts 400--499)

           Title 48--Federal Acquisition Regulations System

 Chapter 1  Federal Acquisition Regulation (Parts 1--99)
 Chapter 2  Defense Acquisition Regulations System, Department of 
                Defense (Parts 200--299)
 Chapter 3  Health and Human Services (Parts 300--399)
 Chapter 4  Department of Agriculture (Parts 400--499)
 Chapter 5  General Services Administration (Parts 500--599)
 Chapter 6  Department of State (Parts 600--699)
 Chapter 7  Agency for International Development (Parts 700--799)
 Chapter 8  Department of Veterans Affairs (Parts 800--899)
 Chapter 9  Department of Energy (Parts 900--999)
Chapter 10  Department of the Treasury (Parts 1000--1099)
Chapter 12  Department of Transportation (Parts 1200--1299)
Chapter 13  Department of Commerce (Parts 1300--1399)
Chapter 14  Department of the Interior (Parts 1400--1499)
Chapter 15  Environmental Protection Agency (Parts 1500--1599)
Chapter 16  Office of Personnel Management, Federal Employees 
                Health Benefits Acquisition Regulation (Parts 
                1600--1699)
Chapter 17  Office of Personnel Management (Parts 1700--1799)
Chapter 18  National Aeronautics and Space Administration (Parts 
                1800--1899)
Chapter 19  Broadcasting Board of Governors (Parts 1900--1999)
Chapter 20  Nuclear Regulatory Commission (Parts 2000--2099)
Chapter 21  Office of Personnel Management, Federal Employees 
                Group Life Insurance Federal Acquisition 
                Regulation (Parts 2100--2199)
Chapter 23  Social Security Administration (Parts 2300--2399)
Chapter 24  Department of Housing and Urban Development (Parts 
                2400--2499)
Chapter 25  National Science Foundation (Parts 2500--2599)
Chapter 28  Department of Justice (Parts 2800--2899)
Chapter 29  Department of Labor (Parts 2900--2999)
Chapter 30  Department of Homeland Security, Homeland Security 
                Acquisition Regulation (HSAR) (Parts 3000--3099)
Chapter 34  Department of Education Acquisition Regulation (Parts 
                3400--3499)
Chapter 51  Department of the Army Acquisition Regulations (Parts 
                5100--5199)

[[Page 607]]

Chapter 52  Department of the Navy Acquisition Regulations (Parts 
                5200--5299)
Chapter 53  Department of the Air Force Federal Acquisition 
                Regulation Supplement (Parts 5300--5399) 
                [Reserved]
Chapter 54  Defense Logistics Agency, Department of Defense (Parts 
                5400--5499)
Chapter 57  African Development Foundation (Parts 5700--5799)
Chapter 61  Civilian Board of Contract Appeals, General Services 
                Administration (Parts 6100--6199)
Chapter 63  Department of Transportation Board of Contract Appeals 
                (Parts 6300--6399)
Chapter 99  Cost Accounting Standards Board, Office of Federal 
                Procurement Policy, Office of Management and 
                Budget (Parts 9900--9999)

                       Title 49--Transportation

            Subtitle A--Office of the Secretary of Transportation 
                (Parts 1--99)
            Subtitle B--Other Regulations Relating to 
                Transportation
 Chapter I  Pipeline and Hazardous Materials Safety 
                Administration, Department of Transportation 
                (Parts 100--199)
Chapter II  Federal Railroad Administration, Department of 
                Transportation (Parts 200--299)
  Chapter 
       III  Federal Motor Carrier Safety Administration, 
                Department of Transportation (Parts 300--399)
Chapter IV  Coast Guard, Department of Homeland Security (Parts 
                400--499)
 Chapter V  National Highway Traffic Safety Administration, 
                Department of Transportation (Parts 500--599)
Chapter VI  Federal Transit Administration, Department of 
                Transportation (Parts 600--699)
  Chapter 
       VII  National Railroad Passenger Corporation (AMTRAK) 
                (Parts 700--799)
  Chapter 
      VIII  National Transportation Safety Board (Parts 800--999)
 Chapter X  Surface Transportation Board, Department of 
                Transportation (Parts 1000--1399)
Chapter XI  Research and Innovative Technology Administration, 
                Department of Transportation (Parts 1400--1499) 
                [Reserved]
  Chapter 
       XII  Transportation Security Administration, Department of 
                Homeland Security (Parts 1500--1699)

                   Title 50--Wildlife and Fisheries

 Chapter I  United States Fish and Wildlife Service, Department of 
                the Interior (Parts 1--199)
Chapter II  National Marine Fisheries Service, National Oceanic 
                and Atmospheric Administration, Department of 
                Commerce (Parts 200--299)
  Chapter 
       III  International Fishing and Related Activities (Parts 
                300--399)

[[Page 608]]

Chapter IV  Joint Regulations (United States Fish and Wildlife 
                Service, Department of the Interior and National 
                Marine Fisheries Service, National Oceanic and 
                Atmospheric Administration, Department of 
                Commerce); Endangered Species Committee 
                Regulations (Parts 400--499)
 Chapter V  Marine Mammal Commission (Parts 500--599)
Chapter VI  Fishery Conservation and Management, National Oceanic 
                and Atmospheric Administration, Department of 
                Commerce (Parts 600--699)

[[Page 609]]





           Alphabetical List of Agencies Appearing in the CFR




                      (Revised as of April 1, 2013)

                                                  CFR Title, Subtitle or 
                     Agency                               Chapter

Administrative Committee of the Federal Register  1, I
Administrative Conference of the United States    1, III
Advisory Council on Historic Preservation         36, VIII
Advocacy and Outreach, Office of                  7, XXV
Afghanistan Reconstruction, Special Inspector     22, LXXXIII
     General for
African Development Foundation                    22, XV
  Federal Acquisition Regulation                  48, 57
Agency for International Development              2, VII; 22, II
  Federal Acquisition Regulation                  48, 7
Agricultural Marketing Service                    7, I, IX, X, XI
Agricultural Research Service                     7, V
Agriculture Department                            2, IV; 5, LXXIII
  Advocacy and Outreach, Office of                7, XXV
  Agricultural Marketing Service                  7, I, IX, X, XI
  Agricultural Research Service                   7, V
  Animal and Plant Health Inspection Service      7, III; 9, I
  Chief Financial Officer, Office of              7, XXX
  Commodity Credit Corporation                    7, XIV
  Economic Research Service                       7, XXXVII
  Energy Policy and New Uses, Office of           2, IX; 7, XXIX
  Environmental Quality, Office of                7, XXXI
  Farm Service Agency                             7, VII, XVIII
  Federal Acquisition Regulation                  48, 4
  Federal Crop Insurance Corporation              7, IV
  Food and Nutrition Service                      7, II
  Food Safety and Inspection Service              9, III
  Foreign Agricultural Service                    7, XV
  Forest Service                                  36, II
  Grain Inspection, Packers and Stockyards        7, VIII; 9, II
       Administration
  Information Resources Management, Office of     7, XXVII
  Inspector General, Office of                    7, XXVI
  National Agricultural Library                   7, XLI
  National Agricultural Statistics Service        7, XXXVI
  National Institute of Food and Agriculture      7, XXXIV
  Natural Resources Conservation Service          7, VI
  Operations, Office of                           7, XXVIII
  Procurement and Property Management, Office of  7, XXXII
  Rural Business-Cooperative Service              7, XVIII, XLII, L
  Rural Development Administration                7, XLII
  Rural Housing Service                           7, XVIII, XXXV, L
  Rural Telephone Bank                            7, XVI
  Rural Utilities Service                         7, XVII, XVIII, XLII, L
  Secretary of Agriculture, Office of             7, Subtitle A
  Transportation, Office of                       7, XXXIII
  World Agricultural Outlook Board                7, XXXVIII
Air Force Department                              32, VII
  Federal Acquisition Regulation Supplement       48, 53
Air Transportation Stabilization Board            14, VI
Alcohol and Tobacco Tax and Trade Bureau          27, I
Alcohol, Tobacco, Firearms, and Explosives,       27, II
     Bureau of
AMTRAK                                            49, VII
American Battle Monuments Commission              36, IV
American Indians, Office of the Special Trustee   25, VII

[[Page 610]]

Animal and Plant Health Inspection Service        7, III; 9, I
Appalachian Regional Commission                   5, IX
Architectural and Transportation Barriers         36, XI
     Compliance Board
Arctic Research Commission                        45, XXIII
Armed Forces Retirement Home                      5, XI
Army Department                                   32, V
  Engineers, Corps of                             33, II; 36, III
  Federal Acquisition Regulation                  48, 51
Bilingual Education and Minority Languages        34, V
     Affairs, Office of
Blind or Severely Disabled, Committee for         41, 51
     Purchase from People Who Are
Broadcasting Board of Governors                   22, V
  Federal Acquisition Regulation                  48, 19
Bureau of Ocean Energy Management, Regulation,    30, II
     and Enforcement
Census Bureau                                     15, I
Centers for Medicare & Medicaid Services          42, IV
Central Intelligence Agency                       32, XIX
Chemical Safety and Hazardous Investigation       40, VI
     Board
Chief Financial Officer, Office of                7, XXX
Child Support Enforcement, Office of              45, III
Children and Families, Administration for         45, II, III, IV, X
Civil Rights, Commission on                       5, LXVIII; 45, VII
Civil Rights, Office for                          34, I
Council of the Inspectors General on Integrity    5, XCVIII
     and Efficiency
Court Services and Offender Supervision Agency    5, LXX
     for the District of Columbia
Coast Guard                                       33, I; 46, I; 49, IV
Coast Guard (Great Lakes Pilotage)                46, III
Commerce Department                               2, XIII; 44, IV; 50, VI
  Census Bureau                                   15, I
  Economic Analysis, Bureau of                    15, VIII
  Economic Development Administration             13, III
  Emergency Management and Assistance             44, IV
  Federal Acquisition Regulation                  48, 13
  Foreign-Trade Zones Board                       15, IV
  Industry and Security, Bureau of                15, VII
  International Trade Administration              15, III; 19, III
  National Institute of Standards and Technology  15, II
  National Marine Fisheries Service               50, II, IV
  National Oceanic and Atmospheric                15, IX; 50, II, III, IV, 
       Administration                             VI
  National Telecommunications and Information     15, XXIII; 47, III, IV
       Administration
  National Weather Service                        15, IX
  Patent and Trademark Office, United States      37, I
  Productivity, Technology and Innovation,        37, IV
       Assistant Secretary for
  Secretary of Commerce, Office of                15, Subtitle A
  Technology Administration                       15, XI
  Technology Policy, Assistant Secretary for      37, IV
Commercial Space Transportation                   14, III
Commodity Credit Corporation                      7, XIV
Commodity Futures Trading Commission              5, XLI; 17, I
Community Planning and Development, Office of     24, V, VI
     Assistant Secretary for
Community Services, Office of                     45, X
Comptroller of the Currency                       12, I
Construction Industry Collective Bargaining       29, IX
     Commission
Consumer Financial Protection Bureau              5, LXXXIV; 12, X
Consumer Product Safety Commission                5, LXXI; 16, II
Copyright Office                                  37, II
Copyright Royalty Board                           37, III
Corporation for National and Community Service    2, XXII; 45, XII, XXV
Cost Accounting Standards Board                   48, 99
Council on Environmental Quality                  40, V
Court Services and Offender Supervision Agency    5, LXX; 28, VIII
   for the District of Columbia
[[Page 611]]

Customs and Border Protection                     19, I
Defense Contract Audit Agency                     32, I
Defense Department                                2, XI; 5, XXVI; 32, 
                                                  Subtitle A; 40, VII
  Advanced Research Projects Agency               32, I
  Air Force Department                            32, VII
  Army Department                                 32, V; 33, II; 36, III, 
                                                  48, 51
  Defense Acquisition Regulations System          48, 2
  Defense Intelligence Agency                     32, I
  Defense Logistics Agency                        32, I, XII; 48, 54
  Engineers, Corps of                             33, II; 36, III
  National Imagery and Mapping Agency             32, I
  Navy Department                                 32, VI; 48, 52
  Secretary of Defense, Office of                 2, XI; 32, I
Defense Contract Audit Agency                     32, I
Defense Intelligence Agency                       32, I
Defense Logistics Agency                          32, XII; 48, 54
Defense Nuclear Facilities Safety Board           10, XVII
Delaware River Basin Commission                   18, III
District of Columbia, Court Services and          5, LXX; 28, VIII
     Offender Supervision Agency for the
Drug Enforcement Administration                   21, II
East-West Foreign Trade Board                     15, XIII
Economic Analysis, Bureau of                      15, VIII
Economic Development Administration               13, III
Economic Research Service                         7, XXXVII
Education, Department of                          2, XXXIV; 5, LIII
  Bilingual Education and Minority Languages      34, V
       Affairs, Office of
  Civil Rights, Office for                        34, I
  Educational Research and Improvement, Office    34, VII
       of
  Elementary and Secondary Education, Office of   34, II
  Federal Acquisition Regulation                  48, 34
  Postsecondary Education, Office of              34, VI
  Secretary of Education, Office of               34, Subtitle A
  Special Education and Rehabilitative Services,  34, III
       Office of
  Vocational and Adult Education, Office of       34, IV
Educational Research and Improvement, Office of   34, VII
Election Assistance Commission                    2, LVIII; 11, II
Elementary and Secondary Education, Office of     34, II
Emergency Oil and Gas Guaranteed Loan Board       13, V
Emergency Steel Guarantee Loan Board              13, IV
Employee Benefits Security Administration         29, XXV
Employees' Compensation Appeals Board             20, IV
Employees Loyalty Board                           5, V
Employment and Training Administration            20, V
Employment Standards Administration               20, VI
Endangered Species Committee                      50, IV
Energy, Department of                             2, IX; 5, XXIII; 10, II, 
                                                  III, X
  Federal Acquisition Regulation                  48, 9
  Federal Energy Regulatory Commission            5, XXIV; 18, I
  Property Management Regulations                 41, 109
Energy, Office of                                 7, XXIX
Engineers, Corps of                               33, II; 36, III
Engraving and Printing, Bureau of                 31, VI
Environmental Protection Agency                   2, XV; 5, LIV; 40, I, IV, 
                                                  VII
  Federal Acquisition Regulation                  48, 15
  Property Management Regulations                 41, 115
Environmental Quality, Office of                  7, XXXI
Equal Employment Opportunity Commission           5, LXII; 29, XIV
Equal Opportunity, Office of Assistant Secretary  24, I
     for
Executive Office of the President                 3, I
  Administration, Office of                       5, XV
  Environmental Quality, Council on               40, V

[[Page 612]]

  Management and Budget, Office of                2, Subtitle A; 5, III, 
                                                  LXXVII; 14, VI; 48, 99
  National Drug Control Policy, Office of         21, III
  National Security Council                       32, XXI; 47, 2
  Presidential Documents                          3
  Science and Technology Policy, Office of        32, XXIV; 47, II
  Trade Representative, Office of the United      15, XX
       States
Export-Import Bank of the United States           2, XXXV; 5, LII; 12, IV
Family Assistance, Office of                      45, II
Farm Credit Administration                        5, XXXI; 12, VI
Farm Credit System Insurance Corporation          5, XXX; 12, XIV
Farm Service Agency                               7, VII, XVIII
Federal Acquisition Regulation                    48, 1
Federal Aviation Administration                   14, I
  Commercial Space Transportation                 14, III
Federal Claims Collection Standards               31, IX
Federal Communications Commission                 5, XXIX; 47, I
Federal Contract Compliance Programs, Office of   41, 60
Federal Crop Insurance Corporation                7, IV
Federal Deposit Insurance Corporation             5, XXII; 12, III
Federal Election Commission                       5, XXXVII; 11, I
Federal Emergency Management Agency               44, I
Federal Employees Group Life Insurance Federal    48, 21
     Acquisition Regulation
Federal Employees Health Benefits Acquisition     48, 16
     Regulation
Federal Energy Regulatory Commission              5, XXIV; 18, I
Federal Financial Institutions Examination        12, XI
     Council
Federal Financing Bank                            12, VIII
Federal Highway Administration                    23, I, II
Federal Home Loan Mortgage Corporation            1, IV
Federal Housing Enterprise Oversight Office       12, XVII
Federal Housing Finance Agency                    5, LXXX; 12, XII
Federal Housing Finance Board                     12, IX
Federal Labor Relations Authority                 5, XIV, XLIX; 22, XIV
Federal Law Enforcement Training Center           31, VII
Federal Management Regulation                     41, 102
Federal Maritime Commission                       46, IV
Federal Mediation and Conciliation Service        29, XII
Federal Mine Safety and Health Review Commission  5, LXXIV; 29, XXVII
Federal Motor Carrier Safety Administration       49, III
Federal Prison Industries, Inc.                   28, III
Federal Procurement Policy Office                 48, 99
Federal Property Management Regulations           41, 101
Federal Railroad Administration                   49, II
Federal Register, Administrative Committee of     1, I
Federal Register, Office of                       1, II
Federal Reserve System                            12, II
  Board of Governors                              5, LVIII
Federal Retirement Thrift Investment Board        5, VI, LXXVI
Federal Service Impasses Panel                    5, XIV
Federal Trade Commission                          5, XLVII; 16, I
Federal Transit Administration                    49, VI
Federal Travel Regulation System                  41, Subtitle F
Financial Crimes Enforcement Network              31, X
Financial Research Office                         12, XVI
Financial Stability Oversight Council             12, XIII
Fine Arts, Commission on                          45, XXI
Fiscal Service                                    31, II
Fish and Wildlife Service, United States          50, I, IV
Food and Drug Administration                      21, I
Food and Nutrition Service                        7, II
Food Safety and Inspection Service                9, III
Foreign Agricultural Service                      7, XV
Foreign Assets Control, Office of                 31, V
Foreign Claims Settlement Commission of the       45, V
     United States
Foreign Service Grievance Board                   22, IX
Foreign Service Impasse Disputes Panel            22, XIV

[[Page 613]]

Foreign Service Labor Relations Board             22, XIV
Foreign-Trade Zones Board                         15, IV
Forest Service                                    36, II
General Services Administration                   5, LVII; 41, 105
  Contract Appeals, Board of                      48, 61
  Federal Acquisition Regulation                  48, 5
  Federal Management Regulation                   41, 102
  Federal Property Management Regulations         41, 101
  Federal Travel Regulation System                41, Subtitle F
  General                                         41, 300
  Payment From a Non-Federal Source for Travel    41, 304
       Expenses
  Payment of Expenses Connected With the Death    41, 303
       of Certain Employees
  Relocation Allowances                           41, 302
  Temporary Duty (TDY) Travel Allowances          41, 301
Geological Survey                                 30, IV
Government Accountability Office                  4, I
Government Ethics, Office of                      5, XVI
Government National Mortgage Association          24, III
Grain Inspection, Packers and Stockyards          7, VIII; 9, II
     Administration
Harry S. Truman Scholarship Foundation            45, XVIII
Health and Human Services, Department of          2, III; 5, XLV; 45, 
                                                  Subtitle A,
  Centers for Medicare & Medicaid Services        42, IV
  Child Support Enforcement, Office of            45, III
  Children and Families, Administration for       45, II, III, IV, X
  Community Services, Office of                   45, X
  Family Assistance, Office of                    45, II
  Federal Acquisition Regulation                  48, 3
  Food and Drug Administration                    21, I
  Human Development Services, Office of           45, XIII
  Indian Health Service                           25, V
  Inspector General (Health Care), Office of      42, V
  Public Health Service                           42, I
  Refugee Resettlement, Office of                 45, IV
Homeland Security, Department of                  2, XXX; 6, I; 8, I
  Coast Guard                                     33, I; 46, I; 49, IV
  Coast Guard (Great Lakes Pilotage)              46, III
  Customs and Border Protection                   19, I
  Federal Emergency Management Agency             44, I
  Human Resources Management and Labor Relations  5, XCVII
       Systems
  Immigration and Customs Enforcement Bureau      19, IV
  Transportation Security Administration          49, XII
HOPE for Homeowners Program, Board of Directors   24, XXIV
     of
Housing and Urban Development, Department of      2, XXIV; 5, LXV; 24, 
                                                  Subtitle B
  Community Planning and Development, Office of   24, V, VI
       Assistant Secretary for
  Equal Opportunity, Office of Assistant          24, I
       Secretary for
  Federal Acquisition Regulation                  48, 24
  Federal Housing Enterprise Oversight, Office    12, XVII
       of
  Government National Mortgage Association        24, III
  Housing--Federal Housing Commissioner, Office   24, II, VIII, X, XX
       of Assistant Secretary for
  Housing, Office of, and Multifamily Housing     24, IV
       Assistance Restructuring, Office of
  Inspector General, Office of                    24, XII
  Public and Indian Housing, Office of Assistant  24, IX
       Secretary for
  Secretary, Office of                            24, Subtitle A, VII
Housing--Federal Housing Commissioner, Office of  24, II, VIII, X, XX
     Assistant Secretary for
Housing, Office of, and Multifamily Housing       24, IV
     Assistance Restructuring, Office of
Human Development Services, Office of             45, XIII
Immigration and Customs Enforcement Bureau        19, IV
Immigration Review, Executive Office for          8, V

[[Page 614]]

Independent Counsel, Office of                    28, VII
Indian Affairs, Bureau of                         25, I, V
Indian Affairs, Office of the Assistant           25, VI
     Secretary
Indian Arts and Crafts Board                      25, II
Indian Health Service                             25, V
Industry and Security, Bureau of                  15, VII
Information Resources Management, Office of       7, XXVII
Information Security Oversight Office, National   32, XX
     Archives and Records Administration
Inspector General
  Agriculture Department                          7, XXVI
  Health and Human Services Department            42, V
  Housing and Urban Development Department        24, XII, XV
Institute of Peace, United States                 22, XVII
Inter-American Foundation                         5, LXIII; 22, X
Interior Department                               2, XIV
  American Indians, Office of the Special         25, VII
       Trustee
  Bureau of Ocean Energy Management, Regulation,  30, II
       and Enforcement
  Endangered Species Committee                    50, IV
  Federal Acquisition Regulation                  48, 14
  Federal Property Management Regulations System  41, 114
  Fish and Wildlife Service, United States        50, I, IV
  Geological Survey                               30, IV
  Indian Affairs, Bureau of                       25, I, V
  Indian Affairs, Office of the Assistant         25, VI
       Secretary
  Indian Arts and Crafts Board                    25, II
  Land Management, Bureau of                      43, II
  National Indian Gaming Commission               25, III
  National Park Service                           36, I
  Natural Resource Revenue, Office of             30, XII
  Ocean Energy Management, Bureau of              30, V
  Reclamation, Bureau of                          43, I
  Secretary of the Interior, Office of            2, XIV; 43, Subtitle A
  Surface Mining Reclamation and Enforcement,     30, VII
       Office of
Internal Revenue Service                          26, I
International Boundary and Water Commission,      22, XI
     United States and Mexico, United States 
     Section
International Development, United States Agency   22, II
     for
  Federal Acquisition Regulation                  48, 7
International Development Cooperation Agency,     22, XII
     United States
International Joint Commission, United States     22, IV
     and Canada
International Organizations Employees Loyalty     5, V
     Board
International Trade Administration                15, III; 19, III
International Trade Commission, United States     19, II
Interstate Commerce Commission                    5, XL
Investment Security, Office of                    31, VIII
Iraq Reconstruction, Special Inspector General    5, LXXXVII
     for
James Madison Memorial Fellowship Foundation      45, XXIV
Japan-United States Friendship Commission         22, XVI
Joint Board for the Enrollment of Actuaries       20, VIII
Justice Department                                2, XXVIII; 5, XXVIII; 28, 
                                                  I, XI; 40, IV
  Alcohol, Tobacco, Firearms, and Explosives,     27, II
       Bureau of
  Drug Enforcement Administration                 21, II
  Federal Acquisition Regulation                  48, 28
  Federal Claims Collection Standards             31, IX
  Federal Prison Industries, Inc.                 28, III
  Foreign Claims Settlement Commission of the     45, V
       United States
  Immigration Review, Executive Office for        8, V
  Offices of Independent Counsel                  28, VI
  Prisons, Bureau of                              28, V
  Property Management Regulations                 41, 128
Labor Department                                  5, XLII
  Employee Benefits Security Administration       29, XXV

[[Page 615]]

  Employees' Compensation Appeals Board           20, IV
  Employment and Training Administration          20, V
  Employment Standards Administration             20, VI
  Federal Acquisition Regulation                  48, 29
  Federal Contract Compliance Programs, Office    41, 60
       of
  Federal Procurement Regulations System          41, 50
  Labor-Management Standards, Office of           29, II, IV
  Mine Safety and Health Administration           30, I
  Occupational Safety and Health Administration   29, XVII
  Office of Workers' Compensation Programs        20, VII
  Public Contracts                                41, 50
  Secretary of Labor, Office of                   29, Subtitle A
  Veterans' Employment and Training Service,      41, 61; 20, IX
       Office of the Assistant Secretary for
  Wage and Hour Division                          29, V
  Workers' Compensation Programs, Office of       20, I
Labor-Management Standards, Office of             29, II, IV
Land Management, Bureau of                        43, II
Legal Services Corporation                        45, XVI
Library of Congress                               36, VII
  Copyright Office                                37, II
  Copyright Royalty Board                         37, III
Local Television Loan Guarantee Board             7, XX
Management and Budget, Office of                  5, III, LXXVII; 14, VI; 
                                                  48, 99
Marine Mammal Commission                          50, V
Maritime Administration                           46, II
Merit Systems Protection Board                    5, II, LXIV
Micronesian Status Negotiations, Office for       32, XXVII
Millennium Challenge Corporation                  22, XIII
Mine Safety and Health Administration             30, I
Minority Business Development Agency              15, XIV
Miscellaneous Agencies                            1, IV
Monetary Offices                                  31, I
Morris K. Udall Scholarship and Excellence in     36, XVI
     National Environmental Policy Foundation
Museum and Library Services, Institute of         2, XXXI
National Aeronautics and Space Administration     2, XVIII; 5, LIX; 14, V
  Federal Acquisition Regulation                  48, 18
National Agricultural Library                     7, XLI
National Agricultural Statistics Service          7, XXXVI
National and Community Service, Corporation for   2, XXII; 45, XII, XXV
National Archives and Records Administration      2, XXVI; 5, LXVI; 36, XII
  Information Security Oversight Office           32, XX
National Capital Planning Commission              1, IV
National Commission for Employment Policy         1, IV
National Commission on Libraries and Information  45, XVII
     Science
National Council on Disability                    34, XII
National Counterintelligence Center               32, XVIII
National Credit Union Administration              12, VII
National Crime Prevention and Privacy Compact     28, IX
     Council
National Drug Control Policy, Office of           21, III
National Endowment for the Arts                   2, XXXII
National Endowment for the Humanities             2, XXXIII
National Foundation on the Arts and the           45, XI
     Humanities
National Highway Traffic Safety Administration    23, II, III; 47, VI; 49, V
National Imagery and Mapping Agency               32, I
National Indian Gaming Commission                 25, III
National Institute for Literacy                   34, XI
National Institute of Food and Agriculture        7, XXXIV
National Institute of Standards and Technology    15, II
National Intelligence, Office of Director of      32, XVII
National Labor Relations Board                    5, LXI; 29, I
National Marine Fisheries Service                 50, II, IV
National Mediation Board                          29, X
National Oceanic and Atmospheric Administration   15, IX; 50, II, III, IV, 
                                                  VI

[[Page 616]]

National Park Service                             36, I
National Railroad Adjustment Board                29, III
National Railroad Passenger Corporation (AMTRAK)  49, VII
National Science Foundation                       2, XXV; 5, XLIII; 45, VI
  Federal Acquisition Regulation                  48, 25
National Security Council                         32, XXI
National Security Council and Office of Science   47, II
     and Technology Policy
National Telecommunications and Information       15, XXIII; 47, III, IV
     Administration
National Transportation Safety Board              49, VIII
Natural Resources Conservation Service            7, VI
Natural Resource Revenue, Office of               30, XII
Navajo and Hopi Indian Relocation, Office of      25, IV
Navy Department                                   32, VI
  Federal Acquisition Regulation                  48, 52
Neighborhood Reinvestment Corporation             24, XXV
Northeast Interstate Low-Level Radioactive Waste  10, XVIII
     Commission
Nuclear Regulatory Commission                     2, XX; 5, XLVIII; 10, I
  Federal Acquisition Regulation                  48, 20
Occupational Safety and Health Administration     29, XVII
Occupational Safety and Health Review Commission  29, XX
Ocean Energy Management, Bureau of                30, V
Offices of Independent Counsel                    28, VI
Office of Workers' Compensation Programs          20, VII
Oklahoma City National Memorial Trust             36, XV
Operations Office                                 7, XXVIII
Overseas Private Investment Corporation           5, XXXIII; 22, VII
Patent and Trademark Office, United States        37, I
Payment From a Non-Federal Source for Travel      41, 304
     Expenses
Payment of Expenses Connected With the Death of   41, 303
     Certain Employees
Peace Corps                                       2, XXXVII; 22, III
Pennsylvania Avenue Development Corporation       36, IX
Pension Benefit Guaranty Corporation              29, XL
Personnel Management, Office of                   5, I, XXXV; 45, VIII
  Human Resources Management and Labor Relations  5, XCVII
       Systems, Department of Homeland Security
  Federal Acquisition Regulation                  48, 17
  Federal Employees Group Life Insurance Federal  48, 21
       Acquisition Regulation
  Federal Employees Health Benefits Acquisition   48, 16
       Regulation
Pipeline and Hazardous Materials Safety           49, I
     Administration
Postal Regulatory Commission                      5, XLVI; 39, III
Postal Service, United States                     5, LX; 39, I
Postsecondary Education, Office of                34, VI
President's Commission on White House             1, IV
     Fellowships
Presidential Documents                            3
Presidio Trust                                    36, X
Prisons, Bureau of                                28, V
Procurement and Property Management, Office of    7, XXXII
Productivity, Technology and Innovation,          37, IV
     Assistant Secretary
Public Contracts, Department of Labor             41, 50
Public and Indian Housing, Office of Assistant    24, IX
     Secretary for
Public Health Service                             42, I
Railroad Retirement Board                         20, II
Reclamation, Bureau of                            43, I
Recovery Accountability and Transparency Board    4, II
Refugee Resettlement, Office of                   45, IV
Relocation Allowances                             41, 302
Research and Innovative Technology                49, XI
     Administration
Rural Business-Cooperative Service                7, XVIII, XLII, L
Rural Development Administration                  7, XLII
Rural Housing Service                             7, XVIII, XXXV, L
Rural Telephone Bank                              7, XVI

[[Page 617]]

Rural Utilities Service                           7, XVII, XVIII, XLII, L
Saint Lawrence Seaway Development Corporation     33, IV
Science and Technology Policy, Office of          32, XXIV
Science and Technology Policy, Office of, and     47, II
     National Security Council
Secret Service                                    31, IV
Securities and Exchange Commission                5, XXXIV; 17, II
Selective Service System                          32, XVI
Small Business Administration                     2, XXVII; 13, I
Smithsonian Institution                           36, V
Social Security Administration                    2, XXIII; 20, III; 48, 23
Soldiers' and Airmen's Home, United States        5, XI
Special Counsel, Office of                        5, VIII
Special Education and Rehabilitative Services,    34, III
     Office of
State Department                                  2, VI; 22, I; 28, XI
  Federal Acquisition Regulation                  48, 6
Surface Mining Reclamation and Enforcement,       30, VII
     Office of
Surface Transportation Board                      49, X
Susquehanna River Basin Commission                18, VIII
Technology Administration                         15, XI
Technology Policy, Assistant Secretary for        37, IV
Tennessee Valley Authority                        5, LXIX; 18, XIII
Thrift Supervision Office, Department of the      12, V
     Treasury
Trade Representative, United States, Office of    15, XX
Transportation, Department of                     2, XII; 5, L
  Commercial Space Transportation                 14, III
  Contract Appeals, Board of                      48, 63
  Emergency Management and Assistance             44, IV
  Federal Acquisition Regulation                  48, 12
  Federal Aviation Administration                 14, I
  Federal Highway Administration                  23, I, II
  Federal Motor Carrier Safety Administration     49, III
  Federal Railroad Administration                 49, II
  Federal Transit Administration                  49, VI
  Maritime Administration                         46, II
  National Highway Traffic Safety Administration  23, II, III; 47, IV; 49, V
  Pipeline and Hazardous Materials Safety         49, I
       Administration
  Saint Lawrence Seaway Development Corporation   33, IV
  Secretary of Transportation, Office of          14, II; 49, Subtitle A
  Surface Transportation Board                    49, X
  Transportation Statistics Bureau                49, XI
Transportation, Office of                         7, XXXIII
Transportation Security Administration            49, XII
Transportation Statistics Bureau                  49, XI
Travel Allowances, Temporary Duty (TDY)           41, 301
Treasury Department                               5, XXI; 12, XV; 17, IV; 
                                                  31, IX
  Alcohol and Tobacco Tax and Trade Bureau        27, I
  Community Development Financial Institutions    12, XVIII
       Fund
  Comptroller of the Currency                     12, I
  Customs and Border Protection                   19, I
  Engraving and Printing, Bureau of               31, VI
  Federal Acquisition Regulation                  48, 10
  Federal Claims Collection Standards             31, IX
  Federal Law Enforcement Training Center         31, VII
  Financial Crimes Enforcement Network            31, X
  Fiscal Service                                  31, II
  Foreign Assets Control, Office of               31, V
  Internal Revenue Service                        26, I
  Investment Security, Office of                  31, VIII
  Monetary Offices                                31, I
  Secret Service                                  31, IV
  Secretary of the Treasury, Office of            31, Subtitle A
  Thrift Supervision, Office of                   12, V
Truman, Harry S. Scholarship Foundation           45, XVIII
United States and Canada, International Joint     22, IV
     Commission
United States and Mexico, International Boundary  22, XI
   and Water Commission, United States Section
[[Page 618]]

Utah Reclamation Mitigation and Conservation      43, III
     Commission
Veterans Affairs Department                       2, VIII; 38, I
  Federal Acquisition Regulation                  48, 8
Veterans' Employment and Training Service,        41, 61; 20, IX
     Office of the Assistant Secretary for
Vice President of the United States, Office of    32, XXVIII
Vocational and Adult Education, Office of         34, IV
Wage and Hour Division                            29, V
Water Resources Council                           18, VI
Workers' Compensation Programs, Office of         20, I
World Agricultural Outlook Board                  7, XXXVIII

[[Page 619]]



List of CFR Sections Affected



All changes in this volume of the Code of Federal Regulations (CFR) that 
were made by documents published in the Federal Register since January 
1, 2008 are enumerated in the following list. Entries indicate the 
nature of the changes effected. Page numbers refer to Federal Register 
pages. The user should consult the entries for chapters, parts and 
subparts as well as sections for revisions.
For changes to this volume of the CFR prior to this listing, consult the 
annual edition of the monthly List of CFR Sections Affected (LSA). The 
LSA is available at www.fdsys.gov. For changes to this volume of the CFR 
prior to 2001, see the ``List of CFR Sections Affected, 1949-1963, 1964-
1972, 1973-1985, and 1986-2000'' published in 11 separate volumes. The 
``List of CFR Sections Affected 1986-2000'' is available at 
www.fdsys.gov.

                                  2008

21 CFR
                                                                   73 FR
                                                                    Page
Chapter I
510.600 (c)(1) table and (2) table amended.....4077, 8192, 14384, 18442, 
                                                            23067, 35340
520.45a Revised....................................................11027
520.48 Heading and (d)(1)(iii) revised..............................9455
520.100 (d) removed; (e) redesignated as new (d); (b) and new 
        (d)(2)(i)(A) and (B) revised...............................45611
    (b)(2) correctly amended.......................................70276
520.390b (b)(1) amended............................................18442
520.445b (b)(4) amended............................................35340
520.446 (a)(3) and (b)(3) added.....................................4077
520.538 (a) amended................................................33692
520.928 (c)(1) and (2) revised...............................2808, 64885
520.1192 (b)(3) revised; (b)(4) and (e)(1)(ii)(C) removed..........34184
520.1195 (b)(1) and (2) revised.....................................9456
520.1200 Added.....................................................33692
520.1630 (e)(2)(ii) amended; (e)(2)(iii) revised...................45610
520.1720a Revised...................................................8192
520.2123 Revised....................................................6607
520.2123a Revised...................................................6607
520.2123b Revised...................................................6607
520.2123c Revised...................................................6607
520.2200b Revised..................................................35579
520.2215 (c)(3) revised............................................53686
520.2345a (b)(3) removed...........................................18442
520.2380a (c)(3) amended...........................................35340
520.2640 (c) removed; (d) and (e) redesignated as new (c) and (d); 
        (a) and new (d)(1), (2) and (3) revised....................76946
522.246 (b)(3) amended.............................................31358
522.300 Redesignated from 522.311..................................29685
522.940 Removed....................................................12635
522.304 Redesignated from 522.312..................................29685
522.311 Redesignated as 522.300; new 522.311 added.................29685
522.312 Redesignated as 522.304....................................29685
522.313a (e)(2)(ii) amended........................................58872
522.313b (a), (e)(1)(ii) and (2)(i) revised........................45612
522.812 (e)(2)(i), (ii) and (iii) revised..........................17890
    (c) revised; (e)(3) added......................................21819
522.940 Removed....................................................21041
522.955 Revised....................................................21041
522.970 (b)(2) revised; (b)(4) added................................2809
    (b)(2) and (4) revised.........................................28037
522.1055 Removed...................................................12635
522.1160 (a) and (c) revised.......................................21042
522.1182 Revised...................................................12635
    (b)(1) and (7) amended.........................................14385
522.1183 Removed...................................................12635
522.1222a (b) amended...............................................8192
522.1660 Heading revised...........................................14926
522.1660a Heading revised..........................................14926
522.1660b Heading, (e)(1)(i)(A) and (ii) amended...................14926

[[Page 620]]

522.1696a (d)(2)(ii)(A) amended....................................16754
522.1696b (d)(2)(ii) amended.......................................14177
522.2630 (d)(1)(ii) and (2)(ii) revised.............................6018
    (d)(1)(ii) revised.............................................58872
524.2481 (b), (c)(2) and (3) revised...............................79318
526.363 (d)(2) and (3) amended.....................................12262
526.365 Heading and (d) revised.....................................3181
526.1696a Revised..................................................18442
526.1810 Heading, (a), (b) and (d) revised...........................811
529.2150 (a) and (b) revised.......................................25508
530.41 (a)(13) added...............................................38113
    Regulation at 73 FR 38113 eff. date delayed to 11-30-08........48127
    Regulation at 73 FR 38113 withdrawn............................71923
556.34 (b) revised; (c) added......................................11027
556.226 Redesignated from 556.228 and revised......................21819
556.228 Redesignated as 556.226....................................21819
556.570 (b)(3) added...............................................72715
558.4 (d) table amended..............................................812
558.95 (a)(4) amended..............................................35340
558.128 (b)(2) and (e)(1) through (4) tables amended...............35340
558.258 (e)(1) table amended; (e)(3) revised.......................58873
558.274 (a)(2) amended.............................................18442
    (a)(7) and (c)(1)(i) and (ii) tables amended...................35340
558.311 (b)(5) amended.............................................35340
558.342 (e)(1)(iv) and (2) revised.................................18958
558.355 (f)(7)(iv) added............................................6018
    (b)(13) amended................................................35340
558.366 (d) table amended..........................................15884
558.450 (d)(5)(v) table amended; (d)(5)(vi) redesignated as 
        (d)(5)(vii); new (d)(5)(vi) added..........................45875
558.485 (b)(1) amended.............................................15661
    (b)(3) amended.................................................35341
558.500 (d)(1) revised; (d)(2) and (3) redesignated as (d)(4) and 
        (5); new (d)(2), (3) and (e)(3) added; (e)(2)(i) amended 
                                                                   72715
    (e)(2)(x) table amended........................................75323
558.555 (a) and (b) revised; (e) added...............................812
558.625 (f)(2)(ix) added............................................6019
    (b)(3) removed.................................................18442
    (b)(10) and (12) amended.......................................35341
    (a), (f)(1)(vi)(c)(1), (2) and (e)(1) revised..................76947
558.630 (b)(10) amended............................................18442
    Revised........................................................34185
    (b)(2) and (5) amended.........................................35341
558.665 (e) revised.................................................6019
    (e)(3) added...................................................14385
    (e)(2) added...................................................16755
    (e)(5) added...................................................18959
    (e)(4) and (5) redesignated as (e)(5) and (6); new (e)(4)added
                                                                   19432
573.637 Added......................................................64198
573.640 (b)(4)(i) and (ii) correctly amended; CFR correction.......78958
589 Technical correction; eff. 4-27-09.............................63072
589.2000 (a)(1) revised; (c)(4) and (e)(3) added; eff. 4-27-09.....22756
589.2001 Added; eff. 4-27-09.......................................22756

                                  2009

21 CFR
                                                                   74 FR
                                                                    Page
Chapter I
510.600 (c)(1) table and (2) table amended....................6823, 9767
514.1 (a) amended; (b) introductory text revised...................54751
516.3 (b) amended..................................................43050
516.21 (c) removed.................................................43050
520.48 (b) amended.................................................61516
520.100 (b)(3) revised.............................................10484
520.309 (b)(2) amended.............................................21768
520.445b (b)(2) revised............................................62491
520.905a (e) removed; (d) redesignated as new (e); new (d) added; 
        (a), new (e)(1)(i), (iii), (2)(i), (iii), (3)(i), (ii) and 
        (4)(i) revised.............................................17770
    (b) amended....................................................61516
520.905b (b) amended...............................................61516
520.905c (b) amended...............................................61516
520.905d (b)(1) amended............................................61516
520.905e (b) amended...............................................61516
520.1010 (b)(2) amended............................................61516
520.1192 (b)(3), (e)(1)(ii)(A) and (B) removed; (b)(1), (2) and 
        (e)(1)(ii) revised..........................................6542
520.1200 (b) amended...............................................61516
520.1372 Added.....................................................27707
520.1390 Removed...................................................36111
520.1498 Removed...................................................36111
520.1720a (a) and (b)(3) revised; (b)(6) added......................1146
520.2220a (a)(2) amended...........................................60156
520.2261a (a) amended..............................................36112
520.2325a (a)(2) amended...........................................36112

[[Page 621]]

520.2455 (d) removed; (e) redesignated as new (d); new (d)(2) 
        revised.....................................................7180
520.2475 Added.....................................................28875
520.2598 Added.....................................................21767
    (a) amended....................................................30464
522.150 Revised....................................................65689
522.246 (b) amended................................................61516
522.313c (b) revised...............................................34236
522.480 (a)(2) amended.............................................20582
522.955 (d)(1)(i)(B) revised; (d)(1)(i)(C) amended.................66574
522.970 (b)(2) and (4) revised......................................6994
    (b)(1) and (4) revised.........................................34236
522.1004 (b) amended...............................................26952
    (b) revised....................................................47725
522.1010 (b)(4) amended............................................61516
522.1078 (b) amended...............................................61516
522.1079 (b) amended...............................................61516
522.1081 Revised...................................................61516
522.1160 (b) amended...............................................61517
    (a), (b) and (c)(2)(i) revised.................................66048
522.1192 (b)(2) amended.............................................9049
522.1222a (b) amended.......................................36111, 66573
522.1290 Heading, (a), (b) and (d) amended.........................25146
522.1850 (a) revised...............................................67816
522.2112 (b) amended...............................................53164
522.2476 (a)(2) amended............................................61517
522.2477 (b)(2) amended............................................61517
522.2630 (d)(1)(ii) and (2)(ii) revised............................53165
522.2640 Removed; new 522.2640 redesignated from 522.2640a; 
        heading and (e)(1)(ii) amended; (c) removed................11644
522.2640a Redesignated as 522.2640.................................11644
524.590 (b) amended................................................26782
    (c)(3) amended.................................................47436
524.1044f (b) amended..............................................22822
524.1193 (b) amended...............................................36112
524.1195 (b) amended...............................................26782
524.1580b (b)(3) added; (d)(3) revised.............................38342
524.2098 (d)(2) amended............................................19878
526.1696a (c) amended..............................................18990
528 Added...........................................................6823
    Heading corrected; CFR correction..............................58205
529.1186 (b) amended...............................................68530
529.1455 Added......................................................9767
529.1940 Revised...................................................59074
529.2150 (c)(1) amended............................................10484
558.55 (d)(2)(iv) table amended....................................61028
558.58 (e)(1)(iii) table corrected; CFR correction.................13114
    (a)(3), (b)(1) and (2) removed; (b) revised; (e)(1)(i), (ii) 
and (iii) amended..................................................61028
558.128 (e)(2)(iii) table amended..................................27920
558.175 (b) and (d) table amended..................................61028
558.258 (b) and (e)(1) table through (5) table amended.............61517
558.311 (e)(1)(xv) amended.........................................34237
558.342 (e)(1)(x) added............................................59911
    (e)(1)(xi) added...............................................61029
558.355 (f)(3)(ii)(b) revised......................................52885
558.455 (d) redesignated as (e); new (d) added; (b) and new (e) 
        revised....................................................40724
558.500 (e)(1)(ii) and (iii) revised; (e)(1)(iv) added.............66914
558.555 (e)(2), (3) and (4) added..................................41631
558.600 (d)(2) and (e)(1)(i) revised...................................6
558.625 (c)(2)(i) removed; (c)(3) amended..........................52885
558.625 (f)(1)(vi)(b) amended; (f)(1)(vi)(d)(vi) removed...........66915
558.665 (b) and (e) table amended..................................61517
589.2000 Regulation at 73 FR 22756 confirmed.......................18626
    Technical correction...........................................20583
589.2001 Regulation at 73 FR 22756 confirmed.......................18626
    Technical correction...........................................20583

                                  2010

21 CFR
                                                                   75 FR
                                                                    Page
Chapter I
510.600 (c)(1) table and (2) table amended..........................3159
514.1 Regulation at 74 FR 54751 confirmed..........................10413
516.3 (b) amended..................................................69588
516.20 (b)(2) revised..............................................69588
520.23 Revised.....................................................10165
520.314 Revised....................................................10165
520.315 Removed....................................................10165
520.390b (b) revised...............................................55676
520.580 (b)(1) amended.............................................52622
520.645 (b) amended; (d)(1)(i) and (iii) revised...................10165
520.766 Added......................................................67031
520.870 (b) amended; (d)(1)(i) and (iii) revised...................10166
520.1130 Revised...................................................10166
520.1130a Removed..................................................10166

[[Page 622]]

520.1130b Removed..................................................10166
520.1130c Removed..................................................10166
520.1448a (c)(2) amended...........................................66305
520.1616 Heading revised...........................................26646
520.1618 Added.....................................................26646
520.1630 (b) amended...............................................10166
520.1871 (a)(1), (d)(1)(i) and (iii) revised; (b)(1) amended.......54018
520.2043 (b)(2) amended............................................52622
520.2200 Revised...................................................10166
520.2200a Removed..................................................10166
520.2200b Removed..................................................10166
520.2200c Removed..................................................10166
520.2215 (b) amended...............................................69586
520.2260a (a)(1) amended...........................................10166
520.2261a (a) amended; (d) removed.................................10166
520.2261b (b) amended..............................................10166
520.2320 Removed...................................................65565
520.2345d (b)(3), (d)(1)(iii) and (2)(iii) amended.................10166
    (b)(2) and (3) revised; (b)(4) removed; (b)(5) redesignated as 
new (b)(4).........................................................12981
520.2455 (a) and (b) revised.......................................54492
520.2481 Removed...................................................10166
520.2482 Removed...................................................10166
520.2483 Added.....................................................10166
520.2640 (a), (b) and (d)(3)(ii) revised...........................76259
522.23 Revised.....................................................10167
522.90b Heading and (b)(1) amended.................................10167
522.246 (b)(2) amended.............................................22524
522.313a (e)(3) added...............................................4692
    (e)(1)(ii) amended; (e)(3) revised.............................62468
522.533 Heading and (b) revised; (c) added; (d) removed............52622
    Revised........................................................81456
522.558 (c)(2)(ii) revised.........................................60308
522.775 (b) amended................................................10167
522.870 (b) amended................................................10167
522.930 Added......................................................59611
522.956 Added.......................................................1275
    (d)(2) revised.................................................54019
522.970 (b)(1) and (4) revised.....................................13225
    (b), (e)(1)(iii) and (2) revised...............................76260
522.1145 (f)(3)(iii) amended........................................1274
    (c)(2) amended.................................................10167
522.1192 (b)(1), (2) and (e)(2)(ii) revised........................26647
522.1222a (b) amended..............................................10167
522.1696a (b)(1), (2), (d)(2)(ii)(A) and (iii) revised.............54017
522.1696b (b)(1), (2), (d)(2)(i)(A) and (iii)(B) revised...........54017
522.2005 Revised...................................................20269
    (b) and (c) revised............................................38700
522.2200 Revised...................................................10167
522.2260 (d) removed; (e) redesignated as new (d); heading, (a), 
        (b), new (d) introductory text and (1) revised.............10167
522.2471 (e)(1)(i), (ii) and (iii) revised..........................9334
522.2483 Revised...................................................10167
522.2662 (b)(2) amended............................................10167
524.1044i Added....................................................54492
524.1193 (b) and (e)(2) revised....................................26648
524.1445 Added......................................................4693
524.1465 (b) amended...............................................79296
524.1610 Added.....................................................16346
524.2481 Redesignated as 524.2483..................................10168
524.2483 Bedesignated from 524.2481; (b) amended...................10168
526 Heading revised................................................71017
526.363 (b) amended................................................10168
526.365 (b) amended................................................10168
526.464a Heading and (c) revised...................................10168
    (c) revised....................................................71017
526.1130 (b) and (c)(3) amended....................................10168
529.536 Added......................................................21163
529.1940 (d)(2) and (e)(1) revised; (e)(2)(iii) amended............63085
529.2150 (b) amended................................................1021
556.30 Removed.....................................................65565
556.90 Removed.....................................................24394
556.220 Removed....................................................65566
556.680 Removed....................................................65566
558.4 (d) table amended..............................24394, 34361, 65566
558.15 (g)(2) removed; eff. 4-30-10................................16002
558.35 Removed.....................................................65566
558.55 (d)(2) table footnote 1 correctly reinstated; CFR 
        correction.................................................15610
558.128 (b)(2) revised..............................................9334
558.185 (b)(2) removed; (b)(3) redesignated as new (b)(2)..........24394
558.315 Removed....................................................65566
558.325 (a) and (c)(3)(ii) revised; (d)(2)(i) table and (iii) 
        table amended..............................................55676
558.342 (e)(1)(v), (vi) and (vii) amended..........................60309
558.366 (d) table amended...........................................7555
558.376 Removed....................................................65566
558.485 (b)(3) amended.............................................55677

[[Page 623]]

558.500 (e)(2) table amended; (e)(2)(xi) added......................1276
    (e)(3)(iii) and (iv) added......................................5888
    (e)(2)(viii) amended; (e)(2)(xii) removed......................20917
    (e)(2)(xii) and (xiii) added...................................54019
558.630 (b)(5) amended.............................................55677
558.665 (e)(2) table, (4) table and (6) table amended..............11451
573.170 Added......................................................41725

                                  2011

21 CFR
                                                                   76 FR
                                                                    Page
Chapter I
500.1410 (Subpart F) Added.........................................72618
501.22 (k) added...................................................71254
510.600 (c)(1) table and (2) table amended.......2807, 2808, 6327, 11331
    (c)(1) table and (2) table correctly amended...................16532
    (c)(1) table and (2) table amended; eff. 4-11-11.......17777, 39278, 
                                                            40612, 79064
516.3 Regulation at 75 FR 69588 eff. date confirmed................11331
516.20 Regulation at 75 FR 69588 eff. date confirmed...............11331
516.157 (a) amended................................................31470
516.1318 Added......................................................6327
520.100 (b)(4) added...............................................38554
    (b)(4) revised.................................................40808
520.154a Heading, (d)(1)(i), (2)(i), (ii), (A) and (4)(i) 
        correctly revised..........................................53050
520.441 Redesignated from 520.445b; (b)(2) and (3) revised; 
        (d)(4)(iii)(C) amended.....................................49963
520.443 Redesignated from 520.445c; (d) removed; (e) redesignated 
        as new (d); (a), (b) and new (d) introductory text revised
                                                                   49963
520.445 Revised....................................................49649
520.445a Removed...................................................49649
520.445b Redesignated as 520.441...................................49649
520.445c Redesignated as 520.443...................................49649
520.522 (a) and (d) revised........................................78815
520.550 Heading, (a) AND (c)(3) correctly revised; (c)(1) 
        correctly amended..........................................17336
520.622a (a)(1) removed; (a)(5) amended; (b)(2) revised; eff. 4-
        11-11......................................................17777
520.622c (b)(1) and (7) removed; (c)(3) revised; eff. 4-11-11......17777
520.852 Added......................................................78150
520.905a (e)(2)(i), (iii), (3)(i) and (iii) correctly revised......17336
520.905c (e)(2)(iii) correctly revised.............................17337
520.970 Correctly revised..........................................53051
520.970a Correctly removed.........................................53051
520.970b Correctly removed.........................................53051
520.1422 (b) correctly revised.....................................17337
520.1660d (b)(6) amended...........................................17026
520.1720a (b)(6) revised...........................................11331
    (b)(4) removed; eff. 4-11-11...................................17777
520.2043 (d)(1)(iii) correctly revised.............................17337
520.2044 (d)(2) correctly revised..................................17337
520.2045 (b)(2) amended............................................40229
520.2075 Added.....................................................18648
520.2134 Added.....................................................12563
520.2220a (d)(3)(ii) correctly revised.............................17337
520.2220b (d) correctly revised....................................17337
520.2260a (a)(3)(iii) correctly revised............................17337
520.2261a Heading and (c)(3) correctly revised; (c)(2)(iii) 
        correctly amended..........................................17337
520.2261b (d)(1)(ii) and (4)(iii) correctly revised................17338
520.2345d (b)(2) and (d)(2)(iii) correctly revised; (d)(1)(iii) 
        correctly amended..........................................17338
520.2640 (a), (b)(1), (2), (d)(2)(ii), (3)(ii)(A), (B) and (iii) 
        revised; (b)(3) added......................................59024
522.56 Correctly revised...........................................17338
522.90b Heading, (a), (b) and (d) correctly revised................17338
    (d)(2)(iii) correctly revised..................................53051
522.313b (a) correctly revised.....................................17338
522.812 (e)(2)(ii) revised.........................................22611
522.814 Added......................................................72618
522.1002 (a)(2) amended.............................................2808
522.1010 (d)(3)(iii) correctly redesignated as (d)(2)(iii); new 
        (d)(3)(iii) correctly added................................17338
522.1014 Added.....................................................57906
522.1081 (b)(2) amended; eff. 4-11-11..............................17778
522.1083 Added.....................................................27889
    Heading and (a) correctly revised..............................53051
522.1192 (b)(2) revised............................................57906

[[Page 624]]

522.1410 Heading, (a) and (d) correctly revised; (c) correctly 
        removed....................................................53051
522.1450 (d) redesignated as (e); new (d) added; (b) and new 
        (e)(1) and (3) revised.....................................48714
522.1664 Added......................................................3489
522.2240 (e)(3) correctly revised..................................17027
522.2260 (a), (d)(1) and (3) correctly revised.....................53051
522.2690 (b) amended...............................................79064
524.520 Removed; eff. 4-11-11......................................17778
524.814 Revised....................................................72619
524.1132 Added.....................................................78150
524.1193 (b)(1) and (2) amended....................................81807
524.1450 Redesignated from 524.1451; (a), (b) and (e)(1) revised 
                                                                   48715
524.1451 Redesignated as 524.1450..................................48715
524.1580c (b) amended; eff. 4-11-11................................17778
556.227 (b) revised; (c) added.....................................72619
556.292 Added......................................................57907
526.363 (d)(1) correctly revised; (d)(3) correctly amended.........17338
529.536 (c)(3) correctly amended...................................16533
529.50 Correctly redesignated as 529.56 and revised................17339
529.56 Correctly redesignated from 529.50 and revised..............17339
529.1030 (d)(1)(i) and (iv) correctly revised......................17339
529.1186 (b) correctly amended.....................................16533
529.1660 (b)(2) amended............................................17026
529.2150 (b) correctly amended.....................................16533
556.20 Removed.....................................................16291
556.140 Removed....................................................16291
556.240 Removed....................................................16291
556.270 Removed....................................................16291
556.283 Revised....................................................16291
556.286 (b)(1)(iii) and (c) revised................................16291
556.290 Removed....................................................16291
556.320 Removed....................................................16291
556.390 Removed....................................................16291
556.400 Removed....................................................16291
556.520 Removed....................................................16291
556.530 Removed....................................................16291
556.540 (b) removed................................................16291
    Revised........................................................57907
556.550 Removed....................................................16291
556.590 Removed....................................................16291
558.4 (d) table correctly amended...........................16534, 17027
    (d) table amended..............................................76894
558.55 (d)(2)(i) table, (ii) table and (iv) table correctly 
        amended....................................................17027
558.60 Correctly removed...........................................17027
558.342 (d)(2) revised; (e)(1) table amended.......................60721
    (e)(1) table amended...........................................65110
558.355 (f)(3)(x) introductory text and (b) revised................79065
558.485 Heading and (b)(3) revised.................................11331
    (b)(3) amended; eff. 4-11-11...................................17778
558.530 (d)(4)(i) and (xvii) correctly removed.....................16534
558.579 Correctly removed..........................................17027
558.618 (a), (c) and (e) revised...................................76894
558.625 (b)(8), (38) and (80) removed..............................11331
    (b)(42) and (45) removed; eff. 4-11-11.........................17778
558.630 (b)(4) removed; (b)(5) amended; eff. 4-11-11...............17778
558.680 (d)(1)(i) table, (ii) table and (iii) table correctly 
        amended....................................................17027
573.480 Revised.....................................................7106

                                  2012

21 CFR
                                                                   77 FR
                                                                    Page
Chapter I
500 Authority citation revised.....................................50593
500.82 (b) amended.................................................50593
500.84 (c) introductory text revised...............................50593
500.1410 (a) correctly amended......................................9528
510.600 (c)(1) table and (2) table amended......4224, 4896, 5700, 26697, 
         29217, 31723, 32012, 32898, 46613, 47512, 55414, 56769, 60302, 
                                                            60623, 64716
511.1 (b)(4) introductory text, (5)(iii), (6), (8)(ii), (9)(i), 
        (d)(2) and (f)(1) amended; (c) revised.....................25359
511.3 Added........................................................25360
516.20 (b)(2) correctly revised; CFR correction....................18685
516.1215 Removed...................................................32012
516.1318 (c)(2) revised............................................35837
520.48 (b) revised.................................................32012
520.100 (b)(4) revised.............................................55415
520.376 Added......................................................47512
520.390a Revised....................................................4896
520.441 (b)(4) amended..............................................5700

[[Page 625]]

520.538 (a), (d)(1) and (2) revised.................................3928
520.622a (a)(4) removed.............................................4896
520.622b (b) removed................................................4897
520.1044c Revised...................................................4226
520.1100 (b)(2) amended............................................28253
520.1242 Heading revised...........................................28253
520.1242a Heading(V); (b)(4) amended...............................28253
520.1263 Heading revised...........................................20988
520.1263c Heading and (b) revised..................................20988
    (b) revised; (d)(3) added......................................29217
520.1265 (b)(2) amended............................................56770
520.1441 Redesignated from 52.1445; heading revised................47512
520.1443 Redesignated from 52.1446; heading revised................47512
520.1445 Redesignated as 520.1441; new 520.1445 added..............47512
520.1446 Redesignated as 520.1443..................................47512
520.1447 Added......................................................4225
520.1448 Removed...................................................58021
520.1448a Removed..................................................58021
520.1660d (b)(5), (d)(1)(ii)(A)(3), (B)(3), (C)(3) and (iii)(C) 
        amended....................................................28253
520.1696 Heading revised...........................................20988
520.1696a Removed..................................................20988
520.1696b Heading, (a), (b) and (c) heading revised................20988
520.1696c Heading revised; (c) removed.............................20988
520.1696d Heading and (b) revised; (c) removed.....................20988
520.1705 Added.....................................................15960
520.1720c (b)(1) amended............................................4897
520.1760 Added.....................................................15961
520.1860 Added.....................................................76863
520.2130 Revised...................................................60623
520.2220a (a)(2) amended...........................................56770
520.2345 Heading revised...........................................20988
520.2345d (b)(4) revised...........................................20988
520.2455 (b)(2) amended............................................56770
520.2640 (b) introductory text revised.............................29217
520.2645 Added.....................................................55415
522.52 Added.......................................................64717
522.150 (b) amended................................................46613
522.246 (b)(2) amended.............................................60302
522.313a (e)(2)(i), (ii) and (iii) revised.........................26162
522.313c (b), (e)(2)(ii), (3)(ii), (4)(ii) and (8)(i) revised......29218
522.522 (d)(1) and (2) revised......................................4227
522.540 Heading, (a)(2)(ii) and (3)(iii) revised...................32012
522.1083 (c)(1) and (3) revised.....................................4227
522.775 (b) amended................................................60302
522.812 (e)(2)(i), (ii)(A) and (iii) revised.......................55415
    (e)(3)(ii) revised.............................................76863
522.840 (b) amended................................................31723
522.842 (a)(2) amended.............................................31723
522.1004 (b) revised...............................................26697
522.1014 (d)(1)(ii) revised........................................26162
522.1081 (b)(2) removed............................................55414
522.1193 (b) revised...............................................64717
522.1315 (c) revised...............................................39391
522.1462 Removed...................................................55414
522.1642 Removed...................................................55414
522.1680 (b) amended...............................................55414
522.1696a (b)(1), (3), (d)(1)(iii) and (2)(iii) revised.............4897
522.1940 (a)(2) amended............................................31723
522.2460 Added.....................................................39391
522.2476 (b)(1) amended............................................31723
522.2477 (b)(1) amended............................................31723
524.154 (a)(2) and (b)(3) amended..................................64717
524.155 (a)(2) and (b)(3) amended..................................64717
524.390 Revised.....................................................4897
    (b) amended....................................................64717
524.390a Removed....................................................4897
524.390b Removed....................................................4897
524.390d Removed....................................................4897
524.916 Added......................................................47512
524.1044c (b) amended..............................................64717
524.1044f (b) and (c)(2) revised....................................3598
524.1445 (b) revised...............................................46613
524.1484a Removed...................................................4897
524.1484j Removed...................................................4897
524.1484k Removed...................................................4897
524.1880 Removed....................................................4897
524.2483 (b) amended...............................................60302
529.1350 Added.....................................................76863
529.1455 Removed....................................................4897
529.2620 Added.....................................................64717
530.41 (a)(13) added; eff. 4-5-12....................................745
556.733 Added......................................................39391
556.748 Added......................................................55415
558.4 (d) Category I table and Category II table amended...........22668
    (d) Category II table amended..................................24138
558.261 (a)(2), (c)(2)(1) and (e)(2) table revised.................32012
558.274 (a)(7) removed; (c)(1)(i) table and (ii) table amended......4897
558.342 (b)(2) and (e)(1) table amended............................31723

[[Page 626]]

    (e)(1) table amended...........................................76864
558.355 (f)(3)(iv) added; (f)(3)(x)(c) amended......................4228
    (d)(7)(vii), (10)(i) and (ii) revised; (f)(3)(v) removed; 
(f)(7) redesignated as (f)(8); new (f)(7) added....................58021
    (f)(8)(iv) redesignated as (f)(8)(v); new (f)(8)(iv) added.....60623
558.363 (d)(1)(i) introductory text revised........................29218
    (d)(1)(xi)(B) revised; (d)(2) redesignated as (d)(3); (a)(8), 
(c) and new (d)(2) added...........................................64717
558.485 (b)(3) amended..............................................4897
558.500 (e)(1)(i) correctly reinstated; CFR correction.............14272
    (e)(2)(viii) and (x) amended...................................31724
558.600 (e)(1)(i) removed..........................................22668
    (a) revised; (e)(1) table amended..............................24139
558.618 (c)(3)(ii) removed; (e) revised............................60623
558.625 (b)(10), (12) and (67) removed..............................4897
    (b)(90) added..................................................26162
    (b)(40) removed................................................60302
558.630 (b)(2) removed; (b)(5) amended..............................4897
558.665 (e)(2), (4) and (6) amended................................31724

                                  2013

   (Regulations published from January 1, 2013, through April 1, 2013)

21 CFR
                                                                   78 FR
                                                                    Page
Chapter I
510.600 (c)(1) table and (2) table amended............5714, 17596, 17867
    (c)(1) table amended...........................................14668
520.100 (b)(4) and (d)(1) introductory text revised...................23
    (b)(3) amended.................................................17596
520.182 Removed....................................................14669
520.260 Heading revised; (b)(1) and (3) revised....................14669
520.370 (b) amended.................................................5714
520.446 (b)(1) amended.............................................17596
520.447 (b) amended................................................17596
520.580 Heading, (a), (b), (d)(1) and (2) revised..................14669
520.1010 (b)(3) amended............................................17596
520.1044b (b) amended..............................................17596
520.1192 (b)(2) amended............................................17596
520.1193 (b)(2) amended............................................17596
520.1195 (b)(1) amended............................................17596
520.1484 (b)(3) amended............................................17596
520.1720a (b)(2) amended...........................................17596
520.1870 (b)(2) amended............................................17596
520.2043 (b)(1) amended............................................17596
520.2044 (b)(2) amended............................................17596
520.2123c (b) amended..............................................17596
520.2220a (a)(1) amended...........................................17596
520.2260b (f)(1) amended...........................................17596
520.2325a (a)(1) amended...........................................17596
520.2455 (b)(2) revised; (b)(3) added..............................17596
522.23 (b)(2) amended..............................................17597
522.46 Removed.....................................................14669
522.56 (b) amended.................................................17597
522.246 (b)(2) and (3) amended.....................................17597
522.390 (b) amended................................................17597
522.540 (a)(2)(i), (b)(3)(i), (ii), (c)(3)(i), (ii), (d)(2)(i) and 
        (e)(2) amended.............................................17597
522.810 (b) amended................................................17597
522.1010 (b)(3) amended............................................17597
522.1044 (b)(4) amended............................................17597
522.1066 (b) amended...............................................17597
522.1073 Added.....................................................17867
522.1075 Redesignated from 522.1078................................17868
522.1077 Heading revised; (c)(3) amended...........................17868
522.1078 Redesignated as 522.1075..................................17868
522.1086 (b) amended...............................................17597
522.1182 (b)(1), (6) and (7) amended...............................17597
522.1192 (b)(2) amended............................................17597
522.1222a (b) amended..............................................17597
522.1260 (b)(2) amended............................................17597
522.1367 (b) amended................................................5715
522.1660a (b) amended..............................................17597
522.1662a (i)(2) amended...........................................17597
522.1680 (b) amended...............................................17597
522.1696a (b)(2) amended...........................................17597
522.1696b (b)(1), (d)(2)(i)(A) and (iii)(B) amended................17597
522.1720 (b)(1) amended............................................17597
522.1870 Heading, (b), (c)(1)(iii) and (2)(iii) revised............17868
522.2005 (b)(1) amended............................................17597
    (b)(2) amended.................................................17868
522.2120 (b) amended...............................................17597
522.2220 (a)(2)(iii) amended.......................................17597
522.2615 (b) amended...............................................17597
524.1044g (b)(3) amended...........................................17597
524.1193 (b)(2) amended............................................17597
524.2482 (b) amended...............................................17868

[[Page 627]]

529.56 (b) amended.................................................17597
529.469 Removed....................................................14669
529.1003 Removed...................................................14669
529.1044a (b) amended..............................................17597
529.1186 (b) amended........................................14669, 17868
529.2150 (b) amended...............................................17868
558.366 (d) table amended.............................................23
558.485 (b)(6) amended.............................................14669
558.586 (b) amended................................................17597
558.625 (b)(35), (63), (66) and (77) removed.......................14669
558.630 (b)(5) added...............................................14669


                                  [all]